PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Oh, SS; Tcheurekdjian, H; Roth, LA; Nguyen, EA; Sen, S; Galanter, JM; Davis, A; Farber, HJ; Gilliland, FD; Kumar, R; Avila, PC; Brigino-Buenaventura, E; Chapela, R; Ford, JG; LeNoir, MA; Lurmann, F; Meade, K; Serebrisky, D; Thyne, S; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Williams, LK; Borrell, LN; Burchard, EG				Oh, Sam S.; Tcheurekdjian, Haig; Roth, Lindsey A.; Nguyen, Elizabeth A.; Sen, Saunak; Galanter, Joshua M.; Davis, Adam; Farber, Harold J.; Gilliland, Frank D.; Kumar, Rajesh; Avila, Pedro C.; Brigino-Buenaventura, Emerita; Chapela, Rocio; Ford, Jean G.; LeNoir, Michael A.; Lurmann, Fred; Meade, Kelley; Serebrisky, Denise; Thyne, Shannon; Rodriguez-Cintron, William; Rodriguez-Santana, Jose R.; Williams, L. Keoki; Borrell, Luisa N.; Burchard, Esteban G.			Effect of secondhand smoke on asthma control among black and Latino children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Secondhand smoke; prenatal exposure delayed effects; asthma; health status disparities	ENVIRONMENTAL TOBACCO-SMOKE; MATERNAL SMOKING; PARENTAL SMOKING; NATIONAL-HEALTH; DNA METHYLATION; UNITED-STATES; EXPOSURE; WOMEN; PREGNANCY	Background: Among patients with asthma, the clinical effect and relative contribution of maternal smoking during pregnancy (in utero smoking) and current secondhand smoke (SHS) exposure on asthma control is poorly documented, and there is a paucity of research involving minority populations. Objectives: We sought to examine the association between poor asthma control and in utero smoking and current SHS exposure among Latino and black children with asthma. Methods: We performed a case-only analysis of 2 multicenter case-control studies conducted from 2008-2010 with similar protocols. We recruited 2481 Latino and black subjects with asthma (ages 8-17 years) from the mainland United States and Puerto Rico. Ordinal logistic regression was used to estimate the effect of in utero smoking and current SHS exposures on National Heart, Lung, and Blood Institute-defined asthma control. Results: Poor asthma control among children 8 to 17 years of age was independently associated with in utero smoking (odds ratio [OR], 1.5; 95% CI, 1.1-2.0). In utero smoking through the mother was also associated with secondary asthma outcomes, including early-onset asthma (OR, 1.7; 95% CI, 1.1-2.4), daytime symptoms (OR, 1.6; 95% CI, 1.1-2.1), and asthma-related limitation of activities (OR, 1.6; 95% CI, 1.2-2.2). Conclusions: Maternal smoking while in utero is associated with poor asthma control in black and Latino subjects assessed at 8-17 years of age. (J Allergy Clin Immunol 2012;129:1478-83.)	[Oh, Sam S.; Roth, Lindsey A.; Nguyen, Elizabeth A.; Galanter, Joshua M.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Oh, Sam S.] Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA; [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Tcheurekdjian, Haig] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Tcheurekdjian, Haig] Allergy Immunol Associates Inc, Cleveland, OH USA; [Sen, Saunak] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Davis, Adam; Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60614 USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [Chapela, Rocio] INER, Mexico City, DF, Mexico; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA; [LeNoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Thyne, Shannon] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Borrell, Luisa N.] CUNY, Lehman Coll, Grad Program Publ Hlth, Dept Hlth Sci, Bronx, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; Baylor College of Medicine; University of Southern California; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jacobi Medical Center; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; City University of New York (CUNY) System; Lehman College (CUNY)	Oh, SS (corresponding author), UCSF Mission Bay Lung Biol Ctr, Dept Bioengn & Therapeut Sci, Rock Hall,Rm 582,1550 4th St, San Francisco, CA 94158 USA.	Sam.Oh@ucsf.edu	Borrell, Luisa N./G-8753-2018	Borrell, Luisa N./0000-0002-0560-4853; Galanter, Joshua/0000-0002-2561-6384; Nguyen, Elizabeth/0000-0002-8070-6382; Kumar, Rajesh/0000-0002-1962-7108	National Institutes of Health [ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, AI061774, HL079055, DK064695, M01-RR00188]; Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty; Sandler Foundation; American Asthma Foundation; Ernest S. Bazley Grant; Fund for Henry Ford Hospital; National Institutes of Health/National Heart, Lung, and Blood Institute; AsthmaNet-National Institutes of Health; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; NATIONAL CANCER INSTITUTE [T32CA113710, R25CA113710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078885, R01HL079055, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774, U19AI077439, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty; Sandler Foundation; American Asthma Foundation; Ernest S. Bazley Grant; Fund for Henry Ford Hospital; National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AsthmaNet-National Institutes of Health; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported in part by the National Institutes of Health (ES015794, AI077439, HL088133, HL078885, CA113710, AI079139, AI061774, HL079055, DK064695, and M01-RR00188), the Flight Attendant Medical Research Institute (FAMRI), the RWJF Amos Medical Faculty Development Award (to E. G. B.), the Sandler Foundation, the American Asthma Foundation (to E. G. B. and L. K. W.), an Ernest S. Bazley Grant (to P. C. A.), and the Fund for Henry Ford Hospital (to L. K. W.). S.S.O. and E. G. B. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.; S. Sen and J. M. Galanter have received research support from the National Institutes of Health. A. Davis has received research support from the Sandler Foundation. H. J. Farber is a scientific journal editor for Mary Anne Liebert, Inc, and has received research support from the National Institutes of Health. R. Kumar has received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute. P. C. Avila receives research support from the National Institutes of Health and is on the data and safety monitoring boards for Astellas and Biota. J. G. Ford has consultant arrangements with GlaxoSmithKline. K. Meade receives research support from AsthmaNet-National Institutes of Health. L. K. Williams receives research support from the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute. The rest of the authors declare that they have no relevant conflicts of interest.	Akuete K, 2011, PEDIATRICS, V128, pE623, DOI 10.1542/peds.2011-0640; American Lung Association Epidemiology and Statistics Unit, TRENDS ASTHM MORB MO; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Best D, 2009, PEDIATRICS, V124, pE1017, DOI 10.1542/peds.2009-2120; Binns HJ, 2009, PEDIATRICS, V124, P1474, DOI 10.1542/peds.2009-2114; Breton CV, 2011, EPIGENETICS-US, V6, P895, DOI 10.4161/epi.6.7.15768; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Dietz PM, 2011, AM J EPIDEMIOL, V173, P355, DOI 10.1093/aje/kwq381; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Farber HJ, 2008, CHEST, V133, P1367, DOI 10.1378/chest.07-2369; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Guerrero-Preston R, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12378; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80, DOI 10.1016/S1081-1206(10)63090-6; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Kaufmann R. B., 2010, Morbidity and Mortality Weekly Report, V59, P1141; Korea Ministry of Health and Welfare, 2016, DEV NAT BIOM PROGR E; Leonardi-Bee J, 2011, PEDIATRICS, V127, P734, DOI 10.1542/peds.2010-3041; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36, DOI 10.1001/archpedi.155.1.36; National Asthma Education and Prevention Program (National Heart Lung and Blood Institute). Third Expert Panel on the Management of Asthma, 2010, GUID DIAGN MAN ASTH; National Center forHealth Statistics, 2011, HLTH US 2010 SPEC FE; Orr ST, 2005, MATERN CHILD HLTH J, V9, P245, DOI 10.1007/s10995-005-0010-x; Perreira KM, 2006, AM J PUBLIC HEALTH, V96, P1629, DOI 10.2105/AJPH.2004.056598; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; Wongtrakool C, 2007, AM J PHYSIOL-LUNG C, V293, pL611, DOI 10.1152/ajplung.00038.2007; Wright TE, 2011, J PERINATOL, V31, P324, DOI 10.1038/jp.2010.132; Wu ZX, 2009, ENVIRON HEALTH PERSP, V117, P1434, DOI 10.1289/ehp.0800511	35	50	51	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1478	+		10.1016/j.jaci.2012.03.017	http://dx.doi.org/10.1016/j.jaci.2012.03.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22552109	Green Accepted			2022-12-18	WOS:000304764600006
J	Tan, J; Campbell, D; Mehr, S				Tan, John; Campbell, Dianne; Mehr, Sam			Food protein-induced enterocolitis syndrome in an exclusively breast-fed infant-an uncommon entity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Tan, John; Campbell, Dianne; Mehr, Sam] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia	University of Sydney	Tan, J (corresponding author), Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia.	samm@chw.edu.au		Campbell, Dianne/0000-0002-0907-6963; Mehr, Sam/0000-0003-2483-917X				Franke AA, 2006, AM J CLIN NUTR, V84, P406; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746	5	50	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					873	873		10.1016/j.jaci.2011.12.1000	http://dx.doi.org/10.1016/j.jaci.2011.12.1000			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22296754				2022-12-18	WOS:000301189300048
J	Schwarz, A; Navid, F; Sparwasser, T; Clausen, BE; Schwarz, T				Schwarz, Agatha; Navid, Fatemeh; Sparwasser, Tim; Clausen, Bjorn E.; Schwarz, Thomas			In vivo reprogramming of UV radiation-induced regulatory T-cell migration to inhibit the elicitation of contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antigen-presenting cells; contact hypersensitivity; forkhead box protein 3; immunosuppression; in vivo reprogramming; Langerhans cells; regulatory T cells; tissue homing; skin; UV radiation	LANGERIN(+) DENDRITIC CELLS; EPIDERMAL LANGERHANS CELLS; ULTRAVIOLET-RADIATION; INDUCED TOLERANCE; SUPPRESSOR-CELLS; SKIN; EXPRESSION; IDENTIFICATION; AUTOIMMUNITY; RECEPTOR	Background: Regulatory T (Treg) cells induced by UV radiation (UVR) inhibit only the induction and not the elicitation of contact hypersensitivity (CHS) because they migrate into the lymph nodes but not the skin. The tissue-homing receptor expression and migratory behavior of Treg cells can be altered by means of in vitro coincubation with skin-derived antigen-presenting cells. On this in vitro treatment, Treg cells migrate into the skin and thus inhibit the elicitation of CHS. Objective: We attempted to determine whether Treg cells can be induced by UVR in sensitized mice and manipulated entirely in vivo in such a way that they suppress the elicitation of immune responses. Methods: Treg cells were induced by applying contact allergens onto UV-exposed skin in wild-type, langerin diphtheria toxin receptor knock-in, or depletion of Treg cell transgenic mice. Results: UVR-induced Treg cells inhibit the elicitation of CHS in sensitized mice when stimulated by means of an antigen-specific boost through the skin. This requires cutaneous antigen-presenting cells that alter the migratory behavior of Treg cells and drive them out of the lymph nodes into the skin. Conclusions: The indication is that antigen-specific Treg cells can be induced in sensitized hosts and manipulated in such a way that they suppress the elicitation of specific immune reactions. Because this is achieved entirely in vivo without invasive interventions, our findings might have important implications for strategies aiming to induce and use Treg cells in a therapeutic setting. (J Allergy Clin Immunol 2011;128:826-33.)	[Schwarz, Agatha; Navid, Fatemeh; Schwarz, Thomas] Univ Kiel, Dept Dermatol & Allergol, D-24105 Kiel, Germany; [Sparwasser, Tim] TWINCORE, Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hannover, Germany; [Clausen, Bjorn E.] Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands	University of Kiel; Helmholtz Association; Helmholtz-Center for Infection Research; Erasmus University Rotterdam; Erasmus MC	Schwarz, T (corresponding author), Univ Kiel, Dept Dermatol & Allergol, Schittenhelmstr 7, D-24105 Kiel, Germany.	tschwarz@dermatology.uni-kiel.de	Schwarz, Thomas/A-9148-2010; Sparwasser, Tim/AAF-7085-2019; CLAUSEN, Björn Erik/A-8229-2010; Sparwasser, Tim D/AAA-4306-2022	Sparwasser, Tim/0000-0001-5645-902X; CLAUSEN, Björn Erik/0000-0002-2484-7842; 	German Research Foundation [SCHW1177/1-3, SCHW625/4 1]; Netherlands Organization for Scientific Research (NWO) [917-76-365]	German Research Foundation(German Research Foundation (DFG)); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	Supported by grants from the German Research Foundation (SCHW1177/1-3, SCHW625/4 1; to A. S. and T. S.). B. E. C. is a VIDI fellow of the Netherlands Organization for Scientific Research (NWO, 917-76-365).	Aragane Y, 2003, J IMMUNOL, V171, P3801, DOI 10.4049/jimmunol.171.7.3801; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Dudda JC, 2004, J IMMUNOL, V172, P857, DOI 10.4049/jimmunol.172.2.857; ELMETS CA, 1983, J EXP MED, V158, P781, DOI 10.1084/jem.158.3.781; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; GLASS MJ, 1990, J INVEST DERMATOL, V94, P273, DOI 10.1111/1523-1747.ep12874117; Kabelitz D, 2006, CRIT REV IMMUNOL, V26, P291, DOI 10.1615/CritRevImmunol.v26.i4.10; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Maeda A, 2008, J IMMUNOL, V180, P3065, DOI 10.4049/jimmunol.180.5.3065; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; Romani N, 2010, IMMUNOL REV, V234, P120, DOI 10.1111/j.0105-2896.2009.00886.x; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036; Schwarz A, 2000, J IMMUNOL, V165, P1824, DOI 10.4049/jimmunol.165.4.1824; Schwarz A, 2007, J IMMUNOL, V178, P877, DOI 10.4049/jimmunol.178.2.877; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Schwarz T, 2010, J INVEST DERMATOL, V130, P49, DOI 10.1038/jid.2009.217; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; Takahara K, 2002, INT IMMUNOL, V14, P433, DOI 10.1093/intimm/14.5.433; Tang QZ, 2006, IMMUNOL REV, V212, P217, DOI 10.1111/j.0105-2896.2006.00421.x; TOEWS GB, 1980, J IMMUNOL, V124, P445; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; Workman CJ, 2009, CELL MOL LIFE SCI, V66, P2603, DOI 10.1007/s00018-009-0026-2	32	50	53	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					826	833		10.1016/j.jaci.2011.06.005	http://dx.doi.org/10.1016/j.jaci.2011.06.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21762977				2022-12-18	WOS:000296538100019
J	Deffert, C; Olleros, ML; Yuan, HP; Herrmann, FR; Zekry, D; Garcia, I; Krause, KH; Schappi, MG				Deffert, Christine; Olleros, Maria L.; Yuan Huiping; Herrmann, Francois R.; Zekry, Dina; Garcia, Irene; Krause, Karl-Heinz; Schaeppi, Michela G.			Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC GRANULOMATOUS-DISEASE; INFLAMMATORY-BOWEL-DISEASE; PHAGOCYTE NADPH OXIDASE; CROHNS-DISEASE; HYPERINFLAMMATION; NECROSIS; COLITIS		[Deffert, Christine; Schaeppi, Michela G.] Univ Hosp Geneva, Dept Pediat, Pediat Gastroenterol & Transplantat Div, Geneva, Switzerland; [Deffert, Christine; Olleros, Maria L.; Yuan Huiping; Garcia, Irene; Krause, Karl-Heinz; Schaeppi, Michela G.] Fac Med, Dept Pathol & Immunol, Geneva, Switzerland; [Krause, Karl-Heinz] Fac Med, Dept Genet & Lab Med, Geneva, Switzerland; [Herrmann, Francois R.; Zekry, Dina] Univ Hosp Geneva, Dept Rehabil & Geriatr, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Deffert, C (corresponding author), Univ Hosp Geneva, Dept Pediat, Pediat Gastroenterol & Transplantat Div, Geneva, Switzerland.	michela.tempia-caliera@hcuge.ch	HERRMANN, Francois R/B-6710-2011; Schäppi, Michela/D-5363-2012; Schäppi Tempia-Caliera, Michela/A-7619-2012; HERRMANN, Francois/M-7390-2019	HERRMANN, Francois R/0000-0003-1312-1517; Schäppi Tempia-Caliera, Michela/0000-0002-9860-7294; HERRMANN, Francois/0000-0003-1312-1517; Olson, Aaron/0000-0002-5237-400X	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL090558] Funding Source: NIH RePORTER; NCRR NIH HHS [1ULI RR025014-01, UL1 RR025014] Funding Source: Medline; NHLBI NIH HHS [R21-HL90558, R21 HL090558-01A2, R21 HL090558] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		De Ravin SS, 2008, J ALLERGY CLIN IMMUN, V122, P1097, DOI 10.1016/j.jaci.2008.07.050; Freudenberg F, 2010, J ALLERGY CLIN IMMUN, V125, P943, DOI 10.1016/j.jaci.2010.01.035; Hatanaka E, 2004, IMMUNOL LETT, V94, P43, DOI 10.1016/j.imlet.2004.04.016; Huang JS, 2004, CLIN GASTROENTEROL H, V2, P690, DOI 10.1016/S1542-3565(04)00292-7; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Matute JD, 2009, BLOOD, V114, P3309, DOI 10.1182/blood-2009-07-231498; Olleros ML, 2010, J HEPATOL, V53, P1059, DOI 10.1016/j.jhep.2010.05.029; Petersen JE, 2002, J INVEST DERMATOL, V118, P424, DOI 10.1046/j.0022-202x.2001.01691.x; Schappi MG, 2008, J PATHOL, V214, P434, DOI 10.1002/path.2298; Schappi MG, 2008, SEMIN IMMUNOPATHOL, V30, P255, DOI 10.1007/s00281-008-0119-2; Seger RA, 2010, NETH J MED, V68, P334; Soncini E, 2009, BRIT J HAEMATOL, V145, P73, DOI 10.1111/j.1365-2141.2009.07614.x; Tommasini A, 2010, SCAND J GASTROENTERO, V45, P1141, DOI 10.3109/00365521.2010.492529; Uzel G, 2010, CLIN INFECT DIS, V51, P1429, DOI 10.1086/657308; van de Loo FAJ, 2003, AM J PATHOL, V163, P1525, DOI 10.1016/S0002-9440(10)63509-2; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1092, DOI 10.1016/j.jaci.2005.01.016; Warris A, 2003, SCAND J INFECT DIS, V35, P482, DOI 10.1080/00365540310013009	18	50	50	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					677	U355		10.1016/j.jaci.2011.04.027	http://dx.doi.org/10.1016/j.jaci.2011.04.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21601260	Green Accepted, Bronze			2022-12-18	WOS:000294283400034
J	Barlogis, V; Galambrun, C; Chambost, H; Lamoureux-Toth, S; Petit, P; Stephan, JL; Michel, G; Fischer, A; Picard, C				Barlogis, Vincent; Galambrun, Claire; Chambost, Herve; Lamoureux-Toth, Sylvie; Petit, Philippe; Stephan, Jean-Louis; Michel, Gerard; Fischer, Alain; Picard, Capucine			Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS		[Barlogis, Vincent; Galambrun, Claire; Chambost, Herve; Michel, Gerard] Hop Enfants La Timone, Dept Pediat Hematol, Marseille, France; [Petit, Philippe] Hop Enfants La Timone, Serv Radiol Pediat, Marseille, France; [Lamoureux-Toth, Sylvie] Ctr Hosp Avignon, Serv Pediat, Avignon, France; [Stephan, Jean-Louis] Hop Nord St Etienne, Serv Pediat, St Etienne, France; [Fischer, Alain] Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; [Fischer, Alain] Hop Necker Enfants Malad, INSERM, U768, Paris, France; [Fischer, Alain; Picard, Capucine] Paris Descartes Univ, Necker Med Sch, Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, APHP, Study Ctr Primary Immunodeficiency, Paris, France; [Picard, Capucine] INSERM, Lab Human Genet Infect Dis, U980, Paris, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Barlogis, V (corresponding author), Hop Enfants La Timone, Dept Pediat Hematol, Marseille, France.	vincent.barlogis@ap-hm.fr	Picard, Capucine/H-3914-2017	Picard, Capucine/0000-0001-8788-5056; CHAMBOST, HERVE/0000-0002-5319-1969				Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; McDonald DR, 2010, J ALLERGY CLIN IMMUN, V126, P1304, DOI 10.1016/j.jaci.2010.07.034; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	7	50	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					420	422		10.1016/j.jaci.2011.03.025	http://dx.doi.org/10.1016/j.jaci.2011.03.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21546070	Bronze			2022-12-18	WOS:000293280800028
J	Kattan, JD; Konstantinou, GN; Cox, AL; Nowak-Wegrzyn, A; Gimenez, G; Sampson, HA; Sicherer, SH				Kattan, Jacob D.; Konstantinou, George N.; Cox, Amanda L.; Nowak-Wegrzyn, Anna; Gimenez, Gustavo; Sampson, Hugh A.; Sicherer, Scott H.			Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY		[Kattan, Jacob D.; Konstantinou, George N.; Cox, Amanda L.; Nowak-Wegrzyn, Anna; Gimenez, Gustavo; Sampson, Hugh A.; Sicherer, Scott H.] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Kattan, JD (corresponding author), Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA.	scott.sicherer@mssm.edu		Konstantinou, George/0000-0003-1371-6764; Nowak-Wegrzyn, Anna/0000-0002-0960-9854				Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; Martin-Munoz MF, 2002, VACCINE, V20, P3409, DOI 10.1016/S0264-410X(02)00228-1; Mayorga C, 2003, ANN ALLERG ASTHMA IM, V90, P238, DOI 10.1016/S1081-1206(10)62148-5; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; *VACC ADV EV REP S, CDC WID RANG ONL DAT	9	50	52	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					215	218		10.1016/j.jaci.2011.04.046	http://dx.doi.org/10.1016/j.jaci.2011.04.046			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21624648				2022-12-18	WOS:000292245600030
J	Sheffer, AL; Campion, M; Levy, RJ; Li, HH; Horn, PT; Pullman, WE				Sheffer, Albert L.; Campion, Marilyn; Levy, Robyn J.; Li, H. Henry; Horn, Patrick T.; Pullman, William E.			Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ecallantide; Evaluation of DX-88's Effects in Mitigating Angioedema 3 and 4; hereditary angioedema; mean symptom complex severity; plasma kallikrein inhibitor; treatment outcome score	KALLIKREIN INHIBITOR; PATHOGENESIS; SYMPTOMS; THERAPY	Background: Hereditary angioedema (HAE) is a rare disorder characterized by recurrent angioedema attacks. Ecallantide, a novel plasma kallikrein inhibitor, inhibits production of bradykinin, the key mediator of these angioedema attacks. Objective: We sought to further characterize the safety and efficacy of ecallantide for HAE attacks by performing an integrated analysis of pooled data from 2 phase 3 studies. Methods: An integrated analysis was conducted with data from 2 randomized, double-blind, placebo-controlled studies in which patients with HAE (age >= 10 years) received 30 mg of subcutaneous ecallantide or placebo within 8 hours of onset of a moderate-to-severe attack at any anatomic site. Efficacy was evaluated by using validated patient-reported outcome measures: the Mean Symptom Complex Severity (MSCS) score and the Treatment Outcome Score (TOS). Results: Compared with placebo, ecallantide resulted in significantly greater reduction in MSCS scores from baseline to 4 hours after dosing (ecallantide [mean +/- SD], -0.97 +/- 0.78; placebo, -0.47 +/- 0.71; P < .001) and a significantly greater increase in TOSs at 4 hours (ecallantide, 55.5 +/- 46.5; placebo, 20.0 +/- 58.9; P < .001). Significantly greater symptomatic improvement over placebo occurred through 24 hours after dosing (MSCS score, P = .028; TOS, P = .039). Ecallantide demonstrated efficacy at all attack sites. The incidence of treatment-emergent adverse events was similar between groups. Conclusions: This integrated analysis supports and expands on the results of the phase 3 studies. Ecallantide appears to be effective and well tolerated for the treatment of HAE attacks. (J Allergy Clin Immunol 2011; 128: 153-9.)	[Sheffer, Albert L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Chestnut Hill, MA 02467 USA; [Levy, Robyn J.] Family Allergy & Asthma Ctr, PC, Atlanta, GA USA; [Li, H. Henry] Inst Asthma & Allergy, Wheaton, IL USA; [Horn, Patrick T.; Pullman, William E.] Dyax Corp, Cambridge, England	Harvard University; Brigham & Women's Hospital	Sheffer, AL (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 850 Boylston St, Chestnut Hill, MA 02467 USA.	asheffer@partners.org			Dyax Corp.; Dyax; CSL Behring; Grifols; Aventis; VeroPharma; Pharming; Shire; Shire/Jerini	Dyax Corp.; Dyax; CSL Behring; Grifols; Aventis(Sanofi-Aventis); VeroPharma; Pharming; Shire; Shire/Jerini	Supported by Dyax Corp. A.L.S. was primarily responsible for drafting the manuscript and revising it critically for content.; Disclosure of potential conflict of interest: A. L. Sheffer has consultant arrangements with Lev Pharmaceuticals and CSL Behring and has served on the DMSC for Pharming. M. Campion has consultant arrangements with Dyax and Cubist Pharmaceuticals, Inc, and holds stock in Cubist Pharmaceuticals, Inc. R. J. Levy has received travel grants from Dyax and CSL Behring and has received research support from Grifols, Aventis, Dyax, VeroPharma, CSL Behring, Pharming, and Shire. H. H. Li has received research support from Dyax, VeroPharma, and Shire/Jerini. P. T. Horn and W. E. Pullman are employed by Dyax.	Banerji A, 2008, ANN ALLERG ASTHMA IM, V100, pS19, DOI 10.1016/S1081-1206(10)60582-0; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Cicardi M, 2010, NEW ENGL J MED, V363, P523, DOI 10.1056/NEJMoa0905079; *CSL BEHR GMBH, 2009, BER C1 EST INH HUM P; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; *DYAX CORP, 2009, KALB DX 88 EC PACK I; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Frank MM, 2008, J ALLERGY CLIN IMMUN, V121, P272, DOI 10.1016/j.jaci.2007.11.019; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Hara T, 1999, ENDOSCOPY, V31, P322; Lehmann A, 2008, EXPERT OPIN BIOL TH, V8, P1187, DOI [10.1517/14712598.8.8.1187, 10.1517/14712598.8.8.1187 ]; *LEV PHARM INC, CINR C1 EST INH HUM; Levy RJ, 2010, ANN ALLERG ASTHMA IM, V104, P523, DOI 10.1016/j.anai.2010.04.012; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SHEFFER AL, 1971, J ALLERGY, V47, P292, DOI 10.1016/S0091-6749(71)80007-6; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; Vernon MK, 2009, QUAL LIFE RES, V18, P929, DOI 10.1007/s11136-009-9509-8; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2009, ALLERGY ASTHMA PROC, V30, P487, DOI 10.2500/aap.2009.30.3277	20	50	52	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					153	U239		10.1016/j.jaci.2011.03.006	http://dx.doi.org/10.1016/j.jaci.2011.03.006			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21481442				2022-12-18	WOS:000292245600020
J	Sanak, M; Gielicz, A; Bochenek, G; Kaszuba, M; Nizankowska-Mogilnicka, E; Szczeklik, A				Sanak, Marek; Gielicz, Anna; Bochenek, Grazyna; Kaszuba, Marek; Nizankowska-Mogilnicka, Ewa; Szczeklik, Andrew			Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled breath condensate; asthma; aspirin intolerance; eicosanoids; mass spectrometry	TANDEM MASS-SPECTROMETRY; CYSTEINYL-LEUKOTRIENES; SENSITIVE ASTHMATICS; BRONCHIAL-ASTHMA; CHALLENGE; PULMONARY; HUMANS; URINE; HYPERSENSITIVITY; PROSTAGLANDINS	Background: Eicosanoids, important signaling and inflammatory molecules, are present in exhaled breath condensate (EBC) in very low concentrations, requiring highly sensitive analytic methods for their quantification. Objective: We sought to assess a vast platform of eicosanoids in different asthma phenotypes, including aspirin-intolerant asthma, by means of a recently developed analytic approach based on mass spectrometry. Methods: EBC from 115 adult asthmatic subjects (62 with aspirin intolerance) and 38 healthy control subjects were assessed quantitatively for 19 eicosanoids by using complementary HPLC, gas chromatography-mass spectrometry, or both. Palmitic acid concentrations were used as a marker for dilution of condensate samples. Results: Asthma was characterized by an increase in arachidonate lipoxygenase products and cysteinyl leukotrienes. The COX pathway was also significantly upregulated in asthmatic subjects. Subjects with aspirin-intolerant asthma were distinguished by a sharp increase in the level of prostaglandin D-2 and E-2 metabolites; their 5- and 15-hydroxyeicosateraenoic acid levels were also higher than in aspirin-tolerant subjects. A classical discriminant analysis permitted us to classify correctly 99% of asthmatic subjects within the study population; the specificity of the analysis was 97%. The eicosanoid profiling allowed for 92% correct classification of aspirin-intolerant subjects. Conclusions: The highly sensitive eicosanoid profiling in EBC makes it possible to detect alterations in asthma, especially in its distinct phenotype characterized by hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. This permits us to discriminate asthmatic subjects from healthy subjects, as well as to distinguish the 2 asthma phenotypes based on the presence or absence of aspirin hypersensitivity. (J Allergy Clin Immunol 2011;127:1141-7.)	[Sanak, Marek; Gielicz, Anna; Bochenek, Grazyna; Kaszuba, Marek; Nizankowska-Mogilnicka, Ewa; Szczeklik, Andrew] Jagiellonian Univ, Coll Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Coll Med, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.	mmszczek@cyf-kr.edu.pl	Kaszuba, Marek/D-2201-2013; Sanak, Marek/AAV-1628-2021	Kaszuba, Marek/0000-0001-8669-3247; Sanak, Marek/0000-0001-7635-8103	Iceland, Liechtenstein, and Norway through the European Economic Area (EEA); European Community; Polish Ministry of Science and Higher Education	Iceland, Liechtenstein, and Norway through the European Economic Area (EEA); European Community(European Commission); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	Supported by a grant from Iceland, Liechtenstein, and Norway through the European Economic Area (EEA) Financial Mechanism and by the U-BIOPRED project carried out under the Innovative Medicines Initiative.; Disclosure of potential conflict of interest: M. Sanak, A. Gielicz, G. Bochenek, M. Kaszuba, E. Nizankowska-Mogilnicka, and A. Szczeklik have received research support from the European Community and the Polish Ministry of Science and Higher Education.	Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; BIANCO S, 1980, EUR J RESPIR DIS, V61, P81; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Claesson HE, 2009, PROSTAG OTH LIPID M, V89, P120, DOI 10.1016/j.prostaglandins.2008.12.003; Dallinga JW, 2010, CLIN EXP ALLERGY, V40, P68, DOI 10.1111/j.1365-2222.2009.03343.x; Debley JS, 2011, CHEST, V139, P16, DOI 10.1378/chest.10-0101; Dressel H, 2010, RESPIRATION, V80, P401, DOI 10.1159/000319945; Fens N, 2009, AM J RESP CRIT CARE, V180, P1076, DOI 10.1164/rccm.200906-0939OC; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; Gaber F, 2008, THORAX, V63, P1076, DOI 10.1136/thx.2008.101196; Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Jinnai N, 2004, HUM MOL GENET, V13, P3203, DOI 10.1093/hmg/ddh332; Kharitonov SA, 2001, CURR OPIN ALLERGY CL, V1, P217, DOI 10.1097/01.all.0000011017.58506.f1; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Kowalski Marek L, 2007, Clin Allergy Immunol, V19, P147; Lu R, 1996, J CLIN INVEST, V98, P1142, DOI 10.1172/JCI118897; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; McCafferty JB, 2004, THORAX, V59, P694, DOI 10.1136/thx.2003.016949; Moreno JJ, 2009, BIOCHEM PHARMACOL, V77, P1, DOI 10.1016/j.bcp.2008.07.033; Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; NIZANKOWSKA E, 1986, EUR J RESPIR DIS, V69, P363; Sachs-Olsen C, 2010, J ALLERGY CLIN IMMUN, V126, pe9; Sachs-Olsen C, 2010, J ALLERGY CLIN IMMUN, V126, P859, DOI 10.1016/j.jaci.2010.07.015; Sanak M, 2004, CLIN EXP ALLERGY, V34, P1899, DOI 10.1111/j.1365-2222.2004.02123.x; Sanak M, 2010, ALLERGY, V65, P663, DOI 10.1111/j.1398-9995.2009.02206.x; Sanak M, 2010, J CHROMATOGR B, V878, P1796, DOI 10.1016/j.jchromb.2010.05.012; Schwarz K, 2010, J AEROSOL MED PULM D, V23, P371, DOI 10.1089/jamp.2009.0809; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; SZCZEKLIK A, 1978, PROSTAGLANDINS, V16, P651, DOI 10.1016/0090-6980(78)90001-1; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szczeklik A., 2009, MIDDELTONS ALLERGY P, V7, P1227, DOI [DOI 10.1016/B978-0-323-05659-5.00069-3, 10.1016/b978-0-323-05659-5.00069-3]; Tsikas D, 1998, J CHROMATOGR B, V717, P201, DOI 10.1016/S0378-4347(98)00210-2; Tsikas D, 1998, ANAL BIOCHEM, V261, P230, DOI 10.1006/abio.1998.2739	42	50	52	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1141	U400		10.1016/j.jaci.2010.12.1108	http://dx.doi.org/10.1016/j.jaci.2010.12.1108			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21315430	Green Published			2022-12-18	WOS:000290018600007
J	Lange, NE; Bunyavanich, S; Silberg, JL; Canino, G; Rosner, BA; Celedon, JC				Lange, Nancy E.; Bunyavanich, Supinda; Silberg, Judy L.; Canino, Glorisa; Rosner, Bernard A.; Celedon, Juan C.			Parental psychosocial stress and asthma morbidity in Puerto Rican twins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psychosocial stress; childhood wheeze; Puerto Rico; parental stress; asthma; paternal stress	INTERNATIONAL DIAGNOSTIC INTERVIEW; HIGH-RISK CHILDREN; EARLY-LIFE; CHILDHOOD ASTHMA; MENTAL-HEALTH; RECURRENT WHEEZE; BIRTH-COHORT; PREVALENCE; DISORDERS; DEPRESSION	Background: Little is known about paternal psychosocial factors and childhood asthma. Objective: We sought to examine the link between maternal and paternal psychosocial stress and asthma outcomes in young children. Methods: Parents of 339 pairs of Puerto Rican twins were interviewed individually about their own psychosocial stress and about asthma in their children at age 1 year and again about their child's asthma at age 3 years. Fathers were asked about symptoms of posttraumatic stress disorder (PTSD), depression, and antisocial behavior. Mothers were asked about depressive symptoms. Outcomes assessed in children included recent asthma symptoms, oral steroid use and hospitalizations for asthma in the prior year, and asthma diagnosis. Generalized estimated equation models were used for the multivariate analysis of parental psychosocial stress and asthma morbidity in childhood. Results: After multivariable adjustment, paternal PTSD symptoms, depression, and antisocial behavior were each associated with increased asthma symptoms at age 1 year (eg, odds ratio, 1.08 for each 1-point increase in PTSD score; 95% CI, 1.03-1.14). Maternal depressive symptoms were associated with an increased risk of asthma hospitalizations at age 1 year. At age 3 years, maternal depressive symptoms were associated with asthma diagnosis and hospitalizations for asthma (odds ratio for each 1-point increase in symptoms, 1.16; 95% CI, 1.00-1.36). In an analysis combining 1- and 3-year outcomes, paternal depression was associated with oral steroid use, maternal depressive symptoms were associated with asthma hospitalizations and asthma diagnosis, and parental depression was associated with hospitalizations for asthma. Conclusions: Both paternal and maternal psychosocial factors can influence asthma morbidity in young Puerto Rican children. (J Allergy Clin Immunol 2011;127:734-40.)	[Celedon, Juan C.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, UPMC,Dept Pediat & Med,Div Pediat Pulm Med Allerg, Pittsburgh, PA 15224 USA; [Lange, Nancy E.; Bunyavanich, Supinda; Rosner, Bernard A.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Lange, Nancy E.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Bunyavanich, Supinda] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA 02115 USA; [Lange, Nancy E.; Bunyavanich, Supinda; Rosner, Bernard A.] Harvard Univ, Sch Med, Boston, MA USA; [Silberg, Judy L.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23284 USA; [Canino, Glorisa] Behav Sci Res Inst, San Juan, PR USA; [Rosner, Bernard A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Virginia Commonwealth University; Harvard University; Harvard T.H. Chan School of Public Health	Celedon, JC (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, UPMC,Dept Pediat & Med,Div Pediat Pulm Med Allerg, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu			National Institutes of Health [HD0496685, HL079966, HL007427]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R01HL079966, K12HL089990] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants HD0496685, HL079966, and HL007427 from the National Institutes of Health.	Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Alegria M, 2004, INT J METH PSYCH RES, V13, P270, DOI 10.1002/mpr.181; Alegria M, 2009, INT J METH PSYCH RES, V18, P84, DOI 10.1002/mpr.280; American Lung Association, 2010, ASTHM CHILDR FACT SH; American Lung Association, 2009, TRENDS ASTHM MORB MO; American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th ed.; Angold A, 1995, INT J METHOD PSYCH, V5, P237; [Anonymous], MOOD FEELINGS QUESTI; [Anonymous], 2010, MOOD FEELINGS QUESTI; Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1042, DOI 10.1097/01.chi.0000227878.58027.3d; Canino G, 2004, ARCH GEN PSYCHIAT, V61, P85, DOI 10.1001/archpsyc.61.1.85; CANINO GJ, 1987, ARCH GEN PSYCHIAT, V44, P727; Caserta MT, 2008, BRAIN BEHAV IMMUN, V22, P933, DOI 10.1016/j.bbi.2008.01.007; Chida Y, 2008, PSYCHOSOM MED, V70, P102, DOI 10.1097/PSY.0b013e31815c1b71; Chida Y, 2007, AM J RESP CRIT CARE, V175, P316, DOI 10.1164/rccm.200607-898OC; Chrousos George P., 2000, Journal of Allergy and Clinical Immunology, V106, pS275; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Crocker D, 2009, CHEST, V136, P1063, DOI 10.1378/chest.09-0013; Dreger LC, 2010, J ALLERGY CLIN IMMUN, V125, P116, DOI 10.1016/j.jaci.2009.09.051; Galea S, 2004, ANN EPIDEMIOL, V14, P520, DOI 10.1016/j.annepidem.2004.01.006; Goodwin RD, 2009, J ASTHMA, V46, P726, DOI 10.1080/02770900903072051; Graham-Bermann SA, 2005, J PEDIATR-US, V146, P349, DOI 10.1016/j.jpeds.2004.10.065; Haczku A, 2010, J ALLERGY CLIN IMMUN, V125, P550, DOI 10.1016/j.jaci.2009.11.005; Haro JM, 2006, INT J METH PSYCH RES, V15, P167, DOI 10.1002/mpr.196; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; LISH JD, 1995, PSYCHIAT RES, V57, P169, DOI 10.1016/0165-1781(95)02632-7; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Marin TJ, 2009, PSYCHOSOM MED, V71, P378, DOI 10.1097/PSY.0b013e318199dbc3; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez-Taboas A, 2006, J TRAUMA STRESS, V19, P439, DOI 10.1002/jts.20144; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x; MRAZEK DA, 1991, J AM ACAD CHILD PSY, V30, P277, DOI 10.1097/00004583-199103000-00017; Murgatroyd C, 2009, NAT NEUROSCI, V12, P1559, DOI 10.1038/nn.2436; Oraka E, 2010, CHEST, V137, P609, DOI 10.1378/chest.09-1777; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Prosser R, 2010, CHRONIC DIS CAN, V30, P46; Reinheckel A, 2000, Z GEBURTSH NEONATOL, V204, P55, DOI 10.1055/s-2000-10197; Shalowitz MU, 2001, AMBUL PEDIATR, V1, P185, DOI 10.1367/1539-4409(2001)001<0185:TROLSA>2.0.CO;2; Sharp LK, 2009, ANN ALLERG ASTHMA IM, V103, P386, DOI 10.1016/S1081-1206(10)60357-2; SHROUT PE, 1992, AM J COMMUN PSYCHOL, V20, P729, DOI 10.1007/BF00942235; Silberg JL, 2010, J CHILD PSYCHOL PSYC, V51, P734, DOI 10.1111/j.1469-7610.2010.02205.x; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; Sugimoto Masako, 2008, Nihon Koshu Eisei Zasshi, V55, P213; Tough SC, 1998, J ASTHMA, V35, P657, DOI 10.3109/02770909809048968; U.S. Census Bureau, 2006, US CENS BUR 2006 200; Undem Bradley J., 2000, Journal of Allergy and Clinical Immunology, V106, pS213; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; Wisnivesky JP, 2010, J ASTHMA, V47, P100, DOI 10.3109/02770900903426989; Wolf JM, 2008, BRAIN BEHAV IMMUN, V22, P433, DOI 10.1016/j.bbi.2007.10.016; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016	61	50	51	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					734	U373		10.1016/j.jaci.2010.11.010	http://dx.doi.org/10.1016/j.jaci.2010.11.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	730FG	21194742	Green Accepted			2022-12-18	WOS:000288018400028
J	Jartti, T; Ruuskanen, O; Mansbach, JM; Vuorinen, T; Camargo, CA				Jartti, Tuomas; Ruuskanen, Olli; Mansbach, Jonathan M.; Vuorinen, Tytti; Camargo, Carlos A., Jr.			Low serum 25-hydroxyvitamin D levels are associated with increased risk of viral coinfections in wheezing children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY SYNCYTIAL VIRUS; VITAMIN-D; HUMAN BOCAVIRUS; PREDNISOLONE; RHINOVIRUS; INFECTION; EFFICACY; AGE		[Jartti, Tuomas; Ruuskanen, Olli] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; [Mansbach, Jonathan M.] Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Vuorinen, Tytti] Univ Turku, Dept Virol, Turku, Finland; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Boston, MA 02114 USA	University of Turku; Harvard University; Boston Children's Hospital; University of Turku; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Jartti, T (corresponding author), Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.	tuomas.jartti@utu.fi	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI077801] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI-77801, K23 AI077801] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196; CAMARGO CA, 2010, PEDIATRICS IN PRESS; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2007, PEDIAT ALLERG IMM-UK, V18, P326, DOI 10.1111/j.1399-3038.2007.00512.x; Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c; Kantola K, 2008, CLIN INFECT DIS, V46, P540, DOI 10.1086/526532; Kantola K, 2009, J CLIN VIROL, V45, P292, DOI 10.1016/j.jcv.2009.04.008; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Linday LA, 2004, ANN OTO RHINOL LARYN, V113, P891, DOI 10.1177/000348940411301108; Marjamaki L, 2004, INT J VITAM NUTR RES, V74, P27, DOI 10.1024/0300-9831.74.1.27; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091; Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710; Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845	18	50	53	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1074	U269		10.1016/j.jaci.2010.09.004	http://dx.doi.org/10.1016/j.jaci.2010.09.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050947	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000283727100028
J	Camargo, CA; Gurner, DM; Smithline, HA; Chapela, R; Fabbri, LM; Green, SA; Malice, MP; Legrand, C; Dass, SB; Knorr, BA; Reiss, TF				Camargo, Carlos A., Jr.; Gurner, Deborah M.; Smithline, Howard A.; Chapela, Rocio; Fabbri, Leonardo M.; Green, Stuart A.; Malice, Marie-Pierre; Legrand, Catherine; Dass, S. Balachandra; Knorr, Barbara A.; Reiss, Theodore F.			A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous montelukast; acute asthma; asthma exacerbation; FEV1; hospitalization; leukotriene receptor antagonist; randomized trial	CONTROLLED-TRIAL; DISCHARGE; MULTICENTER; ADMISSION	Background: Current treatments for acute asthma provide inadequate benefit for some patients. Intravenous montelukast may complement existent therapies. Objective: To evaluate efficacy of intravenous montelukast as adjunctive therapy for acute asthma. Methods: A total of 583 adults with acute asthma were treated with standard care during a <= 60-minute screening period. Patients with FEV1 <= 50% predicted were randomly allocated to intravenous montelukast 7 mg (n = 291) or placebo (n = 292) in addition to standard care. This double-blind treatment period lasted until a decision for discharge, hospital admission, or discontinuation from the study. The primary efficacy endpoint was the time-weighted average change in FEV1 during 60 minutes after drug administration. Secondary endpoints included the time-weighted average change in FEV1 at various intervals (10-120 minutes) and percentage of patients with treatment failure (defined as hospitalization or lack of decision to discharge by 3 hours postadministration). Results: Montelukast significantly increased FEV1 at 60 minutes postdose; the difference between change from baseline for placebo (least-squares mean of 0.22 L; 95% CI, 0.17, 0.27) and montelukast (0.32 L; 95% CI, 0.27, 0.37) was 0.10 L (95% CI, 0.04, 0.16). Similar improvements in FEV1-related variables were seen at all time points (all P <.05). Although treatment failure did not differ between groups (OR 0.92; 95% CI, 0.63, 1.34), a prespecified subgroup analysis suggests likely benefit for intravenous montelukast at US sites. Conclusion: Intravenous montelukast added to standard care in adults with acute asthma produced significant relief of airway obstruction throughout the 2 hours after administration, with an onset of action as early as 10 minutes. (J Allergy Clin Immunol 2010;125:374-80.)	[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA; [Gurner, Deborah M.; Green, Stuart A.; Malice, Marie-Pierre; Legrand, Catherine; Dass, S. Balachandra; Knorr, Barbara A.; Reiss, Theodore F.] Merck Res Labs, Rahway, NJ USA; [Smithline, Howard A.] Tufts Univ, Sch Med, Dept Emergency Med, Baystate Med Ctr, Springfield, MA 01199 USA; [Chapela, Rocio] Inst Nacl Enfermedades Resp, Unidad Invest, Clin Asma, Mexico City, DF, Mexico; [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Resp Dis, Modena, Italy	Harvard University; Harvard Medical School; Massachusetts General Hospital; Merck & Company; Baystate Medical Center; Tufts University; Universita di Modena e Reggio Emilia	Camargo, CA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Fabbri, Leonardo M/I-4055-2012; Camargo, Carlos A./C-2145-2008	Fabbri, Leonardo M/0000-0001-8894-1689; Camargo, Carlos A./0000-0002-5071-7654	Merck Co, Inc.; AstraZeneca; Dev; GlaxoSmithKline; Merck; Novartis	Merck Co, Inc.(Merck & Company); AstraZeneca(AstraZeneca); Dev; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Novartis(Novartis)	Supported by Merck & Co, Inc.; Disclosure of potential conflict of interest: C. A. Camargo has received financial support for consulting. lectures. advisory boards. and medical research for many groups, including AstraZeneca, Dev, GlaxoSmithKline. Merck. and Novartis. L. M. Fabbri receives fees for lecturing, consultancies. and advisory boards from Nycomed, AstraZeneca. Boehringer Ingelheim. Chiesi Farmaceutiei GlaxoSmithKline, Merck Sharp & Dohme, Novartis. Roche. and Pfizer. D. M. Gurner. S. A. Green, M.-P Malice. C. Legrand, S. B. Dass. B. A. Knorr. and T. F Reiss are employed by Merck and Co. Inc. The rest of the authors have declared that they have no conflict of interest.	BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; Berger W, 2007, INT J CLIN PRACT, V61, P663, DOI 10.1111/j.1742-1241.2007.01320.x; Bjermer Leif, 2005, Expert Rev Clin Immunol, V1, P325, DOI 10.1586/1744666X.1.3.325; Blanchard JC, 2003, ACAD EMERG MED, V10, P1289, DOI 10.1197/S1069-6563(03)00501-3; BOLLIGER CT, 1992, SCHWEIZ MED WSCHR, V122, P1823; Cairns CB, 2006, CLIN CHEST MED, V27, P99, DOI 10.1016/j.ccm.2005.11.003; Camargo CA, 2003, AM J RESP CRIT CARE, V167, P528, DOI 10.1164/rccm.200208-802OC; Dempsey OJ, 2000, CHEST, V117, P950, DOI 10.1378/chest.117.4.950; Dockhorn RJ, 2000, THORAX, V55, P260, DOI 10.1136/thorax.55.4.260; *GINA, 2002, NIH PUBL; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Green SA, 2004, THORAX, V59, P100, DOI 10.1136/thorax.2003.006825; Henry RL, 2006, CURR OPIN ALLERGY CL, V6, P172, DOI 10.1097/01.all.0000225155.22156.f9; Jackson P, 2001, J Health Soc Policy, V14, P61, DOI 10.1300/J045v14n01_04; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuitert LME, 2007, DRUGS, V67, P1665, DOI 10.2165/00003495-200767120-00002; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Markoff BA, 2001, CLIN REV ALLERG IMMU, V20, P341, DOI 10.1385/CRIAI:20:3:341; McFadden ER, 2003, AM J RESP CRIT CARE, V168, P740, DOI 10.1164/rccm.200208-902SO; *NAEPP, 2007, NIH PUBL; Nayak A, 2004, EXPERT OPIN PHARMACO, V5, P679, DOI 10.1517/eoph.5.3.679.27358; Price DB, 2003, THORAX, V58, P211, DOI 10.1136/thorax.58.3.211; Raimondi AC, 1997, CHEST, V112, P24, DOI 10.1378/chest.112.1.24; Reiss T. F., 2001, Clinical and Experimental Allergy Reviews, V1, P264, DOI 10.1046/j.1472-9725.2001.t01-1-00012.x; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; Silverman RA, 2002, CHEST, V122, P489, DOI 10.1378/chest.122.2.489; Stewart M, 1998, ARCH DIS CHILD, V79, P219, DOI 10.1136/adc.79.3.219; Tillie-Leblond I, 2005, ALLERGY, V60, P23, DOI 10.1111/j.1398-9995.2005.00632.x; Weber EJ, 2002, AM J MED, V113, P371, DOI 10.1016/S0002-9343(02)01242-1	29	50	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					374	380		10.1016/j.jaci.2009.11.015	http://dx.doi.org/10.1016/j.jaci.2009.11.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159247				2022-12-18	WOS:000274764000014
J	Fessler, MB; Massing, MW; Spruell, B; Jaramillo, R; Draper, DW; Madenspacher, JH; Arbes, SJ; Calatroni, A; Zeldin, DC				Fessler, Michael B.; Massing, Mark W.; Spruell, Brian; Jaramillo, Renee; Draper, David W.; Madenspacher, Jennifer H.; Arbes, Samuel J.; Calatroni, Agustin; Zeldin, Darryl C.			Novel relationship of serum cholesterol with asthma and wheeze in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung; asthma; wheeze; cholesterol; atopy; Hispanic	LOW-DENSITY LIPOPROTEINS; CORONARY-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; RISK-FACTORS; ATHEROSCLEROSIS MESA; PUERTO-RICAN; CARDIOVASCULAR-DISEASE; PULMONARY INFLAMMATION; INSULIN-RESISTANCE; MEXICAN-AMERICANS	Background: Cholesterol exerts complex effects on inflammation. There has been little investigation of whether serum cholesterol is associated with asthma, an inflammatory airways disease with great public health impact. Objective: To determine relationships between levels of 3 serum cholesterol measures (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and non-HDL-C) and asthma/wheeze in a sample representative of the US population. Methods: Cross-sectional study of 7005 participants age; >= 6 years from the 2005 to 2006 National Health and Nutrition Examination Survey. Results: Serum TC and non-HDL-C were lower in patients with current asthma than in subjects without current asthma in the overall population (TC, 188.5 vs 192.2 mg/dL; non-HDL-C, 133.9 vs 137.7 mg/dL; P < .05 for both), whereas HDL-C was not different. Adjusted odds ratios (ORs) from multivariate logistic regression per 1-SD increase of TC and non-HDL-C for current asthma were 0.92 (95% CI, 0.86-0.98) and 0.91 (95% CI, 0.85-0.98), respectively. On racial/ethnic stratification, these relationships reflect marked reductions unique to Mexican Americans (MAs; TC, 171.4 vs 189.3 mg/dL; P < .001; OR, 0.62; 95% CI, 0.48-0.80; non-HDL-C, 119.8 vs 137.9 mg/dL; P < .001; OR, 0.62; 95% CI, 0.48-0.79). Among MAs, the adjusted OR for wheeze requiring medical attention was 0.57 (95% CI, 0.43-0.75) for TC and 0.53 (95% CI, 0.33-0.85) for non-HDL-C. Relationships between cholesterol and asthma/wheeze were independent of body mass index and serum C-reactive protein, and similar between atopic and nonatopic participants. Conclusion: Serum TC and non-HDL-C are inversely related to asthma in the US population, chiefly reflecting a relationship among MAs. (J Allergy Clin Immunol 2009;124:967-74.)	[Fessler, Michael B.; Draper, David W.; Madenspacher, Jennifer H.; Zeldin, Darryl C.] Natl Inst Environm Hlth Sci, Lab Resp Biol, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Massing, Mark W.; Spruell, Brian; Jaramillo, Renee] SRA Int, Durham, NC USA; [Arbes, Samuel J.; Calatroni, Agustin] Rho Fed Syst Div Inc, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); SRA International	Fessler, MB (corresponding author), Natl Inst Environm Hlth Sci, Lab Resp Biol, NIH, Dept Hlth & Human Serv, 111 TW Alexander Dr,POB 12233,Maildrop D2-01, Res Triangle Pk, NC 27709 USA.	fesslerm@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018; Fessler, Michael B/C-6323-2019	Zeldin, Darryl C/0000-0002-2087-7307; Fessler, Michael B/0000-0002-8262-8613	National Institutes of Health; National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102005, Z01ES102005, ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	Al-Shawwa B, 2006, J ASTHMA, V43, P231, DOI 10.1080/02770900600567056; Allison MA, 2008, AM J EPIDEMIOL, V167, P962, DOI 10.1093/aje/kwm402; Arif AA, 2004, J PAEDIATR CHILD H, V40, P189, DOI 10.1111/j.1440-1754.2004.00335.x; Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103a; Baldan A, 2008, J IMMUNOL, V180, P3560, DOI 10.4049/jimmunol.180.5.3560; Baumruker T, 2003, INT IMMUNOL, V15, P1207, DOI 10.1093/intimm/dxg120; Bertoni AG, 2007, DIABETES CARE, V30, P2951, DOI 10.2337/dc07-1042; Bild DE, 2005, CIRCULATION, V111, P1313, DOI 10.1161/01.CIR.0000157730.94423.4B; Brahan D, 2005, PEDIATRICS, V115, pE163, DOI 10.1542/peds.2004-1437; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; CABANA VG, 1989, J LIPID RES, V30, P39; Carroll MD, 2005, JAMA-J AM MED ASSOC, V294, P1773, DOI 10.1001/jama.294.14.1773; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Chen CL, 2007, J CELL SCI, V120, P3509, DOI 10.1242/jcs.006916; Choi HK, 2005, ARTHRIT RHEUM-ARTHR, V53, P528, DOI 10.1002/art.21329; Cohen RT, 2006, CLIN CHEST MED, V27, P401, DOI 10.1016/j.ccm.2006.04.004; Crimmins EM, 2007, AM J PUBLIC HEALTH, V97, P1305, DOI 10.2105/AJPH.2006.091892; Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189; Davidson MH, 2008, ARTERIOSCL THROM VAS, V28, P1582, DOI 10.1161/ATVBAHA.108.172718; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Fessler MB, 2005, AM J RESP CRIT CARE, V171, P606, DOI 10.1164/rccm.200406-729OC; Fessler MB, 2004, J BIOL CHEM, V279, P39989, DOI 10.1074/jbc.M401080200; Flores G, 2002, JAMA-J AM MED ASSOC, V288, P82, DOI 10.1001/jama.288.1.82; HARRISON GJ, 1995, HEART VESSELS, V10, P249, DOI 10.1007/BF01744904; Ho RC, 2005, CYTOKINE, V30, P14, DOI 10.1016/j.cyto.2004.10.015; Holvoet P, 2007, ATHEROSCLEROSIS, V194, P245, DOI 10.1016/j.atherosclerosis.2006.08.002; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hothersall EJ, 2008, THORAX, V63, P1070, DOI 10.1136/thx.2008.100198; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200; Liao YL, 1997, J AM COLL CARDIOL, V30, P1200, DOI 10.1016/S0735-1097(97)00278-7; Litonjua AA, 2008, IMMUNOL ALLERGY CLIN, V28, P603, DOI 10.1016/j.iac.2008.03.005; Liu J, 2006, AM J CARDIOL, V98, P1363, DOI 10.1016/j.amjcard.2006.06.032; Menzies D, 2007, J ALLERGY CLIN IMMUN, V119, P328, DOI 10.1016/j.jaci.2006.10.014; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; Mora S, 2008, CIRCULATION, V118, P993, DOI 10.1161/CIRCULATIONAHA.108.777334; NISTOR A, 1986, AM REV RESPIR DIS, V134, P1266; Picado C, 1999, ALLERGY, V54, P569, DOI 10.1034/j.1398-9995.1999.00024.x; Reaven PD, 2003, AM J CARDIOL, V92, P1198, DOI 10.1016/j.amjcard.2003.07.030; Robertson AKL, 2004, SCAND J IMMUNOL, V59, P285, DOI 10.1111/j.0300-9475.2004.01403.x; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Schafer T, 2003, CLIN EXP ALLERGY, V33, P1360, DOI 10.1046/j.1365-2222.2003.01780.x; SCHULMAN ES, 1987, BIOCHEM BIOPH RES CO, V148, P553, DOI 10.1016/0006-291X(87)90912-0; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; U. S. Census Bureau, US INT PROJ AG SEX R; Wojcik AJ, 2008, J IMMUNOL, V180, P4273, DOI 10.4049/jimmunol.180.6.4273; 1997, MMWR MORB MORTAL WKL, V46, P198	47	50	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					967	974		10.1016/j.jaci.2009.08.005	http://dx.doi.org/10.1016/j.jaci.2009.08.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19800678	Green Accepted, Bronze			2022-12-18	WOS:000272108000014
J	Roesler, E; Weiss, R; Weinberger, EE; Fruehwirth, A; Stoecklinger, A; Mostbock, S; Ferreira, F; Thalhamer, J; Scheiblhofer, S				Roesler, Elisabeth; Weiss, Richard; Weinberger, Esther E.; Fruehwirth, Angelika; Stoecklinger, Angelika; Mostboeck, Sven; Ferreira, Fatima; Thalhamer, Josef; Scheiblhofer, Sandra			Immunize and disappear-Safety-optimized mRNA vaccination with a panel of 29 allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RNA vaccines; DNA vaccines; self-replicating vaccines; type I allergy; vaccination	DNA VACCINES; IGE PRODUCTION; MOUSE MODEL; T-CELLS; RESPONSES; RESPONSIVENESS; INHIBITION; PREVALENCE; INJECTION; EXPOSURE	Background: The spread of type I allergic diseases has reached epidemic dimensions. The success of therapeutic intervention is limited, and hence prophylactic vaccination is now seriously considered. However, immunization of healthy individuals requires safety standards far beyond those applicable for therapeutic approaches. mRNAs encoding allergen molecules represent an attractive tool for preventive vaccination because of the inherent safety features of this vaccine type. Objective: In the current study we investigated whether mRNA constructs would be capable of protecting against type I allergic reactions in a murine model using the grass pollen allergen Phi p 5 and 28 other major pollen, food, animal, mold, and latex allergens. Methods: BALB/c mice were immunized intradermally either with conventional or replicase-based mRNA constructs. Subsequently, animals were sensitized by means of subcutaneous injection of allergen/alum, followed by airway provocation. IgG1/IgG2a/IgE titers were determined by using ELISAs. Allergen-specific functional IgE levels were assessed by using the basophil release assay. Measurement of cytokines in splenocyte cultures and bronchoalveolar lavage fluids were performed by using enzyme-linked immunosorbent spot assays/sandwich ELISAs. Eosinophil and CD8(+) counts in bronchoalveolar lavage specimens were determined by means of flow cytometry. Airway hyperreactivity was assessed with whole-body plethysmography and invasive resistance/dynamic compliance measurement. Results: mRNA vaccination proved its antiallergic efficacy in terms of IgG subclass distribution, functional IgE suppression, reduction of IL-4 and IL-5 levels, induction of IFN-gamma-producing cells, and reduction of airway hyperreactivity and eosinophil counts in the lung. Conclusion: Immunization with mRNA induces T(H)1-biased immune responses similar to those elicited through DNA-based vaccination but additionally offers the advantage of a superior safety profile. Q Allergy Clin Immunol 2009;124:1070-7.)	[Roesler, Elisabeth; Weiss, Richard; Weinberger, Esther E.; Fruehwirth, Angelika; Stoecklinger, Angelika; Ferreira, Fatima; Thalhamer, Josef; Scheiblhofer, Sandra] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, A-5020 Salzburg, Austria; [Mostboeck, Sven] Univ Regensburg, Dept Immunol, Regensburg, Germany	Salzburg University; University of Regensburg	Thalhamer, J (corresponding author), Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	Josef.Thalhamer@sbg.ac.at	Ferreira, Fatima/E-4889-2011; Weiss, Richard/N-7279-2013; Ferreira, Fatima/AAB-4321-2019; Thalhamer, Josef/E-5787-2011	Ferreira, Fatima/0000-0003-0989-2335; Weiss, Richard/0000-0003-3185-7253; Ferreira, Fatima/0000-0003-0989-2335; Thalhamer, Josef/0000-0003-2285-6400; Scheiblhofer, Sandra/0000-0003-2867-9054; Mostbock, Sven/0000-0003-1301-7875	Austrian Science Fund [L181-B13]; Christian Doppler Research Association; Biomay AG, Vienna; Christian Doppler Research Association (CDG); Deutsche Forschungsgemeinschaft; Bayerische Forschungsstiftung; Austrian Science Fund (FWF), Vienna	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay AG, Vienna; Christian Doppler Research Association (CDG); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bayerische Forschungsstiftung; Austrian Science Fund (FWF), Vienna(Austrian Science Fund (FWF))	Supported by the Austrian Science Fund, project no. L181-B13, and the Christian Doppler Research Association.; Disclosure of potential conflict of interest: E. Roesler receives research funding from Biomay AG, Vienna, and Christian Doppler Research Association (CDG), Vienna. R. Weiss receives research funding from Biomay AG, Vienna, and CDG, Vienna. A. Stoecklinger receives research funding from Biomay AG, Vienna, and CDG, Vienna. S. Mostbock receives research support from Deutsche Forschungsgemeinschaft and Bayerische Forschungsstiftung. F. Ferreira receives consulting fees from Biomay AG, Vienna, receives research funding from Biomay AG, Vienna; CDG, Vienna; and Austrian Science Fund (FWF), Vienna. J. Thalhamer receives consulting fees from Biomay AG, Vienna, receives research funding from Biomay AG, Vienna; CDG, Vienna; and FWF, Vienna. S. Scheiblhofer receives research funding from FWF, Vienna.	Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bauer R, 2006, J ALLERGY CLIN IMMUN, V118, P269, DOI 10.1016/j.jaci.2006.03.033; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Carralot JP, 2004, CELL MOL LIFE SCI, V61, P2418, DOI 10.1007/s00018-004-4255-0; Diebold SS, 2009, GENE THER, V16, P359, DOI 10.1038/gt.2008.164; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P334, DOI 10.1016/j.jaci.2007.11.028; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Gabler M, 2006, J ALLERGY CLIN IMMUN, V118, P734, DOI 10.1016/j.jaci.2006.04.048; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hartl A, 2004, METHODS, V32, P328, DOI 10.1016/j.ymeth.2003.08.014; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; Khromykh AA, 2000, CURR OPIN MOL THER, V2, P555; Leitner WW, 2004, VACCINE, V22, P1537, DOI 10.1016/j.vaccine.2003.10.013; Medjitna TDE, 2006, DEV BIOLOGICALS, V126, P261; MEDJITNA TD, 2006, DEV BIOL BASEL, V126, P327; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; RENZ H, 1994, J IMMUNOL, V152, P351; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Scheiblhofer S, 2006, ALLERGY, V61, P828, DOI 10.1111/j.1398-9995.2006.01142.x; Scheiblhofer S, 2007, MOL IMMUNOL, V44, P1879, DOI 10.1016/j.molimm.2006.09.023; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P469, DOI 10.1016/S0091-6749(98)70137-X; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; von Herrath MG, 2003, TRENDS IMMUNOL, V24, P290, DOI 10.1016/S1471-4906(03)00121-2; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Weiss R, 2006, INT ARCH ALLERGY IMM, V139, P332, DOI 10.1159/000091946; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836; Yamamoto S, 2004, AM J RESP CELL MOL, V31, P456, DOI 10.1165/rcmb.2004-0128OC; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548	35	50	62	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1070	1077		10.1016/j.jaci.2009.06.036	http://dx.doi.org/10.1016/j.jaci.2009.06.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665781	Bronze			2022-12-18	WOS:000272108000030
J	Tsai, CL; Sullivan, AF; Gordon, JA; Kaushal, R; Magid, DJ; Blumenthal, D; Camargo, CA				Tsai, Chu-Lin; Sullivan, Ashley F.; Gordon, James A.; Kaushal, Rainu; Magid, David J.; Blumenthal, David; Camargo, Carlos A., Jr.			Quality of care for acute asthma in 63 US emergency departments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; emergency department; guidelines; quality of care	HEALTH-CARE; ADULTS; GUIDELINES; ADMISSION; ADHERENCE; OUTCOMES	Background: Little is known about the quality of acute asthma care in the emergency department (ED). Objectives: We sought to determine the concordance of ED management of acute asthma with National Institutes of Health asthma guidelines, to identify ED characteristics predictive of higher guideline concordance, and to assess whether guideline concordance was associated with hospital admission. Methods: We conducted a retrospective chart review study of acute asthma as part of the National Emergency Department Safety Study. Using a principal diagnosis of asthma, we identified ED visits for acute asthma in 63 urban EDs in 23 US states between 2003 and 2006. Concordance with guideline recommendations was evaluated by using item-by-item quality measures and composite concordance scores both at the patient and ED level. These scores ranged from 0 to 100, with 100 indicating perfect concordance. Results: The cohort consisted of 4,053 subjects; their median age was 34 years, and 64% were women. The overall patient guideline concordance score was 67 (interquartile range, 63-83), and the ED concordance score was 71 (SD, 7). Multivariable analysis showed southern EDs were associated with lower ED concordance scores (beta-coefficient, -8.2; 95% CI, -13.8 to -2.7) compared with northeastern EDs. After adjustment for the severity on ED presentation, patients who received all recommended treatments had a 46% reduction in the risk of hospital admission compared with others. Conclusions: Concordance with treatment recommendations in the National Institutes of Health asthma guidelines was moderate. Significant variations in ED quality of asthma care were found, and geographic differences existed. Greater concordance with guideline-recommended treatments might reduce hospitalizations. (J Allergy Clin Immunol 2009;123:354-61.)	[Tsai, Chu-Lin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Emergency Med Network Coordinating Ctr,Dept Emerg, Boston, MA 02114 USA; [Blumenthal, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA; [Kaushal, Rainu] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Kaushal, Rainu] New York Presbyterian Hosp, New York, NY USA; [Magid, David J.] Univ Colorado, Hlth Sci Ctr, Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA; [Magid, David J.] Univ Colorado, Hlth Sci Ctr, Dept Emergency Med, Aurora, CO USA; [Magid, David J.] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Aurora, CO USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Cornell University; NewYork-Presbyterian Hospital; Kaiser Permanente; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Tsai, CL (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Emergency Med Network Coordinating Ctr,Dept Emerg, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	cltsai@post.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; TSAI, CHU-LIN/0000-0003-4639-1513	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084401] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS013099] Funding Source: Medline; NHLBI NIH HHS [R01 HL084401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINBANI L, 2003, ASTHM PREV HLTH CAR; [Anonymous], 1985, THEORETICAL EPIDEMIO; [Anonymous], 2001, CROSS QUAL CHASM NEW; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; *DEP HLTH HUM SERV, INT CLASS DIS 9 REV, V1; Emond SD, 1999, ANN EMERG MED, V34, P321, DOI 10.1016/S0196-0644(99)70125-3; Gelfand EW, 2006, ANN ALLERG ASTHMA IM, V97, P298, DOI 10.1016/S1081-1206(10)60793-4; Ginde AA, 2008, J ALLERGY CLIN IMMUN, V122, P313, DOI 10.1016/j.jaci.2008.04.024; Halm EA, 2005, CHEST, V128, P1943, DOI 10.1378/chest.128.4.1943; Hosmer W., 2000, APPL LOGISTIC REGRES, V2nd ed.; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Kelly AM, 2004, RESP MED, V98, P777, DOI 10.1016/j.rmed.2004.01.008; Masoudi FA, 2006, CIRCULATION, V114, P1565, DOI 10.1161/CIRCULATIONAHA.106.623652; McDermott MF, 2006, ACAD EMERG MED, V13, P345, DOI 10.1197/j.aem.2005.09.006; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; Mularski RA, 2006, CHEST, V130, P1844, DOI 10.1378/chest.130.6.1844; *NAT ASTHM ED PREV, 1991, GUIDL DIAGN MAN ASTH; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Asthma Education Prevention Program (National Heart Lung and Blood Institute), 1997, 2 NAT ASTHM ED PREV; Navaratnam P, 2008, ANN ALLERG ASTHMA IM, V100, P216, DOI 10.1016/S1081-1206(10)60445-0; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; *OFF MAN BUDG, STAND DEF METR AR; Panageas KS, 2003, ANN INTERN MED, V139, P658, DOI 10.7326/0003-4819-139-8-200310210-00009; Radeos MS, 2004, AM J EMERG MED, V22, P516, DOI 10.1016/j.ajem.2004.08.018; Reeves D, 2007, MED CARE, V45, P489, DOI 10.1097/MLR.0b013e31803bb479; Rowe B H, 2001, Respir Care, V46, P1380; Rowe BH, 2008, CAN RESPIR J, V15, P20, DOI 10.1155/2008/431390; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; *SOC AC EM MED, GRAD MED ED; Sullivan AF, 2007, ACAD EMERG MED, V14, P1182, DOI [10.1197/j.aem.2007.07.014, 10.1111/j.1553-2712.2007.tb02341.x]; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; Weber EJ, 2002, AM J MED, V113, P371, DOI 10.1016/S0002-9343(02)01242-1; Wu AW, 2001, ARCH INTERN MED, V161, P2554, DOI 10.1001/archinte.161.21.2554; Yealy DM, 2005, ANN INTERN MED, V143, P881, DOI 10.7326/0003-4819-143-12-200512200-00006; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	37	50	51	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					354	361		10.1016/j.jaci.2008.10.051	http://dx.doi.org/10.1016/j.jaci.2008.10.051			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19070357	Green Accepted			2022-12-18	WOS:000263495000010
J	Setkowicz, M; Mastalerz, L; Podolec-Rubis, M; Sanak, M; Szczeklik, A				Setkowicz, Malgorzata; Mastalerz, Lucyna; Podolec-Rubis, Magdalena; Sanak, Marek; Szczeklik, Andrzej			Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria; aspirin-induced urticaria; aspirin sensitivity; eicosanoids; leukotriene E-4; prostaglandin D-2	CHRONIC IDIOPATHIC URTICARIA; BRONCHIAL-ASTHMA; HYPERSENSITIVITY; MARKER; AUTOANTIBODIES; INTOLERANCE; MANAGEMENT; ANGIOEDEMA; GUIDELINE	Background: Little is known about the course of aspirin-induced urticaria. A special regulatory role of cysteinyl leukotrienes and prostaglandin D-2 (PGD(2)) has been postulated. Objective: We performed a long-term observation on clinical course, aspirin sensitivity, and urinary eicosanoids in patients with aspirin-induced urticaria. Methods: For 4 years, we followed up 22 patients with chronic idiopathic urticaria and aspirin hypersensitivity who restrained from the use of aspirin and other COX-I inhibitors. Aspirin challenges were performed in 2002 (all results were positive) and repeated in 2006. Levels of urinary leukotriene E-4 (LTE4) and the main PGD2 metabolite, 9 alpha 11 beta PGF(2), were measured at the same time points. Results: During the follow-up period, the severity of urticaria has decreased. In 14 of 22 patients, the results of aspirin challenge remained positive. In 2002, these 14 patients responded to aspirin with a significant increase in urinary LTE4 and 9 alpha 11 beta PGF(2) levels. When studied 4 years later, they showed a similar response of 9 alpha 11 beta PGF(2) (P = .047) and a tendency toward an increase in LTE4 level (P = .057). There was a correlation between the urinary LTE4 concentration after aspirin challenge and the intensity of skin eruptions. The dose of aspirin had no effect on the magnitude of response of both LTE4 and the PGD2 metabolite. In the remaining 8 patients, negative aspirin challenge results were not associated with changes in the urinary eicosanoids studied. Conclusions: Aspirin hypersensitivity manifesting as urticaria/angioedema remains present after 4 years in about two thirds of patients. Aspirin-precipitated skin reactions associate with increased excretion of LTE4 and PGD(2). (J Allergy Clin Immunol 2009;123:174-8.)	[Mastalerz, Lucyna; Sanak, Marek; Szczeklik, Andrzej] Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland; [Setkowicz, Malgorzata; Podolec-Rubis, Magdalena] Jagiellonian Univ, Sch Med, Dept Dermatol, PL-31066 Krakow, Poland	Jagiellonian University; Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.	mmszczek@cyf-kr.edu.pl	Mastalerz, Lucyna/U-5974-2018; Sanak, Marek/AAV-1628-2021	Mastalerz, Lucyna/0000-0002-8994-0036; Sanak, Marek/0000-0001-7635-8103				Asero R, 2007, CLIN EXP DERMATOL, V32, P661, DOI 10.1111/j.1365-2230.2007.02464.x; Asero R, 2002, ANN ALLERG ASTHMA IM, V88, P468, DOI 10.1016/S1081-1206(10)62384-8; Bochenek G, 2004, THORAX, V59, P459, DOI 10.1136/thx.2003.013573; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Grattan CEH, 2007, BRIT J DERMATOL, V157, P1116, DOI 10.1111/j.1365-2133.2007.08283.x; Greaves MW, 2007, CLIN REV ALLERG IMMU, V33, P134, DOI 10.1007/s12016-007-0038-3; GRZELEWSKARZYMOWSKA I, 1988, ALLERGOL IMMUNOPATH, V16, P305; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; 예영민, 2005, 천식 및 알레르기, V25, P194; Kim SH, 2005, CLIN EXP ALLERGY, V35, P339, DOI 10.1111/j.1365-2222.2004.02197.x; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; Mastalerz L, 2006, BRIT J DERMATOL, V154, P256, DOI 10.1111/j.1365-2133.2005.06851.x; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; SANCHEZBORGES M, 2003, ACI INT, V15, P110; Stevenson DD, 2003, MIDDLETONS ALLERGY P, P1695; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; Zembowicz A, 2004, J CUTAN PATHOL, V31, P323, DOI 10.1111/j.0303-6987.2004.0195.x; Zembowicz A, 2003, ARCH DERMATOL, V139, P1577, DOI 10.1001/archderm.139.12.1577; Zuberbier T, 2006, ALLERGY, V61, P321, DOI 10.1111/j.1398-9995.2006.00962.x	23	50	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					174	178		10.1016/j.jaci.2008.09.005	http://dx.doi.org/10.1016/j.jaci.2008.09.005			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18842291	Green Submitted			2022-12-18	WOS:000262793900029
J	Nurmatov, U; Worth, A; Sheikh, A				Nurmatov, Ulugbek; Worth, Allison; Sheikh, Aziz			Anaphylaxis management plans for the acute and long-term management of anaphylaxis: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						anaphylaxis; acute management; long-term condition; self-management	INJECTABLE EPINEPHRINE; CHILDREN; ALLERGY; ADRENALINE; CHILDHOOD; SCHOOLCHILDREN; EPIDEMIOLOGY; COMMUNITY; KNOWLEDGE; SEVERITY	Background: Anaphylaxis management plans (AMPs) are increasingly advocated to improve outcomes and reduce the risk of recurrence in persons with anaphylaxis. A recent systematic review investigating their effectiveness failed to identify any randomized controlled trial evidence to guide clinical decision making. Objectives: We sought to identify and describe available AMPs, assess their acceptability and likely effectiveness, and understand potential facilitators and barriers to their use. Methods: We performed a systematic review of published, unpublished, and ongoing epidemiologic and qualitative studies, searching 13 international databases and contacting an international panel of anaphylaxis experts. Studies were critically appraised using established international criteria and thematically synthesized. Results: Nineteen of 789 potentially eligible studies identified satisfied our inclusion criteria. A number of AMPs exist, and other than agreement on the central importance of early administration of self-administered epinephrine, there is a range of perspectives on what should be included. AMPs are acceptable to patients/caregivers and might considerably reduce the risk of recurrence. This latter finding needs to be interpreted with caution given the substantial risk of bias in the limited number of intervention studies conducted. Access to specialists, problems with follow-up, and indemnity considerations relating to emergency administration of epinephrine in schools are important structural barriers to their wider use. Conclusions: There are currently no universally accepted AMPs. The available evidence to support use of self-management plans is encouraging but is, in comparison with other long-term conditions, such as asthma, extremely weak. The effectiveness and cost-effectiveness of AMPs need to be formally evaluated.	[Nurmatov, Ulugbek; Worth, Allison; Sheikh, Aziz] Univ Edinburgh, Gen Practice Sect, Allergy & Resp Res Grp, Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Gen Practice Sect, Allergy & Resp Res Grp, Div Community Hlth Sci, 20 W Richmond St, Edinburgh EH8 9DX, Midlothian, Scotland.	sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056	Chief Scientist Office [CZG/2/296] Funding Source: researchfish	Chief Scientist Office		Akeson N, 2007, CLIN EXP ALLERGY, V37, P1213, DOI 10.1111/j.1365-2222.2007.02758.x; Antoine L C, 2001, Allerg Immunol (Paris), V33, P357; Blyth TP, 2002, ARCH DIS CHILD, V86, P26, DOI 10.1136/adc.86.1.26; Brown SGA, 2006, MED J AUSTRALIA, V185, P283, DOI 10.5694/j.1326-5377.2006.tb00563.x; *CASP, APPR TOOLS; Choo K, 2007, CLIN EXP ALLERGY, V37, P1090, DOI 10.1111/j.1365-2222.2007.02711.x; CLEGG SK, 2001, AMBUL CHILD HLTH, V7, P169; *COCHR EFF PRACT O, METH PAP; COCHRANE AL, 2004, EFFECTIVENESS EFFICI; Colver A, 2006, BMJ-BRIT MED J, V333, P494, DOI 10.1136/bmj.333.7566.494; Cresswell KM, 2008, J ALLERGY CLIN IMMUN, V121, P1112, DOI 10.1016/j.jaci.2007.12.1180; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Hannaway PJ, 2005, ANN ALLERG ASTHMA IM, V95, P143, DOI 10.1016/S1081-1206(10)61203-3; Hayman GR, 2003, BRIT MED J, V327, P1328, DOI 10.1136/bmj.327.7427.1328; Hourihane JO, 2007, CLIN EXP ALLERGY, V37, P967, DOI 10.1111/j.1365-2222.2007.02754.x; Kapoor S, 2004, ALLERGY, V59, P185, DOI 10.1046/j.1398-9995.2003.00365.x; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; Kim JS, 2005, J ALLERGY CLIN IMMUN, V116, P164, DOI 10.1016/j.jaci.2005.03.039; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lieberman P, 2007, ANN ALLERG ASTHMA IM, V98, P519, DOI 10.1016/S1081-1206(10)60729-6; Litarowsky Jean A, 2004, J Sch Nurs, V20, P279; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Murphy KR, 2006, ANN ALLERG ASTHMA IM, V96, P398, DOI 10.1016/S1081-1206(10)60906-4; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Patel BM, 2006, ANN ALLERG ASTHMA IM, V97, P813, DOI 10.1016/S1081-1206(10)60974-X; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Powers Jill, 2007, J Sch Nurs, V23, P252; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; RAE J, 2007, DOES PRESCRIBING ADR; Rankin KE, 2006, PLOS MED, V3, P1429, DOI 10.1371/journal.pmed.0030326; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Sicherer SH, 2007, PEDIATRICS, V119, P638, DOI 10.1542/peds.2006-3689; Simons FER, 2007, ALLERGY, V62, P827, DOI 10.1111/j.1398-9995.2007.01433.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]	46	50	52	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					353	361		10.1016/j.jaci.2008.05.028	http://dx.doi.org/10.1016/j.jaci.2008.05.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18572231	Bronze			2022-12-18	WOS:000258426300023
J	Vogel, K; Blumer, N; Korthals, M; Mittelstadt, J; Garn, H; Ege, M; von Mutius, E; Gatermann, S; Bufe, A; Goldmann, T; Schwaiger, K; Renz, H; Brandau, S; Bauer, J; Heine, H; Holst, O				Vogel, Kay; Bluemer, Nicole; Korthals, Melanie; Mittelstaedt, Jessica; Garn, Holger; Ege, Markus; von Mutius, Erika; Gatermann, Soeren; Bufe, Albrecht; Goldmann, Torsten; Schwaiger, Karin; Renz, Harald; Brandau, Sven; Bauer, Johann; Heine, Holger; Holst, Otto			Animal shed Bacillus licheniformis spores possess allergy-protective as well as inflammatory properties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy protection; animal shed dust; hygiene hypothesis; Bacillus licheniformis spores; ovalbumin mouse model	COMPLETE GENOME SEQUENCE; REGULATORY T-CELLS; DENDRITIC CELLS; INNATE IMMUNITY; TLR LIGANDS; ASTHMA; RECEPTORS; EXPOSURE; DUST; ENVIRONMENT	Background: Numerous epidemiologic studies have demonstrated an allergy-protective effect of farm life early in childhood. It has been hypothesized that environmental exposure to microbes may contribute to this effect. Because of their small size and thereby their potential for deposition in lower airways of small children, bacterial spores may be candidates for such allergy-protective effects. Objective: To investigate immune responses elicited by exposure to Bacillus spores in experimental settings. Methods: Animal shed and mattress dusts were analyzed for bacteria and fungi by aerobic and anaerobic growth. Bacillus licheniformis, the most prominent microorganism found in these samples, was investigated with respect to spore specific stimulation of pattern recognition receptors, monocyte-derived dendritic cells and T-H-cell polarization in vitro as well as to the prevention of asthma development in a mouse model of allergic asthma. Results: In vitro, B licheniformis spores activated a T(H)1 cytokine expression profile. In vivo application of these spores resulted in less spore-specific but long-lasting immune activation preventing eosinophilia and goblet cell hyperplasia; however, they provoked an influx of neutrophils in lung tissue of asthmatic mice. Conclusion: Bacterial spores may contribute to the allergy-protective properties of farming environments, but their persistence in the lung causes ongoing immune activation in mouse experiments.	[Vogel, Kay; Holst, Otto] Leibniz Ctr Med & Biosci, Div Struct Biochem, Res Ctr Borstel, D-23845 Borstel, Germany; [Mittelstaedt, Jessica; Brandau, Sven] Leibniz Ctr Med & Biosci, Div Immunotherapy, Res Ctr Borstel, D-23845 Borstel, Germany; [Goldmann, Torsten] Leibniz Ctr Med & Biosci, Div Clin & Expt Pathol, Res Ctr Borstel, D-23845 Borstel, Germany; [Bluemer, Nicole; Garn, Holger; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, Fac Med, Marburg, Germany; [Korthals, Melanie; Schwaiger, Karin; Bauer, Johann] Tech Univ Munich, Fac Life & Food Sci, D-8050 Freising Weihenstephan, Germany; [Ege, Markus; von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Gatermann, Soeren] Ruhr Univ Bochum, Inst Hyg & Microbiol, Dept Med Microbiol, Bochum, Germany; [Bufe, Albrecht] Ruhr Univ Bochum, Dept Expt Pneumol, Bochum, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; Philipps University Marburg; Technical University of Munich; University of Munich; Ruhr University Bochum; Ruhr University Bochum	Holst, O (corresponding author), Leibniz Ctr Med & Biosci, Div Struct Biochem, Res Ctr Borstel, Pk Allee 4A, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Ege, Markus/C-1962-2012; Heine, Holger/H-4552-2012; Goldmann, Torsten/E-5906-2010	Ege, Markus/0000-0001-6643-3923; Heine, Holger/0000-0001-8128-5068; Goldmann, Torsten/0000-0002-1621-560X; Garn, Holger/0000-0002-5178-4023; Bufe, Albrecht/0000-0001-7335-9362; von Mutius, Erika/0000-0002-8893-4515; Brandau, Sven/0000-0002-2702-4163				Andersson AM, 1999, J APPL MICROBIOL, V86, P622, DOI 10.1046/j.1365-2672.1999.00706.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Blach-Olszewska Z, 2005, ARCH IMMUNOL THER EX, V53, P245; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Driks A, 2003, P NATL ACAD SCI USA, V100, P3007, DOI 10.1073/pnas.0730807100; Duc LH, 2004, VACCINE, V22, P1873, DOI 10.1016/j.vaccine.2003.11.021; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Errington J, 2003, NAT REV MICROBIOL, V1, P117, DOI 10.1038/nrmicro750; Hawrylowicz CM, 2005, J EXP MED, V202, P1459, DOI 10.1084/jem.20052211; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; LARONE D, 2002, MED IMPORTATN FUNGI; LOGAN NA, 2003, MANUAL CLIN MICROBIO, P445; MADURA LJ, 2007, IMMUNOLOGY, V121, P276; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Mosmann TR, 2005, J IMMUNOL, V175, P5; Most J, 1997, BLOOD, V89, P662, DOI 10.1182/blood.V89.2.662; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; Relman David A., 1993, P489; Revets H, 2005, J IMMUNOL, V174, P1097, DOI 10.4049/jimmunol.174.2.1097; Rey MW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r77; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Sel S, 2007, J IMMUNOL, V178, P7805, DOI 10.4049/jimmunol.178.12.7805; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Sun J, 2005, J IMMUNOL, V174, P742, DOI 10.4049/jimmunol.174.2.742; TISA LS, 1982, APPL ENVIRON MICROB, V43, P1307, DOI 10.1128/AEM.43.6.1307-1310.1982; Veith B, 2004, J MOL MICROB BIOTECH, V7, P204, DOI 10.1159/000079829; von Mutius Erika, 2007, Proc Am Thorac Soc, V4, P212, DOI 10.1513/pats.200701-028AW; Vremec D, 2007, BLOOD, V109, P1165, DOI 10.1182/blood-2006-05-015354; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wittkowski M, 2007, J BIOL CHEM, V282, P19103, DOI 10.1074/jbc.M611551200	35	50	52	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					307	312		10.1016/j.jaci.2008.05.016	http://dx.doi.org/10.1016/j.jaci.2008.05.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18582924	Bronze			2022-12-18	WOS:000258426300015
J	Wagner, S; Radauer, C; Bublin, M; Mann-Sommergruber, KH; Kopp, T; Greisenegger, EK; Vogel, L; Vieths, S; Scheiner, O; Breiteneder, H				Wagner, Stefan; Radauer, Christian; Bublin, Merima; Mann-Sommergruber, Karin Hoff; Kopp, Tamara; Greisenegger, Elli K.; Vogel, Lothar; Vieths, Stefan; Scheiner, Otto; Breiteneder, Heimo			Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bet v 1; Bet v 1.0101; Bet v 1.0401; Bet v 1.1001; isoforms; birch pollen allergy; hypoallergenic variant	IMMUNE-RESPONSES; MAJOR ALLERGEN; IN-VIVO; IMMUNOTHERAPY; IMMUNIZATION; DERIVATIVES; MECHANISMS; REACTIVITY; CELLS	Background: Engineered hypoallergens are currently being investigated for specific immunotherapy of allergic diseases in preclinical and clinical studies. Naturally occurring hypoallergens have by and large not been considered as a source of vaccine candidates. Objective: Evaluation of the antibody response in atopic individuals induced by birch pollen containing isoforms of the major birch pollen allergen Bet v 1. Methods: Isoform-specific antibody isotype responses for Bet v 1.0101, Bet v 1.0401, and Bet v 1.1001 were determined for 35 sera of individuals with birch pollen allergy. Isoform structures were compared and related to IgE-binding inhibitory capacities and induction of mediator release in human Fc epsilon receptor transformed rat basophilic leukemia cells. Results: Bet v 1.0101 induced a predominant IgE response, whereas the significant highest levels of IgG(4) antibodies were directed against Bet v 1.0401. Bet v 1.1001 induced only a minimal antibody response. Structural comparisons revealed that most of the amino acid differences between the isoforms were located on the protein surfaces. IgE induced by Bet v 1.0101 only partly cross-reacted with the 2 other isoforms and bound to them with notably lower affinity. Bet v 1.0401 and Bet v 1.1001 also were poor inducers of mediator release. Conclusion: Bet v I isoforms possess highly variant immunogenic and allergenic properties. Bet v 1.0101 acts as the sensitizing agent, whereas Bet v 1.0401 and Bet v 1.1001 can induce only a minimal IgE response.	[Wagner, Stefan; Radauer, Christian; Bublin, Merima; Mann-Sommergruber, Karin Hoff; Scheiner, Otto; Breiteneder, Heimo] Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, A-1090 Vienna, Austria; [Kopp, Tamara] Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, Vienna, Austria; [Vogel, Lothar; Vieths, Stefan] Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany	Medical University of Vienna; Medical University of Vienna; Paul Ehrlich Institute	Breiteneder, H (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Austria EBO 3Q,Waehringer guertel 18-20, A-1090 Vienna, Austria.	heimo.breiteneder@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449; Greisenegger, Elli/0000-0002-6734-054X; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Bublin, Merima/0000-0002-7191-9431				Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Arquint O, 1999, J ALLERGY CLIN IMMUN, V104, P1239, DOI 10.1016/S0091-6749(99)70019-9; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1690, DOI 10.1046/j.1365-2222.2002.01463.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Hartl A, 1999, INT ARCH ALLERGY IMM, V120, P17, DOI 10.1159/000024216; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Reese G, 2007, J ALLERGY CLIN IMMUN, V119, P944, DOI 10.1016/j.jaci.2006.11.699; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Schenk MF, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-168; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Wing K, 2006, CURR OPIN ALLERGY CL, V6, P482, DOI 10.1097/01.all.0000246625.79988.12	22	50	55	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					246	252		10.1016/j.jaci.2007.08.006	http://dx.doi.org/10.1016/j.jaci.2007.08.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17889932				2022-12-18	WOS:000252372000038
J	Adedoyin, J; Gronlund, H; Oman, H; Johansson, SGO; van Hage, M				Adedoyin, Justus; Gronlund, Hans; Oman, Hans; Johansson, S. G. O.; van Hage, Marianne			Cat IgA, representative of new carbohydrate cross-reactive allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergy; IgA; IgM; cross-reactive; carbohydrates; cat allergen	MAMMALIAN ORIGIN; MAJOR ALLERGEN; POLLEN; ANTIBODIES; MOIETY; EPITOPE; VENOM; IDENTIFICATION; GLYCOPROTEINS; PROTEINS	Background: Allergens from cat are among the most potent elicitors of allergic disease. Four cat allergens have been identified; however, evidence indicates the existence of additional allergens. Objective: In this study, we evaluated IgE sensitization to IgA from cat. Methods: Sera from cat-sensitized patients (n = 81) were analyzed for IgE antibodies to purified cat IgA in the Pharmacia CAP System. Indirect ELISA was performed with cat IgA, cat IgM, and deglycosylated cat IgA. Competitive inhibition ELISA was performed with cat IgA, cat IgM, calf intestine alkaline phosphatase (CIP), and cat serum albumin on solid phase bound cat IgA. IgE reactivity was also evaluated on membrane blotted cat IgA. Results: Thirty-eight percent (31/81) of the cat-sensitized sera were ImmunoCAP-positive to cat IgA. Indirect ELISA demonstrated a high correlation between IgE reactivity to cat IgA and cat IgM (r = 0.94; P < .001). Very low responses were observed to deglycosylated IgA. Strong inhibition of cat IgA was observed in all sera after preincubation with cat IgA and cat IgM. Inhibition was also observed in most sera after preincubation with CIP. Immunoblotting demonstrated that the IgE reactivity was mainly directed to the heavy chain of IgA. Conclusion: This study has revealed a new allergen, cat IgA, containing a novel group of cross-reactive epitopes depending on carbohydrates also present on IgM and partially on CIP. Clinical implications: This new group of cross-reactive carbohydrate IgE epitopes should be taken into consideration when diagnosing patients with suspected animal allergy.	Karolinska Univ Hosp, Clin Immunol & Allergy Unit, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; MIAB, Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Adedoyin, J (corresponding author), Karolinska Univ Hosp, Clin Immunol & Allergy Unit, S-17176 Stockholm, Sweden.	justus.adedoyin@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Gronlund, Hans/0000-0003-4882-7624				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Adedoyin J, 2006, J IMMUNOL METHODS, V310, P117, DOI 10.1016/j.jim.2006.01.001; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bublitz R, 2001, J MASS SPECTROM, V36, P960, DOI 10.1002/jms.200; Erwin EA, 2003, IMMUNOL ALLERGY CLIN, V23, P469, DOI 10.1016/S0889-8561(03)00004-3; Gallagher S., 1999, CURRENT PROTOCOLS MO, p1012A11, DOI DOI 10.12A.11-10.12A.29; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; GJESING B, 1984, ANN ALLERGY, V53, P602; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Harley R, 1998, VET IMMUNOL IMMUNOP, V65, P99, DOI 10.1016/S0165-2427(98)00146-9; Ichikawa K, 2001, INT ARCH ALLERGY IMM, V124, P55, DOI 10.1159/000053667; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OKOSHI S, 1967, Japanese Journal of Veterinary Science, V29, P337; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Reininger R, 2003, CLIN EXP ALLERGY, V33, P1695, DOI 10.1111/j.1365-2222.2003.01817.x; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VAERMAN JP, 1973, RES IMMUNOCHEMISTRY, P91; VAERMAN JP, 1970, STUDIES IGA IMMUNOGL; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	28	50	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					640	645		10.1016/j.jaci.2006.11.637	http://dx.doi.org/10.1016/j.jaci.2006.11.637			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336613	Bronze			2022-12-18	WOS:000244925000017
J	Wu, XQ; Myers, AC; Goldstone, AC; Togias, A; Sanico, AM				Wu, XinQun; Myers, Allen C.; Goldstone, Andrew C.; Togias, Alkis; Sanico, Alvin M.			Localization of nerve growth factor and its receptors in the human nasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nerve growth factor; TrkA; p75; NGF receptors; rhinitis; mast cells; eosinophils; submucosal glands; sensory nerves; epithelium	T-CELL-CLONES; MAST-CELLS; TOPICAL TREATMENT; RELEASE; NEUROTROPHIN; EXPRESSION; HYPERRESPONSIVENESS; EOSINOPHILS; HISTAMINE; ALLERGEN	Background: Nerve growth factor (NGF) is a pluripotent mediator, the levels of which are elevated in nasal lavage fluids of individuals with allergic rhinitis at baseline. Levels of NGF increase after allergen challenge. Objective: In the current study, we tested the hypotheses that mast cells are the main source of human nasal NGF, and that NGF can potentially affect mucosal elements other than nerves. Methods: Immunostaining with antibodies against NGF, tryptase, CD3, eosinophil cationic protein, and the high-affinity (tyrosine kinase A) and low-affinity (p75) receptors for NGF was performed by using human nasal turbinate sections. Results: Double immunofluorescence staining demonstrated NGF in only 2% (median) (1.3, 2.3; 25th, 75th percentiles) of mast cells, 0.2% (0, 0.4) of T cells, but in 62.2% (56.5, 68) of activated eosinophils. With immunohistology, NGF expression was consistently strongest in the submucosal glands and lesser in the epithelial lining. Both high-affinity and low-affinity receptors for NGF were localized not only on nerves, as expected, but also on nasal epithelium, submucosal glands, and some interstitial cells, but not on vascular endothelium. Conclusion: This study demonstrates that submucosal glands, nasal epithelium, and eosinophils constitute the major sources of NGF in the human nasal mucosa. That NGF receptors are found in cells other than nerves supports the notion that the role of this neurotrophin is broader than simple modulation of the sensorineural system. Clinical implications: The distribution of NGF and its receptors and its established release during allergic reactions suggest that this factor participates in the pathophysiology of allergic rhinitis.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Resp & Crit Care Med, Baltimore, MD 21218 USA; Greater Baltimore Med Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Greater Baltimore Medical Center	Togias, A (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Unit Off 7,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	atogias@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001799] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI 01799-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; Bierl MA, 2005, NEUROSCI LETT, V380, P133, DOI 10.1016/j.neulet.2005.01.029; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Bronzetti E, 1995, ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY, VOL 100 - SUPPLEMENT N.1 - 1995, P565; De Vicente JC, 1998, ANN ANAT, V180, P157, DOI 10.1016/S0940-9602(98)80016-2; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541, DOI 10.1164/ajrccm.159.5.9808058; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; FAHNESTOCK M, 1991, CURR TOP MICROBIOL, V165, P1; Fahnestock M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/j.1471-4159.2004.02360.x; Hoglund CO, 2002, EUR RESPIR J, V20, P1110, DOI 10.1183/09031936.02.00205402; Hoglund CO, 2002, PULM PHARMACOL THER, V15, P51, DOI 10.1006/pupt.2001.0314; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; Lambiase A, 1998, NEW ENGL J MED, V338, P1174, DOI 10.1056/NEJM199804233381702; Landi F, 2003, ANN INTERN MED, V139, P635, DOI 10.7326/0003-4819-139-8-200310210-00006; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Matsuda H, 1998, J EXP MED, V187, P297, DOI 10.1084/jem.187.3.297; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202, DOI 10.1152/jappl.1999.86.4.1202; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; Sanico AM, 1999, INT ARCH ALLERGY IMM, V118, P154, DOI 10.1159/000024054; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; Shibayama E, 1996, AM J PATHOL, V148, P1807; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; Xiang Z, 2000, CLIN EXP ALLERGY, V30, P1379, DOI 10.1046/j.1365-2222.2000.00906.x	32	50	58	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					428	433		10.1016/j.jaci.2006.04.037	http://dx.doi.org/10.1016/j.jaci.2006.04.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890768				2022-12-18	WOS:000239877700019
J	Barnes, KC				Barnes, KC			Genetic epidemiology of health disparities in allergy and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergy; genetics; disparities; ethnicity	ACUTE-CHEST-SYNDROME; OXIDE SYNTHASE GENE; SICKLE-CELL-DISEASE; LIPOPOLYSACCHARIDE RECEPTOR CD14; SCHISTOSOMA-MANSONI INFECTION; INTERFERON-GAMMA RECEPTOR; SEVERE HEPATIC-FIBROSIS; HOUSE-DUST MITE; NITRIC-OXIDE; AFRICAN-AMERICANS	The striking racial and ethnic disparities in disease prevalence for common disorders, such as allergic asthma, cannot be explained entirely by environmental, social, cultural, or economic factors, and genetic factors should not be ignored. Unfortunately, genetic studies in underserved minorities are hampered by disagreements over the biologic construct of race and logistic issues, including admixture of different races and ethnicities. Current observations suggest that the frequency of high-risk variants in candidate genes can differ between African Americans, Puerto Ricans, and Mexican Americans, and this might contribute to the differences in disease prevalence. Maintenance of certain allelic variants in the population over time might reflect selective pressures in previous generations. For example, significant associations between markers in certain candidate genes (eg, STAT6, ADRB2, and IFNGR1) for traits such as high total IgE levels observed in resistance to extracellular parasitic disease in one population and atopic asthma in another supports the common disease/common variant model for disease. Herein is a discussion of how genetic variants might explain, at least in part, the marked disparities observed in risk to allergic asthma.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL066583] Funding Source: Medline; NIAID NIH HHS [AI50024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 2004, NAT GENET S11, V36, pS1; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Ashley-Koch A, 2000, AM J EPIDEMIOL, V151, P839; Asturias JA, 1999, J IMMUNOL, V162, P4342; Baharloo S, 2000, AM J HUM GENET, V67, P755, DOI 10.1086/303057; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bertranpetit J, 2003, COLD SPRING HARB SYM, V68, P79, DOI 10.1101/sqb.2003.68.79; Blanton RE, 2005, EUR J HUM GENET, V13, P660, DOI 10.1038/sj.ejhg.5201388; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Caggana M, 1999, GENET MED, V1, P267; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; Cavalli-Sforza L L, 1994, HIST GEOGRAPHY HUMAN; Chen W, 2004, AM J HYPERTENS, V17, P553, DOI 10.1016/j.amjhyper.2004.02.021; Chevillard C, 2003, J IMMUNOL, V171, P5596, DOI 10.4049/jimmunol.171.10.5596; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Cossrow N, 2004, J CLIN ENDOCR METAB, V89, P2590, DOI 10.1210/jc.2004-0339; COWIE CC, 1993, AM J EPIDEMIOL, V137, P719, DOI 10.1093/oxfordjournals.aje.a116732; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; Djilali-Saiah I, 1998, GUT, V43, P187, DOI 10.1136/gut.43.2.187; Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130; Drayna D, 2001, SCIENCE, V291, P1969, DOI 10.1126/science.291.5510.1969; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Else KJ, 1998, INT J PARASITOL, V28, P1145, DOI 10.1016/S0020-7519(98)00087-3; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Gao PS, 1999, CLIN GENET, V56, P164; Gao PS, 2000, J MED GENET, V37, P380; Gao PS, 1999, BIOCHEM BIOPH RES CO, V263, P425, DOI 10.1006/bbrc.1999.1368; Gibot S, 2002, CRIT CARE MED, V30, P969, DOI 10.1097/00003246-200205000-00003; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; Goodman JE, 2004, CARCINOGENESIS, V25, P2467, DOI 10.1093/carcin/bgh260; Gould S.J., 1981, MISMEASURE MAN; Grasemann H, 1999, HUM HERED, V49, P139, DOI 10.1159/000022861; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; HAGAN P, 1992, ALLERGY IMMUNITY HEL; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Henderson SO, 2004, AM J MED SCI, V328, P266, DOI 10.1097/00000441-200411000-00006; Henri S, 2002, J IMMUNOL, V169, P929, DOI 10.4049/jimmunol.169.2.929; Heward JM, 1999, J CLIN ENDOCR METAB, V84, P2398, DOI 10.1210/jc.84.7.2398; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hooper WC, 1999, CHEST, V116, P880, DOI 10.1378/chest.116.4.880; Hubacek JA, 2000, GENES IMMUN, V1, P405, DOI 10.1038/sj.gene.6363691; Hudson LL, 2002, HUM GENET, V111, P452, DOI 10.1007/s00439-002-0807-2; Hudson LL, 2004, J RHEUMATOL, V31, P85; Inoue N, 2002, GASTROENTEROLOGY, V123, P86, DOI 10.1053/gast.2002.34155; Jamerson Kenneth A, 2004, J Clin Hypertens (Greenwich), V6, P4, DOI 10.1111/j.1524-6175.2004.03563.x; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Kittles RA, 2003, ANNU REV GENOM HUM G, V4, P33, DOI 10.1146/annurev.genom.4.070802.110356; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Kouriba B, 2005, J IMMUNOL, V174, P6274, DOI 10.4049/jimmunol.174.10.6274; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Malhotra S, 2004, HYPERTENSION, V44, P866, DOI 10.1161/01.HYP.0000147578.84729.ac; Manolio TA, 2003, HUM GENET, V113, P437, DOI 10.1007/s00439-003-1005-6; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Marsh DG, 1997, NAT GENET, V15, P389; Marshall E, 1998, SCIENCE, V282, P654, DOI 10.1126/science.282.5389.654; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Mathias RA, 2000, AM J PHYS ANTHROPOL, V112, P29, DOI 10.1002/(SICI)1096-8644(200005)112:1<29::AID-AJPA4>3.0.CO;2-5; MCINTOSH I, 1992, FASEB J, V6, P2775, DOI 10.1096/fasebj.6.10.1378801; McKeigue PM, 2000, ANN HUM GENET, V64, P171, DOI 10.1017/S0003480000008022; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Montealegre F, 1996, P R Health Sci J, V15, P113; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; Munthe-Kaas MC, 2004, J ALLERGY CLIN IMMUN, V114, P280, DOI 10.1016/j.jaci.2004.03.050; Ness RB, 2004, AM J EPIDEMIOL, V160, P1033, DOI 10.1093/aje/kwh325; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nickel RG, 1999, HUM IMMUNOL, V60, P738, DOI 10.1016/S0198-8859(99)00039-7; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Palmer LJ, 2000, EUR J HUM GENET, V8, P853, DOI 10.1038/sj.ejhg.5200551; Parra EJ, 2001, AM J PHYS ANTHROPOL, V114, P18, DOI 10.1002/1096-8644(200101)114:1<18::AID-AJPA1002>3.0.CO;2-2; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peisong G, 2004, GENES IMMUN, V5, P58, DOI 10.1038/sj.gene.6364030; Perez-Perdomo R, 2003, J ASTHMA, V40, P465, DOI 10.1081/JAS-120018713; Pritchard JK, 2000, GENETICS, V155, P945; Ramirez-Soriano A, 2005, GENES IMMUN, V6, P646, DOI 10.1038/sj.gene.6364251; Ramsay CE, 1999, HUM GENET, V104, P269, DOI 10.1007/s004390050947; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Serre D, 2004, GENOME RES, V14, P1679, DOI 10.1101/gr.2529604; Sharan K, 2004, BRIT J HAEMATOL, V124, P240, DOI 10.1046/j.1365-2141.2003.04762.x; Shriver Mark D., 2005, Human Genomics, V2, P81; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Sullivan KJ, 2001, AM J RESP CRIT CARE, V164, P2186, DOI 10.1164/ajrccm.164.12.2012090; Swallow DM, 2003, ANNU REV GENET, V37, P197, DOI 10.1146/annurev.genet.37.110801.143820; Tchernitchko D, 2005, EUR J HUM GENET, V13, P513, DOI 10.1038/sj.ejhg.5201344; Tishkoff SA, 2004, NAT GENET, V36, pS21, DOI 10.1038/ng1438; Tishkoff SA, 2003, ANNU REV GENOM HUM G, V4, P293, DOI 10.1146/annurev.genom.4.070802.110226; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87, DOI 10.1159/000237515; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Unkelbach K, 1999, ARTERIOSCL THROM VAS, V19, P932, DOI 10.1161/01.ATV.19.4.932; Weinberg RB, 1999, GENET EPIDEMIOL, V17, P285, DOI 10.1002/(SICI)1098-2272(199911)17:4<285::AID-GEPI4>3.0.CO;2-3; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Wolpoff MH, 1996, SCIENCE, V274, P704; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	112	50	53	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					243	254		10.1016/j.jaci.2005.11.030	http://dx.doi.org/10.1016/j.jaci.2005.11.030			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461122	Bronze			2022-12-18	WOS:000235687300002
J	Nelson, HS				Nelson, HS			Is there a problem with inhaled long-acting beta-adrenergic agonists?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						short-acting beta-agonists; long-acting beta-agonists; adverse reactions; asthma mortality; beta-adrenergic receptor genotypes	EXERCISE-INDUCED BRONCHOCONSTRICTION; AIRWAY INFLAMMATION; ASTHMATIC-PATIENTS; BETA(2)-ADRENERGIC RECEPTOR; BRONCHIAL RESPONSIVENESS; FLUTICASONE PROPIONATE; REGULAR USE; BRONCHODILATOR TOLERANCE; MUCOSAL INFLAMMATION; REDUCED PROTECTION	Short-acting beta(2)-agonists are effective in relieving acute symptoms of asthma and in the short-term prevention of symptoms from stimuli, such as exercise. They are ineffective when used on a regular schedule to improve asthma control. Long-acting beta(2)-agonists, on the other hand, provide sustained bronchodilation and improve asthma control. Regular use of long-acting beta(2)-agonists is not associated with significant tolerance to their bronchodilator action, impairment in the response to albuterol, decreased baseline pulmonary function, increased response to methacholine, or increased risk of adverse cardiac events. Case-control studies do not suggest an increased risk for death or intensive care unit admissions with use of long-acting beta(2)-agonists. In prospective studies in which there has been an increase in asthma deaths or serious asthma exacerbations, this increased risk has not been observed in subjects using inhaled corticosteroids. Where increased deaths have occurred in relation to either short- or long-acting beta(2)-agonists, the events have not occurred equally throughout the exposed population. This suggests that these outcomes were not a direct toxic effect of the drugs and increases the possibility that they resulted from an interaction between relief of symptoms by beta(2)-agonists and delay in seeking medical care.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org						ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Au DH, 2004, AM HEART J, V148, P915, DOI 10.1016/j.ahj.2004.03.048; Au DH, 2000, AM J RESP CRIT CARE, V161, P827, DOI 10.1164/ajrccm.161.3.9904006; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704, DOI 10.1164/ajrccm.155.2.9032216; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bensch G, 2001, ANN ALLERG ASTHMA IM, V86, P19, DOI 10.1016/S1081-1206(10)62351-4; Bhagat R, 1996, J ALLERGY CLIN IMMUN, V97, P47, DOI 10.1016/S0091-6749(96)70282-8; Blais L, 1996, AM J EPIDEMIOL, V144, P1161; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; Boulet LP, 2001, CLIN EXP ALLERGY, V31, P430, DOI 10.1046/j.1365-2222.2001.01014.x; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; Burgess C, 1998, EUR J CLIN PHARMACOL, V54, P141, DOI 10.1007/s002280050435; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; CAMPBELL DA, 1994, EUR RESPIR J, V7, P490, DOI 10.1183/09031936.94.07030490; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CLARK CE, 1993, RESP MED, V87, P227, DOI 10.1016/0954-6111(93)90098-K; COCKCROFT DW, 1995, AM J RESP CRIT CARE, V152, P1485, DOI 10.1164/ajrccm.152.5.7582281; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V2171, P1412; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; Dorinsky PM, 2004, CHEST, V126, p722S, DOI 10.1378/chest.126.4_MeetingAbstracts.722S-a; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Edelman JM, 2000, ANN INTERN MED, V132, P97, DOI 10.7326/0003-4819-132-2-200001180-00002; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Ferguson GT, 2003, CHEST, V123, P1817, DOI 10.1378/chest.123.6.1817; FINKELSTEIN FN, 1994, NEW ENGL J MED, V331, P1314; FitzGerald JM, 1999, J ALLERGY CLIN IMMUN, V103, P427, DOI 10.1016/S0091-6749(99)70467-7; Garcia R, 2001, J INVEST ALLERG CLIN, V11, P176; Garratt AM, 1996, QUAL LIFE RES, V5, P223, DOI 10.1007/BF00434744; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Hancox RJ, 2000, RESP MED, V94, P767, DOI 10.1053/rmed.2000.0820; Haney S, 2005, RESP MED, V99, P566, DOI 10.1016/j.rmed.2004.10.014; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jeffery PK, 2002, EUR RESPIR J, V20, P1378, DOI 10.1183/09031936.02.00542001; JOHNSON M, 1993, LIFE SCI, V52, P2131, DOI 10.1016/0024-3205(93)90728-L; Jones SL, 2001, EUR RESPIR J, V17, P368, DOI 10.1183/09031936.01.17303680; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Korosec M, 1999, AM J MED, V107, P209, DOI 10.1016/S0002-9343(99)00222-3; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; Lanes SF, 1998, AM J RESP CRIT CARE, V158, P857, DOI 10.1164/ajrccm.158.3.9803047; Langley SJ, 1998, EUR RESPIR J, V11, P1081, DOI 10.1183/09031936.98.11051081; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Li Edwards, 2005, J ALLERGY CLIN IMMUN, V115, pS6; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; Martin RM, 1998, THORAX, V53, P558, DOI 10.1136/thx.53.7.558; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Meier CR, 1997, THORAX, V52, P612, DOI 10.1136/thx.52.7.612; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; Nelson HS, 1999, AM J RESP CRIT CARE, V159, P1556, DOI 10.1164/ajrccm.159.5.9807128; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NELSON HS, IN PRESS CHEST; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; OBYME PM, 2001, AM J RESP CRIT CARE, V164, P1192; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; Pace E, 2004, J ALLERGY CLIN IMMUN, V114, P1216, DOI 10.1016/j.jaci.2004.07.052; PAUWELS R, 1998, NEW ENGL J MED, V338, P1405; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Poller U, 1998, CARDIOVASC RES, V40, P211, DOI 10.1016/S0008-6363(98)00101-1; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Sengstock DM, 2002, J CARD FAIL, V8, P232, DOI 10.1054/jcaf.2002.127771; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Suissa S, 1996, AM J RESP CRIT CARE, V154, P1598, DOI 10.1164/ajrccm.154.6.8970341; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Suissa S, 2003, THORAX, V58, P43, DOI 10.1136/thorax.58.1.43; SUISSA S, 1994, EUR RESPIR J, V7, P1602, DOI 10.1183/09031936.94.07091602; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; van Schayck CP, 2002, RESP MED, V96, P155, DOI 10.1053/rmed.2001.1243; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WILKINSON JRW, 1992, BRIT MED J, V305, P931, DOI 10.1136/bmj.305.6859.931; Williams C, 1998, THORAX, V53, P7, DOI 10.1136/thx.53.1.7; WOLFE J, 2005, P AM THORAC SOC, V2, pA128; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366	102	50	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					3	16		10.1016/j.jaci.2005.10.013	http://dx.doi.org/10.1016/j.jaci.2005.10.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387577				2022-12-18	WOS:000235687100001
J	Hirota, T; Suzuki, Y; Hasegawa, K; Obara, K; Matsuda, A; Akahoshi, M; Nakashima, K; Cheng, L; Takahashi, N; Shimizu, M; Doi, S; Fujita, K; Enomoto, T; Ebisawa, M; Yoshihara, S; Nakamura, Y; Kish, F; Shirakawa, T; Tamari, M				Hirota, T; Suzuki, Y; Hasegawa, K; Obara, K; Matsuda, A; Akahoshi, M; Nakashima, K; Cheng, L; Takahashi, N; Shimizu, M; Doi, S; Fujita, K; Enomoto, T; Ebisawa, M; Yoshihara, S; Nakamura, Y; Kish, F; Shirakawa, T; Tamari, M			Functional haplotypes of IL-12B are associated with childhood atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-12B; polymorphism; association; linkage disequilibrium; haplotype	IL12B PROMOTER POLYMORPHISM; P40 HOMODIMER; INTERLEUKIN-12; GENE; CYTOKINE; RECEPTOR; LINKAGE; MARKERS; SUSCEPTIBILITY; IDENTIFICATION	Background: IL-12 is a heterodimeric proinflammatory cytokine that forms a link between innate and adaptive immunity. Although associations between polymorphisms of IL-12B on chromosome 5q31-33 and asthma have been reported, the genetic influences of the polymorphisms and haplotype of IL-12B are unclear. Objective: To examine whether polymorphisms in IL-12B are associated with childhood atopic asthma in a Japanese population. Methods: We identified a total of 13 polymorphisms and characterized the linkage disequilibrium mapping of the gene. Three variants in the promoter and 3' untranslated region were genotyped, and we conducted case-control and case-only association studies between those variants and asthma-related phenotypes (childhood atopic asthma, n = 297; normal controls, n = 555). Haplotype association analysis and functional analysis of these variants were also performed. Results: 3' Untranslated region 10841C > A was significantly associated with the risk of childhood atopic asthma (P = .00062). The -6415 promoter variant, in linkage disequilibrium with the 10841C > A (D' = 0.78 and r(2) = 0.61), was also marginally associated with childhood atopic asthma (P = .051). We analyzed the 2-locus haplotype by using these 2 polymorphisms and found a positive association with haplotype CTCTAA-C (-6415 CTCTAA and 10841C; P =.00078). Furthermore, 10841C > A affects the stability of transcripts, and promoter variant -6415GC enhances the transcriptional level of IL-12B. Conclusion: Our results imply that functional haplotype CTCTAA-C, which affects the instability of transcripts and the lower transcriptional level of IL-12B, has a protective effect in childhood atopic asthma. On the basis of these findings, the IL-12B gene might be involved in the development of atopic asthma through functional genetic polymorphisms.	RIKEN, Inst Phys & Chem Res, Lab Genet & Allerg Dis, SNP Res Ctr,Tsurumi Ku, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chiba, Japan; Kyoto Univ, Grad Sch Publ Hlth, Dept Hlth Promot & Human Behav, Kyoto, Japan; Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan; Shiga Univ Med Sci, Coll Nursing, Shiga, Japan; Wakayama Med Ctr, Japanese Red Cross Soc, Dept Otolaryngol, Wakayama, Japan; Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Kanagawa, Japan; Dokkyo Univ, Sch Med, Dept Pediat, Mibu, Tochigi, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Kagoshima Univ, Sch Dent, Dept Microbiol & Immunol, Kagoshima 890, Japan	RIKEN; Chiba University; Kyoto University; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Shiga University of Medical Science; Dokkyo Medical University; University of Tokyo; Kagoshima University	Tamari, M (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Genet & Allerg Dis, SNP Res Ctr,Tsurumi Ku, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan.	tamari@src.riken.jp	Kaneda-Nakashima, Kazuko/GZM-6591-2022; Akahoshi, Mitsuteru/B-1139-2008; Matsuda, Akira/A-9981-2010; Cheng, Lei/AAT-2690-2021; Tamari, Mayumi/N-5378-2015	Kaneda-Nakashima, Kazuko/0000-0001-6657-5059; Matsuda, Akira/0000-0002-0792-3663; Cheng, Lei/0000-0001-6541-7702; Ebisawa, Motohiro/0000-0003-4117-558X				Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; GILLESSEN S, 1995, EUR J IMMUNOL, V25, P200, DOI 10.1002/eji.1830250133; Hasegawa K, 2004, HUM GENET, V115, P295, DOI 10.1007/s00439-004-1157-z; Heinzel FP, 1997, J IMMUNOL, V158, P4381; Hino A, 2004, AM J PATHOL, V164, P1327, DOI 10.1016/S0002-9440(10)63219-1; Holberg CJ, 2001, J ALLERGY CLIN IMMUN, V108, P772, DOI 10.1067/mai.2001.119158; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Kamada F, 2004, GENES IMMUN, V5, P540, DOI 10.1038/sj.gene.6364124; Khoo SK, 2004, J ALLERGY CLIN IMMUN, V113, P475, DOI 10.1016/j.jaci.2003.10.043; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; LING P, 1995, J IMMUNOL, V154, P116; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; Nakajima T, 2002, AM J HUM GENET, V70, P108, DOI 10.1086/338454; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446; Noguchi E, 2001, GENES IMMUN, V2, P401, DOI 10.1038/sj.gene.6363790; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Suzuki A, 2003, NAT GENET, V34, P395, DOI 10.1038/ng1206; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Wang X, 1999, EUR J IMMUNOL, V29, P2007, DOI 10.1002/(SICI)1521-4141(199906)29:06<2007::AID-IMMU2007>3.0.CO;2-0; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yoshimoto T, 1998, J IMMUNOL, V160, P588	34	50	54	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					789	795		10.1016/j.jaci.2005.06.010	http://dx.doi.org/10.1016/j.jaci.2005.06.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210052				2022-12-18	WOS:000235686600012
J	Fukunaga, A; Bito, T; Tsuru, K; Oohashi, A; Yu, XJ; Ichihashi, M; Nishigori, C; Horikawa, T				Fukunaga, A; Bito, T; Tsuru, K; Oohashi, A; Yu, XJ; Ichihashi, M; Nishigori, C; Horikawa, T			Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cholinergic urticaria; sweat; autologous serum; skin test; histamine release test; acetylcholine test	AFFINITY IGE RECEPTOR; HISTAMINE-RELEASE; AUTOANTIBODIES; ANAPHYLAXIS; COLD	Background: It has been reported that patients with cholinergic urticaria have a type I allergy to autologous sweat; however, the pathogenesis of that disorder has not been fully elucidated. Objective: We investigated the responsiveness to autologous sweat and serum in patients with cholinergic urticaria in relation to their clinical characteristics. We further classified the clinical subtypes that are clearly characterized by responsiveness to in vivo and in vitro tests as well as their clinical features. Methods: Intradermal tests with autologous sweat and serum were performed in 18 patients with cholinergic urticaria. Histamine release from peripheral blood basophils induced by autologous sweat was measured. Results: Eleven of 17 patients with cholinergic urticaria showed positive reactions in skin tests with their own diluted sweat. Substantial amounts of sweat-induced histamine release from autologous basophils were observed in 10 of 17 patients. Eight of 15 patients with cholinergic urticaria showed positive reactions in the autologous serum skin tests. All 6 patients who developed satellite wheals after the acetylcholine test showed hypersensitivity to sweat. Further, patients whose eruptions were coincident with hair follicles showed positive responses to the skin test with autologous serum, whereas patients whose eruptions were not coincident with hair follicles did not. Conclusion: On the basis of these findings, we propose that cholinergic urticaria should be classified into 2 distinct subtypes. The first (nonfollicular) subtype shows strong positive reactions to autologous sweat and negative reactions to autologous serum. The second (follicular) subtype shows weak reactions to autologous sweat and positive reactions to autologous serum.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Dermatol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Horikawa, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Dermatol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	thorikaw@med.kobe-u.ac.jp						Adachi A, 2003, CONTACT DERMATITIS, V48, P133, DOI 10.1034/j.1600-0536.2003.00050.x; Adachi Jun, 1994, Journal of Dermatological Science, V7, P142, DOI 10.1016/0923-1811(94)90088-4; [Anonymous], 1948, TOHOKU J EXP MED, V49, P284; COMMENS CA, 1978, BRIT J DERMATOL, V98, P47, DOI 10.1111/j.1365-2133.1978.tb07332.x; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; FREEDBERG IM, 2003, FITZPATRICKS DERMATO, P1132; Hide M, 2002, ACTA DERM-VENEREOL, V82, P335, DOI 10.1080/000155502320624050; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Itakura E, 2000, BRIT J DERMATOL, V143, P1064, DOI 10.1046/j.1365-2133.2000.03845.x; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; Kobayashi H, 2002, DERMATOLOGY, V204, P173, DOI 10.1159/000057877; KOBZABLACK A, 1996, CLIN EXP DERMATOL, V21, P424; LAWRENCE CM, 1981, BRIT J DERMATOL, V105, P543, DOI 10.1111/j.1365-2133.1981.tb00797.x; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Nishi K, 2000, J IMMUNOL METHODS, V240, P39; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	22	50	52	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					397	402		10.1016/j.jaci.2005.05.024	http://dx.doi.org/10.1016/j.jaci.2005.05.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083796				2022-12-18	WOS:000235686400024
J	Cho, SH; Woo, CH; Yoon, SB; Kim, JH				Cho, SH; Woo, CH; Yoon, SB; Kim, JH			Protein kinase C delta functions downstream of Ca2+ mobilization in Fc epsilon RI signaling to degranulation in mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc epsilon RI signaling; Ca2+; degranulation; PKC-delta; mast cells; asthma	BASOPHILIC RBL-2H3 CELLS; TYROSINE PHOSPHORYLATION; HISTAMINE-RELEASE; CALCIUM CURRENT; RAC; ACTIVATION; IGE; INHIBITION; EXOCYTOSIS; SECRETION	Background: Mobilization of Ca2+ plays an important role in the degranulation of mast cells. Although events upstream of Ca2+ mobilization in the regulation of degranulation are relatively well characterized, the downstream mediators of Ca2+ remain largely unknown. Objective: We sought to characterize the downstream signaling mechanism by which Ca2+ mobilization mediates degranulation in antigen-stimulated mast cells. Methods: The effect of various inhibitors was examined in the antigen-induced or Ca2+ ionophore A23187-induced degranulation process, and the effect of inhibitors on histamine release was tested in the mouse model of asthma. Results: The 8 isoform of protein kinase C (PKC) functions downstream of Ca2+ in the signaling pathway from FcepsilonR1 to degranulation in RBL-2H3 mast cells. Stimulation of cells with either antigen or the Ca2+ ionophore A23187 induced a rapid translocation of PKC-delta from the cytosol to the cellular membranes, and either treatment with the PKC-delta-specific inhibitor rottlerin or infection with an adenovirus; encoding a dominant negative mutant of PKC-delta markedly inhibited degranulation induced with antigen or A23187. Furthermore, both the translocation of PKC-delta and degranulation induced by A23187 were inhibited by prevention of the accumulation of reactive oxygen species normally elicited by the ionophore. Finally, intraperitoneal injection of rottlerin prevented the increase in the concentration of histamine in bronchoalveolar lavage fluid induced by means of antigen challenge in a mouse model of allergic asthma. Conclusion: PKC-delta plays an essential downstream mediatory role in the degranulation elicited by Ca2+ mobilization, and reactive oxygen species mediate the activation of PKC-delta by Ca2+ in the regulation of degranulation.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chang EY, 1997, J IMMUNOL, V159, P2624; CHOI OH, 1994, J BIOL CHEM, V269, P536; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; Guillemot JC, 1997, J CELL SCI, V110, P2215; Hong-Geller E, 2001, P NATL ACAD SCI USA, V98, P1154, DOI 10.1073/pnas.98.3.1154; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P31815, DOI 10.1074/jbc.273.48.31815; Jeong DW, 2002, J BIOL CHEM, V277, P17871, DOI 10.1074/jbc.M200808200; JOHNSON JA, 1995, LIFE SCI, V57, P1027, DOI 10.1016/0024-3205(95)02048-N; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Liu Y, 2001, J LEUKOCYTE BIOL, V69, P831; Ludowyke RI, 1996, J IMMUNOL, V157, P5130; Matsui T, 2000, BIOCHEM BIOPH RES CO, V276, P742, DOI 10.1006/bbrc.2000.3545; Nechushtan H, 2000, BLOOD, V95, P1752, DOI 10.1182/blood.V95.5.1752.005k18_1752_1757; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OZAWA K, 1993, J BIOL CHEM, V268, P2280; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Suzuki H, 1997, J IMMUNOL, V159, P5881; Talior I, 2003, AM J PHYSIOL-ENDOC M, V285, pE295, DOI 10.1152/ajpendo.00044.2003; Tkaczyk C, 2001, CLIN IMMUNOL, V99, P198, DOI 10.1006/clim.2001.4992; Vilarino N, 2001, CELL SIGNAL, V13, P177, DOI 10.1016/S0898-6568(01)00138-3; Woo CH, 2002, BIOCHEM BIOPH RES CO, V298, P392, DOI 10.1016/S0006-291X(02)02432-4; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Yoshimaru T, 2002, CLIN EXP ALLERGY, V32, P612, DOI 10.1046/j.0954-7894.2002.01263.x	36	50	53	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1085	1092		10.1016/j.jaci.2004.07.035	http://dx.doi.org/10.1016/j.jaci.2004.07.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536414				2022-12-18	WOS:000225047800014
J	Sokol, WN				Sokol, WN			Nine episodes of anaphylaxis following cystoscopy caused by Cidex OPA (orthophthalaidehyde) high-level disinfectant in 4 patients after cytoscopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; OPA (ortho-phthalaldehyde); GTA (glutaraldehyde); high-level disinfectant	GLUTARALDEHYDE; ENDOSCOPY; WORKERS; ASTHMA	Background: Ortho-phthalaldehyde (OPA) is a high-level disinfectant commonly used for processing heat-sensitive medical devices. Objective: We report 4 patients who experienced 9 episodes of anaphylaxis following cystoscopy after a urology practice switched from using Cidex (glutaraldehyde [GTA]) to OPA for disinfecting their cystoscopes. Methods: Allergic evaluations consisted of: skin testing to saline, histamine, glycerin, lidocaine, latex, GTA, and OPA and blood tests for total immunoglobulin E (IgE) and latex specific IgE. Findings: The 4 patients were evaluated after 3 of them had experienced 2 episodes of anaphylaxis and one of them 3 episodes following outpatient cystoscopy for ongoing evaluation of bladder cancer. Skin testing of subjects and controls to lidocaine, latex, latex specific IgE, and GTA was negative. Skin testing to OPA resulted in immediate wheal and flare reactions in all 4 patients within 20 minutes and late reactions at 24 hours but negative reactions in controls. Subsequent to the testing, 3 of the patients returned for repeat cystoscopy in which GTA but not OPA was used to disinfect the cystoscopes and tolerated the procedure. Conclusions: OPA solution should be considered a cause of anaphylactic/allergic reactions following cystoscopy and possibly following instrumentation with other medical devices disinfected by this material.	Univ Calif Irvine, Coll Med, Irvine, CA 92717 USA	University of California System; University of California Irvine	Sokol, WN (corresponding author), 2011 Westcliffe Dr 7, Newport Beach, CA 92660 USA.	hrinstitute@aol.com						CORRADO OJ, 1986, HUM TOXICOL, V5, P325, DOI 10.1177/096032718600500505; Curran AD, 1996, ALLERGY, V51, P826; DESTEFANO F, 1999, ARCH CHEST DIS, V53, P50; GANNON PFG, 1995, THORAX, V50, P156, DOI 10.1136/thx.50.2.156; Nettis E, 2002, CONTACT DERMATITIS, V46, P101, DOI 10.1034/j.1600-0536.2002.460208.x; PATCZYNSKI C, 2001, ALLERGY, V56, P1186; Venticinque SG, 2003, ANESTH ANALG, V97, P1260, DOI 10.1213/01.ANE.0000083641.58267.0C	7	50	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					392	397		10.1016/j.jaci.2004.04.031	http://dx.doi.org/10.1016/j.jaci.2004.04.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316522				2022-12-18	WOS:000223405600029
J	Tapia, B; Padial, A; Sanchez-Sabate, E; Alvarez-Ferreira, J; Morel, E; Blanca, M; Bellon, T				Tapia, B; Padial, A; Sanchez-Sabate, E; Alvarez-Ferreira, J; Morel, E; Blanca, M; Bellon, T			Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stevens-Johnson syndrome; toxic epidermal necrolysis; drug allergy; chemokine; CTACK; CCL27; CCR10; exanthema	TOXIC EPIDERMAL NECROLYSIS; GENERALIZED EXANTHEMATOUS PUSTULOSIS; SKIN-ASSOCIATED CHEMOKINE; T-CELLS; CC-CHEMOKINE; LYMPHOCYTE TRAFFICKING; CUTTING EDGE; RECEPTOR; CCR10; EXPRESSION	Background: Drug-induced skin reactions, including toxic epidermal necrolysis and Stevens-Johnson syndrome, are severe buttons cutaneous diseases of uncertain etiology, although cytotoxic T cells seem to be involved. Cutaneous T cell-attracting chemokine (CTACK/CCL27) is selectively expressed in skin and attracts CCR10-expressing cells. Exclusive CTACK expression by keratinocytes; suggests its involvement in inflammatory skin diseases. Objective: We addressed whether CTACK/CCL27 production by the epidermis and CCR10(+) lymphocytes are involved in toxic epidermal necrolysis and Stevens-Johnson syndrome. Methods: We measured CTACK expression by epidermal cells in 2 patients with drug-induced buttons skin reactions and compared it to lesional skin from several drug-induced exanthemas. In parallel we measured CCR10 mRNA in peripheral blood mononuclear cells from the patients during the course of the disease and in lymphocytes infiltrating the skin. Results: CTACK expression levels in skin biopsies from the 2 patients with drug-induced buttons reactions were higher than those found in healthy subjects or in other drug-induced exanthemas. CCR10 mRNA levels were also elevated in peripheral blood lymphocytes and in lesional skin during the acute phase of the disease. Moreover, resolution was associated with a return to baseline of both CTACK and CCR10 receptor expression. Conclusion: CTACK-CCR10 interactions may be involved in the selective recruitment to the skin of cytotoxic lymphocytes in toxic epidermal necrolysis and Stevens-Johnson syndrome, as well as in less severe drug-induced cutaneous diseases.	Hosp Univ La Paz, Res Unit, Madrid 28046, Spain; Hosp Univ La Paz, Dept Allergy, Madrid 28046, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28046, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario La Paz	Bellon, T (corresponding author), Hosp Univ La Paz, Res Unit, PO Castellana 261, Madrid 28046, Spain.	tbellon.hulp@salud.madrid.org	Bellón, Teresa/ABF-4916-2020; Alves Ferreira, Francisco Javier/G-4423-2010; MOREL, ESTHER/AAC-7286-2021	Bellón, Teresa/0000-0002-0138-6879; MOREL, ESTHER/0000-0002-4768-082X				Baird JW, 1999, J BIOL CHEM, V274, P33496, DOI 10.1074/jbc.274.47.33496; Becker DS, 1998, LANCET, V351, P1417, DOI 10.1016/S0140-6736(97)11369-1; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; CARR A, 1994, CLIN EXP IMMUNOL, V97, P260, DOI 10.1111/j.1365-2249.1994.tb06078.x; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hromas R, 1999, BIOCHEM BIOPH RES CO, V258, P737, DOI 10.1006/bbrc.1999.0507; Hudak S, 2002, J IMMUNOL, V169, P1189, DOI 10.4049/jimmunol.169.3.1189; Ishikawa-Mochizuki I, 1999, FEBS LETT, V460, P544, DOI 10.1016/S0014-5793(99)01406-4; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; MIYAUCHI H, 1991, ARCH DERMATOL, V127, P851, DOI 10.1001/archderm.127.6.851; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Padial MA, 2004, BRIT J DERMATOL, V150, P139, DOI 10.1111/j.1365-2133.2004.05717.x; Paquet P, 2000, AM J DERMATOPATH, V22, P413, DOI 10.1097/00000372-200010000-00005; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Posadas SJ, 2000, J ALLERGY CLIN IMMUN, V106, P769, DOI 10.1067/mai.2000.109828; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359, DOI 10.1159/000237032; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922	28	50	54	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					335	340		10.1016/j.jaci.2004.04.034	http://dx.doi.org/10.1016/j.jaci.2004.04.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316512				2022-12-18	WOS:000223405600019
J	Daulat, S; Earl, HS; Casey, W; Gruchalla, RS				Daulat, S; Earl, HS; Casey, W; Gruchalla, RS			Safety of cephalosporin administration to patients with histories of penicillin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY		Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75390 USA; Parkland Hlth & Hosp Syst, Dallas, TX USA; Corvallis Clin, Corvallis, OR USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Daulat, S (corresponding author), Univ Texas, SW Med Ctr, Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							ASSEM E, 1978, J INFECT DIS, V137, pS74; Bernstein IL, 1999, ANN ALLERG ASTHMA IM, V83, pVIII; GIRARD JP, 1968, INT ARCH ALLER A IMM, V33, P428, DOI 10.1159/000230058; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; LEVINE BB, 1973, J INFECT DIS, V128, pS364, DOI 10.1093/infdis/128.Supplement_2.S364; Macy E, 1997, J ALLERGY CLIN IMMUN, V100, P586, DOI 10.1016/S0091-6749(97)70159-3; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; Solensky R, 2000, ANN ALLERG ASTHMA IM, V84, P329, DOI 10.1016/S1081-1206(10)62782-2	10	50	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1220	1222		10.1016/j.jaci.2004.03.023	http://dx.doi.org/10.1016/j.jaci.2004.03.023			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15214363				2022-12-18	WOS:000222091000034
J	Muro, S; Hamid, Q; Olivenstein, R; Taha, R; Rokach, J; Powell, WS				Muro, S; Hamid, Q; Olivenstein, R; Taha, R; Rokach, J; Powell, WS			5-Oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eicosanoids; 5-oxo-ETE; inflammation; asthma; skin; eosinophils; neutrophils; immunocytochemistry	PLATELET-ACTIVATING-FACTOR; INHALED LEUKOTRIENE D-4; AIRWAY HYPERRESPONSIVENESS; EOSINOPHIL RECRUITMENT; CUTANEOUS INJECTION; POTENT STIMULATOR; HUMAN-NEUTROPHILS; INFLAMMATION; EOTAXIN; RANTES	Background: 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is an arachidonic acid metabolite with potent in vitro chemoattractant effects on eosinophils and neutrophils. It has also been shown to induce pulmonary eosinophilia in Brown Norway rats, but it is not known whether it is active in human beings in vivo. Objective: To determine whether 5-oxo-ETE can induce cellular infiltration in patients with atopic asthma and nonatopic control subjects after intradermal administration. Methods: 5-Oxo-ETE was administered intradermally to 11 patients with atopic asthma and 10 nonatopic control subjects. Skin biopsy specimens were taken 6 or 24 hours later and examined by immunocytochemistry for cells expressing specific markers for eosinophils (major basic protein), neutrophils (elastase), macrophages (CD68), lymphocytes (CD3), and mast cells (tryptase). Results: 5-Oxo-ETE (1.5 and 5 mug) elicited the infiltration of both eosinophils and neutrophils into the skin in both control and atopic asthmatic subjects. Increased numbers of eosinophils were observed at 6 and 24 hours after injection, whereas significantly elevated neutrophil numbers were present only after 24 hours. Eosinophils were >3 times higher in patients with atopic asthma compared with control subjects after injection of the highest dose of 5-oxo-ETE. Macrophage numbers were also elevated, but only at the highest dose of 5-oxo-ETE. No effects were observed on the numbers of either lymphocytes or mast cells. Conclusions: 5-Oxo-ETE elicits the infiltration of eosinophils and neutrophils into the skin of human beings in vivo after intradermal administration. Asthmatic subjects are more responsive to this substance than nonallergic control subjects. These results suggest that 5-oxo-ETE may be an important mediator of inflammation.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Powell, William/AAE-9000-2020	Rokach, Joshu/0000-0003-1814-7505; Powell, William/0000-0002-8507-4038	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM WM, 1992, EUR J PHARMACOL, V217, P119, DOI 10.1016/0014-2999(92)90829-S; Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; Beck LA, 1997, J IMMUNOL, V159, P2962; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FREW AJ, 1988, J IMMUNOL, V141, P4158; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Mulder A, 1999, AM J RESP CRIT CARE, V159, P1562, DOI 10.1164/ajrccm.159.5.9810095; Namovic MT, 1996, EUR J PHARMACOL, V315, P81, DOI 10.1016/S0014-2999(96)00590-0; O'Flaherty JT, 1998, J BIOL CHEM, V273, P32535, DOI 10.1074/jbc.273.49.32535; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Pease James E., 2001, Current Opinion in Pharmacology, V1, P248, DOI 10.1016/S1471-4892(01)00044-3; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; RICHARDS IM, 1991, ANN NY ACAD SCI, V629, P274; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SEEDS EAM, 1995, EUR J PHARM-ENVIRON, V293, P369, DOI 10.1016/0926-6917(95)90057-8; Senechal S, 2002, LAB INVEST, V82, P929, DOI 10.1097/01.LAB.0000020417.13757.05; SHAW JO, 1981, J IMMUNOL, V127, P1250; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Sozzani S, 1996, J IMMUNOL, V157, P4664; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; SUN FF, 1991, J LEUKOCYTE BIOL, V50, P140, DOI 10.1002/jlb.50.2.140; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WINKELMANN RK, 1986, ACTA DERM-VENEREOL, V66, P340; Zarini S, 2003, J BIOL CHEM, V278, P11190, DOI 10.1074/jbc.M208496200; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	47	50	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					768	774		10.1016/S0091-6749(03)01888-8	http://dx.doi.org/10.1016/S0091-6749(03)01888-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564360				2022-12-18	WOS:000185831200018
J	Hahn, C; Teufel, M; Herz, U; Renz, H; Erb, KJ; Wohlleben, G; Brocker, EB; Duschl, A; Sebald, W; Grunewald, SM				Hahn, C; Teufel, M; Herz, U; Renz, H; Erb, KJ; Wohlleben, G; Brocker, EB; Duschl, A; Sebald, W; Grunewald, SM			Inhibition of the IL-4/1613 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; in vivo animal models; cytokine inhibitors; therapy	SOLUBLE IL-4 RECEPTOR; AIRWAY INFLAMMATION; INTERLEUKIN 9; EXPRESSION; HYPERRESPONSIVENESS; IGE; PATHOGENESIS; EOSINOPHILIA; ANTIGEN; GENE	Background: IL-4 and IL-13 are considered as key regulators for the development of atopic disease. Objective: This study addresses the therapeutic potential of an IL-4/IL-13 inhibitor on the basis of a mutated IL-4 variant (Q116D, Y119D) during allergic sensitization and in established disease in a murine asthma model with persistent airway pathologic condition. Methods: BALB/c mice were sensitized with ovalbumin intranasally. Mice were treated with the IL-4/IL-13 inhibitor during the sensitization phase or alternatively after ovalbumin allergy was established. Specific antibodies were measured, and histologic lung sections were examined for goblet cell metaplasia. In addition, bronchoalveolar lavages were performed and checked for airway eosinophilia, IL-5 levels, and the number of IL-4 secreting CD4(+) T cells. Furthermore, airway responsiveness to inhaled methacholine was assessed. Results: The inhibition of the IL-4/IL-13 system during allergic sensitization resulted in a dose-dependent reduction of ovalbumin-specific IgEs and inhibition of airway eosinophilia together with decreased IL-5 levels and decreased numbers of IL-4 secreting CD4+ T cells. Moreover, goblet cell metaplasia and airway responsiveness to methacholine could be reduced significantly by the IL-4/IL-13 inhibitor. However, the inhibition of the IL-4/IL-13 system at various time points after allergy as established showed only little effect on all measured allergic parameters. Conclusion: Although the inhibition of the IL-4/IL-13 system can efficiently prevent the development of the allergic phenotype, these cytokines seem to play a minor role in established allergy. This is relevant for estimating the therapeutic effects of 1L-4/IL-13 inhibitors in patients with allergic asthma. (J Allergy Clin Immunol 2003;711:1361-9.).	Univ Wurzburg, Dept Dermatol, Klin & Poliklin & Geschlechtskranhenheiten, D-97080 Wurzburg, Germany; Univ Wurzburg, Zentrum Infekt Forsch, D-97080 Wurzburg, Germany; Univ Wurzburg, Biozentrum Physiol Chem 2, D-97080 Wurzburg, Germany; Univ Marburg, Abt Klin Chem & Mol Diagnost, Marburg, Germany; Salzburg Univ, Inst Chem & Biochem, A-5020 Salzburg, Austria	University of Wurzburg; University of Wurzburg; University of Wurzburg; Philipps University Marburg; Salzburg University	Grunewald, SM (corresponding author), Univ Wurzburg, Dept Dermatol, Klin & Poliklin & Geschlechtskranhenheiten, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Duschl, Albert/E-5872-2011	Duschl, Albert/0000-0002-7034-9860				Barnes PJ, 2001, J ALLERGY CLIN IMMUN, V108, pS72, DOI 10.1067/mai.2001.116435; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Blumchen K, 2001, EXPERT OPIN BIOL TH, V1, P433, DOI 10.1517/14712598.1.3.433; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1999, NATURE, V402, pB18; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Grunewald SM, 2001, INT ARCH ALLERGY IMM, V125, P322, DOI 10.1159/000053833; Grunewald SM, 1997, J BIOL CHEM, V272, P1480, DOI 10.1074/jbc.272.3.1480; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; Hertz M, 2001, J IMMUNOL, V167, P3792, DOI 10.4049/jimmunol.167.7.3792; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holt PG, 1999, NATURE, V402, pB12; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leong KP, 2001, ANN ALLERG ASTHMA IM, V87, P96, DOI 10.1016/S1081-1206(10)62201-6; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; RENAULD JC, 1990, J IMMUNOL, V144, P4235; Renz H, 1996, INT ARCH ALLERGY IMM, V109, P167, DOI 10.1159/000237216; Renz H, 1995, Exp Dermatol, V4, P173, DOI 10.1111/j.1600-0625.1995.tb00242.x; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Steinke JW, 2001, RESP RES, V2, P66, DOI 10.1186/rr40; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhu Z, 2001, AM J RESP CRIT CARE, V164, pS67, DOI 10.1164/ajrccm.164.supplement_2.2106070; Zuberi RI, 2000, J IMMUNOL, V164, P2667, DOI 10.4049/jimmunol.164.5.2667	35	50	57	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1361	1369		10.1067/mai.2003.1527	http://dx.doi.org/10.1067/mai.2003.1527			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789240				2022-12-18	WOS:000183424700028
J	Zemann, B; Schwaerzler, C; Griot-Wenk, M; Nefzger, M; Mayer, P; Schneider, H; de Weck, A; Carballido, JM; Liehl, E				Zemann, B; Schwaerzler, C; Griot-Wenk, M; Nefzger, M; Mayer, P; Schneider, H; de Weck, A; Carballido, JM; Liehl, E			Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-beta expression and prevents allergy in adult life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral tolerance; allergy; regulatory cells; IL-10; TGF-beta	ALVEOLAR MACROPHAGES; T-CELLS; ACTIVE SUPPRESSION; DOUBLE-BLIND; TOLERANCE; RESPONSES; RHINOCONJUNCTIVITIS; IMMUNOTHERAPY; ELIMINATION; INDUCTION	Background: Oral administration of allergens can induce immune tolerance to specific allergens in rodents and hence might be a possibility to prevent and treat allergic diseases in human subjects. However, the gastrointestinal tract of mice is different from that of human subjects. The absorption of specific antigens and subsequent antigen presentation to intestinal T cells is different in both species, making it difficult to extrapolate results. Objective: We investigated primary oral tolerance to ovalbumin (OVA) in an IgE high-responder dog model, which is more predictive for human allergic diseases than corresponding rodent models. Methods: Oral tolerance was induced by means of a 28-day treatment with OVA dissolved in cow's milk. Results: We observed reduced OVA-specific IgE and IgG production in response to ensuing subcutaneous challenges. Allergic conjunctivitis induced by means of ocular and airway provocation was significantly reduced in tolerized animals compared with that seen in nontolerized control animals. In addition, eosinophilia and neutrophilia in bronchoalveolar lavage fluid and bronchoconstriction after airway allergen challenge were significantly suppressed in tolerized animals. Cytokine analysis by means of real-time PCR on bronchoalveloar fluid cells after allergen challenge revealed a high-level expression of IL-10 and transforming growth factor beta predominantly in the CD14(+) population. Conclusion: Feeding infant beagles with OVA for 4 weeks is sufficient to prevent hallmark manifestations of asthma and allergy in adult life. The mechanism of oral tolerance involved an increased expression of IL-10 and transforming growth factor beta cytokines.	Novartis Res Inst, A-1235 Vienna, Austria; HealthEcon AG, Basel, Switzerland; Gerimmun Fdn, Fribourg, Switzerland	Novartis	Zemann, B (corresponding author), Novartis Res Inst, Brunner Str 59, A-1235 Vienna, Austria.							Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; ARAMAKI Y, 1994, IMMUNOL LETT, V40, P21, DOI 10.1016/0165-2478(94)90200-3; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; deWeck AL, 1997, INT ARCH ALLERGY IMM, V113, P55, DOI 10.1159/000237507; DEWECK AL, 1995, INT ARCH ALLERGY IMM, V107, P13, DOI 10.1159/000236918; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Garside P, 1999, GUT, V44, P137, DOI 10.1136/gut.44.1.137; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Pecquet S, 1999, IMMUNOLOGY, V96, P278, DOI 10.1046/j.1365-2567.1999.00678.x; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1994, ANN NY ACAD SCI, V725, P200, DOI 10.1111/j.1749-6632.1994.tb39802.x; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; THEPEN T, 1992, IMMUNOLOGY, V76, P60; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; vanHalteren AGS, 1997, J ALLERGY CLIN IMMUN, V99, P94, DOI 10.1016/S0091-6749(97)81049-4; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Weiner HL, 2000, J CLIN INVEST, V106, P935, DOI 10.1172/JCI11348; Wells HG, 1911, J INFECT DIS, V8, P66, DOI 10.1093/infdis/8.1.66; Whitacre CC, 1996, CLIN IMMUNOL IMMUNOP, V80, pS31, DOI 10.1006/clin.1996.0139; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245	27	50	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1069	1075		10.1067/mai.2003.1411	http://dx.doi.org/10.1067/mai.2003.1411			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743572				2022-12-18	WOS:000182904500022
J	Bodtger, U; Poulsen, LK; Malling, HJ				Bodtger, U; Poulsen, LK; Malling, HJ			Asymptomatic skin sensitization to birch predicts later development of birch pollen allergy in adults: A 3-year follow-up study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; asymptomatic sensitization; symptom development; challenge tests; skin prick test; late-phase reaction; birch pollen; specific IgE; histamine release	MESSENGER-RNA EXPRESSION; COLLEGE-STUDENTS; RHINITIS; IMMUNOTHERAPY; ASTHMA; TESTS; CELLS; IL-5	Background: The skin prick test is the allergologic test of choice, but asymptomatic skin sensitization to aeroallergens is common. However, no data in the literature describe the clinical phenotype of asymptomatic sensitized adults. Objective: The purposes of this investigation were to provide a clinical characterization of skin test-positive subjects without symptoms and to ascertain the predictive values of common allergologic tests. Methods: Asymptomatic adults with positive skin prick test results for birch (n = 15), nonatopic control subjects (n = 25), and birch pollen-allergic patients (n = 6) were followed through use of daily diary cards during 3 consecutive birch pollen seasons. At inclusion and at the 3-year follow-up visit, conjunctival and nasal challenges, intradermal late-phase reaction evaluation, and measurement of specific IgE were performed. Results: Asymptomatic sensitized subjects defined a clinically significant phenotype between nonatopic and allergic subjects in terms of specific IgE levels and susceptibility to conjunctival provocation testing. Sixty percent (n = 9) of the asymptomatic sensitized subjects developed clinical allergy. This was associated with an initial birch skin prick test weal diameter of 4 mm, a positive conjunctival provocation test result, and specific IgE of greater than or equal toCAP class 2, as well as with the presence of other allergies. Specific IgE of greater than or equal toCAP class 2 was 87.5% predictive for allergy development, whereas a negative conjunctival provocation test result was 100% negatively predictive. Nasal provocation testing possessed no additional prognostic information. No changes in clinical phenotype were seen in nonatopic or birch-allergic subjects. Conclusion: Asymptomatic skin sensitization is a risk factor for later allergy development. At risk is any subject with target organ sensitivity, an elevated specific IgE level, and/or a skin prick test weal diameter of >4 mm.	Natl Univ Hosp, Allergy Clin TA 7551, DK-2100 Copenhagen, Denmark		Bodtger, U (corresponding author), Natl Univ Hosp, Allergy Clin TA 7551, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X; Bodtger, Uffe/0000-0002-1231-9209				Bernstein DI, 1997, JAMA-J AM MED ASSOC, V278, P1907, DOI 10.1001/jama.278.22.1907; BJORKSTEN B, 1998, ALLERGY PRINCIPLES P, P816; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; CHAMBERS VV, 1958, J ALLERGY, V29, P249, DOI 10.1016/0021-8707(58)90009-1; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; HAAHTELA T, 1980, ALLERGY, V35, P433, DOI 10.1111/j.1398-9995.1980.tb01790.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; Hertz M, 2001, J IMMUNOL, V167, P3792, DOI 10.4049/jimmunol.167.7.3792; Hlastala MP, 2001, PHYSL RESP; HODAL L, 2000, 0012 AAF DMI; HORAK F, 1985, ARCH OTO-RHINO-LARYN, V242, P239, DOI 10.1007/BF00453546; HORAK F, 1981, WIEN KLIN WOCHENSCHR, V93, P87; Ihaka Ross., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.1080/10618600.1996.10474713, 10.2307/1390807]; Kakinoki Y, 1998, ACTA OTO-LARYNGOL, P152; Katz D H, 1979, Monogr Allergy, V14, P57; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; Nakai Y, 2000, ARCH OTOLARYNGOL, V126, P992, DOI 10.1001/archotol.126.8.992; Ohashi Y, 1998, SCAND J IMMUNOL, V47, P596; Pastorello E A, 1988, Boll Ist Sieroter Milan, V67, P377; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920, DOI 10.1164/ajrccm.162.3.9912030; RACKEMANN FRANCIS M., 1935, JOUR ALLERGY, V6, P184, DOI 10.1016/S0021-8707(35)90292-1; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SKOV PS, 1985, ALLERGY, V40, P213; TAUDORF E, 1988, INT ARCH ALLER A IMM, V86, P225, DOI 10.1159/000234576; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walter SD, 1992, BIOMETRICS, V48, P656; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; ZWICK H, 1991, ALLERGY, V46, P362, DOI 10.1111/j.1398-9995.1991.tb00599.x	30	50	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					149	154		10.1067/mai.2003.37	http://dx.doi.org/10.1067/mai.2003.37			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532111				2022-12-18	WOS:000180465500023
J	Ownby, DR				Ownby, DR			A history of latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CALIFORNIA	Malaysian Rubber Res Inst		latex allergy; natural rubber; surgical gloves	NATURAL-RUBBER LATEX; CONTACT URTICARIA; CROSS-REACTIVITY; HEVEA-BRASILIENSIS; SURGICAL GLOVES; WEEPING FIG; ANAPHYLAXIS; BANANA; HYPERSENSITIVITY; ASTHMA	Archaeologists have found that latex items were used as early as 1600 BC, but it took until approximately 1900 AD before surgical gloves were commonly used. Descriptions of apparent allergic reactions to natural rubber appeared in the medical literature in 1927, and irritant and delayed-contact reactions were reported in 1933. Although irritant and delayed-contact reactions to rubber products were increasingly recognized, immediate-type allergic reactions were not reported again until 1979. However, after 1980, increasing numbers of contact urticarial reactions to latex were reported, and investigations suggested that many of these reactions were IgE-mediated. In 1984, the first anaphylactic reactions caused by latex surgical gloves were reported, followed in 1991 by the first report of a fatal anaphylactic reaction to latex. Increasing recognition of latex allergy led to divergent paths of investigation. Critical early questions were whether the observed reactions were truly IgE-mediated, and if they were IgE-mediated, what was the source of the allergen? If the allergen was present in latex products, where did it come from? Was it present in raw latex or was it added during processing? As knowledge about the allergens improved, efforts were made to develop and test materials for skin testing and for allergen-specific IgE assays. Now more than 10 unique proteins are recognized as major latex allergens. Although much has been learned about latex allergy, important unanswered questions remain, including the sources of latex exposure that led to sensitization, why latex allergy increased dramatically during the 1980s, and the prevalence of latex allergy in diverse populations. This review concentrates on the history of latex use in medicine and the dramatic emergence of immediate-type latex allergy.	Med Coll Georgia, Sect Allergy & Immunol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Ownby, DR (corresponding author), Med Coll Georgia, Sect Allergy & Immunol, BG 1019, Augusta, GA 30912 USA.							AXELSSON G, 1985, ALLERGY, V40, P461, DOI 10.1111/j.1398-9995.1985.tb02687.x; AXELSSON IGK, 1987, ALLERGY, V42, P604, DOI 10.1111/j.1398-9995.1987.tb00391.x; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; BOXER MB, 1994, J ALLERGY CLIN IMMUN, V93, P943, DOI 10.1016/0091-6749(94)90389-1; Brehler R, 1998, ALLERGY, V53, P402, DOI 10.1111/j.1398-9995.1998.tb03912.x; *CDCP, 1987, MMWR-MORBID MORTAL W, V36, P35; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CEUPPENS JL, 1992, LANCET, V339, P492; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DIEZGOMES ML, 1997, ANN ALLERG ASTHMA IM, V80, P24; Downing JG, 1933, NEW ENGL J MED, V208, P196, DOI 10.1056/NEJM193301262080406; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FUCHS T, 1994, J ALLERGY CLIN IMMUN, V93, P951, DOI 10.1016/0091-6749(94)90393-X; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; Grimm A., 1927, KLIN WOCHENSCHR, V6, P1479, DOI 10.1007/BF017185344.; Hosler D, 1999, SCIENCE, V284, P1988, DOI 10.1126/science.284.5422.1988; KLEINHANS D, 1984, CONTACT DERMATITIS, V10, P124, DOI 10.1111/j.1600-0536.1984.tb00363.x; KURUP VP, 1994, ALLERGY PROC, V15, P211, DOI 10.2500/108854194778702711; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657; Siler DJ, 1996, J ALLERGY CLIN IMMUN, V98, P895, DOI 10.1016/S0091-6749(96)80005-4; SLATER J, 1989, NEW ENGL J MED, V17, P1126; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; Stern G, 1927, KLIN WOCHENSCHR, V6, P1096; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; Turjanmaa K., 1984, ALLERGY, V39, pS2; Walbaum JJ., 1960, SURGEONS GLOVE; 1991, FDA MED B, V21, P2	41	50	53	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S27	S32		10.1067/mai.2002.125336	http://dx.doi.org/10.1067/mai.2002.125336			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	586ET	12170240	Bronze			2022-12-18	WOS:000177572200005
J	Johnson, EN; Druey, KM				Johnson, EN; Druey, KM			Heterotrimeric G protein signaling: Role in asthma and allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergic rhinitis; G proteins; inflammation; signal transduction	AIRWAY SMOOTH-MUSCLE; GTPASE-ACTIVATING PROTEINS; LEUKOTRIENE B-4 RECEPTOR; NITRIC-OXIDE SYNTHASE; T-CELL-ACTIVATION; COUPLED RECEPTOR; TYROSINE KINASE; DOWN-REGULATION; BETA-ARRESTINS; MICE LACKING	Asthma and rhinitis are pathophysiologic conditions associated with a prototypical allergic response to inhaled allergens consisting of both neuromechanical and inflammatory components. Heptahelical receptors that bind guanosine triphosphate-binding proteins (G proteins), referred to as G protein-coupled receptors (GPCRs), have been intimately linked with asthma and allergic inflammation for Man. years. G protein signaling mediates responses throughout the immune, nervous, and muscular systems that might contribute to the pathogenesis of allergic processes and asthma. For example, GPCR agonists or antagonists are used as therapies for asthma either by promoting airway smooth muscle relaxation (beta2 adrenergic receptor agonists) or by inhibiting inflammation in the nasal mucosa and airways (cysteinyl leukotriene receptor antagonists), The focus of this review is to explore how downstream signaling cascades elicited by GPCR activation contribute to the allergic phenotype and the mechanism by which pharmaceuticals alter signaling to generate a therapeutic effect. We also discuss physiologic modulators of G protein signaling, such as regulator of G protein signaling proteins and G protein receptor kinases, inasmuch as they represent potential new therapeutic targets in the treatment of atopy and other inflammatory conditions.	NIAID, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Druey, KM (corresponding author), NIAID, Lab Allerg Dis, NIH, 12441 Parklawn Dr,Room 200E, Rockville, MD 20852 USA.							Advenier C, 1999, CLIN EXP ALLERGY, V29, P579; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Barnes PJ, 1999, J ALLERGY CLIN IMMUN, V104, pS10, DOI 10.1016/S0091-6749(99)70269-1; Bartemes KR, 1999, J IMMUNOL, V162, P2982; Beadling C, 1999, J IMMUNOL, V162, P2677; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; Braun MC, 2001, MICROBES INFECT, V3, P99, DOI 10.1016/S1286-4579(00)01357-5; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Chiappara G, 2001, CURR OPIN ALLERGY CL, V1, P85, DOI 10.1097/00130832-200102000-00015; Chiba Y, 1999, BRIT J PHARMACOL, V127, P597, DOI 10.1038/sj.bjp.0702585; Chiba Y, 2001, INFLAMM RES, V50, P333, DOI 10.1007/PL00000253; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; DEVOUASSOUX G, 1999, J IMMUNOO, V163, P107; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DRUEY KM, 2001, SCI STKE, V104, pRE14, DOI DOI 10.1126/STKE.2001.1104.RE1114; DuBuske LM, 2001, ALLERGY ASTHMA PROC, V22, P261; Finney PA, 2000, J CLIN INVEST, V106, P125, DOI 10.1172/JCI8374; Fryer AD, 1998, AM J RESP CRIT CARE, V158, pS154, DOI 10.1164/ajrccm.158.supplement_2.13tac120; Fujikura T, 2001, J ALLERGY CLIN IMMUN, V107, P123, DOI 10.1067/mai.2001.111236; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115, DOI 10.1164/ajrccm.158.supplement_2.13tac700; Hallsworth MP, 2001, BRIT J PHARMACOL, V132, P729, DOI 10.1038/sj.bjp.0703866; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOERNQUIST CE, 1997, J IMMUNOL, V158; Joos GF, 2000, CLIN EXP ALLERGY, V30, P60; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kaburagi Y, 2001, ARCH DERMATOL RES, V293, P350, DOI 10.1007/s004030100230; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kitamura K, 1996, J BIOL CHEM, V271, P7412, DOI 10.1074/jbc.271.13.7412; Kraneveld AD, 2000, EUR J PHARMACOL, V405, P113, DOI 10.1016/S0014-2999(00)00546-X; KRYMSKA VP, 1997, AM J PHYSIOL, V277, pL65; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; Lazzeri N, 2001, AM J RESP CELL MOL, V24, P44, DOI 10.1165/ajrcmb.24.1.4027; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lippert E, 1997, FEBS LETT, V417, P292, DOI 10.1016/S0014-5793(97)01308-2; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Lowry WE, 2002, J BIOL CHEM, V277, P1488, DOI 10.1074/jbc.M110390200; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Lynch KR, 1999, NATURE, V399, P789; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marquardt DL, 1998, ADV EXP MED BIOL, V431, P79; Mohanty JG, 2001, J ALLERGY CLIN IMMUN, V107, P849, DOI 10.1067/mai.2001.114658; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEWMAN DJ, 1979, BIOCHEM PHARMACOL, V47, P330; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Reynolds PN, 1997, CLIN EXP PHARMACOL P, V24, P273, DOI 10.1111/j.1440-1681.1997.tb01819.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; RUDOLPH U, 1995, J CLIN IMMUNOL, V15, pS101, DOI 10.1007/BF01540899; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Stanners J, 1995, J BIOL CHEM, V270, P30635, DOI 10.1074/jbc.270.51.30635; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Sweeney HL, 1998, AM J RESP CRIT CARE, V158, pS95, DOI 10.1164/ajrccm.158.supplement_2.13tac400; Thirstrup S, 2000, RESP MED, V94, P519, DOI 10.1053/rmed.1999.0738; Trakada G, 2000, RESP MED, V94, P992, DOI 10.1053/rmed.2000.0890; Trifilieff A, 2000, J IMMUNOL, V165, P1526, DOI 10.4049/jimmunol.165.3.1526; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; WIDDICOMBE JG, 1983, EUR J RESPIR DIS, V64, P65; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhou J, 1998, EUR J IMMUNOL, V28, P1645, DOI 10.1002/(SICI)1521-4141(199805)28:05<1645::AID-IMMU1645>3.0.CO;2-D	92	50	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					592	602		10.1067/mai.2002.122636	http://dx.doi.org/10.1067/mai.2002.122636			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941304	Bronze			2022-12-18	WOS:000175132600002
J	Lee, YC; Song, CH; Lee, HB; Oh, JL; Rhee, YK; Park, HS; Koh, CY				Lee, YC; Song, CH; Lee, HB; Oh, JL; Rhee, YK; Park, HS; Koh, CY			A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toluene diisocyanate; matrix metalloproteinase; asthma; airway hyperresponsiveness	TISSUE INHIBITOR; POLYMORPHONUCLEAR NEUTROPHILS; BASEMENT-MEMBRANE; INFLAMMATION; COLLAGENASE; MODULATION; MIGRATION; FIBROSIS; DISEASE; SPUTUM	Background: Toluene diisocyanate (TDI) is a leading cause of occupational asthma. TDI-induced asthma is an inflammatory disease of the airways that is associated with airway remodeling. However, there are little data available on the role of matrix metalloproteinases (MMPs) in TDI-induced asthma. Objective: We. evaluated whether MMP-9 participates in the airway inflammation in TDI-induced asthma. An additional aim of the present study was to determine whether MMP inhibitors could be effective therapeutic agents for TDI-induced asthma. Methods: We developed a murine model of TDI-induced asthma to examine the involvement of MMPs by performing 2 sensitizations with 3% TDI and 1 challenge with 1% TDI using ultrasonic nebulization. Results: Marine TDI-induced asthma includes findings of (1) increased inflammatory cells, including neutrophils, lymphocytes, and eosinophils; (2) histologic changes, including infiltration of inflammatory cells around bronchioles, thickened airway epithelium, and accumulation of mucus and debris in the bronchioles; (3) increased MMP-9 activity in inflammatory cells in the airway lumen; and (4) airway hyperresponsiveness. Administration of an MMP inhibitor remarkably reduced all these pathophysiologic findings. Conclusion: We conclude that TDI-induced occupational asthma is associated with the induction of MMP-9 in inflammatory cells, and the inhibition of MMP-9 may be a good therapeutic strategy.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Chonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Anat, Chonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Natl Creat Res Initiat Ctr Endothelial Cells, Chonju 561712, South Korea; Ajou Univ Hosp, Dept Allergy & Clin Immunol, Suwon, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Ajou University; Ajou University Hospital	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, 634-18 Keumamdong, Chonju 561712, South Korea.		Park, Hae-Sim/S-7974-2019; Koh, Gou Young/C-1615-2011	Park, Hae-Sim/0000-0003-2614-0303				BOSCHETTO P, 1987, J ALLERGY CLIN IMMUN, V80, P261, DOI 10.1016/0091-6749(87)90028-5; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; DELACOURT C, 1995, AM J RESP CRIT CARE, V152, P765, DOI 10.1164/ajrccm.152.2.7633740; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; FABBRI LM, 1991, EUR RESPIR J, V4, pS136; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kumagai K, 1999, J IMMUNOL, V162, P4212; MAPP CE, 1987, B EUR PHYSIOPATH RES, V23, P583; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; Park Hae-Sim, 1998, Journal of Korean Medical Science, V13, P21; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; Ricou B, 1996, AM J RESP CRIT CARE, V154, P346, DOI 10.1164/ajrccm.154.2.8756805; Scheerens H, 1999, AM J RESP CRIT CARE, V159, P1074, DOI 10.1164/ajrccm.159.4.9701012; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; SIBILLE Y, 1993, EUR RESPIR J, V6, P1529; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014	26	50	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1021	1026		10.1067/mai.2001.120132	http://dx.doi.org/10.1067/mai.2001.120132			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742282	Green Published			2022-12-18	WOS:000172938400020
J	Sexton, DW; Blaylock, MG; Walsh, GM				Sexton, DW; Blaylock, MG; Walsh, GM			Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: A process upregulated by dexamethasone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epithelial cells; eosinophils; apoptosis; asthma; phagocytic recognition; corticosteroids	PHOSPHOLIPID ASYMMETRY; INFLAMMATORY CELLS; DENDRITIC CELLS; PHAGOCYTOSIS; RECOGNITION; MACROPHAGES; BETA; CORTICOSTEROIDS; ALPHA(V)BETA(5); EXPOSURE	Background: We previously demonstrated receptor-mediated apoptotic-eosinophil engulfment by human small airway epithelial cells, which may represent a potentially important mechanism in the resolution of allergic and asthmatic inflammation. Objective: A549 cells were selected as being representative of alveolar epithelial cells, and their ability to ingest human apoptotic eosinophils was examined in terms of the effects of dexamethasone treatment and the receptor-mediated recognition mechanisms important in this process. Methods: A549 epithelial-cell expression of alphav beta3, alphav beta5, CD36, and the phosphatidylserine receptor was established by using immunostaining and flow cytometry, and inhibition assays were examined by using the role of these receptors in apoptotic-eosinophil recognition by resting and dexamethasone-treated A549 epithelial cells. Electron microscopy confirmed engulfment of apoptotic eosinophils, and receptor clustering around apoptotic eosinophils was examined by using immunofluorescent labeling. Results: A549 epithelial cells recognized and engulfed apoptotic eosinophils but not freshly isolated cells. Dexamethasone enhanced the number of A549 cells ingesting apoptotic eosinophils and dose dependently increased their capacity for ingestion. The tetrapeptide RGDS significantly inhibited apoptotic-eosinophil uptake by A549 cells, indicating a role for integrins in the recognition process. A549 cells expressed alphav beta3, alphav beta5, beta5, CD36, and the phosphatidylserine receptor, and expression of these receptors was not significantly increased after dexamethasone treatment. Engulfment of apoptotic eosinophils by A549 cells involved alphav beta3-, CD36-, alphav beta5-, and phosphatidylserine receptor-mediated recognition mechanisms and was associated with the formation of integrin focal adhesion complexes around apoptotic eosinophils. Conclusions: These data further suggest a nonpassive role for airway epithelium in the resolution of eosinophilic inflammation in asthma.	Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Walsh, GM (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, IMS Bldg, Aberdeen AB25 2ZD, Scotland.		Walsh, Garry/D-4869-2013; Sexton, Darren/AAF-3171-2020	Walsh, Garry/0000-0002-7138-4078; Sexton, Darren/0000-0003-3344-3150				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; Blaylock MG, 1999, J ALLERGY CLIN IMMUN, V104, P1244, DOI 10.1016/S0091-6749(99)70020-5; Cohen JJ, 1999, J ALLERGY CLIN IMMUN, V103, P548, DOI 10.1016/S0091-6749(99)70222-8; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HALL SE, 1994, J IMMUNOL, V153, P3218; HOGG N, 1984, IMMUNOLOGY, V53, P753; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Meagher LC, 1996, J IMMUNOL, V156, P4422; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Sanmugalingham D, 2000, CLIN EXP ALLERGY, V30, P255; Saunders MW, 1999, LARYNGOSCOPE, V109, P785, DOI 10.1097/00005537-199905000-00019; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; Stern M, 1996, AM J PATHOL, V149, P911; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; Walsh GM, 1999, BLOOD, V94, P2827, DOI 10.1182/blood.V94.8.2827.420a04_2827_2835; Walsh GM, 1999, CRIT REV CL LAB SCI, V36, P453, DOI 10.1080/10408369991239277; Walsh GM, 2000, BRIT J HAEMATOL, V111, P61; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	34	50	53	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					962	969		10.1067/mai.2001.119414	http://dx.doi.org/10.1067/mai.2001.119414			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742274				2022-12-18	WOS:000172938400012
J	Sin, AZ; Roche, EM; Togias, A; Lichtenstein, LM; Schroeder, JT				Sin, AZ; Roche, EM; Togias, A; Lichtenstein, LM; Schroeder, JT			Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neurotrophin; cytokine; allergy; basophil; histamine; IgE	MIXED LEUKOCYTE-CULTURES; HISTAMINE-RELEASE; MAST-CELLS; ACTIVATION; SECRETION; RECEPTOR; DIFFERENTIATION; INTERLEUKIN-13; EOSINOPHILS; EXPRESSION	Background: Studies show that nerve growth factor (NGF) exhibits immunomodulatory activity. This neurotrophin is found at high levels in the serum of asthmatic individuals, is released during allergic reactions, and is reported to augment in vitro histamine and leukotriene C4 release by human basophils. Objective: Because basophils represent a substantial source of IL-4 and IL-13, we tested the effects or NGF on the secretion of these cytokines by cells prepared from allergic subjects and cells prepared from nonallergic subjects. Methods. Cytokine and histamine were measured in culture supernatants by ELISA and fluorimetry, respectively. Both real-time RT-PCR and conventional RT-PCR were used to measure IL-13 mRNA expression. NGF receptor expression was determined by 2-color flow cytometry. Results: Basopbil suspensions from allergic subjects secreted some 2.5-fold greater levels of IL-13 when cultured with NGF than did cells prepared from normal control subjects. Flow cytometry revealed no significant differences in TrkA receptors on basophils to explain these findings. The levels of IL-13 secreted by the 2 groups of donors also differed when cells were activated with IL-3 but not when they were activated with anti-IgE antibody. Both NGF and IL-3 failed to induce IL-13 in cell cultures depleted of basophils, suggesting that the measurable IL-13 was indeed basophil-derived. Real-time RT-PCR showed an average induction of IL-13 message above medium control that was 4.3 (+/- 1.7)-fold with NGF and 8.9 (+/- 3.7)-fold with IL-3. Finally, NGF priming resulted in a remarkable enhancement of IL-13 induced by anti-IgE. This was significantly greater than the priming observed for either the IL-4 or histamine when this stimulus was used. Conclusion: NGF (like IL-3) can both directly stimulate IL-13 secretion and modulate IgE-mediated responses in basophils. Its enhanced effect on cells from allergic individuals raises the importance of this cytokine in the pathogenesis of allergic disease.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Dept Med, Unit Off 2, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Dept Med, Unit Off 2, 5501 Ctr,Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042221, R21AI042221, R29AI042221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62204] Funding Source: Medline; NIAID NIH HHS [AI42221, AI07290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1980, MEASUREMENT TOTAL SE; BISCHOFF SC, 1992, BLOOD, V79, P2662; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Burgi B, 1996, J IMMUNOL, V157, P5582; GILBERT HS, 1975, BLOOD, V46, P279; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; HUANG SK, 1995, J IMMUNOL, V155, P2688; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; Oriente A, 2000, J PHARMACOL EXP THER, V292, P988; Redrup AC, 1998, J IMMUNOL, V160, P1957; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; SCHROEDER J, 2001, IN PRESS J ALLERGY C; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 1998, ASTHMA AND ALLERGIC DISEASES, P75, DOI 10.1016/B978-012473340-4/50009-6; Schroeder JT, 1998, J LEUKOCYTE BIOL, V63, P692, DOI 10.1002/jlb.63.6.692; Schroeder JT, 1999, INT ARCH ALLERGY IMM, V118, P87, DOI 10.1159/000024036; Simone MD, 1999, HEMATOL ONCOL, V17, P1; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; TSUDA T, 1991, BLOOD, V77, P971; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; Xiang Z, 2000, CLIN EXP ALLERGY, V30, P1379, DOI 10.1046/j.1365-2222.2000.00906.x	26	50	51	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					387	393						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544458				2022-12-18	WOS:000171215400010
J	Saini, SS; Richardson, JJ; Wofsy, C; Lavens-Phillips, S; Bochner, BS; MacGlashan, DW				Saini, SS; Richardson, JJ; Wofsy, C; Lavens-Phillips, S; Bochner, BS; MacGlashan, DW			Expression and modulation of Fc epsilon RI alpha and Fc epsilon RI beta in human blood basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptors; basophils; IL-3	HIGH-AFFINITY; IMMUNOGLOBULIN-E; PERIPHERAL-BLOOD; IGE ANTIBODY; IN-VIVO; ANTIGEN-BINDING; DOWN-REGULATION; CELLS EXPRESS; RECEPTOR; EOSINOPHILS	Background: The IgE receptor (Fc epsilon RI) may exist as a tetramer (alpha beta gamma2) or a trimer (alpha gamma2) because Fc epsilon RI beta is dispensable for membrane expression of Fc epsilon RI alpha. Fc epsilon RI beta amplifies signaling of FceRI so that regulation of FceRIa: P stoichiometry would affect cellular responsiveness. Objective: We examined basophils from a variety of donors fur differences in their expression of Fc epsilon RI alpha and Fc epsilon RI beta protein. Methods: Enriched blood basophils were assessed at baseline and after IL-3 culture for Fc epsilon RI alpha and Fc epsilon RI beta protein by Western blotting, surface Fc epsilon RI alpha by flow cytometry, and Fc epsilon RI beta mRNA by real-time PCR, Basophil functional response was measured by allergen-triggered histamine release. Results: For the FceRIa subunit, 2 protein bands with molecular weights of 50 kd and 60 kd were identified by Western blots. The 60-kd band correlated to surface-expressed Fc epsilon RI alpha detected by flow cytometry (Spearman R = 0.78, P < .01). Surface FceRIa also correlated with Fc epsilon RI beta protein (Spearman R = 0.92, P < .01), Fc epsilon RI beta protein levels increased disproportionately with higher surface Fc epsilon RI alpha expression, The ratio of Fc epsilon RI beta to FceRIa varied 10-fold among donors and correlated with surface FceRIa. Basophil 50-kd a protein levels were similar despite a 10-fold range in surface Fc epsilon RI alpha expression, implying stores of this protein such as those found in eosinophils, Unlike eosinophils, the basophil 50-kd protein was lost with culture and was absent from supernatants. Levels of p protein and mRNA were enhanced by IL-3 culture, whereas Fc epsilon RI alpha expression (by now cytometry and 60 kd) was not. Conclusion: These findings demonstrate variable stoichiometry of FceRIa:P in whole cells and that this stoichiometry can be altered by IL-3 culture. With the assumption that all detected p protein is surface expressed, these findings suggest a variable stoichiometry for FceRIa:P that is also related to FceRIa surface expression.	Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, Baltimore, MD USA; Univ New Mexico, Dept Math & Stat, Albuquerque, NM 87131 USA	Johns Hopkins University; University of New Mexico	Saini, SS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042220] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42220, AI01564] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; GILBERT HS, 1975, BLOOD, V46, P279; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kita H, 1999, J IMMUNOL, V162, P6901; KUSTER H, 1992, J BIOL CHEM, V267, P12782; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MACGLASHAN DW, 1993, J IMMUNOL, V151, P6358; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J ALLERGY CLIN IMMUN, V61, P176, DOI 10.1016/0091-6749(78)90398-6; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MILLER L, 1989, SCIENCE, V244, P334, DOI 10.1126/science.2523561; Miura K, 2000, J IMMUNOL, V164, P3026, DOI 10.4049/jimmunol.164.6.3026; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; RISKE F, 1991, J BIOL CHEM, V266, P11245; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 1999, J IMMUNOL, V162, P5624; Seminario MC, 1999, J IMMUNOL, V162, P6893; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Sokal R, 1981, BIOMETRY, V2nd; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4	36	50	53	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					832	841		10.1067/mai.2001.114653	http://dx.doi.org/10.1067/mai.2001.114653			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344350	Bronze			2022-12-18	WOS:000168812300011
J	Grote, M; Vrtala, S; Niederberger, V; Valenta, R; Reichelt, R				Grote, M; Vrtala, S; Niederberger, V; Valenta, R; Reichelt, R			Expulsion of allergen-containing materials from hydrated rye grass (Lolium perenne) pollen revealed by using immunogold field emission scanning and transmission electron microscopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						thunderstorm asthma; rye grass pollen; allergens; immunogold labeling; electron microscopy	IGE ANTIBODIES; ASTHMA; LOCALIZATION; PARTICLES; SMALLER; PHL-P-1	Background: Several studies demonstrated episodes of grass pollen-induced allergic asthma after heavy rainfalls. It has been hypothesized that these asthma attacks might be due to the release of respirable allergen-bearing particles from pollen cytoplasm. Objective: In this study we investigated the release mechanism of the most potent and frequently recognized grass pollen allergens, group 1 and group 5, from freshly harvested and subsequently hydrated rye grass pollen at the ultrastructural level, Methods: Rabbit antisera against purified recombinant group 1 and group 5 allergens were used to investigate, by using field emission scanning and transmission immunogold electron microscopy, the allergen release from rye grass pollen grains into isotonic aqueous solutions or water. Results: Pollen grains exposed to isotonic aqueous solutions remained intact and released allergens by means of diffusion. However, pollen grains hydrated in distilled mater or rainwater expelled starch grains and cytoplasmic debris of respirable size. Group 1 and group 5 allergens were observed on and within these materials. Conclusions: Exposure of rye grass pollen to water leads to an expulsion of subcellular allergen-containing pollen components of respirable size. Our ultrastructural data thus support the idea that this release of allergen-containing respirable pollen materials may be a cause of asthma attacks after heavy rainfalls.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Univ Vienna, Dept Pathophysiol, A-1010 Vienna, Austria; Univ Vienna, Dept Otorhinolaryngol, A-1010 Vienna, Austria	University of Munster; University of Vienna; University of Vienna	Grote, M (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert-Koch-Str 31, D-48149 Munster, Germany.			Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P190; Grote M, 1999, INT ARCH ALLERGY IMM, V118, P1, DOI 10.1159/000024024; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; Hayat M.A., 1989, PRINCIPLES TECHNIQUE, DOI DOI 10.1007/978-1-349-09857-6; Hayat MA, 1981, FIXATION ELECT MICRO; HESLOP-HARRISON J, 1979, Annals of Botany (London), V44, P1; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STAFF IA, 1990, HISTOCHEM J, V22, P276, DOI 10.1007/BF01387183; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4	18	50	51	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1140	1145		10.1067/mai.2000.107044	http://dx.doi.org/10.1067/mai.2000.107044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856148				2022-12-18	WOS:000087781800015
J	Lavigne, F; Nguyen, CT; Cameron, L; Hamid, Q; Renzi, PM				Lavigne, F; Nguyen, CT; Cameron, L; Hamid, Q; Renzi, PM			Prognosis and prediction of response to surgery in allergic patients with chronic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; allergy; IL-5; complications of sinus surgery; outcome after sinus surgery	CHRONIC RHINOSINUSITIS; OBJECTIVE ASSESSMENT; CYTOKINE EXPRESSION; MANAGEMENT; RHINITIS; CELLS	Background: Chronic rhinosinusitis (CRS) occurs frequently in patients with atopy, but little is known of the prognosis after surgery and of factors that may predict a poor outcome. Objective: Our purpose was to assess the long-term prognosis in atopic patients with CRS who undergo surgery and whether certain immune markers could predict a worse prognosis in this setting. Methods: Fifteen patients with diffuse involvement of the sinuses on computed tomographic (CT) scan but without nasal polyposis underwent ethmoidectomy with middle meatotomy for CRS when it was clinically indicated. All patients had a biopsy of the inferior turbinate and of the most inflamed areas of the maxillary and ethmoid sinuses at the time of surgery. Follow-up was performed by video endoscopy and by assessment of 2 chronic sinusitis questionnaires at 0, 6, and 24 months postoperatively. The number of lymphocyte subsets (CD3, CD4, CD8), mast cells and eosinophils, and cells expressing IL-4 and IL-5 messenger RNA (mRNA) in all 3 biopsy sites at the time of surgery were compared with the clinical response after surgery. Results: Seven patients had persistent improvement after surgery, with a decrease in pain, rhinorrhea, or nasal obstruction and a decrease in the need for medication. Eight patients were unchanged or worsened after surgery with disabling rhinorrhea and repeated sinusitis. We found no difference in the number of inflammatory cells, lymphocyte subsets, or IL-4 mRNA-positive cells in the sinus mucosa between responders and nonresponders, However, an increased number of cells expressing IL-5 mRNA was found in the ethmoid sinus at the time of surgery in patients who did not respond to the surgical intervention (P =.007). Conclusion: More than 50% of patients with perennial rhinitis and CRS do not improve after surgery, a response that may be predicted by more cells expressing IL-5 mRNA in the ethmoid sinuses. The increased number of cells expressing IL-5 mRNA may have the potential to be used as a marker for prediction of the response to surgery. The worsening of symptoms in some patients with CRS after sinus surgery could be a result of the disturbance of the anatomy of the sinuses and exposure to the environmental allergens.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Universite de Montreal; McGill University	Lavigne, F (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.							Abbas KA, 1997, CELLULAR MOL IMMUNOL; Anand VK, 1997, OTOLARYNG HEAD NECK, V117, pS50, DOI 10.1016/S0194-5998(97)70007-X; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; BERTOLINI JN, 1993, EUR J IMMUNOL, V23, P398, DOI 10.1002/eji.1830230215; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Gliklich RE, 1998, OTOLARYNG HEAD NECK, V118, P344, DOI 10.1016/S0194-5998(98)70313-4; GLIKLICH RE, 1995, LARYNGOSCOPE, V105, P387, DOI 10.1288/00005537-199504000-00010; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hoover GE, 1997, J ALLERGY CLIN IMMUN, V100, P185, DOI 10.1016/S0091-6749(97)70223-9; HOSEMANN W, 1993, AM J RHINOL, V7, P11, DOI 10.2500/105065893781976564; Kamil A, 1998, OTOLARYNG HEAD NECK, V118, P804, DOI 10.1016/S0194-5998(98)70273-6; Kennedy D W, 1992, Laryngoscope, V102, P1; Kennedy DW, 1997, OTOLARYNG CLIN N AM, V30, P313; Kopp W, 1991, FUNCTIONAL ENDOSCOPI; Leopold D, 1997, OTOLARYNG HEAD NECK, V117, pS58, DOI 10.1016/S0194-5998(97)70009-3; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P1; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; LUND VJ, 1994, J LARYNGOL OTOL, V108, P749, DOI 10.1017/S0022215100128014; LUND VJ, 1991, J LARYNGOL OTOL, V105, P832, DOI 10.1017/S0022215100117463; LUND VJ, 1994, J ROY SOC MED, V87, P70; MABRY RL, 1994, OTOLARYNG HEAD NECK, V111, P335, DOI 10.1177/01945998941113P201; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; SALVIN RG, 1985, J ALLERGY CLIN IMMUN, V82, P950; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YING S, 1994, IMMUNOLOGY, V82, P200	26	50	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					746	751		10.1067/mai.2000.105218	http://dx.doi.org/10.1067/mai.2000.105218			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756225				2022-12-18	WOS:000086604100013
J	Day, JH; Briscoe, MP; Rafeiro, E; Ellis, AK; Pettersson, E; Akerlund, A				Day, JH; Briscoe, MP; Rafeiro, E; Ellis, AK; Pettersson, E; Akerlund, A			Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studied in a controlled exposure model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide aqueous nasal spray; Rhinocort Aqua; onset of action; seasonal allergic rhinitis; ragweed pollen; environmental exposure unit; allergy	NASAL SPRAY; DOUBLE-BLIND; EFFICACY; CETIRIZINE; PLACEBO; UNIT; TERFENADINE; ASTEMIZOLE; LORATADINE	Background: Intranasal budesonide aqueous nasal spray (BANS) is recognized as an efficacious treatment for seasonal allergic rhinitis (SAR), but the time to onset of action is not known. Objective: The primary objective was to evaluate the time at which the onset of action of BANS in the symptomatic relief of seasonal allergic rhinitis becomes evident within 12 hours after a single dose in a controlled ragweed pollen exposure setting. Methods: The study was of a double-blind, randomized, parallel-group design, testing BANS (64 mu g and 256 mu g) and placebo on ragweed-sensitive subjects with symptoms for at feast 1 year by using a controlled pollen challenge system (Environmental Exposure Unit). The efficacy variables a ere the combined nasal score (the sum of blocked nose, runny nose, and sneezing-itchy nose), individual nasal symptoms, overall evaluation of treatment efficacy reported by participants on diaries, and peak nasal inspiratory flow (PNIF), Results: A total of 217 participants were treated with BANS or placebo. At 7 to 12 hours, BANS was better than placebo in reducing combined nasal and blocked nose symptoms. For PNIF, the time to onset of action was shortest for 256 mu g of BANS relative to placebo (3 hours, P = .003). BANS 64 mu g was better than placebo in reducing the individual scores of blocked nose, runny nose, and sneezing itchy nose from 3 to 5 hours after administration. Treatment efficacy was higher for those receiving BANS compared with placebo starting at 5 hours. All treatments were well tolerated, and no specific adverse events occurred. Conclusions: The onset of action of Intranasal BANS was 7 hours according to combined nasal and blocked nose symptom scores. Evidence of earlier response was observed at 3 hours for runny nose and PNIF.	Kingston Gen Hosp, Div Allergy & Immunol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; AstraZeneca R&D, Lund, Sweden	Queens University - Canada; Queens University - Canada; AstraZeneca	Day, JH (corresponding author), Kingston Gen Hosp, Div Allergy & Immunol, 76 Stuart St, Kingston, ON K7L 2V7, Canada.			Ellis, Anne/0000-0002-0725-2353				Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; Day JH, 1999, ANN ALLERG ASTHMA IM, V83, P83, DOI 10.1016/S1081-1206(10)62616-6; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163, DOI 10.1016/S1081-1206(10)63104-3; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638, DOI 10.1016/S0091-6749(98)70172-1; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533, DOI 10.1016/S1081-1206(10)63062-1; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; LINDQVIST N, 1989, CLIN OTOLARYNGOL, V14, P519, DOI 10.1111/j.1365-2273.1989.tb00416.x; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; Stern MA, 1997, AM J RHINOL, V11, P323, DOI 10.2500/105065897781446658; SVENSJO E, 1985, PROG RESPIR RES, V19, P173	14	50	53	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					489	494		10.1067/mai.2000.104550	http://dx.doi.org/10.1067/mai.2000.104550			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719298	Bronze			2022-12-18	WOS:000088946700014
J	Papi, A; Papadopoulos, NG; Degitz, K; Holgate, ST; Johnston, SL				Papi, A; Papadopoulos, NG; Degitz, K; Holgate, ST; Johnston, SL			Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinovirus; intercellular adhesion molecule-1; corticosteroids	NF-KAPPA-B; TRANSCRIPTIONAL REGULATION; MOMETASONE FUROATE; II PNEUMOCYTES; IN-VITRO; T-CELLS; ASTHMA; ICAM-1; EXPRESSION; INFECTIONS	Background: Rhinoviruses are associated with the majority of asthma exacerbations. To date, the pathogenesis of virus-induced asthma exacerbations is still unclear, and no safe effective therapy is available, Intercellular adhesion molecule-1 (ICAM-1) has a central role in inflammatory cell recruitment to the airways in asthma and is the receptor for 90% of rhinoviruses. We have previously shown that rhinovirus infection of lower airway epithelium induces ICAM-1 expression by a transcriptional mechanism that is critically nuclear factor-kappa B-dependent. Objective: The purpose of this study was to investigate the effect of systemic (hydrocortisone [HC], dexamethasone [DM]) and topical (mometasone furoate [MF]) corticosteroids on rhinovirus-induced ICAM-1 up-regulation. Methods: Cultured primary bronchial or transformed (A549) respiratory epithelial cells were pretreated with corticosteroids for 16 hours and infected with rhinovirus type 16 for 8 hours. ICAM-1 surface expression was evaluated by flow cytometry, In A549 cells ICAM-1 messenger RNA was evaluated by specific reverse transcription-PCR and promoter activation by chloramphenicol acetyltransferase assay. Results: We observed inhibition of rhinovirus-induced ICAM-1 up-regulation with corticosteroid pretreatment in both primary bronchial epithelial and A549 cells. In A549 cells systemic and topical corticosteroids demonstrated a dose-dependent inhibition with similar efficacy (inhibitory concentration 50% 10(-10) mol/L, 10(-11) mol/L, and 10(-11) mol/L for HC, DM, and MF respectively). MF also inhibited ICAM-1 messenger RNA induction by rhinovirus infection in a dose-dependent manner. MF completely inhibited rhinovirus-induced ICAM-1 promoter activation. HC, DM, and MF had no direct effect on rhinovirus infectivity and replication in cultured cells. Conclusion: Corticosteroids decrease rhinovirus-induced ICAM-1 up-regulation in respiratory epithelial cells and modulate pretranscriptional mechanisms. This effect may be important for the therapeutic control of virus-induced asthma exacerbations.	Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England; Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Southampton; University of Munich	Johnston, SL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Resp Med, Norfolk Pl, London W2 1PG, England.		Papi, alberto/AAC-1888-2019; N.G., Papadopoulos/L-8670-2013; Johnston, Sebastian Lennox/I-2423-2012; Papadopoulos, Nikolaos/ABE-1774-2021	N.G., Papadopoulos/0000-0002-4448-3468; Johnston, Sebastian Lennox/0000-0003-3009-9200; Papadopoulos, Nikolaos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872; PAPI, ALBERTO/0000-0002-6924-4500				Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; BARTON BE, 1991, IMMUNOPHARM IMMUNOT, V13, P251, DOI 10.3109/08923979109019704; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; CUNNINGHAM AC, 1994, J CELL SCI, V107, P443; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GIP L, 1998, TODAY THER TRENDS, V5, P21; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GUZMAN J, 1994, EUR RESPIR J, V7, P736, DOI 10.1183/09031936.94.07040736; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, pS46, DOI 10.1164/ajrccm/152.4_Pt_2.S46; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEFF AR, 1991, AM J PHYSIOL, V260, P189; MANOLITSAS ND, 1994, EUR RESPIR J, V7, P1439, DOI 10.1183/09031936.94.07081439; MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 1997, CLIN EXP ALLERGY, V27, P721, DOI 10.1046/j.1365-2222.1997.00090.x; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	39	50	52	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				318	326		10.1016/S0091-6749(00)90082-4	http://dx.doi.org/10.1016/S0091-6749(00)90082-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669853				2022-12-18	WOS:000085402200017
J	Weiss, ST				Weiss, ST			Parasites and asthma/allergy: What is the relationship?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						parasites; helminths; asthma; allergy; genetics; atopy; IgE	ALLERGIC REACTIVITY; TROPICAL ENVIRONMENT; SCHISTOSOMA-MANSONI; ANTHELMINTIC TREATMENT; HELMINTHIC INFECTION; SLUM CHILDREN; IGE RESPONSE; ASTHMA; PREVALENCE; CELLS	Asthma prevalence is increasing in Western industrialized countries. The infectious theory of asthma onset hypothesizes that lower levels of IL-12 result in reduced T(H)1 stimulation and failure of the neonate to deviate from its T(H)2 bias at birth. Helminthic infections may influence T(H)2 immune responses and hence immune development. Although ecologic data would support a protective effect of parasitic infection on asthma development, this may be due to other exposures, To date, there is no conclusive evidence that parasitic infection protects against asthma development.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Weiss, ST (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.							BEFUS AD, 1982, PROG ALLERGY, V31, P76; CARSWELL F, 1977, CLIN ALLERGY, V7, P445, DOI 10.1111/j.1365-2222.1977.tb01475.x; CHEAH JS, 1972, AUST NZ J MED, V2, P383, DOI 10.1111/j.1445-5994.1972.tb03940.x; GRANT EN, 1999, J ALLERGY CLIN IMM S, V104, pS109; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; HAGEL I, 1993, T ROY SOC TROP MED H, V87, P16, DOI 10.1016/0035-9203(93)90401-B; JARRETT E E E, 1973, Clinical Allergy, V3, P203, DOI 10.1111/j.1365-2222.1973.tb01322.x; JOUBERT JR, 1979, S AFR MED J, V56, P599; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; King CL, 1997, J IMMUNOL, V158, P294; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1999, THORAX, V54, P659, DOI 10.1136/thx.54.8.659; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1984, CLIN ALLERGY, V14, P233, DOI 10.1111/j.1365-2222.1984.tb02202.x; LYNCH NR, 1992, J INVEST ALLERG CLIN, V2, P97; MACFARLANE JT, 1979, CLIN ALLERGY, V9, P333, DOI 10.1111/j.1365-2222.1979.tb02491.x; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MASTERS S, 1985, EPIDEMIOL REV, V7, P49, DOI 10.1093/oxfordjournals.epirev.a036285; MILLER HRP, 1984, VET IMMUNOL IMMUNOP, V6, P167, DOI 10.1016/0165-2427(84)90051-5; *NAT HEART LUNG BL, 1991, PUBL NAT HEART LUNG; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; PRITCHARD DI, 1983, CLIN EXP IMMUNOL, V54, P469; Rodrigues V, 1996, AM J HUM GENET, V59, P453; TULLIS DCH, 1970, NEW ENGL J MED, V282, P370, DOI 10.1056/NEJM197002122820706; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; TURTON JA, 1976, LANCET, V2, P686; VANDELLEN RG, 1971, NEW ENGL J MED, V285, P146, DOI 10.1056/NEJM197107152850304; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; WARRELL DA, 1975, Q J MED, V44, P325; WOLSTENHOLME RJ, 1979, CLIN ALLERGY, V9, P325, DOI 10.1111/j.1365-2222.1979.tb02490.x; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	35	50	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				205	210		10.1016/S0091-6749(00)90067-8	http://dx.doi.org/10.1016/S0091-6749(00)90067-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669838				2022-12-18	WOS:000085402200002
J	Thomassen, MJ; Raychaudhuri, B; Dweik, RA; Farver, C; Buhrow, L; Malur, A; Connors, MJ; Drazba, J; Hammel, J; Erzurum, SC; Kavuru, MS				Thomassen, MJ; Raychaudhuri, B; Dweik, RA; Farver, C; Buhrow, L; Malur, A; Connors, MJ; Drazba, J; Hammel, J; Erzurum, SC; Kavuru, MS			Nitric oxide regulation of asthmatic airway inflammation with segmental allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alveolar macrophage; asthma; nitric oxide; transcription factors; nuclear factor-kappa B; activator protein-1; segmental allergen challenge	COLONY-STIMULATING FACTOR; KAPPA-B; ACTIVATION; INHALATION; INHIBITION; LUNG	Background: Despite evidence of increased nitric oxide (NO) in asthmatic compared with healthy individuals, the role of NO in airway inflammation is unclear. Objective: The purpose of the study was to determine the in vivo effects of localized allergen challenge on airway NO levels and transcription factor activation. Methods: In this study localized allergen challenge was used as a model of asthmatic excerbation to determine the relationship of NO to airway inflammation. Results: With allergen challenge, asthmatic patients had a rise in airway KO levels, whereas NO levels in healthy controls did not change. The Increased NO in asthma with allergen challenge compared with healthy control subjects was associated with an increase in inflammatory cytokines (GM-CSF and macrophage inflammatory protein-1) in epithelial lining fluid and eosinophilic infiltrate in bronchoalveolar lavage fluid (BAL) and biopsy specimens. To investigate the mechanisms of cytokine gene expression, activation of the transcription factors activator protein-1 and nuclear factor-kappa B (NF-kappa B) in cells from BAL were evaluated. Activator protein-1 was not activated before or after local allergen challenge. In contrast, NF-kappa B activation was less in BAL, cells from asthmatic patients with increased NO in comparison with controls. Conclusion: Our studies are the first to suggest an inverse correlation between NF-kappa B and airway KO in a localized segmental allergen challenge model in allergic asthmatic patients. The current study demonstrates that activation of the inflammatory response (eg, cytokines, cellular infiltrate) in allergic asthmatic patients is temporally associated with increased airway NO. We propose that NO that is up-regulated by cytokines is part of an autoregulatory feedback loop (ie, allergen challenge stimulates inflammatory cytokine production, which in turn stimulates NO production, and NO down-regulates cytokine production).	Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Thomassen, MJ (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Desk A90,9500 Euclid Ave, Cleveland, OH 44195 USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61, DOI 10.1002/jlb.59.1.61; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; Dinakar C, 1999, ANN ALLERG ASTHMA IM, V82, P217, DOI 10.1016/S1081-1206(10)62600-2; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Gustafsson LE, 1998, EUR RESPIR J, V11, p49S; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; HASKILL S, 1988, J IMMUNOL, V140, P1690; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128, DOI 10.1164/ajrccm.153.1.8542105; Kavuru MS, 1999, CLIN CHEST MED, V20, P153, DOI 10.1016/S0272-5231(05)70133-7; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Lundberg JON, 1997, NAT MED, V3, P30, DOI 10.1038/nm0197-30; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; *NAT HEART LUNG BL, 1997, 2 NIH; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; Raychaudhuri B, 1999, AM J RESP CELL MOL, V21, P311, DOI 10.1165/ajrcmb.21.3.3611; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Schulze-Osthoff Klaus, 1997, P239; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279, DOI 10.1165/ajrcmb.17.3.2998m	28	50	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1174	1182		10.1016/S0091-6749(99)70010-2	http://dx.doi.org/10.1016/S0091-6749(99)70010-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588998				2022-12-18	WOS:000084289200009
J	Hong, SJ; Michael, JG; Fehringer, A; Leung, DYM				Hong, SJ; Michael, JG; Fehringer, A; Leung, DYM			Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanuts; food allergen; T cells; pepsin	RUSH IMMUNOTHERAPY; CONTROLLED TRIAL; DOUBLE-BLIND; ALLERGEN; ANAPHYLAXIS; FRAGMENTS; ASTHMA; POLLEN; FOOD	Background: Peanuts are a common cause of fond-induced anaphylaxis and fatalities. Previous studies have demonstrated that rush immunotherapy to crude peanut extract reduces clinical symptoms triggered by oral peanut challenges, but the immunotherapy was associated with an unacceptably high incidence of systemic allergic reactions. One approach to reduce the frequency of allergic reactions would be to use a modified: peanut antigen with low allergenic properties. Objective: We sought to determine the immunologic characteristics: of crude intact peanut extract before and after pepsin digestion. Methods: Pie used IgE immunoblotting and assessment of T-lymphocyte responses to intact and peptic digests of peanut extracts, Results: Western blot analysis of sera from 5 subjects with peanut allergy showed multiple IgE-reactive proteins in crude intact peanut extract that were eliminated after pepsin treatment: of the peanut extract, In contrast, pepsin-digested peanut induced significant T-cell proliferation responses (stimulation index = 30) in vitro in PBMCs from 7 subjects with peanut allergy, albeit at lower levels than that induced by intact peanut (stimulation index = 66), Furthermore, IFN-gamma production was induced by intact peanut and pepsin-digested peanut in a concentration-dependent manner. Importantly, T-cell lines generated in response to intact peanut also reacted to pepsin-digested peanut, indicating cross-reactive T-cell epitopes in intact and pepsin-digested peanut, Conclusion:These findings suggest that pepsin-digested peanut may be useful in peanut immunotherapy because pepsin digestion eliminates IgE reactivity but maintains T-cell reactivity.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Ohio; University of Cincinnati	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [5 MO1 RR00051] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; FERGUSON TA, 1983, CELL IMMUNOL, V78, P1, DOI 10.1016/0008-8749(83)90254-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; NORMAN PS, 1993, ANN ALLERGY, V71, P330; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; STANDRING R, 1988, INT ARCH ALLER A IMM, V87, P337, DOI 10.1159/000234698; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	17	50	55	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				473	477		10.1016/S0091-6749(99)70396-9	http://dx.doi.org/10.1016/S0091-6749(99)70396-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452774				2022-12-18	WOS:000082364800045
J	Hanninen, AR; Mikkola, JH; Kalkkinen, N; Turjanmaa, K; Ylitalo, L; Reunala, T; Palosuo, T				Hanninen, AR; Mikkola, JH; Kalkkinen, N; Turjanmaa, K; Ylitalo, L; Reunala, T; Palosuo, T			Increased allergen production in turnip (Brassica rapa) by treatments activating defense mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; IgE; cross-reaction; disease resistance; pathogenesis-related protein; prohevein; ethylene; salicylic acid; natural rubber latex; Brassicaceae	SYSTEMIC ACQUIRED-RESISTANCE; PATHOGENESIS-RELATED PROTEINS; MAJOR LATEX ALLERGEN; NATURAL-RUBBER LATEX; INSECT ALPHA-AMYLASE; DISEASE RESISTANCE; CHROMOSOMAL LOCATION; GENE-EXPRESSION; PLANT DEFENSE; HEVEIN	Background: Practical applications to enhance the productivity of agriculture by using plants with improved resistance to pathogens are expected to increase in the near future. Defense proteins play an important role in pathogen resistance, and some defense-related proteins are significant cross-reacting allergens. For example, cross-allergies are common among patients allergic to natural rubber latex (NRL), which contains many defense-related proteins. Objective: Using a model plant (ie, turnip), we studied whether allergen contents increase after treatments activating defense mechanisms of the plants. Methods: Whole or wounded turnips treated with salicylic acid, ethephon, or water mere incubated for 2, 4, or 8 days, Allergen content was investigated by IgE immunoblotting with sera from patients allergic to NRL, An induced protein that bound IgE most intensively was purified and Further characterized by mass analysis, amino acid sequencing, IgE-ELISA, and skin prick tests. Results: In immunoblotting, clear IgE-binding bands were discernible only in samples from chemically treated plants. IgE was bound most intensively to a protein with an apparent molecular weight of 25 kd in SDS-PAGE and with a determined molecular weight of 18.7 kd, Sequenced peptides of the 18.7-kd protein showed over 70% homology to prohevein, a major allergen of NRL, and to many other prohevein-like defense proteins. In ELISA, sera from 30 of 34 (88%) adults and 21 of 26 (81%) children previously shown to have IgE against prohevein bound to the purified protein. In skin prick testing with the protein, 4 of 6 patients allergic to NRL had positive reactions, Conclusion: These results demonstrate that activating defense mechanisms of plants may considerably increase their allergen content.	Natl Publ Hlth Inst, Immunobiol Lab, FIN-00300 Helsinki, Finland; Inst Occupat Hlth, Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland; Univ Helsinki Hosp, Helsinki, Finland; Tampere Univ Hosp, Tampere, Finland	Finland National Institute for Health & Welfare; Finnish Institute of Occupational Health; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital	Palosuo, T (corresponding author), Natl Publ Hlth Inst, Immunobiol Lab, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Kalkkinen, Nisse EJ/B-3923-2010					AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Alenius H., 1996, Journal of Allergy and Clinical Immunology, V97, P321, DOI 10.1016/S0091-6749(96)80772-X; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Banerjee B, 1997, J IMMUNOL, V159, P5724; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Delaney TP, 1997, PLANT PHYSIOL, V113, P5, DOI 10.1104/pp.113.1.5; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; Fritig B, 1998, CURR OPIN IMMUNOL, V10, P16, DOI 10.1016/S0952-7915(98)80025-3; GARCIAMAROTO F, 1990, PLANT MOL BIOL, V14, P845, DOI 10.1007/BF00016517; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; Grison R, 1996, NAT BIOTECHNOL, V14, P643, DOI 10.1038/nbt0596-643; Hunt MD, 1996, CRIT REV PLANT SCI, V15, P583, DOI 10.1080/07352689609382371; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MENA M, 1992, PLANT MOL BIOL, V20, P451, DOI 10.1007/BF00040604; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; OHASHI Y, 1992, PLANT CELL PHYSIOL, V33, P819; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; POTTER S, 1993, MOL PLANT MICROBE IN, V6, P680, DOI 10.1094/MPMI-6-680; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shah DM, 1997, CURR OPIN BIOTECH, V8, P208, DOI 10.1016/S0958-1669(97)80104-8; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; Uknes S, 1996, NEW PHYTOL, V133, P3, DOI 10.1111/j.1469-8137.1996.tb04337.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WRIGHT HT, 1991, J MOL EVOL, V33, P283, DOI 10.1007/BF02100680; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9; YALPANI N, 1994, PLANTA, V193, P372, DOI 10.1007/BF00201815	40	50	53	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					194	201		10.1016/S0091-6749(99)70135-1	http://dx.doi.org/10.1016/S0091-6749(99)70135-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400861				2022-12-18	WOS:000081738900031
J	Shardonofsky, FR; Venzor, J; Barrios, R; Leong, KP; Huston, DP				Shardonofsky, FR; Venzor, J; Barrios, R; Leong, KP; Huston, DP			Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-5; airway hyperresponsiveness; inhaled therapy; eosinophils	AIRWAY HYPERRESPONSIVENESS; INTRATRACHEAL INSTILLATION; MOUSE MODEL; GUINEA-PIGS; INTERLEUKIN-5; INFLAMMATION; IL-5; LUNG; HYPERREACTIVITY; EOSINOPHILIA	Background: IL-5 is central to the pathogenesis of airway eosinophilic inflammation and hyperresponsiveness associated with both atopic and nonatopic asthma, The therapeutic potential of IL-5 antagonists in asthma is supported by the inhibition of airway eosinophilia and hyperresponsiveness in animal models receiving neutralizing anti-IL-5 mAbs intravenously or intraperitoneally, Objective: The purpose of this study was to test the hypothesis that mAbs against IL-5 delivered by way of the respiratory tract are as effective as those delivered intraperitoneally in diminishing the pulmonary eosinophilic inflammation and airway hyperresponsiveness in a murine model of ovalbumin-induced asthma. Methods: Ovalbumin-sensitized Balb/c mice were given an anti-IL-5 mAb delivered intranasally or an isotype-matched control mAb delivered intranasally before respiratory challenge with ovalbumin, Outcome variables included respiratory system resistance responses to methacholine, bronchoalveolar lavage fluid cellularity, and lung histopathology. Results: Anti-IL-5 mAbs administered intranasally to ovalbumin-sensitized and challenged mice significantly decreased eosinophil counts in bronchoalveolar lavage fluid and lung tissue and significantly reduced airway hyperresponsiveness relative to ovalbumin-sensitized and challenged mice that received either no mAb treatment or an isotype-matched control mAb, Similar results were obtained when an anti-IL-5 mAb was given intraperitoneally. Conclusion: This is the first study to demonstrate that delivery of anti-IL-5 mAbs into the respiratory tract is efficacious in attenuating the asthma phenotype in a murine model. These results provide impetus for the development of inhaled IL-5 antagonists for the treatment of human asthma.	Baylor Coll Med, Dept Pediat, Sect Pediat Pulm, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Shardonofsky, FR (corresponding author), Baylor Coll Med, Dept Pediat, Sect Pediat Pulm, 1102 Bates St,Suite 410, Houston, TX 77030 USA.			Huston, David/0000-0002-2332-0010				ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; Dickason RR, 1996, J IMMUNOL, V156, P1030; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; Egan R. W., 1997, Journal of Allergy and Clinical Immunology, V99, pS122; ELBON CL, 1995, AM J RESP CELL MOL, V12, P320, DOI 10.1165/ajrcmb.12.3.7873198; FAWCETT DW, 1994, BLOOM FAWCETT TXB HI, P244; FOLKESSON HG, 1990, ACTA PHYSIOL SCAND, V139, P347, DOI 10.1111/j.1748-1716.1990.tb08933.x; FOLKESSON HG, 1993, ACTA PHYSIOL SCAND, V147, P173, DOI 10.1111/j.1748-1716.1993.tb09486.x; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HENDERSON D, 1997, J CLIN INVEST, V100, P3083; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hogan SP, 1998, J IMMUNOL, V161, P1501; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515, DOI 10.1164/ajrccm.155.5.9154851; Kraneveld AD, 1997, AM J RESP CRIT CARE, V156, P367, DOI 10.1164/ajrccm.156.2.9608101; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; LAUZON AM, 1991, J APPL PHYSIOL, V71, P1159, DOI 10.1152/jappl.1991.71.3.1159; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LOPEZ AF, 1988, J EXP MED, V167, P43; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510, DOI 10.1165/ajrcmb.16.5.9160833; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; POZO VD, 1995, EUR J IMMUNOL, V22, P1919; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; VANOOSTERHOUT AJM, 1995, AM J RESP CRIT CARE, V151, P177, DOI 10.1164/ajrccm.151.1.7812550; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YIN S, 1997, J IMMUNOL, V158, P3539; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	37	50	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					215	221		10.1016/S0091-6749(99)70138-7	http://dx.doi.org/10.1016/S0091-6749(99)70138-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400864				2022-12-18	WOS:000081738900034
J	Fost, DA; Leung, DYM; Martin, RJ; Brown, EE; Szefler, SJ; Spahn, JD				Fost, DA; Leung, DYM; Martin, RJ; Brown, EE; Szefler, SJ; Spahn, JD			Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; prednisone; methylprednisolone; clarithromycin; asthma; pharmacokinetics	PHARMACOKINETIC ANALYSIS; ASTHMA; TROLEANDOMYCIN; PREDNISOLONE; HYPERRESPONSIVENESS; CORTICOSTEROIDS; CHILDREN; LUNG	Background: Macrolide antibiotics have long been used as steroid-sparing agents in patients with severe steroid-dependent asthma. Their efficacy and their propensity to potentiate glucocorticoid adverse effects have been attributed in part to their ability to delay glucocorticoid clearance. Objective: We sought to determine whether clarithromycin, a newer macrolide antibiotic, can alter the pharmacokinetic profile of oral glucocorticoids and thereby increase the risk of steroid-induced adverse effects. Methods: An open-label study in a paired design (before and after treatment) was conducted in a hospital-based outpatient clinic. Participants were 6 adult patients (mean age, 30 years) with mild-to-moderate asthma. Prednisone (40 mg/1.73 m(2)) and methylprednisolone (40 mg/1.73 m(2)) were given as single randomized doses on consecutive study days before and on days 8 and 9 of a clarithromycin (500 mg twice daily) course. Twelve-hour pharmacokinetic profiles with measurement of plasma methylprednisolone and prednisolone levels were taken before and after clarithromycin therapy. Results: Clarithromycin therapy resulted in a 65% reduction of methylprednisolone clearance and significantly higher mean plasma methylprednisolone concentrations compared with preclarithromycin concentrations but had no significant effect on prednisolone clearance or mean prednisolone plasma concentrations. Conclusions: Clinicians must be aware of potential drug interactions that could place patients at increased risk for steroid-induced adverse effects. Such an effect has been demonstrated between clarithromycin and methylprednisolone, two drugs that may be administered concomitantly in asthma. To avoid potential steroid-enhancing effects, prednisone should be substituted for methylprednisolone during prolonged courses of clarithromycin therapy.	Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Dept Pediat, Div Allergy Clin Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Dept Med, Div Pulm Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Spahn, JD (corresponding author), Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Div Clin Pharmacol, 1400 Jackson St K-926, Denver, CO 80206 USA.				NCRR NIH HHS [5 MO1 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BALL BD, 1990, ANN ALLERGY, V65, P37; BARTOSZEK M, 1987, CLIN PHARMACOL THER, V42, P424, DOI 10.1038/clpt.1987.173; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; EBLING WF, 1986, J PHARM SCI, V75, P760, DOI 10.1002/jps.2600750807; EBLING WF, 1984, J CHROMATOGR, V305, P271, DOI 10.1016/S0378-4347(00)83342-3; GREOS LS, 1991, AM REV RESPIR DIS, V144, P586, DOI 10.1164/ajrccm/144.3_Pt_1.586; GREOS LS, 1990, AM REV RESPIR DIS, V141, P933; HAHN DL, 1996, EUR RESPIR REV, V6, P224; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JUSKO WJ, 1992, APPL PHARMACOKINETIC; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; KHALAFALLAH N, 1984, J PHARMACOL EXP THER, V229, P719; KONNO S, 1993, LIFE SCI, V52, pPL25, DOI 10.1016/0024-3205(93)90154-U; KRAFT M, 1996, AM J RESP CRIT CARE, V153, pA412; LAFORCE CF, 1983, J ALLERGY CLIN IMMUN, V72, P34, DOI 10.1016/0091-6749(83)90049-0; MIYATAKE H, 1991, CHEST, V99, P670, DOI 10.1378/chest.99.3.670; NELSON HS, 1993, AM REV RESPIR DIS, V147, P398, DOI 10.1164/ajrccm/147.2.398; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; PERITI P, 1992, CLIN PHARMACOKINET, V23, P106, DOI 10.2165/00003088-199223020-00004; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; SEGGEV JS, 1986, ANN ALLERGY, V57, P263; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V84, P867, DOI 10.1016/0091-6749(89)90381-3	26	50	52	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1031	1035		10.1016/S0091-6749(99)70175-2	http://dx.doi.org/10.1016/S0091-6749(99)70175-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359882				2022-12-18	WOS:000080929500009
J	Hedlin, G; Wille, S; Browaldh, L; Hildebrand, H; Holmgren, D; Lindfors, A; Nordvall, SL; Lowenstein, H				Hedlin, G; Wille, S; Browaldh, L; Hildebrand, H; Holmgren, D; Lindfors, A; Nordvall, SL; Lowenstein, H			Immunotherapy in children with allergic asthma: Effect on bronchial hyperreactivity and pharmacotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; children; asthma; cat, dust mite, and pollen allergy; bronchial hyperreactivity; budesonide	RESPONSIVENESS; DUST; CAT; HISTAMINE; SYMPTOMS; SYSTEM; DOG	Background: Immunotherapy has been shown to reduce allergen sensitivity to allergens such as cat and dust mite. The aim of this study was to investigate the effect of cat or dust mite immunotherapy on bronchial hyperreactivity and the need for inhaled corticosteroids in children with asthma, cat or dust mite allergy, and hay fever. Subjects: Twenty-nine children, 7 to 16 years old, completed the 3-year study. They were randomly allocated to receive cat/dust mite or placebo and birch/timothy immunotherapy. Methods: Before immunotherapy was begun and then once each year, bronchial histamine challenges were performed. Bronchial allergen challenge with the perennial allergen was done before and after the 3-year study. Pharmacotherapy was given according to a standardized protocol. Results: PC20 allergen increased significantly in both the active immunotherapy group (P < .001) and in the placebo-pollen group (P < .05). PC20 histamine increased continuously in the active immunotherapy group (P < .05 and P = .002 after 1 and 3 years, respectively) and had also increased after 3 years in the placebo-pollen group (P < .05), The difference between the 2 groups was significant for PC20 allergen (P = .001) but not for PC20 histamine. There was no significant change in the dose of inhaled budesonide needed for symptom control in either of the groups. Conclusion: Pollen immunotherapy combined with inhaled corticosteroids results in improvement of both cat/dust mite bronchial sensitivity and hyperresponsiveness to histamine. The combination of cat or dust mite, pollen immunotherapy, and inhaled budesonide enhances this improvement.	Huddinge Univ Hosp, Karolinska Inst, Dept Pediat, S-14186 Huddinge, Sweden; Halmstad Cty Hosp, Dept Pediat, Halmstad, Sweden; East Hosp, Dept Pediat, Gothenburg, Sweden; Karolinska Inst, Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; St Goran Karolinska Hosp, Stockholm, Sweden; ALK Labs, Horsholm, Denmark	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Hedlin, G (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Pediat, B57, S-14186 Huddinge, Sweden.			Wille, Soren/0000-0002-0017-5922				Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; JACOBSEN L, 1990, CLIN CHEM, V36, P1189; LYNCH MJ, 1989, J BIOLUM CHEMILUM, V4, P615, DOI 10.1002/bio.1170040181; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1	13	50	51	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					609	614		10.1016/S0091-6749(99)70232-0	http://dx.doi.org/10.1016/S0091-6749(99)70232-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200009	Bronze			2022-12-18	WOS:000079723900012
J	LaForce, C				LaForce, C			Use of nasal steroids in managing allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTRANASAL FLUTICASONE PROPIONATE; AQUEOUS BECLOMETHASONE DIPROPIONATE; EOSINOPHIL CATIONIC PROTEIN; TRIAMCINOLONE ACETONIDE; TOPICAL GLUCOCORTICOSTEROIDS; MOLECULAR MECHANISMS; PERENNIAL RHINITIS; CLINICAL EFFICACY; MEDIATOR RELEASE; POLLEN SEASON	Intranasal steroids are highly effective drugs for treating patients with allergic rhinitis, First-line use of intranasal steroids is becoming increasingly common, and intranasal steroids can be used alone or in combination with other therapies to achieve optimal improvement in rhinitis symptoms, The major adverse effect of intranasal steroids is local irritation. This article reviews the mechanism of action of corticosteroids, the effects of intranasal steroids on chemical mediators of inflammation, and the risks and benefits associated with their use.	Univ N Carolina, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	LaForce, C (corresponding author), N Carolina Clin Res, 4301 Lake Boone Trail,Suite 309A, Raleigh, NC 27607 USA.							Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; ARGENTI D, 1994, J CLIN PHARMACOL, V34, P854, DOI 10.1002/j.1552-4604.1994.tb02051.x; Barnes PJ, 1996, J ALLERGY CLIN IMMUN, V97, P159, DOI 10.1016/S0091-6749(96)80216-8; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BAROODY F, 1989, J ALLERGY CLIN IMMUN, V82, P163; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; Bircher AJ, 1996, BRIT J DERMATOL, V135, P310, DOI 10.1046/j.1365-2133.1996.d01-996.x; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; Daley-Yates Peter T., 1998, Allergy (Copenhagen), V53, P158; Davies RJ, 1997, CLIN THER, V19, P27; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; Falcoz C., 1996, European Respiratory Journal Supplement, V9, p162S; FALCOZ C, 1996, BR J CLIN PHARM, V41, P459; Fokkens WJ, 1997, ALLERGY, V52, P29, DOI 10.1111/j.1398-9995.1997.tb04819.x; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GARRELDS IM, 1995, EUR J PHARMACOL, V275, P295, DOI 10.1016/0014-2999(95)00049-Q; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; GRONBORG H, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb00691.x; GUYRE PM, 1991, ANTIINFLAMMATORY STE, P199; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; Howland WC, 1996, CLIN EXP ALLERGY, V26, P18, DOI 10.1111/j.1365-2222.1996.tb00654.x; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; KATO M, 1994, LUNG, V172, P113; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; LAFORCE C, 1985, J ALLERGY CLIN IMMUN, V75, P186, DOI 10.1016/0091-6749(85)90461-0; LAFORCE CF, 1994, J FAM PRACTICE, V38, P145; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LINDQVIST N, 1989, CLIN EXP ALLERGY, V19, P71, DOI 10.1111/j.1365-2222.1989.tb02347.x; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; McDowall JE, 1997, CLIN DRUG INVEST, V14, P44, DOI 10.2165/00044011-199714010-00006; *MED EC CO, 1998, PHYS DESK REF, P572; *MED EC CO, 1998, PHYS DESK REF, P889; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V91, P298; MELTZER EO, 1987, IMMUNOL ALLERGY CLIN, V7, P57; MICHELS MI, 1967, ANN ALLERGY, V25, P569; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; Munk ZM, 1996, ANN ALLERG ASTHMA IM, V77, P277, DOI 10.1016/S1081-1206(10)63320-0; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; Naclerio RM, 1993, ALLERGIC NONALLERGIC, P114; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; ORGEL HA, 1991, J ALLERGY CLIN IMMUN, V88, P257, DOI 10.1016/0091-6749(91)90336-M; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; PELIKAN Z, 1974, ACTA ALLERGOL, V29, P337, DOI 10.1111/j.1398-9995.1974.tb01470.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; Pullerits T, 1997, J ALLERGY CLIN IMMUN, V100, P601, DOI 10.1016/S0091-6749(97)70162-3; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; Ratner P, 1996, ALLERGY ASTHMA PROC, V17, P149, DOI 10.2500/108854196779165049; REED JC, 1986, J IMMUNOL, V137, P150; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; *SCHER CORP, 1998, NAS PROD MON; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHOENWETTER W, 1995, CLIN THER, V17, P479, DOI 10.1016/0149-2918(95)80113-8; Selner JC, 1995, CLIN THER, V17, P1099, DOI 10.1016/0149-2918(95)80088-3; SIEGEL SC, 1991, RHINITIS, P232; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOWNLEY RG, 1987, ANN ALLERGY, V58, P1; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; WALLEN N, 1991, J IMMUNOL, V147, P3490; Wang DY, 1997, INT ARCH ALLERGY IMM, V114, P185, DOI 10.1159/000237665; Weido AJ, 1996, ANN ALLERG ASTHMA IM, V77, P407, DOI 10.1016/S1081-1206(10)63340-6; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x	90	50	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	2	S			S388	S394		10.1016/S0091-6749(99)70218-6	http://dx.doi.org/10.1016/S0091-6749(99)70218-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	179CL	10069899				2022-12-18	WOS:000079305900005
J							AAAAI Board Directors	Idiopathic environmental intolerances	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							MULTIPLE CHEMICAL SENSITIVITIES; IMMUNOLOGICAL EVALUATION; 20TH-CENTURY DISEASE; CLINICAL ECOLOGY; ILLNESS; EXPOSURE; DISORDER; EPIDEMIC; STRESS; FORMALDEHYDE		Amer Acad Allergy Asthma & Immunol, AAAAI Execut Off, Milwaukee, WI 53202 USA		Amer Acad Allergy Asthma & Immunol, AAAAI Execut Off, 611 E Wells St, Milwaukee, WI 53202 USA.							ABBEY SE, 1991, AM J PSYCHIAT, V148, P1638; *AM AC ALL IMM, 1986, J ALLERGY CLIN IMMUN, V78, P269; Ashford N. A., 1991, CHEM EXPOSURES LOW L; BARRETT S, 1994, MULTIPLE CHEM SENSIT; BASCOM R, 1992, TOXICOL IND HEALTH, V8, P221; Beard George Miller, 1881, AM NERVOUSNESS ITS C; BELL IR, 1992, BIOL PSYCHIAT, V32, P218, DOI 10.1016/0006-3223(92)90105-9; BELL IR, 1982, CLIN ECOL, V1, P15; BELL IR, 1982, CLIN ECOLOGY NEW MED; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; BLACK DW, 1993, PSYCHOSOMATICS, V34, P131, DOI 10.1016/S0033-3182(93)71903-9; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; BLACK DW, 1993, REGUL TOXICOL PHARM, V18, P23, DOI 10.1006/rtph.1993.1041; BLONZ ER, 1986, JAMA-J AM MED ASSOC, V256, P3138, DOI 10.1001/jama.256.22.3138; *BOARD INT SOC REG, 1993, REGUL TOXICOL PHARM, V18, P79; BOLLAWILSON K, 1988, J OCCUP ENVIRON MED, V30, P684; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; BRODSKY CM, 1983, J OCCUP ENVIRON MED, V25, P459, DOI 10.1097/00043764-198306000-00011; BRODSKY CM, 1987, OCCUP MED, V2, P695; BRODSKY CM, 1989, PATIENT CARE, V11, P41; BROOKS SM, 1985, J OCCUP ENVIRON MED, V27, P473; BROUGHTON A, 1988, COMMENTS TOXICOL, V2, P155; *CA MED ASS SCI BO, 1986, W J MED, V144, P239; *COMM ENV HYP, 1985, REP HOC COMM ENV HYP; COTTERILL JA, 1982, LANCET, V1, P628; *COUNC SCI AFF, 1992, JAMA-J AM MED ASSOC, V268, P1634; CROOK WG, 1983, YEAST CONNECTION MED; CULLEN MR, 1987, OCCUP MED, V2, P655; DAGER SR, 1987, AM J PSYCHIAT, V144, P1056; DAVIDOFF LL, 1992, TOXICOL IND HEALTH, V8, P229; DICKEY LD, 1976, CLIN ECOLOGY; DOTY RL, 1988, ARCH OTOLARYNGOL, V114, P1422; EDELSTEIN PH, 1993, CLIN INFECT DIS, V16, P741, DOI 10.1093/clind/16.6.741; FAUST HS, 1981, J OCCUP ENVIRON MED, V23, P22, DOI 10.1097/00043764-198101000-00013; Fink JN, 1993, ALLERGY PRINCIPLES P, P1415; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P177, DOI 10.1016/S0091-6749(05)80063-6; GREEN GM, 1994, JAMA-J AM MED ASSOC, V272, P391, DOI 10.1001/jama.1994.03520050071033; GREEN MA, 1985, JAMA-J AM MED ASSOC, V253, P842; GRIECO MH, 1985, JAMA-J AM MED ASSOC, V253, P842; HALLER E, 1993, J CLIN PSYCHIAT, V54, P196; *INT PROGR CHEM SA, 1997, INT ARCH OCC ENV HEA, V69, P224; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KING DS, 1981, BIOL PSYCHIAT, V16, P3; KIPEN H, 1992, TOXICOL IND HEALTH, V8, P125; KLEIN GL, 1985, ANN ALLERGY, V55, P22; KRUG SE, 1992, PEDIATR EMERG CARE, V8, P280, DOI 10.1097/00006565-199210000-00008; Lessof M, 1997, HUM EXP TOXICOL, V16, P233, DOI 10.1177/096032719701600414; LEVIN AS, 1992, TOXICOL IND HEALTH, V8, P95; LEVIN AS, 1997, OCCUP MED STATE ART, V2, P669; LEVINE SA, 1983, J ORTHOMOL MED, V12, P166; LEVINE SA, 1983, J BIOSOC RES, V4, P102; LEVINE SA, 1983, J BIOSOC RES, V4, P51; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; MADISON RE, 1991, ENVIRON HEALTH PERSP, V94, P219, DOI 10.2307/3431314; MARKS PJ, 1994, IMMUNOL ALLERGY CLIN, V14, P521; MCGOVERN JJ, 1983, ARCH OTOLARYNGOL, V109, P292; MEGGS WJ, 1992, TOXICOL IND HEALTH, V8, P203; MEGGS WJ, 1993, ENVIRON HEALTH PERSP, V101, P234, DOI 10.2307/3431548; MILLER CS, 1992, TOXICOL IND HEALTH, V8, P181; *NAT RES COUNC, 1992, MULT CHEM SENS; PATTERSON R, 1985, NEW ENGL REG ALLERGY, V6, P135; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V79, P705; POST RM, 1992, AM J PSYCHIAT, V149, P999; Randolph T.G., 1962, HUMAN ECOLOGY SUSCEP; RANDOLPH TG, 1977, ANN ALLERGY, V39, P215; RANDOLPH TG, 1966, INT J SOC PSYCHIATR, V12, P245, DOI 10.1177/002076406601200401; RANDOLPH TG, 1956, J LAB CLIN MED, V48, P934; RANDOLPH TG, 1980, ALTERNATIVE APPROACH; Rea W.J., 1992, CHEM SENSITIVITY; REA WJ, 1976, ANN ALLERGY, V37, P101; REA WJ, 1978, ANN ALLERGY, V40, P243; REA WJ, 1977, ANN ALLERGY, V38, P245; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V67, P333, DOI 10.1016/0091-6749(81)90076-2; ROOT DE, 1985, P NAT C HAZ WAST ENV, P150; ROSENBERG SJ, 1991, J OCCUP MED, V33, P737; *ROYAL COLL PHYS R, 1995, CLIN EXP ALLERGY, V25, P586; SCHOTTENFELD RS, 1985, AM J PSYCHIAT, V142, P198; SELNER JC, 1992, TOXICOL IND HEALTH, V8, P145; Shorter E., 1992, PARALYSIS FATIGUE HI; SHUSTERMAN D, 1988, J OCCUP ENVIRON MED, V30, P565; SIMON GE, 1993, ANN INTERN MED, V119, P97, DOI 10.7326/0003-4819-119-2-199307150-00001; SIMON GE, 1992, TOXICOL IND HEALTH, V8, P41; SPARKS PJ, 1990, WESTERN J MED, V153, P28; SPARKS PJ, 1994, J OCCUP ENVIRON MED, V36, P718; STAUDENMAYER H, 1993, ANN ALLERGY, V71, P538; STAUDENMAYER H, 1987, J CLIN PSYCHOL, V43, P156, DOI 10.1002/1097-4679(198701)43:1<156::AID-JCLP2270430127>3.0.CO;2-B; STAUDENMAYER H, 1990, J PSYCHOSOM RES, V34, P259, DOI 10.1016/0022-3999(90)90082-F; STAUDENMAYER H, 1989, J PSYCHOL TYPE, V18, P59; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; STEWART DE, 1990, PSYCHOSOMATICS, V31, P153, DOI 10.1016/S0033-3182(90)72188-3; TERR AI, 1987, J ALLERGY CLIN IMMUN, V79, P423, DOI 10.1016/0091-6749(87)90357-5; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; TERR AI, 1989, J OCCUP ENVIRON MED, V31, P257, DOI 10.1097/00043764-198903000-00012; TERR AI, 1993, REGUL TOXICOL PHARM, V18, P54, DOI 10.1006/rtph.1993.1044; TERR AI, 1993, ALLERGY PRINCIPLES P, P1778; THRASHER JD, 1989, AM J IND MED, V15, P187, DOI 10.1002/ajim.4700150207; *US DEP DEF, 1992, COND PERS WAR; White LJ, 1989, ANN INTERN MED, V111, P168, DOI 10.7326/0003-4819-111-2-168; ZIEM GE, 1992, TOXICOL IND HEALTH, V4, P73; 1996, REG TOXICOL PHARM, V24, pS188	100	50	52	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				36	40						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM					2022-12-18	WOS:000078112300006
J	O'Byrne, PM; Pedersen, S				O'Byrne, PM; Pedersen, S			Measuring efficacy and safety of different inhaled corticosteroid preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; DOSE-RESPONSE; SEVERE ASTHMA; TRIAMCINOLONE ACETONIDE; ADRENAL SUPPRESSION; BRONCHIAL-ASTHMA; LUNG-FUNCTION; BUDESONIDE; CHILDREN	Inhaled corticosteroids are the mainstay of treatment for persistent asthma because of their proven efficacy, which is better than any other class of antiasthma therapy. Concerns about unwanted systemic effects with long-term use has, however, limited their use. Efforts have been made to develop inhaled corticosteroids with less systemic activity for a given clinical effect, thereby improving their therapeutic index. Many different study designs and outcome variables have been used to compare different inhaled corticosteroids. Differences in pharmacologic properties between drugs are most easily and accurately measured and quantified by measures of systemic effects. However, these differences should always be related to differences in clinical effects, It is difficult to draw firm conclusions with respect to the therapeutic index of different inhaled corticosteroids because no direct placebo-controlled, dose-response comparisons of clinical effects have been made. Despite this caveat, the available studies suggest that microgram for microgram, when delivered by a pressurized metered-dose inhaler (pMDI), fluticasone propionate (FP) is mure effective than beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), or budesonide; however, the efficacy of budesonide delivered by Turbuhaler is equipotent to that of PP delivered by pMDI or Diskhaler and more effective than that of BDP. When comparative safety is considered, budesonide or TAA delivered by pMDI have less systemic activity than FP delivered by pMDI, whereas BDP and FP delivered by pMDI appear to be equivalent. Also, budesonide delivered by Turbuhaler has less systemic activity than FP delivered by Diskhaler.	McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Asthma Res Grp, Hamilton, ON L8N 3Z5, Canada; Odense Univ, Kolding Hosp, Dept Pediat, Kolding, Denmark	McMaster University; McMaster University; Kolding Hospital; University of Southern Denmark	O'Byrne, PM (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, 120 Main St W, Hamilton, ON L8N 3Z5, Canada.			O'Byrne, Paul/0000-0003-0979-281X				Agertoft L, 1993, Pediatr Allergy Immunol, V4, P152, DOI 10.1111/j.1399-3038.1993.tb00084.x; AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; Agertoft L, 1997, J ALLERGY CLIN IMMUN, V99, P773, DOI 10.1016/S0091-6749(97)80011-5; AGERTOFT L, 1998, IN PRESS ARCH CHILD; Andersson Morgan, 1995, Rhinology (Utrecht), V33, P18; ANDERSSON N, 1994, AM J RESP CRIT CARE, V149, pA467; AYRES JG, 1995, EUR RESPIR J, V8, P579; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BASRAN G, 1995, THORAX, V50, pP469; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V80, P213; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; Boorsma M, 1996, EUR RESPIR J, V9, P1427, DOI 10.1183/09031936.96.09071427; BRAMBILLA C, 1994, DRUG INVEST, V8, P49, DOI 10.1007/BF03257426; Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; CLARK D, 1996, BR J CLIN PHARM, V42, P264; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; DAHL R, 1998, CHEST, V104, P352; DAY J, 1998, 16 INT S INF ALL NOS, P142; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; ELLULMICALLEF R, 1983, BRIT J CLIN PHARMACO, V15, P419, DOI 10.1111/j.1365-2125.1983.tb01524.x; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; Falcoz C, 1997, J ALLERGY CLIN IMMUN, V99, P2041; GRAHNEN A, 1996, AM J RESP CRIT CARE, V153, pA338; GROVE A, 1994, BRIT J CLIN PHARMACO, V38, P527, DOI 10.1111/j.1365-2125.1994.tb04394.x; GRUVSTAD E, 1980, DRUG EXP CLIN RES, V6, P385; HATTER JG, 1963, NEW ENGL J MED, V269, P591; HEUCK C, 1995, EUR RESP J S19, V8, pS470; HOFFMANNSTREB A, 1993, MONATSSCHR KINDERH, V141, P508; Hogger P, 1993, EUR RESP J S17, V6, p584S; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; JOHNSON M, 1995, INT ARCH ALLERGY IMM, V107, P439, DOI 10.1159/000237073; LARSSON AM, 1998, DRUG METAB DISPOS, V26, P623; LARSSON AM, 1997, AM J RESP CRIT CARE, V155, pA353; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P608, DOI 10.1001/archderm.1962.01590110044005; MILLERLARSSON A, 1994, AM J RESP CRIT CARE, V149, pA466; MORROWBROWN H, 1980, TOPICAL STEROID TREA, P66; NICOLAIZIK WH, 1994, AM J RESP CRIT CARE, V150, P624, DOI 10.1164/ajrccm.150.3.8087329; O'Byrne P, 1996, CAN RESPIR J, V3, P169; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Stern MA, 1997, AM J RHINOL, V11, P323, DOI 10.2500/105065897781446658; Thorsson L, 1997, BRIT J CLIN PHARMACO, V43, P155, DOI 10.1046/j.1365-2125.1997.d01-1425.x; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Toogood J H, 1994, Int J Risk Saf Med, V5, P1, DOI 10.3233/JRS-1994-5102; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Wilson AM, 1997, AM J RESP CRIT CARE, V156, P1274, DOI 10.1164/ajrccm.156.4.97-03029; WONG J, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415-a	53	50	53	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				879	886		10.1016/S0091-6749(98)70322-7	http://dx.doi.org/10.1016/S0091-6749(98)70322-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847425				2022-12-18	WOS:000077690700001
J	Sigman, K; Ghibu, F; Sommerville, W; Toledano, BJ; Bastein, Y; Cameron, L; Hamid, QA; Mazer, B				Sigman, K; Ghibu, F; Sommerville, W; Toledano, BJ; Bastein, Y; Cameron, L; Hamid, QA; Mazer, B			Intravenous immunoglobulin inhibits IgE production in human B lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intravenous Ig; IgE; B lymphocytes; cell cycle	GAMMA-GLOBULIN THERAPY; IMMUNE GLOBULIN; CELL DIFFERENTIATION; IN-VITRO; TYROSINE PHOSPHORYLATION; F(AB')(2) FRAGMENTS; ACTIVATION; ASTHMA; RECEPTOR; FC-GAMMA-RIIB1	Background: Intravenous immunoglobulin (IVIG) is commonly used as both an immune-enhancing and immune-modulating agent. Treatment with high doses of IVIG diminishes IgE secretion in patients with severe steroid-dependent asthma. Objective: We studied the action of IVIG on IgE production in highly purified B lymphocytes stimulated without additional T cells to determine the action of IVIG on B lymphocytes. Methods: Human B cells were purified from tonsils, and T lymphocytes were removed by E-rosetting. B cells were cultured with IL-4 (400 U/mL) and anti-CD40 antibodies (1 mu g/mL), with or without additional IVIG. Cell proliferation was determined by (3)[H]-thymidine uptake, and supernatant IgE was determined by ELISA, Cell cycle analysis was performed by flow cytometry, and IgE transcripts were measured by in situ hybridization. Results: IVIG (5 mg/mL) decreased B-cell proliferation in IL-4/anti-CD40-stimulated B cells by an average of 74% (+/-6%). Addition of IVIG up to 48 hours after initiation of cell culture led to significant diminution of cell proliferation at 96 to 120 hours. This effect was dose dependent, with 10 mg/mL being the most effective and doses under 0.1 mg/mL having minimal effect. IVIG diminished the number of stimulated cells progressing in the cell cycle by 30%, and there was no difference in cell viability between IVIG-treated and lVIG-untreated cells. The production of IgE in culture by anti-CD40/IL-4-stimulated B lymphocytes was curtailed by greater than 80% after addition of 5 mg/mL IVIG, This was associated with a decrease in IgE (epsilon) transcripts in IVIG-treated cultures. Conclusion: These data indicate that diminution of IgE production in anti-CD40/IL-4-stimulated B cells by IVIG is due to inhibition of early events related to proliferation and progression in the cell cycle.	McGill Univ, Montreal Childrens Hosp, Div Clin Immunol & Allergy, Res Inst, Montreal, PQ H3H 1P3, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	McGill University; McGill University	Mazer, B (corresponding author), McGill Univ, Montreal Childrens Hosp, Div Clin Immunol & Allergy, Res Inst, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.							AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; ANDERSSON U, 1994, IMMUNOL REV, V139, P21, DOI 10.1111/j.1600-065X.1994.tb00855.x; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; BUSSEL J B, 1991, P253; Chacko GW, 1996, J IMMUNOL, V157, P2234; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CYPCAR D, 1993, J ALLERGY CLIN IMMUN, V92, P362, DOI 10.1016/0091-6749(93)90114-U; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL FL; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825, DOI 10.1164/ajrccm.155.6.9196081; DURANDY A, 1981, J CLIN INVEST, V67, P867, DOI 10.1172/JCI110104; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Gelfand EW, 1996, CLIN EXP IMMUNOL, V104, P61, DOI 10.1111/cei.1996.104.s1.61; Gergely J, 1996, SCAND J IMMUNOL, V44, P1; HAAS H, 1995, J CLIN IMMUNOL, V14, P172; JAKOBSSON T, 1994, ALLERGY, V49, P413, DOI 10.1111/j.1398-9995.1994.tb00833.x; JUJO K, 1993, J ALLERGY CLIN IMMUN, V91, P1206, DOI 10.1016/0091-6749(93)90324-9; KIMATA H, 1995, J ALLERGY CLIN IMMUN, V95, P771, DOI 10.1016/S0091-6749(95)70185-0; Klaesson S, 1996, SCAND J IMMUNOL, V43, P574, DOI 10.1046/j.1365-3083.1996.d01-72.x; KONDO N, 1991, J CLIN IMMUNOL, V11, P152, DOI 10.1007/BF00918683; KONDO N, 1994, SCAND J IMMUNOL, V40, P37, DOI 10.1111/j.1365-3083.1994.tb03430.x; LacroixDesmazes S, 1996, CLIN EXP RHEUMATOL, V14, pS9; LEUNG DYM, 1989, J ALLERGY CLIN IMMUN, V84, P588, DOI 10.1016/0091-6749(89)90195-4; MAZER B, 1994, PRACT ALLERGY IMMUNO, V9, P104; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MOBINI N, 1995, ANN ALLERG ASTHMA IM, V74, P119; Nachbaur D, 1997, IMMUNOLOGY, V90, P212, DOI 10.1046/j.1365-2567.1997.d01-2148.x; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; Sarkar S, 1996, J BIOL CHEM, V271, P20182, DOI 10.1074/jbc.271.33.20182; Stohl W, 1996, CLIN IMMUNOL IMMUNOP, V79, P122, DOI 10.1006/clin.1996.0059; STOHL W, 1985, CLIN EXP IMMUNOL, V62, P200; STOHL W, 1986, J IMMUNOL, V136, P4407; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Toledano BJ, 1997, J IMMUNOL, V158, P3705; TSUBAKIO T, 1983, CLIN EXP IMMUNOL, V53, P697; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369	37	50	51	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					421	427		10.1016/S0091-6749(98)70130-7	http://dx.doi.org/10.1016/S0091-6749(98)70130-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768583	Bronze			2022-12-18	WOS:000076212800015
J	Shusterman, DJ; Murphy, MA; Balmes, JR				Shusterman, DJ; Murphy, MA; Balmes, JR			Subjects with seasonal allergic rhinitis and nonrhinitic subjects react differentially to nasal provocation with chlorine gas	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; nasal irritation; rhinomanometry	ENVIRONMENTAL TOBACCO-SMOKE; RESPIRATORY-TRACT; NEUROPEPTIDES; SENSITIVITY; INHALATION; IRRITATION	Background: Nasal irritation and associated symptoms (nasal congestion, rhinorrhea, and sinus headache) are important elements of the response to indoor and outdoor air pollution. Marked interindividual variability in such symptoms has been suggested clinically and epidemiologically, but little experimental data exist on this issue. Objective: We sought to test the hypothesis that subjects with seasonal allergic rhinitis (SAR) exhibit a more marked physiologic response (congestion) after nasal irritant provocation than do nonrhinitic subjects. Methods: We studied eight subjects with SAR and eight nonrhinitc subjects; subjects with SAR were studied out of season. In a single-blind crossover study, subjects had their nasal airway resistance (NAR) measured in triplicate before, immediately after, and 15 minutes after a 15-minute exposure to either filtered air or 0.5 ppm chlorine in filtered air, administered through a nasal mask in a climate-controlled chamber, Log transformed NAR values were analyzed in a repeated-measures analysis of variance model, with confirmatory testing using paired t tests. Results: The net (chlorine minus air day) percent change in NAR from baseline (before exposure) to immediately after exposure was +24% in the SAR group and +3% in the nonrhinitic group (p < 0.05), The corresponding net changes from baseline to 15 minutes after exposure were +21% in the SAR group and -1% in the nonrhinitic group (p < 0.05). Conclusions: The observed augmented nasal congestive response of subjects with SAR versus nonrhinitic subjects to a controlled low-level chemical irritant provocation is consistent with epidemiologic surveys showing a higher prevalence of nasal symptoms among subjects with SAR than nonrhinitic subjects in environments involving irritant air pollutants.	Univ Calif San Francisco, Div Environm & Occupat Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shusterman, DJ (corresponding author), Univ Calif Berkeley, Richmond Field Stn, Upper Airway Biol Lab, 1301 So 46th St,Bldg 112, Richmond, CA 94804 USA.		Balmes, John/L-6281-2019		NIDCD NIH HHS [K08 DC00121] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000121] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANGLEN DM, 1981, THESIS UMI ANN ARBOR; BARANIUK JN, 1994, CL ALLER IM, V4, P79; BARANIUK JN, 1992, J ALLERGY CLIN IMMUN, V90, P1045, DOI 10.1016/0091-6749(92)90121-H; BARANIUK JN, 1990, J ALLERGY CLIN IMMUN, V86, P620, DOI 10.1016/S0091-6749(05)80226-X; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BASCOM R, 1992, ANN NY ACAD SCI, V641, P225, DOI 10.1111/j.1749-6632.1992.tb16546.x; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304, DOI 10.1164/ajrccm/143.6.1304; Cain W.S., 1986, P IAQ 86 MAN IND AIR, P126; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P619; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P351; Clement P A, 1984, Rhinology, V22, P151; COMETTOMUNIZ JE, 1992, ANN NY ACAD SCI, V641, P137, DOI 10.1111/j.1749-6632.1992.tb16539.x; CUMMINGS KM, 1991, INT J EPIDEMIOL, V20, P121, DOI 10.1093/ije/20.1.121; DAlessandro A, 1996, CHEST, V109, P331, DOI 10.1378/chest.109.2.331; FISK WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; HALL HI, 1993, INDOOR AIR, V3, P206; KHARRAZI M, 1994, HAZARDOUS WASTE AND PUBLIC HEALTH: INTERNATIONAL CONGRESS ON THE HEALTH EFFECTS OF HAZARDOUS WASTE, P806; KJEERGAARD SK, 1995, P HLTH BUILD 95, V1, P567; KREISS K, 1989, OCCUP MED, V4, P575; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; ROTMAN HH, 1983, J APPL PHYSIOL, V54, P1120, DOI 10.1152/jappl.1983.54.4.1120; SHUSTERMAN D, 1991, ENVIRON HEALTH PERSP, V94, P25, DOI 10.2307/3431288; Shusterman D, 1997, ARCH ENVIRON HEALTH, V52, P334, DOI 10.1080/00039899709602208; SILVER WL, 1992, ANN NY ACAD SCI, V641, P152, DOI 10.1111/j.1749-6632.1992.tb16540.x; SOLOMON WR, 1995, PROVOCATION TESTING, P647; STANKUS RP, 1988, CURRENT PULMONOLOGY, V9, P369; Tomkinson A, 1996, AM J RHINOL, V10, P161, DOI 10.2500/105065896781794923; *US EPA, 1994, 1992 TOX REL INV PUB; Wallace L. A., 1993, INDOOR AIR, V3, P193, DOI [10.1111/j.1600-0668.1993.t01-1-00005.x, DOI 10.1111/J.1600-0668.1993.T01-1-00005.X]; WIDDICOMBE JG, 1990, RESP MED, V84, P3, DOI 10.1016/S0954-6111(08)80001-7; WILLES SR, 1992, ARCH ENVIRON HEALTH, V47, P223, DOI 10.1080/00039896.1992.9938353	32	50	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				732	740		10.1016/S0091-6749(98)70302-1	http://dx.doi.org/10.1016/S0091-6749(98)70302-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648699				2022-12-18	WOS:000074414200004
J	Graft, DF; Golden, DBK; Reisman, RE; Valentine, MD; Yunginger, JW				Graft, DF; Golden, DBK; Reisman, RE; Valentine, MD; Yunginger, JW		Comm Insects	The discontinuation of Hymenoptera venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STING CHALLENGE; CHILDREN; ALLERGY		Amer Acad Allergy Asthma & Immunol, Execut Off, Milwaukee, WI 53202 USA		Graft, DF (corresponding author), Amer Acad Allergy Asthma & Immunol, Execut Off, 611 E Wells St, Milwaukee, WI 53202 USA.							BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; GOLDBERG A, 1994, J ALLERGY CLIN IMMUN, V93, P997, DOI 10.1016/S0091-6749(94)70047-8; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; GRAFT DF, 1994, ANN ALLERGY, V73, P481; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7	22	50	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					573	575						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600490				2022-12-18	WOS:000073697400001
J	Laube, BL; Edwards, AM; Dalby, RN; Creticos, PS; Norman, PS				Laube, BL; Edwards, AM; Dalby, RN; Creticos, PS; Norman, PS			The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cromolyn sodium; aerosol deposition	METERED-DOSE INHALER; AEROSOL DISTRIBUTION; SALINE AEROSOL; DEPOSITION; CROMOGLYCATE; AIRWAYS; RESPONSIVENESS; METHACHOLINE; OBSTRUCTION; RESPONSES	Background: Approximately one third of patients with allergy-induced asthma who are treated with aerosolized cromolyn sodium (CS) fail to achieve a full therapeutic effect. This lack of effectiveness could involve nonhomogeneous distribution of drug in the lung as a result of high inspiratory flow rates. Objective: We sought to determine the efficacy of slow versus faster inhalation of CS in protecting against allergen challenge in patients with asthma. Methods: Eight patients with asthma underwent two allergen challenges 30 minutes after pretreatment with CS that was inhaled from a large holding chamber at similar to 30 L/min or similar to 70 L/min. Percent decreases in FEV1 at a common dose of allergen on the two challenge days were compared. Values of skew tan indicator of aerosol distribution homogeneity) obtained from gamma camera lung images after slow and faster inhalation of radiolabeled CS were also compared. Results: Mean (+/- SD) allergen-induced decrease in FEV1 was 5.4% +/- 4.2% after slow inspiration of CS, which was significantly less than the allergen-induced decrease in FEV1 after faster inhalation of CS with 12.6% +/- 11% (p < 0.05). Mean skew values were also significantly decreased after slow inspiration of CS, and differences in decreases in allergen FEV1 and skew values for the two breathing maneuvers were significantly correlated. Conclusion: These data indicate that protection against allergen-induced asthma can be optimized by slowly inspiring CS from a large holding chamber compared with faster inhalation of the drug. These results appear to be related to enhanced distribution homogeneity of CS within the lungs.	Johns Hopkins Univ, Inst Med, Baltimore, MD USA; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA	Johns Hopkins University; University of Southampton; University System of Maryland; University of Maryland Baltimore	Laube, BL (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, 615 N Wolfe St,Room 2001, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NIAID NIH HHS [1 U01 AI3 1867-04] Funding Source: Medline; NIEHS NIH HHS [ES-03819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[BROMPTON HOSPITAL Medical Research Council Collaborative Trial], 1972, BRIT MED J, V4, P383; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1988, EUR RESPIR J, V1, P890; CHURCH MK, 1989, ANN ALLERGY, V62, P215; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DOLOVICH MB, 1976, J APPL PHYSIOL, V40, P468, DOI 10.1152/jappl.1976.40.3.468; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; ELLIS JL, 1994, AM J RESP CRIT CARE, V150, P717, DOI 10.1164/ajrccm.150.3.8087342; GRANT IWB, 1976, BRIT MED J, V1, P361; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HENDELES L, 1995, J ALLERGY CLIN IMMUN, V95, P505, DOI 10.1016/S0091-6749(95)70312-8; KOHLER D, 1988, RESPIRATION, V53, P65; LAUBE BL, 1984, AEROSOL SCI TECH, V3, P97, DOI 10.1080/02786828408958997; LAUBE BL, 1988, J NUCL MED, V29, P1057; LAUBE BL, 1986, AM REV RESPIR DIS, V133, P740; LAUBE BL, 1992, J ALLERGY CLIN IMMUN, V89, P510, DOI 10.1016/0091-6749(92)90317-U; MACEY DJ, 1982, J NUCL MED, V23, P731; NATHAN RA, 1995, J ALLERGY CLIN IMMUN, V95, P388; NEWMAN SP, 1991, INT J PHARM, V74, P203, DOI 10.1016/0378-5173(91)90238-J; NEWMAN SP, 1989, THORAX, V44, P706, DOI 10.1136/thx.44.9.706; RICHARDS R, 1988, THORAX, V43, P611, DOI 10.1136/thx.43.8.611; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378	22	50	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				475	483		10.1016/S0091-6749(98)70376-8	http://dx.doi.org/10.1016/S0091-6749(98)70376-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564800	hybrid			2022-12-18	WOS:000073113500009
J	Essayan, DM; Huang, SK; KageySobotka, A; Lichtenstein, LM				Essayan, DM; Huang, SK; KageySobotka, A; Lichtenstein, LM			Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin 4; interleukin 5; interferon-gamma; T lymphocyte; monocyte; phosphodiesterase; ragweed	CYCLIC-AMP-PHOSPHODIESTERASE; BLOOD MONONUCLEAR-CELLS; NUCLEOTIDE PHOSPHODIESTERASE; ADENOSINE-MONOPHOSPHATE; T-CELLS; ATOPIC-DERMATITIS; INTERFERON-GAMMA; JURKAT CELLS; INTERLEUKIN-4; MODULATION	Elevations of intracellular cyclic AMP, achieved with the use of phosphodiesterase (PDE) inhibitors, cause functional downregulation of most inflammatory cells. Rolipram, an inhibitor selective for the PDE4 isozyme, can markedly downregulate antigen-driven proliferation and cytokine gene expression of unfractionated human peripheral blood mononuclear cells. However; it is unclear whether PDE4 inhibitors in a mixed-cell system exert their immunosuppressive effect on the lymphocyte or on the monocyte fraction. We have used an adherence-based protocol for separating peripheral blood mononuclear cells, isolated from atopic individuals, into lymphocyte and monocyte fractions and have selectively treated these populations with rolipram prior to reconstituting the cell cultures to their original lymphocyte/monocyte proportions. Cellular responses to both ragweed and tetanus toroid were analyzed for both proliferation and gene expression of proinflammatory cytokines. A dose-dependent downregulation of ragweed- and tetanus toxoid-driven proliferative responses was achieved by pretreatment of lymphocytes from peripheral blood with rolipram. This downregulation was significantly greater than that achieved with pretreatment of monocytes. Pretreatment of both populations failed to show synergistic downregulation of proliferation. Lymphocyte pretreatment with rolipram also resulted in marked downregulation of gene expression for IL-4, IL-5, and intelferon-gamma compared to monocyte pretreatment in both ragweed- and tetanus toxoid-driven systems. Interestingly, monocyte pretreatment in these systems resulted in significant downregulation of IL-2 gene expression compared to lymphocyte pretreatment. Flow cytometric analysis failed to show alterations in any of a panel of surface activation and signal transducing molecules by rolipram treatment with or without antigen stimulation. We conclude that in a mixed cell system, PDE4 inhibitors downregulate antigen-driven proliferation and gene expression of proinflammatory cytokines predominantly through their effects on lymphocytes rather than monocytes.			Essayan, DM (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,DIV CLIN IMMUNOL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.		Huang, Shau-Ku/F-5509-2010		NIAID NIH HHS [AI07290, AI34002] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CHAN SC, 1993, J ALLERGY CLIN IMMUN, V91, P1179, DOI 10.1016/0091-6749(93)90321-6; CHAN SC, 1993, J LAB CLIN MED, V121, P44; CHAN SC, 1993, J INVEST DERMATOL, V100, P681, DOI 10.1111/1523-1747.ep12472344; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DENT G, 1994, AM J RESP CELL MOL, V10, P565, DOI 10.1165/ajrcmb.10.5.8179921; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DREES M, 1993, CANCER RES, V53, P3058; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; ESSAYAN DM, 1995, AM J RESP CELL MOL, V13, P692, DOI 10.1165/ajrcmb.13.6.7576707; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; GRISWOLD DE, 1993, INFLAMMATION, V17, P333, DOI 10.1007/BF00918994; HENNEY CS, 1972, J IMMUNOL, V108, P1526; HOLDEN CA, 1986, J INVEST DERMATOL, V87, P372, DOI 10.1111/1523-1747.ep12524844; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; KRAUSE DS, 1991, J IMMUNOL, V146, P2285; KUMAI M, 1993, IMMUNOLOGY, V79, P174; LEWIS GM, 1993, AGENTS ACTIONS, V39, pC89, DOI 10.1007/BF01972730; LI SH, 1992, J INVEST DERMATOL, V99, P65, DOI 10.1111/1523-1747.ep12611858; MOLNARKIMBER K, 1993, AGENTS ACTIONS, V39, pC77, DOI 10.1007/BF01972726; NICHOLSON CD, 1994, PULM PHARMACOL THER, V7, P1; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Prussin C., 1996, Journal of Allergy and Clinical Immunology, V97, P299, DOI 10.1016/S0091-6749(96)80684-1; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; WACHOLTZ MC, 1991, CELL IMMUNOL, V135, P285, DOI 10.1016/0008-8749(91)90274-F; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	32	50	55	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				28	37		10.1016/S0091-6749(97)81041-X	http://dx.doi.org/10.1016/S0091-6749(97)81041-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003208	Bronze			2022-12-18	WOS:A1997WD06100005
J	BRONSKY, E; BOGGS, P; FINDLAY, S; GAWCHIK, S; GEORGITIS, J; MANSMANN, H; SHOLLER, L; WOLFE, J; MELTZER, E; MORRIS, R; MUNK, Z; PAULL, B; PLESKOW, W; RATNER, P; DANZIG, M; HARRISON, J; LORBER, R				BRONSKY, E; BOGGS, P; FINDLAY, S; GAWCHIK, S; GEORGITIS, J; MANSMANN, H; SHOLLER, L; WOLFE, J; MELTZER, E; MORRIS, R; MUNK, Z; PAULL, B; PLESKOW, W; RATNER, P; DANZIG, M; HARRISON, J; LORBER, R			COMPARATIVE EFFICACY AND SAFETY OF A ONCE-DAILY LORATADINE-PSEUDOEPHEDRINE COMBINATION VERSUS ITS COMPONENTS ALONE AND PLACEBO IN THE MANAGEMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SCH 434 QD; LORATADINE; PSEUDOEPHEDRINE; SEASONAL ALLERGIC RHINITIS	NON-SEDATING ANTIHISTAMINE; HAY-FEVER; TERFENADINE; DECONGESTANT; MG	Background: The treatment of symptoms of seasonal allergic rhinitis often requires the use of a decongestant to improve nasal congestion, along with an antihistamine to adequately control other nasal as well as nonnasal symptoms. Methods: In this double-blind, placebo-controlled multicenter study, 874 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated with one of the following: SCH 434 QD (a combination of 10 mg of loratadine in the coating and 240 mg of pseudoephedrine sulfate in an extended-release cove) once daily, 10 mg of loratadine once daily, 120 mg of pseudoephedrine sulfate every 12 hours, or placebo for 2 weeks. Results: SCH 434 QD was consistently superior to placebo in controlling the symptoms of seasonal allergic rhinitis. Composite symptom scores (total, total nasal, and total nonnasal) were reduced significantly in patients treated with SCH 434 QD as compared with placebo (p < 0.01). When compared with its individual components, reductions in mean symptom scores were consistently greater, numerically, in patients treated with SCH 434 QD than in patients who were treated with either loratadine or pseudoephedrine alone. SCH 434 QD was superior to pseudoephedrine in reudcing nonnasal symptoms at all time points (p < 0.01), and superior to loratadine in relieving nasal stuffiness nt end point (p < 0.01). In the physicians' evaluation of therapeutic response, the SCH 434 QD group had the greatest number of patients with a good or excellent response at end point (58%). All treatments were generally well tolerated with no serious or unusual adverse events. Insomnia and nervousness, adverse events commonly associated with pseudoephedrine, were noted in a significantly greater number of patients treated with SCH 434 QD or pseudoephedrine (p less than or equal to 0.04) as compared with those treated with loratadine or placebo. Conclusions: The results of the study demonstrate that SCH 434 QD is more effective than placebo or either of its components alone in the treatment of seasonal allergic rhinitis.	SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033; AAAA MED RES GRP,SALT LAKE CITY,UT; ASTHMA ALLERGY CLIN,SHREVEPORT,LA; ALLERGY CTR AUSTIN,AUSTIN,TX; CROZER CHESTER MED CTR,CHESTER,PA; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; THOMAS JEFFERSON UNIV HOSP,PHILADELPHIA,PA; MINNESOTA CLIN STUDY CTR,MINNEAPOLIS,MN; PK NICOLLET FDN,MINNEAPOLIS,MN; ALLERGY CTR INC,HOUSTON,TX; PAULL RES INT,BRYAN,TX; SCRIPPS CLIN & HOSP,ENCINITAS,CA; SYLVANA RES,SAN ANTONIO,TX; ASTHMA ASSOC SANTA CLARA VALLEY,SAN JOSE,CA; ALLERGY & ASTHMA MED GRP & RES GRP,SAN DIEGO,CA	Merck & Company; Schering Plough Corporation; Wake Forest University; Wake Forest Baptist Medical Center; Jefferson University; Scripps Research Institute								BANOV CH, 1989, J INT MED RES, V17, P150, DOI 10.1177/030006058901700206; BRUTTMANN G, 1987, J INT MED RES, V15, P63, DOI 10.1177/030006058701500201; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; DIAMOND L, 1981, ANN ALLERGY, V47, P87; DOCKHORN RJ, 1988, J ALLERGY CLIN IMMUN, V81, P178, DOI 10.1016/0091-6749(88)90275-8; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; GUTKOWSKI A, 1988, J ALLERGY CLIN IMMUN, V81, P902, DOI 10.1016/0091-6749(88)90948-7; HOWARTH PH, 1991, CLIN EXP ALLERGY, V21, P2; IRANDER K, 1990, ALLERGY, V45, P86, DOI 10.1111/j.1398-9995.1990.tb00463.x; KEMP JP, 1987, AM J RHINOL, V1, P151; OEI HD, 1988, ANN ALLERGY, V61, P436; SIMONS FER, 1989, DRUGS, V38, P313; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P725, DOI 10.1016/0091-6749(88)91045-7; STILLWAGON PK, 1987, ANN ALLERGY, V58, P442; STORMS WW, 1989, J ALLERGY CLIN IMMUN, V83, P1083, DOI 10.1016/0091-6749(89)90450-8; TARNASKY PR, 1990, J FAM PRACTICE, V30, P71; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4	18	50	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					139	147		10.1016/S0091-6749(95)70001-3	http://dx.doi.org/10.1016/S0091-6749(95)70001-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636050				2022-12-18	WOS:A1995RQ00100001
J	BRONSKY, EA; DRUCE, H; FINDLAY, SR; HAMPEL, FC; KAISER, H; RATNER, P; VALENTINE, MD; WOOD, CC				BRONSKY, EA; DRUCE, H; FINDLAY, SR; HAMPEL, FC; KAISER, H; RATNER, P; VALENTINE, MD; WOOD, CC			A CLINICAL-TRIAL OF IPRATROPIUM BROMIDE NASAL SPRAY IN PATIENTS WITH PERENNIAL NONALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NONALLERGIC RHINITIS; IPRATROPIUM; RHINORRHEA; NASAL SPRAY; SAFETY; EFFICACY		Intranasal ipratropium bromide has been shown to significantly reduce rhinorrhea. Use of a freon-propelled intranasal preparation has resulted in side effects associated with the drying properties of the propellant The purpose of the present trial was to study the safety and efficacy of a new isotonic aqueous ipratropium bromide nasal spray pump, specifically in patients with perennial nonallergic rhinitis. Two hundred thirty-three patients participated in an 8-week double-blind parallel comparison of ipratropium bromide nasal spray with its vehicle, a saline solution. Treatment with the ipratropium spray resulted in a 30% reduction in rhinorrhea; this reduction was significantly greater than that seen with the saline vehicle. There was a modest reduction in postnasal drip, sneezing, and congestion with both treatments, which may be attributable to the salutary effects of the saline solution. Patients also perceived a significant reduction in the degree to which rhinorrhea interfered with their daily activities and moods. Treatment was well tolerated, with no drug-related systemic adverse events and no evidence of nasal rebound on discontinuation of treatment Minor, infrequent episodes of nasal dryness and epistaxis were the only significant adverse events reported; these did not limit treatment.	AAAA MED RES GRP,SALT LAKE CITY,UT									BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V89, P1065, DOI 10.1016/0091-6749(92)90290-I; DRUCE HM, 1992, ANN ALLERGY, V69, P53; JACOBS RL, 1987, IMMUNOL ALLERGY CLIN, V7, P93; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; WAGENMANN M, 1994, J CLIN EXP ALLERGY, V24, P288	6	50	50	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1117	1122		10.1016/S0091-6749(95)70215-6	http://dx.doi.org/10.1016/S0091-6749(95)70215-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751528				2022-12-18	WOS:A1995QY91800007
J	GOUNNI, AS; LAMKHIOUED, B; DELAPORTE, E; DUBOST, A; KINET, JP; CAPRON, A; CAPRON, M				GOUNNI, AS; LAMKHIOUED, B; DELAPORTE, E; DUBOST, A; KINET, JP; CAPRON, A; CAPRON, M			THE HIGH-AFFINITY IGE RECEPTOR ON EOSINOPHILS - FROM ALLERGY TO PARASITES OR FROM PARASITES TO ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RELEASE; CELLS		INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,INSERM,U167, CNRS 624, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, DERMATOL SERV, F-59037 LILLE, FRANCE; NIAID, MOLEC ALLERGY & IMMUNOL SECT, ROCKVILLE, MD 20852 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			LAMKHIOUED, Bouchaib/AAL-4201-2021; Capron, monique/Z-2207-2019; Gounni, Abdelilah Soussi/AAH-3456-2020	Capron, monique/0000-0001-5625-5158; Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				BLANK U, 1991, J BIOL CHEM, V266, P2639; CAPRON M, 1989, CHEM IMMUNOL, V47, P128; CAPRON M, 1991, EUR J IMMUNOL, V21, P2423, DOI 10.1002/eji.1830211019; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; KHALIFE J, 1986, J IMMUNOL, V137, P1659; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; TRUONG MJ, 1993, EUR J IMMUNOL, V23, P3230, DOI 10.1002/eji.1830231228; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	12	50	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1214	1216		10.1016/0091-6749(94)90334-4	http://dx.doi.org/10.1016/0091-6749(94)90334-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798562				2022-12-18	WOS:A1994QA02000014
J	WELLER, PF; DVORAK, AM				WELLER, PF; DVORAK, AM			LIPID BODIES - INTRACELLULAR SITES FOR EICOSANOID FORMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; NONSPECIFIC ESTERASE-ACTIVITY; PROTEIN-KINASE-C; GUINEA-PIG; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; ULTRASTRUCTURAL-LOCALIZATION; ENDOTHELIAL-CELLS; COMPLEMENTARY-DNA; HUMAN EOSINOPHILS				WELLER, PF (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DANA 617,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372, R01AI022571, R01AI020241] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20241, AI22571, AI33372] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; COIMBRA A, 1971, J HISTOCHEM CYTOCHEM, V19, P551, DOI 10.1177/19.9.551; COMAI K, 1974, PROSTAG OTH LIPID M, V6, P375, DOI 10.1016/0090-6980(74)90010-0; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DVORAK AM, 1984, J CELL BIOL, V99, P1678, DOI 10.1083/jcb.99.5.1678; DVORAK AM, 1983, J IMMUNOL, V131, P2965; DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511; DVORAK AM, 1987, J HISTOCHEM CYTOCHEM, V35, P351, DOI 10.1177/35.3.3819377; DVORAK AM, 1990, BLOOD CELL BIOCH MEG, P237; DVORAK AM, 1994, IN PRESS INT ARCH AL; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAINES KA, 1987, BIOCHEM J, V241, P55, DOI 10.1042/bj2410055; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; LAPOSATA M, 1988, J BIOL CHEM, V263, P3266; LILES WC, 1987, J IMMUNOL, V138, P3396; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MONAHAN RA, 1981, BLOOD, V58, P1089; MONAHANEARLEY RA, 1987, J HISTOCHEM CYTOCHEM, V35, P531, DOI 10.1177/35.5.3559181; RAULF M, 1988, IMMUNOLOGY, V64, P51; ROBINSON JM, 1982, J CELL BIOL, V95, P933, DOI 10.1083/jcb.95.3.933; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SCHNEEBERGER EE, 1971, EXP CELL RES, V69, P193, DOI 10.1016/0014-4827(71)90325-9; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; SMITH WL, 1981, PROGR LIPID RES, P103; STUBBS CD, 1980, BIOCHEMISTRY-US, V19, P2756, DOI 10.1021/bi00553a034; WELLER PF, 1991, J CELL BIOL, V113, P137, DOI 10.1083/jcb.113.1.137; WELLER PF, 1985, BLOOD, V65, P1269; WELLER PF, 1991, AM J PATHOL, V138, P141; WELLER PF, 1989, AM J PATHOL, V135, P947; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC, P22; [No title captured]	32	50	51	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1151	1156		10.1016/0091-6749(94)90325-5	http://dx.doi.org/10.1016/0091-6749(94)90325-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798553				2022-12-18	WOS:A1994QA02000005
J	SABAN, R; HAAKFRENDSCHO, M; ZINE, M; RIDGWAY, J; GORMAN, C; PRESTA, LG; BJORLING, D; SABAN, M; JARDIEU, P				SABAN, R; HAAKFRENDSCHO, M; ZINE, M; RIDGWAY, J; GORMAN, C; PRESTA, LG; BJORLING, D; SABAN, M; JARDIEU, P			HUMAN FCERI-IGG AND HUMANIZED ANTI-IGE MONOCLONAL-ANTIBODY MAE11 BLOCK PASSIVE SENSITIZATION OF HUMAN AND RHESUS-MONKEY LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; HUMAN; LUNG; SENSITIZATION; ANTIBODY	GUINEA-PIG; MAST-CELL; SULFIDOPEPTIDE-LEUKOTRIENES; HISTAMINE-RELEASE; ESCHERICHIA-COLI; IMMUNOGLOBULIN-E; HUMAN AIRWAYS; CONTRACTION; INHIBITION; RECEPTOR	IgE antibodies are thought to play an important role in the induction of allergic inflammation of the bronchi. In this study we assessed the capacity of two inhibitors, FcERI-IgG, an immunoadhesin made up of the alpha chain of the high-affinity IgE receptor joined to a truncated IgG heavy chain, and MaE11, a humanized murine anti-human IgE antibody, to prevent allergen sensitization. Lung parenchyma strips from rhesus monkeys and human beings were passively sensitized for 20 hours with serum from a ragweed-sensitive patient in the presence of 0, 1-, 5-, or 10-fold concentrations of the inhibitors relative to IgE. The parenchymal strips were then suspended in a superfusion apparatus for measurement of isometric tone and collection of superfusate for histamine analysis in response to challenge with antigen E (AgE). Nonsensitized tissues did nor react to AgE challenge whereas AgE challenge of passively sensitized tissues resulted in a time-dependent parenchymal contraction and histamine release. Both FcERT-IgC and MaE11 completely abolished the AgE-induced contraction and histamine release in a dose-dependent manner. rn addition, passively sensitized lung tissues failed to respond to direct challenge with either FcERT-IgG or MaE11. The results of this study suggest that FcERI-IgG and MaE11 may have important immunotherapeutic benefit for the amelioration of IgE-mediated diseases.	GENENTECH INC, PROT ENGN, SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech	SABAN, R (corresponding author), UNIV WISCONSIN, SCH VET MED, DEPT SURG SCI, SMOOTH MUSCLE LAB, 2015 LINDEN DR W, MADISON, WI 53706 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000167] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00167] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADAMS GK, 1979, J IMMUNOL, V122, P555; Ashkenazi A, 1993, Int Rev Immunol, V10, P219, DOI 10.3109/08830189309061697; AUSTEN KF, MOL ASPECTS ACUTE AL, P293; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; BANIYASH M, 1986, J IMMUNOL, V136, P588; BLANK U, 1991, J BIOL CHEM, V266, P2639; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; COLEMAN JW, 1985, EUR J IMMUNOL, V15, P966, DOI 10.1002/eji.1830150920; CREESE BR, 1986, CLIN EXP PHARMACOL P, V13, P103, DOI 10.1111/j.1440-1681.1986.tb00323.x; CRIVELLARI MT, 1991, BIOCHEM PHARMACOL, V42, P419, DOI 10.1016/0006-2952(91)90730-S; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FISHLEDER RI, 1984, J PHARMACOL EXP THER, V230, P534; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HODGES TL, 1991, ANTIMICROB AGENTS CH, V35, P2580, DOI 10.1128/AAC.35.12.2580; ISHIZAKA T, 1983, J IMMUNOL, V130, P2357; MCKENNIFF M, 1988, EUR J PHARMACOL, V153, P149, DOI 10.1016/0014-2999(88)90601-2; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; NAPIER FE, 1990, BRIT J PHARMACOL, V100, P247, DOI 10.1111/j.1476-5381.1990.tb15790.x; NAPIER FE, 1989, PROSTAG OTH LIPID M, V38, P227, DOI 10.1016/0090-6980(89)90085-3; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; UNDEM BJ, 1987, AM REV RESPIR DIS, V136, P1183, DOI 10.1164/ajrccm/136.5.1183	28	50	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					836	843		10.1016/0091-6749(94)90151-1	http://dx.doi.org/10.1016/0091-6749(94)90151-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7525678				2022-12-18	WOS:A1994PR24000008
J	AWAD, JA; MORROW, JD; ROBERTS, LJ				AWAD, JA; MORROW, JD; ROBERTS, LJ			DETECTION OF THE MAJOR URINARY METABOLITE OF PROSTAGLANDIN D-2 IN THE CIRCULATION - DEMONSTRATION OF ELEVATED LEVELS IN PATIENTS WITH DISORDERS OF SYSTEMIC MAST-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PROSTAGLANDIN D-2; MASTOCYTOSIS; ANAPHYLAXIS NICOTINIC ACID; PROSTAGLANDIN METABOLISM	SPECTROMETRIC ASSAY; RELEASE; ANAPHYLAXIS; 9-ALPHA,11-BETA-PROSTAGLANDIN-F2; QUANTIFICATION; IDENTIFICATION; MASTOCYTOSIS; HISTAMINE; TRYPTASE; INVIVO	The symptoms and hemodynamic alterations chat accompany episodes of systemic mast cell activation have been largely attributed to excessive prostaglandin (PG)D-2 release. Quantification of the major urinary metabolite of PGD(2) has been invaluable in elucidating a role for PGD(2) in these clinical entities and in the biochemical evaluation of systemic mastocytosis. With the use of a modified mass spectrometric assay for the major urinary metabolite of PGD(2), this metabolite was detected in plasma from 10 normal volunteers (3.5 +/- 1.4 pg/ml). Ingestion of niacin, which induces endogenous release of PGD(2), increased plasma levels of this metabolite 6.3 to 33 times above the upper limit of normal by 2 hours. Thereafter levels declined gradually but remained elevated for lip to 6 to 8 hours. In contrast circulating levels of 9 alpha,11 beta-PGF(2), the initial metabolite of PGD(2), peaked by 30 minutes and returned to baseline by 2 hours. The clinical utility of measuring the major urinary metabolite in the circulation was demonstrated by detection of markedly increased levels in plasma and serum from patients with systemic mastocytosis and a patient with a severe type I allergic reaction. Thus in the biochemical evaluation of episodes of systemic mast cell activation and endeavors to further elucidate the role of PGD(2) in human disease, there are kinetic advantages of measuring the major urinary metabolite of PGD(2) in the circulation. One particular advantage is the evaluation of clinical events, which only in retrospect are suspected to be associated with excessive release of PGD(2), yet plasma or serum was obtained proximate to the event.	VANDERBILT UNIV, DEPT MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN USA	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, R01GM042056] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07028] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM42056] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARZUBIAGA C, 1991, J ALLERGY CLIN IMMUN, V87, P88, DOI 10.1016/0091-6749(91)90216-B; AWAD JA, 1993, J BIOL CHEM, V268, P4161; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; FELDMAN JM, 1983, ARCH INTERN MED, V143, P2099, DOI 10.1001/archinte.143.11.2099; GRANSTROM E, 1982, BIOCHIM BIOPHYS ACTA, V713, P46, DOI 10.1016/0005-2760(82)90165-5; GRANSTROM E, 1982, BIOCHIM BIOPHYS ACTA, V713, P555, DOI 10.1016/0005-2760(82)90316-2; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LISTON TE, 1985, P NATL ACAD SCI USA, V82, P6030, DOI 10.1073/pnas.82.18.6030; LISTON TE, 1985, J BIOL CHEM, V260, P3172; MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9; MORROW JD, 1991, NEW ENGL J MED, V324, P716, DOI 10.1056/NEJM199103143241102; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; MURPHY RC, 1982, METHOD ENZYMOL, V86, P547; PRAKASH C, 1988, J CHEM SOC PERK T 1, P2821, DOI 10.1039/p19880002821; ROBERTS LJ, 1991, J INVEST DERMATOL, V96, pS19, DOI 10.1111/1523-1747.ep12468945; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; WENDELBORN DF, 1990, METHOD ENZYMOL, V187, P51	22	50	51	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					817	824		10.1016/0091-6749(94)90371-9	http://dx.doi.org/10.1016/0091-6749(94)90371-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182221				2022-12-18	WOS:A1994NL91900002
J	GOSSET, P; MALAQUIN, F; DELNESTE, Y; WALLAERT, B; CAPRON, A; JOSEPH, M; TONNEL, AB				GOSSET, P; MALAQUIN, F; DELNESTE, Y; WALLAERT, B; CAPRON, A; JOSEPH, M; TONNEL, AB			INTERLEUKIN-6 AND INTERLEUKIN-1-ALPHA PRODUCTION IS ASSOCIATED WITH ANTIGEN-INDUCED LATE NASAL RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTERLEUKIN-6; INTERLEUKIN-1-ALPHA; LATE NASAL RESPONSE; ALLERGEN CHALLENGE; CYTOKINES; INFLAMMATORY MEDIATORS; ALLERGIC RHINITIS; GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR-ALPHA	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; FACTOR-ALPHA; ALVEOLAR MACROPHAGES; ENDOTHELIAL-CELLS; ACTIVATING FACTOR; MEDIATOR RELEASE; GENE-EXPRESSION; CHALLENGE; EOSINOPHILS	Background: Cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1alpha, IL-6 and granulocyte macrophage-colony stimulating factor (GM-CSF) are able to potentiate allergic inflammation and seem to be implicated in the development of the late allergic reaction. Methods: To study the time course of cytokine production, sequential lavages were performed after nasal allergen challenge. Thirteen patients with allergic rhinitis and four healthy subjects were exposed to grass pollen (n = 6 and n = 2, respectively) or dust mite allergen (n = 7 and n = Z respectively). Results: Among the patients with allergic rhinitis, a single early response (single responders) developed in four, eight exhibited a dual response (dual responders) and one patient as well as the four healthy subjects did not respond. In addition to the measurement of IL-1alpha, IL-6, TNF-alpha and GM-CSF concentrations by ELISA, the release of histamine, tryptase, and eosinophil cationic protein was also evaluated by radioimmunoassay performed on nasal lavage fluids. Concerning meditor levels in nasal lavage fluid, neither histamine release nor cytokine elevation were noted in healthy subjects. As previously described, histamine, tryptase, and eosinophil cationic protein were released in single and dual responders. Concerning TNF-alpha was undetectable in the majority of nasal lavages and an increase in GM-CSF concentration was occasionally observed whatever the type of response. In contrast, an increase in IL-1alpha and IL-6 levels was observed for dual responders during the early period (12.6 +/- 3 and 9.2 +/- 2 pg/ml, respectively; p < 0.01 in both cases) and at a higher level during the late period (14.5 +/- 4, p not significant and 16 7 +/- 8 pg/ml, respectively, p < 0. 01) when compared with baseline values (7.2 +/- 2.2 and 2 +/- 0.7 pg/ml, respectively). For single responders IL-1alpha and IL-6 secretion was detected mainly during the early period Conclusion: These data suggest a role for IL-1alpha in the induction and perennisation of the inflammatory reaction in allergic rhinitis, whereas the role of IL-6 remains to be investigated	INST PASTEUR,CIBP,CNRS,624,INSERM,U167,F-59019 LILLE,FRANCE; CHRU,HOP CALMETTE,SERV PNEUMOL & IMMUNOALLERGOL,LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	GOSSET, P (corresponding author), INST PASTEUR,CJF 9006,BP 245,F-59019 LILLE,FRANCE.		Gosset, Philippe/C-6174-2018; DELNESTE, Yves/K-7367-2015; Delneste, Yves/O-3956-2016	Gosset, Philippe/0000-0002-4043-6429; DELNESTE, Yves/0000-0002-2142-596X; 				AFFORD S C, 1992, American Review of Respiratory Disease, V145, pA127; BARTHELSON R, 1990, J ALLERGY CLIN IMMUN, V86, P193, DOI 10.1016/S0091-6749(05)80066-1; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CAUX C, 1990, BLOOD, V75, P2292; DEBS RJ, 1989, J IMMUNOL, V143, P964; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LUGER TA, 1983, J IMMUNOL, V131, P816; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; PINCUS SH, 1986, J IMMUNOL, V137, P3509; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POBER JS, 1986, J IMMUNOL, V137, P1893; ROUBIN R, 1987, CLIN EXP IMMUNOL, V70, P484; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; SHAAFSMA MR, 1989, BLOOD, V74, P2398; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SILBERSTEIN DS, 1986, P NATL ACAD SCI USA, V83, P1055, DOI 10.1073/pnas.83.4.1055; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; TAKIZAWA H, 1992, American Review of Respiratory Disease, V145, pA123; VANDENABEELE P, 1990, J IMMUNOL METHODS, V135, P25, DOI 10.1016/0022-1759(90)90252-Q; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WARREN JS, 1988, AM J PATHOL, V130, P489; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	38	50	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					878	890		10.1016/0091-6749(93)90066-O	http://dx.doi.org/10.1016/0091-6749(93)90066-O			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258622	Bronze			2022-12-18	WOS:A1993ML89300014
J	WOODBAKER, R; HOLGATE, ST				WOODBAKER, R; HOLGATE, ST			THE COMPARATIVE ACTIONS AND ADVERSE EFFECT PROFILE OF SINGLE DOSES OF H(1)-RECEPTOR ANTIHISTAMINES IN THE AIRWAYS AND SKIN OF SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANTIHISTAMINES; ASTHMA; H(1)-RECEPTOR ANTAGONISTS	HISTAMINE H-1 ANTAGONIST; RECEPTOR ANTAGONIST; TERFENADINE; CETIRIZINE; ASTEMIZOLE; CHLORPHENIRAMINE; METHACHOLINE; RELEASE; INVIVO; BRONCHOCONSTRICTION	Background: The development of potent H-1-receptor antagonists that are free of adverse effects has renewed interest in their use in the treatment of asthma. Methods: We performed a study of the action of chlorpheniramine, terfenadine, brompheniramine, cetirizine, cyproheptadine, clemastine, and astemizole compared with placebo on histamine-induced skin wheals and bronchoconstriction in a single group of patients with asthma. Another group underwent methacholine bronchoprovocation. Results: Antihistamine pretreatment increased mean baseline measurements of forced expiratory volume in 1 second (FEV1) between 2.58% and 9.28% compared with placebo, which was significant for all drugs except brompheniramine and clemastine. Compared with placebo, all antihistamines provided significant protection against histamine-induced bronchoconstriction when measured as the provocation concentration required to cause a 20% fall in FEV1; terfenadine and cetirizine provided significantly greater protection than other antihistamines. Protection against histamine-induced skin wheals, measured as the slope of the log concentration-response curve, was only significant for the new drugs, terfenadine and cetirizine. There was a good correlation between the protective effect of the drugs in the skin and airways (r = 0.85; p < 0.01). No significant difference in methacholine provocation concentration required to cause a 20% fall in FEV1 values between treatments was found. Conclusions: The new H-1-receptor antagonists terfenadine and cetirizine provided significantly better protection than the older antihistamines against the action of histamine in the skin and airways. None of the antihistamines showed evidence of anticholinergic activity in the asthmatic airways at the doses studied.	SOUTHAMPTON GEN HOSP,DEPT IMMUNOPHARMACOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								ARBESMAN C, 1947, J ALLERGY, V17, P275; ARMITAGE P, 1980, STATISTICAL METHODS, P444; BERKOW R, 1987, MERCK MANUAL, P2517; BRANDON ML, 1980, ANN ALLERGY, V44, P71; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; DEVOS C, 1987, ANN ALLERGY, V59, P278; EISER NM, 1981, CLIN SCI, V60, P363, DOI 10.1042/cs0600363; FEDEL R, 1987, CLIN ALLERGY, V17, P373; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FORNEAU E, 1933, ARCH INT PHARMACOD T, V46, P178; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HEYKANTS J, 1986, DRUG DEVELOP RES, V8, P71, DOI 10.1002/ddr.430080109; HINTZE KL, 1975, DRUG METAB DISPOS, V3, P1; LADURON PM, 1982, MOL PHARMACOL, V21, P294; LEBEL B, 1988, CLIN ALLERGY, V18, P605, DOI 10.1111/j.1365-2222.1988.tb02912.x; LEVY L, 1947, J ALLERGY, V18, P244, DOI 10.1016/0021-8707(47)90048-8; LUI M, 1990, AM REV RESPIR DIS, V142, P126; NABE M, 1989, CLIN EXP ALLERGY, V19, P515, DOI 10.1111/j.1365-2222.1989.tb02426.x; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; PEETS EA, 1972, J PHARMACOL EXP THER, V180, P464; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1988, J ALLERGY CLIN IMMUN, V82, P1113, DOI 10.1016/0091-6749(88)90151-0; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; STERNBERG L, 1948, Ann Allergy, V6, P569; THAM R, 1978, ARZNEIMITTEL-FORSCH, V28-1, P1017; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; WEINER M, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1193; WOODBAKER R, 1990, AGENTS ACTIONS, V30, P284, DOI 10.1007/BF01969062; WOODWARD JK, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1154	39	50	53	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1005	1014		10.1016/0091-6749(93)90213-Y	http://dx.doi.org/10.1016/0091-6749(93)90213-Y			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8098339	Bronze			2022-12-18	WOS:A1993LC97800007
J	HSIEH, KH; NG, CK				HSIEH, KH; NG, CK			INCREASED PLASMA PLATELET-ACTIVATING-FACTOR IN CHILDREN WITH ACUTE ASTHMATIC ATTACKS AND DECREASED INVIVO AND INVITRO PRODUCTION OF PLATELET-ACTIVATING-FACTOR AFTER IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PLATELET-ACTIVATING FACTOR; ASTHMA; IMMUNOTHERAPY; CHILDREN	HOUSE-DUST; FACTOR PAF; SUPPRESSOR CELLS; RELEASE; HYPOSENSITIZATION; ANTAGONIST; GENERATION; RESPONSES; BASOPHILS; ALLERGEN	Background: To explore the possible role of platelet-activating factor (PAF) in the pathogenesis of bronchial asthma, circulating PAF and in vitro production of PAF were studied. Methods: Radioimmunoassay kits were used in 15 children with acute asthmatic attacks, in 25 newly diagnosed asthmatic children, in 25 good and 18 poor responders to immunotherapy, and in 18 healthy controls. Results: The results demonstrated the following: (1) PAF was present in the blood of healthy controls. (2) New patients had much higher circulating PAF than did healthy controls (p < 0.005), and the circulating PAF decreased after immunotherapy in good (p < 0.005) but not in poor responders. (3) The circulating PAF increased up to 20 times that of healthy controls during acute asthmatic attacks. (4) The spontaneous and allergen-stimulated secretion of PAF were markedly increased in new patients and decreased to normal after successful immunotherapy (p < 0.005). (5) No increased spontaneous and allergen-stimulated production of PAF was found during acute attacks, but granulocytes from those patients still produced the greatest amount of PAF when stimulated with calcium ionophore A23187. (6) Although a major portion of allergen-induced PAF was secreted, less than 10% of ionophore-induced PAF was secreted. Conclusion: The findings that the circulating PAF increased markedly during acute asthmatic attacks and the enhanced in vivo and in vitro productions of PAF decreased to normal after successful immunotherapy strongly suggest that PAF may be involved in the pathogenesis of bronchial asthma.	NATL TAIWAN UNIV HOSP,COLL MED,DEPT PEDIAT,TAIPEI 10016,TAIWAN	National Taiwan University; National Taiwan University Hospital	HSIEH, KH (corresponding author), NATL TAIWAN UNIV HOSP,COLL MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL & RHEUMATOL,7 CHUNG SHAN S RD,TAIPEI 10016,TAIWAN.							AOKI S, 1987, J PHYSL, V394, P130; ARDLIE NG, 1970, BRIT J HAEMATOL, V19, P7, DOI 10.1111/j.1365-2141.1970.tb01596.x; ARNOUX B, 1982, AM REV RESPIR DIS, V125, P70; BENVENISTE J, 1972, J EXP MED, V136, P1365; BETZ SJ, 1980, J IMMUNOL, V125, P2749; BOROWSKA SC, 1986, AGENTS ACTIONS, V18, P176; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CARAMELO C, 1984, BIOCHEM BIOPH RES CO, V120, P789, DOI 10.1016/S0006-291X(84)80176-X; COYLE A, 1987, CLIN RES, V35, pA254; CUSS FM, 1986, LANCET, V2, P189; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; Fabbri L M, 1985, Prog Biochem Pharmacol, V20, P18; GATEAU O, 1984, AM REV RESPIR DIS, V139, pA3; GRANDEL KE, 1985, FED PROC, V44, P184; GUINOT P, 1987, PROSTAGLANDINS, V34, P723, DOI 10.1016/0090-6980(87)90295-4; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HSIEH KH, 1991, CHEST, V99, P877, DOI 10.1378/chest.99.4.877; HSIEH KH, 1988, J CLIN IMMUNOL, V8, P171, DOI 10.1007/BF00917563; HSIEH KH, 1987, J ASTHMA, V24, P19, DOI 10.3109/02770908709073189; HSIEH KH, 1984, J ALLERGY CLIN IMMUN, V74, P34, DOI 10.1016/0091-6749(84)90084-8; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LAZANAS M, 1988, ARCH DERMATOL RES, V280, P124, DOI 10.1007/BF00417717; LIAO TN, 1991, J ALLERGY CLIN IMMUN, V86, P894; LOCKEY RF, 1976, BRONCHIAL ASTHMA MEC, P613; MAZZONI L, 1983, J PHYSL, V365, P107; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MUINO JC, 1990, ALLERGY CLIN IMMUNOL, V2, P75; NAKADA S, 1985, ANN ALLERGY, V54, P437; Noon L, 1911, LANCET, V1, P1572; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P119; PINCKARD RN, 1984, IMMUNOPHARMACOLOGY L, P73; PINCKARD RN, 1979, J IMMUNOL, V123, P1234; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SANCHEZCRESPO M, 1980, IMMUNOLOGY, V40, P645; SANCHEZCRESPO M, 1983, AM J PHYSIOL, V244, P706; STEVENSON JS, 1987, FED PROC, V46, pA1454; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WANG JY, 1989, ASIAN PAC J ALLERGY, V7, P119	44	50	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					650	657		10.1016/0091-6749(93)90271-G	http://dx.doi.org/10.1016/0091-6749(93)90271-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436778				2022-12-18	WOS:A1993KN54800013
J	WALD, ER				WALD, ER			MICROBIOLOGY OF ACUTE AND CHRONIC SINUSITIS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; BACTERIOLOGY; MICROBIOLOGY	ACUTE MAXILLARY SINUSITIS; BACTERIOLOGIC FEATURES	To determine the bacteriologic cause of acute sinusitis, a sample of sinus secretions must be obtained from one of the paranasal sinuses without contamination by normal respiratory or oral flora that colonize mucosal surfaces. When maxillary sinus aspiration is performed on children who have signs and symptoms of acute sinusitis, bacteria are recovered in high density from 70%. In patients with acute, subacute, or chronic sinusitis who are generally well except for persistent respiratory symptoms, of nasal discharge or cough or both, the usual bacterial isolates are Streptococcus pneumoniae, Haemophilus influenzae, an Moraxella catarrhalis. In contrast, anaerobic organisms and staphylococci should be suspected in patients who have very long-standing symptoms or in those whose symptoms are so severe or complicated that sinus surgery is undertaken.			WALD, ER (corresponding author), UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,SCH MED,3705 5TH AVE,PITTSBURGH,PA 15213, USA.							BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; RODRIGUEZ RS, 1988, INTERSCIENCE C ANTIM; SHAPIRO ED, 1982, J INFECT DIS, V146, P589, DOI 10.1093/infdis/146.5.589; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; WALD ER, 1989, J PEDIATR-US, V115, P28, DOI 10.1016/S0022-3476(89)80324-5; WALD ER, 1984, J PEDIATR-US, V104, P297, DOI 10.1016/S0022-3476(84)81018-5; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302	11	50	51	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			452	460		10.1016/0091-6749(92)90168-2	http://dx.doi.org/10.1016/0091-6749(92)90168-2			9	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527336	Bronze			2022-12-18	WOS:A1992JP52100009
J	ARRUDA, LK; PLATTSMILLS, TAE; LONGBOTTOM, JL; ELDAHR, JM; CHAPMAN, MD				ARRUDA, LK; PLATTSMILLS, TAE; LONGBOTTOM, JL; ELDAHR, JM; CHAPMAN, MD			ASPERGILLUS-FUMIGATUS - IDENTIFICATION OF 16, 18, AND 45 KD ANTIGENS RECOGNIZED BY HUMAN-IGG AND IGE ANTIBODIES AND MURINE MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPERGILLUS FUMIGATUS; ASPERGILLOSIS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ASTHMA; FUNGAL ALLERGENS; MONOCLONAL ANTIBODIES	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; DERMATOPHAGOIDES-PTERONYSSINUS; MOLECULAR-WEIGHT; CYSTIC-FIBROSIS; MAJOR ALLERGEN; BINDING; PROTEIN; ELISA; ASSAY; SERUM	The immunochemical properties of antigens produced by Aspergillus fumigatus were investigated with biochemical purification techniques in conjunction with the production of murine monoclonal antibodies (MAbs) and binding studies with human IgG and IgE antibodies. A. fumigatus antigens were partially purified by gel filtration and hydrophobic interaction chromatography on phenyl-Sepharose. Two fractions that eluted with either 2 mol/L or 0.15 mol/L of NaCl demonstrated strong binding to human IgG and IgE antibodies. Immunoprecipitation analysis with IgG antibodies from six patients with different Aspergillus-related diseases demonstrated that the 2M and 0.15M fractions contained major antigens of molecular weight 18 kd (Asp f I) and 45 kd, respectively. The I-125-labeled 2M fraction was used to compare IgG antibodies to A. fumigatus in sera from 25 patients with Aspergillus-related diseases. IgG antibodies were significantly higher in patients with allergic bronchopulmonary aspergillosis (geometric mean, 437 U/ml) than in patients with asthma (geometric mean, 14 U/ml; p < 0.001), but undetectable (<5 U/ml) in 43148 control subjects. A good correlation was found between levels of IgG antibodies to the I-125-labeled 0.15M fraction and the I-125-labeled 2M fraction in sera from 106 patients with cystic fibrosis (r = 0. 77; p < 0.001). Five murine IgG MAbs and two IgM MAbs were raised against the 2M fraction, and immunoprecipitation with the IgG MAb demonstrated two distinct antigens within the 2M fraction, Asp f I, and a 16 kd antigen. The results of a solid-phase RIA with IgG MAb 4A6 demonstrated that approximately 85% of A. fumigatus-allergic patients with allergic bonchopulmonary aspergillosis had IgE antibodies to Asp f I. The three protein antigens defined in these studies are useful probes for investigating the immunopathogenesis of diseases associated with colonization by A. fumigatus.	BROMPTON HOSP, INST CARDIOTHORAC, DEPT ALLERGY & CLIN IMMUNOL, LONDON SW3 6HP, ENGLAND; TULANE UNIV, SCH MED, DEPT PEDIAT, NEW ORLEANS, LA 70112 USA	Royal Brompton Hospital; Tulane University	ARRUDA, LK (corresponding author), UNIV VIRGINIA, DEPT MED & MICROBIOL, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.		Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024687, R01AI020565, R01AI030840, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20565, AI 30840, AI 24687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDOORY Y, 1985, ASPERGILLOSIS, P1; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; BARDANA E, 1980, CRC CRIT REV CLIN LA, V13, P85; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DENNING DW, 1991, NEW ENGL J MED, V324, P654, DOI 10.1056/NEJM199103073241003; EL-DAHR J, 1990, Journal of Allergy and Clinical Immunology, V85, P241; FRASER DW, 1979, JAMA-J AM MED ASSOC, V242, P1631, DOI 10.1001/jama.242.15.1631; FRATAMICO PM, 1991, INFECT IMMUN, V59, P309, DOI 10.1128/IAI.59.1.309-315.1991; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HARVEY C, 1987, J ALLERGY CLIN IMMUN, V79, P324, DOI 10.1016/0091-6749(87)90149-7; HARVEY C, 1986, CLIN EXP IMMUNOL, V65, P206; HENDRIX WC, IN PRESS AM REV RESP; HUTCHESON P S, 1991, Journal of Allergy and Clinical Immunology, V87, P196, DOI 10.1016/0091-6749(91)91515-U; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; KEMENY DM, 1988, J IMMUNOL METHODS, V108, P105, DOI 10.1016/0022-1759(88)90408-5; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176, DOI 10.1159/000234568; KURUP VP, 1989, J CLIN MICROBIOL, V27, P1312, DOI 10.1128/JCM.27.6.1312-1316.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATGE JP, 1991, INFECT IMMUN, V59, P2586; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LEUNG PSC, 1988, INT ARCH ALLER A IMM, V85, P416, DOI 10.1159/000234544; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P18, DOI 10.1016/0091-6749(86)90109-0; LONGBOTTOM JL, 1983, J ALLERGY CLIN IMMUN, V72, P668, DOI 10.1016/0091-6749(83)90627-9; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; PEPYS J, 1959, NATURE, V184, P1328, DOI 10.1038/1841328a0; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; SAMUELSEN H, 1991, ALLERGY, V46, P115, DOI 10.1111/j.1398-9995.1991.tb00554.x; SCHONHEYDER H, 1987, SCAND J INFECT DIS, P1; SLAVIN RG, 1978, INT ARCH ALLER A IMM, V56, P325, DOI 10.1159/000232038; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	36	50	51	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1166	1176		10.1016/0091-6749(92)90301-H	http://dx.doi.org/10.1016/0091-6749(92)90301-H			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607551				2022-12-18	WOS:A1992HZ74800012
J	TAYLOR, IK; OSHAUGHNESSY, KM; CHOUDRY, NB; ADACHI, M; PALMER, JBD; FULLER, RW				TAYLOR, IK; OSHAUGHNESSY, KM; CHOUDRY, NB; ADACHI, M; PALMER, JBD; FULLER, RW			A COMPARATIVE-STUDY IN ATOPIC SUBJECTS WITH ASTHMA OF THE EFFECTS OF SALMETEROL AND SALBUTAMOL ON ALLERGEN-INDUCED BRONCHOCONSTRICTION, INCREASE IN AIRWAY REACTIVITY, AND INCREASE IN URINARY LEUKOTRIENE-E4 EXCRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGEN CHALLENGE; ASTHMA, CYSTEINYL LEUKOTRIENES; LEUKOTRIENE-E4; BETA-2-AGONISTS	LUNG MAST-CELLS; BRONCHIAL RESPONSIVENESS; SODIUM CROMOGLYCATE; IPRATROPIUM BROMIDE; HISTAMINE-RELEASE; ANTIGEN CHALLENGE; INHIBITION; RESPONSES; DRUGS; TERBUTALINE	Salmeterol (SM) is a novel beta(2)-adrenoceptor agonist with a duration of action in excess of 12 hours. Evidence from in vitro studies has also demonstrated that, unlike the short-acting beta(2)-agonists, such as salbutamol (SB), it may have some anti-inflammatory properties. With a randomized, double-blind, crossover design, we have compared the inhibitory effects of SM (50-mu-g) and SB (200-mu-g) delivered by metered-dose inhaler on allergen-induced bronchoconstriction, changes in airway reactivity, and urinary leukotriene (LT) E4 excretion in 12 atopic subjects with mild asthma. The immediate bronchoconstriction to allergen was significantly reduced by both beta(2)-agonists (p < 0.005), when reduction was expressed either in terms of maximum fall in FEV1 at 15 minutes after allergen (percent fall in FEV1, mean +/- SEM: 6.2 +/- 4.9, SM; 5.7 +/- 2.5, SB; 40.4 +/- 6.3, placebo) or the area under the FEV1 time curve (AUC) for the first 120 minutes after allergen. Four hours after challenge, results in the SB-treated and placebo-treated groups were not significantly different and demonstrated a small persistent bronchoconstriction compared to bronchodilatation in the SM-treated group (percent fall in FEV1, respectively, 9.3 +/- 3.7, 14.3 +/- 7.1, and -6.3 +/- 2.7; p < 0.005, SM versus SB; p < 0.02, SM versus placebo). Expressed in terms of AUC, only SM significantly reduced bronchoconstriction in the period 120 to 240 minutes after allergen (p < 0.01). The changes in airway reactivity 4 hours after allergen were (doubling doses of histamine, median, and range) - 1.34 (-4.06 to 0.56) placebo; -0.20 (-3.29 to 1.14) SB; and 1.39 (-1.22 to 5.60) SM (p < 0.005, SB and SM versus placebo; p < 0.005, SM versus SB). There were no differences between groups in urinary LTE4 excretion for either the 0 to 120-, 120 to 240-, or total 0 to 240-minute collection periods after allergen inhalation (p > 0.1). Therefore, although both drugs have inhibitory effects on allergen-induced bronchoconstriction, neither drug significantly reduced allergen-induced cysteinyl leukotriene production. This finding suggests that the major effect of inhaled beta(2)-agonists in allergen challenge is relaxation of airway smooth muscle and not the inhibition of mediator release from pulmonary inflammatory cells.	GLAXO GRP RES LTD,DEPT RESP MED,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline	TAYLOR, IK (corresponding author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DU CANE RD,LONDON W12 ONN,ENGLAND.							BAKER A J, 1990, American Review of Respiratory Disease, V141, pA394; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BOYD G, 1990, THORAX, V45, pP340; BRITTAIN RT, 1990, LUNG, V168, P111, DOI 10.1007/BF02718122; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; BUSSE WW, 1989, J ALLERGY CLIN IMMUN, V84, P658, DOI 10.1016/0091-6749(89)90293-5; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DAHL R, 1986, EUR J RESPIR DIS, V69, P263; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; ERJEFALT I, 1986, ACTA PHYSIOL SCAND, V128, P653, DOI 10.1111/j.1748-1716.1986.tb08027.x; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; HOLGATE ST, 1988, Q J MED, V66, P5; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUGHES JM, 1983, EUR J PHARMACOL, V95, P239; JOHNSON M, 1990, LUNG, V168, P115, DOI 10.1007/BF02718123; KEYZER JJ, 1984, J ALLERGY CLIN IMMUN, V74, P240, DOI 10.1016/0091-6749(84)90252-5; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LUPINETTI MD, 1989, AM REV RESPIR DIS, V140, P932, DOI 10.1164/ajrccm/140.4.932; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; PALMER JBD, 1990, EUR RESP J S10, V3, pS225; RHODEN KJ, 1988, J APPL PHYSIOL, V65, P700, DOI 10.1152/jappl.1988.65.2.700; RICHMOND R, 1987, J CHROMATOGR-BIOMED, V417, P241, DOI 10.1016/0378-4347(87)80117-2; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; STILES GL, 1984, PHYSIOL REV, V64, P661, DOI 10.1152/physrev.1984.64.2.661; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, AM REV RESPIR DIS, V143, P119, DOI 10.1164/ajrccm/143.1.119; TAYLOR IK, 1990, J APPL PHYSIOL, V69, P591, DOI 10.1152/jappl.1990.69.2.591; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; VATHENEN AS, 1988, LANCET, V1, P554; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322	41	50	50	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					575	583		10.1016/0091-6749(92)90325-V	http://dx.doi.org/10.1016/0091-6749(92)90325-V			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1346794				2022-12-18	WOS:A1992HD75300010
J	SHEFFER, AL				SHEFFER, AL			THE NATIONAL-ASTHMA-EDUCATION-PROGRAM ATTACKS ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SHEFFER, AL (corresponding author), EXPERT PANEL MANAGEMENT ASTHMA,110 FRANCIS ST,BOSTON,MA 02215, USA.							BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; Busse W.W., 1989, J RESPIR DIS, V10, P72; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683	6	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					468	469		10.1016/0091-6749(91)90002-6	http://dx.doi.org/10.1016/0091-6749(91)90002-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993806	Bronze			2022-12-18	WOS:A1991EX98700002
J	BEL, EH; TIMMERS, MC; DIJKMAN, JH; STAHL, EG; STERK, PJ				BEL, EH; TIMMERS, MC; DIJKMAN, JH; STAHL, EG; STERK, PJ			THE EFFECT OF AN INHALED LEUKOTRIENE ANTAGONIST, L-648,051, ON EARLY AND LATE ASTHMATIC REACTIONS AND SUBSEQUENT INCREASE IN AIRWAY RESPONSIVENESS IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	Merck & Company	BEL, EH (corresponding author), STATE UNIV LEIDEN HOSP,MED CTR,MED CTR,DEPT PULMONOL,LUNG FUNCT LAB C2P73,RIJNSBURGERWEG 10,2333 AA LEIDEN,NETHERLANDS.		Sterk, P.J./AAK-8175-2020					ABRAHAM WM, 1987, AM REV RESPIR DIS, V135, pS49; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BEL EH, 1987, AM REV RESPIR DIS, V136, P979, DOI 10.1164/ajrccm/136.4.979; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; BRUYNZEEL PLB, 1985, FEBS LETT, V189, P350, DOI 10.1016/0014-5793(85)81054-1; BURNS CB, 1985, J APPL PHYSIOL, V59, P1590, DOI 10.1152/jappl.1985.59.5.1590; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1987, ANN ALLERGY, V59, P89; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1987, AM REV RESPIR DIS, V136, pS24, DOI 10.1164/ajrccm/136.4_Pt_2.S24; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAHLEN SE, 1988, AM REV RESPIR DIS, V137, pA234; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; EVANS JM, 1988, THORAX, V43, pP836; GARCIA JGN, 1987, AM REV RESPIR DIS, V136, P161, DOI 10.1164/ajrccm/136.1.161; HARGREAVE FE, 1985, CHEST, V87, pS202, DOI 10.1378/chest.87.5_Supplement.202S; HOLGATE ST, 1987, AM REV RESPIR DIS, V135, pS57; HOLGATE ST, 1986, EUR J RESPIR DI S144, V69, P34; INGENITO E P, 1988, American Review of Respiratory Disease, V137, P309; INGRAM RH, 1987, AM REV RESPIR DIS, V136, pS62, DOI 10.1164/ajrccm/136.4_Pt_2.S62; JONES TR, 1986, CAN J PHYSIOL PHARM, V64, P1535, DOI 10.1139/y86-258; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KIRBY J G, 1987, American Review of Respiratory Disease, V135, pA312; KRELL R D, 1989, Pulmonary Pharmacology, V2, P27, DOI 10.1016/S0952-0600(89)80006-7; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; LEE TH, 1981, LANCET, V2, P304; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PETERS SP, 1987, AM REV RESPIR DIS, V135, P1196; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SCHWARTZBERG SB, 1987, PROSTAG LEUKOTR ESS, V26, P143, DOI 10.1016/0262-1746(87)90109-0; STERK PJ, 1986, AM REV RESPIR DIS, V134, P714; TOCCO DJ, 1988, DRUG METAB DISPOS, V16, P697; TOMIOKA K, 1988, AM REV RESPIR DIS, V137, pA136; Young R N, 1988, Agents Actions Suppl, V23, P113; ZAKRZEWSKI JT, 1985, BR J CLIN PHARM, V19, P594; ZAMEL N, 1984, B EUR PHYSIOPATH RES, V20, P471	43	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1067	1075		10.1016/0091-6749(90)90052-6	http://dx.doi.org/10.1016/0091-6749(90)90052-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2191993				2022-12-18	WOS:A1990DK50900013
J	JAROLIM, E; POULSEN, LK; STADLER, BM; MOSBECH, H; OESTERBALLE, O; KRAFT, D; WEEKE, B				JAROLIM, E; POULSEN, LK; STADLER, BM; MOSBECH, H; OESTERBALLE, O; KRAFT, D; WEEKE, B			A LONG-TERM FOLLOW-UP-STUDY OF HYPOSENSITIZATION WITH IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIENNA,INST GEN & EXPTL PATHOL,A-1010 VIENNA,AUSTRIA; VIBORG SYGEHUS,DEPT PEDIAT,VIBORG,DENMARK; STATE UNIV HOSP COPENHAGEN,DEPT MED TTA,CLIN ALLERGOL LAB,COPENHAGEN,DENMARK	University of Vienna; Aarhus University; University of Copenhagen	JAROLIM, E (corresponding author), INSELSPITAL BERN,INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND.		Poulsen, Lars K/J-3065-2019; Jensen-Jarolim, Erika/C-5120-2018	Poulsen, Lars K/0000-0002-1730-847X; Jensen-Jarolim, Erika/0000-0003-4019-5765				AALBERSE RC, 1983, J IMMUNOL, V130, P722; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; Cooke RA, 1937, J EXP MED, V66, P689, DOI 10.1084/jem.66.6.689; DEARDS MJ, 1986, INT ARCH ALLER A IMM, V80, P253, DOI 10.1159/000234061; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; DJURUP R, 1984, ALLERGY, V34, P51; FERRANTE A, 1986, INT ARCH ALLER A IMM, V81, P284, DOI 10.1159/000234148; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HONG CS, 1986, J IMMUNOL METHODS, V95, P195; IGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51; ISHIZAKA K, 1975, INT ARCH ALLER A IMM, V49, P255, DOI 10.1159/000231405; KEMENY DM, 1989, INT ARCH ALLER A IMM, V88, P247, DOI 10.1159/000234799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HB, 1988, J ALLERGY CLIN IMMUN, V82, P11, DOI 10.1016/0091-6749(88)90044-9; LESOURD B, 1989, J ALLERGY CLIN IMMUN, V83, P563, DOI 10.1016/0091-6749(89)90067-5; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; MYAZAWA H, 1988, J ALLERGY CLIN IMMUN, V82, P407; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; OESTERBALLE O, 1981, ALLERGY, V36, P183; OESTERBALLE O, 1982, ALLERGY, V37, P169; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; POULSEN LK, 1985, ALLERGY, V40, P405, DOI 10.1111/j.1398-9995.1985.tb02679.x; RADL J, 1988, CLIN CHEM, V34, P1839; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566	33	50	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					996	1004		10.1016/0091-6749(90)90043-4	http://dx.doi.org/10.1016/0091-6749(90)90043-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2355159	Bronze			2022-12-18	WOS:A1990DK50900004
J	TOOGOOD, JH; FRANKISH, CW; JENNINGS, BH; BASKERVILLE, JC; BORGA, O; LEFCOE, NM; JOHANSSON, SA				TOOGOOD, JH; FRANKISH, CW; JENNINGS, BH; BASKERVILLE, JC; BORGA, O; LEFCOE, NM; JOHANSSON, SA			A STUDY OF THE MECHANISM OF THE ANTIASTHMATIC ACTION OF INHALED BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VICTORIA HOSP, DEPT MED, LONDON N6A 4G5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT STAT & ACTUARIAL SCI, LONDON N6A 3K7, ONTARIO, CANADA; AB DRACO, DEPT CLIN RES, S-22101 LUND, SWEDEN; AB DRACO, DEPT RES & DEV, PHARMACOKINET LAB, S-22101 LUND, SWEDEN	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario)								ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; ANDERSSON M, 1987, J ALLERGY CLIN IMMUN, V79, P345, DOI 10.1016/0091-6749(87)90153-9; ANDERSSON P, 1984, J PHARM PHARMACOL, V36, P763, DOI 10.1111/j.2042-7158.1984.tb04868.x; BJERRUM P, 1985, ALLERGY, V40, P65, DOI 10.1111/j.1398-9995.1985.tb04156.x; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P263; BRATTSAND R, 1982, CORTICOSTEROID TREAT, P62; BRATTSAND R, 1985, GLUCOCORTICOSTEROIDS, P145; BRODGEN RN, 1984, DRUGS, V28, P99; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; CHAPLIN MD, 1980, J ALLERGY CLIN IMMUN, V65, P445, DOI 10.1016/0091-6749(80)90238-9; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GRUVSTAD E, 1980, DRUG EXP CLIN RES, V6, P385; HARRIS DM, 1980, TOPICAL STEROID TREA, P34; HEDDLE RJ, 1984, BRIT MED J, V289, P651, DOI 10.1136/bmj.289.6446.651; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; LINDQVIST N, 1989, CLIN EXP ALLERGY, V19, P71, DOI 10.1111/j.1365-2222.1989.tb02347.x; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; ORGEL HA, 1983, ANN ALLERGY, V51, P21; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; PEDERSEN S, 1985, CLIN ALLERGY, V15, P473, DOI 10.1111/j.1365-2222.1985.tb02297.x; PIPKORN U, 1989, CLIN EXP ALLERGY, V19, P19, DOI 10.1111/j.1365-2222.1989.tb02338.x; PIPKORN U, 1982, ALLERGY, V37, P591, DOI 10.1111/j.1398-9995.1982.tb02345.x; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; RYRFELDT A, 1984, CLIN PHARMACOL THER, V35, P525, DOI 10.1038/clpt.1984.71; SPRINGER C, 1987, ARCH DIS CHILD, V62, P815, DOI 10.1136/adc.62.8.815; TOOGOOD JH, 1983, CHEST, V84, P349; TOOGOOD JH, 1979, LANCET, V2, P1185; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; 1985, SAS USERS GUIDE STAT, P507	39	50	50	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					872	880		10.1016/0091-6749(90)90071-B	http://dx.doi.org/10.1016/0091-6749(90)90071-B			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332564	Bronze			2022-12-18	WOS:A1990DD95900009
J	VANREE, R; CLEMENS, JGJ; AALBERS, M; STAPEL, SO; AALBERSE, RC				VANREE, R; CLEMENS, JGJ; AALBERS, M; STAPEL, SO; AALBERSE, RC			CHARACTERIZATION WITH MONOCLONAL AND POLYCLONAL ANTIBODIES OF A NEW MAJOR ALLERGEN FROM GRASS-POLLEN IN THE GROUP-I MOLECULAR-WEIGHT RANGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam								Aalberse R C, 1983, Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M, P137; AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; DEARDS MJ, 1986, INT ARCH ALLER A IMM, V80, P253, DOI 10.1159/000234061; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; JOHNSON P, 1965, EUR POLYM J, V1, P63; KAHN CR, 1986, MOL IMMUNOL, V23, P1281, DOI 10.1016/0161-5890(86)90013-1; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; LOWENSTEIN H, 1987, ALLERGY INT TXB, P87; MALLEY A, 1967, J IMMUNOL, V99, P825; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DG, 1988, INT ARCH ALLER A IMM, V85, P194; MECHERI S, 1985, INT ARCH ALLER A IMM, V78, P283, DOI 10.1159/000233899; MOURAD W, 1986, J IMMUNOL METHODS, V89, P53, DOI 10.1016/0022-1759(86)90031-1; SMART IJ, 1983, INT ARCH ALLER A IMM, V72, P243, DOI 10.1159/000234875; STANDRING R, 1987, INT ARCH ALLER A IMM, V83, P96, DOI 10.1159/000234338	23	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					144	151		10.1016/0091-6749(89)90489-2	http://dx.doi.org/10.1016/0091-6749(89)90489-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913133				2022-12-18	WOS:A1989T041900020
J	SEARS, MR				SEARS, MR			INCREASING ASTHMA MORTALITY - FACT OR ARTIFACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SEARS, MR (corresponding author), UNIV OTAGO,SCH MED,DEPT MED,POB 913,DUNEDIN,NEW ZEALAND.							British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HARRISON AC, 1986, AM REV RESPIR DIS, V133, pA178; JACKSON R, IN PRESS CHEST; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SLY RM, 1984, ANN ALLERGY, V53, P20; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; 1977, 1975 MAN INT STAT CL, V1	18	50	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					957	960		10.1016/0091-6749(88)90130-3	http://dx.doi.org/10.1016/0091-6749(88)90130-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3060512				2022-12-18	WOS:A1988R631100001
J	EGGLESTON, PA				EGGLESTON, PA			UPPER AIRWAY INFLAMMATORY DISEASES AND BRONCHIAL HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University					NHLBI NIH HHS [HL 30532] Funding Source: Medline; NIAID NIH HHS [AI-21073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BOUCHER RC, 1977, J ALLERGY CLIN IMMUN, V60, P134, DOI 10.1016/0091-6749(77)90039-2; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; BUSSE W, 1987, J ALLERGY CLIN IMMUN, V79, P133; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DALES RE, 1987, AM REV RESPIR DIS, V135, P817, DOI 10.1164/arrd.1987.135.4.817; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FREEMAN GL, 1962, AM J DIS CHILD, V104, P330, DOI 10.1001/archpedi.1962.02080030332002; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GUMP DW, 1976, AM REV RESPIR DIS, V113, P465; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HALPERIN SA, 1985, AM REV RESPIR DIS, V32, P876; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HORN MEC, CHEST S, V63, P44; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; HUHTI E, 1974, ANN ALLERGY, V33, P145; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; LAITINEN L A, 1976, American Review of Respiratory Disease, V113, P194; LEMANSKE RF, 1980, AM REV RESPIR DIS, V122, P213; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MORGAN EJ, 1976, THORAX, V31, P80, DOI 10.1136/thx.31.1.80; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SHAPIRO GG, 1974, PEDIATRICS, V55, P867; STEPHENS NL, 1980, AIRWAY REACTIVITY ME, P110; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1978, J ALLERGY CLIN IMMUN, V61, P158, DOI 10.1016/0091-6749(78)90339-1; UTELL MJ, 1980, AM REV RESPIR DIS, V121, P233; WALSH JJ, 1961, ARCH INTERN MED, V108, P376, DOI 10.1001/archinte.1961.03620090048006; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; WIDDICOMBE JG, 1962, J APPL PHYSIOL, V17, P613, DOI 10.1152/jappl.1962.17.4.613; WINTHER B, 1984, ACTA OTOLARYNGOL S S, V413, P19	51	50	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1036	1041		10.1016/0091-6749(88)90176-5	http://dx.doi.org/10.1016/0091-6749(88)90176-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286731	Green Published, Bronze			2022-12-18	WOS:A1988N703700021
J	YOSHIDA, K; ANDO, M; SAKATA, T; ARAKI, S				YOSHIDA, K; ANDO, M; SAKATA, T; ARAKI, S			ENVIRONMENTAL MYCOLOGICAL STUDIES ON THE CAUSATIVE AGENT OF SUMMER-TYPE HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,1-1-1 HONJO,KUMAMOTO 860,JAPAN	Kumamoto University								ANDO M, 1986, AM REV RESPIR DIS, V134, P177; BANASZAK EF, 1974, AM REV RESPIR DIS, V110, P585; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARBORIAK JJ, 1972, J ALLERGY CLIN IMMUN, V49, P81, DOI 10.1016/0091-6749(72)90059-0; CAMPBELL JA, 1983, AM REV RESPIR DIS, V127, P495, DOI 10.1164/arrd.1983.127.4.495; CARMOSOUSA L, 1970, YEASTS TAXONOMIC STU, P1309; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; GERBER JD, 1973, AM REV RESPIR DIS, V108, P1124; KAWAI T, 1984, CHEST, V85, P311, DOI 10.1378/chest.85.3.311; Kreger-van Rij NJW, 1984, YEAST TAXONOMIC STUD, P1; LUMPKINS ED, 1973, ANN ALLERGY, V31, P361; MAKINO S, 1982, JPN J ALLERGOL, V31, P1074; MIYAGAWA T, 1978, CLIN ALLERGY, V8, P501, DOI 10.1111/j.1365-2222.1978.tb01503.x; MORROW MB, 1964, ANN ALLERGY, V22, P575; RICHARDS M, 1954, J ALLERGY, V116, P429; SAITO K, 1904, J COLL SCI TOKYO, V18, P1; SEELIGER H. P. R., 1963, Sabouraudia, V2, P248; SHIMAZU K, 1984, AM REV RESPIR DIS, V130, P407; SODA K, 1986, AM REV RESPIR DIS, V133, P83, DOI 10.1164/arrd.1986.133.1.83; TOURVILLE DR, 1972, J ALLERGY CLIN IMMUN, V49, P245, DOI 10.1016/0091-6749(72)90087-5; VOGEL RA, 1966, J INFECT DIS, V116, P573, DOI 10.1093/infdis/116.5.573	22	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					475	483		10.1016/0091-6749(88)90920-7	http://dx.doi.org/10.1016/0091-6749(88)90920-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3276765				2022-12-18	WOS:A1988M099300018
J	DAHL, R; HENRIKSEN, JM; HARVING, H				DAHL, R; HENRIKSEN, JM; HARVING, H			RED WINE ASTHMA - A CONTROLLED CHALLENGE STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DAHL, R (corresponding author), AARHUS KOMMUNEHOSP,DEPT RESP DIS,DK-8000 AARHUS C,DENMARK.							BAKER GJ, 1982, THOR SOC AUST, V12, P213; BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; DAVIS W B, 1980, American Review of Respiratory Disease, V121, P124; DEVRIES K, 1976, B INT UNION TUBERC, V51, P617; FISCHER P, 1984, INDOOR AIR, V3, P219; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GERSHWIN ME, 1985, J ALLERGY CLIN IMMUN, V75, P411, DOI 10.1016/0091-6749(85)90080-6; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HERXHEIMER H., 1963, ARCH INTERNATL PHARMACODYN ET THER, V144, P310; MONERETVOUTRIN DA, 1983, 11 P INT C ALL CLIN, P175; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; Salter H, 1863, LANCET, Vii, P558; ZEE JA, 1983, AM J ENOL VITICULT, V34, P6; 1983, APPROVED ADDITIVES F, P62	15	50	52	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1126	1129		10.1016/0091-6749(86)90261-7	http://dx.doi.org/10.1016/0091-6749(86)90261-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782677				2022-12-18	WOS:A1986F302600007
J	HEILBORN, H; HJEMDAHL, P; DALESKOG, M; ADAMSSON, U				HEILBORN, H; HJEMDAHL, P; DALESKOG, M; ADAMSSON, U			COMPARISON OF SUBCUTANEOUS INJECTION AND HIGH-DOSE INHALATION OF EPINEPHRINE - IMPLICATIONS FOR SELF-TREATMENT TO PREVENT ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAROLINSKA INST, DEPT PHARMACOL, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet	HEILBORN, H (corresponding author), DANDERYD HOSP, DEPT MED, S-18288 DANDERYD, SWEDEN.			Hjemdahl, Paul/0000-0001-5346-275X				ACKROYD JF, 1981, J ROY SOC MED, V74, P567, DOI 10.1177/014107688107400801; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BRANDSTETTER RD, 1980, AM J HOSP PHARM, V37, P1326, DOI 10.1093/ajhp/37.10.1326; Cooke RA, 1922, J IMMUNOL, V7, P119; DAVIES DS, 1978, SCAND J RESPIR DIS, V103, P44; FAHMY NR, 1981, ANESTHESIOLOGY, V55, P329, DOI 10.1097/00000542-198109000-00028; GREENBERG MI, 1979, JACEP-J AM COLL EMER, V8, P500, DOI 10.1016/S0361-1124(79)80294-4; HAMBERGER B, 1980, LIFE SCI, V26, P1465, DOI 10.1016/0024-3205(80)90267-2; HJEMDAHL P, 1983, ACTA PHYSIOL SCAND, P45; HJEMDAHL P, 1979, LIFE SCI, V25, P131, DOI 10.1016/0024-3205(79)90384-9; HJEMDAHL P, 1984, AM J PHYSIOL, V247, pE13, DOI 10.1152/ajpendo.1984.247.1.E13; HOEHNE JH, 1970, J ALLERGY, V46, P336, DOI 10.1016/0021-8707(70)90084-5; LARSSON K, 1985, J ALLERGY CLIN IMMUN, V75, P586, DOI 10.1016/0091-6749(85)90034-X; MOSS J, 1981, CIRCULATION, V63, P210, DOI 10.1161/01.CIR.63.1.210; REVENAS B, 1981, ACTA PHYSIOL SCAND, V111, P249, DOI 10.1111/j.1748-1716.1981.tb06733.x; ROBERTS JR, 1979, JACEP-J AM COLL EMER, V8, P53, DOI 10.1016/S0361-1124(79)80036-2; ROBERTS JR, 1979, JACEP-J AM COLL EMER, V8, P515, DOI 10.1016/S0361-1124(79)80298-1; SELTZER A, 1958, Med Ann Dist Columbia, V27, P131; SILVERGLADE A, 1970, J AMER MED ASSOC, V214, P763, DOI 10.1001/jama.1970.03180040065030; 1981, BR MED J, V282, P1011	20	50	51	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1174	1179		10.1016/0091-6749(86)90268-X	http://dx.doi.org/10.1016/0091-6749(86)90268-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782679				2022-12-18	WOS:A1986F302600014
J	FRICK, OL				FRICK, OL			EFFECT OF RESPIRATORY AND OTHER VIRUS-INFECTIONS ON IGE IMMUNOREGULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FRICK, OL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [3P50 AI11010] Funding Source: Medline; PHS HHS [R01-15233] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V62, P167, DOI 10.1016/0091-6749(78)90102-1; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CHIORAZZI N, 1977, J IMMUNOL, V118, P48; Cooke RA, 1916, J IMMUNOL, V1, P201; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FITZPATRICK FA, 1980, J IMMUNOL, V125, P431; FRICK OL, 1983, AM J VET RES, V44, P440; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; FRICK OL, 1980, J ALLERGY CLIN IMMUN, V65, P166; Hippocrates, 1939, GENUINE WORKS HIPPOC; HIRASHIMA M, 1981, J IMMUNOL, V127, P1804; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KATZ DH, 1979, J IMMUNOL, V122, P2184; KATZ DH, 1978, IMMUNOL REV, V41, P77, DOI 10.1111/j.1600-065X.1978.tb01461.x; KATZ DH, 1982, PROG ALLERGY, V32, P105; LESKOWITZ S, 1960, J IMMUNOL, V84, P58; LEVINE BB, 1971, FED P, V30, P4; MALKIEL S, 1952, J ALLERGY, V23, P352, DOI 10.1016/0021-8707(52)90055-5; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MORSE JH, 1977, J CLIN INVEST, V50, P683; MUNOZ JA, 1977, IMMUNOLOGY 4, P123; ORR TSC, 1971, IMMUNOLOGY, V20, P185; OVARY Z, 1981, INT ARCH ALLER A IMM, V66, P8, DOI 10.1159/000232859; PATTERSON R, 1960, J ALLERGY, V31, P351, DOI 10.1016/0021-8707(60)90071-X; PERELMUTTER L, 1978, ANN ALLERGY, V41, P158; PIERSON JM, 1983, J ALLERGY CLIN IMMUN, V71, P139; RACKEMANN FRANCIS M., 1940, JOUR ALLERGY, V11, P147, DOI 10.1016/S0021-8707(40)90829-2; SAMPSON HA, 1983, PEDIATR CLIN N AM, V30, P773; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1980, J ALLERGY CLIN IMMUN, V66, P233, DOI 10.1016/0091-6749(80)90045-7; SUEMURA M, 1979, J IMMUNOL, V123, P918; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TADA T, 1971, J IMMUNOL, V106, P1012; UEDE T, 1984, J IMMUNOL, V133, P359; UEDE T, 1983, J IMMUNOL, V130, P649; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WITTICH F. W., 1941, JOUR ALLERGY, V12, P247, DOI 10.1016/S0021-8707(41)80008-2; YODOI J, 1981, J IMMUNOL, V127, P1579; YODOI J, 1981, J IMMUNOL, V126, P877; YODOI J, 1980, J IMMUNOL, V125, P1436; YODOI J, 1979, J IMMUNOL, V123, P455	46	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			1013	1018		10.1016/0091-6749(86)90295-2	http://dx.doi.org/10.1016/0091-6749(86)90295-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537084	Bronze			2022-12-18	WOS:A1986E971900016
J	MUSSAFFI, H; SPRINGER, C; GODFREY, S				MUSSAFFI, H; SPRINGER, C; GODFREY, S			INCREASED BRONCHIAL RESPONSIVENESS TO EXERCISE AND HISTAMINE AFTER ALLERGEN CHALLENGE IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HADASSAH UNIV HOSP,DEPT PEDIAT,POB 24035,IL-91240 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,PULM LAB,IL-91240 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; BARYISHAY E, 1984, LUNG, V162, P195, DOI 10.1007/BF02715648; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CARTIER A, 1980, American Review of Respiratory Disease, V121, P61; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKROFT DW, 1979, AM REV RESPIR DIS, V199, P505; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LORING SH, 1977, J APPL PHYSIOL, V42, P946, DOI 10.1152/jappl.1977.42.6.946; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SHORE S, 1983, J APPL PHYSIOL, V55, P22, DOI 10.1152/jappl.1983.55.1.22; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882	17	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				48	52		10.1016/0091-6749(86)90321-0	http://dx.doi.org/10.1016/0091-6749(86)90321-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944374				2022-12-18	WOS:A1986AZD3600009
J	FRIEDMAN, MM; KALINER, M				FRIEDMAN, MM; KALINER, M			INSITU DE-GRANULATION OF HUMAN NASAL MUCOSAL MAST-CELLS - ULTRASTRUCTURAL FEATURES AND CELL-CELL ASSOCIATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	FRIEDMAN, MM (corresponding author), GEORGETOWN UNIV,SCH MED,DIV MOLEC VIROL & IMMUNOL,5640 FISHERS LANE,ROCKVILLE,MD 20852, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI022665] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-22665] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON AO, 1981, CELLULAR FUNCTIONS I, P29; AOKI M, 1981, J ULTRA MOL STRUCT R, V74, P255, DOI 10.1016/S0022-5320(81)80116-5; AUSTEN KF, 1974, PROGR IMMUNOLOGY 2, V2, P61; BRINKMAN GL, 1968, J ULTRA MOL STRUCT R, V23, P115, DOI 10.1016/S0022-5320(68)80035-8; BROOKOFF D, 1982, BLOOD, V59, P646; BURWEN SJ, 1977, J CELL BIOL, V74, P690, DOI 10.1083/jcb.74.3.690; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; DOBBINS WO, 1969, GASTROENTEROLOGY, V56, P268; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HASHIMOT.K, 1966, J INVEST DERMATOL, V46, P139, DOI 10.1038/jid.1966.23; HAYAT MA, 1972, BASIC ELECTRON MICRO; HIBBS RG, 1960, AM HEART J, V60, P121, DOI 10.1016/0002-8703(60)90067-3; HOSHI H, 1978, LAB INVEST, V38, P67; ISHIZAKA K, 1974, PROG IMMUNOL 2, V4, P7; IWAMOTO TAKEO, 1965, INVEST OPHTHALMOL, V4, P815; Jorpes JE., 1937, Z MIKR ANAT FORSCH, V42, P279; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KAWANAMI O, 1979, LAB INVEST, V40, P717; KINSOLVING CR, 1974, J PHARM EXP THER, V192, P654; LAMB D, 1982, THORAX, V37, P334, DOI 10.1136/thx.37.5.334; LAZARUS SC, 1979, J APPL PHYSIOL, V46, P919, DOI 10.1152/jappl.1979.46.5.919; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; Mygind N, 1978, NASAL ALLERGY; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P278, DOI 10.1016/0091-6749(80)90156-6; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915; SAKAI N, 1981, AM J ANAT, V161, P11, DOI 10.1002/aja.1001610103; TROTTER C M, 1974, Clinical Allergy, V4, P421, DOI 10.1111/j.1365-2222.1974.tb01403.x; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; TUFT L, 1936, J ALLERGY, V7, P238; WEINSTOCK A, 1967, J ULTRA MOL STRUCT R, V17, P245, DOI 10.1016/S0022-5320(67)80046-7; WEISS L, 1976, ANAT RECORD, V186, P161, DOI 10.1002/ar.1091860204; Williams M. A., 1977, PRACTICAL METHODS EL, V6; WILLINGHAM MC, 1984, J HISTOCHEM CYTOCHEM, V32, P455, DOI 10.1177/32.4.6323574	37	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					70	82		10.1016/0091-6749(85)90807-3	http://dx.doi.org/10.1016/0091-6749(85)90807-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	2409123				2022-12-18	WOS:A1985AMV8400010
J	GRIFFIN, DE; COOPER, SJ; HIRSCH, RL; JOHNSON, RT; DESORIANO, IL; ROEDENBECK, S; VAISBERG, A				GRIFFIN, DE; COOPER, SJ; HIRSCH, RL; JOHNSON, RT; DESORIANO, IL; ROEDENBECK, S; VAISBERG, A			CHANGES IN PLASMA IGE LEVELS DURING COMPLICATED AND UNCOMPLICATED MEASLES-VIRUS INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PERUANA CAYETANO HEREDIA,DEPT MICROBIOL,LIMA,PERU; UNIV PERUANA CAYETANO HEREDIA,DEPT PEDIAT,LIMA,PERU; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; UNIV PERUANA CAYETANO HEREDIA,DEPT NEUROL,LIMA,PERU	Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Johns Hopkins University; Universidad Peruana Cayetano Heredia	GRIFFIN, DE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205, USA.			Vaisberg, Abraham/0000-0003-1487-7770	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS015721] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 15721] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; ARNEBORN P, 1983, INFECT IMMUN, V39, P29, DOI 10.1128/IAI.39.1.29-37.1983; BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90400-1; BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V62, P167, DOI 10.1016/0091-6749(78)90102-1; BERG T, 1969, INT ARCH ALLERGY APP, V36, P220; BLACK FL, 1976, VIRAL INFECTIONS HUM, P297; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CHIORAZZI N, 1976, J IMMUNOL, V117, P1629; COOVADIA HM, 1978, INT ARCH ALLER A IMM, V56, P14, DOI 10.1159/000231998; DEGUCHI H, 1983, J IMMUNOL, V131, P2751; DESAI HN, 1978, INT ARCH ALLER A IMM, V57, P312, DOI 10.1159/000232120; FINKEL A, 1973, CELL IMMUNOL, V6, P41, DOI 10.1016/0008-8749(73)90004-X; FRICK OL, 1983, AM J VET RES, V44, P440; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; FRICK OL, 1980, BASIC CLIN IMMUNOL, P274; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GENDELMAN HE, 1984, ANN NEUROL, V15, P353, DOI 10.1002/ana.410150409; GRAVES M, 1984, J VIROL, V49, P409, DOI 10.1128/JVI.49.2.409-412.1984; GRIFFIN DE, 1983, INFECT IMMUN, V41, P861, DOI 10.1128/IAI.41.2.861-864.1983; HAMAOKA T, 1973, J EXP MED, V138, P538, DOI 10.1084/jem.138.3.538; HASSNER A, 1983, J IMMUNOL, V130, P1567; HELMS S, 1956, ACTA TUBERC SCAND, V35, P166; HIRASHIMA M, 1981, J IMMUNOL, V126, P838; HIRASHIMA M, 1981, J IMMUNOL, V127, P1810; HIRASHIMA M, 1982, J IMMUNOL, V128, P1919; HIRSCH RL, 1984, CLIN IMMUNOL IMMUNOP, V31, P1, DOI 10.1016/0090-1229(84)90184-3; ISHIZAKA K, 1983, J IMMUNOL, V131, P2751; ISHIZAKA K, 1983, LYMPHOKINES, V8, P41; JOFFE MI, 1981, CLIN IMMUNOL IMMUNOP, V20, P215, DOI 10.1016/0090-1229(81)90179-3; JOFFE MI, 1983, J CLIN INVEST, V72, P971, DOI 10.1172/JCI111069; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KANTOCH M, 1980, ACTA VIROL, V24, P119; KATONA IM, 1980, ANN ALLERGY, V45, P295; KATZ DH, 1974, J IMMUNOL, V113, P974; KATZ DH, 1980, IMMUNOLOGY, V42, P1; KELKAR SD, 1977, ACTA VIROL, V21, P417; KISHIMOT.T, 1973, J IMMUNOL, V111, P1; KLEIN G, 1976, INT J CANCER, V17, P71; KOPROWSKI H, 1962, AM J DIS CHILD, V103, P273, DOI 10.1001/archpedi.1962.02080020285019; LACHMANN PJ, 1974, P ROY SOC MED, V67, P1120, DOI 10.1177/003591577406701115; LEARY, 1983, P NATL ACAD SCI USA, V80, P4045; MACCARTHY K, 1958, AMA J DIS CHILD, V96, P500; MILLER DL, 1964, BRIT MED J, V2, P75, DOI 10.1136/bmj.2.5401.75; ORR TSC, 1971, IMMUNOLOGY, V20, P185; PAVRI K, 1979, T ROY SOC TROP MED H, V73, P451, DOI 10.1016/0035-9203(79)90174-3; PAVRI KM, 1980, INFECT IMMUN, V28, P290, DOI 10.1128/IAI.28.1.290-291.1980; PERELMUTTER L, 1979, J ALLERGY CLIN IMMUN, V64, P127, DOI 10.1016/0091-6749(79)90046-0; PERELMUTTER L, 1978, ANN ALLERGY, V41, P158; RINALDO CR, 1977, J INFECT DIS, V136, P677; RINGDEN O, 1983, BLOOD, V61, P1190; RUCKLE G, 1957, J IMMUNOL, V79, P361; SARYAN F, 1983, J CLIN INVEST, V71, P556; SARYAN JA, 1983, J IMMUNOL, V130, P242; SCOTT RM, 1980, J INFECT DIS, V141, P1, DOI 10.1093/infdis/141.1.1; STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WESLEY A, 1978, CLIN EXP IMMUNOL, V32, P540; WHITTLE HC, 1980, CLIN EXP IMMUNOL, V42, P144; WHITTLE HC, 1978, J CLIN INVEST, V62, P678, DOI 10.1172/JCI109175; YAMANAKA T, 1976, TOHOKU J EXP MED, V120, P225, DOI 10.1620/tjem.120.225; YODOI J, 1981, J IMMUNOL, V127, P1579; YODOI J, 1981, J IMMUNOL, V126, P877	67	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					206	213		10.1016/0091-6749(85)90703-1	http://dx.doi.org/10.1016/0091-6749(85)90703-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3160758				2022-12-18	WOS:A1985APE8800015
J	KEMP, JP; CHERVINSKY, P; ORGEL, HA; MELTZER, EO; NOYES, JH; MINGO, TS				KEMP, JP; CHERVINSKY, P; ORGEL, HA; MELTZER, EO; NOYES, JH; MINGO, TS			CONCOMITANT BITOLTEROL MESYLATE AEROSOL AND THEOPHYLLINE FOR ASTHMA THERAPY, WITH 24-HR ELECTROCARDIOGRAPHIC MONITORING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PEDIAT ALLERGY MED GRP,SAN DIEGO,CA; ALLERGY ASSOCIATES,NEW BEDFORD,MA; STERLING WINTHROP RES INST,RENSSELAER,NY 12144									BARCLAY J, 1981, BRIT J CLIN PHARMACO, V11, P203, DOI 10.1111/j.1365-2125.1981.tb01125.x; BARCLAY J, 1981, LANCET, V2, P369; BRISSON GR, 1972, J CLIN INVEST, V51, P232, DOI 10.1172/JCI106808; CAMPBELL IA, 1977, THORAX, V32, P424, DOI 10.1136/thx.32.4.424; CHOOKANG YF, 1969, BMJ-BRIT MED J, V2, P287, DOI 10.1136/bmj.2.5652.287; CLARK TJH, 1981, J ASTHMA, V18, P39, DOI 10.3109/02770908109118310; Ellis EF, 1978, ALLERGY PRINCIPLES P, P434; FREEDMAN BJ, 1971, THORAX, V26, P46, DOI 10.1136/thx.26.1.46; GRANT IWB, 1981, LANCET, V2, P36; HIGBEE MD, 1982, J ALLERGY CLIN IMMUN, V70, P377, DOI 10.1016/0091-6749(82)90028-8; HORROBIN DF, 1977, PROSTAGLANDINS, V13, P33, DOI 10.1016/0090-6980(77)90040-5; INMAN WHW, 1969, LANCET, V2, P279; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; KASS I, 1980, CHEST, V78, P283, DOI 10.1378/chest.78.2.283; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LEGGE JS, 1971, BRIT MED J, V1, P637, DOI 10.1136/bmj.1.5750.637; LONNERHOLM G, 1981, BRIT MED J, V282, P1029, DOI 10.1136/bmj.282.6269.1029; MIECH RP, 1979, BIOCHEM PHARMACOL, V28, P3687, DOI 10.1016/0006-2952(79)90422-2; NICKLAS RA, 1982, NEW ENGL J MED, V307, P557; PIERSON DJ, 1980, CHEST, V77, P176, DOI 10.1378/chest.77.2.176; SHAPIRO GG, 1981, PEDIATRICS, V67, P508; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WEINBERGER M, 1980, EUR J RESPIR DIS, V61, P120; WEINBERGER M, 1981, LANCET, V2, P370; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WILSON JD, 1981, LANCET, V1, P1235; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; 1981, FDA DRUG B, V11, P19	33	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					32	43		10.1016/0091-6749(84)90481-0	http://dx.doi.org/10.1016/0091-6749(84)90481-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693665	Bronze			2022-12-18	WOS:A1984SB99000005
J	LEE, TH; NAGAKURA, T; PAPAGEORGIOU, N; CROMWELL, O; IIKURA, Y; KAY, AB				LEE, TH; NAGAKURA, T; PAPAGEORGIOU, N; CROMWELL, O; IIKURA, Y; KAY, AB			SPECIAL PROBLEMS - MEDIATORS IN EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND; NATL CHILDRENS HOSP,DEPT ALLERGY,TOKYO 154,JAPAN	Royal Brompton Hospital; National Center for Child Health & Development - Japan			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1983, AM REV RESPIR DIS, V127, P228; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BENDOV I, 1982, AM REV RESPIR DIS, V125, P530, DOI 10.1164/arrd.1982.125.5.530; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; HOWARTH PH, 1983, THORAX, V38, P705; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, LANCET, V1, P520; LEE TH, 1983, LANCET, V2, P164; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEE TH, ASTHMA PHYSL IMMUNOP; LEE TH, AM REV RESPIR DIS; MATALON S, 1982, J APPL PHYSIOL, V52, P1161, DOI 10.1152/jappl.1982.52.5.1161; MCFADDEN ER, 1980, J ALLERGY CLIN IMMUN, V66, P472, DOI 10.1016/0091-6749(80)90008-1; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MCFADDEN ER, ASTHMA PHYSL IMMUNOP; MORGAN DJR, 1983, THORAX, V38, P771, DOI 10.1136/thx.38.10.771; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NAGY L, 1983, EUR J RESPIR DIS, V64, P161; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; ROY AC, 1974, BIOCHEM PHARMACOL, V23, P917, DOI 10.1016/0006-2952(74)90223-8; SLY RM, 1974, J ALLERGY CLIN IMMUN, V53, P82; STOKES TC, 1981, BRIT J DIS CHEST, V75, P1, DOI 10.1016/S0007-0971(81)80002-2; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V68, P391; WILSON NM, 1982, THORAX, V37, P657, DOI 10.1136/thx.37.9.657; YUN KBR, 1976, JAMA, V236, P927	42	50	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					634	639		10.1016/0091-6749(84)90296-3	http://dx.doi.org/10.1016/0091-6749(84)90296-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6201522	Bronze			2022-12-18	WOS:A1984SS04600003
J	LUTSKY, I; TEICHTAHL, H; BARSELA, S				LUTSKY, I; TEICHTAHL, H; BARSELA, S			OCCUPATIONAL ASTHMA DUE TO POULTRY MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHAIM SHEBA MED CTR, DIV RESP DIS, IL-52621 TEL HASHOMER, ISRAEL; HADASSAH MED CTR, DEPT MED A, JERUSALEM, ISRAEL	Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	LUTSKY, I (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT COMPARAT MED, IL-91010 JERUSALEM, ISRAEL.							BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; DEVANEY JA, 1978, POULTRY SCI, V57, P1217, DOI 10.3382/ps.0571217; Frankland A. W., 1953, Ann Allergy Minneapolis, V11, P445; LOOMIS E C, 1970, Journal of Economic Entomology, V63, P1885, DOI 10.1093/jee/63.6.1885; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; PEPYS J, 1972, P ROY SOC MED, V65, P271, DOI 10.1177/003591577206500320; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; Voorhorst R., 1964, Allergie Asthma, V10, P329; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577	11	50	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					56	60		10.1016/0091-6749(84)90484-6	http://dx.doi.org/10.1016/0091-6749(84)90484-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693668				2022-12-18	WOS:A1984SB99000008
J	GRAMMER, LC; SHAUGHNESSY, MA; SUSZKO, IM; SHAUGHNESSY, JJ; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; SUSZKO, IM; SHAUGHNESSY, JJ; PATTERSON, R			A DOUBLE-BLIND HISTAMINE PLACEBO-CONTROLLED TRIAL OF POLYMERIZED WHOLE GRASS FOR IMMUNOTHERAPY OF GRASS ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOPE COLL,HOLLAND,MI 49423	Hope College	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI-11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FRANKLAND AW, 1962, CLIN SCI, V23, P95; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1982, J CLIN IMMUNOL, V2, P10, DOI 10.1007/BF00915972; LEVY DA, 1980, REGULATORY CONTROL S, P178; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V72, P129, DOI 10.1016/0091-6749(83)90519-5; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1973, J IMMUNOL, V110, P414	13	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					448	453		10.1016/0091-6749(83)90580-8	http://dx.doi.org/10.1016/0091-6749(83)90580-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6355247	Bronze			2022-12-18	WOS:A1983RR91600004
J	WEISS, JW; ROSSING, TH; MCFADDEN, ER; INGRAM, RH				WEISS, JW; ROSSING, TH; MCFADDEN, ER; INGRAM, RH			RELATIONSHIP BETWEEN BRONCHIAL RESPONSIVENESS TO HYPERVENTILATION WITH COLD AND METHACHOLINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP, SHIPLEY INST MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 17873, HL 17382, HL 16463] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P347; KIVITY S, 1981, CLIN RES PROC, V17, P243; MENKES HA, 1980, AM REV RESPIR DIS, V121, P619; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281	8	50	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					140	144		10.1016/0091-6749(83)90521-3	http://dx.doi.org/10.1016/0091-6749(83)90521-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6350408				2022-12-18	WOS:A1983RD95900006
J	BROOKS, SM				BROOKS, SM			THE EVALUATION OF OCCUPATIONAL AIRWAYS DISEASE IN THE LABORATORY AND WORKPLACE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BROOKS, SM (corresponding author), UNIV CINCINNATI, MED CTR, DEPT ENVIRONM HLTH, DIV CLIN STUDIES, CINCINNATI, OH 45267 USA.				NHLBI NIH HHS [HL 22415] Funding Source: Medline; NIEHS NIH HHS [ES-00159] Funding Source: Medline; NIOSH CDC HHS [OH-07091] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [T42OH007091, T15OH007091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNSTEIN IL, 1973, INT C SERIES, V323, P112; BOUHUYS A, 1967, AM REV RESPIR DIS, V95, P89; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOUSHEY HA, 1975, PHYSIOLOGIST, V18, P148; Brooks S M, 1981, Chest, V80, P30; BROOKS S M, 1981, American Review of Respiratory Disease, V123, P133; BROOKS SM, 1977, J OCCUP ENVIRON MED, V19, P192; BROOKS SM, 1977, SCAND J WORK ENV HEA, V3, P53, DOI 10.5271/sjweh.2790; BROOKS SM, 1980, REV RESPIR DIS, V121, P117; BROOKS SM, 1980, NIOSH HHE7839 HLTH H; BRUCKNER HC, 1967, JOM-J OCCUP MED, V9, P518, DOI 10.1097/00043764-196710000-00006; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; Card WI, 1935, LANCET, V2, P1348; CELFEND HH, 1963, J ALLERGY, V34, P374; CHANYEUNG M, 1976, AM REV RESPIR DIS, V114, P1027; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COOPER WC, 1964, IND HYG J, V25, P431; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; DOPICO GA, 1977, AM REV RESPIR DIS, V115, P915; DOSMAN JA, 1980, AM REV RESPIR DIS, V121, P11; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; FREEDMAN SO, 1968, J ALLERGY, V42, P233, DOI 10.1016/S0021-8707(68)90118-4; FREEDMAN SO, 1966, MOD TREAT, V3, P838; GALLAGHER J S, 1982, Journal of Allergy and Clinical Immunology, V69, P134; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GANELIN RS, 1964, JAMA-J AM MED ASSOC, V188, P108; GRONEMEYER W, 1958, EUROPEAN ACADEMY ALL, P29; HANSEN K, 1958, EUROPEAN ACADEMY ALL, P29; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HIGGINS ITT, 1974, EPA650174007 ENV HLT; Ishizaki T, 1973, J Occup Med, V15, P580; JOHNSTON TG, 1951, J ALLERGY, V22, P494, DOI 10.1016/0021-8707(51)90105-0; JONES RN, 1979, BRIT J IND MED, V36, P305; KAMMERMEYER JK, 1973, J ALLERGY CLIN IMMUN, V52, P73, DOI 10.1016/0091-6749(73)90079-1; KERN RA, 1939, J ALLERGY, V10, P64; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MCKAY R T, 1981, American Review of Respiratory Disease, V123, P132; McKay R T, 1981, Chest, V80, P61; MICHEL H, 1958, EUROPEAN ACADEMY ALL, P35; MURPHY RLH, 1976, BRONCHIAL ASTHMA MEC, P517; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; ORDMAN D, 1949, S Afr Med J, V23, P973; ORDMAN D., 1947, South African Medical Journal, V21, P737; PARKERS WR, 1974, OCCUPATIONAL LUNG DI, P450; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PEPYS J, 1972, Clinical Allergy, V2, P189, DOI 10.1111/j.1365-2222.1972.tb01282.x; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; PEPYS J, 1978, ALLERGY PRINCIPLES P, P812; PILAT L, 1967, ACTA ALLERGOL, V22, P39, DOI 10.1111/j.1398-9995.1967.tb03188.x; RAGHUPRASAD PK, 1980, J ALLERGY CLIN IMMUN, V65, P285, DOI 10.1016/0091-6749(80)90157-8; SCHWARTING HH, 1968, EUROPEAN ACADEMY ALL, P278; SEATON A, 1975, OCCUPATIONAL LUNG DI, P251; SKOULAS A, 1964, J Occup Med, V6, P359; SMITH AB, 1980, J OCCUP ENVIRON MED, V22, P327, DOI 10.1097/00043764-198005000-00005; TAYLOR AN, 1977, LANCET, V2, P847; VANDERVORT R, 1979, J OCCUP MED, V19, P189; VOORHORST R, 1958, EUROPEAN ACADEMY ALL, P260; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1978, DHEW PHS CDC NIOSH78; 1980, AM THORACIC SOC NEWS, V6	66	50	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					56	66		10.1016/0091-6749(82)90202-0	http://dx.doi.org/10.1016/0091-6749(82)90202-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7086003				2022-12-18	WOS:A1982NY71500013
J	REISMAN, RE; MUELLER, U; WYPYCH, J; ELLIOTT, W; ARBESMAN, CE				REISMAN, RE; MUELLER, U; WYPYCH, J; ELLIOTT, W; ARBESMAN, CE			COMPARISON OF THE ALLERGENICITY AND ANTIGENICITY OF YELLOW JACKET AND HORNET VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14203; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14203; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI14501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; ESKRIDGE EM, 1982, TOXICON; GOLDEN DBK, 1981, 37TH P ANN M AM AC A, P57; HAMILTON RG, 1979, J IMMUNOL, V122, P1173; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V69, P290; SIMON RP, 1969, ANN ENTOMOL SOC AM, V62, P277, DOI 10.1093/aesa/62.2.277; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	12	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					268	274		10.1016/S0091-6749(82)80003-1	http://dx.doi.org/10.1016/S0091-6749(82)80003-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	6801104	Bronze			2022-12-18	WOS:A1982NF69700003
J	MCFADDEN, ER				MCFADDEN, ER			BETA-2 RECEPTOR AGONIST - METABOLISM AND PHARMACOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP,DEPT MED,PETER BENT BRIGHAM DIV,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	MCFADDEN, ER (corresponding author), BRIGHAM & WOMENS HOSP,SHIPLEY INST MED,BOSTON,MA 02115, USA.							ANDERSON RGG, 1977, BIOCH SMOOTH MUSCLE, P203; BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BENJAMIN C, 1972, MED P JOHANNESBURG, V18, P35; BLACKWELL EW, 1970, BRIT J PHARMACOL, V39, P194; CHOOKANG YF, 1969, BMJ-BRIT MED J, V2, P287, DOI 10.1136/bmj.2.5652.287; CRUZ RS, 1974, AM REV RESPIR DIS, V109, P458; ERIKSSON NE, 1978, SCAND J RESPIR DIS, V59, P30; GURIN S, 1947, J BIOL CHEM, V170, P545; GURWITZ D, 1980, DEV PHARMACOL THERAP, V1, P265, DOI 10.1159/000455545; HESS SM, 1961, J PHARMACOL EXP THER, V134, P129; HORNBLAD Y, 1976, EUR J CLIN PHARMACOL, V10, P9, DOI 10.1007/BF00561543; HUHTI E, 1978, CHEST, V73, P348, DOI 10.1378/chest.73.3.348; INNES IR, 1975, PHARMACOL BASIS, P477; JACK D, 1978, ALLERGY PRINCIPLES P, P404; JAMES TD, 1979, JAMA-J AM MED ASSOC, V241, P704; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; KOELLE GB, 1975, PHARMACOLOGICAL BASI, P424; LARSSON S, 1977, SCAND J RESPIR DIS, V58, P5; MCFADDEN ER, 1980, AM REV RESPIR DIS, V122, P89, DOI 10.1164/arrd.1980.122.5P2.89; MEZEY RJ, 1978, AM REV RESPIR DIS, V118, P677, DOI 10.1164/arrd.1978.118.4.677; MOSSBERG B, 1976, SCAND J RESPIR DIS, V57, P119; MUITTARI A, 1978, RESPIRATION, V35, P173, DOI 10.1159/000193874; PATTERSON JW, 1968, LANCET, V1, P426; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SACKNER MA, 1975, CHEST, V68, P616, DOI 10.1378/chest.68.5.616; SHENFIELD GM, 1973, THORAX, V28, P124, DOI 10.1136/thx.28.2.124; SPECTOR S, 1972, PHARMACOL REV, V24, P191; STEEN SN, 1977, CHEST, V72, P724, DOI 10.1378/chest.72.6.724; SVEDMYR N, 1978, PHARMACOL THER PT B, V3, P397, DOI 10.1016/S0306-039X(78)90005-3; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TAI E, 1967, THORAX, V22, P543, DOI 10.1136/thx.22.6.543; TANDON MK, 1980, CHEST, V77, P429, DOI 10.1378/chest.77.3.429; TATTERSFIELD AE, 1969, NEW ENGL J MED, V281, P1323, DOI 10.1056/NEJM196912112812402; TURNHEIM K, 1971, EUR J PHARMACOL, V15, P231, DOI 10.1016/0014-2999(71)90178-6; VAN ASA, 1973, SCAND J RESPIR DIS, V54, P28; VANDENBERG W, 1980, ANN ALLERGY, V44, P239	36	50	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					91	97		10.1016/0091-6749(81)90164-0	http://dx.doi.org/10.1016/0091-6749(81)90164-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6114117	Bronze			2022-12-18	WOS:A1981MD16200002
J	MYERS, G; DONLON, M; KALINER, M				MYERS, G; DONLON, M; KALINER, M			MEASUREMENT OF URINARY HISTAMINE - DEVELOPMENT OF METHODOLOGY AND NORMAL VALUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,BETHESDA,MD 20205; ARMED FORCES RADIOBIOL RES INST,NATL NAVAL MED CTR,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; Walter Reed National Military Medical Center								ADAM HM, 1950, Q J EXP PHYSIOL CMS, V35, P281, DOI 10.1113/expphysiol.1950.sp000954; ATACK C, 1978, ACTA PHARMACOL TOX, V42, P35; AUSTEN KF, 1976, METHODS IMMUNOLOGY I, V5, P126; BEALL GN, 1965, INT ARCH ALLER A IMM, V26, P1; Beaven M A, 1978, Monogr Allergy, V13, P1; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; DAVIS TP, 1978, CLIN CHEM, V24, P1317; DEIM K, 1970, SCI TABLES, P661; DUNER H, 1956, SCAND J CLIN LAB INV, V8, P296, DOI 10.3109/00365515609049287; HORAKOVA Z, 1977, CLIN CHIM ACTA, V79, P447, DOI 10.1016/0009-8981(77)90441-7; KAPELLERADLER R, 1956, CLIN CHIM ACTA, V1, P197, DOI 10.1016/0009-8981(56)90066-3; KAPELLERADLER R, 1957, BIOCHIM BIOPHYS ACTA, V25, P394, DOI 10.1016/0006-3002(57)90484-5; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MELL LD, 1979, J LIQ CHROMATOGR, V2, P1393, DOI 10.1080/01483917908060145; MITCHELL RG, 1956, BRIT J PHARM CHEMOTH, V11, P462, DOI 10.1111/j.1476-5381.1956.tb00018.x; OATES JA, 1962, CLIN CHIM ACTA, V7, P488; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Shore PA, 1971, METHODS BIOCH ANAL S, P89, DOI [10.1002/9780470110409.ch3, DOI 10.1002/9780470110409.CH3]; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TIETZ NW, 1976, FUNDAMENTALS CLIN CH, P994	22	50	50	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					305	311		10.1016/0091-6749(81)90026-9	http://dx.doi.org/10.1016/0091-6749(81)90026-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204786	Bronze			2022-12-18	WOS:A1981LL69700009
J	REISMAN, RE				REISMAN, RE			AMERICAN-ACADEMY-OF-ALLERGY - POSITION STATEMENTS - CONTROVERSIAL TECHNIQUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BENSON TE, 1976, J ALLERGY CLIN IMMUN, V58, P471, DOI 10.1016/0091-6749(76)90190-1; BLACK AP, 1956, PEDIATRICS, V17, P716; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BRENEMAN JC, 1973, ANN ALLERGY, V31, P382; BRENEMAN JC, 1974, ANN ALLERGY, V33, P164; BRONSKY EA, 1971, J ALLERGY, V47, P104; Bryan W T, 1971, Otolaryngol Clin North Am, V4, P523; BRYAN W. T. K., 1960, LARYNGOSCOPE, V70, P810; BRYAN WTK, 1973, OTOLARYNGOLOGY, V3, P69; BRYAN WTK, 1967, T AM SOC OPHTHALMOL, V8, P14; CHAMBERS VV, 1958, J ALLERGY, V29, P93; CRAWFORD LV, 1976, J ALLERGY CLIN IMMUN, V57, P236; DICKEY LD, 1971, J AMER MED ASSOC, V217, P214, DOI 10.1001/jama.1971.03190020072026; DRAPER LW, 1972, ARCH OTOLARYNGOL, V95, P169; FRANKLIN W, 1949, J ALLERGY, V20, P375, DOI 10.1016/0021-8707(49)90027-1; GLASSOCK RJ, 1968, J EXP MED, V127, P573, DOI 10.1084/jem.127.3.573; GOLBERT TM, 1971, J AMER MED ASSOC, V217, P1703, DOI 10.1001/jama.1971.03190120069019; GOLBERT TM, 1975, J ALLERGY CLIN IMMUN, V56, P170, DOI 10.1016/0091-6749(75)90089-5; GREEN M, 1974, ANN ALLERGY, V33, P274; HANSEL FK, 1968, ALLERGY IMMUNITY OTO, P134; HAWKINS D, 1968, IMMUNOLOGY, V14, P665; HIRSCH, 1980, J ALLERGY CLIN IMMUN, V5, P192; HOSEN H, 1972, Journal of Asthma Research, V10, P131, DOI 10.3109/02770907209108773; KAILIN EW, 1971, J AMER MED ASSOC, V217, P78; LEE CH, 1969, ARCH OTOLARYNGOL, V90, P87; LEE CH, 1969, ARCH OTOLARYNGOL, V90, P173; LEE CH, 1961, MED B, V25, P9; LEHMAN CW, 1980, ANN ALLERGY, V45, P144; LEHMAN CW, 1980, ANN ALLERGY, V45, P150; LERNER RA, 1968, J IMMUNOL, V100, P1277; LIEBERMAN P, 1974, JAMA-J AM MED ASSOC, V231, P728; LOWELL FC, 1975, J ALLERGY CLIN IMMUN, V56, P168, DOI 10.1016/0091-6749(75)90088-3; LOWELL FC, 1972, J AMER MED ASSOC, V220, P1624; MCPHAUL JJ, 1969, TRANSPLANT P, V1, P964; MILLER JB, 1977, ANN ALLERGY, V38, P185; Morris DL, 1971, ANN ALLERGY, V27, P289; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PLESCH J, 1947, Med Press, V218, P128; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P205; RINKEL HJ, 1964, ARCHIV OTOLARYNGOL, V79, P71, DOI 10.1001/archotol.79.1.87; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; SAMTER M, 1972, JAMA-J AM MED ASSOC, V215, P1210; SQUIER TL, 1947, J ALLERGY, V18, P156, DOI 10.1016/0021-8707(47)90101-9; VANMETRE TE, 1979, J ALLERGY CLIN IMMUN, V64, P235, DOI 10.1016/0091-6749(79)90138-6; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VAUGHAN WT, 1948, PRACTICE ALLERGY, P985; WILLOUGHBY JW, 1965, ANN ALLERGY, V23, P543; WILLOUGHBY JW, 1974, OTOLARYNG CLIN N AM, V7, P579	49	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					333	338		10.1016/0091-6749(81)90076-2	http://dx.doi.org/10.1016/0091-6749(81)90076-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7014691	Bronze			2022-12-18	WOS:A1981LQ56300001
J	ASHMAN, RF; SAXON, A; STEVENS, RH				ASHMAN, RF; SAXON, A; STEVENS, RH			PROFILE OF MULTIPLE LYMPHOCYTE FUNCTIONAL DEFECTS IN ACQUIRED HYPOGAMMAGLOBULINEMIA, DERIVED FROM INVITRO-CELL RECOMBINATION ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ASHMAN, RF (corresponding author), UNIV CALIF LOS ANGELES,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024, USA.							BLAESE RM, 1974, J EXP MED, V140, P1097, DOI 10.1084/jem.140.4.1097; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOM PD, 1976, CLIN EXP IMMUNOL, V23, P77; CICCIMARRA F, 1976, J CLIN INVEST, V57, P1386, DOI 10.1172/JCI108407; DELACONCHA EG, 1977, CLIN EXP IMMUNOL, V27, P208; DUTTON RW, 1975, TRANSPLANT REV, V26, P39; FU SM, 1978, J EXP MED, V148, P1423, DOI 10.1084/jem.148.5.1423; FUDENBERG H, 1971, PEDIATRICS, V47, P927; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GREBENAU MD, 1978, J IMMUNOL, V120, P1046; HUTTEROTH TH, 1977, KLIN WOCHENSCHR, V55, P743, DOI 10.1007/BF01476961; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRAKAUER RS, 1977, J IMMUNOL, V118, P1385; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; PORTARO JK, 1978, CLIN IMMUNOL IMMUNOP, V11, P339, DOI 10.1016/0090-1229(78)90058-2; SAXON A, 1977, J IMMUNOL, V118, P1872; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SEEGER RC, 1976, CLIN EXP IMMUNOL, V26, P1; SIEGAL FP, 1978, NEW ENGL J MED, V299, P172, DOI 10.1056/NEJM197807272990404; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; STEVENS RH, 1979, IMMUNOLOGY, V36, P407; VITETTA ES, 1977, IMMUNOL REV, V37, P50, DOI 10.1111/j.1600-065X.1977.tb00245.x; WALDMANN TA, 1974, LANCET, V2, P609; WALDMANN TA, 1976, FED PROC, V35, P2067; WERNET P, 1974, P NATL ACAD SCI USA, V71, P531, DOI 10.1073/pnas.71.2.531; WU LYE, 1973, J CLIN INVEST, V52, P3180, DOI 10.1172/JCI107518	26	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					242	256		10.1016/0091-6749(80)90151-7	http://dx.doi.org/10.1016/0091-6749(80)90151-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JN548	6965681	Bronze			2022-12-18	WOS:A1980JN54800002
J	ROOKLIN, AR; LAMPERT, SI; JAEGER, EA; MCGEADY, SJ; MANSMANN, HC				ROOKLIN, AR; LAMPERT, SI; JAEGER, EA; MCGEADY, SJ; MANSMANN, HC			POSTERIOR SUBCAPSULAR CATARACTS IN STEROID-REQUIRING ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THOMAS JEFFERSON UNIV JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; CHILDRENS HEART HOSP, PHILADELPHIA, PA USA	Jefferson University								ACKERMAN GL, 1968, NEW ENGL J MED, V278, P405, DOI 10.1056/NEJM196802222780801; BIHARI M, 1968, AM J DIS CHILD, V116, P604, DOI 10.1001/archpedi.1968.02100020608006; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BRAVER DA, 1966, J PEDIATR-US, V69, P735, DOI 10.1016/S0022-3476(66)80117-8; CREWS SJ, 1963, BRIT MED J, P1644; DUNAND P, 1975, J ALLERGY CLIN IMMUN, V55, P123; FALLIERS CJ, 1972, J ALLERGY CLIN IMMUN, V49, P156, DOI 10.1016/0091-6749(72)90109-1; FORMAN AR, 1977, AM J OPHTHALMOL, V84, P75, DOI 10.1016/0002-9394(77)90328-2; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HAVRE DC, 1965, ARCH OPHTHALMOL-CHIC, V73, P818; KERREBIJN KF, 1968, ARCH DIS CHILD, V43, P556, DOI 10.1136/adc.43.231.556; SADEGHIN.A, 1969, PEDIATRICS, V43, P277; SEVEL D, 1977, J ALLERGY CLIN IMMUN, V60, P215, DOI 10.1016/0091-6749(77)90132-4; SHAPIRO GG, 1976, J ALLERGY CLIN IMMUN, V57, P430, DOI 10.1016/0091-6749(76)90058-0; SHIONO H, 1977, CLIN PEDIATR, V16, P726, DOI 10.1177/000992287701600810; Spaeth G L, 1966, Int Ophthalmol Clin, V6, P915, DOI 10.1097/00004397-196606040-00009; SUNDMARK E, 1966, ACTA OPHTHALMOL, V44, P291; VANMETRE TE, 1962, SOUTHERN MED J, V55, P1305, DOI 10.1097/00007611-196212000-00012	19	50	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					383	386		10.1016/0091-6749(79)90210-0	http://dx.doi.org/10.1016/0091-6749(79)90210-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	447940	Bronze			2022-12-18	WOS:A1979GY51400003
J	SIRAGANIAN, RP; SANDBERG, AL				SIRAGANIAN, RP; SANDBERG, AL			CHARACTERIZATION OF MOUSE ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SIRAGANIAN, RP (corresponding author), NIDR,MICROBIOL & IMMUNOL LAB,BLDG 10,ROOM 2B 12,BETHESDA,MD 20014, USA.							ARONSSON T, 1974, INT ARCH ALLER A IMM, V47, P224, DOI 10.1159/000231216; Berrens L, 1971, CHEM ATOPIC ALLERGEN; BRANDT R, 1973, INT ARCH ALLER A IMM, V45, P447, DOI 10.1159/000231062; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P427, DOI 10.1159/000230859; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P419, DOI 10.1159/000230858; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1972, BIOCHEMISTRY-US, V11, P367, DOI 10.1021/bi00753a010; LEVY DA, 1975, INT ARCH ALLER A IMM, V49, P219, DOI 10.1159/000231399; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSKY II, 1975, ANN ALLERGY, V35, P201; MARSH DG, 1975, ANTIGENS, V3, P271; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; PONTERIUS G, 1973, INT ARCH ALLER A IMM, V44, P679, DOI 10.1159/000230970; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; TAYLOR AN, 1977, LANCET, V2, P847; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	24	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					435	442		10.1016/0091-6749(79)90219-7	http://dx.doi.org/10.1016/0091-6749(79)90219-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	109484				2022-12-18	WOS:A1979GY51400012
J	KARR, RM; LEHRER, SB; BUTCHER, BT; SALVAGGIO, JE				KARR, RM; LEHRER, SB; BUTCHER, BT; SALVAGGIO, JE			COFFEE WORKERS ASTHMA - CLINICAL APPRAISAL USING RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KARR, RM (corresponding author), TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.							Bernton HS, 1923, AM J MED SCI, V165, P196; BERNTON HS, 1973, JAMA-J AM MED ASSOC, V223, P1146; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COULSON EJ, 1950, J ALLERGY, V21, P554, DOI 10.1016/0021-8707(50)90107-9; DIXON WJ, 1957, INTRO STATISTICAL AN, P209; FIGLEY KD, 1950, J ALLERGY, V21, P545, DOI 10.1016/0021-8707(50)90106-7; FREEDMAN SO, 1961, NATURE, V192, P241, DOI 10.1038/192241a0; FREEDMAN SO, 1966, J ALLERGY, V38, P277, DOI 10.1016/0021-8707(66)90022-0; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; LAYTON LL, 1962, J ALLERGY, V33, P232, DOI 10.1016/0021-8707(62)90089-8; LAYTON LL, 1965, INT ARCH ALLER A IMM, V28, P116, DOI 10.1159/000229652; LAYTON LL, 1965, J ALLERGY, V36, P84, DOI 10.1016/0021-8707(65)90035-3; LAYTON LL, 1968, INT ARCH ALLER A IMM, V33, P417, DOI 10.1159/000230057; LAYTON LL, 1966, J ALLERGY, V38, P279; LEHRER SB, CLIN ALLERGY; LOWELL FC, 1966, J ALLERGY, V38, P276, DOI 10.1016/0021-8707(66)90021-9; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1	19	50	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					143	148		10.1016/0091-6749(78)90098-2	http://dx.doi.org/10.1016/0091-6749(78)90098-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	681627				2022-12-18	WOS:A1978FP55400003
J	MACCIA, CA; GALLAGHER, JS; ATAMAN, G; GLUECK, HI; BROOKS, SM; BERNSTEIN, IL				MACCIA, CA; GALLAGHER, JS; ATAMAN, G; GLUECK, HI; BROOKS, SM; BERNSTEIN, IL			PLATELET THROMBOPATHY IN ASTHMATIC-PATIENTS WITH ELEVATED IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,COLL MED,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DIV HEMATOL COAGULAT,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,DIV CLIN STUDIES,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati; University of Cincinnati								ANTON AH, 1962, J PHARMACOL EXP THER, V138, P360; ARDLIE NG, 1967, THROMB DIATH HAEMOST, V18, P670; BENVENISTE J, 1974, NATURE, V249, P581, DOI 10.1038/249581a0; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V49, P219; BRAUNSTEIN KM, 1976, CLIN RES, V24, pA46; BROOKS SM, 1974, AM REV RESPIR DIS, V109, P198; COLLINS JV, 1975, Q J MED, V44, P259; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FISHEL C W, 1970, Federation Proceedings, V29, P640; GROTTUM KA, 1969, BRIT J HAEMATOL, V17, P373, DOI 10.1111/j.1365-2141.1969.tb01383.x; HARDISTY RM, 1965, BRIT J HAEMATOL, V11, P258, DOI 10.1111/j.1365-2141.1965.tb06586.x; HARDISTY RM, 1972, BRIT J HAEMATOL, V23, P679, DOI 10.1111/j.1365-2141.1972.tb03483.x; HARWELL WB, 1973, J ALLERGY CLIN IMMUN, V51, P274, DOI 10.1016/0091-6749(73)90129-2; HIRT M, 1968, PSYCHOSOMATICS, V9, P340; Ivy AC, 1941, J LAB CLIN MED, V26, P1812; MANNUCCI PM, 1973, 4 C INT SOC THROMB H, P39; MCDONALD JR, 1974, J ALLERGY CLIN IMMUN, V54, P200, DOI 10.1016/0091-6749(74)90062-1; MUSTARD JF, 1975, AM J PHYSL, V228, P175; NIEWIAROWSKI S, 1969, NATURE, V222, P1269, DOI 10.1038/2221269a0; OBRIEN JR, 1971, LANCET, V2, P741; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAPAPORT SI, 1957, AM J MED SCI, V234, P678, DOI 10.1097/00000441-195712000-00006; ROSSI EC, 1975, J LAB CLIN MED, V85, P300; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; SCHWARTZ HJ, 1973, INT ARCH ALLER A IMM, V45, P899, DOI 10.1159/000231088; SOLINGER A, 1973, J ALLERGY CLIN IMMUN, V51, P29; SOLINGER A, 1973, J ALLERGY CLIN IMMUN, V52, P318, DOI 10.1016/0091-6749(73)90052-3; TSCHOPP TB, 1972, BLOOD-J HEMATOL, V40, P217, DOI 10.1182/blood.V40.2.217.217; WALKER SR, 1972, J PHARM PHARMACOL, V24, P525, DOI 10.1111/j.2042-7158.1972.tb09051.x; WEISS HJ, 1972, ANN NY ACAD SCI, V201, P161, DOI 10.1111/j.1749-6632.1972.tb16297.x; WEISS HJ, 1968, J CLIN INVEST, V47, P2169, DOI 10.1172/JCI105903; WERK EE, 1964, J CLIN INVEST, V43, P1824, DOI 10.1172/JCI105056; WIDE L, 1967, LANCET, V2, P1105; WILKINSON GR, 1968, J PHARMACOL EXP THER, V162, P139	35	50	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					101	108		10.1016/0091-6749(77)90210-X	http://dx.doi.org/10.1016/0091-6749(77)90210-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	833379				2022-12-18	WOS:A1977CV62200002
J	SOTER, NA; JOSHI, NP; TWAROG, FJ; ZEIGER, RS; ROTHMAN, PM; COLTEN, HR				SOTER, NA; JOSHI, NP; TWAROG, FJ; ZEIGER, RS; ROTHMAN, PM; COLTEN, HR			DELAYED COLD-INDUCED URTICARIA - DOMINANTLY INHERITED DISORDER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,ROBERT B BRIGHAM HOSP,SCH MED,DEPT DERMATOL,DIV DERMATOL,BOSTON,MA 02120; HARVARD UNIV,ROBERT B BRIGHAM HOSP,SCH MED,DEPT PEDIAT,DIV DERMATOL,BOSTON,MA 02120; HARVARD UNIV,ROBERT B BRIGHAM HOSP,SCH MED,DEPT MED,DIV DERMATOL,BOSTON,MA 02120; CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital				Zeiger, Robert/0000-0001-5788-5063; Soter, Nicholas/0000-0003-3518-3209				BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BORSOS T, 1970, MOLECULAR BASIS COMP; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; CURZON G, 1970, BRIT J PHARMACOL, V39, P653, DOI 10.1111/j.1476-5381.1970.tb10373.x; DOEGLAS HMG, 1974, ARCH DERMATOL, V110, P382, DOI 10.1001/archderm.110.3.382; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P395; KENT JF, 1963, AM J TROP MED HYG, V12, P103, DOI 10.4269/ajtmh.1963.12.103; Kile RL., 1940, J AM MED ASS, V114, P1067, DOI [10.1001/jama.1940.62810120003010b, DOI 10.1001/JAMA.1940.62810120003010B]; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MITTAL KK, 1968, TRANSPLANTATION, V6, P913, DOI 10.1097/00007890-196811000-00006; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; SAMS WM, 1974, IMMUNOLOGICAL ASPECT, P3; SARKANY I, 1958, P ROY SOC MED, V58, P622; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; ZEIGER RS, 1976, J ALLERGY CLIN IMMUN, V58, P172, DOI 10.1016/0091-6749(76)90152-4	23	50	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					294	297		10.1016/0091-6749(77)90050-1	http://dx.doi.org/10.1016/0091-6749(77)90050-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	66242				2022-12-18	WOS:A1977DB88600004
J	SHEREFF, RH; HARWELL, W; LIEBERMAN, P; ROSENBERG, EW; ROBINSON, H				SHEREFF, RH; HARWELL, W; LIEBERMAN, P; ROSENBERG, EW; ROBINSON, H			EFFECT OF BETA-ADRENERGIC STIMULATION AND BLOCKADE ON IMMEDIATE HYPERSENSITIVITY SKIN-TEST REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE, MED UNITS, DEPT PREVENT & COMMUNITY MED, DIV DERMATOL, KNOXVILLE, TN USA; UNIV TENNESSEE, MED UNITS, DEPT PREVENT & COMMUNITY MED, DIV ALLERGY & IMMUNOL, KNOXVILLE, TN USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville								AMER SM, 1973, SCIENCE, V179, P807; CALNAN CD, 1969, T ST JOHNS HOSP DERM, V55, P105; DUNCAN DB, 1966, BIOMETRICS, V22, P26, DOI 10.2307/2528211; HEMELS HGW, 1970, BRIT J DERMATOL, V83, P312, DOI 10.1111/j.1365-2133.1970.tb15706.x; ICHIKAWA A, 1972, BIOCHEM PHARMACOL, V21, P2615, DOI 10.1016/0006-2952(72)90229-8; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; KALZ F, 1950, ARCH DERMATOL SYPH, V61, P772, DOI 10.1001/archderm.1950.01530120063005; LICHTENSTEIN LM, 1971, INT ARCH ALLER A IMM, V41, P56, DOI 10.1159/000230488; LUGNIER C, 1972, EUR J PHARMACOL, V19, P134, DOI 10.1016/0014-2999(72)90090-8; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MCNEILL RS, 1964, LANCET, V2, P1101; MIER PD, 1970, BRIT J DERMATOL, V83, P364, DOI 10.1111/j.1365-2133.1970.tb15717.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TRINER L, 1972, LIFE SCI, V11, P817, DOI 10.1016/0024-3205(72)90159-2; VANSELOW NA, 1967, MANUAL CLINICAL ALLE; WARNDORF.JA, 1970, BRIT J DERMATOL, V83, P306, DOI 10.1111/j.1365-2133.1970.tb15705.x; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103	17	50	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	6					328	333		10.1016/0091-6749(73)90091-2	http://dx.doi.org/10.1016/0091-6749(73)90091-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R5074	4752931				2022-12-18	WOS:A1973R507400002
J	Lee, PY; Platt, CD; Weeks, S; Grace, RF; Maher, G; Gauthier, K; Devana, S; Vitali, S; Randolph, AG; McDonald, DR; Geha, RS; Chou, J				Lee, Pui Y.; Platt, Craig D.; Weeks, Sabrina; Grace, Rachael F.; Maher, George; Gauthier, Kasey; Devana, Sridevi; Vitali, Sally; Randolph, Adrienne G.; McDonald, Douglas R.; Geha, Raif S.; Chou, Janet			Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SOCS1; Evans syndrome; autoimmune hemolytic anemia; immune thrombocytopenia; COVID-19; MIS-C; SARS-CoV-2	INTERFERON-GAMMA; I INTERFERONS; ACTIVATION; SUPPRESSOR	Background: We studied 2 unrelated patients with immune thrombocytopenia and autoimmune hemolytic anemia in the setting of acute infections. One patient developed multisystem inflammatory syndrome in children in the setting of a severe acute respiratory syndrome coronavirus 2 infection. Objectives: We sought to identify the mechanisms underlying the development of infection-driven autoimmune cytopenias. Methods: Whole-exome sequencing was performed on both patients, and the impact of the identified variants was validated by functional assays using the patients' PBMCs. Results: Each patient was found to have a unique heterozygous truncation variant in suppressor of cytokine signaling 1 (SOCS1). SOCS1 is an essential negative regulator of type I and type II IFN signaling. The patients' PBMCs showed increased levels of signal transducer and activator of transcription 1 phosphorylation and a transcriptional signature characterized by increased expression of type I and type II IFN-stimulated genes and proapoptotic genes. The enhanced IFN signature exhibited by the patients' unstimulated PBMCs parallels the hyperinflammatory state associated with multisystem inflammatory syndrome in children, suggesting the contributions of SOCS1 in regulating the inflammatory response characteristic of multisystem inflammatory syndrome in children. Conclusions: Heterozygous loss-of-function SOCS1 mutations are associated with enhanced IFN signaling and increased immune cell activation, thereby predisposing to infectionassociated autoimmune cytopenias.	[Lee, Pui Y.; Platt, Craig D.; Weeks, Sabrina; McDonald, Douglas R.; Geha, Raif S.; Chou, Janet] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Grace, Rachael F.] Harvard Med Sch, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Maher, George; Gauthier, Kasey] Sanford Childrens Hosp, Div Pediat Hematol Oncol, Sioux Falls, SD USA; [Devana, Sridevi] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Devana, Sridevi] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Vitali, Sally; Randolph, Adrienne G.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Div Crit Care Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Sanford Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Chou, J (corresponding author), One Blackfan Circle,Karp Bldg,10th Floor, Boston, MA 02115 USA.	Janet.Chou@childrens.harvard.edu		Grace, Rachael/0000-0001-7302-0449; Randolph, Adrienne/0000-0002-3084-3071	National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases [K08-AR074562]; National Institutes of Health: Centers for Disease Control and Prevention; National Institutes of Health: Eunice Kennedy Shriver National Institute of Child Health and Human Development [R21HD095228]; National Institutes of Health: National Institute of Allergy and Infectious Diseases [5K08AI116979, R01-AI139633]; Perkin Fund; Samara Jan Turkel Center for Autoimmune Diseases	National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health: Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institutes of Health (NIH) - USA); National Institutes of Health: Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health: National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Perkin Fund; Samara Jan Turkel Center for Autoimmune Diseases	This work was supported by the National Institutes of Health: National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant no. K08-AR074562 to P.Y.L.), Centers for Disease Control and Prevention (to A.G.R.), Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no. R21HD095228 to A.G.R.), National Institute of Allergy and Infectious Diseases (grant no. 5K08AI116979 to J.C. and grant no. R01-AI139633 to R.S.G.), the Perkin Fund (to R.S.G.), and the Samara Jan Turkel Center for Autoimmune Diseases (to J.C.).	Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Capes A, 2020, ANN HEMATOL, V99, P1679, DOI 10.1007/s00277-020-04137-9; Jaime-Perez JC, 2018, J BLOOD MED, V9, P171, DOI 10.2147/JBM.S176144; Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Fenner JE, 2006, NAT IMMUNOL, V7, P33, DOI 10.1038/ni1287; Fujimoto M, 2004, INT IMMUNOL, V16, P303, DOI 10.1093/intimm/dxh030; Galeotti C, 2020, NAT REV RHEUMATOL, V16, P413, DOI 10.1038/s41584-020-0448-7; Guiducci C, 2010, NATURE, V465, P937, DOI 10.1038/nature09102; Kiefer K, 2012, IMMUNOL CELL BIOL, V90, P498, DOI 10.1038/icb.2012.10; Lazarian G, 2020, BRIT J HAEMATOL, V190, P29, DOI 10.1111/bjh.16794; Li M, 2020, BRIT J HAEMATOL, V190, pE59, DOI 10.1111/bjh.16846; Li Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3017; Liau NPD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04013-1; Lin FC, 2014, BLOOD, V124, P3699, DOI 10.1182/blood-2014-01-549527; Lopez C, 2020, BRIT J HAEMATOL, V190, P31, DOI 10.1111/bjh.16786; Malireddi RKS, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00077; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; Rice GI, 2017, J CLIN IMMUNOL, V37, P123, DOI 10.1007/s10875-016-0359-1; Rice GI, 2014, NAT GENET, V46, P503, DOI 10.1038/ng.2933; Srivastava S, 2014, J EXP MED, V211, P961, DOI 10.1084/jem.20131556; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; Wahlster L, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28382; Zagorski E, 2020, BRIT J HAEMATOL, V190, pE183, DOI 10.1111/bjh.16892	25	49	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1194	+		10.1016/j.jaci.2020.07.033	http://dx.doi.org/10.1016/j.jaci.2020.07.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32853638	Green Published, Bronze			2022-12-18	WOS:000588153700021
J	Della-Torre, E; Rigamonti, E; Perugino, C; Baghai-Sain, S; Sun, N; Kaneko, N; Maehara, T; Rovati, L; Ponzoni, M; Milani, R; Lanzillotta, M; Mahajan, V; Mattoo, H; Molineris, I; Deshpande, V; Stone, JH; Falconi, M; Manfredi, AA; Pillai, S				Della-Torre, Emanuel; Rigamonti, Elena; Perugino, Cory; Baghai-Sain, Simona; Sun, Na; Kaneko, Naoki; Maehara, Takashi; Rovati, Lucrezia; Ponzoni, Maurilio; Milani, Raffaella; Lanzillotta, Marco; Mahajan, Vinay; Mattoo, Hamid; Molineris, Ivan; Deshpande, Vikram; Stone, John H.; Falconi, Massimo; Manfredi, Angelo A.; Pillai, Shiv			B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG(4); IgG(4)-related disease; B cells; plasmablasts; fibrosis; fibroblasts; rituximab; lysyl oxidase homolog 2; platelet-derived growth factor	CYTOTOXIC T-LYMPHOCYTES; LYSYL OXIDASE; IGG4-RELATED DISEASE; SYSTEMIC-SCLEROSIS; GENE-EXPRESSION; CELL DEPLETION; PDGF RECEPTOR; RITUXIMAB; ACTIVATION; EFFICACY	Background: IgG(4)-related disease (IgG(4)-RD) is a fibroinflammatory condition marked by rapid clinical improvement after selective depletion of B lymphocytes with rituximab. This feature suggests that B cells might participate in fibrogenesis and wound healing. Objective: In the present work we aimed to demonstrate that B lymphocytes contribute directly to tissue fibrosis in patients with IgG(4)-RD. Methods: Total circulating CD19(+) B lymphocytes, naive B cells, memory B cells, or plasmablasts from patients with IgG(4)-RD were cultivated with human fibroblasts. Profibrotic soluble factors and collagen production in cocultures were assessed by using ELISAs and Luminex assays. RNA sequencing and quantitative RT-PCR were used to assess fibroblast activation in the presence of B cells, as well as induction of profibrotic pathways in B-cell subsets. Relevant profibrotic and inflammatory molecules were confirmed in vitro by using functional experiments and on IgG(4)-RD tissue sections by using multicolor immunofluorescence studies. Results: B cells from patients with IgG(4)-RD (1) produced the profibrotic molecule platelet-derived growth factor B and stimulated collagen production by fibroblasts; (2) expressed enzymes implicated in extracellular matrix remodeling, such as lysyl oxidase homolog 2; (3) produced the chemotactic factors CCL4, CCL5, and CCL11; and (4) induced production of these same chemokines by activated fibroblasts. Plasmablasts expressed sets of genes implicated in fibroblast activation and proliferation and therefore represent cells with intrinsic profibrotic properties. Conclusion: We have demonstrated that B cells contribute directly to tissue fibrosis in patients with IgG4-RD. These unanticipated profibrotic properties of B lymphocytes, particularly plasmablasts, might be relevant for fibrogenesis in patients with other fibroinflammatory disorders and for wound-healing processes in physiologic conditions.	[Della-Torre, Emanuel; Rigamonti, Elena; Rovati, Lucrezia; Ponzoni, Maurilio; Lanzillotta, Marco; Falconi, Massimo; Manfredi, Angelo A.] Univ Vita Salute San Raffaele, Milan, Italy; [Ponzoni, Maurilio] IRCCS San Raffaele Sci Inst, Pathol Unit, Milan, Italy; [Milani, Raffaella] IRCCS San Raffaele Sci Inst, Immunohematol & Transfus Med Unit, Milan, Italy; [Falconi, Massimo] IRCCS San Raffaele Sci Inst, Div Pancreat Surg, Milan, Italy; [Perugino, Cory; Stone, John H.] Harvard Med Sch, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Della-Torre, Emanuel; Perugino, Cory; Sun, Na; Kaneko, Naoki; Maehara, Takashi; Rovati, Lucrezia; Mahajan, Vinay; Pillai, Shiv] Harvard Med Sch, Ragon Inst MGH MIT & Harvard, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Della-Torre, Emanuel; Manfredi, Angelo A.] IRCCS San Raffaele Sci Inst, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy; [Kaneko, Naoki; Maehara, Takashi] Kyushu Univ, Sect Oral & Maxillofacial Oncol, Div Maxillofacial Diagnost & Surg Sci, Fac Dent Sci, Fukuoka, Japan; [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Baghai-Sain, Simona; Molineris, Ivan] IRCCS San Raffaele Sci Inst, Ctr Translat Genom & Bioinformat, Milan, Italy; [Mattoo, Hamid] Sanofi, Immunol & Inflammat Therapeut Area, Cambridge, MA USA	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Kyushu University; Harvard University; Massachusetts General Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Sanofi-Aventis	Della-Torre, E (corresponding author), Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Via Olgettina 60, I-20132 Milan, Italy.	dellatorre.emanuel@hsr.it	Rovati, Lucrezia/AAA-7216-2022; Lanzillotta, Marco/AAG-4578-2019; Mahajan, Vinay S/AAF-3303-2019; Della Torre, Emanuel/AAB-5024-2022; Manfredi, Angelo A./C-7018-2014	Rovati, Lucrezia/0000-0003-1222-9825; Lanzillotta, Marco/0000-0002-4522-2921; Manfredi, Angelo A./0000-0001-8370-6970; Falconi, Massimo/0000-0001-9654-7243	"Cariplo Foundation [TRIDEO 2014-Research]; "Italian Association for Cancer Research (AIRC)/Cariplo Foundation; AIRC [IG 2017-20351, 531000]; National Institutes of Health (NIH) [U19 AI110495]; "Collegio Ghislieri'' (Pavia, Italy); NIH [AI 113163]; Japanese Society for the Promotion of Science Postdoctoral Fellowship for Studies Abroad	"Cariplo Foundation(Fondazione Cariplo); "Italian Association for Cancer Research (AIRC)/Cariplo Foundation(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); "Collegio Ghislieri'' (Pavia, Italy); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japanese Society for the Promotion of Science Postdoctoral Fellowship for Studies Abroad	The study was funded by a "Giovani Ricercatori 2018-Research Grant'' award from the "Cariplo Foundation'' (to E.D.-T.), by a "TRIDEO 2014-Research Grant'' award (to E.D.-T). from the "Italian Association for Cancer Research (AIRC)/Cariplo Foundation,'' by an AIRC IG 2017-20351 (to A.A.M.), by the "531000'' Italian Ministry of Health, and by National Institutes of Health (NIH) grant U19 AI110495 (to S.P.). E.D.-T. received support from the "Collegio Ghislieri'' (Pavia, Italy), C.P. was supported by NIH grant T32 AR007258, V.M. was supported by NIH grant AI 113163, and T.M. was supported by a Japanese Society for the Promotion of Science Postdoctoral Fellowship for Studies Abroad.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Aumiller V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00270-0; Babarovic E, 2012, AM J CLIN PATHOL, V137, P870, DOI 10.1309/AJCPT5Y2JRIUUCUB; Baroni SS, 2006, NEW ENGL J MED, V354, P2667; Benazet JD, 2009, SCIENCE, V323, P1050, DOI 10.1126/science.1168755; Benhamou Y, 2016, AM J HEMATOL, V91, P1246, DOI 10.1002/ajh.24559; Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Carruthers MN, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/259408; Cheng T, 2014, J MOL CELL BIOL, V6, P506, DOI 10.1093/jmcb/mju039; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cuevas EP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44988; Della-Torre E, 2015, CLIN EXP IMMUNOL, V181, P191, DOI 10.1111/cei.12641; Della-Torre E, 2018, ARTHRITIS RHEUMATOL, V70, P1133, DOI 10.1002/art.40469; Della-Torre E, 2018, J NEUROL NEUROSUR PS, V89, P441, DOI 10.1136/jnnp-2017-316519; Della-Torre E, 2015, ANN RHEUM DIS, V74, P2236, DOI 10.1136/annrheumdis-2014-205799; Della-Torre E, 2014, ANN RHEUM DIS, V73, P1434, DOI 10.1136/annrheumdis-2014-205187; Demoulin JB, 2014, CYTOKINE GROWTH F R, V25, P273, DOI 10.1016/j.cytogfr.2014.03.003; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Ding W, 2010, BLOOD, V116, P2984, DOI 10.1182/blood-2010-02-269894; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Durozard P, 2019, MULT SCLER J, V25, P828, DOI 10.1177/1352458518772748; Eckert RC, 2004, CYTOM PART A, V59A, P182, DOI 10.1002/cyto.a.20052; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Francois A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4352; Furukawa S, 2015, CLIN IMMUNOL, V156, P9, DOI 10.1016/j.clim.2014.10.008; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; Guo XH, 2014, J DIGEST DIS, V15, P202, DOI 10.1111/1751-2980.12126; Ho YY, 2014, NAT REV RHEUMATOL, V10, P390, DOI 10.1038/nrrheum.2014.53; Ikenaga N, 2017, GUT, V66, P1697, DOI 10.1136/gutjnl-2016-312473; Jordan S, 2015, ANN RHEUM DIS, V74, P1188, DOI 10.1136/annrheumdis-2013-204522; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Keir GJ, 2014, RESPIROLOGY, V19, P353, DOI 10.1111/resp.12214; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Lanzillotta M, 2019, CLIN EXP RHEUMATOL, V37, pS159; Lanzillotta M, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1718-5; Lanzillotta M, 2017, CURR TOP MICROBIOL, V401, P85, DOI 10.1007/82_2016_58; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maehara T, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800050; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Mattoo H, 2014, J ALLERGY CLIN IMMUN, V134, P679, DOI 10.1016/j.jaci.2014.03.034; Meyringer R, 2007, J RHEUMATOL, V34, P747; Michel M, 2017, AM J HEMATOL, V92, P23, DOI 10.1002/ajh.24570; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Perugino CA, 2019, J ALLERGY CLIN IMMUN, V143, P736, DOI 10.1016/j.jaci.2018.05.011; Piemonti L, 2002, DIABETES, V51, P55, DOI 10.2337/diabetes.51.1.55; Pillai S, 2011, CURR OPIN IMMUNOL, V23, P721, DOI 10.1016/j.coi.2011.10.007; Rimar D, 2014, ARTHRITIS RHEUMATOL, V66, P726, DOI 10.1002/art.38277; Rockey DC, 2015, NEW ENGL J MED, V372, P1138, DOI 10.1056/NEJMra1300575; Santos A, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0710-z; Sato S, 2003, J INVEST DERMATOL, V120, P542, DOI 10.1046/j.1523-1747.2003.12097.x; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; Shimosegawa T, 2011, PANCREAS, V40, P352, DOI 10.1097/MPA.0b013e3182142fd2; Shiokawa M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq0997; Su G, 2014, CURR PROTOC BIOINFOR, V47; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trombetta J.J., 2014, CURR PROTOC MOL BIOL, V107; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Watanabe T, 2012, ARTHRITIS RHEUM-US, V64, P914, DOI 10.1002/art.33386; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Yang M, 2013, CELL MOL IMMUNOL, V10, P122, DOI 10.1038/cmi.2012.60	66	49	53	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					968	+		10.1016/j.jaci.2019.07.004	http://dx.doi.org/10.1016/j.jaci.2019.07.004			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31319101	Bronze, Green Accepted			2022-12-18	WOS:000518756700033
J	Cait, A; Cardenas, E; Dimitriu, PA; Amenyogbe, N; Dai, D; Cait, J; Sbihi, H; Stiemsma, L; Subbarao, P; Mandhane, PJ; Becker, AB; Moraes, TJ; Sears, MR; Lefebvre, DL; Azad, MB; Kollmann, T; Turvey, SE; Mohn, WW				Cait, Alissa; Cardenas, Erick; Dimitriu, Pedro A.; Amenyogbe, Nelly; Dai, Darlene; Cait, Jessica; Sbihi, Hind; Stiemsma, Leah; Subbarao, Padmaja; Mandhane, Piush J.; Becker, Allen B.; Moraes, Theo J.; Sears, Malcolm R.; Lefebvre, Diana L.; Azad, Meghan B.; Kollmann, Tobias; Turvey, Stuart E.; Mohn, William W.			Reduced genetic potential for butyrate fermentation in the gut microbiome of infants who develop allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; microbiome; metagenome; butyrate	LONGITUDINAL DEVELOPMENT CHILD; REGULATORY T-CELLS; CHAIN FATTY-ACIDS; ATOPIC-DERMATITIS; DIETARY FIBER; BIRTH COHORT; ASTHMA; DISEASE; RISK; DEGRADATION	Background: Allergic disease is the most frequent chronic health issue in children and has been linked to early-life gut microbiome dysbiosis. Many lines of evidence suggest that microbially derived short-chain fatty acids, and particularly butyrate, can promote immune tolerance. Objective: We sought to determine whether bacterial butyrate production in the gut during early infancy is protective against the development of atopic disease in children. Methods: We used shotgun metagenomic analysis to determine whether dysbiosis in butyrate fermentation could be identified in human infants, before their developing allergic disease. Results: We found that the microbiome of infants who went on to develop allergic sensitization later in childhood lacked genes encoding key enzymes for carbohydrate breakdown and butyrate production. Conclusions: Our findings support the importance of microbial carbohydrate metabolism during early infancy in protecting against the development of allergies.	[Cait, Alissa; Cardenas, Erick; Dimitriu, Pedro A.; Amenyogbe, Nelly; Stiemsma, Leah; Mohn, William W.] Univ British Columbia, Life Sci Inst, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Dai, Darlene; Sbihi, Hind; Stiemsma, Leah; Kollmann, Tobias; Turvey, Stuart E.] Univ British Columbia, BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Cait, Jessica] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Subbarao, Padmaja; Moraes, Theo J.] Univ Toronto, Dept Pediat & Physiol, Toronto, ON, Canada; [Subbarao, Padmaja; Moraes, Theo J.] Hosp Sick Children, Toronto, ON, Canada; [Mandhane, Piush J.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Mandhane, Piush J.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Becker, Allen B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada; [Sears, Malcolm R.; Lefebvre, Diana L.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Azad, Meghan B.] Univ Manitoba, Childrens Hosp, Dev Origins Chron Dis Children Network DEVOTION, Dept Pediat & Child Hlth,Res Inst Manitoba, Winnipeg, MB, Canada	University of British Columbia; BC Childrens Hospital; University of British Columbia; University of British Columbia; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Alberta; University of Alberta; University of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Mohn, WW (corresponding author), Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T IZ3, Canada.; Turvey, SE (corresponding author), 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sturvey@cw.bc.ca; wmohn@mail.ubc.ca	Moraes, Theo/CAJ-3254-2022; Azad, Meghan/H-7226-2019; Turvey, Stuart/HGV-1191-2022	Moraes, Theo/0000-0001-9968-6601; Azad, Meghan/0000-0002-5942-4444; Turvey, Stuart/0000-0003-1599-1065; Kollmann, Tobias/0000-0003-2403-9762	Canadian Institutes of Health Research (CIHR) [148781]; CIHR; Allergy, Genes and Environment Network of Centres of Excellence; Genome Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Allergy, Genes and Environment Network of Centres of Excellence; Genome Canada(Genome Canada)	This study was supported by a project grant (148781) from the Canadian Institutes of Health Research (CIHR). In addition, core funding for the Canadian Healthy Infant Longitudinal Development study was provided by CIHR, the Allergy, Genes and Environment Network of Centres of Excellence, and Genome Canada.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arrieta MC, 2018, J ALLERGY CLIN IMMUN, V142, P424, DOI 10.1016/j.jaci.2017.08.041; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Berthon BS, 2013, RESPIROLOGY, V18, P447, DOI 10.1111/resp.12015; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Cait A, 2018, MUCOSAL IMMUNOL, V11, P785, DOI 10.1038/mi.2017.75; Cantarel BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028742; Castro-Nallar E, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0121-1; Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163; Correa RO, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.17; Dharma C, 2018, CLIN EXP ALLERGY, V48, P48, DOI 10.1111/cea.13063; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1111/j.1654-1103.2003.tb02228.x; Ellwood P, 2013, THORAX, V68, P351, DOI 10.1136/thoraxjnl-2012-202285; Flint HJ, 2012, GUT MICROBES, V3, P289, DOI 10.4161/gmic.19897; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Geirnaert A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11734-8; German JB, 2008, NESTLE NUTR WORKS SE, V62, P205, DOI 10.1159/000146322; Hunt MC, 2012, BBA-MOL BASIS DIS, V1822, P1397, DOI 10.1016/j.bbadis.2012.03.009; Ismail IH, 2016, PEDIAT ALLERG IMM-UK, V27, P838, DOI 10.1111/pai.12646; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Jovel J, 2016, FRONT MICROBIOL, V21, P51; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lombard V, 2014, NUCLEIC ACIDS RES, V42, pD490, DOI 10.1093/nar/gkt1178; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Mahowald MA, 2009, P NATL ACAD SCI USA, V106, P5859, DOI 10.1073/pnas.0901529106; Marcobal A, 2012, CLIN MICROBIOL INFEC, V18, P12, DOI 10.1111/j.1469-0691.2012.03863.x; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Rodriguez JM, 2015, MICROB ECOL HEALTH D, V26, DOI 10.3402/mehd.v26.26050; Miliku K, 2018, ALLERGY, V73, P2070, DOI 10.1111/all.13476; Moraes TJ, 2015, PAEDIATR PERINAT EP, V29, P84, DOI 10.1111/ppe.12161; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Nayfach S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0611-7; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Poretsky R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093827; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; Reynolds LA, 2017, NAT REV IMMUNOL, V17, P518, DOI 10.1038/nri.2017.39; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schleimer RP, 2017, J ALLERGY CLIN IMMUN, V139, P1752, DOI 10.1016/j.jaci.2017.04.010; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; Stiemsma LT, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0173-6; Subbarao P, 2015, THORAX, V70, P998, DOI 10.1136/thoraxjnl-2015-207246; Takaro TK, 2015, J EXPO SCI ENV EPID, V25, P580, DOI 10.1038/jes.2015.7; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Thio CLP, 2018, J ALLERGY CLIN IMMUN, V142, P1867, DOI 10.1016/j.jaci.2018.02.032; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Tran MM, 2018, J ALLERGY CLIN IMMUN, V141, P601, DOI 10.1016/j.jaci.2017.08.024; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Vatanen T, 2018, NATURE, V562, P589, DOI 10.1038/s41586-018-0620-2; Vital M, 2014, MBIO, V5, DOI 10.1128/mBio.00889-14; Wang J, 2016, DNA CELL BIOL, V35, P203, DOI 10.1089/dna.2015.3037; Wickham H, 2016, GGPLOT2 ELEGANT GRAP, P266; Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623; Ze XL, 2012, ISME J, V6, P1535, DOI 10.1038/ismej.2012.4	67	49	52	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1638	+		10.1016/j.jaci.2019.06.029	http://dx.doi.org/10.1016/j.jaci.2019.06.029			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31279007	Bronze			2022-12-18	WOS:000500694900021
J	Dua, S; Ruiz-Garcia, M; Bond, S; Durham, SR; Kimber, I; Mills, C; Roberts, G; Skypala, I; Wason, J; Ewan, P; Boyle, R; Clark, A				Dua, Shelley; Ruiz-Garcia, Monica; Bond, Simon; Durham, Stephen R.; Kimber, Ian; Mills, Clare; Roberts, Graham; Skypala, Isabel; Wason, James; Ewan, Pamela; Boyle, Robert; Clark, Andrew			Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; allergy; thresholds; exercise and sleep deprivation	ORAL FOOD CHALLENGE; DOSE DISTRIBUTIONS; MANAGEMENT; ANAPHYLAXIS; DIAGNOSIS; ADOLESCENTS; CHILDREN; COLITIS; ASTHMA; RISKS	Background: Peanut allergy causes severe and fatal reactions. Current food allergen labeling does not address these risks adequately against the burden of restricting food choice for allergic patients because of limited data on thresholds of reactivity and the influence of everyday factors. Objective: We estimated peanut threshold doses for a United Kingdom population with peanut allergy and examined the effect of sleep deprivation and exercise. Methods: In a crossover study, after blind challenge, participants with peanut allergy underwent 3 open peanut challenges in random order: with exercise after each dose, with sleep deprivation preceding challenge, and with no intervention. Primary outcome was the threshold dose triggering symptoms (in milligrams of protein). Primary analysis estimated the difference between the nonintervention challenge and each intervention in log threshold (as percentage change). Dose distributions were modeled, deriving eliciting doses in the population with peanut allergy. Results: Baseline challenges were performed in 126 participants, 100 were randomized, and 81 (mean age, 25 years) completed at least 1 further challenge. The mean threshold was 214 mg (SD, 330 mg) for nonintervention challenges, and this was reduced by 45% (95% CI, 21% to 61%; P = .001) and 45% (95% CI, 22% to 62%; P = .001) for exercise and sleep deprivation, respectively. Mean estimated eliciting doses for 1% of the population were 1.5 mg (95% CI, 0.8-2.5 mg) during nonintervention challenge (n = 81), 0.5 mg (95% CI, 0.2-0.8 mg) after sleep, and 0.3 mg (95% CI, 0.1-0.6 mg) after exercise. Conclusion: Exercise and sleep deprivation each significantly reduce the threshold of reactivity in patients with peanut allergy, putting them at greater risk of a reaction. Adjusting reference doses using these data will improve allergen risk management and labeling to optimize protection of consumers with peanut allergy.	[Dua, Shelley; Clark, Andrew] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England; [Ruiz-Garcia, Monica; Boyle, Robert] Imperial Coll London, Dept Med, Sect Paediat, London, England; [Bond, Simon] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge Clin Trials Unit, Cambridge, England; [Durham, Stephen R.] Imperial Coll, Fac Med, Natl Heart & Lung Inst, Allergy & Clin Immunol,Sect Inflammat Repair & De, London, England; [Durham, Stephen R.; Skypala, Isabel] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Kimber, Ian] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Mills, Clare] Univ Manchester, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Roberts, Graham] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Resp Biomed Res Ctr, Southampton, Hants, England; [Roberts, Graham] Univ Southampton, Fac Med, Southampton, Hants, England; [Skypala, Isabel] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Wason, James] Cambridge Inst Publ Hlth, MRC Biostat Unit, Cambridge, England; [Wason, James] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Dua, Shelley; Ewan, Pamela; Clark, Andrew] Addenbrookes Hosp, Dept Allergy, Cambridge, England; [Boyle, Robert] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England	University of Cambridge; Imperial College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; University of Manchester; University of Manchester; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; Imperial College London; MRC Biostatistics Unit; University of Cambridge; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Nottingham	Dua, S (corresponding author), Univ Cambridge, Dept Med, Sch Clin Med, Addenbrookes Hosp, Box 40,Hills Rd, Cambridge CB2 0QQ, England.	shelley.dua@addenbrookes.nhs.uk	Bond, Simon/AAB-9077-2020	Bond, Simon/0000-0003-2528-1040; Roberts, Graham/0000-0003-2252-1248; Wason, James/0000-0002-4691-126X; Ewan, Pamela/0000-0003-1298-4417	Food Standards Agency (UK government) [T07R0013]; MRC [MC_UU_00002/6] Funding Source: UKRI	Food Standards Agency (UK government); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Food Standards Agency (UK government; grant no. T07R0013), who had no involvement in the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the article for publication.	Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Brockow K, 2015, J ALLERGY CLIN IMMUN, V135, P977, DOI 10.1016/j.jaci.2014.08.024; Christensen MJ, 2018, J ALLER CL IMM-PRACT, V6, P514, DOI 10.1016/j.jaip.2017.12.023; Gue M, 1997, AM J PHYSIOL-GASTR L, V272, pG84, DOI 10.1152/ajpgi.1997.272.1.G84; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Jarvinen KM, 2009, J ALLERGY CLIN IMMUN, V124, P1267, DOI 10.1016/j.jaci.2009.10.006; Jia CE, 2013, J ALLERGY CLIN IMMUN, V131, P695, DOI 10.1016/j.jaci.2012.08.023; Klemans RJB, 2015, CLIN EXP ALLERGY, V45, P1237, DOI 10.1111/cea.12558; Lieberman JA, 2011, J ALLERGY CLIN IMMUN, V128, P1120, DOI 10.1016/j.jaci.2011.07.012; Marrs T, 2013, PEDIAT ALLERG IMM-UK, V24, P222, DOI 10.1111/pai.12013; Million M, 1999, AM J PHYSIOL-GASTR L, V276, pG1027, DOI 10.1152/ajpgi.1999.276.4.G1027; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; R Development Core Team, 2014, R FDN STAT COMP; Remington BC, 2015, ALLERGY, V70, P813, DOI 10.1111/all.12625; Robertson ON, 2013, FOOD ADDIT CONTAM A, V30, P1467, DOI 10.1080/19440049.2013.804953; Robson-Ansley P, 2010, CURR OPIN ALLERGY CL, V10, P312, DOI 10.1097/ACI.0b013e32833b9bb0; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Stiefel G, 2017, CLIN EXP ALLERGY, V47, P719, DOI 10.1111/cea.12957; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; van Erp FC, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/s13601-014-0043-6; Wang M, 2015, PROGR SCREENING USDA; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193; Yun J, 2009, INTERN MED J, V39, P475, DOI 10.1111/j.1445-5994.2009.01967.x; Zhu JM, 2015, FOOD CHEM TOXICOL, V80, P92, DOI 10.1016/j.fct.2015.02.023	32	49	49	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1584	+		10.1016/j.jaci.2019.06.038	http://dx.doi.org/10.1016/j.jaci.2019.06.038			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31319102	Green Accepted, Bronze			2022-12-18	WOS:000500694900016
J	Kim, EH; Yang, LN; Ye, P; Guo, RS; Li, QF; Kulis, MD; Burks, AW				Kim, Edwin H.; Yang, Luanna; Ye, Ping; Guo, Rishu; Li, Quefeng; Kulis, Michael D.; Burks, A. Wesley			Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; sublingual immunotherapy; food immunotherapy; food desensitization; sustained unresponsiveness; food allergy treatments	ORAL IMMUNOTHERAPY; FOOD ALLERGY; SUSTAINED UNRESPONSIVENESS; ANAPHYLACTIC REACTIONS; DOUBLE-BLIND; PLACEBO; FATALITIES; IMPACT	Background: Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment. Objective: We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy. Methods: Children with peanut allergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure. Results: Thirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG 4 levels increased significantly after peanut SLIT. Conclusion: Extended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanut allergy that was balanced with ease of administration and a favorable safety profile.	[Kim, Edwin H.] Univ N Carolina, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol, Chapel Hill, NC 27515 USA; [Yang, Luanna; Ye, Ping; Guo, Rishu; Kulis, Michael D.; Burks, A. Wesley] Univ N Carolina, Sch Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Chapel Hill, NC 27515 USA; [Li, Quefeng] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Kim, EH (corresponding author), 3004C Mary Ellen Jones Bldg,116 Manning Dr, Chapel Hill, NC 27599 USA.	edwinkim@email.unc.edu		Kim, Edwin/0000-0001-6418-1785	National Institutes of Health/National Center for Complementary and Integrative Health [R01-AT-004435]; Wallace Research Foundation; National Center for Complementary & Integrative Health [R01AT004435] Funding Source: NIH RePORTER	National Institutes of Health/National Center for Complementary and Integrative Health; Wallace Research Foundation; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the National Institutes of Health/National Center for Complementary and Integrative Health (R01-AT-004435) and the Wallace Research Foundation.	Baumert JL, 2018, J ALLER CL IMM-PRACT, V6, P457, DOI 10.1016/j.jaip.2017.05.006; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Burk CM, 2016, CLIN EXP ALLERGY, V46, P347, DOI 10.1111/cea.12635; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Fleischer DM, 2019, JAMA-J AM MED ASSOC, V321, P946, DOI 10.1001/jama.2019.1113; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Greenhawt M, 2018, ANN ALLERG ASTHMA IM, V121, P575, DOI 10.1016/j.anai.2018.06.018; Iweala Onyinye I, 2018, Curr Gastroenterol Rep, V20, P17, DOI 10.1007/s11894-018-0624-y; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Purington N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02057; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007	27	49	49	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1320	+		10.1016/j.jaci.2019.07.030	http://dx.doi.org/10.1016/j.jaci.2019.07.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31493887	hybrid, Green Accepted			2022-12-18	WOS:000495004700022
J	Muramatsu, K; Ujiie, H; Kobayashi, I; Nishie, W; Izumi, K; Ito, T; Yoshimoto, N; Natsuga, K; Iwata, H; Shimizu, H				Muramatsu, Ken; Ujiie, Hideyuki; Kobayashi, Ichiro; Nishie, Wataru; Izumi, Kentaro; Ito, Takamasa; Yoshimoto, Norihiro; Natsuga, Ken; Iwata, Hiroaki; Shimizu, Hiroshi			Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cell; scurfy mouse; immunodysregulation; polyendocrinopathy; enteropathy; X-linked syndrome; bullous pemphigoid; BP230; type XVII collagen; signal transducer and activator of transcription 6	LINKED SYNDROME IPEX; IMMUNE DYSREGULATION; TRANSCRIPTION FACTOR; SCURFY MICE; IGG AUTOANTIBODIES; ELDERLY-PATIENTS; ANTIBODIES; ENTEROPATHY; DISEASE; POLYENDOCRINOPATHY	Background: Regulatory T (Treg) cells play a crucial role in peripheral immune tolerance in multiple organs, including the skin. Thus far, the effect of peripheral immune tolerance failure on autoantibody-related autoimmune reactions to the skin is unclear. Objective: We sought to elucidate the target autoantigens in the skin under the condition of Treg cell dysfunction caused by forkhead box P3 (Foxp3) gene mutations in scurfy mice and patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Methods: Sera and skin from scurfy mice and sera from patients with IPEX syndrome were analyzed to detect target autoantigens by using immunofluorescence studies, ELISAs, and immunoblotting. The pathogenicity of scurfy IgG was examined by using a passive transfer experiment. CD4(+) T cells from scurfy mice were transferred to immunodeficient mice to examine their pathogenicity. Signal transducer and activator of transcription 6 (Stat6)(-/-) scurfy mice were analyzed to further clarify the molecular pathway of autoantibody production. Follicular helper T-cell counts are measured in Stat6(-/-) scurfy mice and scurfy mice. Results: Scurfy mice spontaneously generated IgG autoantibodies to the dermal-epidermal junction, which had been class-switched from IgM within 12 days after birth. The target autoantigens were murine BP230 and type XVII collagen (COL17). The scurfy polyclonal autoantibodies did not induce skin fragility in neonatal mice. Autoantibody production was induced by CD4(+) T cells from scurfy mice and was ameliorated by Stat6 gene knockout in association with a decrease of follicular helper T cells. We also identified autoantibodies to COL17 and BP230 in patients with IPEX syndrome and found an association between production of autoantibodies to COL17 and an eczematous skin phenotype. Conclusions: Dysregulation of Treg cells generates autoantibodies to COL17 and BP230 in vivo.	[Muramatsu, Ken; Ujiie, Hideyuki; Nishie, Wataru; Izumi, Kentaro; Ito, Takamasa; Yoshimoto, Norihiro; Natsuga, Ken; Iwata, Hiroaki; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan; [Kobayashi, Ichiro] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan	Hokkaido University; Hokkaido University	Ujiie, H; Shimizu, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	h-ujiie@med.hokudai.ac.jp; shimizu@med.hokudai.ac.jp	MURAMATSU, Ken/AAT-6946-2021	Muramatsu, Ken/0000-0001-6212-0751	JSPS KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan [15K19667]; Okinaka Memorial Institute for Medical Research; Takeda Science Foundation; Rohto Dermatology Research Award; GlaxoSmithKline Japan	JSPS KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Okinaka Memorial Institute for Medical Research; Takeda Science Foundation(Takeda Science Foundation (TSF)); Rohto Dermatology Research Award; GlaxoSmithKline Japan(GlaxoSmithKline)	Supported in part by JSPS KAKENHI grant number 15K19667 (to H.U.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Okinaka Memorial Institute for Medical Research; the Takeda Science Foundation; the Rohto Dermatology Research Award; and GlaxoSmithKline Japan Research Grant 2015.	Aschermann S, 2013, P NATL ACAD SCI USA, V110, P19042, DOI 10.1073/pnas.1313547110; Bene J, 2016, BRIT J DERMATOL, V175, P296, DOI 10.1111/bjd.14601; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BLAIR PJ, 1994, J IMMUNOL, V153, P3764; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Budinger L, 1998, J CLIN INVEST, V102, P2082, DOI 10.1172/JCI3335; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Cooper SM, 2005, CLIN EXP DERMATOL, V30, P551, DOI 10.1111/j.1365-2230.2005.01866.x; Curry JL, 2017, J CUTAN PATHOL, V44, P158, DOI 10.1111/cup.12858; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Feldrihan V, 2014, HUM IMMUNOL, V75, P354, DOI 10.1016/j.humimm.2014.01.005; Feliciani C, 2009, BRIT J DERMATOL, V161, P306, DOI 10.1111/j.1365-2133.2009.09266.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; Hadaschik EN, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0538-0; Hayakawa T, 2016, EUR J DERMATOL, V26, P155, DOI 10.1684/ejd.2015.2719; Hayatsu N, 2017, IMMUNITY, V47, P268, DOI 10.1016/j.immuni.2017.07.008; Hofmann SC, 2010, J EUR ACAD DERMATOL, V24, P587, DOI 10.1111/j.1468-3083.2009.03480.x; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huter EN, 2010, J INVEST DERMATOL, V130, P1391, DOI 10.1038/jid.2010.16; ISHIKO A, 1993, J CLIN INVEST, V91, P1608, DOI 10.1172/JCI116368; Izumi K, 2016, J INVEST DERMATOL, V136, P2201, DOI 10.1016/j.jid.2016.06.622; Jour G, 2016, J CUTAN PATHOL, V43, P688, DOI 10.1111/cup.12717; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kiss M, 2005, J AUTOIMMUN, V24, P1, DOI 10.1016/j.jaut.2004.09.007; Kobayashi I, 2001, J MED GENET, V38, P874, DOI 10.1136/jmg.38.12.874; Kobayashi I, 2011, CLIN IMMUNOL, V141, P83, DOI 10.1016/j.clim.2011.05.010; Leung CL, 2001, J CELL BIOL, V154, P691, DOI 10.1083/jcb.200012098; Li QJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068145; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Lo Schiavo A, 2013, CLIN DERMATOL, V31, P391, DOI 10.1016/j.clindermatol.2013.01.006; Mayer CT, 2014, J AUTOIMMUN, V50, P23, DOI 10.1016/j.jaut.2013.08.010; McGinness JL, 2006, J AM ACAD DERMATOL, V55, P143, DOI 10.1016/j.jaad.2005.08.047; Meijer JM, 2015, BRIT J DERMATOL, V173, P1274, DOI 10.1111/bjd.13874; Mochel MC, 2016, J CUTAN PATHOL, V43, P787, DOI 10.1111/cup.12735; Morita R, 2015, J DERMATOL, V42, P657, DOI 10.1111/1346-8138.12848; Naidoo J, 2016, CANCER IMMUNOL RES, V4, P383, DOI 10.1158/2326-6066.CIR-15-0123; Natsuga K, 2012, J IMMUNOL, V188, P5792, DOI 10.4049/jimmunol.1003402; Nieves DS, 2004, ARCH DERMATOL, V140, P466, DOI 10.1001/archderm.140.4.466; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Nishie W, 2015, AM J PATHOL, V185, P1361, DOI 10.1016/j.ajpath.2015.01.012; Nishie W, 2014, J DERMATOL SCI, V73, P179, DOI 10.1016/j.jdermsci.2013.12.001; Ruiz-Arguelles A, 2003, CURR PHARM DESIGN, V9, P1881, DOI 10.2174/1381612033454379; Sahoo A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8997; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sasai S, 2014, ACTA DERM-VENEREOL, V94, P734, DOI 10.2340/00015555-1848; Schmidt E, 2000, ARCH DERMATOL, V136, P174, DOI 10.1001/archderm.136.2.174; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schmidt T, 2014, BRIT J DERMATOL, V171, P212, DOI 10.1111/bjd.12936; Suscovich TJ, 2012, EUR J IMMUNOL, V42, P2305, DOI 10.1002/eji.201242391; Toyonaga E, 2017, J INVEST DERMATOL, V137, P2552, DOI 10.1016/j.jid.2017.07.831; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Ujiie H, 2016, J IMMUNOL, V196, P1517, DOI 10.4049/jimmunol.1501774; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Wada M, 2016, J INVEST DERMATOL, V136, P938, DOI 10.1016/j.jid.2015.11.030; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Zillikens D, 1999, J DERMATOL SCI, V20, P134, DOI 10.1016/S0923-1811(99)00019-5	59	49	49	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1818	+		10.1016/j.jaci.2018.03.014	http://dx.doi.org/10.1016/j.jaci.2018.03.014			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29704593	Bronze			2022-12-18	WOS:000452315800017
J	Mitselou, N; Hallberg, J; Stephansson, O; Almqvist, C; Melen, E; Ludvigsson, JF				Mitselou, Niki; Hallberg, Jenny; Stephansson, Olof; Almqvist, Catarina; Melen, Erik; Ludvigsson, Jonas F.			Cesarean delivery, preterm birth, and risk of food allergy: Nationwide Swedish cohort study of more than 1 million children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; preterm birth; cesarean delivery; children	CHILDHOOD ASTHMA; SECTION; DIAGNOSIS; WEIGHT; MODE; SENSITIZATION; METAANALYSIS; ASSOCIATION; POPULATION; PREVENTION	Background: Little is known about early-life risk factors for food allergy in children. Objectives: We examined the association between perinatal characteristics and future risk of food allergy in offspring. Methods: This nationwide Swedish cohort study of 1,086,378 children born in Sweden in 2001-2012 used prospectively recorded data from health care registers. Using Cox regression, we estimated hazard ratios (HRs) with 95% CIs for the association between perinatal characteristics (eg, cesarean delivery and preterm birth) and food allergy as defined by diagnoses in the National Patient Register, adjusting for infant sex and maternal factors (age at delivery, country of birth, parity, smoking, body mass index, and asthma/pulmonary disease). Results: During the 13-year follow-up, 26,732 (2.5%) children were given a diagnosis of food allergy. Food allergy was positively associated with cesarean delivery (HR, 1.21; 95% CI, 1.18-1.25), large for gestational age (HR, 1.15; 95% CI, 1.10-1.19), and low 5-minute Apgar score (HR, 1.22; 95% CI, 1.10-1.36) but negatively associated with very preterm birth (<32 weeks of gestation: HR, 0.74; 95% CI, 0.56-0.98). No association was found between food allergy and moderately preterm birth, low birth weight, or small for gestational age. Risk estimates were similar when the outcome was restricted to 2 records of diagnosed food allergy. In 1,000 children undergoing cesarean delivery, an extra 5 developed food allergy compared with the reference group, suggesting that 17% of food allergy in children born by means of cesarean delivery can be explained by this exposure (attributable fraction). Conclusions: Cesarean delivery was associated with increased risk of food allergy, whereas very preterm birth decreased risk.	[Mitselou, Niki; Ludvigsson, Jonas F.] Karolinska Inst, Orebro Univ Hosp, Dept Pediat, Stockholm, Sweden; [Hallberg, Jenny; Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Stephansson, Olof] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; [Stephansson, Olof] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Almqvist, Catarina; Ludvigsson, Jonas F.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Hallberg, Jenny; Melen, Erik] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Hallberg, Jenny] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Allergy & Pulmonol Unit, Stockholm, Sweden; [Ludvigsson, Jonas F.] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England; [Ludvigsson, Jonas F.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Karolinska Institutet; Orebro University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital; University of Nottingham; Columbia University	Mitselou, N (corresponding author), Orebro Univ Hosp, Dept Pediat, S-70185 Orebro, Sweden.	nikimitselou@gmail.com	Ludvigsson, Jonas F/A-8560-2012	Ludvigsson, Jonas F/0000-0003-1024-5602; Mitselou, Niki/0000-0001-8056-9915; Stephansson, Olof/0000-0003-1528-4563	Swedish Research Council; Stockholm County Council (ALF); Swedish Heart-Lung Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council (ALF)(Stockholm County Council); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation)	E.M. and C.A. are supported by grants from the Swedish Research Council, Stockholm County Council (ALF), and Swedish Heart-Lung Foundation.	Allen KJ, 2016, J ALLER CL IMM-PRACT, V4, P215, DOI 10.1016/j.jaip.2015.10.010; Almqvist C, 2012, CLIN EXP ALLERGY, V42, P1369, DOI 10.1111/j.1365-2222.2012.04021.x; Alpan O, 2001, Curr Allergy Asthma Rep, V1, P572, DOI 10.1007/s11882-001-0067-6; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Boyce JA, 2011, NUTR RES, V31, P61, DOI 10.1016/j.nutres.2011.01.001; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Castro-Rodriguez JA, 2016, J ALLER CL IMM-PRACT, V4, P1111, DOI 10.1016/j.jaip.2016.05.003; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Gupta M, 2017, CLIN DERMATOL, V35, P398, DOI 10.1016/j.clindermatol.2017.03.013; Hanson M, 2011, AM J CLIN NUTR, V94, p1754S, DOI 10.3945/ajcn.110.001206; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Koplin J, 2008, PEDIAT ALLERG IMM-UK, V19, P682, DOI 10.1111/j.1399-3038.2008.00731.x; Kvenshagen B, 2009, ACTA PAEDIATR, V98, P324, DOI 10.1111/j.1651-2227.2008.01074.x; Laubereau B, 2004, ARCH DIS CHILD, V89, P993, DOI 10.1136/adc.2003.043265; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; Ortqvist AK, 2013, PHARMACOEPIDEM DR S, V22, P850, DOI 10.1002/pds.3465; Ortqvist AK, 2009, PEDIATRICS, V124, pE737, DOI 10.1542/peds.2009-0305; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3rd ed; Sackeyfio A, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d747; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Savage J, 2016, J ALLER CL IMM-PRACT, V4, P196, DOI 10.1016/j.jaip.2015.11.024; Schlinzig T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184748; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; Siltanen M, 2011, J ALLERGY CLIN IMMUN, V127, P935, DOI 10.1016/j.jaci.2010.12.1107; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Turcanu V, 2017, CURR OPIN IMMUNOL, V48, P92, DOI 10.1016/j.coi.2017.08.009; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Voort AMMSVD, 2014, J ALLERGY CLIN IMMUN, V133, P1317, DOI 10.1016/j.jaci.2013.12.1082	34	49	50	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1510	+		10.1016/j.jaci.2018.06.044	http://dx.doi.org/10.1016/j.jaci.2018.06.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30213656	Bronze, Green Accepted			2022-12-18	WOS:000449429800014
J	Mallia, P; Webber, J; Gill, SK; Trujillo-Torralbo, MB; Calderazzo, MA; Finney, L; Bakhsoliani, E; Fame, H; Singanayagam, A; Footitt, J; Hewitt, R; Kebadze, T; Aniscenko, J; Padmanaban, V; Molyneaux, PL; Adcock, IM; Barnes, PJ; Ito, K; Elkin, SL; Kon, OM; Cookson, WO; Moffat, MF; Johnston, SL; Tregoning, JS				Mallia, Patrick; Webber, Jessica; Gill, Simren K.; Trujillo-Torralbo, Maria-Belen; Calderazzo, Maria Adelaide; Finney, Lydia; Bakhsoliani, Eteri; Fame, Hugo; Singanayagam, Aran; Footitt, Joseph; Hewitt, Richard; Kebadze, Tatiana; Aniscenko, Julia; Padmanaban, Vijay; Molyneaux, Philip L.; Adcock, Ian M.; Barnes, Peter J.; Ito, Kazihuro; Elkin, Sarah L.; Kon, Onn Min; Cookson, William O.; Moffat, Miriam F.; Johnston, Sebastian L.; Tregoning, John S.			Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; glucose; viral infection; airway inflammation; bacterial infection	RHINOVIRUS INFECTION; BLOOD-GLUCOSE; EXACERBATIONS; HYPERGLYCEMIA; COPD; FIBROSIS; PATHOGENESIS; INCREASES; TRANSPORT; METFORMIN	Background: Patients with chronic obstructive pulmonary disease (COPD) have increased susceptibility to respiratory tract infection, which contributes to disease progression and mortality, but mechanisms of increased susceptibility to infection remain unclear. Objectives: The aim of this study was to determine whether glucose concentrations were increased in airway samples (nasal lavage fluid, sputum, and bronchoalveolar lavage fluid) from patients with stable COPD and to determine the effects of viral infection on sputum glucose concentrations and how airway glucose concentrations relate to bacterial infection. Methods: We measured glucose concentrations in airway samples collected from patients with stable COPD and smokers and nonsmokers with normal lung function. Glucose concentrations were measured in patients with experimentally induced COPD exacerbations, and these results were validated in patients with naturally acquired COPD exacerbations. Relationships between sputum glucose concentrations, inflammatory markers, and bacterial load were examined. Results: Sputum glucose concentrations were significantly higher in patients with stable COPD compared with those in control subjects without COPD. In both experimental virus induced and naturally acquired COPD exacerbations, sputum and nasal lavage fluid glucose concentrations were increased over baseline values. There were significant correlations between sputum glucose concentrations and sputum inflammatory markers, viral load, and bacterial load. Airway samples with higher glucose concentrations supported more Pseudomonas aeruginosa growth in vitro. Conclusions: Airway glucose concentrations are increased in patients with stable COPD and further increased during COPD exacerbations. Increased airway glucose concentrations might contribute to bacterial infections in both patients with stable and those with exacerbated COPD. This has important implications for the development of nonantibiotic therapeutic strategies for the prevention or treatment of bacterial infection in patients with COPD.	[Mallia, Patrick; Trujillo-Torralbo, Maria-Belen; Calderazzo, Maria Adelaide; Bakhsoliani, Eteri; Fame, Hugo; Singanayagam, Aran; Footitt, Joseph; Hewitt, Richard; Kebadze, Tatiana; Aniscenko, Julia; Molyneaux, Philip L.; Elkin, Sarah L.; Kon, Onn Min; Johnston, Sebastian L.] Imperial Coll, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Finney, Lydia; Adcock, Ian M.; Barnes, Peter J.; Ito, Kazihuro] Imperial Coll, Natl Heart & Lung Inst, Airways Dis Sect, London, England; [Cookson, William O.; Moffat, Miriam F.] Imperial Coll, Natl Heart & Lung Inst, Mol Genet & Genom Sect, London, England; [Mallia, Patrick; Singanayagam, Aran; Padmanaban, Vijay; Elkin, Sarah L.; Kon, Onn Min; Johnston, Sebastian L.] Imperial Coll Healthcare, Natl Hlth Serv Trust, London, England; [Webber, Jessica] Cardiff Univ, Sch Med, UHW Main Bldg Heath Pk, Cardiff, S Glam, Wales; [Gill, Simren K.; Tregoning, John S.] Imperial Coll London, Virol Sect, Mucosal Infect & Immun Grp, St Marys Campus, London, England	Imperial College London; Imperial College London; Imperial College London; Cardiff University; Imperial College London	Tregoning, JS (corresponding author), Imperial Coll London, Virol Sect, Mucosal Infect & Immun Grp, St Marys Campus, London, England.	john.trogoning@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012; Cookson, William/HHC-1790-2022; Adcock, Ian/L-3217-2019; Ito, Kazuhiro/AAF-5994-2019; Finney, Lydia/AAA-1274-2020; Farne, Hugo/H-3349-2015	Johnston, Sebastian Lennox/0000-0003-3009-9200; Regis, Eteri/0000-0001-9862-2147; Farne, Hugo/0000-0003-2556-3953; Singanayagam, Aran/0000-0001-9849-0033; finney, lydia/0000-0003-2226-9513; Barnes, Peter/0000-0002-5122-4018; Mallia, Patrick/0000-0002-5747-9978; Tregoning, John/0000-0001-8093-8741; Adcock, Ian/0000-0003-2101-8843	Cystic Fibrosis Trust & British Lung Foundation (BLF) Summer Studentship [ss15-7]; Imperial College Healthcare Trust Biomedical Research Centre Grant [P33132]; Academy of Medical Sciences; Wellcome Trust Starter Grant; Imperial College Antimicrobial Resistance consortium fellowship; Medical Research Council Program Grant [G0600879]; British Medical Association; BLF/Severin Wunderman Family Foundation Lung Research Program Grant [P00/2]; Imperial College; NIHR BRC funding scheme; NIHR Senior Investigator Award; NIHR Clinical Lecturer funding scheme; MRC [G0600879] Funding Source: UKRI	Cystic Fibrosis Trust & British Lung Foundation (BLF) Summer Studentship; Imperial College Healthcare Trust Biomedical Research Centre Grant; Academy of Medical Sciences(Academy of Medical Sciences (AMS)); Wellcome Trust Starter Grant; Imperial College Antimicrobial Resistance consortium fellowship; Medical Research Council Program Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Medical Association; BLF/Severin Wunderman Family Foundation Lung Research Program Grant; Imperial College; NIHR BRC funding scheme; NIHR Senior Investigator Award; NIHR Clinical Lecturer funding scheme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a Cystic Fibrosis Trust & British Lung Foundation (BLF) Summer Studentship (ss15-7), an Imperial College Healthcare Trust Biomedical Research Centre Grant (P33132), Academy of Medical Sciences and Wellcome Trust Starter Grant, Imperial College Antimicrobial Resistance consortium fellowship, Medical Research Council Program Grant G0600879, British Medical Association H.C. Roscoe Fellowships, BLF/Severin Wunderman Family Foundation Lung Research Program Grant P00/2, Imperial College and NIHR BRC funding scheme, NIHR Senior Investigator Award, and the NIHR Clinical Lecturer funding scheme.	Astrand A, 2017, BRIT J PHARMACOL, V174, P836, DOI 10.1111/bph.13741; Baker EH, 2017, CHEST; Baker EH, 2007, J APPL PHYSIOL, V102, P1969, DOI 10.1152/japplphysiol.01425.2006; Beasley V, 2012, INT J CHRONIC OBSTR, V7, P555, DOI 10.2147/COPD.S28286; Bilodeau C, 2016, J CYST FIBROS, V15, P43, DOI 10.1016/j.jcf.2015.04.002; Brennan AL, 2007, J CYST FIBROS, V6, P101, DOI 10.1016/j.jcf.2006.03.009; Cazzola M, 2012, AM J RESP CELL MOL, V47, P509, DOI 10.1165/rcmb.2011-0449OC; Footitt J, 2016, CHEST, V149, P62, DOI 10.1378/chest.14-2637; Garnett JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076283; Garnett JP, 2013, THORAX, V68, P835, DOI 10.1136/thoraxjnl-2012-203178; Garnett JP, 2012, EUR RESPIR J, V40, P1269, DOI 10.1183/09031936.00052612; Garnett JP, 2012, J IMMUNOL, V189, P373, DOI 10.4049/jimmunol.1200718; George SN, 2014, EUR RESPIR J, V44, P87, DOI 10.1183/09031936.00223113; Gill SK, 2016, SCI REP-UK, V6, DOI 10.1038/srep27636; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hitchings AW, 2016, THORAX, V71, P587, DOI 10.1136/thoraxjnl-2015-208035; Huang YJ, 2010, OMICS, V14, P9, DOI 10.1089/omi.2009.0100; Kummer U, 2007, BIOPHYS J, V92, P2597, DOI 10.1529/biophysj.106.086769; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Mallia P, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-116; Mallia P, 2012, AM J RESP CRIT CARE, V186, P1117, DOI 10.1164/rccm.201205-0806OC; Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC; Martin C, 2015, EUR RESPIR REV, V24, P78, DOI 10.1183/09059180.00011614; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Molyneaux PL, 2013, AM J RESP CRIT CARE, V188, P1224, DOI 10.1164/rccm.201302-0341OC; Molyneaux PL, 2014, AM J RESP CRIT CARE, V190, P906, DOI 10.1164/rccm.201403-0541OC; Nseir S, 2006, CRIT CARE MED, V34, P2959, DOI 10.1097/01.CCM.0000245666.28867.C6; Pezzulo AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016166; Philips BJ, 2005, THORAX, V60, P761, DOI 10.1136/thx.2004.035766; Philips BJ, 2003, INTENS CARE MED, V29, P2204, DOI 10.1007/s00134-003-1961-2; Sethi Sanjay, 2009, Proc Am Thorac Soc, V6, P532, DOI 10.1513/pats.200905-025DS; Van Sambeek L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119938; Wilkinson TMA, 2017, THORAX, V72, P919, DOI 10.1136/thoraxjnl-2016-209023	33	49	53	3	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					815	+		10.1016/j.jaci.2017.10.017	http://dx.doi.org/10.1016/j.jaci.2017.10.017			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29310905	Green Published, hybrid			2022-12-18	WOS:000443726500014
J	Bartemes, KR; Kita, H				Bartemes, Kathleen R.; Kita, Hirohito			Innate and adaptive immune responses to fungi in the airway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Fungi; innate immunity; adaptive immunity; airway	PROTEASE-ACTIVATED RECEPTOR-2; THYMIC STROMAL LYMPHOPOIETIN; REGULATORY T-CELLS; DUST MITE ALLERGEN; ASPERGILLUS-FUMIGATUS; LYMPHOID-CELLS; ALTERNARIA-ALTERNATA; ANTIFUNGAL IMMUNITY; LUNG INFLAMMATION; EPITHELIAL-CELLS	Fungi are ubiquitous outdoors and indoors. Exposure, sensitization, or both to fungi are strongly associated with development of asthma and allergic airway diseases. Furthermore, global climate change will likely increase the prevalence of fungi and enhance their antigenicity. Major progress has been made during the past several years regarding our understanding of antifungal immunity. Fungi contain cell-wall molecules, such as beta-glucan and chitin, and secrete biologically active proteases and glycosidases. Airway epithelial cells and innate immune cells, such as dendritic cells, are equipped with cell-surface molecules that react to these fungal products, resulting in production of cytokines and proinflammatory mediators. As a result, the adaptive arm of antifungal immunity, including T(H)1-, T(H)2-, and T(H)17-type CD4(+) T cells, is established, reinforcing protection against fungal infection and causing detrimental immunopathology in certain subjects. We are only in the beginning stages of understanding the complex biology of fungi and detailed mechanisms of how they activate the immune response that can protect against or drive diseases in human subjects. Here we describe our current understanding with an emphasis on airway allergic immune responses. The gaps in our knowledge and desirable future directions are also discussed.	Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN USA; [Kita, Hirohito] Mayo Clin, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA.; Kita, H (corresponding author), Mayo Clin, Dept Med, 200 First St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu		Bartemes, Kathleen/0000-0003-4561-3233	National Institutes of Health [T32 AI07047, R01 AI71106, R01 AI128729, R01 HL117823]; Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI128729, R37AI071106, R01AI071106, T32AI007047] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (T32 AI07047 to K.R.B. and R01 AI71106, R01 AI128729, and R01 HL117823 to H.K.) and the Mayo Foundation.	Agarwal R, 2011, MED MYCOL, V49, pS150, DOI 10.3109/13693786.2010.504752; Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Bozza S, 2002, J IMMUNOL, V168, P1362, DOI 10.4049/jimmunol.168.3.1362; Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Casadevall A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002808; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Chowdhary A, 2014, CRIT REV MICROBIOL, V40, P30, DOI 10.3109/1040841X.2012.754401; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Chung YJ, 2010, INHAL TOXICOL, V22, P460, DOI 10.3109/08958370903380712; Comoy EE, 1998, J IMMUNOL, V160, P2456; Crameri R, 2002, EUR RESPIR J, V19, P151, DOI 10.1183/09031936.02.00229102; de Vries RP, 2001, MICROBIOL MOL BIOL R, V65, P497, DOI 10.1128/MMBR.65.4.497-522.2001; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Doherty TA, 2012, J IMMUNOL, V188, P2622, DOI 10.4049/jimmunol.1101632; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fraczek MG, 2017, J ALLERGY CLIN IMMUN; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Garth JM, 2017, J IMMUNOL, V199, P2140, DOI 10.4049/jimmunol.1602186; Genster N, 2016, J INNATE IMMUN, V8, P579, DOI 10.1159/000447714; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Green Brett James, 2006, Allergol Int, V55, P131, DOI 10.2332/allergolint.55.131; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hamilos Daniel L, 2010, Proc Am Thorac Soc, V7, P245, DOI 10.1513/pats.200909-098AL; Hardison SE, 2012, NAT IMMUNOL, V13, P817, DOI 10.1038/ni.2369; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hollins PD, 2004, INT J BIOMETEOROL, V48, P137, DOI 10.1007/s00484-003-0188-9; Homma T, 2016, AM J RESP CELL MOL, V54, P60, DOI 10.1165/rcmb.2015-0062OC; Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Ibrahim ZA, 2013, MOL IMMUNOL, V56, P739, DOI 10.1016/j.molimm.2013.07.008; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Iliev ID, 2017, NAT REV IMMUNOL, V17, P635, DOI 10.1038/nri.2017.55; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Inoue Y, 2005, J IMMUNOL, V175, P5439, DOI 10.4049/jimmunol.175.8.5439; Jolink H, 2017, J INFECTION, V74, P81, DOI 10.1016/j.jinf.2016.10.010; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kim HK, 2014, INT ARCH ALLERGY IMM, V163, P92, DOI 10.1159/000356341; Kimura Y, 2014, J BIOL CHEM, V289, P31565, DOI 10.1074/jbc.M114.581322; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Kouzaki H, 2013, AM J RESP CELL MOL, V49, P741, DOI 10.1165/rcmb.2012-0304OC; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Lake JA, 2009, J EXP BOT, V60, P3123, DOI 10.1093/jxb/erp147; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Larenas-Linnemann D, 2016, J ALLER CL IMM-PRACT, V4, P405, DOI 10.1016/j.jaip.2015.10.015; Leonardi I, 2018, SCIENCE, V359, P232, DOI 10.1126/science.aao1503; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Lilly LM, 2014, INFECT IMMUN, V82, P1315, DOI 10.1128/IAI.01172-13; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Loures FV, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00261; Loures FV, 2010, INFECT IMMUN, V78, P1078, DOI 10.1128/IAI.01198-09; Loures FV, 2009, J IMMUNOL, V183, P1279, DOI 10.4049/jimmunol.0801599; Mari A, 2003, CLIN EXP ALLERGY, V33, P1429, DOI 10.1046/j.1365-2222.2003.01783.x; Matsuwaki Y, 2009, J IMMUNOL, V183, P6708, DOI 10.4049/jimmunol.0901220; McAleer JP, 2016, J IMMUNOL, V197, P97, DOI 10.4049/jimmunol.1502566; McClure R, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00386; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Muniz VS, 2018, J ALLERGY CLIN IMMUN, V141, P571, DOI 10.1016/j.jaci.2017.07.048; Murai H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030280; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Netea MG, 2003, J INFECT DIS, V188, P320, DOI 10.1086/376456; O'Driscoll BR, 2009, CLIN EXP ALLERGY, V39, P1677, DOI 10.1111/j.1365-2222.2009.03339.x; O'Grady SM, 2013, J PHYSIOL-LONDON, V591, P4595, DOI 10.1113/jphysiol.2013.254649; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Oczypok EA, 2015, J ALLERGY CLIN IMMUN, V136, P747, DOI 10.1016/j.jaci.2015.03.011; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Pant H, 2009, LARYNGOSCOPE, V119, P1046, DOI 10.1002/lary.20170; Peay KG, 2016, NAT REV MICROBIOL, V14, P434, DOI 10.1038/nrmicro.2016.59; Porter P, 2009, MUCOSAL IMMUNOL, V2, P504, DOI 10.1038/mi.2009.102; Porter PC, 2014, J ALLERGY CLIN IMMUN, V134, P325, DOI 10.1016/j.jaci.2014.04.028; Porter PC, 2011, TRENDS IMMUNOL, V32, P43, DOI 10.1016/j.it.2010.11.007; Portnoy JM, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0643-4; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rick EM, 2016, J INVEST ALLERG CLIN, V26, P344, DOI 10.18176/jiaci.0122; Rivera A, 2011, J EXP MED, V208, P369, DOI 10.1084/jem.20100906; Rodrigues J, 2016, EXPERT REV CLIN IMMU, V12, P531, DOI 10.1586/1744666X.2016.1142874; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Samuchiwal SK, 2017, J BIOL CHEM, V292, P8195, DOI 10.1074/jbc.M116.769422; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schleimer RP, 2017, J ALLERGY CLIN IMMUN, V139, P1752, DOI 10.1016/j.jaci.2017.04.010; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Taghavi M, 2017, EUR J PHARMACOL, V808, P8, DOI 10.1016/j.ejphar.2016.11.013; Templeton SP, 2010, MED MYCOL, V48, P217, DOI 10.3109/13693780903420658; Toki S., 2018, J ALLERGY CLIN IMMUN; Traynor TR, 2000, J IMMUNOL, V164, P2021, DOI 10.4049/jimmunol.164.4.2021; Trzeciak-Ryczek A, 2015, POSTEP HIG MED DOSW, V69, P469, DOI 10.5604/17322693.1148747; Twaroch TE, 2015, ALLERGY ASTHMA IMMUN, V7, P205, DOI 10.4168/aair.2015.7.3.205; Uchida M, 2017, ALLERGY, V72, P1521, DOI 10.1111/all.13158; Underhill DM, 2015, IMMUNITY, V43, P845, DOI 10.1016/j.immuni.2015.10.023; van de Veerdonk FL, 2017, NAT REV MICROBIOL, V15, P661, DOI 10.1038/nrmicro.2017.90; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Van Dyken SJ, 2011, J IMMUNOL, V187, P2261, DOI 10.4049/jimmunol.1100972; van Woerden HC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-69; Verma A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019612; Verma M., 2017, J ALLERGY CLIN IMMUN; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; Walker JA, 2018, NAT REV IMMUNOL, V18, P121, DOI 10.1038/nri.2017.118; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2491::AID-IMMU2491&gt;3.0.CO;2-R; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; Williams PB, 2016, J ALLER CL IMM-PRACT, V4, P386, DOI 10.1016/j.jaip.2015.11.016; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Wolf J, 2010, ENVIRON HEALTH PERSP, V118, P1223, DOI 10.1289/ehp.0901867; Yoon J, 2008, J IMMUNOL, V181, P2907, DOI 10.4049/jimmunol.181.4.2907; Zhang ZH, 2017, J ALLERGY CLIN IMMUN, V139, P54, DOI 10.1016/j.jaci.2016.02.031; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	130	49	51	3	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					353	363		10.1016/j.jaci.2018.06.015	http://dx.doi.org/10.1016/j.jaci.2018.06.015			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	30080527	Bronze, Green Accepted			2022-12-18	WOS:000440664400002
J	Heeringa, JJ; Karim, AF; van Laar, JAM; Verdijk, RM; Paridaens, D; van Hagen, PM; van Zelm, MC				Heeringa, Jorn J.; Karim, A. Faiz; van Laar, Jan A. M.; Verdijk, Robert M.; Paridaens, Dion; van Hagen, P. Martin; van Zelm, Menno C.			Expansion of blood IgG(4)(+) B, T(H)2, and regulatory T cells in patients with IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG(4); B cell; IgG(4)-related disease; T helper cell; regulatory T cell; plasma cell; flow cytometry; sarcoidosis; principal component analysis	IGG4-RELATED DISEASE; IMMUNOGLOBULIN G4; PLASMA-CELLS; IGG4; TH2; LYMPHOCYTES; MECHANISMS; RITUXIMAB; NAIVE; STANDARDIZATION	Background: IgG(4)-related disease (IgG(4)-RD) is a systemic fibroinflammatory condition affecting various organs and has a diverse clinical presentation. Fibrosis and accumulation of IgG(4)(+) plasma cells in tissue are hallmarks of the disease, and IgG(4)-RD is associated with increased IgG(4) serum levels. However, disease pathogenesis is still unclear, and these cellular and molecular parameters are neither sensitive nor specific for the diagnosis of IgG(4)-RD. Objective: Here we sought to develop a flow cytometric gating strategy to reliably identify blood IgG(4)(+) B cells to study their cellular and molecular characteristics and investigate their contribution in disease pathogenesis. Methods: Sixteen patients with histologically confirmed IgG(4)-RD, 11 patients with sarcoidosis, and 30 healthy subjects were included for 11-color flow cytometric analysis of peripheral blood for IgG(4)-expressing B cells and T-H subsets. In addition, detailed analysis of activation markers and chemokine receptors was performed on IgG(4)-expressing B cells, and IgG(4) transcripts were analyzed for somatic hypermutations. Results: Cellular and molecular analyses revealed increased numbers of blood IgG(4)(+) memory B cells in patients with IgG(4)-RD. These cells showed reduced expression of CD27 and CXCR5 and increased signs of antibody maturation. Furthermore, patients with IgG(4)-RD, but not patients with sarcoidosis, had increased numbers of circulating plasmablasts and CD21(low) B cells, as well as T(H)2 and regulatory T cells, indicating a common disease pathogenesis in patients with IgG(4)-RD. Conclusion: These results provide new insights into the dysregulated IgG(4) response in patients with IgG(4)-RD. A specific "peripheral lymphocyte signature" observed in patients with IgG(4)-RD, could support diagnosis and treatment monitoring.	[Heeringa, Jorn J.; Karim, A. Faiz; van Laar, Jan A. M.; van Hagen, P. Martin] Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands; [Karim, A. Faiz; van Laar, Jan A. M.; van Hagen, P. Martin] Erasmus MC, Univ Med Ctr, Dept Internal Med, Rotterdam, Netherlands; [Verdijk, Robert M.] Erasmus MC, Univ Med Ctr, Dept Pathol, Rotterdam, Netherlands; [Paridaens, Dion] Rotterdam Eye Hosp, Dept Oculoplast & Orbital Surg, Rotterdam, Netherlands; [van Zelm, Menno C.] Monash Univ, Dept Pathol & Immunol, Cent Clin Sch, Level 6 Burnet Ctr,89 Commercial Rd, Melbourne, Vic 3004, Australia; [van Zelm, Menno C.] Alfred Hosp, Melbourne, Vic, Australia	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Rotterdam Eye Hospital; Monash University; Florey Institute of Neuroscience & Mental Health	van Zelm, MC (corresponding author), Monash Univ, Dept Pathol & Immunol, Cent Clin Sch, Level 6 Burnet Ctr,89 Commercial Rd, Melbourne, Vic 3004, Australia.	menno.vanzelm@monash.edu	; van Zelm, Menno/O-4404-2015	Verdijk, Robert M/0000-0003-1437-214X; Paridaens, Dion/0000-0001-6762-3614; van Zelm, Menno/0000-0003-4161-1919	Sophia Children's Hospital Fund; National Health and Medical Research Council [GNT1117687]	Sophia Children's Hospital Fund; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	J. J. Heeringa has received a grant from Sophia Children's Hospital Fund. M. C. van Zelm has received grants from Sophia Children's Hospital Fund and the National Health and Medical Research Council (Senior Research Fellowship GNT1117687) and has patents EP 2780711 B1 for IgE expressing B cells and WO 2016068714 A2 for reagents, methods, and kits for diagnosing primary immunodeficiencies. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; AALBERSE RC, 1983, J IMMUNOL, V130, P722; Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Akdis CA, 2014, J CLIN INVEST, V124, P4678, DOI 10.1172/JCI78891; Akiyama M, 2015, ARTHRITIS RHEUMATOL, V67, P2476, DOI 10.1002/art.39209; ANDERSON CL, 1980, J IMMUNOL, V125, P2735; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Blanchard-Rohner G, 2009, BLOOD, V114, P4998, DOI 10.1182/blood-2009-03-211052; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Costa ES, 2010, LEUKEMIA, V24, P1927, DOI 10.1038/leu.2010.160; Culver EL, 2015, ANN RHEUM DIS, V74, P944, DOI 10.1136/annrheumdis-2014-206405; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Fischer T, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0113-5; Frulloni L, 2009, NEW ENGL J MED, V361, P2135, DOI 10.1056/NEJMoa0903068; Gomez-Cabrero D, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-S2-S4; Good KL, 2009, J IMMUNOL, V182, P890, DOI 10.4049/jimmunol.182.2.890; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jackson KJL, 2014, IMMUNOL CELL BIOL, V92, P729, DOI 10.1038/icb.2014.44; Jacobi AM, 2003, ARTHRITIS RHEUM, V48, P1332, DOI 10.1002/art.10949; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Kanari H, 2010, INT ARCH ALLERGY IMM, V152, P47, DOI 10.1159/000312125; Karim AF, 2016, NETH J MED, V74, P110; Karim F, 2017, OPHTHAL PLAST RECONS, V33, pS162, DOI 10.1097/IOP.0000000000000625; Karim F, 2017, NEW ENGL J MED, V376, P599, DOI 10.1056/NEJMc1614275; Karim F, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0079-3; Kelly DF, 2009, IMMUNOLOGY, V127, P134, DOI 10.1111/j.1365-2567.2008.02934.x; Khosroshahi A, 2014, ARTHRITIS RHEUMATOL, V66, P213, DOI 10.1002/art.38193; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Khosroshahi A, 2010, ARTHRITIS RHEUM-US, V62, P1755, DOI 10.1002/art.27435; Kuo TT, 2009, PATHOL INT, V59, P844, DOI 10.1111/j.1440-1827.2009.02456.x; Kusuda T, 2011, PANCREAS, V40, P1120, DOI 10.1097/MPA.0b013e31821fc796; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Lighaam LC, 2014, J ALLERGY CLIN IMMUN, V133, P267, DOI 10.1016/j.jaci.2013.07.044; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Mattoo H, 2014, ALLERGY, V69, P399, DOI 10.1111/all.12342; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Mattoo H, 2014, J ALLERGY CLIN IMMUN, V134, P679, DOI 10.1016/j.jaci.2014.03.034; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Miyake K, 2008, MOD RHEUMATOL, V18, P86, DOI 10.1007/s10165-007-0010-3; Miyoshi H, 2008, PANCREAS, V36, P133, DOI 10.1097/MPA.0b013e3181577553; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Narula N, 2010, DIGEST DIS SCI, V55, P3047, DOI 10.1007/s10620-010-1287-1; Ngwa TN, 2014, PANCREAS, V43, P704, DOI 10.1097/MPA.0000000000000118; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Saadoun D, 2013, ARTHRITIS RHEUM-US, V65, P1085, DOI 10.1002/art.37828; Sah RP, 2011, CURR OPIN RHEUMATOL, V23, P108, DOI 10.1097/BOR.0b013e3283413469; Stone JH, 2015, MAYO CLIN PROC, V90, P927, DOI 10.1016/j.mayocp.2015.03.020; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Tsuboi H, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3924; Umehara H, 2012, MOD RHEUMATOL, V22, P1, DOI 10.1007/s10165-011-0508-6; van Zelm MC, 2014, IMMUNOL CELL BIOL, V92, P645, DOI 10.1038/icb.2014.48; van Zelm MC, 2014, J ALLERGY CLIN IMMUN, V134, P135, DOI 10.1016/j.jaci.2013.11.015; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Warnatz K, 2002, IMMUNOBIOLOGY, V206, P502, DOI 10.1078/0171-2985-00198; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; Zen Y, 2007, MODERN PATHOL, V20, P884, DOI 10.1038/modpathol.3800836; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697	74	49	51	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1831	+		10.1016/j.jaci.2017.07.024	http://dx.doi.org/10.1016/j.jaci.2017.07.024			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28830675				2022-12-18	WOS:000432148200028
J	Khodoun, MV; Tomar, S; Tocker, JE; Wang, YH; Finkelman, FD				Khodoun, Marat V.; Tomar, Sunil; Tocker, Joel E.; Wang, Yui Hsi; Finkelman, Fred D.			Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; antibodies; cytokines; food allergy; mice; treatment; triglycerides	TYPE-2 IMMUNITY; INDUCED ANAPHYLAXIS; ATOPIC-DERMATITIS; MAST-CELLS; EOSINOPHILIC ESOPHAGITIS; EPITHELIAL-CELLS; ORAL TOLERANCE; UP-REGULATION; RESPONSES; PROMOTES	Background: Food allergy (FA) is an increasing problem that has no approved treatment. The pro-T(H)2 cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) are associated with FA, and mAbs to these cytokines are reported to suppress murine FA development. Objective: We sought to determine whether anti-pro-T(H)2 cytokine mAbs can block both FA maintenance and induction. Methods: IgE-mediated FA was induced in BALB/c mice by oral gavage with medium-chain triglycerides (MCTs) plus egg white (EW) and was characterized by increased numbers of lamina propria T(H)2 cells, mast cells, and eosinophils, shock (hypothermia), mast cell degranulation (increased serum mouse mast cell protease 1), increased serum IgG1 anti-EW and IgE levels, and increased IL-4 and IL-13 secretion after MCT/EW challenge. Mice were injected with anti-IL-25, IL-33 receptor, and/or TSLP mAbs before initial oral gavage with MCT/EW to suppress FA development; treatment with the same mAbs was initiated after FA development to suppress established FA. Results: Injection of an mAb to IL-25, IL-33 receptor, or TSLP strongly inhibited FA development. No single mAb to a pro-T(H)2 cytokine could suppress established FA, and optimal FA suppression required treatment with a cocktail of all 3 anti-proT(H)2 mAbs. Treatment with the 3-mAb cocktail during initial MCT/EW immunization induced EW tolerance. Conclusion: All of the pro-T(H)2 cytokines are required to induce our model of FA, whereas any pro-T(H)2 cytokine can maintain established FA. Pro-T(H)2 cytokines prevent oral tolerance. Combined treatment with antagonists to all 3 pro-T(H)2 cytokines or with an inhibitor of pro-T(H)2 cytokine production might be able to suppress established human FA.	[Khodoun, Marat V.; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH 45267 USA; [Khodoun, Marat V.] Cincinnati Dept Vet Affairs Med Ctr, Dept Res, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Dept Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Tocker, Joel E.] Inflammat Res Assoc, Narberth, Wales; [Tomar, Sunil; Wang, Yui Hsi] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Clin Immunol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Allergy Immunol & Rheumatol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	finkelfd@ucmail.uc.edu			US Department of Veterans Affairs; Food Allergy Research Education; National Institutes of Health [R01 AI112626-01, 2U19 AI070235-11]; Department of Defense [W81XWH-15-1-0517]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI112626, U19AI070235] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); Food Allergy Research Education; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Merit Award (to F.D.F. and M.V.K.) from the US Department of Veterans Affairs, a grant (to F.D.F. and M.V.K.) from Food Allergy Research & Education, National Institutes of Health grants R01 AI112626-01 (to Y.-H.W. and F.D.F.) and 2U19 AI070235-11 (to Y.-H.W.), and Department of Defense grant W81XWH-15-1-0517 (to Y.-H.W. and F.D.F.).	Aktar MK, 2015, ALLERGY, V70, P846, DOI 10.1111/all.12633; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Birmingham NP, 2007, INT ARCH ALLERGY IMM, V144, P203, DOI 10.1159/000103993; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Burks W, 2003, PEDIATRICS, V111, P1617; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Finkelman FD, 1999, INT IMMUNOL, V11, P1811, DOI 10.1093/intimm/11.11.1811; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Finkelman FD, 2003, CURRENT PROTOC IMMUN; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Judd LM, 2016, AM J PHYSIOL-GASTR L, V310, pG13, DOI 10.1152/ajpgi.00290.2015; Li JN, 2013, J ALLERGY CLIN IMMUN, V131, P442, DOI 10.1016/j.jaci.2012.10.011; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Sanderson C J, 1988, Dev Biol Stand, V69, P23; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Smith KA, 2012, INFECT IMMUN, V80, P3481, DOI 10.1128/IAI.00436-12; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wavrin S, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0047-x; Zhao AP, 2003, J IMMUNOL, V171, P948, DOI 10.4049/jimmunol.171.2.948; Zhu JF, 2010, CELL RES, V20, P4, DOI 10.1038/cr.2009.138	48	49	54	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					171	+		10.1016/j.jaci.2017.02.046	http://dx.doi.org/10.1016/j.jaci.2017.02.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28552763	Bronze			2022-12-18	WOS:000419312200023
J	Ohanyan, T; Schoepke, N; Bolukbasi, B; Metz, M; Hawro, T; Zuberbier, T; Peveling-Oberhag, A; Staubach, P; Maurer, M; Weller, K				Ohanyan, Tatevik; Schoepke, Nicole; Bolukbasi, Bediha; Metz, Martin; Hawro, Tomasz; Zuberbier, Torsten; Peveling-Oberhag, Adriane; Staubach, Petra; Maurer, Marcus; Weller, Karsten			Responsiveness and minimal important difference of the urticaria control test	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							QUALITY-OF-LIFE; OMALIZUMAB; VALIDATION; MANAGEMENT; INDEX		[Ohanyan, Tatevik; Schoepke, Nicole; Bolukbasi, Bediha; Metz, Martin; Hawro, Tomasz; Zuberbier, Torsten; Maurer, Marcus; Weller, Karsten] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany; [Peveling-Oberhag, Adriane; Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz	Weller, K (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany.	karsten.weller@charite.de	Maurer, Marcus/ABG-2174-2020; Metz, Martin/B-8799-2009	Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Zuberbier, Torsten/0000-0002-1466-8875; Hawro, Tomasz/0000-0001-9990-1332; Weller, Karsten/0000-0003-4437-0313	Urticaria Network eV; Urtikaria Netzwerk Berlin Brandenburg eV	Urticaria Network eV; Urtikaria Netzwerk Berlin Brandenburg eV	We thank all patients who made this study possible and the members of the Urticaria Specialty Clinic Berlin for their help during this project, especially Nicole Klameth, Nadja Tampier, Max Spindler, and Hesna Gozlukaya. We also thank Robert F. Ofenloch from Department of Clinical and Social Medicine, University Hospital Heidelberg, Germany, for helpful discussions related to the SDC data. Finally, we thank the Urticaria Network eV (www.urtikaria.net) and the Urtikaria Netzwerk Berlin Brandenburg eV (www.urtikaria-netzwerk-bb.de) for supporting this work.	Baiardini I, 2005, ALLERGY, V60, P1073, DOI 10.1111/j.1398-9995.2005.00833.x; Baiardini I, 2011, ALLERGY, V66, P840, DOI 10.1111/j.1398-9995.2011.02580.x; de Vet HC, 2011, MEASUREMENT MED PRAC, P241; de Vet HCW, 2010, J CLIN EPIDEMIOL, V63, P804, DOI 10.1016/j.jclinepi.2009.12.015; DEYO RA, 1986, J CHRON DIS, V39, P897, DOI 10.1016/0021-9681(86)90038-X; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Koti I, 2013, DERMATOLOGY, V226, P371, DOI 10.1159/000351711; Lennox RD, 2004, ANN ALLERG ASTHMA IM, V93, P142, DOI 10.1016/S1081-1206(10)61466-4; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Mlynek A, 2009, ALLERGY, V64, P927, DOI 10.1111/j.1398-9995.2008.01920.x; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 2015, J INVEST DERMATOL, V135, P67, DOI 10.1038/jid.2014.306; Staubach P, 2016, ALLERGY, V71, P1135, DOI 10.1111/all.12870; van der Roer N, 2006, SPINE, V31, P578, DOI 10.1097/01.brs.0000201293.57439.47; Weller K, 2013, J EUR ACAD DERMATOL, V27, P43, DOI 10.1111/j.1468-3083.2011.04370.x; Weller K, 2013, J EUR ACAD DERMATOL, V27, pe8, DOI 10.1111/j.1468-3083.2011.04387.x; Weller K, 2014, J ALLERGY CLIN IMMUN, V133, P1365, DOI 10.1016/j.jaci.2013.12.1076; Weller K, 2011, ARCH DERMATOL, V147, P1221, DOI 10.1001/archdermatol.2011.310; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	25	49	52	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1710	+		10.1016/j.jaci.2017.04.050	http://dx.doi.org/10.1016/j.jaci.2017.04.050			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28625805	Bronze			2022-12-18	WOS:000417206000029
J	Bartnikas, LM; Huffaker, MF; Sheehan, WJ; Kanchongkittiphon, W; Petty, CR; Leibowitz, R; Hauptman, M; Young, MC; Phipatanakul, W				Bartnikas, Lisa M.; Huffaker, Michelle F.; Sheehan, William J.; Kanchongkittiphon, Watcharoot; Petty, Carter R.; Leibowitz, Robert; Hauptman, Marissa; Young, Michael C.; Phipatanakul, Wanda			Impact of school peanut-free policies on epinephrine administration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; anaphylaxis; school; epinephrine	QUALITY-OF-LIFE; FOOD ALLERGY; TREE NUTS; CHILDREN; ADULTS; HEALTH	Background: Children with food allergies spend a large proportion of time in school but characteristics of allergic reactions in schools are not well studied. Some schools self-designate as peanut-free or have peanut-free areas, but the impact of policies on clinical outcomes has not been evaluated. Objective: We sought to determine the effect of peanut-free policies on rates of epinephrine administration for allergic reactions in Massachusetts public schools. Methods: In this retrospective study, we analyzed (1) rates of epinephrine administration in all Massachusetts public schools and (2) Massachusetts public school nurse survey reports of school peanut-free policies from 2006 to 2011 and whether schools self-designated as "peanut-free'' based on policies. Rates of epinephrine administration were compared for schools with or without peanut-restrictive policies. Results: The percentage of schools with peanut-restrictive policies did not change significantly in the study time frame. There was variability in policies used by schools self-designated as peanut-free. No policy was associated with complete absence of allergic reactions. Both self-designated peanut-free schools and schools banning peanuts from being served in school or brought from home reported allergic reactions to nuts. Policies restricting peanuts from home, served in schools, or having peanut-free classrooms did not affect epinephrine administration rates. Schools with peanut-free tables, compared to without, had lower rates of epinephrine administration (incidence rate per 10,000 students 0.2 and 0.6, respectively, P = .009). Conclusions: These data provide a basis for evidence-based school policies for children with food allergies. Further studies are required before decisions can be made regarding peanut-free policies in schools.	[Bartnikas, Lisa M.; Sheehan, William J.; Petty, Carter R.; Hauptman, Marissa; Young, Michael C.; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA USA; [Bartnikas, Lisa M.; Sheehan, William J.; Hauptman, Marissa; Young, Michael C.; Phipatanakul, Wanda] Harvard Med Sch, Boston, MA USA; [Huffaker, Michelle F.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA; [Kanchongkittiphon, Watcharoot] Childrens Hosp Michigan, Detroit, MI 48201 USA; [Leibowitz, Robert] Div Primary Care & Hlth Access, Sch Hlth Unit, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Stanford University; Children's Hospital of Michigan	Phipatanakul, W (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	wanda.phipatanakul@childrens.harvard.edu		Hauptman, Marissa/0000-0002-0028-8927	National Institutes of Health (NIH) [R01 AI 073964, U01 AI 110397, K24 AI 106822, K23 AI 104780]; NIH Pediatric Research Loan Repayment Program grant [L40 AI 113590]; Allergy and Asthma Awareness Initiative, Inc.; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources) [UL1 TR001102]; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000169, UL1TR000170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI126614, K23AI104780, K24AI106822, U01AI110397, K23AI106945] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Pediatric Research Loan Repayment Program grant; Allergy and Asthma Awareness Initiative, Inc.; Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health); Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research is supported by the National Institutes of Health (NIH grant nos. R01 AI 073964, U01 AI 110397, and K24 AI 106822; PI, W.P.; grant no. K23 AI 104780; PI, W.J.S.) and an NIH Pediatric Research Loan Repayment Program grant (grant no. L40 AI 113590; PI, L.M.B.). Funding was provided by The Allergy and Asthma Awareness Initiative, Inc. This work was conducted with support from Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award no. UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH.	Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bacal LR, 2013, PEDIATR ANN, V42, P141, DOI 10.3928/00904481-20130619-12; Banerjee DK, 2007, ARCH DIS CHILD, V92, P980, DOI 10.1136/adc.2006.113118; Carlisle SK, 2010, J SCH NURS, V26, P360, DOI 10.1177/1059840510369482; Centers for Disease Control and Prevention, 2013, VOL GUID MAN FOOD AL; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hostetler TL, 2012, ANN ALLERG ASTHMA IM, V108, P25, DOI 10.1016/j.anai.2011.09.012; Kao L, 2013, ANN ALLERG ASTHMA IM, V111, P282, DOI 10.1016/j.anai.2013.07.010; Knorr RS, 2004, ENVIRON HEALTH PERSP, V112, P1424, DOI 10.1289/ehp.7146; Lieberman JA, 2010, ANN ALLERG ASTHMA IM, V105, P282, DOI 10.1016/j.anai.2010.07.011; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; Longo G, 2013, LANCET, V382, P1656, DOI 10.1016/S0140-6736(13)60309-8; McIntyre CL, 2005, PEDIATRICS, V116, P1134, DOI 10.1542/peds.2004-1475; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; O'Neil CE, 2012, NUTR RES, V32, P185, DOI 10.1016/j.nutres.2012.01.005; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Robinson JM, 2012, J SCH NURS, V28, P187, DOI 10.1177/1059840511429686; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Shah SS, 2014, J ALLER CL IMM-PRACT, V2, P288, DOI 10.1016/j.jaip.2013.09.016; Shemesh E, 2013, PEDIATRICS, V131, pE10, DOI 10.1542/peds.2012-1180; Sicherer SH, 2010, PEDIATRICS, V126, P1232, DOI 10.1542/peds.2010-2575; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Young MC, 2009, J ALLERGY CLIN IMMUN, V124, P175, DOI 10.1016/j.jaci.2009.04.004; Zadikoff EH, 2014, J SCHOOL HEALTH, V84, P342, DOI 10.1111/josh.12147	26	49	50	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					465	473		10.1016/j.jaci.2017.01.040	http://dx.doi.org/10.1016/j.jaci.2017.01.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28347736	Green Accepted, Bronze			2022-12-18	WOS:000406855500019
J	Tangye, SG; Pillay, B; Randall, KL; Avery, DT; Phan, TG; Gray, P; Ziegler, JB; Smart, JM; Peake, J; Arkwright, PD; Hambleton, S; Orange, J; Goodnow, CC; Uzel, G; Casanova, JL; Reyes, SOL; Freeman, AF; Su, HC; Ma, CS				Tangye, Stuart G.; Pillay, Bethany; Randall, Katrina L.; Avery, Danielle T.; Tri Giang Phan; Gray, Paul; Ziegler, John B.; Smart, Joanne M.; Peake, Jane; Arkwright, Peter D.; Hambleton, Sophie; Orange, Jordan; Goodnow, Christopher C.; Uzel, Gulbu; Casanova, Jean-Laurent; Lugo Reyes, Saul Oswaldo; Freeman, Alexandra F.; Su, Helen C.; Ma, Cindy S.			Dedicator of cytokinesis 8-deficient CD4(+) T cells are biased to a T(H)2 effector fate at the expense of T(H)1 and T(H)17 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dedicator of cytokinesis 8; CD4(+) T-cell differentiation; T(H)2 skewing; allergy; atopic disease; chronic mucocutaneous candidiasis; viral immunity	HYPER-IGE SYNDROME; CHRONIC MUCOCUTANEOUS CANDIDIASIS; LINKED LYMPHOPROLIFERATIVE DISEASE; BONE-MARROW-TRANSPLANTATION; HUMAN B-CELLS; DOCK8 DEFICIENCY; ATOPIC-DERMATITIS; TH17 CELLS; MUTATIONS; MEMORY	Background: Dedicator of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency caused by autosomal recessive loss-of- function mutations in DOCK8. This disorder is characterized by recurrent cutaneous infections, increased serum IgE levels, and severe atopic disease, including food-induced anaphylaxis. However, the contribution of defects in CD4(+) T cells to disease pathogenesis in these patients has not been thoroughly investigated. Objective: We sought to investigate the phenotype and function of DOCK8-deficient CD4(+) T cells to determine (1) intrinsic and extrinsic CD4 1 T-cell defects and (2) how defects account for the clinical features of DOCK8 deficiency. Methods: We performed in-depth analysis of the CD4(+) T-cell compartment of DOCK8-deficient patients. We enumerated subsets of CD4(+) T helper cells and assessed cytokine production and transcription factor expression. Finally, we determined the levels of IgE specific for staple foods and house dust mite allergens in DOCK8-deficient patients and healthy control subjects. Results: DOCK8-deficient memory CD4 1 T cells were biased toward a T(H)2 type, and this was at the expense of T(H)1 and T(H)17 cells. In vitro polarization of DOCK8-deficient naive CD4(+) T cells revealed the TH2 bias and TH17 defect to be T-cell intrinsic. Examination of allergen-specific IgE revealed plasma IgE from DOCK8-deficient patients is directed against staple food antigens but not house dust mites. Conclusion: Investigations into the DOCK8-deficient CD4(+) T cells provided an explanation for some of the clinical features of this disorder: the T(H)2 bias is likely to contribute to atopic disease, whereas defects in T(H)1 and T(H)17 cells compromise antiviral and antifungal immunity, respectively, explaining the infectious susceptibility of DOCK8-deficient patients.	[Tangye, Stuart G.; Pillay, Bethany; Avery, Danielle T.; Tri Giang Phan; Goodnow, Christopher C.; Ma, Cindy S.] Garvan Inst Med Res, Div Immunol, Darlinghurst, NSW, Australia; [Tangye, Stuart G.; Pillay, Bethany; Tri Giang Phan; Goodnow, Christopher C.; Ma, Cindy S.] Univ New South Wales, St Vincents Clin Sch, Darlinghurst, NSW, Australia; [Randall, Katrina L.] John Curtin Sch Med Res, Dept Immunol, Acton, ACT, Australia; [Randall, Katrina L.] Australian Natl Univ, Sch Med, Acton, ACT, Australia; [Gray, Paul; Ziegler, John B.] Univ New South Wales, Sch Womens & Childrens Hlth, Randwick, NSW, Australia; [Smart, Joanne M.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Parkville, Vic, Australia; [Peake, Jane] Univ Queensland, Brisbane, Qld, Australia; [Peake, Jane] Lady Cilento Childrens Hosp, Brisbane, Qld, Australia; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester M13 9PL, Lancs, England; [Hambleton, Sophie] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Hambleton, Sophie] Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Orange, Jordan] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Ctr Human Immunobiol, Houston, TX 77030 USA; [Orange, Jordan] Baylor Coll Med, Dept Pediat, Div Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Orange, Jordan] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Orange, Jordan] Texas Childrens Hosp, Houston, TX 77030 USA; [Uzel, Gulbu; Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Su, Helen C.] NIAID, Lab Host Def, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Necker Branch, INSERM,U1163,Inst IMAGINE,Necker Med Sch, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol & Immunol Unit, Paris, France; [Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Lugo Reyes, Saul Oswaldo] Natl Inst Pediat, Immunodeficiencies Res Unit, Mexico City, DF, Mexico	Garvan Institute of Medical Research; University of New South Wales Sydney; Australian National University; John Curtin School of Medical Research; Australian National University; University of New South Wales Sydney; Royal Children's Hospital Melbourne; University of Queensland; Royal Manchester Children's Hospital; University of Manchester; Newcastle University - UK; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute	Tangye, SG; Ma, CS (corresponding author), Garvan Inst Med Res, Div Immunol, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	tangye@garvan.org.au; c.ma@garvan.org.au	Su, Helen C/H-9541-2015; Reyes, Saul O Lugo/AAP-7951-2021; Randall, Katrina L/F-1883-2013; Casanova, Jean-Laurent/I-3418-2017; S, Cindy/B-2340-2012; Tangye, Stuart G/H-4023-2014; Goodnow, Christopher C/V-8108-2018; Reyes, Saul O Lugo/AAS-7621-2021	Su, Helen C/0000-0002-5582-9110; Reyes, Saul O Lugo/0000-0002-3730-4150; S, Cindy/0000-0001-5387-8413; Tangye, Stuart G/0000-0002-5360-5180; Goodnow, Christopher C/0000-0001-5296-6155; Reyes, Saul O Lugo/0000-0002-3730-4150; Casanova, Jean-Laurent/0000-0002-7782-4169; Pillay, Bethany/0000-0001-7964-544X; Peake, Jane/0000-0001-9003-5861; Gray, Paul/0000-0003-2057-3968; orange, jordan/0000-0001-7117-7725; Hambleton, Sophie/0000-0001-7954-3267	National Health and Medical Research Council (NHMRC) of Australia [1060303, 596813, 1016953, 1022922]; Rockefeller University Center for Clinical and Translational Science [5UL1RR024143]; Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases; NHMRC of Australia [1008820, 1042925]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001193] Funding Source: NIH RePORTER; The Sir Jules Thorn Charitable Trust [12JTA] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Rockefeller University Center for Clinical and Translational Science; Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); The Sir Jules Thorn Charitable Trust	Supported by research grants awarded by the National Health and Medical Research Council (NHMRC) of Australia (to C.S.M. and S.G.T.: 1060303, 596813, and 1016953; to K.L.R.: 1022922), and Rockefeller University Center for Clinical and Translational Science (5UL1RR024143 to J.-L.C.). This research was supported in part by the Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases. C.S.M. is a recipient of a Career Development Fellowship (1008820), and S.G.T. is a Principal Research Fellowship (1042925) from the NHMRC of Australia and a Fulbright Senior Scholar.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Altin JA, 2011, J ALLERGY CLIN IMMUN, V127, P1277, DOI 10.1016/j.jaci.2010.12.1081; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Azik F, 2015, TURKISH J PEDIATR, V57, P112; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Berglund LJ, 2013, BLOOD, V122, P3940, DOI 10.1182/blood-2013-06-506865; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Boisson B, 2013, IMMUNITY, V39, P676, DOI 10.1016/j.immuni.2013.09.002; Boisson-Dupuis S, 2015, IMMUNOL REV, V264, P103, DOI 10.1111/imr.12272; Boos AC, 2014, ALLERGY, V69, P943, DOI 10.1111/all.12416; Boztug H, 2012, PEDIATR HEMAT ONCOL, V29, P585, DOI 10.3109/08880018.2012.714844; Brandt K, 2002, SCAND J IMMUNOL, V56, P572, DOI 10.1046/j.1365-3083.2002.01170.x; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; Crawford G, 2013, BLOOD, V122, P2052, DOI 10.1182/blood-2013-02-482331; Dasouki M, 2011, CLIN IMMUNOL, V141, P128, DOI 10.1016/j.clim.2011.06.003; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Deenick EK, 2013, J EXP MED, V210, P2739, DOI 10.1084/jem.20130323; Engelhardt KR, 2015, J ALLERGY CLIN IMMUN, V136, P402, DOI 10.1016/j.jaci.2014.12.1945; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Flesch IEA, 2015, IMMUNOL CELL BIOL, V93, P517, DOI 10.1038/icb.2015.32; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Gomez-Rodriguez J, 2009, IMMUNITY, V31, P587, DOI 10.1016/j.immuni.2009.07.009; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Happel CS, 2016, J ALLERGY CLIN IMMUN, V137, P1895, DOI 10.1016/j.jaci.2015.11.017; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Ives ML, 2013, J ALLERGY CLIN IMMUN, V132, P400, DOI 10.1016/j.jaci.2013.05.029; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Janssen E, 2014, J ALLERGY CLIN IMMUN, V134, P1365, DOI 10.1016/j.jaci.2014.07.042; Janssen E, 2014, CLIN IMMUNOL, V150, P220, DOI 10.1016/j.clim.2013.12.006; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Kastirr I, 2015, J IMMUNOL, V195, P3617, DOI 10.4049/jimmunol.1501016; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Ling Y, 2015, J EXP MED, V212, P619, DOI 10.1084/jem.20141065; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2016, J EXP MED, V213, P1589, DOI 10.1084/jem.20151467; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Ma CS, 2005, J CLIN INVEST, V115, P1049, DOI 10.1172/JCI23139; Ma CS, 2004, IMMUNOL CELL BIOL, V82, P67, DOI 10.1046/j.0818-9641.2003.01206.x; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Moens L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00065; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; Plunkett FJ, 2005, MECH AGEING DEV, V126, P855, DOI 10.1016/j.mad.2005.03.006; Puel A, 2008, J IMMUNOL, V180, P647, DOI 10.4049/jimmunol.180.1.647; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Ruusala A, 2004, FEBS LETT, V572, P159, DOI 10.1016/j.febslet.2004.06.095; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Singh SP, 2008, J IMMUNOL, V180, P214, DOI 10.4049/jimmunol.180.1.214; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; Su HC, 2011, ANN NY ACAD SCI, V1246, P26, DOI 10.1111/j.1749-6632.2011.06295.x; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Zhang Q, 2014, J EXP MED, V211, P2549, DOI 10.1084/jem.20141307; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	71	49	51	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					933	949		10.1016/j.jaci.2016.07.016	http://dx.doi.org/10.1016/j.jaci.2016.07.016			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27554822	Green Accepted			2022-12-18	WOS:000397295800026
J	Min, JY; Ocampo, CJ; Stevens, WW; Price, CPE; Thompson, CF; Homma, T; Huang, JH; Norton, JE; Suh, LA; Pothoven, KL; Conley, DB; Welch, KC; Shintani-Smith, S; Peters, AT; Grammer, LC; Harris, KE; Hulse, KE; Kato, A; Modyanov, NN; Kern, RC; Schleimer, RP; Tan, BK				Min, Jin-Young; Ocampo, Christopher J.; Stevens, Whitney W.; Price, Caroline P. E.; Thompson, Christopher F.; Homma, Tetsuya; Huang, Julia H.; Norton, James E.; Suh, Lydia A.; Pothoven, Kathryn L.; Conley, David B.; Welch, Kevin C.; Shintani-Smith, Stephanie; Peters, Anju T.; Grammer, Leslie C., III; Harris, Kathleen E.; Hulse, Kathryn E.; Kato, Atsushi; Modyanov, Nikolai N.; Kern, Robert C.; Schleimer, Robert P.; Tan, Bruce K.			Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H, K-ATPase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; eotaxin-1/CCL11; eotaxin-2/CCL24; eotaxin-3/CCL26; omeprazole; proton pump inhibitors; IL-13; epithelial cells; H(+)-K(+)-exchanging ATPase; eosinophils	INNATE LYMPHOID-CELLS; EPITHELIAL-CELLS; EOSINOPHILIC ESOPHAGITIS; GENE-EXPRESSION; AIRWAY ACIDIFICATION; GASTRIC H,K-ATPASE; ATP1AL1 GENE; INTERLEUKIN-13; ASTHMA; PH	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by tissue eosinophilia that is associated with poor prognosis. Recent findings that proton pump inhibitors (PPIs) directly modulate the expression of eotaxin-3, an eosinophil chemoattractant, in patients with eosinophilic diseases suggest therapeutic potential for PPIs in those with CRSwNP. Objective: We assessed the effect of type 2 mediators, particularly IL-13 and eotaxin-3, on tissue eosinophilia and disease severity in patients with chronic rhinosinusitis (CRS). Further investigation focused on PPI suppression of eotaxin-3 expression in vivo and in vitro, with exploration of underlying mechanisms. Methods: Type 2 mediator levels in nasal tissues and secretions were measured by using a multiplex immunoassay. Eotaxin-3 and other chemokines expressed in IL-13-stimulated human sinonasal epithelial cells (HNECs) and BEAS-2B cells with or without PPIs were assessed by using ELISA, Western blotting, real-time PCR, and intracellular pH imaging. Results: Nasal tissues and secretions from patients with CRSwNP had increased IL-13, eotaxin-2, and eotaxin-3 levels, and these were positively correlated with tissue eosinophil CRS (P < .05). IL-13 stimulation of HNECs and BEAS-2B cells dominantly induced eotaxin-3 expression, which was significantly inhibited by PPIs (P < .05). Patients with CRS taking PPIs also showed lower in vivo eotaxin-3 levels compared with those without PPIs (P < .05). Using intracellular pH imaging and altering extracellular K+, we found that IL-13 enhanced H+, K+-exchange, which was blocked by PPIs and the mechanistically unrelated H, K-ATPase inhibitor, SCH-28080. Furthermore, knockdown of ATP12A (gene for the nongastric H, K-ATPase) significantly attenuated IL-13-induced eotaxin-3 expression in HNECs. PPIs also had effects on accelerating IL-13-induced eotaxin-3 mRNA decay. Conclusion: Our results demonstrated that PPIs reduce IL-13-induced eotaxin-3 expression by airway epithelial cells. Furthermore, mechanistic studies suggest that the nongastric H, K-ATPase is necessary for IL-13-mediated epithelial responses, and its inhibitors, including PPIs, might be of therapeutic value in patients with CRSwNP by reducing epithelial production of eotaxin-3.	[Min, Jin-Young; Price, Caroline P. E.; Thompson, Christopher F.; Huang, Julia H.; Conley, David B.; Welch, Kevin C.; Shintani-Smith, Stephanie; Kato, Atsushi; Kern, Robert C.; Schleimer, Robert P.; Tan, Bruce K.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, 676 North St Clair,Suite 1325, Chicago, IL 60611 USA; [Ocampo, Christopher J.; Stevens, Whitney W.; Homma, Tetsuya; Norton, James E.; Suh, Lydia A.; Pothoven, Kathryn L.; Peters, Anju T.; Grammer, Leslie C., III; Harris, Kathleen E.; Hulse, Kathryn E.; Kato, Atsushi; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Homma, Tetsuya] Showa Univ, Sch Med, Dept Internal Med, Div Resp Med & Allergol, Tokyo, Japan; [Modyanov, Nikolai N.] Univ Toledo, Dept Physiol & Pharmacol, Coll Med, 2801 W Bancroft St, Toledo, OH 43606 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Showa University; University System of Ohio; University of Toledo	Tan, BK (corresponding author), Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, 676 North St Clair,Suite 1325, Chicago, IL 60611 USA.	b-tan@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138; /0000-0002-9590-7419	National Institutes of Health (NIH) [K23DC012067]; Chronic Rhinosinusitis Integrative Studies Program (CRISP) [U19 AI106683]; Triological Society/American College of Surgeon; Ernest S. Bazley Foundation;  [R01 HL078860];  [R01 HL068546];  [R01 AI072570];  [R01 AI104733]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS023011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, P01AI106683, R01AI104733, U19AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chronic Rhinosinusitis Integrative Studies Program (CRISP); Triological Society/American College of Surgeon; Ernest S. Bazley Foundation; ; ; ; ; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health (NIH) grant K23DC012067 (to B.K.T.); Chronic Rhinosinusitis Integrative Studies Program (CRISP) U19 AI106683 (to B.K.T., R.C.K., K.E.H, A.K., and R.P.S.); R01 HL078860, R01 HL068546, R01 AI072570, and R01 AI104733; the Triological Society/American College of Surgeons; (to B.K.T.) and the Ernest S. Bazley Foundation.	Altman KW, 2011, OTOLARYNG HEAD NECK, V145, P783, DOI 10.1177/0194599811415589; Arppe R, 2014, NANOSCALE, V6, P6837, DOI 10.1039/c4nr00461b; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, INT J BIOCHEM CELL B, V37, P2559, DOI 10.1016/j.biocel.2005.06.010; Carlo C, 2005, WORLD J GASTROENTERO, V11, P7657, DOI 10.3748/wjg.v11.i48.7657; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Cho DY, 2009, AM J RHINOL ALLERGY, V23, pE10, DOI 10.2500/ajra.2009.23.3389; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; Danahay H, 2002, AM J PHYSIOL-LUNG C, V282, pL226, DOI 10.1152/ajplung.00311.2001; De Corso E, 2011, RHINOLOGY, V49, P174, DOI 10.4193/Rhino10.133; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1067/MAI.2002.130051; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Gu ZW, 2011, OTOLARYNG HEAD NECK, V145, P324, DOI 10.1177/0194599811403077; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Heiman AS, 2005, J INTERF CYTOK RES, V25, P82, DOI 10.1089/jir.2005.25.82; Heller NM, 2004, AM J RESP CELL MOL, V31, P573, DOI 10.1165/rcmb.2004-0195OC; HOWDEN CW, 1984, EUR J CLIN PHARMACOL, V26, P641, DOI 10.1007/BF00543502; Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kirchheiner J, 2009, EUR J CLIN PHARMACOL, V65, P19, DOI 10.1007/s00228-008-0576-5; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082; Lamkhioued B, 2000, AM J RESP CRIT CARE, V162, P723, DOI 10.1164/ajrccm.162.2.9901080; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Larose MC, 2015, J ALLERGY CLIN IMMUN, V136, P904, DOI 10.1016/j.jaci.2015.02.039; Li XQ, 2004, DRUG METAB DISPOS, V32, P821, DOI 10.1124/dmd.32.8.821; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Lucendo AJ, 2016, CLIN GASTROENTEROL H, V14, P13, DOI 10.1016/j.cgh.2015.07.041; Matsui MS, 2015, J INVEST DERMATOL, V135, P834, DOI 10.1038/jid.2014.461; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Modyanov N, 2003, ANN NY ACAD SCI, V986, P183, DOI 10.1111/j.1749-6632.2003.tb07158.x; MODYANOV NN, 1991, FEBS LETT, V278, P91, DOI 10.1016/0014-5793(91)80091-G; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; Nakayama T, 2011, RHINOLOGY, V49, P392, DOI 10.4193/Rhino10.261; Neilsen CV, 2010, CLIN EXP ALLERGY, V40, P427, DOI 10.1111/j.1365-2222.2009.03419.x; Okushi T, 2013, AURIS NASUS LARYNX, V40, P548, DOI 10.1016/j.anl.2013.04.010; Padia R, 2016, LARYNGOSCOPE, V126, P1279, DOI 10.1002/lary.25798; Park JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101391; Pawar S, 2007, AM J RHINOL, V21, P695, DOI 10.2500/ajr.2007.21.3098; Pearlman AN, 2008, CURR OPIN OTOLARYNGO, V16, P226, DOI 10.1097/MOO.0b013e3282fdcc9a; Pestov NB, 2006, AM J PHYSIOL-CELL PH, V291, pC366, DOI 10.1152/ajpcell.00042.2006; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Provost V, 2013, J LEUKOCYTE BIOL, V94, P213, DOI 10.1189/jlb.0212074; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Sauty A, 1999, J IMMUNOL, V162, P3549; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Schulz E, 2011, CIRCULATION, V124, P1806, DOI 10.1161/CIRCULATIONAHA.111.061226; Shah VS, 2016, SCIENCE, V351, P503, DOI 10.1126/science.aad5589; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin JM, 2013, J NEUROGASTROENTEROL, V19, P25, DOI 10.5056/jnm.2013.19.1.25; Shin JM, 2009, PFLUG ARCH EUR J PHY, V457, P609, DOI 10.1007/s00424-008-0495-4; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; Soler ZM, 2010, OTOLARYNG HEAD NECK, V142, P64, DOI 10.1016/j.otohns.2009.10.005; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Swarts HGP, 2005, J BIOL CHEM, V280, P33115, DOI 10.1074/jbc.M504535200; Tajiri T, 2013, ANN ALLERG ASTHMA IM, V110, P387, DOI 10.1016/j.anai.2013.01.024; Takabayashi T, 2013, J ALLERGY CLIN IMMUN, V132, P584, DOI 10.1016/j.jaci.2013.02.003; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Vaezi MF, 2010, GASTROENTEROLOGY, V139, P1887, DOI 10.1053/j.gastro.2010.08.039; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; van den Berg JG, 2002, AM J PHYSIOL-RENAL, V282, pF26, DOI 10.1152/ajprenal.0102.2001; Watanabe K, 2002, J IMMUNOL, V168, P1911, DOI 10.4049/jimmunol.168.4.1911; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; WHA BI, 1985, J BIOL CHEM, V260, P4591; Yoshii K, 2015, BIOCHEMISTRY-US, V54, P250, DOI 10.1021/bi5008518; Yuan Q, 2006, EUR J IMMUNOL, V36, P2700, DOI 10.1002/eji.200636112; Zhang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050037	84	49	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					130	+		10.1016/j.jaci.2016.07.020	http://dx.doi.org/10.1016/j.jaci.2016.07.020			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27717558	Green Accepted, Bronze			2022-12-18	WOS:000393996800015
J	Brunner, PM; Khattri, S; Garcet, S; Finney, R; Oliva, M; Dutt, R; Fuentes-Duculan, J; Zheng, XZ; Li, X; Bonifacio, KM; Kunjravia, N; Coats, I; Cueto, I; Gilleaudeau, P; Sullivan-Whalen, M; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Brunner, Patrick M.; Khattri, Saakshi; Garcet, Sandra; Finney, Robert; Oliva, Margeaux; Dutt, Riana; Fuentes-Duculan, Judilyn; Zheng, Xiuzhong; Li, Xuan; Bonifacio, Kathleen M.; Kunjravia, Norma; Coats, Israel; Cueto, Inna; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; triamcinolone acetonide; topical glucocorticosteroids; immune; epidermal	DENDRITIC CELLS; IMMUNE; BARRIER; PIMECROLIMUS; EXPRESSION; ACTIVATION; GUIDELINES; MANAGEMENT; THERAPIES; SHOWS	Background: Topical glucocorticosteroids are considered an efficient treatment option for atopic dermatitis (AD), but a global assessment of glucocorticosteroid responses on key disease circuits upon weeks to months of treatment is currently lacking. Objective: We sought to assess short (4 weeks) and long-term (16 weeks) application of topical glucocorticosteroids on AD skin and define response biomarkers. Methods: The effects of triamcinolone acetonide cream 0.025% were assessed based on gene expression and immunohistochemistry studies at baseline, 4 weeks, and 16 weeks in biopsy specimens from 15 patients with moderate-to-severe AD. Results: At 16 weeks, only 3 patients were clinical responders (by using SCORAD50 criteria), but 6 patients qualified as responders based on histologic criteria. Baseline characteristics indicated more severe disease in nonresponders. While 3 of 15 patients experienced only transient benefit after 4 weeks, others showed progressive improvements toward 16 weeks. Topical glucocorticosteroid use in patients with AD resulted in improvements of the AD genomic signature of 25.6% at 4 weeks and 71.8% at 16 weeks, respectively, and even 123.9% in the histologic responder group. Cytokines (IL-12p40, IL-13, IL-22, CCL17, CCL18, peptidase inhibitor 3 [PI3]/elafin, and S100As) showed consistent decreases from baseline toward 16 weeks with corresponding improvements in epidermal disease hallmarks (keratin 16 and loricrin) in lesional skin from responders (P < .05). Nonresponders largely showed lesser/nonsignificant reductions in key inflammatory and barrier markers (keratin 16, IL-13, IL-22, CCL17, CCL18, PI3/elafin, S100As, and loricrin). The combination of IL-21 and IFN-gamma baseline expression closely predicted individual clinical glucocorticosteroid responses at 16 weeks of treatment. Conclusion: Our study indicates that even low-potency glucocorticosteroids can broadly affect immune and barrier responses in patients with moderate-to-severe AD, associating higher baseline severity with increased steroid resistance in patients with AD.	[Brunner, Patrick M.; Khattri, Saakshi; Garcet, Sandra; Oliva, Margeaux; Dutt, Riana; Fuentes-Duculan, Judilyn; Zheng, Xiuzhong; Li, Xuan; Bonifacio, Kathleen M.; Kunjravia, Norma; Coats, Israel; Cueto, Inna; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA; [Khattri, Saakshi; Oliva, Margeaux; Dutt, Riana; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA; [Khattri, Saakshi; Oliva, Margeaux; Dutt, Riana; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY USA; [Finney, Robert] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol Mt Sinai, New York, NY USA; [Suarez-Farinas, Mayte] Jefferson Med Coll, Dept Dermatol, Philadelphia, PA USA	Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Jefferson University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org		Garcet, Sandra/0000-0002-4465-8547; Brunner, Patrick/0000-0002-3488-3345; Sanyal, Riana/0000-0002-6638-9026	National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1 TR00043]	National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	P.M.B. and M.S.-F. were supported in part by grant UL1 TR00043 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.	Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Brazzini Benedetta, 2002, Am J Clin Dermatol, V3, P47; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harcharik Sara, 2014, Skin Therapy Lett, V19, P5; Hengge UR, 2006, J AM ACAD DERMATOL, V54, P1, DOI 10.1016/j.jaad.2005.01.010; Hoetzenecker W, 2004, J INVEST DERMATOL, V122, P673, DOI 10.1111/j.0022-202X.2004.22324.x; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Jensen JM, 2013, ACTA DERM-VENEREOL, V93, P515, DOI 10.2340/00015555-1533; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; Mizuno K, 2015, J DERMATOL SCI, V80, P45, DOI 10.1016/j.jdermsci.2015.06.016; Mohan GC, 2015, JAMA DERMATOL, V151, P1009, DOI 10.1001/jamadermatol.2015.0250; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Norris DA, 2005, J AM ACAD DERMATOL, V53, pS17, DOI 10.1016/j.jaad.2005.04.027; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P1218, DOI 10.1016/j.jaad.2014.08.038; SINGH G, 1986, INT J DERMATOL, V25, P324, DOI 10.1111/j.1365-4362.1986.tb02258.x; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683	43	49	53	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					169	178		10.1016/j.jaci.2015.12.1323	http://dx.doi.org/10.1016/j.jaci.2015.12.1323			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26948076				2022-12-18	WOS:000379659100019
J	Romano, A; Gaeta, F; Valluzzi, RL; Maggioletti, M; Caruso, C; Quaratino, D				Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Maggioletti, Michela; Caruso, Cristiano; Quaratino, Donato			Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aztreonam; cephalosporins; challenges; cross-reactivity; nonimmediate reactions; penicillins; tolerability; skin tests	BETA-LACTAM ANTIBIOTICS; EVALUATING NONIMMEDIATE REACTIONS; SKIN-TEST; DRUG HYPERSENSITIVITY; ALLERGIC REACTIONS; IMMEDIATE HYPERSENSITIVITY; DELAYED-HYPERSENSITIVITY; DIAGNOSIS; CARBAPENEMS; AMINOPENICILLINS	Background: The few studies performed in adults with T cell-mediated hypersensitivity to penicillins have found a rate of cross-reactivity with cephalosporins ranging from 2.8% to 31.2% and an absence of cross-reactivity with aztreonam. Objective: We sought to evaluate the possibility of using cephalosporins and aztreonam in subjects with documented delayed hypersensitivity to penicillins who especially req(u)ire them. Methods: We conducted a prospective study of 214 consecutive subjects who had 307 nonimmediate reactions to penicillins (almost exclusively aminopenicillins) and had positive patch test and/or delayed-reading skin test responses to at least 1 penicillin reagent. To assess cross-reactivity with cephalosporins and aztreonam and the tolerability of such alternative beta-lactams, all subjects underwent skin tests with cephalexin, cefaclor, cefadroxil, cefuroxime, ceftriaxone, and aztreonam. Subjects with negative responses were challenged with the alternative beta-lactams concerned. Results: All subjects had negative skin test results to cefuroxime, ceftriaxone, and aztreonam and tolerated challenges. Forty (18.7%) of the 214 subjects had positive skin test responses to at least 1 aminocephalosporin. Of the 174 subjects with negative responses, 170 underwent challenges; 1 reacted to cefaclor. Conclusions: These data demonstrate a rate of cross-reactivity between aminopenicillins and aminocephalosporins (ie, cephalexin, cefaclor, and cefadroxil) of around 20%, as well as the absence of cross-reactivity between penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-mediated hypersensitivity to penicillins, almost exclusively aminopenicillins. Therefore these subjects could be treated with cefuroxime, ceftriaxone, and aztreonam. In those who especially require cephalosporin or aztreonam treatment, however, we recommend pretreatment skin tests because negative responses indicate tolerability.	[Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Maggioletti, Michela; Caruso, Cristiano] Complesso Integrato Columbus, Allergy Unit, Via G Moscati 31, I-00168 Rome, Italy; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy; [Quaratino, Donato] IDI IRCCS, Ambulatorio Allergol, Capranica, Italy	IRCCS Oasi Maria SS	Romano, A (corresponding author), Complesso Integrato Columbus, Allergy Unit, Via G Moscati 31, I-00168 Rome, Italy.	aromano.allergy@gmail.com	caruso, cristiano/AAR-9502-2020; Valluzzi, Rocco Luigi/Q-3879-2019; Romano, Antonino/D-3102-2017; Gaeta, Francesco/AAC-7107-2020	caruso, cristiano/0000-0001-7631-029X; Valluzzi, Rocco Luigi/0000-0003-0029-6254; Romano, Antonino/0000-0001-9742-9898; Gaeta, Francesco/0000-0003-2942-7633	MURST (Italian Ministry for University, Scientific and Technological Research)	MURST (Italian Ministry for University, Scientific and Technological Research)(Ministry of Education, Universities and Research (MIUR))	Supported by MURST (Italian Ministry for University, Scientific and Technological Research).	ADKINSON NF, 1984, ANTIMICROB AGENTS CH, V25, P93, DOI 10.1128/AAC.25.1.93; Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; Brockow K, 2002, ALLERGY, V57, P45; Buonomo A, 2011, INT ARCH ALLERGY IMM, V155, P155, DOI 10.1159/000318844; Buonomo A, 1991, J ALLERGY CLIN IMMUN, V87, P78; Caimmi S, 2010, INT ARCH ALLERGY IMM, V153, P53, DOI 10.1159/000301579; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Gaeta F, 2015, J ALLERGY CLIN IMMUN, V135, P972, DOI 10.1016/j.jaci.2014.10.011; Liu XD, 2011, INT J CLIN PHARM TH, V49, P206, DOI 10.5414/CPP49206; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; Park MA, 2010, INT ARCH ALLERGY IMM, V153, P268, DOI 10.1159/000314367; Patriarca G, 2008, INT J IMMUNOPATH PH, V21, P375, DOI 10.1177/039463200802100215; Patriarca G, 1999, ANN ALLERG ASTHMA IM, V83, P257, DOI 10.1016/S1081-1206(10)62650-6; Patriarca G, 1996, J INVEST ALLERG CLIN, V6, P162; Phillips E, 2001, ALLERGY, V56, P790, DOI 10.1034/j.1398-9995.2001.056008790.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Romano A, 2007, ALLERGY, V62, P53, DOI 10.1111/j.1398-9995.2006.01272.x; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; ROMANO A, 1993, CONTACT DERMATITIS, V28, P190, DOI 10.1111/j.1600-0536.1993.tb03389.x; Romano A, 2005, CLIN EXP ALLERGY, V35, P1234, DOI 10.1111/j.1365-2222.2005.02317.x; Romano A, 2004, ALLERGY, V59, P1153, DOI 10.1111/j.1398-9995.2004.00678.x; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; Romano A, 2013, ALLERGY, V68, P1618, DOI 10.1111/all.12299; Romano A, 1999, J ALLERGY CLIN IMMUN, V104, P1113, DOI 10.1016/S0091-6749(99)70100-4; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2010, ALLERGY, V65, P1104, DOI 10.1111/j.1398-9995.2009.02318.x; Romano A, 2015, J ALLERGY CLIN IMMUN, V136; Romano A, 2007, ANN INTERN MED, V146, P266, DOI 10.7326/0003-4819-146-4-200702200-00005; Romano A, 2012, J ALLERGY CLIN IMMUN, V129, P1166, DOI 10.1016/j.jaci.2011.12.995; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Romano A, 2010, J ALLERGY CLIN IMMUN, V126, P994, DOI 10.1016/j.jaci.2010.06.052; Sastre J, 1996, ALLERGY, V51, P383, DOI 10.1111/j.1398-9995.1996.tb04634.x; SAXON A, 1985, AM J MED, V78, P19, DOI 10.1016/0002-9343(85)90198-6; Schiavino D, 2006, INT J IMMUNOPATH PH, V19, P831, DOI 10.1177/039463200601900412; Testi S, 2010, J INVEST ALLERG CLIN, V20, P171; Torres MJ, 2004, ALLERGY, V59, P219, DOI 10.1046/j.1398-9995.2003.00308.x; Trcka J, 2007, J ANTIMICROB CHEMOTH, V60, P107, DOI 10.1093/jac/dkm146; VEGA JM, 1991, ALLERGY, V46, P196, DOI 10.1111/j.1398-9995.1991.tb00570.x	43	49	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					179	186		10.1016/j.jaci.2016.01.025	http://dx.doi.org/10.1016/j.jaci.2016.01.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27016799	Bronze			2022-12-18	WOS:000379659100020
J	Kirchner, B; Pfaffl, MW; Dumpler, J; von Mutius, E; Ege, MJ				Kirchner, Benedikt; Pfaffl, Michael W.; Dumpler, Joseph; von Mutius, Erika; Ege, Markus J.			microRNA in native and processed cow's milk and its implication for the farm milk effect on asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONSUMPTION; CELLS		[Kirchner, Benedikt; Pfaffl, Michael W.] Tech Univ Munich, Anim Sci Physiol, Freising Weihenstephan, Germany; [Dumpler, Joseph] Tech Univ Munich, Food Proc Engn & Dairy Technol, Freising Weihenstephan, Germany; [von Mutius, Erika; Ege, Markus J.] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany	Technical University of Munich; Technical University of Munich; University of Munich	Ege, MJ (corresponding author), Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany.	markus.ege@med.lmu.de	Pfaffl, Michael/G-6622-2013; Dumpler, Joseph/AAD-8536-2020; Ege, Markus/C-1962-2012	Pfaffl, Michael/0000-0002-3192-1019; Ege, Markus/0000-0001-6643-3923; Dumpler, Joseph/0000-0002-7877-2479; Kirchner, Benedikt/0000-0003-3878-0148; von Mutius, Erika/0000-0002-8893-4515				Baier SR, 2014, J NUTR, V144, P1495, DOI 10.3945/jn.114.196436; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Litonjua AA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-52; Loss G, 2015, J ALLERGY CLIN IMMUN, V135, P56, DOI 10.1016/j.jaci.2014.08.044; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Xue LZ, 2012, J IMMUNOL, V188, P694, DOI 10.4049/jimmunol.1102474	10	49	50	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1893	+		10.1016/j.jaci.2015.10.028	http://dx.doi.org/10.1016/j.jaci.2015.10.028			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26707195				2022-12-18	WOS:000377527200035
J	Kulkarni, U; Karsten, CM; Kohler, T; Hammerschmidt, S; Bommert, K; Tiburzy, B; Meng, LZ; Thieme, L; Recke, A; Ludwig, RJ; Pollok, K; Kalies, K; Bogen, B; Boettcher, M; Kamradt, T; Hauser, AE; Langer, C; Huber-Lang, M; Finkelman, FD; Kohl, J; Wong, DM; Manz, RA				Kulkarni, Upasana; Karsten, Christian M.; Kohler, Thomas; Hammerschmidt, Sven; Bommert, Kurt; Tiburzy, Benjamin; Meng, Lingzhang; Thieme, Lara; Recke, Andreas; Ludwig, Ralf J.; Pollok, Karolin; Kalies, Kathrin; Bogen, Bjarne; Boettcher, Martin; Kamradt, Thomas; Hauser, Anja E.; Langer, Christian; Huber-Lang, Markus; Finkelman, Fred D.; Koehl, Joerg; Wong, David M.; Manz, Rudolf Armin			IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasmacytosis; IL-10; immunodeficiency; neutrophil; inflammation	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CELL-DERIVED IL-10; MULTIPLE-MYELOMA; BONE-MARROW; B-CELLS; AUTOIMMUNE-DISEASE; PLASMA-CELLS; INFECTIOUS-DISEASES; CEREBRAL MALARIA; INFLAMMATION	Background: Plasmacytosis (ie, an expansion of plasma cell populations to much greater than the homeostatic level) occurs in the context of various immune disorders and plasma cell neoplasia. This condition is often associated with immunodeficiency that causes increased susceptibility to severe infections. Yet a causative link between plasmacytosis and immunodeficiency has not been established. Objective: Because recent studies have identified plasma cells as a relevant source of the immunosuppressive cytokine IL-10, we sought to investigate the role of IL-10 during conditions of polyclonal and neoplastic plasmacytosis for the regulation of immunity and its effect on inflammation and immunodeficiency. Methods: We used flow cytometry, IL-10 reporter (Vert-X) and B cell-specific IL-10 knockout mice, migration assays, and antibody-mediated IL-10 receptor blockade to study plasmacytosis-associated IL-10 expression and its effect on inflammation and Streptococcus pneumoniae infection in mice. ELISA was used to quantify IL-10 levels in patients with myeloma. Results: IL-10 production was a common feature of normal and neoplastic plasma cells in mice, and IL-10 levels increased with myeloma progression in patients. IL-10 directly inhibited neutrophil migration toward the anaphylatoxin C5a and suppressed neutrophil-dependent inflammation in a murine model of autoimmune disease. MOPC.315.BM murine myeloma leads to an increased incidence of bacterial infection in the airways, which was reversed after IL-10 receptor blockade. Conclusion: We provide evidence that plasmacytosis-associated overexpression of IL-10 inhibits neutrophil migration and neutrophil-mediated inflammation but also promotes immunodeficiency.	[Kulkarni, Upasana; Karsten, Christian M.; Tiburzy, Benjamin; Meng, Lingzhang; Thieme, Lara; Koehl, Joerg; Wong, David M.; Manz, Rudolf Armin] Med Univ Lubeck, Inst System Inflammat Res, Ratzeburger Allee 160, D-23538 Lubeck, Germany; [Recke, Andreas; Ludwig, Ralf J.] Med Univ Lubeck, Inst Expt Dermatol, D-23538 Lubeck, Germany; [Kalies, Kathrin] Med Univ Lubeck, Inst Anat, D-23538 Lubeck, Germany; [Kulkarni, Upasana; Boettcher, Martin; Kamradt, Thomas] Univ Hosp Jena, Inst Immunol, Jena, Germany; [Kohler, Thomas; Hammerschmidt, Sven] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Dept Genet Microorganisms, Greifswald, Germany; [Bommert, Kurt] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Pollok, Karolin; Hauser, Anja E.] Charite, Dept Rheumatol, D-13353 Berlin, Germany; [Pollok, Karolin; Hauser, Anja E.] Charite, German Arthrit Res Ctr, D-13353 Berlin, Germany; [Bogen, Bjarne] Univ Oslo, Ctr Immune Regulat, N-0316 Oslo, Norway; [Bogen, Bjarne] Univ Oslo, KG Jebsen Ctr Influenza Vaccine Res, Inst Immunol, N-0316 Oslo, Norway; [Bogen, Bjarne] Oslo Univ Hosp, N-0450 Oslo, Norway; [Langer, Christian] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany; [Huber-Lang, Markus] Univ Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89069 Ulm, Germany; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH 45221 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.; Koehl, Joerg] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA	University of Lubeck; University of Lubeck; University of Lubeck; Friedrich Schiller University of Jena; Ernst Moritz Arndt Universitat Greifswald; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Oslo; University of Oslo; University of Oslo; Ulm University; Ulm University; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Manz, RA (corresponding author), Med Univ Lubeck, Inst System Inflammat Res, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Rudolf.Manz@uksh.de	Hammerschmidt, Sven/G-2598-2010; Ludwig, Ralf J/A-2629-2008; Huber-Lang, Markus/AAJ-2209-2020; Bommert, Kurt/G-9247-2011; Ludwig, Ralf/F-3996-2018; Manz, Rudolf A/C-8340-2011; Recke, Andreas/C-8963-2009; Kamradt, Thomas/E-9971-2018; Böttcher, Martin/AFQ-7409-2022; Koehl, Joerg/C-8531-2011	Hammerschmidt, Sven/0000-0002-6382-6681; Ludwig, Ralf J/0000-0002-1394-1737; Ludwig, Ralf/0000-0002-1394-1737; Recke, Andreas/0000-0002-7674-1804; Böttcher, Martin/0000-0003-2911-8830; Koehl, Joerg/0000-0003-1121-3178; Kalies, Kathrin/0000-0002-8929-4249; Hauser, Anja Erika/0000-0002-7725-9526; Kamradt, Thomas/0000-0001-8443-5893	Excellence Cluster "Inflammation at Interfaces''; University of Lubeck. U.K; University of Lubeck "SPP-MIA''; US Department of Veterans Affairs; DFG-KFO 21;  [IRTG 1911];  [GRK1727]	Excellence Cluster "Inflammation at Interfaces''; University of Lubeck. U.K; University of Lubeck "SPP-MIA''; US Department of Veterans Affairs(US Department of Veterans Affairs); DFG-KFO 21(German Research Foundation (DFG)); ; 	Supported by the Excellence Cluster "Inflammation at Interfaces,'' the IRTG 1911, and the GRK1727. D.M.W. was supported by an internal program grant of the University of Lubeck. U.K. was supported by the priority program of the University of Lubeck "SPP-MIA.'' F.D.F. is supported by the US Department of Veterans Affairs. K.B. received support from DFG-KFO 21.	Adeyi OA, 2010, AM J TRANSPLANT, V10, P2683, DOI 10.1111/j.1600-6143.2010.03311.x; ALHADITHY H, 1982, ANN RHEUM DIS, V41, P33, DOI 10.1136/ard.41.1.33; Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675; Belnoue E, 2012, J IMMUNOL, V188, P1283, DOI 10.4049/jimmunol.1103169; Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569; BOROS DL, 1989, CLIN MICROBIOL REV, V2, P250, DOI 10.1128/CMR.2.3.250-269.1989; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Caielli S, 2012, CURR OPIN IMMUNOL, V24, P671, DOI 10.1016/j.coi.2012.09.008; Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284; Cassatella MA, 1998, INT J CLIN LAB RES, V28, P148, DOI 10.1007/s005990050036; Chiriac MT, 2007, J PATHOL, V212, P56, DOI 10.1002/path.2157; Elliott ER, 2011, J IMMUNOL, V187, P4319, DOI 10.4049/jimmunol.1100341; Fessler BJ, 2002, BEST PRACT RES CL RH, V16, P281, DOI 10.1053/berh.2001.0226; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Gilliland WR, 2002, ANN RHEUM DIS, V61, P191, DOI 10.1136/ard.61.3.191; Godau J, 2004, J IMMUNOL, V173, P3437, DOI 10.4049/jimmunol.173.5.3437; Grammatikos AP, 2012, TRENDS MOL MED, V18, P101, DOI 10.1016/j.molmed.2011.10.005; GRAU GE, 1990, J EXP MED, V172, P1505, DOI 10.1084/jem.172.5.1505; Guiyedi V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000389; Hartel T, 2011, INFECT IMMUN, V79, P44, DOI 10.1128/IAI.00855-10; HEISE ER, 1982, ENVIRON HEALTH PERSP, V43, P9, DOI 10.2307/3429162; Hiepe F, 2011, NAT REV RHEUMATOL, V7, P170, DOI 10.1038/nrrheum.2011.1; Hofgaard PO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051892; Huggins ML, 1999, LUPUS, V8, P29, DOI 10.1191/096120399678847308; Jensch I, 2010, MOL MICROBIOL, V77, P22, DOI 10.1111/j.1365-2958.2010.07189.x; Kalambokis GN, 2009, INT J LAB HEMATOL, V31, P375, DOI 10.1111/j.1751-553X.2009.01154.x; Karsten CM, 2012, IMMUNOBIOLOGY, V217, P1067, DOI 10.1016/j.imbio.2012.07.015; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Lopez P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078756; Ludwig RJ, 2011, J INVEST DERMATOL, V131, P167, DOI 10.1038/jid.2010.248; Madan R, 2009, J IMMUNOL, V183, P2312, DOI 10.4049/jimmunol.0900185; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; Meyer K, 2008, J VIROL, V82, P2140, DOI 10.1128/JVI.01867-07; Moser K, 2006, CURR OPIN IMMUNOL, V18, P265, DOI 10.1016/j.coi.2006.03.004; Nagase H, 2001, CLIN IMMUNOL, V100, P250, DOI 10.1006/clim.2001.5054; Naicker S, 2007, SEMIN IMMUNOPATHOL, V29, P397, DOI 10.1007/s00281-007-0088-x; Nucci M, 2009, SEMIN HEMATOL, V46, P277, DOI 10.1053/j.seminhematol.2009.03.006; Otsuki T, 2002, LEUKEMIA LYMPHOMA, V43, P969, DOI 10.1080/10428190290021579; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Pelletier N, 2010, NAT IMMUNOL, V11, P1110, DOI 10.1038/ni.1954; Pratt G, 2007, BRIT J HAEMATOL, V138, P563, DOI 10.1111/j.1365-2141.2007.06705.x; Saleh M, 2014, JOVE-J VIS EXP, DOI 10.3791/51174; Scapini P, 2011, P NATL ACAD SCI USA, V108, pE823, DOI 10.1073/pnas.1107913108; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Skok J, 1999, J IMMUNOL, V163, P4284; Suwannaroj S, 1999, J RHEUMATOL, V26, P1400; Tarlinton D, 2008, CURR OPIN IMMUNOL, V20, P162, DOI 10.1016/j.coi.2008.03.016; Teichmann LL, 2012, J IMMUNOL, V188, P678, DOI 10.4049/jimmunol.1102456; Thai KTD, 2011, CLIN MICROBIOL INFEC, V17, P1823, DOI 10.1111/j.1469-0691.2010.03434.x; Tiburzy B, 2014, SEMIN IMMUNOPATHOL, V36, P277, DOI 10.1007/s00281-014-0426-8; Tiburzy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083631; Tsikrikoni A, 2008, J GASTROEN HEPATOL, V23, pE416, DOI 10.1111/j.1440-1746.2008.05309.x; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; Vicioso MA, 1998, EUR CYTOKINE NETW, V9, P247; Wanitpongpun C, 2012, CLIN EXP RHEUMATOL, V30, P825; Winter O, 2010, BLOOD, V116, P1867, DOI 10.1182/blood-2009-12-259457; Wong D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109018; Zamarin D, 2013, LEUKEMIA, V27, P2422, DOI 10.1038/leu.2013.126; Zandman-Goddard G, 2005, AUTOIMMUNITY, V38, P473, DOI 10.1080/08916930500285352	69	49	50	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1487	+		10.1016/j.jaci.2015.10.018	http://dx.doi.org/10.1016/j.jaci.2015.10.018			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26653800	Bronze			2022-12-18	WOS:000376180200025
J	Potaczek, DP; Garn, H; Unger, SD; Renz, H				Potaczek, Daniel P.; Garn, Holger; Unger, Sebastian D.; Renz, Harald			Antisense molecules: A new class of drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Clinical trial; antisense; small interfering RNA; DNAzyme; therapy	INTERCELLULAR-ADHESION MOLECULE-1; PLACEBO-CONTROLLED TRIAL; B SYNTHESIS INHIBITOR; DENSITY-LIPOPROTEIN CHOLESTEROL; INSULIN-RECEPTOR SUBSTRATE-1; DUCHENNE MUSCULAR-DYSTROPHY; I CLINICAL-TRIAL; APOLIPOPROTEIN-B; PHASE-I; DOUBLE-BLIND	An improved understanding of disease pathogenesis leads to identification of novel therapeutic targets. From a pharmacologic point of view, these can be addressed by small chemical compounds, so-called biologicals (eg, mAbs and recombinant proteins), or by a rather new class of molecule based on the antisense concept. Recently, a new wave of clinical studies exploring antisense strategies is evolving. In addition to cancer, they include predominantly trials on infectious and noninfectious diseases, such as chronic inflammatory and metabolic conditions. This article, based on a systematic PubMed literature search, highlights recent developments in this emerging field.	[Potaczek, Daniel P.; Garn, Holger; Unger, Sebastian D.; Renz, Harald] Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany	Philipps University Marburg	Renz, H (corresponding author), Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de		Potaczek, Daniel Piotr/0000-0003-0324-8506; Garn, Holger/0000-0002-5178-4023	PreDicta EC FP7 Collaborative Project [260895]; Universities Giessen and Marburg Lung Centre (UGMLC); German Centre for Lung Research (DZL) [82DZL00502]; German Research Council (DFG) [SFB1021]	PreDicta EC FP7 Collaborative Project; Universities Giessen and Marburg Lung Centre (UGMLC); German Centre for Lung Research (DZL); German Research Council (DFG)(German Research Foundation (DFG))	Supported by the PreDicta EC FP7 Collaborative Project (260895), Universities Giessen and Marburg Lung Centre (UGMLC), the German Centre for Lung Research (DZL; 82DZL00502), and the German Research Council (DFG; SFB1021, project C04).	Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Akdim F, 2011, EUR HEART J, V32, P2650, DOI 10.1093/eurheartj/ehr148; Akdim F, 2010, AM J CARDIOL, V105, P1413, DOI 10.1016/j.amjcard.2010.01.003; Akdim F, 2010, J AM COLL CARDIOL, V55, P1611, DOI 10.1016/j.jacc.2009.11.069; Al-Mahmood S, 2009, J PHARMACOL EXP THER, V329, P496, DOI 10.1124/jpet.108.147496; Amado RG, 2004, HUM GENE THER, V15, P251, DOI 10.1089/104303404322886101; Argov Z, 2007, NEUROLOGY, V69, P699, DOI 10.1212/01.wnl.0000267884.39468.7a; Barakat MR, 2009, EXPERT OPIN INV DRUG, V18, P637, DOI [10.1517/13543780902855316 , 10.1517/13543780902855316]; Belfort R, 2002, AM J OPHTHALMOL, V133, P467; Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654; Berdugo M, 2005, INVEST OPHTH VIS SCI, V46, P4072, DOI 10.1167/iovs.05-0105; Boyer DS, 2002, AM J OPHTHALMOL, V133, P484; Boyer DS, 2002, AM J OPHTHALMOL, V133, P475; Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Buller HR, 2015, NEW ENGL J MED, V372, P232, DOI 10.1056/NEJMoa1405760; Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008; Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Colin S, 2014, J PHARMACOL EXP THER, V349, P107, DOI 10.1124/jpet.113.209346; Cursiefen C, 2014, OPHTHALMOLOGY, V121, P1683, DOI 10.1016/j.ophtha.2014.03.038; Cursiefen C, 2009, OPHTHALMOLOGY, V116, P1630, DOI 10.1016/j.ophtha.2009.04.016; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; DeVincenzo J, 2008, ANTIVIR RES, V77, P225, DOI 10.1016/j.antiviral.2007.11.009; DeVincenzo J, 2010, P NATL ACAD SCI USA, V107, P8800, DOI 10.1073/pnas.0912186107; DiGiusto DL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000931; Farooqi AA, 2014, ONCOTARGETS THER, V7, P2035, DOI 10.2147/OTT.S49652; Fitzgerald K, 2014, LANCET, V383, P60, DOI 10.1016/S0140-6736(13)61914-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gauvreau GM, 2011, ALLERGY, V66, P1242, DOI 10.1111/j.1398-9995.2011.02638.x; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gebhard C, 2013, CURR PHARM DESIGN, V19, P3132; Gish RG, 2011, ANTIVIR THER, V16, P547, DOI 10.3851/IMP1798; Glover JM, 1997, J PHARMACOL EXP THER, V282, P1173; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Goodchild J, 2004, CURR OPIN MOL THER, V6, P120; Graham MJ, 2013, CIRC RES, V112, P1479, DOI 10.1161/CIRCRESAHA.111.300367; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244; Homburg U, 2015, J ALLERGY CLIN IMMUN, V136, P797, DOI 10.1016/j.jaci.2015.02.018; Imaoka H, 2011, CLIN EXP ALLERGY, V41, P1740, DOI 10.1111/j.1365-2222.2011.03816.x; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Kahan BD, 2004, TRANSPLANTATION, V78, P858, DOI 10.1097/01.TP.0000128857.77893.D2; Kain H, 2009, BRIT J CLIN PHARMACO, V68, P169, DOI 10.1111/j.1365-2125.2009.03450.x; Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006; Karnati HK, 2014, TUMOR BIOL, V35, P9505, DOI 10.1007/s13277-014-2477-9; Kastelein JJP, 2006, CIRCULATION, V114, P1729, DOI 10.1161/CIRCULATIONAHA.105.606442; Kipshidze N, 2007, CARDIOVASC REVASCULA, V8, P230, DOI 10.1016/j.carrev.2007.04.002; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Kutryk MJB, 2002, J AM COLL CARDIOL, V39, P281, DOI 10.1016/S0735-1097(01)01741-7; Ladeiras-Lopes R, 2015, INT J CARDIOL, V192, P72, DOI 10.1016/j.ijcard.2015.05.013; Leachman SA, 2010, MOL THER, V18, P442, DOI 10.1038/mt.2009.273; Li ZY, 2014, J CARDIOVASC PHARM, V64, P164, DOI 10.1097/FJC.0000000000000101; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Limmroth V, 2014, NEUROLOGY, V83, P1780, DOI 10.1212/WNL.0000000000000926; Lundin KE, 2015, HUM GENE THER, V26, P475, DOI 10.1089/hum.2015.070; Macpherson JL, 2005, J GENE MED, V7, P552, DOI 10.1002/jgm.705; Maksymowych WP, 2002, J RHEUMATOL, V29, P447; McGowan MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049006; McHutchison JG, 2006, J HEPATOL, V44, P88, DOI 10.1016/j.jhep.2005.09.009; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Miller TM, 2013, LANCET NEUROL, V12, P435, DOI 10.1016/S1474-4422(13)70061-9; Miner P, 2004, ALIMENT PHARM THER, V19, P281, DOI 10.1111/j.1365-2036.2004.01863.x; Miner PB, 2006, ALIMENT PHARM THER, V23, P1403, DOI 10.1111/j.1365-2036.2006.02837.x; Mitsuyasu RT, 2009, NAT MED, V15, P285, DOI 10.1038/nm.1932; Monteleone G, 2015, NEW ENGL J MED, V372, P1104, DOI 10.1056/NEJMoa1407250; Monteleone G, 2012, MOL THER, V20, P870, DOI 10.1038/mt.2011.290; Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217; Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106; Ormonde S, 2012, J MEMBRANE BIOL, V245, P381, DOI 10.1007/s00232-012-9460-4; Potaczek DP, 2014, INT J CARDIOL, V170, P278, DOI 10.1016/j.ijcard.2013.11.029; Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961; Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043; Raal FJ, 2010, LANCET, V375, P998, DOI 10.1016/S0140-6736(10)60284-X; Reitsma PH, 2012, ARTERIOSCL THROM VAS, V32, P563, DOI 10.1161/ATVBAHA.111.242818; Roque F, 2001, ANTISENSE NUCLEIC A, V11, P99, DOI 10.1089/108729001750171335; Sahebkar A, 2013, CLIN THER, V35, P1082, DOI 10.1016/j.clinthera.2013.06.019; Santos RD, 2015, ARTERIOSCL THROM VAS, V35, P689, DOI 10.1161/ATVBAHA.114.304549; Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915; Schreiber S, 2001, GASTROENTEROLOGY, V120, P1339, DOI 10.1053/gast.2001.24015; Sereni D, 1999, J CLIN PHARMACOL, V39, P47, DOI 10.1177/00912709922007552; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Soler M, 2004, ANTIVIR THER, V9, P953; Stein EA, 2014, BEST PRACT RES CL EN, V28, P309, DOI 10.1016/j.beem.2013.10.010; Stein EA, 2012, CIRCULATION, V126, P2283, DOI 10.1161/CIRCULATIONAHA.112.104125; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Sussman J, 2012, ANN NY ACAD SCI, V1275, P13, DOI 10.1111/j.1749-6632.2012.06825.x; Sussman JD, 2008, ANN NY ACAD SCI, V1132, P283, DOI 10.1196/annals.1405.022; Tebas P, 2013, BLOOD, V121, P1524, DOI 10.1182/blood-2012-07-447250; Thomas GS, 2013, J AM COLL CARDIOL, V62, P2178, DOI 10.1016/j.jacc.2013.07.081; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Van Deventer SJH, 2006, ALIMENT PHARM THERAP, V23, P1415, DOI 10.1111/j.1365-2036.2006.02910.x; van Deventer SJH, 2004, GUT, V53, P1646, DOI 10.1136/gut.2003.036160; Visser ME, 2012, EUR HEART J, V33, P1142, DOI 10.1093/eurheartj/ehs023; Visser ME, 2010, J LIPID RES, V51, P1057, DOI 10.1194/jlr.M002915; Voit T, 2014, LANCET NEUROL, V13, P987, DOI 10.1016/S1474-4422(14)70195-4; Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993; Winer L, 2013, JAMA NEUROL, V70, P201, DOI 10.1001/jamaneurol.2013.593; Winkler J, 2013, THER DELIV, V4, P791, DOI [10.4155/TDE.13.47, 10.4155/tde.13.47]; Winkler J, 2010, CHEMMEDCHEM, V5, P1344, DOI 10.1002/cmdc.201000156; Wypasek E, 2014, THROMB RES, V134, P199, DOI 10.1016/j.thromres.2014.01.023; Wypasek E, 2014, POL ARCH MED WEWN, V124, P75, DOI 10.20452/pamw.2091; Wypasek E, 2013, POL ARCH MED WEWN, V123, P646, DOI 10.20452/pamw.1986; Yacyshyn BR, 2005, CLIN EXP IMMUNOL, V141, P141, DOI 10.1111/j.1365-2249.2005.02830.x; Yacyshyn BR, 2002, GUT, V51, P30, DOI 10.1136/gut.51.1.30; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4; Yacyshyn B, 2007, CLIN GASTROENTEROL H, V5, P215, DOI 10.1016/j.cgh.2006.11.001; Yu RZ, 2009, CLIN PHARMACOKINET, V48, P39, DOI 10.2165/0003088-200948010-00003; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; Zamora MR, 2011, AM J RESP CRIT CARE, V183, P531, DOI 10.1164/rccm.201003-0422OC; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3; Zhang YC, 2005, METH MOLEC MED, V106, P11; Zorzi F, 2012, ALIMENT PHARM THER, V36, P850, DOI 10.1111/apt.12051	116	49	51	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1334	1346		10.1016/j.jaci.2015.12.1344	http://dx.doi.org/10.1016/j.jaci.2015.12.1344			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155029	Green Published			2022-12-18	WOS:000376180200005
J	Soler, ZM; Hyer, JM; Rudmik, L; Ramakrishnan, V; Smith, TL; Schlosser, RJ				Soler, Zachary M.; Hyer, J. Madison; Rudmik, Luke; Ramakrishnan, Viswanathan; Smith, Timothy L.; Schlosser, Rodney J.			Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; sinusitis; cluster; quality of life; treatment; prediction; outcomes	MEDICAL THERAPY; SINUS SURGERY; PHENOTYPES	Background: Current clinical classifications of chronic rhinosinusitis (CRS) have weak prognostic utility regarding treatment outcomes. Simplified discriminant analysis based on unsupervised clustering has identified novel phenotypic subgroups of CRS, but prognostic utility is unknown. Objective: We sought to determine whether discriminant analysis allows prognostication in patients choosing surgery versus continued medical management. Methods: A multi-institutional prospective study of patients with CRS in whom initial medical therapy failed who then self-selected continued medical management or surgical treatment was used to separate patients into 5 clusters based on a previously described discriminant analysis using total Sino-Nasal Outcome Test-22 (SNOT-22) score, age, and missed productivity. Patients completed the SNOT-22 at baseline and for 18 months of follow-up. Baseline demographic and objective measures included olfactory testing, computed tomography, and endoscopy scoring. SNOT-22 outcomes for surgical versus continued medical treatment were compared across clusters. Results: Data were available on 690 patients. Baseline differences in demographics, comorbidities, objective disease measures, and patient-reported outcomes were similar to previous clustering reports. Three of 5 clusters identified by means of discriminant analysis had improved SNOT-22 outcomes with surgical intervention when compared with continued medical management (surgery was a mean of 21.2 points better across these 3 clusters at 6 months, P < .05). These differences were sustained at 18 months of follow-up. Two of 5 clusters had similar outcomes when comparing surgery with continued medical management. Conclusion: A simplified discriminant analysis based on 3 common clinical variables is able to cluster patients and provide prognostic information regarding surgical treatment versus continued medical management in patients with CRS.	[Soler, Zachary M.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC550, Charleston, SC 29425 USA; [Hyer, J. Madison; Ramakrishnan, Viswanathan] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Rutledge Ave,MSC550, Charleston, SC 29425 USA; [Rudmik, Luke] Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Calgary, AB, Canada; [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR USA	Medical University of South Carolina; Medical University of South Carolina; University of Calgary; Oregon Health & Science University	Schlosser, RJ (corresponding author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC550, Charleston, SC 29425 USA.	schlossr@musc.edu			National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health, Bethesda, Maryland [R01 DC005805]; NIDCD [R03 DC013651-01]; OptiNose; IntersectENT; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005805, R03DC013651] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health, Bethesda, Maryland; NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); OptiNose; IntersectENT; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Z.M.S. and T.L.S. were supported for this investigation by a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, Maryland (R01 DC005805; PI/PD: T.L.S.). Public clinical trial registration (http://www.clinicaltrials.gov) was #NCT01332136. Z.M.S. was also supported for this investigation by another grant from the NIDCD (R03 DC013651-01). T.L.S. is a consultant for IntersectENT, which is not associated with this manuscript. Z.M.S. is a consultant for Olympus, which is not affiliated with this manuscript. R.J.S. is supported by grants from OptiNose and IntersectENT, neither of which are associated with this manuscript. R.J.S. is also a consultant for Olympus and Arrinex, which are not affiliated with this study.	Balding DJ, 2004, APPL LONGITUDINAL AN; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; DeConde AS, 2014, INT FORUM ALLERGY RH, V4, P972, DOI 10.1002/alr.21408; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Quintanilla-Dieck L, 2012, INT FORUM ALLERGY RH, V2, P437, DOI 10.1002/alr.21057; Ramakrishnan VR, 2015, J ALLERGY CLIN IMMUN, V136, P334, DOI 10.1016/j.jaci.2015.02.008; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; Smith KA, 2014, INT FORUM ALLERGY RH, V4, P823, DOI 10.1002/alr.21366; Smith TL, 2013, INT FORUM ALLERGY RH, V3, P4, DOI 10.1002/alr.21065; Smith TL, 2011, INT FORUM ALLERGY RH, V1, P235, DOI 10.1002/alr.20063; Smith TL, 2010, OTOLARYNG HEAD NECK, V142, P55, DOI 10.1016/j.otohns.2009.10.009; Soler ZM, 2015, INT FORUM ALLERGY RH, V5, P399, DOI 10.1002/alr.21496; Soler ZM, 2010, OTOLARYNG CLIN N AM, V43, P605, DOI 10.1016/j.otc.2010.03.001	15	49	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1054	1062		10.1016/j.jaci.2015.11.019	http://dx.doi.org/10.1016/j.jaci.2015.11.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26806047	Green Accepted, Bronze			2022-12-18	WOS:000373351200011
J	Zhang, YN; Song, J; Wang, H; Wang, H; Zeng, M; Zhai, GT; Ma, J; Li, ZY; Liao, B; Wang, BF; Zhen, Z; Wang, N; Cao, PP; Lin, P; Ning, Q; Liu, Z				Zhang, Ya-Na; Song, Jia; Wang, Hai; Wang, Heng; Zeng, Ming; Zhai, Guan-Ting; Ma, Jin; Li, Zhi-Yong; Liao, Bo; Wang, Bao-Feng; Zhen, Zhen; Wang, Nan; Cao, Ping-Ping; Lin, Peng; Ning, Qin; Liu, Zheng			Nasal IL-4(+)CXCR5(+)CD4(+) T follicular helper cell counts correlate with local IgE production in eosinophilic nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; ectopic lymphoid structure; eosinophil; IgE; IL-4; nasal polyp; T follicular helper cell	MEMORY TFH CELLS; CHRONIC RHINOSINUSITIS	Background: Locally produced IgE contributes to the initiation and development of eosinophilic inflammation in eosinophilic nasal polyps independent of systemic atopy. However, whether CXCR5(+)CD4(+) T follicular helper (T-FH) cells are involved in local IgE production at mucosal sites remains unexplored. Objective: We sought to explore the presence, phenotype, and function of CXCR5(+)CD4(+) T-FH cells in eosinophilic nasal polyp tissues compared with noneosinophilic nasal polyp and control normal nasal tissues. Methods: T-FH cell-surface phenotypes and subsets and B-cell subsets in nasal tissues and peripheral blood were studied by means of flow cytometry. Immunohistochemistry was used to detect the tissue location of T-FH cells. Sorted nasal T-FH cells and CXCR5(-) T cells were cultured with autologous naive B cells purified from blood. Results: Nasal T-FH cells expressed inducible costimulator, programmed cell death protein 1, and the transcription factor B-cell lymphoma 6 (Bcl-6) at an intermediate level when compared with bona fide T-FH cells in tonsils and circulating T-FH cells. Although counts of total T-FH cells and IL-21(+), IFN-gamma(+), and IL-17(+) T-FH cells were increased in both eosinophilic and noneosinophilic nasal polyp tissues compared with those in normal nasal tissues, IL-4(+) T-FH cell counts were only increased in eosinophilic polyp tissues. IL-4 and IL-21 were involved in polyp T-FH cell-induced IgE production from naive B cells, and nasal IL-4(+) T-FH cell counts correlated highly with local IgE levels in vivo. IL-4(+)Bcl-6(+)CD4(+) T-FH cells were identified in ectopic lymphoid structures in eosinophilic nasal polyps. T-FH cells also positively correlated with germinal center B cells and plasma cells in nasal tissues. Conclusion: Nasal IL-4(+) T-FH cells might be involved in local IgE production in eosinophilic nasal polyps.	[Zhang, Ya-Na; Song, Jia; Wang, Hai; Wang, Heng; Zeng, Ming; Zhai, Guan-Ting; Ma, Jin; Li, Zhi-Yong; Liao, Bo; Wang, Bao-Feng; Zhen, Zhen; Wang, Nan; Cao, Ping-Ping; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Peoples R China; [Ning, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis,Inst Infect Dis, Wuhan 430030, Peoples R China; [Zhang, Ya-Na; Lin, Peng] Tianjin First Ctr Hosp, Dept Otolaryngol Head & Neck Surg, Tianjin, Peoples R China; [Zhen, Zhen] Peking Univ, Hosp 1, Dept Otolaryngol Head & Neck Surg, Beijing 100871, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Peking University	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.	zhengliuent@hotmail.com			National Natural Science Foundation of China (NSFC) [81020108018, 81325006, 81200733, 81400449]; Ministry of Health of China [201202005]; Program for Changjiang Scholars and Innovative Research Team in University [IRT_14R20]; 12th 5-year science and technology support program [2014BAI07B04]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Ministry of Health of China; Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); 12th 5-year science and technology support program	Supported by National Natural Science Foundation of China (NSFC) grants 81020108018 and 81325006 (to Z.L.), 81200733 (to H.W.), and 81400449 (to P.-P.C.); a grant from the Ministry of Health of China (201202005); the Program for Changjiang Scholars and Innovative Research Team in University (IRT_14R20); and the 12th 5-year science and technology support program (2014BAI07B04).	Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Ballesteros-Tato A, 2014, IMMUNOL CELL BIOL, V92, P22, DOI 10.1038/icb.2013.62; Bentebibel SE, 2011, P NATL ACAD SCI USA, V108, pE488, DOI 10.1073/pnas.1100898108; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chen MG, 2012, CELL MOL IMMUNOL, V9, P375, DOI 10.1038/cmi.2012.18; Chu Y, 2014, ACTA HISTOCHEM, V116, P539, DOI 10.1016/j.acthis.2013.10.009; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Le Coz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075319; Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Ma CS, 2014, IMMUNOL CELL BIOL, V92, P64, DOI 10.1038/icb.2013.55; Mazerolles F, 2013, J ALLERGY CLIN IMMUN, V131, P1146, DOI 10.1016/j.jaci.2012.12.1519; Mechtcheriakova D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025611; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Schmitt N, 2014, TRENDS IMMUNOL, V35, P436, DOI 10.1016/j.it.2014.06.002; Shi LL, 2014, AM J RESP CRIT CARE, V190, P628, DOI 10.1164/rccm.201402-0234OC; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Vinuesa CG, 2013, IMMUNITY, V39, P417, DOI 10.1016/j.immuni.2013.09.001; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328	31	49	54	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					462	473		10.1016/j.jaci.2015.07.025	http://dx.doi.org/10.1016/j.jaci.2015.07.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26329514	Bronze			2022-12-18	WOS:000369235500015
J	Thyssen, JP; Zirwas, MJ; Elias, PM				Thyssen, Jacob P.; Zirwas, Matthew J.; Elias, Peter M.			Potential role of reduced environmental UV exposure as a driver of the current epidemic of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; irradiation; pathogenesis; phototherapy; skin; UV	THYMIC STROMAL LYMPHOPOIETIN; 25-HYDROXYVITAMIN D LEVELS; VITAMIN-D SUPPLEMENTATION; STRATUM-CORNEUM; SKIN BARRIER; MELANOCYTIC NEVI; ULTRAVIOLET-B; SUN EXPOSURE; EPIDERMAL PERMEABILITY; STAPHYLOCOCCUS-AUREUS	The basis for the sudden and dramatic increase in atopic dermatitis (AD) and related atopic diseases in the second half of the 20th century is unclear. The hygiene hypothesis proposes that the transition from rural to urban living leads to reduced childhood exposure to pathogenic microorganisms. Hence instead of having the normal T(H)1 bias and immune tolerance because of repeated exposure to pathogens, urban dwellers have T(H)2 cell immune activity and atopic disease in a more sterile environment. Various other environmental exposures have been implicated in the explosion of AD (and atopic disorders in general), including breast-feeding, tobacco smoking, alcohol consumption, and exposure to domesticated furry pets. Notably, the key role of a compromised barrier of neonatal skin as a predisposing factor in the development of childhood AD has recently been demonstrated. In this article we review the salubrious effects of suberythemogenic doses of UVB irradiation for the skin barrier. We then discuss how the lack of sufficient UVB exposure could have contributed to the rapid increase in the incidence of AD in developed countries. This hypothesis offers a separate but not competing partial explanation, which should be viewed as not discounting the role of the etiopathogenic factors that also could influence the prevalence of atopic disorders.	[Thyssen, Jacob P.] Univ Copenhagen, Gentofte Univ Hosp, Dept Dermatoallergol, Natl Allergy Res Ctr, Hellerup, Denmark; [Zirwas, Matthew J.] Ohio State Univ, Div Dermatol, Columbus, OH 43210 USA; [Elias, Peter M.] Univ Calif San Francisco, Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94143 USA; [Elias, Peter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of Copenhagen; Herlev & Gentofte Hospital; University System of Ohio; Ohio State University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Thyssen, JP (corresponding author), Gentofte Univ Hosp, Dept Dermatoallergol, Natl Allergy Res Ctr, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	jacob.p.thyssen@regionh.dk	Thyssen, Jacob/ABD-8517-2020	Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	Lundbeck Foundation; Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Lundbeck Foundation(Lundbeckfonden)	J. P. Thyssen is supported by an unrestricted grant from the Lundbeck Foundation.	Aberg KM, 2008, J INVEST DERMATOL, V128, P917, DOI 10.1038/sj.jid.5701099; Amestejani M, 2012, J DRUGS DERMATOL, V11, P327; Barbarot S, 2013, BRIT J DERMATOL, V169, P1257, DOI 10.1111/bjd.12581; Bodekaer M, 2014, PHOTOCH PHOTOBIO SCI, V13, P1598, DOI 10.1039/c4pp00188e; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Brauweiler AM, 2013, J ALLERGY CLIN IMMUN, V131, P421, DOI 10.1016/j.jaci.2012.10.030; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Buddenkotte J, 2010, ALLERGY, V65, P805, DOI 10.1111/j.1398-9995.2010.01995.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Camargo CA, 2014, J ALLERGY CLIN IMMUN, V134, P831, DOI 10.1016/j.jaci.2014.08.002; Carson CG, 2013, DAN MED J, V60; Cela EM, 2015, IMMUNOLOGY, V145, P82, DOI 10.1111/imm.12427; Chaumont A, 2012, ENVIRON RES, V116, P52, DOI 10.1016/j.envres.2012.04.013; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Csoma Z, 2008, NEW ENGL J MED, V358, P2523; Csoma Z, 2011, PEDIATRICS, V128, pE856, DOI 10.1542/peds.2011-0292; DAVID TJ, 1988, ARCH DIS CHILD, V63, P435, DOI 10.1136/adc.63.4.435; Dawe RS, 2003, BRIT J DERMATOL, V148, P626, DOI 10.1046/j.1365-2133.2003.05261.x; Denda M, 2008, J INVEST DERMATOL, V128, P1335, DOI 10.1038/sj.jid.5701168; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Duquia RP, 2007, J AM ACAD DERMATOL, V57, P73, DOI 10.1016/j.jaad.2007.03.012; El Taieb MA, 2013, DERMATITIS, V24, P296, DOI 10.1097/DER.0000000000000010; Elias PM, 2015, EXP DERMATOL, V24, P179, DOI 10.1111/exd.12596; Elias PM, 2009, CURR ALLERGY ASTHM R, V9, P265, DOI [10.1007/s11882-009-0037-y, 10.1097/ACI.0b013e32832e7d36]; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Farrell AM, 1998, J LIPID RES, V39, P2031; Fluhr JW, 2012, BRIT J DERMATOL, V166, P483, DOI 10.1111/j.1365-2133.2011.10659.x; Fluhr JW, 2010, EXP DERMATOL, V19, P483, DOI 10.1111/j.1600-0625.2009.01023.x; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Hart PH, 2001, CLIN EXP PHARMACOL P, V28, P1, DOI 10.1046/j.1440-1681.2001.03392.x; Hata TR, 2014, J EUR ACAD DERMATOL, V28, P781, DOI 10.1111/jdv.12176; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Hay J, 2009, J AM ACAD DERMATOL, V61, P783, DOI 10.1016/j.jaad.2009.04.023; Holan V, 1998, J IMMUNOL, V161, P3237; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Imokawa G, 2009, J DERMATOL SCI, V55, P1, DOI 10.1016/j.jdermsci.2009.04.006; Ishitsuka Y, 2003, ARCH DERMATOL RES, V295, P155, DOI 10.1007/s00403-003-0397-4; JEKLER J, 1992, ACTA DERM-VENEREOL, V72, P33; Jungersted JM, 2011, PHOTODERMATOL PHOTO, V27, P331, DOI 10.1111/j.1600-0781.2011.00618.x; Kallas M, 2006, J EUR ACAD DERMATOL, V20, P143, DOI 10.1111/j.1468-3083.2005.01379.x; Kambayashi H, 2001, J DERMATOL SCI, V27, pS19; Kamo A, 2011, J DERMATOL SCI, V62, P91, DOI 10.1016/j.jdermsci.2011.01.004; Katagiri C, 2003, J DERMATOL SCI, V31, P29, DOI 10.1016/S0923-1811(02)00137-8; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kemp AS, 2013, PEDIAT ALLERG IMM-UK, V24, P493, DOI 10.1111/pai.12085; Kezic S, 2014, FRONT BIOSCI-LANDMRK, V19, P541, DOI 10.2741/4225; Kim TH, 2009, J PINEAL RES, V47, P324, DOI 10.1111/j.1600-079X.2009.00718.x; Krutmann J, 1999, J INVEST DERM SYMP P, V4, P70, DOI 10.1038/sj.jidsp.5640185; KUMAKIRI M, 1978, BRIT J DERMATOL, V99, P65, DOI 10.1111/j.1365-2133.1978.tb01963.x; Kusunoki T, 1999, J ALLERGY CLIN IMMUN, V103, P1148, DOI 10.1016/S0091-6749(99)70191-0; Kuzume K, 2007, PEDIATR ALLERGY IMMU, V18, P281, DOI 10.1111/j.1399-3038.2006.00526.x; LAMAUD E, 1984, BRIT J DERMATOL, V111, P152, DOI 10.1111/j.1365-2133.1984.tb15595.x; Larsen MB, 2014, PHOTOCHEM PHOTOBIOL, V90, P1193, DOI 10.1111/php.12280; Legat FJ, 2003, ARCH DERMATOL, V139, P223, DOI 10.1001/archderm.139.2.223; LEHMANN P, 1991, PHOTODERMATOL PHOTO, V8, P129; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Lindqvist PG, 2014, J INTERN MED, V276, P77, DOI 10.1111/joim.12251; Liu D, 2014, J INVEST DERMATOL, V134, P1839, DOI 10.1038/jid.2014.27; Manicourt DH, 2008, J CLIN ENDOCR METAB, V93, P3893, DOI 10.1210/jc.2007-2663; McCracken J. D., 1991, J RES RURAL ED, V7, P29; McFadden JP, 2015, BRIT J DERMATOL, V172, P584, DOI 10.1111/bjd.13497; McNally NJ, 1998, LANCET, V352, P527, DOI 10.1016/S0140-6736(98)01402-0; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Suarez-Varela MM, 2008, INT J BIOMETEOROL, V52, P833, DOI 10.1007/s00484-008-0177-0; Narbutt J, 2013, ARCH DERMATOL RES, V305, P191, DOI 10.1007/s00403-012-1293-6; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Nikolovski J, 2008, J INVEST DERMATOL, V128, P1728, DOI 10.1038/sj.jid.5701239; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Nurbazlin M, 2013, ASIA PAC J CLIN NUTR, V22, P391, DOI 10.6133/apjcn.2013.22.3.15; NylanderLundqvist E, 1997, ACTA DERM-VENEREOL, V77, P203; Ono M, 2005, PHOTOCHEM PHOTOBIOL, V81, P437, DOI 10.1562/2004-09-06-RA-307.1; PEARSE AD, 1987, J INVEST DERMATOL, V88, P83, DOI 10.1111/1523-1747.ep12465094; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Samochocki Z, 2013, J AM ACAD DERMATOL, V69, P238, DOI 10.1016/j.jaad.2013.03.014; Schauber J, 2008, J INVEST DERMATOL, V128, P816, DOI 10.1038/sj.jid.5701102; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Schram ME, 2010, BRIT J DERMATOL, V162, P964, DOI 10.1111/j.1365-2133.2010.09689.x; SCHWARZ W, 1988, ACTA DERM-VENEREOL, V68, P224; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; Silva SH, 2006, J EUR ACAD DERMATOL, V20, P1114, DOI 10.1111/j.1468-3083.2006.01748.x; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Song BM, 2014, NUTRIENTS, V6, P5806, DOI 10.3390/nu6125806; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; SPENCER TS, 1975, BRIT J DERMATOL, V93, P159; Steinhoff M, 2003, J NEUROSCI, V23, P6176; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Synnerstad I, 2004, ACTA DERM-VENEREOL, V84, P271, DOI 10.1080/00015550410025903; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Thyssen JP, 2012, J ALLERGY CLIN IMMUN, V130, P1204, DOI 10.1016/j.jaci.2012.06.046; Tronnes H, 2013, PEDIAT ALLERG IMM-UK, V24, P782, DOI 10.1111/pai.12170; TUPKER RA, 1995, BRIT J DERMATOL, V133, P365, DOI 10.1111/j.1365-2133.1995.tb02662.x; Tyler Kelly H, 2014, J Clin Aesthet Dermatol, V7, P38; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179; von Kobyletzki G, 1999, BRIT J DERMATOL, V140, P966, DOI 10.1046/j.1365-2133.1999.02839.x; Wallengren J, 2004, ACTA DERM-VENEREOL, V84, P111, DOI 10.1080/00015550310022899; Weber AS, 2010, PEDIAT ALLERG IMM-UK, V21, P1028, DOI 10.1111/j.1399-3038.2010.01030.x; WEFERS H, 1991, J INVEST DERMATOL, V96, P959, DOI 10.1111/1523-1747.ep12476124; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wulf HC, 1998, PHOTODERMATOL PHOTO, V14, P1, DOI 10.1111/j.1600-0781.1998.tb00001.x; Xu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036174; Yoshimura M, 1996, BRIT J DERMATOL, V135, P528; Yoshimura-Mishima M, 1999, J DERMATOL SCI, V19, P31, DOI 10.1016/S0923-1811(98)00046-2; Zahnd WE, 2010, J AM ACAD DERMATOL, V62, P950, DOI 10.1016/j.jaad.2009.08.058	108	49	50	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1163	1169		10.1016/j.jaci.2015.06.042	http://dx.doi.org/10.1016/j.jaci.2015.06.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26298230	Bronze			2022-12-18	WOS:000364787200003
J	da Rosa, JC; Malajian, D; Shemer, A; Rozenblit, M; Dhingra, N; Czarnowicki, T; Khattri, S; Ungar, B; Finney, R; Xu, H; Zheng, XZ; Estrada, YD; Peng, XY; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				da Rosa, Joel Correa; Malajian, Dana; Shemer, Avner; Rozenblit, Mariya; Dhingra, Nikhil; Czarnowicki, Tali; Khattri, Saakshi; Ungar, Benjamin; Finney, Robert; Xu, Hui; Zheng, Xiuzhong; Estrada, Yeriel D.; Peng, Xiangyu; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; allergic contact dermatitis; patch testing; T-cell polarization; human skin; nickel; rubber; fragrance	DELAYED-TYPE HYPERSENSITIVITY; T-CELLS; IMMUNE ABNORMALITIES; TH17 CELLS; SENSITIZATION; CYTOKINE; INFLAMMATION; IL-37; DINITROCHLOROBENZENE; INDIVIDUALS	Background: Atopic dermatitis (AD) is the most common inflammatory disease. The prevalence of allergic contact dermatitis to allergens (eg, fragrance) is higher in patients with AD, despite a trend toward weaker clinical allergic contact dermatitis reactions. The role of the AD skin phenotype in modulating allergic sensitization to common sensitizers has not been evaluated. Objective: We sought to investigate whether patients with AD have altered tissue immune responses on allergen challenge. Methods: Gene expression and immunohistochemistry studies were performed on biopsy specimens from 10 patients with AD and 14 patients without AD patch tested with common contact allergens (nickel, fragrance, and rubber). Results: Although 1085 differentially expressed genes (DEGs) were commonly modulated in patch-tested skin from patients with AD and patients without AD versus control skin, 1185 DEGs were uniquely altered in skin from patients without AD, and only 246 DEGs were altered in skin from patients with AD. Although many inflammatory products (ie, matrix metalloproteinase 12/matrix metalloproteinase 1/S100A9) were upregulated in both groups, higher-magnitude changes and upregulation of interferon responses were evident only in the non-AD group. Stratification by allergen showed decreased expression of immune, T(H)1-subset, and T(H)2-subset genes in nickel-related AD responses, with increasedT(H)17/IL-23 skewing. Rubber/fragrance showed similar trends of lesser magnitude. Negative regulators showed higher expression in patients with AD. Conclusions: Through contact sensitization, our study offers new insights into AD. Allergic immune reactions were globally attenuated and differentially polarized in patients with AD, with significant decreases in levels of T(H)1 products, some increases in levels of T(H)17 products, and inconsistent upregulation in levels of T(H)2 products. The overall hyporesponsiveness in skin from patients with background AD might be explained by baseline immune abnormalities, such as increased T(H)2, T(H)17, and negative regulator levels compared with those seen in non-AD skin.	[da Rosa, Joel Correa; Rozenblit, Mariya; Czarnowicki, Tali; Ungar, Benjamin; Xu, Hui; Zheng, Xiuzhong; Estrada, Yeriel D.; Peng, Xiangyu; Suarez-Farinas, Mayte; Krueger, James G.] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; [Malajian, Dana; Rozenblit, Mariya; Dhingra, Nikhil; Czarnowicki, Tali; Khattri, Saakshi; Ungar, Benjamin; Finney, Robert; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA; [Malajian, Dana] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Shemer, Avner] Tel Hashomer, Dept Dermatol, Tel Aviv, Israel; [Rozenblit, Mariya; Dhingra, Nikhil; Ungar, Benjamin; Peng, Xiangyu; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Dhingra, Nikhil] North Shore Long Isl Jewish Hosp, Dept Med, Manhasset, NY USA; [Finney, Robert] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA	Rockefeller University; Rockefeller University; Columbia University; Icahn School of Medicine at Mount Sinai; Northwell Health; Jefferson University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	eguttman@rockefeller.edu	Correa da Rosa, Joel/Q-4753-2017; Da Rosa, Joel/AAU-1238-2020	Correa da Rosa, Joel/0000-0003-4221-1976; Da Rosa, Joel/0000-0003-4221-1976; Ungar, Benjamin/0000-0003-0882-8163; Rozenblit, Mariya/0000-0002-8874-6688	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award; CTSA grant from Rockefeller University [UL1 TR000043]; American Dermatological Association's Medical Student Fellowship; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award; CTSA grant from Rockefeller University; American Dermatological Association's Medical Student Fellowship; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	J.C.R., J.G.K., M.S.-F., M.R., T.C., N.D., and B.U. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award and by a CTSA grant from Rockefeller University (UL1 TR000043). D.M. was supported by the American Dermatological Association's Medical Student Fellowship.	Clemmensen KKB, 2014, CONTACT DERMATITIS, V71, P75, DOI 10.1111/cod.12229; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Darlenski R, 2013, EXP DERMATOL, V22, P752, DOI 10.1111/exd.12251; DEGROOT AC, 1990, CONTACT DERMATITIS, V22, P273, DOI 10.1111/j.1600-0536.1990.tb01595.x; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dhingra N, 2013, J INVEST DERMATOL, V133, P2311, DOI 10.1038/jid.2013.239; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; FORSBECK M, 1976, ACTA DERM-VENEREOL, V56, P135; Fujita H, 2013, J DERMATOL SCI, V69, P173, DOI 10.1016/j.jdermsci.2012.11.001; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Herro Elise M, 2011, J Clin Aesthet Dermatol, V4, P39; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; Kot M, 2014, DERMATITIS, V25, P72, DOI 10.1097/DER.0000000000000026; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; LAMMINTAUSTA K, 1992, CONTACT DERMATITIS, V26, P234, DOI 10.1111/j.1600-0536.1992.tb00235.x; Landeck L, 2014, CONTACT DERMATITIS, V70, P27, DOI 10.1111/cod.12109; Landeck L, 2011, INT J DERMATOL, V50, P806, DOI 10.1111/j.1365-4632.2010.04754.x; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Li YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107183; Lindemann M, 2003, CLIN EXP ALLERGY, V33, P992, DOI 10.1046/j.1365-2222.2003.01700.x; Lindenberg JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070237; Malajian D, 2013, J AM ACAD DERMATOL, V69, P232, DOI 10.1016/j.jaad.2013.03.012; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Milanez-Almeida P, 2014, EUR J MICROBIOL IMMU, V4, P147, DOI 10.1556/EUJMI-D-14-00022; Moed H, 2005, EXP DERMATOL, V14, P634, DOI 10.1111/j.0906-6705.2005.00344.x; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Newell L, 2013, J INVEST DERMATOL, V133, P2372, DOI 10.1038/jid.2013.148; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Peiser M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/261037; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Pratt Melanie D, 2004, Dermatitis, V15, P176, DOI 10.2310/6620.2004.04038; REES J, 1990, ARCH DERMATOL, V126, P1173, DOI 10.1001/archderm.126.9.1173; Ricciardi L, 2009, CONTACT DERMATITIS, V60, P57, DOI 10.1111/j.1600-0536.2008.01454.x; Ross-Hansen K, 2011, CONTACT DERMATITIS, V64, P24, DOI 10.1111/j.1600-0536.2010.01815.x; Schena D, 2012, DERMATITIS, V23, P275, DOI 10.1097/DER.0b013e318273a3e0; Sharma S, 2008, J IMMUNOL, V180, P5477, DOI 10.4049/jimmunol.180.8.5477; Shaughnessy CN, 2014, J AM ACAD DERMATOL, V70, P102, DOI 10.1016/j.jaad.2013.08.046; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Slifka MK, 2014, J ALLERGY CLIN IMMUN, V133, P439, DOI 10.1016/j.jaci.2013.10.037; Spiewak R, 2005, ANN ALLERG ASTHMA IM, V95, P61, DOI 10.1016/S1081-1206(10)61189-1; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047; Thyssen JP, 2012, BRIT J DERMATOL, V166, P1255, DOI 10.1111/j.1365-2133.2012.10852.x; Thyssen JP, 2013, CONTACT DERMATITIS, V68, P273, DOI 10.1111/cod.12021; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P287, DOI 10.1111/j.1600-0536.2007.01220.x; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Traidl-Hoffmann C, 2008, CLIN EXP ALLERGY, V38, P1412, DOI 10.1111/j.1365-2222.2008.03065.x; van de Veerdonk FL, 2012, P NATL ACAD SCI USA, V109, P3001, DOI 10.1073/pnas.1121534109; Visser MJ, 2014, CONTACT DERMATITIS, V70, P139, DOI 10.1111/cod.12139; Werfel T, 1997, INT ARCH ALLERGY IMM, V113, P384, DOI 10.1159/000237610; Wilke CM, 2011, TRENDS IMMUNOL, V32, P603, DOI 10.1016/j.it.2011.08.003; Wulfing C, 2014, NAT IMMUNOL, V15, P408, DOI 10.1038/ni.2870; Yamaguchi H, 2013, J DERMATOL SCI, V72, P240, DOI 10.1016/j.jdermsci.2013.07.009; Ye L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-69; Zug KA, 2009, DERMATITIS, V20, P149, DOI 10.2310/6620.2009.08097	62	49	49	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					712	720		10.1016/j.jaci.2014.11.017	http://dx.doi.org/10.1016/j.jaci.2014.11.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25583101				2022-12-18	WOS:000351065000018
J	McGowan, EC; Bloomberg, GR; Gergen, PJ; Visness, CM; Jaffee, KF; Sandel, M; O'Connor, G; Kattan, M; Gern, J; Wood, RA				McGowan, Emily C.; Bloomberg, Gordon R.; Gergen, Peter J.; Visness, Cynthia M.; Jaffee, Katy F.; Sandel, Megan; O'Connor, George; Kattan, Meyer; Gern, James; Wood, Robert A.			Influence of early-life exposures on food sensitization and food allergy in an inner-city birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; inner city; Urban Environment and Childhood Asthma cohort; specific IgE	NATIONAL-HEALTH; EGG ALLERGY; PREVALENCE; ASTHMA; ENDOTOXIN; CHILDREN; URBAN; RISK; IGE; HYPERSENSITIVITY	Objective: Previous data suggest that food allergy (FA) might be more common in inner-city children; however, these studies have not collected data on both sensitization and clinical reactivity or early-life exposures. Methods: Children in the Urban Environment and Childhood Asthma birth cohort were followed through age 5 years. Household exposures, diet, clinical history, and physical examinations were assessed yearly; levels of specific IgE to milk, egg, and peanut were measured at 1, 2, 3, and 5 years of age. On the basis of sensitization (IgE >= 0.35 kU/L) and clinical history over the 5-year period, children were classified as having FA or being possibly allergic, sensitized but tolerant, or not allergic/not sensitized. Results: Five hundred sixteen children were included. Overall, 55.4% were sensitized (milk, 46.7%; egg, 31.0%; and peanut, 20.9%), whereas 9.9% were categorized as having FA (peanut, 6.0%; egg, 4.3%; andmilk, 2.7%; 2.5% to > 1 food). The remaining children were categorized as possibly allergic (17.0%), sensitized but tolerant (28.5%), and not sensitized (44.6%). Eighteen (3.5%) reported reactions to foods forwhich IgElevelswere not measured. Food-specific IgE levels were similar in children with FA versus sensitized but tolerant children, except for egg, levels ofwhich were higher in patients with FA at ages 1 and 2 years. FA was associated with recurrent wheeze, eczema, aeroallergen sensitization, male sex, breast-feeding, and lower endotoxin exposure in year 1 but not with race/ethnicity, income, tobacco exposure, maternal stress, or early introduction of solid foods. Conclusions: Even given that this was designed to be a high-risk cohort, the cumulative incidence of FA is extremely high, especially considering the strict definition of FA that was applied and that only 3 common allergens were included.	[McGowan, Emily C.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Dept Med, Baltimore, MD 21287 USA; [McGowan, Emily C.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, Div Allergy Immunol & Pulm Med, St Louis, MO 63130 USA; [Gergen, Peter J.] NIAID, NIH, Bethesda, MD 20892 USA; [Visness, Cynthia M.; Jaffee, Katy F.] Rho Inc, Chapel Hill, NC USA; [Sandel, Megan] Boston Univ, Sch Med, Dept Med, Div Pediat Primary Care, Boston, MA 02118 USA; [O'Connor, George] Boston Univ, Sch Med, Dept Med, Div Pulm Allergy Sleep & Crit Care Med, Boston, MA 02118 USA; [Kattan, Meyer] New York Presbyterian Columbia Univ, Med Ctr, Div Pediat Pulmonol, Dept Pediat, New York, NY USA; [Gern, James] Univ Wisconsin, Sch Med, Dept Pediat, Div Allergy & Immunol, Madison, WI 53706 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rho; Boston University; Boston University; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ, Sch Med, 600 North Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu			National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Health and Human Services [NO1-AI-25496, NO1-AI-25482, HHSN2722 00900052C, HHSN272201000052I]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001077, UL1TR001079] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771, M01RR000533, UL1RR024992, UL1RR024156, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN2722 00900052C, and HHSN272201000052I. Additional support was provided under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02.	Alwis KU, 2006, AM J IND MED, V49, P296, DOI 10.1002/ajim.20264; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Barnig C, 2013, LETT APPL MICROBIOL, V56, P161, DOI 10.1111/lam.12024; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bloom Barbara, 2010, Vital Health Stat 10, P1; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Dreskin SC, 2010, CLIN IMMUNOL, V137, P366, DOI 10.1016/j.clim.2010.08.009; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Flokstra-de Blok BMJ, 2010, ALLERGY, V65, P238, DOI 10.1111/j.1398-9995.2009.02121.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gupta RS, 2012, CLIN PEDIATR, V51, P856, DOI 10.1177/0009922812448526; Keet CA, 2012, J ALLERGY CLIN IMMUN, V130, P1207, DOI 10.1016/j.jaci.2012.07.020; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Kumar R, 2011, PEDIATRICS, V128, pE821, DOI 10.1542/peds.2011-0691; Lee A, 2006, INT ARCH ALLERGY IMM, V141, P396, DOI 10.1159/000095467; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Silvers KM, 2012, J PEDIATR-US, V160, DOI 10.1016/j.jpeds.2011.11.055; Sverremark-Ekstrom E, 2012, PEDIAT ALLERG IMM-UK, V23, P224, DOI 10.1111/j.1399-3038.2012.01290.x; Tay SS, 2007, CLIN EXP ALLERGY, V37, P1512, DOI 10.1111/j.1365-2222.2007.02802.x; Taylor-Black S, 2012, ANN ALLERG ASTHMA IM, V109, P431, DOI 10.1016/j.anai.2012.09.012; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Woods RK, 2002, EUR J CLIN NUTR, V56, P31, DOI 10.1038/sj.ejcn.1601306	37	49	50	0	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					171	U261		10.1016/j.jaci.2014.06.033	http://dx.doi.org/10.1016/j.jaci.2014.06.033			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25129677	Green Accepted			2022-12-18	WOS:000347298200021
J	Bourdin, A; Molinari, N; Vachier, I; Varrin, M; Marin, G; Gamez, AS; Paganin, F; Chanez, P				Bourdin, Arnaud; Molinari, Nicolas; Vachier, Isabelle; Varrin, Muriel; Marin, Gregory; Gamez, Anne-Sophie; Paganin, Fabrice; Chanez, Pascal			Prognostic value of cluster analysis of severe asthma phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Clusters; outcomes; prospective study; exacerbation	IDENTIFICATION; EXACERBATIONS; HISTORY; ADULTS	Background: Cross-sectional severe asthma cluster analysis identified different phenotypes. We tested the hypothesis that these clusters will follow different courses. Objective: We aimed to identify which asthma outcomes are specific and coherently associated with these different phenotypes in a prospective longitudinal cohort. Methods: In a longitudinal cohort of 112 patients with severe asthma, the 5 Severe Asthma Research Program (SARP) clusters were identified by means of algorithm application. Because patients of the present cohort all had severe asthma compared with the SARP cohort, homemade clusters were identified and also tested. At the subsequent visit, we investigated several outcomes related to asthma control at 1 year (6-item Asthma Control Questionnaire [ACQ-6], lung function, and medication requirement) and then recorded the 3-year exacerbations rate and time to first exacerbation. Results: The SARP algorithm discriminated the 5 clusters at entry for age, asthma duration, lung function, blood eosinophil measurement, ACQ-6 scores, and diabetes comorbidity. Four homemade clusters were mostly segregated by best ever achieved FEV1 values and discriminated the groups by a few clinical characteristics. Nonetheless, all these clusters shared similar asthma outcomes related to asthma control as follows. The ACQ-6 score did not change in any cluster. Exacerbation rate and time to first exacerbation were similar, as were treatment requirements. Conclusion: Severe asthma phenotypes identified by using a previously reported cluster analysis or newly homemade clusters do not behave differently concerning asthma control-related outcomes, which are used to assess the response to innovative therapies. This study demonstrates a potential limitation of the cluster analysis approach in the field of severe asthma.	[Bourdin, Arnaud; Vachier, Isabelle; Marin, Gregory; Gamez, Anne-Sophie] Dept Resp Dis, Montpellier, France; [Bourdin, Arnaud; Molinari, Nicolas] Univ Montpellier I, Hop Arnaud Villeneuve, INSERM, U1046, Montpellier, France; [Bourdin, Arnaud; Molinari, Nicolas] Univ Montpellier 2, Hop Arnaud Villeneuve, INSERM, U1046, Montpellier, France; [Molinari, Nicolas; Varrin, Muriel; Marin, Gregory] Grp Hosp Sud Reun, Dept Resp Dis, St Pierre La Reunion, France; [Chanez, Pascal] AP HM, Dept Malad Resp, Marseille, France; [Chanez, Pascal] Aix Marseille Univ, UMR7733, Lab INSERM CNRS 1067, Marseille, France	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; CHU Reunion; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Bourdin, A (corresponding author), Hop Arnaud Villeneuve, Dept Resp Dis, 371 Av Doyen Giraud, F-34295 Montpellier 5, France.	a-bourdin@chu-montpellier.fr	Vachier, Isabelle/AAV-5731-2020; molinari, nicolas/Y-9681-2019	Vachier, Isabelle/0000-0003-2730-5165; chanez, pascal/0000-0003-4059-0917	Janse; AstraZeneca; GlaxoSmithKline; Boston Scientific	Janse; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Boston Scientific(Boston Scientific)	A. Bourdin has board memberships with Boehringer Ingelheim and GlaxoSmithKline. F. Paganin is a board member for Novartis. P. Chanez has board memberships with GlaxoSmithKline, AstraZeneca, Chiesi, and Boston Scientific; has consultant arrangements with Novartis; has received research support from Jansen; has received payment for lectures from AstraZeneca, GlaxoSmithKline, Boston Scientific; and has received travel support from Chiesi, Novartis, and AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest.	Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Bourdin A, 2012, CLIN EXP ALLERGY, V42, P1566, DOI 10.1111/j.1365-2222.2012.04018.x; Bourdin A, 2013, EUR RESPIR J, V41, P1247, DOI 10.1183/09031936.00003313; Bourdin A, 2012, CLIN CHEST MED, V33, P585, DOI 10.1016/j.ccm.2012.06.004; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Federico MJ, 2007, J ALLERGY CLIN IMMUN, V119, P50, DOI 10.1016/j.jaci.2006.10.019; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Halimi L, 2010, J PSYCHOSOM RES, V69, P331, DOI 10.1016/j.jpsychores.2010.02.007; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST	22	49	49	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1043	1050		10.1016/j.jaci.2014.04.038	http://dx.doi.org/10.1016/j.jaci.2014.04.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24985405	Bronze			2022-12-18	WOS:000344938900007
J	Radhakrishnan, DK; Dell, SD; Guttmann, A; Shariff, SZ; Liu, K; To, T				Radhakrishnan, Dhenuka Kannan; Dell, Sharon D.; Guttmann, Astrid; Shariff, Salimah Z.; Liu, Kuan; To, Teresa			Trends in the age of diagnosis of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; incidence; prevalence; rate; epidemiology; administrative data	1ST 6 YEARS; AIRWAY RESPONSIVENESS; LUNG-FUNCTION; CHILDREN; PREVALENCE; LIFE	Background: The cause of rising asthma incidence over time remains unexplained. Examining trends in the age of diagnosis across successive birth cohorts may offer insights into asthma etiology. Objective: To examine trends in the age at asthma diagnosis and the age and proportion of children hospitalized at first asthma diagnosis in Ontario, Canada. Methods: Eight consecutive birth cohorts of children (1993-2000) were observed using administrative data from a universal health insurance plan in Ontario, Canada (population 13 million). Trends in the need for hospitalization and age at asthma diagnosis were examined with descriptive and survival analyses. Results: The records of 1,059,511 children were examined, of whom 201,958 developed asthma in the first 8 years of life, with an average cumulative incidence of 19.1%. Mean age at asthma diagnosis decreased from 4.7 +/- 1.5 years in birth year 1993 to 2.6 +/- 2.0 years in birth year 2000 (P < .0001), with a higher adjusted risk of asthma diagnosis (hazard ratio, 6.7; 95% CI, 6.5-6.9) in the first 3 years of life for children born after 1996 versus children born in the period 1993 to 1995 (hazard ratio, 1.4; 95% CI, 1.3-1.4). The proportion of children hospitalized at asthma diagnosis stayed stable while the age at first asthma hospitalization decreased over time (P < .0001). Conclusions: This study demonstrates a significant increase in asthma incidence and a decrease in the age of asthma diagnosis across multiple birth cohorts. Changes in asthma incidence over time are primarily explained by variations in asthma rates in children younger than 3 years.	[Radhakrishnan, Dhenuka Kannan] Childrens Hosp, London Hlth Sci Ctr, London, ON N6A 5W9, Canada; [Radhakrishnan, Dhenuka Kannan] Western Univ, Dept Pediat, Salt Lake City, UT USA; [Radhakrishnan, Dhenuka Kannan; Shariff, Salimah Z.; Liu, Kuan] Inst Clin Evaluat Sci, London, ON, Canada; [Dell, Sharon D.] Hosp Sick Children, Div Resp Med, Toronto, ON, Canada; [Dell, Sharon D.; Guttmann, Astrid] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Dell, Sharon D.; Guttmann, Astrid] Univ Toronto, Dept Pediat, Toronto, ON M5S 1A1, Canada; [Guttmann, Astrid] Hosp Sick Children, Div Pediat Med, Toronto, ON, Canada; [Guttmann, Astrid; To, Teresa] Inst Clin Evaluat Sci, London, ON, Canada; [To, Teresa] Inst Clin Evaluat Sci, Child Hlth Evaluat Sci, London, ON, Canada; [To, Teresa] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada	London Health Sciences Centre; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Radhakrishnan, DK (corresponding author), Childrens Hosp, London Hlth Sci Ctr, 800 Commissioners Rd East, London, ON N6A 5W9, Canada.	dhenuka@gmail.com		Liu, Kuan/0000-0002-5017-1276; Shariff, Salimah/0000-0002-1219-6763; Dell, Sharon/0000-0003-2169-9407	Hospital for Sick Children Research Training Centre; Ontario Thoracic Society; Ontario Ministry of Health; Academic Medical Organization of Southwestern Ontario (AMOSO); Lawson Health Research Institute (LHRI)	Hospital for Sick Children Research Training Centre; Ontario Thoracic Society; Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Academic Medical Organization of Southwestern Ontario (AMOSO); Lawson Health Research Institute (LHRI)	D. K. R. received a Restracomp award from the Hospital for Sick Children Research Training Centre and a fellowship award from the Ontario Thoracic Society toward this research. A. G. receives salary support from a Canadian Institute for Health Research Applied Chair in Child Health Services and Policy Research. This study was supported by the Institute for Clinical Evaluative Sciences (ICES) Western site. ICES is a nonprofit organization funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Core funding for ICES Western is provided by the Academic Medical Organization of Southwestern Ontario (AMOSO), the Schulich School of Medicine and Dentistry (SSMD), Western University, and the Lawson Health Research Institute (LHRI). The opinions, results, and conclusions are those of the authors and are independent from the funding sources. No endorsement by ICES, AMOSO, SSMD, LHRI, or the Ontario MOHLTC is intended or should be inferred.	Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; [Anonymous], SAS 9 2; [Anonymous], 2013, I CLIN EVALUATIVE SC; Boulet L P, 1999, CMAJ, V161, pSF1; Boulet L P, 1999, Can Respir J, V6, P231; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Chawla J, 2012, PEDIATR PULM, V47, P211, DOI 10.1002/ppul.21537; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fay MP, 1997, STAT MED, V16, P791; Fitzgerald S T, 1992, AAOHN J, V40, P376; Garner Rochelle, 2008, Health Rep, V19, P45; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Kovesi T, 2010, CAN MED ASSOC J, V182, pE172, DOI 10.1503/cmaj.071638; Kwong GNM, 2001, THORAX, V56, P312, DOI 10.1136/thorax.56.4.312; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2002, PEDIATRICS, V109, P362; Pearce N, 2006, INT J TUBERC LUNG D, V10, P125; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Thomas Eleanor M, 2010, Health Rep, V21, P47; To T, 2006, PEDIAT ALLERG IMM-UK, V17, P69, DOI 10.1111/j.1399-3038.2005.00346.x; TO T, 2004, AM J RESP CRIT CARE, V169, pA383; To T, 2004, ICES INV REP; To T, 2006, ICES INV REP; Turner SW, 2009, AM J RESP CRIT CARE, V179, P98, DOI 10.1164/rccm.200805-804OC; Wang Lei, 2008, Birth Defects Research, V84, P54, DOI 10.1002/bdrc.20114; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016	28	49	50	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1057	+		10.1016/j.jaci.2014.05.012	http://dx.doi.org/10.1016/j.jaci.2014.05.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24985402				2022-12-18	WOS:000344938900009
J	Pieper, K; Rizzi, M; Speletas, M; Smulski, CR; Sic, H; Kraus, H; Salzer, U; Fiala, GJ; Schamel, WW; Lougaris, V; Plebani, A; Hammarstrom, L; Recher, M; Germenis, AE; Grimbacher, B; Warnatz, K; Rolink, AG; Schneider, P; Notarangelo, LD; Eibel, H				Pieper, Kathrin; Rizzi, Marta; Speletas, Matthaios; Smulski, Cristian R.; Sic, Heiko; Kraus, Helene; Salzer, Ulrich; Fiala, Gina J.; Schamel, Wolfgang W.; Lougaris, Vassilios; Plebani, Alessandro; Hammarstrom, Lennart; Recher, Mike; Germenis, Anastasios E.; Grimbacher, Bodo; Warnatz, Klaus; Rolink, Antonius G.; Schneider, Pascal; Notarangelo, Luigi D.; Eibel, Hermann			A common single nucleotide polymorphism impairs B-cell activating factor receptor's multimerization, contributing to common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BAFF		[Pieper, Kathrin; Rizzi, Marta; Sic, Heiko; Kraus, Helene; Salzer, Ulrich; Fiala, Gina J.; Schamel, Wolfgang W.; Grimbacher, Bodo; Warnatz, Klaus; Eibel, Hermann] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Pieper, Kathrin; Sic, Heiko; Kraus, Helene] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Speletas, Matthaios; Germenis, Anastasios E.] Univ Thessaly, Fac Med, Dept Immunol & Histocompatibil, Larisa, Greece; [Smulski, Cristian R.; Schneider, Pascal] Univ Lausanne, Fac Med, Dept Biochem, Lausanne, Switzerland; [Fiala, Gina J.; Schamel, Wolfgang W.] Univ Freiburg, Inst Biol 3, Fac Biol, D-79106 Freiburg, Germany; [Fiala, Gina J.; Schamel, Wolfgang W.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Spedali Civili, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Plebani, Alessandro] Univ Brescia, Spedali Civili, A Nocivelli Inst Mol Med, Brescia, Italy; [Hammarstrom, Lennart] Karolinska Inst, Dept Lab Med, Huddinge, Sweden; [Recher, Mike] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Recher, Mike] Childrens Hosp, Manton Ctr Orphan Dis, Res Ctr, Boston, MA 02115 USA; [Rolink, Antonius G.; Notarangelo, Luigi D.] Univ Basel, Dept Biomed, Basel, Switzerland	University of Freiburg; University of Freiburg; University of Thessaly; University of Geneva; University of Lausanne; University of Freiburg; University of Freiburg; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Karolinska Institutet; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Basel	Salzer, U (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany.	hermann.eibel@uniklinik-freiburg.de	Rizzi, Marta/ABE-7264-2020; Germenis, Anastasios/H-5269-2019; Notarangelo, Luigi D/F-9718-2016; Warnatz, Klaus/AAD-3464-2022	Germenis, Anastasios/0000-0002-3315-6947; Notarangelo, Luigi D/0000-0002-8335-0262; Schneider, Pascal/0000-0003-0677-9409; Salzer, Ulrich/0000-0002-1769-1157; de la Rosa (nee Pieper), Kathrin/0000-0003-4809-3157; Recher, Mike/0000-0002-9121-6936; Smulski, Cristian/0000-0003-4186-8116; Fiala, Gina/0000-0002-8226-5584; Rizzi, Marta/0000-0002-5153-6089				Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Losi CG, 2005, J CLIN IMMUNOL, V25, P496, DOI 10.1007/s10875-005-5637-2; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106	7	49	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1222	1225		10.1016/j.jaci.2013.11.021	http://dx.doi.org/10.1016/j.jaci.2013.11.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24406071	Bronze			2022-12-18	WOS:000333531700039
J	Chang, TS; Lemanske, RF; Mauger, DT; Fitzpatrick, AM; Sorkness, CA; Szefler, SJ; Gangnon, RE; Page, CD; Jackson, DJ				Chang, Timothy S.; Lemanske, Robert F., Jr.; Mauger, David T.; Fitzpatrick, Anne M.; Sorkness, Christine A.; Szefler, Stanley J.; Gangnon, Ronald E.; Page, C. David; Jackson, Daniel J.		Childhood Asthma Res Educ CARE	Childhood asthma clusters and response to therapy in clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; clustering; clinical trials; replication; pediatric; therapy response	PHENOTYPES; IDENTIFICATION; IMPUTATION; CHILDREN	Background: Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. Objective: To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in Childhood Asthma Research and Education (CARE) Network clinical trials. Methods: A cluster assignment model was determined by using SARP participant data. A total of 611 participants 6 to 18 years old from 3 CARE trials were assigned to SARP pediatric clusters. Primary and secondary outcomes were analyzed by cluster in each trial. Results: CARE participants were assigned to SARP clusters with high accuracy. Baseline characteristics were similar between SARP and CARE children of the same cluster. Treatment response in CARE trials was generally similar across clusters. However, with the caveat of a smaller sample size, children in the early-onset/severe-lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Giving Effective Responses trial; P=.011) and children in the early-onset/comorbidity cluster had the least clinical efficacy to treatments (eg, -0.076% change in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticosteroid trial). Conclusions: In this study, we replicated SARP pediatric asthma clusters by using a separate, large clinical trials network. Early-onset/severe-lung function and early-onset/comorbidity clusters were associated with differential and limited response to therapy, respectively. Further prospective study of therapeutic response by cluster could provide new insights into childhood asthma treatment.	[Chang, Timothy S.; Gangnon, Ronald E.; Page, C. David] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; [Lemanske, Robert F., Jr.; Sorkness, Christine A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; [Mauger, David T.] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA; [Fitzpatrick, Anne M.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Denver, CO USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Emory University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jackson, DJ (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Sect Allergy Immunol & Rheumatol,Clin Sci Ctr K4, 600 Highland Ave, Madison, WI 53792 USA.	djj@medicine.wisc.edu		Chang, Timothy/0000-0002-9225-9874; Fitzpatrick, Anne/0000-0002-2933-5926; Gangnon, Ronald/0000-0003-2587-6714; Szefler, Stanley/0000-0002-6911-3199	Clinical and Translational Science Award (CTSA) program through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; National Heart, Lung, and Blood Institute (NHLBI) [F30HL112491, 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; Washington University School of Medicine CTSA Infrastructure for Pediatric Research [5UL1RR02499204]; Madison CTSA [1UL1RR025011]; National Center for Research Resources [UL1RR025780];  [M01 RR00036];  [M01 RR00051];  [5M01 RR00997]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, KL2TR000428, UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997, UL1RR025780, M01RR000051, M01RR000036, UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064313, U10HL064305, U10HL064288, U10HL064287, F30HL112491, U10HL064295, U10HL064307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	Clinical and Translational Science Award (CTSA) program through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Washington University School of Medicine CTSA Infrastructure for Pediatric Research; Madison CTSA; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ; ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by the Clinical and Translational Science Award (CTSA) program through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) UL1TR000427 and National Heart, Lung, and Blood Institute (NHLBI) Fellowship F30HL112491. The study was also supported by grants (5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313) from the NHLBI; a grant (5UL1RR02499204) from the Washington University School of Medicine CTSA Infrastructure for Pediatric Research; a grant (1UL1RR025011) from the Madison CTSA; a grant (UL1RR025780) to the Colorado CTSA from the National Center for Research Resources; and grants to the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), National Jewish Health (M01 RR00051), and the University of New Mexico (5M01 RR00997).	Agache I, 2010, PHYSICIAN SPORTSMED, V38, P81, DOI 10.3810/psm.2010.12.1829; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Durham A, 2011, CURR PHARM DESIGN, V17, P674, DOI 10.2174/138161211795428984; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Halekoh U, 2006, J STAT SOFTW, V15, P1, DOI 10.18637/jss.v015.i02; HEITJAN DF, 1991, J R STAT SOC C-APPL, V40, P13; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; Rubin DB, 2004, MULTIPLE IMPUTATION; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sekigawa T, 2009, CLIN EXP ALLERGY, V39, P972, DOI 10.1111/j.1365-2222.2009.03229.x; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Sorkness RL, 2011, J ALLERGY CLIN IMMUN, V127, P1073, DOI 10.1016/j.jaci.2010.12.1079; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Therneau TM, 2003, J COMPUT GRAPH STAT, V12, P156, DOI 10.1198/1061860031365; van Buuren S, 2011, J STAT SOFTW, V45, P1; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	27	49	49	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					363	+		10.1016/j.jaci.2013.09.002	http://dx.doi.org/10.1016/j.jaci.2013.09.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24139497	Green Accepted			2022-12-18	WOS:000332397100008
J	Greer, RL; Morgun, A; Shulzhenko, N				Greer, Renee L.; Morgun, Andrey; Shulzhenko, Natalia			Bridging immunity and lipid metabolism by gut microbiota	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Immunity; immunodeficiency; gut microbiota; intestinal lipid metabolism	INFLAMMATORY-BOWEL-DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; DIET-INDUCED OBESITY; GERM-FREE-MICE; FATTY-ACIDS; EARLY-LIFE; INSULIN-RESISTANCE; PLASMA GHRELIN; IN-VITRO; ENTEROPATHY	The human gut is a unique organ in which hundreds of different microbial species find their habitat and in which different host physiologic functions, such as digestion, nutrition, and immunity, coexist. Although all these players were studied separately for decades, recently, there has been an explosion of studies demonstrating the essential role for interactions between these components in gut function. Furthermore, new systems biology methods provide essential tools to study this complex system as a whole and to identify key elements that define the crosstalk between the gut microbiota, immunity, and metabolism. This review is devoted to several human diseases resulting from the disruption in this crosstalk, including immunodeficiency-associated and environmental enteropathies, celiac disease, inflammatory bowel disease, and obesity. We describe findings in experimental models of these diseases and in germ-free animals that help us understand the mechanisms and test new therapeutic strategies. We also discuss current challenges that the field is facing and propose that a new generation of antibiotics, prebiotics, and probiotics coupled with novel, systems biology-driven diagnostics will provide the basis for future personalized therapy.	[Greer, Renee L.; Shulzhenko, Natalia] Oregon State Univ, Coll Vet Med, Corvallis, OR 97331 USA; [Morgun, Andrey] Oregon State Univ, Coll Pharm, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Shulzhenko, N (corresponding author), 105 Dryden Hall,300 SW 30th St, Corvallis, OR 97331 USA.	natalia.shulzhenko@oregonstate.edu						Agarwal S, 2009, J ALLERGY CLIN IMMUN, V124, P658, DOI 10.1016/j.jaci.2009.06.018; Armougom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007125; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; BALINT JA, 1980, AM J CLIN NUTR, V33, P2276, DOI 10.1093/ajcn/33.11.2276; BATMAN PA, 1989, J CLIN PATHOL, V42, P275, DOI 10.1136/jcp.42.3.275; Battle MA, 2008, GASTROENTEROLOGY, V135, P1676, DOI 10.1053/j.gastro.2008.07.074; BAUER H, 1963, AM J PATHOL, V42, P471; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; BERNET MF, 1993, APPL ENVIRON MICROB, V59, P4121, DOI 10.1128/AEM.59.12.4121-4128.1993; Black KE, 2002, J IMMUNOL, V169, P5595, DOI 10.4049/jimmunol.169.10.5595; Black MM, 2008, LANCET, V371, P454, DOI 10.1016/S0140-6736(08)60215-9; Blanc M, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000598; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Butaye P, 2003, CLIN MICROBIOL REV, V16, P175, DOI 10.1128/CMR.16.2.175-188.2003; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12.1519, 10.3748/wjg.v17.i12. 1519]; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Caricilli AM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001212; Carvalho BM, 2012, DIABETOLOGIA, V55, P2823, DOI 10.1007/s00125-012-2648-4; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Collado MC, 2009, J CLIN PATHOL, V62, P264, DOI 10.1136/jcp.2008.061366; CUMMINS AG, 1990, GUT, V31, P317, DOI 10.1136/gut.31.3.317; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Wit NJW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019145; Desbonnet L, 2010, NEUROSCIENCE, V170, P1179, DOI 10.1016/j.neuroscience.2010.08.005; Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225; Dewey KG, 2008, MATERN CHILD NUTR, V4, P24, DOI 10.1111/j.1740-8709.2007.00124.x; Di Sabatino A, 2005, ALIMENT PHARM THER, V22, P789, DOI 10.1111/j.1365-2036.2005.02639.x; Ding SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012191; Duboc H, 2013, GUT, V62, P531, DOI 10.1136/gutjnl-2012-302578; Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155; Erickson AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049138; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Everard A, 2011, DIABETES, V60, P2775, DOI 10.2337/db11-0227; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; Francois F, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-37; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Galipeau HJ, 2011, J IMMUNOL, V187, P4338, DOI 10.4049/jimmunol.1100854; Gao ZG, 2009, DIABETES, V58, P1509, DOI 10.2337/db08-1637; Gori A, 2011, MUCOSAL IMMUNOL, V4, P554, DOI 10.1038/mi.2011.15; Gori A, 2008, J CLIN MICROBIOL, V46, P757, DOI 10.1128/JCM.01729-07; Graham DB, 2013, TRENDS IMMUNOL; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Guerrant RL, 2008, NUTR REV, V66, P487, DOI 10.1111/j.1753-4887.2008.00082.x; Hallert C, 2003, INFLAMM BOWEL DIS, V9, P116, DOI 10.1097/00054725-200303000-00005; Hapfelmeier S, 2010, SCIENCE, V328, P1705, DOI 10.1126/science.1188454; Hardenberg G, 2012, INFLAMM BOWEL DIS, V18, P85, DOI 10.1002/ibd.21738; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; HOVERSTAD T, 1986, J NUTR, V116, P1772, DOI 10.1093/jn/116.9.1772; HUGHES WS, 1971, ANN INTERN MED, V74, P903, DOI 10.7326/0003-4819-74-6-903; Jumpertz R, 2011, AM J CLIN NUTR, V94, P58, DOI 10.3945/ajcn.110.010132; Kadooka Y, 2010, EUR J CLIN NUTR, V64, P636, DOI 10.1038/ejcn.2010.19; Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198; KATZ SI, 1972, J CLIN INVEST, V51, P2977, DOI 10.1172/JCI107123; Kellermayer R, 2011, FASEB J, V25, P1449, DOI 10.1096/fj.10-172205; Koch J, 1996, NUTRITION, V12, P507, DOI 10.1016/S0899-9007(96)91728-1; Kumar R, 2011, SURGERY, V149, P654, DOI 10.1016/j.surg.2010.11.015; Kupfer Sonia S, 2012, Gastrointest Endosc Clin N Am, V22, P639, DOI 10.1016/j.giec.2012.07.003; Laparra JM, 2010, INT J BIOL MACROMOL, V47, P458, DOI 10.1016/j.ijbiomac.2010.06.015; Laparra JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030744; Letran SE, 2011, J IMMUNOL, V186, P5406, DOI 10.4049/jimmunol.1003576; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Longo-Mbenza B, 2007, INT J CARDIOL, V121, P229, DOI 10.1016/j.ijcard.2006.12.003; Luzi G, 2003, AM J GASTROENTEROL, V98, P118; Macfarlane GT, 2011, J CLIN GASTROENTEROL, V45, pS120, DOI 10.1097/MCG.0b013e31822fecfe; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P117; Malamut G, 2010, AM J GASTROENTEROL, V105, P2262, DOI 10.1038/ajg.2010.214; Mannon PJ, 2006, GASTROENTEROLOGY, V131, P748, DOI 10.1053/j.gastro.2006.06.022; McKay S, 2010, INT HEALTH, V2, P172, DOI 10.1016/j.inhe.2010.07.006; Medina M, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-19; Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723; MILLER ARO, 1988, Q J MED, V69, P1009; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Odstrcil EA, 2010, AM J CLIN NUTR, V92, P704, DOI 10.3945/ajcn.2010.29870; Ohta N, 2002, J IMMUNOL, V169, P460, DOI 10.4049/jimmunol.169.1.460; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Osawa H, 2006, J GASTROENTEROL, V41, P954, DOI 10.1007/s00535-006-1880-4; OZAWA E, 1955, J ANTIBIOT, V8, P212; Petit V, 2007, J LIPID RES, V48, P278, DOI 10.1194/jlr.M600283-JLR200; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rabot S, 2010, FASEB J, V24, P4948, DOI 10.1096/fj.10-164921; Rizzello M, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/670418; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; SAGHER FA, 1991, BRIT J NUTR, V65, P21, DOI 10.1079/BJN19910062; Salminen S, 1998, BRIT J NUTR, V80, pS147, DOI 10.1079/BJN19980108; Sandler RH, 2000, J CHILD NEUROL, V15, P429, DOI 10.1177/088307380001500701; SANFORD JP, 1954, NEW ENGL J MED, V250, P1027, DOI 10.1056/NEJM195406172502403; Schwiertz A, 2010, OBESITY, V18, P190, DOI 10.1038/oby.2009.167; Semova I, 2012, CELL HOST MICROBE, V12, P277, DOI 10.1016/j.chom.2012.08.003; Shanahan F, 2012, NUTR REV, V70, pS31, DOI 10.1111/j.1753-4887.2012.00502.x; Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505; SINGH A, 1972, BIOCHIM BIOPHYS ACTA, V260, P708, DOI 10.1016/0005-2760(72)90019-7; Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000; Sollid LM, 2005, CLIN GASTROENTEROL H, V3, P843, DOI 10.1016/S1542-3565(05)00532-X; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; Stefater MA, 2012, ENDOCR REV, V33, P595, DOI 10.1210/er.2011-1044; Stepankova R, 2003, J PEDIATR GASTR NUTR, V36, P96, DOI 10.1097/00005176-200301000-00018; Stienstra R, 2011, P NATL ACAD SCI USA, V108, P15324, DOI 10.1073/pnas.1100255108; Trasande L, 2013, INT J OBESITY, V37, P16, DOI 10.1038/ijo.2012.132; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Ueno PM, 2011, AM J PHYSIOL-GASTR L, V301, pG612, DOI 10.1152/ajpgi.00531.2010; ULLRICH R, 1991, IMMUNOL RES, V10, P456, DOI 10.1007/BF02919742; Upadhyay V, 2012, NAT IMMUNOL, V13, P947, DOI 10.1038/ni.2403; Varga O, 2010, OBES REV, V11, P792, DOI 10.1111/j.1467-789X.2009.00667.x; Vaughan EE, 2002, ANTON LEEUW INT J G, V82, P341, DOI 10.1023/A:1020672724450; Verdu EF, 2008, AM J PHYSIOL-GASTR L, V294, pG217, DOI 10.1152/ajpgi.00225.2007; Vijay-Kumar M, 2007, J CLIN INVEST, V117, P3909, DOI 10.1172/JCI33084; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858; Wacklin P, 2013, INFLAMM BOWEL DIS, V19, P934, DOI 10.1097/MIB.0b013e31828029a9; Watterson S, 2013, BIOCHIMIE, V95, P613, DOI 10.1016/j.biochi.2012.05.024; Wei XC, 2012, CELL HOST MICROBE, V11, P140, DOI 10.1016/j.chom.2011.12.006; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; WOSTMANN BS, 1983, LAB ANIM SCI, V33, P46; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yokoyama S, 2011, J CLIN IMMUNOL, V31, P1038, DOI 10.1007/s10875-011-9586-7	127	49	51	1	66	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					253	263		10.1016/j.jaci.2013.06.025	http://dx.doi.org/10.1016/j.jaci.2013.06.025			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23905915				2022-12-18	WOS:000322631700002
J	Ives, ML; Ma, CS; Palendira, U; Chan, A; Bustamante, J; Boisson-Dupuis, S; Arkwright, PD; Engelhard, D; Averbuch, D; Magdorf, K; Roesler, J; Peake, J; Wong, M; Adelstein, S; Choo, S; Smart, JM; French, MA; Fulcher, DA; Cook, MC; Picard, C; Durandy, A; Tsumura, M; Kobayashi, M; Uzel, G; Casanova, JL; Tangye, SG; Deenick, EK				Ives, Megan L.; Ma, Cindy S.; Palendira, Umaimainthan; Chan, Anna; Bustamante, Jacinta; Boisson-Dupuis, Stephanie; Arkwright, Peter D.; Engelhard, Dan; Averbuch, Diana; Magdorf, Klaus; Roesler, Joachim; Peake, Jane; Wong, Melanie; Adelstein, Stephen; Choo, Sharon; Smart, Joanne M.; French, Martyn A.; Fulcher, David A.; Cook, Matthew C.; Picard, Capucine; Durandy, Anne; Tsumura, Miyuki; Kobayashi, Masao; Uzel, Gulbu; Casanova, Jean-Laurent; Tangye, Stuart G.; Deenick, Elissa K.			Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autosomal dominant hyper-IgE syndrome; STAT3; STAT1; IL-21; human CD8(+) T cells; memory; differentiation	CHRONIC VIRAL-INFECTION; COMMON GAMMA-CHAIN; IL-21 RECEPTOR; IN-VIVO; IFN-GAMMA; ADAPTIVE IMMUNITY; INBORN-ERRORS; CUTTING EDGE; NK CELLS; IL-15	Background: The capacity of CD8(+) T cells to control infections and mediate antitumor immunity requires the development and survival of effector and memory cells. IL-21 has emerged as a potent inducer of CD8(+) T-cell effector function and memory development in mouse models of infectious disease. However, the role of IL-21 and associated signaling pathways in protective CD8(+) T-cell immunity in human subjects is unknown. Objective: We sought to determine which signaling pathways mediate the effects of IL-21 on human CD8(+) T cells and whether defects in these pathways contribute to disease pathogenesis in patients with primary immunodeficiencies caused by mutations in components of the IL-21 signaling cascade. Methods: Human primary immunodeficiencies resulting from monogenic mutations provide a unique opportunity to assess the requirement for particular molecules in regulating human lymphocyte function. Lymphocytes from patients with loss-offunction mutations in signal transducer and activator of transcription 1 (STAT1), STAT3, or IL-21 receptor (IL21R) were used to assess the respective roles of these genes in human CD8(+) T-cell differentiation in vivo and in vitro. Results: Mutations in STAT3 and IL21R, but not STAT1, led to a decrease in multiple memory CD8(+) T-cell subsets in vivo, indicating that STAT3 signaling, possibly downstream of IL21R, regulates the memory cell pool. Furthermore, STAT3 was important for inducing the lytic machinery in IL-21-stimulated naive CD8(+) T cells. However, this defect was overcome by T-cell receptor engagement. Conclusion: The IL-21R/STAT3 pathway is required for many aspects of human CD8(+) T-cell behavior but in some cases can be compensated byother signals. This helps explain the relatively mild susceptibility to viral disease observed in STAT3-and IL-21Rdeficient subjects.	[Tangye, Stuart G.; Deenick, Elissa K.] St Vincents Hosp, Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW 2010, Australia; [Ives, Megan L.; Ma, Cindy S.; Palendira, Umaimainthan; Tangye, Stuart G.; Deenick, Elissa K.] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW, Australia; [Bustamante, Jacinta; Boisson-Dupuis, Stephanie; Picard, Capucine; Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Necker Branch,Sorbonne Paris Cite, Lab Human Genet Infect Dis,INSERM U90,Inst Imagin, Paris, France; [Bustamante, Jacinta; Picard, Capucine] Hop Necker Enfants Malad, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, Lab Human Genet Infect Dis, New York, NY 10021 USA; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hospital;, Manchester M13 9PL, Lancs, England; [Engelhard, Dan; Averbuch, Diana] Hadassah Hebrew Univ, Med Ctr, Dept Pediatr & Pediat Infect Dis, Jerusalem, Israel; [Magdorf, Klaus] Humboldt Univ, Dept Pediat Pneumol & Immunol, Charite, Berlin, Germany; Univ Clin Carl Gustav Carus, Dept Pediat, Dresden, Germany; [Peake, Jane] Royal Childrens Hosp Brisbane, Dept Paediat & Child Hlth, Brisbane, Qld, Australia; [Wong, Melanie] Childrens Hosp Westmead, Dept Immunol, Westmead, NSW, Australia; [Adelstein, Stephen] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Smart, Joanne M.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia; [French, Martyn A.] Royal Perth Hosp, Dept Clin Immunol, Melbourne, Vic, Australia; [French, Martyn A.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia; [Fulcher, David A.] Westmead Hosp, Inst Clin Pathol & Med Res, Dept Immunol, Westmead, NSW, Australia; [Cook, Matthew C.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Cook, Matthew C.] Canberra Hosp, Dept Immunol, Canberra, ACT, Australia; [Durandy, Anne] Hop Necker Enfants Malad, INSERM, Unite U768, Paris, France; [Durandy, Anne] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Tsumura, Miyuki; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed Sci, Dept Pediat, Hiroshima 730, Japan; [Uzel, Gulbu] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Royal Manchester Children's Hospital; University of Manchester; Hebrew University of Jerusalem; Hadassah University Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Royal Children's Hospital Brisbane; University of Sydney; University of Sydney; Royal Children's Hospital Melbourne; Royal Perth Hospital; University of Western Australia; University of Sydney; Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Deenick, EK (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Immunol Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.deenick@garvan.org.au	Boisson-Dupuis, Stéphanie/I-2040-2017; Adelstein, Stephen/I-7936-2016; Picard, Capucine/H-3914-2017; Peake, Jane/B-4488-2011; Bustamante, Jacinta/H-7877-2017; Palendira, Umaimainthan/AAA-6447-2022; Deenick, Elissa/AAY-8998-2020; Cook, matthew/F-4151-2019; Averbuch, Dina/ABA-6433-2020; Casanova, Jean-Laurent/I-3418-2017; Durandy, Anne/H-7475-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Tangye, Stuart G/H-4023-2014; S, Cindy/B-2340-2012	Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Adelstein, Stephen/0000-0001-7221-6298; Picard, Capucine/0000-0001-8788-5056; Bustamante, Jacinta/0000-0002-3439-2482; Deenick, Elissa/0000-0002-9271-0004; Cook, matthew/0000-0002-3331-9363; Durandy, Anne/0000-0001-7706-8466; Tangye, Stuart G/0000-0002-5360-5180; S, Cindy/0000-0001-5387-8413; Casanova, Jean-Laurent/0000-0002-7782-4169; Peake, Jane/0000-0001-9003-5861; Arkwright, Peter/0000-0002-7411-5375; French, Martyn/0000-0002-4644-1982	National Health and Medical Research Council (NHMRC) of Australia; Cancer Council NSW; Rockefeller University Center for 541 Clinical and Translational science [5UL1RR024143]; NHMRC of Australia; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089970, R37AI095983] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Rockefeller University Center for 541 Clinical and Translational science; NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by project and program grants from the National Health and Medical Research Council (NHMRC) of Australia (to E. K. D., S. G. T., C. S. M., D. A. F., and M. C. C.), Cancer Council NSW (to S. G. T. and U. P.), and Rockefeller University Center for 541 Clinical and Translational science (5UL1RR024143, to J.-L. C.). C. S. M. is a recipient of a Career Development Fellowship and S. G. T. is a recipient of a Principal Research Fellowship from the NHMRC of Australia.	Alves NL, 2005, J IMMUNOL, V175, P755, DOI 10.4049/jimmunol.175.2.755; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Banerjee A, 2010, J IMMUNOL, V185, P4988, DOI 10.4049/jimmunol.1002042; Barker BR, 2007, J IMMUNOL, V179, P3596, DOI 10.4049/jimmunol.179.6.3596; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Berard M, 2003, J IMMUNOL, V170, P5018, DOI 10.4049/jimmunol.170.10.5018; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Brennan AJ, 2010, CELL DEATH DIFFER, V17, P607, DOI 10.1038/cdd.2009.212; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Casey KA, 2007, J IMMUNOL, V178, P7640, DOI 10.4049/jimmunol.178.12.7640; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Chapgier A, 2006, J IMMUNOL, V176, P5078, DOI 10.4049/jimmunol.176.8.5078; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Cui WG, 2011, IMMUNITY, V35, P792, DOI 10.1016/j.immuni.2011.09.017; Di Carlo E, 2004, J IMMUNOL, V172, P1540, DOI 10.4049/jimmunol.172.3.1540; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182; Focosi D, 2010, J LEUKOCYTE BIOL, V87, P107, DOI 10.1189/jlb.0809566; Frederiksen KS, 2008, CANCER IMMUNOL IMMUN, V57, P1439, DOI 10.1007/s00262-008-0479-4; Freeman AF, 2009, PEDIATR RES, V65, p32R, DOI 10.1203/PDR.0b013e31819dc8c5; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; Heimall J, 2010, CLIN REV ALLERG IMMU, V38, P32, DOI 10.1007/s12016-009-8134-1; Hirata O, 2013, HAEMATOLOGICA; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Ichii H, 2004, J IMMUNOL, V173, P883, DOI 10.4049/jimmunol.173.2.883; Ichii H, 2002, NAT IMMUNOL, V3, P558, DOI 10.1038/ni802; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Jiao H, 2008, MOL IMMUNOL, V46, P202, DOI 10.1016/j.molimm.2008.07.001; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; Kotlarz D, 2013, J EXP MED, V210, P433, DOI 10.1084/jem.20111229; Kumanovics A, 2010, J CLIN IMMUNOL, V30, P886, DOI 10.1007/s10875-010-9452-z; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Li YQ, 2005, J IMMUNOL, V175, P2261, DOI 10.4049/jimmunol.175.4.2261; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lodolce JP, 2002, CYTOKINE GROWTH F R, V13, P429, DOI 10.1016/S1359-6101(02)00029-1; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ma HL, 2003, J IMMUNOL, V171, P608, DOI 10.4049/jimmunol.171.2.608; Maraskovsky E, 1996, J IMMUNOL, V157, P5315; Markley JC, 2010, BLOOD, V115, P3508, DOI 10.1182/blood-2009-09-241398; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2009, CURR OPIN IMMUNOL, V21, P487, DOI 10.1016/j.coi.2009.07.013; Moroz A, 2004, J IMMUNOL, V173, P900, DOI 10.4049/jimmunol.173.2.900; Nguyen H, 2010, J LEUKOCYTE BIOL, V87, P43, DOI 10.1189/jlb.0209086; Novy P, 2011, J IMMUNOL, V186, P2729, DOI 10.4049/jimmunol.1003009; Ostiguy V, 2007, J LEUKOCYTE BIOL, V82, P645, DOI 10.1189/jlb.0806494; Parmigiani A, 2011, HUM IMMUNOL, V72, P115, DOI 10.1016/j.humimm.2010.10.015; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Rutishauser RL, 2009, IMMUNITY, V31, P296, DOI 10.1016/j.immuni.2009.05.014; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Strengeil M, 2002, J IMMUNOL, V169, P3600, DOI 10.4049/jimmunol.169.7.3600; Strengell M, 2003, J IMMUNOL, V170, P5464, DOI 10.4049/jimmunol.170.11.5464; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002; Tamang DL, 2006, CYTOKINE, V36, P148, DOI 10.1016/j.cyto.2006.11.008; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; White L, 2007, BLOOD, V109, P3873, DOI 10.1182/blood-2006-09-045278; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194; Yu CR, 1998, J LEUKOCYTE BIOL, V64, P245, DOI 10.1002/jlb.64.2.245; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zeng R, 2007, BLOOD, V109, P4135, DOI 10.1182/blood-2006-10-054973; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	76	49	49	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					400	+		10.1016/j.jaci.2013.05.029	http://dx.doi.org/10.1016/j.jaci.2013.05.029			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23830147	Green Accepted			2022-12-18	WOS:000322631700018
J	Nair, P				Nair, Parameswaran			What is an "eosinophilic phenotype" of asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Sputum eosinophils; blood eosinophils; fraction of exhaled nitric oxide; asthma; phenotype	SPUTUM CELL COUNTS; AIRWAY; EXACERBATIONS; MEPOLIZUMAB; INFLAMMATION; ANTIBODY; DISEASE; TRIAL		[Nair, Parameswaran] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON L8N 4A6, Canada	McMaster University	Nair, P (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	parames@mcmaster.ca						BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; D'silva L, 2007, RESP MED, V101, P2217, DOI 10.1016/j.rmed.2007.05.010; D'silva L, 2011, CAN RESPIR J, V18, P144, DOI 10.1155/2011/430317; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; van Veen IH, 2009, J ALLERGY CLIN IMMUN, V124, P615, DOI 10.1016/j.jaci.2009.06.029; Wenzel S, 2013, N ENGL J MED; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134	23	49	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					81	83		10.1016/j.jaci.2013.05.007	http://dx.doi.org/10.1016/j.jaci.2013.05.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23727039				2022-12-18	WOS:000321052300010
J	Hasan, SA; Eksteen, B; Reid, D; Paine, HV; Alansary, A; Johannson, K; Gwozd, C; Goring, KAR; Vo, T; Proud, D; Kelly, MM				Hasan, Simon A.; Eksteen, Bertus; Reid, Danielle; Paine, Heather V.; Alansary, Abrar; Johannson, Kerri; Gwozd, Carol; Goring, Kimberly-Ann R.; Vo, Tina; Proud, David; Kelly, Margaret M.			Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung; interstitial lung disease; hypersensitivity pneumonitis; fibrosis; inflammation; IL-17A; neutrophils	IDIOPATHIC PULMONARY-FIBROSIS; USUAL INTERSTITIAL PNEUMONIA; LUNG-DISEASE; IMMUNE-RESPONSE; EXPRESSION; MICE; CYTOKINES; CELLS; INTERLEUKIN-17; INFLAMMATION	Background: Chronic hypersensitivity pneumonitis is characterized by pulmonary inflammation and fibrosis in response to repeated inhalation of mainly organic antigens. It is recognized that IL-17A is crucial for the development of pulmonary inflammation in murine models of experimental hypersensitivity pneumonitis, but its role in the development of pulmonary fibrosis has not been determined. Furthermore, the main cell type(s) that produce IL-17A in experimental hypersensitivity pneumonitis have not yet been identified. Objective: Our objectives were to test the hypothesis that IL-17A plays a central role in the development of pulmonary fibrosis in experimental hypersensitivity pneumonitis and to determine the main inflammatory cell type(s) responsible for IL-17A production. Methods: We used a mouse model of experimental hypersensitivity pneumonitis in which IL-17A was inhibited or neutrophils were depleted. We also used IL-17RA-deficient and RAG-2-deficient mice. Lung IL-17A-producing cells were identified by fluorescence-activated cell sorting of myeloid versus lymphoid cell populations, intracellular IL-17A staining, flow cytometry, and quantitative reverse transcription PCR for IL-17A mRNA. Results: We found that the development of pulmonary fibrosis depended on IL-17A and was significantly attenuated by neutrophil depletion. Neutrophils and monocytes/macrophages were the main cell types that expressed IL-17A in our model. Conclusions: We have identified the central roles of IL-17A and neutrophils in the pathogenesis of fibrosis in experimental hypersensitivity pneumonitis. We have also established that nonlymphocytic innate immune cells, specifically neutrophils and monocytes/macrophages, rather than T(H)17 lymphocytes, are the predominant source of IL-17A in experimental hypersensitivity pneumonitis.	[Hasan, Simon A.; Paine, Heather V.; Alansary, Abrar; Gwozd, Carol; Proud, David; Kelly, Margaret M.] Univ Calgary, Airway Inflammat Res Grp, Snyder Inst Chron Dis, Calgary, AB T2N 4Z6, Canada; [Hasan, Simon A.; Paine, Heather V.; Alansary, Abrar; Gwozd, Carol; Goring, Kimberly-Ann R.; Proud, David; Kelly, Margaret M.] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4Z6, Canada; [Eksteen, Bertus; Reid, Danielle; Johannson, Kerri; Vo, Tina] Univ Calgary, Dept Med, Calgary, AB T2N 4Z6, Canada; [Kelly, Margaret M.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB T2N 4Z6, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kelly, MM (corresponding author), Univ Calgary, Hlth Res Innovat Ctr, Snyder Inst Chron Dis, Rm 4AC66, Calgary, AB T2N 4Z6, Canada.	mmkelly@ucalgary.ca	Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210	Alberta Innovates Health Solutions; Lung Association of Alberta and the North West Territories; Medical Research Council [G0601816] Funding Source: researchfish; MRC [G0601816] Funding Source: UKRI	Alberta Innovates Health Solutions; Lung Association of Alberta and the North West Territories; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants from the Alberta Innovates Health Solutions and the Lung Association of Alberta and the North West Territories.	Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510; Bellini A, 2012, MUCOSAL IMMUNOL, V5, P140, DOI 10.1038/mi.2011.60; Borzone G, 2001, AM J RESP CRIT CARE, V163, P1648, DOI 10.1164/ajrccm.163.7.2006132; Brodlie M, 2011, EUR RESPIR J, V37, P1378, DOI 10.1183/09031936.00067110; Burton MJ, 2011, INFECT IMMUN, V79, P4977, DOI 10.1128/IAI.05718-11; Cailes JB, 1996, EUR RESPIR J, V9, P992, DOI 10.1183/09031936.96.09050992; Canadian Centre for Occupational Health and Safety (CCOHS), 1999, WHAT IS FARM LUNG; Chua F, 2007, AM J PATHOL, V170, P65, DOI 10.2353/ajpath.2007.060352; Churg A, 2006, AM J SURG PATHOL, V30, P201, DOI 10.1097/01.pas.0000184806.38037.3c; Churg A, 2009, AM J SURG PATHOL, V33, P1765, DOI 10.1097/PAS.0b013e3181bb2538; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; de Boer OJ, 2010, J PATHOL, V220, P499, DOI 10.1002/path.2667; Dovi JV, 2003, J LEUKOCYTE BIOL, V73, P448, DOI 10.1189/jlb.0802406; Dragon S, 2008, MOL IMMUNOL, V45, P160, DOI 10.1016/j.molimm.2007.04.027; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Fukuda Y, 1998, LAB INVEST, V78, P687; Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662; Gong Y, 2010, CELL TISSUE RES, V339, P437, DOI 10.1007/s00441-009-0908-5; Hayashi T, 1996, AM J PATHOL, V149, P1241; Joshi AD, 2009, AM J RESP CRIT CARE, V179, P705, DOI 10.1164/rccm.200811-1700OC; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kawabata K, 2000, AM J RESP CRIT CARE, V161, P2013, DOI 10.1164/ajrccm.161.6.9904047; Kelly MM, 2008, AM J RESP CELL MOL, V38, P227, DOI 10.1165/rcmb.2007-0045OC; Kelly MM, 2006, AM J RESP CRIT CARE, V174, P557, DOI 10.1164/rccm.200510-1648OC; Kinder BW, 2008, CHEST, V133, P226, DOI 10.1378/chest.07-1948; Leendertse M, 2009, INFECT IMMUN, V77, P485, DOI 10.1128/IAI.00863-08; Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; MARX JJ, 1990, AM J IND MED, V18, P263, DOI 10.1002/ajim.4700180304; Melnikov VY, 2001, J CLIN INVEST, V107, P1145, DOI 10.1172/JCI12089; Meneghin A, 2007, J CLIN INVEST, V117, P530, DOI 10.1172/JCI30595; Miyazaki Y, 2008, CHEST, V134, P1265, DOI 10.1378/chest.08-0866; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moran EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024048; Nagendra S, 2004, CYTOM PART A, V58A, P195, DOI 10.1002/cyto.a.20007; Obayashi Y, 1997, CHEST, V112, P1338, DOI 10.1378/chest.112.5.1338; Ohtani Y, 1999, INTERNAL MED, V38, P896, DOI 10.2169/internalmedicine.38.896; Oo YH, 2012, J HEPATOL, V57, P1044, DOI 10.1016/j.jhep.2012.07.008; Pardo A, 2000, AM J RESP CRIT CARE, V161, P1698, DOI 10.1164/ajrccm.161.5.9907065; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; Ribechini E, 2009, EUR J IMMUNOL, V39, P3538, DOI 10.1002/eji.200939530; Selman M, 1998, Curr Opin Pulm Med, V4, P9, DOI 10.1097/00063198-199801000-00003; Simonian PL, 2009, TRANSL RES, V154, P222, DOI 10.1016/j.trsl.2009.08.006; Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657; Solaymani-Dodaran M, 2007, QJM-INT J MED, V100, P233, DOI 10.1093/qjmed/hcm008; Velden J, 2012, AM J PHYSIOL-RENAL, V302, pF1663, DOI 10.1152/ajprenal.00683.2011; Vourlekis JS, 2004, AM J MED, V116, P662, DOI 10.1016/j.amjmed.2003.12.030; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11; Wetzler C, 2000, J INVEST DERMATOL, V115, P245, DOI 10.1046/j.1523-1747.2000.00029.x; Wilson MS, 2010, J EXP MED, V207, P535, DOI 10.1084/jem.20092121; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yoshimura A, 2010, J BIOCHEM, V147, P781, DOI 10.1093/jb/mvq043; 1998, AM J RESP CRIT CARE, V158, pS1	56	49	51	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1663	+		10.1016/j.jaci.2013.01.015	http://dx.doi.org/10.1016/j.jaci.2013.01.015			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23453796	Bronze			2022-12-18	WOS:000320532800027
J	Posthumus, J; James, HR; Lane, CJ; Matos, LA; Platts-Mills, TAE; Commins, SP				Posthumus, Jonathon; James, Hayley R.; Lane, Charles J.; Matos, Luis A.; Platts-Mills, Thomas A. E.; Commins, Scott P.			Initial description of pork-cat syndrome in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PROTEINS; MEAT; REACTIVITY; ALLERGY		[Posthumus, Jonathon; James, Hayley R.; Platts-Mills, Thomas A. E.; Commins, Scott P.] Univ Virginia Hlth Syst, Dept Internal Med, Charlottesville, VA 22903 USA; [Commins, Scott P.] Univ Virginia Hlth Syst, Dept Pediat, Div Allergy & Immunol, Charlottesville, VA USA; [Lane, Charles J.] Allergy Partners Lynchburg, Lynchburg, VA USA; [Matos, Luis A.] Asthma & Allergy Ctr Lynchburg, Lynchburg, VA USA	University of Virginia; University of Virginia	Posthumus, J (corresponding author), Univ Virginia Hlth Syst, Dept Internal Med, Charlottesville, VA 22903 USA.	spc7w@virginia.edu	Matos, Luis/HDL-7321-2022	Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007496, R21AI087985, U19AI070364, R37AI020565, R01AI020565, K08AI085190] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI020565, R21-AI-087985, R01 AI020565, U19 AI070364, U19-AI-070364, K08 AI085190, K08-AI-1085190, AI-20565, R21 AI087985, T32 AI007496] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayuso R, 1999, ANN ALLERG ASTHMA IM, V83, P399, DOI 10.1016/S1081-1206(10)62837-2; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Drouet M, 2001, Allerg Immunol (Paris), V33, P163; Drouet M, 1996, MONOGR ALLERGY, V32, P164; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Restani P, 1997, J AM COLL NUTR, V16, P383, DOI 10.1080/07315724.1997.10718701; Savi E, 2006, Eur Ann Allergy Clin Immunol, V38, P366; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278	9	49	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					923	925		10.1016/j.jaci.2012.12.665	http://dx.doi.org/10.1016/j.jaci.2012.12.665			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23352634	Green Accepted			2022-12-18	WOS:000315587800046
J	Nieuwenhuizen, NE; Kirstein, F; Jayakumar, J; Emedi, B; Hurdayal, R; Horsnell, WGC; Lopata, AL; Brombacher, F				Nieuwenhuizen, Natalie E.; Kirstein, Frank; Jayakumar, Jaisubash; Emedi, Babele; Hurdayal, Ramona; Horsnell, William G. C.; Lopata, Andreas L.; Brombacher, Frank			Allergic airway disease is unaffected by the absence of IL-4R alpha-dependent alternatively activated macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL-4 receptor alpha; alternatively activated macrophages; M2	ALPHA-DEFICIENT MICE; CD4(+) T-CELLS; ALVEOLAR MACROPHAGES; DENDRITIC CELLS; EXPERIMENTAL ASTHMA; IMMUNE-RESPONSE; INFLAMMATION; LUNG; EXPRESSION; IL-4	Background: Markers of alternatively activated macrophages (AAMs) are upregulated in the lungs of asthmatic patients and in mice with allergic airway disease. AAMs are thought to contribute to the pathogenesis of allergic airway disease by virtue of their decreased NO production and increased production of proline and polyamines, which are important in the synthesis of connective tissues such as collagen. Objective: We aimed to define the role of AAMs in the pathogenesis of allergic airway disease. Methods: The IL-4 receptor alpha (IL-4R alpha) gene is genetically abrogated in macrophages in LysM(cre)IL-4R alpha(-/lox) mice, which therefore have impaired IL-4/IL-13 activation of AAMs through IL-4R types 1 and 2. Responses of LysM(cre)IL-4R alpha(-/lox) mice and IL-4R alpha(-/lox) littermate controls were examined in ovalbumin- and house dust mite-induced allergic airway disease. Results: IL-4R alpha expression was shown to be efficiently depleted from alveolar macrophages, interstitial macrophages, and CD11b(+)MHCII(+) inflammatory macrophages. Although the expression of markers of AAMs such as Ym-1, arginase and found in inflammatory zone 1 was decreased in macrophages of LysM(cre)IL-4R alpha(-/lox) mice in chronic ovalbumin-induced allergic airway disease, airway hyperreactivity, T(H)2 responses, mucus hypersecretion, eosinophil infiltration, and collagen deposition were not significantly reduced. LysM(cre)IL-4R alpha(-/lox) mice and littermate controls also developed similar responses in acute ovalbumin-and house dust mite-induced allergic airway disease. Conclusion: Our results suggest that the presence of AAMs in allergic airway disease may be only an association, as a result of the increased T(H)2 responses present during disease, and that IL-4R alpha-dependent AAMs do not play an important role in the pathology of disease. (J Allergy Clin Immunol 2012;130:743-50.)	[Brombacher, Frank] Univ Cape Town, Fac Hlth Sci, Int Ctr Genet Engn & Biotechnol, Inst Infect Dis & Mol Med,Div Immunol, ZA-7925 Cape Town, South Africa	International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town	Brombacher, F (corresponding author), Univ Cape Town, Fac Hlth Sci, Int Ctr Genet Engn & Biotechnol, Inst Infect Dis & Mol Med,Div Immunol, Level 1 Werner & Beit S,Anzio Rd, ZA-7925 Cape Town, South Africa.	fbrombac@mweb.co.za	Hurdayal, Ramona/AAR-9742-2020; Jayakumar, Jaisubash/AAC-6614-2019; Nieuwenhuizen, Natalie/AAP-2400-2021; Horsnell, William GC/A-9512-2013; Lopata, Andreas L/O-2143-2017; Lopata, Andreas L/C-3831-2012	Lopata, Andreas L/0000-0002-2940-9235; Lopata, Andreas L/0000-0002-2940-9235; Jayakumar, Jaisubash/0000-0001-9359-516X; Hurdayal, Ramona/0000-0001-7758-521X; Nieuwenhuizen, Natalie/0000-0001-5749-2462; Horsnell, William Gordon Charles/0000-0001-7172-408X	National Research Foundation (South Africa); Medical Research Council (South Africa); International Center for Genetic Engineering and Biotechnology (ICGEB); Medical Research Council; Claude Leon Foundation; ICGEB; International Research Training Group 1522; National Research Foundation, RSA; National Health Medical Research Council	National Research Foundation (South Africa)(National Research Foundation - South AfricaSouth African Medical Research Council); Medical Research Council (South Africa); International Center for Genetic Engineering and Biotechnology (ICGEB); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Claude Leon Foundation; ICGEB(Department of Biotechnology (DBT) India); International Research Training Group 1522; National Research Foundation, RSA; National Health Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants from the National Research Foundation (South Africa), the Medical Research Council (South Africa), and the International Center for Genetic Engineering and Biotechnology (ICGEB). F. B. is South African Research Chair holder. F. K. and N.N. were funded by the Medical Research Council, N.N. was also funded by the Claude Leon Foundation, J.J. was funded by the ICGEB, and R. H. was funded by the International Research Training Group 1522.; W. Horsnell received research support from the National Research Foundation, RSA. A. Lopata received research support from the National Health Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest.	Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Brombacher F, 2000, BIOESSAYS, V22, P646, DOI 10.1002/1521-1878(200007)22:7&lt;646::AID-BIES7&gt;3.0.CO;2-9; Brombacher Frank, 2009, V531, P225, DOI 10.1007/978-1-59745-396-7_15; Brys L, 2005, J IMMUNOL, V174, P6095, DOI 10.4049/jimmunol.174.10.6095; Cai YP, 2009, J IMMUNOL, V182, P5393, DOI 10.4049/jimmunol.0803874; Cao YX, 2007, ARTHRITIS RHEUM-US, V56, P861, DOI 10.1002/art.22422; Careau E, 2004, AM J RESP CELL MOL, V31, P22, DOI 10.1165/rcmb.2003-0229OC; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Dewals BG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000689; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Huber S, 2010, BLOOD, V116, P3311, DOI 10.1182/blood-2010-02-271981; Hunter MM, 2010, GASTROENTEROLOGY, V138, P1395, DOI 10.1053/j.gastro.2009.12.041; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kirstein F, 2010, J ALLERGY CLIN IMMUN, V126, P347, DOI 10.1016/j.jaci.2010.04.028; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Le AV, 2007, J IMMUNOL, V178, P7310, DOI 10.4049/jimmunol.178.11.7310; Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Mohrs M, 1999, J IMMUNOL, V162, P7302; Munitz A, 2012, AM J RESP CELL  0603; Nair MG, 2009, J EXP MED, V206, P937, DOI 10.1084/jem.20082048; Nieuwenhuizen N, 2006, J ALLERGY CLIN IMMUN, V117, P1098, DOI 10.1016/j.jaci.2005.12.1357; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000393; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Schebesch C, 1997, IMMUNOLOGY, V92, P478, DOI 10.1046/j.1365-2567.1997.00371.x; SPITERI MA, 1991, CLIN EXP IMMUNOL, V83, P157; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; Taylor MD, 2006, J IMMUNOL, V176, P6918, DOI 10.4049/jimmunol.176.11.6918; THEPEN T, 1991, EUR J IMMUNOL, V21, P2845, DOI 10.1002/eji.1830211128; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang LF, 2009, J PROTEOME RES, V8, P1631, DOI 10.1021/pr800685h; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	48	49	51	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					743	+		10.1016/j.jaci.2012.03.011	http://dx.doi.org/10.1016/j.jaci.2012.03.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22552110	Bronze			2022-12-18	WOS:000308463500025
J	Niggemann, B; Lange, L; Finger, A; Ziegert, M; Muller, V; Beyer, K				Niggemann, Bodo; Lange, Lars; Finger, Antje; Ziegert, Mandy; Mueller, Veronika; Beyer, Kirsten			Accurate oral food challenge requires a cumulative dose on a subsequent day	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; CHILDREN		[Niggemann, Bodo; Ziegert, Mandy] German Red Cross Clin Westend, Berlin, Germany; [Lange, Lars; Finger, Antje] St Marien Hosp, Bonn, Germany; [Mueller, Veronika; Beyer, Kirsten] Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	St. Marien Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Niggemann, B (corresponding author), German Red Cross Clin Westend, Berlin, Germany.	b.niggemann@drk-kliniken-berlin.de						Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Caffarelli C, 2001, LANCET, V358, P1871, DOI 10.1016/S0140-6736(01)06897-0; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Niggemann B, 2004, ALLERGY, V59, P32, DOI 10.1111/j.1398-9995.2004.00571.x; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemenn B, 2007, ALLERGY, V62, P729, DOI 10.1111/j.1398-9995.2007.01396.x; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x	8	49	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					261	263		10.1016/j.jaci.2012.03.021	http://dx.doi.org/10.1016/j.jaci.2012.03.021			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22552112				2022-12-18	WOS:000306644800037
J	Grunebaum, E; Cutz, E; Roifman, CM				Grunebaum, Eyal; Cutz, Ernest; Roifman, Chaim M.			Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adenosine deaminase; immune; deficiency; pulmonary; alveolar; proteinosis	COMBINED IMMUNE-DEFICIENCY; INFLAMMATION; RECEPTORS; DISEASE; ASTHMA; INJURY; MICE	Background: Inherited defects in the function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many other cells and tissues. Objectives: We sought to characterize the frequency and features of pulmonary alveolar proteinosis (PAP) in patients with ADA deficiency. Methods: Clinical and laboratory features of all patients with SCID caused by ADA deficiency in a single center were analyzed. Bronchoalveolar lavage (BAL) fluid and lung biopsy specimens were stained with hematoxylin and eosin and periodic acid-Schiff, visualized by means of electron microscopy, and studied for associated infections. As a control group, BAL fluid and biopsy specimens from 22 patients with SCID caused by other genetic abnormalities were similarly assessed. Results: Among 16 consecutive patients with ADA deficiency, 7 had BAL fluid containing periodic acid-Schiff-positive surfactant-like material with macrophages engulfing degenerating lamellar bodies and/or lung biopsy specimens with alveolar spaces filled with homogeneous granular eosinophilic material and large macrophages. The lung pathology was typical of PAP. Identification of various pathogens coincided with PAP in 3 of these patients. We have diagnosed PAP among patients with ADA deficiency more commonly in the last 10 years than previously (P = .05), likely reflecting increased awareness of this condition. There were no significant differences in the clinical or immunologic characteristics between patients with ADA deficiency with or without PAP. Similar findings of PAP were not found among patients with SCID caused by other genetic abnormalities (P = .001). ADA coupled to polyethylene glycol or allogeneic hematopoietic stem cell transplantation rapidly corrected this pulmonary complication. PAP seems to have contributed to the death of only 1 patient with ADA deficiency. Conclusions: ADA deficiency predisposes to the development of PAP, which could be reversed after enzyme replacement or transplantation. (J Allergy Clin Immunol 2012;129:1588-93.)	[Grunebaum, Eyal; Roifman, Chaim M.] Hosp Sick Children, Div Allergy & Clin Immunol, Toronto, ON M5G 1X8, Canada; [Cutz, Ernest] Hosp Sick Children, Div Pathol, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grunebaum, E (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	Eyal.grunebaum@sickkids.ca						Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Burkhalter A, 1996, AM J CLIN PATHOL, V106, P504; Carey B, 2010, CLIN IMMUNOL, V135, P223, DOI 10.1016/j.clim.2010.02.017; Caruso M, 2009, CURR MED CHEM, V16, P3875, DOI 10.2174/092986709789178055; Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934; Doerschuk CM, 2007, NEW ENGL J MED, V356, P547, DOI 10.1056/NEJMp068259; Douda DN, 2011, J IMMUNOL, V187, P1856, DOI 10.4049/jimmunol.1004201; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Hershfield MS, 2005, EUR J IMMUNOL, V35, P25, DOI 10.1002/eji.200425738; HIRSCHHORN R, 1993, HUM MUTAT, V2, P320, DOI 10.1002/humu.1380020415; Kreindler JL, 2007, NAT MED, V13, P406, DOI 10.1038/nm0407-406; Mohsenin A, 2006, CURR OPIN PULM MED, V12, P54, DOI 10.1097/01.mcp.0000199002.46038.cb; Mohsenin A, 2007, FASEB J, V21, P1026, DOI 10.1096/fj.06-7301com; Nofech-Mozes Y, 2007, PEDIATR NEUROL, V37, P218, DOI 10.1016/j.pediatrneurol.2007.03.011; Pedroza M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022667; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Sauer AV, 2009, BLOOD, V114, P3216, DOI 10.1182/blood-2009-03-209221; Schepp CP, 2008, CRIT CARE, V12, DOI 10.1186/cc6990; Sender V, 2011, J IMMUNOL, V186, P2397, DOI 10.4049/jimmunol.1002446; Seymour JF, 2006, RESPIROLOGY, V11, pS16, DOI 10.1111/j.1440-1843.2006.00801.x; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sokolic R, 2011, BLOOD, V118, P2688, DOI 10.1182/blood-2011-01-329359; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P848, DOI 10.1016/j.jaci.2009.07.003; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303	26	49	50	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1588	1593		10.1016/j.jaci.2012.02.003	http://dx.doi.org/10.1016/j.jaci.2012.02.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22409989				2022-12-18	WOS:000304764600020
J	Hormannsperger, G; Clavel, T; Haller, D				Hoermannsperger, Gabriele; Clavel, Thomas; Haller, Dirk			Gut matters: Microbe-host interactions in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intestinal microbiota; bacteria; barrier function; allergy; asthma; eczema; immune responses; oral tolerance; functional food; probiotic	LACTOBACILLUS-RHAMNOSUS GG; ATOPIC-DERMATITIS; INTESTINAL PERMEABILITY; FECAL MICROBIOTA; ORAL TOLERANCE; GERM-FREE; T-CELLS; BACTERIAL COMMUNITY; AIRWAY INFLAMMATION; EPITHELIAL BARRIER	The human body can be considered a metaorganism made up of its own eukaryotic cells and trillions of microbes that colonize superficial body sites, such as the skin, airways, and gastrointestinal tract. The coevolution of host and microbes brought about a variety of molecular mechanisms, which ensure a peaceful relationship. The mammalian barrier and immune functions warrant simultaneous protection of the host against deleterious infections, as well as tolerance toward harmless commensals. Because these pivotal host functions evolved under high microbial pressure, they obviously depend on a complex network of microbe-host interactions. The rapid spread of immune-mediated disorders, such as autoimmune diseases, inflammatory bowel diseases, and allergies, in westernized countries is thus thought to be due to environmentally mediated disturbances of this microbe-host interaction network. The aim of the present review is to highlight the importance of the intestinal microbiota in shaping host immune mechanisms, with particular emphasis on allergic diseases and possible intervention strategies. (J Allergy Clin Immunol 2012;129:1452-9.)	[Hoermannsperger, Gabriele; Clavel, Thomas; Haller, Dirk] Tech Univ Munich, ZIEL Res Ctr Nutr & Food Sci, CDD Ctr Diet & Dis, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Haller, D (corresponding author), Tech Univ Munich, ZIEL Res Ctr Nutr & Food Sci, CDD Ctr Diet & Dis, Gregor Mendel Str 2, D-85350 Freising Weihenstephan, Germany.	haller@wzw.tum.de		Haller, Dirk/0000-0002-6977-4085				Annacker O, 2000, J IMMUNOL, V164, P3573, DOI 10.4049/jimmunol.164.7.3573; Arslanoglu S, 2008, J NUTR, V138, P1091, DOI 10.1093/jn/138.6.1091; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Batchelor JM, 2010, CLIN EXP DERMATOL, V35, P823, DOI 10.1111/j.1365-2230.2010.03901.x; Benard A, 1996, J ALLERGY CLIN IMMUN, V97, P1173, DOI 10.1016/S0091-6749(96)70181-1; Bird AR, 2010, BENEF MICROBES, V1, P423, DOI 10.3920/BM2010.0041; Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a; Bowman LM, 2001, INFECT IMMUN, V69, P3719, DOI 10.1128/IAI.69.6.3719-3727.2001; Boyle RJ, 2009, CLIN EXP ALLERGY, V39, P1117, DOI 10.1111/j.1365-2222.2009.03305.x; Brandtzaeg P, 2010, BENEF MICROBES, V1, P211, DOI 10.3920/BM2010.0009; Brandtzaeg P, 2010, NAT REV GASTRO HEPAT, V7, P380, DOI 10.1038/nrgastro.2010.80; Brew BK, 2011, PAEDIATR PERINAT EP, V25, P507, DOI 10.1111/j.1365-3016.2011.01233.x; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Dekio I, 2007, J MED MICROBIOL, V56, P1675, DOI 10.1099/jmm.0.47268-0; Dobber R, 1992, Dev Immunol, V2, P141, DOI 10.1155/1992/57057; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Feary J, 2011, ALLERGY, V66, P569, DOI 10.1111/j.1398-9995.2010.02512.x; Fernandez-Blanco JA, 2011, NEUROGASTROENT MOTIL, V23, pE523, DOI 10.1111/j.1365-2982.2011.01777.x; Fourlanos S, 2011, DIABETES, V60, P1237, DOI 10.2337/db10-1360; Fujiwara R, 2010, BRIT J NUTR, V103, P530, DOI 10.1017/S000711450999198X; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; GRAHAM VAL, 1982, LANCET, V1, P418; Gruber C, 2007, ALLERGY, V62, P1270, DOI 10.1111/j.1398-9995.2007.01543.x; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hijazi Z, 2004, ARCH DIS CHILD, V89, P227, DOI 10.1136/adc.2003.027680; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hong PY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009964; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Hyun JG, 2006, AM J GASTROENTEROL, V101, P569, DOI 10.1111/j.1572-0241.2006.00437.x; Ishikawa H, 2008, CLIN EXP IMMUNOL, V153, P127, DOI 10.1111/j.1365-2249.2008.03668.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; JACKSON PG, 1981, LANCET, V1, P1285; Jansson J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006386; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; Krzyzaniak MJ, 2011, SURGERY, V150, P379, DOI 10.1016/j.surg.2011.06.008; Kubota A, 2009, MICROBIOL IMMUNOL, V53, P198, DOI 10.1111/j.1348-0421.2009.00113.x; Kukkonen K, 2010, PEDIAT ALLERG IMM-UK, V21, P67, DOI 10.1111/j.1399-3038.2009.00907.x; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Larsen N, 2011, FEMS MICROBIOL ECOL, V75, P482, DOI 10.1111/j.1574-6941.2010.01024.x; Lyons A, 2010, CLIN EXP ALLERGY, V40, P811, DOI 10.1111/j.1365-2222.2009.03437.x; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Majamaa H, 1996, J ALLERGY CLIN IMMUN, V97, P985, DOI 10.1016/S0091-6749(96)80074-1; Makino H, 2011, APPL ENVIRON MICROB, V77, P6788, DOI 10.1128/AEM.05346-11; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Marschan E, 2008, CLIN EXP ALLERGY, V38, P611, DOI 10.1111/j.1365-2222.2008.02942.x; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McNulty NP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002701; MOREAU MC, 1978, INFECT IMMUN, V21, P532, DOI 10.1128/IAI.21.2.532-539.1978; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Murk W, 2011, PEDIATRICS, V127, P1125, DOI 10.1542/peds.2010-2092; Nakayama J, 2011, FEMS IMMUNOL MED MIC, V63, P397, DOI 10.1111/j.1574-695X.2011.00872.x; Nermes M, 2011, CLIN EXP ALLERGY, V41, P370, DOI 10.1111/j.1365-2222.2010.03657.x; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005090.pub2; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub2; Ouwehand AC, 2009, WORLD J GASTROENTERO, V15, P3261, DOI 10.3748/wjg.15.3261; Penders J, 2011, EUR RESPIR J, V38, P295, DOI 10.1183/09031936.00105010; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rautava S, 2006, PEDIATR RES, V60, P221, DOI 10.1203/01.pdr.0000228317.72933.db; Rescigno M, 2008, CURR OPIN IMMUNOL, V20, P669, DOI 10.1016/j.coi.2008.09.007; Rodriguez B, 2011, FEMS MICROBIOL ECOL, V76, P133, DOI 10.1111/j.1574-6941.2010.01035.x; Rosenfeldt V, 2004, J PEDIATR-US, V145, P612, DOI 10.1016/j.jpeds.2004.06.068; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Schouten B, 2010, J NUTR, V140, P835, DOI 10.3945/jn.109.116061; Scurlock AM, 2010, MUCOSAL IMMUNOL, V3, P345, DOI 10.1038/mi.2010.21; Scurlock AM, 2010, CURR OPIN ALLERGY CL, V10, P587, DOI 10.1097/ACI.0b013e32833fd5eb; Shibata R, 2009, CLIN EXP ALLERGY, V39, P1397, DOI 10.1111/j.1365-2222.2009.03295.x; Steck N, 2011, GASTROENTEROLOGY, V141, P959, DOI 10.1053/j.gastro.2011.05.035; Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Thompson-Chagoyan OC, 2011, INT ARCH ALLERGY IMM, V156, P325, DOI 10.1159/000323893; TLASKALOVAHOGENOVA H, 1983, ANN NY ACAD SCI, V409, P96, DOI 10.1111/j.1749-6632.1983.tb26862.x; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Torii S, 2011, INT ARCH ALLERGY IMM, V154, P236, DOI 10.1159/000321110; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; UMESAKI Y, 1993, IMMUNOLOGY, V79, P32; Vael C, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-68; van der Aa LB, 2010, CLIN EXP ALLERGY, V40, P795, DOI 10.1111/j.1365-2222.2010.03465.x; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Watanabe J, 2008, BRIT J NUTR, V100, P339, DOI 10.1017/S0007114507901221; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yasuda A, 2010, INT J IMMUNOPATH PH, V23, P727, DOI 10.1177/039463201002300306; Ye YL, 2011, CELL MOL IMMUNOL, V8, P453, DOI 10.1038/cmi.2011.17	104	49	54	1	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1452	1459		10.1016/j.jaci.2011.12.993	http://dx.doi.org/10.1016/j.jaci.2011.12.993			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22322009				2022-12-18	WOS:000304764600003
J	Cunningham-Rundles, C; Maglione, PJ				Cunningham-Rundles, Charlotte; Maglione, Paul J.			Common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							NEONATAL FC-RECEPTOR; INTRAVENOUS IMMUNOGLOBULIN; IMMUNE-DEFICIENCY; HUMORAL IMMUNITY; DISEASE; HYPOGAMMAGLOBULINEMIA; UPDATE; ASTHMA		[Cunningham-Rundles, Charlotte; Maglione, Paul J.] Mt Sinai Med Ctr, Div Clin Immunol, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, 1425 Madison Ave, New York, NY 10029 USA.	charlotte.cunningham-rundles@mssm.edu		Maglione, Paul J./0000-0001-6805-7271				Ardeniz O, 2009, CLIN IMMUNOL, V133, P198, DOI 10.1016/j.clim.2009.05.001; Azar AE, 2008, ANN ALLERG ASTHMA IM, V101, P108, DOI 10.1016/S1081-1206(10)60846-0; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Espanol T, 1996, CLIN IMMUNOL IMMUNOP, V80, P333, DOI 10.1006/clin.1996.0132; Fedor ME, 2006, ANN ALLERG ASTHMA IM, V97, P113, DOI 10.1016/S1081-1206(10)61380-4; Hayman G, 2002, BMJ-BRIT MED J, V325, P1213, DOI 10.1136/bmj.325.7374.1213; Knight AK, 2005, CLIN DIAGN LAB IMMUN, V12, P560, DOI 10.1128/CDLI.12.4.560-561.2005; Kuo TT, 2010, J CLIN IMMUNOL, V30, P777, DOI 10.1007/s10875-010-9468-4; Lack G, 1996, J PEDIATR-US, V129, P898, DOI 10.1016/S0022-3476(96)70035-5; LEE AH, 1993, SEMIN ARTHRITIS RHEU, V22, P252, DOI 10.1016/0049-0172(93)80073-O; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Malamut G, 2010, AM J GASTROENTEROL, V105, P2262, DOI 10.1038/ajg.2010.214; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Park JH, 2012, ANN NY ACAD SCI, V1246, P41; Pereira LF, 2002, SCAND J INFECT DIS, V34, P785, DOI 10.1080/00365540260348662; Pourpak Zahra, 2006, Journal of Microbiology Immunology and Infection, V39, P114; Sachs UJH, 2006, IMMUNOLOGY, V119, P83, DOI 10.1111/j.1365-2567.2006.02408.x; van de Ven AAJM, 2011, CRIT REV IMMUNOL, V31, P85, DOI 10.1615/CritRevImmunol.v31.i2.10; Wang J, 2005, J AUTOIMMUN, V25, P57, DOI 10.1016/j.jaut.2005.04.006; Yel L, 2010, J CLIN IMMUNOL, V30, P10, DOI 10.1007/s10875-009-9357-x; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	26	49	51	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1425	U407		10.1016/j.jaci.2012.03.025	http://dx.doi.org/10.1016/j.jaci.2012.03.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22541363	Bronze			2022-12-18	WOS:000303418000045
J	Cho, SH; Hong, SJ; Han, B; Lee, SH; Suh, L; Norton, J; Lin, D; Conley, DB; Chandra, R; Kern, RC; Tan, BK; Kato, A; Peters, A; Grammer, LC; Schleimer, RP				Cho, Seong H.; Hong, Seung J.; Han, Brian; Lee, Sun H.; Suh, Lydia; Norton, James; Lin, David; Conley, David B.; Chandra, Rakesh; Kern, Robert C.; Tan, Bruce K.; Kato, Atsushi; Peters, Anju; Grammer, Leslie C.; Schleimer, Robert P.			Age-related differences in the pathogenesis of chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DIALYSIS-RELATED AMYLOIDOSIS; INFLAMMATORY MEDIATORS; BETA(2)-MICROGLOBULIN; CALPROTECTIN; PROTEINS; CELLS		[Cho, Seong H.; Hong, Seung J.; Han, Brian; Lee, Sun H.; Suh, Lydia; Norton, James; Lin, David; Kato, Atsushi; Peters, Anju; Grammer, Leslie C.; Schleimer, Robert P.] NW Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL USA; [Conley, David B.; Chandra, Rakesh; Kern, Robert C.; Tan, Bruce K.] NW Feinberg Sch Med, Dept Otolaryngol, Chicago, IL USA; [Cho, Seong H.; Hong, Seung J.] Kyung Hee Univ, Div Rheumatol, Dept Med, Sch Med, Seoul, South Korea	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Kyung Hee University	Cho, SH (corresponding author), NW Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL USA.	seong-cho@northwestern.edu	Cho, Seong/I-7102-2015	Grammer, Leslie/0000-0001-6860-2014; Kato, Atsushi/0000-0001-9144-3138	NHLBI NIH HHS [2 R01 HL078860, R01 HL078860, R37 HL068546, R01 HL078860-05A1] Funding Source: Medline; NIAID NIH HHS [R01 AI104733] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI104733] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anand VK, 2004, ANN OTO RHINOL LARYN, V113, P3, DOI 10.1177/00034894041130S502; Busse PJ, 2010, J ALLERGY CLIN IMMUN, V126, P690, DOI 10.1016/j.jaci.2010.08.011; Di Lorenzo G, 2001, INT ARCH ALLERGY IMM, V125, P164, DOI 10.1159/000053811; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND VJ, 1995, ANN OTOLRHINOLLARYNG, V167, pS17; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Niwa T, 1996, KIDNEY INT, V50, P1303, DOI 10.1038/ki.1996.442; Niwa T, 1997, KIDNEY INT, V51, P187, DOI 10.1038/ki.1997.23; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; Ross KF, 2001, INFECT IMMUN, V69, P3248, DOI 10.1128/IAI.69.5.3248-3254.2001; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x	13	49	49	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					858	860		10.1016/j.jaci.2011.12.002	http://dx.doi.org/10.1016/j.jaci.2011.12.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22236731	Green Accepted			2022-12-18	WOS:000301189300039
J	Tulic, MK; Andrews, D; Crook, ML; Charles, A; Tourigny, MR; Moqbel, R; Prescott, SL				Tulic, Meri K.; Andrews, David; Crook, Maxine L.; Charles, Adrian; Tourigny, Michelle R.; Moqbel, Redwan; Prescott, Susan L.			Changes in thymic regulatory T-cell maturation from birth to puberty: Differences in atopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; thymus; immune maturation; children; allergy; sensitization; atopy	STROMAL LYMPHOPOIETIN; CORD BLOOD; EXPRESSION; CYTOKINE; DISEASE; ALLERGEN; COMPARTMENT; SUPPRESSION; THYMECTOMY; ASTHMA	Background: Characterization of regulatory immune pathways is a research priority for both the pathogenesis of allergic disease and potential therapeutic strategies. Objective: The thymus is a rich source of regulatory T (Treg) cells, which offers a novel opportunity to document the maturation of these pathways beyond limited studies on small volumes of peripheral blood available from young children. Methods: Thymus tissue was collected from children undergoing cardiac surgery (age, 1 week to 14 years), and skin prick testing was performed from 12 months of age. The ontogeny of Treg cell maturation and function was examined in atopic (n = 20) and nonatopic (n = 20) children by assessing their phenotype, enumeration, proliferation, and suppressive ability. Results: Age-related changes in the thymic cytokine milieu paralleled the changes seen in peripheral immune function. Specifically, the thymic microenvironment is similarly T-H(2) skewed during the early postnatal period, and this undergoes age-related suppression as the T-H(1) (IFN-gamma) response increased. We detected CD4(+)CD25(+)CD127(lo/-) forkhead box protein 3 (FOXP3)-positive Treg cells in the neonatal thymus. These cells suppressed the proliferative response to allogeneic stimulation of CD4(+)CD25(-) T cells dose dependently. In nonatopic children Treg cell turnover and suppressive function increased with age and paralleled the increase in global thymic FOXP3 mRNA expression, whereas in atopic children Treg cell maturation was significantly delayed compared with that seen in age-matched nonatopic children. Conclusion: These data suggest that the developmental changes in the thymus parallel the recognized changes in peripheral blood responses. There is also a developmental delay in the function of thymic regulatory cells in atopic compared with nonatopic children. These differences are fundamental to understanding early events that lead to immune dysregulation and might predispose to allergic disease. (J Allergy Clin Immunol 2012;129:199-206.)	[Tulic, Meri K.] Univ Western Australia, Sch Paediat & Child Hlth, Fac Med Dent & Hlth Sci, Perth, WA 6009, Australia; [Andrews, David] Princess Margaret Hosp, Div Cardiac Surg, Perth, WA, Australia; [Crook, Maxine L.; Charles, Adrian] Princess Margaret Hosp, Div Paediat Pathol, Perth, WA, Australia; [Tourigny, Michelle R.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Moqbel, Redwan] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada	University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Manitoba	Tulic, MK (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Fac Med Dent & Hlth Sci, Perth, WA 6009, Australia.	mtulic@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014; Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016	Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369; Charles, Adrian/0000-0002-3193-1065	National Health and Medical Research Council (NHMRC); Asthma Bequest Grant	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Asthma Bequest Grant	M.K.T. is supported by a National Health and Medical Research Council (NHMRC) Career Development Award, and S. L. P. is supported by an NHMRC Practitioner Fellowship. This project was supported by an Asthma Bequest Grant.	Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Jiang Qi, 2006, BMC Immunol, V7, P6, DOI 10.1186/1471-2172-7-6; Li DJ, 2009, J REPROD IMMUNOL, V83, P106, DOI 10.1016/j.jri.2009.07.015; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mazzucchelli R, 2008, BLOOD, V112, P3283, DOI 10.1182/blood-2008-02-137414; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nguyen Khoa D, 2010, Allergy Asthma Clin Immunol, V6, P4, DOI 10.1186/1710-1492-6-4; Ogle BM, 2006, J IMMUNOL, V176, P1962, DOI 10.4049/jimmunol.176.3.1962; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Piccirillo CA, 2008, CYTOKINE, V43, P395, DOI 10.1016/j.cyto.2008.07.469; Prelog M, 2009, CLIN IMMUNOL, V130, P123, DOI 10.1016/j.clim.2008.08.023; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Reefer AJ, 2010, J ALLERGY CLIN IMMUN, V126, P1049, DOI 10.1016/j.jaci.2010.07.023; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Torfadottir H, 2006, CLIN EXP IMMUNOL, V145, P407, DOI 10.1111/j.1365-2249.2006.03139.x; Tulic MK, 2011, J ALLERGY CLIN IMMUN, V127, P470, DOI 10.1016/j.jaci.2010.09.020; Tulic MK, 2009, AM J PATHOL, V175, P2043, DOI 10.2353/ajpath.2009.090015; Tuovinen H, 2008, IMMUNOL CELL BIOL, V86, P523, DOI 10.1038/icb.2008.36; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886; Wells WJ, 1998, J THORAC CARDIOV SUR, V115, P1041, DOI 10.1016/S0022-5223(98)70403-9; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wing K, 2005, IMMUNOLOGY, V115, P516, DOI 10.1111/j.1365-2567.2005.02186.x; Wing K, 2002, IMMUNOLOGY, V106, P190, DOI 10.1046/j.1365-2567.2002.01412.x; Xystrakis E, 2007, CURR OPIN ALLERGY CL, V7, P535, DOI 10.1097/ACI.0b013e3282f14d7c; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	36	49	51	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					199	U287		10.1016/j.jaci.2011.10.016	http://dx.doi.org/10.1016/j.jaci.2011.10.016			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22104606				2022-12-18	WOS:000298634000026
J	Nicholson, GC; Kariyawasam, HH; Tan, AJ; Hohlfeld, JM; Quinn, D; Walker, C; Rodman, D; Westwick, J; Jurcevic, S; Kon, OM; Barnes, PJ; Krug, N; Hansel, TT				Nicholson, Grant C.; Kariyawasam, Harsha H.; Tan, Andrew J.; Hohlfeld, Jens M.; Quinn, Deborah; Walker, Christoph; Rodman, David; Westwick, John; Jurcevic, Stipo; Kon, Onn Min; Barnes, Peter J.; Krug, Norbert; Hansel, Trevor T.			The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; nasal allergen challenge; anti-IL-13; mAb	ASTHMA; IL-13; EOSINOPHILS; MEPOLIZUMAB; ANTIBODY; RECEPTOR; INTERLEUKIN-13; EFFICACY; SAFETY; MUCOSA	Background: IL-13 is a key T(H)2 cytokine that is implicated in allergic responses. Objective: We evaluated the effects of an anti-IL-13-blocking antibody compared with placebo on repeated nasal allergen challenge responses in hay fever patients out of season. Methods: We performed a parallel group double-blind study of anti-IL-13 (single dose, 6 mg/kg intravenously, n = 16) and placebo (n = 15), with an additional open label group given a topical nasal corticosteroid (n = 5). Subjects received intranasal timothy grass pollen (Phleum pratense P5 allergen), and serial samples of nasal mucosal lining fluid were taken by using synthetic absorptive matrix and by nasal lavage. Results: Administration of anti-IL-13 on day 1 resulted in a significant decrease in IL-13 levels in synthetic absorptive matrix eluates compared with placebo (area under the curve 0-8 hours, change from baseline) during the late phase after nasal allergen challenge on day 5 (P < .05) and day 7 (P < .01). There were no apparent effects of anti-IL-13 treatment on nasal lavage eosinophil numbers or total nasal symptom scores versus placebo. However, in a subgroup with high late-phase IL-13 levels at screening, there was a trend for a decrease in total nasal symptom scores after nasal allergen challenge on day 5, when compared with subjects with low IL-13 levels (P < .10). Nasal fluticasone caused suppression of IL-13 (P < .05 on day 5) as well as IL-5 (P < .01 on day 5) levels in the late phase compared with placebo. Conclusions: Anti-IL-13 had specific pharmacodynamic action in this nasal allergen challenge model, causing profound inhibition of nasal lining fluid IL-13 responses. In addition, there was a possible effect of anti-IL-13 treatment on total nasal symptom scores in a subgroup with high late-phase nasal IL-13 levels at screening. (J Allergy Clin Immunol 2011;128:800-7.)	[Nicholson, Grant C.; Kariyawasam, Harsha H.; Tan, Andrew J.; Kon, Onn Min; Barnes, Peter J.; Hansel, Trevor T.] Univ London Imperial Coll Sci Technol & Med, NHLI, London SW7 2AZ, England; [Hohlfeld, Jens M.; Krug, Norbert] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Quinn, Deborah; Walker, Christoph; Rodman, David; Westwick, John] Novartis Pharmaceut, Horsham, W Sussex, England; [Jurcevic, Stipo] King Coll, Dept Nephrol & Transplantat, London, England	Imperial College London; Fraunhofer Gesellschaft; Novartis; University of London; King's College London	Hansel, TT (corresponding author), St Marys Hosp, ICRRU, 1st Floor, London W2 1NY, England.	t.hansel@imperial.ac.uk		Hohlfeld, Jens/0000-0003-2646-6186; Kon, Onn Min/0000-0003-2647-4688; Nicholson, Grant/0000-0001-8724-6115; Barnes, Peter/0000-0002-5122-4018	Novartis Pharmaceuticals; Novartis; GlaxoSmithKline; AstraZeneca; Boehringer Ingelheim; TEVA; Roche; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Novartis Pharmaceuticals(Novartis); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); TEVA(Teva Pharmaceutical Industries); Roche(Roche Holding); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by Novartis Pharmaceuticals.; J. M. Hohlsfeld and N. Krug have received research support from Novartis. J. Westwick and D. Quinn are employed by and have received research support from Novartis. P. J. Barnes has received research support from GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, and TEVA. T. T. Hansel has received research support from Novartis, Roche, and GlaxoSmith Kline. The rest of the authors have declared that they have no conflict of interest.	Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Brightling CE, 2010, CLIN EXP ALLERGY, V40, P42, DOI 10.1111/j.1365-2222.2009.03383.x; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V125, P1387, DOI 10.1016/j.jaci.2010.01.039; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; GREIFF L, 1990, CLIN EXP ALLERGY, V20, P253, DOI 10.1111/j.1365-2222.1990.tb02680.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Kariyawasam HH, 2009, AM J RESP CRIT CARE, V179, pA3542; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Miyahara S, 2006, J ALLERGY CLIN IMMUN, V118, P1110, DOI 10.1016/j.jaci.2006.06.014; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; O'Byrne PM, 2009, ALLERGY ASTHMA IMMUN, V1, P3, DOI 10.4168/aair.2009.1.1.3; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Singh D, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-3; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	27	49	52	4	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					800	U490		10.1016/j.jaci.2011.05.013	http://dx.doi.org/10.1016/j.jaci.2011.05.013			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21719078				2022-12-18	WOS:000296538100016
J	Fischer, A; Hacein-Bey-Abina, S; Cavazzana-Calvo, M				Fischer, Alain; Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina			Gene therapy for primary adaptive immune deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene therapy; severe combined immune deficiency; retrovirus; lentivirus; Wiskott-Aldrich syndrome	SEVERE COMBINED IMMUNODEFICIENCY; LENTIVIRAL VECTOR; RECONSTITUTION; DISEASE	Gene therapy has become an option for the treatment of 2 forms of severe combined immunodeficiency (SCID): X-linked SCID and adenosine deaminase deficiency. The results of clinical trials initiated more than 10 years ago testify to sustained and reproducible correction of the underlying T-cell immunodeficiency. Successful treatment is based on the selective advantage conferred on T-cell precursors through their expression of the therapeutic transgene. However, "first-generation" retroviral vectors also caused leukemia in some patients with X-linked SCID because of the constructs' tendency to insert into active genes (eg, proto-oncogenes) in progenitor cells and transactivate an oncogene through a viral element in the long terminal repeat. These elements have been deleted from the vectors now in use. Together with the use of lentiviral vectors (which are more potent for transducing stem cells), these advances should provide a basis for the safe and effective extension of gene therapy's indications in the field of primary immunodeficiencies. Nevertheless, this extension will have to be proved by examining the results of the ongoing clinical trials. (J Allergy Clin Immunol 2011;127:1356-9.)	[Fischer, Alain] INSERM, Pediat Immunol Hematol Dept, U768, Paris, France; [Fischer, Alain; Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina] Univ Paris 05, Paris, France; [Fischer, Alain] Necker Childrens Hosp, AP HP, Immunol & Pediat Hematol Dept, Paris, France; [Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina] Necker Childrens Hosp, AP HP, Biotherapy Dept, Paris, France; [Hacein-Bey-Abina, Salima; Cavazzana-Calvo, Marina] Grp Hosp Univ Ouest, AP HP, Biotherapy Clin Invest Ctr, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP)	Fischer, A (corresponding author), INSERM, Pediat Immunol Hematol Dept, U768, Paris, France.	alain.fischer@inserm.fr		Cavazzana, Marina/0000-0002-0264-0891	INSERM	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Disclosure of potential conflict of interest: A. Fischer has financial interests with INSERM. The rest of the authors have declared that they have no conflict of interest.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Benjelloun F, 2008, MOL THER, V16, P1490, DOI 10.1038/mt.2008.118; Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cattoglio C, 2010, BLOOD, V116, P5507, DOI 10.1182/blood-2010-05-283523; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dave UP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000491; Ferrua F, 2010, CURR OPIN ALLERGY CL, V10, P551, DOI 10.1097/ACI.0b013e32833fea85; Fischer A, 2010, IMMUNOL ALLERGY CLIN, V30, P237, DOI 10.1016/j.iac.2010.02.002; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Grez M, 2011, MOL THER, V19, P28, DOI 10.1038/mt.2010.232; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Hunter MJ, 2011, MOL THER, V19, P113, DOI 10.1038/mt.2010.203; Kustikova O, 2010, SEMIN CANCER BIOL, V20, P269, DOI 10.1016/j.semcancer.2010.06.003; Lagresle-Peyrou C, 2006, BLOOD, V107, P63, DOI 10.1182/blood-2005-05-2032; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Papapetrou EP, 2011, NAT BIOTECHNOL, V29, P73, DOI 10.1038/nbt.1717; Santoni FA, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001008; Szabo E, 2010, NATURE, V468, P521, DOI 10.1038/nature09591; Thrasher AJ, 2005, BLOOD, V105, P4255, DOI 10.1182/blood-2004-12-4837; Urnov FD, 2010, NAT REV GENET, V11, P636, DOI 10.1038/nrg2842; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; Zhang F, 2011, NAT BIOTECHNOL, V29, P149, DOI 10.1038/nbt.1775	33	49	49	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1356	1359		10.1016/j.jaci.2011.04.030	http://dx.doi.org/10.1016/j.jaci.2011.04.030			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21624615				2022-12-18	WOS:000291048500005
J	Thamrin, C; Zindel, J; Nydegger, R; Reddel, HK; Chanez, P; Wenzel, SE; FitzPatrick, S; Watt, RA; Suki, B; Frey, U				Thamrin, Cindy; Zindel, Joel; Nydegger, Regula; Reddel, Helen K.; Chanez, Pascal; Wenzel, Sally E.; FitzPatrick, Susan; Watt, Rosemary A.; Suki, Bela; Frey, Urs			Predicting future risk of asthma exacerbations using individual conditional probabilities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peak expiratory flow rate; pulmonary function tests; patient monitoring; risk assessment	EXHALED NITRIC-OXIDE; FLUCTUATION ANALYSIS; END-POINTS; PEAK; SYMPTOMS; ATTACKS; FEV1	Background: Determination of future risk of exacerbations is a key issue in the management of asthma. We previously developed a method to calculate conditional probabilities (pi) of future decreases in lung function by using the daily fluctuations in peak expiratory flow (PEF). Objective: We aimed to extend calculation of pi values to individual patients, validated by using electronically recorded data from 2 past clinical trials. Methods: Twice-daily PEF data were analyzed from 78 patients with severe (study A) and 61 patients with poorly controlled (study B) asthma. For each patient, the pi value was calculated from 5000 PEF data points simulated based on the correlation and distribution properties of observed PEF. Given an initial PEF, the pi value was defined as the probability of a decrease in PEF to less than 80% of predicted value on 2 consecutive days within a month. These probabilities were then compared with actual occurrences of such events and clinically defined exacerbations within the following month. Results: pi Values were related to actual occurrences of decreases in PEF (adjusted R-2 > 0.800 for both studies). Every increase of 10% in pi value was associated with an odds ratio of having a future exacerbation of 1.24 (95% CI, 1.07-1.43) for study A and 1.13 (95% CI, 1.02-1.26) for study B, with better sensitivity and specificity than clinic-measured FEV1. Conclusion: These results from 2 independent datasets with differing asthmatic populations and differing exacerbation criteria provide support that clinically relevant quantification of individual future risk of exacerbations is possible. (J Allergy Clin Immunol 2011;127:1494-502.)	[Frey, Urs] Univ Basel, Univ Childrens Hosp UKBB, CH-4056 Basel, Switzerland; [Thamrin, Cindy; Zindel, Joel; Nydegger, Regula; Frey, Urs] Univ Bern, CH-3012 Bern, Switzerland; [Thamrin, Cindy; Zindel, Joel; Nydegger, Regula; Frey, Urs] Inselspital Bern, Dept Paediat, Div Resp Med, Bern, Switzerland; [Reddel, Helen K.] Woolcock Inst Med Res, Glebe, NSW, Australia; [Chanez, Pascal] Univ Mediterranee Marseille, CNRS, INSERM, Dept Malad Resp,AP HM,U600,UMR6212, Marseille, France; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA; [FitzPatrick, Susan; Watt, Rosemary A.] Centocor Res & Dev Inc, Malvern, PA USA; [Suki, Bela] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	University of Basel; University of Bern; University of Bern; University Hospital of Bern; University of Sydney; Woolcock Institute of Medical Research; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johnson & Johnson; Johnson & Johnson USA; Boston University	Frey, U (corresponding author), Univ Basel, Univ Childrens Hosp UKBB, CH-4056 Basel, Switzerland.	urs.frey@ukbb.ch	Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Reddel, Helen/0000-0002-6695-6350; Zindel, Joel/0000-0003-3685-9338; Thamrin, Cindy/0000-0003-3284-3558; chanez, pascal/0000-0003-4059-0917	Allen & Hanburys/Thoracic Society of Australia; New Zealand Respiratory Research Fellowship; Centocor; AstraZeneca	Allen & Hanburys/Thoracic Society of Australia; New Zealand Respiratory Research Fellowship; Centocor; AstraZeneca(AstraZeneca)	C.T. was funded by a Allen & Hanburys/Thoracic Society of Australia and New Zealand Respiratory Research Fellowship. R. A. W. and S. F. are employed by Johnson & Johnson. Centocor R&D, a fully-owned subsidiary of Johnson & Johnson, is the owner of the dataset of study A, whereas AstraZeneca Pty Ltd is the owner of the dataset study B. R. A. W. and S. F. assisted with interpretation of the original datasets but did not influence the aims and analyses of this study.; P. Chanez has consultant arrangements with AstraZeneca and Centocor, and receives grant support from Centocor. S. E. Wenzel has had consultant arrangements with Centocor and has received research support from Centocor. H. K. Reddel has participated on advisory boards for, received speaker's honoraria, and received research funding from AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Boggs P B, 1999, Jt Comm J Qual Improv, V25, P163; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; Cernelc M, 2002, J APPL PHYSIOL, V92, P1817, DOI 10.1152/japplphysiol.00675.2001; Federico MJ, 2007, J ALLERGY CLIN IMMUN, V119, P50, DOI 10.1016/j.jaci.2006.10.019; Forno E, 2010, CHEST, V138, P1156, DOI 10.1378/chest.09-2426; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Frey U, 2008, LANCET, V372, P1088, DOI 10.1016/S0140-6736(08)61450-6; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; GINA, 2002, GLOB STRAT ASTHM MAN; Halonen M, 2006, ALLERGY ASTHMA PROC, V27, P328, DOI 10.2500/aap.2006.27.2888; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Kaza V, 2007, CURR OPIN PULM MED, V13, P1; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Reddel HK, 2006, CURR OPIN PULM MED, V12, P75, DOI 10.1097/01.mcp.0000198065.65704.08; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Thamrin C, 2009, EUR RESPIR J, V33, P486, DOI 10.1183/09031936.00106208; Thomson Neil C, 2008, BMC Pulm Med, V8, P27, DOI 10.1186/1471-2466-8-27; Tierney WM, 2004, J GEN INTERN MED, V19, P237, DOI 10.1111/j.1525-1497.2004.30311.x; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	34	49	50	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1494	U261		10.1016/j.jaci.2011.01.018	http://dx.doi.org/10.1016/j.jaci.2011.01.018			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21333347				2022-12-18	WOS:000291048500027
J	Bush, RK; Swenson, C; Fahlberg, B; Evans, MD; Esch, R; Busse, WW				Bush, Robert K.; Swenson, Cheri; Fahlberg, Beth; Evans, Michael D.; Esch, Robert; Busse, William W.			House dust mite sublingual immunotherapy: Results of a US trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; immunotherapy; house dust mites; Dermatophagoides farinae; house dust mite allergy	DOUBLE-BLIND; ALLERGIC RHINITIS; SWALLOW IMMUNOTHERAPY; PEDIATRIC-PATIENTS; CLINICAL-TRIALS; GRASS-POLLEN; ASTHMA; EFFICACY; CHILDREN; METAANALYSIS	Background: Few trials of sublingual immunotherapy (SLIT) in the United States have been reported. Objective: This randomized, placebo-controlled feasibility SLIT study compared the safety and physiologic effects of high-versus low-dose Dermatophagoides farinae vaccine. Methods: Thirty-one D farinae-sensitive adults with allergic rhinitis with or without mild intermittent asthma were eligible for randomization to high-dose maintenance vaccine (n = 10, 4200 allergen units [approximately 70 mu g of Der f 1/d]), low-dose maintenance vaccine (n = 10; 60 allergen units [approximately 1 mu g of Der f 1/d]), or placebo (n = 11) over 12 to 18 months. Medication-symptom scores and adverse events were monitored, serum D farinae-specific IgE and IgG4 levels were measured, and bronchial reactivity to D farinae was determined at baseline and 6-month intervals. Results: Of the 31 randomized subjects, 6 withdrew because of non-treatment-ascribed events. Four withdrew because of treatment-ascribed effects: high-dose group, 1 of 10 (gastrointestinal symptoms); low-dose group, 1 of 10 (gastrointestinal symptoms); and placebo group, 2 of 11 (headache and increased nasal symptoms). Thus 21 subjects completed the study: high-dose group, 9; low-dose group, 7; and placebo group, 5. Eleven of the 21 subjects experienced mild-to-moderate gastrointestinal symptoms, throat irritation, or both (high-dose group, 5/9; low-dose group, 4/7; and placebo group, 2/5). No severe systemic reactions were noted. No differences in symptom-medication scores were found. High-dose SLIT increased the bronchial threshold to allergen challenge and increased serum D farinae-specific IgG4 levels, whereas low-dose SLIT and placebo had no significant effect. Conclusions: High-dose D farinae SLIT was generally tolerable, increased serum D farinae-specific IgG4 levels, and improved the bronchial threshold to allergen challenge. Larger US trials are warranted. (J Allergy Clin Immunol 2011;127:974-81.)	[Bush, Robert K.; Swenson, Cheri; Fahlberg, Beth; Busse, William W.] Univ Wisconsin, Sect Allergy Immunol Pulm Crit Care & Sleep Med, Madison, WI USA; [Bush, Robert K.] William S Middleton VA Hosp, Madison, WI USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Esch, Robert] Greer Labs, Res & Dev, Lenoir, NC USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bush, RK (corresponding author), K9-410 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.	rkb@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993	NIH NCCAM [R21 AT002326]; National lnstitutes of Health (NIH); Greer Laboratories; NIH/National Institute of Allergy and Infectious Diseases (NIAID); NIH/National Heart, Lung, and Blood Institute (NHLBI); Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT002326] Funding Source: NIH RePORTER	NIH NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National lnstitutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greer Laboratories; NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by NIH NCCAM R21 AT002326. Greer Laboratories, Lenoir, NC, provided allergen extracts and sublingual immunotherapy delivery devices.; Disclosure of potential conflict of interest: R. K. Bush receives honoraria from Northwestern University, receives research support from the National lnstitutes of Health (NIH) and Greer Laboratories, and is an Associate Editor of the Journal of Allergy and Clinical Immunology. R. Esch is employed by Greer Laboratories. W. W. Busse is on advisory boards for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, GlaxoSmithKline, Pfizer, MedImmune, and Genentech; and receives research support from the NIH/National Institute of Allergy and Infectious Diseases (NIAID), NIH/National Heart, Lung, and Blood Institute (NHLBI), Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. The rest of the authors have declared that they have no conflict of interest.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Busse WW, 2007, J ALLERGY CLIN IMMUN, V120, P1012, DOI 10.1016/j.jaci.2007.09.016; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; CANONICA GW, 2009, WORLD ALLERGY ORGAN, V64, P233; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; OHAGUIBEL IM, 2005, J INVESTIG ALLERGOL, V15, P9; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V119, P796, DOI 10.1016/j.jaci.2007.01.009; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Tan RA, 2003, IMMUNOL ALLERGY CLIN, V23, P251, DOI 10.1016/S0889-8561(02)00080-2; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]	33	49	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					974	U225		10.1016/j.jaci.2010.11.045	http://dx.doi.org/10.1016/j.jaci.2010.11.045			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21333346				2022-12-18	WOS:000289055800019
J	Apter, AJ; Garcia, LA; Boyd, RC; Wang, XM; Bogen, DK; Ten Have, T				Apter, Andrea J.; Garcia, Laura A.; Boyd, Rhonda C.; Wang, Xingmei; Bogen, Daniel K.; Ten Have, Thomas			Exposure to community violence is associated with asthma hospitalizations and emergency department visits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; quality of life; emergency department visits; community violence; inner-city asthma	QUALITY-OF-LIFE; SOCIOECONOMIC-STATUS; DEPRESSIVE SYMPTOMS; HEALTH; QUESTIONNAIRE; WOMEN; PREVALENCE; CHILDREN; STRESS; VICTIMIZATION	Background: Exposure to community violence (ECV) has been associated with asthma morbidity of children living in inner-city neighborhoods. Objective: To examine with prospective longitudinal data whether ECV is independently associated with asthma-related health outcomes in adults. Methods: Adults with moderate-severe asthma, recruited from clinics serving inner-city neighborhoods, completed questionnaires covering sociodemographics, asthma severity, and ECV and were followed for 26 weeks. Longitudinal models were used to assess unadjusted and adjusted associations of subsequent asthma outcomes (emergency department [ED] visits, hospitalizations, FEV(1), quality of life). Results: A total of 397 adults, 47 +/- 14 years old, 73% women, 70% African American, 7% Latino, mean FEV(1) 66% +/- 19%, 133 with hospitalizations and 222 with ED visits for asthma in the year before entry, were evaluated. Ninety-one reported ECV. Controlling for age, sex, race/ethnicity, and household income, those exposed to violence had 2.27 (95% CI, 1.32-3.90) times more asthma-related ED visits per month and 2.49 (95% CI, 1.11-5.60) times more asthma-related hospitalizations per month over the 26-week study period compared with those unexposed. Violence-exposed participants also had 1.71 (95% CI, 1.14-2.56) times more overall ED visits per month and 1.72 (95% CI, 0.95-3.11) times more overall hospitalizations per month from any cause. Asthma-related quality of life was lower in the violence-exposed participants (-0.40; 95% CI, -0.77 to -0.025; P = .04). Effect modification by depressive symptoms was only statistically significant for the ECV association with overall ED visits and quality-of-life outcomes (P <.01). Conclusion: In adults, ECV is associated with increased asthma hospitalizations and emergency care for asthma or any condition and with asthma-related quality of life. (J Allergy Clin Immunol 2010;126:552-7.)	[Apter, Andrea J.; Garcia, Laura A.] Univ Penn, Sect Allergy & Immunol, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Wang, Xingmei; Ten Have, Thomas] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Bogen, Daniel K.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Boyd, Rhonda C.] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu	Boyd, Rhonda/D-5268-2009	Boyd, Rhonda/0000-0001-8799-229X; Ten Have, Thomas/0000-0003-0026-3073	NIH/NHLBI;  [HL073932];  [HL088469];  [HL099612]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL099612, R01HL073932, K02HL088469] Funding Source: NIH RePORTER	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by HL073932, HL088469, and HL099612 (A.J.A.); and HL073932 and HL099612 (L.A.G., X.W., D.K.B., T.T.H.).; Disclosure of potential conflict of interest: A.J. Apter receives research support from the NIH/NHLBI. R.C. Boyd is a grant reviewer for the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Acevedo-Garcia D, 2000, SOC SCI MED, V51, P1143, DOI 10.1016/S0277-9536(00)00016-2; Aisenberg E, 2007, J INTERPERS VIOLENCE, V22, P1227, DOI 10.1177/0886260507304292; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 2007, 3 NIH US DEP HLTH HU; Apter AJ, 1999, J ALLERGY CLIN IMMUN, V103, P72, DOI 10.1016/S0091-6749(99)70528-2; Berz JB, 2007, J PEDIATR PSYCHOL, V32, P154, DOI 10.1093/jpepsy/jsj123; Bossarte RM, 2009, J URBAN HEALTH, V86, P242, DOI 10.1007/s11524-008-9340-5; Bromberger JT, 2004, AM J PUBLIC HEALTH, V94, P1378, DOI 10.2105/AJPH.94.8.1378; Brown JR, 2005, J INTERPERS VIOLENCE, V20, P1478, DOI 10.1177/0886260505278604; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen TW, 2009, CLIN RADIOL, V64, P38, DOI 10.1016/j.crad.2008.06.005; Clark C, 2008, J URBAN HEALTH, V85, P22, DOI 10.1007/s11524-007-9229-8; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Cohen RT, 2008, AM J RESP CRIT CARE, V178, P453, DOI 10.1164/rccm.200711-1629OC; COOLEY MR, 1995, J AM ACAD CHILD PSY, V34, P201, DOI 10.1097/00004583-199502000-00015; Gaskin DJ, 2009, MED CARE RES REV, V66, P578, DOI 10.1177/1077558709336445; Gee GC, 2004, ENVIRON HEALTH PERSP, V112, P1645, DOI 10.1289/ehp.7074; Gupta RS, 2008, J ALLERGY CLIN IMMUN, V121, P639, DOI 10.1016/j.jaci.2007.11.036; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Leidy NK, 1998, AM J RESP CRIT CARE, V158, P1082, DOI 10.1164/ajrccm.158.4.9708130; LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350; Marin TJ, 2009, PSYCHOSOM MED, V71, P378, DOI 10.1097/PSY.0b013e318199dbc3; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; Mirabeau-Beale KL, 2009, GYNECOL ONCOL, V114, P353, DOI 10.1016/j.ygyno.2009.05.009; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Morenoff JD, 2003, AM J SOCIOL, V108, P976, DOI 10.1086/374405; Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; Nguyen HT, 2004, PSYCHIAT RES, V126, P177, DOI 10.1016/j.psychres.2004.02.004; Radloff L., CTR EPIDEMIOLOGIC ST; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richters J. E., 1990, SURVEY CHILDRENS EXP; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Surkan PJ, 2006, MATERN CHILD HLTH J, V10, P375, DOI 10.1007/s10995-005-0056-9; Swahn MH, 2006, AM J PUBLIC HEALTH, V96, P802, DOI 10.2105/AJPH.2005.066514; Williams DR, 2009, PEDIATRICS, V123, pS174, DOI 10.1542/peds.2008-2233H; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965	44	49	49	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					552	557		10.1016/j.jaci.2010.07.014	http://dx.doi.org/10.1016/j.jaci.2010.07.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	646CF	20816190	Green Accepted			2022-12-18	WOS:000281512500022
J	Cohen, RT; Raby, BA; Van Steen, K; Fuhlbrigge, AL; Celedon, JC; Rosner, BA; Strunk, RC; Zeiger, RS; Weiss, ST				Cohen, Robyn T.; Raby, Benjamin A.; Van Steen, Kristel; Fuhlbrigge, Anne L.; Celedon, Juan C.; Rosner, Bernard A.; Strunk, Robert C.; Zeiger, Robert S.; Weiss, Scott T.		Childhood Asthma Management Progra	In utero smoke exposure and impaired response to inhaled corticosteroids in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; in utero smoke exposure; airway responsiveness; inhaled corticosteroids	ENVIRONMENTAL TOBACCO-SMOKE; SELF-REPORTED SMOKING; MATERNAL SMOKING; LUNG-FUNCTION; CIGARETTE-SMOKING; AIRWAY RESPONSIVENESS; RESPIRATORY HEALTH; PARENTAL SMOKING; PREGNANT-WOMEN; INCREASES	Background: Few studies have examined the effects of in utero smoke exposure (IUS) on lung function in children with asthma, and there are no published data on the impact of IUS on treatment outcomes in children with asthma. Objectives: To explore whether IUS exposure is associated with increased airway responsiveness among children with asthma and whether IUS modifies the response to treatment with inhaled corticosteroids (ICSs). Methods: To assess the impact of parent-reported IUS exposure on airway responsiveness in childhood asthma, we performed a repeated-measures analysis of methacholine PC20 data from the Childhood Asthma Management Program, a 4-year, multicenter, randomized, double-masked, placebo-controlled trial of 1041 children age 5 to 12 years comparing the long-term efficacy of ICS with mast cell stabilizing agents or placebo. Results: Although improvement was seen in both groups, children with asthma and IUS exposure had on average 26% less of an improvement in airway responsiveness over time compared with unexposed children (P = .01). Moreover, while children who were not exposed to IUS who received budesonide experienced substantial improvement in PC20 compared with untreated children (1.25-fold increase; 95% CI, 1.03-1.50; P = .02), the beneficial effects of budesonide were attenuated among children with a history of IUS exposure (1.04-fold increase, 95% CI, 0.65-1.68; P = .88). Conclusion: In utero smoke exposure reduces age-related improvements in airway responsiveness among children with asthma. Moreover, IUS appears to blunt the beneficial effects of ICS use on airways responsiveness. These results emphasize the importance of preventing this exposure through smoking cessation counseling efforts with pregnant women. (J Allergy Clin Immunol 2010;126:491-7.)	[Cohen, Robyn T.; Raby, Benjamin A.; Fuhlbrigge, Anne L.; Celedon, Juan C.; Rosner, Bernard A.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Raby, Benjamin A.; Fuhlbrigge, Anne L.; Celedon, Juan C.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Raby, Benjamin A.; Fuhlbrigge, Anne L.; Celedon, Juan C.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Van Steen, Kristel] Univ Liege, Inst Montefiore, B-4000 Liege, Belgium; [Strunk, Robert C.] Washington Univ, Dept Pediat, Div Allergy & Pulm Med, Sch Med, St Louis, MO 63130 USA; [Strunk, Robert C.] St Louis Childrens Hosp, St Louis, MO USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Liege; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of California System; University of California San Diego; Kaiser Permanente	Cohen, RT (corresponding author), Drexel Univ, Coll Med, Dept Pediat, 3601 A St, Philadelphia, PA 19134 USA.	robyn.cohen@drexelmed.edu	Raby, Benjamin/AAK-3866-2021; Cohen, Robyn/AAC-9326-2019	Cohen, Robyn/0000-0002-6902-3118; Van Steen, Kristel/0000-0001-9868-5033; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052]; National Center for Research Resources [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; NHLBI/NIH [K08 HL074193]; National Institutes of Health; Philadelphia Health and Education Corp; Trustees of the Alumni/ae Association of the Women's Medical College of Pennsylvania; AstraZeneca; Aerocrine; Genentech; GlaxoSmithKline; Merck; DIVISION OF LUNG DISEASES [N01HR016044] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR002719, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074193] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Philadelphia Health and Education Corp; Trustees of the Alumni/ae Association of the Women's Medical College of Pennsylvania; AstraZeneca(AstraZeneca); Aerocrine; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. B. A. R. is a recipient of a Mentored Clinical Scientist Development Award from NHLBI/NIH (K08 HL074193).; Disclosure of potential conflict of interest: R. T. Cohen has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the Philadelphia Health and Education Corp, and Trustees of the Alumni/ae Association of the Women's Medical College of Pennsylvania. B. A. Raby is an editor for Up-ToDate. A. L. Fuhlbrigge was previously a consultant, advisory board member, and speaker for Merck and is currently a consultant for GlaxoSmithKline. B. A. Rosner has received research support from the National Institutes of Health. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, and Merck and has received research support (through Kaiser Permanente) from AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, and Merck. The rest of the authors have declared that they have no conflict of interest.	Carlsen KCL, 1997, EUR RESPIR J, V10, P1774, DOI 10.1183/09031936.97.10081774; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Christensen AE, 2004, PAEDIATR PERINAT EP, V18, P73, DOI 10.1111/j.1365-3016.2003.00520.x; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Elliot J, 1998, AM J RESP CRIT CARE, V158, P802, DOI 10.1164/ajrccm.158.3.9709055; Elliot JG, 2003, AM J RESP CRIT CARE, V167, P45, DOI 10.1164/rccm.2110005; England LJ, 2007, NICOTINE TOB RES, V9, P1005, DOI 10.1080/14622200701491255; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; Hofhuis W, 2003, ARCH DIS CHILD, V88, P1086, DOI 10.1136/adc.88.12.1086; Jaakkola JJK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-48; Jedrychowski W, 1998, J EXPO ANAL ENV EPID, V8, P347; Klebanoff MA, 2001, PAEDIATR PERINAT EP, V15, P140, DOI 10.1046/j.1365-3016.2001.00321.x; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Parna K, 2005, MATERN CHILD HLTH J, V9, P385, DOI 10.1007/s10995-005-0022-6; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; Pickett KE, 2005, PAEDIATR PERINAT EP, V19, P368, DOI 10.1111/j.1365-3016.2005.00660.x; Piedimonte G, 2002, RESP RES, V3, DOI 10.1186/rr185; Raby BA, 2005, AM J RESP CRIT CARE, V172, P552, DOI 10.1164/rccm.200501-010OC; SAETTA M, 1985, AM REV RESPIR DIS, V132, P894; Sekhon HS, 2004, EUR RESPIR J, V23, P906, DOI 10.1183/09031936.04.00069604; Sekhon HS, 2001, AM J RESP CRIT CARE, V164, P989, DOI 10.1164/ajrccm.164.6.2011097; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; Singh SP, 2003, AM J RESP CRIT CARE, V168, P342, DOI 10.1164/rccm.200211-1262OC; Skorge TD, 2005, AM J RESP CRIT CARE, V172, P61, DOI 10.1164/rccm.200409-1158OC; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005; Wongtrakool C, 2007, AM J PHYSIOL-LUNG C, V293, pL611, DOI 10.1152/ajplung.00038.2007; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	38	49	51	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					491	497		10.1016/j.jaci.2010.06.016	http://dx.doi.org/10.1016/j.jaci.2010.06.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673983	Green Accepted, Bronze			2022-12-18	WOS:000281512500013
J	Codispoti, CD; Levin, L; LeMasters, GK; Ryan, P; Reponen, T; Villareal, M; Burkle, J; Stanforth, S; Lockey, JE; Hershey, GKK; Bernstein, DI				Codispoti, Christopher D.; Levin, Linda; LeMasters, Grace K.; Ryan, Patrick; Reponen, Tiina; Villareal, Manuel; Burkle, Jeff; Stanforth, Sherry; Lockey, James E.; Hershey, Gurjit K. Khurana; Bernstein, David I.			Breast-feeding, aeroallergen sensitization, and environmental exposures during infancy are determinants of childhood allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tobacco; atopy; rhinitis; endotoxin; breast-feeding; allergy; diesel; siblings; infants; African American	UPDATED PRACTICE PARAMETER; BIRTH COHORT; RISK-FACTORS; HOUSE-DUST; HAY-FEVER; ASTHMA; AGE; CHILDREN; ASSOCIATION; CINCINNATI	Background: Infant predictors of early childhood allergic rhinitis (AR) are poorly understood. Objective: We sought to identify environmental exposures and host factors during infancy that predict AR at age 3 years. Methods: High-risk children from greater Cincinnati were followed annually from ages 1 to 3 years. AR was defined as sneezing, runny, or blocked nose in the prior 12 months and a positive skin prick test (SPT) response to 1 or more aeroallergens. Environmental and standardized medical questionnaires determined exposures and clinical outcomes. Primary activity area dust samples were analyzed for house dust endotoxin (HDE) and (1-3)beta-D-glucan. Fine particulate matter sampled at 27 monitoring stations was used to estimate personal elemental carbon attributable to traffic exposure by using a land-use regression model. Results: Of 361 children in this analysis, 116 had AR, and 245 were nonatopic and nonsymptomatic. Prolonged breast-feeding in African American children (adjusted odds ratio [aOR], 0.8; 95% CI, 0.6-0.9) and multiple children in the home during infancy was protective against AR (aOR, 0.4; 95% CI, 0.2-0.8). Food SPT response positivity and tree SPT response positivity in infancy increased the risk of AR at age 3 years (aOR of 4.4 [95% CI, 2.1-9.2] and aOR of 6.8 [95% CI, 2.5-18.7], respectively). HDE exposure was associated with AR; the effect was dependent on exposure level. Elemental carbon attributable to traffic and environmental tobacco smoke exposure showed no effect on AR. Conclusion: Prolonged breast-feeding in African American subjects and multiple children in the home during infancy reduced the risk of AR at age 3 years. SPT response positivity to food and tree allergens enhanced risk. The HDE effect on AR was related to exposure. (J Allergy Clin Immunol 2010;125:1054-60.)	[Codispoti, Christopher D.; Villareal, Manuel; Stanforth, Sherry; Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45221 USA; [Codispoti, Christopher D.; Levin, Linda; LeMasters, Grace K.; Ryan, Patrick; Reponen, Tiina; Burkle, Jeff; Lockey, James E.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; [Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Bernstein, DI (corresponding author), Univ Cincinnati, Dept Internal Med, Div Immunol Allergy & Rheumatol, 231 Albert Sabin Way, Cincinnati, OH 45221 USA.	bernstdd@ucmail.uc.edu	Ryan, Patrick H/L-7062-2015; Ryan, Patrick/HDO-1133-2022	Khurana Hershey, Gurjit/0000-0001-6663-977X; Burkle, Jeff/0000-0002-4670-2193	National Institute of Environmental Health Services [ES 11170, ES 10957]; National Institute of Allergy and Infectious Diseases [AI 60515 T32]; ConAgra Packaged Foods; Ohio Cancer Research Associates; National Institutes of Health (NIH); US Department of Housing and Urban Development (HUD); Refractory Ceramic Fiber Coalition; US Department of Transportation/Volpe; Agency for Toxic Substances and Disease Registry (ATSDR); National Institute for Occupational Safety and Health (NIOSH) Education and Research Center (ERC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957, R01ES011170] Funding Source: NIH RePORTER	National Institute of Environmental Health Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ConAgra Packaged Foods; Ohio Cancer Research Associates; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Housing and Urban Development (HUD); Refractory Ceramic Fiber Coalition; US Department of Transportation/Volpe; Agency for Toxic Substances and Disease Registry (ATSDR); National Institute for Occupational Safety and Health (NIOSH) Education and Research Center (ERC)(European Research Council (ERC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institute of Environmental Health Services grants ES 11170 and ES 10957 and National Institute of Allergy and Infectious Diseases grant AI 60515 T32.; Disclosure of potential conflict of interest: L. Levin receives research support from ConAgra Packaged Foods, the Ohio Cancer Research Associates, the National Institutes of Health (NIH), the US Department of Housing and Urban Development (HUD), the Refractory Ceramic Fiber Coalition, and the US Department of Transportation/Volpe. G. K. Le Masters receives research support from the National Institute of Allergy and Infectious Diseases (NIAID), the Agency for Toxic Substances and Disease Registry (ATSDR), the National Institute of Environmental Health Sciences (NIEHS), the Refractory Fiber Coalition, ConAgra Packaged Foods, the National Institute for Occupational Safety and Health (NIOSH) Education and Research Center (ERC), and the Department of Transportation/Volpe. P. Ryan receives research support from the NIEHS, ConAgra Foods, and HUD. T. Reponen receives research support from the NIEHS, HUD, and NIOSH. J. E. Lockey receives research support from the Ohio Bureau of Workers' Compensation, the Refractory Ceramic Fiber Coalition, NIOSH, ConAgra Packaged Foods, NIEHS, NIH/NIEHS, Waterstone/EPA, NIOSH ERC, Underwriters Laboratories, ATSDR, and DOT/Volpe and has provided expert witness testimony for the Department of Justice in the US v. W. R. Grace & Co, et al, civil action. D. I. Bernstein receives research support from the NIEHS/NIH and NIOSH/CDC. The rest of the authors have declared that they have no conflict of interest.	Adhikari A, 2003, ATMOS ENVIRON, V37, P4723, DOI 10.1016/j.atmosenv.2003.08.021; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Biagini JM, 2006, PEDIAT ALLERG IMM-UK, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; *BRESTF PROM CONS, 2005, WOM INF CHILDR; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Guerra S, 2002, ALLERGY ASTHMA PROC, V23, P303; Hu SH, 2006, ATMOS ENVIRON, V40, pS378, DOI 10.1016/j.atmosenv.2006.02.038; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Lee YL, 2003, EUR RESPIR J, V21, P964, DOI 10.1183/09031936.03.00094602; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Li RW, 2002, BIRTH-ISS PERINAT C, V29, P251, DOI 10.1046/j.1523-536X.2002.00199.x; Martuzevicius D, 2004, ATMOS ENVIRON, V38, P1091, DOI 10.1016/j.atmosenv.2003.11.015; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Osborne M, 2006, PEDIAT ALLERG IMM-UK, V17, P450, DOI 10.1111/j.1399-3038.2006.00414.x; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Riedl MA, 2005, J IMMUNOL, V174, P7440, DOI 10.4049/jimmunol.174.11.7440; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; *TIBCO SOFTW INC, 2000, S PLUS 2000; *USDA, 2009, WOM INF CHILDR WIC; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; 2006, MMWR MORB MORTAL WKL, V55, P335	35	49	50	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1054	1060		10.1016/j.jaci.2010.02.004	http://dx.doi.org/10.1016/j.jaci.2010.02.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392478	Green Accepted			2022-12-18	WOS:000277686700014
J	Zaidi, AK; Saini, SS; MacGlashan, DW				Zaidi, Asifa K.; Saini, Sarbjit S.; MacGlashan, Donald W., Jr.			Regulation of Syk kinase and FcR beta expression in human basophils during treatment with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; basophils; anti-IgE; signal transduction	EPSILON-RI EXPRESSION; ANTI-IGE ANTIBODY; NONRELEASER BASOPHILS; MEDIATOR RELEASE; TYROSINE KINASE; MAST-CELL; IN-VIVO; SECRETION; POPULATION; URTICARIA	Background: In human basophils from different subjects, maximum IgE-mediated histamine release and the level of Syk protein expression correlate well. Recent studies suggest that in some patients treated with omalizumab, the response to stimulation with anti-IgE antibody increases. In unrelated studies there is also evidence that the composition of Fc is an element of RI in basophils differs among subjects. This observation raised the possibility that the stoichiometry of FcR beta/Fc epsilon RI alpha is not fixed to a 1:1 ratio and might be modifiable during changes in the basophil's environment. Objective: We sought to determine whether treatment with omalizumab results in increases in Syk expression and anti-IgE mediated histamine release and disproportionately alters the relative presence of FcR beta and Fc is an element of RI alpha. Method: Syk, Fc is an element of RI alpha, and FcR beta expression was monitored during the treatment of subjects with omalizumab. Results: Treatment with omalizumab reduced histamine release from peripheral blood leukocytes stimulated with cat allergen in vitro, but histamine release stimulated with anti-IgE antibody increased 2-fold. Expression of Syk increased 1.86-fold. There was no change in the expression of c-Cbl, a signaling element that is sensitive to the presence of IL-3, and no increase in response to formyl-met-leu-phe (tripeptide), a response that also increases in the presence of IL-3. There was a 60% decrease in the FcR beta/Fc is an element of R1 alpha ratio in patients treated with omalizumab. Conclusions: In the context of previous studies, these studies provide support for a proposal that Syk expression is modulated in vivo through an IgE-dependent mechanism and that the ratio of Fc is an element of RI alpha and beta subunits in basophils is influenced by factors extrinsic to the cell. (J Allergy Clin Immunol 2010;125:902-8.)	[Zaidi, Asifa K.; Saini, Sarbjit S.; MacGlashan, Donald W., Jr.] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, DW (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			National Institutes of Health [AI20253, AI070345]; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253, U19AI070345] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI20253 and AI070345 to D.W.M.; Disclosure of potential conflict of interest: S. S. Saini has consulted for and received research support from Genentech. The rest of the authors have declared that they have no conflict of interest.	Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; ECKMAN JA, 2009, J ALLERGY CLIN IMMUN; Eckman JA, 2008, J INVEST DERMATOL, V128, P1956, DOI 10.1038/jid.2008.55; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; GILBERT HS, 1975, BLOOD, V46, P279; Ishmael S, 2009, J LEUKOCYTE BIOL, V86, P313, DOI 10.1189/jlb.1208724; Ishmael SS, 2010, J LEUKOCYTE BIOL, V87, P291, DOI 10.1189/jlb.0509336; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2005, INT ARCH ALLERGY IMM, V138, P29, DOI 10.1159/000087355; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1472, DOI 10.1016/j.jaci.2004.07.064; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan D, 2008, J ALLERGY CLIN IMMUN, V121, P1500, DOI 10.1016/j.jaci.2008.04.019; MacGlashan DW, 2008, J IMMUNOL, V180, P4208, DOI 10.4049/jimmunol.180.6.4208; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Matsuda A, 2009, INVEST OPHTH VIS SCI, V50, P2871, DOI 10.1167/iovs.08-3022; Miura K, 2001, J IMMUNOL, V167, P2282, DOI 10.4049/jimmunol.167.4.2282; Miura K, 2001, CLIN EXP ALLERGY, V31, P1732, DOI 10.1046/j.1365-2222.2001.01236.x; Oliver JM, 2010, INT ARCH ALLERGY IMM, V151, P275, DOI 10.1159/000250436; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Schroeder JT, 2010, J ALLERGY CLIN IMMUN, V125, P896, DOI 10.1016/j.jaci.2009.10.021; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Rensen ELJ, 2009, ALLERGY, V64, P72, DOI 10.1111/j.1398-9995.2008.01881.x; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3; Youssef LA, 2002, J ALLERGY CLIN IMMUN, V110, P366, DOI 10.1067/mai.2002.127562	36	49	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					902	908		10.1016/j.jaci.2009.12.996	http://dx.doi.org/10.1016/j.jaci.2009.12.996			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20236696	Green Accepted, Bronze			2022-12-18	WOS:000276787900017
J	Joseph, A; Brasington, R; Kahl, L; Ranganathan, P; Cheng, TP; Atkinson, J				Joseph, Amy; Brasington, Richard; Kahl, Leslie; Ranganathan, Prabha; Cheng, Tammy P.; Atkinson, John			Immunologic rheumatic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rheumatoid arthritis; seronegative spondyloarthritis; juvenile rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Sjogren syndrome; scleroderma polymyositis; dermatomyositis; and inclusion-body myositis	PRIMARY SJOGRENS-SYNDROME; IDIOPATHIC INFLAMMATORY MYOPATHIES; MYOSITIS-SPECIFIC AUTOANTIBODIES; PULMONARY MANIFESTATIONS; CLASSIFICATION CRITERIA; ANKYLOSING-SPONDYLITIS; TRANSGENIC RATS; DOUBLE-BLIND; DISEASE; PLACEBO	We provide the basics for clinicians who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases (ie, RA, seronegative spondyloarthropathy, SLE, antiphospholipid syndrome, Sjogren syndrome, scleroderma, and polymyositis/dermatomyositis) will be covered. In the past decade, treatment for RA and seronegative spondyloarthropathy has substantially improved. Their treatment has been revolutionized by the use of methotrexate and, more recently, TNF inhibitors, T-cell costimulation modulators, and B-cell depletion. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction.'' The hope is that if the major mediators of Sjogren syndrome, SLE, or scleroderma can be identified and then blocked, as in the example of TNF inhibitors in patients with RA, more specific treatments will become available. Thus RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed. (J Allergy Clin Immunol 2010;125:S204-15.)	[Joseph, Amy; Brasington, Richard; Kahl, Leslie; Ranganathan, Prabha; Cheng, Tammy P.; Atkinson, John] Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, St Louis, MO 63110 USA; [Joseph, Amy] St Louis VA Med Ctr, St Louis, MO USA	Washington University (WUSTL)	Atkinson, J (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Rheumatol, 660 S Euclid Ave,Campus Box 8045, St Louis, MO 63110 USA.	jatkinso@dom.wustl.edu		Atkinson, John/0000-0002-2514-3441; Joseph, Amy/0000-0003-2200-9711	BioGen Idec; Bristol-Myers Squibb; Abbott; Abbott Pharmaceuticals	BioGen Idec(Biogen); Bristol-Myers Squibb(Bristol-Myers Squibb); Abbott(Abbott Laboratories); Abbott Pharmaceuticals(Abbott Laboratories)	Disclosure of potential conflict of interest: A. Joseph is on the speakers' bureau for Takeda Pharmaceuticals. R. Brasington is a speaker for Centocor, UCB, Abbott, and Bristol-Myers Squibb; has received research support from BioGen Idec, Bristol-Myers Squibb, and Abbott; and has provided expert witness testimony on the topics of systemic lupus erythematosus and rheumatoid arthritis. T. P. Cheng has received research support from Abbott Pharmaceuticals. The rest of the authors have declared that they have no conflict of interest.	AD ACR, 1999, ARTHRITIS RHEUM, V42, P1785; ANDERSON LG, 1972, CLIN EXP IMMUNOL, V10, P199; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; Dass S, 2008, ANN RHEUM DIS, V67, P1541, DOI 10.1136/ard.2007.083865; De Keyser F, 1998, RHEUM DIS CLIN N AM, V24, P785, DOI 10.1016/S0889-857X(05)70042-9; Denton CP, 2008, ANN RHEUM DIS, V67, P1222, DOI 10.1136/ard.2007.079921; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Hengstman GJD, 2001, CURR OPIN RHEUMATOL, V13, P476, DOI 10.1097/00002281-200111000-00004; Ioannidis JPA, 2002, ARTHRITIS RHEUM, V46, P741, DOI 10.1002/art.10221; Ito I, 2005, AM J RESP CRIT CARE, V171, P632, DOI 10.1164/rccm.200403-417OC; Jonsson R, 2000, SCAND J RHEUMATOL, V29, P341; Jonsson R, 2005, SJOGRENS SYNDROME, P1681; Kavanaugh A, 2000, ARCH PATHOL LAB MED, V124, P71; Kwoh CK, 2002, ARTHRITIS RHEUM-US, V46, P328; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Lemp MA, 2007, OCUL SURF, V5, P75; Lim W, 2006, JAMA-J AM MED ASSOC, V295, P1050, DOI 10.1001/jama.295.9.1050; de Padilla CML, 2008, CURR OPIN RHEUMATOL, V20, P669, DOI 10.1097/BOR.0b013e3283157538; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; Mariette X, 1999, LEUKEMIA LYMPHOMA, V33, P93, DOI 10.3109/10428199909093729; Mitsias DI, 2006, LUPUS, V15, P255, DOI 10.1191/0961203306lu2290rr; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Orchard TR, 2000, GASTROENTEROLOGY, V118, P274, DOI 10.1016/S0016-5085(00)70209-5; Parke AL, 2008, RHEUM DIS CLIN N AM, V34, P907, DOI 10.1016/j.rdc.2008.08.012; Petrone D, 2002, ARTHRITIS RHEUM, V46, P748, DOI 10.1002/art.510; Radtke MA, 2009, J EUR ACAD DERMATOL, V23, P683, DOI 10.1111/j.1468-3083.2009.03159.x; Ramos-Casals Manuel, 2002, Autoimmunity Reviews, V1, P238, DOI 10.1016/S1568-9972(02)00057-5; Segal B, 2008, RHEUM DIS CLIN N AM, V34, P885, DOI 10.1016/j.rdc.2008.08.001; Seror R, 2007, ANN RHEUM DIS, V66, P351, DOI 10.1136/ard.2006.057919; Sparsa A, 2002, ARCH DERMATOL, V138, P885, DOI 10.1001/archderm.138.7.885; Tashkin DP, 2006, NEW ENGL J MED, V354, P2655, DOI 10.1056/NEJMoa055120; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Theander E, 2004, ARTHRITIS RHEUM-US, V50, P1262, DOI 10.1002/art.20176; Theander E, 2006, ANN RHEUM DIS, V65, P796, DOI 10.1136/ard.2005.041186; van der Heijde D, 2008, ARTHRITIS RHEUM-US, V58, P1324, DOI 10.1002/art.23471; van der Heijde D, 2008, ARTHRITIS RHEUM-US, V58, P3063, DOI 10.1002/art.23901; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Vivino FB, 1999, ARCH INTERN MED, V159, P174, DOI 10.1001/archinte.159.2.174; Wiendl H, 2008, NEUROTHERAPEUTICS, V5, P548, DOI 10.1016/j.nurt.2008.08.008; Zintzaras E, 2005, ARCH INTERN MED, V165, P2337, DOI 10.1001/archinte.165.20.2337; Zochling J, 2006, ANN RHEUM DIS, V65, P442, DOI 10.1136/ard.2005.041137	43	49	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S204	S215		10.1016/j.jaci.2009.10.067	http://dx.doi.org/10.1016/j.jaci.2009.10.067			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176259	Bronze			2022-12-18	WOS:000280170600018
J	Jung, JA; Kita, H; Yawn, BP; Boyce, TG; Yoo, KH; McGree, ME; Weaver, AL; Wollan, P; Jacobson, RM; Juhn, YJ				Jung, Ji A.; Kita, Hirohito; Yawn, Barbara P.; Boyce, Thomas G.; Yoo, Kwang H.; McGree, Michaela E.; Weaver, Amy L.; Wollan, Peter; Jacobson, Robert M.; Juhn, Young J.			Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; allergic rhinitis; serious pneumococcal disease; epidemiology; risk; pneumococcal pneumonia; Rochester Epidemiology Project	INNATE IMMUNE-RESPONSE; ALLERGIC RHINITIS; BRONCHIAL HYPERRESPONSIVENESS; CELLULAR IMMUNITY; DERMATITIS SKIN; UNITED-STATES; SYMPTOMS; CHILDREN; EPIDEMIOLOGY; INFLAMMATION	Background: We reported an increased risk of serious pneumococcal disease (SPD) among patients with asthma. It is not known whether this is true for patients with other atopic conditions. Objective: To determine the relationship between atopic conditions other than asthma and SPD. Methods: The study subjects were residents of Rochester, Minn, who developed SPD between 1964 and 1983 and their 2 sex-matched and age-matched controls. We used a population-based computer-linked medical diagnosis system to identify all individuals with potential SPD. All records were reviewed by using explicit predetermined criteria for SPD. All individuals with atopic conditions were identified by the physician diagnoses including atopic dermatitis or eczema, allergic rhinitis, and hay fever documented in medical records. The associations between these atopic conditions and SPD were assessed by using conditional logistic regression. Results: A total of 3941 records were reviewed, and we identified 174 SPD cases. Of these 174 cases, 50.6% were male, and 94.3% were Caucasian. Twenty-six (14.9%) of the SPD cases and 29 (8.3%) of the controls had atopy. Atopic conditions other than asthma were associated with an increased risk of SPD (odds ratio, 2.13; 95% CI, 1.04-4.35; P = .04) after adjusting for smoking status, previous high-risk conditions for SPD, educational status, and ethnicity. Conclusion: Like asthma, other atopic conditions, particularly atopic dermatitis, are associated with an increased risk of SPD. There may be a common immunogenetic mechanism underlying increased risk of SPD among individuals with either asthma or other atopic conditions. Our study findings need to be studied further. (J Allergy Clin Immunol 2010;125:217-21.)	[Juhn, Young J.] Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, Rochester, MN 55905 USA; [McGree, Michaela E.; Weaver, Amy L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Jung, Ji A.] Hallym Univ, Coll Med, Dept Pediat & Adolescent Med, Seoul, South Korea; [Yawn, Barbara P.; Wollan, Peter] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yoo, Kwang H.] Konkuk Univ, Sch Med, Dept Internal Med, Seoul, South Korea	Mayo Clinic; Mayo Clinic; Hallym University; Olmsted Medical Center; Konkuk University; Konkuk University Medical Center	Juhn, YJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu		Jacobson, Robert/0000-0002-6355-8752	NIH [R01 AI 56133]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR30582]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by an NIH grant (R01 AI 56133) from the National Institute of Allergy and Infectious Diseases and made possible by the Rochester Epidemiology Project (R01-AR30582) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.	*ADV COMM IMM PRAC, 2008, ACIP PROV REC US PNE; *AM AC PED, 2006, RED BOOK 2006; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Barnard JMR, 2007, INVESTIG BIBLIOTECOL, V21, P7; Beck LA, 2008, J ALLERGY CLIN IMMUN, V121, pS37, DOI 10.1016/j.jaci.2007.12.152; Blair C, 2001, J ALLERGY CLIN IMMUN, V108, P424, DOI 10.1067/mai.2001.117793; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; Choi SH, 2007, ALLERGY, V62, P1051, DOI 10.1111/j.1398-9995.2007.01403.x; Gordon B, 2008, J ALLERGY CLIN IMMUN, V121, pS209, DOI 10.1016/j.jaci.2007.12.778; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GROVE DI, 1975, BRIT J DERMATOL, V92, P611, DOI 10.1111/j.1365-2133.1975.tb03139.x; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Kaetzel CS, 2005, IMMUNOL REV, V206, P83, DOI 10.1111/j.0105-2896.2005.00278.x; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kyllonen H, 2006, CLIN EXP ALLERGY, V36, P192, DOI 10.1111/j.1365-2222.2006.02419.x; Luo RS, 2005, EMBO J, V24, P34, DOI 10.1038/sj.emboj.7600490; Nathan R, 2008, J ALLERGY CLIN IMMUN, V121, pS208, DOI 10.1016/j.jaci.2007.12.777; Nurse B, 2000, J ALLERGY CLIN IMMUN, V106, P84, DOI 10.1067/mai.2000.107397; Obaro S, 2002, J MED MICROBIOL, V51, P98, DOI 10.1099/0022-1317-51-2-98; Ohashi Y, 1997, SCAND J IMMUNOL, V46, P67, DOI 10.1046/j.1365-3083.1997.d01-87.x; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Schneider LC, 2008, J ALLERGY CLIN IMMUN, V121, pS272, DOI 10.1016/j.jaci.2007.12.1080; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; WEST P, 1988, SOC SCI MED, V27, P291, DOI 10.1016/0277-9536(88)90262-6	33	49	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					217	221		10.1016/j.jaci.2009.10.045	http://dx.doi.org/10.1016/j.jaci.2009.10.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109748	Green Accepted			2022-12-18	WOS:000273660500027
J	Mucida, D; Salek-Ardakani, S				Mucida, Daniel; Salek-Ardakani, Shahram			Regulation of T(H)17 cells in the mucosal surfaces	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intestine; lung; mucosal; T(H)17; regulatory T cells	ROR-GAMMA-T; INFLAMMATORY-BOWEL-DISEASE; GROWTH-FACTOR-BETA; RETINOIC-ACID; TH17 CELLS; DENDRITIC CELLS; HOST-DEFENSE; TGF-BETA; AIRWAY INFLAMMATION; HELPER-CELLS	The mucosal surfaces represent the main intersection between jawed vertebrates and the environment. The mucosal surface of the intestine alone forms the largest surface that is exposed to exogenous antigens as well as the largest collection of lymphoid tissue in the body. Therefore, a protective immune activity must coexist with efficient regulatory mechanisms to maintain a health status of these organisms. The discovery of a new lineage of T-H cells that produce IL-17 has provided valuable new insight into host defense and the pathogenesis of inflammatory diseases at the mucosal surfaces. Of particular interest for these surfaces, it has been reported that peripherally-induced regulatory T cells and T(H)17 effector cells arise in a mutually exclusive fashion, depending on whether they are activated in the presence of TGF-beta or TGF-beta plus inflammatory cytokines such as IL-6. This review addresses the protective and pathogenic roles of T(H)17 cells in the mucosal surfaces and potential regulatory mechanisms that control their development. (J Allergy Clin Immunol 2009;123:997-1003.)	[Mucida, Daniel] La Jolla Inst Allergy & Immunol, Div Dev Immunol, La Jolla, CA 92037 USA; [Salek-Ardakani, Shahram] La Jolla Inst Allergy & Immunol, Div Mol Immunol, La Jolla, CA 92037 USA	La Jolla Institute for Immunology; La Jolla Institute for Immunology	Mucida, D (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.	mucida@liai.org		Mucida, Daniel/0000-0002-0000-0452	Crohn's and Colitis Foundation of America; National Institutes of Health [AI77079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI077079] Funding Source: NIH RePORTER	Crohn's and Colitis Foundation of America; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Career Development Award from the Crohn's and Colitis Foundation of America to D.M., and National Institutes of Health grant AI77079 to S.S.A.	Albanesi C, 2009, J EXP MED, V206, P249, DOI 10.1084/jem.20080129; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Aujla SJ, 2007, EXP LUNG RES, V33, P507, DOI 10.1080/01902140701756604; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bilsborough J, 2003, IMMUNOLOGY, V108, P481, DOI 10.1046/j.1365-2567.2003.01606.x; Boniface K, 2008, IMMUNOL REV, V226, P132, DOI 10.1111/j.1600-065X.2008.00714.x; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Cheroutre H, 2004, ANNU REV IMMUNOL, V22, P217, DOI 10.1146/annurev.immunol.22.012703.104522; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Dubin PJ, 2007, INFLAMM RES, V56, P221, DOI 10.1007/s00011-007-6187-2; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Johnson RP, 2008, NEW ENGL J MED, V358, P2287, DOI 10.1056/NEJMcibr0802134; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Linden A, 2002, ALLERGY, V57, P769, DOI 10.1034/j.1398-9995.2002.02164.x; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lochner M, 2008, J EXP MED, V205, P1381, DOI 10.1084/jem.20080034; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; MASSACESI L, 1991, J CLIN INVEST, V88, P1331, DOI 10.1172/JCI115438; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Schambach F, 2007, EUR J IMMUNOL, V37, P2396, DOI 10.1002/eji.200737621; Simonian PL, 2009, J IMMUNOL, V182, P657, DOI 10.4049/jimmunol.182.1.657; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; VAZ NM, 1977, J ALLERGY CLIN IMMUN, V60, P110, DOI 10.1016/0091-6749(77)90035-5; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Wu Q, 2007, MICROBES INFECT, V9, P78, DOI 10.1016/j.micinf.2006.10.012; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zaph C, 2008, J EXP MED, V205, P2191, DOI 10.1084/jem.20080720; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zelante T, 2007, EUR J IMMUNOL, V37, P2695, DOI 10.1002/eji.200737409; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	68	49	52	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					997	1003		10.1016/j.jaci.2009.03.016	http://dx.doi.org/10.1016/j.jaci.2009.03.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19362732	Green Accepted			2022-12-18	WOS:000266309400003
J	Yang, JJ; Burchard, EG; Choudhry, S; Johnson, CC; Ownby, DR; Favro, D; Chen, J; Akana, M; Ha, C; Kwok, PY; Krajenta, R; Havstad, SL; Joseph, CL; Seibold, MA; Shriver, MD; Williams, LK				Yang, James J.; Burchard, Esteban G.; Choudhry, Shweta; Johnson, Christine C.; Ownby, Dennis R.; Favro, David; Chen, Justin; Akana, Matthew; Ha, Connie; Kwok, Pui-Yan; Krajenta, Richard; Havstad, Suzanne L.; Joseph, Christine L.; Seibold, Max A.; Shriver, Mark D.; Williams, L. Keoki			Differences in allergic sensitization by self-reported race and genetic ancestry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						self-reported race; race-ethnicity; continental population group; IgE; allergic sensitization	TRAFFIC PARTICULATE MATTER; SERUM IGE LEVELS; BRONCHIAL HYPERRESPONSIVENESS; ENVIRONMENT INTERACTIONS; RACIAL DISPARITIES; AFRICAN-AMERICAN; IMMUNOGLOBULIN-E; CD14 C-260T; POPULATION; INFERENCE	Background: Many allergic conditions occur more frequently in African American patients when compared with white patients; however, it is not known whether this represents genetic predisposition or disparate environmental exposures. Objective: We sought to assess the relationship of self-reported race and genetic ancestry to allergic sensitization. Methods: We included 601 women enrolled in a population-based cohort study whose self-reported race was African American or white. Genetic ancestry was estimated by using markers that differentiate West African and European ancestry. We assessed the relationship between allergic sensitization (defined as >= 1 allergen-specific IgE results) and both self-reported race and genetic ancestry. Regression models adjusted for sociodemographic variables, environmental exposures, and location of residence. Results: The average proportion of West African ancestry in African American participants was 0.69, whereas the mean proportion of European ancestry in white participants was 0.79. Self-reported African American race was associated with allergic sensitization when compared with those who reported being white (adjusted odds ratio, 2.19; 95% CI, 1.22-3.93), even after adjusting for other variables. Genetic ancestry was not significantly associated with allergic sensitization after accounting for location of residence (adjusted odds ratio, 2.09 for urban vs suburban residence; 951% CI, 1.32-3.31). Conclusion: Self-reported race and location of residence appeared to be more important predictors of allergic sensitization when compared with genetic ancestry, suggesting that the disparity in allergic sensitization by race might be primarily a result of environmental factors rather than genetic differences.	[Favro, David; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; [Yang, James J.; Johnson, Christine C.; Krajenta, Richard; Havstad, Suzanne L.; Joseph, Christine L.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Med, Detroit, MI 48202 USA; [Burchard, Esteban G.; Choudhry, Shweta; Seibold, Max A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Burchard, Esteban G.; Seibold, Max A.] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; [Chen, Justin; Akana, Matthew; Ha, Connie; Kwok, Pui-Yan] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Ownby, Dennis R.] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; [Shriver, Mark D.] Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hths.org	Kwok, Pui-Yan/F-7725-2014	Kwok, Pui-Yan/0000-0002-5087-3059; Chen, Justin/0000-0002-1661-4547; Johnson, Christine Cole/0000-0002-6864-6604; Shriver, Mark/0000-0003-0006-0479	Henry Ford Hospital; Sandler Program for Asthma Research; National Institute of Allergy and Infectious Diseases [AI61774, AI50681, AI59415]; National Heart, Lung. and Blood Institute [HL79055]; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050681, R01AI059415, R21AI059415, R01AI050681, R01AI061774] Funding Source: NIH RePORTER	Henry Ford Hospital; Sandler Program for Asthma Research; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung. and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grams from the Fund for Henry Ford Hospital, the Sandler Program for Asthma Research, and the National Institute of Allergy and Infectious Diseases (AI61774, AI50681, and AI59415) and the National Heart, Lung. and Blood Institute (HL79055), National Institutes of Health.	Bamshad M, 2007, CURR OPIN PEDIATR, V19, P613, DOI 10.1097/MOP.0b013e3282f163ca; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9; Fernvik E, 2002, J TOXICOL ENV HEAL A, V65, P1025, DOI 10.1080/152873902760125200; Fernvik E, 2002, CLIN EXP ALLERGY, V32, P602, DOI 10.1046/j.0954-7894.2002.01347.x; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; Guthery SL, 2007, AM J HUM GENET, V81, P1221, DOI 10.1086/522239; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Mountain JL, 2004, NAT GENET, V36, pS48, DOI 10.1038/ng1456; Myers R. H, 1990, CLASSICAL MODERN REG, V2nd; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Perlin SA, 1999, J EXPO ANAL ENV EPID, V9, P29, DOI 10.1038/sj.jea.7500024; Pritchard JK, 2000, GENETICS, V155, P945; RAUH VA, 2002, ENVIRON HEALTH PER S, V110, pS323; Risch N, 2002, GENOME BIOL, V3, DOI [10.1186/GB-2002-3-7-COMMENT2007, DOI 10.1186/GB-2002-3-7-C0MMENT2007, 10.1186/gb-2002-3-7-comment2007]; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; SAS Institute Inc, 2004, SAS STAT US GUID VER; Schulz A, 2000, SOC SCI MED, V51, P1639, DOI 10.1016/S0277-9536(00)00084-8; Schulz AJ, 2002, MILBANK Q, V80, P677, DOI 10.1111/1468-0009.00028; Simons E, 2007, J URBAN HEALTH, V84, P577, DOI 10.1007/s11524-007-9205-3; Sinha M, 2006, NEW ENGL J MED, V354, P421, DOI 10.1056/NEJMc052515; Sugrue T.J., 2005, ORIGINS URBAN CRISIS; Tang H, 2005, GENET EPIDEMIOL, V28, P289, DOI 10.1002/gepi.20064; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7; Williams LK, 2008, ANN ALLERG ASTHMA IM, V100, P128, DOI 10.1016/S1081-1206(10)60421-8; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Winker MA, 2004, JAMA-J AM MED ASSOC, V292, P1612, DOI 10.1001/jama.292.13.1612; Wu BL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-317; 2004, MMWR MORB MORTAL WKL, V53, P145	35	49	49	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					820	827		10.1016/j.jaci.2008.07.044	http://dx.doi.org/10.1016/j.jaci.2008.07.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014772	Green Accepted, Bronze			2022-12-18	WOS:000259989000030
J	Zhang, TT; Okkenhaug, K; Nashed, BF; Puri, KD; Knight, ZA; Shokat, KM; Vanhaesebroeck, B; Marshall, AJ				Zhang, Ting-ting; Okkenhaug, Klaus; Nashed, Baher F.; Puri, Kamal D.; Knight, Zachary A.; Shokat, Kevan M.; Vanhaesebroeck, Bart; Marshall, Aaron J.			Genetic or pharmaceutical blockade of p110 delta phosphoinositide 3-kinase enhances IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; allergy; B lymphocyte; immunoglobulin class switch; signal transduction; phosphoinositide 3-kinase	INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; ALLERGIC AIRWAY INFLAMMATION; NF-KAPPA-B; IL-4 INDUCTION; CELL ANTIGEN; CD40 LIGAND; IN-VIVO; ACTIVATION; DIFFERENTIATION	Background: Recent studies indicate that pharmaceutical blockade of phosphoinositide 3-kinase (PI3K) signaling enzymes might be effective in reducing allergic airway inflammation. Signals generated by the p110 delta PI3K isoform play critical roles in signaling through antigen and cytokine receptors and were shown to be required for induction of type 2, but not type 1, cytokine responses. Objective: We sought to determine the effect of genetic or pharmaceutical inactivation of p110 delta PI3K on induction of IgE responses. Methods: We determined the effect of p110 delta inactivation on induction of systemic IgE responses and on the ability of purified B lymphocytes to undergo IgE isotype switch in vitro. IgG and IgE germline transcription, postswitch transcription, protein expression, and secretion were measured, as well as cell division and expression of activation-induced cytidine deaminase. an enzyme required for isotype switch. Results: Paradoxically, inactivation of p110 delta PI3K led to markedly increased IgE responses, despite reduced production of other antibody isotypes. This result was seen by using genetic inactivation of P110 delta inhibition with IC87114 compound or blockade with the broad-spectrum PI3K inhibitors PIK-90 and PI-103. Significant increases in IgG1/IgE double-positive cells were observed, indicating that inactivation of PI3K leads to uncontrolled sequential switching from IgG1 to IgE. Disruption of p110 delta signaling results in increased germline transcription at the E locus and increased activation-induced cytidine deaminase expression, suggesting deregulation at the level of the isotype switch process. Conclusion: Blockade of PI3K signaling leads to markedly enhanced B-cell switch to IgE and increased IgE levels in vivo, despite reduced type 2 cytokine production.	[Zhang, Ting-ting; Nashed, Baher F.; Marshall, Aaron J.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada; [Zhang, Ting-ting; Nashed, Baher F.; Marshall, Aaron J.] CIHR Natl Training Program Allergy & Asthma Res, Winnipeg, MB, Canada; [Okkenhaug, Klaus] Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge, England; [Puri, Kamal D.] Calistoga Pharmceut, Seattle, WA USA; [Knight, Zachary A.; Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Vanhaesebroeck, Bart] Univ London, Inst Canc, Queen Marys Sch Med & Dent, London WC1E 7HU, England	University of Manitoba; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of London; Queen Mary University London	Marshall, AJ (corresponding author), Univ Manitoba, Dept Immunol, 730 William Ave, Winnipeg, MB, Canada.	marshall@ms.umanitoba.ca	Okkenhaug, Klaus/D-5149-2012; Okkenhaug, Klaus/H-3154-2019	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Knight, Zachary/0000-0001-7621-1478; Zhang, Ting-ting/0000-0002-7868-9624; Marshall, Aaron/0000-0002-1175-5498	Canadian Institutes of Health Research [MOP-42382]; CIHR National Training Program in Allergy and Asthma Research; SickKids Foundation (Toronto); Manitoba Institute of Child Health; Canada Research Chair	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CIHR National Training Program in Allergy and Asthma Research(Canadian Institutes of Health Research (CIHR)); SickKids Foundation (Toronto); Manitoba Institute of Child Health; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	Supported by the Canadian Institutes of Health Research (MOP-42382), the CIHR National Training Program in Allergy and Asthma Research, the SickKids Foundation (Toronto), and the Manitoba Institute of Child Health. T.Z. was supported by studentships from the Manitoba Institute of Child Health and the CIHR National Training Program in Allergy and Asthma Research. A.J.M. was supported by a Canada Research Chair.	AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Bilancio A, 2006, BLOOD, V107, P642, DOI 10.1182/blood-2005-07-3041; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Corry DB, 1999, NATURE, V402, pB18; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Donahue AC, 2007, EUR J IMMUNOL, V37, P2923, DOI 10.1002/eji.200737281; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Frasca D, 2004, J IMMUNOL, V172, P2155, DOI 10.4049/jimmunol.172.4.2155; Fruman DA, 2004, CURR OPIN IMMUNOL, V16, P314, DOI 10.1016/j.coi.2004.03.014; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; Iciek LA, 1997, J IMMUNOL, V158, P4769; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kashiwada M, 2007, IMMUNOL RES, V39, P194, DOI 10.1007/s12026-007-0075-2; KATONA IM, 1983, J IMMUNOL, V130, P350; Kinoshita K, 2000, CURR OPIN IMMUNOL, V12, P195, DOI 10.1016/S0952-7915(99)00072-2; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Lewkowich IP, 2002, EUR J IMMUNOL, V32, P3536, DOI 10.1002/1521-4141(200212)32:12<3536::AID-IMMU3536>3.0.CO;2-U; MANDLER R, 1993, J IMMUNOL, V150, P407; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nashed BF, 2007, EUR J IMMUNOL, V37, P416, DOI 10.1002/eji.200636401; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Omori SA, 2006, IMMUNITY, V25, P545, DOI 10.1016/j.immuni.2006.08.015; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Rush JS, 2002, J IMMUNOL, V168, P2676, DOI 10.4049/jimmunol.168.6.2676; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SNAPPER CM, 1988, J IMMUNOL, V141, P489; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; Sudowe S, 2000, SCAND J IMMUNOL, V51, P461; Vercelli D, 2002, CL ALLER IM, V16, P179; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161	41	49	53	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					811	819		10.1016/j.jaci.2008.08.008	http://dx.doi.org/10.1016/j.jaci.2008.08.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014771	Bronze			2022-12-18	WOS:000259989000029
J	Busse, WW; Lemanske, RF				Busse, William W.; Lemanske, Robert F., Jr.			Expert Pane Report 3: Moving forward to improve asthma caire	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CORTICOSTEROIDS		Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, J5-219 CSC,Box 2452,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; MURPHY S, 1997, GUIDELINES DIAGNOSIS, P1; *NAT HEART LUNG BL, 2007, J ALLERGY CLIN IMMUN, V120, pS93; *NAT HEART LUNG BL, 3 EPR NAT HEART LUNG; O'Byrne PM, 2007, J ALLERGY CLIN IMMUN, V119, P1332, DOI 10.1016/j.jaci.2007.03.007; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V87, P468, DOI 10.1016/0091-6749(91)90002-6; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596	9	49	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1012	1014		10.1016/j.jaci.2007.09.016	http://dx.doi.org/10.1016/j.jaci.2007.09.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983868				2022-12-18	WOS:000250973400003
J	Schaller, M; Hogaboam, CM; Lukacs, N; Kunkel, SL				Schaller, Matthew; Hogaboam, Cory M.; Lukacs, Nicholas; Kunkel, Steven L.			Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; chemokine; exacerbation; pulmonary; respiratory virus; rhinovirus; influenza; respiratory syncytial virus; rhinovirus	INFLUENZA-A VIRUS; AIRWAY EPITHELIAL-CELLS; PERSISTENT ADENOVIRAL INFECTION; TUMOR-NECROSIS-FACTOR; CD8(+) T-CELLS; NF-KAPPA-B; SYNCYTIAL-VIRUS; CYTOKINE RESPONSES; RHINOVIRUS INFECTION; NASAL SECRETIONS	A number of investigations have linked respiratory via] infections and the intensity and subsequent exacerbation of asthma through host response mechanisms. For example, it is likely that the immune-inflammatory response to respiratory syncytial virus can cause a predisposition toward an intense inflammatory reaction associated with asthma, and adenovirus might cause exacerbation of the immune response associated with chronic obstructive pulmonary disease. In each of these situations, the host's immune response plays a critical mechanistic role through the production of certain cytokines and chemokines. Specific aspects of these augmented immune responses are determined by the biology of the virus, the genetic variability of the host, and the cytokine-chemokine phenotype of the involved tissue. For instance, the type 1/type 2 cytokine ratio in the airways during infection with rhinovirus determines how long the viral infection endures. By this same theory, it has been demonstrated that chemokine levels produced during respiratory syncytial virus infection determine host responses to later immune stimuli in the lung, with the potential to augment the asthmatic response. Further research in this area will clarify cytokines, chemokines, or cell targets, which will provide the basis for next-generation therapies.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kunkel, SL (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Room 4071,BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	slkunkel@umich.edu	hogaboam, cory/M-3578-2014; Hogaboam, Cory M./AAI-1433-2021; Lukacs, Nicholas W/ABH-5583-2020; Schaller, Matthew/AAL-7640-2020	Hogaboam, Cory M./0000-0003-3366-4850; 				Barends M, 2004, J INFECT DIS, V189, P1866, DOI 10.1086/386341; Barends M, 2004, CLIN EXP ALLERGY, V34, P488, DOI 10.1111/j.1365-2222.2004.01906.x; Barends M, 2002, CLIN EXP ALLERGY, V32, P463, DOI 10.1046/j.1365-2222.2002.01317.x; Becker S, 1999, IMMUNOBIOLOGY, V201, P88, DOI 10.1016/S0171-2985(99)80049-7; BECKER S, 1991, J IMMUNOL, V147, P4307; Becker S, 1997, AM J PHYSIOL-LUNG C, V272, pL512, DOI 10.1152/ajplung.1997.272.3.L512; Bonville CA, 1999, PEDIATR ALLERGY IMMU, V10, P39, DOI 10.1034/j.1399-3038.1999.101005.x; Booth JL, 1999, AM J RESP CELL MOL, V21, P521, DOI 10.1165/ajrcmb.21.4.3677; Bowen GP, 2002, HUM GENE THER, V13, P367, DOI 10.1089/10430340252792503; BROCKLEBANK JT, 1972, LANCET, V2, P497; Bussfeld D, 1998, CELL IMMUNOL, V186, P1, DOI 10.1006/cimm.1998.1295; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; Chapman TJ, 2005, VIROLOGY, V340, P296, DOI 10.1016/j.virol.2005.06.023; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; DOUGLAS RG, 1974, INFECT IMMUN, V9, P506, DOI 10.1128/IAI.9.3.506-510.1974; Douville RN, 2006, J IMMUNOL, V176, P5848, DOI 10.4049/jimmunol.176.10.5848; Elliott MB, 2004, J MED VIROL, V73, P300, DOI 10.1002/jmv.20091; Everard ML, 2006, CURR OPIN ALLERGY CL, V6, P56, DOI 10.1097/01.all.0000200506.62048.06; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Garofalo RP, 2005, J MED VIROL, V75, P282, DOI 10.1002/jmv.20268; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Harcourt J, 2006, J IMMUNOL, V176, P1600, DOI 10.4049/jimmunol.176.3.1600; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Hess C, 2004, BLOOD, V104, P3463, DOI 10.1182/blood-2004-03-1067; Higginbotham JN, 2002, HUM GENE THER, V13, P129, DOI 10.1089/10430340152712683; John AE, 2005, EUR J IMMUNOL, V35, P108, DOI 10.1002/eji.200425439; John AE, 2003, EUR J IMMUNOL, V33, P1677, DOI 10.1002/eji.200323930; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1997, J INFECT DIS, V175, P323, DOI 10.1093/infdis/175.2.323; Kaufmann A, 2001, IMMUNOBIOLOGY, V204, P603, DOI 10.1078/0171-2985-00099; Kawaguchi M, 2001, CLIN EXP ALLERGY, V31, P873, DOI 10.1046/j.1365-2222.2001.01103.x; Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC; Konig B, 1996, J LEUKOCYTE BIOL, V60, P253; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; Marsland BJ, 2004, CLIN EXP ALLERGY, V34, P1299, DOI 10.1111/j.1365-2222.2004.02021.x; Matikainen S, 2000, VIROLOGY, V276, P138, DOI 10.1006/viro.2000.0542; Matsukura S, 1998, AM J RESP CELL MOL, V18, P255, DOI 10.1165/ajrcmb.18.2.2822; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Noah TL, 2000, CLIN IMMUNOL, V97, P43, DOI 10.1006/clim.2000.4914; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; Noble V, 1997, ARCH DIS CHILD, V76, P315, DOI 10.1136/adc.76.4.315; Oh JW, 2002, PEDIAT ALLERG IMM-UK, V13, P350, DOI 10.1034/j.1399-3038.2002.02018.x; Olszewska-Pazdrak B, 1998, J VIROL, V72, P4756, DOI 10.1128/JVI.72.6.4756-4764.1998; Pacifico L, 2000, CLIN INFECT DIS, V31, P834, DOI 10.1086/314049; Pala P, 2002, EUR RESPIR J, V20, P376, DOI 10.1183/09031936.02.00249902; Papadopoulos NG, 2001, CLIN EXP ALLERGY, V31, P1060, DOI 10.1046/j.1365-2222.2001.01112.x; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Peebles RS, 2001, J INFECT DIS, V184, P1374; Pichler M, 2001, PEDIATR PULM, V32, P367, DOI 10.1002/ppul.1145; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Salentin R, 2003, J LEUKOCYTE BIOL, V74, P252, DOI 10.1189/jlb.1102565; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sprenger H, 1996, J EXP MED, V184, P1191, DOI 10.1084/jem.184.3.1191; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Sung RYT, 2001, EUR J PEDIATR, V160, P117, DOI 10.1007/s004310000676; Takata H, 2004, J IMMUNOL, V173, P2231, DOI 10.4049/jimmunol.173.4.2231; Tong HH, 2003, INFECT IMMUN, V71, P4289, DOI 10.1128/IAI.71.8.4289-4296.2003; Topham DJ, 2001, J IMMUNOL, V167, P6983, DOI 10.4049/jimmunol.167.12.6983; Tripp RA, 2001, NAT IMMUNOL, V2, P732, DOI 10.1038/90675; van Benten IJ, 2001, ALLERGY, V56, P949, DOI 10.1034/j.1398-9995.2001.00212.x; WATSON ML, 1993, AM J RESP CELL MOL, V8, P365, DOI 10.1165/ajrcmb/8.4.365; Wohlleben G, 2003, J IMMUNOL, V170, P4601, DOI 10.4049/jimmunol.170.9.4601; Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001; Zhao J, 2002, PEDIATR ALLERGY IMMU, V13, P47, DOI 10.1034/j.1399-3038.2002.00051.x; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	76	49	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					295	302		10.1016/j.jaci.2006.05.025	http://dx.doi.org/10.1016/j.jaci.2006.05.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890750	Green Published, Bronze			2022-12-18	WOS:000239877700001
J	Flicker, S; Steinberger, P; Ball, T; Krauth, MT; Verdino, P; Valent, P; Almo, S; Valenta, R				Flicker, S; Steinberger, P; Ball, T; Krauth, MT; Verdino, P; Valent, P; Almo, S; Valenta, R			Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: Importance for allergenic activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass pollen allergy; allergen; Phl p 1; 3-dimensional structure; recombinant allergen fragment; epitope; monoclonal human IgE antibodies	PHL P 5; FC-EPSILON-RI; MONOCLONAL-ANTIBODIES; HISTAMINE-RELEASE; BINDING-SITES; J-REGION; GENE; IMMUNOTHERAPY; LOCUS; IDENTIFICATION	Background: The major timothy grass pollen allergen Phl p 1 is one of the most potent and frequently recognized environmental allergens. Objective: We sought to study at a molecular and structural level the IgE recognition of Phl p 1 and its relation to allergenic activity. Methods: Monoclonal human IgE antibody fragments specific for Phl p 1 and group 1 allergens from various grasses were isolated from a combinatorial library made of lymphocytes from patients with grass pollen allergy. Recombinant Phl p 1 fragments and the 3-dimensional structure of Phi p 1 were used to localize the major binding site for the IgE antibodies. A rPhl p 1 fragment containing this binding site was expressed in Escherichia coli, purified, and tested for IgE reactivity and allergenic activity with sera and basophils from patients with grass pollen allergy. Results: Monoclonal antibodies, as well as polyclonal serum IgE, from patients with grass pollen allergy defined a C-terminal fragment of Phl p 1 that represents a sterically oriented portion on the Phl p 1 structure. This Phl p 1 portion bound most of the allergen-specific IgE antibodies and contained the majority of the allergenic activity of Phl p 1. Conclusion: IgE recognition of spatially clustered epitopes on allergens might be a general factor determining their allergenic activity. Clinical implications: Geographic distribution of IgE epitopes on an allergen might influence its allergenic activity and hence explain discrepancies between diagnostic test results based on IgE serology and provocation testing. It might also form a basis for the development of low allergenic vaccines.	Univ Vienna, Gen Hosp, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, A-1090 Vienna, Austria; Med Univ Vienna, Gen Hosp, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; Albert Einstein Coll Med, Dept Biochem, New York, NY USA; Scripps Res Inst La Jolla, Dept Mol Biol, Wilson Lab, La Jolla, CA USA	University of Vienna; Medical University of Vienna; Yeshiva University; Scripps Research Institute	Valenta, R (corresponding author), Univ Vienna, Gen Hosp, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Test, PV/U-9451-2019; Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693; Steinberger, Peter/0000-0001-6848-4097				Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; ESCH RE, 1989, J IMMUNOL, V142, P179; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; HIETER PA, 1980, CELL, V22, P197, DOI 10.1016/0092-8674(80)90168-3; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; MATTILA PS, 1995, EUR J IMMUNOL, V25, P2578, DOI 10.1002/eji.1830250926; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; PARGENT W, 1991, EUR J IMMUNOL, V21, P1821, DOI 10.1002/eji.1830210807; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schramm G, 1997, J ALLERGY CLIN IMMUN, V99, P781, DOI 10.1016/S0091-6749(97)80012-7; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; VANREE R, 1995, INT ARCH ALLERGY IMM, V106, P250, DOI 10.1159/000236850; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6	35	49	53	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1336	1343		10.1016/j.jaci.2006.02.012	http://dx.doi.org/10.1016/j.jaci.2006.02.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750995				2022-12-18	WOS:000238332300020
J	Cianferoni, A; Massaad, M; Feske, S; de la Fuente, MA; Gallego, L; Ramesh, N; Geha, RS				Cianferoni, A; Massaad, M; Feske, S; de la Fuente, MA; Gallego, L; Ramesh, N; Geha, RS			Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deficient IL-2 gene expression in Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						WASP; IL-2 gene regulation; NF-kappa B; NF-AT; Erk; Jnk; c-fos; c-Jun	NF-KAPPA-B; SYNDROME PROTEIN; CYTOSKELETAL REARRANGEMENT; ACTIN POLYMERIZATION; IGE RECEPTOR; MAST-CELLS; LYMPHOCYTES; WASP; INDUCTION; PROMOTER	Background: Proliferation and IL-2 production in response to T-cell receptor ligation are impaired in patients with Wiskott-Aldrich syndrome (WAS). The transcription factors nuclear factor-kappa B (NF-kappa B), nuclear factor of activated T cells (NF-AT), and activating protein-1 (AP-1) play a critical role in IL-2 gene expression. Objective: To investigate the mechanisms of impaired IL-2 production after T-cell receptor ligation in T cells deficient in WAS protein (WASP). Methods: T cells from WASP(-/-) mice were stimulated with anti-CD3 and anti-CD28. Nuclear NF-kappa B, NF-AT, and AP-1 DNA-binding activity was examined by electroshift mobility assay. NF-ATp dephosphorylation and nuclear localization were examined by Western blot and indirect immunofluorescence. Phosphorylation of the mitogen-activated protein kinases Erk and Jnk, and of their nuclear substrates Elk-1 and c-Jun, was examined by Western blot. Expression of mRNA for IL-2 and the NF-kappa B-dependent gene A20 and of the AP-1 components c-fos and c-Jun was examined by quantitative RT-PCR. Results: Nuclear translocation and activity of NF-kappa B were normal in T cells from WASP(-/-) mice. In contrast, NF-ATp dephosphorylation and nuclear localization, nuclear AP-1 binding activity, and expression of c-fos, but not c-Jun, were all impaired. Phosphorylation of Jnk, c-Jun, and Erk were normal. However, nuclear translocation of phosphorylated Erk and phosphorylation of its nuclear substrate Elk1, which activates the c-fos promoter, were impaired. Conclusion: These results suggest that WASP is essential for NF-ATp activation, and for nuclear translocation of p-Erk, Elk1 phosphorylation, and c-fos gene expression in T cells. These defects underlie defective IL-2 expression and T-cell proliferation in WAS.	Childrens Hosp, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Res Inst Biomed Res, Ctr Blood, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pediat & Med, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard University	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave,Karp 10, Boston, MA 02215 USA.	raif.geha@childrens.harvard.edu	Feske, stefan/ABB-3554-2021; de la Fuente, Miguel A/C-7478-2013	Feske, stefan/0000-0001-5431-8178; de la Fuente, Miguel A/0000-0003-4619-8756	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714, R21AI054933] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59561] Funding Source: Medline; NIAID NIH HHS [AI054933, AI35714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Burns S, 2004, BLOOD, V104, P3454, DOI 10.1182/blood-2004-04-1678; Cannon JL, 2004, J IMMUNOL, V173, P1658, DOI 10.4049/jimmunol.173.3.1658; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Huang W, 2005, J IMMUNOL, V174, P2602, DOI 10.4049/jimmunol.174.5.2602; Imai K, 2003, CURR OPIN ALLERGY CL, V3, P427, DOI 10.1097/01.all.0000104452.09202.9c; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; Malewicz M, 2003, J BIOL CHEM, V278, P32825, DOI 10.1074/jbc.M304000200; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; McGuire KL, 1997, J IMMUNOL, V159, P1319; Morales-Tirado V, 2004, J IMMUNOL, V173, P726, DOI 10.4049/jimmunol.173.2.726; Nemeth ZH, 2004, J CELL PHYSIOL, V200, P71, DOI 10.1002/jcp.10477; Ochs Hans D, 2005, Curr Opin Hematol, V12, P284, DOI 10.1097/01.moh.0000168520.98990.19; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pelletier C, 1998, J IMMUNOL, V161, P4768; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pivniouk VI, 2003, INT IMMUNOL, V15, P1431, DOI 10.1093/intimm/dxg148; Prieschl EE, 1996, J IMMUNOL, V157, P2645; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Silvin C, 2001, J BIOL CHEM, V276, P21450, DOI 10.1074/jbc.M010729200; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	41	49	49	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1364	1371		10.1016/j.jaci.2005.09.006	http://dx.doi.org/10.1016/j.jaci.2005.09.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337472	Bronze, Green Published			2022-12-18	WOS:000235687000031
J	Craig, TJ; Hanks, CD; Fisher, LH				Craig, TJ; Hanks, CD; Fisher, LH			How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; sleep; congestion; somnolence; quality of life	QUALITY-OF-LIFE; BUDESONIDE	Therapy for rhinitis improves sleep quality and symptoms of daytime sleepiness. This improvement with therapy may be secondary to anti-inflammatory effects, leading to a reduction of inflammatory mediators, or to a mechanical reduction of congestion directly leading to improvement in sleep disturbance. We combined our data from 3 placebo-controlled studies of intranasal corticosteroids in patients with perennial rhinitis to determine whether a correlation between the reduction of congestion and improved sleep and daytime somnolence existed. The pooled data of budesonide, flunisolide, and fluticasone demonstrated significantly decreased nasal congestion, sleep problems, and sleepiness in treated patients. The data demonstrated a correlation between a reduction in nasal congestion and an improvement of sleep (P <.01) and daytime somnolence (P =.01). Thus, topical intranasal corticosteroids should be used to decrease nasal congestion and to improve sleep and daytime somnolence in patients manifesting these symptoms.	Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy Crit Care,Allergy Immunol Traini, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Craig, TJ (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy Crit Care,Allergy Immunol Traini, 500 Univ Dr, Hershey, PA 17033 USA.	tcraig@psu.edu						CANVOVA CR, 2004, RESPIRATION, V71, P138; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Craig TJ, 2003, ALLERGY ASTHMA PROC, V24, P53; Hughes K, 2003, ALLERGY, V58, P380, DOI 10.1034/j.1398-9995.2003.00093.x; Kremer B, 2002, CLIN EXP ALLERGY, V32, P1310, DOI 10.1046/j.1365-2745.2002.01483.x; Krouse HJ, 2002, OTOLARYNG HEAD NECK, V126, P607, DOI 10.1067/mhn.2002.125300; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Mansfield LE, 2004, ANN ALLERG ASTHMA IM, V92, P240, DOI 10.1016/S1081-1206(10)61554-2; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; Mintz M, 2004, ANN ALLERG ASTHMA IM, V92, P255, DOI 10.1016/S1081-1206(10)61557-8; *SAS I INC, 1996, SAS STAT SOFTW CHANG, P531; Stuck BA, 2004, J ALLERGY CLIN IMMUN, V113, P663, DOI 10.1016/j.jaci.2003.12.589; VONESH EF, 1997, LINEAR NONLINEAR MOD, P160; Young T, 1997, J ALLERGY CLIN IMMUN, V99, P757; ZWILLICH C, 1981, AM REV RESPIR DIS, V81, P159	15	49	55	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1264	1266		10.1016/j.jaci.2005.10.009	http://dx.doi.org/10.1016/j.jaci.2005.10.009			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337455				2022-12-18	WOS:000235687000014
J	Fregonese, L; Swan, FJ; van Schadewijk, A; Dolhnikoff, M; Santos, MA; Daha, MR; Stolk, J; Tschernig, T; Sterk, PJ; Hiemstra, PS; Rabe, KF; Mauad, T				Fregonese, L; Swan, FJ; van Schadewijk, A; Dolhnikoff, M; Santos, MA; Daha, MR; Stolk, J; Tschernig, T; Sterk, PJ; Hiemstra, PS; Rabe, KF; Mauad, T			Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						complement; C3aR; C5aR; fatal asthma; lung tissue; mild intermittent asthma; submucosal vessels; parenchymal vessels; epithelium	CENTRAL-NERVOUS-SYSTEM; COMPLEMENT FACTORS C3A; NONMYELOID CELLS; EMERGENCY-ROOM; AIR-POLLUTION; LAVAGE FLUID; ACTIVATION; INFLAMMATION; EOSINOPHILS; DISEASE	Background: The mechanisms leading to death from asthma are not completely understood. Recent studies suggest the involvement of the anaphylatoxins C3a and C5a, generated during complement activation, and their receptors C3aR and C5aR in the pathogenesis of asthma. Objective: The aim of our study was to investigate the expression of C3aR and C5aR in fatal asthma. Methods: We analyzed lung tissue from 14 subjects who died of asthma (fatal asthma; FA) and 14 subjects who died of nonpulmonary causes (controls) and bronchial biopsy specimens from 16 subjects with mild intermittent asthma (MIA). C3aR and C5aR expression was evaluated by immunohistochemistry, and a semiquantitative analysis of the intensity of staining was performed according to a visual analogue scale (score, 0-3). Results: C3aR was expressed on airway epithelium, smooth muscle, submucosal, and parenchymal vessels. C5aR was expressed on myeloid cells infiltrating the submucosa and on airway epithelium. Statistical analysis demonstrated higher expression of C3aR on submucosal vessels in FA compared with controls and MIA (median [minimum-maximum], controls, 0.24 [0-1.48]; MIA, 0.0 [0-1.00]; FA, 1.56 [0.13-3]; P =.002). C3aR was also increased on parenchymal vessels in FA (controls, 0.56 [0-2.00]; FA, 1.81 [0.5-3]; P =.0004). C5aR expression on airway epithelium was increased in FA compared with controls and MIA (controls, 1.25 [0.25-3]; MIA, 1.00 [0-2.00]; FA, 3.00 [1.13-3.00]; P = .001). Conclusion: The results of our study suggest a role of complement in FA.	Leiden Univ, Med Ctr, Dept Pulm, NL-2233 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, NL-2233 ZA Leiden, Netherlands; Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; Hannover Med Sch, Hannover, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidade de Sao Paulo; Hannover Medical School	Fregonese, L (corresponding author), Leiden Univ, Med Ctr, Dept Pulm, Albinusdreef 2, NL-2233 ZA Leiden, Netherlands.	l.lfregonese@lumc.nl	Mauad, Thais/G-1254-2012; Hiemstra, Pieter S/K-8587-2018; Rabe, Klaus F./AAW-6296-2021; Sterk, P.J./AAK-8175-2020; Dolhnikoff, Marisa/B-9019-2013; Adriano dos Santos, Mario/C-7503-2011	Mauad, Thais/0000-0002-3354-1466; Hiemstra, Pieter S/0000-0002-0238-5982; Rabe, Klaus F./0000-0002-7020-1401; Dolhnikoff, Marisa/0000-0002-9073-9989				Abe M, 2001, J IMMUNOL, V167, P4651, DOI 10.4049/jimmunol.167.8.4651; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; Beasley CRW, 1998, LUNG BIOL HEALTH DIS, V115, P13; Bland JM, 2003, ULTRASOUND OBST GYN, V22, P85, DOI 10.1002/uog.122; Boutin-Forzano S, 2004, RESPIRATION, V71, P134, DOI 10.1159/000076673; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Corsico A, 2003, J APPL PHYSIOL, V95, P441, DOI 10.1152/japplphysiol.01018.2002; Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; EHRENGRUBER MU, 1994, FEBS LETT, V346, P181, DOI 10.1016/0014-5793(94)00463-3; ELSNER J, 1994, BLOOD, V83, P3324; Fauroux B, 2000, PEDIATR PULM, V30, P41; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 1997, AM J PATHOL, V150, P31; Harkin DW, 2004, J VASC SURG, V39, P196, DOI 10.1016/j.jvs.2003.07.001; Hasegawa K, 2004, HUM GENET, V115, P295, DOI 10.1007/s00439-004-1157-z; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Hiltermann JTN, 1999, FREE RADICAL BIO MED, V27, P1448, DOI 10.1016/S0891-5849(99)00191-4; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Jacoby DB, 2002, JAMA-J AM MED ASSOC, V287, P755, DOI 10.1001/jama.287.6.755; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kita H, 1998, LUNG BIOL HEALTH DIS, V115, P157; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; LANGLOIS PF, 1989, J ALLERGY CLIN IMMUN, V83, P11, DOI 10.1016/0091-6749(89)90472-7; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; Lukacs NW, 2001, AM J PHYSIOL-LUNG C, V280, pL512, DOI 10.1152/ajplung.2001.280.3.L512; Marc MM, 2004, AM J RESP CELL MOL, V31, P216, DOI 10.1165/rcmb.2003-0394OC; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com; Monsinjon T, 2001, FEBS LETT, V487, P339, DOI 10.1016/S0014-5793(00)02320-6; MOUSLI M, 1992, J IMMUNOL, V148, P2456; NAGATA S, 1987, J ALLERGY CLIN IMMUN, V80, P24, DOI 10.1016/S0091-6749(87)80186-0; Nakano Y, 2003, J ALLERGY CLIN IMMUN, V112, P525, DOI 10.1067/mai.2003.1710; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Riedemann NC, 2003, J LEUKOCYTE BIOL, V74, P966, DOI 10.1189/jlb.0403137; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Strunk RC, 1998, LUNG BIOL HEALTH DIS, V115, P31; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Szebeni J, 2003, SHOCK, V20, P347, DOI 10.1097/01.shk.0000082444.66379.17; TAKAFUJI S, 1994, INT ARCH ALLERGY IMM, V104, P27, DOI 10.1159/000236743; Tan WC, 2003, AM J MED, V115, P272, DOI 10.1016/S0002-9343(03)00353-X; Taube C, 2003, AM J RESP CRIT CARE, V168, P1333, DOI 10.1164/rccm.200306-739OC; WEIBEL ER, 1998, FISHMANS PULMONARY D, P21; Wenzel S, 2003, CHEST, V123, p405S, DOI 10.1378/chest.123.3_suppl.405S-a; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	56	49	54	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1148	1154		10.1016/j.jaci.2005.01.068	http://dx.doi.org/10.1016/j.jaci.2005.01.068			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940127	Bronze			2022-12-18	WOS:000229815400007
J	Dorman, SC; Babirad, I; Post, J; Watson, RM; Foley, R; Jones, GL; O'Byrne, PM; Sehmi, R				Dorman, SC; Babirad, I; Post, J; Watson, RM; Foley, R; Jones, GL; O'Byrne, PM; Sehmi, R			Progenitor egress from the bone marrow after allergen challenge: Role of stromal cell-derived factor 1 alpha and eotaxin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD34; progenitor cell mobilization; asthma; SDF-1 alpha-CXCR4; eotaxin-CCR3	CC-CHEMOKINE RECEPTOR-3; CIRCULATING EOSINOPHILS; AIRWAY RESPONSIVENESS; ASTHMATIC RESPONSES; CD34(+) CELLS; MOBILIZATION; CYTOKINES; SDF-1; CHEMOATTRACTANT; DIFFERENTIATION	Background: CCR3 expression on CD34(+) cells mediates migration to cotaxin in vitro. CXCR4 and stromal cell-derived factor (SDF)-1 alpha are important for stem cell homing to hemopoietic compartments. Objective: To study chemokine-mediated progenitor cell traffic in allergic inflammation. Methods: Bone marrow (BM) aspirates were obtained at baseline from normal subjects; atopic subjects without asthma; and subjects with asthma before, 5 hours after, and 24 hours after allergen inhalation (dual and early responders). Changes in chemokine receptor expression and migration were assessed. Results: Expression of CXCR4, but not CCR3, on BM CD34(+) cells was greater in normal subjects compared with atopic subjects with asthma. Likewise, SDF-1 alpha, but not eotaxin, stimulated a greater migrational response by BM CD34(+) cells from normal subjects compared with subjects with asthma. For all subjects, a positive correlation was found between intensity of CXCR4 expression and magnitude of CD34+ cell response to SDF-1 alpha. Allergen inhalation attenuated both intensity of CXCR4 expression and SDF-1 alpha levels in marrow from dual compared with early responders 24 hours postallergen. In contrast, the intensity of CCR3 expression on BM CD34(+) cells increased in dual compared with early responders at 24 hours postallergen. In addition, an increase in migrational responsiveness of BM CD34(+) cells to eotaxin and a decrease to SDF-1 alpha 24 hours postallergen was found in dual responder subjects with asthma. Conclusion: After allergen inhalation in subjects with asthma, a downregulation in CXCR4 intensity on BM CD34(+) cells and a reduction in BM SDF-1 alpha levels may reduce progenitor retention to marrow stroma promoting peripheral egress, possibly mediated by the CCR3/eotaxin axis.	McMaster Univ, St Josephs Hosp, Firestone Inst Resp Hlth, Asthma Res Grp,St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 4A6, Canada	McGill University; McMaster University; McMaster University	Sehmi, R (corresponding author), McMaster Univ, St Josephs Hosp, Firestone Inst Resp Hlth, Asthma Res Grp,St Josephs Healthcare, Luke Wing,Rm L314-6,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	sehmir@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Broxmeyer HE, 2001, INT J HEMATOL, V74, P9, DOI 10.1007/BF02982544; Cashman J, 2002, BLOOD, V99, P792, DOI 10.1182/blood.V99.3.792; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P565, DOI 10.1164/rccm.200307-1024OC; DORMAN SC, 2004, AM J RESP CRIT CARE, V169, P549; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lamkhioued B, 2003, J IMMUNOL, V170, P537, DOI 10.4049/jimmunol.170.1.537; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Sehmi R, 2000, CHEM IMMUNOL, V76, P29; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; Sweeney EA, 2001, ANN NY ACAD SCI, V938, P48; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; Zeibecoglou K, 1999, J ALLERGY CLIN IMMUN, V103, P99, DOI 10.1016/S0091-6749(99)70532-4	26	49	54	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					501	507		10.1016/j.jaci.2004.11.017	http://dx.doi.org/10.1016/j.jaci.2004.11.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753896	Bronze			2022-12-18	WOS:000227687000011
J	Adler, A; Tager, I; Quintero, DR				Adler, A; Tager, I; Quintero, DR			Decreased prevalence of asthma among farm-reared children compared with those who are rural but not farm-reared	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; farm; epidemiology; childhood	DAY-CARE ATTENDANCE; ALLERGIC DISEASES; FAMILY-SIZE; SYMPTOMS; SCHOOLCHILDREN; RESIDENCE; EXPOSURE; PROTECT; URBAN; ATOPY	Background: Farm exposure has been associated with decreased asthma prevalence. Objectives: We compared asthma prevalence among rural farm-reared and non-farm-reared children and examined farm demographic and environmental factors. Methods: We performed a cross-sectional, population-based survey among 36,500 rural kindergarten through 12th grade school children. Surveys were distributed through schools and returned by mail. Results: Of the 4152 participants, 18% had lived or were currently living on a farm. Compared to other rural children, farm children had more siblings (3.0 vs 2.5; P <.015), were more likely to be breast-fed (64% vs 58%; P <.002), to have pets (88% vs 79%; P <.001), and were less likely to have attended daycare (39% vs 50%; P <.001). Farm-reared children were less likely to have had a history of wheezing (28% vs 34%; P <.003) or a diagnosis of asthma (22% vs 26%; P <.002). This effect was greater among children younger than 10 years of age than among older children. There was no difference in the frequency of either asthma or non-asthma allergy symptoms during the previous 12 months. When analyzed by age and sex, decreased asthma prevalence was associated with farm rearing among younger children more than among adolescents. Farm residence beginning during the first 5 years, but not later, was associated with decreased rates of ever asthma (23.7% vs 33.7%; P <.005). Conclusions: Asthma, but not other manifestations of allergy, is less commonly reported among farm-reared children. Early exposures may be more important than those occurring later. Without ongoing exposures, their effects on disease expression may diminish over time.	Med Coll Wisconsin, Milwaukee, WI 53226 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Med Coll Wisconsin, Dept Pediat,Div Pediat Pulmonol, Berkeley, CA 94720 USA	Medical College of Wisconsin; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Adler, A (corresponding author), Med Coll Wisconsin, MS777A,9000 W Wisconsin Ave, Milwaukee, WI 53226 USA.	aadler@mail.mcw.edu						Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Blumenthal MN, 2000, ALLERGY ASTHMA PROC, V21, P55, DOI 10.2500/108854100778249042; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Braback L, 2001, Lakartidningen, V98, P5322; Brabin BJ, 1998, ANN TROP PAEDIATR, V18, pS33, DOI 10.1080/02724936.1998.11747978; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; *CCD, 2003, NAT CTR ED STAT; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80, DOI 10.1016/S1081-1206(10)63090-6; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Johnson CC, 2002, CURR OPIN ALLERGY CL, V2, P133, DOI 10.1097/00130832-200204000-00009; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Nystad W, 2000, ANN MED, V32, P390, DOI 10.3109/07853890008995945; Oberle D, 2001, THORAX, V56, P896; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Platts-Mills TAE, 2001, MEDIAT INFLAMM, V10, P288, DOI 10.1080/09629350152700902; Platts-Mills Thomas A E, 2002, Curr Allergy Asthma Rep, V2, P175, DOI 10.1007/s11882-002-0013-2; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301, DOI 10.1159/000237008; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2001, EUR RESPIR J, V18, P872, DOI 10.1183/09031936.01.00268401; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wieringa MH, 2001, EUR RESPIR J, V17, P422, DOI 10.1183/09031936.01.17304220; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WJST M, 1992, MONATSSCHR KINDERH, V140, P769; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; 1997, AN SIST SANIT NAVAR, V20, P57	39	49	50	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					67	73		10.1016/j.jaci.2004.10.008	http://dx.doi.org/10.1016/j.jaci.2004.10.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637549				2022-12-18	WOS:000226267000009
J	Limb, SL; Brown, KC; Wood, RA; Wise, RA; Eggleston, PA; Tonascia, J; Hamilton, RG; Adkinson, NF				Limb, SL; Brown, KC; Wood, RA; Wise, RA; Eggleston, PA; Tonascia, J; Hamilton, RG; Adkinson, NF			Adult asthma severity in individuals with a history of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; asthma severity; atopy; adult asthma outcomes	HOUSE-DUST MITE; RISK-FACTORS; EXPOSURE; CHILDREN; COHORT; HEIGHT; AGE	Background: Childhood asthma can have a range of outcomes in adulthood. Objective: To identify clinical features and exposures associated with persistence and severity of childhood asthma in adulthood. Methods: Eighty-five of 121 subjects previously enrolled in a study of immunotherapy for childhood allergic asthma (age 5-12 years) were re-evaluated with allergy skin testing, spirometry, and interviews about asthma symptoms and medications. These young adults (age 17-30 years; 74% male) all had moderate to severe childhood asthma. Adult asthma severity was scored by using a modified version of National Heart, Lung, and Blood Institute severity categories. Results: Thirteen (15.3%) of 85 adult subjects were in remission despite persistent childhood asthma. Another 19 subjects (22.4%) had only intermittent asthma. The remaining 53 had persistent asthma, of whom 12 (14.1%) had mild asthma, 25 (29.4%) had moderate asthma, and 16 (18.8%) had severe asthma. Subjects in remission, compared with subjects with intermittent or persistent asthma, had lower total serum IgE in childhood (412 ng/mL vs 1136 ng/mL vs 968 ng/ml.; P =.02) and fewer positive allergy skin tests (7 vs 9 vs 10 from panel of 18; P =.02). Subjects in remission also had milder childhood asthma, indicated by lower average daily medication usage scores (1.6 vs 3.5 vs 4.4; P =.005) and lower percentage of days on inhaled corticosteroids (13.7% vs 24.7% vs 40.9%; P =.008). No significant association was found between current asthma severity and childhood immunotherapy (P =.46). Conclusion: The prognosis of childhood allergic asthma in adulthood is largely determined early in life. The degree of atopy appears to be a critical determinant of asthma persistence.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Div Pulmonol & Crit Care Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Adkinson, NF (corresponding author), JHAAC, Rm 2A-62,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	fadkinso@hmi.edu		Wise, Robert/0000-0002-8353-2349	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR02719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; GERRITSEN J, 1991, AM REV RESPIR DIS, V143, P1468, DOI 10.1164/ajrccm/143.6.1468; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Kuczmarski R.J., 2000, CDC GROWTH CHARTS US; LIMB SL, UNPUB; Liu Andrew H., 2004, Journal of Allergy and Clinical Immunology, V113, pS19, DOI 10.1016/j.jaci.2003.10.034; *NAT HERAT LUNG BL, 1997, PUBLICATION; Norjavaara E, 2000, J PEDIATR-US, V137, P25, DOI 10.1067/mpd.2000.107384; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; ROORDA RJ, 1993, AM REV RESPIR DIS, V148, P1490, DOI 10.1164/ajrccm/148.6_Pt_1.1490; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802	18	49	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					61	66		10.1016/j.jaci.2004.09.032	http://dx.doi.org/10.1016/j.jaci.2004.09.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637548	Bronze			2022-12-18	WOS:000226267000008
J	Alexis, NE; Lay, JC; Almond, M; Peden, DB				Alexis, NE; Lay, JC; Almond, M; Peden, DB			Inhalation of low-dose endotoxin favors local T(H)2 response and primes airway phagocytes in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; phagocytosis; T(H)2 cytokines; mCD14; CD11b	NEUTROPHIL RESPONSE; OZONE EXPOSURE; INFLAMMATORY RESPONSE; CD11B EXPRESSION; ATOPIC ASTHMA; INHALED LPS; LIPOPOLYSACCHARIDE; PARTICLES; RESPONSIVENESS; ALLERGEN	Background: We previously reported that inhalation of 5 mug of endotoxin (30,000 endotoxin units [EU]) induced airway neutrophilia and decreased phagocytosis by airway monocytes, macrophages, and neutrophils. Conversely, we recently reported that very low doses of endotoxin, which are not associated with neutrophil influx, enhance response to allergen in the nasal and bronchial airway. Objective: We sought to determine whether endotoxin (0-10,000 EU) at doses that do not induce airway neutrophilia prime airway phagocyte function, alter expression of relevant cell-surface receptors (membrane-bound CD14 [mCD14] and CD11b/CR3), and cause induction of a T(H)2 cytokine profile in the airway. Methods: Thirteen nonallergic healthy volunteers were challenged on separate occasions with escalating doses of Clinical Center Reference Endotoxin (CCRE; 0, 2500, 5000, and 10,000 EU), with 9 volunteers completing the entire dose range. Sputum cells and fluid-phase components were recovered 6 hours after challenge. Sputum inflammatory cells were analyzed by means of flow cytometry for mCD14 and CD11b expression and immune function (phagocytosis of IgG-opsonized zymosan particles). Results: At all doses of CCRE, there was no increase in airway neutrophils relative to that caused by saline. However, inhalation of 10,000 EU enhanced phagocytosis (monocytes and macrophages), upregulated expression of CD11b and mCD14 (monocytes and neutrophils), and increased IL-13 levels, whereas IFN-gamma levels were significantly decreased. Conclusion: The 10,000-EU dose of CCRE is subthreshold for inducing airway neutrophilia but primes phagocyte function and cell-surface receptor expression in the presence of increased IL-13 and decreased IFN-gamma levels. We speculate that low-dose endotoxin challenge skews airway inflammation in a T(H)2 direction in vivo.	Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Alexis, NE (corresponding author), 104 Mason Farm Rd, Chapel Hill, NC 27599 USA.	Neil_Alexis@med.unc.edu	Lay, John/A-6380-2012	Peden, David/0000-0003-4526-4627	NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [2R01 HL62624, 1R01 HL66559] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066559, R01HL062624] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2000, CLIN IMMUNOL, V97, P21, DOI 10.1006/clim.2000.4911; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; ALTAVILLA D, 1989, IMMUNOPHARMACOLOGY, V17, P99, DOI 10.1016/0162-3109(89)90055-6; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elder ACP, 2000, INHAL TOXICOL, V12, P227, DOI 10.1080/089583700750019585; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Goldsmith CAW, 2002, INHAL TOXICOL, V14, P325, DOI 10.1080/08958370252870989; Goldsmith CAW, 1999, INHAL TOXICOL, V11, P981; Gust R, 1998, AM J RESP CRIT CARE, V157, P1919, DOI 10.1164/ajrccm.157.6.9704110; Imrich A, 1999, TOXICOL APPL PHARM, V159, P117, DOI 10.1006/taap.1999.8731; Liu AH, 2001, ALLERGY ASTHMA PROC, V22, P337; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Ning YY, 2000, J TOXICOL ENV HEAL A, V59, P165, DOI 10.1080/009841000156952; Sibelius U, 2002, CRIT CARE MED, V30, P2306, DOI 10.1097/00003246-200210000-00020; Ward PA, 1999, ARCH SURG-CHICAGO, V134, P666, DOI 10.1001/archsurg.134.6.666; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269	24	49	49	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1325	1331		10.1016/j.jaci.2004.09.002	http://dx.doi.org/10.1016/j.jaci.2004.09.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577830				2022-12-18	WOS:000225577400011
J	Roth-Walter, F; Scholl, I; Untersmayr, E; Fuchs, R; Boltz-Nitulescu, G; Weissenbock, A; Scheiner, O; Gabor, F; Jensen-Jarolim, E				Roth-Walter, F; Scholl, I; Untersmayr, E; Fuchs, R; Boltz-Nitulescu, G; Weissenbock, A; Scheiner, O; Gabor, F; Jensen-Jarolim, E			M cell targeting with Ateuria aurantia lectin as a novel approach for oral allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aleuria aurantia lectin; M cell; gastrointestinal tract; oral immunotherapy; allergy; birch pollen; microspheres; PLGA; Salmonella typhimurium	MEDIATED DRUG-DELIVERY; WHEAT-GERM-AGGLUTININ; SALMONELLA-TYPHIMURIUM; ALEURIA-AURANTIA; BINDING CHARACTERISTICS; CRYSTAL-STRUCTURE; BRUSH CELLS; CACO-2; HISTOCHEMISTRY; NEURAMINIDASE	Background: The extent and quality of the immune response to orally applied allergens may critically depend on the precise site of uptake at the intestinal mucosa. Objective: The aim of this study was to construct allergen vehicles optimized for oral allergen immunotherapy. Methods: By using a murine model, we examined the immunomodulatory effect of birch pollen proteins entrapped in poly(D,L-lactide-co-glycolide) microspheres, which were specifically targeted to enterocytes or to M cells, in an ongoing T(H)2 response. BALB/c mice express different carbohydrates on these 2 cell types. To target the sialylic residues on murine enterocytes, we functionalized microspheres with wheat germ agglutinin (WGA) and, to target a-L-fucose on M cells, with a lectin from Aleuria aurantia (AAL), the orange peel mushroom. Results: Both WGA and AAL functionalization enhanced binding to human Caco2 cells substantially, which express sialylic and, as carcinoma cells, also et-L-fucose residues. Different groups of BALB/c mice were first sensitized to birch pollen and subsequently fed with birch pollen-loaded functionalized (WGA microspheres, AAL microspheres) or nonfunctionalized, birch pollen extract-loaded particles. When mice were fed with AAL microspheres, birch pollen-specific IgG2a, but not IgG1 or IgE, increased significantly. As expected, in a 3 H-thymidin assay, their splenocytes proliferated specifically on birch pollen stimulation. Both targeting strategies, using WGA or AAL, induced IL-10 as well as IL-4 production. However, in AAL microsphere-treated mice, IFN-gamma synthesis was significantly increased, which may be responsible for the significant IgG2a production in this group. Conclusion: Our data indicate that targeting M cells by using AAL-coated allergen vehicles may be a promising strategy for oral allergen immunotherapy.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, Vienna, Austria	Medical University of Vienna; University of Vienna	Jensen-Jarolim, E (corresponding author), Med Univ Vienna, Dept Pathophysiol, AKH-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Erika.Jensen-jarolim@meduniwien.ac.at	Roth-Walter, Franziska/V-4651-2017; Untersmayr, Eva/GRY-4470-2022; Jensen-Jarolim, Erika/C-5120-2018	Roth-Walter, Franziska/0000-0001-5005-9228; Jensen-Jarolim, Erika/0000-0003-4019-5765; Untersmayr, Eva/0000-0002-1963-499X				Bellanti JA, 1998, ALLERGY ASTHMA PROC, V19, P337, DOI 10.2500/108854198778612735; Chandrasekaran E, 2003, CARBOHYD RES, V338, P887, DOI 10.1016/S0008-6215(03)00021-1; Chung F, 2001, MEDIAT INFLAMM, V10, P51, DOI 10.1080/09629350120054518; Clark MA, 1998, INFECT IMMUN, V66, P1237, DOI 10.1128/IAI.66.3.1237-1243.1998; Clark MA, 2000, ADV DRUG DELIVER REV, V43, P207, DOI 10.1016/S0169-409X(00)00070-3; Clark MA, 2001, ADV DRUG DELIVER REV, V50, P81, DOI 10.1016/S0169-409X(01)00149-1; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; Ertl B, 2000, J DRUG TARGET, V8, P173, DOI 10.3109/10611860008996863; Fujihashi M, 2003, BIOCHEMISTRY-US, V42, P11093, DOI 10.1021/bi034983z; Fujimura Y, 2004, VIRCHOWS ARCH, V444, P36, DOI 10.1007/s00428-003-0898-8; Gabor F, 2003, STP PHARMA SCI, V13, P3; Gabor F, 1998, J CONTROL RELEASE, V55, P131, DOI 10.1016/S0168-3659(98)00043-1; Gabor F, 2002, INT J PHARM, V237, P227, DOI 10.1016/S0378-5173(02)00049-2; Gebert A, 2000, HISTOCHEM CELL BIOL, V113, P389; Gebhard A, 1999, J HISTOCHEM CYTOCHEM, V47, P799, DOI 10.1177/002215549904700609; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; HOYER LL, 1991, J BIOCHEM-TOKYO, V110, P462, DOI 10.1093/oxfordjournals.jbchem.a123603; Ignatius AA, 1996, BIOMATERIALS, V17, P831, DOI 10.1016/0142-9612(96)81421-9; JAROLIM E, 1989, INT ARCH ALLER A IMM, V88, P180, DOI 10.1159/000234778; JEPSON MA, 1995, J DRUG TARGET, V3, P75, DOI 10.3109/10611869509015938; Jepson MA, 1996, J ANAT, V189, P507; Jepson MA, 1998, TRENDS MICROBIOL, V6, P359, DOI 10.1016/S0966-842X(98)01337-7; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Kay AB, 2003, CURR OPIN PHARMACOL, V3, P220, DOI 10.1016/S1471-4892(03)00038-9; Liener I.E., 1986, LECTINS PROPERTIES F; Litwin A, 1996, ANN ALLERG ASTHMA IM, V77, P132, DOI 10.1016/S1081-1206(10)63499-0; Loessner H, 2004, EXPERT OPIN BIOL TH, V4, P157, DOI 10.1517/14712598.4.2.157; Mayer L, 2004, NAT REV IMMUNOL, V4, P407, DOI 10.1038/nri1370; MOWAT AM, 1986, IMMUNOLOGY, V58, P677; Packard KA, 2003, INT IMMUNOPHARMACOL, V3, P909, DOI 10.1016/S1567-5769(02)00235-7; Pecquet S, 2000, VACCINE, V18, P1196, DOI 10.1016/S0264-410X(99)00384-9; Pusztai A, 1999, DRUGS PHARM SCI, V98, P387; Sansonetti PJ, 1999, SEMIN IMMUNOL, V11, P193, DOI 10.1006/smim.1999.0175; Scholl I, 2004, CLIN EXP ALLERGY, V34, P315, DOI 10.1111/j.1365-2222.2004.01884.x; Sharma R, 1996, HISTOCHEM CELL BIOL, V105, P459, DOI 10.1007/BF01457659; Sharma R, 1998, J HISTOCHEM CYTOCHEM, V46, P143, DOI 10.1177/002215549804600202; Spahn TW, 2001, EUR J IMMUNOL, V31, P1278, DOI 10.1002/1521-4141(200104)31:4<1278::AID-IMMU1278>3.0.CO;2-A; TACKET CO, 1991, J INFECT DIS, V163, P901, DOI 10.1093/infdis/163.4.901; TePas EC, 2004, ANN ALLERG ASTHMA IM, V92, P25, DOI 10.1016/S1081-1206(10)61706-1; Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.2002.20.1.142; Walter F, 2004, BIOCHEM BIOPH RES CO, V315, P281, DOI 10.1016/j.bbrc.2004.01.057; Wang XH, 2003, J IMMUNOL, V171, P4717, DOI 10.4049/jimmunol.171.9.4717; Weissenboeck A, 2004, PHARM RES-DORDR, V21, P1917, DOI 10.1023/B:PHAM.0000045247.09724.26; Wimmerova M, 2003, J BIOL CHEM, V278, P27059, DOI 10.1074/jbc.M302642200	44	49	53	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1362	1368		10.1016/j.jaci.2004.08.010	http://dx.doi.org/10.1016/j.jaci.2004.08.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577836				2022-12-18	WOS:000225577400017
J	Chen, WG; Daines, MO; Hershey, GKK				Chen, WG; Daines, MO; Hershey, GKK			Turning off signal transducer and activator of transcription (STAT): The negative regulation of STAT signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						cytokine; Jak-STAT; STAT; methylation; suppressor of cytokine signaling; protein inhibitor of activated STAT; phosphatase; review	PROTEIN-TYROSINE-PHOSPHATASE; SEVERE COMBINED IMMUNODEFICIENCY; MICE LACKING SUPPRESSOR; DNA-BINDING ACTIVITY; INTERLEUKIN-2-RECEPTOR BETA-CHAIN; STIMULATED JAK/STAT PATHWAY; LEUKEMIA INHIBITORY FACTOR; NUCLEAR EXPORT SIGNAL; SOCS-BOX MOTIF; SERINE PHOSPHORYLATION	Signal transducer and activator of transcription (STAT) proteins are a group of transcription factors that transmit signals from the extracellular milieu of cells to the nucleus. They are crucial for the signaling of many cytokines that are mediators of allergic inflammation. Considerable information is known about the activation of STATs and their role in gene transcription; comparably much less is known about how STAT signaling is regulated. Because STATs are critical for the induction of many genes crucial for the allergic cascade and immune host defense, understanding the regulation of these molecules will provide novel insights into allergic and immunodeficiency disorders and will likely identify new targets for therapeutic interventions. This review will summarize the current understanding of the regulation of STAT signaling, emphasizing recent observations.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Daines, Michael/0000-0003-2464-9034; Khurana Hershey, Gurjit/0000-0001-6663-977X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046652] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI46652-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ali S, 2003, J BIOL CHEM, V278, P52021, DOI 10.1074/jbc.M306758200; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Arora T, 2003, J BIOL CHEM, V278, P21327, DOI 10.1074/jbc.C300119200; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; Brockdorff JL, 2002, CYTOKINE, V20, P141, DOI 10.1006/cyto.2002.1986; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Chen WG, 2004, J IMMUNOL, V172, P6744, DOI 10.4049/jimmunol.172.11.6744; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cho SS, 1996, J IMMUNOL, V157, P4781; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Daines MO, 2003, J BIOL CHEM, V278, P30971, DOI 10.1074/jbc.M301094200; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Giordanetto F, 2003, PROTEIN ENG, V16, P115, DOI 10.1093/proeng/gzg015; Gollob JA, 1999, J IMMUNOL, V162, P4472; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Hanson EM, 2003, J BIOL CHEM, V278, P3903, DOI 10.1074/jbc.M211747200; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Morinobu A, 2002, P NATL ACAD SCI USA, V99, P12281, DOI 10.1073/pnas.182618999; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Puck JM, 1997, BLOOD, V89, P1968; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; Rigacci S, 2003, BIOCHEM BIOPH RES CO, V312, P360, DOI 10.1016/j.bbrc.2003.10.126; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rogers RS, 2003, J BIOL CHEM, V278, P30091, DOI 10.1074/jbc.M301344200; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schindler CW, 2002, J CLIN INVEST, V109, P1133, DOI 10.1172/JCI200215644; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stoiber D, 1999, J IMMUNOL, V163, P2640; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tamura K, 2003, INT ARCH ALLERGY IMM, V131, P33, DOI 10.1159/000070432; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Toyoda H, 2004, J IMMUNOL, V172, P3905, DOI 10.4049/jimmunol.172.6.3905; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Wang YL, 2004, J BIOL CHEM, V279, P25196, DOI 10.1074/jbc.M313668200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Xue HH, 2002, INT IMMUNOL, V14, P1263, DOI 10.1093/intimm/dxf101; Yamada T, 2002, J BIOL CHEM, V277, P28830, DOI 10.1074/jbc.M201781200; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	181	49	57	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					476	489		10.1016/j.jaci.2004.06.042	http://dx.doi.org/10.1016/j.jaci.2004.06.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356544				2022-12-18	WOS:000223799600002
J	Asakura, T; Ishii, Y; Chibana, K; Fukuda, T				Asakura, T; Ishii, Y; Chibana, K; Fukuda, T			Leukotriene D-4 stimulates collagen production from myofibroblasts transformed by TGF-beta	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl leukotrienes; CysLT1 receptor; growth factor; transforming growth factor beta; fibroblast; myofibroblast; airway remodeling; bronchial asthma; montelukast; alpha-smooth muscle actin	AIRWAY SMOOTH-MUSCLE; BRONCHOALVEOLAR LAVAGE FLUID; CELL PROLIFERATION; ALLERGEN CHALLENGE; LUNG FIBROBLASTS; GUINEA-PIG; IN-VITRO; SUBEPITHELIAL FIBROSIS; CYSTEINYL LEUKOTRIENES; RECEPTOR EXPRESSION	Background: Airway remodeling has an important role in the pathogenesis of bronchial asthma. Many mediators that influence the pathophysiology of bronchial asthma, especially cysteinyl leukotrienes (CysLTs) and TGF-beta(1), are involved in airway remodeling. Objective: To know whether TGF-beta(1) alters fibroblast responsiveness to CysLTs, we examined the effects of leukotriene (LT) D-4 on collagen production from fibroblasts and from myofibroblasts transformed by TGF-beta(1). We also examined whether TGF-beta(1) upregulates CysLT1 receptor (CysLT1R) expression in fibroblasts. Methods: Concentrations of procollagen in the human fetal lung fibroblast (HFL) 1 cell supernatant were measured by using an enzyme immunoassay kit in the presence or absence of various concentrations of LTD4, TGF-beta(1), CysLT1R antagonist, or some combination of these. The mRNA expression of CysLT1R and alpha-smooth muscle actin as a marker of myofibroblasts was measured by means of real-time PCR. Furthermore, protein expression of CysLTIR on fibroblasts was measured by means of flow cytometric analysis. Results: TGF-beta(1) stimulated collagen production from HFL-1 cells, but LTD4 alone did not. LTD4 in combination with TGF-beta(1) increased collagen production compared with TGF-beta(1) alone. Real-time PCR showed that stimulation with TGF-beta(1) significantly upregulated CysLTIR and alpha-smooth muscle actin mRNA expression in HFL-1 cells. Conclusions: LTD4 increased collagen production by upregulating CysLT1R induced by TGF-beta(1). In the TGF-beta-rich milieu, activated myolibroblasts expressing CysLT1R can respond to CysLTs and produce large amounts of extracellular matrix, thereby contributing to airway remodeling. These data suggest that treatment with leukotriene receptor antagonists might prevent airway remodeling in patients with asthma.	Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi 3210293, Japan	Dokkyo Medical University	Ishii, Y (corresponding author), Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	ishiiysk@dokkyomed.ac.jp						Adachi S, 1998, LIFE SCI, V63, P1779, DOI 10.1016/S0024-3205(98)00452-4; ARAKAWA H, 1993, BRIT J PHARMACOL, V110, P127, DOI 10.1111/j.1476-5381.1993.tb13781.x; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUD L, 1987, J IMMUNOL, V138, P1190; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; BISGAARD H, 1987, CLIN ALLERGY, V17, P95, DOI 10.1111/j.1365-2222.1987.tb02326.x; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P261, DOI 10.1111/j.1365-2222.1993.tb00320.x; Chibana K, 2003, J IMMUNOL, V170, P4290, DOI 10.4049/jimmunol.170.8.4290; COHEN P, 1995, AM J PHYSIOL, V269, P151; Coker RK, 1997, AM J PATHOL, V150, P981; Cokugras H, 2001, THORAX, V56, P25, DOI 10.1136/thorax.56.1.25; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Hastie AT, 2002, AM J RESP CRIT CARE, V165, P266, DOI 10.1164/ajrccm.165.2.2101069; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; HUA XY, 1985, N-S ARCH PHARMACOL, V330, P136, DOI 10.1007/BF00499906; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; ISHIDA K, 1993, BRIT J PHARMACOL, V108, P700, DOI 10.1111/j.1476-5381.1993.tb12864.x; JOHNSON HG, 1983, PROSTAGLANDINS, V25, P237, DOI 10.1016/0090-6980(83)90107-7; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014, DOI 10.1152/ajplung.1996.271.6.L1014; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROCHE WR, 1989, LANCET, V1, P520; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Sato T, 1996, CLIN EXP ALLERGY, V26, P957; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; TAYLOR GW, 1989, LANCET, V1, P584; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WANG CG, 1993, AM REV RESPIR DIS, V148, P413, DOI 10.1164/ajrccm/148.2.413; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WOODWARD DF, 1983, EUR J PHARMACOL, V93, P9, DOI 10.1016/0014-2999(83)90025-0; ZHANG K, 1994, AM J PATHOL, V145, P114	49	49	50	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					310	315		10.1016/j.jaci.2004.04.037	http://dx.doi.org/10.1016/j.jaci.2004.04.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316508				2022-12-18	WOS:000223405600015
J	Bochner, BS				Bochner, BS			Verdict in the case of therapies versus eosinophils: The jury is still out	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophil; phenotype; therapy; targets; asthma	MAJOR BASIC-PROTEIN; IL-5 RECEPTOR-ALPHA; AIRWAY HYPERRESPONSIVENESS; MURINE MODEL; P-SELECTIN; ALLERGIC INFLAMMATION; DECREASED EXPRESSION; SMALL-MOLECULE; MAST-CELLS; ASTHMA	Eosinophils are regarded by many as fundamental to the pathophysiology of allergic diseases, including asthma. An improved understanding of the mechanisms involved in these responses is therefore of great relevance to asthma pathogenesis and the development of new therapeutics. Most therapies that are effective in reducing allergic inflammation in animals and human subjects diminish tissue eosinophilia and levels of eosinophil-derived mediators. However, recent efforts with more selective eosinophil-suppressive therapies have failed to affect disease, bringing into question the role of eosinophils in asthma. This article will provide a brief overview of the role of eosinophils in allergic diseases, followed by a discussion of both eosinophil-specific and eosinophil-selective therapeutic targets, with a focus on cell-surface molecules. The known and theoretic benefits and risks of these strategies will also be covered.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA	Johns Hopkins University	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; Aizawa H, 2002, J ALLERGY CLIN IMMUN, V109, P176, DOI 10.1067/mai.2002.120550; ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; *ASTHM TCSOTGO, 1997, NAT GENET, V15, P389; Barnes PJ, 2000, J ALLERGY CLIN IMMUN, V106, P5, DOI 10.1067/mai.2000.107930; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Bochner BS, 2003, THERAPEUTIC TARGETS, P223; Bochner BS, 2001, SAMTERS IMMUNOLOGICA, P244; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Canning BJ, 2003, CURR OPIN PHARMACOL, V3, P244, DOI 10.1016/S1471-4892(03)00045-6; Chauhan S, 2003, J STEROID BIOCHEM, V84, P441, DOI 10.1016/S0960-0760(03)00065-7; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Culley FJ, 2003, EUR J IMMUNOL, V33, P1302, DOI 10.1002/eji.200323509; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Dhanak D, 2001, BIOORG MED CHEM LETT, V11, P1445, DOI 10.1016/S0960-894X(01)00249-9; DiScipio RG, 1999, J IMMUNOL, V162, P1127; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Ebisawa M, 1995, LEUKOCYTE TYPING, Vone, P1036; FILLEY WV, 1982, LANCET, V2, P11; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foster PS, 2002, TRENDS MOL MED, V8, P162, DOI 10.1016/S1471-4914(02)02302-X; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; GAUVREAU GM, 2003, IN PRESS J ALLERGY C; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; GLEICH GJ, 1996, INHALED GLUCOCORTICO, P279; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gregory B, 2003, J IMMUNOL, V170, P5359, DOI 10.4049/jimmunol.170.11.5359; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Katoh S, 2003, J CLIN INVEST, V111, P1563, DOI [10.1172/JCI200316583, 10.1172/JCI16583]; Kay AB, 2003, AM J RESP CRIT CARE, V167, P1586, DOI 10.1164/rccm.2304001; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kingham PJ, 2003, PULM PHARMACOL THER, V16, P9, DOI 10.1016/S1094-5539(02)00093-7; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kita H, 1999, J IMMUNOL, V162, P6901; KITA H, 2003, MIDDLETONS ALLERGY P, P305; KLION AD, 2004, IN PRESS J ALLERGY C; Koo GC, 2003, AM J RESP CRIT CARE, V167, P1400, DOI 10.1164/rccm.200207-696OC; Kozma GT, 2003, INT IMMUNOL, V15, P963, DOI 10.1093/intimm/dxg095; Kudlacz E, 2002, J PHARMACOL EXP THER, V301, P747, DOI 10.1124/jpet.301.2.747; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lefort J, 1996, J CLIN INVEST, V97, P1117, DOI 10.1172/JCI118505; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Menzies-Gow A, 2002, CURR OPIN PULM MED, V8, P33, DOI 10.1097/00063198-200201000-00006; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mitsumori S, 2003, J MED CHEM, V46, P2446, DOI 10.1021/jm0205189; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; O'Reilly M, 2002, J RECEPT SIGNAL TR R, V22, P431, DOI 10.1081/RRS-120014612; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Okada S, 1998, J IMMUNOL, V160, P4010; Pereira S., 2003, Journal of Allergy and Clinical Immunology, V111, pS268, DOI 10.1016/S0091-6749(03)80960-0; Phipps S., 2003, Journal of Allergy and Clinical Immunology, V111, pS278, DOI 10.1016/S0091-6749(03)80998-3; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; RENZETTI LM, 2003, AM J RESP CRIT CARE, V167, pA640; Rizzo CA, 2002, J ALLERGY CLIN IMMUN, V109, P404, DOI 10.1067/mai.2002.122459; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; ROTHENBERG ME, 2004, IN PRESS J ALLERGY C; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Seminario MC, 1999, J IMMUNOL, V162, P6893; Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336; SUGIYAMA K, 2002, AM JR ESP CRIT CARE, V167, pA494; Tachimoto H, 2000, CHEM IMMUNOL, V76, P45; Tedla N, 2003, P NATL ACAD SCI USA, V100, P1174, DOI 10.1073/pnas.0337567100; Temple R, 2001, AM J RESP CELL MOL, V25, P425, DOI 10.1165/ajrcmb.25.4.4456; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Venanzi S, 2001, CLIN EXP ALLERGY, V31, P1220, DOI 10.1046/j.1365-2222.2001.01132.x; Walsh GM, 1996, BLOOD, V87, P2815, DOI 10.1182/blood.V87.7.2815.bloodjournal8772815; Warrior U, 2003, J BIOMOL SCREEN, V8, P324, DOI 10.1177/1087057103008003010; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; White JR, 2000, J BIOL CHEM, V275, P36626, DOI 10.1074/jbc.M006613200; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Yousef GM, 2002, GENE, V286, P259, DOI 10.1016/S0378-1119(02)00432-8; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	97	49	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					3	9		10.1016/j.jaci.2003.09.046	http://dx.doi.org/10.1016/j.jaci.2003.09.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713900				2022-12-18	WOS:000187837900001
J	Heinzmann, A; Jerkic, SP; Ganter, K; Kurz, T; Blattmann, S; Schuchmann, L; Gerhold, K; Berner, R; Deichmann, KA				Heinzmann, A; Jerkic, SP; Ganter, K; Kurz, T; Blattmann, S; Schuchmann, L; Gerhold, K; Berner, R; Deichmann, KA			Association study of the IL13 variant Arg110Gln in atopic diseases and juvenile idiopathic arthritis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial asthma; atopy; juvenile idiopathic arthritis; IL-13; association; genetic	RHEUMATOID-ARTHRITIS; ASTHMA; IL-13; GENE; PREVALENCE; DISORDERS; CHILDREN; TH1	Background: It has previously been shown that various inflammatory diseases, such as diabetes mellitus, bronchial asthma, chronic inflammatory bowel diseases, and rheumatoid arthritis, are in some circumstances genetically linked to the same chromosomal regions. Consequently, common genes underlying the pathogenetics of these diseases have been proposed. Chronic inflammatory disorders can be subdivided by their predominant immune response, either T(H)1 or T(H)2. For example, juvenile idiopathic arthritis (JIA) is a T(H)1 disease, and bronchial asthma is a T(H)2 disease. Objectives: The present study investigated the polymorphism Arg110Gln within the IL13 gene, a strong T(H)2 cytokine. We attempted to determine whether it is associated with these 2 diseases and whether this would reflect the T(H)1/T(H)2 paradigm. Methods: Arg110Gln was typed in 4 different populations: asthmatic children, atopic children, children with JIA, and a control population. Statistical analysis was performed by using logistic and linear regression analysis of serum IgE levels and the Armitage trend test. Results: The variant Gln110 was shown to be associated with increased total serum IgE levels in our atopic population (P = .006) and was weakly associated with bronchial asthma (P = .04). There was no association of the variant with JIA when compared with the control population. However, the variant Gln110 was significantly less frequent in children with JIA compared with its presence in children with bronchial asthma (P = .007). Conclusion: This is the first study to compare the same gene variant in T(H)1 and T(H)2 chronic inflammatory diseases. The results suggest that the same gene variant might protect from one disease and make an individual susceptible to the other.	Univ Freiburg, Univ Childrens Hosp, D-79106 Freiburg, Germany; Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Heinzmann, A (corresponding author), Univ Freiburg, Univ Childrens Hosp, Mathildenstr 1, D-79106 Freiburg, Germany.		Berner, Reinhard/P-7351-2017	Berner, Reinhard/0000-0002-6216-9173				Allanore Y, 1998, LANCET, V351, P497, DOI 10.1016/S0140-6736(05)78684-0; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P328, DOI 10.1067/mai.2002.126480; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; GARE BA, 1992, PEDIATRICS, V90, P950; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hilliquin P, 2000, RHEUMATOLOGY, V39, P1020, DOI 10.1093/rheumatology/39.9.1020; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Kleinbaum DG, 1987, APPL REGRESSION ANAL; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; KUEHR J, 1992, CLIN EXP ALLERGY, V22, P839, DOI 10.1111/j.1365-2222.1992.tb02829.x; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; Malleson PN, 1996, J RHEUMATOL, V23, P1981; Meerwaldt R, 2002, CLIN EXP ALLERGY, V32, P254, DOI 10.1046/j.1365-2222.2002.01311.x; Morita Y, 2001, RHEUMATOL INT, V20, P49, DOI 10.1007/s002960000074; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Palmer LJ, 2000, EUR J HUM GENET, V8, P853, DOI 10.1038/sj.ejhg.5200551; Petty Ross E., 1998, Journal of Rheumatology, V25, P1991; Rudwaleit M, 2002, ANN RHEUM DIS, V61, P968, DOI 10.1136/ard.61.11.968; Scola MP, 2002, J RHEUMATOL, V29, P369; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Tremlett HL, 2002, QJM-INT J MED, V95, P753, DOI 10.1093/qjmed/95.11.753; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214; Xu JF, 2002, HUM GENET, V111, P573, DOI 10.1007/s00439-002-0819-y; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	35	49	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					735	739		10.1016/S0091-6749(03)01887-6	http://dx.doi.org/10.1016/S0091-6749(03)01887-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564352	Bronze			2022-12-18	WOS:000185831200013
J	Moretti, ME; Caprara, D; Coutinho, CJ; Bar-Oz, B; Berkovitch, M; Addis, A; Jovanovski, E; Schuler-Faccini, L; Koren, G				Moretti, ME; Caprara, D; Coutinho, CJ; Bar-Oz, B; Berkovitch, M; Addis, A; Jovanovski, E; Schuler-Faccini, L; Koren, G			Fetal safety of loratadine use in the first trimester of pregnancy: A multicenter study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						loratadine; pregnancy; allergy; teratogens; birth defect	RHINITIS; EXPOSURE; ALLERGY; ASTHMA	Background: Women in their childbearing years often require drug therapy for allergic conditions. Loratadine, a newer nonsedating antihistamine, is often used because of its preferred side effect profile. To date no published data exist on the safety of loratadine use in pregnancy. Objective: We sought to determine whether the use of loratadine in the first trimester of pregnancy was associated with an increased risk for major malformations. Secondary outcomes included rates of miscarriage, birth weights, and gestational age at delivery. Methods: All women were prospectively enrolled from 4 participating centers. Detailed maternal medical history and drug exposures were collected at intake, whereas pregnancy complications and outcomes were collected at follow-up. A group of unexposed control subjects were recruited and followed up in a similar manner. Results: This report includes follow-up on 161 loratadine exposed pregnancies and an equal number of unexposed control subjects. Maternal characteristics (age, pregnancy history, alcohol consumption, and smoking habits) were not different between the 2 groups. There were 5 malformations observed in the exposed group and 6 in the control group, which was not significantly different (P = .9) Similarly, the live birth rate, gestational age at delivery, and birth weights were not different between the 2 groups. Conclusion: These results suggest that loratadine use in pregnancy is not associated with a large risk for major malformations. Further studies are warranted to confirm these findings and to increase study power. (J Allergy Clin Immunol 2003;111:479-83.).	Hosp Sick Children, Motherisk Program, Toronto, ON M5G 1X8, Canada; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel; Mario Negri Inst Pharmacol Res, Milan, Italy; Univ Fed Rio Grande do Sul, Rio Grand Do Sul, Brazil; Clin Hosp, Porto Alegre, RS, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Hebrew University of Jerusalem; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universidade Federal do Rio Grande do Sul	Koren, G (corresponding author), Hosp Sick Children, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		SCHULER-FACCINI, LAVINIA/C-8309-2013; SCHULER-FACCINI, LAVINIA/K-2927-2016; Koren, Gideon/AAG-7726-2019; Addis, Antonio/K-1865-2019; Addis, Antonio/J-7894-2016	SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Koren, Gideon/0000-0002-9234-0875; Addis, Antonio/0000-0003-0962-9959; Addis, Antonio/0000-0003-0962-9959				Diav-Citrin O, 2001, TERATOLOGY, V63, P186, DOI 10.1002/tera.1033; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Einarson A, 1997, ANN ALLERG ASTHMA IM, V78, P183, DOI 10.1016/S1081-1206(10)63385-6; Kallen B, 1999, DRUG INF J, V33, P1135; KEMMETT D, 1991, BRIT J DERMATOL, V125, P59, DOI 10.1111/j.1365-2133.1991.tb06041.x; Loebstein R, 1999, J ALLERGY CLIN IMMUN, V104, P953, DOI 10.1016/S0091-6749(99)70074-6; MABRY RL, 1986, SOUTHERN MED J, V79, P965, DOI 10.1097/00007611-198608000-00012; Pastuszak A, 1996, J ALLERGY CLIN IMMUN, V98, P748, DOI 10.1016/S0091-6749(96)70122-7; *SCH PLOUGH CORP, 2001, PROD MON CLAR; Schatz M, 1997, CLIN PERINATOL, V24, P407, DOI 10.1016/S0095-5108(18)30173-8; SCHATZ M, 1988, NEW ENGL REG ALLERGY, V9, P545, DOI 10.2500/108854188778965627; Seto A, 1997, AM J PERINAT, V14, P119, DOI 10.1055/s-2007-994110; SORRI M, 1980, Rhinology (Utrecht), V18, P83; TOPPOZADA H, 1982, J LARYNGOL OTOL, V96, P613, DOI 10.1017/S0022215100092902	14	49	50	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					479	483		10.1067/mai.2003.130	http://dx.doi.org/10.1067/mai.2003.130			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642825				2022-12-18	WOS:000181639500006
J	Chinen, J; Shearer, WT				Chinen, J; Shearer, WT			Molecular virology and immunology of HIV infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						HIV; AIDS; chemokine; cytokine; vaccine; immunology; CD4; lymphocyte; monocyte	HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; COMPLEMENT-MEDIATED ENHANCEMENT; NEUTRALIZING ANTIBODY-RESPONSE; CELLULAR IMMUNE-RESPONSES; DISEASE PROGRESSION; ENVELOPE GLYCOPROTEINS; PERIPHERAL-BLOOD; PROTECTIVE ROLE; LYMPH-NODE	Great progress has been made with respect to our understanding of the immunopathogenesis of AIDS and the infectious agent, HIV, that causes the disease. HIV, a human retrovirus with tropism for CD4(+) T cells and monocytes, induces a decrease of T-cell counts, T-cell dysfunction, and, ultimately, immunodeficiency. HIV also causes B-cell dysfunction characterized by polyclonal activation, hypergammaglobulinemia, and lack of specific antibody responses. Chemokine receptors-mainly CCR5 and CXCR4-have been found to be necessary for viral entry into the host cell, a step that can be inhibited by chemokine-related molecules that are ligands for those receptors. After HIV infection, a strong cellular immunity develops and partially controls viral replication. It can take several years for HIV infection to become clinically evident. Studies in long-term nonprogressors have shown the determinant roles of both helper and cytotoxic T cells in the control of HIV disease. Advances in HIV immunology research are currently being applied in the development of prophylactic and therapeutic vaccines.	Texas Childrens Hosp, Allergy & Immunol Serv, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Allergy & Immunol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chinen, J (corresponding author), Texas Childrens Hosp, Allergy & Immunol Serv, 6621 Fannin St MC 1-3291, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR 00188] Funding Source: Medline; NIAID NIH HHS [AI 27551, AI 36211] Funding Source: Medline; NICHD NIH HHS [HD 41983] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, U01AI027551] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Berkowitz RD, 1998, J VIROL, V72, P10108, DOI 10.1128/JVI.72.12.10108-10117.1998; BORKOWSKY W, 1992, J PEDIATR-US, V120, P371, DOI 10.1016/S0022-3476(05)80899-6; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bouhlal H, 2001, J IMMUNOL, V166, P3377, DOI 10.4049/jimmunol.166.5.3377; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Boyer JD, 2000, J INFECT DIS, V181, P476, DOI 10.1086/315229; Bruunsgaard H, 1997, SCAND J IMMUNOL, V46, P91, DOI 10.1046/j.1365-3083.1997.d01-98.x; Buge SL, 1999, J VIROL, V73, P7430, DOI 10.1128/JVI.73.9.7430-7440.1999; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P165; Chattergoon M, 1997, FASEB J, V11, P753, DOI 10.1096/fasebj.11.10.9271360; Chehimi J, 1996, AIDS RES HUM RETROV, V12, P1141, DOI 10.1089/aid.1996.12.1141; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; Chinen J, 2001, J ALLERGY CLIN IMMUN, V108, P265, DOI 10.1067/mai.2001.116573; Cho MW, 2001, J VIROL, V75, P2224, DOI 10.1128/JVI.75.5.2224-2234.2001; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Clerici M, 1996, AIDS RES HUM RETROV, V12, P1053, DOI 10.1089/aid.1996.12.1053; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Corey L, 2001, J INFECT DIS, V183, P563, DOI 10.1086/318523; Crotty S, 1999, J VIROL, V73, P9485, DOI 10.1128/JVI.73.11.9485-9495.1999; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Davis NL, 2000, J VIROL, V74, P371, DOI 10.1128/JVI.74.1.371-378.2000; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Farnet C M, 1996, AIDS, V10 Suppl A, pS3, DOI 10.1097/00002030-199601001-00002; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; GARCIA JA, 1994, AIDS, V8, pS13; Gea-Banacloche JC, 2000, J IMMUNOL, V165, P1082, DOI 10.4049/jimmunol.165.2.1082; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GIBB D, 1995, PEDIATR INFECT DIS J, V14, P129, DOI 10.1097/00006454-199502000-00009; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GOODGLICK L, 1995, J IMMUNOL, V155, P5151; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gorse GJ, 2001, AIDS RES HUM RETROV, V17, P1175, DOI 10.1089/088922201316912781; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Guillemard E, 2001, BLOOD, V98, P2166, DOI 10.1182/blood.V98.7.2166; Hendel H, 1999, J IMMUNOL, V162, P6942; HONDA M, 1990, J IMMUNOL, V145, P4059; Hu DJ, 1999, AIDS, V13, P873, DOI 10.1097/00002030-199905280-00002; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Just JJ, 1995, HUM IMMUNOL, V44, P156, DOI 10.1016/0198-8859(95)00034-8; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kirschner D, 2000, J ACQ IMMUN DEF SYND, V24, P352; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; LUCIW PA, 1996, FILDS VIROLOGY; MacDonald KS, 2001, J INFECT DIS, V183, P503, DOI 10.1086/318092; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; Margolick JB, 1998, CLIN IMMUNOL IMMUNOP, V88, P256, DOI 10.1006/clin.1998.4577; Mascola JR, 2001, CURR OPIN IMMUNOL, V13, P489, DOI 10.1016/S0952-7915(00)00246-6; McCormack S, 2000, VACCINE, V18, P1166, DOI 10.1016/S0264-410X(99)00388-6; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; McElrath MJ, 2000, AIDS RES HUM RETROV, V16, P907, DOI 10.1089/08892220050042846; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; Moir S, 2001, P NATL ACAD SCI USA, V98, P10362, DOI 10.1073/pnas.181347898; MONTEFIORI DC, 1989, ANTIVIR RES, V11, P137, DOI 10.1016/0166-3542(89)90025-9; Moonis M, 2001, AIDS, V15, P1941, DOI 10.1097/00002030-200110190-00005; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868; Nokta MA, 2001, AIDS, V15, P161, DOI 10.1097/00002030-200101260-00004; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Palumbo PE, 1998, JAMA-J AM MED ASSOC, V279, P756, DOI 10.1001/jama.279.10.756; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P9848, DOI 10.1073/pnas.94.18.9848; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Parren PWHI, 1999, AIDS, V13, pS137; Patke CL, 2000, J ALLERGY CLIN IMMUN, V105, P975, DOI 10.1067/mai.2000.105315; Patterson BK, 2001, J CLIN INVEST, V107, P287, DOI 10.1172/JCI11481; Paul ME, 2001, J ALLERGY CLIN IMMUN, V108, P258, DOI 10.1067/mai.2001.117179; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Pellegrin I, 1996, J ACQ IMMUN DEF SYND, V11, P438, DOI 10.1097/00042560-199604150-00003; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Polacino P, 1999, J VIROL, V73, P618, DOI 10.1128/JVI.73.1.618-630.1999; REISINGER EC, 1990, AIDS, V4, P961, DOI 10.1097/00002030-199010000-00003; Rodriguez C, 1996, CLIN IMMUNOL IMMUNOP, V81, P191, DOI 10.1006/clin.1996.0176; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenberg YJ, 1999, SEMIN IMMUNOL, V11, P139, DOI 10.1006/smim.1999.0169; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Saha K, 2001, NAT MED, V7, P65, DOI 10.1038/83365; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; Scharf O, 2001, J VIROL, V75, P6558, DOI 10.1128/JVI.75.14.6558-6565.2001; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Sleasman JW, 1996, AIDS, V10, P1477, DOI 10.1097/00002030-199611000-00004; Spiegel HML, 2000, J VIROL, V74, P1018, DOI 10.1128/JVI.74.2.1018-1022.2000; Stoiber H, 2001, IMMUNOL REV, V180, P168, DOI 10.1034/j.1600-065X.2001.1800115.x; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Than S, 1997, J INFECT DIS, V175, P47, DOI 10.1093/infdis/175.1.47; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; Tritel M, 2001, J VIROL, V75, P5473, DOI 10.1128/JVI.75.12.5473-5481.2001; Ullum H, 1998, J INFECT DIS, V177, P331, DOI 10.1086/514192; Valentine FT, 1998, AIDS RES HUM RETROV, V14, pS161; Verrier F, 2000, J VIROL, V74, P10025, DOI 10.1128/JVI.74.21.10025-10033.2000; Wasik TJ, 1999, J IMMUNOL, V162, P4355; Wasik TJ, 2000, EUR J IMMUNOL, V30, P117, DOI 10.1002/1521-4141(200001)30:1&lt;117::AID-IMMU117&gt;3.0.CO;2-4; Weller IVD, 2001, BRIT MED J, V322, P1410, DOI 10.1136/bmj.322.7299.1410; WRIGHT SC, 1988, J IMMUNOL, V141, P99; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; YARCHOAN R, 1986, J CLIN INVEST, V78, P439, DOI 10.1172/JCI112595; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	124	49	50	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					189	198	UNSP 1/10/126226	10.1067/mai.2002.126226	http://dx.doi.org/10.1067/mai.2002.126226			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170257				2022-12-18	WOS:000177509800001
J	Pabst, R; Tschernig, T				Pabst, R; Tschernig, T			Perivascular capillaries in the lung: An important but neglected vascular bed in immune reactions?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung vasculature; compartments; periarterial capillaries; immune reactions	AIRWAY INFLAMMATION; INHALED ALLERGEN; MURINE LUNG; T-CELLS; DENDRITIC CELLS; MOUSE LUNG; IN-VIVO; MICE; MODEL; RECRUITMENT	In allergic and inflammatory immune reactions of the respiratory tract, leukocytes migrate into the different compartments of the lung. The air space can easily be sampled by means of bronchoalveolar lavage. However, the subset composition in the bronchial wall or the lung interstitium often differs considerably from that of the bronchoalveolar lavage fluid. A further compartment involved in very heterogeneous immune reactions in the lung has thus far not been mentioned: the periarterial space. In numerous experiments in different species with virus, bacteria, fungi, or allergens, there was not only a leukocyte infiltration of the bronchial lamina propria but also infiltration around branches of the pulmonary artery. This thus far neglected compartment consists of a different type of capillary. Thus it is important not to overlook this area in studies on allergic or inflammatory immune reactions of the lung.	Hannover Med Sch, Ctr Anat 4120, Dept Funct & Appl Anat, D-30625 Hannover, Germany	Hannover Medical School	Pabst, R (corresponding author), Hannover Med Sch, Ctr Anat 4120, Dept Funct & Appl Anat, Carl Neuberg Str 1, D-30625 Hannover, Germany.							Bullard DC, 1997, J IMMUNOL, V159, P2058; Burr JS, 2001, AM J RESP CELL MOL, V24, P563, DOI 10.1165/ajrcmb.24.5.4375; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.0.CO;2-L; D'Ambrosio D, 2001, AM J RESP CRIT CARE, V164, P1266, DOI 10.1164/ajrccm.164.7.2103011; Dixon AE, 2000, AM J PHYSIOL-LUNG C, V279, pL583, DOI 10.1152/ajplung.2000.279.3.L583; Duez C, 1996, EUR J IMMUNOL, V26, P1088, DOI 10.1002/eji.1830260520; Ferreira PG, 2001, EUR J ANAT, V5, P67; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Foxwell AR, 2001, INFECT IMMUN, V69, P2636, DOI 10.1128/IAI.69.4.2636-2642.2001; GUNTHEROTH WG, 1982, J APPL PHYSIOL, V53, P510, DOI 10.1152/jappl.1982.53.2.510; Guzman CA, 1999, J INFECT DIS, V179, P901, DOI 10.1086/314655; Hamada K, 2000, AM J RESP CRIT CARE, V161, P1285, DOI 10.1164/ajrccm.161.4.9906137; Henderson WR, 2000, J IMMUNOL, V164, P3360, DOI 10.4049/jimmunol.164.6.3360; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Ichikawa S, 1996, ARCH HISTOL CYTOL, V59, P87, DOI 10.1679/aohc.59.87; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/ajrccm.164.12.2012059; Kanehiro A, 2000, AM J RESP CRIT CARE, V162, P1132, DOI 10.1164/ajrccm.162.3.9910100; Kuebler WM, 1997, J PHYSIOL-LONDON, V501, P375, DOI 10.1111/j.1469-7793.1997.375bn.x; Kurup VP, 2001, CLIN IMMUNOL, V98, P327, DOI 10.1006/clim.2000.4993; LAITINEN A, 1990, EUR RESPIR J, V3, pS658; Lambrecht BN, 2001, INT ARCH ALLERGY IMM, V124, P432, DOI 10.1159/000053778; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Luettig B, 2001, AM J RESP CELL MOL, V25, P69, DOI 10.1165/ajrcmb.25.1.4414; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Madtes DK, 2001, AM J RESP CELL MOL, V24, P599, DOI 10.1165/ajrcmb.24.5.4192; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; MCDONALD DM, 1990, EUR RESPIR J, V3, pS572; Mitzner W, 2000, AM J PATHOL, V157, P93, DOI 10.1016/S0002-9440(10)64521-X; Nishida T, 2001, MICROSC RES TECHNIQ, V53, P246, DOI 10.1002/jemt.1091; Okada M, 2000, VACCINE, V18, P2825, DOI 10.1016/S0264-410X(00)00077-3; Orme IM, 2001, J LEUKOCYTE BIOL, V70, P1; Pabst R, 1999, SARCOIDOSIS VASC DIF, V16, P197; Pabst R., 2000, ASTHMA RHINITIS, P543; Pan LH, 2000, AM J RESP CRIT CARE, V161, P1689, DOI 10.1164/ajrccm.161.5.9812016; Sato N, 2000, AM J RESP CRIT CARE, V161, P1681, DOI 10.1164/ajrccm.161.5.9907104; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; STAUB NC, 1967, J APPL PHYSIOL, V22, P227, DOI 10.1152/jappl.1967.22.2.227; Todt J, 2000, J IMMUNOL, V164, P4037, DOI 10.4049/jimmunol.164.8.4037; Turner J, 2001, INFECT IMMUN, V69, P3264, DOI 10.1128/IAI.69.5.3264-3270.2001; UHLIG S, 1995, AM J PATHOL, V146, P1235; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; VERLOOP MC, 1949, ACTA ANAT, V7, P1; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; Walzl G, 2000, J EXP MED, V192, P1317, DOI 10.1084/jem.192.9.1317; WIDDICOMBE JG, 2000, ASTHMA RHINITIS, P721; Wilson JW, 2001, THORAX, V56, P899, DOI 10.1136/thorax.56.12.899; Yasumizu R, 2000, IMMUNOBIOLOGY, V202, P213, DOI 10.1016/S0171-2985(00)80029-7; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457, DOI 10.1165/ajrcmb.25.4.4505	51	49	49	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					209	214	UNSP 1/88/126836	10.1067/mai.2002.126836	http://dx.doi.org/10.1067/mai.2002.126836			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170259				2022-12-18	WOS:000177509800003
J	Broadfield, E; McKeever, TM; Scrivener, S; Venn, A; Lewis, SA; Britton, J				Broadfield, E; McKeever, TM; Scrivener, S; Venn, A; Lewis, SA; Britton, J			Increase in the prevalence of allergen skin sensitization in successive birth cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen skin sensitization; longitudinal; age; cohort effect	COMMUNITY POPULATION-SAMPLE; SERUM IMMUNOGLOBULIN-E; PRICK TEST RESPONSE; TEST REACTIVITY; IGE LEVELS; SMOKING; EOSINOPHILIA; ASTHMA; AGE; AEROALLERGENS	Background: Little is known about longitudinal trends in the prevalence of allergen skin sensitization in the general population. Objective: We sought to measure the change in prevalence of allergen skin sensitization over a 9-year period in a cohort of adults and hence to determine whether cross-sectional differences in prevalence between age groups are due to an aging or cohort effect. Methods: In 1991 and 2000, we measured skin sensitization, defined its a wheal diameter of 3 mm or larger than that elicited by a saline control, to Dermatophagoides pteronyssinus, cat fur, mixed grass, Aspergillus funtigatus, and Cladosporium herbarum in a cohort of 1339 adults from Nottingham aged between 18 and 71 years in 1991. Subjects were divided into six 9-year successive birth cohorts, and the effects of birth cohort and the within-subject change from 1991 to 2000 were analyzed in a generalized estimating equation logit model. Results: The unadjusted prevalence of sensitization to any allergen was 30.5% in 1991 and 31.8% in 2000. In cross-sectional analyses the prevalence of sensitization decreased with increasing age at both surveys (risk ratio, 2.15; 95% confidence interval [CI], 1.45-3.17 for 18- to 26-year-old patients relative to 63- to 70-year-old patients in the 1991 survey). In longitudinal analysis there was no within-subject change in sensitization from 1991 to 2000 (adjusted odds ratio, 1.07; 95% Cl, 0.97-1.19), but there was a significant cohort effect (adjusted odds ratio per successive 9 year cohort, 1.27; 95% CI, 1.18-1.37). Conclusion: The cross-sectional decrease in allergen sensitization with age in the general population arises predominantly from a secular increase in sensitization prevalence with successive birth cohorts and not to a loss of sensitization within subjects over time. As a result of this cohort effect, the prevalence of allergic sensitization has increased in this general adult population sample.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Broadfield, E (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.			McKeever, Tricia/0000-0003-0914-0416				BACKER V, 1992, ANN ALLERGY, V69, P116; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb00055.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BRITTON J, 1994, LANCET, V344, P357, DOI 10.1016/S0140-6736(94)91399-4; BRITTON J, 1995, AM J RESP CRIT CARE, V151, pA31; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; CHANYEUNG M, 1985, ARCH ENVIRON HEALTH, V40, P53, DOI 10.1080/00039896.1985.10545889; Eriksson NE, 1996, J INVEST ALLERG CLIN, V6, P36; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; FIXA B, 1975, GERONTOLOGY, V21, P177, DOI 10.1159/000212043; Gergen PJ, 2000, CLIN EXP ALLERGY, V30, P1717, DOI 10.1046/j.1365-2222.2000.00971.x; GILLIS S, 1981, J CLIN INVEST, V67, P937, DOI 10.1172/JCI110143; GIRARD JP, 1977, CLIN EXP IMMUNOL, V27, P85; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KRILIS S, 1985, AUST NZ J MED, V15, P421, DOI 10.1111/j.1445-5994.1985.tb02764.x; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; Mariotta S, 1992, Allergol Immunopathol (Madr), V20, P197; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; ORYSZCZYN MP, 1991, ANN ALLERGY, V67, P355; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; Simola M, 1999, ANN ALLERG ASTHMA IM, V82, P152, DOI 10.1016/S1081-1206(10)62589-6; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; *UK GEN REG OFF, 1966, CLASS OCC	28	49	51	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					969	974		10.1067/mai.2002.124772	http://dx.doi.org/10.1067/mai.2002.124772			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063526				2022-12-18	WOS:000176442700012
J	Gruchalla, RS				Gruchalla, RS			Drug metabolism, danger signals, and drug-induced hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						adverse drug reactions; allergic drug reactions; drug determinants; drug metabolism; danger hypothesis	CYTOTOXIC T-CELLS; IGE-ANTIBODIES; ALLERGIC REACTIONS; CUTANEOUS REACTIONS; PENICILLIN ALLERGY; CROSS-REACTIVITY; DELAYED-HYPERSENSITIVITY; ANAPHYLACTOID REACTIONS; PERIPHERAL-BLOOD; SULFAMETHOXAZOLE	One of the most difficult challenges for the practicing allergist/immunologist today is that of evaluating and managing patients who present with histories of drug-induced reactions. Adverse drug reactions are heterogenous, and a single drug can often cause a multitude of reactions. Because the mechanisms responsible for many of these reactions are not known, they can be, and often are, difficult to classify. Moreover, for those that have features consistent with immune-mediated mechanisms, our diagnostic tools remain limited, because little is known about the relevant immunogenic determinants of most drugs. Despite these challenges, management approaches must be devised for patients who present with histories of drug-induced disease. Simply telling such a patient to avoid all drugs that have been associated with previous adverse events leaves both the patient and the referring physician frustrated. The initial part of this review focuses on exciting current research that is furthering our understanding of the mechanisms responsible for drug-induced reactions. Because it will take time to translate this new information into clinical practice, the latter part of the review focuses on ways to evaluate and manage patients who present with drug-induced reactions using the tools and the knowledge that are currently available.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Allergy & Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gruchalla, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							ADKINSON N, 1998, ALLERGY PRINCIPLES P, V2, P1212; Adkinson N. F. Jr., 1998, Clinical and Experimental Allergy, V28, P37; ANNE S, 1995, ANN ALLERG ASTHMA IM, V74, P167; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; Bald B A., 2000, ALLERGY CLIN IMMUNOL, V12, P206; Baldo B A, 2001, Curr Allergy Rep, V1, P23, DOI 10.1007/s11882-001-0093-4; BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; BALDO BA, 1983, ANAESTH INTENS CARE, V11, P194, DOI 10.1177/0310057X8301100302; BALDO BA, 1993, ANN FR ANESTH, V12, P131, DOI 10.1016/S0750-7658(05)81022-6; BALDO BA, 1991, CLIN REV ALLERG, V9, P295; Baldo BA, 2001, CURR OPIN ALLERGY CL, V1, P327, DOI 10.1097/01.all.0000011034.96839.aa; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BRANDER C, 1995, J IMMUNOL, V155, P2670; Brugnolo F, 1999, J IMMUNOL, V163, P1053; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; CRIBB AE, 1990, MOL PHARMACOL, V38, P744; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1991, J PHARMACOL EXP THER, V259, P1241; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; de Weck A L, 1974, Monogr Allergy, V8, P120; Dearman RJ, 1996, IMMUNOLOGY, V89, P502, DOI 10.1046/j.1365-2567.1996.d01-778.x; Dearman RJ, 1996, TOXICOL APPL PHARM, V138, P308, DOI 10.1006/taap.1996.0129; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; DEWECK AL, 1965, INT ARCH ALLER A IMM, V27, P221, DOI 10.1159/000229614; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Empedrad RB, 2000, J ALLERGY CLIN IMMUN, V105, pS272, DOI 10.1016/S0091-6749(00)91231-4; Gaspard I, 2000, J CLIN IMMUNOL, V20, P107, DOI 10.1023/A:1006682413834; Griem P, 1998, IMMUNOL TODAY, V19, P133, DOI 10.1016/S0167-5699(97)01219-X; GRUCHALLA R, 2001, IN PRESS SAMTERS IMM; Gruchalla RS, 1998, J ALLERGY CLIN IMMUN, V101, P371, DOI 10.1016/S0091-6749(98)70250-7; Gruchalla RS, 2000, LANCET, V356, P1505, DOI 10.1016/S0140-6736(00)02885-3; HARLE DG, 1990, MOL IMMUNOL, V27, P1063, DOI 10.1016/0161-5890(90)90094-G; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; HARLE DG, 1990, INT ARCH ALLER A IMM, V92, P439, DOI 10.1159/000235177; HARLE DG, 1984, LANCET, V1, P930; HARLE DG, 1986, CLIN ALLERGY, V16, P493, DOI 10.1111/j.1365-2222.1986.tb01984.x; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1995, BRIT J DERMATOL, V132, P215; HERTL M, 1993, BRIT J DERMATOL, V128, P619, DOI 10.1111/j.1365-2133.1993.tb00255.x; HERTL M, 1995, J INVEST DERMATOL, V105, pS95, DOI 10.1038/jid.1995.19; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Janeway CA, 1996, CURR BIOL, V6, P519, DOI 10.1016/S0960-9822(02)00531-6; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JUGERT FK, 1994, J INVEST DERMATOL, V102, P970, DOI 10.1111/1523-1747.ep12384210; KALISH RS, 1994, J ALLERGY CLIN IMMUN, V94, P465, DOI 10.1016/0091-6749(94)90202-X; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; KALISH RS, 1990, J IMMUNOL, V145, P3706; KALISH RS, 1994, J CLIN INVEST, V93, P2039, DOI 10.1172/JCI117198; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; LEVINE BB, 1976, TXB IMMUNOPATHOLOGY, V1, P403; LOFSTROM A, 1986, ACTA DERM-VENEREOL, V66, P200; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MauriHellweg D, 1996, J IMMUNOL, V157, P1071; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; Mikami Chikage, 1999, Journal of Dermatology (Tokyo), V26, P633; MOSS RB, 1984, J PEDIATR-US, V104, P460, DOI 10.1016/S0022-3476(84)81117-8; Moulon C, 1998, J INVEST DERMATOL, V111, P360, DOI 10.1046/j.1523-1747.1998.00306.x; MUKHTAR H, 1989, DRUG METAB REV, V20, P657, DOI 10.3109/03602538909103568; Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Park BK, 2000, TOXICOLOGY, V153, P39, DOI 10.1016/S0300-483X(00)00303-6; PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581; PARK BK, 1992, BRIT J CLIN PHARMACO, V34, P377, DOI 10.1111/j.1365-2125.1992.tb05647.x; PARK BK, 1986, J ROY COLL PHYS LOND, V20, P195; Park BK, 2001, TOXICOLOGY, V158, P11, DOI 10.1016/S0300-483X(00)00397-8; PARKER C, 1980, CLIN IMMUNOLOGY, P1220; Pham NH, 1996, J MOL RECOGNIT, V9, P287, DOI 10.1002/(SICI)1099-1352(199607)9:4<287::AID-JMR340>3.3.CO;2-C; Pichler WJ, 1998, ALLERGY, V53, P225, DOI 10.1111/j.1398-9995.1998.tb03881.x; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; Posadas SJ, 2000, J ALLERGY CLIN IMMUN, V106, P769, DOI 10.1067/mai.2000.109828; Pumphrey RSH, 1999, LANCET, V353, P1157, DOI 10.1016/S0140-6736(99)00449-3; Reilly TP, 2000, J INVEST DERMATOL, V114, P1164, DOI 10.1046/j.1523-1747.2000.00985.x; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; ROMANO A, 1995, ALLERGY, V50, P113; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412, DOI 10.1046/j.1365-2222.1998.00419.x; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1990, ARCH DERMATOL, V126, P94, DOI 10.1001/archderm.126.1.94; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; UETRECHT JP, 1992, DRUG METAB REV, V24, P299, DOI 10.3109/03602539208996297; Uetrecht JP, 1999, CHEM RES TOXICOL, V12, P387, DOI 10.1021/tx980249i; WOLKENSTEIN P, 1995, ARCH DERMATOL, V131, P544, DOI 10.1001/archderm.131.5.544; Yawalkar N, 2000, CLIN EXP ALLERGY, V30, P847; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zhao ZJ, 2000, J IMMUNOL METHODS, V242, P43, DOI 10.1016/S0022-1759(00)00213-1	107	49	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					475	488		10.1067/mai.2001.118509	http://dx.doi.org/10.1067/mai.2001.118509			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590368				2022-12-18	WOS:000171760300001
J	Haselden, BM; Larche, M; Meng, Q; Shirley, K; Dworski, R; Kaplan, AR; Bates, C; Robinson, DS; Ying, S; Kay, AB				Haselden, BM; Larche, M; Meng, Q; Shirley, K; Dworski, R; Kaplan, AR; Bates, C; Robinson, DS; Ying, S; Kay, AB			Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocyte; Fel d 1; asthma; bronchoscopy; peptide epitope	MESSENGER-RNA EXPRESSION; ALLERGEN INHALATION CHALLENGE; PHASE CUTANEOUS RESPONSES; ATOPIC ASTHMA; MAST-CELLS; LAVAGE; BIOPSIES; IL-4; LYMPHOCYTES; BASOPHILS	Background: Isolated late asthmatic reactions can be provoked by intradermal challenge of allergen-derived T-cell peptide epitopes. Objective: The purpose of this study was to determine whether the isolated LAR is associated with the local accumulation of inflammatory cells, the expression of T(H)2 cytokines, and the production of pharmacologic mediators. Methods: A randomized, placebo-controlled, crossover study design was used. The investigation involved bronchial and skin biopsies and bronchoalveolar lavage (BAL) fluids from 8 cat-allergic subjects who developed significant late asthmatic reactions 6 hours after intradermal injection of Fel d I chain 1-derived peptides (FC1Ps). Results: Immunostaining of bronchial biopsy specimens showed no changes in the numbers of eosinophils, neutrophils, basophils, mast cells, CD3(+), CD4(+) or CD8(+) T cells, CD25 cells or macrophages, or cells mRNA(+) for IL-4, IL-5, or IL-13 when the FC1P day was compared with the diluent control day. There were also no significant differences in eosinophil numbers, either in BAL fluids or in peripheral blood after FC1P challenge. Furthermore, there were no significant alterations in the concentrations of histamine, histamine-releasing factors, or eicosanoids (LTC4/D-4/E-4, PGD(2), PGE(2), TXB2, PGF(2 alpha)) in BAL fluids. FC1Ps induced a significant (P < .05) elevation in CD8(+) cells in the skin and an unexpected decrease in IL-5 in BAL fluids (P = .043). Conclusion: Part of the asthma process might involve Tcell-dependent airway narrowing with no requirement for IgE, mast cells, or infiltrating inflammatory cells.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, London SW3 6LY, England; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Med Univ S Carolina, Charleston, SC 29425 USA; Natl Jewish Hosp, Denver, CO USA	Imperial College London; Vanderbilt University; Medical University of South Carolina; National Jewish Health	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.		Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593	NIGMS NIH HHS [GM 15431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Braun A, 2000, CLIN EXP ALLERGY, V30, P178; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; DWORSKI R, 1989, AM REV RESPIR DIS, V139, P46, DOI 10.1164/ajrccm/139.1.46; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Forsythe P, 2000, CLIN EXP ALLERGY, V30, P225; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 1999, J ALLERGY CLIN IMMUN, V103, pS230; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hoyne GF, 1995, CURR OPIN IMMUNOL, V7, P757, DOI 10.1016/0952-7915(95)80044-1; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Oldfield WLG, 2000, J ALLERGY CLIN IMMUN, V105, pS380, DOI 10.1016/S0091-6749(00)91537-9; OLDFIELD WLG, IN PRESS J IMMUNOL; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 1997, J IMMUNOL, V158, P3539	26	49	53	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					394	401		10.1067/mai.2001.117460	http://dx.doi.org/10.1067/mai.2001.117460			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544459				2022-12-18	WOS:000171215400011
J	Demoly, P; Messaad, D; Sahla, H; Fabre, J; Faucherre, V; Andre, P; Reynes, J; Godard, P; Bousquet, J				Demoly, P; Messaad, D; Sahla, H; Fabre, J; Faucherre, V; Andre, P; Reynes, J; Godard, P; Bousquet, J			Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						trimethoprim-sulfamethoxazole; cotrimoxazole; desensitization; graded challenge; HIV; tolerance; hypersensitivity	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; RAPID ORAL DESENSITIZATION; IMMUNE-DEFICIENCY-SYNDROME; TRIMETHOPRIM/SULFAMETHOXAZOLE; EFFICACY	Background: Hypersensitivity reactions to trimethoprim-sulfamethoxazole (TMP-SR IX) are very common in HIV-infected patients, leading to drug discontinuation. However, it is the drug of choice as prophylaxis for Pneumocystis carinii pneumonia. Objectives: We sought to determine the safety and long-term efficacy of a 6-hour TMP-SMX-graded challenge in a group of hypersensitive HIV-infected patients. Methods: Forty-four consecutive HIV-infected patients with documented TMP-SMX hypersensitivity were seen in our outpatient allergy department. They ingested 12 doses of increasing amounts of TMP-SMX at half-hour intervals. Thereafter, they took 80/400 mg TMP-SMX daily and were advised to "treat through" every nonbullous cutaneous adverse reaction. Results: All 44 patients tolerated the procedure without any adverse reactions during the day of challenge. Eleven of the 44 patients experienced mild hypersensitivity reactions on days 1 to 2 (8 patients) and 8 to 10 (3 patients), consisting mainly on a 1-day pruritic maculopapular eruption. Two patients stopped TMP-SMX at day 1, and 2 stopped it at days 10 and 15, giving an overall success rate at 1 month of 91% (40 of 44). Two were successfully rechallenged late. After a median follow-np of 10 months, 42 patients were taking TMP-SMX without any adverse reaction, giving an overall success rate of 95%. Conclusions: A 6-hour graded challenge with cautious "treating through" of mild reactions enables more patients to take TMP-SMX and is safe and effective.	CHU Montpellier, Hop Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier 5, France; Hop Guy de Chauliac, Montpellier, France; Hop St Eloi, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Demoly, P (corresponding author), CHU Montpellier, Hop Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier 5, France.		Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Demoly, Pascal/0000-0001-7827-7964; 				ABSAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001, DOI 10.1016/S0091-6749(94)70048-6; BACHMEYER C, 1995, AIDS, V9, P299, DOI 10.1097/00002030-199509030-00013; BelchiHernandez J, 1996, ANN ALLERG ASTHMA IM, V76, P355, DOI 10.1016/S1081-1206(10)60037-3; BISSUEL F, 1995, AIDS, V9, P407, DOI 10.1097/00002030-199509040-00021; Caumes E, 1997, ARCH DERMATOL, V133, P465, DOI 10.1001/archderm.133.4.465; CHANOCK SJ, 1994, PEDIATRICS, V93, P519; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; GLUCKSTEIN D, 1995, CLIN INFECT DIS, V20, P849, DOI 10.1093/clinids/20.4.849; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; Kalanadhabhatta V, 1996, ANN ALLERG ASTHMA IM, V77, P394, DOI 10.1016/S1081-1206(10)63338-8; NGUYEN MT, 1995, AIDS, V9, P573, DOI 10.1097/00002030-199506000-00007; Palusci VJ, 1996, PEDIATR INFECT DIS J, V15, P456, DOI 10.1097/00006454-199605000-00015; PIKETTY C, 1995, J INFECT DIS, V172, P611, DOI 10.1093/infdis/172.2.611; Rich JD, 1997, ANN ALLERG ASTHMA IM, V79, P409, DOI 10.1016/S1081-1206(10)63034-7; WHITE MV, 1989, ANN ALLERGY, V62, P177	15	49	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1033	1036		10.1016/S0091-6749(98)70343-4	http://dx.doi.org/10.1016/S0091-6749(98)70343-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847446				2022-12-18	WOS:000077690700023
J	Hirahara, K; Saito, S; Serizawa, N; Sasaki, R; Sakaguchi, M; Inouye, S; Taniguchi, Y; Kaminogawa, S; Shiraishi, A				Hirahara, K; Saito, S; Serizawa, N; Sasaki, R; Sakaguchi, M; Inouye, S; Taniguchi, Y; Kaminogawa, S; Shiraishi, A			Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific T-H1 and T-H2 cell responses in Cry j 2-primed mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Japanese cedar pollen; pollinosis; oral immunotherapy; oral tolerance; peptide; T cell epitope; T-H1/T-H2; IgE	JAPANESE CEDAR POLLEN; 2ND MAJOR ALLERGEN; SUGI BASIC-PROTEIN; J-I; MONOCLONAL-ANTIBODIES; AUTOIMMUNE-DISEASES; ANTIGENIC ANALYSES; CHOLERA-TOXIN; TOLERANCE; INDUCTION	Background: Oral immunotherapy with a peptide for allergic immune responses is theoretically a promising therapy but has not been established yet. Objective: To evaluate immune suppressive efficacy of oral administration of an immunodominant peptide, we investigated changes in T-cell proliferation, T-H1- and T-H2-cytokine production, and T-H1- and T-H2-mediated antibody production in mice after oral administration of a peptide. Methods: Peptide p246-259, containing a dominant T-cell determinant of Cry j 2, which is the major allergen in Japanese cedar pollen, was used in this study. Groups of mice received p246-259 or PBS alone before or after they were primed intranasally with Cry j 2 and cholera toxin. In another experiment mice were primed intraperitoneally with Cry j 2 and alum, Proliferative response and cytokine production by nasal-associated lymph node cells against Cry j 2 were investigated. Amounts of systemic anti-Cry j 2 IgE and IgG antibodies were also measured. Results: Oral administration of the peptide to mice before, or even after, the sensitization induced oral tolerance in T-cell responses against the allergen; the tolerance was associated with decreased production of T-H1 (IFN-gamma and IL-2) and T-H2 (IL-4) cytokines. Allergen-specific T-H1-mediated (IgG2a and IgG2b) and T-H2-mediated (IgG1 and IgE) antibody responses were also inhibited. Conclusions: Oral administration of a dominant T-cell determinant peptide induces immunologic tolerance in both T-H1 and T-H2 cell responses against the whole protein allergen. Our study is the first, to our knowledge, to demonstrate the potential for peptide-based oral immunotherapy in order to treat allergic immune responses.	Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Jikei Univ, Sch Med, Tokyo, Japan; Natl Inst Infect Dis, Tokyo, Japan; Hayashibara Biochem Labs Inc, Okayama, Japan; Univ Tokyo, Tokyo, Japan	Daiichi Sankyo Company Limited; Jikei University; National Institute of Infectious Diseases (NIID); Hayashibara Biochemical Laboratories, Inc.; University of Tokyo	Shiraishi, A (corresponding author), Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.		Inouye, Sharon/R-7216-2019					BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; GARSIDE P, 1995, J IMMUNOL, V154, P5649; Harrison LC, 1996, J EXP MED, V184, P2167, DOI 10.1084/jem.184.6.2167; Hashiguchi S, 1996, ALLERGY, V51, P621, DOI 10.1111/j.1398-9995.1996.tb04682.x; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; HETZEL C, 1995, INT ARCH ALLERGY IMM, V107, P275, DOI 10.1159/000237001; HIRAHARA K, 1995, CLIN IMMUNOL IMMUNOP, V76, P12, DOI 10.1006/clin.1995.1082; HOUTEN NV, 1996, J IMMUNOL, V157, P1337; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Ishikawa T, 1997, INT ARCH ALLERGY IMM, V113, P255, DOI 10.1159/000237563; KAWASHIMA T, 1992, INT ARCH ALLERGY IMM, V98, P110, DOI 10.1159/000236173; KAWASHIMA T, 1992, INT ARCH ALLERGY IMM, V98, P118, DOI 10.1159/000236174; Ke Y, 1997, J IMMUNOL, V158, P3610; KOMIYAMA N, 1994, BIOCHEM BIOPH RES CO, V201, P1021, DOI 10.1006/bbrc.1994.1804; MARINARO M, 1995, J IMMUNOL, V155, P4621; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MELAMED D, 1994, EUR J IMMUNOL, V24, P1974, DOI 10.1002/eji.1830240906; Melamed D, 1996, INT IMMUNOL, V8, P717, DOI 10.1093/intimm/8.5.717; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; NAMBA M, 1994, FEBS LETT, V353, P124, DOI 10.1016/0014-5793(94)01022-6; Nicodemus C, 1997, INT ARCH ALLERGY IMM, V113, P326, DOI 10.1159/000237590; Norman PS, 1997, INT ARCH ALLERGY IMM, V113, P224, DOI 10.1159/000237553; SAKAGUCHI M, 1989, J IMMUNOL METHODS, V116, P181, DOI 10.1016/0022-1759(89)90202-0; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Sugimura K, 1996, ALLERGY, V51, P732; SUKO M, 1995, INT ARCH ALLERGY IMM, V107, P278, DOI 10.1159/000237002; TAMURA S, 1994, VACCINE, V12, P419, DOI 10.1016/0264-410X(94)90118-X; Wallner BP, 1996, CLIN IMMUNOL IMMUNOP, V80, P105, DOI 10.1006/clin.1996.0102; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wildner G, 1996, EUR J IMMUNOL, V26, P2140, DOI 10.1002/eji.1830260927; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X	36	49	54	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				961	967		10.1016/S0091-6749(98)70334-3	http://dx.doi.org/10.1016/S0091-6749(98)70334-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847437				2022-12-18	WOS:000077690700014
J	Wedi, B; Raap, U; Lewrick, H; Kapp, A				Wedi, B; Raap, U; Lewrick, H; Kapp, A			IL-4-induced apoptosis in peripheral blood eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; apoptosis; IL-4; Fas antigen	PLATELET-ACTIVATING-FACTOR; PROGRAMMED CELL-DEATH; ATOPIC-DERMATITIS; IN-VIVO; INFLAMMATORY MEDIATORS; HUMAN NEUTROPHILS; INTERFERON-GAMMA; GENE-EXPRESSION; MESSENGER-RNA; T-CELLS	Background: The regulation of eosinophil survival and apoptosis may play a major role in diseases demonstrating increased numbers of circulating and tissue eosinophils such as allergic reactions. Because few promoters of eosinophil apoptosis have been described so far, the objective of this study was to elucidate the role of endogenous factors on eosinophil survival and apoptosis. Methods and Results: Highly purified peripheral blood eosinophils were analyzed in the time course from 24 up to 144 hours in culture. Eosinophil survival was assessed with trypan blue dye exclusion and apoptosis was determined by DNA fragmentation gel analysis and ELISA technique with anti-histone antibodies. We confirmed previous results demonstrating prolonged eosinophil survival and inhibited apoptosis by IL-3, IL-5, and GM-CSF. In contrast, eosinophil apoptosis was significantly enhanced by corticosteroids, particularly dexamethasone and hydrocortisone. However IL-1 beta, IL-8, IL-12, platelet-activating factor, TNF-alpha, and eotaxin had no effect on eosinophil survival or apoptosis when compared with culture medium alone. In contrast, IL-4 at concentrations of 100 U/mL or more inhibited eosinophil survival and induced apoptosis. This effect was time dependent and abrogated by preincubation with neutralizing anti-IL-4 antibodies. However, after 96 hours in coincubation, IL-4 did overcome the survival-prolonging effect of IL-3, IL-5, and GM-CSF. IL-4 did not enhance eosinophil surface expression of APO-1/Fas antigen (CD95), In assessing IL-4-mediated effects on eosinophil function, we found no response by means of the release of eosinophil cationic protein or reactive oxygen species. Conclusions: Taken together, our data present direct evidence for the presence of functional IL-4 receptors on human eosinophils and indicate that IL-4 may lead to resolution of chronic inflammation by induction of eosinophil apoptosis.	Hannover Med Univ, Dept Dermatol & Allergol, D-30449 Hannover, Germany	Hannover Medical School	Wedi, B (corresponding author), Hannover Med Univ, Dept Dermatol, Ricklinger Str 5, D-30449 Hannover, Germany.		Wedi, Bettina/ABE-3636-2021	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276				ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BASKAR P, 1990, J IMMUNOL, V144, P2321; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; COX G, 1995, J IMMUNOL, V154, P4719; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; DUBOIS GR, 1994, J INVEST DERMATOL, V102, P843, DOI 10.1111/1523-1747.ep12382362; ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304; Elsner J, 1996, BLOOD, V88, P4684, DOI 10.1182/blood.V88.12.4684.bloodjournal88124684; FACCIOLI LH, 1991, IMMUNOLOGY, V73, P222; Girard D, 1997, BIOCHEM J, V325, P147, DOI 10.1042/bj3250147; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hebestreit H, 1996, EUR J IMMUNOL, V26, P1775, DOI 10.1002/eji.1830260817; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; LEIST M, 1994, J IMMUNOL, V153, P1778; MALY FE, 1988, ANAL BIOCHEM, V168, P462, DOI 10.1016/0003-2697(88)90344-2; MANGAN DF, 1992, J IMMUNOL, V148, P1812; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; NONAKA M, 1995, J IMMUNOL, V155, P3234; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; RODGERS S, 1994, BRIT J HAEMATOL, V86, P746, DOI 10.1111/j.1365-2141.1994.tb04824.x; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SANZ MJ, 1995, J IMMUNOL, V154, P1364; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1986; Schrier DJ, 1998, J LEUKOCYTE BIOL, V63, P359, DOI 10.1002/jlb.63.3.359; Schroder JM, 1996, J LEUKOCYTE BIOL, V59, P1; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TEPPER RI, 1994, J ALLERGY CLIN IMMUN, V94, P1225, DOI 10.1016/0091-6749(94)90336-0; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; VALENT P, 1994, J ALLERGY CLIN IMMUN, V94, P1177, DOI 10.1016/0091-6749(94)90329-8; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALLEN N, 1991, J IMMUNOL, V147, P3490; WARRINGA RAJ, 1992, BLOOD, V79, P1836; Wedi B, 1996, ALLERGY, V51, P676; WEDI B, 1997, J ALLERGY CLIN IMMUN, V100, P1; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; ZECKKAPP G, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb02481.x	49	49	51	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1013	1020		10.1016/S0091-6749(98)70340-9	http://dx.doi.org/10.1016/S0091-6749(98)70340-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847443				2022-12-18	WOS:000077690700020
J	Tsai, LC; Chao, PL; Shen, HD; Tang, RB; Chang, TC; Chang, ZN; Hung, MW; Lee, L; Chua, KY				Tsai, LC; Chao, PL; Shen, HD; Tang, RB; Chang, TC; Chang, ZN; Hung, MW; Lee, L; Chua, KY			Isolation and characterization of a novel 98-kd Dermatophagoides farinae mite allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monoclonal antibodies; mite allergen; paramyosin; Dermatophagoides farinae	HOUSE-DUST MITE; GROUP-III ALLERGEN; MONOCLONAL-ANTIBODIES; ASTHMATIC-CHILDREN; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GRASS-POLLEN; IGE ANTIBODY; PARAMYOSIN; IDENTIFICATION	Background: Exposure to allergens from house dust mites is a significant cause of immediate hypersensitivity. Thus far, the active mite allergens defined are low molecular weight (MW) proteins or glycoproteins. However, other important mite allergens remain to be investigated. In this study a high MW mite antigen with a high IgE-binding activity was characterized. Methods: An Anti-Dermatophagoides farinae (Df) monoclonal antibody, mAb642, which recognized a 98-kd allergenic mite protein, was used for affinity chromatography, The purified Df642 was characterized biochemically and immunologically. Results: Competitive ELISA demonstrated that mAb642 was inhibited by the interaction between serum IgE from allergic patients and Df642 antigen in a dose-dependent fashion. The IgE reactivity to both 98-kd and 92-kd components was removed or diminished by preincubation of asthmatic sera with Df642-coated CNBr-activated cellulose-4B gel. Two-dimensional immunoblot analysis revealed that there are at least 4 isoforms of Df642 that represent a minor component in the crude mite extract. The allergenicity of Df642 was assayed by IgE immunoassay with a large panel of 67 sera from asthmatic patients with positive skin reactions, and Df 642 showed positive IgE reactivity with more than 80% of the sera tested. Thus it should be classified as an important allergen. In addition, amino acid sequence analysis revealed that Df642 shares more than 50% homology,vith paramyosin from invertebrates. Conclusion: We have identified and characterized a 98-kd house dust mite allergen that showed greater than 80% IgE reactivity with sera from patients allergic to mites. This is the first high MW allergen characterized to date, and it shares high sequence homology with paramyosins in invertebrates.	Vet Gen Hosp, Dept Med Res, Taipei 11217, Taiwan; Vet Gen Hosp, Dept Pediat, Taipei 11217, Taiwan; Natl Univ Singapore, Dept Med, Singapore 117548, Singapore; Natl Yang Ming Univ, Dept Biotechnol, Singapore, Singapore; Natl Def Med Ctr, Dept Biochem, Singapore, Singapore	National University of Singapore	Tsai, LC (corresponding author), Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan.							AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; AKI T, 1994, INT ARCH ALLERGY IMM, V103, P349, DOI 10.1159/000236653; AKI T, 1994, J BIOCHEM, V115, P435, DOI 10.1093/oxfordjournals.jbchem.a124356; ANDDO T, 1993, CLIN EXP ALLERGY, V23, P777; CHANG ZN, 1991, ALLERGY, V46, P520, DOI 10.1111/j.1398-9995.1991.tb00615.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364, DOI 10.1159/000236478; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Chua KY, 1998, J ALLERGY CLIN IMMUN, V101, pS156; COHEN C, 1987, BIOSCIENCE REP, V7, P11, DOI 10.1007/BF01122722; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; KOJIMA S, 1987, J IMMUNOL, V139, P2044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LIN KL, 1991, ANN ALLERGY, V67, P63; MACKENZIE JM, 1980, CELL, V22, P747, DOI 10.1016/0092-8674(80)90551-6; PEARCE EJ, 1988, P NATL ACAD SCI USA, V85, P5678, DOI 10.1073/pnas.85.15.5678; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHEN HD, 1990, ELECTROPHORESIS, V11, P878, DOI 10.1002/elps.1150111018; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SHEN HD, 1995, CLIN EXP ALLERGY, V25, P1000, DOI 10.1111/j.1365-2222.1995.tb00403.x; SHEN HD, 1995, CLIN EXP ALLERGY, V25, P416, DOI 10.1111/j.1365-2222.1995.tb01072.x; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; STEWART GA, 1992, IMMUNOLOGY, V75, P29; TANG RB, 1990, CLIN EXP ALLERGY, V20, P33, DOI 10.1111/j.1365-2222.1990.tb02772.x; TANG RB, 1988, J ASTHMA, V25, P83, DOI 10.3109/02770908809071358; THOMAS WR, 1993, CLIN EXP ALLERGY, V23, P350, DOI 10.1111/j.1365-2222.1993.tb00338.x; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; TSAI LC, 1990, J ASTHMA, V27, P95, DOI 10.3109/02770909009073303; TSAI LC, 1987, ASIA PAC COMMUN BIOC, V1, P133; WANG WC, 1988, J BIOL CHEM, V263, P4576; YASEUDA H, 1993, CLIN EXP ALLERGY, V23, P384	39	49	53	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					295	303		10.1016/S0091-6749(98)70099-5	http://dx.doi.org/10.1016/S0091-6749(98)70099-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723675	Bronze			2022-12-18	WOS:000075537100024
J	Bernardini, R; Novembre, E; Ingargiola, A; Veltroni, M; Mugnaini, L; Cianferoni, A; Lombardi, E; Vierucci, A				Bernardini, R; Novembre, E; Ingargiola, A; Veltroni, M; Mugnaini, L; Cianferoni, A; Lombardi, E; Vierucci, A			Prevalence and risk factors of latex sensitization in an unselected pediatric population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; sensitization; atopy; prevalence; children	ALLERGY; HYPERSENSITIVITY; SKIN	Background: The prevalence of latex sensitization has been investigated in population groups considered at high risk, but it has not been systematically surveyed among the general population. Objective: We sought to determine the prevalence of and the risk factors associated with latex sensitization in a general pediatric population. Methods: We investigated 1175 children (mean age +/- SD, 105 +/- 17.5 months) in II elementary schools in Tuscany (Italy). All parents answered a questionnaire, and children underwent skin prick tests (SPTs) with latex, six aeroallergens (Dermatophagoides pteronyssinus, D. farinae, cat, grass pollen, Alternaria tenuis, and Parietaria judaica), three food allergens (milk, egg white, and wheat), and three insect venoms (honeybee, wasp, and Polistes). Results: Eight subjects (0.7%; mean age +/- SD, 123 +/- 9.28 months) had positive SPT responses to latex. No children showed allergic reactions to latex. One or more positive SPT responses to aeroallergens were present in 340 children (28.9%); one or more positive SPT responses to food allergens were present in 26 (2.2%); one or more positive SPT responses to aeroallergens, food allergens, or both were present in 353 (30.0%); and one or more positive SPT responses to one or more insect venoms were present in 43 subjects (3.7%). Significant (p < 0.05) risk factors associated with latex sensitization included: positive SPT responses to aeroallergens, food allergens, or both; a positive response to one or more insect venoms; a positive response to mite, milk, egg white, wheat, honeybee venom, wasp venom, Polistes venom, or a combination thereof; and increased age. Conclusion: This report shows a very low prevalence of latex sensitization with an absence of clinical symptoms to latex. This study demonstrates a significant association between latex sensitization and the presence of one or more positive SPT responses to aeroallergens, food allergens, or both; one or more positive SPT responses to one or more insect venoms; and increased age.	Univ Florence, A Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, I-50132 Florence, Italy	University of Florence	Bernardini, R (corresponding author), Univ Florence, A Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Via Luca Giordano 13, I-50132 Florence, Italy.		Lombardi, Enrico/K-3356-2016	Lombardi, Enrico/0000-0003-4749-9091				[Anonymous], 1989, ALLERGY S10, V10, P1; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Dillard SF, 1992, INT LATEX C SENSITIV, P23; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; Novembre E, 1997, ALLERGY, V52, P101, DOI 10.1111/j.1398-9995.1997.tb02553.x; NOVEMBRE E, 1995, ALLERGY, V50, P511, DOI 10.1111/j.1398-9995.1995.tb01187.x; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; SLATER JE, 1997, ALLERGY ALLERGIC DIS, P981; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; *TASK FORC ALL REA, 1993, J ALLERGY CLIN IMMUN, V92, P16; Terrados S, 1997, ALLERGY, V52, P200, DOI 10.1111/j.1398-9995.1997.tb00975.x; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7; YASSIN MS, 1994, ANN ALLERGY, V72, P245	19	49	51	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					621	625		10.1016/S0091-6749(98)70169-1	http://dx.doi.org/10.1016/S0091-6749(98)70169-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600498				2022-12-18	WOS:000073697400009
J	van den Heuvel, MM; Vanhee, DDC; Postmus, PE; Hoefsmit, ECM; Beelen, RHJ				van den Heuvel, MM; Vanhee, DDC; Postmus, PE; Hoefsmit, ECM; Beelen, RHJ			Functional and phenotypic differences of monocyte-derived dendritic cells from allergic and nonallergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic disease; antigen presentation; asthma; Candida albicans antigen; CD11b; dendritic cells; HLA-DR; house dust mite allergen; immunoglobulin receptors; mixed leukocyte reaction; purified protein derivative	FC-EPSILON-RI; LANGERHANS CELLS; BRONCHIAL-ASTHMA; ANTIGEN; IGE; INTERLEUKIN-4; LYMPHOCYTES; SUPERFAMILY; MACROPHAGES; ACTIVATION	Background: Several studies suggest a role for dendritic cells in the pathogenesis of allergic disease. Objective: The purpose of this study was to compare function and phenotype of monocyte-derived dendritic cells (MoDC) from allergic asthmatic patients and healthy control subjects. Methods: MoDCs were developed by incubating adherent monocytes for 5 days with IL-4 and granulocyte-macrophage colony-stimulating factor. Phenotype was assessed with flow cytometry, and the antigen-presenting function was assessed with the allogeneic mixed leukocyte reaction and an autologous specific antigen presentation. Results: The morphology of the MoDCs was characteristic for immature dendritic cells. MoDCs from allergic asthmatic patients showed phenotypic differences in the expression of HLA-DR, CD11b, and the high-affinity receptor for IgE. A clearly enhanced accessory potential of MoDCs from atopic asthmatic patients in the mixed leukocyte reaction was also shown. Moreover, house dust mite-specific T-cell proliferation was increased. Conclusion: This study suggests the involvement of dendritic cells in the pathogenesis of atopic asthma by an increased immunostimulatory capacity of MoDCs.	Free Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Dept Chest Dis, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Beelen, RHJ (corresponding author), Free Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, Van de Boechorstr 7, NL-1081 BT Amsterdam, Netherlands.		van den Heuvel, Michel M/D-9491-2017	van den Heuvel, Michel M/0000-0002-6372-2153				AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BOLTZNITULESCU G, 1995, J LEUKOCYTE BIOL, V58, P256, DOI 10.1002/jlb.58.2.256; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Fanger NA, 1996, J IMMUNOL, V157, P541; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; HUTTER C, 1991, FEMS MICROBIOL IMMUN, V5, P309; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MUDDE GC, 1995, ALLERGY, V50, P193, DOI 10.1111/j.1398-9995.1995.tb01132.x; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; POULTER LW, 1986, SCAND J IMMUNOL, V24, P351; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; RUPPERT J, 1991, IMMUNOBIOLOGY, V182, P449, DOI 10.1016/S0171-2985(11)80209-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHEVACH EM, 1995, CURRENT PROTOCOLS IM; SIMON JC, 1990, J IMMUNOL, V145, P2087; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TOMITA K, 1995, J ALLERGY CLIN IMMUN, V96, P230, DOI 10.1016/S0091-6749(95)70012-9; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; ZHOU LJ, 1992, J IMMUNOL, V149, P735; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	25	49	50	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				90	95		10.1016/S0091-6749(98)70198-8	http://dx.doi.org/10.1016/S0091-6749(98)70198-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449506				2022-12-18	WOS:000071539800014
J	deVries, IJM; LangeveldWildschut, EG; vanReijsen, FC; Bihari, IC; BruijnzeelKoomen, CAFM; Thepen, T				deVries, IJM; LangeveldWildschut, EG; vanReijsen, FC; Bihari, IC; BruijnzeelKoomen, CAFM; Thepen, T			Nonspecific T-cell homing during inflammation in atopic dermatitis: Expression of cutaneous lymphocyte-associated antigen and integrin alpha E beta 7 on skin-infiltrating T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; contact dermatitis; irritant reaction; cutaneous lymphocyte-associated antigen; atopy patch test; lymphocyte extravasation; cutaneous inflammation; T-cell homing	INTESTINAL LYMPHOCYTES; PATCH TEST; IN-SITU; RECEPTOR; RECIRCULATION; STIMULATION; ANTIBODIES; ALLERGENS; HECA-452; BINDING	Atopic dermatitis (AD) is a chronic skin disorder, characterized by infiltration of activated memory CD4(+) T cells into skin. A model to study the onset of allergic inflammation in a patient with AD is the atopy patch test (APT), in which, by epicutaneous application of aeroallergen, an eczematous reaction is induced in 50% of sensitized patients with AD. Extravasation of T cells into skin is thought to be critically dependent on expression of the surface molecule cutaneous lymphocyte-associated antigen (CLA), which recognizes and binds its ligand E-selectin on endothelium. We studied the dynamics of expression of CLA and the gut homing receptor alpha E beta 7 (HML-1) on T cells in the skin of patients with AD and in APT reactions and nickel and sodium lauryl sulfate patch test reactions by means of immunohistochemical double staining of skin biopsy specimens. The results show an increase in the number of CD3(+) T cells in the lesional skin of patients with AD, APT reactions, and nickel and sodium lauryl sulfate patch test reactions as compared with nonlesional skin of the same patients and nonatopic individuals. In contrast, the percentages of CLA(+) T cells in the lesional skin of patients with AD, in the APT reactions, and in sodium lauryl sulfate and nickel patch test reactions were decreased. In addition, we found a marked expression of alpha E beta 7 by T cells present in skin, indicating a nonspecific influx of T cells during allergic skin inflammation. We propose that during allergic skin inflammation CLA expression is not a prerequisite for cutaneous T-cell infiltration. CLA expression may be important for T cells to extravasate from blood into skin during immune surveillance or for retention of allergen-specific T cells in skin.			deVries, IJM (corresponding author), UNIV UTRECHT HOSP,DEPT DERMATOL ALLERGOL G02124,POSTBUS 85500,NL-3508 GA UTRECHT,NETHERLANDS.		de Vries, Jolanda I.J.M./F-5563-2010	de Vries, Jolanda I.J.M./0000-0002-8653-4040				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BOS JD, 1993, ARCH DERMATOL RES, V285, P179, DOI 10.1007/BF00372006; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BREW R, 1995, SCAND J IMMUNOL, V41, P533; BURSTONE MS, 1958, J NATL CANCER I, V20, P601; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CLAASSEN E, 1986, J HISTOCHEM CYTOCHEM, V34, P989, DOI 10.1177/34.8.2426338; COLDITZ IG, 1991, IMMUNOL CELL BIOL, V69, P215, DOI 10.1038/icb.1991.31; ERLE DJ, 1994, AM J RESP CELL MOL, V10, P237, DOI 10.1165/ajrcmb.10.3.7509610; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KANE CJM, 1990, J CELL PHYSIOL, V144, P144, DOI 10.1002/jcp.1041440119; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Liu L, 1996, IMMUNOLOGY, V88, P207, DOI 10.1111/j.1365-2567.1996.tb00006.x; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; PICKER LJ, 1992, CURR OPIN IMMUNOL, V4, P2277; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SCHIEFERDECKER HL, 1990, J IMMUNOL, V144, P2541; SEGHAL PB, 1990, J INVEST DERMATOL, V94; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; vanReijsen FC, 1997, J INVEST DERMATOL, V108, P530, DOI 10.1111/1523-1747.ep12291799	33	49	51	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					694	701		10.1016/S0091-6749(97)70175-1	http://dx.doi.org/10.1016/S0091-6749(97)70175-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389301	Bronze			2022-12-18	WOS:A1997YG20200018
J	Barletta, B; Afferni, C; Tinghino, R; Mari, A; DiFelice, G; Pini, C				Barletta, B; Afferni, C; Tinghino, R; Mari, A; DiFelice, G; Pini, C			Cross-reactivity between Cupressus arizonica and Cupressus sempervirens pollen extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cupressus arizonica; Cupressus sempervirens; allergens; characterization crossreactivity; diagnosis IgE; blotting inhibition; ELISA inhibition	IGE ANTIBODIES; CYPRESS POLLEN; IDENTIFICATION; ALLERGY; POLLINOSIS; COMPONENTS; BINDING; FRANCE; CEDAR; SOUTH	Background: Cupressus arizonica and C. sempervirens, two species belonging to the Cupressaceae family, are recognized as an important cause of respiratory allergies in countries with a Mediterranean climate. Objective: The relationship between pollen extracts from these two species was studied by evaluating the reactivity with polyclonal rabbit antisera and human IgE. Methods: The two extracts were analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Cross-reactivity was evaluated by ELISA and immunoblotting inhibition experiments. Results: The electrophoretic patterns of the two extracts are quite different, although some components display identical molecular weights. The immunoblotting developed with human IgE from subjects allergic to members of the Cupressaceae family indicated that two major IgE-reactive components, displaying molecular weights of about 43,000 and 36,000 d, were similarly detected in both extracts. Inhibition experiments showed a high degree of cross-reactivity between the two extracts when tested with rabbit polyclonal antibodies against C. arizonica and C. sempervirens. When tested with human IgE inhibition methods, both extracts were able to reciprocally inhibit all of the IgE-reactive bands, although C. arizonica extract was always a better inhibitor. Conclusions: C. arizonica and C. sempervirens extracts are highly cross-reactive at the IgE level and share a number of common epitopes also identified by polyclonal rabbit antisera.	IST SUPER SANITA, DEPT IMMUNOL, I-00161 ROME, ITALY	Istituto Superiore di Sanita (ISS)			AFFERNI, CLAUDIA/B-9978-2016; BARLETTA, BIANCA/B-9980-2016; Di Felice, Gabriella/B-9985-2016	AFFERNI, CLAUDIA/0000-0002-8567-7365; Di Felice, Gabriella/0000-0001-7387-9683				AFFERNI C, 1995, BIOLOGICALS, V23, P239, DOI 10.1006/biol.1995.0040; BASS D, 1991, MED J AUSTRALIA, V155, P572, DOI 10.5694/j.1326-5377.1991.tb93901.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIAFFA MF, 1993, ANN ALLERGY, V71, P45; CHARPIN D, 1990, REV FR ALLERGOL, V30, P21, DOI 10.1016/S0335-7457(05)80141-8; CHARPIN D, 1993, CLIN EXP ALLERGY, V23, P435, DOI 10.1111/j.1365-2222.1993.tb00350.x; CIMIGNOLI E, 1992, EUR J AEROBIOL, V8, P465; CORBI AL, 1986, MOL IMMUNOL, V23, P1357, DOI 10.1016/0161-5890(86)90021-0; DAYAN YB, 1995, CLIN EXP ALLERGY, V25, P456, DOI 10.1111/j.1365-2222.1995.tb01077.x; DE CESARE F, 1993, ALLERGY, V48, P248; DIFELICE G, 1994, J ALLERGY CLIN IMMUN, V94, P547, DOI 10.1016/0091-6749(94)90212-7; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; HUANG X, 1995, ALLERGY, V50, P648, DOI 10.1111/j.1398-9995.1995.tb02581.x; JOHANSSON E, 1991, CLIN EXP ALLERGY, V21, P511, DOI 10.1111/j.1365-2222.1991.tb01693.x; KAUFMAN HS, 1988, ANN ALLERGY, V60, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBESKIND A., 1960, ANN ALLERGY, V18, P663; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; MUCCI N, 1992, ALLERGY, V47, P424, DOI 10.1111/j.1398-9995.1992.tb02083.x; ORDMAN D, 1945, S AFR MED J, V19, P142; PANZANI R, 1986, ANN ALLERGY, V56, P460; PANZANI R, 1986, ANN ALLERGY, V57, P26; Panzani R., 1991, ALLERGENIC POLLEN PO, P81; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TAS J, 1965, ACTA ALLERGOL, V20, P405, DOI 10.1111/j.1398-9995.1965.tb03073.x	32	49	50	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					797	804		10.1016/S0091-6749(96)70129-X	http://dx.doi.org/10.1016/S0091-6749(96)70129-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876556	Bronze			2022-12-18	WOS:A1996VM66500013
J	Choy, AC; Patterson, R; Patterson, DR; Grammer, LC; Greenberger, PA; McGrath, KG; Harris, KE				Choy, AC; Patterson, R; Patterson, DR; Grammer, LC; Greenberger, PA; McGrath, KG; Harris, KE			Undifferentiated somatoform idiopathic anaphylaxis: Nonorganic symptoms mimicking idiopathic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						idiopathic anaphylaxis; somatoform; prednisone		Background: Northwestern University's Division of Allergy and Immunology has had experience with the diagnosis and treatment of more than 350 patients with idiopathic anaphylaxis (IA). In 1992 we reported a group of patients with IA whose presentations mimicked IA, but IA and other organic causes were later excluded. Psychologic factors were suspected as the underlying problem. These patients were classified as IA-variant. Management of these causes was extremely difficult. There was significant morbidity and high and unnecessary costs. Objective: We aim to distinguish the nature of this disease and to highlight the evaluation and treatment of this group of patients. Methods: Their cases are reviewed and reported. Results: Common features included (1) presenting symptoms mimicking IA, (2) no objective findings that correlated with 1, (3) no response to the therapeutic regimen for IA, (4) meeting the Diagnostic and Statistical Manual of Mental Disorders criteria for undifferentiated somatoform disorder, and (5) significant wasted health care expenditure. Conclusions: This group of patients were better defined as having undifferentiated somatoform-IA. An algorithm was proposed to expedite the diagnosis of the disease so that with early recognition of the disease, unwarranted repetitive consultations, tests, and inappropriate therapy can be avoided.	NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV ALLERGY IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, NW MEM HOSP, ERNEST S BAZLEY ASTHMA & ALLERG DIS CTR, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT REHABIL MED, SEATTLE, WA 98104 USA	Northwestern University; Northwestern Memorial Hospital; Northwestern University; Northwestern University; Harborview Medical Center; University of Washington; University of Washington Seattle			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Grammer, Leslie/0000-0001-6860-2014				BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; DITTO AM, IN PRESS ANN ALLERGY; ORFAN NA, 1992, ALLERGY PROC, V13, P35, DOI 10.2500/108854192778878953; PATTERSON R, 1990, J ALLERGY CLIN IMMUN, V85, P86, DOI 10.1016/0091-6749(90)90226-T; PATTERSON R, 1993, ANN ALLERGY, V71, P40; PATTERSON R, 1992, ALLERGY PROC, V13, P133, DOI 10.2500/108854192778878791; PATTERSON R, 1993, ALLERGIC DISEASES DI, P206; SANSAN W, 1991, ANN ALLERGY, V67, P359; WONG S, 1991, ANN INTERN MED, V114, P133, DOI 10.7326/0003-4819-114-2-133; 1987, DIAGNOSTIC STATISTIC, P261	10	49	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				893	900		10.1016/S0091-6749(95)70225-3	http://dx.doi.org/10.1016/S0091-6749(95)70225-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543746				2022-12-18	WOS:A1995TN12400005
J	TERADA, N; KONNO, A; TOGAWA, K				TERADA, N; KONNO, A; TOGAWA, K			BIOCHEMICAL-PROPERTIES OF EOSINOPHILS AND THEIR PREFERENTIAL ACCUMULATION MECHANISM IN NASAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1993 Conference	JUL   17, 1993	TOKYO, JAPAN				RECOMBINANT HUMAN INTERLEUKIN-5; ADHESION MOLECULE-1 ICAM-1; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; IL-5; EXPRESSION; ACTIVATION; MUCOSA; DEGRANULATION; FIBRONECTIN	Recent information intensely suggests that eosinophils are pivotal proinflammatory cells in a variety of allergic inflammatory diseases including bronchial asthma, nasal allergy, hypereosinophilic syndrome, and various cutaneous diseases. Eosinophils, via their release of basic proteins and lipid mediators, are strongly implicated in the onset of allergic symptoms of the nose. They play an important role particularly in nasal swelling and hyperreactivity. Despite the current multitude of research investigating eosinophils in vitro, the mechanism that mediates and controls the accumulation of eosinophils in vivo is incompletely understood, fn this article the following issues will be addressed: (1) How do eosinophils migrate into the nasal mucosa? (2) What factors contribute to preferential eosinophil accumulation and their degranulation in nasal mucosa? (3) How can we inhibit the eosinophil accumulation and activation?	CHIBA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,CHIBA 280,JAPAN	Chiba University	TERADA, N (corresponding author), AKITA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,1-1-1 HONDO,AKITA 010,JAPAN.							ABUGHAZALEH RJ, 1989, J IMMUNOL, V142, P2293; ANWER ARF, 1993, J EXP MED, V177, P839; BEAGLEY KW, 1989, J IMMUNOL, V141, P2305; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRADDING P, 1993, J IMMUNOL, V151, P3853; CAPRON M, 1988, CR ACAD SCI III-VIE, V307, P397; CHIHARA J, 1992, J LIPID MEDIATOR, V5, P159; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DAHL R, 1985, ANN M EUROPEAN ACADE; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DOBRINA A, 1991, J CLIN INVEST, V88, P120; DUSTIN ML, 1988, IMMUNOL TODAY, V9, P213, DOI 10.1016/0167-5699(88)91216-9; DUSTIN ML, 1986, J IMMUNOL, V137, P245; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRIGAS R, 1990, LAB INVEST, V42, P35; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HARRIMAN GR, 1988, J IMMUNOL, V140, P3033; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; KONNO A, IN PRESS INT ARCH AL; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P2656; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NUMAO T, 1989, 7TH P S IMM TOK, P101; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHOW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SMITH JB, 1992, PEDIATR RES, V32, P465, DOI 10.1203/00006450-199210000-00018; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TERADA N, 1991, Japanese Journal of Allergology, V40, P181; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; TERADA N, 1994, ACTA OTO-LARYNGOL, V114, P203, DOI 10.3109/00016489409126043; TERADA N, UNPUB INTERLEUKIN 5; TERADA N, 1993, ACTA OTOLARYNGOL S S, V506, P57; TERADA N, 1990, 14 P WORLD C OT HEAD, P1765; TERADA N, 1992, PRACT OTOL KYOTO S, V57, P52; TERADA N, 1989, J OTOLARYNGOL JPN, V92, P1337; TERADA N, UNPUB INHIBITORY EFF; TERADA N, 1992, P OTOL KYOTO, V57, P46; Terada Nobuhisa, 1993, Japanese Journal of Allergology, V42, P87; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WATASE T, 1986, JJIAO, V4, P21; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; YAMADA A, 1991, J IMMUNOL, V146, P53; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	48	49	52	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			629	642		10.1016/0091-6749(94)90140-6	http://dx.doi.org/10.1016/0091-6749(94)90140-6			14	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	8083472				2022-12-18	WOS:A1994PH23500009
J	BUFE, A; BECKER, WM; SCHRAMM, G; PETERSEN, A; MAMAT, U; SCHLAAK, M				BUFE, A; BECKER, WM; SCHRAMM, G; PETERSEN, A; MAMAT, U; SCHLAAK, M			MAJOR ALLERGEN PHL-P-VA (TIMOTHY GRASS) BEARS AT LEAST 2 DIFFERENT IGE-REACTIVE EPITOPES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TIMOTHY GRASS POLLEN; MAJOR ALLERGEN; GROUP V ALLERGENS; ISOALLERGENS; PHL P VA; CDNA CLONING; POLYMERASE CHAIN REACTION; FUSION PROTEIN; EPITOPES	AMINO-ACID SEQUENCE; IMMUNOLOGICAL REACTIVITY; POLLEN ALLERGENS; PRATENSE POLLEN; CDNA CLONING; PURIFICATION; ANTIBODIES; RECEPTOR; PROTEIN; CHAIN	It is established that most grass pollen allergens consist of several isoforms of which the function is mainly still unknown. A number of these allergens belonging to group V have been cloned sequenced, and expressed. Antigenic sites and IgE-reactive epitopes of the major allergen Phl p Va, are unknown. We have identified the complete cDNA sequence of a Phl p Va isoallergen by immunoscreening of a timothy grass pollen cDNA library and mired oligonucleotide primed amplification of N-terminal cDNA. Additionally, we found an incomplete isoallergenic cDNA clone of the same protein. Immunoreactivity of the fusion proteins with patients' sera and monoclonal antibodies showed that the clones represent group Va allergens. Comparison of deduced amino acid sequences with published sequences of Lol p V and Poa p IX revealed a homology of 81.1% and 86.9%, respectively. With affinity-purified IgE antibodies recognizing the recombinant fusion protein, we can demonstrate the existence of a common group V IgE-reactive epitope. By construction of both an N-terminal and a C-terminal peptide of the complete Phl p Va and cross-inhibition, we identified at least two different IgE epitopes. Eleven patients showed variable IgE immunoreactivities to both IgE-reactive epitopes.			BUFE, A (corresponding author), FORSCHUNGSINST BORSTEL, PK ALLEE 22, D-23845 BORSTEL, GERMANY.			Bufe, Albrecht/0000-0001-7335-9362				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; ANSARI AA, 1989, J BIOL CHEM, V264, P11181; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BECKER WM, 1988, BIOCH ENG, P440; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; DONOVAN GR, 1990, MONOGR ALLERGY, V28, P52; DREBORG S, 1986, HDB EXPT IMMUNOLOGY, V1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; IPSEN H, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P219; JILEK A, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P39; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEWIN B, 1990, GENES, V4, P497; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARKERT ML, 1992, PEDIATR ALLERGY IMMU, V3, P49; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MOHAPATRA SS, 1990, INT ARCH ALLER A IMM, V91, P362, DOI 10.1159/000235142; ONG EK, 1993, ALLERGY, V48, P126; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; PETERSEN A, 1992, ELECTROPHORESIS, V13, P736, DOI 10.1002/elps.11501301158; PETERSEN A, 1993, BIOL CHEM H-S, V374, P855, DOI 10.1515/bchm3.1993.374.7-12.855; PETERSEN A, 1993, IN PRESS CLIN EXP AL; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAMM G, 1993, ALLERGY, V48, P127; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SIVANOVICH A, 1991, J BIOL CHEM, V260, P1204; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VRTALA S, 1993, J IMMUNOL, V151, P4773; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004; WILLIAMSON AR, 1973, ANN NY ACAD SCI, V209, P210, DOI 10.1111/j.1749-6632.1973.tb47530.x; ZHANG L, 1992, MOL IMMUNOL, V29, P1383, DOI 10.1016/0161-5890(92)90175-W	42	49	53	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					173	181		10.1016/0091-6749(94)90037-X	http://dx.doi.org/10.1016/0091-6749(94)90037-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	7520460				2022-12-18	WOS:A1994PC92600006
J	IMAYAMA, S; SHIMOZONO, Y; HOASHI, M; YASUMOTO, S; OHTA, S; YONEYAMA, K; HORI, Y				IMAYAMA, S; SHIMOZONO, Y; HOASHI, M; YASUMOTO, S; OHTA, S; YONEYAMA, K; HORI, Y			REDUCED SECRETION OF IGA TO SKIN SURFACE OF PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SECRETORY IGA; SWEAT; SKIN; ATOPIC DERMATITIS	STAPHYLOCOCCUS-AUREUS; EPITHELIAL RECEPTOR; IMMUNOGLOBULIN-A; POLYMERIC IG; COMPONENT; EXPRESSION; COLONIZATION; DEFICIENCY; CELLS; GAMMA	To investigate whether the secretory form of immunoglobulin A (sIgA) was reduced on the skin surface in atopic dermatitis, the amount of sIgA present in sweat was measured in 40 patients with atopic dermatitis and in 50 healthy volunteers by attaching a cellulose membrane disk (10 x 10 mm) to the inner aspect of the upper arm skin for 24 hours. The secretory form of IgA, which was absorbed to the membrane and accumulated during the period of application, was revealed as dots by an enzyme immunoassay in which antibodies for IgA and for the secretory component were used. The density and number of dots (per mm(2)/day), which corresponded to the openings of eccrine excretory ducts, were determined with a densitometer. The mean amount of sIgA secreted by those patients was 3.86 +/- 0.71 pg/mm(2)/day (range, 0 to 21.17 pg/mm(2)/day), whereas that of the control subjects was significantly higher (p < 0.001), 16.79 +/- 2.80 pg/mm(2)/day (range, 0.79 to 133.77 pg/mm(2)/day). This may be related to the high incidence of bacterial and viral skin infections seen in patients with atopic dermatitis, and in addition, to the development of eczematous lesions through a defect in ridding the skin of allergens and/or microorganisms.	HISAMITSU PHARMACEUT, TOSU, SAGA, JAPAN	Hisamitsu Pharmaceutical Co Ltd	IMAYAMA, S (corresponding author), KYUSHU UNIV, FAC MED, DEPT DERMATOL, FUKUOKA 812, JAPAN.							BIENENSTOCK J, 1983, GASTROENTEROLOGY, V84, P178; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; BOTHOREL B, 1992, ARCH DERMATOL RES, V284, P135, DOI 10.1007/BF00372705; BRANDT GC, 1986, CAN HIST REV, V67, P626; CHAMPION RH, 1986, TXB DERMATOLOGY, P419; FUKUDA H, 1991, Japanese Journal of Allergology, V40, P626; HANIFIN JM, 1986, J ALLERGY CLIN IMMUN, V78, P563, DOI 10.1016/0091-6749(86)90071-0; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; Hoashi Mariko, 1992, Journal of Dermatology (Tokyo), V19, P972, DOI 10.1111/j.1346-8138.1992.tb03815.x; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; IMAYAMA S, UNPUB BR J DERMATOL; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; ISHIGURO Y, 1982, CLIN CHIM ACTA, V116, P237; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; KIISTALA R, 1992, ACTA DERM-VENEREOL, V72, P106; KUBOTA Y, 1992, Journal of Dermatology (Tokyo), V19, P177, DOI 10.1111/j.1346-8138.1992.tb03202.x; Kubota Yumiko, 1993, Journal of Dermatology (Tokyo), V20, P85, DOI 10.1111/j.1346-8138.1993.tb03836.x; KVALE D, 1988, J IMMUNOL, V140, P3086; LEUNG DYM, 1987, DERMATOLOGY GENERAL, P1385; LIBLAU RS, 1992, INT ARCH ALLERGY IMM, V99, P16, DOI 10.1159/000236330; METZE D, 1991, J INVEST DERMATOL, V96, P439, DOI 10.1111/1523-1747.ep12469908; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; NORHAGEN G, 1989, J CLIN IMMUNOL, V9, P279, DOI 10.1007/BF00918659; OKADA T, 1988, J INVEST DERMATOL, V90, P648, DOI 10.1111/1523-1747.ep12560807; PHILLIPS JO, 1990, J IMMUNOL, V145, P1740; PLEBANI A, 1982, CLIN ALLERGY, V12, P403, DOI 10.1111/j.1365-2222.1982.tb02545.x; RAIMIREZ P, 1983, J IMMUNOL METHODS, V62, P15; SOLLID LM, 1987, J IMMUNOL, V138, P4303; STOKES CR, 1975, NATURE, V255, P745, DOI 10.1038/255745a0; TANAKA Y, 1989, ACTA DERM-VENEREOL, P93; TROJANOWSKI JQ, 1983, J HISTOCHEM CYTOCHEM, V31, P1217, DOI 10.1177/31.10.6350434; WILLIAMS REA, 1990, BRIT J DERMATOL, V123, P493	32	49	51	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					195	200		10.1016/0091-6749(94)90040-X	http://dx.doi.org/10.1016/0091-6749(94)90040-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064071				2022-12-18	WOS:A1994PC92600009
J	WONG, JT; RIPPLE, RE; MACLEAN, JA; MARKS, DR; BLOCH, KJ				WONG, JT; RIPPLE, RE; MACLEAN, JA; MARKS, DR; BLOCH, KJ			VANCOMYCIN HYPERSENSITIVITY - SYNERGISM WITH NARCOTICS AND DESENSITIZATION BY A RAPID CONTINUOUS INTRAVENOUS PROTOCOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VANCOMYCIN; HYPERSENSITIVITY; DESENSITIZATION; THRESHOLD; NARCOTIC	RED-MAN SYNDROME; HISTAMINE-RELEASE; BACTERICIDAL ACTIVITY; SLOW INFUSION; PHARMACOKINETICS; PROPHYLAXIS; ALLERGY	Background: We examined the clinical spectrum of patients with persistent adverse reactions to vancomycin, assessed contributing factors, and evaluated the efficacy and safety of a rapid continuous intravenous ''desensitization'' protocol in these patients. Methods: Seven patients with serious staphylococcal infections resistant to beta-lactam antibiotics whose adverse reactions to vancomycin persisted despite slowing of the vancomycin infusion and pretreatment with H-1-antihistamine were studied. All seven patients underwent a rapid continuous intravenous desensitization protocol with multiple small increases in vancomycin concentration tightly regulated with a syringe pump. Results: Most of the seven patients safely achieved, during the first day, a vancomycin infusion rate (VIR) sufficient, or close to sufficient, to provide the desired vancomycin dose. In three patients there appeared to be a threshold VIR beyond which adverse reactions were repeatedly elicited; these reactions abated when the VIR was slightly lowered. Narcotic administration was found to adversely affect treatment with vancomycin. After concurrent narcotic administration was discontinued in three patients, they and the other four patients successfully completed the full course of treatment with vancomycin. Conclusion: Patients whose adverse reactions to vancomycin did not respond to slowing of the infusion rate and additional H-1-antihistamines can be safely treated with a rapid continuous intravenous desensitization protocol and discontinuance of narcotic administration.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; MASSACHUSETTS GEN HOSP,GEN MED SERV,ALLERGY UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	WONG, JT (corresponding author), MASSACHUSETTS GEN HOSP,GEN MED SERV,CLIN IMMUNOL UNIT,COX 5,BOSTON,MA 02114, USA.							APPEL GB, 1977, NEW ENGL J MED, V296, P722, DOI 10.1056/NEJM197703312961305; BOECKH M, 1988, ANTIMICROB AGENTS CH, V32, P92, DOI 10.1128/AAC.32.1.92; CLAYMAN MD, 1989, ARCH INTERN MED, V149, P1425, DOI 10.1001/archinte.149.6.1425; COLE DR, 1985, LANCET, V2, P280; COOK FV, 1978, ANN INTERN MED, V88, P813, DOI 10.7326/0003-4819-88-6-813; DAVIS RL, 1986, ANN INTERN MED, V104, P285, DOI 10.7326/0003-4819-104-2-285_2; FARWELL AP, 1984, SOUTHERN MED J, V77, P664, DOI 10.1097/00007611-198405000-00034; FORRENCE EA, 1990, DICP ANN PHARMAC, V24, P369, DOI 10.1177/106002809002400405; GERACI JE, 1977, MAYO CLIN PROC, V52, P631; GERACI JE, 1958, P STAFF M MAYO CLIN, V33, P172; KUCERS A, 1975, USE ANTIBIOTICS COMP, P417; LAGAST H, 1986, J ANTIMICROB CHEMOTH, V18, P513, DOI 10.1093/jac/18.4.513; LERNER A, 1984, ANN INTERN MED, V100, P157, DOI 10.7326/0003-4819-100-1-157_1; LIN RY, 1990, ARCH INTERN MED, V150, P2197, DOI 10.1001/archinte.150.10.2197; MOSS J, 1983, ANESTHESIOLOGY, V59, P330, DOI 10.1097/00000542-198310000-00011; NEWFIELD P, 1979, ANN INTERN MED, V91, P581, DOI 10.7326/0003-4819-91-4-581; ODIO C, 1984, AM J DIS CHILD, V138, P17, DOI 10.1001/archpedi.1984.02140390009004; PAU AK, 1985, NEW ENGL J MED, V313, P756; POLK RE, 1988, J INFECT DIS, V157, P502, DOI 10.1093/infdis/157.3.502; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; ROTHENBERG HJ, 1959, JAMA-J AM MED ASSOC, V171, P1101, DOI 10.1001/jama.1959.73010260008010b; SAHAI J, 1989, J INFECT DIS, V160, P876, DOI 10.1093/infdis/160.5.876; SOUTHORN PA, 1986, MAYO CLIN PROC, V61, P721, DOI 10.1016/S0025-6196(12)62773-6; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WALLACE MR, 1991, J INFECT DIS, V164, P1180, DOI 10.1093/infdis/164.6.1180	25	49	52	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					189	194		10.1016/0091-6749(94)90039-6	http://dx.doi.org/10.1016/0091-6749(94)90039-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	7914900				2022-12-18	WOS:A1994PC92600008
J	QUIRCE, S; CUEVAS, M; OLAGUIBEL, JM; TABAR, AI				QUIRCE, S; CUEVAS, M; OLAGUIBEL, JM; TABAR, AI			OCCUPATIONAL ASTHMA AND IMMUNOLOGICAL RESPONSES INDUCED BY INHALED CARMINE AMONG EMPLOYEES AT A FACTORY MAKING NATURAL DYES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANNATTO; ANTHRAQUINONES; ARTHROPODS; BRONCHIAL PROVOCATION TEST; CARMINE; COCHINEAL; CURCUMA; DYES; OCCUPATIONAL ASTHMA; RAST	REACTIVE DYES; EXPOSED WORKERS	Carmine is a natural red dye widely used as a food coloring agent and for cosmetic manufacture. It is extracted from the dried females of the insect Dactylopius coccus var. Costa (cochineal). Although it has been reported that inhalation of carmine may give rise to occupational asthma and extrinsic allergic alveolitis, there is little evidence of its immunogenic capacity. We studied nine current employees at a factory making natural dyes and one former employee who had left this plant after occupational asthma developed. A current employee had work-related symptoms of rhinitis and asthma that were confirmed by bronchial provocation tests, and another worker had rhinitis. Immunologic sensitization to carmine and cochineal was evaluated by means of skin testing and determination of serum-specific IgE and IgG subclass antibodies by RAST and ELISA, respectively. The specificity of the RAST assay was investigated by RAST inhibition with different fractions of carmine. The three workers with respiratory symptoms had positive skin prick test reactions to both carmine and cochineal. An immediate response to the bronchial provocation test with carmine and cochineal was observed in the current employee with asthma. Specific IgE antibodies against carmine and cochineal were found only in this worker. RAST inhibition studies indicated that the main allergen had a molecular weight between 10 and 30 kd. Specific IgG antibodies against carmine and cochineal, mainly the subclasses IgG(1), IgG(3), And IgG(4), were found in the 10 subjects surveyed. These findings suggest carmine may induce immunologic responses, most likely IgE mediated in workers with symptoms of occupational asthma.	HOSP VIRGEN CAMINO,DEPT ALLERGY,PAMPLONA,SPAIN; HOSP RAMON Y CAJAL,DEPT IMMUNOL,MADRID,SPAIN	Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; Hospital Universitario Ramon y Cajal			RIVERA, JOSE MARIA OLAGUIBEL/AAK-3845-2020; s, q/AAD-7171-2020	RIVERA, JOSE MARIA OLAGUIBEL/0000-0002-9126-4559; 				ALANKO K, 1978, CLIN ALLERGY, V8, P25, DOI 10.1111/j.1365-2222.1978.tb00444.x; BELLAS TE, 1990, CLIN REV ALLERG, V8, P15; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHRISTIANSEN M L, 1981, European Journal of Respiratory Diseases Supplement, V62, P82; DIETEMANNMOLARD A, 1991, LANCET, V338, P460, DOI 10.1016/0140-6736(91)91096-D; DOCKER A, 1987, BRIT J IND MED, V44, P534; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; LEVINE BB, 1961, J EXP MED, V14, P875; LLOYD AG, 1980, FOOD CHEM, V5, P91, DOI 10.1016/0308-8146(80)90067-9; NISH WA, 1991, ANN ALLERGY, V66, P129; PARK HS, 1991, J ALLERGY CLIN IMMUN, V87, P639, DOI 10.1016/0091-6749(91)90382-X; RODRIGUEZ A, 1990, Clinical and Experimental Allergy, V20, P43; TENABENE A, 1987, Archives des Maladies Professionnelles de Medecine du Travail et de Securite Sociale, V48, P569; THOREN K, 1986, CONTACT DERMATITIS, V15, P186, DOI 10.1111/j.1600-0536.1986.tb01323.x; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; WASS U, 1990, J ALLERGY CLIN IMMUN, V85, P642, DOI 10.1016/0091-6749(90)90105-D	17	49	52	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				44	52		10.1016/0091-6749(94)90231-3	http://dx.doi.org/10.1016/0091-6749(94)90231-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308181				2022-12-18	WOS:A1994MT78100005
J	VANMILLIGEN, FJ; VANTHOF, W; VANDENBERG, M; AALBERSE, RC				VANMILLIGEN, FJ; VANTHOF, W; VANDENBERG, M; AALBERSE, RC			IGE EPITOPES ON THE CAT (FELIS-DOMESTICUS) MAJOR ALLERGEN FEL D-I - A STUDY WITH OVERLAPPING SYNTHETIC PEPTIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FEL D I; SYNTHETIC PEPTIDES; IGE EPITOPES	INDIVIDUAL AMINO-ACIDS; MONOCLONAL-ANTIBODIES; SEQUENCE-ANALYSIS; BINDING; PROTEIN; SITES; DERMATOPHAGOIDES; LOCALIZATION; SPECIFICITY; DETERMINANT	Background: The major cat allergen Fel d I is composed of two disulfide-linked polypeptide chains, chain 1 (70 amino acid residues) and chain 2 (92 amino acid residues). Reduction and alkylation of Fel d I eliminates almost all antigenic and allergenic activity, and detection of linear epitopes with synthetic peptides is therefore not expected. Methods: We synthesized synthetic peptides of both chains of about 14 amino acid residues, overlapping by 7 residues. The peptides were coupled to Sepharose (Pharmacia, Uppsala, Sweden) and tested with sera of patients with cat allergy. Results: Three peptides showed specific binding of human IgE, residues 25-38 and 46-59 of chain 1 and residue 15-28 of chain 2. IgE binding was inhibited by Fel d I and the corresponding peptide. Of 61 patients with cat allery tested, 65% showed IgE binding to at least one of the peptides; 46% showed IgE binding to peptide 25-38, 11% to peptide 46-59, and 28% to peptide 15-28. Each peptide was recognized by only one of the 78 patients with negative RAST results. By affinity chromatography with peptide-Sepharose anti-Fel d I antibodies were also confirming the specificity of IgE binding to the peptides. The percentage of IgE antibodies against Fel d I reactive with the peptides varied with the serum and the peptide-Sepharose used and ranged from 2% to 55%. Conclusions: Because the affinity of IgE binding to the peptides was very low and only serum samples with high titers of Fel d I-specific IgE antibodies (RAST 4+/5+) showed significant tools for comparing IgE and IgG responses and for studying the relationship to the T-cell epitopes on this molecule.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Amsterdam								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1976, PROTIDES BIOL FLUIDS, P725; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; APPEL JR, 1990, J IMMUNOL, V144, P976; ATASSI H, 1986, EUR J IMMUNOL, V16, P229, DOI 10.1002/eji.1830160304; ATASSI H, 1985, FEBS LETT, V188, P96, DOI 10.1016/0014-5793(85)80882-6; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BOND JF, 1992, J ALLERGY CLIN IMMUN, V89, P230; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; CHAPMAN M, 1990, Journal of Allergy and Clinical Immunology, V85, P170; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DUFFORT O, 1988, IMMUNOL LETT, V17, P71, DOI 10.1016/0165-2478(88)90104-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; ELSAYED S, 1989, INT ARCH ALLER A IMM, V89, P410, DOI 10.1159/000234984; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; MAGNUSSON CGM, 1986, INT ARCH ALLER A IMM, V80, P329, DOI 10.1159/000234074; MAZUR G, 1988, MOL IMMUNOL, V25, P1005, DOI 10.1016/0161-5890(88)90007-7; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; SAVOCA R, 1991, J IMMUNOL METHODS, V141, P245, DOI 10.1016/0022-1759(91)90151-5; VANMILLIGEN FJ, 1990, INT ARCH ALLER A IMM, V92, P375, DOI 10.1159/000235168; VANMILLIGEN FJ, 1993, INT ARCH ALLER A IMM, V99, P63; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VANTHOF W, IN PRESS ALLERGY; WALSH BJ, 1989, J IMMUNOL METHODS, V121, P275, DOI 10.1016/0022-1759(89)90171-3	33	49	54	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				34	43		10.1016/0091-6749(94)90230-5	http://dx.doi.org/10.1016/0091-6749(94)90230-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	7508463				2022-12-18	WOS:A1994MT78100004
J	JUNIPER, EF; GUYATT, GH; ARCHER, B; FERRIE, PJ				JUNIPER, EF; GUYATT, GH; ARCHER, B; FERRIE, PJ			AQUEOUS BECLOMETHASONE DIPROPIONATE IN THE TREATMENT OF RAGWEED POLLEN INDUCED RHINITIS - FURTHER EXPLORATION OF AS NEEDED USE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HAY FEVER; RAGWEED POLLEN; BECLOMETHASONE DIPROPIONATE; QUALITY OF LIFE	THERAPEUTIC EFFICACY; PHARMACODYNAMIC PROPERTIES; NASAL SPRAY; RHINOCONJUNCTIVITIS; BUDESONIDE; ASTHMA	Background: The objective of this study was to compare regular and ''as required'' (prn) use of aqueous beclomethasone dipropionate nasal spray (Beconase AQ nasal spray) in the treatment of ragweed pollen-induced rhinitis and to examine possible predictors of unsatisfactory symptom control in the group of patients who used it on a prn basis. Methods: Sixty adults with ragweed pollen-induced rhinitis, who had participated in previous hay fever studies or who responded to media notices, were enrolled in the study. The study design was a randomized, unblinded, parallel group comparison between regular use (400 mug daily) and prn use of Beconase AQ spray during the 6 weeks of the ragweed pollen season. Patients recorded daily symptoms and medication use in diaries. The Rhinoconjunctivitis Quality of Life Questionnaire was administered, and patient satisfaction with symptom control was assessed at clinic visits. Results: Symptoms and quality of life tended to be better in the regular group, but differences were not statistically significant. Twenty-seven percent of patients in the prn group reported unsatisfactory control of symptoms; they experienced significantly worse symptoms and quality of life than the remainder of the prn group and used significantly more Beconase. No obvious predictors of unsatisfactory control were identified. Patients who achieved satisfactory control in the prn group had symptom and quality of life scores that were very similar to those of the regular group. Conclusions: Most patients can use Beconase AQ as needed successfully for the treatment of hay fever, but there may be an apparently unpredictable minority who do not achieve satisfactory symptom control or quality of life with this approach and who require regular treatment.	MCMASTER UNIV,MED CTR,DEPT RADIOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University								BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; JUNIPER EF, 1992, CAN MED ASSOC J, V147, P887; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; PAKES GE, 1980, DRUGS, V19, P397, DOI 10.2165/00003495-198019060-00001; VANZIELEGHEM MA, 1987, J ALLERGY CLIN IMMUN, V79, P887, DOI 10.1016/0091-6749(87)90237-5	8	49	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				66	72		10.1016/0091-6749(93)90039-I	http://dx.doi.org/10.1016/0091-6749(93)90039-I			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335858				2022-12-18	WOS:A1993LQ35300011
J	JUNTUNENBACKMAN, K; JARVINEN, P; SORVA, R				JUNTUNENBACKMAN, K; JARVINEN, P; SORVA, R			SERUM EOSINOPHIL CATIONIC PROTEIN DURING TREATMENT OF ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; CHILDREN; GLUCOCORTICOIDS; BUDESONIDE; SODIUM CROMOGLYCATE; EOSINOPHIL CATIONIC PROTEIN	ATOPIC-DERMATITIS; RESPIRATORY-TRACT; GRANULE PROTEINS; ALLERGEN; ACTIVATION; BLOOD; ECP; HYPERRESPONSIVENESS; INFLAMMATION; SECRETION	Background: Serum eosinophil cationic protein (ECP) is suggested to reflect the degree of bronchial inflammation and hyperreactivity in patients with asthma. We measured serum ECP levels before and 1 and 5 months after treatment with inhaled budesonide (n = 10) or sodium cromoglycate (SCG) (n = 7) in children with asthma. Methods: The daily dose of budesonide was 800 mug/m2 during the first month and 400 mug/m2 during the next 4 months. ECP levels were determined by radioimmunoassay. Results: ECP decreased during the 5 months of treatment (p = 0. 020 for treatment groups combined; p = 0.049 for the budesonide group; p = NS for the SCG group). The higher the serum ECP level at entry, the more it decreased during treatment, both in the budesonide group (r = -0.697, p < 0.05) and in the SCG group (r = -0.893, p < 0.05). No correlation was found between the ECP level and the ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1%) or between changes in these. However, basal pulmonary function was reduced in 8 of 16 subjects only, and FEV1% did not change significantly in either group. Thus the absence of a correlation is understandable. Conclusions: The clinical value of the sensitive decrease in serum ECP remains to be established.	HELSINKI UNIV,CENT HOSP,DEPT ALLERG DIS,MEILAHDENTIE 2,SF-00250 HELSINKI,FINLAND; UNITED LABS LTD,HELSINKI,FINLAND	University of Helsinki								ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FELTELIUS N, 1987, ANN RHEUM DIS, V46, P403, DOI 10.1136/ard.46.5.403; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; HALLGREN R, 1985, CLIN EXP IMMUNOL, V59, P539; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; JUHLIN L, 1991, ACTA DERM-VENEREOL, V71, P495; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; LAVO B, 1989, AM J MED, V87, P655, DOI 10.1016/0002-9343(89)90726-2; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; VENGE P, 1989, European Respiratory Journal, V2, p430S; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N	26	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				34	38		10.1016/0091-6749(93)90034-D	http://dx.doi.org/10.1016/0091-6749(93)90034-D			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335852				2022-12-18	WOS:A1993LQ35300006
J	KURUP, VP; KELLY, KJ; TURJANMAA, K; ALENIUS, H; REUNALA, T; PALOSUO, T; FINK, JN				KURUP, VP; KELLY, KJ; TURJANMAA, K; ALENIUS, H; REUNALA, T; PALOSUO, T; FINK, JN			IMMUNOGLOBULIN-E REACTIVITY TO LATEX ANTIGENS IN THE SERA OF PATIENTS FROM FINLAND AND THE UNITED-STATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; IGE ANTIBODY; ELISA; ANAPHYLAXIS; SKIN PRICK TEST; LATEX ALLERGY	CONTACT URTICARIA; GLOVE CONTACT; RUBBER; ANAPHYLAXIS; ALLERGY	Background: Patients with later sensitivity and later antigens from the United States and Finland, two countries where allergic reactions to latex have been widely reported, were evaluated to determine the spectrum of immune responses. Methods: Sera from 27 patients from Finland and 18 from the United States with latex allergy and control sera from nonsensitive individuals were studied for latex-specific IgE antibodies. Four antigen preparations were used. two extracted from gloves and one each extracted from rubber tree sap from Malaysia and India. All 45 patients had skin prick test results that were positive to latex antigens, and all sera were evaluated by enzyme-linked immunosorbent assay (ELISA) with the various antigens. Results: There were considerable differences in the reactivity of patient sera with the different antigens. Only 50% of the sera from patients with latex allergy from Finland demonstrated significant levels of IgE to later as determined by enzyme-linked immunosorbent assay. These patients showed more reactivity with rubber tree sap antigens than with glove antigens. However, 72% of the patients from the United States demonstrated antibodies to latex, and no marked differences were noted between the antigen extracts. Conclusions: The results indicate that reagents such as rubber tree sap, which contain multiple clinically significant antigenic components, should be included in evaluation of latex allergy and that differences in patient populations may result in serologic variances.	MED COLL WISCONSIN,ZABLOCKI VET ADM MED CTR,DEPT PEDIAT,ALLERGY IMMUNOL RES SECT,MILWAUKEE,WI 53295; TAMPERE UNIV HOSP,DEPT DERMATOL,TAMPERE,FINLAND; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND; UNIV HOSP HELSINKI,DEPT DERMATOL,HELSINKI,FINLAND	Medical College of Wisconsin; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	KURUP, VP (corresponding author), MED COLL WISCONSIN,ZABLOCKI VET ADM MED CTR RES,DEPT MED,ALLERGY IMMUNOL SECT,151-I,MILWAUKEE,WI 53295, USA.			Kelly, Kevin/0000-0002-2954-6117				ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; AXELSSON IGK, 1988, ACTA PAEDIATR SCAND, V77, P314, DOI 10.1111/j.1651-2227.1988.tb10652.x; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; BELSITO DV, 1990, DERMATOL CLIN, V8, P61, DOI 10.1016/S0733-8635(18)30523-0; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; KURUP VP, 1986, ZBL BAKT-INT J MED M, V261, P509; KURUP VP, IN PRESS ALLERGY P; MOHAMMAD K, 1989, J IMMUNOL METHODS, V117, P141, DOI 10.1016/0022-1759(89)90129-4; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P59; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; ZACHARISEN MC, 1992, J ALLERGY CLIN IMMUN, V89, P225	18	49	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1128	1134		10.1016/0091-6749(93)90314-6	http://dx.doi.org/10.1016/0091-6749(93)90314-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509575	Bronze			2022-12-18	WOS:A1993LG74000003
J	BOULET, LP; TURCOTTE, H; TENNINA, S				BOULET, LP; TURCOTTE, H; TENNINA, S			COMPARATIVE EFFICACY OF SALBUTAMOL, IPRATROPIUM, AND CROMOGLYCATE IN THE PREVENTION OF BRONCHOSPASM INDUCED BY EXERCISE AND HYPEROSMOLAR CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOULET, LP (corresponding author), HOP LAVAL,UNITE RECH PNEUMOL,CHEMIN ST FOY,ST FOY G1V 4G5,QUEBEC,CANADA.							ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; BANKS JR, 1986, J ALLERGY CLIN IMMUN, V78, P51, DOI 10.1016/0091-6749(86)90114-4; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BELCHER NG, 1986, J ALLERGY CLIN IMMUN, V77, P163; BONER AL, 1985, EUR J RESPIR DIS, V66, P21; BORUT TC, 1977, J ALLERGY CLIN IMMUN, V60, P127, DOI 10.1016/0091-6749(77)90038-0; BOULET LP, 1987, THORAX, V42, P953, DOI 10.1136/thx.42.12.953; BUNGAARD A, 1986, EUR J RESPIR DIS, V68, P1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1978, CLIN ALLERGY, V8, P361, DOI 10.1111/j.1365-2222.1978.tb00471.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CROPP GJA, 1979, J ALLERGY CLIN IMMUN, V64, P627, DOI 10.1016/0091-6749(79)90026-5; DORWARD AJ, 1982, CLIN ALLERGY, V12, P355, DOI 10.1111/j.1365-2222.1982.tb02539.x; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ELLIS EF, 1984, J ALLERGY CLIN IMMUN, V73, P690, DOI 10.1016/0091-6749(84)90307-5; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; GODDEN D, 1983, THORAX, V38, P226; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; HIGENBOTTAM T, 1983, EUR J RESPIR DIS 2 S, V128, P421; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JONES NL, 1982, CLIN EXERCISE TESTIN, P83; KIVITY S, 1986, ANN ALLERGY, V57, P355; KONIG P, 1984, J ALLERGY CLIN IMMUN, V73, P686, DOI 10.1016/0091-6749(84)90306-3; MORRIS HG, 1986, AM J MED, V81, P6; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SIMONE P, 1986, RESPIRATION, V50, P192, DOI 10.1159/000195125; SIMONE P, 1986, RESPIRATION, V50, P209, DOI 10.1159/000195129; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SPADA E L, 1984, Respiration, V46, P56; STORMS WW, 1986, AM J MED, V1, P61; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; TULLETT WM, 1982, THORAX, V37, P737, DOI 10.1136/thx.37.10.737; WOLKOVE N, 1981, ANN ALLERGY, V47, P311; 1987, AM REV RESPIR DIS, V136, P225	41	49	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					882	887		10.1016/0091-6749(89)90101-2	http://dx.doi.org/10.1016/0091-6749(89)90101-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2523921				2022-12-18	WOS:A1989U716100007
J	LEUNG, DYM; AMBROSINO, DM; ARBEIT, RD; NEWTON, JL; GEHA, RS				LEUNG, DYM; AMBROSINO, DM; ARBEIT, RD; NEWTON, JL; GEHA, RS			IMPAIRED ANTIBODY-RESPONSES IN THE HYPERIMMUNOGLOBULIN-E SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; VET ADM MED CTR JAMAICA PLAIN,MED SERV,BOSTON,MA 02130	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	LEUNG, DYM (corresponding author), CHILDRENS HOSP MED CTR,DIV ALLERGY & IMMUNOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022058, R01AI020373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-37260] Funding Source: Medline; NIAID NIH HHS [AI-20373, AI-22058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909; AMBROSINO DM, 1983, INFECT IMMUN, V29, P709; ARCHIBALD AR, 1965, BIOCH J, V65, pC19; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P148; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; DONABEDIAN H, 1982, J CLIN INVEST, V69, P1155, DOI 10.1172/JCI110551; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; HILL HR, 1974, LANCET, V2, P617; LANE HC, 1981, J EXP MED, V154, P1043, DOI 10.1084/jem.154.4.1043; LEUNG DYM, 1986, J CLIN IMMUNOL, V6, P273, DOI 10.1007/BF00917327; NAHM MH, 1986, J IMMUNOL, V137, P3484; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; RIESEN WF, 1976, SCAND J IMMUNOL, V5, P383, DOI 10.1111/j.1365-3083.1976.tb00292.x; SCHMITT C, 1983, J CLIN IMMUNOL, V3, P178, DOI 10.1007/BF00915490; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SCHUR PH, 1979, PEDIATR RES, V13, P181, DOI 10.1203/00006450-197903000-00010; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SMITH TF, 1984, J PEDIATR-US, V105, P896, DOI 10.1016/S0022-3476(84)80073-6; SODERBERGWARNER M, 1983, PEDIATR RES, V17, P820, DOI 10.1203/00006450-198310000-00011; STIEHM ER, 1966, PEDIATRICS, V37, P715; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633; ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7	27	49	49	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1082	1087		10.1016/0091-6749(88)90873-1	http://dx.doi.org/10.1016/0091-6749(88)90873-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379221	Bronze			2022-12-18	WOS:A1988P002300003
J	SHER, TH; SCHWARTZ, HJ				SHER, TH; SCHWARTZ, HJ			ALLERGIC ASPERGILLUS SINUSITIS WITH CONCURRENT ALLERGIC BRONCHOPULMONARY ASPERGILLUS - REPORT OF A CASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED & PEDIAT,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106	Case Western Reserve University; University Hospitals of Cleveland								BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; RICKETTI AJ, 1983, ARCH INTERN MED, V143, P1553, DOI 10.1001/archinte.143.8.1553; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLAVIN RG, 1983, ALLERGY PRINCIPLES P, P1067; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	16	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				844	846		10.1016/0091-6749(88)90940-2	http://dx.doi.org/10.1016/0091-6749(88)90940-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3372907				2022-12-18	WOS:A1988N703600012
J	STANKUS, RP; ONEIL, CE				STANKUS, RP; ONEIL, CE			ANTIGENIC ALLERGENIC CHARACTERIZATION OF AMERICAN AND GERMAN-COCKROACH EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, SCH MED, DEPT MED, ALLERGY & CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA	Tulane University								BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SANDERS G, 1985, J ALLERGY CLIN IMMUN, V75, P146, DOI 10.1016/0091-6749(85)90302-1; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4	8	49	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					548	557		10.1016/0091-6749(88)90195-9	http://dx.doi.org/10.1016/0091-6749(88)90195-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100011
J	SEARS, MR				SEARS, MR			ASTHMA MORBIDITY AND MORTALITY - NEW-ZEALAND	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH & GEN PRACTICE,AUCKLAND,NEW ZEALAND; ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,HAMILTON L8S 4L8,ONTARIO,CANADA	University of Auckland; McGill University; McMaster University; McMaster University	SEARS, MR (corresponding author), UNIV OTAGO,SCH MED,DEPT MED,POB 913,DUNEDIN,NEW ZEALAND.							[Anonymous], 1984, Thorax, V39, P505; ANYON CP, 1974, NEW ZEAL MED J, V79, P822; ASHER MI, 1986, AM REV RESPIR DIS, V133, pA58; BLANC ADJ, 1966, SO YOU HAVE ASTHMA; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; CAMPBELL AH, 1976, MED J AUSTRALIA, V1, P386, DOI 10.5694/j.1326-5377.1976.tb140697.x; GANDEVIA B, 1973, MED J AUSTRALIA, V1, P273, DOI 10.5694/j.1326-5377.1973.tb119742.x; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JONES DT, IN PRESS BR J DIS CH; MCQUEEN F, 1979, NEW ZEAL MED J, V89, P335; MILNE G A, 1969, New Zealand Medical Journal, V70, P27; MITCHELL EA, 1984, NEW ZEAL MED J, V97, P67; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1982, NEW ZEAL MED J, V95, P533; SLY RM, 1984, ANN ALLERGY, V53, P20; STANHOPE JM, 1979, NEW ZEAL MED J, V90, P279; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; THORNLEY PE, 1983, BRIT MED J, V286, P890; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILSON JD, 1981, LANCET, V1, P1235; 1977, MANUAL INT STATISTIC, V1	27	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			383	388		10.1016/0091-6749(87)90055-8	http://dx.doi.org/10.1016/0091-6749(87)90055-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3305668				2022-12-18	WOS:A1987K103700007
J	FORD, SA; BALDO, BA				FORD, SA; BALDO, BA			IDENTIFICATION OF BERMUDA GRASS (CYNODON-DACTYLON) POLLEN ALLERGENS BY ELECTROBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL N SHORE HOSP,KOLLING INST MED RES,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney								AAS K, 1975, INT ARCH ALLER A IMM, V49, P44, DOI 10.1159/000231375; BALDO BA, 1983, ALLERGY, V38, P535, DOI 10.1111/j.1398-9995.1983.tb04137.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WP, 1983, ANAL BIOCHEM, V129, P31, DOI 10.1016/0003-2697(83)90047-7; FORD SA, 1986, INT ARCH ALLER A IMM, V79, P120, DOI 10.1159/000233957; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FORD SA, 1986, INT ARCH ALLER A IMM, V81, P193, DOI 10.1159/000234134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MEYERS RL, 1971, J ALLERGY, V47, P100; MEYERS RL, 1972, J ALLERGY CLIN IMMUN, V49, P114; NEUHOFF V, 1984, ELECTROPHORESIS 84, P317; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; ORREN A, 1977, S AFR MED J, V51, P586; SCHUMACHER M J, 1982, Journal of Allergy and Clinical Immunology, V69, P145; SMART IJ, 1980, INT ARCH ALLER A IMM, V62, P179, DOI 10.1159/000232510; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOVEY ER, 1984, INT ARCH ALLER A IMM, V75, P322, DOI 10.1159/000233641; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRINCA J C, 1962, Med J Aust, V49(1), P969	20	49	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					711	720		10.1016/0091-6749(87)90201-6	http://dx.doi.org/10.1016/0091-6749(87)90201-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571765				2022-12-18	WOS:A1987H434900004
J	CARRINGTON, DM; EARL, HS; SULLIVAN, TJ				CARRINGTON, DM; EARL, HS; SULLIVAN, TJ			STUDIES OF HUMAN IGE TO A SULFONAMIDE DETERMINANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas								ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BAER RL, 1971, IMMUNOLOGICAL DISEAS, P973; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; DEHAAN P, 1979, ALLERGY, V34, P111; GROSE WE, 1979, ANTIMICROB AGENTS CH, V15, P447, DOI 10.1128/AAC.15.3.447; HJORTH N, 1968, TXB DERMATOLOGY, V1, P255; KOHN J, 1981, ANAL BIOCHEM, V115, P375, DOI 10.1016/0003-2697(81)90020-8; KRAFT D, 1981, CLIN ALLERGY, V11, P579, DOI 10.1111/j.1365-2222.1981.tb02178.x; LAWSON DH, 1983, INHIBITION FOLATE ME, P207; MAYER RL, 1964, PROG ALLERGY, V4, P79; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; RATNER B, 1943, ALLERGY ANAPHYLAXIS, P579; SAGONA MA, 1985, J ALLERGY CLIN IMMUN, V75, P659, DOI 10.1016/0091-6749(85)90090-9; SARKANY I, 1967, LANCET, V1, P743; SHERMAN WB, 1947, AM J MED, V2, P588, DOI 10.1016/0002-9343(47)90049-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1984, J ALLERGY CLIN IMMUN, V74, P594, DOI 10.1016/0091-6749(84)90112-X; SULZBERGER MB, 1947, J ALLERGY, V18, P92, DOI 10.1016/0021-8707(47)90120-2; UEDA M, 1972, CHEM PHARM BULL, V20, P2047; WARRINGTON RJ, 1983, CLIN ALLERGY, V13, P235, DOI 10.1111/j.1365-2222.1983.tb02593.x; WORMSER GP, 1979, ANN INTERN MED, V91, P420, DOI 10.7326/0003-4819-91-3-420; YAMAMOTO I, 1977, INT ARCH ALLER A IMM, V54, P538, DOI 10.1159/000231874	25	49	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					442	447		10.1016/0091-6749(87)90361-7	http://dx.doi.org/10.1016/0091-6749(87)90361-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	2434548				2022-12-18	WOS:A1987G479500006
J	GRASSI, J; DIDIERLAURENT, A; STADLER, BM				GRASSI, J; DIDIERLAURENT, A; STADLER, BM			QUANTITATIVE-DETERMINATION OF TOTAL AND SPECIFIC HUMAN IGE WITH THE USE OF MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GRASSI, J (corresponding author), CENS,DEPT BIOL,ETUDES RADIOIMMUNOL LAB,PHARMACOL & IMMUNOL SECT,F-91191 GIF SUR YVETTE,FRANCE.							ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; ALI M, 1980, CLIN ALLERGY, V10, P203, DOI 10.1111/j.1365-2222.1980.tb02098.x; BENNICH H, 1969, J IMMUNOL, V102, P826; BENNICH HH, 1968, B WORLD HEALTH ORGAN, V38, P151; BRIGHTON WD, 1974, DEV BIOL STAND, V29, P166; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHANDLER HM, 1983, INT ARCH ALLER A IMM, V72, P267, DOI 10.1159/000234879; EKINS R, 1984, MONOCLONAL ANTIBODIE, P149; EKINS RP, 1977, S AIEA, P241; EVANS R, 1982, J ALLERGY CLIN IMMUN, V69, P245, DOI 10.1016/0091-6749(82)90106-3; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GUERIN B, 1983, THESIS U P M CURIE S; Guesdon J L, 1981, Methods Enzymol, V73, P471; Hoffman D R, 1981, Methods Enzymol, V73, P656; HOFFMAN DR, 1973, J ALLERGY CLIN IMMUN, V51, P303, DOI 10.1016/0091-6749(73)90132-2; HOFFMAN DR, 1980, ANN ALLERGY, V45, P343; HONG CS, UNPUB J IMMUNOL METH; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IMAGAWA M, 1981, CLIN CHIM ACTA, V117, P199, DOI 10.1016/0009-8981(81)90039-5; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KNUTTIMULLER JM, UNPUB ALLERGY; LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, P85; MAGNUSSON CGM, 1982, J ALLERGY CLIN IMMUN, V70, P326, DOI 10.1016/0091-6749(82)90021-5; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; SANTRACH PJ, 1981, J ALLERGY CLIN IMMUN, V67, P97, DOI 10.1016/0091-6749(81)90003-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SPIEGELBERG HL, 1983, J IMMUNOL, V131, P3001; STADLER BM, 1982, J IMMUNOL, V128, P1620; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V62, P83, DOI 10.1016/0091-6749(78)90083-0; ZEISS CR, 1973, J IMMUNOL, V110, P414	40	49	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					808	822		10.1016/0091-6749(86)90378-7	http://dx.doi.org/10.1016/0091-6749(86)90378-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3519735				2022-12-18	WOS:A1986C869400005
J	IIKURA, Y; INUI, H; NAGAKURA, T; LEE, TH				IIKURA, Y; INUI, H; NAGAKURA, T; LEE, TH			FACTORS PREDISPOSING TO EXERCISE-INDUCED LATE ASTHMATIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; JIKEI UNIV SCH MED,DEPT PEDIAT,TOKYO 105,JAPAN	Harvard University; Harvard Medical School; Jikei University	IIKURA, Y (corresponding author), NATL CHILDRENS HOSP,DEPT ALLERGY,3-35-31 TAISHIDO,SETAGAYA KU,TOKYO 154,JAPAN.		Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; BALFOURLYNN L, 1981, ARCH DIS CHILD, V56, P450, DOI 10.1136/adc.56.6.450; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P107, DOI 10.1016/0091-6749(83)90200-2; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT, 1983, LANCET, V2, P253; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HARGREAVE FE, ASTHMA PHYSL IMMUNOP; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HETZEL MR, 1981, THORAX, V36, P481, DOI 10.1136/thx.36.7.481; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LEE TH, 1982, CLIN ALLERGY, V12, P39; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	26	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					285	289		10.1016/0091-6749(85)90059-4	http://dx.doi.org/10.1016/0091-6749(85)90059-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968338				2022-12-18	WOS:A1985ABZ0500009
J	LONG, WF; TAYLOR, RJ; WAGNER, CJ; LEAVENGOOD, DC; NELSON, HS				LONG, WF; TAYLOR, RJ; WAGNER, CJ; LEAVENGOOD, DC; NELSON, HS			SKIN-TEST SUPPRESSION BY ANTIHISTAMINES AND THE DEVELOPMENT OF SUBSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									ARNOLD SB, 1979, ANN INTERN MED, V91, P345, DOI 10.7326/0003-4819-91-3-345; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; GLAUBIGER GA, 1977, CIRCULATION, V56, P158; GOODMAN LS, 1980, PHARMACOL BASIS THER, P622; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; PECK AW, 1975, EUR J CLIN PHARMACOL, V8, P455, DOI 10.1007/BF00562321; TIPTON WR, 1981, LUNG, V159, P199, DOI 10.1007/BF02713916; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3	10	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					113	117		10.1016/0091-6749(85)90813-9	http://dx.doi.org/10.1016/0091-6749(85)90813-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008809				2022-12-18	WOS:A1985AMV8400016
J	ZEIGER, RS				ZEIGER, RS			ATOPY IN INFANCY AND EARLY-CHILDHOOD - NATURAL-HISTORY AND ROLE OF SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											ZEIGER, RS (corresponding author), KAISER PERMANENTE MED CTR,DEPT ALLERGY,7060 CLAIREMONT MESA BLVD,SAN DIEGO,CA 92111, USA.			Zeiger, Robert/0000-0001-5788-5063				AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ASCOLI A, 1902, Z PHYSL CHEM, V36, P498; Balyeat RM, 1928, AM J MED SCI, V176, P332, DOI 10.1097/00000441-192809000-00003; BERGER M, 1980, J IMMUNOL, V125, P2437; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BJORKSTEN F, 1981, ACTA MED SCAND, V209, P299; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CAREY TN, 1933, J ALLERGY, V5, P488; CHIPPS BE, 1978, ANN ALLERGY, V41, P211; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DELESPESSE G, 1983, MONOGR ALLERGY, V18, P83; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HANNAWAY PJ, 1970, ANN ALLERGY, V28, P413; IMBER WE, 1977, J ALLERGY CLIN IMMUN, V60, P47, DOI 10.1016/0091-6749(77)90082-3; INDRAJANA T, 1971, ANN ALLERGY, V29, P639; JUTO P, 1982, CLIN ALLERGY, V12, P409, DOI 10.1111/j.1365-2222.1982.tb02546.x; KAUFMAN H S, 1971, Clinical Allergy, V1, P363, DOI 10.1111/j.1365-2222.1971.tb00787.x; KJELLMAN NIM, 1981, LANCET, V1, P993; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P495; KORGSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KROUSE HA, 1980, IMMUNOL ALLERGY PRAC, V2, P13; LANGELAND T, 1983, CLIN ALLERGY, V13, P371, DOI 10.1111/j.1365-2222.1983.tb02611.x; LEVIN S, 1971, PEDIATR RES, V5, P87, DOI 10.1203/00006450-197102000-00028; MATHESON A, 1952, PEDIATRICS, V10, P181; MATTHEW DJ, 1977, LANCET, V1, P321; MELLON M, 1985, J ALLERGY CLIN IMMUN, V75, P178, DOI 10.1016/0091-6749(85)90431-2; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; NAESLUND J, 1946, ACTA MED SCAND, V170, P390; NELSON H, 1983, ANN ALLERGY, V4, P411; OCONNOR RD, 1984, NEW ENGL REGIONAL AL, V5, P149; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P533, DOI 10.1016/0091-6749(82)90179-8; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; RADERMECKER M, 1974, INT ARCH ALLER A IMM, V47, P285, DOI 10.1159/000231221; RATNER B, 1952, AMA AM J DIS CHILD, V83, P309, DOI 10.1001/archpedi.1952.02040070055006; Ratner B, 1927, J IMMUNOL, V14, P303; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; Schatz M, 1983, ALLERGY PRINCIPLES P, P935; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; SINGER AD, 1974, J ALLERGY CLIN IMMUN, V53, P94; SMITH K, 1961, OBSTET GYNECOL, V18, P673; STEVENSON DD, 1971, J ALLERGY CLIN IMMUN, V48, P61, DOI 10.1016/0091-6749(71)90088-1; Sulzberger MB, 1940, ARCH DERMATOL SYPH, V41, P1029, DOI 10.1001/archderm.1940.01490120031004; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANASPEREN PP, 1984, ACTA PAEDIATR SCAND, V73, P80; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WOOLCOCK AJ, 1976, AUST NZ J MED, V6, P158, DOI 10.1111/j.1445-5994.1976.tb03313.x; YATES VM, 1983, BRIT J DERMATOL, V108, P639, DOI 10.1111/j.1365-2133.1983.tb01075.x; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6	63	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					633	639		10.1016/0091-6749(85)90086-7	http://dx.doi.org/10.1016/0091-6749(85)90086-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	3159782				2022-12-18	WOS:A1985ALA8400001
J	MIDDLETON, E				MIDDLETON, E			AIRWAY SMOOTH-MUSCLE, ASTHMA, AND CALCIUM-IONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	MIDDLETON, E (corresponding author), SUNY BUFFALO,DEPT MED,BUFFALO,NY 14260, USA.							ANDERSON SD, 1983, ALLERGY, V38, P289, DOI 10.1111/j.1398-9995.1983.tb04122.x; ANTMAN E, 1980, NEW ENGL J MED, V302, P1269, DOI 10.1056/NEJM198006053022301; ARRUZAZABALA MD, 1982, AGENTS ACTIONS, V12, P596, DOI 10.1007/BF01965066; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BIERMAN CW, J ALLERGY CLIN IMMUN; BOSTROM SL, 1981, NATURE, V292, P777, DOI 10.1038/292777a0; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRUGMAN TM, 1983, AM REV RESPIR DIS, V127, P14, DOI 10.1164/arrd.1983.127.1.14; CASTEELS R, 1980, CHEST, V78, P150, DOI 10.1378/chest.78.1_Supplement.150; CERRINA J, 1982, AM REV RESPIR DIS, V125, P64; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; CERRINA J, 1982, AM REV RESPIR DIS, V125, P226; Cheung W.Y., 1980, CALCIUM CELL FUNCTIO, V1; CHURCH J, 1980, CAN J PHYSIOL PHARM, V58, P254, DOI 10.1139/y80-044; COBURN RF, 1977, FED PROC, V36, P2692; CONTI MA, 1980, FED PROC, V39, P1569; CORRIS PA, 1983, AM REV RESPIR DIS, V128, P991; CREESE BR, 1983, PROSTA LEUKOTR MED, V11, P161, DOI 10.1016/0262-1746(83)90016-1; CUMELLA J, 1983, J ALLERGY CLIN IMMUN, V71, P94, DOI 10.1016/0091-6749(83)90145-8; DARNELL M, 1982, AM REV RESPIR DIS, V125, P225; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DEVYNCK MA, 1981, HYPERTENSION, V3, P397, DOI 10.1161/01.HYP.3.4.397; DHILLON DS, 1981, BRIT J PHARMACOL, V74, P180; DOUGLAS WW, 1978, CIBA F S, V54, P61; DOWNS DD, 1981, BR J PHARM, V73, P252; EBERLIN LB, 1982, AM REV RESPIR DIS, V125, P225; EMANUEL MB, 1979, BRIT J CLIN PHARMACO, V7, P189, DOI 10.1111/j.1365-2125.1979.tb00920.x; ENNIS M, 1983, AGENTS ACTIONS, V13, P144, DOI 10.1007/BF01967319; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; FANTA CH, 1983, BR J PHARM, V78, P687; FARLEY JM, 1977, J PHARMACOL EXP THER, V201, P199; FARLEY JM, 1978, J PHARMACOL EXP THER, V207, P340; FINDLAY SR, 1981, J IMMUNOL, V126, P1728; FLECKENSTEIN A, 1977, ANNU REV PHARMACOL, V17, P149, DOI 10.1146/annurev.pa.17.040177.001053; GODFRAIND T, 1981, FED PROC, V40, P2866; GOODMAN FR, 1981, NEW PERSPECTIVES CAL, P217; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HARTLEY JPR, 1979, THORAX, V34, P571, DOI 10.1136/thx.34.5.571; HARTSHORNE DJ, 1981, ANNU REV PHYSIOL, V43, P519, DOI 10.1146/annurev.ph.43.030181.002511; HARVEY JE, 1981, CLIN SCI, V60, P579, DOI 10.1042/cs0600579; HENDERSON AF, 1983, THORAX, V38, P512, DOI 10.1136/thx.38.7.512; HENDERSON AF, 1983, AM REV RESPIR DIS, V127, P549, DOI 10.1164/arrd.1983.127.5.549; HIDAKA H, 1981, MOL PHARMACOL, V20, P571; HIMORI N, 1980, BRIT J PHARMACOL, V68, P595, DOI 10.1111/j.1476-5381.1980.tb10848.x; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1980, CLIN SCI, V59, P155, DOI 10.1042/cs0590155; HOLGATE ST, J ALLERGY CLIN IMMUN; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HURWITZ L, 1971, ANNU REV PHARMACOLOG, V11, P303, DOI 10.1146/annurev.pa.11.040171.001511; ISHIZAKA T, 1983, J IMMUNOL, V130, P2357; JENSEN C, 1983, ALLERGY, V38, P233, DOI 10.1111/j.1398-9995.1983.tb01616.x; JOHNSON HG, 1983, ALLERGY PRINCIPLES P, P613; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KUMAR MA, 1978, J PHARMACOL EXP THER, V206, P528; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; LEE TH, 1983, LANCET, V1, P520; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LUNARDI LO, 1982, BRAZ J MED BIOL RES, V15, P269; MALO PE, 1982, J PHARMACOL EXP THER, V221, P410; MANN JS, 1983, CLIN SCI, V65, P22; MARONE G, 1983, MONOGR ALLERGY, V18, P290; MARTORANO MG, 1981, BR J PHARM, V72, P175; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; MEARES RA, 1971, MED J AUSTRALIA, V2, P25, DOI 10.5694/j.1326-5377.1971.tb50396.x; MEHTA JL, 1982, HOSP FORMUL, V17, P251; MIADONNA A, 1983, ANN ALLERGY, V51, P201; MIDDLETON E, 1981, BIOCHEM PHARMACOL, V30, P2867, DOI 10.1016/0006-2952(81)90428-7; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; MIDDLETON E, 1963, NATURE, V198, P758, DOI 10.1038/198758a0; MUELLER E, 1979, NATURE, V281, P682, DOI 10.1038/281682a0; MUELLER HS, 1981, AM J MED, V71, P645, DOI 10.1016/0002-9343(81)90229-1; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NASTUK WL, 1972, CELLULAR BIOL TOXICI, P10; NORN S, 1983, EUR J RESPIR DIS, V64, P394; PATAKAS D, 1983, J ALLERGY CLIN IMMUN, V72, P269, DOI 10.1016/0091-6749(83)90031-3; PATEL KR, 1981, CLIN ALLERGY, V11, P429, DOI 10.1111/j.1365-2222.1981.tb01615.x; PATEL KR, 1982, CLIN ALLERGY, V12, P15; PATEL KR, 1983, CLIN ALLERGY, V13, P119, DOI 10.1111/j.1365-2222.1983.tb02578.x; PATTERSON JW, 1982, PERSPECTIVES ASTHMA, V1, P20; POSTNOV YV, 1980, PFLUG ARCH EUR J PHY, V385, P85, DOI 10.1007/BF00583919; PUTNEY JW, 1981, NEW PERSPECTIVES CAL, P169; ROLLA G, 1982, LANCET, V1, P1305; RUSSI EW, 1983, AM REV RESPIR DIS, V127, P675; SCHEID CR, 1979, NATURE, V277, P32, DOI 10.1038/277032a0; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SIEGEL H, 1982, THESIS STATE U NEW Y; SIROIS P, 1981, PROSTAG LEUKOTR ESS, V7, P327, DOI 10.1016/0161-4630(81)90137-3; SO SY, 1982, CLIN ALLERGY, V12, P595, DOI 10.1111/j.1365-2222.1982.tb02558.x; STENSON WF, 1983, ALLERGY PRINCIPLES P, P653; STEWART RM, 1981, RESP PHYSIOL, V45, P333, DOI 10.1016/0034-5687(81)90016-5; SUZUKI T, 1982, EUR J PHARMACOL, V85, P155, DOI 10.1016/0014-2999(82)90460-5; TAKENAWA T, 1982, CELL CALCIUM, V3, P359, DOI 10.1016/0143-4160(82)90023-9; TANIZAKI Y, 1983, INT ARCH ALLER A IMM, V72, P102, DOI 10.1159/000234850; TRIGGLE DJ, 1983, ALLERGY, V38, P1, DOI 10.1111/j.1398-9995.1983.tb00849.x; TRIGGLE DJ, 1980, CHEST, V78, P174, DOI 10.1378/chest.78.1_Supplement.174; TRIGGLE DJ, 1980, TRENDS PHARMACOL SCI, V1, P395, DOI 10.1016/0165-6147(80)90061-9; TRIGGLE DJ, 1981, NEW PERSPECTIVES CAL, P1; VANBREEMEN C, 1979, PHARMACOL REV, V30, P167; WALTER JB, 1982, AM REV RESPIR DIS, V125, P226; WEISS EB, 1982, ALLERGY, V37, P513, DOI 10.1111/j.1398-9995.1982.tb02334.x; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WILLIAMS DO, 1981, BRIT MED J, V283, P348, DOI 10.1136/bmj.283.6287.348; YEN SS, 1981, BIOCHEM BIOPH RES CO, V103, P774, DOI 10.1016/0006-291X(81)90516-7	105	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					643	650		10.1016/0091-6749(84)90298-7	http://dx.doi.org/10.1016/0091-6749(84)90298-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6143769				2022-12-18	WOS:A1984SS04600005
J	SCHWARTZ, HJ; CHESTER, EH				SCHWARTZ, HJ; CHESTER, EH			BRONCHOSPASTIC RESPONSES TO AEROSOLIZED METABISULFITE IN ASTHMATIC SUBJECTS - POTENTIAL MECHANISMS AND CLINICAL IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HILLCREST HOSP,PULM LAB,CLEVELAND,OH; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Case Western Reserve University								BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; GUNNISON AF, 1981, FOOD COSMET TOXICOL, V19, P667, DOI 10.1016/0015-6264(81)90519-8; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; LAST JA, 1980, TOXICOL APPL PHARM, V55, P229, DOI 10.1016/0041-008X(80)90084-8; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WERTH GR, 1982, J ALLERGY CLIN IMMUN, V70, P143, DOI 10.1016/0091-6749(82)90243-3	12	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					511	513		10.1016/0091-6749(84)90387-7	http://dx.doi.org/10.1016/0091-6749(84)90387-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491097				2022-12-18	WOS:A1984TN62000009
J	SOGN, DD				SOGN, DD			PENICILLIN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SOGN, DD (corresponding author), NIAID,IMMUNOL ALLERG & IMMUNOL DIS PROGRAM,BLDG 31,ROOM 7A50,BETHESDA,MD 20205, USA.							ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ADKINSON NF, CURRENT THERAPY ALLE; BIERMAN CW, 1972, J AMER MED ASSOC, V220, P1098, DOI 10.1001/jama.220.8.1098; BROWN BC, 1964, JAMA, V189, P87; DEWDNEY JM, 1977, ANTIGENS, V4, P72; FELLNER MJ, 1971, J IMMUNOL, V167, P1440; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GIRARD JP, 1968, INT ARCH ALLER A IMM, V33, P428, DOI 10.1159/000230058; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; GRIECO MH, 1967, ARCH INTERN MED, V119, P141, DOI 10.1001/archinte.119.2.141; HOROWITZ L, 1975, NEW ENGL J MED, V292, P1243; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; JUHLIN L, 1977, INT ARCH ALLER A IMM, V54, P19, DOI 10.1159/000231804; KABINS SA, 1965, JAMA, V193, P163; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; LEVINE BB, 1965, FED PROC, V24, P45; LEVINE BB, 1965, J EXP MED, V121, P873, DOI 10.1084/jem.121.6.873; LEY AB, 1958, SCIENCE, V127, P1118, DOI 10.1126/science.127.3306.1118; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; PARKER CW, 1975, N ENGL J MED, V292, P735; PORTER J, 1977, LANCET, V1, P587; ROTSCHILD PD, 1966, JAMA, V196, P372; SAXON A, 1983, Reviews of Infectious Diseases, V5, pS368; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; STEMBER RH, 1973, J ALLERGY CLIN IMMUN, V5, P100; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; TOMPSETT R, 1967, ARCH INTERN MED, V120, P565, DOI 10.1001/archinte.120.5.565; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P155, DOI 10.1016/0091-6749(80)90063-9; 1966, B J HOPKINS HOSP, V118, P352	34	49	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					589	593		10.1016/0091-6749(84)90111-8	http://dx.doi.org/10.1016/0091-6749(84)90111-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491105	Bronze			2022-12-18	WOS:A1984TQ16300008
J	LARRICK, JW; BUCKLEY, CE; MACHAMER, CE; SCHLAGEL, GD; YOST, JA; BLESSINGMOORE, J; LEVY, D				LARRICK, JW; BUCKLEY, CE; MACHAMER, CE; SCHLAGEL, GD; YOST, JA; BLESSINGMOORE, J; LEVY, D			DOES HYPERIMMUNOGLOBULINEMIA-E PROTECT TROPICAL POPULATIONS FROM ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV, MED CTR, DEPT MICROBIOL IMMUNOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; UNIV COLORADO, SCH MED, DEPT SURG, DENVER, CO 80202 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21218 USA; STANFORD UNIV, MED CTR, SCH MED, CHILDRENS HOSP, DEPT PEDIAT, STANFORD, CA 94305 USA; SUMMER INST LINGUIST, QUITO, ECUADOR; STANFORD UNIV, MED CTR,SCH MED,CHILDRENS HOSP,CANC BIOL RES LAB, STANFORD, CA 94305 USA	Duke University; Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Johns Hopkins University; Children's Hospital Los Angeles; Stanford University; Children's Hospital Los Angeles; Stanford University								[Anonymous], 1979, MED ANTHROPOL, V3, P147; BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; Bennich H, 1971, Adv Immunol, V13, P1; BUCKLEY CE, 1982, J ALLERGY CLIN IMMUN, V69, P25, DOI 10.1016/0091-6749(82)90083-5; CONROY MC, 1977, J IMMUNOL, V118, P1317; DELISI C, 1979, J IMMUNOL, V122, P2286; FERGUSON A, 1979, MAST CELL ITS ROLE H, P159; FERNEX M, 1968, MAST CELL SYSTEM ITS, P60; GERRARD JW, 1977, ANN ALLERGY, V38, P396; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; ISHIZAKA T, 1981, J ALLERGY CLIN IMMUN, V67, P90, DOI 10.1016/0091-6749(81)90002-6; JARRETT EEE, 1972, IMMUNOLOGY, V23, P749; JARRETT EEE, 1971, CLIN EXP IMMUNOL, V9, P585; JARRETT EEE, 1973, VET REC, V93, P480, DOI 10.1136/vr.93.18.480; JOHANSSON SG, 1968, LANCET, V1, P1118; KAPLAN JE, 1980, AM J TROP MED HYG, V29, P1012, DOI 10.4269/ajtmh.1980.29.1012; KAPLAN JE, 1980, AM J TROP MED HYG, V29, P298, DOI 10.4269/ajtmh.1980.29.298; LARRICK JW, 1981, J ALLERGY CLIN IMM S, V67, P61; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; METZGER H, 1978, IMMEDIATE HYPERSENSI, P561; NEEL JV, 1970, SCIENCE, V170, P815, DOI 10.1126/science.170.3960.815; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; REID MJ, 1981, J ALLERGY CLIN IMMUN, V67, P263, DOI 10.1016/0091-6749(81)90020-8; SIMPSON WL, 1963, ANN NY ACAD SCI, V103, P4, DOI 10.1111/j.1749-6632.1963.tb53689.x; STANWORTH D R, 1971, Clinical Allergy, V1, P25, DOI 10.1111/j.1365-2222.1971.tb02445.x; SYDBOM A, 1980, AGENTS ACTIONS, V10, P137, DOI 10.1007/BF02024195	28	49	49	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					184	188		10.1016/0091-6749(83)90097-0	http://dx.doi.org/10.1016/0091-6749(83)90097-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6822694				2022-12-18	WOS:A1983QC18800002
J	VANDENBERG, W; LEFERINK, JG; FOKKENS, JK; KREUKNIET, J; MAES, RAA; BRUYNZEEL, PLB				VANDENBERG, W; LEFERINK, JG; FOKKENS, JK; KREUKNIET, J; MAES, RAA; BRUYNZEEL, PLB			CLINICAL IMPLICATIONS OF DRUG-INDUCED DESENSITIZATION OF THE BETA-RECEPTOR AFTER CONTINUOUS ORAL USE OF TERBUTALINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP UTRECHT,DEPT PULM DIS,3511 GV UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,CTR HUMAN TOXICOL,UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,DEPT MED PHYS,UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University								BROOKS SM, 1979, CHEST, V75, P232, DOI 10.1378/chest.75.2_Supplement.232; BRUYNZEEL PLB, 1979, ANN ALLERGY, V43, P105; BRUYNZEEL PLB, 1981, 29TH P PROT BIOL FLU; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CAMPBELL IA, 1977, THORAX, V32, P424, DOI 10.1136/thx.32.4.424; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONOLLY ME, 1977, BRIT J PHARMACOL, V59, P17, DOI 10.1111/j.1476-5381.1977.tb06971.x; CONOLLY ME, 1973, CHEST S, V63, P16; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; FOKKENS JK, 1981, EUR J RESPIR DIS; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KALISKER A, 1977, J ALLERGY CLIN IMMUN, V60, P259, DOI 10.1016/0091-6749(77)90141-5; LARSSON S, 1974, Scandinavian Journal of Respiratory Diseases Supplementum, V88, P54; LEFERINK JG, 1977, J CHROMATOGR, V143, P299, DOI 10.1016/S0378-4347(00)81810-1; LEFERINK JG, 1981, ARZNEIMITTELFORSCH; MANO K, 1979, LIFE SCI, V25, P1925, DOI 10.1016/0024-3205(79)90614-3; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MUKHERJEE C, 1976, P NATL ACAD SCI USA, V73, P1494, DOI 10.1073/pnas.73.5.1494; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; Siegel S., 1956, NONPARAMETRIC STAT B; TOLONE G, 1979, BRIT J EXP PATHOL, V60, P269; VANDENBERG W, 1980, ANN ALLERGY, V44, P235; VANDENBERG W, 1981, EUR J RESPIR DIS; VANDENBERG W, 1981, INT J CLIN PHARM BIO; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	33	49	49	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					410	417		10.1016/0091-6749(82)90115-4	http://dx.doi.org/10.1016/0091-6749(82)90115-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	6281324				2022-12-18	WOS:A1982NP93400002
J	NATHAN, RA; SEGALL, N; SCHOCKET, AL				NATHAN, RA; SEGALL, N; SCHOCKET, AL			A COMPARISON OF THE ACTIONS OF H-1 AND H-2 ANTIHISTAMINES ON HISTAMINE-INDUCED BRONCHOCONSTRICTION AND CUTANEOUS WHEAL RESPONSE IN ASTHMATIC-PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,DIV CLIN IMMUNOL,DENVER,CO 80262; ALLERGY ASSOC,COLORADO SPRINGS,CO; INTERNAL MED GRP ATLANTA,ATLANTA,GA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DUNLOP LS, 1977, BRIT J PHARMACOL, V59, P475; EISER NM, 1979, THORAX, V34, P703; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HERXHEIMER H, 1949, BRIT MED J, V1, P901; KARLIN JM, 1972, ANN ALLERGY, V30, P342; LARSON EW, 1976, APPL ENVIRON MICROB, V31, P150, DOI 10.1128/AEM.31.1.150-151.1976; LEOPOLD JD, 1979, BRIT J CLIN PHARMACO, V8, P249, DOI 10.1111/j.1365-2125.1979.tb01010.x; MACONOCHIE JG, 1979, BRIT J CLIN PHARMACO, V7, P231, DOI 10.1111/j.1365-2125.1979.tb00927.x; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; NATHAN RA, 1979, AM REV RESPIR DIS, V120, P1251; RATNER B, 1947, J PEDIATR, V30, P583, DOI 10.1016/S0022-3476(47)80051-4; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P23, DOI 10.1016/0091-6749(79)90078-2; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; WINER BJ, 1971, STATISTICAL PRINCIPL, P518; 1950, J ALLERGY, V21, P255; 1962, AM REV RESPIR DIS, V85, P762	22	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					171	177		10.1016/0091-6749(81)90057-9	http://dx.doi.org/10.1016/0091-6749(81)90057-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	6109741	Bronze			2022-12-18	WOS:A1981LG77800002
J	OGILVY, CS; DUBOIS, AB; DOUGLAS, JS				OGILVY, CS; DUBOIS, AB; DOUGLAS, JS			EFFECTS OF ASCORBIC-ACID AND INDOMETHACIN ON THE AIRWAYS OF HEALTHY MALE-SUBJECTS WITH AND WITHOUT INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHN B PIERCE FDN LAB,290 CONGRESS AVE,NEW HAVEN,CT 06519; YALE UNIV,NEW HAVEN,CT 06520	Yale University; The John B Pierce Laboratory, Inc; Yale University					NHLBI NIH HHS [HL 23959] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEGRA J, 1976, J ALLERGY CLIN IMMUN, V58, P546, DOI 10.1016/0091-6749(76)90200-1; BOUHUYS A, 1969, J CLIN INVEST, V48, P1159, DOI 10.1172/JCI106073; BRINK C, 1980, BRIT J PHARMACOL, V69, P383, DOI 10.1111/j.1476-5381.1980.tb07026.x; BRINK C, 1978, POL J PHARMACOL PHAR, V30, P157; BURNS JJ, 1975, PHARMACOL BASIS, P1564; DASILVA AM, 1976, PROSTAGLANDINS, V11, P71; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; DUBOIS AB, 1956, J CLIN INVEST, V35, P336; DUNCAN PG, 1980, J PHARMACOL EXP THER, V215, P434; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GRODZINSKA L, 1975, J PHARM PHARMACOL, V27, P88, DOI 10.1111/j.2042-7158.1975.tb09414.x; KORDANSKY D, 1977, P AM C ALLERGY IMMUN; KORDANSKY DW, 1979, J ALLERGY CLIN IMMUN, V63, P61, DOI 10.1016/0091-6749(79)90163-5; KREISMAN H, 1977, LUNG, V154, P223; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; OGILVY C S, 1978, Physiologist, V21, P86; OREHEK J, 1975, J PHARMACOL EXP THER, V194, P554; OREHEK J, 1973, NATURE-NEW BIOL, V245, P84, DOI 10.1038/newbio245084a0; PUGH DM, 1975, BRIT J PHARMACOL, V53, pP469; STEEL L, 1980, J ALLERGY CLIN IMMUN, V64, P1287; VALIC F, 1973, BRIT J IND MED, V30, P381; VARGAFTI.BB, 1972, EXPERIENTIA, V28, P59, DOI 10.1007/BF01928265; WASSERMAN MA, 1980, EUR J PHARMACOL, V66, P53, DOI 10.1016/0014-2999(80)90294-0; Wright IS, 1937, ARCH INTERN MED, V60, P264, DOI 10.1001/archinte.1937.00180020088007; ZUSKIN E, 1973, J ALLERGY CLIN IMMUN, V51, P218, DOI 10.1016/0091-6749(73)90141-3; ZUSKIN E, 1976, LUNG, V154, P17, DOI 10.1007/BF02713515	26	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					363	367		10.1016/0091-6749(81)90081-6	http://dx.doi.org/10.1016/0091-6749(81)90081-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7229225				2022-12-18	WOS:A1981LQ56300006
J	FISH, JE; ANKIN, MG; KELLY, JF; PETERMAN, VI				FISH, JE; ANKIN, MG; KELLY, JF; PETERMAN, VI			COMPARISON OF RESPONSES TO POLLEN EXTRACT IN SUBJECTS WITH ALLERGIC-ASTHMA AND NON-ASTHMATIC SUBJECTS WITH ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,PULM SECT,EVANSTON,IL 60201; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,EVANSTON,IL 60201	Northwestern University; Northwestern University								AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BROWN R, 1978, AM REV RESPIR DIS, V118, P685, DOI 10.1164/arrd.1978.118.4.685; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DEBEULE R, 1974, ALLERGY 74, P349; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FISH JE, 1977, J ALLERGY CLIN IMMUN, V60, P41, DOI 10.1016/0091-6749(77)90081-1; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; Meltzer SJ, 1910, J AMER MED ASSOC, V55, P1021, DOI 10.1001/jama.1910.04330120043014; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NADEL JA, 1977, AM REV RESPIR DIS, V115, P117; PERESS L, 1976, AM J MED, V61, P165, DOI 10.1016/0002-9343(76)90165-0; PERMUTT S, 1973, P15; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P266; PRIDE NB, 1967, J APPL PHYSIOL, V23, P646, DOI 10.1152/jappl.1967.23.5.646; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; Snedecor G.W., 1980, STAT METHODS, V7; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WOOLCOCK AJ, 1966, AM J MED, V41, P259, DOI 10.1016/0002-9343(66)90021-0; Wyman M., 1872, AUTUMNAL CATARRH; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	27	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					154	161		10.1016/0091-6749(80)90201-8	http://dx.doi.org/10.1016/0091-6749(80)90201-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	7351448				2022-12-18	WOS:A1980JF19900012
J	SMITH, LJ; SHELHAMER, JH; KALINER, M				SMITH, LJ; SHELHAMER, JH; KALINER, M			CHOLINERGIC NERVOUS-SYSTEM AND IMMEDIATE HYPERSENSITIVITY .2. AN ANALYSIS OF PUPILLARY RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIH,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA	SMITH, LJ (corresponding author), WALTER REED ARMY MED CTR,ALLERGY CLIN,WASHINGTON,DC 20012, USA.							AUSTON KF, 1978, IMMUNOLOGICAL DISEAS, P781; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; GOODMAN CS, 1970, PHARMACOLOGIC BASIS, P466; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; NADEL JA, 1976, BRONCHIAL ASTHMA, P156; REED CE, 1978, ALLERGY PRINCIPLES P, P659; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SZENTIVANYI A, 1976, BRONCHIAL ASTHMA MEC, P137; ZINN KM, 1972, PUPIL, P29	11	49	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					374	378		10.1016/0091-6749(80)90116-5	http://dx.doi.org/10.1016/0091-6749(80)90116-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7440854	Bronze			2022-12-18	WOS:A1980KQ96500005
J	HALLIWELL, REW; KUNKLE, GA				HALLIWELL, REW; KUNKLE, GA			RADIOALLERGOSORBENT TEST IN DIAGNOSIS OF CANINE ATOPIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH VET MED,DEPT CLIN STUDIES,PHILADELPHIA,PA 19174	University of Pennsylvania								AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; ARKINS JA, 1969, J ALLERGY, V44, P108, DOI 10.1016/0021-8707(69)90006-9; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; ERICKSON NE, 1976, INT ARCH ALLERGY APP, V52, P335; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HALLIWELL RE, 1973, J IMMUNOL, V110, P422; HALLIWELL RE, 1972, CLIN EXP IMMUNOL, V10, P399; HALLIWELL RE, 1971, VET REC, V89, P209, DOI 10.1136/vr.89.8.209; HALLIWELL REW, 1975, ANN NY ACAD SCI, V254, P476, DOI 10.1111/j.1749-6632.1975.tb29195.x; HALLIWELL REW, 1975, TRANSPLANT P, V7, P537; HALLIWELL REW, UNPUBLISHED; HALLIWELL REW, 1973, THESIS U CAMBRIDGE; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; PATTERSON R, 1960, J ALLERGY, V31, P351, DOI 10.1016/0021-8707(60)90071-X; RILEY JF, 1959, MAST CELL; VRIESENDORP HM, 1975, TRANSPLANT P, V7, P375; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WIDE L, 1967, LANCET, V2, P1105	20	49	49	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					236	242		10.1016/0091-6749(78)90213-0	http://dx.doi.org/10.1016/0091-6749(78)90213-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701658				2022-12-18	WOS:A1978FS39200007
J	SOLOMON, WR; BURGE, HP; BOISE, JR				SOLOMON, WR; BURGE, HP; BOISE, JR			AIRBORNE ASPERGILLUS-FUMIGATUS LEVELS OUTSIDE AND WITHIN A LARGE CLINICAL CENTER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SOLOMON, WR (corresponding author), UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ALLERGY SECT,ANN ARBOR,MI 48109, USA.							AISNER J, 1976, JAMA-J AM MED ASSOC, V235, P411, DOI 10.1001/jama.235.4.411; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; Barnett H.L., 1972, ILLUSTRATED GENERA I; COLEN J, 1961, ANN ALLERGY, V19, P1399; DAVIES RR, 1962, LANCET, V2, P1295; EVANS HC, 1972, T BRIT MYCOL SOC, V59, P516, DOI 10.1016/S0007-1536(72)80136-0; GAGE AA, 1974, ARCH SURG-CHICAGO, V101, P384; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; HUDSON HJ, 1969, T BRIT MYCOL SOC, V52, P153, DOI 10.1016/S0007-1536(69)80168-3; HUDSON HJ, 1973, T BRIT MYCOL SOC, V60, P596, DOI 10.1016/S0007-1536(73)80049-X; KRAMER CL, 1960, MYCOLOGIA, V52, P545, DOI 10.2307/3756087; LOURIDAS G, 1976, RESPIRATION, V33, P281, DOI 10.1159/000193743; MALLEA M, 1972, ACTA ALLERGOL, V27, P273, DOI 10.1111/j.1398-9995.1972.tb01426.x; MULLINS J, 1976, CLIN ALLERGY, V6, P209, DOI 10.1111/j.1365-2222.1976.tb01899.x; NOBLE WC, 1963, J GEN MICROBIOL, V32, P397, DOI 10.1099/00221287-32-3-397; NOVEY HS, 1975, WESTERN J MED, V122, P491; PADY S. M., 1956, CANADIAN JOUR BOT, V34, P1, DOI 10.1139/b56-001; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; Raper KB, 1965, GENUS ASPERGILLUS GE; ROSE HD, 1972, AM REV RESPIR DIS, V105, P306; ROSEN PP, 1976, NEW ENGL J MED, V295, P1319; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P46, DOI 10.1016/0091-6749(76)90078-6; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V55, P90; STAIB F, 1974, DEUT MED WOCHENSCHR, V99, P1804, DOI 10.1055/s-0028-1108050	27	49	51	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					56	60		10.1016/0091-6749(78)90073-8	http://dx.doi.org/10.1016/0091-6749(78)90073-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	350933				2022-12-18	WOS:A1978FG87000011
J	Lee, SW; Yon, DK; James, CC; Lee, S; Koh, HY; Sheen, YH; Oh, JW; Han, MY; Sugihara, G				Lee, Seung Won; Yon, Dong Keon; James, Chase C.; Lee, Shinhae; Koh, Hyun Yong; Sheen, Youn Ho; Oh, Jae-Won; Han, Man Yong; Sugihara, George			Short-term effects of multiple outdoor environmental factors on risk of asthma exacerbations: Age-stratified time-series analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; air pollutant; weather condition; aeroallergen; human rhinovirus; influenza virus	AIR-POLLUTION; HOSPITAL ADMISSIONS; WEATHER; AEROALLERGENS; SYMPTOMS; IMPACT	Background: Although the different age groups had differences in sensitivity of asthma exacerbations (AEs) to environmental factors, no comprehensive study has examined the age-stratified effects of environmental factors on AEs. Objective: We sought to examine the short-term effects in age-stratified groups (infants, preschool children, school-aged children, adults, and the elderly) of outdoor environmental factors (air pollutants, weather conditions, aeroallergens, and respiratory viral epidemics) on AEs. Methods: We performed an age-stratified analysis of the short-term effects of 4 groups of outdoor environmental factors on AEs in Seoul Metropolitan City (Korea) from 2008 and 2012. The statistical analysis used a Poisson generalized linear regression model, with a distributed lag nonlinear model for identification of lagged and nonlinear effects and convergent cross-mapping for identification of causal associations. Results: Analysis of the total population (n = 10,233,519) indicated there were 28,824 AE events requiring admission to an emergency department during the study period. Diurnal temperature range had significant effects in pediatric (infants, preschool children, and school-aged children) and elderly (relative risk [RR], 1.056-1.078 and 1.016, respectively) subjects. Tree and weed pollen, human rhinovirus, and influenza virus had significant effects in school-aged children (RR, 1.014, 1.040, 1.042, and 1.038, respectively). Tree pollen and influenza virus had significant effects in adults (RR, 1.026 and 1.044, respectively). Outdoor air pollutants (particulate matter of <= 10 mu m in diameter, nitrogen dioxide, ozone, carbon monoxide, and sulfur dioxide) had significant short-term effects in all age groups (except for carbon monoxide and sulfur dioxide in infants). Conclusion: These findings provide a need for the development of tailored strategies to prevent AE events in different age groups.	[Lee, Seung Won] CHA Univ, Grad Sch Med, Seongnam, South Korea; [Lee, Seung Won] Sejong Univ, Coll Software Convergence, Dept Data Sci, Seoul, South Korea; [Yon, Dong Keon; Lee, Shinhae; Han, Man Yong] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Pediat, Seongnam, South Korea; [Yon, Dong Keon] Republ Korea Army, Med Corps, Seongnam, South Korea; [James, Chase C.; Sugihara, George] Univ Calif San Diego, Scripps Inst Oceanog, San Diego, CA 92103 USA; [Koh, Hyun Yong] Harvard Med Sch, Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Sheen, Youn Ho] CHA Univ, Sch Med, CHA Gangnam Med Ctr, Dept Pediat, Seoul, South Korea; [Oh, Jae-Won] Hanyang Univ, Coll Med, Guri Hosp, Dept Pediat, Guri, South Korea	Pochon Cha University; Sejong University; Pochon Cha University; University of California System; University of California San Diego; Scripps Institution of Oceanography; Harvard University; Boston Children's Hospital; Harvard Medical School; Pochon Cha University; Hanyang University	Han, MY (corresponding author), CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Pediat, Seongnam, South Korea.; Han, MY (corresponding author), CHA Univ, Dept Pediat, Sch Med, 351 Yatap Dong, Seongnam 463712, Gyeonggi Do, South Korea.	drmesh@gmail.com	Yon, Dong Keon/M-1264-2017; Koh, Hyun Yong/AAX-4374-2020; Lee, Seung Won/GQQ-7259-2022; Lee, Seung Won/AAK-9460-2021	Yon, Dong Keon/0000-0003-1628-9948; Koh, Hyun Yong/0000-0002-3995-4341; Lee, Seung Won/0000-0001-5632-5208; Lee, Seung Won/0000-0001-5632-5208	CHA University School of Medicine, Seongnam, Republic of Korea; Influenza and Respiratory Viruses Surveillance Project of the Korea Centers for Disease Control and Prevention, Republic of Korea	CHA University School of Medicine, Seongnam, Republic of Korea; Influenza and Respiratory Viruses Surveillance Project of the Korea Centers for Disease Control and Prevention, Republic of Korea	Supported by CHA University School of Medicine, Seongnam, Republic of Korea. This work was partially supported by the Influenza and Respiratory Viruses Surveillance Project of the Korea Centers for Disease Control and Prevention, Republic of Korea.	Andersen ZJ, 2008, THORAX, V63, P710, DOI 10.1136/thx.2007.085480; Chen K, 2016, CLIN EXP ALLERGY, V46, P1416, DOI 10.1111/cea.12795; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Deyle ER, 2016, P NATL ACAD SCI USA, V113, P13081, DOI 10.1073/pnas.1607747113; Dunn RM, 2015, AM J RESP CRIT CARE, V192, P551, DOI 10.1164/rccm.201503-0426OC; Eggo RM, 2016, P NATL ACAD SCI USA, V113, P2194, DOI 10.1073/pnas.1518677113; Brito FF, 2010, J INVEST ALLERG CLIN, V20, P295; Gasparrini A, 2010, STAT MED, V29, P2224, DOI 10.1002/sim.3940; Gerke AK, 2014, RESPIROLOGY, V19, P116, DOI 10.1111/resp.12165; Graudenz GS, 2006, J ALLERGY CLIN IMMUN, V118, P1126, DOI 10.1016/j.jaci.2006.07.005; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Ivey Marsha A., 2001, Allergology International, V50, P29, DOI 10.1046/j.1440-1592.2001.00198.x; Jo EJ, 2017, RESP MED, V124, P79, DOI 10.1016/j.rmed.2017.02.010; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Kim Hyeong Yun, 2014, Korean J Pediatr, V57, P205, DOI 10.3345/kjp.2014.57.5.205; Kim JH, 2012, J KOREAN MED SCI, V27, P350, DOI 10.3346/jkms.2012.27.4.350; Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008; Kloepfer KM, 2010, IMMUNOL ALLERGY CLIN, V30, P553, DOI 10.1016/j.iac.2010.08.002; Kwon DS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012618; Kwon JW, 2016, ALLERGY ASTHMA IMMUN, V8, P512, DOI 10.4168/aair.2016.8.6.512; Lee CC, 2012, ECOHEALTH, V9, P427, DOI 10.1007/s10393-012-0803-5; Lee SW, 2017, ALLERGY ASTHMA IMMUN, V9, P517, DOI 10.4168/aair.2017.9.6.517; Li SS, 2014, ANN ALLERG ASTHMA IM, V112, P348, DOI 10.1016/j.anai.2014.01.007; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Mireku N, 2009, ANN ALLERG ASTHMA IM, V103, P220, DOI 10.1016/S1081-1206(10)60185-8; Orellano P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174050; Sugihara G, 2012, SCIENCE, V338, P496, DOI 10.1126/science.1227079; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Xu ZW, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-12; Yang TU, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084873; Zheng XQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117773	31	48	48	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1542	+		10.1016/j.jaci.2019.08.037	http://dx.doi.org/10.1016/j.jaci.2019.08.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31536730	Bronze			2022-12-18	WOS:000500694900013
J	Brinkman, P; Wagener, AH; Hekking, PP; Bansal, AT; Maitland-van der Zee, AH; Wang, YY; Weda, H; Knobel, HH; Vink, TJ; Rattray, NJ; D'Amico, A; Pennazza, G; Santonico, M; Lefaudeux, D; De Meulder, B; Auffray, C; Bakke, PS; Caruso, M; Chanez, P; Chung, KF; Corfield, J; Dahlen, SE; Djukanovic, R; Geiser, T; Horvath, I; Krug, N; Musial, J; Sun, K; Riley, JH; Shaw, DE; Sandstrom, T; Sousa, AR; Montuschi, P; Fowler, SJ; Sterk, PJ				Brinkman, Paul; Wagener, Ariane H.; Hekking, Pieter-Paul; Bansal, Aruna T.; Maitland-van der Zee, Anke-Hilse; Wang, Yuanyue; Weda, Hans; Knobel, Hugo H.; Vink, Teunis J.; Rattray, Nicholas J.; D'Amico, Arnaldo; Pennazza, Giorgio; Santonico, Marco; Lefaudeux, Diane; De Meulder, Bertrand; Auffray, Charles; Bakke, Per S.; Caruso, Massimo; Chanez, Pascal; Chung, Kian F.; Corfield, Julie; Dahlen, Sven-Erik; Djukanovic, Ratko; Geiser, Thomas; Horvath, Ildiko; Krug, Nobert; Musial, Jacek; Sun, Kai; Riley, John H.; Shaw, Dominic E.; Sandstrom, Thomas; Sousa, Ana R.; Montuschi, Paolo; Fowler, Stephen J.; Sterk, Peter J.		U-BIOPRED Study Grp	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Electronic nose technology; exhaled breath; volatile organic compound; follow-up; severe asthma; unbiased clustering; eosinophils; neutrophils; oral corticosteroids	VOLATILE ORGANIC-COMPOUNDS; EXHALED NITRIC-OXIDE; CLUSTER-ANALYSIS; GENE-EXPRESSION; PROFILES; DISCRIMINATION; BLOOD; CELLS	Background: Severe asthma is a heterogeneous condition, as shown by independent cluster analyses based on demographic, clinical, and inflammatory characteristics. A next step is to identify molecularly driven phenotypes using `` omics'' technologies. Molecular fingerprints of exhaled breath are associated with inflammation and can qualify as noninvasive assessment of severe asthma phenotypes. Objectives: We aimed (1) to identify severe asthma phenotypes using exhaled metabolomic fingerprints obtained from a composite of electronic noses (eNoses) and (2) to assess the stability of eNose-derived phenotypes in relation to withinpatient clinical and inflammatory changes. Methods: In this longitudinal multicenter study exhaled breath samples were taken from an unselected subset of adults with severe asthma from the U-BIOPRED cohort. Exhaled metabolites were analyzed centrally by using an assembly of eNoses. Unsupervised Ward clustering enhanced by similarity profile analysis together with K-means clustering was performed. For internal validation, partitioning around medoids and topological data analysis were applied. Samples at 12 to 18 months of prospective follow-up were used to assess longitudinal within-patient stability. Results: Data were available for 78 subjects (age, 55 years [interquartile range, 45-64 years]; 41% male). Three eNosedriven clusters (n = 26/33/19) were revealed, showing differences in circulating eosinophil (P = .045) and neutrophil (P = .017) percentages and ratios of patients using oral corticosteroids (P = .035). Longitudinal within-patient cluster stability was associated with changes in sputum eosinophil percentages (P = .045). Conclusions: We have identified and followed up exhaled molecular phenotypes of severe asthma, which were associated with changing inflammatory profile and oral steroid use. This suggests that breath analysis can contribute to the management of severe asthma.	[Brinkman, Paul; Wagener, Ariane H.; Hekking, Pieter-Paul; Maitland-van der Zee, Anke-Hilse; Sterk, Peter J.] Univ Amsterdam, Amsterdam UMC, Dept Resp Med, Amsterdam, Netherlands; [Bansal, Aruna T.] Acclarogen, St Johns Innovat Ctr, Cambridge, England; [Wang, Yuanyue; Weda, Hans; Vink, Teunis J.] Philips Res, Eindhoven, Netherlands; [Knobel, Hugo H.] Philips Lighting, Eindhoven, Netherlands; [Rattray, Nicholas J.] Yale Univ, Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA; [D'Amico, Arnaldo] Univ Roma Tor Vergata, Dept Elect Engn, Rome, Italy; [Pennazza, Giorgio; Santonico, Marco] Campus Biomed Univ, Unit Elect Sensor Syst, CIR, Rome, Italy; [Lefaudeux, Diane; De Meulder, Bertrand; Auffray, Charles] UCBL, European Inst Syst Biol & Med, CIRI, UMR5308,CNRS,ENS,INSERM, Lyon, France; [Bakke, Per S.] Univ Bergen, Inst Med, Bergen, Norway; [Caruso, Massimo] Univ Catania, Hosp Univ, Dept Clin & Expt Med, Catania, Italy; [Chanez, Pascal] Aix Marseille Univ Marseille, AP HM, Dept Malad Resp, U1067,INSERM, Aix En Provence, France; [Chung, Kian F.] Imperial Coll London, Natl Heart & Lung Inst, UK Biomed Res Unit, Royal Brompton & Harefield NHS Trust, London, England; [Corfield, Julie] AstraZeneca R&D, Molndal, Sweden; [Corfield, Julie] Areteva R&D, Nottingham, England; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Djukanovic, Ratko] Univ Southampton, NIHR Southampton Resp Biomed Res Unit, Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Geiser, Thomas] Univ Hosp Bern, Dept Pulm Med, Bern, Switzerland; [Horvath, Ildiko] Semmelweis Univ, Dept Pulmonol, Budapest, Hungary; [Krug, Nobert] Fraunhofer Inst Toxicol & Expt Med Hannover, Hannover, Germany; [Musial, Jacek] Jagiellonian Univ, Coll Med, Dept Med, Krakow, Poland; [Sun, Kai] Imperial Coll London, Data Sci Inst, South Kensington Campus, London, England; [Riley, John H.; Sousa, Ana R.] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, England; [Shaw, Dominic E.] Univ Nottingham, Resp Res Unit, Nottingham, England; [Sandstrom, Thomas] Umea Univ, Dept Publ Hlth & Clin Med, Dept Med, Resp Med Unit, Umea, Sweden; [Montuschi, Paolo] Univ Cattolica Sacro Cuore, Dept Pharmacol, Fac Med, Rome, Italy; [Fowler, Stephen J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Med & Human Sci, Resp Res Grp, Manchester, Lancs, England; [Fowler, Stephen J.] Univ Hosp South Manchester, NIHR Translat Res Fac Resp Med, Manchester, Lancs, England; [Fowler, Stephen J.] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England	University of Amsterdam; St Johns Innovation Centre - UK; Philips; Philips Research; Philips; Yale University; University of Rome Tor Vergata; University Campus Bio-Medico - Rome Italy; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Bergen; University of Catania; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; AstraZeneca; Karolinska Institutet; University of Southampton; University of Bern; University Hospital of Bern; Semmelweis University; Fraunhofer Gesellschaft; Jagiellonian University; Collegium Medicum Jagiellonian University; Imperial College London; GlaxoSmithKline; University of Nottingham; Umea University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Manchester; Wythenshawe Hospital NHS Foundation Trust	Brinkman, P (corresponding author), Univ Amsterdam, Dept Resp Med, Acad Med Ctr, F5-259,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	p.brinkman@amc.uva.nl	Horváth, Ildikó/GPP-6088-2022; Brinkman, Paul/AAV-5110-2021; Rattray, Nicholas/AAX-7283-2021; Sterk, P.J./AAK-8175-2020; Caruso, Massimo/P-4161-2016; Chung, Kian Fan/B-1872-2012; Maitland-van der Zee, Anke/I-9572-2016; shaw, dominick/N-1293-2014	Caruso, Massimo/0000-0002-4412-2080; Chung, Kian Fan/0000-0001-7101-1426; Djukanovic, Ratko/0000-0001-6039-5612; Maitland-van der Zee, Anke/0000-0002-0414-3442; Fowler, Stephen/0000-0002-4524-1663; MONTUSCHI, Paolo/0000-0001-5589-1750; Rattray, Nicholas/0000-0002-3528-6905; shaw, dominick/0000-0003-4106-8469; chanez, pascal/0000-0003-4059-0917; Brinkman, Paul/0000-0003-4546-8478	Innovative Medicines Initiative (IMI) Joint Undertaking [115010]; European Union; European Federation of Pharmaceutical Industries and Associations (EFPIA)	Innovative Medicines Initiative (IMI) Joint Undertaking; European Union(European Commission); European Federation of Pharmaceutical Industries and Associations (EFPIA)	U-BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in-kind contributions (www.imi.europa.eu).	Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Arasaradnam RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108750; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; Basanta M, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-72; Beauchamp J, 2011, J BREATH RES, V5, DOI 10.1088/1752-7155/5/3/037103; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Bigler J, 2017, AM J RESP CRIT CARE, V195, P1311, DOI 10.1164/rccm.201604-0866OC; Bos LD, 2016, J ALLERGY CLIN IMMUN, V138, P970, DOI 10.1016/j.jaci.2016.08.004; Bos LDJ, 2013, J APPL PHYSIOL, V115, P1487, DOI 10.1152/japplphysiol.00685.2013; Bourdin A, 2014, J ALLERGY CLIN IMMUN, V134, P1043, DOI 10.1016/j.jaci.2014.04.038; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Brinkman P, 2017, CLIN EXP ALLERGY, V47, P1159, DOI 10.1111/cea.12965; Choi S, 2017, J ALLERGY CLIN IMMUN, V140, P690, DOI 10.1016/j.jaci.2016.11.053; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Clarke KR, 2008, J EXP MAR BIOL ECOL, V366, P56, DOI 10.1016/j.jembe.2008.07.009; Coumou H, 2016, EXPERT REV RESP MED, V10, P1093, DOI 10.1080/17476348.2017.1236688; de Vries R, 2015, J BREATH RES, V9, DOI 10.1088/1752-7155/9/4/046001; de Vries R, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01817-2017; Di Natale C, 2007, SENSOR ACTUAT B-CHEM, V121, P238, DOI 10.1016/j.snb.2006.09.038; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Fens N, 2011, EUR RESPIR J, V38, P1301, DOI 10.1183/09031936.00032911; Fens N, 2009, AM J RESP CRIT CARE, V180, P1076, DOI 10.1164/rccm.200906-0939OC; Gaugg MT, 2017, J BREATH RES, V11, DOI 10.1088/1752-7163/aa7caa; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Holgate ST, 2011, EUR J CLIN INVEST, V41, P1339, DOI 10.1111/j.1365-2362.2011.02534.x; Honkoop PJ, 2015, J ALLERGY CLIN IMMUN, V135, P682, DOI 10.1016/j.jaci.2014.07.016; Ibrahim B, 2011, THORAX, V66, P804, DOI 10.1136/thx.2010.156695; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Konno S, 2018, ANN AM THORAC SOC, V15, P33, DOI 10.1513/AnnalsATS.201701-065OC; Kuo Chih-Hsi Scott, 2017, Eur Respir J, V49, DOI 10.1183/13993003.02135-2016; Lawal O, 2018, J BREATH RES, V12, DOI 10.1088/1752-7163/aa8efc; Lever J, 2017, NAT METHODS, V14, P641, DOI 10.1038/nmeth.4346; Lewis NS, 2004, ACCOUNTS CHEM RES, V37, P663, DOI 10.1021/ar030120m; Liang ZY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003774; McShane LM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-220; Meyer N, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0136-8; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Montuschi P, 2010, CHEST, V137, P790, DOI 10.1378/chest.09-1836; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Newby C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102987; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Petsky HL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005603.pub3; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Plaza V, 2015, J INVEST ALLERG CLIN, V25, P431; RAND WM, 1971, J AM STAT ASSOC, V66, P846, DOI 10.2307/2284239; Seys SF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0524-y; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Siddiqui S, 2018, J ALLERGY CLIN IMMUN, V142, P1457, DOI 10.1016/j.jaci.2017.12.982; van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142; van der Schee MP, 2013, CLIN EXP ALLERGY, V43, P1217, DOI 10.1111/cea.12147; van der Schee MP, 2013, J BREATH RES, V7, DOI 10.1088/1752-7155/7/1/016002; Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634; Wheelock CE, 2013, EUR RESPIR J, V42, P802, DOI 10.1183/09031936.00078812; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; YEOMANS KA, 1982, J ROY STAT SOC D-STA, V31, P221; Zaihra T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0232-2; 2008, EUR RESPIR J, V32, P545, DOI DOI 10.1183/09031936.00155307; 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI DOI 10.1016/J.JACI.2010.10.024	66	48	48	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1811	+		10.1016/j.jaci.2018.10.058	http://dx.doi.org/10.1016/j.jaci.2018.10.058			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30529449	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000466784600017
J	Malik, K; He, H; Huynh, TN; Tran, G; Mueller, K; Doytcheva, K; Renert-Yuval, Y; Czarnowicki, T; Magidi, S; Chou, M; Estrada, YD; Wen, HC; Peng, XY; Xu, H; Zheng, XZ; Krueger, JG; Paller, AS; Guttman-Yassky, E				Malik, Kunal; He, Helen; Thy Nhat Huynh; Tran, Gary; Mueller, Kelly; Doytcheva, Kristina; Renert-Yuval, Yael; Czarnowicki, Tali; Magidi, Shai; Chou, Margaret; Estrada, Yeriel D.; Wen, Huei-Chi; Peng, Xiangyu; Xu, Hui; Zheng, Xiuzhong; Krueger, James G.; Paller, Amy S.; Guttman-Yassky, Emma			Ichthyosis molecular fingerprinting shows profound T(H)17 skewing and a unique barrier genomic signature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; atopic dermatitis; immune; inflammation; epidermal barrier; Netherton syndrome; congenital ichthyosiform erythroderma; lamellar ichthyosis; epidermolytic ichthyosis; IL-17; TNF-alpha; IL-36; targeted therapy; precision medicine	RECESSIVE CONGENITAL ICHTHYOSIS; QUALITY-OF-LIFE; ATOPIC-DERMATITIS; NETHERTON-SYNDROME; TRANSGLUTAMINASE 1; HARLEQUIN ICHTHYOSIS; STRATUM-CORNEUM; SYSTEMIC RETINOIDS; CONTACT-DERMATITIS; CONTROLLED-TRIAL	Background: Ichthyoses are a group of rare skin disorders lacking effective treatments. Although genetic mutations are progressively delineated, comprehensive molecular phenotyping of ichthyotic skin could suggest much-needed pathogenesis-based therapy. Objective: We sought to profile the molecular fingerprint of the most common orphan ichthyoses. Methods: Gene, protein, and serum studies were performed on skin and blood samples from 29 patients (congenital ichthyosiform erythroderma, n = 9; lamellar ichthyosis, n = 8; epidermolytic ichthyosis, n = 8; and Netherton syndrome, n = 4), as well as age-matched healthy control subjects (n = 14), patients with psoriasis (n = 30), and patients with atopic dermatitis (AD; n = 16). Results: Using criteria of a fold change of greater than 2 and a false discovery rate of less than 0.05, 132 differentially expressed genes were shared commonly among all ichthyoses, including many IL-17 and TNF-alpha-coregulated genes, which are considered hallmarks of psoriasis (defensin beta 4A, kynureninase, and vanin 3). Although striking upregulation of TH17 pathway genes (IL17F and IL36B/G) resembling that seen in patients with psoriasis was common to all patients with ichthyoses in a severity-related manner, patients with Netherton syndrome showed the greatest T-cell activation (inducible costimulator [ICOS]) and a broader immune phenotype with T(H)1/IFN-gamma, OASL, and T(H)2/IL-4 receptor/IL-5 skewing, although less than seen in patients with AD (all P < .05). Ichthyoses lacked the epidermal differentiation and tight junction alterations of patients with AD (loricrin, filaggrin, and claudin 1) but showed characteristic alterations in lipid metabolism genes (ELOVL fatty acid elongase 3 and galanin), with parallel reductions in extracellular lipids and corneocyte compaction in all ichthyoses except epidermolytic ichthyosis, suggesting phenotypic variations. Transepidermal water loss, a functional barrier measure, significantly correlated with IL-17-regulated gene expression (IL17F and IL36A/IL36B/IL36G). Conclusion: Similar to patients with AD and psoriasis, in whom cytokine dysregulation and barrier impairment orchestrate disease phenotypes, psoriasis-like immune dysregulation and lipid alterations characterize the ichthyoses. These data support the testing of IL-17/IL-36-targeted therapeutics for patients with ichthyosis similar to those used in patients with psoriasis.	[Malik, Kunal; He, Helen; Czarnowicki, Tali; Magidi, Shai; Chou, Margaret; Estrada, Yeriel D.; Wen, Huei-Chi; Peng, Xiangyu; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Malik, Kunal; He, Helen; Czarnowicki, Tali; Magidi, Shai; Chou, Margaret; Estrada, Yeriel D.; Wen, Huei-Chi; Peng, Xiangyu; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Immunol Inst, New York, NY 10029 USA; [Czarnowicki, Tali; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Thy Nhat Huynh; Tran, Gary; Mueller, Kelly; Doytcheva, Kristina; Paller, Amy S.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Thy Nhat Huynh; Tran, Gary; Mueller, Kelly; Doytcheva, Kristina; Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Renert-Yuval, Yael] Hebrew Univ Jerusalem, Dept Dermatol, Med Ctr, Jerusalem, Israel	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Hebrew University of Jerusalem	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021; Renert-Yuval, Yael/AAP-5414-2020		Foglia Family Foundation Endowment; Northwestern University Skin Disease Research Center [NIAMS P30AR057216]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216, R01AR068392] Funding Source: NIH RePORTER	Foglia Family Foundation Endowment; Northwestern University Skin Disease Research Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Foglia Family Foundation Endowment. We acknowledge Core resources provided by the Northwestern University Skin Disease Research Center (NIAMS P30AR057216). Genetic testing of the majority of patients was performed in the laboratory of Dr. Keith Choate, Yale University.	Akagi A, 2013, J DERMATOL, V40, P752, DOI 10.1111/1346-8138.12209; Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI24834; Akiyama M, 2010, AM J PATHOL, V176, P1592, DOI 10.2353/ajpath.2010.090597; Bauer A, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006651; Blunder S, 2017, J INVEST DERMATOL, V137, P706, DOI 10.1016/j.jid.2016.09.034; Briot A, 2010, J INVEST DERMATOL, V130, P2736, DOI 10.1038/jid.2010.233; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Carrier Y, 2011, J INVEST DERMATOL, V131, P2428, DOI 10.1038/jid.2011.234; Casal ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170708; Chamcheu JC, 2011, ARCH BIOCHEM BIOPHYS, V508, P123, DOI 10.1016/j.abb.2010.12.019; Cheung KL, 2016, J EXP MED, V213, P2399, DOI 10.1084/jem.20160258; Chiricozzi A, 2014, EXPERT OPIN THER TAR, V18, P513, DOI 10.1517/14728222.2014.889686; Chiricozzi A, 2013, EXPERT OPIN INV DRUG, V22, P993, DOI 10.1517/13543784.2013.806483; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Choate KA, 1998, J AM ACAD DERMATOL, V38, P325, DOI 10.1016/S0190-9622(98)70575-4; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, p[1091, e1]; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; D'Erme AM, 2015, J INVEST DERMATOL, V135, P1025, DOI 10.1038/jid.2014.532; DALE BA, 1990, J INVEST DERMATOL, V94, P6, DOI 10.1111/1523-1747.ep12873301; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Diaz LZ, 2013, DERMATOL THER, V26, P39, DOI 10.1111/j.1529-8019.2012.01517.x; Dietrich D, 2016, CYTOKINE, V84, P88, DOI 10.1016/j.cyto.2016.05.012; DiGiovanna JJ, 2003, AM J CLIN DERMATOL, V4, P81, DOI 10.2165/00128071-200304020-00002; DiGiovanna JJ, 2001, J AM ACAD DERMATOL, V45, pS176, DOI 10.1067/mjd.2001.113721; DiGiovanna JJ, 2013, DERMATOL THER, V26, P26, DOI 10.1111/j.1529-8019.2012.01527.x; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Fang H, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0384-y; Fontao L, 2011, J INVEST DERMATOL, V131, P1947, DOI 10.1038/jid.2011.124; Fuentes-Duculan J, 2017, EXP DERMATOL, V26, P721, DOI 10.1111/exd.13271; Furio L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005389; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Ganemo A, 2004, EUR J DERMATOL, V14, P61; Ganemo A, 2003, J ADV NURS, V44, P412, DOI 10.1046/j.0309-2402.2003.02820.x; Gordon KB, 2016, NEW ENGL J MED, V375, P345, DOI 10.1056/NEJMoa1512711; Gordon KB, 2012, J INVEST DERMATOL, V132, P304, DOI 10.1038/jid.2011.304; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Guttman-Yassky E, 2018, EXP DERMATOL, V27, P409, DOI 10.1111/exd.13336; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haneda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159673; Hannula-Jouppi K, 2016, JAMA DERMATOL, V152, P435, DOI 10.1001/jamadermatol.2015.5827; Hannula-Jouppi K, 2014, J ALLERGY CLIN IMMUN, V134, P985, DOI 10.1016/j.jaci.2014.07.008; Harden JL, 2016, J ALLERGY CLIN IMMUN, V137, P1830, DOI 10.1016/j.jaci.2015.09.055; Harden JL, 2015, J AUTOIMMUN, V64, P66, DOI 10.1016/j.jaut.2015.07.008; Hellstrom Pigg M, 2016, ACTA DERM-VENEREOL, V96, P932, DOI 10.2340/00015555-2418; Hirabayashi T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14609; Hosomi N, 2008, BRIT J DERMATOL, V159, P744, DOI [10.1111/j.1365-2133.2008.08706.x, 10.1111/j.1365-2133.2008.08706]; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; ISHIDAYAMAMOTO A, 1994, BRIT J DERMATOL, V131, P767, DOI 10.1111/j.1365-2133.1994.tb08578.x; Jansen PAM, 2009, J INVEST DERMATOL, V129, P2167, DOI 10.1038/jid.2009.67; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Johnston A, 2017, J ALLERGY CLIN IMMUN, V140, P109, DOI 10.1016/j.jaci.2016.08.056; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Kamsteeg M, 2010, BRIT J DERMATOL, V162, P568, DOI 10.1111/j.1365-2133.2009.09547.x; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kawashima J, 2005, CLIN EXP DERMATOL, V30, P429, DOI 10.1111/j.1365-2230.2005.01818.x; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim J, 2016, J INVEST DERMATOL, V136, P2173, DOI 10.1016/j.jid.2016.04.032; Kirchmeier P, 2017, ACTA DERM-VENEREOL, V97, P102, DOI 10.2340/00015555-2510; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Kusakabe M, 2017, ACTA DERM-VENEREOL, V97, P397, DOI 10.2340/00015555-2550; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lebwohl M, 2003, LANCET, V361, P1197, DOI 10.1016/S0140-6736(03)12954-6; Lee SH, 2017, IMMUNOL LETT, V184, P67, DOI 10.1016/j.imlet.2017.02.004; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; Li H, 2012, J INVEST DERMATOL, V132, P2368, DOI 10.1038/jid.2012.160; Li J, 2016, INFLAMM BOWEL DIS, V22, P1779, DOI 10.1097/MIB.0000000000000811; Lopez-Ferrer A, 2015, EXPERT REV CLIN IMMU, V11, P1177, DOI 10.1586/1744666X.2015.1095092; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Mahil SK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2514; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; Malik K, 2017, CLIN EXP ALLERGY, V47, P1648, DOI 10.1111/cea.13040; Malik K, 2017, DERMATOL CLIN, V35, P317, DOI 10.1016/j.det.2017.02.006; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Marukian NV, 2016, F1000RES, V5; Mazereeuw-Hautier J, 2012, BRIT J DERMATOL, V166, P646, DOI 10.1111/j.1365-2133.2011.10701.x; Nakajima K, 2013, J INVEST DERMATOL, V133, P2555, DOI 10.1038/jid.2013.199; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; Newcomb DC, 2012, J IMMUNOL, V188, P1027, DOI 10.4049/jimmunol.1102216; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nomura T, 2008, J INVEST DERMATOL, V128, P1436, DOI 10.1038/sj.jid.5701205; Numata S, 2016, EXP DERMATOL, V25, P657, DOI 10.1111/exd.13000; O'Shaughnessy RFL, 2010, HUM MOL GENET, V19, P2594, DOI 10.1093/hmg/ddq145; Oji V, 2006, EUR J DERMATOL, V16, P349; Oji V, 2010, J AM ACAD DERMATOL, V63, P607, DOI 10.1016/j.jaad.2009.11.020; Oji V, 2009, AM J CLIN DERMATOL, V10, P351, DOI 10.2165/11311070-000000000-00000; Ortega-Recalde O, 2016, BRIT J DERMATOL, V175, P1372, DOI 10.1111/bjd.14969; Paller AS, 2018, J AM ACAD DERMATOL, V78, P498, DOI 10.1016/j.jaad.2017.10.026; Paller AS, 2017, J ALLERGY CLIN IMMUN, V139, P152, DOI 10.1016/j.jaci.2016.07.019; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pietrusinski M, 2015, CLIN EXP DERMATOL, V40, P921, DOI 10.1111/ced.12456; Renner ED, 2009, J ALLERGY CLIN IMMUN, V124, P536, DOI 10.1016/j.jaci.2009.06.009; Roth W, 2012, J CELL SCI, V125, P5269, DOI 10.1242/jcs.116574; Saito R, 2017, BRIT J DERMATOL, V176, P249, DOI 10.1111/bjd.14807; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; SAURAT JH, 1992, J AM ACAD DERMATOL, V27, pS23, DOI 10.1016/S0190-9622(08)80256-3; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Sticherling M, 2016, AUTOIMMUN REV, V15, P1167, DOI 10.1016/j.autrev.2016.09.004; Styperek AR, 2010, PEDIATR DERMATOL, V27, P325, DOI 10.1111/j.1525-1470.2010.01160.x; Suarez-Farinas M, 2012, J INVEST DERMATOL, V132, P2552, DOI 10.1038/jid.2012.184; Takeichi T, 2017, BRIT J DERMATOL, V177, pE62, DOI 10.1111/bjd.15315; Tay YK, 1999, ASIAN PAC J ALLERGY, V17, P137; Thomas AC, 2009, AM J PATHOL, V174, P970, DOI 10.2353/ajpath.2009.080860; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Ullah R, 2016, INT J DERMATOL, V55, P524, DOI 10.1111/ijd.12950; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Vahidnezhad H, 2017, J INVEST DERMATOL, V137, P678, DOI 10.1016/j.jid.2016.11.012; Vahlquist A, 2008, ACTA DERM-VENEREOL, V88, P4, DOI 10.2340/00015555-0415; Van Gysel D, 2001, DERMATOLOGY, V202, P99, DOI 10.1159/000051607; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Walsh PT, 2018, ANN NY ACAD SCI, V1417, P23, DOI 10.1111/nyas.13280; Wang ZC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12846; WELLS RS, 1966, BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5493.947; Yalcin AD, 2016, IMMUNOPHARM IMMUNOT, V38, P162, DOI 10.3109/08923973.2015.1115518; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zuniga LA, 2010, J IMMUNOL, V185, P6947, DOI 10.4049/jimmunol.1001269	134	48	48	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					604	618		10.1016/j.jaci.2018.03.021	http://dx.doi.org/10.1016/j.jaci.2018.03.021			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29803800	Bronze, Green Accepted			2022-12-18	WOS:000457718700020
J	McWilliam, V; Peters, R; Tang, MLK; Dharmage, S; Ponsonby, AL; Gurrin, L; Perrett, K; Koplin, J; Allen, KJ; Dwyer, T; Lowe, A; Wake, M; Robertson, C				McWilliam, Vicki; Peters, Rachel; Tang, Mimi L. K.; Dharmage, Shyamali; Ponsonby, Anne-Louise; Gurrin, Lyle; Perrett, Kirsten; Koplin, Jennifer; Allen, Katrina J.; Dwyer, Terence; Lowe, Adrian; Wake, Melissa; Robertson, Colin		HlthNuts Investigators	Patterns of tree nut sensitization and allergy in the first 6 years of life in a population-based cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; sensitization; tree nut allergy; prevalence; population	MEDIATED FOOD ALLERGY; NATURAL-HISTORY; PREVALENCE; PEANUT; HEALTHNUTS; REACTIVITY; FEATURES; CRITERIA; CHILDREN	Background: Longitudinal population-based data regarding tree nut allergy are limited. Objectives: We sought to determine the population prevalence of tree nut allergy at age 6 years and explore the relationship between egg and peanut allergy at age 1 year and development of tree nut allergy at age 6 years. Methods: A population-based sample of 5276 children was recruited at age 1 year and followed up at age 6 years. At age 1 year, allergies to egg and peanut were determined by means of oral food challenge, and parents reported their child's history of reaction to tree nuts. Challenge-confirmed tree nut allergy was assessed at age 6 years. Results: At age 1 year, the prevalence of parent-reported tree nut allergy was 0.1% (95% CI, 0.04% to 0.2%). Only 18.5% of infants had consumed tree nuts in the first year of life. At age 6 years, challenge-confirmed tree nut allergy prevalence was 3.3% (95% CI, 2.8% to 4.0%), with cashew the most common (2.7%; 95% CI, 2.2% to 3.3%). Of children with peanut allergy only at age 1 year, 27% (95% CI, 16.1% to 39.7%) had tree nut allergy at age 6 years compared with 14% (95% CI, 10.4% to 17.9%) of those with egg allergy only and 37% (95% CI, 27.2% to 47.4%) of those with both peanut and egg allergy. Conclusions: Tree nut allergy is uncommon in the first year of life, likely because of limited tree nut consumption. At age 6 years, tree nut allergy prevalence is similar to peanut allergy prevalence. More than a third of children with both peanut and egg allergy in infancy have tree nut allergy at age 6 years. Understanding how to prevent tree nut allergy should be an urgent priority for future research.	[McWilliam, Vicki; Peters, Rachel; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Perrett, Kirsten; Koplin, Jennifer; Allen, Katrina J.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [McWilliam, Vicki; Peters, Rachel; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Dharmage, Shyamali] Univ Melbourne, Ctr Epidemiol & Biostat, Allergy & Lung Hlth Unit, Parkville, Vic, Australia; [Perrett, Kirsten] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Parkville, Vic, Australia; [McWilliam, Vicki; Tang, Mimi L. K.; Perrett, Kirsten; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Gurrin, Lyle; Perrett, Kirsten] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia; [Allen, Katrina J.] Univ Manchester, Manchester, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	McWilliam, Vicki/S-9462-2019; Tang, Mimi/ABD-8350-2020; Perrett, Kirsten/P-8813-2019; Allen, Katrina/I-4361-2018; Ponsonby, Anne-Louise/AAE-4351-2019; Wake, Melissa/J-1396-2012	Tang, Mimi/0000-0002-3839-5293; Perrett, Kirsten/0000-0002-5683-996X; Allen, Katrina/0000-0002-1921-4493; Wake, Melissa/0000-0001-7501-9257; McWilliam, Vicki/0000-0002-5000-2181; Koplin, Jennifer/0000-0002-7576-5142; Dharmage, Shyamali/0000-0001-6063-1937; Peters, Rachel/0000-0002-2411-6628; Ponsonby, Anne-Louise/0000-0002-6581-3657	National Health and Medical Research Council (NHMRC) of Australia [1006215]; Australian Food Allergy Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research [1041420]; NHMRC awards; Melbourne Children's Clinician Scientist Fellowship; GlaxoSmithKline; Novartis; Pfizer; Novavax; MedImmune; NHMRC	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Food Allergy Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research(National Health and Medical Research Council (NHMRC) of Australia); NHMRC awards(National Health and Medical Research Council (NHMRC) of Australia); Melbourne Children's Clinician Scientist Fellowship; GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Pfizer(Pfizer); Novavax; MedImmune(AstraZenecaMedimmune); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council (NHMRC) of Australia (ID 1006215), the Australian Food Allergy Foundation, the Victorian Government's Operational Infrastructure Support Program, and the NHMRC Centre for Food and Allergy Research (ID 1041420). K.J.A, L.G., A.-L.P, and S.D. hold NHMRC awards. V.M.'s PhD scholarship was funded by NHMRC funded Centre for Food and Allergy Research (CFAR). K.P. holds a Melbourne Children's Clinician Scientist Fellowship, and her institute has received research grants from GlaxoSmithKline, Novartis, Pfizer, Novavax, and MedImmune.	Andorf S, 2017, J ALLER CL IMM-PRACT, V5, P1325, DOI 10.1016/j.jaip.2017.01.016; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Cousin M, 2017, PEDIAT ALLERG IMM-UK, V28, P245, DOI 10.1111/pai.12698; Eigenmann PA, 2017, J ALLER CL IMM-PRACT, V5, P296, DOI 10.1016/j.jaip.2016.08.014; Elizur A, 2018, ALLERGY, V73, P593, DOI 10.1111/all.13353; Ewan PW, 1996, BRIT MED J, V312, P1074; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Geiselhart S, 2018, MOL IMMUNOL, V100, P71, DOI 10.1016/j.molimm.2018.03.011; Kaya A, 2013, PEDIAT ALLERG IMM-UK, V24, P456, DOI 10.1111/pai.12097; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; McWilliam V, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0555-8; Mustafayev R, 2013, ALLERGOL IMMUNOPATH, V41, P387, DOI 10.1016/j.aller.2012.05.005; Orhan F, 2009, CLIN EXP ALLERGY, V39, P1027, DOI 10.1111/j.1365-2222.2009.03263.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Sasaki M, 2018, J ALLERGY CLIN IMMUN, V141, P391, DOI 10.1016/j.jaci.2017.05.041; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Venter C, 2006, PEDIAT ALLERG IMM-UK, V17, P356, DOI 10.1111/j.1399-3038.2006.00428.x; Williamson EJ, 2014, RESPIROLOGY, V19, P625, DOI 10.1111/resp.12312	23	48	48	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					644	+		10.1016/j.jaci.2018.07.038	http://dx.doi.org/10.1016/j.jaci.2018.07.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30171872	Green Published, Bronze			2022-12-18	WOS:000457718700023
J	Vukmanovic-Stejic, M; Chambers, ES; Suarez-Farinas, M; Sandhu, D; Fuentes-Duculan, J; Patel, N; Agius, E; Lacy, KE; Turner, CT; Larbi, A; Birault, V; Noursadeghi, M; Mabbott, NA; Rustin, MHA; Krueger, JG; Akbar, AN				Vukmanovic-Stejic, Milica; Chambers, Emma S.; Suarez-Farinas, Mayte; Sandhu, Daisy; Fuentes-Duculan, Judilyn; Patel, Neil; Agius, Elaine; Lacy, Katie E.; Turner, Carolin T.; Larbi, Anis; Birault, Veronique; Noursadeghi, Mandad; Mabbott, Neil A.; Rustin, Malcolm H. A.; Krueger, James G.; Akbar, Arne N.			Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aging; p38 mitogen-activated protein kinase; varicella zoster virus; inflammation	CELL-MEDIATED-IMMUNITY; VARICELLA-ZOSTER-VIRUS; OBSTRUCTIVE PULMONARY-DISEASE; PERSISTENT LCMV INFECTION; MEMORY T-CELLS; IN-VIVO; HERPES-ZOSTER; TNF-ALPHA; SKIN; MACROPHAGES	Background: Immunity decreases with age, which leads to reactivation of varicella zoster virus (VZV). In human subjects age-associated immune changes are usually measured in blood leukocytes; however, this might not reflect alterations in tissue specific immunity. Objectives: We used a VZV antigen challenge system in the skin to investigate changes in tissue-specific mechanisms involved in the decreased response to this virus during aging. Methods: We assessed cutaneous immunity based on the extent of erythema and induration after intradermal VZV antigen injection. We also performed immune histology and transcriptomic analyses on skin biopsy specimens taken from the challenge site in young (<40 years) and old (>65 years) subjects. Results: Old human subjects exhibited decreased erythema and induration, CD4+ and CD8+ T-cell infiltration, and attenuated global gene activation at the site of cutaneous VZV antigen challenge compared with young subjects. This was associated with increased sterile inflammation in the skin in the same subjects related to p38 mitogen-activated protein kinase-related proinflammatory cytokine production (P <.0007). We inhibited systemic inflammation in old subjects by means of pretreatment with an oral small-molecule p38 mitogen-activated protein kinase inhibitor (Losmapimod; GlaxoSmithKline, Brentford, United Kingdom), which reduced both serum C-reactive protein levels and peripheral blood monocyte secretion of IL-6 and TNF-alpha. In contrast, cutaneous responses to VZV antigen challenge were increased significantly in the same subjects (P <.0003). Conclusion: Excessive inflammation in the skin early after antigen challenge retards antigen-specific immunity. However, this can be reversed by inhibition of inflammatory cytokine production that can be used to promote vaccine efficacy and the treatment of infections and malignancy during aging.	[Vukmanovic-Stejic, Milica; Chambers, Emma S.; Sandhu, Daisy; Patel, Neil; Agius, Elaine; Lacy, Katie E.; Turner, Carolin T.; Noursadeghi, Mandad; Akbar, Arne N.] UCL, Div Infect & Immun, Rayne Bldg,5 Univ St, London WC1E 6EJ, England; [Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Sandhu, Daisy; Patel, Neil; Agius, Elaine; Lacy, Katie E.; Rustin, Malcolm H. A.] Royal Free Hosp, Dept Dermatol, London, England; [Lacy, Katie E.] Guys & St Thomas Hosp, NIHR Biomed Res Ctr, London, England; [Lacy, Katie E.] Kings Coll London, Cutaneous Med & Immunotherapy, St Johns Inst Dermatol, Div Genet & Mol Med,Sch Med,Guys Hosp, London, England; [Larbi, Anis] ASTAR, Inst Biomed Sci, Singapore, Singapore; [Birault, Veronique] Francis Crick Inst, London, England; [Mabbott, Neil A.] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Mabbott, Neil A.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland	University of London; University College London; Rockefeller University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Agency for Science Technology & Research (A*STAR); Francis Crick Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Vukmanovic-Stejic, M; Akbar, AN (corresponding author), UCL, Div Infect & Immun, Rayne Bldg,5 Univ St, London WC1E 6EJ, England.	m.vukmanovic-stejic@ucl.ac.uk; a.akbar@ucl.ac.uk	Chambers, Emma/AAI-3521-2021; Larbi, Anis/ABE-5868-2020	Chambers, Emma/0000-0003-0990-8835; Noursadeghi, Mahdad/0000-0002-4774-0853; Akbar, Arne/0000-0002-3763-9380; Turner, Carolin/0000-0002-1905-2834	Medical Research Council (MRC) Grand Challenge in Experimental Medicine (MICA) Grant [MR/M003833/1]; MRC New Investigator award [G0901102]; Dermatrust; British Skin Foundation [BSF5012]; National Institute for Health Research University College London Hospitals Biomedical Research Centre; BBSRC [BBS/E/D/10002071, BBS/E/D/20002174, BB/L025302/1, BB/G530433/1, BB/H020519/1] Funding Source: UKRI; MRC [MR/M003833/1, MR/N017749/1, G0901102] Funding Source: UKRI	Medical Research Council (MRC) Grand Challenge in Experimental Medicine (MICA) Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC New Investigator award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dermatrust; British Skin Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council (MRC) Grand Challenge in Experimental Medicine (MICA) Grant (MR/M003833/1 to A.N.A., M.V.-S., V.B., N.A.M., and M.N.), an MRC New Investigator award (G0901102 to M.V.-S.), Dermatrust (to A.N.A.), the British Skin Foundation (BSF5012 to A.N.A.), and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Abendroth A, 2001, SEMIN IMMUNOL, V13, P27, DOI 10.1006/smim.2001.0293; Agius E, 2009, J EXP MED, V206, P1929, DOI 10.1084/jem.20090896; Akbar AN, 2013, CLIN EXP IMMUNOL, V173, P163, DOI 10.1111/cei.12107; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Bouree P, 2003, PATHOL BIOL, V51, P581, DOI 10.1016/j.patbio.2003.09.004; Di Mitri D, 2011, J IMMUNOL, V187, P2093, DOI 10.4049/jimmunol.1100978; Diffey BL, 2005, BRIT J DERMATOL, V153, P679, DOI 10.1111/j.1365-2133.2005.06799.x; Dominguez A, 2016, EXPERT REV VACCINES, P1; Fehr S, 2015, CELL PHYSIOL BIOCHEM, V36, P2237, DOI 10.1159/000430188; Fourati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10369; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Furman D, 2017, NAT MED, V23, P174, DOI 10.1038/nm.4267; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Hernandez AL, 2015, J CLIN INVEST, V125, P4212, DOI 10.1172/JCI81151; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lanna A, 2017, NAT IMMUNOL, V18, P354, DOI 10.1038/ni.3665; Lanna A, 2014, NAT IMMUNOL, V15, P965, DOI 10.1038/ni.2981; Laube S, 2004, AGEING RES REV, V3, P69, DOI 10.1016/j.arr.2003.08.003; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Levin MJ, 2012, CURR OPIN IMMUNOL, V24, P494, DOI 10.1016/j.coi.2012.06.002; Lomas DA, 2012, J CLIN PHARMACOL, V52, P416, DOI 10.1177/0091270010397050; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MARRIE TJ, 1988, J ALLERGY CLIN IMMUN, V81, P836, DOI 10.1016/0091-6749(88)90939-6; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; Min B, 2015, J CLIN INVEST, V125, P4002, DOI 10.1172/JCI84690; MOESGAARD F, 1987, ALLERGY, V42, P591, DOI 10.1111/j.1398-9995.1987.tb00389.x; Muyanja E, 2014, J CLIN INVEST, V124, P1, DOI [10.1172/JCI72323, DOI 10.1172/JCI72323]; Natsuaki Y, 2014, NAT IMMUNOL, V15, P1064, DOI 10.1038/ni.2992; Oxman MN, 2009, J AM OSTEOPATH ASSOC, V109, pS13; Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816; Patterson H, 2014, CLIN EXP IMMUNOL, V176, P1, DOI 10.1111/cei.12248; Pence BD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036403; Reed JR, 2004, J EXP MED, V199, P1433, DOI 10.1084/jem.20040178; Sadaoka K, 2008, J INFECT DIS, V198, P1327, DOI 10.1086/592219; Sweeney SE, 2009, NAT REV RHEUMATOL, V5, P475, DOI 10.1038/nrrheum.2009.171; Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214; Thome JJC, 2015, TRENDS IMMUNOL, V36, P428, DOI 10.1016/j.it.2015.05.003; Vossen MTM, 2005, J INFECT DIS, V191, P198, DOI 10.1086/426866; Vukmanovic-Stejic M, 2008, J CLIN INVEST, V118, P3639, DOI 10.1172/JCI35834; Vukmanovic-Stejic M, 2015, J INVEST DERMATOL, V135, P1752, DOI 10.1038/jid.2015.63; Vukmanovic-Stejic M, 2013, J IMMUNOL, V190, P977, DOI 10.4049/jimmunol.1201331; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Watanabe R, 2017, J CLIN INVEST, V127, P2725, DOI 10.1172/JCI92167; Watz H, 2014, LANCET RESP MED, V2, P63, DOI 10.1016/S2213-2600(13)70200-5; Wilson EB, 2013, SCIENCE, V340, P202, DOI 10.1126/science.1235208; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Zhang WC, 2015, CELL RES, V25, P893, DOI 10.1038/cr.2015.87	48	48	48	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					844	856		10.1016/j.jaci.2017.10.032	http://dx.doi.org/10.1016/j.jaci.2017.10.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29155150	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000443726500017
J	Renz, H; Adkins, BD; Bartfeld, S; Blumberg, RS; Farber, DL; Garssen, J; Ghazal, P; Hackam, DJ; Marsland, BJ; Mccoy, KD; Penders, J; Prinz, I; Verhasselt, V; von Mutius, E; Weiser, JN; Wesemann, DR; Hornef, MW				Renz, Harald; Adkins, Becky D.; Bartfeld, Sina; Blumberg, Richard S.; Farber, Donna L.; Garssen, Johan; Ghazal, Peter; Hackam, David J.; Marsland, Benjamin J.; McCoy, Kathy D.; Penders, John; Prinz, Immo; Verhasselt, Valerie; von Mutius, Erika; Weiser, Jeffrey N.; Wesemann, Duane R.; Hornef, Mathias W.			The neonatal window of opportunity-early priming for life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							MICROBIOTA		[Renz, Harald] Univ Marburg, Marburg, Germany; [Adkins, Becky D.] Univ Miami, Miami, FL USA; [Bartfeld, Sina] Univ Wurzburg, Wurzburg, Germany; [Blumberg, Richard S.] Harvard Univ, Cambridge, MA 02138 USA; [Farber, Donna L.] Columbia Univ, Med Ctr, New York, NY USA; [Garssen, Johan] Univ Utrecht, Fac Sci, UIPS, Utrecht, Netherlands; [Ghazal, Peter] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Hackam, David J.] Johns Hopkins Univ, Baltimore, MD USA; [Marsland, Benjamin J.] Univ Hosp Lausanne, Lausanne, Switzerland; [McCoy, Kathy D.] Univ Calgary, Calgary, AB, Canada; [Penders, John] Maastricht Univ, Care & Publ Hlth Res Inst Caphri, Maastricht, Netherlands; [Penders, John] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Med Microbiol, Maastricht, Netherlands; [Prinz, Immo] Hannover Med Sch, Hannover, Germany; [Verhasselt, Valerie] Univ Western Australia, Sch Mol Sci, Family Larsson Rosenquist Fdn Chair Human Lactol, Perth, WA, Australia; [von Mutius, Erika] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Munich, Germany; [von Mutius, Erika] German Ctr Lung Res, CPC M, Munich, Germany; [Weiser, Jeffrey N.] NYU, Sch Med, New York, NY USA; [Wesemann, Duane R.] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; [Hornef, Mathias W.] RWTH Univ Hosp, Aachen, Germany	Philipps University Marburg; University of Miami; University of Wurzburg; Harvard University; Columbia University; Utrecht University; University of Edinburgh; Johns Hopkins University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Calgary; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Hannover Medical School; University of Western Australia; University of Munich; New York University; Harvard University; Brigham & Women's Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Renz, H (corresponding author), Univ Marburg, Inst Lab Med, Baldingerstr 35043, D-35043 Marburg, Germany.	harald.renz@uk-gm.de	Verhasselt, Valerie/AAO-2373-2020; McCoy, Kathy/ABD-5814-2021; Penders, John/A-1280-2011; Prinz, Immo/A-3026-2010	Penders, John/0000-0001-9146-5919; Weiser, Jeffrey/0000-0001-7168-8090; Wesemann, Duane/0000-0002-6690-944X; Prinz, Immo/0000-0002-8789-9578; Bartfeld, Sina/0000-0003-2493-8282; Farber, Donna/0000-0001-8236-9183; Hackam, David/0000-0001-5195-8807; Ghazal, Peter/0000-0003-0035-2228; Hornef, Mathias/0000-0001-6096-9110; verhasselt, valerie/0000-0002-5732-9048	Volkswagen Foundation, Hannover, Germany; Nutricia Research Foundation; Dutch government funding (NWO); European Union; EDB; German Research Foundation [SPP1656, SPP1580, IRTG1273, Ho-2237/12-1]; Niedersachsen Research Network on Neuroinfectiology (N-RENNT); SNSF [SNSF310030_134902]; European Research Council [281785]; VIDI grant from the Netherlands Organisation for Scientific Research; Joint Programme Initiatives grant (Intestinal Microbiomics GI-MDH) within the Healthy Diet for Healthy Living programme; German Lung Center, Disease Area of Allergy and Asthma; German Research Foundation (DFG); German Federal Ministry of Education and Research (BMBF); Dutch government funding (CCC); Dutch government funding (STW); Dutch government funding (RAAK/PRO); Dutch government funding (TKI);  [SFB900]; MRC [G0701289] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319, R01DK083752, R01DK117186, T32DK007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078238] Funding Source: NIH RePORTER	Volkswagen Foundation, Hannover, Germany(Volkswagen); Nutricia Research Foundation(Danone Nutricia); Dutch government funding (NWO); European Union(European Commission); EDB; German Research Foundation(German Research Foundation (DFG)); Niedersachsen Research Network on Neuroinfectiology (N-RENNT); SNSF(Swiss National Science Foundation (SNSF)); European Research Council(European Research Council (ERC)European Commission); VIDI grant from the Netherlands Organisation for Scientific Research; Joint Programme Initiatives grant (Intestinal Microbiomics GI-MDH) within the Healthy Diet for Healthy Living programme; German Lung Center, Disease Area of Allergy and Asthma; German Research Foundation (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Dutch government funding (CCC); Dutch government funding (STW); Dutch government funding (RAAK/PRO); Dutch government funding (TKI); ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The conference and the preparation of this manuscript were supported by an unrestricted grant of the Volkswagen Foundation, Hannover, Germany. J.G. receives grants from Nutricia Research Foundation, Dutch government funding (NWO, CCC, STW, RAAK/PRO, TKI), the European Union, and EDB. Research in M.W.H.'s laboratory is supported by the German Research Foundation (SPP1656, SPP1580, IRTG1273, and Ho-2237/12-1) and the Niedersachsen Research Network on Neuroinfectiology (N-RENNT). K.D.M. is supported by a grant from the SNSF (SNSF310030_134902) and the European Research Council (FP/2007-2013) agreement number 281785. J.P. is supported by a VIDI grant from the Netherlands Organisation for Scientific Research and a Joint Programme Initiatives grant (Intestinal Microbiomics GI-MDH) within the Healthy Diet for Healthy Living programme. I.P. is supported by the grant of the SFB900 (project B8). H.R. is supported by the German Lung Center, Disease Area of Allergy and Asthma. E.M. receives research grants from the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF).	Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Egan CE, 2016, J CLIN INVEST, V126, P495, DOI 10.1172/JCI83356; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Smith CL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5649; Torow N, 2017, J IMMUNOL, V198, P557, DOI 10.4049/jimmunol.1601253; Turfkruyer M, 2016, MUCOSAL IMMUNOL, V9, P479, DOI 10.1038/mi.2015.114; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Zens KD, 2017, J EXP MED, V214, P2915, DOI 10.1084/jem.20170521	10	48	48	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1212	1214		10.1016/j.jaci.2017.11.019	http://dx.doi.org/10.1016/j.jaci.2017.11.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29247715	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000429197800005
J	Turi, KN; Romick-Rosendale, L; Ryckman, KK; Hartert, TV				Turi, Kedir N.; Romick-Rosendale, Lindsey; Ryckman, Kelli K.; Hartert, Tina V.			A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Metabolomics; asthma; respiratory tract infections; systems approach	EXHALED BREATH CONDENSATE; RESPIRATORY SYNCYTIAL VIRUS; LIQUID-CHROMATOGRAPHY; FALSE DISCOVERIES; ELECTRONIC NOSE; INDUCED SPUTUM; HUMAN URINE; BIOMARKER; STABILITY; SERUM	Because asthma is a disease that results from host-environment interactions, an approach that allows assessment of the effect of the environment on the host is needed to understand the disease. Metabolomics has appealing potential as an application to study pathways to childhood asthma development. The objective of this review is to provide an overview of metabolomics methods and their application to understanding host-environment pathways in asthma development. We reviewed recent literature on advances in metabolomics and their application to study pathways to childhood asthma development. We highlight the (1) potential of metabolomics in understanding the pathogenesis of disease and the discovery of biomarkers; (2) choice of metabolomics techniques, biospecimen handling, and data analysis; (3) application to studying the role of the environment on asthma development; (4) review of metabolomics applied to the outcome of asthma; (5) recommendations for application of metabolomics-based -omics data integration in understanding disease pathogenesis; and (6) limitations. In conclusion, metabolomics allows use of biospecimens to identify useful biomarkers and pathways involved in disease development and subsequently to inform a greater understanding of disease pathogenesis and endotypes and prediction of the clinical course of childhood asthma phenotypes.	[Turi, Kedir N.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA; [Romick-Rosendale, Lindsey] Cincinnati Childrens Hosp Med Ctr, Div Pathol & Lab Med, Cincinnati, OH 45229 USA; [Ryckman, Kelli K.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Ryckman, Kelli K.] Univ Iowa, Coll Publ Hlth, Dept Pediat, Iowa City, IA USA; [Ryckman, Kelli K.] Univ Iowa, Carver Coll Med, Iowa City, IA USA	Vanderbilt University; Cincinnati Children's Hospital Medical Center; University of Iowa; University of Iowa; University of Iowa	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu		Turi, Kedir/0000-0002-3853-9357; Ryckman, Kelli/0000-0002-9496-4147; Romick-Rosendale, Lindsey/0000-0002-7252-1193	National Institutes of Health [U19AI95227, K24 AI 77930, R21HD087864, T32HL087738]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD087864] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002243] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL087738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095227, K24AI077930] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	Supported in part by National Institutes of Health grants U19AI95227, K24 AI 77930, R21HD087864, and T32HL087738.	Ahmadzai H, 2013, CLIN CHEM LAB MED, V51, P1343, DOI 10.1515/cclm-2012-0593; Alonso A, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00023; Atzei A, 2011, J MATERN-FETAL NEO M, V24, P60, DOI 10.3109/14767058.2011.607012; Bakakos P, 2011, CURR MED CHEM, V18, P1415, DOI 10.2174/092986711795328337; Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785; Bartel J, 2013, COMPUT STRUCT BIOTEC, V4, DOI 10.5936/csbj.201301009; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Bernini P, 2011, J BIOMOL NMR, V49, P231, DOI 10.1007/s10858-011-9489-1; Bhatnagar BS, 2007, PHARM DEV TECHNOL, V12, P505, DOI 10.1080/10837450701481157; Bickel PJ, 2009, PHILOS T R SOC A, V367, P4313, DOI 10.1098/rsta.2009.0164; Blaise BJ, 2016, ANAL CHEM, V88, P5179, DOI 10.1021/acs.analchem.6b00188; Blume C, 2013, EUR J PHARM BIOPHARM, V84, P394, DOI 10.1016/j.ejpb.2012.12.014; Booth SC, 2013, COMPUT STRUCT BIOTEC, V4, DOI 10.5936/csbj.201301003; Broadhurst DI, 2006, METABOLOMICS, V2, P171, DOI 10.1007/s11306-006-0037-z; Caldeira M, 2012, J CHROMATOGR A, V1254, P87, DOI 10.1016/j.chroma.2012.07.023; Carraro S, 2013, ALLERGY, V68, P110, DOI 10.1111/all.12063; Carraro S, 2007, AM J RESP CRIT CARE, V175, P986, DOI 10.1164/rccm.200606-769OC; Chandler JD, 2016, AM J PHYSIOL-REG I, V311, pR906, DOI 10.1152/ajpregu.00298.2016; Cuhadar S, 2013, BIOCHEM MEDICA, V23, P70, DOI 10.11613/BM.2013.009; Dallinga JW, 2010, CLIN EXP ALLERGY, V40, P68, DOI 10.1111/j.1365-2222.2009.03343.x; Dame ZT, 2015, METABOLOMICS, V11, P1864, DOI 10.1007/s11306-015-0840-5; de Chassey B, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0115-1; Dodig S, 2013, BIOCHEM MEDICA, V23, P281; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Draper J, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-227; Dunn WB, 2013, METABOLOMICS, V9, pS44, DOI 10.1007/s11306-012-0434-4; Dunn WB, 2012, BIOANALYSIS, V4, P2249, DOI [10.4155/bio.12.204, 10.4155/BIO.12.204]; Durek P, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-100; Emwas AH, 2016, J PROTEOME RES, V15, P360, DOI 10.1021/acs.jproteome.5b00885; Emwas AH, 2015, METABOLOMICS, V11, P872, DOI 10.1007/s11306-014-0746-7; Esther CR, 2009, AM J PHYSIOL-LUNG C, V296, pL987, DOI 10.1152/ajplung.90512.2008; Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, P258, DOI 10.1016/j.jaci.2013.10.012; Fowler SJ, 2015, THORAX, V70, P320, DOI 10.1136/thoraxjnl-2014-206273; Fronius M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00146; Gahleitner F, 2013, BIOANALYSIS, V5, P2239, DOI 10.4155/bio.13.184; Gieger C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000282; Gika HG, 2008, J CHROMATOGR A, V1189, P314, DOI 10.1016/j.chroma.2007.10.066; Gika HG, 2007, J PROTEOME RES, V6, P3291, DOI 10.1021/pr070183p; Gowda GAN, 2008, EXPERT REV MOL DIAGN, V8, P617, DOI 10.1586/14737159.8.5.617; Ho C S, 2003, Clin Biochem Rev, V24, P3; Idle JR, 2007, CELL METAB, V6, P348, DOI 10.1016/j.cmet.2007.10.005; Ioannidis JPA, 2011, SCIENCE, V334, P1230, DOI 10.1126/science.1211811; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Johnson CH, 2012, ANNU REV PHARMACOL, V52, P37, DOI 10.1146/annurev-pharmtox-010611-134748; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kettunen J, 2012, NAT GENET, V44, P269, DOI 10.1038/ng.1073; Kim S, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2170-4; Kim YI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113100; Kohler I, 2016, BIOANALYSIS, V8, P1509, DOI 10.4155/bio-2016-0090; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kuban P, 2013, ANAL CHIM ACTA, V805, P1, DOI 10.1016/j.aca.2013.07.049; Kupczyk M, 2012, J INTERN MED, V272, P121, DOI 10.1111/j.1365-2796.2012.02558.x; Lee H, 2013, KOREAN J INTERN MED, V28, P285, DOI 10.3904/kjim.2013.28.3.285; Lee YH, 2009, AM J DENT, V22, P241; Leung TF, 2013, THER ADV RESPIR DIS, V7, P297, DOI 10.1177/1753465813496863; Lewis NS, 2004, ACCOUNTS CHEM RES, V37, P663, DOI 10.1021/ar030120m; Lock EF, 2013, BIOINFORMATICS, V29, P2610, DOI 10.1093/bioinformatics/btt425; Lysenko A, 2016, BIODATA MIN, V9, DOI 10.1186/s13040-016-0102-8; Ma HW, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100177; Magdeldin S, 2016, PROTEOMICS, V16, P80, DOI 10.1002/pmic.201500214; Maniscalco JM, 2007, MAR MAMMAL SCI, V23, P306, DOI 10.1111/j.1748-7692.2007.00103.x; Mattarucchi E, 2012, BIOMED CHROMATOGR, V26, P89, DOI 10.1002/bmc.1631; McGeachie MJ, 2015, IMMUN INFLAMM DIS, V3, P224, DOI 10.1002/iid3.61; Mendivil CO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123344; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Milner JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097238; Misra BB, 2016, ELECTROPHORESIS, V37, P86, DOI 10.1002/elps.201500417; Montuschi P, 2009, J CHROMATOGR B, V877, P1272, DOI 10.1016/j.jchromb.2009.01.036; Moschino L, 2015, PAEDIATR RESPIR REV, V16, P205, DOI 10.1016/j.prrv.2015.05.001; Nicholas B, 2009, BIOCHEM SOC T, V37, P868, DOI 10.1042/BST0370868; Pacchiarotta T, 2012, BIOANALYSIS, V4, P919, DOI [10.4155/bio.12.61, 10.4155/BIO.12.61]; Papin JF, 2013, AM J PHYSIOL-LUNG C, V304, pL530, DOI 10.1152/ajplung.00173.2012; Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Rehak NN, 2000, CLIN CHEM LAB MED, V38, P335, DOI 10.1515/CCLM.2000.049; Renukaradhya GJ, 2015, J CONTROL RELEASE, V219, P622, DOI 10.1016/j.jconrel.2015.09.047; Ritter JB, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-61; Roberts LD, 2012, CURR PROTOC MOL BIOL; Rosenling T, 2011, CLIN CHEM, V57, P1703, DOI 10.1373/clinchem.2011.167601; Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038; Satagopam V, 2016, BIG DATA-US, V4, P97, DOI 10.1089/big.2015.0057; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Scarlata S, 2015, EXPERT REV MOL DIAGN, V15, P933, DOI 10.1586/14737159.2015.1043895; Schoenebeck B, 2015, BBA-PROTEINS PROTEOM, V1854, P741, DOI 10.1016/j.bbapap.2015.01.015; Scrivo R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0445-5; Serkova NJ, 2011, AM J RESP CRIT CARE, V184, P647, DOI 10.1164/rccm.201103-0474CI; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shen RL, 2009, BIOINFORMATICS, V25, P2906, DOI 10.1093/bioinformatics/btp543; Sinha A, 2012, EUR RESPIR J, V39, P500, DOI 10.1183/09031936.00047711; Smolinska A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095668; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Stone MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084471; Teahan O, 2006, ANAL CHEM, V78, P4307, DOI 10.1021/ac051972y; Theodoridis G, 2011, MASS SPECTROM REV, V30, P884, DOI 10.1002/mas.20306; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tisch U, 2014, J BREATH RES, V8, DOI 10.1088/1752-7155/8/2/027103; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q; Turi KN, 2016, AM J RESP CRIT CARE, V193; Tzoulaki I, 2014, AM J EPIDEMIOL, V180, P129, DOI 10.1093/aje/kwu143; van de Kant KDG, 2013, EUR RESPIR J, V41, P183, DOI 10.1183/09031936.00122411; van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142; van den Oord EJCG, 2008, AM J MED GENET B, V147B, P637, DOI 10.1002/ajmg.b.30650; van der Schee MP, 2015, EUR RESPIR J, V45, P440, DOI 10.1183/09031936.00044414; Veenstra TD, 2012, GENOME MED, V4, DOI 10.1186/gm339; Vinaixa M, 2012, METABOLITES, V2, P775, DOI 10.3390/metabo2040775; Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923; Worley B, 2013, CURR METABOL, V1, P92, DOI 10.2174/2213235X11301010092; Wu JQ, 2015, EXPERT REV PROTEOMIC, V12, P623, DOI 10.1586/14789450.2015.1094380; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329; Yang W, 2013, ANAL CHEM, V85, P2606, DOI 10.1021/ac303576b; Yin PY, 2015, ANAL BIOANAL CHEM, V407, P4879, DOI 10.1007/s00216-015-8565-x	115	48	51	4	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1191	1201		10.1016/j.jaci.2017.04.021	http://dx.doi.org/10.1016/j.jaci.2017.04.021			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28479327	Green Accepted, Bronze			2022-12-18	WOS:000429197800003
J	Luo, JL; Feng, J; Yu, G; Yang, P; Mack, MR; Du, JH; Yu, WH; Qian, AH; Zhang, YJ; Liu, SB; Yin, SJ; Xu, A; Cheng, JZ; Liu, QY; O'Neil, RG; Xia, Y; Ma, L; Carlton, SM; Kim, BS; Renner, K; Liu, Q; Hu, HZ				Luo, Jialie; Feng, Jing; Yu, Guang; Yang, Pu; Mack, Madison R.; Du, Junhui; Yu, Weihua; Qian, Aihua; Zhang, Yujin; Liu, Shenbin; Yin, Shijin; Xu, Amy; Cheng, Jizhong; Liu, Qingyun; O'Neil, Roger G.; Xia, Yang; Ma, Liang; Carlton, Susan M.; Kim, Brian S.; Renner, Kenneth; Liu, Qin; Hu, Hongzhen			Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transient receptor potential vanilloid 4; chronic itch; macrophage; keratinocyte	DELAYED-TYPE HYPERSENSITIVITY; MOUSE MODEL; CONTACT SENSITIVITY; SENSITIZATION PHASE; DENDRITIC CELLS; TRPV4 CHANNEL; DRY SKIN; MICE; INFLAMMATION; PLATELETS	Background: Chronic itch is a highly debilitating symptom that underlies many medical disorders with no universally effective treatments. Although unique neuronal signaling cascades in the sensory ganglia and spinal cord have been shown to critically promote the pathogenesis of chronic itch, the role of skin-associated cells remains poorly understood. Objective: We sought to examine the cutaneous mechanisms underlying transient receptor potential vanilloid 4 (TRPV4)-mediated allergic and nonallergic chronic itch. Methods: Expression of TRPV4 in chronic itch and healthy control skin preparations was examined by using real-time RT-PCR. Trpv4(eGFP) mice were used to study the expression and function of TRPV4 in the skin by means of immunofluorescence staining, flow cytometry, calcium imaging, and patch-clamp recordings. Genetic and pharmacologic approaches were used to examine the role and underlying mechanisms of TRPV4 in mouse models of dry skin-associated chronic itch and spontaneous scratching associated with squaric acid dibutylester-induced allergic contact dermatitis. Results: TRPV4 is selectively expressed by dermal macrophages and epidermal keratinocytes in mice. Lineage-specific deletion of TRPV4 in macrophages and keratinocytes reduces allergic and nonallergic chronic itch in mice, respectively. Importantly, TRPV4 expression is significantly increased in skin biopsy specimens from patients with chronic idiopathic pruritus in comparison with skin from healthy control subjects. Moreover, TRPV4-dependent chronic itch requires 5-hydroxytryptamine (5-HT) signaling secondary to activation of distinct 5-HT receptors in mice with allergic and those with nonallergic chronic itch conditions. Conclusion: Our study reveals previously unrecognized mechanisms by which TRPV4-expressing epithelial and immune cells in the skin critically and dynamically mediate chronic itch and unravels novel targets for therapeutics in the setting of chronic itch.	[Luo, Jialie; Feng, Jing; Yu, Guang; Yang, Pu; Mack, Madison R.; Liu, Shenbin; Xu, Amy; Kim, Brian S.; Liu, Qin; Hu, Hongzhen] Washington Univ, Sch Med, Dept Anesthesiol, Ctr Study Itch, Campus Box 8054,660 South Euclid Ave, St Louis, MO 63110 USA; [Ma, Liang; Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, Campus Box 8054,660 South Euclid Ave, St Louis, MO 63110 USA; [Yu, Guang] Nanjing Univ Chinese Med, Sch Med & Life Sci, Nanjing, Jiangsu, Peoples R China; [Du, Junhui; Carlton, Susan M.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Yu, Weihua] Chongqing Med Univ, Dept Anat, Chongqing, Peoples R China; [Qian, Aihua] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Zhang, Yujin; Xia, Yang] Univ Texas Houston, Dept Biochem & Mol Biol, Med Sch Houston, Houston, TX USA; [O'Neil, Roger G.] Univ Texas Houston, Dept Integrat Biol & Pharmacol, Med Sch Houston, Houston, TX USA; [Yin, Shijin] South Cent Univ Nationalities, Coll Pharm, Wuhan, Hubei, Peoples R China; [Cheng, Jizhong] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Liu, Qingyun] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; [Liu, Qingyun] Univ Texas Hlth Sci Ctr Houston, Texas Therapeut Inst, Houston, TX 77030 USA; [Renner, Kenneth] Univ South Dakota, Dept Biol, Ctr Brain & Behav Res, Vermillion, SD USA	Washington University (WUSTL); Washington University (WUSTL); Nanjing University of Chinese Medicine; University of Texas System; University of Texas Medical Branch Galveston; Chongqing Medical University; Shanghai Jiao Tong University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; South Central Minzu University; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of South Dakota	Liu, Q; Hu, HZ (corresponding author), Washington Univ, Sch Med St Louis, Dept Anesthesiol, Ctr Study Itch, Campus Box 8054,660 South Euclid Ave, St Louis, MO 63110 USA.	qinliu@wustl.edu; hongzhen.hu@wustl.edu	Feng, Jing/C-1729-2018; Yu, Weihua/GLR-7246-2022; Kim, Brian/GZK-6649-2022	Feng, Jing/0000-0001-6726-7912; Kim, Brian/0000-0002-8100-7161; Mack, Madison/0000-0003-2812-0349; Hu, Hongzhen/0000-0002-8967-7522	National Institutes of Health [R01GM101218A, R01DK103901]; Center for the Study of Itch of the Department of Anesthesiology of Washington University;  [R01DA019921];  [R01EY024704];  [R01AR070116];  [R01DK098401];  [P30DK052574]; NATIONAL EYE INSTITUTE [R01EY024704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI125743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577, R01AR070116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK098401, P30DK052574, R01DK103901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM101218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA019921] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for the Study of Itch of the Department of Anesthesiology of Washington University; ; ; ; ; ; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported in whole or in part by grants from the National Institutes of Health: (R01GM101218A and R01DK103901) and the Center for the Study of Itch of the Department of Anesthesiology of Washington University (to H.H.), grant R01DA019921 (to K.R.), R01EY024704 (to Q.L.), R01AR070116 (to B.S.K.), R01DK098401 (to R.G.O.), and P30DK052574 (to Washington University DDRCC).	Akiyama T, 2010, PAIN, V151, P378, DOI 10.1016/j.pain.2010.07.024; Akiyama T, 2016, J INVEST DERMATOL, V136, P154, DOI 10.1038/JID.2015.388; Akiyama T, 2013, NEUROSCIENCE, V250, P697, DOI 10.1016/j.neuroscience.2013.07.035; Akiyama T, 2012, J INVEST DERMATOL, V132, P1886, DOI 10.1038/jid.2012.52; Alessandri-Haber N, 2005, PAIN, V118, P70, DOI 10.1016/j.pain.2005.07.016; Alexander R, 2013, BRIT J PHARMACOL, V168, P761, DOI 10.1111/j.1476-5381.2012.02186.x; Berger TG, 2013, JAMA-J AM MED ASSOC, V310, P2443, DOI 10.1001/jama.2013.282023; Chen Y, 2016, J BIOL CHEM, V291, P10252, DOI 10.1074/jbc.M116.716464; Chun KH, 2000, J LEUKOCYTE BIOL, V68, P471; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Everaerts W, 2010, P NATL ACAD SCI USA, V107, P19084, DOI 10.1073/pnas.1005333107; Farage MA, 2009, AM J CLIN DERMATOL, V10, P73, DOI 10.2165/00128071-200910020-00001; Garcia-Elias A, 2014, HANDB EXP PHARMACOL, V222, P293, DOI 10.1007/978-3-642-54215-2_12; Geba GP, 1996, J IMMUNOL, V157, P557; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Gros E, 2012, CLIN EXP ALLERGY, V42, P1161, DOI 10.1111/j.1365-2222.2012.03964.x; Han L, 2013, NAT NEUROSCI, V16, P174, DOI 10.1038/nn.3289; Han SK, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002353; Hill ND, 2015, CLIN DERMATOL, V33, P300, DOI 10.1016/j.clindermatol.2014.12.001; Lechner SG, 2011, NEURON, V69, P332, DOI 10.1016/j.neuron.2010.12.028; Lee MG, 2008, J IMMUNOL, V180, P2251, DOI 10.4049/jimmunol.180.4.2251; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Lin ZM, 2012, AM J HUM GENET, V90, P558, DOI 10.1016/j.ajhg.2012.02.006; Lombardi F, 2012, PLATELETS, V23, P17, DOI 10.3109/09537104.2011.594190; Luo JL, 2015, CELL MOL LIFE SCI, V72, P3201, DOI 10.1007/s00018-015-1904-4; Luo JL, 2012, J INVEST DERMATOL, V132, P2158, DOI 10.1038/jid.2012.144; Mamenko M, 2015, AM J PHYSIOL-RENAL, V308, pF275, DOI 10.1152/ajprenal.00485.2014; Matterne U, 2009, ACTA DERM-VENEREOL, V89, P250, DOI 10.2340/00015555-0641; McNicol Archibald, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P99, DOI 10.2174/187152908784533739; Miyamoto T, 2002, JPN J PHARMACOL, V88, P285, DOI 10.1254/jjp.88.285; Morita T, 2015, NEURON, V87, P124, DOI 10.1016/j.neuron.2015.05.044; Nordlind K, 2008, EXP DERMATOL, V17, P301, DOI 10.1111/j.1600-0625.2007.00670.x; Qu LT, 2014, BRAIN, V137, P1039, DOI 10.1093/brain/awu007; Roberts AC, 2011, BIOL PSYCHIAT, V69, P1185, DOI 10.1016/j.biopsych.2010.12.037; Ryskamp DA, 2011, J NEUROSCI, V31, P7089, DOI 10.1523/JNEUROSCI.0359-11.2011; Sato K, 1998, J IMMUNOL, V161, P6835; Sokabe Takaaki, 2010, Commun Integr Biol, V3, P619, DOI 10.4161/cib.3.6.13461; Steinhoff M, 2009, J INVEST DERMATOL, V129, P531, DOI 10.1038/jid.2008.440; Suman M, 2003, J DERMATOL, V30, P649, DOI 10.1111/j.1346-8138.2003.tb00453.x; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tamagawa-Mineoka R, 2015, J DERMATOL SCI, V77, P93, DOI 10.1016/j.jdermsci.2014.10.003; Tamoutounour S, 2013, IMMUNITY, V39, P925, DOI 10.1016/j.immuni.2013.10.004; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; Thorneloe KS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004276; Vergnolle N, 2010, BRIT J PHARMACOL, V159, P1161, DOI 10.1111/j.1476-5381.2009.00590.x; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wuescher LM, 2015, J THROMB HAEMOST, V13, P303, DOI 10.1111/jth.12795; Xu AZ, 2016, J AM ACAD DERMATOL, V74, P1017, DOI 10.1016/j.jaad.2015.11.029; Yin SJ, 2013, J CLIN INVEST, V123, P3941, DOI 10.1172/JCI66413; Yosipovitch G., 2004, International Journal of Cosmetic Science, V26, P1, DOI 10.1111/j.0142-5463.2004.00199.x	51	48	51	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					608	+		10.1016/j.jaci.2017.05.051	http://dx.doi.org/10.1016/j.jaci.2017.05.051			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28807414	Green Accepted, Bronze			2022-12-18	WOS:000424410800017
J	Karta, MR; Rosenthal, PS; Beppu, A; Vuong, CY; Miller, M; Das, S; Kurten, RC; Doherty, TA; Broide, DH				Karta, Maya R.; Rosenthal, Peter S.; Beppu, Andrew; Vuong, Christine Y.; Miller, Marina; Das, Sudipta; Kurten, Richard C.; Doherty, Taylor A.; Broide, David H.			beta(2) integrins rather than beta(1) integrins mediate Alternaria-induced group 2 innate lymphoid cell trafficking to the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cell; integrin; adhesion; Alternaria alternata	PERIPHERAL-BLOOD; INFLAMMATION; ACTIVATION; EXPRESSION	Background: Group 2 innate lymphoid cells (ILC2s) expand in the lungs of mice during type 2 inflammation induced by the fungal allergen Alternaria alternata. The increase in ILC2 numbers in the lung has been largely attributed to local proliferation and whether ILC2s migrate from the circulation to the lung after Alternaria exposure is unknown. Objective: We examined whether human (lung, lymph node, and blood) and mouse lung ILC2s express beta(1) and beta(2) integrin adhesion molecules and whether these integrins are required for trafficking of ILC2s into the lungs of mice. Methods: Human and mouse ILC2s were assessed for surface expression of beta(1) and beta(2) integrin adhesion molecules by using flow cytometry. The role of beta(1) and beta(2) integrins in ILC2 trafficking to the lungs was assessed by in vivo blocking of these integrins before airway exposure to Alternaria in mice. Results: Both human and mouse lung ILC2s express high levels of beta(1) and beta(2) integrin adhesion receptors. Intranasal administration of Alternaria challenge reduced ILC2 numbers in the bone marrow and concurrently increased blood and lung ILC2 numbers. In vivo blocking of beta(2) integrins (CD18) significantly reduced ILC2 numbers in the lungs but did not alter ILC2 proliferation, apoptosis, and function. In contrast, in vivo blocking of beta(1) integrins or alpha(4) integrins did not affect lung ILC2 numbers. Conclusion: ILC2 numbers increase in the mouse lung not only through local proliferation but also through trafficking from the circulation into the lung using beta(2) rather than beta(1) or alpha(4) integrins.	[Karta, Maya R.; Rosenthal, Peter S.; Beppu, Andrew; Vuong, Christine Y.; Miller, Marina; Das, Sudipta; Doherty, Taylor A.; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Kurten, Richard C.] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Kurten, Richard C.] Arkansas Childrens Hosp, Res Inst, 800 Marshall St, Little Rock, AR 72202 USA	University of California System; University of California San Diego; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Broide, DH (corresponding author), Biomed Sci Bldg,Rm 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090; Doherty, Taylor/0000-0003-3256-0398	National Institutes of Health (NIH) [AI 107779, AI 38425, AI 70535, AI 242236, AI 72115]; NIH grant [T32 AI 007469]; NIH [AI 114585]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI107779, R37AI038425, U19AI070535, R01AI114585, R01AI072115, T32AI007469, R01AI124236, R01AI038425] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) grants AI 107779, AI 38425, AI 70535, AI 242236, and AI 72115 (to D.H.B.), NIH grant T32 AI 007469 (to M.R.K.), and NIH grant AI 114585 (to T.A.D.).	Barlow JL, 2014, CURR OPIN ALLERGY CL, V14, P397, DOI 10.1097/ACI.0000000000000090; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bernink JH, 2014, CURR OPIN IMMUNOL, V31, P115, DOI 10.1016/j.coi.2014.10.007; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431; Di Rosa F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011; Doherty TA, 2015, J INVEST ALLERG CLIN, V25, P1; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Hogg N, 2011, NAT REV IMMUNOL, V11, P416, DOI 10.1038/nri2986; Johansson Mats W, 2013, Front Pharmacol, V4, P33, DOI 10.3389/fphar.2013.00033; Karta MR, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0581-6; Kim BS, 2015, COLD SPRING HARB PER, P7; Kim HK, 2014, INT ARCH ALLERGY IMM, V163, P92, DOI 10.1159/000356341; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Miyazaki Y, 2008, J IMMUNOL, V180, P590, DOI 10.4049/jimmunol.180.1.590; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Ridger VC, 2001, J IMMUNOL, V166, P3484, DOI 10.4049/jimmunol.166.5.3484; Ruiter B, 2015, CLIN EXP ALLERGY, V45, P1214, DOI 10.1111/cea.12568; Sakai Y, 2015, PATHOL INT, V65, P344, DOI 10.1111/pin.12294; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Sung KLP, 1997, J IMMUNOL, V158, P919; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wojno EDT, 2015, MUCOSAL IMMUNOL, V8, P1313, DOI 10.1038/mi.2015.21; Yang SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022560; Zarbock A, 2008, AM J PATHOL, V172, P1, DOI 10.2353/ajpath.2008.070502	40	48	48	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					329	+		10.1016/j.jaci.2017.03.010	http://dx.doi.org/10.1016/j.jaci.2017.03.010			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28366795	Bronze, Green Accepted			2022-12-18	WOS:000419312200038
J	Schwager, C; Kull, S; Behrends, J; Rockendorf, N; Schocker, F; Frey, A; Homann, A; Becker, WM; Jappe, U				Schwager, Christian; Kull, Skadi; Behrends, Jochen; Roeckendorf, Niels; Schocker, Frauke; Frey, Andreas; Homann, Arne; Becker, Wolf-Meinhard; Jappe, Uta			Peanut oleosins associated with severe peanut allergy-importance of lipophilic allergens for comprehensive allergy diagnostics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; lipophilic allergens; oleosins; Ara h 10; Ara h 11; Ara h 14; Ara h 15; BAT; roasting; epitope mapping	ARA H 2; IGE-CROSS-LINKING; OIL-BODIES; BIRCH POLLEN; PROTEINS; PURIFICATION; CHILDREN; ISOFORMS; BINDING; EUROPREVALL	Background: Peanut allergy is one of the most common and most severe food allergies in Western countries and its accurate diagnosis to prevent potential life-threatening allergic reactions is crucial. However, aqueous extracts used for routine diagnostic measurements are devoid of lipophilic allergens such as oleosins. We have recently succeeded in the isolation and purification of these unique proteins, and the present study evaluates their allergenic potential and clinical relevance. Objective: We sought to assess allergenicity and sensitization prevalence of oleosins obtained from both raw and in-shell roasted peanuts. In addition, we tested the utilization of natural and recombinant oleosins for allergy diagnostic purposes. Methods: Oleosin sensitization, prevalence, and impact of thermal processing were analyzed by immunoblot with sera from 52 peanut-allergic individuals displaying different clinical phenotypes. The application of natural and recombinant oleosins for allergy diagnostics was investigated by basophil activation test (BAT). IgE-binding epitopes were identified by oligopeptide microarray. Results: Sensitization to oleosins was observed exclusively in peanut-allergic subjects suffering from severe systemic reactions. IgE-binding capacity of oleosins derived from in-shell roasted peanuts was increased as shown by immunoblot analysis and BAT. Both natural and recombinant molecules can be used to identify oleosin-sensitized patients by BAT. A linear epitope of Ara h 15 was determined that displays high similarity to other seed-derived oleosins. Conclusions: Oleosins are clinically relevant peanut allergens and most likely associated with severe allergic symptoms. In shell roasting increases their allergenicity, which is consistent with the observation that most allergic reactions are in connection with roasted peanuts.	[Schwager, Christian; Kull, Skadi; Schocker, Frauke; Homann, Arne; Becker, Wolf-Meinhard; Jappe, Uta] German Ctr Lung Res DZL, ARCN, Prior Res Area Asthma & Allery, Div Clin & Mol Allergol,Res Ctr Borstel, Borstel, Germany; [Behrends, Jochen] Res Ctr Borstel, Core Facil Fluorescence Cytometry, Borstel, Germany; [Roeckendorf, Niels; Frey, Andreas] German Ctr Lung Res DZL, ARCN, Prior Res Area Asthma & Allergy, Res Ctr Borstel,Div Mucosal Immunol & Diagnost, Borstel, Germany; [Jappe, Uta] Univ Lubeck, Dept Internal Med, Interdisciplinary Allergy Outpatient Clin, Lubeck, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel; University of Lubeck	Jappe, U (corresponding author), Parkallee 35, D-23845 Borstel, Germany.	ujappe@fz-borstel.de			German Research Foundation (DFG) [JA 1007/2-1]	German Research Foundation (DFG)(German Research Foundation (DFG))	This study was supported by the German Research Foundation (DFG) (grant no. JA 1007/2-1). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akkerdaas JH, 2006, MOL NUTR FOOD RES, V50, P18, DOI 10.1002/mnfr.200500147; Ballmer-Weber BK, 2015, ALLERGY, V70, P391, DOI 10.1111/all.12574; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Cabanillas B, 2015, FOOD CHEM, V183, P18, DOI 10.1016/j.foodchem.2015.03.023; Cabanos C, 2011, PROTEIN J, V30, P457, DOI 10.1007/s10930-011-9351-z; Cao YY, 2015, FOOD CHEM, V177, P288, DOI 10.1016/j.foodchem.2015.01.052; Chang MT, 2013, J AGR FOOD CHEM, V61, P9666, DOI 10.1021/jf4019195; Chirumbolo S, 2011, CYTOM PART A, V79A, P102, DOI 10.1002/cyto.a.21008; Chirumbolo Salvatore, 2008, Clin Mol Allergy, V6, P12, DOI 10.1186/1476-7961-6-12; Chung SY, 2001, J AGR FOOD CHEM, V49, P3911, DOI 10.1021/jf001186o; Datema MR, 2015, J ALLERGY CLIN IMMUN, V136, P382, DOI 10.1016/j.jaci.2014.12.1949; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; GARCIAMAS J, 1995, PLANT MOL BIOL, V27, P205, DOI 10.1007/BF00019192; Glaumann S, 2013, J ALLER CL IMM-PRACT, V1, P698, DOI 10.1016/j.jaip.2013.08.010; Haider SR, 2010, ANAL BIOANAL CHEM, V397, P655, DOI 10.1007/s00216-010-3588-9; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Homann A, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0706-7; Huang MD, 2015, PLANT PHYSIOL, V169, P453, DOI 10.1104/pp.15.00634; Husain Z, 2012, J AM ACAD DERMATOL, V66, P136, DOI 10.1016/j.jaad.2011.02.031; Johnson KL, 2016, J AGR FOOD CHEM, V64, P1406, DOI 10.1021/acs.jafc.5b05492; Klemans RJB, 2013, CLIN EXP ALLERGY, V43, P967, DOI 10.1111/cea.12136; Klemans RJB, 2013, J ALLER CL IMM-PRACT, V1, P632, DOI 10.1016/j.jaip.2013.07.014; Knol EF, 2006, MOL NUTR FOOD RES, V50, P620, DOI 10.1002/mnfr.200500272; Kukkonen AK, 2015, ALLERGY, V70, P1239, DOI 10.1111/all.12671; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; LEE K, 1995, PLANT J, V7, P603, DOI 10.1046/j.1365-313X.1995.7040603.x; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; LI M, 1992, J BIOL CHEM, V267, P8245; Li M, 2002, J BIOL CHEM, V277, P37888, DOI 10.1074/jbc.M202721200; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Maurer S, 2013, J PHYS CHEM B, V117, P13872, DOI 10.1021/jp403893n; Millichip M, 1996, BIOCHEM J, V314, P333, DOI 10.1042/bj3140333; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; MURPHY DJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P86, DOI 10.1016/0167-4781(91)90156-G; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Niggemann B, 2011, ALLERGO J, V20, P149; Ozcan MM, 2010, J OLEO SCI, V59, P1, DOI 10.5650/jos.59.1; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Petersen A, 2015, J ALLERGY CLIN IMMUN, V136, P1295, DOI 10.1016/j.jaci.2015.04.010; Petersen A, 2014, BIOL CHEM, V395, P239, DOI 10.1515/hsz-2013-0206; Pons L, 1998, J CHROMATOGR B, V706, P131, DOI 10.1016/S0378-4347(97)00530-6; Pons L, 2002, ALLERGY, V57, P88, DOI 10.1034/j.1398-9995.57.s72.16.x; Riascos J. M., 2009, THESIS; Riecken S, 2008, THESIS, P69; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Scholl I, 2005, J IMMUNOL, V175, P6645, DOI 10.4049/jimmunol.175.10.6645; Schwager C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123419; Sharma M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01188; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; TZEN JTC, 1993, PLANT PHYSIOL, V101, P267, DOI 10.1104/pp.101.1.267; TZEN JTC, 1990, PLANT PHYSIOL, V94, P1282, DOI 10.1104/pp.94.3.1282; Tzen JTC, 1997, J BIOCHEM-TOKYO, V121, P762, DOI 10.1093/oxfordjournals.jbchem.a021651; Vissers YM, 2011, CLIN EXP ALLERGY, V41, P1631, DOI 10.1111/j.1365-2222.2011.03830.x; Weangsripanaval T, 2005, J NUTR, V135, P1738, DOI 10.1093/jn/135.7.1738; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Zuidmeer-Jongejan L, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-4	63	48	50	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1331	+		10.1016/j.jaci.2017.02.020	http://dx.doi.org/10.1016/j.jaci.2017.02.020			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28342912	Bronze			2022-12-18	WOS:000414304300013
J	Caubet, JC; Bencharitiwong, R; Ross, A; Sampson, HA; Berin, MC; Nowak-Wegrzyn, A				Caubet, Jean Christoph; Bencharitiwong, Ramon; Ross, Andrew; Sampson, Hugh A.; Berin, M. Cecilia; Nowak-Wegrzyn, Anna			Humoral and cellular responses to casein in patients with food protein-induced enterocolitis to cow's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; non-IgE-mediated; food; allergy; T(H)1 response; T(H)2 response; humoral response; T cells	CLINICAL-FEATURES; SMALL-INTESTINE; TNF-ALPHA; T-CELLS; ALLERGY; CHILDREN; MANAGEMENT; INFANTS; ANAPHYLAXIS; DIAGNOSIS	Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergymanifesting within 1 to 4 hours of food ingestion with repetitive emesis and lethargy. Objective: We sought to characterize immune responses to casein in children with FPIES caused by cow's milk (CM). Methods: Total IgE and IgM, CM-specific IgG, and caseinspecific IgE, IgG, IgG(4), and IgM levels, as well as immunoglobulin free light chains, were measured in both patients with active and those with resolved CM-FPIES. Proliferating casein/T-effector cell counts were measured in children with CM-FPIES, children with IgE-mediated CM allergy, and those tolerating CM. Cytokine concentrations in the supernatants were quantified. Serum cytokine and tryptase levels were measured before and after a positive oral food challenge (OFC) result and compared with levels in those with a negative OFC result. Results: We found low levels of CM and casein-specific IgG and casein-specific IgG(4) in patients with CM-FPIES versus those tolerating CM (P < .05). Although we found both a high CD4(+) T cell-proliferative response and T(H)2 cytokines production after casein stimulation in children with CM-FPIES, results were similar to those in control subjects. Significantly lower secretion of IL-10 and higher secretion of IL-9 by casein-stimulated T cells were found in patients with CM-FPIES versus those with IgE-mediated CM allergy. Lower baseline serum levels of IL-10 and higher tryptase levels were found in active CM-FPIES versus resolved CM-FPIES. We found a significant increase in serum IL-10 and IL-8 levels after a positive OFC result. Conclusions: We confirm the paucity of humoral response in patients with CM-FPIES. IL-10 might play a key role in acquisition of tolerance in patients with CM-FPIES. Increased serum IL-8 levels in patients with active FPIES suggest neutrophil involvement. Elevated baseline serum tryptase levels in patients with active FPIES suggest low-grade intestinal mast cell activation or increased mast cell load.	[Caubet, Jean Christoph] Univ Hosp Geneva, Div Pediat Allergy, Geneva, Switzerland; [Bencharitiwong, Ramon; Ross, Andrew; Sampson, Hugh A.; Berin, M. Cecilia; Nowak-Wegrzyn, Anna] Kravis Childrens Hosp, Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Dept Pediat,Div Allergy & Immunol, New York, NY USA	University of Geneva; Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Kravis Childrens Hosp, Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY 10029 USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854; berin, cecilia/0000-0002-9051-9249	National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) [UL1 TR-000067]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000067] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported in part by UL1 TR-000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH).	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Banzato C, 2013, EUR ANN ALLERGY CLIN, V45, P209; Barrios Y, 2014, AM J GASTROENTEROL, V109, P1085, DOI 10.1038/ajg.2014.127; Battaglia M, 2004, ANN NY ACAD SCI, V1029, P142, DOI 10.1196/annals.1309.031; Benlounes N, 1996, J ALLERGY CLIN IMMUN, V98, P781, DOI 10.1016/S0091-6749(96)70127-6; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863, DOI 10.1016/S0091-6749(99)70300-3; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Caubet JC, 2011, EXPERT REV CLIN IMMU, V7, P317, DOI [10.1586/eci.11.13, 10.1586/ECI.11.13]; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Chung HL, 1999, J ALLERGY CLIN IMMUN, V103, P1195, DOI 10.1016/S0091-6749(99)70199-5; Commins SP, 2013, CURR ALLERGY ASTHM R, V13, P72, DOI 10.1007/s11882-012-0315-y; Crittenden RG, 2005, J AM COLL NUTR, V24, p582S, DOI 10.1080/07315724.2005.10719507; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; Fernandes BN, 2012, J ALLERGY CLIN IMMUN, V130, P1199, DOI 10.1016/j.jaci.2012.06.017; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; HEINER DC, 1962, AM J DIS CHILD, V103, P634, DOI 10.1001/archpedi.1962.02080020649003; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Jarvinen KM, 2012, ANN ALLERG ASTHMA IM, V109, P221, DOI 10.1016/j.anai.2012.06.020; Jarvinen KM, 2011, CURR OPIN ALLERGY CL, V11, P255, DOI 10.1097/ACI.0b013e32834694d8; Jyonouchi S, 2014, CLIN EXP ALLERGY, V44, P58, DOI 10.1111/cea.12201; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Kimura M, 2012, INT ARCH ALLERGY IMM, V157, P58, DOI 10.1159/000323896; Knipping K, 2014, ACTA PAEDIATR, V103, P766, DOI 10.1111/apa.12651; Konstantinou GN, 2014, PEDIAT ALLERG IMM-UK, V25, P651, DOI 10.1111/pai.12288; Lemon-Mule H, 2008, CURR ALLERGY ASTHM R, V8, P201, DOI 10.1007/s11882-008-0034-6; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Monteseirin J, 2004, J LEUKOCYTE BIOL, V76, P692, DOI 10.1189/jlb.0903441; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Mori F, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/679381; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, P590, DOI 10.1016/j.jaci.2012.09.005; Muraro A, 2014, ALLERGY, V69, P1008, DOI 10.1111/all.12429; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; POWELL GK, 1976, J PEDIATR-US, V88, P840, DOI 10.1016/S0022-3476(76)81128-6; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Rijnierse A, 2010, J IMMUNOL, V185, P653, DOI 10.4049/jimmunol.0901129; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Sahiner UM, 2014, ALLERGY, V69, P265, DOI 10.1111/all.12317; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111	55	48	50	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					572	583		10.1016/j.jaci.2016.02.047	http://dx.doi.org/10.1016/j.jaci.2016.02.047			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27545065	Bronze			2022-12-18	WOS:000397002400023
J	Keles, S; Charbonnier, LM; Kabaleeswaran, V; Reisli, I; Genel, F; Gulez, N; Al-Herz, W; Narayanaswamy, R; Perez-Atayde, A; Karaca, NE; Necil, K; Wu, H; Geha, RS; Chatila, TA				Keles, Sevgi; Charbonnier, Louis Marie; Kabaleeswaran, Venkataraman; Reisli, Ismail; Genel, Ferah; Gulez, Nesrin; Al-Herz, Waleed; Ramesh, Narayanaswamy; Perez-Atayde, Antonio; Karaca, Neslihan E.; Kutukculer, Necil; Wu, Hao; Geha, Raif S.; Chatila, Talal A.			Dedicator of cytokinesis 8 regulates signal transducer and activator of transcription 3 activation and promotes T(H)17 cell differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cell division cycle 42; dedicator of cytokinesis 8; guanine nucleotide exchange factor; hyper-IgE syndrome; mucocutaneous candidiasis; suppressor of cytokine signaling 3; signal transducer and activator of transcription 3; T(H)17	HYPER-IGE SYNDROME; STAT3 MUTATIONS; DOCK8; PROTEIN; DEFICIENCY; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; INFECTIONS; PHENOTYPE	Background: The autosomal recessive hyper-IgE syndrome (HIES) caused by dedicator of cytokinesis 8 (DOCK8) deficiency shares clinical features with autosomal dominant HIES because of signal transducer and activator of transcription 3 (STAT3) mutations, including recurrent infections and mucocutaneous candidiasis, which are suggestive of T(H)17 cell dysfunction. The mechanisms underlying this phenotypic overlap are unclear. Objective: We sought to elucidate common mechanisms operating in the different forms of HIES. Methods: We analyzed the differentiation of CD4(+) T-H cell subsets in control and DOCK8-deficient subjects. We also examined the role of DOCK8 in regulating STAT3 activation in T cells. T-H cell differentiation was analyzed by ELISA, flow cytometry, and real-time PCR measurements of cytokines and T-H cell transcription factors. The interaction of DOCK8 and STAT3 signaling pathways was examined by using flow cytometry, immunofluorescence, coimmunoprecipitation, and gene expression analysis. Results: There was a profound block in the differentiation of DOCK8-deficient naive CD4(+) T cells into T(H)17 cells. A missense mutation that disrupts DOCK8 guanine nucleotide exchange factor (GEF) activity while sparing protein expression also impaired T(H)17 cell differentiation. DOCK8 constitutively associated with STAT3 independent of GEF activity, whereas it regulated STAT3 phosphorylation in a GEF activity-dependent manner. DOCK8 also promoted STAT3 translocation to the nucleus and induction of STAT3-dependent gene expression. Conclusion: DOCK8 interacts with STAT3 and regulates its activation and the outcome of STAT3-dependent TH17 differentiation. These findings might explain the phenotypic overlap between DOCK8 deficiency and autosomal dominant HIES.	[Keles, Sevgi; Charbonnier, Louis Marie; Ramesh, Narayanaswamy; Wu, Hao; Geha, Raif S.; Chatila, Talal A.] Boston Childrens Hosp, Harvard Med Sch, Div Immunol, Boston, MA USA; [Kabaleeswaran, Venkataraman; Wu, Hao] Boston Childrens Hosp, Harvard Med Sch, Dept Pediat, Program Mol & Cellular Med, Boston, MA USA; [Perez-Atayde, Antonio] Boston Childrens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; [Keles, Sevgi; Reisli, Ismail] Necmettin Erbakan Univ, Meram Med Fac, Div Pediat Immunol & Allergy, Konya, Turkey; [Genel, Ferah; Gulez, Nesrin] Behcet Uz State Hosp, Div Pediat Immunol, Izmir, Turkey; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; Ege Univ, Div Pediat Immunol, Izmir, Turkey	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Necmettin Erbakan University; Selcuk University; Izmir Dr Behcet Uz Children's Disease & Surgery Training & Research Hospital; Kuwait University; Ege University	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, One Blackfan Circle, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Karaca, Neslihan/AAW-1924-2020; gulez, nesrin/ABF-5609-2020; Narayanaswamy, Ramesh/G-9236-2012	Karaca, Neslihan/0000-0002-2202-7082; gulez, nesrin/0000-0002-3343-6949; Narayanaswamy, Ramesh/0000-0002-6373-0372; Chatila, Talal/0000-0001-7439-2762; Charbonnier, Louis-Marie/0000-0002-4594-7893	National Institutes of Health [5R01AI065617]; Scientific and Technological Research Council of Turkey [1059B191300622]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100315, R01AI065617] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scientific and Technological Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (5R01AI065617, to T.A.C.) and a grant from the Scientific and Technological Research Council of Turkey (1059B191300622 to S.K.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; Al-Zahrani D, 2014, CLIN IMMUNOL, V153, P104, DOI 10.1016/j.clim.2014.04.005; [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; Delano WL, 2002, PYMOL MOLECULAR GRAP; Dobbs K, 2015, NEW ENGL J MED, V372, P2409, DOI 10.1056/NEJMoa1413462; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engelhardt KR, 2015, J ALLERGY CLIN IMMUN, V136, P402, DOI 10.1016/j.jaci.2014.12.1945; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Ham H, 2013, J IMMUNOL, V190, P3661, DOI 10.4049/jimmunol.1202792; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Janssen E, 2014, J ALLERGY CLIN IMMUN, V134, P1365, DOI 10.1016/j.jaci.2014.07.042; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Keles S, 2014, J ALLERGY CLIN IMMUN, V133, P1753, DOI 10.1016/j.jaci.2014.03.032; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kulkarni K, 2011, J BIOL CHEM, V286, P25341, DOI 10.1074/jbc.M111.236455; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; McGhee SA, 2010, DIS MARKERS, V29, P151, DOI [10.1155/2010/397291, 10.3233/DMA-2010-0740]; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Pai SY, 2014, J ALLERGY CLIN IMMUN, V134, P221, DOI 10.1016/j.jaci.2014.02.023; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Singh AK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5603; Su HC, 2011, ANN NY ACAD SCI, V1246, P26, DOI 10.1111/j.1749-6632.2011.06295.x; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yang J, 2009, SCIENCE, V325, P1398, DOI 10.1126/science.1174468; Zhang L, 2006, MOL CELL BIOCHEM, V288, P179, DOI 10.1007/s11010-006-9137-3; Zhang Q, 2014, J EXP MED, V211, P2549, DOI 10.1084/jem.20141307; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	48	48	50	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1384	+		10.1016/j.jaci.2016.04.023	http://dx.doi.org/10.1016/j.jaci.2016.04.023			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27350570	Green Accepted, Bronze			2022-12-18	WOS:000389542700018
J	Spertini, F; DellaCorte, G; Kettner, A; de Blay, F; Jacobsen, L; Jutel, M; Worm, M; Charlon, V; Reymond, C				Spertini, Francois; DellaCorte, Gilles; Kettner, Alexander; de Blay, Frederic; Jacobsen, Lars; Jutel, Marek; Worm, Margitta; Charlon, Vincent; Reymond, Christophe			Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; birch pollen allergy; Bet v 1; contiguous overlapping peptides; synthetic peptides; aluminum hydroxide; IgG(4); IgE; desensitization; clinical trial	CLINICAL-EFFICACY; POLLEN; BIRCH; SAFETY; VACCINE; TABLET; RHINITIS; CAT; CELLS	Background: An immunotherapy formulation consisting of 3 contiguous overlapping peptides (COPs) derived from Bet v 1, the major birch pollen allergen, showed good clinical tolerability in a previous phase I/IIa clinical trial. Objectives: We sought to evaluate the efficacy and safety of allergen-specific immunotherapy using 2 dose regimens of Bet v 1 COPs versus placebo in subjects with birch pollen-induced allergic rhinoconjunctivitis. Methods: A randomized, double-blind, placebo-controlled phase IIb clinical trial was performed to assess the efficacy of Bet v 1 COP immunotherapy during the 2013 birch pollen season. Before the season, Bet v 1 COPs (50 and 100 mu g in aluminum hydroxide) or placebo (saline and aluminum hydroxide) were administered as 5 subcutaneous injections to 239 adults with allergic rhinoconjunctivitis to birch pollen. Bet v 1 COPs at 25 or 50 mu g were administered on day 1, and 50 or 100 mu g was administered on days 8, 15, 29, and 57, respectively. Patients were monitored for adverse events during the treatment period and assessed for combined rhinoconjunctivitis symptom and medication scores, as well as quality of life. Results: Rhinoconjunctivitis symptom and medication scores improved in both Bet v 1 COP-treated groups, reaching statistical significance over placebo in the 50-mu g group (least squares mean, -0.23; 26% improvement; P = .015). Both active groups showed significant improvement in quality of life and nighttime nasal symptom scores, supporting the primary end point findings. Bet v 1 COP injections were well tolerated, with a higher frequency of systemic adverse events in the 100-mu g group. Conclusion: Two months of preseasonal immunotherapy with 3 COPs derived from Bet v 1 at a 50-mu g dose showed promising efficacy, small risk for systemic reactions, and immunomodulatory changes in this single-season, dose-finding, phase IIb trial in patients allergic to birch pollen.	[Spertini, Francois] CHU Vaudois, Div Immunol & Allergy, Rue Bugnon, CH-1011 Lausanne, Switzerland; [DellaCorte, Gilles; Kettner, Alexander; Charlon, Vincent; Reymond, Christophe] Anergis SA, Epalinges, Switzerland; [de Blay, Frederic] Strasbourg Univ, Strasbourg Univ Hosp, Chest Dis Dept, Federat Translat Med, Strasbourg, France; [Jacobsen, Lars] Allergy Learning & Consulting, Copenhagen, Denmark; [Jutel, Marek] Silesian Piasts Univ Med, ALL MED Med Res Inst, Dept Clin Immunol, Wroclaw, Poland; [Worm, Margitta] Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Wroclaw Medical University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Spertini, F (corresponding author), CHU Vaudois, Div Immunol & Allergy, Rue Bugnon, CH-1011 Lausanne, Switzerland.	francois.spertini@chuv.ch		Worm, Margitta/0000-0002-3449-1245; JUTEL, MAREK/0000-0003-1555-9379	Anergis SA (Epalinges, Switzerland)	Anergis SA (Epalinges, Switzerland)	Supported by Anergis SA (Epalinges, Switzerland).	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Audran R, 2005, INFECT IMMUN, V73, P8017, DOI 10.1128/IAI.73.12.8017-8026.2005; Audran R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007304; Birnbaum J, 2003, CLIN EXP ALLERGY, V33, P58, DOI 10.1046/j.1365-2222.2003.01564.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; Cuzick J, 2005, LANCET, V365, P1308, DOI 10.1016/S0140-6736(05)61026-4; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Little RJA, 1987, STAT ANAL MISSING DA; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nony E, 2015, ALLERGY, V70, P795, DOI 10.1111/all.12622; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pellaton Celine, 2013, Clin Transl Allergy, V3, P17, DOI 10.1186/2045-7022-3-17; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029	35	48	49	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					162	168		10.1016/j.jaci.2016.02.044	http://dx.doi.org/10.1016/j.jaci.2016.02.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27373329	Bronze			2022-12-18	WOS:000379659100018
J	Suzuki, Y; Maazi, H; Sankaranarayanan, I; Lam, J; Khoo, B; Soroosh, P; Barbers, RG; Ou, JHJ; Jung, JU; Akbari, O				Suzuki, Yuzo; Maazi, Hadi; Sankaranarayanan, Ishwarya; Lam, Jonathan; Khoo, Bryant; Soroosh, Pejman; Barbers, Richard G.; Ou, J. -H. James; Jung, Jae U.; Akbari, Omid			Lack of autophagy induces steroid-resistant airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autophagy; asthma; lung inflammation; neutrophilic asthma; corticosteroid-resistance asthma	SELECTIVE AUTOPHAGY; LUNG INFLAMMATION; CYSTIC-FIBROSIS; SEVERE ASTHMA; CELL-DEATH; HYPERREACTIVITY; IMMUNITY; INDUCTION; INFECTION; ALLERGEN	Background: Neutrophilic corticosteroid-resistant asthma accounts for a significant proportion of asthma; however, little is known about the mechanisms that underlie the pathogenesis of the disease. Objective: We sought to address the role of autophagy in lung inflammation and the pathogenesis of corticosteroid-resistant neutrophilic asthma. Methods: We developed CD11c-specific autophagy-related gene 5 (Atg5)(-/-) mice and used several murine models to investigate the role of autophagy in asthmatic patients. Results: For the first time, we found that deletion of the Atg5 gene specifically in CD11c(+) cells, which leads to impairment of the autophagy pathway, causes unprovoked spontaneous airway hyperreactivity and severe neutrophilic lung inflammation in mice. We found that severe lung inflammation impairs the autophagy pathway, particularly in pulmonary CD11c(+) cells in wild-type mice. We further found that adoptive transfer of Atg5(-/-), but not wild-type, bone marrow-derived dendritic cells augments lung inflammation with increased IL-17A levels in the lungs. Our data indicate that neutrophilic asthma in Atg5(-/-) mice is glucocorticoid resistant and IL-17A dependent. Conclusion: Our results suggest that lack of autophagy in pulmonary CD11c(+) cells induces neutrophilic airway inflammation and hyperreactivity.	[Suzuki, Yuzo; Maazi, Hadi; Sankaranarayanan, Ishwarya; Lam, Jonathan; Khoo, Bryant; Ou, J. -H. James; Jung, Jae U.; Akbari, Omid] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Barbers, Richard G.] Univ So Calif, Keck Sch Med, Div Pulm & Crit Care, Los Angeles, CA 90033 USA; [Soroosh, Pejman] Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA USA	University of Southern California; University of Southern California; Johnson & Johnson; Johnson & Johnson USA	Akbari, O (corresponding author), Univ So Calif, Keck Sch Med, Norris Res Tower,NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	Soroosh, Pejman/AAD-8386-2021; Suzuki, Yuzo/AAE-6747-2020	Suzuki, Yuzo/0000-0001-6154-9791; Maazi, Hadi/0000-0002-8979-3769	National Institutes of Health Public Health Service [R01 AI 066020, R01 ES 021801, R21 ES 024707, R01 HL110609, R01 AI073099]; American Association of Immunology (AAI) Careers in Immunology Fellowship [004815-00001]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL110609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066020, R01AI073099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048, R01ES021801, R01ES025786, R21ES024707] Funding Source: NIH RePORTER	National Institutes of Health Public Health Service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); American Association of Immunology (AAI) Careers in Immunology Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Studies described in this article were financially supported by National Institutes of Health Public Health Service Grants R01 AI 066020, R01 ES 021801, and R21 ES 024707 (to O.A.) and R01 HL110609 and R01 AI073099 (to J.U.J.). H.M. is supported by an American Association of Immunology (AAI) Careers in Immunology Fellowship (004815-00001).	Abdulrahman BA, 2011, AUTOPHAGY, V7, P1359, DOI 10.4161/auto.7.11.17660; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; [Anonymous], 2009, J Indian Med Assoc, V107, P506; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen M, 2014, NAT MED, V20, P507, DOI 10.1038/nm.3521; Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107; Chung KF, 1999, EUR RESPIR J, V13, P1198; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Haldar P, 2007, J ALLERGY CLIN IMMUN, V119, P1043, DOI 10.1016/j.jaci.2007.02.042; Harris J, 2007, IMMUNITY, V27, P505, DOI 10.1016/j.immuni.2007.07.022; Haspel JA, 2011, AM J RESP CRIT CARE, V184, P1237, DOI 10.1164/rccm.201106-0966CI; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Kerzerho J, 2013, J ALLERGY CLIN IMMUN, V131, P1048, DOI 10.1016/j.jaci.2012.09.027; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Lombardi V, 2012, MUCOSAL IMMUNOL, V5, P432, DOI 10.1038/mi.2012.20; Lomia M, 2006, RESP MED, V100, P1988, DOI 10.1016/j.rmed.2006.02.018; Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Martin LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033454; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Mi S, 2011, J IMMUNOL, V187, P3003, DOI 10.4049/jimmunol.1004081; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moreira AP, 2011, J CLIN INVEST, V121, P4420, DOI 10.1172/JCI44999; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nakamoto M, 2012, IMMUNITY, V36, P658, DOI 10.1016/j.immuni.2012.03.003; Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Poon AH, 2012, J ALLERGY CLIN IMMUN, V129, P569, DOI 10.1016/j.jaci.2011.09.035; Ryter SW, 2012, ANNU REV PHYSIOL, V74, P377, DOI 10.1146/annurev-physiol-020911-153348; Tanaka A, 2012, AM J RESP CELL MOL, V46, P507, DOI 10.1165/rcmb.2009-0415OC; Wildenberg ME, 2012, GASTROENTEROLOGY, V142, P1493, DOI 10.1053/j.gastro.2012.02.034; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Zhao ZJ, 2008, CELL HOST MICROBE, V4, P458, DOI 10.1016/j.chom.2008.10.003	50	48	53	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1382	+		10.1016/j.jaci.2015.09.033	http://dx.doi.org/10.1016/j.jaci.2015.09.033			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26589586	Green Accepted, Bronze			2022-12-18	WOS:000376180200012
J	Schwitzguebel, AJP; Jandus, P; Lacroix, JS; Seebach, JD; Harr, T				Schwitzguebel, Adrien J-P.; Jandus, Peter; Lacroix, Jean-Silvain; Seebach, Joerg D.; Harr, Thomas			Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Sinusitis; rhinitis; chronic; recurrence; respiratory tract infections; immunoglobulins; immune deficiency syndromes; IgG deficiency; common variable immunodeficiency; hypersensitivity	REFRACTORY CHRONIC RHINOSINUSITIS; COMMON VARIABLE IMMUNODEFICIENCY; PNEUMOCOCCAL ANTIBODY-TITERS; IGG SUBCLASS LEVELS; CHRONIC SINUSITIS; HUMORAL IMMUNODEFICIENCY; SERUM IMMUNOGLOBULINS; DIAGNOSTIC-CRITERIA; IMMUNE-DEFICIENCY; PREVALENCE	Background: Several studies have shown a high prevalence of immunoglobulin deficiencies in patients with chronic rhinosinusitis (CRS). Objective: We sought to perform a systematic review and meta-analysis to estimate this prevalence more precisely and to identify patients who need substitution treatment. Methods: All case series published after 1990 describing patients with CRS, which was defined as symptomatic rhinosinusitis for more than 12 weeks and documented immunoglobulin deficiencies (including deficiencies of IgG with subclasses, IgA, and IgM; specific antibody deficiencies; and potential common variable immunodeficiency), were retrieved. A meta-analysis of the proportion of any combination of common variable immunodeficiency, IgG deficiency, IgA deficiency, and IgM deficiency in patients with CRS was performed by using logit transformation of the prevalence. Recurrent CRS was defined as rhinosinusitis not controlled by appropriate conservative management for 4 months, and difficult-to-treat CRS was defined as noncontrollable rhinosinusitis despite successful sinus surgery and appropriate conservative management for at least 1 year. Results: The meta-analysis revealed a prevalence of pooled IgG, IgA, and IgM deficiencies in 13% of patients with recurrent CRS and 23% of patients with difficult-to-treat CRS. The prevalence of IgG subclass deficiency (5% to 50%) and specific antibody deficiency (8% to 34%) was increased in patients with CRS, as was the prevalence of respiratory allergies in patients with recurrent CRS (31% to 72%). Conclusion: Immunoglobulin deficiency is a frequent condition in patients with CRS. An even higher prevalence of atopy was observed in patients with recurrent CRS. Therefore immunoglobulin titers and accurate allergy diagnostic workups are strongly recommended in these patients to provide specific treatments for symptom alleviation. However, there is a need for larger prospective studies addressing the effect of specific therapeutic interventions for CRS.	[Schwitzguebel, Adrien J-P.; Jandus, Peter; Seebach, Joerg D.; Harr, Thomas] Univ Hosp Geneva, Div Immunol & Allergy, Dept Med Specialties, CH-1205 Geneva, Switzerland; [Schwitzguebel, Adrien J-P.; Jandus, Peter; Seebach, Joerg D.; Harr, Thomas] Fac Med, Geneva, Switzerland; [Lacroix, Jean-Silvain] Univ Geneva, Dept Neurosci, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Schwitzguebel, AJP (corresponding author), Univ Hosp Geneva, Div Immunol & Allergy, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.	Adrien.schwitzguebel@latour.ch; thomas.harr@hcuge.ch	Seebach, Jörg/AAA-3746-2020	Seebach, Jorg/0000-0001-5748-4577	CSL Behring; MEDA Pharma; Menarini; Biotest; Octapharma	CSL Behring; MEDA Pharma; Menarini(Menarini Group); Biotest; Octapharma	P. Jandus has received research support from CSL Behring; has received lecture fees from MEDA Pharma; has received payment for manuscript translation from Menarini; has received travel support from CSL Behring, Biotest, and Octapharma; and is on the board of the European Society for Immunodeficiency. The rest of the authors declare that they have no relevant conflicts of interest.	Alqudah M, 2010, AM J RHINOL ALLERGY, V24, P409, DOI 10.2500/ajra.2010.24.3532; Ameratunga R, 2013, CLIN EXP IMMUNOL, V174, P203, DOI 10.1111/cei.12178; ARMENAKA M, 1994, ANN ALLERGY, V72, P507; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bhattacharyya N, 2011, OTOLARYNG HEAD NECK, V144, P440, DOI 10.1177/0194599810391852; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Bossuyt X, 2005, J ALLERGY CLIN IMMUN, V115, P872, DOI 10.1016/j.jaci.2005.01.039; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Carr TF, 2011, AM J RHINOL ALLERGY, V25, P241, DOI 10.2500/ajra.2011.25.3653; Chee L, 2001, LARYNGOSCOPE, V111, P233, DOI 10.1097/00005537-200102000-00008; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cui YH, 2009, RHINOLOGY, V47, P187; Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517; Desalu OO, 2009, J INVEST ALLERG CLIN, V19, P474; Famuyiwa F, 2012, LUNG, V190, P291, DOI 10.1007/s00408-012-9375-y; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fried AJ, 2009, CLIN MICROBIOL REV, V22, P396, DOI 10.1128/CMR.00001-09; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Gelfand EW, 2013, J ALLERGY CLIN IMMUN, V131, P1001, DOI 10.1016/j.jaci.2013.02.028; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Hidalgo H, 1996, ANN ALLERG ASTHMA IM, V76, P341, DOI 10.1016/S1081-1206(10)60035-X; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hoover GE, 1997, J ALLERGY CLIN IMMUN, V100, P185, DOI 10.1016/S0091-6749(97)70223-9; Hunter JP, 2014, J CLIN EPIDEMIOL, V67, P897, DOI 10.1016/j.jclinepi.2014.03.003; Iwabuchi Y, 1997, ARCH OTOLARYNGOL, V123, P602; Jarvis D, 2012, ALLERGY, V67, P91, DOI 10.1111/j.1398-9995.2011.02709.x; Jiang RS, 2004, OTOLARYNG HEAD NECK, V130, P563, DOI 10.1016/j.otohns.2003.07.014; Konno S, 2012, ALLERGY, V67, P653, DOI 10.1111/j.1398-9995.2012.02793.x; Lack G, 1996, J PEDIATR-US, V129, P898, DOI 10.1016/S0022-3476(96)70035-5; Lam HT, 2011, CLIN TRANSLATIONAL A, V1, P1; Lepage N, 2010, CLIN BIOCHEM, V43, P694, DOI 10.1016/j.clinbiochem.2010.02.003; Levin TA, 2006, ANN ALLERG ASTHMA IM, V97, P650, DOI 10.1016/S1081-1206(10)61095-2; LUND VJ, 1991, J OTOLARYNGOL, V20, P379; May A, 1999, EUR ARCH OTO-RHINO-L, V256, P445, DOI 10.1007/s004050050186; Musher DM, 1997, J INVEST MED, V45, P57; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Ocampo CJ, 2013, AM J RHINOL ALLERGY, V27, P34, DOI 10.2500/ajra.2013.27.3831; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Safdarian N, 2008, J ALLERGY CLIN IMMUN, V121, pS265, DOI 10.1016/j.jaci.2007.12.1051; Sahlstrand-Johnson P, 2011, RHINOLOGY, V49, P420, DOI 10.4193/Rhino11.101; Scadding G. K., 1994, Rhinology (Utrecht), V32, P15; Schauer U, 2003, CLIN CHEM, V49, P1924, DOI 10.1373/clinchem.2003.022350; Seppanen M, 2006, CLIN EXP IMMUNOL, V145, P219, DOI 10.1111/j.1365-2249.2006.03134.x; Seppanen M, 2014, EXPERT REV CLIN IMMU, V10, P1, DOI 10.1586/1744666X.2014.870478; Vanlerberghe L, 2006, B-ENT, V2, P161; Vlaminck S, 2013, CLIN TRANSL ALLERGY, V3, pO12; Wasserman RL, 2011, AM J OTOLARYNG, V32, P329, DOI 10.1016/j.amjoto.2010.05.001; Wilson KF, 2014, INT FORUM ALLERGY RH, V4, P93, DOI 10.1002/alr.21258; Woodbury K, 2011, CURR OPIN OTOLARYNGO, V19, P1, DOI 10.1097/MOO.0b013e3283420e92; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	51	48	50	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1523	1531		10.1016/j.jaci.2015.07.016	http://dx.doi.org/10.1016/j.jaci.2015.07.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26329513	Bronze			2022-12-18	WOS:000366044300013
J	Postma, DS; Weiss, ST; van den Berge, M; Kerstjens, HAM; Koppelman, GH				Postma, Dirkje S.; Weiss, Scott T.; van den Berge, Maarten; Kerstjens, Huib A. M.; Koppelman, Gerard H.			Revisiting the Dutch hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; Dutch hypothesis; allergy; hyperresponsiveness	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; RANDOMIZED CONTROLLED-TRIAL; INHALED CORTICOSTEROID TREATMENT; LONG-TERM TREATMENT; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; RISK-FACTOR; ADENOSINE 5'-MONOPHOSPHATE	The Dutch hypothesis was first articulated in 1961, when many novel and advanced scientific techniques were not available, such as genomics techniques for pinpointing genes, gene expression, lipid and protein profiles, and the microbiome. In addition, computed tomographic scans and advanced analysis techniques to dissect (small) airways disease and emphysema were not available. At that time, the group of researchers under the visionary guidance of Professor N. G. M. Orie put forward that both genetic and environmental factors can determine whether one would have airway obstructive diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Moreover, they stipulated that the phenotype of obstructive airway disease could be affected by sex and changes with aging. Orie and colleagues' call to carefully phenotype patients with obstructive airways diseases has been adopted by many current researchers in an attempt to determine the heterogeneity of both asthma andCOPD to better define these diseases and optimize their treatment. The founders of the Dutch hypothesis were far ahead of their time, and we can learn from their insights. We should fully characterize all patients in our clinical practice and not just state that they have asthma, COPD, or asthma and COPD overlap syndrome. This detailed phenotyping can help in understanding these obstructive airway diseases and provide guidance for disease management.	[Postma, Dirkje S.; van den Berge, Maarten; Kerstjens, Huib A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands; [Postma, Dirkje S.; van den Berge, Maarten; Kerstjens, Huib A. M.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [Weiss, Scott T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands	University of Groningen; University of Groningen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Groningen	Postma, DS (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol & TB, POB 30-001, NL-9700 RB Groningen, Netherlands.	d.s.postma@umcg.nl	Kerstjens, Huib/N-4754-2017; Koppelman, Gerard/AAG-9187-2020	Kerstjens, Huib/0000-0001-7705-7927; Koppelman, Gerard/0000-0001-8567-3252; van den Berge, Maarten/0000-0002-9336-7340	Chiesi; Boehringer Ingelheim; Takeda; Teva; GlaxoSmithKline; Pfizer; AstraZeneca; Novartis; Dutch Lung Foundation; Stichting Astma Bestrijding	Chiesi(Chiesi Pharmaceuticals Inc); Boehringer Ingelheim(Boehringer Ingelheim); Takeda(Takeda Pharmaceutical Company Ltd); Teva(Teva Pharmaceutical Industries); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); AstraZeneca(AstraZeneca); Novartis(Novartis); Dutch Lung Foundation; Stichting Astma Bestrijding	D. S. Postma has received consultancy fees from Chiesi, Boehringer Ingelheim, Takeda, Teva, and GlaxoSmithKline and has received research support from Chiesi. M. van den Berge has received research support from Chiesi, AstraZeneca, GlaxoSmithKline, and Teva. H. A. M. Kerstjens is on the Boehringer Board; has received consultancy fees from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, AstraZeneca, Novartis, and Chiesi; and has received research support from Novartis. G. H. Koppelman has received research support from the Dutch Lung Foundation, Stichting Astma Bestrijding. S. T. Weiss declares that he has no relevant conflicts of interest.	Albert P, 2012, THORAX, V67, P701, DOI 10.1136/thoraxjnl-2011-201458; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bathoorn E., 2009, INT J CHRONIC OBSTR, V4, P101; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; Brightling CE, 2011, PULM PHARMACOL THER, V24, P324, DOI 10.1016/j.pupt.2010.11.001; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Broekema M, 2011, AM J RESP CRIT CARE, V183, P310, DOI 10.1164/rccm.201003-0494OC; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2013, LANCET RESP MED, V1, P564, DOI 10.1016/S2213-2600(13)70086-9; Christenson SA, 2015, AM J RESP CRIT CARE, V191, P758, DOI 10.1164/rccm.201408-1458OC; Dijkstra AE, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-11; Fattahi F, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-10; FLETCHER CM, 1984, THORAX, V39, P81, DOI 10.1136/thx.39.2.81; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035; Global Initiative for Asthma (GINA), NHLBI WHO WORKSH; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183; Hardin M, 2014, EUR RESPIR J, V44, P341, DOI 10.1183/09031936.00216013; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hospers JJ, 2000, EPIDEMIOLOGY, V11, P261, DOI 10.1097/00001648-200005000-00006; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924, DOI 10.1164/ajrccm.159.3.9804024; Jansen DF, 1999, AM J RESP CRIT CARE, V160, P259, DOI 10.1164/ajrccm.160.1.9811015; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Koenig SM, 2008, RESP MED, V102, P665, DOI 10.1016/j.rmed.2007.12.023; LANGE P, 1989, EUR RESPIR J, V2, P811; Lapperre TS, 2009, ANN INTERN MED, V151, P517, DOI 10.7326/0003-4819-151-8-200910200-00004; Leigh R, 2006, EUR RESPIR J, V27, P964, DOI 10.1183/09031936.06.00072105; Li XN, 2013, J ALLERGY CLIN IMMUN, V132, P313, DOI 10.1016/j.jaci.2013.01.051; Liesker JJW, 2011, RESP MED, V105, P1853, DOI 10.1016/j.rmed.2011.07.002; Loppow D, 2001, RESP MED, V95, P115, DOI 10.1053/rmed.2000.0960; McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955; Nuijsink M, 2007, EUR RESPIR J, V30, P457, DOI 10.1183/09031936.00111806; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; ORIE N G, 1961, Ned Tijdschr Geneeskd, V105, P2136; Orie NG, 1961, BRONCHITIS; Orie NGM, 1964, BRONCHITIS; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3; Postma DS, 2011, AM J RESP CRIT CARE, V183, P1588, DOI 10.1164/rccm.201011-1796PP; POSTMA DS, 1991, AM REV RESPIR DIS, V143, P1458, DOI 10.1164/ajrccm/143.6.1458; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; PRIDE NB, 1987, B EUR PHYSIOPATH RES, V23, P369; RAMSDALE EH, 1990, MED CLIN N AM, V74, P741, DOI 10.1016/S0025-7125(16)30549-1; Rijcken B, 1991, THESIS U GRONINGEN G; Rutgers SR, 1998, AM J RESP CRIT CARE, V157, P880, DOI 10.1164/ajrccm.157.3.9709100; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; Smolonska J, 2014, EUR RESPIR J, V44, P860, DOI 10.1183/09031936.00001914; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; van den Berge M, 2013, ALLERGY, V68, P16, DOI 10.1111/all.12062; van den Berge M, 2012, EUR RESPIR J, V40, P1098, DOI 10.1183/09031936.00169711; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; VERMEIRE PA, 1991, EUR RESPIR J, V4, P490; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Wang XB, 2004, AM J RESP CRIT CARE, V169, P941, DOI 10.1164/rccm.2201011; Wong EHC, 2014, LANCET RESP MED, V2, P657, DOI 10.1016/S2213-2600(14)70107-9; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1	74	48	48	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					521	529		10.1016/j.jaci.2015.06.018	http://dx.doi.org/10.1016/j.jaci.2015.06.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26343936	Bronze			2022-12-18	WOS:000360913300001
J	Milara, J; Peiro, T; Armengot, M; Frias, S; Morell, A; Serrano, A; Cortijo, J				Milara, Javier; Peiro, Teresa; Armengot, Miquel; Frias, Soledad; Morell, Anselm; Serrano, Adela; Cortijo, Julio			Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MUC1; corticosteroid resistance; nasal polyp; chronicrhinosinusitis; glucocorticoid receptor	GROWTH-FACTOR RECEPTOR; AIRWAY EPITHELIAL-CELLS; BETA-CATENIN; IN-VITRO; EXPRESSION; DEXAMETHASONE; ACTIVATION; EFFICACY; PATHWAY; DISEASE	Background: A number of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to oral corticosteroids. Mucin 1 (MUC1) shows anti-inflammatory properties, and its cytoplasmic tail (CT) interacts with transcription factors, facilitating their nuclear translocation. Because glucocorticoid receptor (GR) nuclear translocation is key to the anti-inflammatory effect of corticosteroids, we hypothesized that MUC1 is involved in the effectiveness of corticosteroids. Objective: To analyze the role of MUC1 in corticosteroid effectiveness in different cohorts of patients with CRSwNP and elucidate the possible mechanisms involved. Methods: Seventy-three patients with CRSwNP took oral corticosteroids for 15 days. Corticosteroid resistance was evaluated by nasal endoscopy. The expression of MUC1 and MUC1 CT was evaluated by real-time PCR, Western blotting, and immunohistochemistry. Beas-2B knockdown with RNA interference for MUC1 (siRNA-MUC1) was used to analyze the role of MUC1 in the anti-inflammatory effects of dexamethasone. Results: Nineteen patients had nasal polyps that were resistant to oral corticosteroids (NP-CR). MUC1 expression was downregulated in these patients. Primary epithelial cells from patients with NP-CR were insensitive to the anti-inflammatory effects of dexamethasone. In siRNA-MUC1 Beas-2B, dexamethasone showed weaker anti-inflammatory effects, a reduced inhibition of phospho-extracellular-signal-regulated kinases 1/2, a less severe mitogen-activated protein kinase phosphatase 1 increase, and a reduced GR nuclear translocation. Immunoprecipitation experiments revealed that MUC1-CT and GR alpha form protein complexes and translocate to the nucleus in response to dexamethasone. MUC1-CT-GR alpha complex was downregulated in NP-CR tissue. Conclusion: MUC1-CT participates in the corticosteroid response that mediates GR alpha nuclear translocation. The low expression of MUC1 in patients with CRSwNP may participate in corticosteroid resistance.	[Peiro, Teresa] Univ Politecn Valencia, Dept Biotechnol, E-46022 Valencia, Spain; [Milara, Javier; Peiro, Teresa; Morell, Anselm; Serrano, Adela; Cortijo, Julio] Res Fdn Gen Hosp Valencia, Valencia, Spain; [Peiro, Teresa; Morell, Anselm; Cortijo, Julio] Univ Valencia, Fac Med, Dept Pharmacol, E-46003 Valencia, Spain; [Armengot, Miquel] Univ Valencia, Dept Med, Fac Med, E-46003 Valencia, Spain; [Cortijo, Julio] CIBERES, Hlth Inst Carlos III, Barcelona, Spain	Universitat Politecnica de Valencia; University of Valencia; University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Milara, J (corresponding author), Consorcio Hosp Gen Univ, Unidad Investigacion, Avenida tres cruces S-N, E-46014 Valencia, Spain.	xmilara@hotmail.com	Armengot, Miguel/E-4664-2016	Armengot, Miguel/0000-0001-8258-6292; Morell, Anselm/0000-0001-7002-7792; Peiro, Teresa/0000-0002-5704-8537; MILARA, JAVIER/0000-0001-6033-4211	Spanish government [SAF2011-26443, ADE10/00020]; FIS (Spanish government) [CP11/00293]; CIBERES (Spanish government) [CB06/06/0027]; FIS [PI11/02618]; Generalitat Valenciana [ACIF/2010/114]; Regional Government Prometeo "Generalitat Valenciana" [II/2013/014]; CENIT program (Spanish government)	Spanish government(Spanish GovernmentEuropean Commission); FIS (Spanish government)(Instituto de Salud Carlos III); CIBERES (Spanish government); FIS(Instituto de Salud Carlos III); Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Regional Government Prometeo "Generalitat Valenciana"; CENIT program (Spanish government)	This work was supported by grants SAF2011-26443 (Spanish government; to J.C.), FIS CP11/00293 (Spanish government; to J. M.), CIBERES (Spanish government; CB06/06/0027), ADE10/00020 (Spanish government), FIS PI11/02618 (M. A.), and ACIF/2010/114 (Generalitat Valenciana; to T.P.) as well as research grants from Regional Government Prometeo II/2013/014 (J.C., J.M.) "Generalitat Valenciana.'' Support from the CENIT program (Spanish government) was obtained.	Anwar MA, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.28; Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 2010, J STEROID BIOCHEM, V120, P76, DOI 10.1016/j.jsbmb.2010.02.018; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Chen YT, 2010, AM J PATHOL, V177, P1255, DOI 10.2353/ajpath.2010.091129; Choi BR, 2006, EXP MOL MED, V38, P466, DOI 10.1038/emm.2006.55; DINGSOR G, 1985, Rhinology (Utrecht), V23, P49; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Imai M, 2004, IMMUNOLOGY, V111, P291, DOI 10.1111/j.0019-2805.2004.01815.x; JOHANSEN LV, 1993, CLIN OTOLARYNGOL, V18, P524, DOI 10.1111/j.1365-2273.1993.tb00628.x; Kato K, 2012, J IMMUNOL, V188, P2014, DOI 10.4049/jimmunol.1102405; Kim KC, 2008, AM J RESP CELL MOL, V39, P644, DOI 10.1165/rcmb.2008-0169TR; Kobayashi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027627; Kyo Yoshiyuki, 2012, Am J Respir Cell Mol Biol, V46, P149, DOI 10.1165/rcmb.2011-0142OC; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Li P, 2010, CLIN INVEST MED, V33, pE181; Li YS, 2010, AM J PHYSIOL-LUNG C, V298, pL558, DOI 10.1152/ajplung.00225.2009; Liu XP, 2010, INFECT IMMUN, V78, P5314, DOI 10.1128/IAI.00681-10; Martinez-Anton A, 2008, ALLERGY, V63, P1368, DOI 10.1111/j.1398-9995.2008.01678.x; Mercado N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041582; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Seo KY, 2007, CORNEA, V26, P709, DOI 10.1097/ICO.0b013e31804f5a09; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Tos M, 1998, AM J RHINOL, V12, P183, DOI 10.2500/105065898781390217; Ueno K, 2008, AM J RESP CELL MOL, V38, P263, DOI 10.1165/rcmb.2007-0336RC; Valera FCP, 2009, CLIN EXP ALLERGY, V39, P81, DOI 10.1111/j.1365-2222.2008.03144.x; VIROLAINEN E, 1980, Rhinology (Utrecht), V18, P9; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Zhang Q, 2013, ACTA OTO-LARYNGOL, V133, P165, DOI 10.3109/00016489.2012.717713; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	38	48	51	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					470	476		10.1016/j.jaci.2014.07.011	http://dx.doi.org/10.1016/j.jaci.2014.07.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25159466				2022-12-18	WOS:000349372300020
J	Xia, MC; Hu, SM; Fu, YY; Jin, WS; Yi, QY; Matsui, Y; Yang, J; McDowell, MA; Sarkar, S; Kalia, V; Xiong, N				Xia, Mingcan; Hu, Shaomin; Fu, Yaoyao; Jin, Wensen; Yi, Qiyi; Matsui, Yurika; Yang, Jie; McDowell, Mary Ann; Sarkar, Surojit; Kalia, Vandana; Xiong, Na			CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemokine receptor CCR10; skin-resident T cells; regulatory T cells; migration; maintenance; immune homeostasis; allergy; dermatitis; inflammation; skin infection; Leishmania species	CUTTING EDGE; INTERLEUKIN 22; RM CELLS; CHEMOKINE; RECEPTOR; TISSUE; GAMMA; IDENTIFICATION; EXPRESSION; INFECTION	Background: CCR10 and CCL27 make up the most skin-specific chemokine receptor/ligand pair implicated in skin allergy and inflammatory diseases, including atopic dermatitis and psoriasis. This pair is thought to regulate the migration, maintenance, or both of skin T cells and is suggested to be therapeutic targets for treatment of skin diseases. However, the functional importance of CCR10/CCL27 in vivo remains elusive. Objective: We sought to determine the expression and function of CCR10 in different subsets of skin T cells under both homeostatic and inflammatory conditions to gain a mechanistic insight into the potential roles of CCR10 during skin inflammation. Methods: Using heterozygous and homozygous CCR10 knockout/enhanced green fluorescent protein knockin mice, we assessed the expression of CCR10 on regulatory and effector T cells of healthy and inflamed skin induced by chemicals, pathogens, and autoreactive T cells. In addition, we assessed the effect of CCR10 knockout on the maintenance and functions of different T cells and inflammatory status in the skin during different phases of the immune response. Results: CCR10 expression is preferentially induced on memory-like skin-resident T cells and their progenitors for their maintenance in homeostatic skin but not expressed on most skin-infiltrating effector T cells during inflammation. In CCR10 knockout mice the imbalanced presence and dysregulated function of resident regulatory and effector T cells result in over-reactive and prolonged innate and memory responses in the skin, leading to increased clearance of Leishmania species infection in the skin. Conclusion: CCR10 is a critical regulator of skin immune homeostasis.	[Xia, Mingcan; Hu, Shaomin; Fu, Yaoyao; Yang, Jie; Sarkar, Surojit; Kalia, Vandana; Xiong, Na] Penn State Univ, Ctr Mol Immunol & Infect Dis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Matsui, Yurika] Penn State Univ, Cell & Dev Biol Grad Program, University Pk, PA 16802 USA; [Jin, Wensen; Yi, Qiyi] Anhui Med Univ, Teaching & Res Sect Nucl Med, Hefei, Peoples R China; [McDowell, Mary Ann] Univ Notre Dame, Eck Inst Global Hlth, Dept Biol Sci, Notre Dame, IN 46556 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Anhui Medical University; University of Notre Dame	Xiong, N (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	nux1@psu.edu		Matsui, Yurika/0000-0003-0731-2499; Yi, Qiyi/0000-0001-5143-8828	National Institutes of Health; Penn State University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071043, T32AI074551] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Penn State University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a National Institutes of Health grant and institutional funds from Penn State University (to N.X.).	Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Campbell JJ, 2007, J IMMUNOL, V178, P3358, DOI 10.4049/jimmunol.178.6.3358; Chen L, 2006, INT IMMUNOL, V18, P1233, DOI 10.1093/intimm/dxl054; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gebhardt T, 2011, NATURE, V477, P216, DOI 10.1038/nature10339; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hong K, 1999, J IMMUNOL, V162, P7480; Hu SM, 2011, P NATL ACAD SCI USA, V108, pE1035, DOI 10.1073/pnas.1100156108; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Jin Y, 2010, J IMMUNOL, V185, P5723, DOI 10.4049/jimmunol.1001612; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; McCully ML, 2012, BLOOD, V120, P4591, DOI 10.1182/blood-2012-05-433037; Mirshahpanah P, 2008, EXP DERMATOL, V17, P30, DOI 10.1111/j.1600-0625.2007.00630.x; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Nicolas L, 2000, INFECT IMMUN, V68, P6561, DOI 10.1128/IAI.68.12.6561-6566.2000; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Rosenblum MD, 2011, NATURE, V480, P538, DOI 10.1038/nature10664; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Sharma R, 2009, J IMMUNOL, V183, P1065, DOI 10.4049/jimmunol.0804354; Soler D, 2003, BLOOD, V101, P1677, DOI 10.1182/blood-2002-07-2348; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Tubo NJ, 2011, AM J PATHOL, V178, P2496, DOI 10.1016/j.ajpath.2011.02.031; Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008	33	48	49	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					634	+		10.1016/j.jaci.2014.03.010	http://dx.doi.org/10.1016/j.jaci.2014.03.010			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24767879	Green Accepted			2022-12-18	WOS:000341372400016
J	Haynes, BF; Moody, MA; Alam, M; Bonsignori, M; Verkoczy, L; Ferrari, G; Gao, F; Tomaras, GD; Liao, HX; Kelsoe, G				Haynes, Barton F.; Moody, M. Anthony; Alam, Munir; Bonsignori, Mattia; Verkoczy, Laurent; Ferrari, Guido; Gao, Feng; Tomaras, Georgia D.; Liao, Hua-Xin; Kelsoe, Garnett			Progress in HIV-1 vaccine development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV-1; vaccine; T cells; B cells; broadly neutralizing antibodies	HUMAN-IMMUNODEFICIENCY-VIRUS; BROADLY NEUTRALIZING ANTIBODIES; EFFICACY TRIAL; B-CELLS; IMMUNE-RESPONSES; VIRION CAPTURE; 2F5; REGION; AFFINITY; EPITOPE	The past 2 years have seen a number of basic and translational science advances in the quest for development of an effective HIV-1 vaccine. These advances include discovery of new envelope targets of potentially protective antibodies, demonstration that CD8(+) T cells can control HIV-1 infection, development of immunogens to overcome HIV-1 T-cell epitope diversity, identification of correlates of transmission risk in an HIV-1 efficacy trial, and mapping of the coevolution of HIV-1 founder envelope mutants in infected subjects with broad neutralizing antibodies, thereby defining broad neutralizing antibody developmental pathways. Despite these advances, a promising HIV-1 vaccine efficacy trial published in 2013 did not prevent infection, and the HIV-1 vaccine field is still years away from deployment of an effective vaccine. This review summarizes what some of the scientific advances have been, what roadblocks still remain, and what the most promising approaches are for progress in design of successful HIV-1 vaccine candidates.	[Haynes, Barton F.; Moody, M. Anthony; Alam, Munir; Bonsignori, Mattia; Verkoczy, Laurent; Ferrari, Guido; Gao, Feng; Tomaras, Georgia D.; Liao, Hua-Xin; Kelsoe, Garnett] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA; [Haynes, Barton F.; Alam, Munir; Bonsignori, Mattia; Gao, Feng; Liao, Hua-Xin] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA; [Haynes, Barton F.; Tomaras, Georgia D.; Kelsoe, Garnett] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA; [Moody, M. Anthony] Duke Univ, Sch Med, Dept Pediat, Durham, NC 27710 USA; [Verkoczy, Laurent] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; [Ferrari, Guido; Tomaras, Georgia D.] Duke Univ, Sch Med, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Haynes, BF (corresponding author), Duke Univ, Med Ctr, Duke Human Vaccine Inst, 2 Genome Court,4090 MSRBII Bldg, Durham, NC 27710 USA.	hayne002@mc.duke.edu	Alam, S. Munir/AAC-6711-2019; Moody, M/AAB-6947-2020; Bonsignori, Mattia/AAE-7678-2019; Ferrari, Guido/A-6088-2015; Tomaras, Georgia/J-5041-2016; Ferrari, Guido/Z-2137-2019	Moody, M/0000-0002-3890-5855; Bonsignori, Mattia/0000-0003-2973-2101; Ferrari, Guido/0000-0001-7747-3349; Bayer, Diana/0000-0001-7181-7446	National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery) [UM1-AI100645]; Bill & Melinda Gates Foundation [OPP1033098]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI100645] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, UM1-AI100645), and the Bill & Melinda Gates Foundation (OPP1033098).	Alam SM, 2013, P NATL ACAD SCI USA, V110, P18214, DOI 10.1073/pnas.1317855110; Aussedat B, 2013, J AM CHEM SOC, V135, P13113, DOI 10.1021/ja405990z; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Bonsignori M, 2014, J CLIN INVEST, V124, P1835, DOI 10.1172/JCI73441; Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12; Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416; Chen Y, 2013, J IMMUNOL, V191, P1260, DOI 10.4049/jimmunol.1300770; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Dal Porto JM, 1998, J IMMUNOL, V161, P5373; Dennison SM, 2009, J VIROL, V83, P10211, DOI 10.1128/JVI.00571-09; Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285; Gaebler C, 2013, J IMMUNOL METHODS, V397, P47, DOI 10.1016/j.jim.2013.09.003; Gray ES, 2011, J VIROL, V85, P4828, DOI 10.1128/JVI.00198-11; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874; Haynes BF, 2008, IMMUNITY, V28, P10, DOI 10.1016/j.immuni.2007.12.005; Haynes Barton F., 2005, Human Antibodies, V14, P59; Haynes BF, 2013, CURR OPIN HIV AIDS, V8, P326, DOI 10.1097/COH.0b013e328361d178; Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Haynes BF, 2010, CURR OPIN HIV AIDS, V5, P362, DOI 10.1097/COH.0b013e32833d2e90; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hoot S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003106; Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625; Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342; Klasse PJ, 2013, J VIROL, V87, P9873, DOI 10.1128/JVI.01226-13; Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594; Korber BT, 2009, J VIROL, V83, P8300, DOI 10.1128/JVI.00114-09; Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Liu PH, 2014, J VIROL, V88, P5165, DOI 10.1128/JVI.03765-13; Liu PH, 2013, J VIROL, V87, P7828, DOI 10.1128/JVI.02737-12; Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627; Mao YD, 2013, P NATL ACAD SCI USA, V110, P12438, DOI 10.1073/pnas.1307382110; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696; Meffre E, 2001, J CLIN INVEST, V108, P879, DOI 10.1172/JCI13051; Meyerson JR, 2013, P NATL ACAD SCI USA, V110, P513, DOI 10.1073/pnas.1214810110; Moody MA, 2012, J VIROL, V86, P7496, DOI 10.1128/JVI.00426-12; Moody MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025797; Moore PL, 2012, NAT MED, V18, P1688, DOI 10.1038/nm.2985; Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600; Pancera M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055701; Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Robb ML, 2012, LANCET INFECT DIS, V12, P531, DOI 10.1016/S1473-3099(12)70088-9; Roederer M, 2014, NATURE, V505, P502, DOI 10.1038/nature12893; Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Santra S, 2012, VIROLOGY, V428, P121, DOI 10.1016/j.virol.2012.03.012; Santra S, 2010, NAT MED, V16, P324, DOI 10.1038/nm.2108; Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08; Scheid JF, 2009, J IMMUNOL METHODS, V343, P65, DOI 10.1016/j.jim.2008.11.012; Shen XY, 2010, P NATL ACAD SCI USA, V107, P5972, DOI 10.1073/pnas.0912381107; Shen XY, 2009, J VIROL, V83, P3617, DOI 10.1128/JVI.02631-08; Shih TAY, 2002, NAT IMMUNOL, V3, P570, DOI 10.1038/ni803; Shih TAY, 2002, NAT IMMUNOL, V3, P399, DOI 10.1038/ni776; Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754; TOMARAS GD, 2013, AIDS VACC M BARC SPA; Tomaras GD, 2014, VACCINES, V2, P15, DOI 10.3390/vaccines2010015; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tomaras GD, 2011, J VIROL, V85, P11502, DOI 10.1128/JVI.05363-11; Verkoczy L, 2013, J IMMUNOL, V191, P2538, DOI 10.4049/jimmunol.1300971; Verkoczy L, 2011, J IMMUNOL, V187, P3785, DOI 10.4049/jimmunol.1101633; Verkoczy L, 2011, CURR OPIN IMMUNOL, V23, P383, DOI 10.1016/j.coi.2011.04.003; Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029; Yang G, 2013, J EXP MED, V210, P241, DOI 10.1084/jem.20121977; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572	79	48	51	3	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					3	10		10.1016/j.jaci.2014.04.025	http://dx.doi.org/10.1016/j.jaci.2014.04.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	25117798	Green Accepted			2022-12-18	WOS:000338930300001
J	Birrell, MA; Bonvini, SJ; Dubuis, E; Maher, SA; Wortley, MA; Grace, MS; Raemdonck, K; Adcock, JJ; Belvisi, MG				Birrell, Mark A.; Bonvini, Sara J.; Dubuis, Eric; Maher, Sarah A.; Wortley, Michael A.; Grace, Megan S.; Raemdonck, Kristof; Adcock, John J.; Belvisi, Maria G.			Tiotropium modulates transient receptor potential V1 (TRPV1) in airway sensory nerves: A beneficial off-target effect?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sensory nerves; vagus; cough; ion channels; capsaicin; anticholinergics	ACTING MUSCARINIC ANTAGONIST; GUINEA-PIG; PROSTAGLANDIN E-2; COUGH; BROMIDE; GLYCOPYRROLATE; SENSITIVITY; BRONCHODILATORS; PHARMACOLOGY; CONTRACTION	Background: Recent studies have suggested that the long-acting muscarinic receptor antagonist tiotropium, a drug widely prescribed for its bronchodilator activity in patients with chronic obstructive pulmonary disease and asthma, improves symptoms and attenuates cough in preclinical and clinical tussive agent challenge studies. The mechanism by which tiotropium modifies tussive responses is not clear, but an inhibition of vagal tone and a consequent reduction in mucus production from submucosal glands and bronchodilation have been proposed. Objective: The aim of this study was to investigate whether tiotropium can directly modulate airway sensory nerve activity and thereby the cough reflex. Methods: We used a conscious cough model in guinea pigs, isolated vagal sensory nerve and isolated airway neuron tissue- and cell-based assays, and in vivo single-fiber recording electrophysiologic techniques. Results: Inhaled tiotropium blocked cough and single C-fiber firing in the guinea pig to the transient receptor potential (TRP) V1 agonist capsaicin, a clinically relevant tussive stimulant. Tiotropium and ipratropium, a structurally similar muscarinic antagonist, inhibited capsaicin responses in isolated guinea pig vagal tissue, but glycopyrrolate and atropine did not. Tiotropium failed to modulate other TRP channel-mediated responses. Complementary data were generated in airway-specific primary ganglion neurons, demonstrating that tiotropium inhibited capsaicin-induced, but not TRPA1-induced, calcium movement and voltage changes. Conclusion: For the first time, we have shown that tiotropium inhibits neuronal TRPV1-mediated effects through a mechanism unrelated to its anticholinergic activity. We speculate that some of the clinical benefit associated with taking tiotropium (eg, in symptom control) could be explained through this proposed mechanism of action.	[Birrell, Mark A.; Bonvini, Sara J.; Dubuis, Eric; Maher, Sarah A.; Wortley, Michael A.; Grace, Megan S.; Raemdonck, Kristof; Adcock, John J.; Belvisi, Maria G.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London	Belvisi, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Exhibit Rd, London SW7 2AZ, England.	m.belvisi@imperial.ac.uk	Raemdonck, Kristof/K-5554-2013; Grace, Megan/AAA-7285-2019; Raemdonck, Kristof/Y-7125-2019	Raemdonck, Kristof/0000-0002-7073-7484; Bonvini, Sara/0000-0002-5292-8316; Wortley, Michael/0000-0001-8622-5339; dubuis, eric/0000-0001-7658-4178	Medical Research Council [MRC UK: G0800196, G0800195, MR/K020293/1]; NHLI Trust; MRC; Wellcome Trust [089301/Z/09/Z]; Boehringer-Ingelheim; MRC [G0800196, MR/K020293/1, G0800195] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B, G0800196] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLI Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Boehringer-Ingelheim(Boehringer Ingelheim); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	M.A.B., S. A. M., and M. S. G. were funded by project grants from the Medical Research Council (MRC UK: G0800196; G0800195; MR/K020293/1). S.J.B. and M. A. W. were supported by NHLI Trust and MRC studentships, respectively. E. D. was funded by a Wellcome Trust project grant (089301/Z/09/Z) and latterly by a research grant from Boehringer-Ingelheim. Consumables were funded by Boehringer-Ingelheim. The human tissue experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.	Adcock JJ, 2003, BRIT J PHARMACOL, V138, P407, DOI 10.1038/sj.bjp.0705056; BARNES PJ, 1995, LIFE SCI, V56, P853, DOI 10.1016/0024-3205(95)00020-7; Belvisi MG, 2008, BRIT J PHARMACOL, V155, P547, DOI 10.1038/bjp.2008.298; BELVISI MG, 1992, EUR J PHARMACOL, V215, P341, DOI 10.1016/0014-2999(92)90054-8; Bhattacharya A, 2007, J PHARMACOL EXP THER, V323, P665, DOI 10.1124/jpet.107.127258; Birrell MA, 2009, AM J RESP CRIT CARE, V180, P1042, DOI 10.1164/rccm.200905-0665OC; BOLSER DC, 1995, EUR J PHARMACOL, V277, P159, DOI 10.1016/0014-2999(95)00076-W; Bouyssou T, 2009, AM J RESP CRIT CARE, V179; Buckley J, 2011, THORAX, V66, P1029, DOI 10.1136/thx.2010.158568; Burki NK, 2010, PULM PHARMACOL THER, V23, P279, DOI 10.1016/j.pupt.2010.02.002; Chou MZ, 2004, BIOCHEMISTRY-US, V43, P2501, DOI 10.1021/bi035981h; Delescluse I, 2012, BRIT J PHARMACOL, V166, P1822, DOI 10.1111/j.1476-5381.2012.01891.x; Dicpinigaitis PV, 2008, LUNG, V186, P369, DOI 10.1007/s00408-008-9114-6; DISSE B, 1993, LIFE SCI, V52, P537, DOI 10.1016/0024-3205(93)90312-Q; Gavalda A, 2012, LIFE SCI, V90, P301, DOI 10.1016/j.lfs.2011.12.002; Gavva NR, 2008, TRENDS PHARMACOL SCI, V29, P550, DOI 10.1016/j.tips.2008.08.003; Gosens R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-73; Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443; Gross NJ, 2006, EUR J PHARMACOL, V533, P36, DOI 10.1016/j.ejphar.2005.12.072; Haddad EB, 1999, BRIT J PHARMACOL, V127, P413, DOI 10.1038/sj.bjp.0702573; Hansel TT, 2005, CHEST, V128, P1974, DOI 10.1378/chest.128.4.1974; HOLMES PW, 1992, RESP MED, V86, P425, DOI 10.1016/S0954-6111(06)80010-7; Jia YX, 1998, J AUTON PHARMACOL, V18, P257, DOI 10.1046/j.1365-2680.1998.18587.x; Joos GF, 2010, EXPERT OPIN INV DRUG, V19, P257, DOI 10.1517/13543780903505084; Kwong K, 2005, J PHYSIOL-LONDON, V564, P437, DOI 10.1113/jphysiol.2004.078725; Lewis CA, 2007, PULM PHARMACOL THER, V20, P325, DOI 10.1016/j.pupt.2006.12.001; Li J. Q., 2002, Autonomic & Autacoid Pharmacology, V22, P57, DOI 10.1046/j.1474-8673.2002.00242.x; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; LOWRY R, 1988, CHEST, V93, P1186, DOI 10.1378/chest.93.6.1186; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; Molassiotis A, 2010, RESP MED, V104, P934, DOI 10.1016/j.rmed.2010.02.010; Nash MS, 2012, J PHARMACOL EXP THER, V342, P389, DOI 10.1124/jpet.112.191932; Papakosta M, 2011, J BIOL CHEM, V286, P39663, DOI 10.1074/jbc.M111.273581; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; POUNSFORD JC, 1985, THORAX, V40, P662, DOI 10.1136/thx.40.9.662; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Raemdonck K, 2012, THORAX, V67, P19, DOI 10.1136/thoraxjnl-2011-200365; Reilly RM, 2012, J PHARMACOL EXP THER, V342, P416, DOI 10.1124/jpet.111.190314; Round P, 2011, BRIT J CLIN PHARMACO, V72, P921, DOI 10.1111/j.1365-2125.2011.04040.x; TAKAHASHI T, 1994, AM J RESP CRIT CARE, V150, P1640, DOI 10.1164/ajrccm.150.6.7952627; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Thorneloe KS, 2008, J PHARMACOL EXP THER, V326, P432, DOI 10.1124/jpet.108.139295; VANWYK M, 1994, EUR J CLIN PHARMACOL, V46, P437, DOI 10.1007/BF00191907; Verkindre C, 2010, RESP MED, V104, P1482, DOI 10.1016/j.rmed.2010.04.006; Watabiki T, 2011, J PHARMACOL EXP THER, V336, P743, DOI 10.1124/jpet.110.175570	46	48	50	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					679	+		10.1016/j.jaci.2013.12.003	http://dx.doi.org/10.1016/j.jaci.2013.12.003			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24506933	hybrid, Green Published			2022-12-18	WOS:000332397600008
J	Krug, N; Gupta, A; Badorrek, P; Koenen, R; Mueller, M; Pivovarova, A; Hilbert, J; Wetzel, K; Hohlfeld, JM; Wood, C				Krug, Norbert; Gupta, Abhya; Badorrek, Philipp; Koenen, Ruediger; Mueller, Meike; Pivovarova, Anna; Hilbert, James; Wetzel, Kristiane; Hohlfeld, Jens M.; Wood, Chester			Efficacy of the oral chemoattractant receptor homologous molecule on T(H)2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemoattractant receptor homologous molecule on T(H)2 cells; BI 671800; environmental challenge chamber; prostaglandin D-2; seasonal allergic rhinitis; inflammation	GRASS-POLLEN; NASAL-MUCOSA; DOUBLE-BLIND; TH2 CELLS; CRTH2; CHALLENGE; PROSTAGLANDIN; INFLAMMATION; SYMPTOMS; OC000459	Background: The inflammatory response in patients with seasonal allergic rhinitis (SAR) is partly mediated by the prostaglandin D-2 receptor chemoattractant receptor homologous molecule on T(H)2 cells (CRTH2). Objective: We sought to investigate the efficacy and safety of the oral CRTH2 antagonist BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 mu g once daily), or oral montelukast (10 mg once daily) administered for 2 weeks in patients with SAR. Methods: In this randomized, double-blind, placebo-controlled, partial-crossover study, participants aged 18 to 65 years with a positive skin prick test to Dactylis glomerata pollen were exposed to out-of-season allergen in the environmental challenge chamber for 6 hours. The primary efficacy variable was the total nasal symptom score assessed as the area under the curve (AUC)(0-6h). Results: In total, 146 patients (63.7% male; mean age, 36.1 years) were randomized. The adjusted mean total nasal symptom score AUC(0-6h) was significantly reduced versus placebo with 200 mg of BI 671800 (absolute difference, -0.85; percentage difference, 217%; P=.0026), montelukast (absolute difference, -0.74; percentage difference, 215%; P=.0115), and fluticasone propionate (absolute difference, -1.64; percentage difference, -33%; P<.0001). Compared with placebo, BI 671800 significantly reduced nasal eosinophil values (P<.05 for all doses), significantly inhibited nasal inflammatory cytokine levels (IL-4 and eotaxin, P<.05; 200 mg twice daily), and induced a dose-related reduction in ex vivo prostaglandin D-2-mediated eosinophil shape change. Conclusion: Two hundred milligrams of BI 671800 twice daily demonstrated efficacy in treating SAR symptoms induced by environmental challenge chamber allergen exposure and had a favorable safety profile.	[Krug, Norbert; Badorrek, Philipp; Mueller, Meike; Hohlfeld, Jens M.] Fraunhofer Inst Toxicol & Expt Med ITEM, D-30625 Hannover, Germany; [Gupta, Abhya; Koenen, Ruediger; Pivovarova, Anna; Wetzel, Kristiane] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany; [Hilbert, James; Wood, Chester] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	Fraunhofer Gesellschaft; Boehringer Ingelheim; Boehringer Ingelheim	Krug, N (corresponding author), Fraunhofer Inst Toxicol & Expt Med ITEM, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	norbert.krug@item.fraunhofer.de		Hohlfeld, Jens/0000-0003-2646-6186; Badorrek, Philipp/0000-0003-2490-0583	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	We thank Anja Casper for her important contribution as a clinical trial coordinator. Editorial and writing assistance was provided by Elena Garonna, PhD, of PAREXEL, which was funded by Boehringer Ingelheim.	Bachert C, 1999, INT ARCH ALLERGY IMM, V118, P375, DOI 10.1159/000024141; Badorrek P, 2009, INT J CLIN PHARM TH, V47, P71; Badorrek P, 2011, ANN ALLERG ASTHMA IM, V106, P336, DOI 10.1016/j.anai.2010.12.018; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Cameron L, 2009, ALLERGY, V64, P1478, DOI 10.1111/j.1398-9995.2009.02053.x; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Erin EM, 2005, ALLERGY, V60, P1524, DOI 10.1111/j.1398-9995.2005.00928.x; Hall I, 2012, EUR RESP J S56, V40, p312S; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042; Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lukacs NW, 2008, AM J PHYSIOL-LUNG C, V295, pL767, DOI 10.1152/ajplung.90351.2008; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Nicholson GC, 2011, J ALLERGY CLIN IMMUN, V128, P800, DOI 10.1016/j.jaci.2011.05.013; Okano M, 2006, AM J RHINOL, V20, P342, DOI 10.2500/ajr.2006.20.2865; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Pettipher R, 2012, J MED CHEM, V55, P2915, DOI 10.1021/jm2013997; Ratner PH, 2006, ANN ALLERG ASTHMA IM, V97, P657, DOI 10.1016/S1081-1206(10)61097-6; Serrano CD, 2012, J INVEST ALLERG CLIN, V22, P351; Sin Betul, 2011, Proc Am Thorac Soc, V8, P106, DOI 10.1513/pats.201008-057RN; Singh D, 2013, EUR RESPIR J, V41, P46, DOI 10.1183/09031936.00092111; Stearns BA, 2009, BIOORG MED CHEM LETT, V19, P4647, DOI 10.1016/j.bmcl.2009.06.085; Sutherland R, 2012, EUR RESP J S56, V40, p546S; Xue LZ, 2009, J IMMUNOL, V182, P7580, DOI 10.4049/jimmunol.0804090	28	48	50	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					414	+		10.1016/j.jaci.2013.10.013	http://dx.doi.org/10.1016/j.jaci.2013.10.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24332218	Bronze			2022-12-18	WOS:000332397100016
J	Movassagh, H; Shan, LY; Halayko, AJ; Roth, M; Tamm, M; Chakir, J; Gounni, AS				Movassagh, Hesam; Shan, Lianyu; Halayko, Andrew J.; Roth, Michael; Tamm, Michael; Chakir, Jamila; Gounni, Abdelilah S.			Neuronal chemorepellent Semaphorin 3E inhibits human airway smooth muscle cell proliferation and migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway smooth muscle cell; migration; platelet-derived growth factor; plexinD1; proliferation; semaphorin 3E	GROWTH-FACTOR; EXPRESSION; ASTHMA; ANGIOGENESIS; PROGRESSION; ACTIVATION; PLEXIND1; MODULATE; SEMA3E; BRAIN	Background: Chronic airway diseases, including asthma, are characterized by increased airway smooth muscle (ASM) mass that is due in part to growth factor-mediated ASM cell proliferation and migration. However, the molecular mechanisms underlying these effects are not completely understood. Semaphorin 3E (Sema3E) has emerged as an essential mediator involved in cell migration, proliferation, and angiogenesis, although its role in ASM cell function is not investigated. Objectives: We sought to determine the expression of Sema3E receptor, plexinD1, in human ASM cells (HASMCs); effect of Sema3E on basal and platelet-derived growth factor (PDGF)-induced proliferation and migration; and underlying signaling pathways. Methods: Expression of plexinD1 in HASMCs was studied with RT-PCR, immunostaining, and flow cytometry. The effect of Sema3E on HASMC proliferation and migration was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation, cell count, and Boyden chamber assay. Sema3E-mediated intracellular signaling was investigated with fluorescent microscopy, flow cytometry, Rac1 activation, and Western blot analysis. Results: HASMCs from healthy persons expressed plexinD1 more than HASMCs from asthmatic patients. Sema3E increased plexinD1 expression in HASMCs from asthmatic patients. Recombinant Sema3E inhibited PDGF-mediated HASMC proliferation and migration, which was associated with F-actin depolymerization, suppression of PDGF-induced Rac1 guanosine triphosphatase activity, and Akt and extracellular signal-regulated kinase 1 and 2 phosphorylation. Bronchial biopsies from patients with mild asthma displayed immunoreactivity of plexinD1, suggesting the potential in vivo role of Sema3E-PlexinD1 axis in HASMC function. Conclusion: This study provides the first evidence that Sema3E receptor is expressed and plays functional roles in HASMCs. Our data suggest a regulatory role of Sema3E in PDGF-mediated proliferation and migration, leading to downregulation of ASM remodeling.	[Movassagh, Hesam; Shan, Lianyu; Gounni, Abdelilah S.] Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0T5, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0T5, Canada; [Roth, Michael; Tamm, Michael] Univ Basel, Univ Basel Hosp, Basel, Switzerland; [Chakir, Jamila] Univ Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada	University of Manitoba; University of Manitoba; University of Basel; Laval University	Gounni, AS (corresponding author), Univ Manitoba, Dept Immunol, Fac Med, 419 Apotex Ctr,750 McDermot Ave, Winnipeg, MB R3E 0T5, Canada.	gounni@cc.umanitoba.ca	Gounni, Abdelilah Soussi/AAH-3456-2020; Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821; Gounni, Abdelilah/0000-0003-1265-6560; Halayko, Andrew/0000-0002-7865-4552; Soussi Gounni, Abdelilah/0000-0002-7282-0388	Canadian Institutes of Health Research (CIHR); Manitoba Health Research Council (MHRC); Manitoba Research Chair; MHRC; Swiss National Foundation [310030_130740/1]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council (MHRC); Manitoba Research Chair; MHRC; Swiss National Foundation(Swiss National Science Foundation (SNSF))	Supported by a grant from the Canadian Institutes of Health Research (CIHR) and Manitoba Health Research Council (MHRC). A.S.G. is supported by Manitoba Research Chair. H.M. is supported by a studentship from MHRC. M.R. is supported by the Swiss National Foundation (310030_130740/1).	Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS; Burgess JK, 2008, J CELL PHYSIOL, V216, P673, DOI 10.1002/jcp.21450; Casazza A, 2010, J CLIN INVEST, V120, P2684, DOI 10.1172/JCI42118; Chauvet S, 2007, NEURON, V56, P807, DOI 10.1016/j.neuron.2007.10.019; Chiu HY, 2011, CYTOKINE, V56, P726, DOI 10.1016/j.cyto.2011.09.024; Choi YI, 2008, IMMUNITY, V29, P888, DOI 10.1016/j.immuni.2008.10.008; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Enomoto Y, 2009, J ALLERGY CLIN IMMUN, V124, P913, DOI 10.1016/j.jaci.2009.08.044; Fixman ED, 2007, EUR RESPIR J, V29, P379, DOI 10.1183/09031936.00053506; Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900; Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810; Gerthoffer William T, 2008, Proc Am Thorac Soc, V5, P97, DOI 10.1513/pats.200704-051VS; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Goncharova EA, 2006, NAT PROTOC, V1, P2933, DOI 10.1038/nprot.2006.434; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Gounni AS, 2004, J IMMUNOL, V173, P2771, DOI 10.4049/jimmunol.173.4.2771; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Hirota JA, 2011, AM J RESP CELL MOL, V45, P566, DOI 10.1165/rcmb.2010-0277OC; Ito I, 2009, CLIN EXP ALLERGY, V39, P1370, DOI 10.1111/j.1365-2222.2009.03293.x; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kajiwara Keiichi, 2009, Allergology International, V58, P573, DOI 10.2332/allergolint.09-OA-0113; Lalani SR, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.017640; Lee HS, 2009, AM J RESP CRIT CARE, V180, P1056, DOI 10.1164/rccm.200905-0740OC; Liu D, 2006, CIRC RES, V98, P480, DOI 10.1161/01.RES.0000205764.85931.4b; Makino N, 2008, FEBS LETT, V582, P3935, DOI 10.1016/j.febslet.2008.10.040; Mann F, 2007, PROG NEUROBIOL, V82, P57, DOI 10.1016/j.pneurobio.2007.02.011; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; Moriya J, 2010, CIRC RES, V106, P391, DOI 10.1161/CIRCRESAHA.109.210815; Moynihan BJ, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-84; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Papakonstantinou E, 2012, AM J RESP CELL MOL, V47, P759, DOI 10.1165/rcmb.2012-0101OC; Puschel AW, 2007, ADV EXP MED BIOL, V600, P12; Redhu NS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006153; Roth L, 2009, CELL MOL LIFE SCI, V66, P649, DOI 10.1007/s00018-008-8518-z; Sakurai A, 2010, MOL CELL BIOL, V30, P3086, DOI 10.1128/MCB.01652-09; Shan LY, 2010, J IMMUNOL, V184, P7134, DOI 10.4049/jimmunol.0902515; Simeone-Penney MC, 2008, AM J PHYSIOL-LUNG C, V294, pL698, DOI 10.1152/ajplung.00529.2007; Steinbach K, 2002, EXP CELL RES, V279, P52, DOI 10.1006/excr.2002.5595; Su XM, 2008, PATHOBIOLOGY, V75, P42, DOI 10.1159/000113794; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Vadasz Z, 2010, AUTOIMMUN REV, V9, P825, DOI 10.1016/j.autrev.2010.07.014; Wanschel A, 2013, ARTERIOSCL THROM VAS, V33, P886, DOI 10.1161/ATVBAHA.112.300941; Watanabe S, 2009, J ALLERGY CLIN IMMUN, V124, P59, DOI 10.1016/j.jaci.2009.03.024; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	52	48	48	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					560	+		10.1016/j.jaci.2013.06.011	http://dx.doi.org/10.1016/j.jaci.2013.06.011			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23932461				2022-12-18	WOS:000332397100033
J	Henderson, LA; Frugoni, F; Hopkins, G; de Boer, H; Pai, SY; Lee, YN; Walter, JE; Hazen, MM; Notarangelo, LD				Henderson, Lauren A.; Frugoni, Francesco; Hopkins, Gregory; de Boer, Helen; Pai, Sung-Yun; Lee, Yu Nee; Walter, Jolan E.; Hazen, Melissa M.; Notarangelo, Luigi D.			Expanding the spectrum of recombination-activating gene 1 deficiency: A family with early-onset autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RAG MUTATIONS; IMMUNODEFICIENCY; DEFECTS; DISEASE; CELLS		[Henderson, Lauren A.; Frugoni, Francesco; Lee, Yu Nee; Walter, Jolan E.; Hazen, Melissa M.; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Hopkins, Gregory; de Boer, Helen; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA USA; [Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Div Pediat Allergy Immunol, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Stem Cell Inst, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University	Henderson, LA (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA USA.	Melissa.Hazen@childrens.harvard.edu; Luigi.Notarangelo@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Pai, Sung-Yun/AAH-7762-2019; Lee, Yu Nee/T-2360-2017	Notarangelo, Luigi D/0000-0002-8335-0262; Pai, Sung-Yun/0000-0002-0158-8147; Frugoni, Francesco/0000-0002-1769-8121; Lee, Yu Nee/0000-0001-8648-5253	NIAID NIH HHS [U54 AI082973, 5P01AI076210-04, U54AI082973, K08 AI103035, P01 AI076210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, K08AI103035, P01AI076210] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Ehl S, 2005, J CLIN INVEST, V115, P3140, DOI 10.1172/JCI25221; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Ohm-Laursen L, 2008, J CLIN IMMUNOL, V28, P588, DOI 10.1007/s10875-008-9210-7; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927	9	48	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					969	971		10.1016/j.jaci.2013.06.032	http://dx.doi.org/10.1016/j.jaci.2013.06.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23891352	Green Accepted			2022-12-18	WOS:000325096500025
J	Sokol, H; Georgin-Lavialle, S; Canioni, D; Barete, S; Damaj, G; Soucie, E; Bruneau, J; Chandesris, MO; Suarez, F; Launay, JM; Aouba, A; Grandpeix-Guyodo, C; Lanternier, F; Grosbois, B; de Gennes, C; Cathebras, P; Fain, O; Hoyeau-Idrissi, N; Dubreuil, P; Lortholary, O; Beaugerie, L; Ranque, B; Hermine, O				Sokol, Harry; Georgin-Lavialle, Sophie; Canioni, Danielle; Barete, Stephane; Damaj, Gandhi; Soucie, Erinn; Bruneau, Julie; Chandesris, Marie-Olivia; Suarez, Felipe; Launay, Jean-Marie; Aouba, Achille; Grandpeix-Guyodo, Catherine; Lanternier, Fanny; Grosbois, Bernard; de Gennes, Christian; Cathebras, Pascal; Fain, Olivier; Hoyeau-Idrissi, Nadia; Dubreuil, Patrice; Lortholary, Olivier; Beaugerie, Laurent; Ranque, Brigitte; Hermine, Olivier			Gastrointestinal manifestations in mastocytosis: A study of 83 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; mast cells; c-Kit; gastrointestinal tract	MUCOSAL MAST-CELLS; SYSTEMIC MASTOCYTOSIS; KIT MUTATION; DISEASE; DISORDERS; ABNORMALITIES; MALABSORPTION; INVOLVEMENT; TRYPTASE; ADULTS	Background: Mastocytosis is a heterogeneous disease characterized by mast cell accumulation in 1 or more organs. Gastrointestinal manifestations of systemic mastocytosis have been previously studied in small cohorts of patients, and no specific histologic description is available. Objective: We sought to assess the clinical and pathologic features of gastrointestinal manifestations in patients with mastocytosis. Methods: Medical history and gastrointestinal symptoms of patients with mastocytosis (n = 83) were compared with those of matched healthy subjects (n = 83) by means of patient questionnaire. Data were analyzed for epidemiologic, clinical, biological, and genetic factors associated with gastrointestinal symptoms for patients with mastocytosis. A comparative analysis of gastrointestinal histology from patients with mastocytosis (n = 23), control subjects with inflammatory bowel disease (n = 17), and healthy subjects (n 5 19) was performed. Results: The following gastrointestinal symptoms occurred more frequently and were more severe in patients with mastocytosis than in healthy subjects: bloating (33% vs 7.2%, P < .0001), abdominal pain (27.3% vs 4.8%, P < .0001), nausea (23% vs 8.4%, P = .02), and diarrhea (33.85% vs 1.2%, P < .0001). Patients with mastocytosis had a significantly higher incidence of personal history of duodenal ulcer (P = .02). Wild-type (WT) c-Kit was associated with diarrhea (P = .03). Specific histologic lesions were present in patients with mastocytosis but were not correlated with clinical symptoms. Conclusion: Gastrointestinal manifestations in patients with mastocytosis are highly prevalent and often severe. Clinical symptoms do not correspond to histologic findings, are nonspecific, and can simulate irritable bowel syndrome.	[Sokol, Harry; Beaugerie, Laurent] Univ Paris 06, Hop St Antoine, AP HP, Serv Gastroenterol & Nutr, Paris, France; [Georgin-Lavialle, Sophie] Univ Paris 06, Equipe AVENIR, Lab INSERM U1057, UMR CNRS 7203, Paris, France; [Sokol, Harry; Hermine, Olivier] INRA, MICALIS, Equipe Interact Bacteries Commensales & Probiot A, Jouy En Josas, France; [Sokol, Harry; Georgin-Lavialle, Sophie; Damaj, Gandhi; Chandesris, Marie-Olivia; Grandpeix-Guyodo, Catherine; Dubreuil, Patrice; Lortholary, Olivier; Hermine, Olivier] Fac Med, Ctr Reference Mastocytoses, Paris, France; [Sokol, Harry; Georgin-Lavialle, Sophie; Canioni, Danielle; Damaj, Gandhi; Bruneau, Julie; Chandesris, Marie-Olivia; Suarez, Felipe; Aouba, Achille; Grandpeix-Guyodo, Catherine; Dubreuil, Patrice; Lortholary, Olivier; Hermine, Olivier] AP HP Necker Enfants Malades, Paris, France; [Georgin-Lavialle, Sophie] Univ Paris 06, Hop Tenon, Serv Med Interne, Paris, France; [Canioni, Danielle; Bruneau, Julie] Hop Necker Enfants Malad, CNRS UMR 8147, Paris, France; [Canioni, Danielle; Bruneau, Julie] Univ Paris 05, Fac Med, Anat Pathol Lab, Paris Sorbonne Cite, F-75743 Paris 15, France; [Barete, Stephane] Univ Paris 06, Hop Tenon, Serv Dermatol, Paris, France; [Damaj, Gandhi; Hermine, Olivier] Univ Picardie, Ctr Hosp Univ, Hop Sud, Serv Hematol, Amiens, France; [Soucie, Erinn; Dubreuil, Patrice] Aix Marseille Univ, Inst Paoli Calmettes, CRCM Signaling Hematopoiesis & Mech Oncogenesis, INSERM,CNRS,UMR7258,U1068, F-13284 Marseille, France; [Suarez, Felipe; Aouba, Achille] Univ Paris 05, Serv Hematol Adultes, Paris Sorbonne Cite, Fac Med, F-75743 Paris 15, France; [Launay, Jean-Marie] Univ Paris 07, Hop Lariboisiere, Lab Biochim & Biol Mol, Paris, France; [Launay, Jean-Marie] AP HP, Paris, France; [Lanternier, Fanny; Lortholary, Olivier] Univ Paris 05, Fac Med, Paris Sorbonne Cite, Serv Malad Fectieuses & Trop, F-75743 Paris 15, France; [Lanternier, Fanny; Lortholary, Olivier] AP HP Necker Enfants Malades, Ctr Infectiol Necker Pasteur, Paris, France; [Grosbois, Bernard] CHU Hop Sud, Serv Med Interne, Rennes, France; [de Gennes, Christian] Univ Paris 06, CHU Pitie Salpetriere, AP HP, Serv Med Interne, Paris, France; [Cathebras, Pascal] Hop Nord St Etienne, Serv Med Interne, St Etienne, France; [Fain, Olivier] Univ Paris 13, Hop Jean Verdier, Serv Med Interne, Bondy, France; [Fain, Olivier] AP HP, Bondy, France; [Hoyeau-Idrissi, Nadia] Univ Paris 06, AP HP St Antoine, Serv Anatomopathol, Paris, France; [Ranque, Brigitte] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Med Interne,Paris Sorbonne Cite, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Hermine, O (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Hematol Adultes,CNRS UMR 8147, 149 Rue Sevres, F-75743 Paris 15, France.	ohermine@gmail.com	Soucie, Erinn L/R-1731-2016; Dubreuil, Patrice/V-4816-2019; Hermine, Olivier/Q-7072-2018; sokol, harry/ABA-8991-2020; Sokol, Harry/E-2290-2019; Lanternier, Fanny/AAQ-2815-2021; dubreuil, patrice/F-5346-2011; ranque, brigitte/B-7298-2014	Soucie, Erinn L/0000-0001-6347-3954; Dubreuil, Patrice/0000-0003-1155-1150; sokol, harry/0000-0002-2914-1822; Sokol, Harry/0000-0002-2914-1822; dubreuil, patrice/0000-0003-1155-1150; CHANDESRIS, Marie-Olivia/0000-0002-9795-1085; Hermine, Olivier/0000-0003-2574-3874; ranque, brigitte/0000-0001-8549-2275; Bruneau, Julie/0000-0001-5519-8489	Association Franc, aise pour les Initiatives et la Recherche sur le Mastocyte et les Mastocytoses (AFIRMM); Canceropole de l'ile de France; CNRS-AP-HP; INSERM; la Ligue Nationale Contre le Cancer equipe labellisee; INCA; Ligue contre le cancer et INCA	Association Franc, aise pour les Initiatives et la Recherche sur le Mastocyte et les Mastocytoses (AFIRMM); Canceropole de l'ile de France; CNRS-AP-HP; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); la Ligue Nationale Contre le Cancer equipe labellisee; INCA(Institut National du Cancer (INCA) France); Ligue contre le cancer et INCA	Supported by Association Franc, aise pour les Initiatives et la Recherche sur le Mastocyte et les Mastocytoses (AFIRMM), Canceropole de l'ile de France. S.G.-L. is a recipient of a fellowship from CNRS-AP-HP. This work was financed by INSERM, la Ligue Nationale Contre le Cancer equipe labellisee (to P.D.), MRT (to P.D. and O.H.), and INCA (to P.D. and O.H.).; Disclosure of potential conflict of interest: H. Sokol has consultancy arrangements with Enterome and with Danone. G. Damaj is a Board member for Mundipharma and has received one or more grants from or has one or more grants pending with Mundipharma and Roche. J.-M. Launay has received one or more grants from or has one or more grants pending with PHRC C07-33 Genes et autisme. F. Lanternier has received one or more payments for lecturing from or is on the speakers' bureau for and has received one or more payments for travel/accommodations/meeting expenses from Gilead Science and MSD. B. Grosbois is a Board member for Octapharma. P. Dubreuil has been supported by one or more grants from INCa and Ligue nationale Contre le Cancer and is employed by and owns stock/stock options in AB Science. L. Beaugerie has consultancy arrangements with Abbott and has received one or more payments for the development of educational presentations for Abbott, MSD, and Ferring Pharmaceuticals. O. Hermine has been supported by one or more grants from Ligue contre le cancer et INCA. The rest of the authors declare that they have no relevant conflicts of interest.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; AWAD JA, 1994, J ALLERGY CLIN IMMUN, V93, P817, DOI 10.1016/0091-6749(94)90371-9; Bedeir A, 2006, AM J SURG PATHOL, V30, P1478, DOI 10.1097/01.pas.0000213310.51553.d7; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; BRAVERMAN DZ, 1985, AM J GASTROENTEROL, V80, P30; BREDFELDT JE, 1980, AM J GASTROENTEROL, V74, P133; CHERNER JA, 1988, GASTROENTEROLOGY, V95, P657, DOI 10.1016/S0016-5085(88)80012-X; DANTZIG PI, 1975, ARCH INTERN MED, V135, P1514, DOI 10.1001/archinte.135.11.1514; DEMIS DJ, 1963, ANN INTERN MED, V59, P194, DOI 10.7326/0003-4819-59-2-194; DEMIS DJ, 1961, ARCH DERMATOL, V83, P127, DOI 10.1001/archderm.1961.01580070133015; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; FISHMAN RS, 1979, MAYO CLIN PROC, V54, P51; FRIEDMAN BS, 1989, AM J MED, V87, P649; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Georgin-Lavialle S, 2013, BLOOD, V121, P1285, DOI 10.1182/blood-2012-07-442400; Georgin-Lavialle S, 2012, EUR J HAEMATOL, V89, P47, DOI 10.1111/j.1600-0609.2012.01761.x; GRANERUS G, 1983, J INVEST DERMATOL, V80, P410, DOI 10.1111/1523-1747.ep12555351; Gupta R, 2002, ACTA HAEMATOL-BASEL, V107, P123, DOI 10.1159/000046642; Hahn HP, 2007, AM J SURG PATHOL, V31, P1669, DOI 10.1097/PAS.0b013e318078ce7a; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton MJ, 2011, J ALLERGY CLIN IMMUN, V128, P147, DOI 10.1016/j.jaci.2011.04.037; Hermine O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002266; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; HORAN RF, 1990, J ALLERGY CLIN IMMUN, V85, P852, DOI 10.1016/0091-6749(90)90067-E; Jensen RT, 2000, HEMATOL ONCOL CLIN N, V14, P579, DOI 10.1016/S0889-8588(05)70298-7; Joris M, 2012, CASE REP HEMATOL, V2012, DOI 10.1155/2012/517546; Kirsch R, 2008, MODERN PATHOL, V21, P1508, DOI 10.1038/modpathol.2008.158; Krauth MT, 2007, HAEMATOLOGICA, V92, pE126, DOI 10.3324/haematol.11996; Lanternier F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001906; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; POYNARD T, 1982, NEW ENGL J MED, V307, P186; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Scolapio JS, 1996, GASTROINTEST ENDOSC, V44, P608, DOI 10.1016/S0016-5107(96)70019-6; SCOTT BB, 1975, GUT, V16, P918, DOI 10.1136/gut.16.11.918; Siegert SI, 2004, AM J CLIN PATHOL, V122, P560, DOI 10.1309/2880LF7Q6XK3HA3Q; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Swerdlow SH., 2017, WHO CLASSIFICATION T; Takasaki Y, 1998, INTERNAL MED, V37, P484, DOI 10.2169/internalmedicine.37.484; Tebbe B, 1998, DERMATOLOGY, V197, P101, DOI 10.1159/000017978; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; Valent P, 2003, BRIT J HAEMATOL, V122, P695, DOI 10.1046/j.1365-2141.2003.04575.x; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8	44	48	50	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					866	+		10.1016/j.jaci.2013.05.026	http://dx.doi.org/10.1016/j.jaci.2013.05.026			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23890756				2022-12-18	WOS:000325096500013
J	Berroth, A; Kuhnl, J; Kurschat, N; Schwarz, A; Stab, F; Schwarz, T; Wenck, H; Folster-Holst, R; Neufang, G				Berroth, Andreas; Kuehnl, Jochen; Kurschat, Nina; Schwarz, Agatha; Staeb, Franz; Schwarz, Thomas; Wenck, Horst; Foelster-Holst, Regina; Neufang, Gitta			Role of fibroblasts in the pathogenesis of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; leukemia inhibitory factor; fibroblast; keratinocyte; organotypic culture; differentiation; stratification	LEUKEMIA INHIBITORY FACTOR; BARRIER FUNCTION; KERATINOCYTE PROLIFERATION; STAT3 ACTIVATION; FACTOR LIF; IN-VIVO; SKIN; DIFFERENTIATION; FILAGGRIN; CYTOKINE	Background: Atopic dermatitis (AD) is a common dermatosis that highly impairs a patient's quality of life. The recent discovery that epidermal barrier defects caused by an aberrant differentiation process of keratinocytes are comparably important to the well-characterized changes in immune response patterns attributed a crucial role to the keratinocytes. Fibroblasts are able to alter proliferation and differentiation of keratinocytes, but their role in AD is not yet fully understood. Objective: We sought to determine the role of fibroblasts in skin proliferation and differentiation in patients with AD. Methods: We used human 3-dimensional organotypic skin cultures consisting of atopic fibroblasts and healthy keratinocytes, as well as healthy fibroblasts and atopic keratinocytes, and compared them with their controls. The expression of differentiation markers in these organotypic cultures were analyzed by using immunohistology and quantitative RT-PCR. Furthermore, the fundamental role of fibroblast-secreted leukemia inhibitory factor was assessed by using small interfering RNA-mediated knockdown cultures. Results: We observed that atopic fibroblasts influence the proliferation of keratinocytes and the terminal differentiation process, resulting in an in vivo-like morphology of AD. Subsequently, healthy fibroblasts were able to restore the structural deficits of the epidermis consisting of atopic keratinocytes. Partially, these effects were due to a reduced expression of the differentiation-associated cytokine leukemia inhibitory factor by atopic fibroblasts. Conclusion: These data demonstrate that fibroblasts and the modulation of fibroblast-derived factors might be new therapeutic targets for the alleviation of AD.	[Berroth, Andreas; Kuehnl, Jochen; Kurschat, Nina; Staeb, Franz; Wenck, Horst; Neufang, Gitta] Beiersdorf AG, Res & Dev, D-20245 Hamburg, Germany; [Schwarz, Agatha; Schwarz, Thomas; Foelster-Holst, Regina] Univ Kiel, Dept Dermatol & Allergol, Kiel, Germany	Beiersdorf AG; University of Kiel	Neufang, G (corresponding author), Beiersdorf AG, Res Skin Care, Unnastr 48, D-20245 Hamburg, Germany.	gitta.neufang@beiersdorf.com	Schwarz, Thomas/A-9148-2010		Spirig; Therakos; Astellas; Allergica	Spirig; Therakos; Astellas(Astellas Pharmaceuticals); Allergica	Disclosure of potential conflict of interest: A. Berroth, J. Kuhnl, N. Kurschat, F. Stab, and H. Wenck are employed by Beiersdorf AG. T. Schwarz has received one or more payments for lecturing from or is on the speakers' bureau for Spirig and Therakos. R. Folster-Holst is a Board member for Johnson & Johnson and has received one or more payments for lecturing from or is on the speakers' bureau for Astellas and Allergica. A. Schwarz declares that she has no relevant conflicts of interest.	Adachi T, 2005, J NEUROSCI RES, V79, P608, DOI 10.1002/jnr.20373; Banner LR, 1998, J NEUROSCI, V18, P5456, DOI 10.1523/JNEUROSCI.18-14-05456.1998; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; BRAUNSTEIN S, 1994, J INVEST DERMATOL, V103, P601, DOI 10.1111/1523-1747.ep12396936; Brown GS, 1992, GROWTH FACTORS, V7, P41, DOI 10.3109/08977199209023936; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; De Benedetto A, 2010, J ALLERGY CLIN IMMUN, V127; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; El Ghalbzouri A, 2004, LAB INVEST, V84, P102, DOI 10.1038/labinvest.3700014; Elliott J, 2006, DEV BIOL, V300, P583, DOI 10.1016/j.ydbio.2006.09.002; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hernandez-Quintero M, 2006, CELL TISSUE RES, V325, P77, DOI 10.1007/s00441-006-0173-9; Hirao T, 2003, EXP DERMATOL, V12, P591, DOI 10.1034/j.1600-0625.2003.00007.x; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Ishikawa H, 1997, ARCH DERMATOL RES, V289, P551, DOI 10.1007/s004030050238; Kirschner N, 2010, EUR J CELL BIOL, V89, P839, DOI 10.1016/j.ejcb.2010.07.010; Korge B, 2009, HAUTARZT, V60, P522, DOI 10.1007/s00105-009-1779-0; KRUEGER GG, 1990, J INVEST DERMATOL, V95, pS56, DOI 10.1111/1523-1747.ep12505791; Langlais D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000224; Lee JH, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3077182; Lee SH, 2006, YONSEI MED J, V47, P293, DOI 10.3349/ymj.2006.47.3.293; Maas-Szabowski N, 1999, J CELL SCI, V112, P1843; McGrath JA, 2008, AUSTRALAS J DERMATOL, V49, P67, DOI 10.1111/j.1440-0960.2008.00443.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Murray P, 2001, DIFFERENTIATION, V68, P227, DOI 10.1046/j.1432-0436.2001.680410.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peters EMJ, 2006, J INVEST DERMATOL, V126, P1937, DOI 10.1038/sj.jid.5700429; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Roggenkamp D, 2013, J INVEST DERMATOL; SAIAG P, 1985, SCIENCE, V230, P669, DOI 10.1126/science.2413549; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SMOLA H, 1994, TOXICOL IN VITRO, V8, P641, DOI 10.1016/0887-2333(94)90034-5; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; TUPKER RA, 1990, BRIT J DERMATOL, V123, P199, DOI 10.1111/j.1365-2133.1990.tb01847.x; Wu R, 2003, MOL MED, V9, P77, DOI 10.2119/2003-00001.Wu; Xie P, 1999, LEUKEMIA RES, V23, P1113, DOI 10.1016/S0145-2126(99)00141-1; Zhu M, 2001, J IMMUNOL, V166, P2049, DOI 10.4049/jimmunol.166.3.2049	42	48	50	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1547	+		10.1016/j.jaci.2013.02.029	http://dx.doi.org/10.1016/j.jaci.2013.02.029			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23582515				2022-12-18	WOS:000320532800013
J	Lemiere, C; Boulet, LP; Chaboillez, S; Forget, A; Chiry, S; Villeneuve, H; Prince, P; Maghni, K; Kennedy, WA; Blais, L				Lemiere, Catherine; Boulet, Louis-Phillippe; Chaboillez, Simone; Forget, Amelie; Chiry, Samah; Villeneuve, Helene; Prince, Philippe; Maghni, Karim; Kennedy, Wendy A.; Blais, Lucie			Work-exacerbated asthma and occupational asthma: Do they really differ?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cost; health care use; occupational asthma; sputum eosinophils; work-exacerbated asthma	SPUTUM CELL COUNTS; AIRWAY INFLAMMATION; REPRODUCIBILITY; VALIDATION; MANAGEMENT; DIAGNOSIS; SYMPTOMS; EXPOSURE	Background: Although work-exacerbated asthma (WEA) is a prevalent condition likely to have an important societal burden, there are limited data on this condition. Objectives: The aims of this study were (1) to compare the clinical, functional, and inflammatory characteristics of workers with WEA and occupational asthma (OA) and (2) compare health care use and related costs between workers with WEA and OA, as well as between workers with work-related asthma (WRA; ie, WEA plus OA) and those with non-work-related asthma (NWRA) in a prospective study. Methods: We performed a prospective observational study of workers with and without WRA with a 2-year follow-up. The diagnosis of OA and WEA was based on the positivity and negativity of results on specific inhalation challenges, respectively. Results: One hundred fifty-four subjects were enrolled: 53 with WEA, 68 with OA, and 33 control asthmatic subjects (NWRA). WEA was associated with more frequent prescriptions of inhaled corticosteroids (odds ratio [OR], 4.4; 95% CI, 1.4-13.6; P = .009), a noneosinophilic phenotype (OR, 0.3; 95% CI, 0.1-0.9; P = .04), a trend toward a lower FEV1 (OR, 0.9; 95% CI, 0.9-1.0; P = .06), and a higher proportion of smokers (OR, 2.5; 95% CI, 0.96-9.7; P = .06) than the diagnosis of OA. The health care use of WRA and related costs were 10-fold higher than those of NWRA. Conclusion: Workers with WEA appeared to have features of greater asthma severity than workers with OA. In contrast with OA, WEA was associated with a noneosinophilic phenotype. Both OA and WEA were associated with greater health care use and 10-fold higher direct costs than NWRA. (J Allergy Clin Immunol 2013;131:704-10.)	[Lemiere, Catherine; Chaboillez, Simone; Forget, Amelie; Chiry, Samah; Maghni, Karim; Kennedy, Wendy A.; Blais, Lucie] Univ Montreal, Hop Sacre Coeur Montreal Quebec Canada, Montreal, PQ, Canada; [Boulet, Louis-Phillippe; Villeneuve, Helene; Prince, Philippe] Inst Univ Cardiol & Pneumol Quebec, Unite Rech Pneumol, Quebec City, PQ, Canada; [Blais, Lucie] Univ Montreal, Fac Pharm, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal	Lemiere, C (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin West, Montreal, PQ H4J 1C5, Canada.	catherine.lemiere@umontreal.ca			Centers for Disease Control and Prevention (CDC) [R01 OH008391]; AllerGen; AstraZeneca; GlaxoSmithKline; Merck Frosst; Novartis; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH008391] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); AllerGen; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck Frosst; Novartis(Novartis); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))	Supported by cooperative agreement no. R01 OH008391 from the Centers for Disease Control and Prevention (CDC).; C. Lemiere has received grants from the CDC and AllerGen; is a consultant for GlaxoSmithKline, Merck, and AstraZeneca; has received payment for lectures, including service on speakers' bureaus, and payment for development of educational presentations from AstraZeneca. L.-P. Boulet is on the advisory boards for, received research support from, and received lecture fees from AstraZeneca, GlaxoSmithKline, Merck Frosst, and Novartis. H. Villeneuve and K. Maghni have received research support from the CDC. P. Prince has received research support from the CDC and travel expenses from AllerGen NCE. The rest of the authors declare that they have no relevant conflicts of interest.	Allard G, CHIFFRE STRATEGE COS; Andersson E, 2006, EUR RESPIR J, V27, P720, DOI 10.1183/09031936.06.00034305; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Association AHQ, 2003, DIAGN REGR GEST STAT; Breton CV, 2006, OCCUP ENVIRON MED, V63, P411, DOI 10.1136/oem.2005.025064; CARTIER A, 1994, EUR RESPIR J, V7, P153, DOI 10.1183/09031936.94.07010153; Chiry S, 2009, AM J IND MED, V52, P447, DOI 10.1002/ajim.20695; Choi JS, 2012, RESPIROLOGY, V17, P322, DOI 10.1111/j.1440-1843.2011.02097.x; de Groene GJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006308.pub3; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Henneberger PK, 2011, AM J RESP CRIT CARE, V184, P368, DOI 10.1164/rccm.812011ST; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Juniper E, 1994, HISTAMINE METHACHOLI; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202a; Le Moual N, 2008, AM J RESP CRIT CARE, V177, P4, DOI 10.1164/rccm.200703-415PP; Lemay A., 2008, COMMUNICATION; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lemiere C, 2011, AM THOR SOC 2011 INT, pA1183; Lemiere C, 2007, J ALLERGY CLIN IMMUN, V120, P1354, DOI 10.1016/j.jaci.2007.07.043; Lougheed MD, 2010, CAN RESPIR J, V17, P15, DOI 10.1155/2010/827281; Maestrelli P, 2009, J ALLERGY CLIN IMMUN, V123, P531, DOI 10.1016/j.jaci.2009.01.057; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Prince P, 2012, CHEST, V141, P1522, DOI 10.1378/chest.11-1134; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303	33	48	50	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					704	+		10.1016/j.jaci.2012.08.024	http://dx.doi.org/10.1016/j.jaci.2012.08.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23058644				2022-12-18	WOS:000315587800010
J	Bin, LH; Kim, BE; Brauweiler, A; Goleva, E; Streib, J; Ji, YD; Schlievert, PM; Leung, DYM				Bin, Lianghua; Kim, Byung Eui; Brauweiler, Anne; Goleva, Elena; Streib, Joanne; Ji, Yinduo; Schlievert, Patrick M.; Leung, Donald Y. M.			Staphylococcus aureus alpha-toxin modulates skin host response to viral infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; Staphylococcus aureus; herpes simplex virus; vaccinia virus; alpha-toxin; a disintegrin and metalloprotease 10	HERPES-SIMPLEX-VIRUS; ATOPIC-DERMATITIS; FILAGGRIN MUTATIONS; VACCINIA VIRUS; SHOCK-SYNDROME; HEMOLYSIN; DISEASE; INFLUENZA; MECHANISMS; VIRULENCE	Background: Patients with atopic dermatitis (AD) with a history of eczema herpeticum have increased staphylococcal colonization and infections. However, whether Staphylococcus aureus alters the outcome of skin viral infection has not been determined. Objective: We investigated whether S aureus toxins modulated host response to herpes simplex virus (HSV) 1 and vaccinia virus (VV) infections in normal human keratinocytes (NHKs) and in murine infection models. Methods: NHKs were treated with S aureus toxins before incubation of viruses. BALB/c mice were inoculated with S aureus 2 days before VV scarification. Viral loads of HSV-1 and VV were evaluated by using real-time PCR, a viral plaque-forming assay, and immunofluorescence staining. Small interfering RNA duplexes were used to knockdown the gene expression of the cellular receptor of alpha-toxin, a disintegrin and metalloprotease 10 (ADAM10). ADAM10 protein and alpha-toxin heptamers were detected by using Western blot assays. Results: We demonstrate that sublytic staphylococcal alpha-toxin increases viral loads of HSV-1 and VV in NHKs. Furthermore, we demonstrate in vivo that the VV load is significantly greater (P < .05) in murine skin inoculated with an alpha-toxin-producing S aureus strain compared with murine skin inoculated with the isogenic alpha-toxin-deleted strain. The viral enhancing effect of alpha-toxin is mediated by ADAM10 and is associated with its pore-forming property. Moreover, we demonstrate that a-toxin promotes viral entry in NHKs. Conclusion: The current study introduces the novel concept that staphylococcal alpha-toxin promotes viral skin infection and provides a mechanism by which S aureus infection might predispose the host toward disseminated viral infections. (J Allergy Clin Immunol 2012;130:683-91.)	[Bin, Lianghua; Kim, Byung Eui; Brauweiler, Anne; Goleva, Elena; Streib, Joanne; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Schlievert, Patrick M.] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Ji, Yinduo] Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA	National Jewish Health; University of Iowa; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Rm K926I, Denver, CO 80206 USA.	leungd@njhealth.org		Schlievert, Patrick/0000-0001-8314-9369; Kim, Byung Eui/0000-0003-4923-1814	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network [HHSN272201000020C, R01 AR41256]; National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network contract HHSN272201000020C and R01 AR41256.; P. M. Schlievert has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Abeck D, 1998, BRIT J DERMATOL, V139, P13; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bengali Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017248; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin L, 2011, J ALLERGY CLIN IMMUN, V127, pAB148, DOI 10.1016/j.jaci.2010.12.587; Bin LH, 2011, J ALLERGY CLIN IMMUN, V127, P430, DOI 10.1016/j.jaci.2010.11.013; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; BRAMLEY AJ, 1989, INFECT IMMUN, V57, P2489, DOI 10.1128/IAI.57.8.2489-2494.1989; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; Di Giovine P, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002277; Finelli L, 2008, PEDIATRICS, V122, P805, DOI 10.1542/peds.2008-1336; Fraser JD, 2008, IMMUNOL REV, V225, P226, DOI 10.1111/j.1600-065X.2008.00681.x; Frazee BW, 2007, ANN EMERG MED, V50, P612, DOI 10.1016/j.annemergmed.2007.09.005; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Hovanessian AG, 2007, BIOCHIMIE, V89, P779, DOI 10.1016/j.biochi.2007.02.003; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Inoshima I, 2011, NAT MED, V17, P1310, DOI 10.1038/nm.2451; Inoshima N, 2012, J INVEST DERMATOL, V132, P1513, DOI 10.1038/jid.2011.462; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kallen AJ, 2009, ANN EMERG MED, V53, P358, DOI 10.1016/j.annemergmed.2008.04.027; Kennedy AD, 2010, J INFECT DIS, V202, P1050, DOI 10.1086/656043; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Liang XD, 2009, INFECT IMMUN, V77, P977, DOI 10.1128/IAI.00920-08; Lin YC, 2011, BIOCHEMISTRY-US, V50, P7157, DOI 10.1021/bi200435n; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V257, P1053, DOI 10.1001/jama.257.8.1053; Monti G, 1996, DERMATOLOGY, V193, P83, DOI 10.1159/000246218; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Ong PY, 2010, IMMUNOL ALLERGY CLIN, V30, P309, DOI 10.1016/j.iac.2010.05.001; Orynbayeva Z, 2007, J VIROL, V81, P1140, DOI 10.1128/JVI.01345-06; Rahn E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025464; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Tomita T, 1997, BIOSCI BIOTECH BIOCH, V61, P565, DOI 10.1271/bbb.61.565; Valeva A, 2006, J BIOL CHEM, V281, P26014, DOI 10.1074/jbc.M601960200; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208; Wardenburg JB, 2007, NAT MED, V13, P1405, DOI 10.1038/nm1207-1405; Wardenburg JB, 2007, INFECT IMMUN, V75, P1040, DOI 10.1128/IAI.01313-06; Weidmann M, 2003, J CLIN MICROBIOL, V41, P1565, DOI 10.1128/JCM.41.4.1565-1568.2003; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107; Yoon M, 2002, J VIROL, V76, P7203, DOI 10.1128/JVI.76.14.7203-7208.2002	51	48	54	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					683	+		10.1016/j.jaci.2012.06.019	http://dx.doi.org/10.1016/j.jaci.2012.06.019			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22840852	Green Accepted			2022-12-18	WOS:000308463500017
J	Massoud, AH; Guay, J; Shalaby, KH; Bjur, E; Ablona, A; Chan, D; Nouhi, Y; McCusker, CT; Mourad, MW; Piccirillo, CA; Mazer, BD				Massoud, Amir H.; Guay, Julie; Shalaby, Karim H.; Bjur, Eva; Ablona, Aidan; Chan, Daniel; Nouhi, Yasaman; McCusker, Christine T.; Mourad, M. Walid; Piccirillo, Ciriaco A.; Mazer, Bruce D.			Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; asthma; regulatory T cells; dendritic cells; IgG; immune modulation; airway hyperresponsiveness	FC-GAMMA RECEPTORS; DENDRITIC CELLS; ANTIINFLAMMATORY ACTIVITY; IN-VIVO; IVIG; DISEASE; IGG; DIFFERENTIATION; INFECTION; ASTHMA	Background: Intravenous immunoglobulin (IVIG) is a frequently used disease-modifying therapy for a large spectrum of autoimmune and inflammatory conditions, yet its mechanisms of action are incompletely understood. Using a robust murine model of antigen-driven allergic airways disease, we have demonstrated that IVIG markedly improves ovalbumin (OVA)-induced airway hyperresponsiveness characterized by 4- to 6-fold enhancement in regulatory T (Treg) cells in pulmonary and associated lymphoid tissues. Objective: We sought to determine whether IVIG induces antigen-specific Treg cells and to address cellular interactions that lead to induction of Treg cells by IVIG. Methods: C57Bl/6 mice were sensitized and challenged by means of intranasal OVA exposure. IVIG or albumin control was administered 24 hours before challenge. Treg cells were tracked by using green fluorescent protein (GFP)-forkhead box protein 3 (Foxp3) knock-in reporter mice (Foxp3(GFP)), and Treg cell and dendritic cell (DC) phenotypes and activities were elucidated by using coculture and flow cytometry. Results: IVIG therapy of OVA-sensitized and OVA-challenged mice induced antigen-specific forkhead box protein 3 (Foxp3)-positive Treg cells from non-Treg cell precursors. The induced Treg cells home specifically to the lungs and draining lymph nodes and have greatly potentiated suppressive activity compared with that seen in Treg cells purified from control mice. Induction of Treg cells is mediated by tolerogenic DCs generated after IVIG exposure. Compared with albumin-treated, OVA-exposed mice, IVIG-primed DCs express altered Notch ligands, including increased Delta-4 and reduced Jagged-1 levels, reflecting decreased T(H)2 polarization. Furthermore, IVIG-primed DCs can stimulate Treg cell differentiation from uncommitted Foxp3(-) CD4(+) T cells ex vivo, and adoptive transfer of IVIG-primed DCs abrogates airway hyperresponsiveness and induces Treg cells. Conclusion: The anti-inflammatory effects of IVIG therapy can be mediated by the immunomodulation of DCs, creating a bridge that induces antigen-specific, highly suppressive Treg cells. (J Allergy Clin Immunol 2012;129:1656-65.)	[Massoud, Amir H.; Guay, Julie; Shalaby, Karim H.; Ablona, Aidan; Chan, Daniel; Nouhi, Yasaman; Mazer, Bruce D.] McGill Univ, Meakins Christie Labs, Ctr Hlth, Res Inst, Montreal, PQ H3H 1P3, Canada; [Mourad, M. Walid] Univ Montreal, Dept Immunol & Microbiol, Hop St Luc, Res Inst, Montreal, PQ, Canada; [Bjur, Eva; Piccirillo, Ciriaco A.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3H 1P3, Canada; [McCusker, Christine T.] McGill Univ, Ctr Hlth, Div Allergy & Immunol, Dept Pediat, Montreal, PQ H3H 1P3, Canada	McGill University; Universite de Montreal; McGill University; McGill University	Mazer, BD (corresponding author), McGill Univ, Meakins Christie Labs, Ctr Hlth, Res Inst, 3626 St Urbain, Montreal, PQ H3H 1P3, Canada.	bruce.mazer@mcgill.ca	Massoud, Amir Hossein/AAO-2940-2021		Talecris Biotherapuetics; Canadian Institutes for Health Research (CIHR) [ISO115295, MOP67211]; McGill University Health Center-Research Institute; Montreal Chest Institute; Strauss Family Foundation; Fonds de Recherche en Sante du Quebec (FRSQ)	Talecris Biotherapuetics; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); McGill University Health Center-Research Institute; Montreal Chest Institute; Strauss Family Foundation; Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	Supported by Talecris Biotherapuetics (Clinical Investigation Program) and the Canadian Institutes for Health Research (CIHR grants ISO115295 [B. D. M.] and MOP67211 [C. A. P.]), the McGill University Health Center-Research Institute, the Montreal Chest Institute, and the Strauss Family Foundation. A. H. M. was the recipient of a Fonds de Recherche en Sante du Quebec (FRSQ) Student Scholarship. B. D. M. is a Chercheur National of the FRSQ. C. A. P. holds a CIHR Canada Research Chair.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2009, CURR OPIN IMMUNOL, V21, P153, DOI 10.1016/j.coi.2009.03.010; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2010, J CLIN IMMUNOL, V30, pS9, DOI 10.1007/s10875-010-9405-6; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Ballow M, 1999, CLIN IMMUNOL, V91, P123, DOI 10.1006/clim.1999.4722; Ballow M, 2011, J ALLERGY CLIN IMMUN, V127, P315, DOI 10.1016/j.jaci.2010.10.030; Bayry J, 2003, ARTHRITIS RHEUM-US, V48, P3497, DOI 10.1002/art.11346; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Crow AR, 2009, J THROMB HAEMOST, V7, P245, DOI 10.1111/j.1538-7836.2009.03420.x; Crow AR, 2003, J PEDIAT HEMATOL ONC, V25, pS14, DOI 10.1097/00043426-200312001-00004; Crow AR, 2001, BRIT J HAEMATOL, V115, P679, DOI 10.1046/j.1365-2141.2001.03136.x; d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; Dunne PJ, 2009, J IMMUNOL, V183, P400, DOI 10.4049/jimmunol.0900169; Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947; Gupta M, 2001, J CLIN IMMUNOL, V21, P193, DOI 10.1023/A:1011039216251; Huang H, 2010, J IMMUNOL, V185, P5003, DOI 10.4049/jimmunol.0903446; Huang MT, 2009, J IMMUNOL, V183, P4745, DOI 10.4049/jimmunol.0804371; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Kaufman GN, 2011, CLIN EXP ALLERGY, V41, P718, DOI 10.1111/j.1365-2222.2010.03663.x; Kessel A, 2007, J IMMUNOL, V179, P5571, DOI 10.4049/jimmunol.179.8.5571; McCusker C, 2002, J ALLERGY CLIN IMMUN, V110, P891, DOI 10.1067/mai.2002.130048; McCusker CT, 2004, CURR OPIN ALLERGY CL, V4, P11, DOI 10.1097/01.all.0000113683.18759.cc; Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232; Nimmerjahn F, 2007, P NATL ACAD SCI USA, V104, P8433, DOI 10.1073/pnas.0702936104; Nimmerjahn F, 2007, J EXP MED, V204, P11, DOI 10.1084/jem.20061788; Olivito B, 2010, CLIN EXP RHEUMATOL, V28, pS93; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Preston JA, 2011, EUR RESPIR J, V37, P53, DOI 10.1183/09031936.00049510; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Schmidt-Weber CB, 2005, CURR ALLERGY ASTHM R, V5, P356, DOI 10.1007/s11882-005-0006-z; Seite JF, 2010, BLOOD, V116, P1698, DOI 10.1182/blood-2009-12-261461; Shalaby KH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-82; Siragam V, 2006, NAT MED, V12, P688, DOI 10.1038/nm1416; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Yamamoto M, 2010, CLIN EXP IMMUNOL, V162, P315, DOI 10.1111/j.1365-2249.2010.04243.x; Zhang N, 2009, IMMUNITY, V30, P458, DOI 10.1016/j.immuni.2008.12.022	43	48	50	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1656	+		10.1016/j.jaci.2012.02.050	http://dx.doi.org/10.1016/j.jaci.2012.02.050			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22564681				2022-12-18	WOS:000304764600028
J	Pongracic, JA; Bock, SA; Sicherer, SH				Pongracic, Jacqueline A.; Bock, S. Allan; Sicherer, Scott H.			Oral food challenge practices among allergists in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Pongracic, Jacqueline A.] Northwestern Univ, Childrens Mem Hosp, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60614 USA; [Bock, S. Allan] Univ Colorado, Dept Pediat, Denver, CO USA; [Sicherer, Scott H.] Mt Sinai Sch Med, Elliott & Roslyn Jaffe Food Allergy Inst, New York, NY USA; [Bock, S. Allan] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University of Colorado System; University of Colorado Denver; Icahn School of Medicine at Mount Sinai; National Jewish Health	Pongracic, JA (corresponding author), Northwestern Univ, Childrens Mem Hosp, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60614 USA.	j-pongracic@northwestern.edu						[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; DunnGalvin A, 2010, CLIN EXP ALLERGY, V40, P476, DOI 10.1111/j.1365-2222.2010.03454.x; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042	4	48	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					564	566		10.1016/j.jaci.2011.09.024	http://dx.doi.org/10.1016/j.jaci.2011.09.024			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22035656				2022-12-18	WOS:000299951700041
J	Siltanen, M; Wehkalampi, K; Hovi, P; Eriksson, JG; Strang-Karlsson, S; Jarvenpaa, AL; Andersson, S; Kajantie, E				Siltanen, Mirjami; Wehkalampi, Karoliina; Hovi, Petteri; Eriksson, Johan G.; Strang-Karlsson, Sonja; Jarvenpaa, Anna-Liisa; Andersson, Sture; Kajantie, Eero			Preterm birth reduces the incidence of atopy in adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; allergy; skin prick test; total IgE; allergen-specific IgE; prematurity; very low birth weight; gestational age	1ST 6 YEARS; RISK-FACTORS; FETAL-GROWTH; FOLLOW-UP; DEVELOPMENTAL ORIGINS; CESAREAN-SECTION; GESTATIONAL-AGE; LUNG-FUNCTION; YOUNG-ADULTS; HAY-FEVER	Background: Immunologic pathways are primed in early life. Preterm birth can influence this process and thereby affect whether a person will have atopy later in life. Previous studies on the effects of preterm birth on atopy in adulthood have been inconclusive and limited to children or subjects born moderately preterm. Objective: Our aim was to compare the incidence of atopy among young adults who were born preterm and at very low birth weight (<= 1500 g) with that of term-born young adults (control subjects). Methods: The study comprised 166 adults who were born preterm and at very low birth weight and 172 control subjects, all of whom were from the Helsinki Study of Very Low Birth Weight Adults. We assessed atopic predisposition at ages 18 to 27 years using skin prick tests for 6 common aeroallergens and measurements of serum concentrations of total IgE and 3 types of allergen-specific (cat, birch, and timothy) IgE. We asked the subjects whether they had been given a diagnosis of asthma or allergic rhinitis or had atopic eczema and analyzed data by using logistic or linear regression, adjusting for potential confounding factors. Results: The risk for having at least 1 positive reaction on a skin prick test was reduced (adjusted odds ratio, 0.43; 95% CL, 0.23-0.79, P = .007), and the concentration of cat-specific IgE was less (25% less; 95% CI, 43% to 2.3% less; P = .033) in sera from very-low-birth-weight subjects compared with that seen in sera from control subjects. Within the very-low-birth-weight group, those born at an earlier gestational age were less likely to have positive skin prick test reactions (adjusted odds ratio for 1 week, 0.82; 95% CI, 0.68-0.98, P = .029) and less likely to have high levels of allergen-specific IgE. Cumulative incidences of atopic disease were similar between adults of very low birth weight and control subjects. Conclusions: Young adults born prematurely and at very low birth weight have a lower incidence of atopy than adults who were born full term. This finding supports the hypothesis that the risk for atopy is determined during early stages of development. (J Allergy Clin Immunol 2011;127:935-42.)	[Siltanen, Mirjami; Wehkalampi, Karoliina; Hovi, Petteri; Eriksson, Johan G.; Strang-Karlsson, Sonja; Kajantie, Eero] Natl Inst Hlth & Welf, Div Welf & Hlth Promot, Dept Chron Dis Prevent, Diabet Prevent Unit, FIN-00271 Helsinki, Finland; [Siltanen, Mirjami] Hyvinkaa Hosp, Hyvinkaa, Finland; [Wehkalampi, Karoliina; Hovi, Petteri; Strang-Karlsson, Sonja; Jarvenpaa, Anna-Liisa; Andersson, Sture; Kajantie, Eero] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland; [Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland; [Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland; [Eriksson, Johan G.] Vasa Cent Hosp, Vaasa, Finland; [Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Vaasa Central Hospital; Folkhalsan Research Center	Kajantie, E (corresponding author), Natl Inst Hlth & Welf, Div Welf & Hlth Promot, Dept Chron Dis Prevent, Diabet Prevent Unit, Mannerheimintie 164,POB 30, FIN-00271 Helsinki, Finland.	eero.kajantie@helsinki.fi		Eriksson, Johan/0000-0002-2516-2060	Finnish Foundation for Pediatric Research; Finska Lakaresallskape; Finnish Special Governmental Subsidy for Health Sciences; Academy of Finland; Biomedicum Helsinki Foundation; Emil Aaltonen Foundation; Finnish Concordia Foundation; Finnish Medical Society Duodecim; Finnish National Graduate School of Clinical Investigation; Jalmari and Rauha Ahokas Foundation; Juho Vainio Foundation; Novo Nordisk Foundation; Paivikki and Sakari Sohlberg Foundation; Pediatric Graduate School; Clinical Graduate School in Paediatrics and Obstetrics/Gynaecology; University of Helsinki; Perklen Foundation; Research Foundation for the Orion Corporation; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation; Waldemar von Frenckell Foundation; Vasa Nation; Wiipurilainen Osakunta at Helsinki University; Wilhelm and Else Stockmann Foundation; Yrjo Jahnsson Foundation; Finnish Foundation of Pediatric Research	Finnish Foundation for Pediatric Research; Finska Lakaresallskape; Finnish Special Governmental Subsidy for Health Sciences; Academy of Finland(Academy of Finland); Biomedicum Helsinki Foundation; Emil Aaltonen Foundation; Finnish Concordia Foundation; Finnish Medical Society Duodecim; Finnish National Graduate School of Clinical Investigation; Jalmari and Rauha Ahokas Foundation; Juho Vainio Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Paivikki and Sakari Sohlberg Foundation; Pediatric Graduate School; Clinical Graduate School in Paediatrics and Obstetrics/Gynaecology; University of Helsinki; Perklen Foundation; Research Foundation for the Orion Corporation; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Waldemar von Frenckell Foundation; Vasa Nation; Wiipurilainen Osakunta at Helsinki University; Wilhelm and Else Stockmann Foundation; Yrjo Jahnsson Foundation; Finnish Foundation of Pediatric Research	The Helsinki Study of Very Low Birth Weight Adults has received grant support from the following sources: the Finnish Foundation for Pediatric Research (E. K., K. W., M. S., P. H., and S. A.), Finska Lakaresallskapet (J.G.E. and S. A.), the Finnish Special Governmental Subsidy for Health Sciences (J.G.E. and S. A.), the Academy of Finland (K. W., J.G.E., S. A., and E. K.), the Biomedicum Helsinki Foundation (S. S. K.), the Emil Aaltonen Foundation, the Finnish Concordia Foundation (S. S. K.), the Finnish Medical Society Duodecim (E. K.), the Finnish National Graduate School of Clinical Investigation (S. S. K.), the Jalmari and Rauha Ahokas Foundation (E. K.), the Juho Vainio Foundation (J.G.E. and E. K.), the Novo Nordisk Foundation (J.G.E. and E. K.), the Paivikki and Sakari Sohlberg Foundation (J.G.E. and E. K.), the Pediatric Graduate School (P. H. and S. S. K.), the Clinical Graduate School in Paediatrics and Obstetrics/Gynaecology (P. H.), the University of Helsinki (J.G.E.), the Perklen Foundation (S. S. K.), the Research Foundation for the Orion Corporation (P. H.), the Signe and Ane Gyllenberg Foundation (J.G.E. and E. K.), the Sigrid Juselius Foundation (S. A. and E. K.), the Waldemar von Frenckell Foundation (S. S. K.), Vasa Nation (S. S. K.), Wiipurilainen Osakunta (E. K.) at Helsinki University, the Wilhelm and Else Stockmann Foundation (S. S. K.), and the Yrjo Jahnsson Foundation (P. H., J.G.E., and E. K.).; Disclosure of potential conflict of interest: M. Siltanen has received research support from the Finnish Foundation of Pediatric Research. The rest of the authors have declared that they have no conflict of interest.	Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Bostanci I, 2008, PEDIATR INT, V50, P648, DOI 10.1111/j.1442-200X.2008.02631.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; DAVID TJ, 1988, ARCH DIS CHILD, V63, P435, DOI 10.1136/adc.63.4.435; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187; Gluckman PD, 2010, J DEV ORIG HLTH DIS, V1, P6, DOI 10.1017/S2040174409990171; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Hack M, 2009, J DEV BEHAV PEDIATR, V30, P460, DOI 10.1097/DBP.0b013e3181ba0fba; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Hesselmar B, 2002, ACTA PAEDIATR, V91, P992, DOI 10.1080/080352502760272713; Hovi P, 2007, NEW ENGL J MED, V356, P2053, DOI 10.1056/NEJMoa067187; Hovi P, 2010, J PEDIATR-US, V156, P54, DOI 10.1016/j.jpeds.2009.07.022; Hovi P, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000135; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; Keski-Nisula L, 2009, AM J REPROD IMMUNOL, V62, P293, DOI 10.1111/j.1600-0897.2009.00738.x; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; Kwinta P, 2009, PEDIAT ALLERG IMM-UK, V20, P458, DOI 10.1111/j.1399-3038.2008.00814.x; Laerum BN, 2005, CLIN EXP ALLERGY, V35, P1022, DOI 10.1111/j.1365-2222.2005.02289.x; Laerum BN, 2004, RESP MED, V98, P611, DOI 10.1016/j.rmed.2004.01.003; Leadbitter P, 1999, THORAX, V54, P905, DOI 10.1136/thx.54.10.905; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; LUCAS A, 1990, ARCH DIS CHILD, V65, P411, DOI 10.1136/adc.65.4.411; Macaubas C, 2000, PEDIATR ALLERGY IMMU, V11, P9, DOI 10.1034/j.1399-3038.2000.00502.x; Mai XM, 2003, PEDIATR ALLERGY IMMU, V14, P184, DOI 10.1034/j.1399-3038.2003.00045.x; Mallen CD, 2008, J ASTHMA, V45, P309, DOI 10.1080/02770900801911194; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; Paavonen EJ, 2007, PEDIATRICS, V120, P778, DOI 10.1542/peds.2007-0540; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Pihkala J, 1989, Duodecim, V105, P1540; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rasanen M, 2001, Twin Res, V4, P392; Remes ST, 2008, PEDIAT ALLERG IMM-UK, V19, P541, DOI 10.1111/j.1399-3038.2007.00707.x; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Savilahti E, 2008, CURR OPIN ALLERGY CL, V8, P243, DOI 10.1097/ACI.0b013e3282ffb134; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; SILTANEN M, 2004, THESIS U HELSINKI YL; Stazi MA, 2002, PEDIAT ALLERG IMM-UK, V13, P105, DOI 10.1034/j.1399-3038.2002.00070.x; Steffensen FH, 2000, EPIDEMIOLOGY, V11, P185, DOI 10.1097/00001648-200003000-00018; Sudo N, 1997, J IMMUNOL, V159, P1739; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166	59	48	52	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					935	942		10.1016/j.jaci.2010.12.1107	http://dx.doi.org/10.1016/j.jaci.2010.12.1107			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21333345				2022-12-18	WOS:000289055800015
J	O'Regan, GM; Campbell, LE; Cordell, HJ; Irvine, AD; McLean, WHI; Brown, SJ				O'Regan, Grainne M.; Campbell, Linda E.; Cordell, Heather J.; Irvine, Alan D.; McLean, W. H. Irwin; Brown, Sara J.			Chromosome 11q13.5 variant associated with childhood eczema: An effect supplementary to filaggrin mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; atopic dermatitis; atopy; inflammatory skin disease; skin barrier	OF-FUNCTION VARIANTS; POLYMORPHISMS; GENETICS; COMPLEX; RISK	Background: Atopic eczema is a common inflammatory skin disease with multifactorial etiology. The genetic basis is incompletely understood; however, loss of function mutations in the filaggrin gene (FLG) are the most significant and widely replicated genetic risk factor reported to date. The first genome-wide association study in atopic eczema recently identified 2 novel genetic variants in association with eczema susceptibility: a single nucleotide polymorphism on chromosome 11q13.5 (rs7927894) and a single nucleotide polymorphism (rs877776) within the gene encoding hornerin on chromosome 1q21. Objective: To test the association of these 2 novel variants with pediatric eczema and to investigate their interaction with FLG null mutations. Methods: Case-control study to investigate the association of rs7927894, rs877776 and the 4 most prevalent FLG null mutations with moderate-severe eczema in 511 Irish pediatric cases and 1000 Irish controls. Comprehensive testing for interaction between each of the loci was also performed. Results: The association between rs7927894 and atopic eczema was replicated in this population (P = .0025, chi(2) test; odds ratio, 1.27; 95% CI, 1.09-1.49). The 4 most common FLG null variants were strongly associated with atopic eczema (P = 1.26 x 10(-50); combined odds ratio, 5.81; 95% CI, 4.51-7.49). Interestingly, the rs7927894 association was independent of the well-established FLG risk alleles and may be multiplicative in its effect. There was no significant association between rs877776 and pediatric eczema in this study. Conclusion: Single nucleotide polymorphism rs7927894 appears to mark a genuine eczema susceptibility locus that will require further elucidation through fine mapping and functional analysis. (J Allergy Clin Immunol 2010;125:170-4.)	[McLean, W. H. Irwin] Univ Dundee, Div Mol Med, Inst Med Sci, Epithelial Genet Grp,Coll Life Sci & Med, Dundee DD1 5EH, Scotland; [Campbell, Linda E.; McLean, W. H. Irwin; Brown, Sara J.] Univ Dundee, Div Mol Med, Coll Dent, Epithelial Genet Grp, Dundee DD1 5EH, Scotland; [Campbell, Linda E.; McLean, W. H. Irwin; Brown, Sara J.] Univ Dundee, Div Mol Med, Coll Nursing, Epithelial Genet Grp, Dundee DD1 5EH, Scotland; [O'Regan, Grainne M.; Irvine, Alan D.; Brown, Sara J.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland; [Cordell, Heather J.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England; [Irvine, Alan D.] Univ Dublin Trinity Coll, Inst Mol Med, Dublin 2, Ireland	University of Dundee; University of Dundee; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Newcastle University - UK; Trinity College Dublin	McLean, WHI (corresponding author), Univ Dundee, Div Mol Med, Inst Med Sci, Epithelial Genet Grp,Coll Life Sci & Med, Dow St, Dundee DD1 5EH, Scotland.	w.h.i.mclean@dundee.ac.uk; brownsj@tcd.ie	Brown, Sara J/AAF-7095-2019; McLean, William HI/C-6352-2009; Irvine, Alan D/A-3982-2008	Brown, Sara J/0000-0002-3232-5251; Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757; Cordell, Heather/0000-0002-1879-5572	Children's Research Center; Medical Research Council and DebRA UK; Wellcome Trust; European Commission; British Heart Foundation; MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: researchfish	Children's Research Center; Medical Research Council and DebRA UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	G. M. O'Regan has received research support from the Children's Research Center. W. H. I. McLean has received research grants from the Medical Research Council and DebRA UK. S. J. Brown has received research support from the Wellcome Trust. A. D. Irvine has received research support from the Children's Medical and Research Foundation, Crumlin, and the Health Research Board, Ireland. H. J. Cordell has received research support from The Wellcome Trust, the European Commission, and the British Heart Foundation. The other author has declared that she has no conflict of interest. I. McLean has filed patents relating to genetic testing and therapy development aimed at the filaggrin gene.	Beattie PE, 2006, BRIT J DERMATOL, V155, P145, DOI 10.1111/j.1365-2133.2006.07185.x; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Van Limbergen J, 2009, INFLAMM BOWEL DIS, V15, P1492, DOI 10.1002/ibd.20926; Wang R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002705; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wu ZH, 2009, J INVEST DERMATOL, V129, P1446, DOI 10.1038/jid.2008.370	26	48	51	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					170	174		10.1016/j.jaci.2009.10.046	http://dx.doi.org/10.1016/j.jaci.2009.10.046			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109745	Green Published, hybrid			2022-12-18	WOS:000273660500020
J	Gold, DR; Bloomberg, GR; Cruikshank, WW; Visness, CM; Schwarz, J; Kattan, M; O'Connor, GT; Wood, RA; Burger, MS; Wright, RJ; Witter, F; Lee-Parritz, A; Sperling, R; Sadovsky, Y; Togias, A; Gern, JE				Gold, Diane R.; Bloomberg, Gordon R.; Cruikshank, William W.; Visness, Cynthia M.; Schwarz, John; Kattan, Meyer; O'Connor, George T.; Wood, Robert A.; Burger, Melissa S.; Wright, Rosalind J.; Witter, Frank; Lee-Parritz, Aviva; Sperling, Rhoda; Sadovsky, Yoel; Togias, Alkis; Gern, James E.			Parental characteristics, somatic fetal growth, and season of birth influence innate and adaptive cord blood cytokine responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; immune response; cord blood; birth cohort; gestational age; cytokines	INTERFERON-GAMMA PRODUCTION; HUMAN IMMUNE-SYSTEM; ENVIRONMENTAL ALLERGENS; POSTNATAL-DEVELOPMENT; CHILDHOOD ASTHMA; ATOPIC DISEASE; UNITED-STATES; 1ST YEAR; SENSITIZATION; PREDICTOR	Background: Immunologic responses at birth likely relate to subsequent risks for allergic diseases and wheezing in infancy; however, the influences of parental characteristics and prenatal factors on neonatal immune responses are incompletely understood. Objective: This study investigates potential correlations between urban parental, prenatal, and perinatal factors on innate and adaptive stimuli-induced cytokine responses. Methods: Five hundred sixty and 49 children of parents with and without allergic disease or asthma, respectively, were enrolled into a prospective birth cohort study (Urban Environment and Childhood Asthma). Cord blood mononuclear cells were incubated with innate and adaptive immune stimuli, and cytokine responses (ELISA) were compared with season of birth, parental characteristics, in utero stressors, and fetal growth. Results: Many cytokine responses varied by season of birth, including 2-fold to 3-fold fluctuations with specific IFN-alpha and IFN-gamma responses. Birth weight was inversely associated with IFN-gamma responses to respiratory syncytial virus.(R = -0.16), but positively associated with IL-8 responses to a variety of innate stimuli (R = 0.08-0.12). Respiratory syncytial virus-induced cytokine responses were 21% to 54% lower in children of mothers with asthma. Cytokine responses were generally lower in babies born to parents with allergy/asthma. Conclusions: Innate cytokine responses are associated with parental allergic or airway disease, somatic fetal growth, ethnicity, and season of birth. Collectively, these findings suggest that urban prenatal exposures and familial factors affect the development of the fetal immune system. (J Allergy Clin Immunol 2009;124:1078-87.)	[Gern, James E.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Ctr Clin Sci, Madison, WI 53792 USA; [Gold, Diane R.; Wright, Rosalind J.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, St Louis, MO USA; [Cruikshank, William W.; O'Connor, George T.; Lee-Parritz, Aviva] Boston Univ, Sch Med, Boston, MA 02118 USA; [Visness, Cynthia M.; Schwarz, John] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Kattan, Meyer] Columbia Univ, Sch Med, New York, NY USA; [Wood, Robert A.; Witter, Frank] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Sperling, Rhoda] Mt Sinai Sch Med, New York, NY USA; [Sadovsky, Yoel] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Togias, Alkis] NIAID, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Boston University; Columbia University; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gern, JE (corresponding author), Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Ctr Clin Sci, K4-918,600 Highland Ave, Madison, WI 53792 USA.	gern@medicine.wise.edu		Lee-Parritz, Aviva/0000-0003-4655-7720; O'Connor, George/0000-0002-6476-3926	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-AI-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02]; National Institutes of Health (NIH); Environmental Protection Agency; American Thoracic Society; Massachusetts Medical Society; Merck Inc; AstraZeneca; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533, UL1RR024992, UL1RR025771, UL1RR024156, M01RR000052, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency(United States Environmental Protection Agency); American Thoracic Society; Massachusetts Medical Society; Merck Inc(Merck & Company); AstraZeneca(AstraZeneca); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Contracts number NO1-AI-25496 and NO1-AI-25482, and from the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02. The National Institute of Allergy and Infectious Diseases participated in the development of the study protocol and monitors its implementation.; Disclosure of potential conflict of interest: C. M. Visness is employed by Rho Federal Systems Division, Inc. D. R. Gold receives grant support from the National Institutes of Health (NIH) and the Environmental Protection Agency and is a member of the American Thoracic Society and the Massachusetts Medical Society. G. R. Bloomberg receives grant support from the NIH/National Institute of Allergy and Infectious Diseases. W. W. Cruikshank receives grant support from the NIH. J. Schwarz is employed by Rho. M. Kattan receives grant support from the NIH/National Institute of Allergy and Infectious Diseases. R. A. Wood is on the advisory board for Dey, receives grant support from Genentech and the NIH, and is on the advisory board for Food Allergy and Anaphylaxis Network (FAAN). Y. Sadovsky receives grant support from the NIH. J. E. Gem is on the speakers' bureau for Merck Inc and receives grant support from Merck Inc and AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	Allam JP, 2005, ALLERGY, V60, P743, DOI 10.1111/j.1398-9995.2005.00815.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; CHUNG EK, 2007, BMJ-BRIT MED J, V92, pF68; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Dembinski J, 2003, CYTOKINE, V21, P200, DOI 10.1016/S1043-4666(02)00498-2; Dillie KTS, 2008, CLIN EXP ALLERGY, V38, P298, DOI 10.1111/j.1365-2222.2007.02891.x; Dombkowski KJ, 2008, ANN EPIDEMIOL, V18, P290, DOI 10.1016/j.annepidem.2007.11.012; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gold DR, 2005, J ALLERGY CLIN IMMUN, V116, P38, DOI 10.1016/j.jaci.2005.04.033; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Guerra S, 2002, ALLERGY ASTHMA PROC, V23, P303; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Knudsen TB, 2007, J ASTHMA, V44, P257, DOI 10.1080/02770900701246832; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kuzume K, 2007, PEDIATR ALLERGY IMMU, V18, P281, DOI 10.1111/j.1399-3038.2006.00526.x; Laskowska M, 2007, J MATERN-FETAL NEO M, V20, P527, DOI 10.1080/14767050701412719; Lendor C, 2008, ANN ALLERG ASTHMA IM, V101, P193, DOI 10.1016/S1081-1206(10)60209-8; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Lo HC, 2002, NUTRITION, V18, P604, DOI 10.1016/S0899-9007(01)00811-5; Ly NP, 2007, PEDIATRICS, V119, pE171, DOI 10.1542/peds.2006-0524; Ly NP, 2005, J CLIN IMMUNOL, V25, P314, DOI 10.1007/s10875-005-4699-5; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Mondestin-Sorrentino M, 2007, AM J REPROD IMMUNOL, V57, P482, DOI 10.1111/j.1600-0897.2007.00468.x; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 2000, ALLERGY, V55, P470; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Raby BA, 2006, J ALLERGY CLIN IMMUN, V117, P298, DOI 10.1016/j.jaci.2005.10.041; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; RCore Team, 2022, R LANG ENV STAT COMP; Rogers BB, 2002, HUM PATHOL, V33, P335, DOI 10.1053/hupa.2002.32214; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Shimoya K, 1999, MOL HUM REPROD, V5, P885, DOI 10.1093/molehr/5.9.885; Shreffler WG, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-29; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Umetsu DT, 2005, LANCET, V365, P98, DOI 10.1016/S0140-6736(05)17714-9; VanDurenSchmidt K, 1997, PEDIATR RES, V41, P128, DOI 10.1203/00006450-199701000-00020; Willwerth BM, 2006, ANN ALLERG ASTHMA IM, V96, P445, DOI 10.1016/S1081-1206(10)60912-X; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yerkovich ST, 2007, PEDIATR RES, V62, P547, DOI 10.1203/PDR.0b013e3181568105; Yoo Y, 2005, ALLERGY, V60, P1327, DOI 10.1111/j.1398-9995.2005.00856.x	60	48	50	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1078	1087		10.1016/j.jaci.2009.08.021	http://dx.doi.org/10.1016/j.jaci.2009.08.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895995	Bronze, Green Accepted			2022-12-18	WOS:000272108000031
J	Philip, G; van Adelsberg, J; Loeys, T; Liu, N; Wong, P; Lai, E; Dass, SB; Reiss, TF				Philip, George; van Adelsberg, Janet; Loeys, Thomas; Liu, Nancy; Wong, Peggy; Lai, Eseng; Dass, S. Balachandra; Reiss, Theodore F.			Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin D receptor gene promoter; asthma susceptibility; airway disease; montelukast	PROSTAGLANDIN D-2; RECEPTOR VARIANTS; PTGDR GENE; MONTELUKAST; CRTH2; PLACEBO	Background: Prostaglandin D-2 is a proinflammatory mediator believed to be important in asthma and allergic rhinitis (AR). Allelic variants in the prostaglandin D2 receptor type 1 (DP1) gene (PTGDR) have been suggested to be associated with asthma susceptibility. Objectives: We sought to investigate the efficacy of the DP1 antagonist laropiprant (alone or with montelukast) in asthma and seasonal AR and explore whether sequence variations in PTGDR are associated with asthma severity. Methods: For asthma, in a double-blind crossover study, 100 patients with persistent asthma were randomized to placebo or laropiprant, 300 mg/d for 3 weeks, followed by addition of montelukast, 10 mg/d for 2 weeks. PTGDR promoter haplotypes were categorized as high, medium, or low transcriptional efficiency. The primary efficacy end point was FEV1. For AR, in a double-blind parallel-group study, 767 patients sensitized to a regionally prevalent fall allergen with symptomatic fall rhinitis were allocated to laropiprant, 25 mg/d or 100 mg/d; cetirizine, 10mg/d; or placebo for 2 weeks. The primary end point was the Daytime Nasal Symptoms Score. Results: For asthma, no significant differences in FEV1 or asthma symptoms were noted for laropiprant versus placebo or laropiprant plus montelukast vs montelukast (differences between montelukast and placebo: P <= .001). No clear association was seen between haplotype pair (ie, diplotype) and asthma severity. For AR, although cetirizine (vs placebo) demonstrated an improvement in the Daytime Nasal Symptoms Score (P < .001), laropiprant did not. Conclusion: Laropiprant did not demonstrate efficacy in asthmatic patients or patients with AR. Variations in PTGDR did not appear related to baseline asthma severity or treatment response (NCT00533208; NCT00783601). (J Allergy Clin Immunol 2009;124:942-8.)	[Philip, George; van Adelsberg, Janet; Loeys, Thomas; Liu, Nancy; Wong, Peggy; Lai, Eseng; Dass, S. Balachandra; Reiss, Theodore F.] Merck Res Labs, Rahway, NJ 07055 USA	Merck & Company	Philip, G (corresponding author), Merck & Co Inc, Clin Res, 351 N Sumneytown Pike,UG3D-66, N Wales, PA 19454 USA.	george_philip@merck.com		Loeys, Tom/0000-0003-4551-5502	Merck Research Laboratories	Merck Research Laboratories(Merck & Company)	Supported by a grant from the Merck Research Laboratories.	Arimura A, 2001, J PHARMACOL EXP THER, V298, P411; Bousquet J., 2003, Clinical and Experimental Allergy Reviews, V3, P43, DOI 10.1046/j.1472-9725.2003.00063.x; Cheng K, 2006, P NATL ACAD SCI USA, V103, P6682, DOI 10.1073/pnas.0601574103; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; *GLOB IN ASTHM, 2006, NIH PUBL; Kabashima K, 2003, PROSTAG LEUKOTR ESS, V69, P187, DOI 10.1016/S0952-3278(03)00080-2; Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005; Lai E, 2008, CLIN PHARMACOL THER, V83, P840, DOI 10.1038/sj.clpt.6100345; LEUNG TF, PEDIAT ALLERGY IMMUN; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Mansur AH, 2004, THORAX, V59, P876, DOI 10.1136/thx.2003.014092; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Morita H, 2005, NEW ENGL J MED, V352, P837; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Okano M, 2006, AM J RHINOL, V20, P342, DOI 10.2500/ajr.2006.20.2865; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Santanello NC, 1997, EUR RESPIR J, V10, P646; Sanz C, 2006, ALLERGY, V61, P543, DOI 10.1111/j.1398-9995.2006.01025.x; Storms W, 2007, EXPERT OPIN PHARMACO, V8, P2173, DOI 10.1517/14656566.8.13.2173; Tsai YJ, 2006, J ALLERGY CLIN IMMUN, V118, P1242, DOI 10.1016/j.jaci.2006.07.045; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; Van Hecken A, 2007, EUR J CLIN PHARMACOL, V63, P135, DOI 10.1007/s00228-006-0211-2; Wei L, 2006, STAT MED, V25, P2043, DOI 10.1002/sim.2336	25	48	50	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					942	948		10.1016/j.jaci.2009.07.006	http://dx.doi.org/10.1016/j.jaci.2009.07.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19748656				2022-12-18	WOS:000272108000010
J	Zock, JP; Plana, E; Anto, JM; Benke, G; Blanc, PD; Carosso, A; Dahlman-Hoglund, A; Heinrich, J; Jarvis, D; Kromhout, H; Lillienberg, L; Mirabelli, MC; Norback, D; Olivieri, M; Ponzio, M; Radon, K; Soon, A; van Sprundel, M; Sunyer, J; Svanes, C; Toren, K; Verlato, G; Villani, S; Kogevinas, M				Zock, Jan-Paul; Plana, Estel; Anto, Josep M.; Benke, Geza; Blanc, Paul D.; Carosso, Aurelia; Dahlman-Hoglund, Anna; Heinrich, Joachim; Jarvis, Deborah; Kromhout, Hans; Lillienberg, Linnea; Mirabelli, Maria C.; Norbaeck, Dan; Olivieri, Mario; Ponzio, Michela; Radon, Katja; Soon, Argo; van Sprundel, Marc; Sunyer, Jordi; Svanes, Cecilie; Toren, Kjell; Verlato, Giuseppe; Villani, Simona; Kogevinas, Manolis			Domestic use of hypochlorite bleach, atopic sensitization, and respiratory symptoms in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hypochlorite bleach; household; atopy; allergy; respiratory	HEALTH SURVEY-II; SODIUM-HYPOCHLORITE; CHLORAMINE GAS; HOUSEHOLD CLEANERS; CHRONIC-BRONCHITIS; HYDROCHLORIC-ACID; CHLORINE BLEACH; RISK-FACTORS; ASTHMA; EXPOSURE	Background: Professional use of hypochlorite (bleach) has been associated with respiratory symptoms. Bleach is capable of inactivating allergens, and there are indications that its domestic use may reduce the risk of allergies in children. Objective: To study the associations between household use of bleach and atopic sensitization, allergic diseases, and respiratory health status in adults. Methods: We identified 3626 participants of the European Community Respiratory Health Survey 11 in 10 countries who did the cleaning in their homes and for whom data on specific serum IgE to 4 environmental allergens were available. Frequency of bleach use and information on respiratory symptoms were obtained in face-to-face interviews. House dust mite and cat allergens in mattress dust were measured in a subsample. Associations between the frequency of bleach use and health outcomes were evaluated by using multivariable mixed logistic regression analyses. Results: The use of bleach was associated with less atopic sensitization (odds ratio [OR], 0.75; 95% CI, 0.63-0.89). This association was apparent for specific IgE to both indoor (cat) and outdoor (grass) allergens, and was consistent in various subgroups, including those without any history of respiratory problems (OR, 0.85). Dose-response relationships (P<.05) were apparent for the frequency of bleach use and sensitization rates. Lower respiratory tract symptoms, but not allergic symptoms, were more prevalent among those using bleach 4 or more days per week (OR, 1.24-1.49). The use of bleach was not associated with indoor allergen concentrations. Conclusion: People who clean their homes with hypochlorite bleach are less likely to be atopic but more likely to have respiratory symptoms. (J Allergy Clin Immunol 2009;124:7318.)	[Zock, Jan-Paul; Plana, Estel; Anto, Josep M.; Mirabelli, Maria C.; Sunyer, Jordi; Kogevinas, Manolis] Ctr Res Environm Epidemiol, E-08003 Barcelona, Spain; [Zock, Jan-Paul; Plana, Estel; Anto, Josep M.; Mirabelli, Maria C.; Sunyer, Jordi; Kogevinas, Manolis] Municipal Inst Med Res IMIM Hosp del Mar, Barcelona, Spain; [Zock, Jan-Paul; Plana, Estel; Anto, Josep M.; Mirabelli, Maria C.; Sunyer, Jordi; Kogevinas, Manolis] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Anto, Josep M.; Sunyer, Jordi] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, Spain; [Benke, Geza] Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic 3800, Australia; [Blanc, Paul D.] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA; [Carosso, Aurelia] ASL 2 Reg Piemonte, Div Pneumol & Allergol, Turin, Italy; [Dahlman-Hoglund, Anna; Lillienberg, Linnea; Toren, Kjell] Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; [Heinrich, Joachim] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London SW7 2AZ, England; [Kromhout, Hans] Univ Utrecht, Inst Risk Assessment Sci, Environm Epidemiol Div, NL-3508 TC Utrecht, Netherlands; [Norbaeck, Dan] Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; [Olivieri, Mario] Univ Verona, Dept Med & Publ Hlth, Unit Occupat Med, I-37100 Verona, Italy; [Verlato, Giuseppe] Univ Verona, Unit Epidemiol & Med Stat, Dept Med & Publ Hlth, I-37100 Verona, Italy; [Ponzio, Michela; Villani, Simona] Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; [Radon, Katja] Univ Munich, Inst Occupat & Environm Med, Unit Occupat & Environm Epidemiol & NetTeaching, Munich, Germany; [Soon, Argo] Univ Tartu, Dept Publ Hlth, Tartu, Estonia; [van Sprundel, Marc] Univ Antwerp, Dept Epidemiol & Community Hlth, Antwerp, Belgium; [Svanes, Cecilie] Univ Bergen, Inst Med, Dept Thorac Med, N-5020 Bergen, Norway; [Kogevinas, Manolis] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Monash University; University of California System; University of California San Francisco; Sahlgrenska University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; Utrecht University; Uppsala University; University of Verona; University of Verona; University of Pavia; University of Munich; University of Tartu; University of Antwerp; University of Bergen; University of Crete	Zock, JP (corresponding author), Ctr Res Environm Epidemiol, Barcelona Biomed Res Pk,Dr Aiguader 88, E-08003 Barcelona, Spain.	jpzock@creal.cat	Bono, Roberto/J-8954-2012; Zock, Jan-Paul/P-5034-2018; Kogevinas, Manolis/C-3918-2017; Sánchez-Ramos, José Luis/G-1259-2011; Burgos, Felip/E-5734-2015; Anto, J M/H-2676-2014; Jarvis, Deborah/E-6494-2011; Corsico, Angelo Guido/AAC-8138-2019; Heinrich, Joachim/N-1720-2013; Svanes, Cecilie/N-7556-2017; Kromhout, Hans/A-9159-2008; Sunyer, Jordi/G-6909-2014; Rolla, Giovanni/C-9901-2009; Ciccone, Giovannino/K-3136-2016; Verlato, Giovanna/H-2202-2018	Bono, Roberto/0000-0002-2471-6594; Zock, Jan-Paul/0000-0002-2941-6259; Kogevinas, Manolis/0000-0002-9605-0461; Sánchez-Ramos, José Luis/0000-0001-7187-9989; Burgos, Felip/0000-0002-4938-4581; Anto, J M/0000-0002-4736-8529; Corsico, Angelo Guido/0000-0002-8716-4694; Heinrich, Joachim/0000-0002-9620-1629; Svanes, Cecilie/0000-0001-8512-5192; Kromhout, Hans/0000-0002-4233-1890; Sunyer, Jordi/0000-0002-2602-4110; Rolla, Giovanni/0000-0001-5997-7172; Ciccone, Giovannino/0000-0001-7644-9574; /0000-0003-2517-6515; Verlato, Giovanna/0000-0003-4613-7427; Mirabelli, Maria/0000-0002-3540-0085; Jarvis, Deborah/0000-0002-1753-3896; Grassi, Mario/0000-0001-6612-8566; Burney, Peter/0000-0001-8635-5678; Cerveri, Isa/0000-0003-0337-043X; Norback, Dan/0000-0002-5174-6668; ROMANO, Canzio/0000-0001-5294-9793; Plana, Estel/0000-0001-8675-7503	European Commission; US National Institutes of Health [1 R01 HL062633]; Spanish Ministry of Health and Consumption [01/3058]; European Community [97/0035-01,99/0034-01, 99/0034-02]; Hospital Universitario de Albacete; Consejeria de Sanidad; Antwerp, Fund for Scientific Research, Flanders, Belgium [G.0402.00]; University of Antwerp, Flemish Health Ministry: Barcelona, SEPAR, Public Health Service [R01 HI-62633-01]; FIS [99/0034-02, 97/0035-01, 99/0034-01]; CIRIT [1999SGR 00241]; Red Respira ISCII; Basel, Swiss National Science Foundation, Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund, USC NIEHS Center [5P30 ES07048]; Norwegian Research Council; Norwegian Asthma and Allergy Association; Glaxo Wellcome AS; Erfurt, GSF-National Research Centre for Environment and Health; Deutsche Forschungsgemeinschaft [FR 1526/1-1, MA 711/4-1]; Galdakao, Basque Health Department; Goteborg. Swedish Heart Lung Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Asthma and Allergy Foundation; Swedish Cancer and Allergy Foundation; Ministry of Health, Direction de la Recherche Clinique; Ministere de l'Emploi et de la Solidarite; USC NIEHS [5P30 ES07048]; Direction Generale de la Sante; CHU de Grenoble; Comite des Maladies Respiratoires de I'Isere; GSF-National Research Centre for Environment and Health; Ipswich and Norwich, Asthma UK; Direction Generale de la Same; UCB-Phama (France); Aventis (France); Ministry of Health, Direction de lit Recherche Clinique; GlaxoSmithKline Italy; Italian Ministry of University and Scientific and Technological Research; Estonian Science Foundation Turin; ASL 4 Regione Piemonte; Swedish Heart Lung Foundation; Swedish Cancer and Allergy Foundation; Verona; University of Verona; National Health and Medical Research Council of Australia; National Institutes of Health; European Union; Ministry of Health, Spain; Ministry of Health, Catalonia; Medical Research Council [G0801056B] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Health and Consumption(Spanish Government); European Community(European Commission); Hospital Universitario de Albacete; Consejeria de Sanidad; Antwerp, Fund for Scientific Research, Flanders, Belgium; University of Antwerp, Flemish Health Ministry: Barcelona, SEPAR, Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); FIS(Instituto de Salud Carlos III); CIRIT; Red Respira ISCII; Basel, Swiss National Science Foundation, Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund, USC NIEHS Center(Swiss National Science Foundation (SNSF)); Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Asthma and Allergy Association; Glaxo Wellcome AS; Erfurt, GSF-National Research Centre for Environment and Health; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Galdakao, Basque Health Department; Goteborg. Swedish Heart Lung Foundation; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Asthma and Allergy Foundation; Swedish Cancer and Allergy Foundation; Ministry of Health, Direction de la Recherche Clinique; Ministere de l'Emploi et de la Solidarite; USC NIEHS; Direction Generale de la Sante(General Electric); CHU de Grenoble; Comite des Maladies Respiratoires de I'Isere; GSF-National Research Centre for Environment and Health; Ipswich and Norwich, Asthma UK; Direction Generale de la Same; UCB-Phama (France); Aventis (France)(Sanofi-Aventis); Ministry of Health, Direction de lit Recherche Clinique; GlaxoSmithKline Italy(GlaxoSmithKline); Italian Ministry of University and Scientific and Technological Research(Ministry of Education, Universities and Research (MIUR)); Estonian Science Foundation Turin; ASL 4 Regione Piemonte; Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Cancer and Allergy Foundation; Verona; University of Verona; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission); Ministry of Health, Spain(Spanish Government); Ministry of Health, Catalonia; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	G. Benke has received research Support from the National Health and Medical Research Council of Australia. P. D. Blanc has rec1eived research support from the National Institutes of Health, UC Tobacco Related Diseases, and FAMRI and has served as an expert witness on hepatotoxicity and inhalation injury. J. Sunyer has received research support from the European Union, Ministry of Health, Spain, and the Ministry of Health, Catalonia. The rest of the authors have declared that they have no conflict of interest.	Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Ellison-Loschmann L, 2007, EUR RESPIR J, V29, P897, DOI 10.1183/09031936.00101606; Gorguner M, 2004, INHAL TOXICOL, V16, P87, DOI 10.1080/08958370490265004; Harrop J, 2007, CLIN EXP ALLERGY, V37, P526, DOI 10.1111/j.1365-2222.2007.02679.x; Heinrich J, 2006, J ALLERGY CLIN IMMUN, V118, P674, DOI 10.1016/j.jaci.2006.06.012; Jacobs JH, 2007, EUR RESPIR J, V29, P690, DOI 10.1183/09031936.00024706; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; Martyny JW, 2005, J ALLERGY CLIN IMMUN, V116, P630, DOI 10.1016/j.jaci.2005.05.008; Matsui E, 2003, J ALLERGY CLIN IMMUN, V111, P396, DOI 10.1067/mai.2003.11; Medina-Ramon M, 2006, EUR RESPIR J, V27, P1196, DOI 10.1183/09031936.06.00085405; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Mirabelli MC, 2007, OCCUP ENVIRON MED, V64, P474, DOI 10.1136/oem.2006.031203; MRVOS R, 1993, SOUTHERN MED J, V86, P654, DOI 10.1097/00007611-199306000-00013; Nickmilder M, 2007, PEDIAT ALLERG IMM-UK, V18, P27, DOI 10.1111/j.1399-3038.2006.00487.x; Pascuzzi TA, 1998, MIL MED, V163, P102, DOI 10.1093/milmed/163.2.102; PLANA E, 2007, EUR RESP J S38, V30, pS4; RACIOPPI F, 1994, FOOD CHEM TOXICOL, V32, P845, DOI 10.1016/0278-6915(94)90162-7; REISZ GR, 1986, CHEST, V89, P49, DOI 10.1378/chest.89.1.49; Simpson A, 2003, CURR OPIN ALLERGY CL, V3, P7, DOI 10.1097/01.all.0000053261.39029.7a; Smit LAM, 2008, EUR RESPIR J, V31, P1241, DOI 10.1183/09031936.00090607; Sunyer J, 2007, ALLERGY, V62, P142, DOI 10.1111/j.1398-9995.2006.01184.x; Tanen DA, 1999, NEW ENGL J MED, V341, P848, DOI 10.1056/NEJM199909093411115; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Zock JP, 2007, AM J RESP CRIT CARE, V176, P735, DOI 10.1164/rccm.200612-1793OC; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	32	48	49	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					731	738		10.1016/j.jaci.2009.06.007	http://dx.doi.org/10.1016/j.jaci.2009.06.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665775				2022-12-18	WOS:000270802800017
J	Werther, RL; Crawford, NW; Boniface, K; Kirkwood, CD; Smart, JM				Werther, Rebecca L.; Crawford, Nigel W.; Boniface, Karen; Kirkwood, Carl D.; Smart, Joanne M.			Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Werther, Rebecca L.; Smart, Joanne M.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Crawford, Nigel W.] Royal Childrens Hosp, SAEFVIC Immunizat Safety Serv, Dept Gen Med, Melbourne, Vic, Australia; [Werther, Rebecca L.; Crawford, Nigel W.] Univ Melbourne, Dept Pediat, Melbourne, Vic 3010, Australia; [Crawford, Nigel W.] Murdoch Childrens Res Inst, NHMRC CCRE Childhood & Adolescent Immunizat, Melbourne, Vic, Australia; [Boniface, Karen; Kirkwood, Carl D.] Murdoch Childrens Res Inst, Enter Virus Grp, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Murdoch Children's Research Institute	Werther, RL (corresponding author), Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia.	rebecca.werther@rch.org.au						Anderson EJ, 2008, LANCET INFECT DIS, V8, P642, DOI 10.1016/S1473-3099(08)70231-7; Buttery JP, 2007, CURR OPIN INFECT DIS, V20, P253, DOI 10.1097/QCO.0b013e32813aeaac; Elschner M, 2002, J VET MED B, V49, P77, DOI 10.1046/j.1439-0450.2002.00510.x; National Health and Medical Research Council, 2008, AUSTR IMM HDB; 2009, MORB MORTAL WKLY REP, V58, P1	5	48	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					600	600		10.1016/j.jaci.2009.07.005	http://dx.doi.org/10.1016/j.jaci.2009.07.005			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19660805	Bronze			2022-12-18	WOS:000274315900029
J	Pedersen, L; Lund, TK; Barnes, PJ; Kharitonov, SA; Backer, V				Pedersen, Lars; Lund, Thomas K.; Barnes, Peter J.; Kharitonov, Sergei A.; Backer, Vibeke			Airway, responsiveness and inflammation in adolescent elite swimmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; airway hyperresponsiveness; airway responsiveness; asthma; elite swimmers; eucapnic voluntary hyperpnea; exercise-induced bronchoconstriction; methacholine; respirtaory symptoms	EUCAPNIC VOLUNTARY HYPERVENTILATION; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; BREATH CONDENSATE; INDUCED SPUTUM; RISK-FACTORS; ASTHMA; EXERCISE; CHILDREN; PH	Background: Whereas increased airway hyperresponsiveness (AHR) and airway inflammation are well documented in adult elite athletes, it remains uncertain whether the same airway changes are present in adolescents involved in elite sport. Objective: To investigate airway responsiveness and airway inflammation in adolescent elite swimmers. Methods: We performed a cross-sectional study on adolescent elite swimmers (n = 33) and 2 control groups: unselected adolescents (n = 35) and adolescents with asthma (n = 212). The following tests were performed: questionnaire, exhaled nitric oxide (FeNO), spirometry, induced sputum, methacholine challenge, eucapnic voluntary hyperpnea (EVH) test, and exhaled breath condensate pH. Results: There were no differences in FeNO, exhaled breath condensate pH, cellular composition in sputum, or prevalence of AHR to either EVH or methacholine among the 3 groups. When looking at airway responsiveness as a continuous variable, the swimmers were more responsive to EVH than unselected subjects, but less responsive to metbacholine compared with subjects with asthma. We found no differences in the prevalence of respiratory symptoms between the swimmers and the unselected adolescents. There was no difference in FeNO, cellular composition of sputum, airway reactivity, or prevalence of having AHR to methacholine and/or EVH between swimmers with and without respiratory symptoms. Conclusion: Adolescent elite swimmers do not have significant signs of airway damage after only a few years of intense training and competition. This leads us to believe that elite swimmers do not have particularly susceptible airways when they take up competitive swimming when young, but that they develop respiratory symptoms, airway inflammation, and AHR during their swimming careers.	[Pedersen, Lars; Lund, Thomas K.; Backer, Vibeke] Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Resp Med L, Resp & Allergy Res Unit, DK-2400 Copenhagen NV, Denmark; [Pedersen, Lars; Barnes, Peter J.; Kharitonov, Sergei A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England	University of Copenhagen; Bispebjerg Hospital; Imperial College London	Pedersen, L (corresponding author), Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Resp Med L, Resp & Allergy Res Unit, Bispebjerg 23, DK-2400 Copenhagen NV, Denmark.	lars.pedersen@dadlnet.dk	Pedersen, Lars/AAX-4382-2021; Backer, Vibeke/I-9573-2014; Backer, Vibeke/AAQ-9379-2021	Pedersen, Lars/0000-0002-5950-652X; Backer, Vibeke/0000-0002-7806-7219; Lund, Thomas Kromann/0000-0002-8987-3136; Barnes, Peter/0000-0002-5122-4018; Kharitonov, Sergei/0000-0001-7448-1650				American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Bernard A, 2006, ENVIRON HEALTH PERSP, V114, P1567, DOI 10.1289/ehp.8461; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Bonsignore MR, 2003, CLIN EXP ALLERGY, V33, P14, DOI 10.1046/j.1365-2222.2003.01557.x; Bonsignore MR, 2003, MED SCI SPORT EXER, V35, P1146, DOI 10.1249/01.MSS.0000074581.08023.25; Carpagnano GE, 2004, CHEST, V125, P2005, DOI 10.1378/chest.125.6.2005; DREBORG S, 1987, THESIS LINKOPING U L; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; *GINA, 2007, GLOB STRAT ASTHM MAN; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; Helenius IJ, 1997, THORAX, V52, P157, DOI 10.1136/thx.52.2.157; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; INBAR O, 1980, EUR J APPL PHYSIOL O, V44, P43, DOI 10.1007/BF00421762; *INT OL COMM MED C, 2008, BETA2 ADR AG OL GAM; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Leung TF, 2006, PEDIATR PULM, V41, P87, DOI 10.1002/ppul.20296; Lumme A, 2003, EUR RESPIR J, V22, P113, DOI 10.1183/09031936.03.00112403; LUND T, 2008, SCAND J MED SCI 0217; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nysom K, 1997, EUR RESPIR J, V10, P1591, DOI 10.1183/09031936.97.10071591; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Paget-Brown AO, 2006, CHEST, V129, P426, DOI 10.1378/chest.129.2.426; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Piacentini GL, 2007, J ALLERGY CLIN IMMUN, V119, P1559, DOI 10.1016/j.jaci.2007.01.050; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; Rasmussen F, 2002, PEDIATR PULM, V34, P164, DOI 10.1002/ppul.10155; Rosias PPR, 2004, PEDIATR PULM, V38, P107, DOI 10.1002/ppul.20056; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2004, MED SCI SPORT EXER, V36, P405, DOI 10.1249/01.MSS.0000117118.77267.BF; Spanevello A, 1999, THORAX, V54, P37, DOI 10.1136/thx.54.1.37; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Ulrik CS, 1996, RESP MED, V90, P623, DOI 10.1016/S0954-6111(96)90021-9; Varraso R, 2002, TOXICOL IND HEALTH, V18, P269, DOI 10.1191/0748233702th150oa; Verges S, 2005, CHEST, V127, P1935, DOI 10.1378/chest.127.6.1935; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	50	48	49	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					322	327		10.1016/j.jaci.2008.04.041	http://dx.doi.org/10.1016/j.jaci.2008.04.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18554704				2022-12-18	WOS:000258426300018
J	Mandhane, PJ; Greene, JM; Sears, MR				Mandhane, Piush J.; Greene, Justina M.; Sears, Malcolm R.			Interactions between breast-feeding, specific parental atopy, and sex on development of asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; sex; breast-feeding; parental atopy	CHILDHOOD ASTHMA; FOLLOW-UP; BRONCHIAL REACTIVITY; RESPIRATORY ILLNESS; POPULATION-SAMPLE; BIRTH COHORT; RISK-FACTORS; NEW-ZEALAND; HAY-FEVER; CHILDREN	Background: The influence of breast-feeding on the risk of developing atopy and asthma remains controversial. Objective: To examine asthma and atopy outcomes by sex, reported specific parental history of atopy, and breast-feeding. Methods: In a birth cohort, we examined childhood asthma and atopy (positive skin prick tests) by sex and breast-feeding in relation to maternal and paternal atopy. Interactions were explored in logistic regression models. Results: For boys, breast-feeding (odds ratio [OR], 1.63; 95% CI, 0.93-2.87; P =.09) and maternal atopy (OR, 1.95; 95% CI, 0.934.08; P =.08) were each associated with atopy at age 13 years. Breast-feeding increased the risk for atopy among boys with paternal atopy (OR, 7.39; 95% CI, 2.21-24.66) compared with non-breast-fed boys with paternal atopy, but did not significantly further increase risk among subjects with maternal atopy. For girls, breast-feeding (OR, 0.74; 95% CI, 0.41-1.31) and maternal and paternal atopy were not independent risk factors for atopy at age 13 years. However, breast-feeding increased the risk for atopy in girls with maternal atopy (OR, 3.13; 95% CI, 1.20-8.14) compared with non-breast-fed girls with maternal atopy. There was no such effect among subjects with paternal atopy. Results for the outcome of asthma followed a similar pattern. Conclusion: The influence of breast-feeding on development of atopy and asthma differs by sex and by maternal and paternal atopy, and is most significant among subjects at lower baseline risk. Clinical implications: Analyses of environmental risk factors for asthma and atopy should be stratified by specific parental atopy and sex.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada	McMaster University	Sears, MR (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca						Aarts C, 2000, INT J EPIDEMIOL, V29, P1041, DOI 10.1093/ije/29.6.1041; Al-Harthi L, 2000, J INTERF CYTOK RES, V20, P719, DOI 10.1089/10799900050116426; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Choi MH, 2002, RAPID COMMUN MASS SP, V16, P2221, DOI 10.1002/rcm.845; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261, DOI 10.1001/archpedi.155.11.1261; Frey U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/rccm.200307-1002OC; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Henriksen AH, 2003, RESP MED, V97, P491, DOI 10.1053/rmed.2002.1470; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; KALOGEROMITROS D, 1995, CLIN EXP ALLERGY, V25, P461, DOI 10.1111/j.1365-2222.1995.tb01078.x; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079, DOI 10.1001/archpedi.1994.02170100077015; LEME AS, 2005, P AM THORAC SOC, V2, pA889; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MANDHANE PJ, 2006, EUR RESPIR J, V28, pS796; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Oddy W H, 2000, Breastfeed Rev, V8, P5; Osman M, 2003, ARCH DIS CHILD, V88, P587, DOI 10.1136/adc.88.7.587; Ponsonby AL, 1999, THORAX, V54, P664, DOI 10.1136/thx.54.8.664; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 2003, PEDIATR PULM, V36, P366, DOI 10.1002/ppul.10374; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sears MR, 2003, LANCET, V361, P175, DOI 10.1016/S0140-6736(03)12206-4; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SEARS MR, 1982, NEW ZEAL MED J, V95, P533; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; Siersted HC, 1998, BRIT MED J, V316, P651, DOI 10.1136/bmj.316.7132.651; Silva P., 1996, CHILD ADULT DUNEDIN; Sulit LG, 2005, AM J RESP CRIT CARE, V171, P659, DOI 10.1164/rccm.200403-398OC; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; Tantisira KG, 2001, RESP RES, V2, P324, DOI 10.1186/rr81; Wright AL, 2000, ADV EXP MED BIOL, V478, P131; Yeatts K, 2003, PEDIATRICS, V111, P1046, DOI 10.1542/peds.111.5.1046	43	48	49	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1359	1366		10.1016/j.jaci.2007.01.043	http://dx.doi.org/10.1016/j.jaci.2007.01.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17353035				2022-12-18	WOS:000247232800010
J	Williams, MA; Porter, M; Horton, M; Guo, J; Roman, J; Williams, D; Breysse, P; Georas, SN				Williams, Marc A.; Porter, Michael; Horton, Maureen; Guo, Jia; Roman, Jessica; Williams, D'Ann; Breysse, Patrick; Georas, Steve N.			Ambient particulate matter directs nonclassic dendritic cell activation and a mixed T(H)1/T(H)2-like cytokine response by naive CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; dendritic cell; toll-like receptors; pollutants; cytokines	AIRWAY HYPERRESPONSIVENESS; INFLAMMATION; PARTICLES; ASTHMA; RECRUITMENT; INHALATION; RECEPTOR-4; INFECTION; POLLUTION; ALLERGY	Background: Dendritic cells (DCs) translate environmental cues into T-cell activating signals, and are centrally involved in allergic airway inflammation. Ambient particulate matter (APM) is ubiquitous and associated with allergic diseases, but it is unknown whether APM directly activates DCs. Objective: To study comprehensively the effects of APM on myeloid DC phenotype and function. Methods: Development of DC was modeled using human CD34(+) progenitor cells. APM was collected from ambient outdoor air in Baltimore city. We studied the effects of APM on DC activation in vitro, compared with LPS. Results: Ambient particulate matter enhanced DC expression of costimulatory receptors but suppressed the expression of both the endocytosis receptor CD206 and uptake of fluorescein isothiocyanate-conjugated dextran. The expression of the Toll-like pattern-recognition receptors Toll-like receptor 2 and Toll-like receptor 4 was also blunted. APM-exposed DCs secreted less IL-12 and IL-6 but exhibited increased secretion of IL-18 and IL-10 compared with LPS stimulation. A T(H)2-like pattern of cytokine production was seen in cocultures of APM-stimulated DCs and alioreactive naive CD4(+) T cells where the IL-13 to IFN-gamma ratio was reversed. This contrasted with the T(H)1 polarizing effects of LPS on DCs. Conclusion: We report for the first time that APM-exposed DCs direct a complex T(H)1/T(H)2-like pattern of T-cell activation by mechanisms that involve nonclassic activation of DCs. Clinical implications: Inhaled APM can act directly on DCs as a danger signal to direct a proallergic pattern of innate immune activation.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bloomberg Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Williams, MA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Div Pulm, 601 Elmwood Ave,Room KMRB 2-9609,Box 692, Rochester, NY 14642 USA.	marc_williams@urmc.rochester.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, P01ES009606] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES03819, P01 ES09606] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARANYI C, 1983, TOXICOL LETT, V19, P63, DOI 10.1016/0378-4274(83)90263-1; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Boasen J, 2005, J ALLERGY CLIN IMMUN, V116, P185, DOI 10.1016/j.jaci.2005.03.015; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Chuang TH, 2004, NAT IMMUNOL, V5, P495, DOI 10.1038/ni1066; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; EGGELSTON PA, 1999, ENV HLTH PERSPECT, V107, P439; Eggleston PA, 2000, CLIN REV ALLERG IMMU, V18, P311, DOI 10.1385/CRIAI:18:3:311; Eisenbarth SC, 2004, J IMMUNOL, V172, P4527, DOI 10.4049/jimmunol.172.7.4527; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; El-Mezzein REH, 2001, CLIN EXP IMMUNOL, V126, P193, DOI 10.1046/j.1365-2249.2001.01664.x; Ettmayer P, 2006, AM J RESP CRIT CARE, V173, P599, DOI 10.1164/rccm.200503-468OC; HATCH GE, 1981, AM REV RESPIR DIS, V124, P167; Heinrich J, 2004, CURR OPIN ALLERGY CL, V4, P341, DOI 10.1097/00130832-200410000-00003; JAKAB GJ, 1993, TOXICOL APPL PHARM, V121, P167, DOI 10.1006/taap.1993.1142; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Sabroe I, 2002, CLIN EXP ALLERGY, V32, P984, DOI 10.1046/j.1365-2745.2002.01451.x; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; SCHWARTZ J, 1993, ENVIRON RES, V62, P7, DOI 10.1006/enrs.1993.1083; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taussig D, 1998, Hematology, V3, P277, DOI 10.1080/10245332.1998.11746400; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Vermaelen K, 2005, AM J RESP CRIT CARE, V172, P530, DOI 10.1164/rccm.200410-1384SO; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; Williams MA, 2002, J HEMATOTH STEM CELL, V11, P829, DOI 10.1089/152581602760404630; Williams Marc, 2006, Expert Rev Clin Immunol, V2, P59, DOI 10.1586/14787210.2.1.59; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Zelikoff JT, 2003, INHAL TOXICOL, V15, P131, DOI 10.1080/08958370304478	40	48	49	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					488	497		10.1016/j.jaci.2006.10.022	http://dx.doi.org/10.1016/j.jaci.2006.10.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17187851				2022-12-18	WOS:000244327900030
J	Allakhverdi, Z; Fitzpatrick, D; Boisvert, A; Baba, N; Bouguermouh, S; Sarfati, M; Delespesse, G				Allakhverdi, Zoulfia; Fitzpatrick, David; Boisvert, Annie; Baba, Nobuyasu; Bouguermouh, Salim; Sarfati, Marika; Delespesse, Guy			Expression of CD103 identifies human regulatory T-cell subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human regulatory T cells; CD103; FoxP3; CD25; neonatal lymphocytes; dendritic cells; alloreactive T cells; TGF-beta	TRANSCRIPTION FACTOR FOXP3; TGF-BETA; INTEGRIN ALPHA(E)BETA(7); DENDRITIC CELLS; CUTTING EDGE; INDUCTION; TOLERANCE; LYMPHOCYTES; GENERATION; CD25(+)	Background: Analysis of naturally occurring T regulatory CD4(+) (nTreg) cells in human diseases is hampered by the lack of specific surface marker. Indeed, the CD25 antigen, which is typically used to identify nTreg cells, is also expressed on activated effector T cells. Objective: We sought to examine whether CD4(+) T cells bearing CD103 are suppressor cells, regardless of CD25 coexpression. Methods: We first compared freshly isolated tonsillar CD103(+)CD25(-) cells with their CD103(-)CD25(high) counterparts for their capacity to suppress T-cell response and their expression of FoxP3 mRNA. Next CD103 was induced on neonatal or adult CD4(+) T cells stimulated with allogeneic dendritic cells, and the CD103(+) and CD103(-) fractions were compared as above. Results: Tonsillar CD4(+)CD103(+)CD25(-) T cells displayed comparable suppressive activity and contained similar amounts of FoxP3 mRNA as their CD103(-)CD25(high) counterparts. In vitro-generated alloantigen-primed CD103+ cells coexpressed CD25, suppressed T-cell activation, and contained more FoxP3 mRNA than the CD103(-)CD25(+) cells isolated from the same cultures. Finally, neonatal alloreactive cells contained more CD103(+) Treg cells than their adult counterparts and, unlike the latter, became hyporesponsive to the priming alloantigens. Conclusions: The examination of CD103 and CD25 coexpression allows identification of 3 subsets of human CD4(+) nTreg cells, and the detection of CD103 on CD4(+) T cells identifies nTYeg cells, regardless of CD25 coexpression. Clinical implications: The greater induction of CD103(+) suppressor cells by cord blood should be related to its successful clinical use as an alternative to adult bone marrow transplantation.	Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, Montreal, PQ H2L 4M1, Canada; Notre Dame Hosp, CHUM Res Ctr, Immunoregulat Lab, Montreal, PQ H2L 4M1, Canada; Amgen Inc, Immunol Syst, Seattle, WA USA	Universite de Montreal; Universite de Montreal; Amgen	Delespesse, G (corresponding author), Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, 1560 Sherbrooke E St Pav Mailloux,M4211-K, Montreal, PQ H2L 4M1, Canada.	guy.delespesse@sympatico.ca	Allakhverdi, Zoulfia/AAG-1379-2019; Baba, Nobuyasu/AAF-8593-2019	Baba, Nobuyasu/0000-0001-9945-080X				Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allakhverdi Z, 2005, ALLERGY, V60, P1157, DOI 10.1111/j.1398-9995.2005.00861.x; Ballen KK, 2005, BLOOD, V105, P3786, DOI 10.1182/blood-2004-10-4125; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; Chen TC, 2004, J IMMUNOL, V172, P5900, DOI 10.4049/jimmunol.172.10.5900; Dujardin HC, 2004, P NATL ACAD SCI USA, V101, P14473, DOI 10.1073/pnas.0403303101; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Feng Y, 2002, J EXP MED, V196, P877, DOI 10.1084/jem.20020178; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Joffre O, 2004, BLOOD, V103, P4216, DOI 10.1182/blood-2004-01-0005; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Lecoeur H, 2002, J IMMUNOL METHODS, V265, P81, DOI 10.1016/S0022-1759(02)00072-8; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003; Rao PE, 2005, J IMMUNOL, V174, P1446, DOI 10.4049/jimmunol.174.3.1446; Riemann H, 1996, J IMMUNOL, V156, P1799; RISDON G, 1995, P NATL ACAD SCI USA, V92, P2413, DOI 10.1073/pnas.92.6.2413; Robinson PW, 2001, IMMUNOLOGY, V103, P146, DOI 10.1046/j.1365-2567.2001.01232.x; Roncarolo Maria Grazia, 2003, Novartis Found Symp, V252, P115; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Sigmundsdottir H, 2004, CLIN IMMUNOL, V111, P119, DOI 10.1016/j.clim.2004.01.003; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Suffia I, 2005, J IMMUNOL, V174, P5444, DOI 10.4049/jimmunol.174.9.5444; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; Wei WZ, 2004, CANCER IMMUNOL IMMUN, V53, P73, DOI 10.1007/s00262-003-0444-1; Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282; Zenclussen AC, 2005, AM J PATHOL, V166, P811, DOI 10.1016/S0002-9440(10)62302-4; Zhang GX, 2002, J IMMUNOL, V168, P2501, DOI 10.4049/jimmunol.168.5.2501	37	48	52	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1342	1349		10.1016/j.jaci.2006.07.034	http://dx.doi.org/10.1016/j.jaci.2006.07.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17137867				2022-12-18	WOS:000242880300022
J	Lent, AM; Harbeck, R; Strand, M; Sills, M; Schmidt, K; Efaw, B; Lebo, T; Nelson, HS				Lent, Anne M.; Harbeck, Ronald; Strand, Matthew; Sills, Michael; Schmidt, Kimberly; Efaw, Benjamin; Lebo, Terri; Nelson, Harold S.			Immunologic response to administration of standardized dog allergen extract at differing doses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; acetone-precipitated dog extract; Can f1; cytokine; allergen-specific IgE; allergen-specific IgG(4); skill prick test; late cutaneous response	PLACEBO-CONTROLLED IMMUNOTHERAPY; DOUBLE-BLIND; T-CELLS; IGE; GENERATION; ANTIBODIES	Background: The immunologic response to immunotherapy with dog extract is not well characterized. Objective: The purpose of this study was to examine the immunologic response to 3 doses of dog extract expressed as their Can f 1 content. Methods: Cluster immunotherapy was administered to 28 patients with dog allergy who were randomly assigned to 1 of 4 treatment arms: placebo or acetone-precipitated extract containing 0.6 mu g, 3.0 mu g, or 15.0 mu g Can f 1 per 0.5 mL maintenance dose. Studies included titrated skin prick tests, the late cutaneous response, titrated nasal challenge with dog extract, and serum allergen-specific IgE and IgG(4). Dog allergen-stimulated lymphocyte proliferation was performed with measurement of secreted cytokines by ELISA and of intracellular cytokines by flow cytometry. Results: There was a significant dose-dependent response in suppression of titrated skin prick tests and suppression of the late cutaneous response. There was a significant increase from baseline in dog-specific IgG4 in both the high-dose and low-dose groups and a dose-dependent suppression of secreted TNF-alpha and increase in secreted TGF-beta. There was a dose-dependent trend in suppression of secreted IL-4 with a significant decrease from baseline in the high-dose group. There were no significant changes in symptom scores; lymphocyte proliferation; secreted IFN-gamma, IL-10, or IL-5; or intracellular cytokine production. Conclusion: The dose-response in immunologic parameters after immunotherapy with dog extract is similar to that previously demonstrated with cat extract. Clinical implications: The greatest and most consistent response is seen with a dose containing 15 mu g Can f 1.	Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80206 USA	National Jewish Health	Lent, AM (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, 1400 Jackson St, Denver, CO 80206 USA.	lenta@njc.org	Strand, Matt/AAU-3762-2021	Strand, Matt/0000-0002-9083-5989				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Antony PA, 2002, J IMMUNOTHER, V25, P202, DOI 10.1097/00002371-200205000-00002; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Chanez P, 1996, ALLERGY, V51, P850; Conover William Jay, 1998, PRACTICAL NONPARAMET, V350; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; GEHIHAR K, 1999, CLIN EXP ALLERGY, V29, P497; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; Meiser JB, 2001, J ALLERGY CLIN IMMUN, V107, P744, DOI 10.1067/mai.2001.114340; NAGAYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388, DOI 10.1016/0091-6749(85)90077-6; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P635, DOI 10.1016/j.jaci.2004.01.741; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; 2004, BD BIOSCIENCES IMMUN	23	48	50	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1249	1256		10.1016/j.jaci.2006.07.055	http://dx.doi.org/10.1016/j.jaci.2006.07.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157654				2022-12-18	WOS:000242880300007
J	Ye, YM; Kim, CW; Kim, HR; Kim, HM; Suh, CH; Nahm, DH; Park, HS; Redlich, CA; Wisnewski, AV				Ye, Young-Min; Kim, Cheol-Woo; Kim, Hyung-Ryul; Kim, Hyun-Mi; Suh, Chang-Hee; Nahm, Dong-Ho; Park, Hae-Sim; Redlich, Carrie A.; Wisnewski, Adam V.			Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational diseases; IgE; IgG; occupational exposures; asthma; MALDI-MS	HUMAN SERUM-ALBUMIN; OCCUPATIONAL ASTHMA; IGG ANTIBODIES; HUMAN LUNG; IN-VITRO; IDENTIFICATION; PROTEINS; WORKERS; PATHOGENESIS; ISOCYANATES	Background: Toluene diisocyanate (TDI), a widely used aromatic diisocyanate with the potential to cause asthma, reacts with albumin in the airway fluid, which acts as a carrier protein for chemical presentation to the immune system. Structural elucidation of TDI-albumin conjugates is crucial to understanding the human immune response to TDI exposure. Objective: Investigate the dependence of TDI's antigenicity on the biophysics of exposure and its association with TDI asthma. Methods: Toluene diisocyanate-albumin conjugates were generated by exposing albumin to TDI in liquid or vapor phase (liquid or vapor TDI-albumin, respectively). Conjugates were characterized by native gel electrophoresis and matrix-assisted laser desorption/ionization-mass spectrometry, and used as antigens in ELISA assays for serum specific-IgE and IgG. Results: The physical phase of TDI (vapor vs liquid) affects the formation of TDI-albumin conjugates, with measurable differences in the amount of TDI per albumin molecule, migration in native gels, matrix-assisted laser desorption/ionization-mass spectrometry mass/charge spectra, and antigenicity. Vapor TDI-albumin conjugates were recognized by IgE from 44% of subjects with TDI asthma, whereas liquid TDI-albumin conjugates are recognized by IgE from only 17% of these patients. A significant (P <.05) association between TDI exposure and vapor TDI-albumin specific serum IgG was also observed. Conclusion: Biophysics of TDI exposure substantially affects formation of TDI-albumin conjugates recognized by the immune system in association with exposure and asthma. Clinical implications: The data suggest that serology may help identify TDI asthmatics and exposed workers if the appropriate form of TDI is used as the antigenic basis for analysis.	Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon 442721, South Korea; Inha Univ, Inchon, South Korea; Yonsei Univ, Seoul, South Korea; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Ajou University; Inha University; Yonsei University; Yale University	Park, HS (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Youngtonggu Wonchondong San-5, Suwon 442721, South Korea.	hspark@ajou.ac.kr	Park, Hae-Sim/S-7974-2019; Suh, Chang-Hee/H-9723-2019	Suh, Chang-Hee/0000-0001-6156-393X; Park, Hae-Sim/0000-0003-2614-0303	NHLBI NIH HHS [R01 HL062622-03, R01 HL062622, R01 HL062622-07, HL62622] Funding Source: Medline; NIEHS NIH HHS [ES00355] Funding Source: Medline; NIOSH CDC HHS [OH3457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH003457] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; COLIGAN JE, 1998, CURRENT PROTOCOLS IM; Cummings Barbara J, 2002, Appl Occup Environ Hyg, V17, P863, DOI 10.1080/10473220290107066; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; JIN RZ, 1993, CHEM RES TOXICOL, V6, P906, DOI 10.1021/tx00036a023; Karol M H, 1982, Fundam Appl Toxicol, V2, P108, DOI 10.1016/S0272-0590(82)80090-0; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35, DOI 10.1016/S1081-1206(10)61647-X; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; PAGGIARO PL, 1983, CLIN ALLERGY, V13, P75, DOI 10.1111/j.1365-2222.1983.tb02570.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Park HS, 2002, CLIN EXP ALLERGY, V32, P198, DOI 10.1046/j.1365-2222.2002.01290.x; Park HS, 2002, CLIN EXP ALLERGY, V32, P551, DOI 10.1046/j.0954-7894.2002.01349.x; PETERS J M, 1975, Environmental Health Perspectives, V11, P97, DOI 10.2307/3428330; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Sastre J, 2003, EUR RESPIR J, V22, P364, DOI 10.1183/09031936.03.00045103; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wisnewski AV, 2004, J ALLERGY CLIN IMMUN, V113, P1178, DOI 10.1016/j.jaci.2004.03.009; Wisnewski AV, 2002, ENVIRON HEALTH PERSP, V110, P901, DOI 10.1289/ehp.02110901; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330, DOI 10.1164/ajrccm.162.6.2002086	31	48	49	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					885	891		10.1016/j.jaci.2006.06.026	http://dx.doi.org/10.1016/j.jaci.2006.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030242	Green Published			2022-12-18	WOS:000241434200016
J	Passlacqua, G; Musarra, A; Pecora, S; Amoroso, S; Antonicelli, L; Cadario, G; Di Gioacchino, M; Lombardi, C; Ridolo, E; Sacerdoti, G; Schiavino, D; Senna, G				Passlacqua, G; Musarra, A; Pecora, S; Amoroso, S; Antonicelli, L; Cadario, G; Di Gioacchino, M; Lombardi, C; Ridolo, E; Sacerdoti, G; Schiavino, D; Senna, G			Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ADHERENCE		Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Natl Healthcare Syst, Allergy Unit, Reggio Di Calabria, Italy; ALK Abello Italy, Milan, Italy; Civic Hosp Palermo, Palermo, Italy; Univ Osped Riuniti, Azienda Osped, Allergy Unit, Ancona, Italy; S Giovanni Battista Hosp, Div Clin Immunol & Allergy, Turin, Italy; Policlin Colledara, Allergy Unit, Chieti, Italy; FBF S Orsola, Pneumoallergol Unit, Brescia, Italy; Univ Parma, Policlin Federico II, Dept Clin Sci, Naples, Italy; Policlin Gemelli, Allergy Unit, Rome, Italy; Verona Gen Hosp, Allergy Unit, Verona, Italy	University of Genoa; ALK-Abello AS; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Parma; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Passlacqua, G (corresponding author), Univ Genoa, Dept Internal Med, Pad Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.		Di Gioacchino, Mario/C-5545-2019; Senna, Gianenrico/AAC-5201-2022	Di Gioacchino, Mario/0000-0002-9224-5886; Senna, Gianenrico/0000-0003-4172-3216				Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Haynes RB, 1979, COMPLIANCE HEALTHCAR; Johansson SGO, 1998, ALLERGY, V53, P1; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j.jaci.2004.03.013; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; LOWER T, 1993, ANN ALLERGY, V70, P480; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; TINKELMAN D, 1995, ANN ALLERG ASTHMA IM, V74, P241	10	48	54	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					946	948		10.1016/j.jaci.2005.12.1312	http://dx.doi.org/10.1016/j.jaci.2005.12.1312			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630956				2022-12-18	WOS:000236862800034
J	Ebmeyer, J; Furukawa, M; Pak, K; Ebmeyer, U; Sudhoff, H; Broide, D; Ryan, AF; Wasserman, S				Ebmeyer, J; Furukawa, M; Pak, K; Ebmeyer, U; Sudhoff, H; Broide, D; Ryan, AF; Wasserman, S			Role of mast cells in otitis media	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						otitis media; allergy; mast cell; NTHi; ovalbumin; mast cell-deficient mice; Haemophilus influenzae	NECROSIS-FACTOR-ALPHA; MIDDLE-EAR EFFUSIONS; INNATE IMMUNITY; AIRWAY INFLAMMATION; EUSTACHIAN-TUBE; HISTAMINE; ALLERGY; MEMBRANE; MUCOSA; MODEL	Background: New pathophysiologic concepts are needed to explain the clinically observed connection between the allergic diathesis and otitis media. Although mast cells, unlike lymphocytes, are common in the normal middle ear mucosa, their potential role in innate immunity of the middle ear and in the expression of inflammatory responses in that space to bacterial challenge, as opposed to allergy, has received relatively little attention. Objective: In the current study, we examine the contributions of mast cells to the pathogenesis of bacterially induced inflammation in the middle ear and thus to otitis media. Methods: Wild-type mice, mast cell-deficient mice, and mast cell-deficient mice whose mast cell populations were restored by transplantation of bone marrow-derived mast cells were challenged by using models of bacterial and allergic middle ear inflammation. Results: Our results indicate that mast cells account for a substantial proportion of the innate immune response to bacteria in the middle ear. Conclusion: This mechanism may link responses to allergy and infection in the middle ear mucosa, and thus the mast cell may be a critical control element in the pathogenesis of otitis media.	Univ Calif San Diego, Sch Med, Dept Surg, Div Otolaryngol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; Univ Wurzburg, Dept Otorhinolaryngol Head & Neck Surg, Wurzburg, Germany; Tohoku Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Sendai, Miyagi 980, Japan; Ruhr Univ Bochum, Dept Otorhinolaryngol Head & Neck Surg, D-4630 Bochum, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wurzburg; Tohoku University; Ruhr University Bochum	Ryan, AF (corresponding author), Univ Calif San Diego, Sch Med, Dept Surg Otolaryngol, Fir Bldg,Rm 106,9500 Gilman Dr, La Jolla, CA 92093 USA.	aryan@ucsd.edu	Sudhoff, Holger/AAV-9741-2020	Sudhoff, Holger/0000-0002-9274-5645; Broide, David/0000-0001-8405-9090	NIDCD NIH HHS [DC00129, DC006279] Funding Source: Medline; BLRD VA [I01 BX001205] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006279] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); BLRD VA; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Veterans Affairs(US Department of Veterans Affairs)		Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; ALBIIN N, 1986, ANN OTO RHINOL LARYN, V95, P2, DOI 10.1177/00034894860950S501; BERGER G, 1984, ACTA OTO-LARYNGOL, V98, P385, DOI 10.3109/00016488409107578; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOISVERT P, 1985, ANN OTO RHINOL LARYN, V94, P212, DOI 10.1177/000348948509400224; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Eriksson PO, 2001, LARYNGOSCOPE, V111, P1264, DOI 10.1097/00005537-200107000-00023; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1999, FUNDAMENTAL IMMUNOLO, P1137; HURST DS, 1990, OTOLARYNG HEAD NECK, V102, P664, DOI 10.1177/019459989010200607; Hurst DS, 2000, ALLERGY, V55, P435, DOI 10.1034/j.1398-9995.2000.00289.x; Hurst DS, 1999, INT J PEDIATR OTORHI, V49, pS315; Hurst DS, 1999, LARYNGOSCOPE, V109, P471, DOI 10.1097/00005537-199903000-00024; Ikeda T, 2003, IMMUNOL LETT, V88, P21, DOI 10.1016/S0165-2478(03)00031-2; Jang CH, 2002, INT J PEDIATR OTORHI, V66, P37, DOI 10.1016/S0165-5876(02)00185-4; Kakizoe E, 1999, INFLAMM RES, V48, P318, DOI 10.1007/s000110050467; Labadie RF, 1999, OTOLARYNG HEAD NECK, V121, P687, DOI 10.1053/hn.1999.v121.a100502; LIM DJ, 1979, CLIN OTOLARYNGOL, V4, P213, DOI 10.1111/j.1365-2273.1979.tb01888.x; LIM DJ, 1974, ANN OTO RHINOL LARYN, V83, P5, DOI 10.1177/0003489474083S1102; LIM DJ, 1971, ANN OTO RHINOL LARYN, V80, P838, DOI 10.1177/000348947108000611; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Melhus A, 2003, APMIS, V111, P989, DOI 10.1034/j.1600-0463.2003.1111012.x; Mercer-Jones MA, 1999, J LEUKOCYTE BIOL, V65, P249, DOI 10.1002/jlb.65.2.249; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; Mucha SM, 2003, CURR ALLERGY ASTHM R, V3, P232, DOI 10.1007/s11882-003-0045-2; Narkio-Makela M, 1999, CLIN EXP IMMUNOL, V116, P401; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; PALVA T, 1991, ACTA OTO-LARYNGOL, V111, P349, DOI 10.3109/00016489109137399; Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0; RYAN AF, 1986, ANN OTO RHINOL LARYN, V95, P242, DOI 10.1177/000348948609500307; Smirnova MG, 2002, EUR CYTOKINE NETW, V13, P161; STENFORS LE, 1985, AM J OTOLARYNG, V6, P217, DOI 10.1016/S0196-0709(85)80088-0; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; WIDEMAR L, 1984, ACTA OTO-LARYNGOL, V98, P302, DOI 10.3109/00016488409107567	41	48	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1129	1135		10.1016/j.jaci.2005.07.026	http://dx.doi.org/10.1016/j.jaci.2005.07.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275387				2022-12-18	WOS:000235686700028
J	Chuaychoo, B; Hunter, DD; Myers, AC; Kollarik, M; Undem, BJ				Chuaychoo, B; Hunter, DD; Myers, AC; Kollarik, M; Undem, BJ			Allergen-induced substance P synthesis in large-diameter sensory neurons innervating the lungs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic inflammation; phenotypic switch; neurogenic inflammation; substance P; nodose ganglion; sensory nerve; vagus nerve	NERVE GROWTH-FACTOR; VAGAL AFFERENT NEURONS; PHENOTYPIC SWITCH; INFLAMMATION; EXPRESSION; PLASTICITY; HYPERSENSITIVITY; IDENTIFICATION; TACHYKININS; MECHANISMS	Background: Tachykinins such as substance P are localized in unmyelinated slow-conducting C fibers that can be activated by noxious stimuli and tissue inflammation. Substance P is seldom expressed in fast-conducting large-diameter (A-fiber) vagal sensory neurons. We have previously found that allergic inflammation causes a phenotypic change in tachykinergic innervation of the trachea such that the production of substance P is induced in large-diameter sensory neurons projecting mechanosensitive A fibers to the trachea. Objective: To evaluate whether allergic inflammation also induces substance P synthesis in large-diameter sensory stretch-receptor neurons innervating guinea pig lungs, and to investigate potential mechanisms by which this may occur. Methods: Sensitized guinea pigs were exposed to allergen (ovalbumin) aerosol. One day later, immunohistochemical analysis was performed on vagal sensory neurons that had been retrogradely labeled from the lungs. Results: Ovalbumin inhalation caused a significant increase in substance P expression in large-diameter neurofilament-positive nodose ganglion neurons that innervate the lungs (P < .05). This effect was decreased by ipsilateral vagotomy. Exposing isolated nodose ganglia to the sensitizing antigen, ovalbumin, also significantly increased substance P expression compared with control. Conclusion: Allergic inflammation induces substance P synthesis in large-diameter (A-fiber) nodose ganglion neurons innervating guinea pig lungs. This could contribute to the hyperreflexia seen in allergic airway disease. The full expression of this phenotypic switch in vagus nodose ganglion neurons requires intact vagus nerve, but if allergen reached the systemic circulation in sufficient quantities, it could also affect substance P synthesis by local activation of vagal ganglionic mast cells.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Undem, BJ (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bundem@jhmi.edu						Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; Bonham AC, 2004, PULM PHARMACOL THER, V17, P453, DOI 10.1016/j.pupt.2004.09.008; Bonini S, 1999, INT ARCH ALLERGY IMM, V118, P159, DOI 10.1159/000024055; Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysiol.2003.057885; Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5; Carr MJ, 2002, AM J RESP CRIT CARE, V165, P1071, DOI 10.1164/ajrccm.165.8.2108065; Carr MJ, 2001, ENVIRON HEALTH PERSP, V109, P567, DOI 10.2307/3454671; COLERIDGE JCG, 1984, REV PHYSIOL BIOCH P, V99, P1, DOI 10.1007/BFb0027715; Dinh QT, 2004, CLIN EXP ALLERGY, V34, P1474, DOI 10.1111/j.1365-2222.2004.02066.x; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Groneberg DA, 2004, ALLERGY, V59, P1139, DOI 10.1111/j.1398-9995.2004.00665.x; Hunter DD, 1999, AM J RESP CRIT CARE, V159, P1943, DOI 10.1164/ajrccm.159.6.9808078; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P1985, DOI 10.1164/ajrccm.161.6.9908051; KUMMER W, 1992, NEUROSCIENCE, V49, P715, DOI 10.1016/0306-4522(92)90239-X; LAWSON SN, 1993, BRAIN RES BULL, V30, P239, DOI 10.1016/0361-9230(93)90250-F; LILLY CM, 1995, AM J RESP CRIT CARE, V151, P548, DOI 10.1164/ajrccm.151.2.7531100; LUNDBERG JM, 1984, CELL TISSUE RES, V235, P251; LUNDBERG JM, 1995, CAN J PHYSIOL PHARM, V73, P908, DOI 10.1139/y95-125; Ma QP, 1996, PAIN, V67, P97, DOI 10.1016/0304-3959(96)03105-3; Mazzone SB, 2004, PULM PHARMACOL THER, V17, P361, DOI 10.1016/j.pupt.2004.09.021; MYERS AC, 1991, J PHARMACOL EXP THER, V259, P104; Myers AC, 2002, AM J PHYSIOL-LUNG C, V282, pL775, DOI 10.1152/ajplung.00353.2001; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NOGUCHI K, 1994, J NEUROSCI RES, V37, P596, DOI 10.1002/jnr.490370506; NOGUCHI K, 1995, J NEUROSCI, V15, P7633; Riccio MM, 1996, J PHYSIOL-LONDON, V496, P521, DOI 10.1113/jphysiol.1996.sp021703; Rumsey WL, 2001, J PHARMACOL EXP THER, V298, P307; SPRINGALL DR, 1987, J AUTONOM NERV SYST, V20, P155, DOI 10.1016/0165-1838(87)90113-5; Undem BJ, 2004, J PHYSIOL-LONDON, V556, P905, DOI 10.1113/jphysiol.2003.060079; UNDEM BJ, 1993, J AUTONOM NERV SYST, V44, P35, DOI 10.1016/0165-1838(93)90376-6; UNDEM BJ, 1985, AM REV RESPIR DIS, V131, P260; Wilfong ER, 2004, AM J RESP CELL MOL, V30, P793, DOI 10.1165/rcmb.2003-0303OC; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	34	48	54	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					325	331		10.1016/j.jaci.2005.04.005	http://dx.doi.org/10.1016/j.jaci.2005.04.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083787				2022-12-18	WOS:000235686400014
J	Coker, HA; Harries, HE; Banfield, GK; Carr, VA; Durham, SR; Chevretton, E; Hobby, P; Sutton, BJ; Gould, HJ				Coker, HA; Harries, HE; Banfield, GK; Carr, VA; Durham, SR; Chevretton, E; Hobby, P; Sutton, BJ; Gould, HJ			Biased use of V(H)5 IgE-positive B cells in the nasal mucosa in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; allergic rhinitis; V(H)5; superantigen; B lymphocyte; mucosa	STAPHYLOCOCCAL PROTEIN-A; V-H GENES; SOMATIC HYPERMUTATION; PATIENT; SUPERANTIGEN; MUTATION; TRANSCRIPTS; REPERTOIRE; ANTIBODY; HOTSPOTS	Background: IgE antibody-producing B cells are enriched in the nasal mucosa in patients with allergic rhinitis because of local class switching to IgE. The expressed IgE V-H genes also undergo somatic hypermutation in situ to generate clonal families. The antigenic driving force behind these events is unknown. Objective: To examine the possible involvement of a superantigen in allergic rhinitis, we compared the variable (VH) gene use and patterns of somatic mutation in the expressed IgE heavy-chain genes in nasal biopsy specimens and blood from allergic patients and the IgA Vu use in the same biopsy specimens and also those from nonallergic controls. Methods: We extracted mRNA from the nasal biopsy specimens of 13 patients and 4 nonallergic control subjects and PBMCs from 7 allergic patients. IgE and IgA VH regions were RT-PCR amplified, and the DNA sequences were compared with those of control subjects. We constructed a molecular model of V(H)5 to locate amino acids of interest. Results: We observed a significantly increased frequency of IgE and IgA V(H)5 transcripts in the nasal mucosa of the allergic patients compared with the normal PBMC repertoire. Within IgE and IgA V(H)5 sequences in the nasal mucosa, the distribution of replacement amino acids was skewed toward the immunoglobulin framework regions. Three of 4 nonintrinsic hotspots of mutation identified in the V(H)5 sequences were in framework region 1. The hotspots and a conserved V(H)5-specific framework residue form a tight cluster on the surface of V(H)5. Conclusion: Our results provide evidence for the activity of a superantigen in the nasal mucosa in patients with allergic rhinitis.	Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England; Imperial Coll, Natl Heart & Lung Inst, London, England; Guys Hosp, Dept Resp Med & Allergy, London SE1 9RT, England	University of London; King's College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Coker, HA (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England.			Coker, Heather/0000-0001-9570-944X; Gould, Hannah/0000-0003-0411-688X	MRC [G0200486] Funding Source: UKRI; Medical Research Council [G0200486] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bachert C, 2003, CURR ALLERGY ASTHM R, V3, P523, DOI 10.1007/s11882-003-0065-y; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; Brezinschek HP, 2000, INT IMMUNOL, V12, P767, DOI 10.1093/intimm/12.6.767; BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; Ellyard JI, 2004, BLOOD, V103, P3805, DOI 10.1182/blood-2003-09-3109; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; Janezic A, 1998, J ALLERGY CLIN IMMUN, V101, P391, DOI 10.1016/S0091-6749(98)70253-2; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Potter KN, 1996, J IMMUNOL, V157, P2982; Potter KN, 2002, J IMMUNOL, V169, P3777, DOI 10.4049/jimmunol.169.7.3777; RANDEN I, 1993, EUR J IMMUNOL, V23, P2682, DOI 10.1002/eji.1830231044; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Silverman GJ, 2002, CLIN IMMUNOL, V102, P117, DOI 10.1006/clim.2001.5143; SNOW RE, 1995, J IMMUNOL, V154, P5576; Snow RE, 1998, EUR J IMMUNOL, V28, P3354, DOI 10.1002/(SICI)1521-4141(199810)28:10<3354::AID-IMMU3354>3.0.CO;2-Z; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; SNOW RE, 1989, LUNG BIOL HLTH DIS, P323; Sutton B, 2000, IMMUNOL TODAY, V21, P177, DOI 10.1016/S0167-5699(00)01589-9; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99	31	48	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					445	452		10.1016/j.jaci.2005.04.032	http://dx.doi.org/10.1016/j.jaci.2005.04.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083804				2022-12-18	WOS:000235686400032
J	Leung, SY; Eynott, P; Nath, P; Chung, KF				Leung, SY; Eynott, P; Nath, P; Chung, KF			Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial hyperresponsiveness; airway remodeling; airway inflammation; ciclesonide; fluticasone propionate	CELL-DNA-SYNTHESIS; INHALED FLUTICASONE; INDUCED SPUTUM; NITRIC-OXIDE; PROLIFERATION; HYPERPLASIA; EXPOSURE; ASTHMA; HYPERRESPONSIVENESS; GLUCOCORTICOIDS	Background: Several topical corticosteroids are available as anti-inflammatory treatment for asthma. Their comparative effects on allergic inflammation and airway remodeling are unclear. Objective: We compared the effects of ciclesonide with those of fluticasone propionate in a Brown Norway rat model of chronic allergic asthma. Methods: Rats sensitized and exposed to ovalbumin (OVA) were treated with dry powder vehicle, ciclesonide, or fluticasone (0.01, 0.03, and 0.1 mg/kg administered intratracheally) 24 hours and 1 hour before each of 6 OVA exposures. In a second protocol we administered 0.1 mg/kg ciclesonide or fluticasone only after the third OVA exposure. Results: Ciclesonide at all doses inhibited the allergen-induced increase in airway eosinophils and T cells, reduced goblet cell hyperplasia, and decreased 5-bromo-2'-deoxyuridine-immunoreactive airway smooth muscle (ASM) and epithelial cells. At 0.03 and 0.1 mg/kg ciclesonide, bronchial hyperresponsiveness (BHR) was also inhibited. Fluticasone did not attenuate allergen-induced BHR, despite inhibiting airway eosinophils and T cells, goblet cell hyperplasia, and 5-bromo-2'-deoxyuridine-immunoreactive ASM and epithelial cells. Fluticasone (0.1 mg/kg) caused a significant reduction in body weight (9%) compared with ciclesonide (0.1 mg/kg). Ciclesonide did not change plasma corticosterone levels, whereas fluticasone (0.1 mg/kg) reduced them. In the second protocol both fluticasone and ciclesonide inhibited BHR, bronchial inflammation, goblet cell hyperplasia, and ASM proliferation. Conclusion: Ciclesonide potently inhibited chronic allergic inflammation, remodeling, and BHR without having an effect on body weight and the hypothalamic-pituitary-adrenal axis. Fluticasone prevented airway inflammation but not BHR, but both fluticasone and ciclesonide are effective at reversal of BHR, inflammation, and remodeling features.	Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Chung, KF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019; Leung, Suet Yi/T-9620-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Leung, Suet Yi/0000-0001-8614-4619				AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BELVISI MG, 2001, AM J RESP CRIT C S 2, V163, pA589; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Bundschuh DS, 2001, AM J RESP CRIT CARE, V163, pA588; Chrousos GP, 1998, NEUROIMMUNOMODULAT, V5, P288, DOI 10.1159/000026349; Dent Gordon, 2002, Curr Opin Investig Drugs, V3, P78; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; Dunnill M S, 1971, Ciba Found Study Group, V38, P35; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; ELWOOD W, 1992, INT ARCH ALLERGY IMM, V99, P91, DOI 10.1159/000236340; Eynott PR, 2003, J PHARMACOL EXP THER, V304, P22, DOI 10.1124/jpet.102.040295; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HACZKU A, 1994, AM J RESP CRIT CARE, V150, P23, DOI 10.1164/ajrccm.150.1.8025754; HOSSAIN S, 1970, J PATHOL, V101, P171, DOI 10.1002/path.1711010212; Inoue H, 1999, LUNG, V177, P53, DOI 10.1007/PL00007627; ISHII Y, 1983, EXP HEMATOL, V11, P178; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Kanniess F, 2001, PULM PHARMACOL THER, V14, P141, DOI 10.1006/pupt.2001.0288; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Larsen BB, 2003, ALLERGY, V58, P207, DOI 10.1034/j.1398-9995.2003.00052.x; LIPWORTH BJ, 1995, THORAX, V50, P105, DOI 10.1136/thx.50.2.105; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Parameswaran K, 2000, Can Respir J, V7, P313; ROCHE WR, 1989, LANCET, V1, P520; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; Sawatzky DA, 2002, AM J PHYSIOL-LUNG C, V282, pL1279, DOI 10.1152/ajplung.00279.2001; SEVEL D, 1977, J ALLERGY CLIN IMMUN, V60, P215, DOI 10.1016/0091-6749(77)90132-4; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219, DOI 10.1111/j.1476-5381.1995.tb15127.x; Van Schoor J, 2002, EUR RESPIR J, V19, P997, DOI 10.1183/09031936.02.01112001; Vanacker NJ, 2002, EUR RESPIR J, V20, P873, DOI 10.1183/09031936.02.02562001; Vanacker NJ, 2002, CLIN EXP ALLERGY, V32, P914, DOI 10.1046/j.1365-2222.2002.01394.x; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674, DOI 10.1164/ajrccm.163.3.2004160; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309	38	48	53	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					989	996		10.1016/j.jaci.2005.01.036	http://dx.doi.org/10.1016/j.jaci.2005.01.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867856				2022-12-18	WOS:000229055100014
J	Jahn-Schmid, B; Fischer, GF; Bohle, B; Fae, I; Gadermaier, G; Dedic, A; Ferreira, F; Ebner, C				Jahn-Schmid, B; Fischer, GF; Bohle, B; Fae, I; Gadermaier, G; Dedic, A; Ferreira, F; Ebner, C			Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; mugwort pollinosis; Art v 1; HLA association; HLA-DRB1*01; peptide immunotherapy	SHORT RAGWEED ALLERGEN; PEPTIDE BINDING; HLA-DR; BEE VENOM; IMMUNOTHERAPY; RESPONSES; CELERY; CAT; IDENTIFICATION; INDUCTION	Background: Mugwort pollen allergens are the main cause of pollinosis in late summer in Europe. Ninety-five percent of patients allergic to mugwort are sensitized to the major allergen Art v 1. In contrast to other common pollen allergens that contain multiple T-cell epitopes, Art v 1 contains only 1 immunodominant T-cell epitope (Art v 1(25-36)). Objective: To characterize the minimal epitope of Art v 1(25-36) and to investigate a possible association of Art v I reactivity with HLA class II phenotypes. Methods: Art v 1-specific T-cell lines and clones were established from 51 patients with clinically defined mugwort pollen allergy and IgE specific for Art v 1. To define minimal epitopes and binding sites within Art v 1(25-36), truncated and single-substitution analog peptides were used for T-cell stimulation. To study HLA restriction, monoclonal anti-HLA antibodies and antigen-presenting cells with defined HLA-DRB and -DQB1 alleles were used. HLA typing of patients with allergy was performed by hybridization with sequence-specific oligonucleotides, PCR, and nucleotide sequencing. Results: In 96% of the patients, a cellular response to Art v 1(25-36) was obtained, and a core region of 5 to 10 amino acids containing 3 to 5 amino acids essential for T-cell reactivity was defined. The frequency of HLA-DRBI*01 in patients recognizing Art v 1(25-36) was significantly increased as compared with healthy controls (69 % vs 21 %; odds ratio, 8.45; P < 10(-6)), and HLA-DRB1*01 was identified as the main restriction element for the presentation of the inummodominant epitope. Conclusions: Allergy to Art v 1 is characterized by a uniform T-cell response. The disease is apparently associated with the HLA-DRI phenotype. Therefore, mugwort pollinosis is an ideal candidate for a peptide-based immunotherapy.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Blood Grp Serol, A-1090 Vienna, Austria; Salzburg Univ, Dept Immunol & Allergol, A-5020 Salzburg, Austria	Medical University of Vienna; Medical University of Vienna; Salzburg University	Jahn-Schmid, B (corresponding author), Med Univ Vienna, Dept Pathophysiol, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	beatrice.jahn-sclimid@meduniwien.ac.at	Gadermaier, Gabriele/L-5997-2015; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019	Gadermaier, Gabriele/0000-0002-4886-417X; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Bohle, Barbara/0000-0002-5105-7985				BARRY KA, 2004, SPRINGER SEMIN IMMUN, V25, P391; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Faux JA, 1997, CLIN EXP ALLERGY, V27, P578, DOI 10.1111/j.1365-2222.1997.tb00748.x; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; FISCHER G, 1997, HLA 1997, P194; FUTIN FG, 1976, ARTEMISIA; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; HILL CM, 1994, J IMMUNOL, V152, P2890; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; HUANG SK, 1995, J IMMUNOL, V154, P6157; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; Larche Mark, 2004, Clin Allergy Immunol, V18, P641; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Schmid-Grendelmeier P, 2003, J ALLERGY CLIN IMMUN, V111, P1328, DOI 10.1067/mai.2003.1495; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Southwood S, 1998, J IMMUNOL, V160, P3363; SPIEKSMA FTM, 1980, CLIN ALLERGY, V10, P319, DOI 10.1111/j.1365-2222.1980.tb02114.x; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; Wopfner N, 2002, BIOL CHEM, V383, P1779, DOI 10.1515/BC.2002.199; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	34	48	50	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					399	404		10.1016/j.jaci.2004.10.010	http://dx.doi.org/10.1016/j.jaci.2004.10.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696102				2022-12-18	WOS:000227043600030
J	Kim, JO; Kim, DH; Chang, WS; Hong, CW; Park, SH; Kim, SH; Kang, CY				Kim, JO; Kim, DH; Chang, WS; Hong, CW; Park, SH; Kim, SH; Kang, CY			Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural killer T cell; alpha-galactosylceramide; asthma	NKT CELLS; CUTTING EDGE; ORAL TOLERANCE; IMMUNE-SYSTEM; MICE; RECOGNITION; ACTIVATION; CD1D; IL-4; HYPERREACTIVITY	Background: Allergic asthma is an inflammatory lung disease caused by a T(H)2-driven immune response. However, intranasal exposures to soluble antigen lead to mucosal tolerance, and the mechanism involved in generation of T(H)2 responses to inert inhaled allergens is unknown. Objective: The aim of this study was to investigate whether CD1d-restrieted natural killer T (NKT) cells can contribute to the induction of T(H)2-dependent allergic asthma in a mouse model. Methods: To investigate the effect of NKT cells on the development of asthma, NKT cell ligand, alpha-galactosylceramide (alphaGC), was used with antigens. We intranasally sensitized Balb/c mice with various combinations of antigen and alphaGC for 3 consecutive days and challenged them 2 weeks later with an aerosol of ovalbumin. NKT cell-deficient or To cell-deficient mice were immunized by administering ovalbumin and alphaGC together, and ovalbumin inhalation. Results: Only when immunized with ovalbumin plus alphaGC, airway hyperreactivity, airway eosinophils, elevated IgE level, and T(H)2-cytokine production were observed in Balb/c mice. Ovalbumin alone, alphaGC alone, or BSA plus alphaGC-immunized mice did not induce asthma. Studies in NKT cell-deficient, or CD4(+) T-cell-deficient mice intranasally exposed to ovalbumin plus alphaGC did not show the development of asthma. An increase of NKT cells in bronchoalveolar lavage was observed in the pathologic states. Conclusion: These data demonstrate that NKT cells can play crucial roles in allergen sensitization and pathologic states in asthma. Furthermore, our new asthma model using alphaGC will be very useful to induce asthma and to dissect the role of NKT cells and other cells in asthma.	Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Korea Univ, Lab Mol Immunol, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Seoul Natl Univ, Inst Nat Prod Res, Coll Pharm, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea University; Seoul National University (SNU)	Kang, CY (corresponding author), Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea.	cykang@snu.ac.kr		Kim, Sanghee/0000-0001-9125-9541				Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BENDELAC A, 1995, J EXP MED, V182, P1001; Bilenki L, 2004, EUR J IMMUNOL, V34, P345, DOI 10.1002/eji.200324303; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Carnaud C, 1999, J IMMUNOL, V163, P4647; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Chung Y, 2002, IMMUNOBIOLOGY, V206, P408, DOI 10.1078/0171-2985-00190; Eberl G, 2000, EUR J IMMUNOL, V30, P985, DOI 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hong SM, 1999, IMMUNOL REV, V169, P31, DOI 10.1111/j.1600-065X.1999.tb01304.x; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kitamura H, 1999, J EXP MED, V189, P1121, DOI 10.1084/jem.189.7.1121; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsuda JL, 2001, P NATL ACAD SCI USA, V98, P12636, DOI 10.1073/pnas.221445298; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Ronet C, 2001, J IMMUNOL, V166, P1755, DOI 10.4049/jimmunol.166.3.1755; Singh N, 1999, J IMMUNOL, V163, P2373; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Takikawa H, 1998, TETRAHEDRON, V54, P3141, DOI 10.1016/S0040-4020(98)00065-9; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	32	48	53	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1332	1338		10.1016/j.jaci.2004.09.004	http://dx.doi.org/10.1016/j.jaci.2004.09.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577831	Bronze			2022-12-18	WOS:000225577400012
J	Burgess, JK; Ge, Q; Boustany, S; Black, JL; Johnson, PRA				Burgess, JK; Ge, Q; Boustany, S; Black, JL; Johnson, PRA			Increased sensitivity of asthmatic airway smooth muscle cells to prostaglandin E2 might be mediated by increased numbers of E-prostanoid receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; prostaglandin E-2; prohferation; EP receptors; airway smooth muscle	EP(2) SUBTYPE; EXPRESSION; CLONING; CDNA; EP2; CYCLO-OXYGENASE-2; PROLIFERATION; AGONIST; PROTEIN; CULTURE	Background: An increase in airway smooth muscle (ASM) cell proliferation leads to an increase in the bulk of the ASM, one of the characteristic features of asthma. We have previously shown that ASM cells from asthmatic individuals proliferate more than those from nonasthmatic subjects. This increased growth might be due to compromised inhibitory mechanisms within the ASM of asthmatic subjects. Objective: The purpose of this study was to determine whether the proliferative control exerted by prostaglandin E-2 (PGE(2)) was altered in the asthmatic ASM cells. Methods: We used tritated thymidine uptake to measure cell proliferation and cell-surface ELISAs to detect the presence of cell-surface receptors on ASM cells isolated from asthmatic and nonasthmatic individuals. Results: The asthmatic ASM cells were significantly more sensitive to proliferation inhibition by PGE(2) than the nonasthmatic cells (P < .02). The PGE(2) (E-prostanoid [EP]) receptors EP2 and EP3 were detected on asthmatic and nonasthmatic smooth muscle cells in culture. There were significantly more receptors on the asthmatic cells. The asthmatic cells also had increased sensitivity to proliferation inhibition by EP2-specific agonists but not by EP3-specific agonists. Conclusion: The increased growth observed in asthmatic ASM cells is not the result of impaired responsiveness to PGE(2). In contrast, these cells have increased sensitivity. This increased sensitivity might be mediated by the increased numbers of EP2 receptors on the surface.	Univ Sydney, Dept Pharmacol, Resp Res Grp, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Woolcock Inst Med Res, Sydney, NSW, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Burgess, JK (corresponding author), Univ Sydney, Dept Pharmacol, Resp Res Grp, Bosch Bldg D05, Sydney, NSW 2006, Australia.		Ge, Qi/D-3988-2013; Burgess, Janette/M-7117-2019; Black, Judith L/C-6559-2008; Burgess, Janette K/A-3597-2010	Burgess, Janette/0000-0001-9868-9966				Belvisi MG, 1998, BRIT J PHARMACOL, V125, P1102, DOI 10.1038/sj.bjp.0702104; BORGER P, 2003, AM J RESP CRIT CARE, V167, pA331; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DURANDARCZYNSKA W, 1993, HISTOCHEMISTRY, V100, P465, DOI 10.1007/BF00267827; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; FLORIO C, 1994, AM J PHYSIOL, V266, pL131, DOI 10.1152/ajplung.1994.266.2.L131; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; HICKS C, 1994, J IMMUNOL METHODS, V170, P83, DOI 10.1016/0022-1759(94)90248-8; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Katsuyama M, 1998, BIOCHEM J, V330, P1115, DOI 10.1042/bj3301115; Konger RL, 2002, AM J PATHOL, V161, P2065, DOI 10.1016/S0002-9440(10)64485-9; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Pang LH, 1998, AM J PHYSIOL-LUNG C, V275, pL322, DOI 10.1152/ajplung.1998.275.2.L322; Pang LH, 1998, BRIT J PHARMACOL, V125, P1320, DOI 10.1038/sj.bjp.0702193; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; REGAN JW, 1994, MOL PHARMACOL, V46, P213; REIMER R, 1992, PROSTAGLANDINS, V44, P485, DOI 10.1016/0090-6980(92)90142-G; ROTH M, 2003, AM J RESP CRIT CARE, V167, pA34; Smock SL, 1999, GENE, V237, P393, DOI 10.1016/S0378-1119(99)00323-6; SONNENBURG WK, 1990, J BIOL CHEM, V265, P8479; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; Tani K, 2001, BIOORG MED CHEM LETT, V11, P2025, DOI 10.1016/S0960-894X(01)00359-6; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; WATABE A, 1993, J BIOL CHEM, V268, P20175	31	48	50	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					876	881		10.1016/j.jaci.2004.02.029	http://dx.doi.org/10.1016/j.jaci.2004.02.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131569				2022-12-18	WOS:000221269000009
J	TenBrook, JA; Wolf, MP; Hoffman, SN; Rosenwasser, LJ; Konstam, MA; Salem, DN; Wong, JB				TenBrook, JA; Wolf, MP; Hoffman, SN; Rosenwasser, LJ; Konstam, MA; Salem, DN; Wong, JB			Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; peanut allergy; coronary artery disease; congestive heart failure; beta-adrenergic receptor antagonists	ASSOCIATION TASK-FORCE; MYOCARDIAL-INFARCTION; ACC/AHA GUIDELINES; AMERICAN-COLLEGE; NATURAL-HISTORY; NUT ALLERGY; MANAGEMENT; BLOCKADE; PREVALENCE; FOOD	Background: beta-Blocker therapy postmyocardial infarction is generally recommended because it reduces mortality. However, beta-blockers may increase anaphylaxis mortality in the growing population of patients with peanut-induced anaphylaxis. Objective: We sought to assess the risks and benefits of beta-blocker therapy among patients with peanut allergy and heart disease. Methods: We created a Markov model for patients with heart disease at risk for peanut-induced anaphylaxis to compare life expectancy with the following strategies: (1) beta-blocker and (2) no beta-blocker. Meta-analysis and a literature review were used to estimate model parameters. We performed sensitivity analysis to explore parameter uncertainty. Results: For peanut-allergic patients who are postmyocardial infarction or who have congestive heart failure, the heart disease benefit of beta-blockers outweighs the increased likelihood of dying from anaphylaxis, increasing life expectancy by 9.4 and 17.4 months, respectively. beta-Blocker was preferred unless (1) the annual rate of moderate to severe anaphylaxis exceeded 6.0% for postmyocardial infarction and 15% for congestive heart failure patients; (2) beta-blocker therapy increased the incidence of moderate to severe anaphylaxis >2.5-fold for postmyocardial infarction and >5.8-fold for congestive heart failure patients; (3) anaphylaxis case fatality exceeded 6.5% postmyocardial infarction; or (4) beta-blocker therapy increased anaphylaxis case fatality >25-fold postmyocardial infarction. Conclusion: Our results suggest that for patients postmyocardial infarction or with congestive heart failure who are at risk for peanut-induced anaphylaxis, beta-blocker use should still improve survival. However, the epidemiology of anaphylaxis and effects of beta-blocker therapy on anaphylaxis incidence and mortality require further study.	Tufts Univ, New England Med Ctr, Div Clin Decis Making Informat & Telemed, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Med, Div Cardiol, Boston, MA 02111 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Clin Immunol & Allergy, Denver, CO USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; National Jewish Health	Wong, JB (corresponding author), Tufts Univ, New England Med Ctr, Div Clin Decis Making Informat & Telemed, 750 Washington St,Box 302, Boston, MA 02111 USA.	jwong@tufts-nemc.org		Wong, John/0000-0003-4203-9010				*AM HEART ASS, 2002, HEART STROK STAT 200; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BRODY JE, 2002, NY TIMES        0924, pF7; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; DANCHIN N, 2002, CLIN EVIDENCE CONCIS, V8, P4; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Foucard T, 1999, ALLERGY, V54, P261, DOI 10.1034/j.1398-9995.1999.00924.x; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hourihane JO, 1998, ALLERGY, V53, P84, DOI 10.1111/j.1398-9995.1998.tb04971.x; HOURIHANE JO, 1995, BRIT MED J, V311, P1434, DOI 10.1136/bmj.311.7017.1434b; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; LANG DM, 1995, DRUG SAFETY, V12, P299, DOI 10.2165/00002018-199512050-00002; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P., 1998, ALLERGY PRINCIPLES P, P1079; *NATL CTR HLTH STA, 1991, VIT STAT US, V2; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; *PDR, 2003, PHYS DESK REF; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Soriano JB, 1997, PROG CARDIOVASC DIS, V39, P445, DOI 10.1016/S0033-0620(97)80039-4; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65	43	48	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					977	982		10.1016/j.jaci.2004.02.043	http://dx.doi.org/10.1016/j.jaci.2004.02.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131583	Bronze			2022-12-18	WOS:000221269000023
J	Fritz, SB; Terrell, JE; Conner, ER; Kukowska-Latallo, JF; Baker, JR				Fritz, SB; Terrell, JE; Conner, ER; Kukowska-Latallo, JF; Baker, JR			Nasal mucosal gene expression in patients with allergic rhinitis with and without nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; allergic rhinitis; gene expression; gene-chip array; quantitative PCR	MAST-CELL TRYPTASE; BINDING-PROTEIN; UTEROGLOBIN; FAMILY; ATOPY; ESTRAMUSTINE; MAMMAGLOBIN; SUBUNIT; ASTHMA	Background: Nasal polyps are a common problem that is difficult to diagnose and treat, in part because the cause of nasal polyposis is unknown. Although information on the pathogenesis of polyposis is lacking, there are reports suggesting that a genetic predisposition underlies this disorder. Objective: We sought to better understand the basis of nasal polyposis associated with allergic rhinitis. We hypothesize that the expression of unique genes is associated with the nasal polyposis phenotype. Methods: We examined 12,000 human genes transcribed in the nasal mucosa of patients with allergic rhinitis with and without nasal polyps. Biopsy specimens of the mucosa of patients with and without polyps were obtained after the patients refrained from the use of topical or systemic steroid therapy for 2 weeks. Results: Thirty-four genes were differentially expressed between the patient groups, including those for inflammatory molecules and putative growth factors. The greatest differential expression identified by the array analysis was for a group of genes associated with neoplasia, including mammaglobin, a gene transcribed 12-fold higher in patients with polyps compared with control patients with rhinitis alone. Quantitative RT-PCR confirmed this differential expression and documented that the number of mammaglobin mRNA copies is actually 64-fold greater in tissues of patients with polyps versus control patients. The specificity of mammaglobin protein expression was evaluated by means of immunohistochemistry, which showed specific staining in nasal polyp mucosal goblet cells only in patients with polyps. Conclusion: These data suggest that nasal polyposis involves deregulated cell growth, using gene activation in some ways similar to a neoplasm. In addition, mammaglobin, a gene of unknown function associated with breast neoplasia, might be related to polyp growth.	Univ Michigan, Sch Med, Ctr Biol Nanotechnol, Div Clin Immunol & Allergy,Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Otolaryngol, Ann Arbor, MI 48103 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Sch Med, Ctr Biol Nanotechnol, Div Clin Immunol & Allergy,Med Ctr, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK20572, DK58771] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Autieri MV, 2001, ARTERIOSCL THROM VAS, V21, P1421, DOI 10.1161/hq0901.095566; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Carter D, 2003, CLIN CANCER RES, V9, P749; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; Diamandis EP, 2002, CLIN CHEM, V48, P1198; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P783, DOI 10.1017/S0022215100147462; Fleming TP, 2000, ANN NY ACAD SCI, V923, P78, DOI 10.1111/j.1749-6632.2000.tb05521.x; FORSGREN B, 1979, P NATL ACAD SCI USA, V76, P3149, DOI 10.1073/pnas.76.7.3149; Greisner WA, 1996, ALLERGY ASTHMA PROC, V17, P283, DOI 10.2500/108854196778662192; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; HENDERSON WR, 1992, J PATHOL, V166, P395, DOI 10.1002/path.1711660412; HEYNS W, 1983, J STEROID BIOCHEM, V19, P1689, DOI 10.1016/0022-4731(83)90345-X; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; Lascaratos JG, 2000, ANN OTO RHINOL LARYN, V109, P871, DOI 10.1177/000348940010900916; LEUNG BS, 1992, CANCER LETT, V66, P77, DOI 10.1016/0304-3835(92)90283-2; Luxenberger W, 2000, EUR ARCH OTO-RHINO-L, V257, P137, DOI 10.1007/s004050050210; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MOLONEY JR, 1980, CLIN OTOLARYNGOL, V5, P183, DOI 10.1111/j.1365-2273.1980.tb01645.x; PERKINS JA, 1989, OTOLARYNG HEAD NECK, V101, P641, DOI 10.1177/019459988910100605; Reszka E, 2001, Int J Occup Med Environ Health, V14, P99; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Settipane G A, 1991, Rhinol Suppl, V11, P33; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; Slavin RG, 1997, JAMA-J AM MED ASSOC, V278, P1849, DOI 10.1001/jama.278.22.1849; SLAVIN RG, 1992, ARCH OTOLARYNGOL, V118, P771; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOOP AE, 1991, J ALLERGY CLIN IMMUN, V87, P470, DOI 10.1016/0091-6749(91)90004-8; SZEPETOWSKI P, 1994, GENOMICS, V19, P399, DOI 10.1006/geno.1994.1083; WALLS AF, 1995, INT ARCH ALLERGY IMM, V107, P372, DOI 10.1159/000237039; Watson MA, 1998, ONCOGENE, V16, P817, DOI 10.1038/sj.onc.1201597; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258	35	48	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1057	1063		10.1016/j.jaci.2003.09.042	http://dx.doi.org/10.1016/j.jaci.2003.09.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657858				2022-12-18	WOS:000187154200005
J	Calam, R; Gregg, L; Simpson, B; Morris, J; Woodcock, A; Custovic, A				Calam, R; Gregg, L; Simpson, B; Morris, J; Woodcock, A; Custovic, A			Childhood asthma, behavior problems, and family functioning	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child behavior; family relations	MANCHESTER ASTHMA; CHILDREN; RISK; DEPRESSION; PREGNANCY; MORBIDITY; INVENTORY; SYMPTOMS; ALLERGY; PARENTS	Background: Studies of families of asthmatic children indicate associations between psychological factors and asthma symptoms. Objective: We investigated relations between psychosocial factors and the development of respiratory symptoms within a large prospective cohort study. Methods: The children were prenatally assigned to high, medium, or low risk for asthma development on the basis of parental atopy and family history of allergic disease. When the children were 3 years of age, parents completed the Eyberg Child Behavior Inventory (ECBI), Family Relationships Index (FRI), Hospital Anxiety and Depression Scale (HAD), and General Health Questionnaire (GHQ). Results: Data from 663 participants were analyzed. ECBI intensity scores were significantly higher for children with parentally reported respiratory symptoms. Symptomatic low-risk children (both parents nonatopic, no family history of allergic disease) were particularly likely to have elevated behavior problem ratings. None of the other family psychosocial variables showed this pattern. Child behavior problems were, however, significantly positively correlated with the other family psychosocial variables. Logistic regression indicated that behavior problem scores were associated with 3 or more attacks of wheeze (P = .03, OR = 1.023), irrespective of risk group. Conclusions: Children at 3 years of age with symptoms suggestive of asthma are at elevated risk of behavior problems. Children from families without a history of asthma and allergic diseases may be particularly vulnerable to behavioral disturbance. Families may benefit from additional advice on management of their child's behavior, particularly if parents do not have the experience of having the illness themselves.	Acad Div Clin Psychol, Manchester, Lancs, England; NW Lung Ctr, Manchester, Lancs, England; S Manchester Univ Hosp Trust, Dept Med Stat, Manchester, Lancs, England	University of Manchester	Calam, R (corresponding author), Univ Manchester, Acad Div Clin Psychol, Educ & Res Ctr, Wythenshawe Hosp, 2nd Floor, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Calam, Rachel/0000-0002-4385-1687; Woodcock, Ashley/0000-0002-5428-8578; Gregg, Lynsey/0000-0001-5683-5574				Bergmann R, 1998, EUR RESPIR J, V12, p9S; BERNARDBONNIN AC, 1995, J ALLERGY CLIN IMMUN, V95, P34, DOI 10.1016/S0091-6749(95)70150-8; Burns GL, 2001, CHILD FAM BEHAV THER, V23, P15, DOI 10.1300/J019v23n01_02; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Frankel K, 1998, J ASTHMA, V35, P621, DOI 10.3109/02770909809048964; Goldberg D.P., 1978, MANUAL GEN HLTH QUES; HERMANNS J, 1989, J PSYCHOSOM RES, V33, P469, DOI 10.1016/0022-3999(89)90008-1; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Lovejoy MC, 2000, CLIN PSYCHOL REV, V20, P561, DOI 10.1016/S0272-7358(98)00100-7; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V104, pS169, DOI 10.1016/S0091-6749(99)70058-8; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430, DOI 10.1097/00004703-200112000-00011; Miller BD, 1995, PEDIATR ASTHMA ALLER, V9, P133, DOI 10.1089/pai.1995.9.133; Moos RH., 1994, FAMILY ENV SCALE MAN, V3; Mrazek DA, 1998, J CHILD PSYCHOL PSYC, V39, P247, DOI 10.1111/1469-7610.00318; ROBINSON EA, 1980, J CLIN CHILD PSYCHOL, V9, P22, DOI 10.1080/15374418009532938; Sanders MR, 2000, J CONSULT CLIN PSYCH, V68, P624, DOI 10.1037//0022-006X.68.4.624; SCHOBINGER R, 1992, J PSYCHOSOM RES, V36, P743, DOI 10.1016/0022-3999(92)90132-L; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; WALKER LS, 1995, J PEDIATR PSYCHOL, V20, P329, DOI 10.1093/jpepsy/20.3.329; WALMBOLDT FS, 1995, J PSYCHOSOM RES, V39, P995; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; Weinstein AG, 1997, J ASTHMA, V34, P345, DOI 10.3109/02770909709067225; Weinstein AG, 1997, ANN ALLERG ASTHMA IM, V79, P311, DOI 10.1016/S1081-1206(10)63020-7; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	48	52	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					499	504		10.1067/mai.2003.1639	http://dx.doi.org/10.1067/mai.2003.1639			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	719XW	13679807				2022-12-18	WOS:000185231200007
J	Radinsky, S; Bonagura, VR				Radinsky, S; Bonagura, VR			Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIBODY DEFICIENCIES; REPLACEMENT THERAPY; IMMUNODEFICIENCY; GLOBULIN; HOME		N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA	Northwell Health	Radinsky, S (corresponding author), N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA.			Bonagura, Vincent/0000-0002-0681-2099				Abrahamsen TG, 1996, PEDIATRICS, V98, P1127; BERGER M, 1980, ANN INTERN MED, V93, P55, DOI 10.7326/0003-4819-93-1-55; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; GARDULF A, 1995, LANCET, V345, P365; Gardulf A, 2001, J CLIN IMMUNOL, V21, P150, DOI 10.1023/A:1011051704960; HAMMARSTROM L, 1994, IMMUNOL REV, V139, P43, DOI 10.1111/j.1600-065X.1994.tb00856.x; Stiehm ER, 1997, PEDIATR INFECT DIS J, V16, P696, DOI 10.1097/00006454-199707000-00012; Stiehm ER, 1998, J ALLERGY CLIN IMMUN, V101, P848, DOI 10.1016/S0091-6749(98)70314-8; Sundin U, 1998, CLIN EXP IMMUNOL, V112, P341; Thampakkul S, 2001, IMMUNOL ALLERGY CLIN, V21, P165, DOI 10.1016/S0889-8561(05)70198-3	11	48	48	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					630	633		10.1067/mai.2003.1688	http://dx.doi.org/10.1067/mai.2003.1688			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679829				2022-12-18	WOS:000185231200029
J	Cates, EC; Gajewska, BU; Goncharova, S; Alvarez, D; Fattouh, R; Coyle, AJ; Gutierrez-Ramos, JC; Jordana, M				Cates, EC; Gajewska, BU; Goncharova, S; Alvarez, D; Fattouh, R; Coyle, AJ; Gutierrez-Ramos, JC; Jordana, M			Effect of GM-CSF on immune, inflammatory, and clinical responses to ragweed in a novel mouse model of mucosal sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic airway inflammation; asthma; experimental model; GM-CSF murine clinical symptoms; ragweed; T(H)2	BRONCHIAL EPITHELIAL-CELLS; ALLERGIC LUNG INFLAMMATION; MURINE MODEL; NONASTHMATIC SUBJECTS; ASTHMATIC-PATIENTS; CYTOKINE RELEASE; DENDRITIC CELLS; IGE RESPONSES; P-SELECTIN; SERUM IGE	Background: Conventional models of allergic airway inflammation involve intraperitoneal administration of ovalbumin in conjunction with a chemical adjuvant (generally aluminum hydroxide) to generate allergic airways inflammation. Here we have investigated the effect of respiratory mucosal exposure to a ragweed extract in the absence of chemical adjuvant on the generation of allergic responses. Objectives: We sought to develop a mouse model of ragweed-induced allergic airway inflammation through mucosal sensitization and to investigate the role of GM-CSF in this process. Methods: Ragweed was delivered intranasally to an airway microenvironment enriched with GM-CSF, which was achieved by means of either multiple coadministrations of recombinant GM-CSF or a single delivery of an adenoviral vector carrying the GM-CSF transgene. Results: Administration of a purified ragweed extract leads to T(H)2 sensitization (and not inhalation tolerance) accompanied by mild airway inflammation, modest clinical symptoms, and moderate production of T(H)2 cytokines by splenocytes on ragweed restimulation. The administration of anti-GM-CSF antibodies in conjunction with ragweed diminished T(H)2-associated cytokine production. These responses were amplified by enriching the airway microenvirimment with GM-CSF. Under these conditions, all T(H)2-associated immune-inflamniatory responses, as well as the clinical responses, were considerably enhanced. To investigate the mechanism underlying these effects we examined lung mononuclear cells by means of flow cytometry and detected a substantial expansion of antigen-presenting cells, particularly dendritic cells, as well as a substantially increased activation of these antigen-presenting cells, as demonstrated by the expression of B7 molecules, particularly B7.2. Conclusion: GM-CSF plays an important role in the generation of allergic inumme-inflammatory responses to ragweed.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 3Z5, Canada; McMaster Univ, Ctr Gene Therapeut, Div Resp Dis & Allergy, Hamilton, ON L8S 3Z5, Canada; Millennium Pharmaceut Inc, Cambridge, MA USA	McMaster University; McMaster University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Jordana, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, 1200 Main St W, Hamilton, ON L8S 3Z5, Canada.		Alvarez, David/D-2992-2012	Cates, Elizabeth/0000-0002-1138-6784; Fattouh, Ramzi/0000-0001-6573-6367				Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Daro E, 2002, CYTOKINE, V17, P119, DOI 10.1006/cyto.2001.0995; Delgado M, 2000, ANN NY ACAD SCI, V921, P68; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Gajewska BU, 2001, J CLIN INVEST, V108, P577, DOI 10.1172/JCI200112627; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363, DOI 10.1152/ajplung.2001.280.2.L363; Kaneko M, 2000, J ALLERGY CLIN IMMUN, V105, P1202, DOI 10.1067/mai.2000.106731; King C, 1998, J IMMUNOL, V161, P3645; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Magone MT, 2000, J ALLERGY CLIN IMMUN, V105, P299, DOI 10.1016/S0091-6749(00)90080-0; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; Masten BJ, 1999, J IMMUNOL, V162, P1310; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MerayoLloves J, 1996, J ALLERGY CLIN IMMUN, V97, P1129, DOI 10.1016/S0091-6749(96)70268-3; Miyazaki D, 2000, INVEST OPHTH VIS SCI, V41, P3850; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P317; Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336; Sur S, 1996, J IMMUNOL, V157, P4173; Sur S, 1999, J IMMUNOL, V162, P6284; Swirski FK, 2002, CLIN EXP ALLERGY, V32, P411, DOI 10.1046/j.1365-2222.2002.01291.x; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; Walker C, 1998, J IMMUNOL, V161, P1962; Whitcup SM, 1999, CLIN IMMUNOL, V93, P107, DOI 10.1006/clim.1999.4775; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512	39	48	49	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1076	1086		10.1067/mai.2003.1460	http://dx.doi.org/10.1067/mai.2003.1460			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743573				2022-12-18	WOS:000182904500023
J	Nakao, A; Sagara, H; Setoguchi, Y; Okada, T; Okumura, K; Ogawa, H; Fukuda, T				Nakao, A; Sagara, H; Setoguchi, Y; Okada, T; Okumura, K; Ogawa, H; Fukuda, T			Expression of Smad7 in bronchial epithelial cells is inversely correlated to basement membrane thickness and airway hyperresponsiveness in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transforming growth factor beta; Smad7; asthma; airway remodeling	GROWTH-FACTOR-BETA; GENE-EXPRESSION; I RECEPTORS; TENASCIN; FIBROSIS	Background: Smad7 is an intracellular antagonist of transforming growth factor beta (TGF-beta) signaling, which could determine the intensity or duration of the TGF-beta signal. Because TGF-beta has been implicated in the development of airway remodeling in asthma on the basis of its strong capacity to induce extracellular matrix production, it is possible that Smad7 also plays some roles in the regulation of the process. Objective: We sought to determine the relationships between Smad7 expression in bronchial biopsy samples from asthmatic subjects and clinicopathologic features. Methods: Bronchial biopsy specimens were obtained from 40 asthmatic subjects and 6 healthy control subjects. Expression levels of Smad7 on a histologic section were estimated by immunohistochemical staining. In addition, the roles of Smad7 in TGF-beta-mediated transcriptional responses were studied by in vitro studies. Results: Smad7 immunoreactivity was detected mainly in bronchial epithelial cells in control and asthmatic subjects. Interestingly, asthmatic subjects exhibited less Smad7 immunoreactivity in bronchial epithelial cells than normal subjects. Expression levels of Smad7 in bronchial epithelial cells were inversely correlated with basement membrane thickness and airway hyperresponsiveness in asthmatic subjects. In addition, abrogation of endogenous Smad7 expression through use of an antisense oligonucleotide enhanced transcriptional responses to TGF-beta, whereas overexpression of Smad7 inhibited TGF-beta-induced plasminogen activator inhibitor 1 production in a human bronchial epithelial cell line, BEAS2B cells. Conclusion: These findings suggest that Smad7 is a key molecule that defines the susceptibility of bronchial epithelial cells to TGF-beta action and that regulation of Smad7 expression in bronchial epithelial cells might be related to the development of airway remodeling and airway hyperresponsiveness in asthma.	Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Dokkyo Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan; Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University; Dokkyo Medical University; Juntendo University	Nakao, A (corresponding author), Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Setoguchi, Yasuhiro/AAE-1448-2021	Setoguchi, Yasuhiro/0000-0002-0892-6364				Brodin G, 1999, CANCER RES, V59, P2731; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GERWIN BI, 1990, AM J PHYSIOL, V259, pL262, DOI 10.1152/ajplung.1990.259.4.L262; Holgate S. T., 2001, Clinical and Experimental Allergy Reviews, V1, P59, DOI 10.1046/j.1472-9725.2001.00006.x; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LINNALA A, 1995, AM J RESP CELL MOL, V13, P578, DOI 10.1165/ajrcmb.13.5.7576694; Makino S, 2000, INT ARCH ALLERGY IMM, V121, P1; MAKINO S, 1984, JPN J ALLERGOL, V33, P167; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROCHE WR, 1989, LANCET, V1, P520; SETOGUCHI Y, 1994, BLOOD, V84, P2946; SPRENGERS ED, 1987, BLOOD, V69, P381; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066	25	48	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					873	878		10.1067/mai.2002.129236	http://dx.doi.org/10.1067/mai.2002.129236			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464953				2022-12-18	WOS:000179777400009
J	Teuber, SS; del Val, G; Morigasaki, S; Jung, HR; Eisele, PH; Frick, OL; Buchanan, BB				Teuber, SS; del Val, G; Morigasaki, S; Jung, HR; Eisele, PH; Frick, OL; Buchanan, BB			The atopic dog as a model of peanut and tree nut food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						canine; dog; food allergy; model; peanut; tree nut; walnut; Brazil nut	INTRADERMAL SKIN-TESTS; IMMUNOGLOBULIN-E; JUGLANS-REGIA; MURINE MODEL; RESPONSES; HYPERSENSITIVITY; IDENTIFICATION; PREVALENCE; PROTEINS; ALBUMIN	Background: Animal models are needed that mimic human IgE-mediated peanut and tree nut allergy. Atopic dogs have been previously used in a model of food allergy to cow's milk, beef, wheat, and soy, with the demonstration of specific IgE production and positive oral challenges similar to those seen in human subjects. Objective: We sought to sensitize dogs to peanut, walnut, and Brazil nut and to assess whether sensitization is accompanied by clinical reactions and whether there is cross-reactivity among the different preparations. Methods: Eleven dogs were sensitized subcutaneously by using an established protocol with 1 mug each of peanut, English walnut, or Brazil nut protein extracts in alum first at birth and then after modified live virus vaccinations at 3, 7, and 11 weeks of age. The dogs were sensitized to other allergens, including soy and either wheat or barley. Intradermal skin tests, IgE immunoblotting to nut proteins, and oral challenges were performed with ground nut preparations. Results: At 6 months of age, the dogs' intradermal skin test responses were positive to the nut extracts. IgE immunoblotting to peanut, walnut, and Brazil nut showed strong recognition of proteins in the aqueous preparations. Each of the 4 peanut- and the 3 Brazil nut-sensitized dogs and 3 of the 4 walnut-sensitized dogs reacted on oral challenge with the corresponding primary immunogen at age 2 years. None of the peanut-sensitized dogs reacted clinically with walnut or Brazil nut challenges. One of the walnut-sensitized dogs had delayed (overnight) vomiting to Brazil nut. Conclusions: On the basis of measurements of the mean amount of allergen eliciting a skin test response in dogs, the hierarchy of reactivity by skin testing is similar to the clinical experience in human subjects (peanut > tree nuts > wheat soy > barley). Cross-reactivity, which was not apparent between soy and peanut or tree nuts or between peanut and tree. nuts, was slight between walnut and Brazil nut. The results give further support to the dog as a model of human food allergy.	Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Davis, Sch Vet Med, Anim Resource Serv, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Pediat, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Davis; University of California System; University of California San Francisco	Teuber, SS (corresponding author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Dept Internal Med, 1 Shields Ave-TB 192, Davis, CA 95616 USA.		Morigasaki, Susumu/Q-6981-2017	Morigasaki, Susumu/0000-0002-6938-5119				Bartolome B, 1997, Allergol Immunopathol (Madr), V25, P135; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; Dearman RJ, 2000, FOOD CHEM TOXICOL, V38, P351, DOI 10.1016/S0278-6915(99)00159-3; del Val G, 1999, J ALLERGY CLIN IMMUN, V103, P690, DOI 10.1016/S0091-6749(99)70244-7; ELWOOD CM, 1994, J SMALL ANIM PRACT, V35, P199, DOI 10.1111/j.1748-5827.1994.tb01689.x; Ermel RW, 1997, LAB ANIM SCI, V47, P40; FAO/WHO, 2001, EV ALL GEN MOD FOODS; Helm RM, 2002, J ALLERGY CLIN IMMUN, V109, P136, DOI 10.1067/mai.2002.120551; HOGAN MB, 1994, J LAB CLIN MED, V123, P899; Houben GF, 1997, ENVIRON TOXICOL PHAR, V4, P127, DOI 10.1016/S1382-6689(97)10053-9; Ito K, 1997, EUR J IMMUNOL, V27, P3427, DOI 10.1002/eji.1830271243; Knippels LMJ, 2000, ALLERGY, V55, P251, DOI 10.1034/j.1398-9995.2000.00403.x; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; MAPP C, 1985, AM REV RESPIR DIS, V132, P292; Mueller RS, 2000, AUST VET J, V78, P392, DOI 10.1111/j.1751-0813.2000.tb11824.x; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; PATERSON S, 1995, J SMALL ANIM PRACT, V36, P529, DOI 10.1111/j.1748-5827.1995.tb02803.x; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; STURE GH, 1995, VET IMMUNOL IMMUNOP, V44, P293, DOI 10.1016/0165-2427(94)05306-D; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1; Vaden SL, 2000, J VET INTERN MED, V14, P60, DOI 10.1892/0891-6640(2000)014&lt;0060:FHRISC&gt;2.3.CO;2	26	48	56	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					921	927		10.1067/mai.2002.130056	http://dx.doi.org/10.1067/mai.2002.130056			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464960				2022-12-18	WOS:000179777400016
J	Roumestan, C; Henriquet, C; Johnson, M; Demoly, P; Bousquet, J; Mathieu, M				Roumestan, C; Henriquet, C; Johnson, M; Demoly, P; Bousquet, J; Mathieu, M			Relative transactivation and transrepression potencies of fluticasone propionate (FP) and mometasone furoate (MF)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									INSERM, Montpellier 5, France; Hosp Arnaud Villeneuve, Montpellier 5, France; GlaxoSmithKline, Uxbridge, Middx, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; GlaxoSmithKline			Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Demoly, Pascal/0000-0001-7827-7964; 					0	48	49	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1		S		731	S240	S241		10.1016/S0091-6749(02)81866-8	http://dx.doi.org/10.1016/S0091-6749(02)81866-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519UX					2022-12-18	WOS:000173744800728
J	Vancheri, C; Mastruzzo, C; Armato, F; Tomaselli, V; Magri, S; Pistorio, MP; LaMicela, M; D'Amico, L; Crimi, N				Vancheri, C; Mastruzzo, C; Armato, F; Tomaselli, V; Magri, S; Pistorio, MP; LaMicela, M; D'Amico, L; Crimi, N			Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; allergy; ECP; eosinophils; heparin; nasal lavages	INHALED HEPARIN; P-SELECTIN; ANTIGEN CHALLENGE; VCAM-1 EXPRESSION; ENDOTHELIAL-CELLS; CATIONIC PROTEIN; TIME-COURSE; INFLAMMATION; RESPONSES; ASTHMA	Background: Recently, several studies have shown that heparin possesses various anti-inflammatory and antiallergic properties, It has been proposed that heparin might play an important role in limiting the inflammatory events associated with asthma and allergic rhinitis by neutralizing inflammatory mediators, such as eosinophil cationic protein and major basic protein, and by limiting eosinophil recruitment. Objective: To test the hypothesis that heparin can limit the extent and magnitude of eosinophilic inflammation, we examined the effect of inhaled intranasal heparin on nasal response to allergen challenge in 10 patients with allergic rhinitis. Methods: The capacity of heparin to reduce nasal response was studied by evaluating symptom score, eosinophil cationic protein concentration, and eosinophil counts in nasal lavage fluids 10, 60, and 360 minutes after allergen challenge. Results: Pretreatment with intranasal heparin produced a significant reduction in symptom score 10 minutes after allergen challenge and reduced the eosinophil influx at each time point after antigen challenge, statistical significance being reached 60 and 360 minutes after allergen challenge. Similarly, the amount of eosinophil cationic protein in the nasal wash was reduced at each time point; this reached statistical significance 360 minutes after allergic challenge. Conclusion: Heparin was shown to provide protection with respect to nasal allergen challenge. The mechanism by which heparin produces its protective activity seems to be related to the neutralization of cosinophil cationic protein as well as to the reduction of cosinophil recruitment.	Univ Catania, Inst Resp Dis, I-95125 Catania, Italy	University of Catania	Vancheri, C (corresponding author), Univ Catania, Inst Resp Dis, Via Passo Gravina 187, I-95125 Catania, Italy.		Crimi, Nunzio/AAL-2994-2020; VANCHERI, Carlo/K-9417-2016	Crimi, Nunzio/0000-0002-8591-4535; VANCHERI, Carlo/0000-0002-5120-9926				AHMED T, 1992, AM REV RESPIR DIS, V145, P566, DOI 10.1164/ajrccm/145.3.566; AHMED T, 1994, J APPL PHYSIOL, V76, P893, DOI 10.1152/jappl.1994.76.2.893; AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; BARCHET C, 1999, INT ARCH ALLERGY IMM, V118, P375; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160, DOI 10.1164/ajrccm/147.1.160; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790, DOI 10.1164/ajrccm.153.6.8665036; EKRE HPT, 1986, INT J IMMUNOPHARMACO, V8, P277, DOI 10.1016/0192-0561(86)90109-8; FREDENS K, 1991, ALLERGY, V46, P27, DOI 10.1111/j.1398-9995.1991.tb00538.x; Garrigo J, 1996, AM J RESP CRIT CARE, V153, P1702, DOI 10.1164/ajrccm.153.5.8630624; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; KANWAR S, 1996, EUR SURG RES, V28, P428; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; Lipscombe RJ, 1998, J LEUKOCYTE BIOL, V63, P342, DOI 10.1002/jlb.63.3.342; LUCIO J, 1992, J APPL PHYSIOL, V73, P1093, DOI 10.1152/jappl.1992.73.3.1093; MATZNER Y, 1984, THROMB HAEMOSTASIS, V52, P134; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MENG H, 1995, J CELL PHYSIOL, V165, P40, DOI 10.1002/jcp.1041650106; NELSON RM, 1993, BLOOD, V82, P3253; PAGE CP, 1993, AGENT ACTION SUPPL, V41, P13; PEDERSEN B, 1995, ALLERGY, V50, P794; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; Polosa R, 1997, J ALLERGY CLIN IMMUN, V99, P338, DOI 10.1016/S0091-6749(97)70051-4; Preuss JMH, 2000, BRIT J PHARMACOL, V129, P1585, DOI 10.1038/sj.bjp.0703247; Ricca V, 2000, J ALLERGY CLIN IMMUN, V105, P54, DOI 10.1016/S0091-6749(00)90177-5; Saito H, 1996, INT ARCH ALLERGY IMM, V111, P126, DOI 10.1159/000237357; SEEDS EAM, 1993, J LIPID MEDIATOR, V7, P269; Seeds EAM, 1995, PULM PHARMACOL, V8, P97, DOI 10.1006/pulp.1995.1012; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; TEIXEIRA MM, 1993, BRIT J PHARMACOL, V110, P1496, DOI 10.1111/j.1476-5381.1993.tb13991.x; TYRELL DJ, 1995, TRENDS PHARMACOL SCI, V16, P198; WANG D, 1995, ALLERGY, V50, P147; WRIGHT TC, 1983, J CELL PHYSL, V124, P21	36	48	51	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					703	708		10.1067/mai.2001.118785	http://dx.doi.org/10.1067/mai.2001.118785			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692092				2022-12-18	WOS:000172523800007
J	Barnes, PJ				Barnes, PJ			Cytokine-directed therapies for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; asthma; eosinophil; IL-4; cytokine	ALLERGIC DISEASE; CROHNS-DISEASE; INTERLEUKIN-10; EOSINOPHILIA; INFLAMMATION; EXPRESSION; ANTIBODY; MICE	Increasing knowledge of the pathophysiologic roles of various cytokines in atopic diseases has provided the basis for the development of novel therapies. Strategic approaches for cytokine inhibition include the blocking of transcription factors that lead to their expression. blockade after their release, cytokine receptor antagonism, and the inhibition of signaling pathways that are activated after cytokine-receptor binding. The proinflammatory cytokines IL-5, IL-4, IL-13, and TNF-a are among the therapeutic targets. Results with a humanized anti-IL-5 have been disappointing. Although successful in markedly reducing circulating eosinophils and in preventing eosinophil accumulation in airways, the humanized anti-IL-5 was unable to affect early or late responses to allergen or to reduce airway reactivity to methacholine challenge in patients with asthma. On the other hand, a soluble IL-4 receptor antagonist has shown clinical benefits for patients with moderate asthma who ho require daily inhaled corticosteroids. Agents that target IL-13 and TNF-alpha remain to be evaluated in asthmatic inflammation. The use of cytokines with anti-inflammatory effects may also have therapeutic value. The evaluation of Such agents in human beings. including IL-10, IL-12, and IFN-gamma, is at a preliminary stage, but so far results have not been encouraging.	Natl Heart & Lung Inst, Div Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Natl Heart & Lung Inst, Div Thorac Med, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				Barnes PJ, 1998, PHARMACOL REV, V50, P515; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Egan RW, 1996, ALLERGY, V51, P71, DOI 10.1111/j.1398-9995.1996.tb00038.x; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Foster PS, 1999, CLIN EXP ALLERGY, V29, P12; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kim TS, 1997, J IMMUNOL, V158, P4137; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leonard JP, 1997, BLOOD, V90, P2541; Li L, 1999, J IMMUNOL, V162, P2477; Losman JA, 1999, J IMMUNOL, V162, P3770; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; Shi HZ, 1997, AM J RESP CELL MOL, V16, P220, DOI 10.1165/ajrcmb.16.3.9070605; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YATES DH, 1993, AM REV RESPIR DIS, V147, pA1011; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	26	48	57	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2		S			S72	S76		10.1067/mai.2001.116435	http://dx.doi.org/10.1067/mai.2001.116435			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	466VB	11498676				2022-12-18	WOS:000170665900002
J	Boner, AL				Boner, AL			Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adrenal corticotropic hormone; beclamethasone dipropionate; cortisol; flunisolide; fluticasone propionate; corticosteroid; intranasal corticosteroid; hypothalamus; mometasone furoate; triamcinolone acetonide	AQUEOUS NASAL SPRAY; SEASONAL ALLERGIC RHINITIS; URINARY FREE CORTISOL; LONG-TERM SAFETY; TRIAMCINOLONE ACETONIDE; BECLOMETHASONE DIPROPIONATE; INHALED CORTICOSTEROIDS; ADRENOCORTICAL FUNCTION; FLUTICASONE PROPIONATE; GLUCOCORTICOID THERAPY	In adults, morning plasma cortisol levels are twice that of late afternoon and evening values. In children, a delay in the time of onset in peak cortisol levels has been observed in those treated with inhaled corticosteroids. Consequently, the single morning cortisol level has a low sensitivity for detecting adrenal insufficiency in children. It is not clear which test is best for detection of clinically relevant hypothalamic-pituitary-adrenal (HPA) axis suppression in children; 24-hour plasma cortisol is a good test because it measures biologically active, free cortisol levels for the entire day and is noninvasive. For research purposes, the 24-hour integrated concentration plasma cortisol test Is preferred. Studies that have looked at HPA axis suppression with intranasal corticosteroids indicate that overall, intranasal corticosteroids have minimal effect on the HPA axis. A review of the literature reveals one study in which there was a decreased output of urinary cortisol during treatment with either budesonide or fluticasone propionate in adults. Other studies of fluticasone propionate or budesonide have shown no effect on the HPA axis in children. Beclomethasone dipropionate was shown to affect urinary cortisol output in one study of healthy volunteers. However, in a long-term study in children, no effect on the HPA axis was found. Mometasone furoate has been extensively studied in more than 20 trials of adults and children. No effects on the HPA axis were detected in either children or adults. It is unlikely that children are more sensitive to corticosteroids than are adults. There seems to be little point in performing routine monitoring of adrenal function in children who are treated with intranasal corticosteroid treatment.	Policlin Borgo Roma, Pediat Clin, I-37134 Verona, Italy; Univ Verona, Dept Pediat, I-37100 Verona, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona	Boner, AL (corresponding author), Policlin Borgo Roma, Pediat Clin, Viale Menegone, I-37134 Verona, Italy.							Agertoft L, 1993, Pediatr Allergy Immunol, V4, P152, DOI 10.1111/j.1399-3038.1993.tb00084.x; Allen ED, 1997, PEDIATR PULM, V24, P397, DOI 10.1002/(SICI)1099-0496(199712)24:6<397::AID-PPUL4>3.0.CO;2-E; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; CHALEW SA, 1990, J CLIN ENDOCR METAB, V71, P952, DOI 10.1210/jcem-71-4-952; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; Davies RJ, 1997, CLIN THER, V19, P27; EDELMAN DA, 1996, RESP CARE, V11, P1025; FEISS G, 1992, J ALLERGY CLIN IMMUN, V89, P1151, DOI 10.1016/0091-6749(92)90299-H; FIREMAN P, 1991, TODAYS THERAPEUTIC T, V9, P21; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; GALANT SP, 1994, J PEDIATR-US, V125, P628; GROSSMAN J, 1993, PEDIATRICS, V92, P594; HARRISON BDW, 1982, CLIN ENDOCRINOL, V17, P109, DOI 10.1111/j.1365-2265.1982.tb01570.x; HOLT PR, 1990, CLIN EXP ALLERGY, V20, P145, DOI 10.1111/j.1365-2222.1990.tb02659.x; HONOUR JW, 1994, RESP MED, V88, P9, DOI 10.1016/S0954-6111(05)80035-6; Howland WC, 1996, CLIN EXP ALLERGY, V26, P18, DOI 10.1111/j.1365-2222.1996.tb00654.x; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; KAMADA AK, 1992, PEDIATR PULM, V12, P71, DOI 10.1002/ppul.1950120202; KIMMERLE R, 1985, AM J MED, V79, P535, DOI 10.1016/0002-9343(85)90046-4; KNUTSSON U, 1995, J ENDOCRINOL, V144, P301, DOI 10.1677/joe.0.1440301; Kokron CM, 1997, J INVEST ALLERG CLIN, V7, P51; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; LAW CM, 1986, LANCET, V1, P942; LINDQVIST N, 1986, ALLERGY, V41, P179, DOI 10.1111/j.1398-9995.1986.tb00298.x; Lipworth BJ, 1998, J ALLERGY CLIN IMMUN, V101, pS8; Lipworth BJ, 1997, THORAX, V52, P476, DOI 10.1136/thx.52.5.476; MCINTYRE HD, 1995, THORAX, V50, P1280, DOI 10.1136/thx.50.12.1280; *MED CONTR AG, 1998, SAF INH NAS CORT PIN; Meltzer EO, 1998, CLIN PEDIATR, V37, P1, DOI 10.1177/000992289803700101; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157, DOI 10.1016/S0091-6749(98)70379-3; ORTH DN, 1998, WILLIAMS TXB ENDOCRI, P517; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; PEDERSEN SE, 1997, INHALED GLUCOCORTICO, P551; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PRAHL P, 1987, ALLERGY, V42, P541, DOI 10.1111/j.1398-9995.1987.tb00379.x; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V69, P208, DOI 10.1016/0091-6749(82)90101-4; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; STAUB JJ, 1979, CLIN ENDOCRINOL, V10, P595, DOI 10.1111/j.1365-2265.1979.tb02119.x; STEWART PM, 1988, LANCET, V1, P1208; Synnerstad B, 1996, BRIT J CLIN PRACT, V50, P363; TINKELMAN D, 1990, ANN ALLERGY, V64, P234; TOOGOOD JH, 1982, CLIN ALLERGY, V12, P95, DOI 10.1111/j.1365-2222.1982.tb03131.x; WELCH MJ, 1994, CLIN THER, V16, P253; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; Wilson AM, 1998, J CLIN ENDOCR METAB, V83, P922, DOI 10.1210/jc.83.3.922; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; WURTHWEIN G, 1990, BIOPHARM DRUG DISPOS, V11, P381, DOI 10.1002/bdd.2510110503; ZADIK Z, 1980, J CLIN ENDOCR METAB, V51, P1099, DOI 10.1210/jcem-51-5-1099	59	48	52	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S32	S39		10.1067/mai.2001.115564	http://dx.doi.org/10.1067/mai.2001.115564			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449204				2022-12-18	WOS:000170230600006
J	Zou, X; Block, M; Lofman, C; Nilsson, G				Zou, X; Block, M; Lofman, C; Nilsson, G			IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; cross-linkage; degranulation; Fc epsilon RI; IgE; mast cells; regranulation; time-lapse photography	RELEASE	Background: Mast cells are long-lived resident cells that are of great importance in an allergic reaction. It has previously been suggested that after IgE-mediated degranulation mast cells can undergo regranulation. Such a process is probably of great importance with respect to the severity and perpetuation of the allergic response. Objective: Our purpose was to investigate whether mast cells recover from degranulation and whether they still have the potential to release a granule-associated mediator and upregulate certain cytokine genes. Methods: Mouse mast cells were repeatedly activated by IgE and specific antigen with a 24-hour or 48-hour interval. During each of the 2 activation stages, release of beta -hexosaminidase was measured by means of enzymatic colorimetric analysis, and IL-13 and IL-6 mRNA was detected by ribonuclease protection assay. Both scanning electron microscopy and time-lapse photography were used to reveal the process of mast cell recovery. Results: We found that re-activation of degranulated mast cells in response to high-affinity IgE-receptor cross-linkage triggers beta -hexosaminidase release and upregulation of IL-13 and IL-6 gene expression levels similar to what is seen in the initial activation. Scanning electron microscopy documented cells at various stages during the recovery process 30 minutes after the activation. With time-lapse photography, a single cell that had undergone degranulation could be visualized consecutively during its recovery process. Conclusion: Mast cells can recover after an IgE-mediated activation and can repeatedly release beta -hexosaminidase and express IL-6 and IL-13 mRNA after re-activation.	Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Res Grp Mast Cell Biol, SE-75185 Uppsala, Sweden; Uppsala Univ, Biol Microscopy & Imaging Unit, SE-75185 Uppsala, Sweden; Uppsala Univ, Dept Anim Dev & Genet, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Nilsson, G (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Res Grp Mast Cell Biol, SE-75185 Uppsala, Sweden.			Nilsson, Gunnar/0000-0001-6795-5512; Xiang, Zou/0000-0003-3925-0296				ARORA N, 1993, INT ARCH ALLERGY IMM, V100, P319, DOI 10.1159/000236432; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; BURWEN SJ, 1982, TISSUE CELL, V14, P125, DOI 10.1016/0040-8166(82)90012-X; DVORAK AM, 1987, CELL IMMUNOL, V105, P199, DOI 10.1016/0008-8749(87)90068-2; DVORAK AM, 1986, LAB INVEST, V54, P663; Gagari E, 1997, BLOOD, V89, P2654, DOI 10.1182/blood.V89.8.2654; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; KOBAYASI T, 1969, ACTA DERM-VENEREOL, V49, P369; Kurosawa M, 1998, CLIN EXP ALLERGY, V28, P1007; Lofman C, 1997, NAT MED, V3, P930, DOI 10.1038/nm0897-930; NILSSON G, 1999, INFLAMMATION BASIC P, P97; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Xiang Z, 2000, CLIN EXP ALLERGY, V30, P1379, DOI 10.1046/j.1365-2222.2000.00906.x	15	48	50	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					116	121						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447391				2022-12-18	WOS:000170171200016
J	Aihara, Y; Kotoyori, T; Takahashi, Y; Osuna, H; Ohnuma, S; Ikezawa, Z				Aihara, Y; Kotoyori, T; Takahashi, Y; Osuna, H; Ohnuma, S; Ikezawa, Z			The necessity for dual food intake to provoke food-dependent exercise-induced anaphylaxis (FEIAn): A case report of FEIAn with simultaneous intake of wheat and umeboshi	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food-dependent exercise-induced anaphylaxis; wheat; umeboshi; dual food challenge; histamine release test; cromolyn sodium; forced expiratory volume	DISODIUM-CROMOGLYCATE; SODIUM CROMOGLYCATE; PHYSICAL ALLERGY; CHILDREN; RELEASE; FORM	Background: Food-dependent exercised-induced anaphylaxis (FEIAn) is classified among the physical allergies, Many different food allergens have been reported, but the pathophysiology of FEIAn remains unknown. Furthermore, provocation tests with a suspected food do not always succeed in patients with FEIAn, Objective: We sought to clarify and investigate causative foods and mechanisms of FEIAn in a 14-year-old boy, In addition, we tested in vivo and in vitro effects of cromolyn sodium in the same patient. Methods: We used open challenge tests for the provocation of FEIAn and measured changes in plasma histamine levels and FEV1, In addition, we investigated the mechanism of FEIAn in this case with in vitro histamine release testing. Results: The patient was diagnosed as having FEIAn by provocation testing with a simultaneous intake of wheat and ume-boshi, but not when each food was eaten singly, followed by exercise. In addition, his plasma histamine level increased transiently and forced expiratory volume I, expressed as a percentage change from baseline, decreased significantly, A synergistic effect on in vitro histamine release testing with 2 kinds of the causative foods was shown. Administration of cromolyn sodium proved to be effective on both the in vitro and in vivo tests, Conclusion: This is the first report of FEIAn provoked by the test with a simultaneous intake of 2 kinds of food. This case might in part explain negative challenge test results in patients with FEIAn.	Yokohama City Univ, Med Ctr, Dept Pediat, Minami Ku, Yokohama, Kanagawa 2320024, Japan; Yokohama City Univ, Med Ctr, Dept Dermatol, Minami Ku, Yokohama, Kanagawa 2320024, Japan	Yokohama City University; Yokohama City University	Aihara, Y (corresponding author), Yokohama City Univ, Med Ctr, Dept Pediat, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.							ANDRE F, 1991, ALLERGY PROC, V12, P293, DOI 10.2500/108854191778879142; BROSTOFF J, 1979, LANCET, V1, P1268; BRUCE R A, 1963, Pediatrics, V32, P742; BUCHBINDER EM, 1983, JAMA-J AM MED ASSOC, V250, P2973, DOI 10.1001/jama.250.21.2973; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI 10.1016/0091-6749(88)90185-6; Caffarelli C, 1996, J ALLERGY CLIN IMMUN, V98, P762, DOI 10.1016/S0091-6749(96)70125-2; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Drebotg S, 1989, ALLERGY S10, V44, P22; FUKUTOMI O, 1992, ANN ALLERGY, V68, P438; GRANT JA, 1985, ANN ALLERGY, V54, P35; Hanakawa Y, 1998, BRIT J DERMATOL, V138, P898; IWASAKI E, 1982, YAKURI CHIRYO, V10, P2919; JUJI F, 1994, ANN ALLERGY, V72, P452; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; OBATA T, 1989, Acta Paediatrica Japonica, V31, P340; ORR T S C, 1970, Clinical and Experimental Immunology, V7, P745; ORR TSC, 1969, NATURE, V223, P197, DOI 10.1038/223197b0; PAPAGEORGIOU N, 1983, J ALLERGY CLIN IMMUN, V72, P75, DOI 10.1016/0091-6749(83)90055-6; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; Romano A, 1997, INT ARCH ALLERGY IMM, V113, P505, DOI 10.1159/000237629; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; VERBOV J, 1985, DERMATOLOGICA, V171, P60, DOI 10.1159/000249390	29	48	50	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1100	1105		10.1067/mai.2001.115627	http://dx.doi.org/10.1067/mai.2001.115627			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398092				2022-12-18	WOS:000169454800026
J	Geha, RS; Beiser, A; Ren, C; Patterson, R; Greenberger, PA; Grammer, LC; Ditto, AM; Harris, KE; Shaughnessy, MA; Yarnold, PR; Corren, J; Saxon, A				Geha, RS; Beiser, A; Ren, C; Patterson, R; Greenberger, PA; Grammer, LC; Ditto, AM; Harris, KE; Shaughnessy, MA; Yarnold, PR; Corren, J; Saxon, A			Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monosodium glutamate; monosodium glutamate symptom complex; sensitivity to food additives	FOOD-ADDITIVES; ASTHMA	Background: The frequency of reactions reported to occur after the consumption of monosodium glutamate (MSG) is the subject of controversy. Objective: We conducted a multicenter, multiphase, double-blind, placebo-controlled study with a crossover design to evaluate reactions reportedly caused by MSG. Methods: In 3 of 4 protocols (A, B, acid C), MSG was administered without Food. A positive response was scored if the subject reported 2 or more symptoms from a list of 10 symptoms reported to occur after ingestion of MSG-containing foods within 2 hours. In protocol A 130 self-selected reportedly MSG-reactive volunteers were challenged with 5 g of MSG and with placebo on separate days (days 1 and 2), Of the 86 subjects who reacted to MSG, placebo, or both in protocol A, 69 completed protocol B to determine whether the response was consistent and dose dependent. To further examine the consistency and reproducibility of reactions to MSG, 12 of the 19 subjects who responded to 5 g of MSG but not to placebo in both protocols A and B were given, in protocol C, 2 challenges, each consisting of 5 g of MSG versus placebo. Results: Of 130 subjects in protocol A, 50 (38.5%) responded to MSG only, 17 (13.1%) responded to placebo only (P <.05), and 19 (14.6%) responded to both. Challenge with increasing doses of MSG in protocol B was associated with increased response rates. Only half (n = 19) of 37 subjects who reacted to 5 g of MSG but not placebo in protocol A reacted similarly in protocol B, suggesting inconsistency in the response. Two of the 19 subjects responded in both challenges to MSG but not placebo in protocol C; however, their symptoms were not reproducible in protocols A through C. These 2 subjects were challenged in protocol D 3 times with placebo and 3 times with 5 g of MSG in the presence of food. Both responded to only one of the MSG challenges in protocol D. Conclusion: The results suggest that large doses of MSG given without food may elicit more symptoms than a placebo in individuals who believe that they react adversely to MSG. However, neither persistent nor serious effects from MSG ingestion are observed, and the responses were not consistent on retesting.	Childrens Hosp, Div Immunol, Boston, MA 02178 USA; Harvard Univ, Dept Pediat, Boston, MA 02115 USA; Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA; Northwestern Univ, Div Allergy, Chicago, IL 60611 USA; Northwestern Univ, Div Gen Med, Chicago, IL 60611 USA; Univ Calif Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston University; Northwestern University; Northwestern University; University of California System; University of California Los Angeles	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02178 USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Grammer, Leslie/0000-0001-6860-2014; Yarnold, Paul/0000-0002-1648-739X; Beiser, Alexa/0000-0001-8551-7778				ALLEN DH, 1987, J ALLERGY CLIN IMMUN, V80, P530, DOI 10.1016/0091-6749(87)90003-0; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; *FOOD DRUG ADM, 1996, FDA MED B       0103; GANN D, 1977, SOUTHERN MED J, V70, P879, DOI 10.1097/00007611-197707000-00036; KENNEY RA, 1986, FOOD CHEM TOXICOL, V24, P351, DOI 10.1016/0278-6915(86)90014-1; KENNEY RA, 1972, AM J CLIN NUTR, V25, P140; KENNEY RA, 1976, GLUTAMIC ACID ADV BI, P363; KWOK RHM, 1968, NEW ENGL J MED, V278, P796; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; RAITEN DJ, 1995, FEDERATION AM SOC EX, P1; RATNER D, 1984, ISRAEL J MED SCI, V20, P252; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; SCHAUMBURG HH, 1969, SCIENCE, V163, P826, DOI 10.1126/science.163.3869.826; VANBEVER HP, 1989, ALLERGY, V44, P588; WILKIN JK, 1986, J AM ACAD DERMATOL, V15, P225, DOI 10.1016/S0190-9622(86)70161-8; Woessner KM, 1999, J ALLERGY CLIN IMMUN, V104, P305, DOI 10.1016/S0091-6749(99)70371-4; Yang WH, 1997, J ALLERGY CLIN IMMUN, V99, P757, DOI 10.1016/S0091-6749(97)80008-5	17	48	50	3	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					973	980		10.1067/mai.2000.110794	http://dx.doi.org/10.1067/mai.2000.110794			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080723				2022-12-18	WOS:000167865200025
J	Horner, AA; Nguyen, MD; Ronaghy, A; Cinman, N; Verbeek, S; Raz, E				Horner, AA; Nguyen, MD; Ronaghy, A; Cinman, N; Verbeek, S; Raz, E			DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; gene vaccination; immunostimulatory sequence oligodeoxynucleotides; CpG motifs; immunotherapy	IMMUNOSTIMULATORY DNA; AIRWAY HYPERRESPONSIVENESS; CPG OLIGODEOXYNUCLEOTIDES; DEFICIENT MICE; PEANUT ALLERGY; MURINE MODEL; IMMUNOTHERAPY; INFLAMMATION; IMMUNIZATION; SEQUENCES	Background: Anaphylactic hypersensitivity is the most serious clinical concern facing allergists. However, for the majority of anaphylactic hypersensitivities, avoidance is the only therapeutic option presently available. Objective: This study evaluated the effectiveness of primary gene and protein-immunostimulatory DNA vaccination in the prevention of anaphylactic hypersensitivity in a murine model. Methods: Female C3H/HeJ mice were immunized with a plasmid encoding beta-galactosidase (beta-gal) or beta-gal protein plus an immunostimulatory sequence oligodeoxynucleotide. The mice were then T-H2 sensitized to beta-gal by coinjection with alum and pertussis and then intravenously challenged with this model allergen, Results: Primary gene and protein-immunostimulatory DNA vaccination of subsequently T-H2-sensitized mice reduced the risk of death after anaphylactic challenge from 100% to 674 and 58%, respectively (P < .018 vs control mice). In addition, gene and protein-immunostimulatory DNA vaccination reduced postchallenge plasma histamine levels by greater than 4-fold (P < .05 vs control mite), Consistent with previous studies, these DNA-based vaccination strategies were further shown to blunt the development of T-H2-biased immune responses after allergen sensitization. Vaccination with protein alone, the experimental equivalent of a traditional immunotherapy reagent, provided no protection from anaphylaxis nor did it prevent the development of a T-H2-biased immune profile after allergen sensitization. Conclusion: The present series of experiments demonstrate that both gene vaccination and coimmunization with protein and immunostimulatory DNA are effective in attenuating the development of anaphylactic hypersensitivity in subsequently T-H2 sensitized mice.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	University of California System; University of California San Diego; University of California System; University of California San Diego; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI40682, AI01490] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001490, P01AI040682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Broide D, 1998, J IMMUNOL, V161, P7054; COFFMAN RL, 1988, MONOGR ALLERGY, V24, P96; Davis HL, 1998, J IMMUNOL, V160, P870; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GRAFT DF, 1993, BRONCHIAL ASTHMA, P934; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Horner AA, 1998, CELL IMMUNOL, V190, P77, DOI 10.1006/cimm.1998.1400; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1997, J IMMUNOL, V158, P3635; Kohama Y, 1999, J ALLERGY CLIN IMMUN, V104, P1231, DOI 10.1016/S0091-6749(99)70018-7; Li XM, 1999, J IMMUNOL, V162, P3045; MARQUARDT DL, 1993, ALLERGY PRINCIPLES P, P1525; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; OVARY Z, 1970, IMMUNOLOGY, V19, P715; Raz E, 1998, ASTHMA AND ALLERGIC DISEASES, P417, DOI 10.1016/B978-012473340-4/50034-5; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Slater J. E., 1997, Journal of Allergy and Clinical Immunology, V99, pS504; SORENSEN HT, 1989, ALLERGY, V44, P288, DOI 10.1111/j.1398-9995.1989.tb01071.x; Sur S, 1999, J IMMUNOL, V162, P6284	30	48	49	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					349	356		10.1067/mai.2000.107933	http://dx.doi.org/10.1067/mai.2000.107933			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932080				2022-12-18	WOS:000088708100019
J	Holt, PG; Rudin, A; Macaubas, C; Holt, BJ; Rowe, J; Loh, R; Sly, PD				Holt, PG; Rudin, A; Macaubas, C; Holt, BJ; Rowe, J; Loh, R; Sly, PD			Development of immunologic memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; children; T(H)1/T(H)2; vaccines; cytokines	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; EARLY-CHILDHOOD; ENVIRONMENTAL ALLERGENS; POSTNATAL MATURATION; INHALANT ALLERGENS; TH2 CELLS; SERUM IGE; INFANCY; RESPONSES	Background: Recent findings suggest that a hallmark of the atopic phenotype is reduced capacity to respond to vaccine antigens, as well as to environmental allergens, during infancy. This deficiency, which is most marked for the cytokine IFN-gamma, appears transient but can result in a long-lasting imbalance within T helper cell (T-H) memory responses to allergens. Indirect evidence suggests that parallel effects may occur within immunologic memory responses against vaccine antigens in atopic children. Objective: Our purpose was to compare vaccine antigen-specific T-H memory responses in atopic and nonatopic children. Methods: We analyzed specific serum IgG and cytokine responses to pertactin and tetanus antigens as well as to mitogen (PHA) and house dust mite (HDM) allergen in 25 HDM-sensitized atopic and 25 nonatopic 6-year-old children who were vaccinated and boosted with diphtheria-tetanus-pertussis (DTP) vaccine. Results: PBMCs from the atopic subjects produced higher levels of T(H)1 and T(H)2 cytokines to HDM allergen and PHA. Vaccine antibody titers were normal in the atopic subjects; vaccine-specific T(H)2 responses were rarely detectable, yet T(H)1 (IFN-gamma) responses, in particular against tetanus, were frequent and higher in the atopic subjects (121.5 [SE 64.3] vs 8.0 [3.5] pg/mL culture fluid, P = .04). Corresponding pertactin responses were comparable in both groups. Conclusions: At the completion of the full primer-booster DTP vaccination regimen, levels of vaccine-specific immunity in atopic 6-year-old children are at least equivalent to their nonatopic counterparts, indicating that the transient atopy-associated deficiency in T(H)1 function in childhood can be successfully overcome by appropriate vaccination and boosting regimens.	TVW Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; Univ Western Australia, Dept Microbiol, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Paediat, Nedlands, WA 6009, Australia; Univ Gothenburg, Dept Med Microbiol & Immunol, Gothenburg, Sweden; Princess Margaret Hosp Children, Dept Clin Immunol, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; University of Gothenburg; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.		Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Study, Raine/K-4517-2013	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Rudin, Anna/0000-0002-4137-1276				BYRON KA, 1994, CLIN EXP ALLERGY, V24, P878, DOI 10.1111/j.1365-2222.1994.tb01810.x; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; Pohl D, 1997, ALLERGY, V52, P732, DOI 10.1111/j.1398-9995.1997.tb01230.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, LANCET, V351, P1489, DOI 10.1016/S0140-6736(05)78871-1; Prescott SL, 1998, J IMMUNOL, V160, P4730; Randolph DA, 1999, J IMMUNOL, V162, P2375; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Ryan M, 1998, IMMUNOLOGY, V93, P1, DOI 10.1046/j.1365-2567.1998.00401.x; SCHAUER U, 1991, CLIN EXP IMMUNOL, V83, P25; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	33	48	48	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1117	1122		10.1067/mai.2000.105804	http://dx.doi.org/10.1067/mai.2000.105804			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856144				2022-12-18	WOS:000087781800011
J	Stellato, C; Atsuta, J; Bickel, CA; Schleimer, RP				Stellato, C; Atsuta, J; Bickel, CA; Schleimer, RP			An in vitro comparison of commonly used topical glucocorticoid preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; basophil; eosinophil; epithelial cells; allergy	BRONCHIAL EPITHELIAL-CELLS; BASOPHIL HISTAMINE-RELEASE; ANTI-INFLAMMATORY STEROIDS; EOSINOPHIL SURVIVAL; RESISTANT ASTHMA; T-CELLS; INHIBITION; METABOLISM; ACTIVATION; CYTOKINES	Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B. Methods: Cells were treated for 24 hours with increasing concentrations (range 10(-13) to 10(-6) mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge, HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry, Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR, Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP congruent to TAA ss HC, Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5-induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR, The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF a PP much greater than BUD > TAA > HC congruent to BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive, Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects.	Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA; Mie Natl Hosp, Tsu, Mie, Japan	Johns Hopkins University	Stellato, C (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355				Atsuta J, 1999, AM J RESP CELL MOL, V20, P643, DOI 10.1165/ajrcmb.20.4.3265; Atsuta J, 1997, AM J RESP CELL MOL, V17, P571, DOI 10.1165/ajrcmb.17.5.2685; BOCHNER BS, 1996, IMMUNOMODULATION ALL, P12; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; EDSBACKER S, 1997, INHALED GLUCOCORTICO, P381; GILBERT HS, 1975, BLOOD, V46, P279; GILLIS S, 1979, J IMMUNOL, V123, P1632; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; KARIN M, 1997, INHALED GLUCOCORTICO, P29; LAMAS AM, 1991, J IMMUNOL, V147, P254; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LOTTALARSSON E, 1980, J IMMUNOL, V124, P2828; *NAT ASTHM ED PROG, 1997, NIH PUBL; PROUD D, 1993, ASTHMA, P199; REDDEL RR, 1988, CANCER RES, V48, P1904; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1991, AM J RESP CELL MOL, V4, P166, DOI 10.1165/ajrcmb/4.2.166; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHLEIMER RP, 1992, J ASTHMA, V29, P303, DOI 10.3109/02770909209044790; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHLEIMER RP, 1997, TOPICAL GLUCOCORTICO, P203; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; SCHLEIMER RP, 1998, ALLERGY PRINCIPLES P, P638; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Spahn JD, 1996, J ALLERGY CLIN IMMUN, V98, P1073, DOI 10.1016/S0091-6749(96)80194-1; STELLATO C, 1997, ASTHMA, P1569; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; WALLEN N, 1991, J IMMUNOL, V147, P3490; WARNER JA, 1987, J IMMUNOL METHODS, V105, P107, DOI 10.1016/0022-1759(87)90419-4; WURTHWEIN G, 1990, BIOPHARM DRUG DISPOS, V11, P381, DOI 10.1002/bdd.2510110503	33	48	53	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				623	629		10.1016/S0091-6749(99)70334-9	http://dx.doi.org/10.1016/S0091-6749(99)70334-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482838				2022-12-18	WOS:000082870000026
J	Gauvreau, GM; Watson, RM; Rerecich, TJ; Baswick, E; Inman, MD; O'Byrne, PM				Gauvreau, GM; Watson, RM; Rerecich, TJ; Baswick, E; Inman, MD; O'Byrne, PM			Repeatability of allergen-induced airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen challenge; sputum eosinophils; reproducibility; sample size; anti-inflammatory therapy	INDUCED ASTHMATIC RESPONSES; MAJOR BASIC-PROTEIN; INDUCED SPUTUM; CHALLENGE; PHASE; EOSINOPHILS; ANTAGONIST; REPRODUCIBILITY; RESPONSIVENESS; CELLS	Background: Allergen inhalation challenge is a useful clinical model to investigate the effects of asthma therapies on allergen-induced airway responses; however, the repeatability of allergen-induced airway inflammation is not known. Objective: The purpose of this study was to investigate the repeatability of allergen-induced increases in sputum eosinophils. This information will allow the prediction of the number of subjects required in studies evaluating asthma therapies. Methods: Seventeen subjects completed 2 allergen challenges using the same dose of allergen, at least 3 weeks apart. Allergen-induced airway responses were measured for 7 hours after challenge. Differential cell counts from induced sputum were determined the day before and 7 and 24 hours after challenge; methacholine PC20 was measured the day before and 24 hours after challenge. Results: The intraclass correlation coefficient for maximum percent late fall in FEV1 was 0.32 and for the area of the late response was 0.61. The sample size predicted to be necessary to observe 50% attenuation of the maximum percent late fall in FEV1 and the late area under the curve with a power of 0.95 was 9 subjects. The intraclass correlation coefficient for percent of allergen-induced sputum eosinophils was 0.60 at 7 hours and 0.53 at 24 hours after challenge. With a randomized cross-over study design, the sample size predicted to be necessary to observe 50% attenuation of allergen-induced percent of eosinophils with a power of 0.95 was 5 subjects. Conclusion: Allergen inhalation challenge with measurements of sputum eosinophils is a noninvasive and reliable method for evaluating the anti-inflammatory effects of asthma therapies.	McMaster Univ, Hlth Sci Ctr, Dept Med, Asthma Res Grp, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	O'Byrne, PM (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Asthma Res Grp, Rm 3U-1,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			O'Byrne, Paul/0000-0003-0979-281X				AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282, DOI 10.1164/ajrccm/144.6.1282; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V151, pA397; FREITAG A, 1993, THORAX, V48, P594, DOI 10.1136/thx.48.6.594; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; MANNING PJ, 1991, EUR RESPIR J, V4, P667; Norman G., 2014, BIOSTATISTICS BARE E, V4; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Streiner DLNG, 1995, HLTH MEASUREMENT SCA, P104; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604, DOI 10.1164/ajrccm/146.3.604; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540	31	48	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					66	71		10.1016/S0091-6749(99)70115-6	http://dx.doi.org/10.1016/S0091-6749(99)70115-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400841				2022-12-18	WOS:000081738900010
J	Burastero, SE; Magnani, Z; Confetti, C; Abbruzzese, L; Oddera, S; Balbo, P; Rossi, GA; Crimi, E				Burastero, SE; Magnani, Z; Confetti, C; Abbruzzese, L; Oddera, S; Balbo, P; Rossi, GA; Crimi, E			Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation to autologous T-H2 lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; monocyte-macrophages; antigen presentation; costimulation; CD80; CD86	PERIPHERAL-BLOOD MONOCYTES; T-CELL PROLIFERATION; BRONCHIAL-ASTHMA; SELECTIVE RECRUITMENT; PRESENT ANTIGEN; LUNG; ACTIVATION; B7-2; RESPONSIVENESS; COSTIMULATION	Background: Alveolar macrophages (AMs) are more efficient antigen-presenting cells in allergic individuals than in nonatopic subjects. Objective: We studied whether this difference may be correlated to increased expression of membrane costimulatory molecules, such as the B7 molecules (CD80 and CD86). Methods: Eleven subjects with allergic asthma sensitized to Dermatoplagoides pteronyssinus and 5 healthy nonatopic volunteers underwent bronchoalveolar lavage, and the costimulatory molecule expression on AMs was evaluated. Peripheral blood T cells, either freshly isolated or as established D pteronyssinus-specific cell lines, were cultured with autologous monocytes or AMs as antigen-presenting cells. In vitro allergen-induced proliferation and cytokine production were evaluated in the presence of B7-blocking reagents. Results: Allergic individuals had a significantly higher proportion of AMs expressing the CD80 molecule than control subjects (28.5% +/- 14.8% vs 1.4% +/- 1.2%; P < .001), whereas no difference was observed in CD86 expression (2.0% +/- 2.3% vs 1.1% +/- 0.6; P > .1). In a large proportion of the asthmatic subjects we studied, AMs were presenting soluble antigens (tetanus toroid and streptolysin-O) to freshly isolated T cells more efficiently than AMs from nonatopic control subjects. Finally, both T-cell proliferation and cytokine production of D pteronyssinus-specific established T-cell lines were inhibited by a CD80-blocking antibody in a dose-dependent manner. Conclusion: Costimulation by means of CD80 expressed by AMs is probably involved in the amplification of the allergen-specific T-lymphocyte response in the airways of asthmatic subjects.	San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; G Gaslini Inst, Milan, Italy; Univ Genoa, Chair Resp Physiol, Genoa, Italy; Osped Gattinara, AOR 11, Vercelli, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Burastero, SE (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		, Burastero/AAN-2425-2020; Magnani, Zulma Irene/AAN-7588-2020	, Burastero/0000-0001-7302-6381; Magnani, Zulma Irene/0000-0001-7612-6097				Agea E, 1998, CLIN EXP ALLERGY, V28, P1359; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P224; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; Bezdicek P, 1997, LUNG SCI FDN, V1, P859; Borgonovo B, 1997, J ALLERGY CLIN IMMUN, V100, P669, DOI 10.1016/S0091-6749(97)70172-6; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; Burastero SE, 1998, CLIN IMMUNOL IMMUNOP, V89, P110, DOI 10.1006/clin.1998.4589; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; Fleischer J, 1996, IMMUNOLOGY, V89, P592, DOI 10.1046/j.1365-2567.1996.d01-785.x; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GANT V, 1992, AM REV RESPIR DIS, V146, P900, DOI 10.1164/ajrccm/146.4.900; GANT VA, 1991, CLIN EXP IMMUNOL, V86, P494; Gause WC, 1997, IMMUNOL TODAY, V18, P115, DOI 10.1016/S0167-5699(97)01005-0; HANCE AJ, 1997, LUNG SCI FDN, V1, P821; Harris N, 1997, J EXP MED, V185, P177, DOI 10.1084/jem.185.1.177; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; INA Y, 1991, EUR RESPIR J, V4, P88; LANE P, 1993, IMMUNOLOGY, V80, P56; LEM VM, 1985, J IMMUNOL, V135, P1766; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LIPSCOMB MF, 1982, J IMMUNOL, V128, P111; LYONS CR, 1983, J IMMUNOL, V130, P1113; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; REYNOLDS HY, 1991, PHYSIOL REV, V71, P1117, DOI 10.1152/physrev.1991.71.4.1117; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SPITERI MA, 1994, EUR RESPIR J, V7, P1431, DOI 10.1183/09031936.94.07081431; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017	30	48	53	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1136	1142		10.1016/S0091-6749(99)70189-2	http://dx.doi.org/10.1016/S0091-6749(99)70189-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359896				2022-12-18	WOS:000080929500023
J	Hoshino, M; Sim, J; Shimizu, K; Nakayama, H; Koya, A				Hoshino, M; Sim, J; Shimizu, K; Nakayama, H; Koya, A			Effect of AA-2414, a thromboxane A(2) receptor antagonist, on airway inflammation in subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						thromboxane A(2); airway inflammation; chemokines; bronchial hyperresponsiveness	MESSENGER-RNA; BRONCHIAL HYPERRESPONSIVENESS; SYNTHETASE INHIBITOR; ATOPIC SUBJECTS; MAST-CELLS; T-CELL; RANTES; EOSINOPHILS; EXPRESSION; MACROPHAGES	Background: Asthma is a chronic inflammatory disease of the airways. The chemokines are potent chemoattractants for eosinophils and other types of cells associated with allergic inflammation. AA-2414, a new thromboxane A(2) receptor antagonist, reduces bronchial hyperresponsiveness in asthmatic subjects, but its mechanism of action is unclear. Objective: We tested the hypothesis that the beneficial effects of AA-2414 in asthma result from reduction in the number of inflammatory cells infiltrating the airway associated with inhibition of chemokine release. Methods: We studied bronchial biopsy specimens from 51 asthmatic subjects before and after oral treatment with AA-2414 (80 mg/day) or matched placebo for 4 months in a double-blind manner. Biopsy specimens were examined by immunohistochemistry. Each subject recorded symptom score and peak expiratory flow (PEF). Lung function and bronchial responsiveness to methacholine were measured before and after treatment. Results: After treatment, significant improvements in symptom score (P < .05), PEF (P < .01), diurnal variation of PEF (P < .01), and bronchial responsiveness (P < .01) were observed in the AA-2414 group compared with the placebo group. These improvements were accompanied by a significant decrease in the number of submucosal EG2(+) eosinophils (P < .05). There was also a reduction in the number of cells expressing RANTES (P < .05) and macrophage inflammatory protein (MIP)-1 alpha (P < .05) in the epithelium and of cells expressing monocyte chemotactic protein-3 (P < .01), RANTES (P < .05), NLIP-1 alpha (P < .01), and eotaxin (P < .01) in the submucosa in the AA-2414 treatment group. A significant correlation was found between the number of EG2(+) eosinophils and numbers of monocyte chemotactic protein-3(+) (r(s) = 0.52, P < .005), MIP-1 alpha(+) (r(s) = 0.34, P < .05), and eotaxin(+) cells (r(s) = 0.47, P < .01) in the submucosa There was a significant negative correlation between the increase in bronchial responsiveness and the change in number of submucosal EG2(+) cells (r(s) = -0.65, P < .001). Conclusions: These findings suggest that AA-2414 treatment of patients with asthma may inhibit activated eosinophil infiltration in part by modulating the expression of chemokines in bronchial tissues.	Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, Tokyo, Japan		Hoshino, M (corresponding author), Toho Univ, Sch Med, Dept Internal Med 2, Ota Ku, 6-11-1 Omori-nishi, Tokyo, Japan.							Agrawal DK, 1997, INFLAMMATION, V21, P1, DOI 10.1023/A:1027330506697; *AM THOR SOC, 1988, AM REV RESPIR DIS, V136, P225; ASHIDA Y, 1989, PROSTAGLANDINS, V38, P91, DOI 10.1016/0090-6980(89)90019-1; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Caughey GE, 1997, J IMMUNOL, V158, P351; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; FAIRFAX AJ, 1983, CLIN EXP IMMUNOL, V52, P393; FOEGH ML, 1986, SCAND J IMMUNOL, V23, P599, DOI 10.1111/j.1365-3083.1986.tb01993.x; FUJIMURA M, 1991, J ALLERGY CLIN IMMUN, V87, P23, DOI 10.1016/0091-6749(91)90208-6; FUJIMURA M, 1986, THORAX, V41, P955, DOI 10.1136/thx.41.12.955; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HIRAMOTO A, 1997, JPN J ALLERGOL, V46, P825; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; ITOH K, 1993, EUR J PHARMACOL, V239, P159, DOI 10.1016/0014-2999(93)90989-U; KUHN DC, 1993, PROSTAG OTH LIPID M, V46, P195, DOI 10.1016/0090-6980(93)90003-P; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; Narita S, 1996, INT ARCH ALLERGY IMM, V109, P161, DOI 10.1159/000237215; NUSING R, 1990, EICOSANOIDS, V3, P175; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Shi H, 1998, EUR RESPIR J, V11, P624; SHIMADA T, 1995, JPN J OCULAR PHARM, V9, P35; SHIRAISHI M, 1989, J MED CHEM, V32, P2214, DOI 10.1021/jm00129a030; STELLATO C, 1995, J IMMUNOL, V155, P410; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; TAKAMI M, 1995, INT ARCH ALLERGY IMM, V106, P401, DOI 10.1159/000236873; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Ying S, 1996, EUR J IMMUNOL, V26, P70, DOI 10.1002/eji.1830260111	38	48	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1054	1061		10.1016/S0091-6749(99)70179-X	http://dx.doi.org/10.1016/S0091-6749(99)70179-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359886	Bronze			2022-12-18	WOS:000080929500013
J	Siegel, RM; Fleisher, TA				Siegel, RM; Fleisher, TA			The role of Fas and related death receptors in autoimmune and other disease states	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Fas; APO-1; CD95; autoimmune lymphoproliferative syndrome; autoimmunity; therapy; lymphocytes; apoptosis	DOMAIN-CONTAINING RECEPTOR; TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; SYSTEMIC LUPUS-ERYTHEMATOSUS; LIGAND-INDUCED APOPTOSIS; CONFER IMMUNE PRIVILEGE; MATURE T-LYMPHOCYTES; LYMPHOPROLIFERATIVE SYNDROME; DENDRITIC CELLS; B-CELLS	The Pas receptor, also known as APO-1 or CD95, has emerged as a hey initiator of apoptotic programmed cell death in a variety of cell types. CD4(+) T cells are unique in their ability to commit "suicide" by stimulating their own Pas receptors with secreted or membrane-bound Pas ligand. This takes place in the setting of repeated stimulation with T-cell antigens and is thought to be a mechanism for controlling the expansion of T cells during viral infections and autoimmune disease states. T cells can also trigger apoptosis in B cells, macrophages, and other cell types through Pas ligand, These interactions negatively regulate the immune system but can also contribute to immunopathology, as occurs in Pas-mediated damage of target tissues in hepatitis and other organ-specific autoimmune diseases. The dual role of Pas in the immune response complicates the understanding of its role in disease states and may limit its potential as a therapeutic target, Despite the many roles of Pas in immunoregulation, findings in experimental mouse strains and human patients with genetic deficiencies in the Pas pathway have shown that the main result of disrupting this pathway in vivo is systemic autoimmunity and a predisposition toward lymphoid malignancies. The role of Pas in various cell types and the lessons we have learned from Fas-deficient patients with the autoimmune lymphoproliferative syndrome will be discussed.	NIAID, Immunol Lab, Bethesda, MD 20892 USA; NIH, Dept Clin Pathol, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Fleisher, TA (corresponding author), Bldg 10,Rm 2C306,10 Ctr Dr,Msc 1508, Bethesda, MD 20892 USA.		Siegel, Richard/C-7592-2009	Siegel, Richard/0000-0001-5953-9893				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen HC, 1998, J IMMUNOL, V161, P4257; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Combadiere B, 1998, J EXP MED, V187, P349, DOI 10.1084/jem.187.3.349; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; EMLEN W, 1994, J IMMUNOL, V152, P3685; Erikson J, 1998, IMMUNOL RES, V17, P49, DOI 10.1007/BF02786430; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foote LC, 1996, J IMMUNOL, V157, P1878; Fujisawa K, 1996, J CLIN INVEST, V98, P271, DOI 10.1172/JCI118789; Fuss IJ, 1997, J IMMUNOL, V158, P1912; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Gandhi RT, 1998, J EXP MED, V187, P1113, DOI 10.1084/jem.187.7.1113; Georgescu L, 1997, J CLIN INVEST, V100, P2622, DOI 10.1172/JCI119806; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Gougeon ML, 1996, J IMMUNOL, V156, P3509; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hayashi N, 1997, J GASTROEN HEPATOL, V12, pS223, DOI 10.1111/j.1440-1746.1997.tb00504.x; HERRON LR, 1993, J IMMUNOL, V151, P3450; Hornung F, 1997, J IMMUNOL, V159, P3816; Infante AJ, 1998, J PEDIATR-US, V133, P629, DOI 10.1016/S0022-3476(98)70102-7; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACKSON C, 1998, IN PRESS AM J HUM GE; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Kikuchi H, 1996, J LEUKOCYTE BIOL, V60, P778, DOI 10.1002/jlb.60.6.778; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Koppi TA, 1997, EUR J IMMUNOL, V27, P3161, DOI 10.1002/eji.1830271212; Kuroda K, 1996, J IMMUNOL, V157, P1422; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LeDeist F, 1996, LANCET, V348, P719, DOI 10.1016/S0140-6736(96)02293-3; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Lu LN, 1997, J IMMUNOL, V158, P5676; Luttmann W, 1998, EUR J IMMUNOL, V28, P2057, DOI 10.1002/(SICI)1521-4141(199807)28:07<2057::AID-IMMU2057>3.0.CO;2-T; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MARTIN DA, 1999, IN PRESS P NATL ACAD; Mitsiades N, 1998, J CLIN ENDOCR METAB, V83, P2199, DOI 10.1210/jc.83.6.2199; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEMAZEE D, 1991, J IMMUNOL, V147, P2536; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shima Y, 1996, LEUKEMIA LYMPHOMA, V23, P521, DOI 10.3109/10428199609054860; Shiota G, 1998, RES COMMUN MOL PATH, V101, P3; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Simon HU, 1997, J IMMUNOL, V158, P3902; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Van Parijs L, 1998, IMMUNITY, V8, P265, DOI 10.1016/S1074-7613(00)80478-1; WADSWORTH S, 1990, EUR J IMMUNOL, V20, P723, DOI 10.1002/eji.1830200403; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	100	48	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				729	738		10.1016/S0091-6749(99)70412-4	http://dx.doi.org/10.1016/S0091-6749(99)70412-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329802				2022-12-18	WOS:000080470200002
J	Koro, O; Furutani, K; Hide, M; Yamada, S; Yamamoto, S				Koro, O; Furutani, K; Hide, M; Yamada, S; Yamamoto, S			Chemical mediators in atopic dermatitis: Involvement of leukotriene B-4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; type I allergy; late-phase response; histamine; leukotriene B-4; neutrophil chemotactic activity	LATE-PHASE RESPONSE; MAST-CELLS; HUMAN-SKIN; ANTIGEN CHALLENGE; IMMUNOGLOBULIN-E; IGE; HISTAMINE; SITES; EICOSANOIDS; NEUTROPHILS	Background: The mediators produced from a type I allergic reaction have not get been able to explain the pathogenesis of atopic dermatitis (AD), Objective: The purpose of this study was to elucidate the involvement of leukotriene (LT) B-4 produced from a type I allergic reaction in the pathogenesis of AD. Method: The release of LTB4 was measured both in vitro, in passively sensitized and antigen-challenged human skin slices, as well as in vivo, in skin chambers on patients with AD. Results: LTB4 was released from in vitro human skin by stimulation of the antigen (54.9 +/- 14.6 pg/g wet weight of skin by antigen challenge and 28.0 +/- 11.1 pg/g in control skin, P <.002). Antigen-specific release of LTB4 and histamine was also observed in vivo in nonlesional skin from the patients with AD by using the skin chamber technique. Conclusion: LTB4 release during type I allergic reaction in human skin has been determined in vitro. The released LTB4 possibly contributes to cellular response at the acute inflammatory lesion of AD.	Hiroshima Univ, Sch Med, Dept Dermatol, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Koro, O (corresponding author), Hiroshima Univ, Sch Med, Dept Dermatol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034				ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ALAM R, 1994, J IMMUNOL, V152, P1298; ATKINS PC, 1989, J ALLERGY CLIN IMMUN, V83, P136, DOI 10.1016/0091-6749(89)90488-0; BARR RM, 1988, BRIT J PHARMACOL, V94, P773, DOI 10.1111/j.1476-5381.1988.tb11588.x; BERNHISELBROADB.J, 1991, HDB ATOPIC ECZEMA, P204; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRAIN S, 1984, J INVEST DERMATOL, V83, P70, DOI 10.1111/1523-1747.ep12261712; CARSWELL F, 1986, LANCET, V2, P13, DOI 10.1016/S0140-6736(86)92560-2; CHAMPION MD, 1983, J ALLERGY CLIN IMMUN, V72, P27; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FOGH K, 1989, J ALLERGY CLIN IMMUN, V83, P450, DOI 10.1016/0091-6749(89)90132-2; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; FREELAND HS, 1988, AM REV RESPIR DIS, V138, P389, DOI 10.1164/ajrccm/138.2.389; GLAUSER FL, 1977, ANN ALLERGY, V38, P104; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GREAVES MW, 1972, IMMUNOLOGY, V23, P239; JAKOBSSON PJ, 1991, EUR J BIOCHEM, V196, P395, DOI 10.1111/j.1432-1033.1991.tb15829.x; JONES HE, 1975, BRIT J DERMATOL, V92, P17; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; MASSEY W, 1993, J IMMUNOL, V150, P1084; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MITCHELL EB, 1982, LANCET, V1, P127; NORMAN PS, 1983, ALLERGY PRINCIPLES P, V2, P295; OBAYASHI T, 1985, CLIN CHIM ACTA, V149, P55, DOI 10.1016/0009-8981(85)90273-6; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; RESHEF A, 1989, J ALLERGY CLIN IMMUN, V84, P678, DOI 10.1016/0091-6749(89)90296-0; RING J, 1985, ACTA DERM-VENEREOL, P9; ROBINSON C, 1989, J INVEST DERMATOL, V93, P397, DOI 10.1111/1523-1747.ep12280290; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; Sawada K, 1997, CLIN EXP ALLERGY, V27, P225; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TSURUTA Y, 1981, J CHROMATOGR, V224, P105, DOI 10.1016/S0378-4347(00)80142-5; UDEN AM, 1983, INT ARCH ALLER A IMM, V72, P91, DOI 10.1159/000234847; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	41	48	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					663	670		10.1016/S0091-6749(99)70240-X	http://dx.doi.org/10.1016/S0091-6749(99)70240-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200017				2022-12-18	WOS:000079723900021
J	Olivenstein, R; Taha, R; Minshall, EM; Hamid, QA				Olivenstein, R; Taha, R; Minshall, EM; Hamid, QA			IL-4 and IL-5 mRNA expression in induced sputum of asthmatic subjects: Comparison with bronchial wash	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sputum; IL-4; IL-5; bronchial wash; airways inflammation; lymphocytes; eosinophils	BRONCHOALVEOLAR LAVAGE FLUID; ATOPIC ASTHMA; AIRWAY INFLAMMATION; MESSENGER-RNA; ACTIVATED EOSINOPHILS; BIOPSY SPECIMENS; HEALTHY-SUBJECTS; LYMPHOCYTES-T; CELLS; ALLERGEN	Background: The local production of T-H2-type cytokines is thought to orchestrate the ongoing eosinophilic inflammation and contribute to the pathophysiologic features of allergic asthma, Previous studies investigating cytokine expression in asthmatic individuals have used invasive fiberoptic bronchoscopy techniques. To date, there have been no reports of cytokine mRNA expression in induced sputum as a means of quantifying local inflammatory events. Objectives:We examined whether IL-4, IL-5, and IFN-gamma mRNA expression could be detected in cells from induced sputum in subjects with mild asthma and normal control subjects. In addition, we compared the profile of inflammatory cells and cytokine mRNA in sputum and bronchial mash fluid. Methods: Cells positive for IL-4, IL-5, and IFN-gamma mRNA mere determined by using in situ hybridization on cytospun aliquots of sputum induced by successive inhalations of hypertonic saline. Inflammatory cells were quantified by using immunologic cell surface markers and immunocytochemistry. Results: IL-4 and IL-5 mRNA were detected in the sputum of all asthmatic subjects, and the number of cells expressing these cytokines was significantly higher than that found in control subjects. Colocalization studies showed CD3-positive T cells were the major sources of IL-4 and IL-5 mRNA. Conclusions: This study demonstrates that induced sputum can be used to detect mRNA for T-H2-type cytokines in bronchial asthma and that the increase in IL-4 and IL-5 mRNA expression is similar to that seen with more invasive techniques. The qualitative differences in inflammatory cell numbers between sputum induction and bronchial mash are consistent with their sampling of different airway compartments.	McGill Univ, Royal Victoria Hosp, Meakins Christie Labs, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Montreal Chest Res Inst, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477, DOI 10.1164/ajrccm/145.6.1477; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BELLITA V, 1997, AM J RESP CRIT CARE, V156, pA386; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DEL PG, 1988, J IMMUNOL, V140, P4193; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FREW AJ, 1988, J IMMUNOL, V141, P4158; GELDER CM, 1995, THORAX, V50, P1033, DOI 10.1136/thx.50.10.1033; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1992, BLOOD, V80, P1496; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Keatings VM, 1997, THORAX, V52, P372, DOI 10.1136/thx.52.4.372; KELLY CA, 1987, THORAX, V42, P624, DOI 10.1136/thx.42.8.624; Kidney JC, 1996, AM J RESP CRIT CARE, V153, P540, DOI 10.1164/ajrccm.153.2.8564094; Louis R, 1997, AM J RESP CRIT CARE, V155, P466, DOI 10.1164/ajrccm.155.2.9032180; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; VANVYVE T, 1992, CHEST, V102, P356, DOI 10.1378/chest.102.2.356; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WHIMSTER WF, 1984, AM REV RESPIR DIS, V129, P985; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	37	48	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				238	245		10.1016/S0091-6749(99)70497-5	http://dx.doi.org/10.1016/S0091-6749(99)70497-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949314				2022-12-18	WOS:000078630100010
J	Lipworth, BJ; Aziz, I				Lipworth, BJ; Aziz, I			A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchoprotection; downregulation; subsensitivity; methacholine; albuterol; salmeterol; formoterol	BRONCHODILATOR SUBSENSITIVITY; INHALED FORMOTEROL; SALBUTAMOL; TACHYPHYLAXIS; TOLERANCE; SYMPTOMS; PREVENT	Background: Regular treatment with inhaled, long-acting beta(2)-agonists is associated with subsensitivity for bronchoprotective effects, It is not known whether a high dose of short-acting beta(2)-agonist could overcome this subsensitivity. Objectives: The objective of this study was to investigate the acute effects of a high dose of inhaled albuterol on methacholine-induced bronchoconstriction in patients receiving regular treatment with salmeterol or formoterol, Methods: Ten stable asthmatic subjects (mean age, 34 years; FEV1, 77% of predicted value), all taking inhaled corticosteroids (methacholine PD20 < 500 mu g), were recruited into a randomized, single-blind, crossover study After an initial 1-week run-in period, subjects underwent 3 separate treatment periods each of 9 days (separated by a washout of at least 5 days) comprising inhaled placebo twice daily, inhaled salmeterol dry powder 50 mu g twice daily, or inhaled formoterol dry powder 12 mu g twice daily Methacholine challenge was performed 1 hour after the first dose and after 7 days of treatment. After 9 days of treatment, a third methacholine challenge was performed 1 hour after inhalation of a single 1600 mu g dose of albuterol dry powder. Results: There was significant (P < .001) improvement in geometric mean PD20 after the first dose of active treatment as compared with placebo (78 mu g) versus salmeterol (266 mu g, a 3.4-fold difference [95% CI 1.9 to 6.1]) and versus formoterol (318 mu g a 4.1-fold difference [95% CI 2.3 to 7.3]). This bronchoprotection diminished with regular treatment, although it remained significant (P < .01) compared with placebo (68 mu g) versus salmeterol (144 mu g, a 2.1-fold difference [95% CI 1.2 to 3.8]) and versus formoterol (230 mu g, a 3.4-fold difference [95% CI 1.9 to 6.2]). After 9 days, the protection afforded by a single dose of albuterol after placebo pretreatment (889 mu g) was significantly (P = .005) higher in comparison with albuterol protection after salmeterol pretreatment (338 mu g, a 2.7-fold difference [95% CI 1.1 to 6.8]) and after formoterol pretreatment (247 mu g, a 3.6-fold difference [95% 1.4 to 9.1]). Conclusions: Thus in stable asthmatic subjects receiving regular salmeterol or formoterol, bronchoprotective subsensitivity was not overcome by administering a high dose of albuterol, Further studies are required to evaluate the clinical relevance of this pharmacologic phenomenon when albuterol is used in acute asthma.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Resp Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; ARVIDSSON P, 1991, EUR RESPIR J, V4, P1168; AZIZ I, 1998, THORAX S4, V53, pA74; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; KALLSTROM BL, 1994, BRIT J PHARMACOL, V43, P687; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Langley SJ, 1998, EUR RESPIR J, V11, P1081, DOI 10.1183/09031936.98.11051081; Lipworth B, 1998, AM J MED, V104, P431, DOI 10.1016/S0002-9343(98)00086-2; Lipworth BJ, 1997, LANCET, V350, P18; Molimard M, 1998, EUR RESPIR J, V11, P583; *NAT ASTHM ED PREV, 1997, NIH PUBL; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Tan KS, 1997, AM J RESP CRIT CARE, V156, P28, DOI 10.1164/ajrccm.156.1.9610113; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342	25	48	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				88	92		10.1016/S0091-6749(99)70530-0	http://dx.doi.org/10.1016/S0091-6749(99)70530-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893190				2022-12-18	WOS:000078112300014
J	Fernandez-Caldas, E; Quirce, S; Maranon, F; Gomez, MLD; Botella, HG; Roman, RL				Fernandez-Caldas, E; Quirce, S; Maranon, F; Gomez, MLD; Botella, HG; Roman, RL			Allergenic cross-reactivity between third stage larvae of Hysterothylacium aduncum and Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FISH		CBF LETI SA, Res Labs, Madrid 28760, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; Univ La Laguna, Fac Pharm, Dept Parasitol, E-38207 San Cristobal la Laguna, Spain	Hospital Universitario Ramon y Cajal; Universidad de la Laguna	Fernandez-Caldas, E (corresponding author), CBF LETI SA, Res Labs, Calle Sol 5,Tres Cantos, Madrid 28760, Spain.		s, q/AAD-7171-2020					Adroher FJ, 1996, PARASITOL RES, V82, P253, DOI [10.1007/s004360050105, 10.1007/s004360050120]; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; Pascual CY, 1997, ALLERGY, V52, P514, DOI 10.1111/j.1398-9995.1997.tb02594.x	5	48	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				554	555		10.1016/S0091-6749(98)70364-1	http://dx.doi.org/10.1016/S0091-6749(98)70364-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9580257				2022-12-18	WOS:000073113500020
J	Boluda, L; Alonso, C; Fernandez-Caldas, E				Boluda, L; Alonso, C; Fernandez-Caldas, E			Purification, characterization, and partial sequencing of two new allergens of Olea europaea	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Joint Meeting of AAAAI/AAI	FEB 21-26, 1997	SAN FRANCISCO, CALIFORNIA	AAAAI, AAI		Olea europaea; allergen; Ole e 1; Ole e 4; Ole e 5; superoxide dismutase; allergic rhinitis; asthma	AMINO-ACID-SEQUENCE; MAJOR ALLERGEN; E-I; POLLEN PROTEINS; HYPERSENSITIVITY; NOMENCLATURE; FAMILY	Background: The inhalation of olive (Olea europaea) pollen is an important cause of allergic respiratory diseases in southern Europe and California. Objective: The aims of this study were to characterize the allergenic composition of O. europaea pollen collected in California and to purify two important allergens. Methods: One hundred grams of O. europaea pollen was extracted dialyzed in 10 kd cut-off membranes and lyophilized. Allergen characterization was done by sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting. Two allergens were isolated by gel filtration, ion exchange, and hydrophobic interaction chromatography and sequenced. Results: Ole e 4 has an apparent molecular weight, under reducing conditions, of 32 kd and pIs between 4.65 and 5.1. The N-terminal was blocked and the analysis of the amino acid sequence of two internal regions revealed no homology with other known proteins. Ole e 5 has a molecular weight of 16 kd and pIs between 5.1 and 6.5. The amino acid sequence of the N-terminal showed a high degree of homology with superoxide dismutase of several plant species. Ole e 4 and Ole e 5 had an IgE binding frequency by immunoblot of 80% and 35%, respectively. Conclusions: Olive pollen extracts have a heterogeneous composition, with several important allergens. One of these allergens showed a high degree of homology with a superoxide dismutase.	CBF LETI SA, Res & Dev, Madrid 28760, Spain; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Caldas, E (corresponding author), CBF LETI SA, Res & Dev, Calle Sol 5,Tres Cantos, Madrid 28760, Spain.							BARBER D, 1990, ANN ALLERGY, V64, P43; BATANERO E, 1994, EUR J BIOCHEM, V221, P187, DOI 10.1111/j.1432-1033.1994.tb18728.x; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BATANERO E, 1995, ALLERGY S, V50; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; CARREIRA J, 1993, 7 INT P EHRL SEM, P155; COROMINAS M, 1990, ALLERGOL IMMUNOPATH, V18, P297; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DIEZGOMEZ ML, 1987, ALLERGY, V42, P74, DOI 10.1111/j.1398-9995.1987.tb02190.x; JORAL A, 1993, J INVEST ALLERG CLIN, V3, P103; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; Lewis WH VP, 1983, AIRBORNE ALLERGENIC; Liccardi G, 1996, J INVEST ALLERG CLIN, V6, P371; LOMBARDERO M, 1992, J ALLERGY CLIN IMMUN, V89, P884, DOI 10.1016/0091-6749(92)90445-8; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; Rodriguez R, 1995, ECACI '95 - XVI EUROPEAN CONGRESS OF ALLERGOLOGY AND CLINICAL IMMUNOLOGY, PROCEEDINGS I, P671; RUBIO N, 1987, J CHROMATOGR, V403, P312, DOI 10.1016/S0021-9673(00)96369-6; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; VELA C, 1982, INT ARCH ALLER A IMM, V68, P289, DOI 10.1159/000233116; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; Waisel Y, 1996, ALLERGY, V51, P819, DOI 10.1111/j.1398-9995.1996.tb00028.x; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K	30	48	51	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				210	216		10.1016/S0091-6749(98)70385-9	http://dx.doi.org/10.1016/S0091-6749(98)70385-9			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500754				2022-12-18	WOS:000072244800010
J	Rachelefsky, GS; Chervinsky, P; Meltzer, EO; Morris, RM; Seltzer, JM; Skoner, DP; Storms, WW; Wood, RA				Rachelefsky, GS; Chervinsky, P; Meltzer, EO; Morris, RM; Seltzer, JM; Skoner, DP; Storms, WW; Wood, RA			An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [Vancenase AQ (VNS)] on long-term growth in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	48	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			979	S236	S236						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800975
J	Sarpong, SB; Wood, RA; Karrison, T; Eggleston, PA				Sarpong, SB; Wood, RA; Karrison, T; Eggleston, PA			Cockroach allergen (Bla g 1) in school dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust analysis; schools; cockroach allergen; African-American; urban	F-I ALLERGENS; INNER-CITY; SWEDISH SCHOOLS; ASTHMA; CHILDREN; PREVALENCE	Background: Cockroach allergen, Bla g 1, is an important indoor allergen. Although household exposure has been documented, little is known about the potential for exposure outside the home. Objective: We investigated the settled dust concentration of Bla g 1 in 147 samples collected from classrooms, kitchens, cafeterias, and other sites in four primary schools in the city of Baltimore. Methods: School authorities were questioned about characteristics of schools, teachers, and students, as well as cockroach control and cleaning procedures, Settled dust samples were collected with a hand-held vacuum cleaner from the floors of all classrooms, food-related areas, and other sites of the schools over a 3-week period. A sample collection in each school took 1 to 2 days. Dust samples from each room were pooled and analyzed as a single sample for Bla g 1 by using a two-site monoclonal ELISA. Results: One hundred two (69%) of the 147 samples had detectable Bla g 1 and were within the range reported by other investigators in inner city homes. There was no difference between the median levels of Bla g 1 in three schools: school 1 (5.2 U/gm), school 2 (3.0 U/gm), and school 4 (2.7 U/gm); but school 3 had a significantly lower level (<0.8 U/gm, p < 0.001), The median level from the food-related areas was significantly higher than the median classroom level (p = 0.048). School 3 had fewer students on subsidized lunch, fewer African-American students, and fewer students per teacher. Bla g 1 levels were compared in the different schools while controlling for potential confounding variables by a stepwise multiple regression analysis with a logit model for ordinal responses. On the basis of this analysis. Bla g 1 levels in schools 1, 2, and 4 differed significantly from levels in schools 3 (p < 0.001 in each case). Food-related areas had significantly higher levels than classrooms (p = 0.048). Floor level, the presence of a sink and the presence of carpeting did not have significant effects. Conclusions: We conclude that Bla g 1 is detectable at potentially significant concentrations in some inner city schools. Furthermore, the level of exposure is different between different schools and between sites within individual schools.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,BALTIMORE,MD 21218; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	Johns Hopkins University; University of Chicago	Sarpong, SB (corresponding author), UNIV CHICAGO,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,E 65TH ST LAKE MICHIGAN,CHICAGO,IL 60649, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030773] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30773-S1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agresti A., 1984, ANAL ORDINAL CATEGOR; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1988, CHEST, V94, P185, DOI 10.1378/chest.94.1.185; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; DYBENDAL T, 1989, CLIN EXP ALLERGY, V19, P217, DOI 10.1111/j.1365-2222.1989.tb02367.x; Eggleston P., 1996, Journal of Allergy and Clinical Immunology, V97, P301, DOI 10.1016/S0091-6749(96)80694-4; EINARSSON R, 1995, J ALLERGY CLIN IMMUN, V95, P1049, DOI 10.1016/S0091-6749(95)70108-7; EVANS R, 1987, CHEST S, V91, P655; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HAMILTON S, 1992, NEW ENGL REV-MIDDLEB, V14, P96; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KOEHLER PG, 1987, J ECON ENTOMOL, V80, P446, DOI 10.1093/jee/80.2.446; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHULANER FA, 1970, PEDIATRICS, V45, P465; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	21	48	49	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					486	492		10.1016/S0091-6749(97)70074-5	http://dx.doi.org/10.1016/S0091-6749(97)70074-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111492	hybrid			2022-12-18	WOS:A1997WU27400010
J	CuestaHerranz, J; delasHeras, M; Fernandez, M; Lluch, M; Figueredo, E; Umpierrez, A; Lahoz, C				CuestaHerranz, J; delasHeras, M; Fernandez, M; Lluch, M; Figueredo, E; Umpierrez, A; Lahoz, C			Allergic reaction caused by local anesthetic agents belonging to the amide group	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHALLENGE; HISTORY				CuestaHerranz, J (corresponding author), FDN JIMENEZ DIAZ,SERV ALERGIA,C REYES CATOLICOS 2,E-28040 MADRID,SPAIN.							CHANDLER MJ, 1987, J ALLERGY CLIN IMMUN, V79, P883, DOI 10.1016/0091-6749(87)90236-3; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; FREGERT S, 1979, CONTACT DERMATITIS, V5, P185, DOI 10.1111/j.1600-0536.1979.tb04835.x; Gall H, 1996, J ALLERGY CLIN IMMUN, V97, P933, DOI 10.1016/S0091-6749(96)80067-4; SCHATZ M, 1984, J ALLERGY CLIN IMMUN, V74, P606, DOI 10.1016/0091-6749(84)90114-3	5	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					427	428		10.1016/S0091-6749(97)70064-2	http://dx.doi.org/10.1016/S0091-6749(97)70064-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058702	Bronze			2022-12-18	WOS:A1997WM42200023
J	Spitzauer, S; Pandjaitan, B; Muhl, S; Ebner, C; Kraft, D; Valenta, R; Rumpold, H				Spitzauer, S; Pandjaitan, B; Muhl, S; Ebner, C; Kraft, D; Valenta, R; Rumpold, H			Major cat and dog allergens share IgE epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergy; dog allergy; immunoblotting; IgE-immunoblot inhibition; IgE-cross-reactivity	MAMMALIAN ORIGIN; CROSS-REACTIVITY; SERUM-ALBUMIN; DOMESTIC CAT; EXTRACTS; PURIFICATION; PROTEINS; IDENTIFICATION; SALIVA; DANDER	Background: Patients allergic to cats and dogs frequently display IgE reactivity against allergens from different animals, suggesting a cross-sensitization to common allergenic determinants. Although albumins have been recognized as relevant cross-reactive allergens, little is known regarding cross-reactive epitopes of the major cat and dog allergens. Objective: In this study, sera from patients allergic to cats and/or dogs were used to investigate the presence of common IgE epitopes among the major cat and dog allergens. Methods: The IgE reactivity profile of 109 patients who were allergic to allergens from several species of animals was determined with nitrocellulose-blotted cat and dog allergens. Sera from patients who were strongly allergic to the major cat and dog allergens were tested for the presence of cross-reactive IgE antibodies by one-dimensional and two-dimensional immunoblot inhibition experiments and by quantitative measurements obtained with the CAP-FEIA system (Pharmacia). Results: Sixty-eight of 109 patients with animal allergy showed IgE reactivity to cat allergens and dog allergens. Sera from patients with both cat and dog allergy detected allergens of similar molecular weight in nitrocellulose-blotted cat and dog hair/dander extracts. Common, as well as species-restricted, IgE epitopes of the major cat and dog allergens could be demonstrated by IgE inhibition studies. Conclusion: shared IgE epitopes of the major cat and dog allergens may provide an explanation for the clinical observation that allergies to cats and dogs are frequently associated.	UNIV VIENNA,INST GEN & EXPT PATHOL,AKH,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MED & CHEM LAB DIAG,AKH,VIENNA,AUSTRIA	University of Vienna; University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; DIDIERLAURENT A, 1984, INT ARCH ALLER A IMM, V73, P27, DOI 10.1159/000233433; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1976, J ALLERGY CLIN IMMUN, V57, P560, DOI 10.1016/0091-6749(76)90007-5; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; SPITZAUER S, 1991, INT ARCH ALLER A IMM, V94, P346, DOI 10.1159/000235399; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTO T, 1982, INT ARCH ALLER A IMM, V69, P311, DOI 10.1159/000233192; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; WUTHRICH B, 1979, CLIN ALLERGY, V9, P191, DOI 10.1111/j.1365-2222.1979.tb01541.x; WUTHRICH B, 1985, CLIN ALLERGY, V15, P87, DOI 10.1111/j.1365-2222.1985.tb02260.x; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	30	48	50	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				100	106		10.1016/S0091-6749(97)70306-3	http://dx.doi.org/10.1016/S0091-6749(97)70306-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003217				2022-12-18	WOS:A1997WD06100014
J	Nicklas, RA; Bernstein, IL; BlessingMoore, J; Fineman, SM; Gutman, AA; Lee, RE; Li, JT; Berger, WE; Spector, SL; Greenberger, P; Pearlman, D; Zeitz, S; Blaiss, M; Condemi, JJ; Dykewicz, MS; Hannaway, PJ; Lockey, RF; Nicholas, SS; Reid, MJ; Shapiro, GG; Wood, RA				Nicklas, RA; Bernstein, IL; BlessingMoore, J; Fineman, SM; Gutman, AA; Lee, RE; Li, JT; Berger, WE; Spector, SL; Greenberger, P; Pearlman, D; Zeitz, S; Blaiss, M; Condemi, JJ; Dykewicz, MS; Hannaway, PJ; Lockey, RF; Nicholas, SS; Reid, MJ; Shapiro, GG; Wood, RA			Practice parameters for allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; HOUSE DUST MITE; RAPID VENOM IMMUNOTHERAPY; IMPORTED FIRE ANT; SYSTEMIC REACTIONS; DOUBLE-BLIND; SUPPRESSOR CELLS; CONTROLLED TRIAL; POLLEN EXTRACTS; SEMINAL PLASMA				Nicklas, RA (corresponding author), AAAAI, EXECUT OFF, 611 E WELLS ST, MILWAUKEE, WI 53202 USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; AMARALMARQUES R, 1978, ALLERGOL IMMUNOPATH, V6, P231; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BERNSTEIN JA, 1993, OBSTET GYNECOL, V82, P667; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; BOSE R, 1984, J IMMUNOL, V133, P2474; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; BOUSQUET J, 1987, AM REV RESPIR DIS, V135, pA135; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CHEN YH, 1994, J IMMUNOL, V152, P3; CLEVELAND CH, 1992, IMMUNOL ALLERGY CLIN, V12, P39; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DUBUSKE LM, 1992, IMMUNOL ALLERGY CLIN, V12, P145; FRANCIS NATHAN, 1941, JOUR ALLERGY, V12, P559, DOI 10.1016/S0021-8707(41)90203-4; Freeman J, 1930, LANCET, V1, P744; GEHA RS, 1983, J CLIN INVEST, V71, P46, DOI 10.1172/JCI110750; GOLDSTEIN GL, 1981, ANN ALLERGY, V47, P333; GRAMMER LC, 1992, IMMUNOL ALLERGY CLIN, V12, P95; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HJORTH NIELS, 1958, ACTA ALLERGOL, V12, P316, DOI 10.1111/j.1398-9995.1958.tb03088.x; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; HYLANDER RD, 1989, J ALLERGY CLIN IMMUN, V83, P232; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; KAGEN SL, 1992, IMMUNOL ALLERGY CLIN, V12, P177; LANNER A, 1984, Journal of Allergy and Clinical Immunology, V73, P141; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOVELESS MH, 1957, J IMMUNOL, V79, P68; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; MAUNSELL K, 1971, LANCET, V1, P967; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; MITTMAN RJ, 1990, J ALLERGY CLIN IMMUN, V86, P954, DOI 10.1016/S0091-6749(05)80159-9; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; NELSON BL, 1986, ANN ALLERGY, V56, P331; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; OHEHIR RE, 1991, CLIN EXP ALLERGY, V21, P209, DOI 10.1111/j.1365-2222.1991.tb00832.x; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1992, MED CLIN N AM, V76, P977, DOI 10.1016/S0025-7125(16)30335-2; OPPENHEIMER JJ, 1995, PRAC ALLERGY IMMUNOL, V10, P3; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; PECK HM, 1964, P SOC EXP BIOL MED, V116, P523, DOI 10.3181/00379727-116-29296; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; RIGG D, 1990, AM J OBSTET GYNECOL, V162, P332, DOI 10.1016/0002-9378(90)90380-P; RING J, 1982, BRIT J DERMATOL, V107, P597, DOI 10.1111/j.1365-2133.1982.tb00412.x; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROHR AS, 1984, J ALLERGY CLIN IMMUN, V73, P369, DOI 10.1016/0091-6749(84)90410-X; SAINTREMY JMR, 1988, EUR J IMMUNOL, V18, P1009, DOI 10.1002/eji.1830180706; SCINTO JD, 1992, IMMUNOL ALLERGY CLIN, V12, P53; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; TURKELTAUB PC, 1991, ALLERGEN IMMUNOTHERA, P171; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; VANMETRE TE, 1993, ALLERGY PRINCIPLES P, P1489; Weber R W, 1989, J Allergy Clin Immunol, V84, P1093, DOI 10.1016/0091-6749(89)90160-7; ZACHARIAE H, 1985, ACTA DERM-VENEREOL, P48; 1992, IMMUNOTHERAPY IGE ME, V12, P1	67	48	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1001	1011		10.1016/S0091-6749(96)80183-7	http://dx.doi.org/10.1016/S0091-6749(96)80183-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378					2022-12-18	WOS:A1996WB37800001
J	Lantner, RR				Lantner, RR			Ciprofloxacin desensitization in a patient with cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANAPHYLACTOID REACTIONS				Lantner, RR (corresponding author), LOYOLA UNIV,MED CTR,DEPT PATHOL,ALLERGY IMMUNOL SECT,MAYWOOD,IL 60153, USA.							DAVILA I, 1993, ALLERGY, V48, P388, DOI 10.1111/j.1398-9995.1993.tb02413.x; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; DEAMER RL, 1992, ANN PHARMACOTHER, V26, P1081, DOI 10.1177/106002809202600905; MILLER MS, 1991, PEDIATR INFECT DIS J, V10, P164, DOI 10.1097/00006454-199102000-00020; SCHACHT P, 1988, INFECTION, V16, pS29, DOI 10.1007/BF01650504	5	48	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				1001	1002		10.1016/S0091-6749(95)70240-7	http://dx.doi.org/10.1016/S0091-6749(95)70240-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543732				2022-12-18	WOS:A1995TN12400020
J	VANBERESTEIJN, ECH; MEIJER, RJGM; SCHMIDT, DG				VANBERESTEIJN, ECH; MEIJER, RJGM; SCHMIDT, DG			RESIDUAL ANTIGENICITY OF HYPOALLERGENIC INFANT FORMULAS AND THE OCCURRENCE OF MILK-SPECIFIC IGE ANTIBODIES IN PATIENTS WITH CLINICAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COWS MILK ALLERGY; ANTIGENICITY; ELISA; COW MILK HYDROLYSATE FORMULA; ALPHA-LACTALBUMIN; BETA-LACTOGLOBULIN; BOVINE SERUM ALBUMIN; BOVINE IGG; CASEIN; HYPOALLERGENIC	CASEIN HYDROLYSATE FORMULA; HUMAN-SERUM ANTIBODIES; HUMAN-BREAST-MILK; COW MILK; BETA-LACTOGLOBULIN; WHEY PROTEINS; CHILDREN; ALLERGENICITY; LACTALBUMIN; ANAPHYLAXIS	Background: Milk protein hydrolysates are frequently used in milk substitutes for children with cow's milk allergy. However, cases of hypersensitivity to commercially available hypoallergenic infant formulas based on milk protein hydrolysates have been reported. Objective: Our purpose was to determine the immunologic response of milk protein-specific IgE and IgG in the serum of patients allergic to cow's milk against foul commercially available hypoallergenic milk protein hydrolysates and eight infant formulas. Methods: Antibody levels in patients' serum and milk protein-specific residual antigenicity of the hypoallergenic products were determined by indirect and competitive ELISA. Results: Patients allergic to cow's milk had IgE and Ige antibodies to several protein fractions of cow's milk; intraindividual and interindividual variation in the concentrations of these antibodies was considerable. In general, IgE and IgG residual antigenicity of individual milk proteins in the hypoallergenic products was lower compared with that of the intact milk protein bur immunoreactive epitopes could still be detected in all products. Their number varied considerably among the individual milk proteins and also differed among products. Conclusions: The individual sensitization pattern of the patient allergic to cow's milk and the milk protein-specific residual antigenicity might be considered as possible laboratory predictors of adverse reactions to hypoallergenic products. Their determination could be a useful preclinical screening test for pediatricians to select a formula adapted to the individual patient.	NETHERLANDS INST DAIRY RES,DEPT BIOPHYS CHEM,6710 BA EDE,NETHERLANDS	NIZO Food Research	VANBERESTEIJN, ECH (corresponding author), NETHERLANDS INST DAIRY RES,DEPT NUTR,POB 20,6710 BA EDE,NETHERLANDS.							ASSELIN J, 1989, J FOOD SCI, V54, P1037, DOI 10.1111/j.1365-2621.1989.tb07938.x; BAHNA SL, 1978, ANN ALLERGY, V41, P1; BELL K, 1964, NATURE, V204, P1275, DOI 10.1038/2041275a0; BOCK SA, 1990, J ALLERGY CLIN IMMUN, V84, P272; BUSINCO L, 1994, CLIN EXP ALLERGY, V24, P42, DOI 10.1111/j.1365-2222.1994.tb00915.x; BUSINCO L, 1989, ANN ALLERGY, V62, P333; CHURCH FC, 1985, ANAL BIOCHEM, V146, P343, DOI 10.1016/0003-2697(85)90549-4; CLYNE PS, 1991, PEDIATRICS, V87, P439; CORDLE CT, 1991, J PEDIATR GASTR NUTR, V13, P270, DOI 10.1097/00005176-199110000-00006; DEAN TP, 1992, CLIN EXP ALLERGY, V23, P205; ELLIS MH, 1991, J PEDIATR-US, V118, P74, DOI 10.1016/S0022-3476(05)81849-9; ENA JM, 1995, J FOOD SCI, V60, P104, DOI 10.1111/j.1365-2621.1995.tb05616.x; FRISTER H, 1988, FRESEN Z ANAL CHEM, V30, P631; FRITSCHE R, 1990, INT ARCH ALLER A IMM, V93, P289, DOI 10.1159/000235256; GJESING B, 1986, ALLERGY, V41, P51, DOI 10.1111/j.1398-9995.1986.tb00275.x; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HEYMAN MB, 1990, J PEDIATR GASTR NUTR, V10, P253, DOI 10.1097/00005176-199002000-00020; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; KUITUNEN M, 1994, ALLERGY, V49, P354, DOI 10.1111/j.1398-9995.1994.tb02281.x; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LAU S, 1989, FOOD ALLERGY INFANCY, P173; LEBENTHAL E, 1975, PEDIATR CLIN N AM, V22, P827; LIFSCHITZ CH, 1988, J PEDIATR GASTROENTR, V77, P141; LOVEGROVE JA, 1993, GUT, V34, P203, DOI 10.1136/gut.34.2.203; MAEDA S, 1993, ACTA PAEDIATR, V82, P1012, DOI 10.1111/j.1651-2227.1993.tb12800.x; MAKINENKILJUNEN S, 1992, ALLERGY, V47, P347, DOI 10.1111/j.1398-9995.1992.tb02070.x; OLDAEUS G, 1991, PEDIATR ALLERGY IMMU, V4, P156; OTANI H, 1985, Japanese Journal of Zootechnical Science, V56, P67; OTANI H, 1987, Japanese Journal of Zootechnical Science, V58, P474; OTANI H, 1989, MILCHWISSENSCHAFT, V44, P131; OTANI H, 1989, MILCHWISSENSCHAFT, V44, P267; PICANTINI GL, 1994, ALLERGY, V49, P361; PLEBANI A, 1990, ANN ALLERGY, V64, P279; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; RUGO E, 1992, CLIN EXP ALLERGY, V22, P635, DOI 10.1111/j.1365-2222.1992.tb00180.x; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; SCHMIDT DG, 1993, NETH MILK DAIRY J, V47, P15; TAYLOR SL, 1986, J FOOD PROTECT, V49, P239, DOI 10.4315/0362-028X-49.3.239; VANBERESTEIJN ECH, 1994, J FOOD PROTECT, V57, P619, DOI 10.4315/0362-028X-57.7.619; VISSER S, 1992, J CHROMATOGR, V599, P205, DOI 10.1016/0021-9673(92)85474-8; 1989, ISO STANDARDS HDB, V3, P413	43	48	49	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					365	374		10.1016/S0091-6749(95)70056-0	http://dx.doi.org/10.1016/S0091-6749(95)70056-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560639				2022-12-18	WOS:A1995RU66000009
J	BUTTERFIELD, JH; GLEICH, GJ				BUTTERFIELD, JH; GLEICH, GJ			RESPONSE OF 6 PATIENTS WITH IDIOPATHIC-HYPEREOSINOPHILIC-SYNDROME TO INTERFERON-ALFA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EOSINOPHILIC ENDOMYOCARDIAL DISEASE; CHRONIC MYELOGENOUS LEUKEMIA; ELEVATED SERUM LEVELS; CLINICOPATHOLOGIC CORRELATION; ALPHA-INTERFERON; THERAPY; MANIFESTATIONS; HYDROXYUREA; RECEPTOR		MAYO CLIN & MAYO GRAD SCH MED, DEPT INTERNAL MED, DIV ALLERG DIS, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO GRAD SCH MED, DEPT IMMUNOL, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic	BUTTERFIELD, JH (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031155, R37AI009728, R37AI015231, R01AI009728, R01AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31155, AI 15231, AI 09728] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHIMBAUD E, 1988, AM J HEMATOL, V27, P302, DOI 10.1002/ajh.2830270414; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; BUSCH FW, 1991, ANN INTERN MED, V114, P338, DOI 10.7326/0003-4819-114-4-338_2; BUSH RK, 1978, ARCH INTERN MED, V138, P1244, DOI 10.1001/archinte.138.8.1244; BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; CHAMBERS LA, 1990, APHERESIS, V337, P83; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; COUTANT G, 1993, ANN MED INTERNE, V144, P243; DALE DC, 1976, J LAB CLIN MED, V87, P487; DASILVA MAP, 1988, CANCER GENET CYTOGEN, V32, P109, DOI 10.1016/0165-4608(88)90317-2; DAVIES J, 1981, BRIT HEART J, V46, P438; DAVIES J, 1983, Q J MED, V52, P23; DINE G, 1992, PRESSE MED, V21, P1776; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FLAUM MA, 1981, BLOOD, V58, P1012; GALVANI DW, 1983, BR JHAEMATOL, V73, P475; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; KENNEDY BJ, 1972, CANCER-AM CANCER SOC, V29, P1052, DOI 10.1002/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7; KOBAYASHI M, 1993, JPN J CLIN HEMATOL, V34, P367; LEIFERMAN KM, 1982, JAMA-J AM MED ASSOC, V247, P1018, DOI 10.1001/jama.247.7.1018; MARSHALL GM, 1989, AM J PEDIAT HEMATOL, V11, P178; MURPHY PT, 1990, BRIT J HAEMATOL, V75, P619, DOI 10.1111/j.1365-2141.1990.tb07811.x; Parrillo J E, 1977, Trans Assoc Am Physicians, V90, P135; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; PRIN L, 1991, BLOOD, V78, P2626; PRIN L, 1989, CLIN EXP IMMUNOL, V78, P383; RATAIN MJ, 1987, BLOOD, V69, P872; SCHOOLEY RT, 1981, BLOOD, V58, P1021; SMIT AJ, 1991, CANCER-AM CANCER SOC, V67, P2826, DOI 10.1002/1097-0142(19910601)67:11<2826::AID-CNCR2820671119>3.0.CO;2-#; SPRY CJF, 1983, Q J MED, V52, P1; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WEMMER U, 1988, HAUTARZT, V39, P42; WYNN SR, 1987, J PEDIATR-US, V111, P94, DOI 10.1016/S0022-3476(87)80352-9; YARBRO JW, 1968, CANCER RES, V28, P1082; ZABEL P, 1991, ANN HEMATOL, V62, P230, DOI 10.1007/BF01729838; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	37	48	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1318	1326		10.1016/0091-6749(94)90348-4	http://dx.doi.org/10.1016/0091-6749(94)90348-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798572				2022-12-18	WOS:A1994QA02000028
J	KINBERG, KA; HOPP, RJ; BIVEN, RE; GALLAGHER, JC				KINBERG, KA; HOPP, RJ; BIVEN, RE; GALLAGHER, JC			BONE-MINERAL DENSITY IN NORMAL AND ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BONE DENSITY; CHILDREN; CORTICOSTEROIDS; ABSORPTIOMETRY CALCIUM	INHALED BUDESONIDE; GENETIC-DETERMINANTS; AIRWAY INFLAMMATION; GROWTH; MASS; METABOLISM; CHILDHOOD; CALCIUM; OSTEOPOROSIS; DISEASE	Background: The largest increase in bone mass occurs during childhood and adolescence. A subnormal bone mass is associated with increased risk of fracture. Bone mass is influenced by height, age, race, exercise, and stage of puberty. It is adversely affected by chronic disease states and corticosteroid use. We performed a cross-sectional study of bone density in children with moderate to severe asthma who were treated with inhaled corticosteroids, inhaled cromolyn, oral corticosteroids, or a combination of these, and we compared them with normal children. Methods: A cross-sectional study of bone density, measured either by dual-photon or dual-energy absorptiometry was performed on 97 normal white and 30 asthmatic white children, aged 5 to 18. Average daily calcium intake, height, weight, and Tanner stage were determined. The total daily and lifetime doses of inhaled corticosteroids in children with asthma were calculated. T tests, multiple regression, chi square analysis, and analysis of covariance were performed. Results: No significant difference in bone density was demonstrated between children with asthma and normal control subjects. No measure (including calcium intake, Tanner stage, daily or lifetime inhaled corticosteroid dose, or duration of illness), except for height and age, provided a significant contribution to the explanation of bone density in children with asthma. Conclusion: Children and adolescents with moderate to severe asthma, including those treated with inhaled corticosteroids, do not appear to have adversely affected bone mass. There was, however, the possibility of a type II error in this study because of the sample size.	CREIGHTON UNIV, SCH MED, DEPT PEDIAT, OMAHA, NE 68178 USA; CREIGHTON UNIV, SCH MED, DEPT MED, OMAHA, NE USA	Creighton University; Creighton University			Hopp, Russell/K-4578-2019	gallagher, john christopher/0000-0002-5129-9183				ALI NJ, 1989, THORAX, V44, pP900; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BELL NH, 1991, J BONE MINER RES, V6, P719; BROWN DCP, 1989, ANN ALLERGY, V63, P47; CHAN GM, 1991, AM J DIS CHILD, V145, P631, DOI 10.1001/archpedi.1991.02160060049019; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; CHESNEY RW, 1988, J PEDIATR, V113, P172; Cochran W.G, 1957, STAT METHODS, V6th ed; DESCHEPPER J, 1991, J NUCL MED, V32, P216; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; FERGUSON AC, 1982, J ALLERGY CLIN IMMUN, V69, P461, DOI 10.1016/0091-6749(82)90122-1; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GIBBENS DT, 1988, J PEDIATR-US, V113, P295, DOI 10.1016/S0022-3476(88)80268-3; GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HOPP R, 1991, J RHEUMATOL, V18, P1235; HOPP R, 1992, J ALLERGY CLIN IMMUN, V89, P343; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; KALINER M, 1989, J ALLERGY CLIN IMMUN, V83, P510, DOI 10.1016/0091-6749(89)90031-6; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; OTT SM, 1990, J CLIN ENDOCR METAB, V71, pA1082; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; PREECE MA, 1986, CLIN ENDOCRINOL META, V15, P453, DOI 10.1016/S0300-595X(86)80006-8; PRICE JF, 1993, RESP MED, V87, P23, DOI 10.1016/S0954-6111(05)80253-7; ROSENBLOOM AL, 1977, DIABETES, V26, P1052, DOI 10.2337/diabetes.26.11.1052; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63, DOI 10.1136/adc.62.1.63; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SORVA R, 1992, J ALLERGY CLIN IMMUN, V90, P808, DOI 10.1016/0091-6749(92)90106-C; SOUTHARD RN, 1991, RADIOLOGY, V179, P735, DOI 10.1148/radiology.179.3.2027984; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BRIT MED J, V302, P627; 1991, NIH913042 DEP HLTH H, P35	44	48	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				490	497		10.1016/0091-6749(94)90205-4	http://dx.doi.org/10.1016/0091-6749(94)90205-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083454				2022-12-18	WOS:A1994PG90700008
J	WARRINGTON, RJ; SILVIUDAN, F; MAGRO, C				WARRINGTON, RJ; SILVIUDAN, F; MAGRO, C			ACCELERATED CELL-MEDIATED IMMUNE-REACTIONS IN PENICILLIN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV MANITOBA,DEPT PATHOL,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	WARRINGTON, RJ (corresponding author), UNIV MANITOBA,DEPT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA.							AHLSTEDT S, 1982, PROG ALLERGY, V30, P67; Lemanske R F Jr, 1991, Adv Intern Med, V36, P171; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; VEGA JM, 1991, ALLERGY, V46, P154, DOI 10.1111/j.1398-9995.1991.tb00560.x	4	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					626	628		10.1016/0091-6749(93)90088-W	http://dx.doi.org/10.1016/0091-6749(93)90088-W			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	7691916				2022-12-18	WOS:A1993MC59000016
J	CIPRANDI, G; BUSCAGLIA, S; PESCE, GP; BAGNASCO, M; CANONICA, GW				CIPRANDI, G; BUSCAGLIA, S; PESCE, GP; BAGNASCO, M; CANONICA, GW			OCULAR CHALLENGE AND HYPERRESPONSIVENESS TO HISTAMINE IN PATIENTS WITH ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV GENOA,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SERV,DIMI,VIALE BENEDETTO XV 6,I-16132 GENOA,ITALY	University of Genoa			Ciprandi, Giorgio/G-7462-2012; canonica, giorgio walter/ABF-2037-2020	Ciprandi, Giorgio/0000-0001-7016-8421; canonica, giorgio walter/0000-0001-8467-2557; Pesce, Giampaola/0000-0002-6294-9110				Abelson M B, 1981, Ann Ophthalmol, V13, P1225; BONINI S, 1992, J ALLERGY CLIN IMMUN, V89, P103, DOI 10.1016/S0091-6749(05)80046-6; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; VANWIJK RG, 1991, CLIN EXP ALLERGY, V21, P661; VRIES KD, 1987, BRONCHIAL HYPERRESPO, P359	6	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1227	1230		10.1016/0091-6749(93)90327-C	http://dx.doi.org/10.1016/0091-6749(93)90327-C			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8099594				2022-12-18	WOS:A1993LG74000016
J	WOOD, RA; MUDD, KE; EGGLESTON, PA				WOOD, RA; MUDD, KE; EGGLESTON, PA			THE DISTRIBUTION OF CAT AND DUST MITE ALLERGENS ON WALL SURFACES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CAT ALLERGEN; DUST MITE; HOUSE DUST	FEL-D-I; CASCADE IMPACTOR; ASTHMA; EXPOSURE; ANTIBODIES; DOMESTICUS; SAMPLES	This study was undertaken to determine the distribution of cat and dust mite allergens on wall surfaces and to assess the value of wall-wipe samples as a measure of allergen exposure. Paired samples were collected from 31 homes, 20 homes with cats and 11 homes without, by vacuuming 1 m2 of carpet and by wiping 1 square foot of an adjacent wall. Felis domesticus allergen I (Fel d I) was detected in 30 of 31 settled dust samples (range, not detectable to 832,000 mU/gm; median, 10,250 mU/gm) and in 27 of 31 wall-wipe samples (range, not detectable to 113.7 mU per filter; median, 1.2 mU per filter). There was a significant correlation between Fel d I content in settled dust and wall-wipe samples (r(s) = 0.73; p < 0.001). To assess the reproducibility of the wall-wipe method, multiple wipe samples were obtained from 20 homes, revealing a mean coefficient of variation of 110%. In contrast to Fel d I, although Dermatophagoides farinae allergen I was detected in 23 of 25 settled dust samples (range, not detectable to 11,888 ng/gm; median, 1178 ng/gm), it was detected in only four of 25 wall-wipe samples. We conclude that cat allergen, but not dust mite allergen, is widely distributed on wall surfaces and that wipe samples provide a simple and effective means of assessing household exposure to cat allergen.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NIAID NIH HHS [AI-21073] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7	12	48	49	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				126	130		10.1016/S0091-6749(05)80049-1	http://dx.doi.org/10.1016/S0091-6749(05)80049-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730832				2022-12-18	WOS:A1992GZ90800015
J	TURPEINEN, M; SORVA, R; JUNTUNENBACKMAN, K				TURPEINEN, M; SORVA, R; JUNTUNENBACKMAN, K			CHANGES IN CARBOHYDRATE AND LIPID-METABOLISM IN CHILDREN WITH ASTHMA INHALING BUDESONIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; CHILDREN; GLUCOCORTICOIDS-TOPICAL; PITUITARY-ADRENAL FUNCTION TESTS; CARBOHYDRATE METABOLISM; LIPID METABOLISM	BECLOMETHASONE DIPROPIONATE; PLASMA-LIPOPROTEINS; SHORT-TERM; PREDNISONE; CORTICOSTEROIDS; CHOLESTEROL; MANAGEMENT	In a longitudinal study, antiasthmatic and metabolic effects of budesonide inhalations in initially high (800-mu-g/m2/day for 1 month) and subsequently lower (400-mu-g/m2/day for 4 months) dosage were evaluated in nine children with asthma, aged 5 to 10 years. The FEV1 increased significantly after high dosage (median, 96.5% versus 105.5%; p = 0.0339). After lower dosage, FEV1 was still higher than at the baseline (106% versus 96.5%; p = 0.0339). Clinically, no additional beta-2-agonist was needed after 2 weeks of treatment. Serum high-density lipoprotein cholesterol increased significantly by 22% after high dosage (medians, 1.18 versus 1.44 mmol/L). A significant decline to 1.31 mmol/L was observed when the dose was reduced (overall, p = 0.0319). The treatment had no significant effect on serum total cholesterol, on serum triglycerides, on the ratio of high-density lipoprotein to total cholesterol, on the body mass index, or on glucose tolerance. The high dosage increased significantly the ratio of serum insulin to blood glucose, calculated from the areas under the incremental 2-hour curves in the glucose tolerance test (medians, 17.3 versus 23.2 mU/mmol). After lower dosage, the ratio declined significantly to 13.5 mU/mmol (overall, p = 0.0164). No significant changes were observed in plasma cortisol in the 2-hour adrenocorticotropic hormone test. The antiasthmatic effect of budesonide inhalations in a dose of 800-mu-g/m2/day for 1 month was accompanied by detectable changes in lipid and carbohydrate metabolism. These metabolic changes were reversible, and the antiasthmatic effect could be maintained by a dose of 400-mu-g/m2 for 4 months without significant systemic effects. This dose is safe and efficient in the maintenance treatment of childhood asthma.			TURPEINEN, M (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT ALLERG DIS, SF-00290 HELSINKI 29, FINLAND.							BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BARAN D, 1987, BRIT J DIS CHEST, V81, P170, DOI 10.1016/0007-0971(87)90135-5; DIXON WJ, 1988, BMDP STATISTICAL SOF, P424; ETTINGER WH, 1987, ATHEROSCLEROSIS, V63, P167, DOI 10.1016/0021-9150(87)90117-1; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; KOVANEN PT, 1990, EUR HEART J, V11, P238, DOI 10.1093/eurheartj/11.suppl_E.238; KRUSZYNSKA YT, 1987, THORAX, V42, P881, DOI 10.1136/thx.42.11.881; LAUTALA P, 1985, ACTA PAEDIATR SCAND, P127; LAW CM, 1986, LANCET, V1, P942; LEISTI S, 1978, PEDIATR RES, V12, P272, DOI 10.1203/00006450-197804000-00005; LENTNER C, 1982, GEIGY SCI TABLES, V2, P178; MARBLE A, 1985, JOSLINS DIABETES MEL, P334; PAGANO G, 1983, J CLIN INVEST, V72, P1814, DOI 10.1172/JCI111141; PERLMAN K, 1982, AM J DIS CHILD, V136, P64, DOI 10.1001/archpedi.1982.03970370066017; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; TASKINEN MR, 1983, J CLIN ENDOCR METAB, V57, P619, DOI 10.1210/jcem-57-3-619; TASKINEN MR, 1988, J CLIN ENDOCR METAB, V67, P291, DOI 10.1210/jcem-67-2-291; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; VIIKARI J, 1985, ACTA PAEDIATR SCAND, P103; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; YERNAULT JC, 1977, CHEST, V71, P698, DOI 10.1378/chest.71.6.698; ZIMMERMAN J, 1984, METABOLISM, V33, P521, DOI 10.1016/0026-0495(84)90006-4	22	48	50	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				384	389		10.1016/0091-6749(91)90101-S	http://dx.doi.org/10.1016/0091-6749(91)90101-S			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890267				2022-12-18	WOS:A1991GG12600033
J	STOOP, AE; VANDERHEIJDEN, HAMD; BIEWENGA, J; VANDERBAAN, S				STOOP, AE; VANDERHEIJDEN, HAMD; BIEWENGA, J; VANDERBAAN, S			LYMPHOCYTES AND NONLYMPHOID CELLS IN HUMAN NASAL POLYPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EOSINOPHIL CHEMOTACTIC FACTORS; CD8 MOLECULES; MUCOSA; SUBSETS; EPITHELIUM; ACTIVATION	Immunohistochemical stainings were performed on polyp specimens of 48 patients and on mucosal biopsy specimens of the middle and inferior turbinates of 23 and 28 patients, respectively. Significantly more CD8+ (suppressor/cytotoxic) than CD4+ (helper/inducer) cells were found in the polyps. The number of CD2+, CD4+, and CD8+ lymphocytes in nasal polyps were very similar to the number in the macroscopically unaffected mucosa of the middle turbinates, whereas scores in the inferior turbinates were lower. In healthy subjects, the differences were smaller. CD22+ B cells were detected in varying numbers in the polyps in more or less organized clusters. Significantly more HLA-DR+ cells were found in polyps and middle turbinates than in the inferior turbinates. Eosinophils were found in moderate to large numbers in polyps of 77% of the patients. Mast cells and plasma cells were detected in moderate numbers, whereas neutrophils were found in 35% of the patients. In the middle and inferior turbinates varying but small numbers of eosinophils, mast cells, plasma cells, and neutrophils were found. In considering these findings, the role of chronic inflammation with T cell-dependent disturbances is discussed with regard to the pathogenesis of nasal polyps.	FREE UNIV AMSTERDAM,FAC MED,DEPT CELL BIOL,1007 MC AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	STOOP, AE (corresponding author), FREE UNIV AMSTERDAM,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,DEBOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.							Brandtzaeg P., 1984, IMMUNOLOGY LUNG UPPE, P28; CAPLIN I, 1971, ANN ALLERGY, V29, P631; CHIKKAPPA G, 1984, BLOOD, V63, P356; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DRAKELEE AB, 1988, J LARYNGOL OTOL, V102, P1099, DOI 10.1017/S0022215100107431; DREXHAGE HA, 1983, CLIN IMMUNOL IMMUNOP, V28, P218, DOI 10.1016/0090-1229(83)90156-3; ERNST PB, 1987, BASIC CLIN IMMUNOL, P159; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; HAMELEERS DMH, 1989, INT ARCH ALLER A IMM, V88, P317, DOI 10.1159/000234818; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HIRASHIMA M, 1986, CLIN IMMUNOL IMMUNOP, V39, P231, DOI 10.1016/0090-1229(86)90087-5; KEIDAN AJ, 1985, CLIN LAB HAEMATOL, V7, P83, DOI 10.1111/j.1365-2257.1985.tb00009.x; KELLY J, 1987, J IMMUNOL METHODS, V96, P127, DOI 10.1016/0022-1759(87)90376-0; KNUTSEN AP, 1988, INT ARCH ALLER A IMM, V85, P208, DOI 10.1159/000234504; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; MULLARKEY MF, 1988, J ALLERGY CLIN IMMUN, V82, P941, DOI 10.1016/0091-6749(88)90037-1; NISHIMOTO K, 1988, ACTA OTO-LARYNGOL, V106, P291, DOI 10.3109/00016488809106439; SAKAGUCHI K, 1986, ACTA OTOLARYNGOL S, V430, P28; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P398; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; SMITH DM, 1987, INT ARCH ALLER A IMM, V82, P83, DOI 10.1159/000234295; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; TAKADA S, 1987, J IMMUNOL, V139, P3231; TAMURA N, 1988, J IMMUNOL, V141, P4291; WILSON JA, 1976, CLIN OTOLARYNGOL, V1, P4, DOI 10.1111/j.1365-2273.1976.tb00635.x; WINTHER B, 1987, ARCH OTOLARYNGOL, V113, P59	27	48	52	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					470	475		10.1016/0091-6749(91)90004-8	http://dx.doi.org/10.1016/0091-6749(91)90004-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993807				2022-12-18	WOS:A1991EX98700003
J	WENTZ, PE; SWANSON, MC; REED, CE				WENTZ, PE; SWANSON, MC; REED, CE			VARIABILITY OF CAT-ALLERGEN SHEDDING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic								ANDERSON MC, 1981, J IMMUNOL, V127, P972; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V75, P563; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; LI Y, 1988, J ALLERGY CLIN IMMUN, V81, P308, DOI 10.1016/0091-6749(88)90794-4; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7	8	48	50	2	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				94	98		10.1016/0091-6749(90)90228-V	http://dx.doi.org/10.1016/0091-6749(90)90228-V			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299111	Bronze			2022-12-18	WOS:A1990CM37800016
J	DELCARPIO, J; KABBASH, L; TURENNE, Y; PREVOST, M; HEBERT, J; BEDARD, PM; NEDILSKI, M; GUTKOWSKI, A; SCHULZ, J				DELCARPIO, J; KABBASH, L; TURENNE, Y; PREVOST, M; HEBERT, J; BEDARD, PM; NEDILSKI, M; GUTKOWSKI, A; SCHULZ, J			EFFICACY AND SAFETY OF LORATADINE (10 MG ONCE DAILY), TERFENADINE (60 MG TWICE DAILY), AND PLACEBO IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CLIN DOMUS MED, MONTREAL, QUEBEC, CANADA; CHU LAVAL, DEPT IMMUNOL & ALLERGY, STE FOY, QUEBEC, CANADA; CTR MED ST HUBERT, ST HUBERT, QUEBEC, CANADA; ST MICHAELS HOSP, TORONTO M5B 1W8, ONTARIO, CANADA; ST MARYS HOSP, DIV IMMUNOL & RHEUMATOL, MONTREAL, QUEBEC, CANADA	Laval University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McGill University	DELCARPIO, J (corresponding author), ROYAL VICTORIA HOSP, DIV ALLERGY & IMMUNOL, 687 PINE AVE, MONTREAL H3A 1A1, QUEBEC, CANADA.							BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BATENHORST RL, 1986, EUR J CLIN PHARMACOL, V31, P247, DOI 10.1007/BF00606669; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; DROUIN MA, 1985, ANN ALLERGY, V55, P747; KASSEM N, 1988, ANN ALLERGY, V60, P505; ROMAN IJ, 1986, ANN ALLERGY, V57, P253	6	48	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				741	746						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2572617				2022-12-18	WOS:A1989CA31400012
J	SLY, RM				SLY, RM			MORTALITY FROM ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP, NATL MED CTR, DEPT ALLERGY & IMMUNOL, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, SCH MED & HLTH SCI, WASHINGTON, DC 20052 USA	Children's National Health System; George Washington University								Adams F, 1856, EXTANT WORKS ARETAEU; ALEXANDER HL, 1963, J ALLERGY, V34, P305, DOI 10.1016/0021-8707(63)90039-X; [Anonymous], 1984, Thorax, V39, P505; ASHER MI, 1988, AM REV RESPIR DIS, V138, P524, DOI 10.1164/ajrccm/138.3.524; ATTAWAY NJ, 1988, J ALLERGY CLIN IMMUN, V81, P306, DOI 10.1016/0091-6749(88)90786-5; BALAZS T, 1982, CARDIOVASCULAR TOXIC, P199; BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BARGER LW, 1988, ANN ALLERGY, V60, P31; BARRIOT P, 1987, CHEST, V92, P460, DOI 10.1378/chest.92.3.460; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BOSCO LA, 1987, J ALLERGY CLIN IMMUN, V80, P398, DOI 10.1016/0091-6749(87)90058-3; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; BURANAKUL B, 1974, AM J DIS CHILD, V128, P343, DOI 10.1001/archpedi.1974.02110280073009; BUTLER JA, 1987, PEDIATRICS, V79, P89; CARSWELL F, 1985, ARCH DIS CHILD, V60, P25, DOI 10.1136/adc.60.1.25; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; COLLINSWILLIAMS C, 1981, CAN MED ASSOC J, V125, P341; CONWAY SP, 1985, ARCH DIS CHILD, V60, P636, DOI 10.1136/adc.60.7.636; CULLINS JM, 1969, BRIT J PHARMACOL, V36, P35; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; DWORETZK.M, 1968, J ALLERGY, V41, P181, DOI 10.1016/0021-8707(68)90041-5; ELLIS ME, 1985, BRIT J DIS CHEST, V79, P43, DOI 10.1016/0007-0971(85)90006-3; GANDEVIA B, 1973, MED J AUSTRALIA, V1, P273, DOI 10.5694/j.1326-5377.1973.tb119742.x; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GLEICH GJ, 1987, J ALLERGY CLIN IMMUN, V80, P412, DOI 10.1016/0091-6749(87)90063-7; HENDELES L, 1985, CHEST, V88, pS103; HILLS E A, 1984, Thorax, V39, P505; IISALO EI, 1969, ACTA MED SCAND, V185, P45; INMAN WHW, 1969, LANCET, V2, P279; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; JOSEPHSON GW, 1980, CHEST, V78, P429, DOI 10.1378/chest.78.3.429; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; KLEBBA AJ, 1980, DHEW PHS801120 INT S, V28; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; KRAVIS LP, 1987, J ALLERGY CLIN IMMUN, V80, P467, DOI 10.1016/0091-6749(87)90077-7; KUNG M, 1984, AM REV RESPIR DIS, V129, P329; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LAENNEC RTH, 1829, TREATISE DISEASES CH; LANOFF G, 1964, ANN ALLERGY, V22, P349; LEVINE JH, 1985, LANCET, V1, P12; LEWIS CE, 1987, J ALLERGY CLIN IMMUN, V80, P498, DOI 10.1016/0091-6749(87)90085-6; LEWIS CE, 1984, PEDIATRICS, V74, P478; MAGNUSSON G, 1973, CARDIOLOGY, V58, P174, DOI 10.1159/000169631; MAGUIRE JF, 1986, J ALLERGY CLIN IMMUN, V78, P631, DOI 10.1016/0091-6749(86)90081-3; MAIMONIDES M, 1963, TREATISE ASTHMA; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; MILLER BD, 1988, J ALLERGY CLIN IMMUN, V81, P306, DOI 10.1016/0091-6749(88)90785-3; MITCHELL EA, 1981, NEW ZEAL MED J, V94, P331; NEVILLE A, 1977, BRIT MED J, V1, P413, DOI 10.1136/bmj.1.6058.413; NEWCOMB RW, 1988, AM J DIS CHILD, V142, P1041, DOI 10.1001/archpedi.1988.02150100035020; NGUYEN MT, 1985, ANN ALLERGY, V55, P448; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; Osler WB, 1892, PRINCIPLES PRACTICE, P498; PALM CR, 1970, J ALLERGY, V46, P257, DOI 10.1016/0021-8707(70)90067-5; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REA HH, 1987, NEW ZEAL MED J, V100, P10; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; RIDING W D, 1970, British Journal of Diseases of the Chest, V64, P37, DOI 10.1016/S0007-0971(70)80047-X; SCHEININ M, 1987, BRIT J CLIN PHARMACO, V24, P645, DOI 10.1111/j.1365-2125.1987.tb03224.x; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SEARS MR, 1986, EUR J RESPIR DIS, V69, P175; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1985, NEW ZEAL MED J, V98, P765; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SLY RM, 1986, ANN ALLERGY, V56, P207; SLY RM, 1989, ANN ALLERGY, V62, P347; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SLY RM, 1986, NEW ENGL REG ALLERGY, V7, P425; SOIFER H, 1957, J PEDIATR-US, V50, P657, DOI 10.1016/S0022-3476(57)80303-5; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPEIZER FE, 1987, J ALLERGY CLIN IMMUN, V80, P368, DOI 10.1016/0091-6749(87)90051-0; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; TAL A, 1984, CHEST, V86, P868, DOI 10.1378/chest.86.6.868; WHITEHURST VE, 1983, J AM COLL TOXICOL, V2, P147, DOI 10.3109/10915818309140676; WILLIAMS AJ, 1987, EUR J RESPIR DIS, V71, P259; WILSON JD, 1981, LANCET, V1, P1235; WISSOW LS, 1988, AM J DIS CHILD, V142, P748, DOI 10.1001/archpedi.1988.02150070062026; ZUMWALT RE, 1987, POSTGRAD MED, V81, P245, DOI 10.1080/00325481.1987.11699876; 1988, NCHS MONTHLY VITAL S, V37; 1950, VITAL STATISTICS US, P60	94	48	49	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				421	434		10.1016/0091-6749(89)90351-5	http://dx.doi.org/10.1016/0091-6749(89)90351-5			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2677091				2022-12-18	WOS:A1989AW76000002
J	FRICK, WE; SEDGWICK, JB; BUSSE, WW				FRICK, WE; SEDGWICK, JB; BUSSE, WW			HYPODENSE EOSINOPHILS IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FRICK, WE (corresponding author), UNIV WISCONSIN,DEPT MED,600 HIGHLAND AVE,MADISON,WI 53792, USA.				NIAID NIH HHS [AI 15685, AI 23181, AI 10404] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023181, R01AI015685, P50AI010404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; CAPRON M, 1984, J IMMUNOL, V132, P462; Cohen SG, 1983, ALLERGY PRINCIPLES P, P701; DESIMONE C, 1986, CLIN EXP IMMUNOL, V63, P466; FRIGAS E, 1980, LAB INVEST, V42, P35; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GLEICH GJ, 1986, NEW ENGL REG ALLERGY, V7, P421; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GOETZL EJ, 1979, ADV INFLAMMATION RES, V1, P152; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; HUBSCHER T, 1975, J IMMUNOL, V114, P1379; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P90, DOI 10.1016/0091-6749(79)90042-3; Kazura J. W., 1980, The eosinophil in health and disease. (Proc. eosinophil centennial, Brook Lodge, Augusta, Michigan, Sep. 24-28 1979)., P231; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KLEBANOFF SJ, 1983, IMMUNOBIOLOGY EOSINO, P276; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OLOFSSON T, 1980, SCAND J HAEMATOL, V24, P254; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PINCUS SH, 1983, J INVEST DERMATOL, V80, P278, DOI 10.1111/1523-1747.ep12534646; PINCUS SH, 1981, BLOOD, V58, P1175; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROBERTS RL, 1985, BLOOD, V65, P433; SHULT PA, 1986, J ALLERGY CLIN IMMUN, V77, P702, DOI 10.1016/0091-6749(86)90414-8; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; WEISBART RH, 1987, BLOOD, V69, P18; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	31	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					119	125		10.1016/0091-6749(88)90061-9	http://dx.doi.org/10.1016/0091-6749(88)90061-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	2899103				2022-12-18	WOS:A1988P400400020
J	HUBERT, D; GAUDRIC, M; GUERRE, J; LOCKHART, A; MARSAC, J				HUBERT, D; GAUDRIC, M; GUERRE, J; LOCKHART, A; MARSAC, J			EFFECT OF THEOPHYLLINE ON GASTROESOPHAGEAL REFLUX IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PARIS 05,HOP COCHIN,DEPT PNEUMOL,F-75270 PARIS 06,FRANCE; UNIV PARIS 05,HOP COCHIN,DEPT GASTROENTEROL,F-75270 PARIS 06,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								ALLEN CJ, 1984, AM REV RESPIR DIS, V129, P645; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BENGTSSON U, 1985, LANCET, V1, P1501; BERQUIST WE, 1981, J ALLERGY CLIN IMMUN, V67, P407, DOI 10.1016/0091-6749(81)90087-7; BERQUIST WE, 1984, J ALLERGY CLIN IMMUN, V73, P253, DOI 10.1016/S0091-6749(84)80016-0; CHRISTENSEN J, 1976, ARCH INTERN MED, V136, P532, DOI 10.1001/archinte.136.5.532; CLEMENCON G H, 1961, Gastroenterologia, V95, P110; DIMARINO AJ, 1982, DIGEST DIS SCI, V27, P1063, DOI 10.1007/BF01391441; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; FOSTER LJ, 1979, JAMA-J AM MED ASSOC, V241, P2613, DOI 10.1001/jama.241.24.2613; GALMICHE JP, 1980, GASTROEN CLIN BIOL, V4, P531; GOODALL RJR, 1981, THORAX, V36, P116, DOI 10.1136/thx.36.2.116; GOYAL RK, 1973, J CLIN INVEST, V52, P337, DOI 10.1172/JCI107189; KAYE MD, 1977, GUT, V18, P709, DOI 10.1136/gut.18.9.709; KJELLEN G, 1981, EUR J RESPIR DIS, V62, P190; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MAYS EE, 1976, JAMA-J AM MED ASSOC, V236, P2626, DOI 10.1001/jama.236.23.2626; NELSON HS, 1984, J ALLERGY CLIN IMMUN, V73, P547, DOI 10.1016/0091-6749(84)90509-8; OVERHOLT RH, 1966, DIS CHEST, V49, P464; PASQUIS P, 1983, B EUR PHYSIOPATH RES, V19, P645; PELLEGRINI CA, 1979, SURGERY, V86, P110; PERRIN-FAYOLLE M, 1980, Poumon et le Coeur, V36, P231; PERRIN-FAYOLLE M, 1980, Poumon et le Coeur, V36, P225; SHAPIRO GG, 1979, PEDIATRICS, V63, P207; SINGH V, 1983, J ASTHMA, V20, P241, DOI 10.3109/02770908309077083; SPAULDING HS, 1982, J ALLERGY CLIN IMMUN, V69, P516, DOI 10.1016/0091-6749(82)90176-2; STANCIU C, 1975, ARCH FR MAL APP DIG, V64, P125; STEIN MR, 1980, ANN ALLERGY, V45, P238; ZFASS AM, 1970, AM J DIG DIS, V15, P303, DOI 10.1007/BF02239282; 1985, LANCET, V2, P1399; [No title captured]	32	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1168	1174		10.1016/0091-6749(88)90886-X	http://dx.doi.org/10.1016/0091-6749(88)90886-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	2897987				2022-12-18	WOS:A1988P002300016
J	REED, CE; MARCOUX, JP; WELSH, PW				REED, CE; MARCOUX, JP; WELSH, PW			EFFECTS OF TOPICAL NASAL TREATMENT ON ASTHMA SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REED, CE (corresponding author), MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905, USA.							AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; BULLEN SS, 1932, J ALLERGY, V4, P402; CHATTERJEE S S, 1974, Clinical Allergy, V4, P343, DOI 10.1111/j.1365-2222.1974.tb01395.x; FRANKLAND A W, 1975, Clinical Allergy, V5, P295, DOI 10.1111/j.1365-2222.1975.tb01866.x; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; MORROWBROWN H, 1984, ALLERGOL IMMUNOPATH, V12, P355; PAINTAL AS, 1973, PHYSIOL REV, V53, P159, DOI 10.1152/physrev.1973.53.1.159; PHIPATANAKUL CS, 1974, ARCH OTOLARYNGOL, V109, P100; REED CE, 1982, ALLERGY PRINCIPLES P, P811; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	12	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1042	1047		10.1016/0091-6749(88)90177-7	http://dx.doi.org/10.1016/0091-6749(88)90177-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3131406				2022-12-18	WOS:A1988N703700022
J	BARNES, PJ				BARNES, PJ			PLATELET-ACTIVATING FACTOR AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARNES, PJ (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT THORAC MED,FULHAM RD,LONDON SW3 6HP,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ARNOUX B, 1985, American Review of Respiratory Disease, V131, pA2; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; AURSUDKIJ B, 1987, American Review of Respiratory Disease, V135, pA160; BARNES NC, 1984, PROSTAGLANDINS, V28, P629, DOI 10.1016/0090-6980(84)90137-0; BARNES P J, 1986, British Journal of Pharmacology, V89, p764P; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1987, AM REV RESPIR DIS, V135, P526; CAMUSSI G, 1983, AM J PATHOL, V112, P75; CHUNG K F, 1987, American Review of Respiratory Disease, V135, pA181; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1987, LANCET, V1, P248; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CHUNG KF, 1987, PAF PULMONARY HYPERR; CUSS FM, 1986, LANCET, V2, P189; DARIUS H, 1986, SCIENCE, V232, P58, DOI 10.1126/science.3082008; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EVANS T W, 1987, American Review of Respiratory Disease, V135, pA315; EVANS TW, J APPL PHYSL; FITZGERALD MF, 1986, BRIT J PHARMACOL, V88, P149, DOI 10.1111/j.1476-5381.1986.tb09481.x; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; GATEAU O, 1984, American Review of Respiratory Disease, V129, pA3; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HENOCQ E, 1986, LANCET, V1, P1378; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEFORT J, 1984, BRIT J PHARMACOL, V82, P525; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; MAZZONI L, 1985, J PHYSL, V365, P107; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MORLEY J, 1984, LANCET, V2, P1142; PERSSON CGA, 1986, LANCET, V2, P1126; ROGERS D F, 1987, American Review of Respiratory Disease, V135, pA160; RUBIN AE, 1986, AM REV RESPIR DIS, V133, P91; SCHELLENBERG RR, 1983, J ALLERGY CLIN IMMUN, V71, P145, DOI 10.1016/0091-6749(83)90351-2; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WIRTZ H, 1986, FED PROC, V45, P418	48	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					152	160		10.1016/0091-6749(88)90234-5	http://dx.doi.org/10.1016/0091-6749(88)90234-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276760				2022-12-18	WOS:A1988M027400023
J	STRUNK, RC				STRUNK, RC			ASTHMA DEATHS IN CHILDHOOD - IDENTIFICATION OF PATIENTS AT RISK AND INTERVENTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO; UNIV COLORADO,SCH MED,DENVER,CO 80202	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					PHS HHS [1-K07-A100543] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURANAKUL B, 1974, AM J DIS CHILD, V128, P343, DOI 10.1001/archpedi.1974.02110280073009; CEBELIN MS, 1980, HUM PATHOL, V11, P123, DOI 10.1016/S0046-8177(80)80129-8; DIRKS JF, 1982, J ASTHMA, V19, P177, DOI 10.3109/02770908209104755; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; FISCHER T J, 1975, Journal of Asthma Research, V13, P27, DOI 10.3109/02770907509104156; GRANT IWB, 1983, BRIT MED J, V286, P374, DOI 10.1136/bmj.286.6362.374; HELZEL MR, 1977, BR MED J, V1, P808; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KRAVIS LP, 1978, ADV ALLERGY ASTHMA, V5, P26; MCCOMBS RP, 1979, JAMA-J AM MED ASSOC, V242, P1521, DOI 10.1001/jama.242.14.1521; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; PALM CR, 1970, J ALLERGY, V46, P257, DOI 10.1016/0021-8707(70)90067-5; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RACKEMANN FM, 1944, J ALLERGY, V15, P249; Read J, 1968, Med J Aust, V1, P879; RICHARDS W, 1965, AM J DIS CHILD, V110, P4, DOI 10.1001/archpedi.1965.02090030010003; SANTIAGO SM, 1980, J ASTHMA RES, V17, P75, DOI 10.3109/02770908009105684; SLY RM, 1984, ANN ALLERGY, V53, P20; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; TIETZ W, 1975, Journal of Asthma Research, V12, P199, DOI 10.3109/02770907509098947; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WILSON JD, 1981, LANCET, V1, P1235; WOOD DW, 1976, CLIN PEDIATR, V15, P677, DOI 10.1177/000992287601500804; [No title captured]; 1969, LANCET, V2, P305; 1980, DIAGNOSTIC STATISTIC; 1982, BR MED J, V285, P1253; 1981, NZ MED J, V1, P299	31	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			472	477		10.1016/0091-6749(87)90078-9	http://dx.doi.org/10.1016/0091-6749(87)90078-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624701				2022-12-18	WOS:A1987K103700026
J	MOSS, RB; HSU, YP; KWASNICKI, JM; REID, MJ; SULLIVAN, MM				MOSS, RB; HSU, YP; KWASNICKI, JM; REID, MJ; SULLIVAN, MM			ISOTYPIC AND ANTIGENIC RESTRICTION OF THE BLOCKING ANTIBODY-RESPONSE TO RYEGRASS POLLEN - CORRELATION OF RYE GROUP-I ANTIGEN-SPECIFIC IGG1 WITH CLINICAL-RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,STANFORD,CA 94305; DAVID GRANT USAF MED CTR,ALLERGY CLIN,TRAVIS AFB,CA 94535	Stanford University			Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				AALBERSE RC, 1983, J IMMUNOL, V130, P722; ADKINSON NF, 1979, J IMMUNOL, V122, P965; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; BRUYNZEEL PLB, 1979, INT ARCH ALLER A IMM, V58, P344, DOI 10.1159/000232211; CHEUNG NKV, 1983, J ALLERGY CLIN IMMUN, V71, P283, DOI 10.1016/0091-6749(83)90082-9; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1983, ALLERGY, V38, P173, DOI 10.1111/j.1398-9995.1983.tb01603.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DJURUP R, 1984, ALLERGY, V39, P51, DOI 10.1111/j.1398-9995.1984.tb01933.x; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GORDON J, 1958, J EXP MED, V108, P37, DOI 10.1084/jem.108.1.37; GWYNN CM, 1979, CLIN ALLERGY, V9, P119, DOI 10.1111/j.1365-2222.1979.tb01530.x; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P312; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; Loveless MH, 1940, J IMMUNOL, V38, P25; MERRETT J, 1984, CLIN EXP IMMUNOL, V56, P645; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P319; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; PATTERSON R, 1983, ALLERGY PRINCIPLES P, P1119; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; REIMER CB, 1984, HYBRIDOMA, V3, P263, DOI 10.1089/hyb.1984.3.263; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SEPPALA IJT, 1984, EUR J IMMUNOL, V14, P868, DOI 10.1002/eji.1830140918; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	44	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					387	398		10.1016/0091-6749(87)90160-6	http://dx.doi.org/10.1016/0091-6749(87)90160-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3819220				2022-12-18	WOS:A1987G179100015
J	CARTIER, A; LARCHEVEQUE, J; MALO, JL				CARTIER, A; LARCHEVEQUE, J; MALO, JL			EXPOSURE TO A SENSITIZING OCCUPATIONAL AGENT CAN CAUSE A LONG-LASTING INCREASE IN BRONCHIAL RESPONSIVENESS TO HISTAMINE IN THE ABSENCE OF SIGNIFICANT CHANGES IN AIRWAY CALIBER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CARTIER, A (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							BARSELA S, 1985, CHEST, V88, P114, DOI 10.1378/chest.88.1.114; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DIMEO MJ, 1981, AM REV RESPIR DIS, V124, P245; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HARIPARSAD D, 1984, CLIN ALLERGY, V14, P81, DOI 10.1111/j.1365-2222.1984.tb02194.x; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; LARCHEVEQUE J, 1985, J ALLERGY CLIN IMMUN, V75, P263; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; PAGGIARO PL, 1984, CLIN ALLERGY, V14, P463, DOI 10.1111/j.1365-2222.1984.tb02230.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; WILSON N, 1982, BMJ-BRIT MED J, V1, P1226	29	48	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1185	1189		10.1016/0091-6749(86)90270-8	http://dx.doi.org/10.1016/0091-6749(86)90270-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782680				2022-12-18	WOS:A1986F302600016
J	TURNER, KJ; DOWSE, GK; STEWART, GA; ALPERS, MP				TURNER, KJ; DOWSE, GK; STEWART, GA; ALPERS, MP			STUDIES ON BRONCHIAL HYPERREACTIVITY, ALLERGIC RESPONSIVENESS, AND ASTHMA IN RURAL AND URBAN CHILDREN OF THE HIGHLANDS OF PAPUA-NEW-GUINEA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN AUSTRALIA, DEPT MICROBIOL, NEDLANDS, WA 6009, AUSTRALIA; PAPUA NEW GUINEA INST MED RES, GOROKA, PAPUA N GUINEA	University of Western Australia; PNG Institute Of Medical Research	TURNER, KJ (corresponding author), PRINCESS MARGARET HOSP, CLIN IMMUNOL RES UNIT, SUBIACO, WA, AUSTRALIA.							ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; ANDERSON HR, 1974, PAPUA NEW GUINEA MED, V17, P165; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DOWSE GK, 1985, CLIN ALLERGY, V15, P429, DOI 10.1111/j.1365-2222.1985.tb02292.x; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; PAUWELS R, 1983, 12 P C EUR AC ALL CL, P147; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RODBARD D, 1974, P S RADIOIMMUNOASSAY, P165; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; TURNER KJ, 1978, PAPUA NEW GUINEA MED, V21, P86; TURNER KJ, 1980, AUST J EXP BIOL MED, V58, P249, DOI 10.1038/icb.1980.25; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; Viswanathan R, 1966, J Indian Med Assoc, V46, P480; WHITLOCK H. V., 1950, JOUR HELMINTHOL, V24, P47, DOI 10.1017/S0022149X00019106; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	21	48	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					558	566		10.1016/0091-6749(86)90345-3	http://dx.doi.org/10.1016/0091-6749(86)90345-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	2420852				2022-12-18	WOS:A1986A938100005
J	BOUSQUET, J; DHIVERT, H; CLAUZEL, AM; HEWITT, B; MICHEL, FB				BOUSQUET, J; DHIVERT, H; CLAUZEL, AM; HEWITT, B; MICHEL, FB			OCCUPATIONAL ALLERGY TO SUNFLOWER POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LAB STALLERGENES,F-94360 JOINVILLE PONT,FRANCE	Stallergenes Greer	BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOUSQUET J, 1984, ALLERGY, V39, P73, DOI 10.1111/j.1398-9995.1984.tb01936.x; CANNET G, 1975, BIOCAPT, V75, P409; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; DUTTON L. O., 1938, JOUR ALLERGY, V9, P607, DOI 10.1016/S0021-8707(38)90310-7; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; JUNIPER E, 1978, THORAX, V33, P700; KONDO T, 1972, JPN J ALLERGY, V21, P294; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEWIS WH, 1979, ANN ALLERGY, V42, P309; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; MANSFIELD LE, 1981, ANN ALLERGY, V47, P154; MOUSSITOU FM, 1951, PRESSA MED ARGENT, V38, P1052; OREHEK J, 1982, EUR J RESPIR DIS, V63, P1; PIGLOWSKI J, 1976, REV FR MAL RESP S1, V4, P81; SUZUKI S, 1975, INT ARCH ALLER A IMM, V48, P800, DOI 10.1159/000231368; Wodehouse RP, 1971, HAY FEVER PLANTS, V2nd	20	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					70	74		10.1016/0091-6749(85)90015-6	http://dx.doi.org/10.1016/0091-6749(85)90015-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968331				2022-12-18	WOS:A1985ABF2600011
J	VANTOORENENBERGEN, AW; DIEGES, PH				VANTOORENENBERGEN, AW; DIEGES, PH			IMMUNOGLOBULIN-E ANTIBODIES AGAINST CORIANDER AND OTHER SPICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VANTOORENENBERGEN, AW (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT CLIN CHEM,ALLERGOL LAB,MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							AARONSON DW, 1980, ALLERGIC DISEASE DIA, P231; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P789; FALLERONI AE, 1981, J ALLERGY CLIN IMMUN, V68, P156, DOI 10.1016/0091-6749(81)90173-1; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; KAUPPINEN K, 1980, CONTACT DERMATITIS, V6, P251, DOI 10.1111/j.1600-0536.1980.tb04924.x; LEVY DA, 1966, J IMMUNOL, V97, P203; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; STOBART T, 1977, HERBS SPICES FLAVOUR, P98; THIEL CL, 1981, KOLNER RAST S, V3, P161	10	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					477	481		10.1016/0091-6749(85)90730-4	http://dx.doi.org/10.1016/0091-6749(85)90730-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	2411778				2022-12-18	WOS:A1985ARC0900010
J	BERQUIST, WE; RACHELEFSKY, GS; ROWSHAN, N; SIEGEL, S; KATZ, R; WELCH, M				BERQUIST, WE; RACHELEFSKY, GS; ROWSHAN, N; SIEGEL, S; KATZ, R; WELCH, M			QUANTITATIVE GASTROESOPHAGEAL REFLUX AND PULMONARY-FUNCTION IN ASTHMATIC-CHILDREN AND NORMAL ADULTS RECEIVING PLACEBO, THEOPHYLLINE, AND METAPROTERENOL SULFATE THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT PEDIAT, DIV ALLERGY IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	BERQUIST, WE (corresponding author), UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT PEDIAT, DIV GASTROENTEROL, LOS ANGELES, CA 90024 USA.				NCRR NIH HHS [CRC RR-00865] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERQUIST WE, 1981, J PEDIATR SURG, V16, P872, DOI 10.1016/S0022-3468(81)80837-8; BERQUIST WE, 1981, PEDIATRICS, V68, P29; BERQUIST WE, 1981, J ALLERGY CLIN IMMUN, V67, P407, DOI 10.1016/0091-6749(81)90087-7; DEES SC, 1974, N C MED J, V35, P230; GOYAL RK, 1978, GASTROENTEROLOGY, V74, P598; JOHNSON LF, 1974, AM J GASTROENTEROL, V62, P325; KATZ RM, 1979, CURR MED RES OPIN, V6, P45; KENNEDY JH, 1962, DIS CHEST, V42, P42; STEIN MR, 1980, ANN ALLERGY, V45, P238	9	48	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					253	258		10.1016/S0091-6749(84)80016-0	http://dx.doi.org/10.1016/S0091-6749(84)80016-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699308				2022-12-18	WOS:A1984SF02000006
J	HSIEH, KH				HSIEH, KH			CHANGES OF LYMPHOPROLIFERATIVE RESPONSES OF T-CELL SUBSETS TO ALLERGEN AND MITOGEN AFTER HYPOSENSITIZATION IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HSIEH, KH (corresponding author), NATL TAIWAN UNIV HOSP,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,TAIPEI 100,TAIWAN.							BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADLEY LM, 1980, SELECTED METHODS IMM, P158; CANONICA GW, 1979, J IMMUNOL, V123, P2669; CANTOR H, 1975, J EXP MED, V141, P1375; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; HEIJNEN CJ, 1979, CELL IMMUNOL, V43, P282, DOI 10.1016/0008-8749(79)90173-4; HSIEH KH, 1980, ANN ALLERGY, V44, P177; HSIEH KH, 1982, ANN ALLERGY, V48, P25; HSIEH KH, 1982, ANN ALLERGY, V48, P345; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LOCKEY RF, 1976, BRONCHIAL ASTHMA MEC, P613; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; MORETTA L, 1977, J EXP MED, V146, P184, DOI 10.1084/jem.146.1.184; Noon L, 1911, LANCET, V1, P1572; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; REINHERZ EL, 1979, J IMMUNOL, V123, P2894; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REINHERZ EL, 1980, J IMMUNOL, V124, P1301; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; VANWAUWE J, 1981, INT J IMMUNOPHARMACO, V3, P203, DOI 10.1016/0192-0561(81)90014-X; YOO TJ, 1977, ACTA ALLERGOL, V32, P227, DOI 10.1111/j.1398-9995.1977.tb01355.x	30	48	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					34	40		10.1016/0091-6749(84)90084-8	http://dx.doi.org/10.1016/0091-6749(84)90084-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6610697				2022-12-18	WOS:A1984SZ64800005
J	SHEPPARD, D; ESCHENBACHER, WL				SHEPPARD, D; ESCHENBACHER, WL			RESPIRATORY WATER-LOSS AS A STIMULUS TO EXERCISE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NO CALIF OCCUPAT HLTH CTR,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SHEPPARD, D (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07159, HL-24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABERNETHY JD, 1968, THORAX, V23, P421, DOI 10.1136/thx.23.4.421; ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; CHANYEUNG M, 1977, CHEST, V71, P320, DOI 10.1378/chest.71.3.320; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; CHENEY FW, 1968, ANESTHESIOLOGY, V29, P1099, DOI 10.1097/00000542-196811000-00004; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; ELWOOD RK, 1982, AM REV RESPIR DIS, V61, P125; ESCHENBACHER WL, 1983, PHYSIOLOGIST, V26, pA115; ESCHENBACHER WL, AM REV RESPIR DIS; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; MAN SFP, 1979, J APPL PHYSIOL, V46, P205, DOI 10.1152/jappl.1979.46.2.205; MCFADDEN ER, 1982, J CLIN INVEST, V69, P700, DOI 10.1172/JCI110498; MILLAR J. S., 1965, BRIT J DIS CHEST, V59, P23, DOI 10.1016/S0007-0971(65)80032-8; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TAM E, 1983, AM REV RESPIR DIS, V127, P250; WELLS RE, 1960, NEW ENGL J MED, V263, P268, DOI 10.1056/NEJM196008112630602	26	48	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					640	642		10.1016/0091-6749(84)90297-5	http://dx.doi.org/10.1016/0091-6749(84)90297-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715729				2022-12-18	WOS:A1984SS04600004
J	MANSFIELD, LE; BOWERS, CH				MANSFIELD, LE; BOWERS, CH			SYSTEMIC REACTION TO PAPAIN IN A NONOCCUPATIONAL SETTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MANSFIELD, LE (corresponding author), WILLIAM BEAUMONT ARMY MED CTR,ALLERGY IMMUNOL SERV,EL PASO,TX 79920, USA.							BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BEECHER WL, 1931, ILLINOIS MED J, V59, P343; FLINDT MLH, 1979, LANCET, V1, P1407; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V68, P98; OSGOOD H, 1945, J ALLERGY, V16, P245, DOI 10.1016/0021-8707(45)90005-0; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x	6	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					371	374		10.1016/0091-6749(83)90064-7	http://dx.doi.org/10.1016/0091-6749(83)90064-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6601123				2022-12-18	WOS:A1983QL12100003
J	SIMONS, FER; LUCIUK, GH; SIMONS, KJ				SIMONS, FER; LUCIUK, GH; SIMONS, KJ			PHARMACOKINETICS AND EFFICACY OF CHLORPHENIRAMINE IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								ATHANIKAR NK, 1979, J CHROMATOGR, V162, P367, DOI 10.1016/S0378-4347(00)81522-4; BILLUPS NF, 1980, AM DRUG INDEX, P139; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; GIBALDI M, 1975, PHARMACOKINETICS, P1; GOTH A, 1978, ALLERGY PRINCIPLES P, P454; HUANG SM, 1980, AM PHARM ASS ACADEMY, V10, P82; PEETS EA, 1972, J PHARMACOL EXP THER, V180, P464; SCHILLER I W, 1951, J Maine Med Assoc, V42, P89; THOMPSON JA, 1980, J PHARM SCI, V69, P707, DOI 10.1002/jps.2600690626; VALLNER JJ, 1979, CURR THER RES CLIN E, V26, P449; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924	12	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					376	381		10.1016/0091-6749(82)90149-X	http://dx.doi.org/10.1016/0091-6749(82)90149-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069073				2022-12-18	WOS:A1982NL28000008
J	RICHERSON, HB; RICHARDS, DW; SWANSON, PA; BUTLER, JE; SUELZER, MT				RICHERSON, HB; RICHARDS, DW; SWANSON, PA; BUTLER, JE; SUELZER, MT			ANTIGEN-SPECIFIC DESENSITIZATION IN A RABBIT MODEL OF ACUTE HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242	University of Iowa	RICHERSON, HB (corresponding author), UNIV IOWA,HOSP & CLIN,COLL MED,DEPT INTERNAL MED,DIV ALLERGY IMMUNOL,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL19873, HL22676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019873, R01HL022676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHERSON GL, 1967, IMMUNOLOGY, V13, P469; BIENENSTOCK J, 1980, IMMUNOLOGY, V41, P249; BUTLER JE, 1978, J ALLERGY CLIN IMMUN, V61, P159, DOI 10.1016/0091-6749(78)90342-1; BUTLER JE, 1978, IMMUNOCHEMISTRY, V15, P131, DOI 10.1016/0161-5890(78)90053-6; BUTLER JE, 1980, ENZYME IMMUNOASSAY, P197; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; DODGE RR, 1978, CHEST, V73, P608, DOI 10.1378/chest.73.5.608; KELLER RH, 1980, FED P, V28, P505; LECLERC C, 1979, CELL IMMUNOL, V45, P199, DOI 10.1016/0008-8749(79)90377-0; MILLER SD, 1979, J IMMUNOL, V123, P2344; PAPERMASTER V, 1978, CELL IMMUNOL, V35, P378, DOI 10.1016/0008-8749(78)90157-0; PARANT M, 1979, SPRINGER SEMIN IMMUN, V2, P101; PEPYS J, 1969, HYPERSENSITIVITY DIS, P77; QUETSCH J, 1977, ANN ALLERGY, V38, P386; RATAJACZAK HV, 1980, AM REV RESPIR DIS, V122, P261; RATAJCZAK HV, 1979, CELL IMMUNOL, V47, P390, DOI 10.1016/0008-8749(79)90348-4; RICHERSON H B, 1980, American Review of Respiratory Disease, V121, P89; RICHERSON HB, 1971, AM REV RESPIR DIS, V104, P568; RICHERSON HB, 1978, AM REV RESPIR DIS, V117, P5; RICHERSON HB, 1974, ANN NY ACAD SCI, V221, P340, DOI 10.1111/j.1749-6632.1974.tb28236.x; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SCHATZ M, 1979, NEW ENGL J MED, V300, P1310, DOI 10.1056/NEJM197906073002305; SCHEFFE H, 1959, ANAL VARIANCE, P55; SCHLUETER DP, 1974, AM J MED, V57, P476, DOI 10.1016/0002-9343(74)90141-7; SONOZAKI H, 1975, J IMMUNOL, V115, P1657; WILKIE BN, 1977, INT ARCH ALLER A IMM, V53, P389, DOI 10.1159/000231776; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182; WILLOUGHBY JB, 1977, J IMMUNOL, V119, P2137; WINER BJ, 1971, STATISTICAL PRINCIPL, P196	30	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					226	234		10.1016/0091-6749(81)90188-3	http://dx.doi.org/10.1016/0091-6749(81)90188-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	6167602				2022-12-18	WOS:A1981MG54400010
J	SPECTOR, S; FARR, R				SPECTOR, S; FARR, R			BRONCHIAL INHALATION CHALLENGE WITH ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SPECTOR, S (corresponding author), NATL JEWISH HOSP & RES CTR,DEPT MED,DENVER,CO 80206, USA.							AAS K, 1975, BRONCHIAL PROVOCATIO, P42; ASSEM E S K, 1973, Clinical Allergy, V3, P161, DOI 10.1111/j.1365-2222.1973.tb01319.x; BOOIJNOO.H, 1970, J ALLERGY, V46, P1, DOI 10.1016/0021-8707(70)90055-9; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HUGGINS KG, 1975, LANCET, V2, P148; INGRAM RH, 1977, NEW ENGL J MED, V297, P596; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MAY C D, 1973, Clinical Allergy, V3, P319, DOI 10.1111/j.1365-2222.1973.tb01340.x; MUITTARI A, 1978, CLIN ALLERGY, V8, P281, DOI 10.1111/j.1365-2222.1978.tb03225.x; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592, DOI 10.1159/000230552; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P7, DOI 10.1016/0091-6749(72)90075-9; PEPYS J, 1974, CLIN ALLERGY, V4, P12; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROSENTHAL RR, 1976, J ALLERGY CLIN IMMUN, V57, P220; SPECTOR SL, 1971, J ALLERGY CLIN IMMUN, V48, P120, DOI 10.1016/0091-6749(71)90093-5; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9	22	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					580	586		10.1016/0091-6749(79)90016-2	http://dx.doi.org/10.1016/0091-6749(79)90016-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512249				2022-12-18	WOS:A1979HX84300004
J	YANG, WH; DORVAL, G; OSTERLAND, CK; GILMORE, NJ				YANG, WH; DORVAL, G; OSTERLAND, CK; GILMORE, NJ			CIRCULATING IMMUNE-COMPLEXES DURING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL VICTORIA HOSP,DEPT MED,DIV CLIN IMMUNOL,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital								AGNELLO V, 1971, J EXP MED, V134, P228; BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; DORVAL G, 1975, J IMMUNOL METHODS, V7, P237, DOI 10.1016/0022-1759(75)90021-6; DORVAL G, 1974, SCAND J IMMUNOL, V3, P405, DOI 10.1111/j.1365-3083.1974.tb01273.x; DORVAL G, 1977, ANN INST PASTEUR IMM, VC128, P159; FAIRSHTER RD, 1977, J ALLERGY CLIN IMMUN, V59, P243, DOI 10.1016/0091-6749(77)90157-9; GHETIE V, 1974, IMMUNOLOGY, V26, P1081; GILMORE NJ, 1978, J ALLERGY CLIN IMMUN, V61, P168, DOI 10.1016/0091-6749(78)90371-8; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; JONDAL M, 1974, SCAND J IMMUNOL, V3, P749; KARSH J, 1978, J RHEUMATOL, V5, P314; KARSH J, 1976, UNION MED CAN, V105, P514; KRONVALL G, 1969, J IMMUNOL, V103, P828; KRONVALL G, 1970, IMMUNOCHEMISTRY, V7, P124, DOI 10.1016/0019-2791(70)90036-4; LAMBERSON H, 1977, CLIN RES, V25, P715; LANGONE JJ, 1978, J IMMUNOL, V121, P333; LANGONE JJ, 1978, J IMMUNOL, V121, P327; LEVINSON AI, 1978, J ALLERGY CLIN IMMUN, V62, P109, DOI 10.1016/0091-6749(78)90087-8; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; STALENHEIM G, 1973, IMMUNOCHEMISTRY, V10, P501, DOI 10.1016/0019-2791(73)90221-8; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; SVEDMYR EA, 1974, INT J CANCER, V13, P891, DOI 10.1002/ijc.2910130617; THEOFILOPOULOS AN, 1974, J EXP MED, V139, P696, DOI 10.1084/jem.139.3.696; WELSH KI, 1975, NATURE, V254, P67, DOI 10.1038/254067a0; ZUBLER RH, 1976, J IMMUNOL, V116, P232	26	48	49	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					300	307		10.1016/0091-6749(79)90123-4	http://dx.doi.org/10.1016/0091-6749(79)90123-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429709				2022-12-18	WOS:A1979GU94300002
J	ADOLPHSON, C; GOODFRIEND, L; GLEICH, GJ				ADOLPHSON, C; GOODFRIEND, L; GLEICH, GJ			REACTIVITY OF RAGWEED ALLERGENS WITH IGE ANTIBODIES - ANALYSES BY LEUKOCYTE HISTAMINE-RELEASE AND RADIOALLERGOSORBENT TEST AND DETERMINATION OF CROSS-REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL VICTORIA HOSP,DIV CLIN IMMUNOL,MONTREAL 112,QUEBEC,CANADA	McGill University; Royal Victoria Hospital	ADOLPHSON, C (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.							ADOLPHSON C, UNPUBLISHED; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GOODFRIEND L, UNPUBLISHED; GRIFFITHS BW, 1972, J CHROMATOGR, V69, P391, DOI 10.1016/S0021-9673(00)92916-9; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HUNTER WM, 1967, HDB EXPT IMMUNOLOGY, P647; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; KING TP, 1974, ALLERGOLOGY, P394; KING TS, COMMUNICATION; LACKLAND H, COMMUNICATION; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LICHTENSTEIN L, 1973, J ALLERGY CLIN IMMUN, V51, P285, DOI 10.1016/0091-6749(73)90130-9; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1975, IMMUNOCHEMISTRY, V12, P539, DOI 10.1016/0019-2791(75)90081-6; MARSH DG, 1975, ANTIGENS, V3, P271; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; ROEBBER M, 1975, J IMMUNOL, V115, P303; ROEBBER M, 1975, THESIS MCGILL U; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; WELSH PW, 1977, J ALLERGY CLIN IMMUN, V60, P104, DOI 10.1016/0091-6749(77)90034-3; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	37	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					197	210		10.1016/0091-6749(78)90208-7	http://dx.doi.org/10.1016/0091-6749(78)90208-7			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	81221	Bronze			2022-12-18	WOS:A1978FS39200002
J	KONIG, P; GODFREY, S				KONIG, P; GODFREY, S			EXERCISE-INDUCED BRONCHIAL LABILITY IN MONOZYGOTIC (IDENTICAL) AND DIZYGOTIC (NONIDENTICAL) TWINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,CARDIOTHORAC INST,DEPT PAEDIAT,LONDON,ENGLAND; HAMMERSMITH HOSP,DEPT PAEDIAT,LONDON,ENGLAND	Royal Brompton Hospital; Imperial College London								Adkinson J, 1920, GENETICS, V5, P363; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; BOWEN R, 1953, J ALLERGY, V24, P236, DOI 10.1016/0021-8707(53)90005-7; CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; Criep Leo H., 1942, JOUR ALLERGY, V13, P591, DOI 10.1016/S0021-8707(42)90072-8; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GODFREY S, 1973, 9 S ADV MED, P293; HARVALD B, 1956, Dan Med Bull, V3, P150; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LEIGH D, 1967, BRONCHIAL ASTHMA; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; SCHNYDER VW, 1960, ACTA GENET STATIST S, V10, P1; SCHWARTZ M, 1952, Acta Allergol Suppl (Copenh), V2, P1; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; Simonds B., 1963, TUBERCULOSIS TWINS; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; SPAICH DIETER, 1936, ZEITSCHR MENSCHL VERERBUNGS U KON STITUTIONSL, V19, P731; Spain WC, 1924, J IMMUNOL, V9, P521	21	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	5					280	287		10.1016/0091-6749(74)90014-1	http://dx.doi.org/10.1016/0091-6749(74)90014-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U6412					2022-12-18	WOS:A1974U641200004
J	NARUSE, T; MIYAKAWA, Y; KITAMURA, K; SHIBATA, S				NARUSE, T; MIYAKAWA, Y; KITAMURA, K; SHIBATA, S			MEMBRANOUS GLOMERULONEPHRITIS MEDIATED BY RENAL TUBULAR EPITHELIAL ANTIGEN-ANTIBODY COMPLEX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,FAC MED,THIRD DEPT INTERN MED,HONGO,TOKYO,JAPAN; UNIV GUNMA,FAC MED,DEPT INTERN MED 3,MAEBASHI 371,JAPAN	University of Tokyo; Gunma University								Bell ET, 1938, AM J PATHOL, V14, P691; COMBES B, 1971, LANCET, V2, P234; DIXON FJ, 1968, AM J MED, V44, P493, DOI 10.1016/0002-9343(68)90050-8; DIXON FJ, 1961, J EXP MED, V113, P899, DOI 10.1084/jem.113.5.899; EDGINGTON TS, 1967, J IMMUNOL, V99, P1199; EDGINGTON TS, 1968, J EXP MED, V127, P555, DOI 10.1084/jem.127.3.555; EDGINGTON TS, 1969, J IMMUNOL, V103, P528; FALLS WF, 1965, ANN INTERN MED, V63, P1047, DOI 10.7326/0003-4819-63-6-1047; GLASSOCK RJ, 1968, J EXP MED, V127, P573, DOI 10.1084/jem.127.3.573; GLUCK MC, 1973, ANN INTERN MED, V78, P1, DOI 10.7326/0003-4819-78-1-1; HEYMANN W, 1959, P SOC EXP BIOL MED, V100, P660; JONES DB, 1957, AM J PATHOL, V33, P313; KOFFLER D, 1971, J EXP MED, V134, pS169; MELLORS RC, 1957, J EXP MED, V106, P191, DOI 10.1084/jem.106.2.191; NARUSE T, 1973, Journal of Immunology, V110, P1163; RASTOGI SP, 1969, Q J MED, V38, P335; SEEGAL BC, 1965, FED PROC, V24, P100; WARD PA, 1969, LANCET, V1, P283	18	48	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	5					311	318		10.1016/0091-6749(74)90017-7	http://dx.doi.org/10.1016/0091-6749(74)90017-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U6412					2022-12-18	WOS:A1974U641200007
J	HARRIS, L				HARRIS, L			COMPARISON OF EFFECT ON BLOOD GASES, VENTILATION, AND PERFUSION OF ISOPROTERENOL-PHENYLEPHRINE AND SALBUTAMOL AEROSOLS IN CHRONIC-BRONCHITIS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		[Anonymous], 1965, LANCET, V1, P775; AVIADO DM, 1957, J PHARMACOL EXP THER, V120, P512; BASS BH, 1969, LANCET, V2, P438; BASS BH, PRIVATE COMMUNICATIO; BRITTAIN RT, 1968, NATURE, V219, P862, DOI 10.1038/219862a0; CHAPMAN T T, 1969, Pharmacologia Clinica, V1, P107, DOI 10.1007/BF00404654; Chapman T T, 1966, J Ir Med Assoc, V59, P184; CHAPMAN TT, 1969, BRIT MED J, V4, P557, DOI 10.1136/bmj.4.5682.557; CHAPMAN TT, 1967, BRIT MED J, V2, P639, DOI 10.1136/bmj.2.5552.639-b; CHAPMAN TT, P EUROPEAN SOC RESPI; CHAPMAN TT, 1971, PROGR RES, V6, P449; CHAPMAN TT, PRIVATE COMMUNICATIO; Ciba Guest Symposium, 1959, THORAX, V14, P286, DOI 10.1136/thx.14.4.286; DALY JJ, 1965, THORAX, V20, P324, DOI 10.1136/thx.20.4.324; DAUM S, 1967, ARZNEI-FORSCHUNG, V17, P565; DULFANO MJ, 1968, ANN INTERN MED, V68, P955, DOI 10.7326/0003-4819-68-4-955; FIELD GB, 1967, CLIN SCI, V32, P279; FREEDMAN BJ, 1968, THORAX, V23, P590, DOI 10.1136/thx.23.6.590; GODFREY S, 1971, British Journal of Diseases of the Chest, V65, P58, DOI 10.1016/0007-0971(71)90006-4; HACKNEY JD, 1958, J APPL PHYSIOL, V12, P425, DOI 10.1152/jappl.1958.12.3.425; HALMAGYI DF, 1959, CLIN SCI, V18, P475; HARRIS LH, 1970, BRIT MED J, V4, P579, DOI 10.1136/bmj.4.5735.579; HOLMES TH, 1971, THERAPEUTICS, V1, P7; HORVATH SM, 1954, AM J PHYSIOL, V178, P387, DOI 10.1152/ajplegacy.1954.178.3.387; HUME KM, 1970, BRIT MED J, V1, P173, DOI 10.1136/bmj.1.5689.173-c; KENNEDY M C S, 1969, British Journal of Diseases of the Chest, V63, P165, DOI 10.1016/S0007-0971(69)80014-8; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; LANGLANDS JH, 1965, LANCET, V2, P315; LEDBETTER MK, 1964, J CLIN INVEST, V43, P2233, DOI 10.1172/JCI105097; LOCKHART A, 1967, CLIN SCI, V32, P177; MACINTYRE J, 1968, BMJ-BRIT MED J, V3, P640, DOI 10.1136/bmj.3.5619.640; MATTILA M, 1966, ACTA MED SCAND, V180, P421; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCHARDY GJR, 1967, CLIN SCI; MEISNER P, 1968, BRIT MED J, V1, P470, DOI 10.1136/bmj.1.5590.470; MIYAMOTO T, 1970, J ALLERGY, V45, P248, DOI 10.1016/0021-8707(70)90135-8; PALMER KNV, 1967, LANCET, V2, P383; PALMER KNV, 1969, LANCET, V2, P1092; PFLUG AE, 1970, AM REV RESPIR DIS, V101, P710; Read J, 1968, Med J Aust, V1, P879; REES HA, 1967, LANCET, V2, P1167; REES HA, 1967, LANCET, V2, P1164; REES HA, 1968, Q J MED, V37, P541; RIDING W D, 1970, British Journal of Diseases of the Chest, V64, P37, DOI 10.1016/S0007-0971(70)80047-X; STIKSA J, 1967, ARZNEI-FORSCHUNG, V17, P568; TAI E, 1967, THORAX, V22, P543, DOI 10.1136/thx.22.6.543; TAI E, 1967, LANCET, V1, P644; WADDELL JA, 1967, BRIT MED J, V2, P402, DOI 10.1136/bmj.2.5549.402; WARRELL DA, 1970, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.5688.65; 1968, LANCET, V1, P1412	50	48	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	2					63	+		10.1016/0091-6749(72)90057-7	http://dx.doi.org/10.1016/0091-6749(72)90057-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5997	5008687	Bronze			2022-12-18	WOS:A1972L599700001
J	Addison, AB; Wong, B; Ahmed, T; Macchi, A; Konstantinidis, I; Huart, C; Frasnelli, J; Fjaeldstad, AW; Ramakrishnan, VR; Rombaux, P; Whitcroft, KL; Holbrook, EH; Poletti, SC; Hsieh, JW; Landis, BN; Boardman, J; Welge-Lussen, A; Maru, D; Hummel, T; Philpott, CM				Addison, Alfred B.; Wong, Billy; Ahmed, Tanzime; Macchi, Alberto; Konstantinidis, Iordanis; Huart, Caroline; Frasnelli, Johannes; Fjaeldstad, Alexander W.; Ramakrishnan, Vijay R.; Rombaux, Philippe; Whitcroft, Katherine L.; Holbrook, Eric H.; Poletti, Sophia C.; Hsieh, Julien W.; Landis, Basile N.; Boardman, James; Welge-Lussen, Antje; Maru, Devina; Hummel, Thomas; Philpott, Carl M.			Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Olfaction; olfactory disorders; viral infections; hyposmia; anosmia; parosmia therapy; COVID-19	SMELL IDENTIFICATION TEST; ODOR IDENTIFICATION; BULB VOLUME; DISORDERS; CLEFT; DISCRIMINATION; UNIVERSITY; RECOVERY	Background: Respiratory tract viruses are the second most common cause of olfactory dysfunction. As we learn more about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the recognition that olfactory dysfunction is a key symptom of this disease process, there is a greater need than ever for evidence-based management of postinfectious olfactory dysfunction (PIOD). Objective: Our aim was to provide an evidence-based practical guide to the management of PIOD (including post-coronavirus 2019 cases) for both primary care practitioners and hospital specialists. Methods: A systematic review of the treatment options available for the management of PIOD was performed. The written systematic review was then circulated among the members of the Clinical Olfactory Working Group for their perusal before roundtable expert discussion of the treatment options. The group also undertook a survey to determine their current clinical practice with regard to treatment of PIOD. Results: The search resulted in 467 citations, of which 107 articles were fully reviewed and analyzed for eligibility; 40 citations fulfilled the inclusion criteria, 11 of which were randomized controlled trials. In total, 15 of the articles specifically looked at PIOD whereas the other 25 included other etiologies for olfactory dysfunction. Conclusions: The Clinical Olfactory Working Group members made an overwhelming recommendation for olfactory training; none recommended monocycline antibiotics. The diagnostic role of oral steroids was discussed; some group members were in favor of vitamin A drops. Further research is needed to confirm the place of other therapeutic options. (J Allergy Clin Immunol 2021;147:1704-19.)	[Addison, Alfred B.; Wong, Billy; Ahmed, Tanzime] East Sussex North Essex Fdn Trust, Ipswich, Suffolk, England; [Macchi, Alberto] ENT Univ Insubria, Italian Acad Rhinol, Varese, Italy; [Konstantinidis, Iordanis] Aristotle Univ Thessaloniki, 2nd ORL Univ Dept, Smell & Taste Clin, Thessaloniki, Greece; [Huart, Caroline; Rombaux, Philippe] Clin Univ St Luc, Dept Otorhinolaryngol, Brussels, Belgium; [Huart, Caroline; Rombaux, Philippe] Catholic Univ Louvain, Inst Neurosci, Brussels, Belgium; [Frasnelli, Johannes] Univ Quebec Trois Rivieres, Dept Anat, Trois Rivieres, PQ, Canada; [Frasnelli, Johannes] Sacre Coeur Hosp Montreal, Res Ctr, Montreal, PQ, Canada; [Fjaeldstad, Alexander W.] Reg Hosp West Jutland, ENT Dept, Flavour Clin, Holstebro, Denmark; [Fjaeldstad, Alexander W.] Aarhus Univ, Flavour Inst, Aarhus, Denmark; [Ramakrishnan, Vijay R.] Univ Colorado, Dept Otolaryngol, Anschutz Med Campus, Aurora, CO USA; [Ramakrishnan, Vijay R.] Univ Colorado, Dept Neurosurg, Anschutz Med Campus, Aurora, CO USA; [Whitcroft, Katherine L.] Ctr Study Senses, Sch Adv Study, Inst Philosophy, London, England; [Whitcroft, Katherine L.] Yorkshire & Humber Sch Surg, South Yorkshire Deanery, Leeds, W Yorkshire, England; [Holbrook, Eric H.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Otolaryngol Head & Neck Surg, Boston, MA 02115 USA; [Poletti, Sophia C.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Otorhinolaryngol Head & Neck Surg, Bern, Switzerland; [Hsieh, Julien W.; Landis, Basile N.] Univ Hosp Geneva, Dept Otorhinolaryngol, Rhinol Olfactol Unit, Geneva, Switzerland; [Boardman, James; Philpott, Carl M.] Fifth Sense, Barrow In Furness, England; [Welge-Lussen, Antje] Univ Basel, Univ Hosp Basel, Dept Otorhinolaryngol, Basel, Switzerland; [Maru, Devina] Royal Coll Gen Practitioners, London, England; [Hummel, Thomas] Tech Univ Dresden, Dept Otorhinolaryngol, Smell & Taste Clin, Dresden, Germany; [Philpott, Carl M.] James Paget Univ Hosp NHS Fdn Trust, Norfolk Smell & Taste Clin, Gorleston, England; [Philpott, Carl M.] Univ East Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England	Aristotle University of Thessaloniki; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; University of Quebec; University of Quebec Trois Rivieres; Universite de Montreal; Aarhus University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of London School of Advanced Study; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Bern; University Hospital of Bern; University of Geneva; University of Basel; Technische Universitat Dresden; University of East Anglia	Philpott, CM (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.	C.Philpott@uea.ac.uk	Maru, Dr Devina/GYE-2250-2022; Philpott, Carl/H-4509-2019; Fjaeldstad, Alexander Wieck/AFO-0788-2022; Frasnelli, Johannes/D-9206-2018	Philpott, Carl/0000-0002-1125-3236; Fjaeldstad, Alexander Wieck/0000-0002-9135-6920; Frasnelli, Johannes/0000-0002-8863-3982; Poletti, Sophia/0000-0002-8623-1197; MARU, DR DEVINA/0000-0003-4344-4069				Addison A., 2018, OTORHINOLARNYNGOLOGI, V11, P61; Aiba T, 1998, ACTA OTO-LARYNGOL, P202; Ajmani GS, 2017, LARYNGOSCOPE, V127, P1753, DOI 10.1002/lary.26558; AKERLUND A, 1995, ACTA OTO-LARYNGOL, V115, P88, DOI 10.3109/00016489509133353; Altundag A, 2015, LARYNGOSCOPE, V125, P1763, DOI 10.1002/lary.25245; Bramerson A, 2004, LARYNGOSCOPE, V114, P733; Briner H. R., 1999, Rhinology (Utrecht), V37, P145; Butowt R, 2021, NEUROSCIENTIST, V27, P582, DOI 10.1177/1073858420956905; CAIN WS, 1988, LARYNGOSCOPE, V98, P83; Cavelier G, EUR ARCH OTORHINOLAR; Choi BY, 2021, CLIN EXP OTORHINOLAR, V14, P88, DOI 10.21053/ceo.2020.00143; Croy I, 2014, EUR ARCH OTO-RHINO-L, V271, P1087, DOI 10.1007/s00405-013-2684-9; Croy I, 2014, CHEM SENSES, V39, P185, DOI 10.1093/chemse/bjt072; Croy I, 2010, EUR ARCH OTO-RHINO-L, V267, P67, DOI 10.1007/s00405-009-1054-0; Dai Q, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/4986034; Damm M, 2004, HNO, V52, P112, DOI 10.1007/s00106-003-0877-z; Damm M, 2014, LARYNGOSCOPE, V124, P826, DOI 10.1002/lary.24340; Dinc AS, 2020, LARYNGOSCOPE, V130, pE35, DOI 10.1002/lary.27992; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; DUNCAN RB, 1962, ARCHIV OTOLARYNGOL, V75, P116; Erskine SE, 2020, CLIN OTOLARYNGOL, V45, P197, DOI 10.1111/coa.13484; Fjaeldstad AW, 2021, LARYNGOSCOPE, V131, pE8, DOI 10.1002/lary.28552; Fleiner F, 2011, INDIAN J OTOLARYNGOL, V63, P5, DOI 10.1007/s12070-010-0063-z; Fonteyn S, 2014, EUR ANN OTORHINOLARY, V131, P87, DOI 10.1016/j.anorl.2013.03.006; Frasnelli J, 2005, EUR ARCH OTO-RHINO-L, V262, P231, DOI 10.1007/s00405-004-0796-y; FRYE RE, 1990, JAMA-J AM MED ASSOC, V263, P1233, DOI 10.1001/jama.263.9.1233; Fukazawa K, 2005, CHEM SENSES, V30, pI212, DOI 10.1093/chemse/bjh189; Geissler K, 2014, EUR ARCH OTO-RHINO-L, V271, P1557, DOI 10.1007/s00405-013-2747-y; Gerkin Richard C, 2020, medRxiv, DOI 10.1101/2020.07.22.20157263; Gudziol V, 2006, LARYNGOSCOPE, V116, P1858, DOI 10.1097/01.mlg.0000234915.51189.cb; Gudziol V, 2009, ARCH OTOLARYNGOL, V135, P291, DOI 10.1001/archoto.2008.524; Gunder N., 2020, INFLUENCE INTRANASAL; Haehner A, 2020, ORL J OTO-RHINO-LARY, V82, P175, DOI 10.1159/000509143; Hedner M, 2010, J CLIN EXP NEUROPSYC, V32, P1062, DOI 10.1080/13803391003683070; Heilmann S, 2004, AM J RHINOL, V18, P29, DOI 10.1177/194589240401800107; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; Henkin RI, 2017, AM J OTOLARYNG, V38, P143, DOI 10.1016/j.amjoto.2016.11.010; Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342; Henkin RI, 2011, AM J MED SCI, V341, P17, DOI 10.1097/MAJ.0b013e3181f1fdc8; Henkin RI, 2009, AM J MED SCI, V337, P396, DOI 10.1097/MAJ.0b013e3181914a97; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hopkins C, 2021, CLIN OTOLARYNGOL, V46, P16, DOI 10.1111/coa.13636; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huart C, 2020, RHINOLOGY, V58, P623, DOI 10.4193/Rhin20.251; Hummel T, 2017, RHINOLOGY, V54, P7, DOI 10.4193/Rhino16.248; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Hummel T, 2002, LARYNGOSCOPE, V112, P2076, DOI 10.1097/00005537-200211000-00031; Hummel T, 1998, ANN NY ACAD SCI, V855, P616, DOI 10.1111/j.1749-6632.1998.tb10632.x; Hummel T., RHINOLOGY; Hummel T., MANAGEMENT SMELL TAS; Hummel T, 2017, EUR ARCH OTO-RHINO-L, V274, P2819, DOI 10.1007/s00405-017-4576-x; Hummel T, 2015, J NEUROL, V262, P1046, DOI 10.1007/s00415-015-7691-x; Hummel T, 2009, LARYNGOSCOPE, V119, P496, DOI 10.1002/lary.20101; Ikeda Katsuhisa, 1995, Rhinology (Utrecht), V33, P162; Jafek BW, 2002, CHEM SENSES, V27, P623, DOI 10.1093/chemse/27.7.623; Kattar N, 2021, OTOLARYNG HEAD NECK, V164, P244, DOI 10.1177/0194599820943550; Kim Byung Guk, 2018, [Korean Journal of Otorhinolaryngology Head and Neck Surgery, 대한이비인후과학회지 두경부외과학], V61, P522, DOI 10.3342/kjorl-hns.2018.00465; Kim DH, 2017, OTOLARYNG HEAD NECK, V156, P371, DOI 10.1177/0194599816679952; Kobal G., 1996, Rhinology (Utrecht), V34, P222; Kollndorfer K, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/140419; Kondo H, 1998, AM J RHINOL, V12, P353, DOI 10.2500/105065898780182390; Konstantinidis I, 2016, RHINOLOGY, V54, P170, DOI [10.4193/Rhin15.264, 10.4193/Rhino15.264]; Konstantinidis I, 2013, LARYNGOSCOPE, V123, pE85, DOI 10.1002/lary.24390; Landis BN, 2004, LARYNGOSCOPE, V114, P1764, DOI 10.1097/00005537-200410000-00017; Landis BN, 2003, LARYNGOSCOPE, V113, P1993, DOI 10.1097/00005537-200311000-00026; Langstaff L, 2019, CLIN OTOLARYNGOL, V44, P715, DOI 10.1111/coa.13351; Lechner M, 2021, CLIN OTOLARYNGOL, V46, P451, DOI 10.1111/coa.13683; Liu DT, 2021, LARYNGOSCOPE, V131, P618, DOI 10.1002/lary.29277; London B, 2008, ANN NEUROL, V63, P159, DOI 10.1002/ana.21293; Maurage P, 2011, BIOL PSYCHOL, V88, P28, DOI 10.1016/j.biopsycho.2011.06.004; Maurage P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023190; McFee RB, 2020, DM-DIS MON, V66, DOI 10.1016/j.disamonth.2020.101058; Menni C, 2020, LOSS SMELL TASTE COM, V1, P1, DOI [10.1101/2020.04.05.20048421, 10.1038/s41591-020-0916-2, DOI 10.1038/S41591-020-0916-2]; Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; MORAN DT, 1992, MICROSC RES TECHNIQ, V23, P103, DOI 10.1002/jemt.1070230202; Mori E, 2016, EUR ARCH OTO-RHINO-L, V273, P939, DOI 10.1007/s00405-015-3701-y; Mori J, 1998, ACTA OTO-LARYNGOL, P197; Mullol J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001256; MURPHY C, 1994, CHEM SENSES, V19, P47, DOI 10.1093/chemse/19.1.47; Nguyen TP, 2018, INT FORUM ALLERGY RH, V8, P977, DOI 10.1002/alr.22140; Paderno A, 2020, OTOLARYNG HEAD NECK, V163, P1144, DOI 10.1177/0194599820939538; Parma V, 2020, CHEM SENSES, V45, P609, DOI 10.1093/chemse/bjaa041; Pekala K, 2016, INT FORUM ALLERGY RH, V6, P299, DOI 10.1002/alr.21669; Pellegrino R, 2017, INT FORUM ALLERGY RH, V7, P185, DOI 10.1002/alr.21869; Pfaar O, 2006, CHEM SENSES, V31, P27, DOI 10.1093/chemse/bjj002; Philpott CM, 2017, CLIN OTOLARYNGOL, V42, P1295, DOI 10.1111/coa.12878; Philpott CM, 2014, CHEM SENSES, V39, P711, DOI 10.1093/chemse/bju043; Poletti SC, 2017, PERCEPTION, V46, P343, DOI 10.1177/0301006616672881; Quint C, 2002, ACTA OTO-LARYNGOL, V122, P877, DOI 10.1080/003655402/000028054; Reden J, 2006, ARCH OTOLARYNGOL, V132, P265, DOI 10.1001/archotol.132.3.265; Reden J, 2012, LARYNGOSCOPE, V122, P1906, DOI 10.1002/lary.23405; Reden J, 2011, LARYNGOSCOPE, V121, P679, DOI 10.1002/lary.21401; Rocke J, 2020, CLIN OTOLARYNGOL, V45, P914, DOI 10.1111/coa.13620; Rombaux P, 2009, RHINOLOGY, V47, P3; Rombaux P, 2012, OTOLARYNG HEAD NECK, V147, P1136, DOI 10.1177/0194599812459704; Rudmik L, 2011, INT FORUM ALLERGY RH, V1, P431, DOI 10.1002/alr.20095; Saatci O, 2020, EUR ARCH OTO-RHINO-L, V277, P2125, DOI 10.1007/s00405-020-05939-3; Sayin I, 2020, OTOLARYNG HEAD NECK, V163, P473, DOI 10.1177/0194599820931820; Schopf V, 2015, RHINOLOGY, V53, P371, DOI [10.4193/Rhin15.065, 10.4193/Rhino15.065]; Schriever VA, 2012, RHINOLOGY, V50, P284, DOI [10.4193/Rhin11.207, 10.4193/Rhino.11.207]; Schriever VA, 2018, J PEDIATR-US, V198, P265, DOI 10.1016/j.jpeds.2018.03.011; Schriever VA, 2014, J AM GERIATR SOC, V62, P384, DOI 10.1111/jgs.12669; Schubert CR, 2011, LARYNGOSCOPE, V121, P873, DOI 10.1002/lary.21416; Seabury SA, 2013, J OCCUP ENVIRON MED, V55, P286, DOI 10.1097/JOM.0b013e3182794417; Seo BS, 2009, ARCH OTOLARYNGOL, V135, P1000, DOI 10.1001/archoto.2009.141; Silas J, 2010, OTOLARYNG HEAD NECK, V143, P603, DOI 10.1016/j.otohns.2010.07.008; Soler ZM, 2016, INT FORUM ALLERGY RH, V6, P293, DOI 10.1002/alr.21655; Sorokowska A, 2019, ORL J OTO-RHINO-LARY, V81, P245, DOI 10.1159/000500559; Sorokowska A, 2017, RHINOLOGY, V55, P17, DOI [10.4193/Rhino16.195, 10.4193/Rhin16.195]; Stenner M, 2008, LARYNGOSCOPE, V118, P1681, DOI 10.1097/MLG.0b013e31817c1368; Suzuki M, 2007, LARYNGOSCOPE, V117, P272, DOI 10.1097/01.mlg.0000249922.37381.1e; Temmel AFP, 2002, ARCH OTOLARYNGOL, V128, P635, DOI 10.1001/archotol.128.6.635; van Kempen M., 1999, Rhinology (Utrecht), V37, P97; Vennemann MM, 2008, J NEUROL, V255, P1121, DOI 10.1007/s00415-008-0807-9; Vent J, 2010, OTOLARYNG HEAD NECK, V142, P505, DOI 10.1016/j.otohns.2010.01.012; Wang Jing-Jie, 2018, World J Otorhinolaryngol Head Neck Surg, V4, P33, DOI 10.1016/j.wjorl.2018.03.002; Wang JH, 2007, LARYNGOSCOPE, V117, P1445, DOI 10.1097/MLG.0b013e318063e878; Whitcroft KL, 2017, CLIN OTOLARYNGOL, V42, P557, DOI 10.1111/coa.12789; Whitcroft KL, 2016, RHINOLOGY, V54, P368, DOI [10.4193/Rhin16.054, 10.4193/Rhino16.054]; Xiang Z, 2020, INT J BIOL SCI, V16, P2382, DOI 10.7150/ijbs.47652; Yamagishi Masuo, 1994, Rhinology (Utrecht), V32, P113; Yan CH, 2019, INT FORUM ALLERGY RH, V9, P165, DOI 10.1002/alr.22240; Yunpeng Z, 2021, EUR ARCH OTO-RHINO-L, V278, P379, DOI 10.1007/s00405-020-06233-y; Zou LQ, 2020, RHINOLOGY, V58, P471, DOI 10.4193/Rhin19.355	126	47	47	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1704	1719		10.1016/j.jaci.2020.12.641	http://dx.doi.org/10.1016/j.jaci.2020.12.641		MAY 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RY1MN	33453291	Green Accepted, Bronze			2022-12-18	WOS:000647680800020
J	Asano, K; Hebisawa, A; Ishiguro, T; Takayanagi, N; Nakamura, Y; Suzuki, J; Okada, N; Tanaka, J; Fukutomi, Y; Ueki, S; Fukunaga, K; Konno, S; Matsuse, H; Kamei, K; Taniguchi, M; Shimoda, T; Oguma, T				Asano, Koichiro; Hebisawa, Akira; Ishiguro, Takashi; Takayanagi, Noboru; Nakamura, Yasuhiko; Suzuki, Junko; Okada, Naoki; Tanaka, Jun; Fukutomi, Yuma; Ueki, Shigeharu; Fukunaga, Koichi; Konno, Satoshi; Matsuse, Hiroto; Kamei, Katsuhiko; Taniguchi, Masami; Shimoda, Terufumi; Oguma, Tsuyoshi		Japan ABPM Res Program	New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic bronchopulmonary aspergillosis; allergic bronchopulmonary mycosis; Aspergillus; diagnosis; eosinophils; fungus; IgE; mucus plugs; severe asthma with fungal sensitization		Background: There are several clinical diagnostic criteria for allergic bronchopulmonary aspergillosis (ABPA). However, these criteria have not been validated in detail, and no criteria for allergic bronchopulmonary mycosis (ABPM) are currently available. Objective: This study proposes new diagnostic criteria for ABPA/ABPM, consisting of 10 components, and compares its sensitivity and specificity to existing methods. Methods: Rosenberg-Patterson criteria proposed in 1977, the International Society for Human and Animal Mycology (ISHAM) criteria proposed in 2013, and this new criteria were applied to 79 cases with pathological ABPM and the control population with allergic mucin in the absence of fungal hyphae (n = 37), chronic eosinophilic pneumonia (n = 64), Aspergillus-sensitized severe asthma (n = 26), or chronic pulmonary aspergillosis (n = 24). These criteria were also applied to the 179 cases with physician-diagnosed ABPA/ABPM in a nationwide Japanese survey. Results: The sensitivity for pathological ABPM with Rosenberg-Patterson criteria, ISHAM criteria, and this new criteria were 25.3%, 77.2%, and 96.2%, respectively. The sensitivity for physician-diagnosed ABPA/ABPM were 49.2%, 82.7%, and 94.4%, respectively. The areas under the curve for the receiver-operating characteristic curves were 0.85, 0.90, and 0.98, respectively. The sensitivity for ABPM cases that were culture-positive for non-Aspergillus fungi were 13.0%, 47.8%, and 91.3%, respectively. Conclusions: The new diagnostic criteria, compared with existing criteria, showed better sensitivity and specificity for diagnosing ABPA/ABPM.	[Asano, Koichiro; Okada, Naoki; Tanaka, Jun; Oguma, Tsuyoshi] Tokai Univ, Dept Med, Sch Med, Div Pulm Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan; [Fukutomi, Yuma; Taniguchi, Masami] Natl Hosp Org Sagamihara Natl Hosp, Clin Res Ctr, Yokohama, Kanagawa, Japan; [Hebisawa, Akira; Nakamura, Yasuhiko] Natl Hosp Org Tokyo Natl Hosp, Clin Lab Ctr, Tokyo, Japan; [Suzuki, Junko] Natl Hosp Org Tokyo Natl Hosp, Dept Resp Med, Tokyo, Japan; [Fukunaga, Koichi] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo 108, Japan; [Matsuse, Hiroto] Toho Univ, Ohashi Med Ctr, Dept Internal Med, Div Respirol, Tokyo, Japan; [Ishiguro, Takashi; Takayanagi, Noboru] Saitama Cardiovasc & Resp Ctr, Dept Resp Med, Saitama, Japan; [Ueki, Shigeharu] Akita Univ, Dept Gen Internal Med, Akita, Japan; [Ueki, Shigeharu] Akita Univ, Clin Lab Med, Akita, Japan; [Konno, Satoshi] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan; [Konno, Satoshi] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan; [Kamei, Katsuhiko] Chiba Univ, Med Mycol Res Ctr, Div Clin Res, Chiba, Japan; [Shimoda, Terufumi] Natl Hosp Org Fukuoka Hosp, Clin Res Ctr, Dept Allergy, Fukuoka, Japan	Tokai University; Keio University; Toho University; Akita University; Akita University; Hokkaido University; Hokkaido University; Chiba University	Asano, K (corresponding author), Tokai Univ, Dept Med, Sch Med, Div Pulm Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	ko-asano@tokai-u.jp	Fukutomi, Yuma/AFQ-4306-2022; Ueki, Shigeharu/I-3566-2019	Ueki, Shigeharu/0000-0002-3537-7735	Japan Agency for Medical Research and Development [JP18ek0410026, JP20ek0410055]	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This study was funded by the Research Grant on Allergic Disease and Immunology, from the Japan Agency for Medical Research and Development, under the grant numbers JP18ek0410026 and JP20ek0410055.	Agarwal R, 2013, CLIN EXP ALLERGY, V43, P850, DOI 10.1111/cea.12141; Agarwal R, 2007, CHEST, V132, P1183, DOI 10.1378/chest.07-0808; Agarwal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061105; Asano K, 2018, ASIA PAC ALLERGY, V8, DOI 10.5415/apallergy.2018.8.e24; BOSKEN CH, 1988, AM J SURG PATHOL, V12, P216, DOI 10.1097/00000478-198803000-00007; Chowdhary A, 2014, CRIT REV MICROBIOL, V40, P30, DOI 10.3109/1040841X.2012.754401; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V81, P646, DOI 10.1016/0091-6749(88)91034-2; Harada K, 2018, ALLERGOL INT, V67, pS12, DOI 10.1016/j.alit.2018.04.009; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; Ishiguro T, 2014, INTERNAL MED, V53, P1407, DOI 10.2169/internalmedicine.53.2230; Kim JH, 2012, ALLERGY ASTHMA IMMUN, V4, P305, DOI 10.4168/aair.2012.4.5.305; Masaki K, 2017, ANN ALLERG ASTHMA IM, V119, P253, DOI 10.1016/j.anai.2017.07.008; Oguma T, 2018, ALLERGOL INT, V67, P79, DOI 10.1016/j.alit.2017.04.011; Reddel HK, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01046-2019; Rick EM, 2016, J INVEST ALLERG CLIN, V26, P344, DOI 10.18176/jiaci.0122; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; Sehgal IS, 2019, MED MYCOL, V57, P270, DOI 10.1093/mmy/myy012; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; Tanimoto H, 2015, CLIN EXP ALLERGY, V45, P1790, DOI 10.1111/cea.12590	21	47	48	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1261	+		10.1016/j.jaci.2020.08.029	http://dx.doi.org/10.1016/j.jaci.2020.08.029		APR 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	32920094	hybrid			2022-12-18	WOS:000637368900015
J	He, HE; Bissonnette, R; Wu, JN; Diaz, A; Proulx, ESC; Maari, C; Jack, C; Louis, M; Estrada, Y; Krueger, JG; Zhang, N; Pavel, AB; Guttman-Yassky, E				He, Helen; Bissonnette, Robert; Wu, Jianni; Diaz, Aisleen; Proulx, Etienne Saint-Cyr; Maari, Catherine; Jack, Carolyn; Louis, Maudeline; Estrada, Yeriel; Krueger, James G.; Zhang, Ning; Pavel, Ana B.; Guttman-Yassky, Emma			Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; tape strips; biomarker; skin; RNA sequencing; T(H)1; T(H)2; T(H)17; immune; epidermal barrier		Background: Our current understanding of atopic dermatitis (AD) and psoriasis pathophysiology is largely derived from skin biopsy studies that cause scarring and may be impractical in large-scale clinical trials. Although tape strips show promise as a minimally invasive technique in these common diseases, a comprehensive molecular profiling characterizing and differentiating the 2 diseases in tape strips is unavailable. Objective: Our aim was to construct a global transcriptome of tape strips from lesional and nonlesional skin of adults with moderate-to-severe AD and psoriasis. Methods: A total of 20 tape strips were obtained from lesional and nonlesional skin of patients with AD and psoriasis and skin from controls (n = 20 each); the strips were subjected to RNA sequencing (RNA-seq), with quantitative RT-PCR validation of immune and barrier biomarkers. Results: We detected RNA-seq profiles in 96 of 100 of samples (96%), with 4123 and 5390 genes differentially expressed in AD and psoriasis lesions versus in controls, respectively (fold change >= 2; false discovery rate [FDR] < 0.05). Nonlesional tape stripped skin from patients with AD was more similar to lesional skin than to nonlesional skin of patients with psoriasis, which showed larger differentiation from lesions. AD and psoriasis tissues shared increases in levels of dendritic cell and T-cell markers (CD3, ITGAX/CD11c, and CD83), but AD tissues showed preferential T(H)2 skewing (IL-13, CCL17/TARC, and CCL18), whereas psoriasis was characterized by higher levels of expression of T(H)17-related (IL-17A/F and IL-36A/IL-36G), T(H)1-related (IFN-gamma and CXCL9/CXCL10), and innate immunity-related (nitric oxide synthase 2/inducible nitric oxide synthase and IL-17C) products (FDR < 0.05). Terminal differentiation (FLG2 and LCE5A), tight junction (CLDN8), and lipid biosynthesis and metabolism (FA2H and ALOXE3) products were significantly downregulated in both AD and psoriasis (FDR < 0.05). Nitric oxide synthase 2/inducible nitric oxide synthase expression (determined by quantitative PCR) differentiated AD and psoriasis with 100% accuracy. Conclusion: RNA-seq tape strip profiling detected distinct immune and barrier signatures in lesional and nonlesional AD and psoriasis skin, suggesting their utility as a minimally invasive alternative to biopsies for detecting disease biomarkers.	[He, Helen; Wu, Jianni; Diaz, Aisleen; Estrada, Yeriel; Zhang, Ning; Pavel, Ana B.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [He, Helen; Wu, Jianni; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA; [Bissonnette, Robert; Proulx, Etienne Saint-Cyr; Maari, Catherine; Jack, Carolyn; Louis, Maudeline] Innovaderm Res, Montreal, PQ, Canada; [Wu, Jianni] Suny Downstate Med Ctr, Coll Med, New York, NY USA; [Diaz, Aisleen] Ponce Hlth Sci Univ, Sch Med, Ponce, PR USA	Icahn School of Medicine at Mount Sinai; Rockefeller University; Innovaderm Research Inc.; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Ponce Health Sciences University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org		, Ana Brandusa/0000-0002-8155-8553				Ainscough JS, 2017, P NATL ACAD SCI USA, V114, pE2748, DOI 10.1073/pnas.1620954114; Amarbayasgalan T, 2013, INT ARCH ALLERGY IMM, V160, P63, DOI 10.1159/000339666; Angelova-Fischer I, 2011, EXP DERMATOL, V20, P351, DOI 10.1111/j.1600-0625.2011.01259.x; Baerveldt EM, 2013, BRIT J DERMATOL, V168, P990, DOI 10.1111/bjd.12175; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Benson NR, 2006, J INVEST DERMATOL, V126, P2234, DOI 10.1038/sj.jid.5700412; Berdyshev E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98006; Berekmeri A, 2018, J ALLERGY CLIN IMMUN, V142, P988, DOI 10.1016/j.jaci.2018.04.031; Bergboer JGM, 2011, AM J PATHOL, V178, P1470, DOI 10.1016/j.ajpath.2010.12.017; Bissonnette R, 2019, J ALLERGY CLIN IMMUN, V144, P1274, DOI 10.1016/j.jaci.2019.06.047; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Broccardo CJ, 2009, J ALLERGY CLIN IMMUN, V124, P1113, DOI 10.1016/j.jaci.2009.07.057; Brunner PM, 2019, J AM ACAD DERMATOL, V81, P510, DOI 10.1016/j.jaad.2019.04.036; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09207-z; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Clausen ML, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20204-8; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Dietrich D, 2016, CYTOKINE, V84, P88, DOI 10.1016/j.cyto.2016.05.012; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dyjack N, 2018, J ALLERGY CLIN IMMUN, V141, P1298, DOI 10.1016/j.jaci.2017.10.046; Emer JJ, 2011, J DRUGS DERMATOL, V10, P735; Emson CL, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-12; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Garzorz-Stark N, 2016, EXP DERMATOL, V25, P767, DOI 10.1111/exd.13077; Ghosh D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144316; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1829, DOI 10.1038/jid.2010.36; Guttman-Yassky E, 2019, JAMA DERMATOL, V155, P1358, DOI 10.1001/jamadermatol.2019.2983; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V144, P482, DOI 10.1016/j.jaci.2018.11.053; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; He H, 2020, ANN ALLERG ASTHMA IM, V124, P70, DOI 10.1016/j.anai.2019.10.013; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Hulshof L, 2019, BRIT J DERMATOL, V180, P621, DOI 10.1111/bjd.16994; Jabbari A, 2012, J INVEST DERMATOL, V132, P246, DOI 10.1038/jid.2011.267; Jansen PAM, 2009, J INVEST DERMATOL, V129, P2167, DOI 10.1038/jid.2009.67; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Januzzi JL, 2013, J CARDIOVASC TRANSL, V6, P493, DOI 10.1007/s12265-013-9459-y; Kamsteeg M, 2010, BRIT J DERMATOL, V162, P568, DOI 10.1111/j.1365-2133.2009.09547.x; Kanwar JR, 2009, CURR MED CHEM, V16, P2373, DOI 10.2174/092986709788682155; Keermann M, 2015, J DERMATOL SCI, V80, P150, DOI 10.1016/j.jdermsci.2015.08.002; Keermann M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1508-2; Kim BE, 2019, J INVEST DERMATOL, V139, P2387, DOI 10.1016/j.jid.2019.03.1160; Kim BE, 2018, ALLERGY ASTHMA IMMUN, V10, P207, DOI 10.4168/aair.2018.10.3.207; Koppes SA, 2016, INT ARCH ALLERGY IMM, V170, P187, DOI 10.1159/000448400; Krueger JG, 2005, ANN RHEUM DIS, V64, P30, DOI 10.1136/ard.2004.031120; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Leung DYM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav2685; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Li WL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2270-1; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Loesche C., 2016, ADV PRECIS MED, V1, P1; McAleer MA, 2019, BRIT J DERMATOL, V180, P586, DOI 10.1111/bjd.17088; Mehul B, 2017, BRIT J DERMATOL, V177, P470, DOI 10.1111/bjd.15346; Morita E, 2010, ALLERGY, V65, P1166, DOI 10.1111/j.1398-9995.2010.02361.x; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Sakabe J, 2014, J ALLERGY CLIN IMMUN, V134, P957, DOI 10.1016/j.jaci.2014.07.054; Sano Y, 2013, CLIN EXP IMMUNOL, V171, P330, DOI 10.1111/cei.12021; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Smits J, 2017, J INVEST DERMATOL, V137, pS212, DOI 10.1016/j.jid.2017.06.003; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Swindell WR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-527; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Todorovic V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45626-w; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Vocca L, 2015, IMMUNOBIOLOGY, V220, P954, DOI 10.1016/j.imbio.2015.02.005; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x; Wachsman W, 2011, BRIT J DERMATOL, V164, P797, DOI 10.1111/j.1365-2133.2011.10239.x; Winget JM, 2016, J INVEST DERMATOL, V136, P1732, DOI 10.1016/j.jid.2016.03.037; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Yamaguchi J, 2009, J DERMATOL SCI, V53, P48, DOI 10.1016/j.jdermsci.2008.08.011; Yan J, 2017, BRIT J DERMATOL, V176, P555, DOI 10.1111/bjd.15249	96	47	48	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					199	212		10.1016/j.jaci.2020.05.048	http://dx.doi.org/10.1016/j.jaci.2020.05.048		JAN 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32709423	Bronze			2022-12-18	WOS:000613645900024
J	Leung, DYM; Berdyshev, E; Goleva, E				Leung, Donald Y. M.; Berdyshev, Evgeny; Goleva, Elena			Cutaneous barrier dysfunction in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; food allergy; skin barrier; peanut allergy; epithelial barrier	PROLIFERATOR-ACTIVATED RECEPTORS; DOWN-REGULATES FILAGGRIN; INNATE IMMUNE-RESPONSE; ATOPIC-DERMATITIS SKIN; STRATUM-CORNEUM LIPIDS; STAPHYLOCOCCUS-AUREUS; TH2 CYTOKINES; FOOD ALLERGY; EPIDERMAL DIFFERENTIATION; TIGHT JUNCTIONS	The fundamental defect(s) that drives atopic dermatitis (AD) remains controversial. "Outside in" proponents point to the important association of filaggrin gene mutations and other skin barrier defects with AD. The "inside out" proponents derive support from evidence that AD occurs in genetic animal models with overexpression of type 2 immune pathways in their skin, and humans with gain-of-function mutations in their type 2 response develop severe AD. The observation that therapeutic biologics, targeting type 2 immune responses, can reverse AD provides compelling support for the importance of "inside out" mechanisms of AD. In this review, we propose a central role for epithelial cell dysfunction that accounts for the dual role of skin barrier defects and immune pathway activation in AD. The complexity of AD has its roots in the dysfunction of the epithelial barrier that allows the penetration of allergens, irritants, and microbes into a cutaneous milieu that facilitates the induction of type 2 immune responses. The AD phenotypes and endotypes that result in chronic skin inflammation and barrier dysfunction are modified by genes, innate/adaptive immune responses, and different environmental factors that cause skin barrier dysfunction. There is also compelling evidence that skin barrier dysfunction can alter the course of childhood asthma, food allergy, and allergic rhinosinusitis. Effective management of AD requires a multipronged approach, not only restoring cutaneous barrier function, microbial flora, and immune homeostasis but also enhancing skin epithelial differentiation.	[Leung, Donald Y. M.; Goleva, Elena] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Berdyshev, Evgeny] Natl Jewish Hlth, Dept Med, Denver, CO USA	National Jewish Health; National Jewish Health	Leung, DYM (corresponding author), Natl Jewish Hlth K801, 1400 Jackson St, Denver, CO 80206 USA.	Leungd@NJHealth.org			National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR41256]; NIH/National Institute of Allergy and Infectious Diseases [U19 AI117673]; NIH/National Center for Research Resources [UL1 RR025780]; Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health	The project was funded in part by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant no. R01 AR41256), NIH/National Institute of Allergy and Infectious Diseases (grant no. U19 AI117673), NIH/National Center for Research Resources (grant no. UL1 RR025780), and the Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health.	Abdou AG, 2012, ANN DIAGN PATHOL, V16, P177, DOI 10.1016/j.anndiagpath.2011.09.005; Archer NK, 2019, J ALLERGY CLIN IMMUN, V143, P1426, DOI 10.1016/j.jaci.2018.08.042; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Berdyshev E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98006; Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022-202X.2004.22424.x; Boske R, 2017, AM J RESP CELL MOL, V56, P575, DOI 10.1165/rcmb.2016-0024OC; Brauweiler AM, 2017, J INVEST DERMATOL, V137, P2030, DOI 10.1016/j.jid.2017.05.003; Brauweiler AM, 2015, J INVEST DERMATOL, V135, P2550, DOI 10.1038/jid.2015.181; Brauweiler AM, 2014, J INVEST DERMATOL, V134, P2114, DOI 10.1038/jid.2014.43; Brauweiler AM, 2013, J ALLERGY CLIN IMMUN, V131, P421, DOI 10.1016/j.jaci.2012.10.030; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Cabanillas B, 2017, CURR OPIN ALLERGY CL, V17, P309, DOI 10.1097/ACI.0000000000000376; Callewaert C, 2020, J INVEST DERMATOL, V140, P191, DOI 10.1016/j.jid.2019.05.024; Cho SH, 2001, J INVEST DERMATOL, V116, P658, DOI 10.1046/j.0022-202x.2001.01331.x; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Davidson WF, 2019, J ALLERGY CLIN IMMUN, V143, P894, DOI 10.1016/j.jaci.2019.01.003; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V128, P242, DOI 10.1016/j.jaci.2011.02.014; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Demehri S, 2012, CANCER CELL, V22, P494, DOI 10.1016/j.ccr.2012.08.017; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Di Piazza M, 2012, CANCER CELL, V22, P479, DOI 10.1016/j.ccr.2012.08.016; Drake DR, 2008, J LIPID RES, V49, P4, DOI 10.1194/jlr.R700016-JLR200; Drislane C, 2020, ANN ALLERG ASTHMA IM, V124, P36, DOI 10.1016/j.anai.2019.10.008; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Egawa G, 2018, ALLERGOL INT, V67, P3, DOI 10.1016/j.alit.2017.10.002; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Elias PM, 2018, ANN ALLERG ASTHMA IM, V121, P653, DOI 10.1016/j.anai.2018.07.008; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Feingold KR, 2014, BBA-MOL CELL BIOL L, V1841, P280, DOI 10.1016/j.bbalip.2013.11.007; Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Franzke CW, 2012, J EXP MED, V209, P1105, DOI 10.1084/jem.20112258; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Goleva E, 2019, J CLIN INVEST, V129, P1463, DOI 10.1172/JCI124608; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1849, DOI 10.1038/jid.2010.67; Guo LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080179; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hachem JP, 2005, J INVEST DERMATOL, V125, P510, DOI 10.1111/j.0022-202X.2005.23838.x; Hayward P, 2005, DEVELOPMENT, V132, P1819, DOI 10.1242/dev.01724; Hill DA, 2018, ANN ALLERG ASTHMA IM, V120, P131, DOI 10.1016/j.anai.2017.10.037; Holgate ST, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.25; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Honda T, 2020, J ALLERGY CLIN IMMUN, V145, P1136, DOI 10.1016/j.jaci.2020.02.008; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishikawa J, 2010, J INVEST DERMATOL, V130, P2511, DOI 10.1038/jid.2010.161; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Jin S, 2014, EXP DERMATOL, V23, P938, DOI 10.1111/exd.12563; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kennedy K, 2018, J ALLERGY CLIN IMMUN, V142, P1740, DOI 10.1016/j.jaci.2018.10.012; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Kim J, 2016, J ALLERGY CLIN IMMUN, V137, P1282, DOI 10.1016/j.jaci.2015.12.1306; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Kisich KO, 2007, J INVEST DERMATOL, V127, P2368, DOI 10.1038/sj.jid.5700861; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; Leung DYM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav2685; Leyva-Castillo JM, 2019, IMMUNITY, V50, P1262, DOI 10.1016/j.immuni.2019.03.023; Lin HY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015842, 10.1371/journal.pone.0019135]; Linehan JL, 2018, CELL, V172, P784, DOI 10.1016/j.cell.2017.12.033; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Lowe AJ, 2018, BRIT J DERMATOL, V178, pE19, DOI 10.1111/bjd.15747; Lowe AJ, 2018, ANN ALLERG ASTHMA IM, V120, P145, DOI 10.1016/j.anai.2017.11.023; Martin PE, 2015, CLIN EXP ALLERGY, V45, P255, DOI 10.1111/cea.12406; Martin PE, 2013, CLIN EXP ALLERGY, V43, P642, DOI 10.1111/cea.12092; Meylan P, 2017, J INVEST DERMATOL, V137, P2497, DOI 10.1016/j.jid.2017.07.834; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Miyaji Y, 2019, ALLERGY CLIN IMMUNOL; Murthy A, 2012, IMMUNITY, V36, P105, DOI 10.1016/j.immuni.2012.01.005; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Nakahigashi K, 2011, J INVEST DERMATOL, V131, P865, DOI 10.1038/jid.2010.395; Nakatsuji T, 2019, ANN ALLERG ASTHMA IM, V122, P263, DOI 10.1016/j.anai.2018.12.003; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nowell C, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a017772; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Oh J, 2013, GENOME RES, V23, P2103, DOI 10.1101/gr.159467.113; Olsson M, 2006, ALLERGY, V61, P1132, DOI 10.1111/j.1398-9995.2006.01151.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P26, DOI 10.1016/j.jaci.2018.11.015; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pendaries V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.29; Pendaries V, 2014, J INVEST DERMATOL, V134, P2938, DOI 10.1038/jid.2014.259; Peters RL, 2017, J ALLERGY CLIN IMMUN, V140, P145, DOI 10.1016/j.jaci.2017.02.019; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Renert-Yuval Y, 2020, ANN ALLERG ASTHMA IM, V124, P28, DOI 10.1016/j.anai.2019.10.005; Romanowska M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005354; Rueter K, 2019, J ALLERGY CLIN IMMUN, V143, P1012, DOI 10.1016/j.jaci.2018.08.037; Ryu WI, 2016, J DERMATOL SCI, V82, P131, DOI 10.1016/j.jdermsci.2016.01.011; Sahle FF, 2015, SKIN PHARMACOL PHYS, V28, P42, DOI 10.1159/000360009; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmuth M, 2008, J LIPID RES, V49, P499, DOI 10.1194/jlr.R800001-JLR200; Sicherer SH, 2019, ALLERGY, V74, P2199, DOI 10.1111/all.13920; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Spaulding AR, 2013, CLIN MICROBIOL REV, V26, P422, DOI 10.1128/CMR.00104-12; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Takigawa H, 2005, DERMATOLOGY, V211, P240, DOI 10.1159/000087018; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tran MM, 2018, J ALLERGY CLIN IMMUN, V141, P601, DOI 10.1016/j.jaci.2017.08.024; Tsakok T, 2019, BRIT J DERMATOL, V180, P464, DOI 10.1111/bjd.16934; Tsilochristou O, 2019, J ALLERGY CLIN IMMUN, V144, P494, DOI 10.1016/j.jaci.2019.04.025; van Smeden J, 2016, CURR PROBL DERMATOL, V49, P8, DOI 10.1159/000441540; van Smeden J, 2014, EXP DERMATOL, V23, P45, DOI 10.1111/exd.12293; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Walker MT, 2018, J ALLERGY CLIN IMMUN, V141, P1711, DOI 10.1016/j.jaci.2018.02.003; Weber S, 2011, DEVELOPMENT, V138, P495, DOI 10.1242/dev.055210; Williams MR, 2017, J INVEST DERMATOL, V137, P377, DOI 10.1016/j.jid.2016.10.008; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yoshida K, 2014, J ALLERGY CLIN IMMUN, V134, P856, DOI 10.1016/j.jaci.2014.08.001; Ziyab AH, 2013, J EUR ACAD DERMATOL, V27, pe420, DOI 10.1111/jdv.12000	134	47	48	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1485	1497		10.1016/j.jaci.2020.02.021	http://dx.doi.org/10.1016/j.jaci.2020.02.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32507227	Green Accepted, Bronze			2022-12-18	WOS:000539157800001
J	Platts-Mills, TAE; Commins, SP; Biedermann, T; van Hage, M; Levin, M; Beck, LA; Diuk-Wasser, M; Jappe, U; Apostolovic, D; Minnicozzi, M; Plaut, M; Wilson, JM				Platts-Mills, Thomas A. E.; Commins, Scott P.; Biedermann, Tilo; van Hage, Marianne; Levin, Michael; Beck, Lisa A.; Diuk-Wasser, Maria; Jappe, Uta; Apostolovic, Danijela; Minnicozzi, Michael; Plaut, Marshall; Wilson, Jeffrey M.			On the cause and consequences of IgE to galactose-alpha-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha-Gal; anaphylaxis; IgE; oligosaccharide allergen; glycolipids; mammalian meat allergy; ticks	LONE STAR TICK; FOREST SERVICE EMPLOYEES; ALPHA-GAL ALLERGY; AMBLYOMMA-AMERICANUM; ANTI-GAL; MONOCLONAL-ANTIBODY; STRUCTURAL-CHARACTERIZATION; NATURAL ANTIBODIES; I SENSITIZATION; T-CELLS	The mammalian meat allergy known as the "alpha-Gal syndrome'' relates to IgE specific for galactose-alpha-1,3-galactose (alpha-Gal), an oligosaccharide that is present in cells and tissues of nonprimate mammals. The recognition of delayed reactions to food derived from mammals in patients with IgE to alpha-Gal and also the association with tick bites have been increasing worldwide. In 2018, the National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology and Transplantation, sponsored a workshop on this emerging tick-related disease. International experts from the fields of tick biology, allergy, immunology, infectious disease, and dermatology discussed the current state of our understanding of this emerging medical condition. The participants provided suggestions for specific research priorities and for the development of resources to advance our knowledge of the mechanisms, diagnosis, management, and prevention of this allergic disease. This publication is a summary of the workshop and the panel's recommendations are presented herein.	[Platts-Mills, Thomas A. E.; Wilson, Jeffrey M.] Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA; [Commins, Scott P.] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; [Commins, Scott P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA; [Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Biedermann, Tilo] Helmholtz Zentrum Munchen, Unit Clin Allergol EKA, Munich, Germany; [van Hage, Marianne; Apostolovic, Danijela] Karolinska Inst & Univ Hosp, Dept Med Solna, Div Immunol & Allergy, Stockholm, Sweden; [Levin, Michael] Univ Cape Town, Div Paediat Allergy, Cape Town, South Africa; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14627 USA; [Diuk-Wasser, Maria] Columbia Univ, Dept Ecol Evolut & Environm Biol, New York, NY USA; [Jappe, Uta] Ctr North ARCN, Airway Res, Res Ctr Borstel, Div Clin & Mol Allergol, Borstel, Germany; [Jappe, Uta] German Ctr Lung Res, Borstel, Germany; [Jappe, Uta] Univ Lubeck, Dept Pneumol, Interdisciplinary Allergy Outpatient Clin, Lubeck, Germany; [Minnicozzi, Michael; Plaut, Marshall] NIAID, Div Allergy Immunol & Transplantat, Allergy Asthma & Airway Biol Branch, NIH, Rockville, MD USA	University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet; Karolinska University Hospital; University of Cape Town; University of Rochester; Columbia University; Forschungszentrum Borstel; University of Lubeck; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Platts-Mills, TAE (corresponding author), Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	Levin, Michael/AAT-2370-2020; Wilson, JM/AAD-6421-2020; Apostolovic, Danijela/J-6089-2019	Levin, Michael/0000-0003-2439-7981; Wilson, JM/0000-0002-5975-1760; Apostolovic, Danijela/0000-0001-8388-6916; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes ofHealth (NIH) [R37-AI-20565]; NIH [R01AI135049, R56AI113095, K08AI85190]; Centers for Disease Control and Prevention [IPA1908943]	National Institutes ofHealth (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	T. A. E. Platts-Mills was supported by the National Institutes ofHealth (NIH) (grant no. R37-AI-20565); has received assay support from Thermo Fisher/Phadia; and has a patent on an IgE assay to alpha-Gal. S. P. Commins was supported by the NIH (grant nos. R01AI135049, R56AI113095, and K08AI85190) and the Centers for Disease Control and Prevention (grant no. IPA1908943); has been on the speaker's bureau at Genentech; and has received author royalties from Up-to-Date. M. van Hage reports grants from H2020 FoodEnTwin GA (no. 810752), the Swedish Research Council, the Stockholm County Council (ALF project), the Swedish Asthma and Allergy Association's Research Foundation, the King Gustaf V 80th Birthday Foundation, the Swedish Heart-Lung Foundation, the Hesselman Foundation, the Swedish Cancer and Allergy Foundation, and the Swedish Association for Allergology; personal fees from BiomayAG, Vienna, Austria, and Hycor Biomedical LLC, Calif; and personal fees from Thermo Fisher Scientific and ALK, outside the submitted work; L. A. Beck is a consultant or Advisory Board Member for Abbvie, Allakos, Arena Pharma, Astra-Zeneca, Connect Biopharma, LEO Pharma, Lilly, Novan, Novartis, Pfizer, Regeneron, Sanofi, UCB, and Vimalan; is or has recently been an investigator for an Abbvie, LEO Pharma, Pfizer, and/or Regeneron clinical trial; and owns stock in Pfizer and Medtronics. D. Apostolovic reports grants from H2020 FoodEnTwin GA (no. 810752) and fromKonsul ThCBerg Foundation, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.	Abdelghany M, 2017, INT J CARDIOL, V232, P1, DOI 10.1016/j.ijcard.2017.01.124; Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Aguilar R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28325-w; Amoah AS, 2018, J ALLERGY CLIN IMMUN, V141, P1130, DOI 10.1016/j.jaci.2017.09.040; Apostolovic D, 2018, ALLERGY, V73, P1525, DOI 10.1111/all.13400; Apostolovic D, 2015, ALLERGY, V70, P1497, DOI 10.1111/all.12695; Apostolovic D, 2020, ALLERGY, V75, P217, DOI 10.1111/all.13978; Apperson CS., 2008, VECTOR-BORNE ZOONOT, V8, P597, DOI [10.11158/saa.10.1.4, 10.1089/vbz.2007.0271, DOI 10.1089/vbz.2007.0271]; Araujo RN, 2016, INT J PARASITOL, V46, P213, DOI 10.1016/j.ijpara.2015.12.005; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; BORREBAECK CAK, 1993, IMMUNOL TODAY, V14, P477, DOI 10.1016/0167-5699(93)90259-N; Bowman AS, 1997, EXP PARASITOL, V87, P121, DOI 10.1006/expr.1997.4201; Brestoff JR, 2018, J ALLER CL IMM-PRACT, V6, P1790, DOI 10.1016/j.jaip.2018.02.010; BROWN SJ, 1980, EXP PARASITOL, V49, P303, DOI 10.1016/0014-4894(80)90067-3; BURNS EC, 1977, J MED ENTOMOL, V14, P247, DOI 10.1093/jmedent/14.2.247; Cabezas-Cruz A, 2017, ALLERGY, V72, P2044, DOI 10.1111/all.13206; Cabezas-Cruz A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32664-z; Cabezas-Cruz A, 2017, TRENDS PARASITOL, V33, P495, DOI 10.1016/j.pt.2017.03.004; Cabezas-Cruz A, 2014, FRONT ZOOL, V11, DOI 10.1186/1742-9994-11-47; Caponetto P, 2013, J ALLER CL IMM-PRACT, V1, P302, DOI 10.1016/j.jaip.2013.01.007; Chandrasekhar JL, 2019, J IMMUNOL, V203, P813, DOI 10.4049/jimmunol.1801156; Chinuki Y, 2016, ALLERGY, V71, P421, DOI 10.1111/all.12804; Choudhary S, 2019, J ALLERGY CLIN IMMUN, V143, pAB252, DOI 10.1016/j.jaci.2018.12.771; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2017, J ALLERGY CLIN IMMUN, V139, pAB193, DOI 10.1016/j.jaci.2016.12.628; Commins SP, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0641-6; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cretin N, 2002, J IMMUNOL, V168, P1479, DOI 10.4049/jimmunol.168.3.1479; Crispell G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01056; Dahlgren FS, 2016, AM J TROP MED HYG, V94, P35, DOI 10.4269/ajtmh.15-0580; Diswall M, 2010, XENOTRANSPLANTATION, V17, P48, DOI 10.1111/j.1399-3089.2009.00564.x; Diuk-Wasser MA, 2006, J MED ENTOMOL, V43, P166, DOI 10.1603/0022-2585(2006)043[0166:SPOHIS]2.0.CO;2; Fischer J, 2017, ALLERGY, V72, P1540, DOI 10.1111/all.13156; Fischer J, 2017, ALLERGY, V72, P764, DOI 10.1111/all.13073; Fischer J, 2016, ALLERGO J, V25, P35, DOI 10.1007/s15007-016-1028-7; Fischer J, 2014, J ALLERGY CLIN IMMUN, V134, P755, DOI 10.1016/j.jaci.2014.05.051; Fryxell RTT, 2015, J MED ENTOMOL, V52, P500, DOI 10.1093/jme/tjv027; Gaines DN, 2014, VECTOR-BORNE ZOONOT, V14, P307, DOI 10.1089/vbz.2013.1509; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; GALILI U, 1987, J EXP MED, V165, P693, DOI 10.1084/jem.165.3.693; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, J BIOL CHEM, V262, P4683; Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110; Gonzalez-Quintela A, 2014, CLIN EXP ALLERGY, V44, P1061, DOI 10.1111/cea.12326; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; HAMADEH RM, 1995, CLIN DIAGN LAB IMMUN, V2, P125, DOI 10.1128/CDLI.2.2.125-131.1995; Hamanova M, 2015, IMMUNOL LETT, V164, P40, DOI 10.1016/j.imlet.2015.02.001; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Harrison OJ, 2019, SCIENCE, V363, P43, DOI 10.1126/science.aat6280; Hashizume H, 2018, J AM ACAD DERMATOL, V78, P1135, DOI 10.1016/j.jaad.2017.12.028; Hawkins RB, 2016, J CARDIAC SURG, V31, P446, DOI 10.1111/jocs.12764; HENDRICKS SP, 1990, J BIOL CHEM, V265, P17621; Hilger C, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0835-9; Homann A, 2017, J ALLERGY CLIN IMMUN, V140, P356, DOI 10.1016/j.jaci.2017.04.019; Iweala O, 2017, J ALLERGY CLIN IMMUN, V139, pAB88, DOI 10.1016/j.jaci.2016.12.237; Iweala OI, 2018, J ALLERGY CLIN IMMUN, V141, pAB288, DOI 10.1016/j.jaci.2017.12.918; Jappe U, 2018, ALLERGY, V73, P93, DOI 10.1111/all.13238; Jappe U, 2010, ALLERGY, V65, P164; Karasuyama H, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01769; Karim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131292; Karpathy SE, 2016, INT J SYST EVOL MICR, V66, P5236, DOI 10.1099/ijsem.0.001502; Kennedy JL, 2013, PEDIATRICS, V131, pE1545, DOI 10.1542/peds.2012-2585; Kim MS, 2020, J ALLER CL IMM-PRACT, V8, P364, DOI 10.1016/j.jaip.2019.08.045; Kollmann D, 2017, ALLERGY, V72, P266, DOI 10.1111/all.12948; Kounis NG, 2016, ATHEROSCLEROSIS, V251, P498, DOI 10.1016/j.atherosclerosis.2016.05.045; Kounis NG, 2013, CLIN THER, V35, P563, DOI 10.1016/j.clinthera.2013.02.022; Labbe SM, 2011, AM J PHYSIOL-ENDOC M, V300, pE445, DOI 10.1152/ajpendo.00579.2010; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Landsteiner K, 1925, J EXP MED, V42, P863, DOI 10.1084/jem.42.6.863; Levin M, 2019, ANN ALLERG ASTHMA IM, V122, P598, DOI 10.1016/j.anai.2019.03.021; Liu S, 2009, TRANSPL P, V41, P398, DOI 10.1016/j.transproceed.2008.10.054; Mabelane T, 2018, PEDIAT ALLERG IMM-UK, V29, P841, DOI 10.1111/pai.12969; Maier S, 2015, CANCER MED-US, V4, P36, DOI 10.1002/cam4.333; McGowan EC, 2019, ANN ALLERG ASTHMA IM, V122, P563, DOI 10.1016/j.anai.2019.03.024; Michel CC, 2015, J LIPID RES, V56, P122, DOI 10.1194/jlr.M055053; Monzon JD, 2016, GENOME BIOL EVOL, V8, P1351, DOI 10.1093/gbe/evw080; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Mozzicato SM, 2014, J ALLER CL IMM-PRACT, V2, P637, DOI 10.1016/j.jaip.2014.04.016; Muglia C, 2015, J ALLER CL IMM-PRACT, V3, P796, DOI 10.1016/j.jaip.2015.04.004; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Nuttall PA, 2019, TICKS TICK-BORNE DIS, V10, P470, DOI 10.1016/j.ttbdis.2018.11.005; Ohdan H, 2000, J IMMUNOL, V165, P5518, DOI 10.4049/jimmunol.165.10.5518; Paddock CD, 2007, CURR TOP MICROBIOL, V315, P289; Park Y, ALPHAGAL CROSS REACT, V8; Parker W, 1997, J CLIN IMMUNOL, V17, P311, DOI 10.1023/A:1027378716015; Pinson ML, 2015, VACCINE, V33, P1231, DOI 10.1016/j.vaccine.2015.01.020; Platts-Mills TAE, 2020, J ALLER CL IMM-PRACT, V8, P15, DOI 10.1016/j.jaip.2019.09.017; Platts-Mills TAE, 2013, CURR OPIN IMMUNOL, V25, P769, DOI 10.1016/j.coi.2013.09.002; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Raghavan RK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209082; Retterer MKC, 2018, J ALLERGY CLIN IMMUN, V141, P1956, DOI 10.1016/j.jaci.2017.08.047; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Ristivojevic MK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30887-8; Rizer J, 2017, CLIN TOXICOL, V55, P668, DOI 10.1080/15563650.2017.1313981; Roenneberg S, 2016, J ALLER CL IMM-PRACT, V4, P531, DOI 10.1016/j.jaip.2015.11.027; Roman-Carrasco P, 2019, ALLERGY, V74, P1956, DOI 10.1111/all.13873; Schmidle P, 2019, J ALLER CL IMM-PRACT, V7, P685, DOI 10.1016/j.jaip.2018.08.026; Sell-Dottin K, 2017, CLIN SURG, V2; Sheeley DM, 1997, ANAL BIOCHEM, V247, P102, DOI 10.1006/abio.1997.2036; Springer YP, 2015, AM J TROP MED HYG, V93, P875, DOI 10.4269/ajtmh.15-0330; Springer YP, 2014, J MED ENTOMOL, V51, P342, DOI 10.1603/ME13115; Steinke JW, 2016, J ALLERGY CLIN IMMUN, V138, P1465, DOI 10.1016/j.jaci.2016.05.021; Stoltz LP, 2019, J ALLER CL IMM-PRACT, V7, P664, DOI 10.1016/j.jaip.2018.07.014; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P322, DOI 10.1016/j.jaip.2018.06.005; Stone CA, 2017, J ALLERGY CLIN IMMUN, V139, P1710, DOI 10.1016/j.jaci.2016.10.037; Sun JS, 2007, NAT MED, V13, P719, DOI 10.1038/nm1601; Swiontek K, 2019, J ALLER CL IMM-PRACT, V7, P1687, DOI 10.1016/j.jaip.2018.12.005; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; van Bueren JJL, 2011, NAT BIOTECHNOL, V29, P574, DOI 10.1038/nbt.1912; van Nunen S, 2007, INTERN MED J, V39, pA132; van Nunen SA, 2018, MED J AUSTRALIA, V208, P316, DOI 10.5694/mja17.00591; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Venturini M, 2018, J INVEST ALLERG CLIN, V28, P106, DOI 10.18176/jiaci.0218; Vidal C, 2016, J INVEST ALLERG CLIN, V26, P388, DOI 10.18176/jiaci.0105; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wilson JM, 2019, AGING-US, V11, P1900, DOI 10.18632/aging.101894; Wilson JM, 2019, J ALLER CL IMM-PRACT, V7, P2348, DOI 10.1016/j.jaip.2019.03.031; Wilson JM, 2018, ARTERIOSCL THROM VAS, V38, P1665, DOI 10.1161/ATVBAHA.118.311222; Wilson JM, 2018, MOL IMMUNOL, V100, P107, DOI 10.1016/j.molimm.2018.03.018; Wilson JM, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0672-7; Wilson JM, 2018, EMJ ALLERGY IMMUNOL, V3, P89; Wolbing F, 2013, ALLERGY, V68, P1085, DOI 10.1111/all.12193; Woodfolk JA, 2015, ALLERGOL INT, V64, P295, DOI 10.1016/j.alit.2015.06.001; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053	128	47	47	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1061	1071		10.1016/j.jaci.2020.01.047	http://dx.doi.org/10.1016/j.jaci.2020.01.047			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32057766	Green Accepted, Bronze			2022-12-18	WOS:000523633400003
J	Fitzpatrick, AM; Gillespie, SE; Mauger, DT; Phillips, BR; Bleecker, ER; Israel, E; Meyers, DA; Moore, WC; Sorkness, RL; Wenzel, SE; Bacharier, LB; Castro, M; Denlinger, LC; Erzurum, SC; Fahy, JV; Gaston, BM; Jarjour, NN; Larkin, A; Levy, BD; Ly, NP; Ortega, VE; Peters, SP; Phipatanakul, W; Ramratnam, S; Teague, WG				Fitzpatrick, Anne M.; Gillespie, Scott E.; Mauger, David T.; Phillips, Brenda R.; Bleecker, Eugene R.; Israel, Elliot; Meyers, Deborah A.; Moore, Wendy C.; Sorkness, Ronald L.; Wenzel, Sally E.; Bacharier, Leonard B.; Castro, Mario; Denlinger, Loren C.; Erzurum, Serpil C.; Fahy, John, V; Gaston, Benjamin M.; Jarjour, Nizar N.; Larkin, Allyson; Levy, Bruce D.; Ly, Ngoc P.; Ortega, Victor E.; Peters, Stephen P.; Phipatanakul, Wanda; Ramratnam, Sima; Teague, W. Gerald			Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; asthma exacerbation; racial disparities; health care use; propensity scoring; inverse probability of treatment weighting	EMERGENCY-DEPARTMENT USE; QUALITY-OF-LIFE; CHILDREN; OUTCOMES; AGE; RELIABILITY; VALIDATION; PREDICTORS; ADHERENCE; LITERACY	Background: Despite advances in asthma care, disparities persist. Black patients are disproportionally affected by asthma and also have poorer outcomes compared with white patients. Objective: We sought to determine associations between black and white patients and asthma-related health care use, accounting for complex relationships. Methods: This study was completed as part of the National Heart, Lung, and Blood Institute's Severe Asthma Research Program, a prospective observational cohort. Between November 2012 and February 2015, it enrolled 579 participants 6 years and older with 1 year of observation time and complete data. Inverse probability of treatment weighting was used to balance racial groups with respect to community and family socioeconomic variables and environmental exposure variables. The primary outcome was emergency department (ED) use for asthma. Secondary outcomes included inhaled corticosteroid use, outpatient physician's office visits for asthma, and asthma-related hospitalization. Results: Black patients had greater odds of ED use over 1 year (odds ratio, 2.19; 95% CI, 1.43-3.35) but also differed in the majority (>50%) of baseline variables measured. After statistical balancing of the racial groups, the difference between black andwhite patients with respect to ED use no longer reached the level of significance. Instead, in secondary analyses black patients were less likely to see an outpatient physician for asthma management (adjusted odds ratio, 0.57; 95% CI, 0.38-0.85). Conclusions: The disparity in ED use was eliminated after consideration of multiple variables. Social and environmental policies and interventions tailored to black populations with a high burden of asthma are critical to reduction (or elimination) of these disparities.	[Fitzpatrick, Anne M.; Gillespie, Scott E.] Emory Univ, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA; [Mauger, David T.; Phillips, Brenda R.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Bleecker, Eugene R.; Meyers, Deborah A.] Univ Arizona, Dept Med, Tucson, AZ USA; [Israel, Elliot; Levy, Bruce D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Moore, Wendy C.; Ortega, Victor E.; Peters, Stephen P.] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; [Sorkness, Ronald L.; Denlinger, Loren C.; Jarjour, Nizar N.; Ramratnam, Sima] Univ Wisconsin, Dept Med, Madison, WI USA; [Wenzel, Sally E.; Larkin, Allyson] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Bacharier, Leonard B.; Castro, Mario] Washington Univ, Dept Med, St Louis, MO USA; [Bacharier, Leonard B.; Castro, Mario] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Erzurum, Serpil C.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA; [Fahy, John, V; Ly, Ngoc P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Fahy, John, V; Ly, Ngoc P.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Gaston, Benjamin M.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Phipatanakul, Wanda] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Teague, W. Gerald] Univ Virginia, Dept Pediat, Charlottesville, VA USA	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Arizona; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Washington University (WUSTL); Cleveland Clinic Foundation; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Case Western Reserve University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Virginia	Fitzpatrick, AM (corresponding author), Emory Univ, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Bacharier, Leonard/0000-0003-0432-2704; Wenzel, Sally/0000-0002-4242-0164; Fitzpatrick, Anne/0000-0002-2933-5926	National Heart, Lung, and Blood Institute [U10 HL109086, U10 HL109146, U10 HL109152, U10 HL109164, U10 HL109168, U10 HL109172, U10 HL109250, U10 HL109257]; National Institutes of Health National Center for Advancing Translational Sciences [UL1 TR001420, UL1 TR000427, UL1 TR001102, UL1 TR002378]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002373, UL1TR002378, UL1TR000427, UL1TR001420, UL1TR001102] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109164, U10HL109146, U10HL109257, U10HL109168, U10HL109086, U10HL109250, U10HL109172] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grants to the Severe Asthma Research Program (SARP): U10 HL109086, U10 HL109146, U10 HL109152, U10 HL109164, U10 HL109168, U10 HL109172, U10 HL109250, and U10 HL109257. In addition, this program is supported through the following National Institutes of Health National Center for Advancing Translational Sciences awards: UL1 TR001420 (Wake Forest University), UL1 TR000427 (University of Wisconsin), UL1 TR001102 (Harvard University), and UL1 TR002378 (Emory University).	Abernathy K, 2016, J PRIM CARE COMMUNIT, V7, P226, DOI 10.1177/2150131916656155; Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; Akinbami Lara J, 2012, NCHS Data Brief, P1; Apter AJ, 2013, J ALLERGY CLIN IMMUN, V132, P321, DOI 10.1016/j.jaci.2013.02.014; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Bacon SL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-125; Baltrus P, 2017, J ASTHMA, V54, P53, DOI 10.1080/02770903.2016.1196367; Beck AF, 2016, JAMA PEDIATR, V170, P695, DOI 10.1001/jamapediatrics.2016.0269; Beck AF, 2014, PEDIATRICS, V133, P431, DOI 10.1542/peds.2013-2437; Beck AF, 2013, J PEDIATR-US, V163, P574, DOI 10.1016/j.jpeds.2013.01.064; Bryant-Stephens T, 2016, J ALLERGY CLIN IMMUN, V138, P1526, DOI 10.1016/j.jaci.2016.10.006; Centers for Disease Control and Prevention National Center for Health Statistics. National health interview survey, 2015, TABL 4 1 CURR ASTHM; Cunningham TJ, 2017, MMWR-MORBID MORTAL W, V66, P444, DOI 10.15585/mmwr.mm6617e1; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Eakin MN, 2012, J ALLERGY CLIN IMMUN, V129, P664, DOI 10.1016/j.jaci.2011.10.013; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; Garcia E, 2015, J ALLERGY CLIN IMMUN, V136, P610, DOI 10.1016/j.jaci.2015.01.030; George M, 2014, J ALLERGY CLIN IMMUN, V134, P1252, DOI 10.1016/j.jaci.2014.07.044; Juniper EF, 1997, EUR RESPIR J, V10, P2285, DOI 10.1183/09031936.97.10102285; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kit BK, 2012, PEDIATRICS, V129, P62, DOI 10.1542/peds.2011-1513; Lawson CC, 2014, ACAD EMERG MED, V21, P1, DOI 10.1111/acem.12285; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Lu DG, 2017, J ASTHMA, V54, P504, DOI 10.1080/02770903.2016.1238927; Malhotra K, 2014, J ASTHMA, V51, P913, DOI 10.3109/02770903.2014.930479; Mersha TB, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-014-0023-x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mitchell SJ, 2016, ACAD PEDIATR, V16, P64, DOI 10.1016/j.acap.2015.06.010; Morphew T, 2013, POPUL HEALTH MANAG, V16, P261, DOI 10.1089/pop.2012.0060; Mudd SS, 2016, ANN ALLERG ASTHMA IM, V117, P490, DOI 10.1016/j.anai.2016.08.031; O'Conor R, 2015, CHEST, V147, P1307, DOI 10.1378/chest.14-0914; Phipatanakul W, 2017, AM J RESP CRIT CARE, V195, P1439, DOI 10.1164/rccm.201607-1453OC; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Scott L, 2011, J ALLERGY CLIN IMMUN, V128, P56, DOI 10.1016/j.jaci.2011.03.020; Silber JH, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1221; Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032; United States Census Bureau, 2010 2014 AM COMM SU; Vinton DT, 2014, EMERG MED J, V31, P526, DOI 10.1136/emermed-2013-202407; Ward B. W., 2017, NCHS DATA BRIEF, V275, P1; Wells KE, 2016, J ALLERGY CLIN IMMUN, V137, P1364, DOI 10.1016/j.jaci.2015.12.1334; Wu CL, 2014, J PEDIATR-US, V164, P827, DOI 10.1016/j.jpeds.2013.11.029	46	47	47	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2052	2061		10.1016/j.jaci.2018.11.022	http://dx.doi.org/10.1016/j.jaci.2018.11.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30635198	Bronze, Green Accepted			2022-12-18	WOS:000470113200011
J	Wang, M; Tan, G; Eljaszewicz, A; Meng, YF; Wawrzyniak, P; Acharya, S; Altunbulakli, C; Westermann, P; Dreher, A; Yan, LY; Wang, CS; Akdis, M; Zhang, L; Nadeau, KC; Akdis, CA				Wang, Ming; Tan, Ge; Eljaszewicz, Andrzej; Meng, Yifan; Wawrzyniak, Paulina; Acharya, Swati; Altunbulakli, Can; Westermann, Patrick; Dreher, Anita; Yan, Liying; Wang, Chengshuo; Akdis, Mubeccel; Zhang, Luo; Nadeau, Kari C.; Akdis, Cezmi A.			Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Laundry detergent; rinse residue; barrier function; tight junction; bronchial epithelial cells; asthma; chronic obstructive pulmonary disease; transcriptome; epigenome	DNA METHYLATION; CLEANING SPRAYS; ASTHMA; EXPRESSION; INCREASE; ENVIRONMENT; CYTOKINES; ALLERGENS; PROTEINS; RHINITIS	Background: Defects in the epithelial barrier have recently been associated with asthma and other allergies. The influence of laundry detergents on human bronchial epithelial cells (HBECs) and their barrier function remain unknown. Objective: We investigated the effects of laundry detergents on cytotoxicity, barrier function, the transcriptome, and the epigenome in HBECs. Methods: Air-liquid interface cultures of primary HBECs from healthy control subjects, patients with asthma, and patients with chronic obstructive pulmonary disease were exposed to laundry detergents and detergent residue after rinsing. Cytotoxicity and epithelial barrier function were evaluated. RNA sequencing, Assay for Transposase Accessible Chromatin with high-throughput sequencing, and DNA methylation arrays were used for checking the transcriptome and epigenome. Results: Laundry detergents and rinse residue showed dosedependent toxic effects on HBECs, with irregular cell shape and leakage of lactate dehydrogenase after 24 hours of exposure. A disrupted epithelial barrier function was found with decreased transepithelial electrical resistance, increased paracellular flux, and stratified tight junction (TJ) immunostaining in HBECs exposed to laundry detergent at 1:25,000 dilutions or rinse residue at further 1:10 dilutions. RNA sequencing analysis showed that lipid metabolism, apoptosis progress, and epithelially derived alarmin-related gene expression were upregulated, whereas cell adhesionrelated gene expression was downregulated by laundry detergent at 1:50,000 dilutions after 24 hours of exposure without substantially affecting chromatin accessibility and DNA methylation. Conclusion: Our data demonstrate that laundry detergents, even at a very high dilution, and rinse residue show significant cell-toxic and directly disruptive effects on the TJ barrier integrity of HBECs without affecting the epigenome and TJ gene expression.	[Wang, Ming; Tan, Ge; Eljaszewicz, Andrzej; Meng, Yifan; Wawrzyniak, Paulina; Altunbulakli, Can; Westermann, Patrick; Dreher, Anita; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Zurich, Switzerland; [Wang, Ming; Tan, Ge; Eljaszewicz, Andrzej; Meng, Yifan; Wawrzyniak, Paulina; Altunbulakli, Can; Westermann, Patrick; Dreher, Anita; Akdis, Mubeccel; Akdis, Cezmi A.] CK CARE, Davos, Switzerland; [Wang, Ming; Meng, Yifan; Wang, Chengshuo; Zhang, Luo] Capital Med Univ, Dept Otolaryngol Head & Neck Surg, Beijing TongRen Hosp, Beijing, Peoples R China; [Wang, Ming; Meng, Yifan; Wang, Chengshuo; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Acharya, Swati; Nadeau, Kari C.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, Dept Med, Sch Med, Stanford, CA 94305 USA; [Tan, Ge] Univ Zurich, ETH Zurich, Funct Genom Ctr Zurich, Zurich, Switzerland; [Yan, Liying] EpigenDx, Hopkinton, MA USA; [Eljaszewicz, Andrzej] Med Univ Bialystok, Dept Regenerat Med & Immune Regulat, Bialystok, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Capital Medical University; Stanford University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Medical University of Bialystok	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Wawrzyniak, Paulina/AAG-3548-2019; Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/AAD-7265-2020; Wawrzyniak, Paulina/HCG-8924-2022	Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Paulina/0000-0001-9641-2103; Tan, Ge/0000-0003-0026-8739; Altunbulakli, Can/0000-0003-2264-7377; Zhang, Luo/0000-0002-0910-9884; Eljaszewicz, Andrzej/0000-0002-8980-1474				Adisesh A, 2011, OCCUP MED-OXFORD, V61, P364, DOI 10.1093/occmed/kqr107; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; Bowatte G, 2018, ALLERGY, V73, P1915, DOI 10.1111/all.13492; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Buenrostro JD, 2015, CURR PROTOC MOL BIOL, V109; Claeson AS, 2016, INT J ENVIRON HEAL R, V26, P448, DOI 10.1080/09603123.2015.1135314; Clifford RL, 2017, J ALLERGY CLIN IMMUN, V139, P112, DOI 10.1016/j.jaci.2016.03.046; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Davis MG, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-4529; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Folletti I, 2017, CURR OPIN ALLERGY CL, V17, P90, DOI 10.1097/ACI.0000000000000349; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Guo SH, 2013, AM J PATHOL, V182, P375, DOI 10.1016/j.ajpath.2012.10.014; Herceg Z, 2016, ADV EXP MED BIOL, V903, P3, DOI 10.1007/978-1-4899-7678-9_1; Islam MS, 2014, BRIT J PHARMACOL, V171, P375, DOI 10.1111/bph.12452; Jenerowicz D, 2012, ANN AGR ENV MED, V19, P475; Kabesch M, 2012, BIOCHIMIE, V94, P2231, DOI 10.1016/j.biochi.2012.07.017; Laborde-Casterot H, 2012, AM J IND MED, V55, P677, DOI 10.1002/ajim.22036; Labrecque M, 2012, CURR OPIN ALLERGY CL, V12, P140, DOI 10.1097/ACI.0b013e32835143b8; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Laumbach RJ, 2012, J ALLERGY CLIN IMMUN, V129, P3, DOI 10.1016/j.jaci.2011.11.021; Le Moual Nicole, 2013, Presse Med, V42, pe317, DOI 10.1016/j.lpm.2013.06.010; Le Moual N, 2012, EUR RESPIR J, V40, P1381, DOI 10.1183/09031936.00197611; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Linneberg A, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2011.02619.x; Loxham M, 2017, J ALLERGY CLIN IMMUN, V139, P1736, DOI 10.1016/j.jaci.2017.04.005; Maksimovic Jovana, 2016, F1000Res, V5, P1281, DOI 10.12688/f1000research.8839.3; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Mitchell PD, 2017, CHEST, V151, P1338, DOI 10.1016/j.chest.2016.10.042; Nedorost S, 2007, DERMATITIS, V18, P212, DOI 10.2310/6620.2007.06052; PEPYS J, 1992, AM J IND MED, V21, P587, DOI 10.1002/ajim.4700210414; Quirce S, 2010, J INVEST ALLERG CLIN, V20, P542; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Seddon AM, 2004, BBA-BIOMEMBRANES, V1666, P105, DOI 10.1016/j.bbamem.2004.04.011; Settimi L, 2018, INJURY PREV, V24, P5, DOI 10.1136/injuryprev-2016-042263; Singh H, 2015, MOL HUM REPROD, V21, P81, DOI 10.1093/molehr/gau087; Stadhouders R, 2018, J ALLERGY CLIN IMMUN, V142, P1793, DOI 10.1016/j.jaci.2017.12.1006; Stelzer Y, 2015, CELL, V163, P218, DOI 10.1016/j.cell.2015.08.046; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; van Rooy FGBGJ, 2009, OCCUP ENVIRON MED, V66, P759, DOI 10.1136/oem.2008.045245; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Xian M, 2016, J ALLERGY CLIN IMMUN, V138, P890, DOI 10.1016/j.jaci.2016.07.003; Yang IV, 2017, J ALLERGY CLIN IMMUN, V140, P14, DOI 10.1016/j.jaci.2017.05.011; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zock JP, 2007, AM J RESP CRIT CARE, V176, P735, DOI 10.1164/rccm.200612-1793OC; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76, DOI 10.5271/sjweh.590	49	47	49	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1892	1903		10.1016/j.jaci.2018.11.016	http://dx.doi.org/10.1016/j.jaci.2018.11.016			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30500342	Bronze			2022-12-18	WOS:000466784600024
J	Bouis, D; Kirstetter, P; Arbogast, F; Lamon, D; Delgado, V; Jung, S; Ebel, C; Jacobs, H; Knapp, AM; Jeremiah, N; Belot, A; Martin, T; Crow, YJ; Andre-Schmutz, I; Korganow, AS; Rieux-Laucat, F; Soulas-Sprauel, P				Bouis, Delphine; Kirstetter, Peggy; Arbogast, Florent; Lamon, Delphine; Delgado, Virginia; Jung, Sophie; Ebel, Claudine; Jacobs, Hugues; Knapp, Anne-Marie; Jeremiah, Nadia; Belot, Alexandre; Martin, Thierry; Crow, Yanick J.; Andre-Schmutz, Isabelle; Korganow, Anne-Sophie; Rieux-Laucat, Frederic; Soulas-Sprauel, Pauline			Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; stimulator of interferon genes; V154M; type I interferon	CGAS/STING-DEPENDENT INNATE; I INTERFERONOPATHIES; IMMUNE-RESPONSES; NUCLEIC-ACIDS; CELLS; VASCULOPATHY; MUTATIONS; PROLIFERATION; ACTIVATION; INFECTION	Background: Autosomal dominant gain-of-function mutations in human stimulator of interferon genes (STING) lead to a severe autoinflammatory disease called STING-associated vasculopathy with onset in infancy that is associated with enhanced expression of interferon-stimulated gene transcripts. Objective: The goal of this study was to analyze the phenotype of a new mouse model of STING hyperactivation and the role of type I interferons in this system. Methods: We generated a knock-in model carrying an amino acid substitution (V154M) in mouse STING, corresponding to a recurrent mutation seen in human patients with STING-associated vasculopathy with onset in infancy. Hematopoietic development and tissue histology were analyzed. Lymphocyte activation and proliferation were assessed in vitro. STING V154M/wild-type (WT) mice were crossed to IFN-alpha/beta receptor (IFNAR) knockout mice to evaluate the type I interferon dependence of the mutant Sting phenotype recorded. Results: In STING V154M/WT mice we detected variable expression of inflammatory infiltrates in the lungs and kidneys. These mice showed a marked decrease in survival and developed a severe combined immunodeficiency disease (SCID) affecting B, T, and natural killer cells, with an almost complete lack of antibodies and a significant expansion of monocytes and granulocytes. The blockade in B-and T-cell development was present from early immature stages in bone marrow and thymus. In addition, in vitro experiments revealed an intrinsic proliferative defect of mature T cells. Although the V154M/WT mutant demonstrated increased expression of interferon-stimulated genes, the SCID phenotype was not reversed in STING V154M/WT IFNAR knockout mice. However, the antiproliferative defect in T cells was rescued partially by IFNAR deficiency. Conclusions: STING gain-of-function mice developed an interferon-independent SCID phenotype with a T-cell, B-cell, and natural killer cell developmental defect and hypogammaglobulinemia that is associated with signs of inflammation in lungs and kidneys. Only the intrinsic proliferative defect of T cells was partially interferon dependent.	[Bouis, Delphine; Arbogast, Florent; Lamon, Delphine; Delgado, Virginia; Jung, Sophie; Knapp, Anne-Marie; Martin, Thierry; Korganow, Anne-Sophie; Soulas-Sprauel, Pauline] Inst Mol & Cellular Biol IBMC, CNRS, Lab Excellence Medalis, UPR Immunopathol & Therapeut Chem 3572, Strasbourg, France; [Kirstetter, Peggy; Ebel, Claudine; Jacobs, Hugues] IGBMC, Illkirch Graffenstaden, France; [Kirstetter, Peggy; Ebel, Claudine; Jacobs, Hugues] INSERM, U964, Illkirch Graffenstaden, France; [Kirstetter, Peggy; Ebel, Claudine; Jacobs, Hugues] Univ Strasbourg, Illkirch Graffenstaden, France; [Arbogast, Florent] Univ Strasbourg, UFR Sci Vie, Strasbourg, France; [Jung, Sophie] Hop Univ Strasbourg, Pole Med & Chirurg Buccodent, Ctr Reference Malad Rares Orales & Dent ORares, Strasbourg, France; [Jung, Sophie] Univ Strasbourg, Fac Chirurg Dent, Strasbourg, France; [Jacobs, Hugues] CNRS, UMR7104, Illkirch Graffenstaden, France; [Jacobs, Hugues] PHENOMIN, CELPHEDIA, ICS, Illkirch Graffenstaden, France; [Knapp, Anne-Marie; Martin, Thierry; Korganow, Anne-Sophie] Univ Strasbourg, UFR Med, Strasbourg, France; [Jeremiah, Nadia] PSL Res Univ, INSERM, U932, Immun & Canc Dept,Inst Curie, Paris, France; [Belot, Alexandre] Hosp Civils Lyon, HFME, Ctr Reference RAISE, Serv Nephrol,Rhumatol,Dermatol,Pediat, Lyon, France; [Belot, Alexandre] Univ Lyon, INSERM, UMR 1111, Lyon, France; [Martin, Thierry; Korganow, Anne-Sophie; Soulas-Sprauel, Pauline] Hop Univ Strasbourg, Natl Reference Ctr Autoimmune Dis, Dept Clin Immunol & Internal Med, Strasbourg, France; [Crow, Yanick J.] INSERM, UMR 1163, Lab Neurogenet & Neuroinflammat, Paris, France; [Crow, Yanick J.; Andre-Schmutz, Isabelle; Rieux-Laucat, Frederic] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Crow, Yanick J.] Univ Edinburgh, Ctr Genom & Expt Med, MRC Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Andre-Schmutz, Isabelle] INSERM, UMR 1163, Lab Human Lymphohematopoiesis, Paris, France; [Rieux-Laucat, Frederic] INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmune Dis, Paris, France; [Soulas-Sprauel, Pauline] Univ Strasbourg, UFR Sci Pharmaceut, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Edinburgh; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Soulas-Sprauel, P (corresponding author), Inst Mol & Cellular Biol IBMC, CNRS, UPR 3572 Immunopathol & Therapeut Chem, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	pauline.soulas@ibmc-cnrs.unistra.fr	Jung, Sophie/AAA-5556-2021; Belot, Alexandre/C-7378-2013; Rieux-Laucat, Frédéric/A-7916-2017; Andre-Schmutz, Isabelle/M-1279-2016; Kirstetter, Peggy/I-9582-2016; Andre, Isabelle/F-6263-2013	Jung, Sophie/0000-0002-7925-1077; Belot, Alexandre/0000-0003-4902-5332; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Kirstetter, Peggy/0000-0001-7592-8004; Andre, Isabelle/0000-0002-3905-9910; Soulas-Sprauel, Pauline/0000-0002-2058-4811; Korganow, Anne-Sophie/0000-0002-1664-6311; Jeremiah, Nadia/0000-0002-7805-6341; Martin, Thierry/0000-0002-2776-2641	Strasbourg University (UdS), Centre National de la Recherche Scientifique (CNRS); Agence Nationale de la Recherche (Lumugene) [ANR-14-CE14-0026-04]; Agence Nationale de la Recherche [ANR-11-EQPX-022]; European Union; Ministere de la Recherche et de la Technologie; Initiative of Excellence (IdEx), Strasbourg University, France; European Research Council [GA 309449]	Strasbourg University (UdS), Centre National de la Recherche Scientifique (CNRS); Agence Nationale de la Recherche (Lumugene)(French National Research Agency (ANR)); Agence Nationale de la Recherche(French National Research Agency (ANR)); European Union(European Commission); Ministere de la Recherche et de la Technologie; Initiative of Excellence (IdEx), Strasbourg University, France; European Research Council(European Research Council (ERC)European Commission)	Supported by grants from Strasbourg University (UdS), Centre National de la Recherche Scientifique (CNRS); Agence Nationale de la Recherche (ANR-14-CE14-0026-04, Lumugene; and ANR-11-EQPX-022); and the European Union-funded (ERDF) project INTERREG V "RARENET." D.B. and F.A. were supported by Ministere de la Recherche et de la Technologie. V.D. was supported by Initiative of Excellence (IdEx), Strasbourg University, France. Y.J.C. acknowledges fellowship support from the European Research Council (GA 309449).	Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010; Burdette DL, 2013, NAT IMMUNOL, V14, P19, DOI 10.1038/ni.2491; Cabatingan MS, 2002, J IMMUNOL, V169, P6795, DOI 10.4049/jimmunol.169.12.6795; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Canesso MCC, 2017, MUCOSAL IMMUNOL, V20, P1; Cerboni S, 2017, J EXP MED, V214, P1769, DOI 10.1084/jem.20161674; Chen HH, 2011, CELL, V147, P436, DOI 10.1016/j.cell.2011.09.022; Clarke SLN, 2016, AM J RESP CRIT CARE, V194, P639, DOI 10.1164/rccm.201510-2102LE; Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x; Dobbs N, 2015, CELL HOST MICROBE, V18, P157, DOI 10.1016/j.chom.2015.07.001; Fan Y, 2008, TRENDS CELL BIOL, V18, P467, DOI 10.1016/j.tcb.2008.08.001; Fan Y, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004131; Fogarty CE, 2017, CELL DEATH DIFFER, V24, P1390, DOI 10.1038/cdd.2017.47; Fremond ML, 2016, J ALLERGY CLIN IMMUN, V138, P1752, DOI 10.1016/j.jaci.2016.07.015; Harrell MI, 2008, J IMMUNOL METHODS, V332, P170, DOI 10.1016/j.jim.2007.11.012; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Jin L, 2008, MOL CELL BIOL, V28, P5014, DOI 10.1128/MCB.00640-08; Kim MY, 2009, CLIN EXP IMMUNOL, V157, P20, DOI 10.1111/j.1365-2249.2009.03932.x; Konig N, 2017, ANN RHEUM DIS, V76, P468, DOI 10.1136/annrheumdis-2016-209841; Kruglov AA, 2013, SCIENCE, V342, P1243, DOI 10.1126/science.1243364; Lane PJL, 2012, ANN NY ACAD SCI, V1247, P1, DOI 10.1111/j.1749-6632.2011.06284.x; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Mackenzie KJ, 2016, EMBO J, V35, P831, DOI 10.15252/embj.201593339; Maelfait J, 2016, CELL REP, V16, P1492, DOI 10.1016/j.celrep.2016.07.002; Marinho FV, 2017, TRENDS MICROBIOL, V25, P906, DOI 10.1016/j.tim.2017.05.008; Melki I, 2017, J ALLERGY CLIN IMMUN, V140, P543, DOI 10.1016/j.jaci.2016.10.031; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Munoz J, 2015, JAMA DERMATOL, V151, P872, DOI 10.1001/jamadermatol.2015.0251; Omoyinmi E, 2015, ARTHRITIS RHEUMATOL, V67, P808, DOI 10.1002/art.38998; Panday A, 2016, ARCH IMMUNOL THER EX, V64, P463, DOI 10.1007/s00005-016-0405-y; Picard C, 2016, CHEST, V150, pE65, DOI 10.1016/j.chest.2016.02.682; Pokatayev V, 2016, J EXP MED, V213, P329, DOI 10.1084/jem.20151464; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Roers A, 2016, IMMUNITY, V44, P739, DOI 10.1016/j.immuni.2016.04.002; Ryoo HD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008797; Schickel JN, 2012, EMBO MOL MED, V4, P1261, DOI 10.1002/emmm.201201595; Sun WX, 2009, P NATL ACAD SCI USA, V106, P8653, DOI 10.1073/pnas.0900850106; Warner JD, 2017, J EXP MED, V214, P3279, DOI 10.1084/jem.20171351; Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003; Zook EC, 2016, NAT IMMUNOL, V17, P775, DOI 10.1038/ni.3481	43	47	47	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					712	+		10.1016/j.jaci.2018.04.034	http://dx.doi.org/10.1016/j.jaci.2018.04.034			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29800647	Green Submitted, Green Published, Bronze			2022-12-18	WOS:000457718700030
J	Haeberle, S; Wei, XY; Bieber, K; Goletz, S; Ludwig, RJ; Schmidt, E; Enk, AH; Hadaschik, EN				Haeberle, Stefanie; Wei, Xiaoying; Bieber, Katja; Goletz, Stephanie; Ludwig, Ralf J.; Schmidt, Enno; Enk, Alexander H.; Hadaschik, Eva N.			Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune bullous disease; bullous pemphigoid; bullous pemphigoid antigen 230; dystonin; regulatory T cells	LINKED SYNDROME IPEX; IMMUNE DYSREGULATION; IGG AUTOANTIBODIES; XVII COLLAGEN; BLISTER FORMATION; VULGARIS ANTIGEN; PASSIVE TRANSFER; ACTIVE DISEASE; DESMOGLEIN 3; SCURFY MICE	Background: Autoimmune bullous diseases/dermatoses (AIBDs) are severe autoantibody-mediated skin diseases. The pathogenic relevance of autoreactive CD4(+) T cells for the induction of autoantibody production remains to be fully evaluated. Scurfy mice lack functional regulatory T (Treg) cells, experience spontaneous activation of autoreactive CD4(+) T cells, and display severe erosive skin lesions suggestive of AIBDs. Objective: We sought to determine whether AIBDs develop in Treg cell-deficient scurfy mice. Methods: Histology, indirect immunofluorescence (IF) microscopy, direct IF, and ELISA were used to prove the presence of AIBDs in scurfy mice. Monoclonal autoantibodies from sera of scurfy mice were screened by using indirect IF on murine skin, and immunoprecipitation and mass spectrometry were used for target antigen identification, followed by confirmation in modified human embryonic kidney cells and murine keratinocytes. Pathogenicity was determined by injecting the autoantibody into neonatal mice and transferring scurfy CD4(+) T cells into nu/nu mice. Results: Autoantibodies against different known autoantigens of AIBDs spontaneously develop in scurfy mice. Histology reveals subepidermal blisters, and direct IF of skin of scurfy mice shows a predominant linear staining pattern. The mAb 20B12 shows a linear staining pattern in indirect IF, recognizes the murine hemidesmosomal protein bullous pemphigoid antigen 230 (BP230) as the target antigen, and cross-reacts with human BP230. Purified mAb 20B12 induces subepidermal blisters in neonatal mice. Transfer of scurfy CD4(+) T cells is sufficient to induce antibodies with reactivity to AIBD autoantigens and subepidermal blisters in the skin of recipient T cell-deficient nu/nu mice. Conclusion: We show that the absence of Treg cells leads to AIBDs by pathogenic autoantibodies targeting BP230.	[Haeberle, Stefanie; Wei, Xiaoying; Enk, Alexander H.; Hadaschik, Eva N.] Heidelberg Univ, Dept Dermatol, Neuenheimer Feld 440, D-69120 Heidelberg, Germany; [Bieber, Katja; Goletz, Stephanie; Schmidt, Enno] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Ludwig, Ralf J.; Schmidt, Enno] Univ Lubeck, LIED, Lubeck, Germany; [Wei, Xiaoying] Southeast Univ, Zhong Da Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China	Ruprecht Karls University Heidelberg; University of Lubeck; University of Lubeck; Southeast University - China	Hadaschik, EN (corresponding author), Heidelberg Univ, Dept Dermatol, Neuenheimer Feld 440, D-69120 Heidelberg, Germany.	Eva.Hadaschik@med.uni-heidelberg.de	Bieber, Katja/K-8826-2014; Ludwig, Ralf/F-3996-2018	Ludwig, Ralf/0000-0002-1394-1737	Deutsche Forschungsgemeinschaft (DFG) [HA-7162/3-1]; DFG-Transregio grant [TRR-156/C04]; CRU 303 Pemphigoid Diseases [SCHM 1686/7-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG-Transregio grant; CRU 303 Pemphigoid Diseases	Supported by a grant from the Deutsche Forschungsgemeinschaft (DFG; HA-7162/3-1; to E.N.H. and A.H.E.), a DFG-Transregio grant (TRR-156/C04; to E.N.H. and A.H.E.), and the CRU 303 Pemphigoid Diseases (SCHM 1686/7-1; to E.S.).	Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Amagai Masayuki, 2008, V10, P167, DOI 10.1159/000131453; Aschermann S, 2013, P NATL ACAD SCI USA, V110, P19042, DOI 10.1073/pnas.1313547110; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bieber K, 2010, EXP DERMATOL, V19, P2, DOI 10.1111/j.1600-0625.2009.00948.x; BLAIR PJ, 1994, J IMMUNOL, V153, P3764; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Dainichi T, 2009, P NATL ACAD SCI USA, V106, P2800, DOI 10.1073/pnas.0809230106; Di Zenzo G, 2008, CLIN IMMUNOL, V128, P415, DOI 10.1016/j.clim.2008.04.012; Di Zenzo G, 2011, J INVEST DERMATOL, V131, P2271, DOI 10.1038/jid.2011.180; Feldrihan V, 2014, HUM IMMUNOL, V75, P354, DOI 10.1016/j.humimm.2014.01.005; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Goletz S, 2014, J AM ACAD DERMATOL, V71, P185, DOI 10.1016/j.jaad.2014.02.036; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Haase C, 1998, J INVEST DERMATOL, V110, P282, DOI 10.1046/j.1523-1747.1998.00126.x; Hadaschik EN, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0538-0; HALL RP, 1993, J INVEST DERMATOL, V101, P9, DOI 10.1111/1523-1747.ep12358276; Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313; Hara H, 2014, EUR J DERMATOL, V24, P488, DOI 10.1684/ejd.2014.2369; Hayakawa T, 2016, EUR J DERMATOL, V26, P155, DOI 10.1684/ejd.2015.2719; Heppe EN, 2017, J INVEST DERMATOL, V137, P1709, DOI 10.1016/j.jid.2017.03.037; Hirose M, 2011, J IMMUNOL, V187, P1176, DOI 10.4049/jimmunol.1100596; Huter EN, 2008, EUR J IMMUNOL, V38, P1814, DOI 10.1002/eji.200838346; Huter EN, 2010, J INVEST DERMATOL, V130, P1391, DOI 10.1038/jid.2010.16; Iwata H, 2016, LAB INVEST, V96, P1301, DOI 10.1038/labinvest.2016.108; Iwata H, 2013, J IMMUNOL, V191, P2978, DOI 10.4049/jimmunol.1300310; Jang JY, 2009, CELL MOL LIFE SCI, V66, P1985, DOI 10.1007/s00018-009-9179-2; Kasperkiewicz M, 2016, J INVEST DERMATOL, V136, P24, DOI 10.1038/JID.2015.356; Kiss M, 2005, J AUTOIMMUN, V24, P1, DOI 10.1016/j.jaut.2004.09.007; Kromminga A, 2004, CLIN IMMUNOL, V111, P146, DOI 10.1016/j.clim.2003.12.007; LABIB RS, 1986, J IMMUNOL, V136, P1231; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lahl K, 2009, J IMMUNOL, V183, P5662, DOI 10.4049/jimmunol.0803762; Leineweber S, 2011, FEBS LETT, V585, P1748, DOI 10.1016/j.febslet.2011.04.071; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Madaio MP, 1998, J AUTOIMMUN, V11, P535, DOI 10.1006/jaut.1998.0217; McGinness JL, 2006, J AM ACAD DERMATOL, V55, P143, DOI 10.1016/j.jaad.2005.08.047; Perriard J, 1999, J INVEST DERMATOL, V112, P141, DOI 10.1046/j.1523-1747.1999.00497.x; Ruiz-Arguelles A, 2003, CURR PHARM DESIGN, V9, P1881, DOI 10.2174/1381612033454379; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Sitaru C, 2005, J CLIN INVEST, V115, P870, DOI 10.1172/JCI200521386; Skaria M, 2000, J INVEST DERMATOL, V114, P998, DOI 10.1046/j.1523-1747.2000.00893.x; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; Thoma-Uszynski S, 2006, J IMMUNOL, V176, P2015, DOI 10.4049/jimmunol.176.3.2015; Thoma-Uszynski S, 2004, J INVEST DERMATOL, V122, P1413, DOI 10.1111/j.0022-202X.2004.22603.x; Ujiie H, 2014, J IMMUNOL, V193, P4415, DOI 10.4049/jimmunol.1400095; Ujiie H, 2012, EXP DERMATOL, V21, P901, DOI 10.1111/exd.12011; Ujiie H, 2012, CLIN IMMUNOL, V142, P167, DOI 10.1016/j.clim.2011.10.002; Ujiie H, 2010, J IMMUNOL, V184, P2166, DOI 10.4049/jimmunol.0903101; Veldman C, 2004, J IMMUNOL, V172, P6468, DOI 10.4049/jimmunol.172.10.6468; Veldman C, 2009, IMMUNOLOGY, V127, P40, DOI 10.1111/j.1365-2567.2008.02932.x; Wada M, 2016, J INVEST DERMATOL, V136, P938, DOI 10.1016/j.jid.2015.11.030; Wollenberg I, 2011, J IMMUNOL, V187, P4553, DOI 10.4049/jimmunol.1101328; Woodley DT, 2005, J INVEST DERMATOL, V124, P958, DOI 10.1111/j.0022-202X.2005.23702.x; WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602; Yokoyama T, 2010, J DERMATOL, V37, P205, DOI 10.1111/j.1346-8138.2009.00797.x; Yokoyama Wayne M, 2006, Curr Protoc Immunol, VChapter 2, DOI 10.1002/0471142735.im0205s74; Yoshida M, 2006, J DERMATOL SCI, V41, P21, DOI 10.1016/j.jdermsci.2005.11.002	62	47	47	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1831	+		10.1016/j.jaci.2018.04.006	http://dx.doi.org/10.1016/j.jaci.2018.04.006			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29704595				2022-12-18	WOS:000452315800018
J	Rosas-Salazar, C; Shilts, MH; Tovchigrechko, A; Schobel, S; Chappell, JD; Larkin, EK; Gebretsadik, T; Halpin, RA; Nelson, KE; Moore, ML; Anderson, LJ; Peebles, RS; Das, SR; Hartert, TV				Rosas-Salazar, Christian; Shilts, Meghan H.; Tovchigrechko, Andrey; Schobel, Seth; Chappell, James D.; Larkin, Emma K.; Gebretsadik, Tebeb; Halpin, Rebecca A.; Nelson, Karen E.; Moore, Martin L.; Anderson, Larry J.; Peebles, R. Stokes, Jr.; Das, Suman R.; Hartert, Tina, V			Nasopharyngeal Lactobacillus is associated with a reduced risk of childhood wheezing illnesses following acute respiratory syncytial virus infection in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; Lactobacillus; Staphylococcus; nasopharynx; respiratory syncytial virus; asthma; wheezing; 16S ribosomal RNA sequencing; infants	EARLY-LIFE; CHILDREN; ASTHMA; MICROBIOME; HOSPITALIZATIONS; STABILITY; SEVERITY; HEALTH; METAANALYSIS; ATOPY	Background: Early life acute respiratory infection (ARI) with respiratory syncytial virus (RSV) has been strongly associated with the development of childhood wheezing illnesses, but the pathways underlying this association are poorly understood. Objective: To examine the role of the nasopharyngeal microbiome in the development of childhood wheezing illnesses following RSV ARI in infancy. Methods: We conducted a nested cohort study of 118 previously healthy, term infants with confirmed RSV ARI by RT-PCR. We used next-generation sequencing of the V4 region of the 16S ribosomal RNA gene to characterize the nasopharyngeal microbiome during RSVARI. Our main outcome of interest was 2-year subsequent wheeze. Results: Of the 118 infants, 113 (95.8%) had 2-year outcome data. Of these, 46 (40.7%) had parental report of subsequent wheeze. There was no association between the overall taxonomic composition, diversity, and richness of the nasopharyngeal microbiome during RSV ARI with the development of subsequent wheeze. However, the nasopharyngeal detection and abundance of Lactobacillus was consistently higher in infants who did not develop this outcome. Lactobacillus also ranked first among the different genera in a model distinguishing infants with and without subsequent wheeze. Conclusions: The nasopharyngeal detection and increased abundance of Lactobacillus during RSV ARI in infancy are associated with a reduced risk of childhood wheezing illnesses at age 2 years.	[Rosas-Salazar, Christian; Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Rosas-Salazar, Christian; Larkin, Emma K.; Gebretsadik, Tebeb; Moore, Martin L.; Anderson, Larry J.; Peebles, R. Stokes, Jr.; Hartert, Tina, V] Vanderbilt Univ, Sch Med, Ctr Asthma Res, Nashville, TN 37232 USA; [Shilts, Meghan H.; Larkin, Emma K.; Peebles, R. Stokes, Jr.; Das, Suman R.; Hartert, Tina, V] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; [Gebretsadik, Tebeb] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Shilts, Meghan H.; Halpin, Rebecca A.; Das, Suman R.] J Craig Venter Inst, Infect Dis Grp, Rockville, MD USA; [Tovchigrechko, Andrey; Schobel, Seth] J Craig Venter Inst, Bioinformat Grp, Rockville, MD USA; [Shilts, Meghan H.; Das, Suman R.] J Craig Venter Inst, Infect Dis Grp, La Jolla, CA USA; [Nelson, Karen E.] J Craig Venter Inst, Genom Med Grp, La Jolla, CA USA; [Moore, Martin L.; Anderson, Larry J.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; J. Craig Venter Institute; Emory University	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Div Allergy Pulm &Critical Care Med, Dept Med, 6107 Med Ctr East, Nashville, TN 37232 USA.; Das, SR (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, 1211 21st Ave South, Nashville, TN 37232 USA.	summan.r.das@vanderbilt.edu; tina.hartert@vanderbilt.edu	Rosas-Salazar, Christian/AAC-8571-2021; Das, Suman/ABB-7273-2020	Rosas-Salazar, Christian/0000-0001-6644-5780; Das, Suman/0000-0003-2496-9724; Schobel, Seth/0000-0002-8967-257X	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [U19AI095227, K24AI77930, HHSN272200900007 C, U19AI110819]; Vanderbilt Institute for Clinical and Translational Research grant support (National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services) [UL1 TR000445, U54RR24975]; Vanderbilt Faculty Research Scholars Program; Parker B. Francis Fellowship Program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445, UL1TR002243] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI077930, U19AI110819, U19AI095227] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Vanderbilt Institute for Clinical and Translational Research grant support (National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services); Vanderbilt Faculty Research Scholars Program; Parker B. Francis Fellowship Program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under award numbers U19AI095227, K24AI77930, HHSN272200900007 C, and U19AI110819; the Vanderbilt Institute for Clinical and Translational Research grant support (National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services, under award numbers UL1 TR000445 and U54RR24975); the Vanderbilt Faculty Research Scholars Program; and the Parker B. Francis Fellowship Program.	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Aitchison J., 1986, MONOGRAPHS STAT APPL; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Baker R, 2008, ANTIVIR RES, V80, P102, DOI 10.1016/j.antiviral.2008.07.003; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P298, DOI 10.1164/rccm.201401-0073OC; Boulesteix AL, 2009, BRIEF BIOINFORM, V10, P556, DOI 10.1093/bib/bbp034; BRAY JR, 1957, ECOL MONOGR, V27, P326, DOI 10.2307/1942268; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Chonmaitree T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180630; Elazab N, 2013, PEDIATRICS, V132, pE666, DOI 10.1542/peds.2013-0246; Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759; Feldman AS, 2015, AM J RESP CRIT CARE, V191, P34, DOI 10.1164/rccm.201405-0901PP; Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Grissom R.J., 2012, EFFECT SIZES RES UNI, V2nd; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hofner B, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0575-3; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Hyde ER, 2014, J ALLERGY CLIN IMMUN, V133, P1220, DOI 10.1016/j.jaci.2013.10.049; Kitazawa H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00201; Kodani M, 2011, J CLIN MICROBIOL, V49, P2175, DOI 10.1128/JCM.02270-10; Lal CV, 2016, SCI REP-UK, V6, DOI 10.1038/srep31023; Larkin EK, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0040-0; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Malveaux FJ, 2009, PEDIATRICS, V123, pS129, DOI 10.1542/peds.2008-2233B; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; McCallum GB, 2013, PEDIATR PULM, V48, P797, DOI 10.1002/ppul.22627; McMurdie PJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003531; Meinshausen N, 2010, J R STAT SOC B, V72, P417, DOI 10.1111/j.1467-9868.2010.00740.x; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; R Development Core Team, 2006, R LANG ENV STAT COMP; Reddy MB, 2016, CURR OPIN ALLERGY CL, V16, P127, DOI 10.1097/ACI.0000000000000252; Regnier SA, 2013, PEDIATR INFECT DIS J, V32, P820, DOI 10.1097/INF.0b013e31829061e8; Rodriguez Hector, 2016, BMC Res Notes, V9, P85, DOI 10.1186/s13104-016-1899-4; Rosas-Salazar C, 2016, J INFECT DIS, V214, P1924, DOI 10.1093/infdis/jiw456; Rosas-Salazar C, 2016, AM J RESP CRIT CARE, V193, P1180, DOI 10.1164/rccm.201512-2350LE; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Scott Karen P, 2015, Microb Ecol Health Dis, V26, P25877, DOI 10.3402/mehd.v26.25877; Shah RD, 2013, J R STAT SOC B, V75, P55, DOI 10.1111/j.1467-9868.2011.01034.x; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Shilts MH, 2016, MICROB ECOL, V71, P233, DOI 10.1007/s00248-015-0663-y; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Tovchigrechko A, 2015, MGSAT STAT ANAL MICR; Tovchigrechko A., 2015, YET ANOTHER PIPELINE; Tsai MH, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2016.10.020; Wu PS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151705; Young VB, 2016, CLIN MICROBIOL INFEC, V22, P905, DOI 10.1016/j.cmi.2016.09.001	57	47	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1447	+		10.1016/j.jaci.2017.10.049	http://dx.doi.org/10.1016/j.jaci.2017.10.049			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29330010	Green Accepted, Bronze			2022-12-18	WOS:000449429800008
J	Maurer, M; Schutz, A; Weller, K; Schoepke, N; Peveling-Oberhag, A; Staubach, P; Muller, S; Jakob, T; Metz, M				Maurer, Marcus; Schuetz, Andrea; Weller, Karsten; Schoepke, Nicole; Peveling-Oberhag, Adriane; Staubach, Petra; Mueller, Sabine; Jakob, Thilo; Metz, Martin			Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VALIDATION; URTICARIA		[Maurer, Marcus; Schuetz, Andrea; Weller, Karsten; Schoepke, Nicole; Metz, Martin] Charite, Dept Dermatol & Allergy, Berlin, Germany; [Peveling-Oberhag, Adriane; Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany; [Mueller, Sabine; Jakob, Thilo] Univ Med Ctr Freiburg, Dept Dermatol, Freiburg, Germany; [Jakob, Thilo] Justus Liebig Univ, Univ Med Ctr Giessen & Marburg, Dept Dermatol & Allergol, Campus Giessen, Giessen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; University of Freiburg; Justus Liebig University Giessen; University Hospital of Giessen & Marburg	Metz, M (corresponding author), Charite, Dept Dermatol & Allergy, Berlin, Germany.	martin.metz@charite.de	Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313	Novartis; Else Kroner-Fresenius-Stiftung	Novartis(Novartis); Else Kroner-Fresenius-Stiftung	We thank Hesna Gozlukaya and Nikki Rooks for excellent technical assistance and the physicians of the Charite urticaria clinic, a GA<SUP>2</SUP>LEN Urticaria Center of Reference and Excellence (UCARE, www.ga2len.net/ucare), for their support and helpful discussions. The trial was an investigator-initiated trial funded, in part, by Novartis and by intramural grants. M. Metz is supported by the Else Kroner-Fresenius-Stiftung.	Abajian M, 2014, IMMUNOL ALLERGY CLIN, V34, P73, DOI 10.1016/j.iac.2013.09.010; Basra MKA, 2008, BRIT J DERMATOL, V159, P997, DOI 10.1111/j.1365-2133.2008.08832.x; Basra MKA, 2015, DERMATOLOGY, V230, P27, DOI 10.1159/000365390; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Grabbe J, 2001, J INVEST DERM SYMP P, V6, P135, DOI 10.1046/j.0022-202x.2001.00025.x; Krause K, 2010, ALLERGY, V65, P1494, DOI 10.1111/j.1398-9995.2010.02409.x; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Metz M, 2011, INT ARCH ALLERGY IMM, V154, P177, DOI 10.1159/000320233; Schoepke N, 2015, CLIN EXP DERMATOL, V40, P399, DOI 10.1111/ced.12547; Schoepke N, 2015, J EUR ACAD DERMATOL, V29, P708, DOI 10.1111/jdv.12661; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342	11	47	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					870	+		10.1016/j.jaci.2017.01.042	http://dx.doi.org/10.1016/j.jaci.2017.01.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28389391	Bronze			2022-12-18	WOS:000409241500030
J	Draijer, C; Boorsma, CE; Robbe, P; Timens, W; Hylkema, MN; Ten Hacken, NH; van den Berge, M; Postma, DS; Melgert, BN				Draijer, Christina; Boorsma, Carian E.; Robbe, Patricia; Timens, Wim; Hylkema, Machteld N.; Ten Hacken, Nick H.; van den Berge, Maarten; Postma, Dirkje S.; Melgert, Barbro N.			Human asthma is characterized by more IRF51+M1 and CD2061+M2 macrophages and less IL-10+M2-like macrophages around airways compared with healthy airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLARIZATION		[Draijer, Christina; Boorsma, Carian E.; Melgert, Barbro N.] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands; [Draijer, Christina; Boorsma, Carian E.; Robbe, Patricia; Timens, Wim; Hylkema, Machteld N.; Ten Hacken, Nick H.; van den Berge, Maarten; Postma, Dirkje S.; Melgert, Barbro N.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Robbe, Patricia; Timens, Wim; Hylkema, Machteld N.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Ten Hacken, Nick H.; van den Berge, Maarten; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	Melgert, BN (corresponding author), Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands.; Melgert, BN (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands.	b.n.melgert@rug.nl	Timens, Wim/K-5570-2013	Timens, Wim/0000-0002-4146-6363; Melgert, Barbro/0000-0001-7091-907X; van den Berge, Maarten/0000-0002-9336-7340	Dutch Lung Foundation [3.2.10.056]; Northern CARA Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007749] Funding Source: NIH RePORTER	Dutch Lung Foundation; Northern CARA Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Dutch Lung Foundation (grant no. 3.2.10.056 to B.N.M.) and the Northern CARA Foundation (B.N.M. and C.D.).	Bourdonnay E, 2015, J EXP MED, V212, P729, DOI 10.1084/jem.20141675; Draijer C, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/632049; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kim YK, 2007, J IMMUNOL, V178, P5375, DOI 10.4049/jimmunol.178.8.5375; Liu L, 2014, J MOL CELL CARDIOL, V76, P15, DOI 10.1016/j.yjmcc.2014.07.021; Melgert BN, 2011, J ALLERGY CLIN IMMUN, V127, P831, DOI 10.1016/j.jaci.2010.10.045; Melgert BN, 2010, AM J RESP CELL MOL, V42, P595, DOI 10.1165/rcmb.2009-0016OC; Meyts I, 2006, J IMMUNOL, V177, P6460, DOI 10.4049/jimmunol.177.9.6460; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008	9	47	50	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					280	+		10.1016/j.jaci.2016.11.020	http://dx.doi.org/10.1016/j.jaci.2016.11.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28007476	Green Published, Bronze			2022-12-18	WOS:000404542000032
J	Seo, J; Kang, JA; Suh, DI; Park, EB; Lee, CR; Choi, SA; Kim, SY; Kim, Y; Park, SH; Ye, M; Kwon, SH; Park, JD; Lim, BC; Lee, DH; Kang, SJ; Choi, M; Park, SG; Chae, JH				Seo, Jieun; Kang, Jung-Ah; Suh, Dong In; Park, Eun-Byeol; Lee, Cho-Rong; Choi, Sun Ah; Kim, Soo Yeon; Kim, Yeji; Park, Sang-Heon; Ye, Michael; Kwon, Soon-Hak; Park, June Dong; Lim, Byung Chan; Lee, Dong Hun; Kang, Suk-Jo; Choi, Murim; Park, Sung-Gyoo; Chae, Jong-Hee			Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHEUMATOID-ARTHRITIS		[Seo, Jieun; Choi, Murim] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea; [Kang, Jung-Ah; Lee, Cho-Rong; Park, Sang-Heon; Park, Sung-Gyoo] Gwangju Inst Sci & Technol, Cell Logist Res Ctr, Gwangju, South Korea; [Kang, Jung-Ah; Lee, Cho-Rong; Park, Sang-Heon; Park, Sung-Gyoo] Gwangju Inst Sci & Technol, Sch Life Sci, Gwangju, South Korea; [Suh, Dong In; Choi, Sun Ah; Kim, Soo Yeon; Park, June Dong; Lim, Byung Chan; Choi, Murim; Chae, Jong-Hee] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Park, Eun-Byeol; Kang, Suk-Jo] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon, South Korea; [Kim, Yeji; Lee, Dong Hun] Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Ye, Michael] Gwangju Inst Sci & Technol, Sch Liberal Arts & Sci, Gwangju, South Korea; [Kwon, Soon-Hak] Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu, South Korea	Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Choi, M (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.; Choi, M (corresponding author), Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea.	murimchoi@snu.ac.kr; sgpark@gist.ac.kr; chaeped1@snu.ac.kr	Lee, Dong Hun/AAS-6021-2021; Choi, Murim/AAP-9120-2021; Park, Sung-Gyoo/H-8652-2019; Kang, Suk-Jo/C-1796-2011	Park, Sung-Gyoo/0000-0003-3702-5765; Lim, Byung Chan/0000-0002-8509-4135; Choi, Murim/0000-0002-9195-1455; Park, June Dong/0000-0001-8113-1384; Kwon, Soonhak/0000-0002-0783-2243	Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry for Health and Welfare, Republic of Korea [HI12C0066]; Brain Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2014M3C7A1046049]; National Research Foundation of Korea [NRF-2016R1A5A1007318, 2016M3C7A1905475]; Silver Health Bio Research Center of Gwangju Institute of Science and Technology; Post-Genome Program of the National Research Foundation - Ministry of Science, ICT & Future Planning [NRF-2014M3C9A2064686]	Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry for Health and Welfare, Republic of Korea; Brain Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; National Research Foundation of Korea(National Research Foundation of Korea); Silver Health Bio Research Center of Gwangju Institute of Science and Technology; Post-Genome Program of the National Research Foundation - Ministry of Science, ICT & Future Planning	A portion of this study was supported by grants from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Republic of Korea (HI12C0066; to J.-H.C.), and the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014M3C7A1046049; to J.-H.C.). Also supported by grants from National Research Foundation of Korea (NRF-2016R1A5A1007318 and 2016M3C7A1905475); the Silver Health Bio Research Center of Gwangju Institute of Science and Technology (to S.-G.P.); and the Post-Genome Program of the National Research Foundation funded by the Ministry of Science, ICT & Future Planning (NRF-2014M3C9A2064686; to M.C.).	Amarasekera M, 2011, ASIA PAC ALLERGY, V1, P12, DOI 10.5415/apallergy.2011.1.1.12; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boyle DL, 2015, ANN RHEUM DIS, V74, P1311, DOI 10.1136/annrheumdis-2014-206028; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Karonitsch T, 2012, ARTHRITIS RHEUM-US, V64, P400, DOI 10.1002/art.33347; Lee S, 2016, J ALLERGY CLIN IMMUN, V137, P327, DOI 10.1016/j.jaci.2015.08.036; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Melkil I, 2015, CURR OPIN IMMUNOL, V37, P1, DOI 10.1016/j.coi.2015.07.008; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Surpris G, 2016, J IMMUNOL, V196, P547, DOI 10.4049/jimmunol.1501415; Yi GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077846	12	47	54	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1396	1399		10.1016/j.jaci.2016.10.030	http://dx.doi.org/10.1016/j.jaci.2016.10.030			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	28041677	hybrid			2022-12-18	WOS:000398771800041
J	Perelygina, L; Plotkin, S; Russo, P; Hautala, T; Bonilla, F; Ochs, HD; Joshi, A; Routes, J; Patel, K; Wehr, C; Icenogle, J; Sullivan, KE				Perelygina, Ludmila; Plotkin, Stanley; Russo, Pierre; Hautala, Timo; Bonilla, Francisco; Ochs, Hans D.; Joshi, Avni; Routes, John; Patel, Kiran; Wehr, Claudia; Icenogle, Joseph; Sullivan, Kathleen E.			Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEASLES		[Perelygina, Ludmila; Icenogle, Joseph] Ctr Dis Control & Prevent, Div Viral Dis, Measles Mumps Rubella & Herpesvirus Lab Branch, Atlanta, GA 30333 USA; [Plotkin, Stanley] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Russo, Pierre] Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; [Bonilla, Francisco] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Ochs, Hans D.] Univ Washington, Seattle, WA 98195 USA; [Ochs, Hans D.] Seattle Childrens Hosp, Seattle, WA USA; [Joshi, Avni] Mayo Clin, Childrens Ctr, Div Allergy Immunol, Rochester, MN USA; [Routes, John] Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Allergy Immunol, Dept Pediat, Milwaukee, WI 53226 USA; [Patel, Kiran] Childrens Healthcare Atlanta, Div Pulm Allergy & Immunol Cyst Fibrosis & Sleep, Atlanta, GA USA; [Wehr, Claudia] Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Wehr, Claudia] Univ Freiburg, Univ Med Ctr Freiburg, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany; [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA	Centers for Disease Control & Prevention - USA; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Oulu; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Mayo Clinic; Children's Hospital of Wisconsin; Medical College of Wisconsin; Children's Healthcare of Atlanta (CHOA); University of Freiburg; University of Freiburg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Sullivan, KE (corresponding author), Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA.	sullivak@mail.med.upenn.edu	Wehr, Claudia/AAZ-5758-2021; Routes, john/AAA-4833-2021	Wehr, Claudia/0000-0002-5037-6175; Routes, john/0000-0001-8378-3773; Hautala, Timo/0000-0001-7889-1614; Perelygina, Ludmila/0000-0003-0812-8124; Bonilla, Francisco/0000-0002-5553-2077	NIAID NIH HHS [U24 AI086037] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U24AI086037] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bodemer C, 2014, CLIN MICROBIOL INFEC, V20, pO656, DOI 10.1111/1469-0691.12573; HANCOCK MP, 1968, J PEDIATR-US, V72, P636, DOI 10.1016/S0022-3476(68)80006-X; Islam SMM, 2000, ACTA OPHTHALMOL SCAN, V78, P590, DOI 10.1034/j.1600-0420.2000.078005590.x; Kreps EO, 2016, OCUL IMMUNOL INFLAMM, V24, P348, DOI 10.3109/09273948.2015.1005239; Nanda A, 2014, AM J DERMATOPATH, V36, P832, DOI 10.1097/DAD.0000000000000112; Sarmiento RE, 1997, VIRUS RES, V50, P15, DOI 10.1016/S0168-1702(97)00048-8; Smitt JHS, 2013, CURR OPIN PEDIATR, V25, P492, DOI 10.1097/MOP.0b013e3283623b9f; Takahashi H, 1996, CLIN INFECT DIS, V22, P36, DOI 10.1093/clinids/22.1.36; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505	9	47	48	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1436	1439		10.1016/j.jaci.2016.06.030	http://dx.doi.org/10.1016/j.jaci.2016.06.030			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27613149	Green Accepted, Bronze			2022-12-18	WOS:000389542700025
J	Bossley, CJ; Fleming, L; Ullmann, N; Gupta, A; Adams, A; Nagakumar, P; Bush, A; Saglani, S				Bossley, Cara J.; Fleming, Louise; Ullmann, Nicola; Gupta, Atul; Adams, Alexandra; Nagakumar, Prasad; Bush, Andrew; Saglani, Sejal			Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric; severe asthma; steroid response; spirometry; inflammation	EXHALED NITRIC-OXIDE; AIRWAY INFLAMMATION; INTRAMUSCULAR TRIAMCINOLONE; CHILDHOOD ASTHMA; CHILDREN; DIFFICULT; RESPONSIVENESS; EOSINOPHILIA; VALIDITY; SAFETY	Background: There is no agreed upon definition of systemic corticosteroid response in asthmatic children. Moreover, pediatric severe therapy-resistant asthma (STRA) isheterogeneous, and thus response to steroids is unlikely to be uniform in all patients. Objective: We sought to evaluate the utility of a multidomain approach incorporating symptoms, lung function, and inflammation to determine steroid responsiveness in pediatric patients with STRA. Methods: Eighty-two children (median age, 12 years) with STRA received a clinically indicated dose of intramuscular steroid. Changes in 4 separate domains were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (Asthma Control Test score, >19/25 or 50% increase), (2) spirometric results (FEV1 >= 80% of predicted value or >= 15% increase), (3) fraction of exhaled nitric oxide levels (<24 ppb), and (4) sputum eosinophil counts (<2.5%). Fifty-four of 82 children had complete data in all 4 domains. Results: Twenty-three (43%) of 54 children had a symptom response, 29 (54%) of 54 had a lung function response, 28 (52%) of 54 had a fraction of exhaled nitric oxide response, and 29 (54%) of 54 had a sputum eosinophil response. Although a similar proportion of children responded to systemic corticosteroids in each domain, there were no reliable predictors of a response pattern. Seven (13%) of 54 were complete responders (response in all domains), 8 (15%) of 54 were nonresponders (no response in any domain), and 39 (72%) of 54 were partial responders (response in >= 1 domain). Conclusions: A multidomain evaluation of systemic steroid responsiveness using pragmatic clinical assessments confirms childhood STRA is heterogeneous and that a complete response in symptoms and inflammatory and physiologic parameters is rare. Individual response patterns to systemic steroids might be useful in guiding the choice of add-on therapies in each child as a step toward achieving personalized medicine.	[Bossley, Cara J.; Fleming, Louise; Ullmann, Nicola; Adams, Alexandra; Nagakumar, Prasad; Bush, Andrew; Saglani, Sejal] Imperial Coll London, Royal Brompton Hosp, Resp Paediat, London, England; [Bossley, Cara J.; Fleming, Louise; Ullmann, Nicola; Adams, Alexandra; Nagakumar, Prasad; Bush, Andrew; Saglani, Sejal] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Bossley, Cara J.] Kings Coll Hosp London, Resp Paediat, London, England; [Fleming, Louise; Ullmann, Nicola; Gupta, Atul; Bush, Andrew; Saglani, Sejal] Imperial Coll London, Natl Heart & Lung Inst, Leukocyte Biol, London, England	Imperial College London; Royal Brompton Hospital; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Imperial College London	Saglani, S (corresponding author), Imperial Coll London, Resp Paediat, 368 Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.saglani@imperial.ac.uk	ULLMANN, NICOLA/K-6140-2016; Saglani, Sejal/AAE-5072-2019; Fleming, Louise/ABD-7452-2020	Ullmann, Nicola/0000-0003-1111-5690; Fleming, Louise/0000-0002-7268-7433	NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; NIHR Respiratory Disease Biomedical Research Unit at the Imperial College London;  [CDF-2014-07-019]; National Institute for Health Research [CDF-2014-07-019] Funding Source: researchfish	NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; NIHR Respiratory Disease Biomedical Research Unit at the Imperial College London; ; National Institute for Health Research(National Institute for Health Research (NIHR))	A.B. was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. S.S. is an NIHR Career Development Fellow (Grant ID: CDF-2014-07-019). A.B. and S.S. are members of the MRC Asthma UK Centre for Allergic Mechanisms of Disease. A.B. is a Principal Investigator in the Asthma UK Centre for Applied Research.	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Adcock IM, 2004, CURR OPIN PHARMACOL, V4, P257, DOI 10.1016/j.coph.2004.02.001; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2000, EUR RESPIR J, V15, P217; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Bray PJ, 2003, HUM MUTAT, V21, P557, DOI 10.1002/humu.10213; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Covar RA, 2004, J ALLERGY CLIN IMMUN, V114, P575, DOI 10.1016/j.jaci.2004.06.036; Fitch PS, 2000, EUR RESPIR J, V16, P1109, DOI 10.1034/j.1399-3003.2000.16f15.x; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Fleming L, 2013, AM J RESP CRIT CARE, V188, P400, DOI 10.1164/rccm.201212-2156LE; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hewitt Richard S, 2009, Prim Care Respir J, V18, P320, DOI 10.4104/pcrj.2009.00060; Jartti T, 2012, PAEDIATR RESPIR REV, V13, P178, DOI 10.1016/j.prrv.2011.11.002; Kashimaa TG, 2009, HUM PATHOL, V40, P226, DOI 10.1016/j.humpath.2008.07.008; Lex C, 2005, PEDIATR PULM, V39, P318, DOI 10.1002/ppul.20159; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Panickar JR, 2007, PEDIATR PULM, V42, P573, DOI 10.1002/ppul.20583; Panickar JR, 2005, PEDIATR PULM, V39, P421, DOI 10.1002/ppul.20176; Pike K, 2013, CLIN RESPIR J, V7, P204, DOI 10.1111/j.1752-699X.2012.00306.x; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; Ullmann N, 2013, ALLERGY, V68, P402, DOI 10.1111/all.12101; van der Valk RJP, 2012, ALLERGY, V67, P265, DOI 10.1111/j.1398-9995.2011.02734.x; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yim RP, 2012, PAEDIATR RESPIR REV, V13, P172, DOI 10.1016/j.prrv.2011.05.002	38	47	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					413	+		10.1016/j.jaci.2015.12.1347	http://dx.doi.org/10.1016/j.jaci.2015.12.1347			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27061250	Green Submitted, Bronze			2022-12-18	WOS:000380835800011
J	Cols, M; Rahman, A; Maglione, PJ; Garcia-Carmona, Y; Simchoni, N; Ko, HBM; Radigan, L; Cerutti, A; Blankenship, D; Pascual, V; Cunningham-Rundles, C				Cols, Montserrat; Rahman, Adeeb; Maglione, Paul J.; Garcia-Carmona, Yolanda; Simchoni, Noa; Ko, Huai-Bin M.; Radigan, Lin; Cerutti, Andrea; Blankenship, Derek; Pascual, Virginia; Cunningham-Rundles, Charlotte			Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; inflammatory complications; mucosal disease; innate lymphoid cells	BONE-MARROW; IMMUNODEFICIENCY; DISEASE; ABNORMALITIES; MULTICENTER; HYPERPLASIA; EFFICACY; SIGNALS; COHORT; BLOOD	Background: Common variable immunodeficiency (CVID) is an antibody deficiency treated with immunoglobulin; however, patients can have noninfectious inflammatory conditions that lead to heightened morbidity and mortality. Objectives: Modular analyses of RNA transcripts in whole blood previously identified an upregulation of many interferon-responsive genes. In this study we sought the cell populations leading to this signature. Methods: Lymphoid cells were measured in peripheral blood of 55 patients with CVID (31 with and 24 without inflammatory/autoimmune complications) by using mass cytometry and flow cytometry. Surface markers, cytokines, and transcriptional characteristics of sorted innate lymphoid cells (ILCs) were defined by using quantitative PCR. Gastrointestinal and lung biopsy specimens of subjects with inflammatory disease were stained to seek ILCs in tissues. Results: The linage-negative, CD127(+), CD161(+) lymphoid population containing T-box transcription factor, retinoic acid-related orphan receptor (ROR) gamma t, IFN-gamma, IL-17A, and IL-22, all hallmarks of type 3 innate lymphoid cells, were expanded in the blood of patients with CVID with inflammatory conditions (mean, 3.7% of PBMCs). ILCs contained detectable amounts of the transcription factors inhibitor of DNA binding 2, T-box transcription factor, and ROR gamma t and increased mRNA transcripts for IL-23 receptor (IL-23R) and IL-26, demonstrating inflammatory potential. In gastrointestinal and lung biopsy tissues of patients with CVID, numerous IFN-gamma+ROR gamma t(+)CD3(-) cells were identified, suggesting a role in these mucosal inflammatory states. Conclusions: An expansion of this highly inflammatory ILC population is a characteristic of patients with CVID with inflammatory disease; ILCs and the interferon signature are markers for the uncontrolled inflammatory state in these patients.	[Cols, Montserrat; Maglione, Paul J.; Garcia-Carmona, Yolanda; Simchoni, Noa; Radigan, Lin; Cerutti, Andrea; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA; [Cols, Montserrat; Rahman, Adeeb; Maglione, Paul J.; Garcia-Carmona, Yolanda; Simchoni, Noa; Radigan, Lin; Cerutti, Andrea; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Ko, Huai-Bin M.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Blankenship, Derek; Pascual, Virginia] Baylor Inst Immunol Res, Dallas, TX USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Baylor Scott & White Health	Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, Dept Med, 1425 Madison Ave, New York, NY 10029 USA.; Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@mssm.edu	Pascual, Virginia/ABD-3099-2020; Ko, Huai-Bin/AAO-2767-2020; Cols, Montserrat/J-3387-2013	Ko, Huai-Bin/0000-0003-1062-2383; Cols, Montserrat/0000-0001-6578-8378; Garcia-Carmona, Yolanda/0000-0003-2562-4752; Cerutti, Andrea/0000-0003-3026-4704; Maglione, Paul J./0000-0001-6805-7271; Rahman, Adeeb/0000-0002-8620-3161	National Institutes of Health [AI 101093, AI-086037, AI-48693, T32-GM007280]; Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693, R21AI101093, P01AI061093, U24AI086037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (AI 101093, AI-086037, AI-48693, and T32-GM007280), the Jeffrey Modell Foundation, and the David S. Gottesman Immunology Chair.	Abbondanzo SL, 2000, AM J SURG PATHOL, V24, P587, DOI 10.1097/00000478-200004000-00015; Agarwal S, 2009, J ALLERGY CLIN IMMUN, V124, P658, DOI 10.1016/j.jaci.2009.06.018; Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Boursiquot JN, 2013, J CLIN IMMUNOL, V33, P84, DOI 10.1007/s10875-012-9778-9; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; Ciccia F, 2015, ANN RHEUM DIS, V74, P1739, DOI 10.1136/annrheumdis-2014-206323; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Cording S, 2014, FEBS LETT, V588, P4176, DOI 10.1016/j.febslet.2014.03.034; Crellin NK, 2010, J EXP MED, V207, P281, DOI 10.1084/jem.20091509; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Fuss IJ, 2013, J CLIN IMMUNOL, V33, P748, DOI 10.1007/s10875-013-9873-6; Ganjalikhani-Hakemi M, 2014, J RES MED SCI, V19, pS30; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932; Gobert D, 2011, BRIT J HAEMATOL, V155, P498, DOI 10.1111/j.1365-2141.2011.08880.x; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Lee JS, 2012, NAT IMMUNOL, V13, P144, DOI 10.1038/ni.2187; Magri G, 2014, NAT IMMUNOL, V15, P354, DOI 10.1038/ni.2830; Mannon PJ, 2006, GASTROENTEROLOGY, V131, P748, DOI 10.1053/j.gastro.2006.06.022; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1916, DOI 10.1002/eji.201242639; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Perry JSA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004140; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Varzaneh FN, 2014, J CLIN IMMUNOL, V34, P524, DOI 10.1007/s10875-014-0053-0; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Warnatz K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00210; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wehr C, 2015, J ALLERGY CLIN IMMUN, V135, P988, DOI 10.1016/j.jaci.2014.11.029	47	47	47	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1206	U836		10.1016/j.jaci.2015.09.013	http://dx.doi.org/10.1016/j.jaci.2015.09.013			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26542033	Green Accepted, Bronze			2022-12-18	WOS:000373351200028
J	Ku, CL; Lin, CH; Chang, SW; Chu, CC; Chan, JFW; Kong, XF; Lee, CH; Rosen, EA; Ding, JY; Lee, WI; Bustamante, J; Witte, T; Shih, HP; Kuo, CY; Chetchotisakd, P; Kiertiburanakul, S; Suputtamongkol, Y; Yuen, KY; Casanova, JL; Holland, SM; Doffinger, R; Browne, SK; Chi, CY				Ku, Cheng-Lung; Lin, Chia-Hao; Chang, Su-Wei; Chu, Chen-Chung; Chan, Jasper F. W.; Kong, Xiao-Fei; Lee, Chen-Hsiang; Rosen, Emily A.; Ding, Jing-Ya; Lee, Wen-I.; Bustamante, Jacinta; Witte, Torsten; Shih, Han-Po; Kuo, Chen-Yen; Chetchotisakd, Ploenchan; Kiertiburanakul, Sasisopin; Suputtamongkol, Yupin; Yuen, Kwok-Yung; Casanova, Jean-Laurent; Holland, Steven M.; Doffinger, Rainer; Browne, Sarah K.; Chi, Chih-Yu			Anti-IFN-gamma autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NONTUBERCULOUS MYCOBACTERIAL INFECTIONS		[Ku, Cheng-Lung; Lin, Chia-Hao; Ding, Jing-Ya; Shih, Han-Po; Kuo, Chen-Yen] Chang Gung Univ, Grad Inst Clin Med Sci, Lab Human Immunol & Infect Dis, Taoyuan, Taiwan; [Ku, Cheng-Lung; Chi, Chih-Yu] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Ku, Cheng-Lung] Chang Gung Mem Hosp, Chang Gung Immunol Consortium, Taoyuan, Taiwan; [Ku, Cheng-Lung] Chang Gung Univ, Taoyuan, Taiwan; [Chang, Su-Wei] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Chan, Jasper F. W.; Yuen, Kwok-Yung] Univ Hong Kong, Queen Mary Hosp, Carol Yu Ctr Infect, Key Lab Emerging Infect Dis,Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Kong, Xiao-Fei; Bustamante, Jacinta; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Lee, Chen-Hsiang] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan; [Lee, Chen-Hsiang] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Rosen, Emily A.; Holland, Steven M.; Browne, Sarah K.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lee, Wen-I.] Chang Gung Mem Hosp, Div Allergy Immunol & Rheumatol, Dept Pediat, Taoyuan, Taiwan; [Bustamante, Jacinta; Casanova, Jean-Laurent] INSERM, U1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Bustamante, Jacinta; Casanova, Jean-Laurent] Paris Descartes Univ, Imagine Inst, Paris, France; [Witte, Torsten] Med Sch Hanover, Clin Immunol & Rheumatol, Hannover, NH, Germany; [Kuo, Chen-Yen] Chang Gung Mem Hosp Linkou, Dept Pediat, Taoyuan, Taiwan; [Chetchotisakd, Ploenchan] Khon Kaen Univ, Srinagarind Hosp, Khon Kaen, Thailand; [Kiertiburanakul, Sasisopin] Ramathibodi Hosp, Fac Med, Bangkok, Thailand; [Suputtamongkol, Yupin] Mahidol Univ, Fac Med, Siriraj Hosp, Div Infect Dis & Trop Med,Dept Med, Bangkok 10700, Thailand; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Immunohematol Unit, Paris, France; [Doffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England; [Doffinger, Rainer] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge, England; [Chi, Chih-Yu] China Med Univ Hosp, Dept Internal Med, Div Infect Dis, Taichung, Taiwan; [Chu, Chen-Chung] Mackay Mem Hosp, Dept Med Res, Immunogenet Lab, Taipei, Taiwan	Chang Gung University; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; University of Hong Kong; Rockefeller University; Chang Gung Memorial Hospital; Chang Gung University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Chang Gung Memorial Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Chang Gung Memorial Hospital; Khon Kaen University; Mahidol University; Mahidol University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; China Medical University Taiwan; China Medical University Hospital - Taiwan; Mackay Memorial Hospital	Ku, CL (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Lab Human Immunol & Infect Dis, Taoyuan, Taiwan.; Ku, CL (corresponding author), China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.; Ku, CL (corresponding author), Chang Gung Mem Hosp, Chang Gung Immunol Consortium, Taoyuan, Taiwan.; Ku, CL (corresponding author), Chang Gung Univ, Taoyuan, Taiwan.	clku@mail.cgu.edu.tw	Witte, Torsten/B-5783-2016; Chan, Jasper F. W./D-8007-2013; KU, Cheng-Lung/AAT-1033-2020; Bustamante, Jacinta/H-7877-2017; Casanova, Jean-Laurent/I-3418-2017	Chan, Jasper F. W./0000-0001-6336-6657; KU, Cheng-Lung/0000-0002-0643-2256; Bustamante, Jacinta/0000-0002-3439-2482; Doffinger, R/0000-0002-9841-3617; Chi, Chih-Yu/0000-0002-1425-8585; Casanova, Jean-Laurent/0000-0002-7782-4169; Yuen, Kwok-yung/0000-0002-2083-1552; Kong, Xiao-Fei/0000-0001-9983-2373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001069, ZIAAI001182, ZIAAI000647] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Browne SK, 2012, NEW ENGL J MED, V367, P725, DOI 10.1056/NEJMoa1111160; Chi CY, 2013, BLOOD, V121, P1357, DOI 10.1182/blood-2012-08-452482; Doffinger R, 2004, CLIN INFECT DIS, V38, pE10, DOI 10.1086/380453; Gonzalez-Galarza FF, 2011, NUCLEIC ACIDS RES, V39, pD913, DOI 10.1093/nar/gkq1128; Hoflich C, 2004, BLOOD, V103, P673, DOI 10.1182/blood-2003-04-1065; Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316; Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x; Patel SY, 2005, J IMMUNOL, V175, P4769, DOI 10.4049/jimmunol.175.7.4769; Reveille JD, 2006, AUTOIMMUN REV, V5, P389, DOI 10.1016/j.autrev.2005.10.012	9	47	47	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					945	948		10.1016/j.jaci.2015.09.018	http://dx.doi.org/10.1016/j.jaci.2015.09.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26522403	Bronze			2022-12-18	WOS:000371897500045
J	Le Guen, T; Touzot, F; Andre-Schmutz, I; Lagresle-Peyrou, C; France, B; Kermasson, L; Lambert, N; Picard, C; Nitschke, P; Carpentier, W; Bole-Feysot, C; Lim, A; Cavazzana, M; Callebaut, I; Soulier, J; Jabado, N; Fischer, A; de Villartay, JP; Revy, P				Le Guen, Tangui; Touzot, Fabien; Andre-Schmutz, Isabelle; Lagresle-Peyrou, Chantal; France, Benoit; Kermasson, Laetitia; Lambert, Nathalie; Picard, Capucine; Nitschke, Patrick; Carpentier, Wassila; Bole-Feysot, Christine; Lim, Annick; Cavazzana, Marina; Callebaut, Isabelle; Soulier, Jean; Jabado, Nada; Fischer, Alain; de Villartay, Jean-Pierre; Revy, Patrick			An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoiesis; immunodeficiency; MYSM1; genetic reversion; histone deubiquitinase	HISTONE H2A DEUBIQUITINASE; FANCONI-ANEMIA; CELL-DEVELOPMENT; EPIGENETIC CONTROL; STEM-CELLS; T-CELLS; MOSAICISM; IMMUNODEFICIENCY; PROGENITOR; CHAINS	Background: Myb-Like, SWIRM, and MPN domains 1 (MYSM1) is a metalloprotease that deubiquitinates the K119-monoubiquitinated form of histone 2A (H2A), a chromatin marker associated with gene transcription silencing. Likewise, it has been reported that murine Mysm1 participates in transcription derepression of genes, among which are transcription factors involved in hematopoietic stem cell homeostasis, hematopoiesis, and lymphocyte differentiation. However, whether MYSM1 has a similar function in human subjects remains unclear. Here we describe a patient presenting with a complete lack of B lymphocytes, T-cell lymphopenia, defective hematopoiesis, and developmental abnormalities. Objectives: We sought to characterize the underlying genetic cause of this syndrome. Methods: We performed genome-wide homozygosity mapping, followed by whole-exome sequencing. Results: Genetic analysis revealed that this novel disorder is caused by a homozygous MYSM1 missense mutation affecting the catalytic site within the deubiquitinase JAB1/MPN/Mov34 (JAMM)/MPN domain. Remarkably, during the course of our study, the patient recovered a normal immunohematologic phenotype. Genetic analysis indicated that this improvement originated from a spontaneous genetic reversion of the MYSM1 mutation in a hematopoietic stem cell. Conclusions: We here define a novel human immunodeficiency and provide evidence that MYSM1 is essential for proper immunohematopoietic development in human subjects. In addition, we describe one of the few examples of spontaneous in vivo genetic cure of a human immunodeficiency.	[Le Guen, Tangui; Touzot, Fabien; France, Benoit; Kermasson, Laetitia; de Villartay, Jean-Pierre; Revy, Patrick] INSERM, UMR 1163, Lab Genome Dynam Immune Syst, F-75015 Paris, France; [Le Guen, Tangui; Touzot, Fabien; Andre-Schmutz, Isabelle; Lagresle-Peyrou, Chantal; France, Benoit; Kermasson, Laetitia; Picard, Capucine; Cavazzana, Marina; Fischer, Alain; de Villartay, Jean-Pierre; Revy, Patrick] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Touzot, Fabien; Andre-Schmutz, Isabelle; Lambert, Nathalie; Picard, Capucine; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Serv Immunol & Hematol Pediat, Paris, France; [Lagresle-Peyrou, Chantal] INSERM, CIC BT 502, F-75015 Paris, France; [Lagresle-Peyrou, Chantal] Hop Necker Enfants Malad, AP HP, Dept Biotherapie, Paris, France; [Lambert, Nathalie; Picard, Capucine; Cavazzana, Marina] Hop Necker Enfants Malad, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Nitschke, Patrick] Univ Paris 06, Serv Bioinformat, Paris, France; [Carpentier, Wassila] Univ Paris 06, Plateforme Postgenom P3S, Paris, France; [Bole-Feysot, Christine] Inst Imagine, Plateforme Genom, Paris, France; [Lim, Annick] Inst Pasteur, Grp Immunoscope, Paris, France; [Callebaut, Isabelle] Univ Paris 06, CNRS, Sorbonne Univ, UMR7590,MNHN,IRD,IUC, Paris, France; [Soulier, Jean] Univ Paris 07, INSERM, U944, Inst Univ Hematol, Paris, France; [Jabado, Nada] McGill Univ, Montreal, PQ, Canada; [Jabado, Nada] Genome Quebec Innovat Ctr, Montreal, PQ, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McGill University	Revy, P (corresponding author), INSERM, UMR 1163, Lab Genome Dynam Immune Syst, Equipe Labelisee La Ligue,Inst Imagine, 24 Bd Montparnasse, F-75015 Paris, France.	patrick.revy@inserm.fr	Jabado, Nada/AAN-4026-2020; Touzot, Fabien/T-7797-2018; Andre-Schmutz, Isabelle/M-1279-2016; Revy, Patrick/H-8137-2017; de Villartay, jean pierre/H-9353-2017; Peyrou, Chantal Lagresle/H-2911-2017; Andre, Isabelle/F-6263-2013; Peyrou, Chantal Lagresle/AAK-9689-2020	Touzot, Fabien/0000-0002-0889-4905; de Villartay, jean pierre/0000-0001-5987-0463; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Andre, Isabelle/0000-0002-3905-9910; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Cavazzana, Marina/0000-0002-0264-0891; FRANCE, Benoit/0000-0002-3216-6115; Revy, Patrick/0000-0003-0758-8022	INSERM; Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue); GIS-Institut des maladies rares; ARC; INCa/Canceropole Ile de France; Institut Imagine; European Research Council (PIDIMMUN grant) [249816]; La Ligue contre le cancer; Canceropole	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue)(Institut National du Cancer (INCA) France); GIS-Institut des maladies rares; ARC(Australian Research Council); INCa/Canceropole Ile de France(Institut National du Cancer (INCA) France); Institut Imagine; European Research Council (PIDIMMUN grant); La Ligue contre le cancer(Ligue nationale contre le cancer); Canceropole(Region Ile-de-France)	Supported by institutional grants from INSERM, Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue), GIS-Institut des maladies rares, ARC, INCa/Canceropole Ile de France, Institut Imagine, and the European Research Council (PIDIMMUN grant no. 249816). This program has received a state subsidy managed by the National Research Agency under the "Investments for the Future'' program bearing the reference ANR-10-IAHU-01. T.L.G received fellowships from La Ligue contre le cancer, and B.F. received fellowships from Canceropole. P.R. is a scientist from Centre National de la Recherche Scientifique (CNRS).	Bennett-Lovsey RM, 2008, PROTEINS, V70, P611, DOI 10.1002/prot.21688; Bousso P, 2000, P NATL ACAD SCI USA, V97, P274, DOI 10.1073/pnas.97.1.274; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Ceccaldi R, 2012, CELL STEM CELL, V11, P36, DOI 10.1016/j.stem.2012.05.013; Doulatov S, 2012, CELL STEM CELL, V10, P120, DOI 10.1016/j.stem.2012.01.006; Ellis NA, 2001, HUM GENET, V108, P167, DOI 10.1007/s004390000447; Gatzka M, 2015, CELL DEATH DIFFER, V22, P1451, DOI 10.1038/cdd.2014.231; Gregory JJ, 2001, P NATL ACAD SCI USA, V98, P2532, DOI 10.1073/pnas.051609898; Gross M, 2002, CYTOGENET GENOME RES, V98, P126, DOI 10.1159/000069805; Hirschhorn R, 2003, J MED GENET, V40, P721, DOI 10.1136/jmg.40.10.721; Jiang XX, 2011, IMMUNITY, V35, P883, DOI 10.1016/j.immuni.2011.11.010; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lim A, 2008, INT IMMUNOL, V20, P105, DOI 10.1093/intimm/dxm125; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McDermott DH, 2015, CELL, V160, P686, DOI 10.1016/j.cell.2015.01.014; Nandakumar V, 2013, P NATL ACAD SCI USA, V110, pE3927, DOI 10.1073/pnas.1308888110; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Nijnik A, 2012, BLOOD, V119, P1370, DOI 10.1182/blood-2011-05-352666; Nishi R, 2014, NAT CELL BIOL, V16, P1016, DOI 10.1038/ncb3028; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Shamseldin HE, 2013, BLOOD, V122, P3844, DOI 10.1182/blood-2013-09-527127; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Touzot F, 2012, BLOOD, V120, P1957, DOI 10.1182/blood-2012-04-426833; Touzot F, 2012, J ALLERGY CLIN IMMUN, V129, P473, DOI 10.1016/j.jaci.2011.09.043; Waisfisz Q, 1999, NAT GENET, V22, P379, DOI 10.1038/11956; Wang T, 2013, BLOOD, V122, P2812, DOI 10.1182/blood-2013-03-489641; Won H, 2014, BLOOD, V124, P2647, DOI 10.1182/blood-2013-10-534313; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024	31	47	47	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1619	U280		10.1016/j.jaci.2015.06.008	http://dx.doi.org/10.1016/j.jaci.2015.06.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26220525				2022-12-18	WOS:000366044300024
J	Ueta, M; Sawai, H; Sotozono, C; Hitomi, Y; Kaniwa, N; Kim, MK; Seo, KY; Yoon, KC; Joo, CK; Kannabiran, C; Wakamatsu, TH; Sangwan, V; Rathi, V; Basu, S; Ozeki, T; Mushiroda, T; Sugiyama, E; Maekawa, K; Nakamura, R; Aihara, M; Matsunaga, K; Sekine, A; Gomes, JAP; Hamuro, J; Saito, Y; Kubo, M; Kinoshita, S; Tokunaga, K				Ueta, Mayumi; Sawai, Hiromi; Sotozono, Chie; Hitomi, Yuki; Kaniwa, Nahoko; Kim, Mee Kum; Seo, Kyoung Yul; Yoon, Kyung-Chul; Joo, Choun-Ki; Kannabiran, Chitra; Wakamatsu, Tais Hitomi; Sangwan, Virender; Rathi, Varsha; Basu, Sayan; Ozeki, Takeshi; Mushiroda, Taisei; Sugiyama, Emiko; Maekawa, Keiko; Nakamura, Ryosuke; Aihara, Michiko; Matsunaga, Kayoko; Sekine, Akihiro; Pereira Gomes, Jose Alvaro; Hamuro, Junji; Saito, Yoshiro; Kubo, Michiaki; Kinoshita, Shigeru; Tokunaga, Katsushi			IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Stevens-Johnson syndrome; toxic epidermal necrolysis; cold medicine; severe mucosal involvement; genome-wide association study; IKZFl; alternative splicing	OCULAR SURFACE COMPLICATIONS; GENOME-WIDE ASSOCIATION; DNA-BINDING PROTEINS; ERYTHEMA MULTIFORME; IKAROS GENE; JAPANESE; POLYMORPHISMS; POPULATION; DRUGS; RISK	Background: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes, including the ocular surface, oral cavity, and genitals. These reactions are very rare but are often associated with inciting drugs, infectious agents, or both. Objective: We sought to identify susceptibility loci for cold medicine related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement (SMI). Methods: A genome-wide association study was performed in 808 Japanese subjects (117 patients with CM-SJS/TEN with SMI and 691 healthy control subjects), and subsequent replication studies were performed in 204 other Japanese subjects (16 cases and 188 control subjects), 117 Korean subjects (27 cases and 90 control subjects), 76 Indian subjects (20 cases and 56 control subjects), and 174 Brazilian subjects (39 cases and 135 control subjects). Results: In addition to the most significant susceptibility region, HLA-A, we identified IKZF1, which encodes Ikaros, as a novel susceptibility gene (meta-analysis, rs4917014 [G vs T]; odds ratio, 0.5; P = 8.5 x 10(-11)). Furthermore, quantitative ratios of the IKZF1 alternative splicing isoforms Ik1 and Ik2 were significantly associated with rs4917014 genotypes. Conclusion: We identified IKZF1 as a susceptibility gene for CM-SJS/TEN with SMI not only in Japanese subjects but also in Korean and Indian subjects and showed that the Ik2/1k1 ratio might be influenced by IKZF1 single nucleotide polymorphisms, which were significantly associated with susceptibility to CM-SJS/TEN with SMI.	[Ueta, Mayumi; Sotozono, Chie] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto 60020841, Japan; [Ueta, Mayumi] Doshisha Univ, Fac Life & Med Sci, Res Ctr Inflammat & Regenerat Med, Kyoto 602, Japan; [Ueta, Mayumi; Sawai, Hiromi; Hitomi, Yuki; Tokunaga, Katsushi] Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo, Japan; [Kaniwa, Nahoko; Sugiyama, Emiko; Maekawa, Keiko; Nakamura, Ryosuke; Saito, Yoshiro] Natl Inst Hlth Sci, Div Med Safety Sci, Tokyo, Japan; [Kim, Mee Kum] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea; [Seo, Kyoung Yul] Yonsei Univ, Coll Med, Severance Hosp, Dept Ophthalmol,Inst Vis Res, Seoul, South Korea; [Yoon, Kyung-Chul] Chonnam Natl Univ, Dept Ophthalmol, Gwagju, South Korea; [Joo, Choun-Ki] Cathol Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul, South Korea; [Kannabiran, Chitra] Prof Brien Holden Eye Res Ctr, Hyderabad, Andhra Pradesh, India; [Sangwan, Virender; Rathi, Varsha; Basu, Sayan] LV Prasad Eye Inst, Cornea & Anterior Segment Serv, Hyderabad, Andhra Pradesh, India; [Wakamatsu, Tais Hitomi; Pereira Gomes, Jose Alvaro] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil; [Ozeki, Takeshi; Mushiroda, Taisei; Kubo, Michiaki] RIKEN, Ctr Integrat Med Sci, Res Grp Pharmacogen, Yokohama, Kanagawa, Japan; [Aihara, Michiko] Yokohama City Univ, Grad Sch Med, Dept Environm Immuno Dermatol, Yokohama, Kanagawa 232, Japan; [Matsunaga, Kayoko] Fujita Hlth Univ, Sch Med, Dept Dermatol, Toyoake, Aichi 47011, Japan; [Sekine, Akihiro] Kyoto Univ, Grad Sch Med, EBM Res Ctr, Kyoto, Japan	Kyoto Prefectural University of Medicine; Doshisha University; University of Tokyo; National Institute of Health Sciences - Japan; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Chonnam National University; Catholic University of Korea; Seoul St. Mary's Hospital; L. V. Prasad Eye Institute; Universidade Federal de Sao Paulo (UNIFESP); RIKEN; Yokohama City University; Fujita Health University; Kyoto University	Tokunaga, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Human Genet, Bunkyo Ku, 7-3-1 Hong, Tokyo 1130033, Japan.	tokunaga@m.u-tokyo.ac.jp	Sangwan, Virender Singh/AAA-1091-2022; Mushiroda, Taisei/E-3022-2010; Kannabiran, Chitra/S-9361-2019; Hitomi, Yuki/V-8236-2019; Seo, Kyoung Yul/I-5484-2019; Wakamatsu, Tais/E-9300-2012; Kubo, Michiaki/N-7947-2015; Rathi, Varsha/W-9064-2019; Basu, Sayan/R-9454-2019; Gomes, Jose Alvaro Pereira/P-4798-2018	Sangwan, Virender Singh/0000-0002-8229-4158; Kannabiran, Chitra/0000-0001-8435-0320; Gomes, Jose Alvaro Pereira/0000-0001-7329-9531; Seo, Kyoung Yul/0000-0002-9855-1980; Basu, Sayan/0000-0001-5030-5003	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese government (Scientific Research on Innovative Areas "Genome Science" and BioBank Japan Project); Japanese Ministry of Health, Labor and Welfare; Kyoto Foundation for the Promotion of Medical Science; Intramural Research Fund of Kyoto Prefectural University of Medicine; Department of Science and Technology, Government of India, under the India-Japan S&T cooperation (to Hyderabad Eye Research Foundation); Grants-in-Aid for Scientific Research [25293355] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese government (Scientific Research on Innovative Areas "Genome Science" and BioBank Japan Project); Japanese Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Kyoto Foundation for the Promotion of Medical Science(Kyoto Foundation for the Promotion of Medical Science); Intramural Research Fund of Kyoto Prefectural University of Medicine; Department of Science and Technology, Government of India, under the India-Japan S&T cooperation (to Hyderabad Eye Research Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese government (Scientific Research on Innovative Areas "Genome Science" and BioBank Japan Project) and also partly by grants-in-aid for scientific research from the Japanese Ministry of Health, Labor and Welfare and a research grant from the Kyoto Foundation for the Promotion of Medical Science and the Intramural Research Fund of Kyoto Prefectural University of Medicine. This project was funded by the Department of Science and Technology, Government of India, under the India-Japan S&T cooperation (to Hyderabad Eye Research Foundation).	BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Fang CM, 2012, GENES IMMUN, V13, P421, DOI 10.1038/gene.2012.10; Forman R, 2002, DRUG SAFETY, V25, P965, DOI 10.2165/00002018-200225130-00006; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Hu SJ, 2013, MOD RHEUMATOL, V23, P205, DOI 10.1007/s10165-012-0706-x; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Leaute-Labreze C, 2000, ARCH DIS CHILD, V83, P347, DOI 10.1136/adc.83.4.347; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Merkenschlager M, 2010, FEBS LETT, V584, P4910, DOI 10.1016/j.febslet.2010.09.042; Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033; Molnar A, 1996, J IMMUNOL, V156, P585; Nishida N, 2007, ANAL BIOCHEM, V364, P78, DOI 10.1016/j.ab.2007.02.005; Nishida N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029967; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; POWER WJ, 1995, OPHTHALMOLOGY, V102, P1669; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Sotozono C, 2007, OPHTHALMOLOGY, V114, P1294, DOI 10.1016/j.ophtha.2006.10.029; Sotozono C, 2009, OPHTHALMOLOGY, V116, P685, DOI 10.1016/j.ophtha.2008.12.048; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Tohkin M, 2013, PHARMACOGENOMICS J, V13, P60, DOI 10.1038/tpj.2011.41; Ueta M, 2008, BRIT J OPHTHALMOL, V92, P989, DOI 10.1136/bjo.2007.136796; Ueta M, 2008, MOL VIS, V14, P550; Ueta M, 2008, INVEST OPHTH VIS SCI, V49, P1809, DOI 10.1167/iovs.07-1401; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P1457, DOI 10.1016/j.jaci.2007.07.048; Ueta M, 2007, BRIT J OPHTHALMOL, V91, P962, DOI 10.1136/bjo.2006.113449; Ueta M, 2007, AM J OPHTHALMOL, V143, P367, DOI 10.1016/j.ajo.2006.09.029; Ueta M, 2014, SCI REP-UK, V4, DOI 10.1038/srep05981; Ueta M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04862; Ueta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043650; Ueta M, 2012, PROG RETIN EYE RES, V31, P551, DOI 10.1016/j.preteyeres.2012.05.003; Ueta M, 2012, J ALLERGY CLIN IMMUN, V129, P1413, DOI 10.1016/j.jaci.2012.01.069; Ueta M, 2010, J ALLERGY CLIN IMMUN, V126, P1218, DOI 10.1016/j.jaci.2010.08.007; Yamane Yumiko, 2007, Allergol Int, V56, P419, DOI 10.2332/allergolint.O-07-483; Yang TP, 2010, BIOINFORMATICS, V26, P2474, DOI 10.1093/bioinformatics/btq452; YETIV JZ, 1980, SOUTH MED J, V73, P599, DOI 10.1097/00007611-198005000-00015	41	47	47	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1538	U240		10.1016/j.jaci.2014.12.1916	http://dx.doi.org/10.1016/j.jaci.2014.12.1916			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25672763				2022-12-18	WOS:000355933400017
J	Berin, MC				Berin, M. Cecilia			Immunopathophysiology of food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; tolerance; vomiting; enteropathy; milk; lymphocytes; serotonin	SMALL INTESTINAL BIOPSY; COWS MILK INTOLERANCE; KILLER T-CELLS; MALABSORPTION-SYNDROME; CLINICAL-FEATURES; CELIAC-DISEASE; JEJUNAL MUCOSA; TNF-ALPHA; CHILDREN; ALLERGY	There is increasing recognition of the non-IgE-mediated gastrointestinal food allergy known as food proteininduced enterocolitis syndrome (FPIES), with several recent publications summarizing the clinical experience with FPIES in the United States, the United Kingdom, Europe, and Australia. Our understanding of the mechanisms linking food exposure to typical symptoms of vomiting, hypotension, and diarrhea has lagged far behind our understanding of the immune mechanisms of IgEmediated food allergy. The goal of this overview is to summarize and critique the current state of knowledge of the immunology of FPIES and to identify major gaps in our knowledge that need to be addressed to make significant gains in developing therapies and prevention strategies for FPIES.	[Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, New York, NY 10029 USA.	cecilia.berin@mssm.edu		berin, cecilia/0000-0002-9051-9249	National Institutes of Health [AI093577]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grant AI093577.	Abadie V, 2011, ANNU REV IMMUNOL, V29, P493, DOI 10.1146/annurev-immunol-040210-092915; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863, DOI 10.1016/S0091-6749(99)70300-3; Burks A W, 1994, Pediatr Allergy Immunol, V5, P40; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Fernandes BN, 2012, J ALLERGY CLIN IMMUN, V130, P1199, DOI 10.1016/j.jaci.2012.06.017; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357, DOI 10.1136/adc.50.5.357; FREIER S, 1969, J PEDIATR-US, V75, P623, DOI 10.1016/S0022-3476(69)80458-0; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P332, DOI 10.1016/j.jaip.2013.05.009; Hankard GF, 1997, J PEDIATR GASTR NUTR, V25, P79, DOI 10.1097/00005176-199707000-00013; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Holbrook T, 2013, J ALLERGY CLIN IMMUN, V132, P1219, DOI 10.1016/j.jaci.2013.06.021; Jyonouchi S, 2014, CLIN EXP ALLERGY, V44, P58, DOI 10.1111/cea.12201; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V92, P909, DOI 10.1016/0091-6749(93)90069-R; Konstantinou GN, 2014, PEDIAT ALLERG IMM-UK, V25, P651, DOI 10.1111/pai.12288; KOSNAI I, 1984, J PEDIATR GASTR NUTR, V3, P368, DOI 10.1097/00005176-198406000-00011; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; KUITUNEN P, 1973, ACTA PAEDIATR SCAND, V62, P585, DOI 10.1111/j.1651-2227.1973.tb17069.x; Ludman S, 2014, ANN ALLERG ASTHMA IM, V113, P290, DOI 10.1016/j.anai.2014.06.020; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, P590, DOI 10.1016/j.jaci.2012.09.005; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; NAGATA S, 1995, J PEDIATR GASTR NUTR, V20, P44, DOI 10.1097/00005176-199501000-00008; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nomura I, 2012, CURR ALLERGY ASTHM R, V12, P297, DOI 10.1007/s11882-012-0272-5; Nomura I, 2011, J ALLERGY CLIN IMMUN, V127, P685, DOI 10.1016/j.jaci.2011.01.019; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2015, J ALLERGY CLIN IMMUN, V135, P1114, DOI 10.1016/j.jaci.2015.03.025; Paust S, 2011, NAT IMMUNOL, V12, P500, DOI 10.1038/ni.2032; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; ROSEKRANS PCM, 1980, J CLIN PATHOL, V33, P125, DOI 10.1136/jcp.33.2.125; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; SAVILAHTI E, 1973, GUT, V14, P491, DOI 10.1136/gut.14.6.491; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sollid LM, 2013, NAT REV IMMUNOL, V13, P294, DOI 10.1038/nri3407; Sopo SM, 2012, CLIN EXP ALLERGY, V42, P1257, DOI 10.1111/j.1365-2222.2012.04027.x; Sopo SM, 2014, INT ARCH ALLERGY IMM, V164, P207, DOI 10.1159/000365104; Sopo SM, 2014, INT ARCH ALLERGY IMM, V164, P137, DOI 10.1159/000363384; Tan J, 2012, J ALLERGY CLIN IMMUN, V129, P873, DOI 10.1016/j.jaci.2011.12.1000; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; Wada H, 2007, PEDIATR INT, V49, P109, DOI 10.1111/j.1442-200X.2007.02294.x; Wada T, 2014, PEDIAT ALLERG IMM-UK, V25, P617, DOI 10.1111/pai.12254	53	47	48	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1108	1113		10.1016/j.jaci.2014.12.1948	http://dx.doi.org/10.1016/j.jaci.2014.12.1948			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25746969	Green Accepted			2022-12-18	WOS:000353980700002
J	Robbins, KA; Wood, RA; Keet, CA				Robbins, Karen A.; Wood, Robert A.; Keet, Corinne A.			Milk allergy is associated with decreased growth in US children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NUTRITIONAL-STATUS; NUTRIENT INTAKE; FOOD ALLERGIES; DIET		[Robbins, Karen A.; Wood, Robert A.; Keet, Corinne A.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA	Johns Hopkins University	Robbins, KA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA.	ckeet1@jhmi.edu		Robbins, Karen/0000-0002-9906-9088; Keet, Corinne/0000-0002-6585-239X	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007, K23AI103187] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR 025005] Funding Source: Medline; NIAID NIH HHS [5T32AI007007-34, 1K23AI103187, K23 AI103187, T32 AI007007] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Centers for Disease Control and Prevention, 2008, NAT HLTH NUTR EX SUR; Centers for Disease Control and Prevention. National Center for Health Statistics, 2010, NAT HLTH NUTR EX SUR; Christie L, 2002, J AM DIET ASSOC, V102, P1648, DOI 10.1016/S0002-8223(02)90351-2; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Flammarion S, 2011, PEDIAT ALLERG IMM-UK, V22, P161, DOI 10.1111/j.1399-3038.2010.01028.x; Isolauri E, 1998, J PEDIATR-US, V132, P1004, DOI 10.1016/S0022-3476(98)70399-3; Jensen VB, 2004, PEDIAT ALLERG IMM-UK, V15, P562, DOI 10.1111/j.1399-3038.2004.00191.x; Kuczmarski RJ, 2000, ADV DATA, V314, P1; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Mehta H, 2013, CURR OPIN ALLERGY CL, V13, P275, DOI 10.1097/ACI.0b013e328360949d; Meyer R, 2014, J HUM NUTR DIET, V27, P227, DOI 10.1111/jhn.12149; PAGANUS A, 1992, ACTA PAEDIATR, V81, P518, DOI 10.1111/j.1651-2227.1992.tb12286.x; Sova C, 2013, NUTR CLIN PRACT, V28, P669, DOI 10.1177/0884533613505870; TIAINEN JM, 1995, EUR J CLIN NUTR, V49, P605	15	47	48	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1466	+		10.1016/j.jaci.2014.08.037	http://dx.doi.org/10.1016/j.jaci.2014.08.037			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25312758	Green Accepted, Bronze			2022-12-18	WOS:000346075400037
J	Morales, DR; Lipworth, BJ; Guthrie, B; Jackson, C; Donnan, PT; Santiago, VH				Morales, Daniel R.; Lipworth, Brian J.; Guthrie, Bruce; Jackson, Cathy; Donnan, Peter T.; Santiago, Virginia H.			Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; aspirin-exacerbated respiratory disease; aspirin-induced asthma; aspirin-sensitive asthma; nonsteroidal anti-inflammatory agents; COX-2 inhibitors; systematic review; meta-analysis; pharmacoepidemiology	CYCLOOXYGENASE-2 INHIBITOR; INDUCED ASTHMA; SENSITIVE PATIENTS; INTOLERANT ASTHMA; CROSS-REACTIVITY; ROFECOXIB; CELECOXIB; MELOXICAM; PATHOGENESIS; PREVALENCE	Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause bronchospasm in susceptible patients with asthma, often termed aspirin-exacerbated respiratory disease (AERD), with the risk being greatest after acute exposure. Selective NSAIDs that preferentially inhibit COX-2 might be safer. Objective: We sought to systematically evaluate changes in symptoms and pulmonary function after acute selective NSAID or COX-2 inhibitor exposure in patients with the AERD phenotype. Methods: A systematic review of databases was performed to identify all blinded, placebo-controlled clinical trials evaluating acute selective NSAID or COX-2 inhibitor exposure in patients with AERD. Effect estimates for changes in respiratory function and symptoms were pooled by using fixed-effects meta-analysis, with heterogeneity investigated. Results: No significant difference in respiratory symptoms (risk difference, -0.01; 95% CI, -0.03 to 0.01; P=.57), decrease in FEV1 of 20% or greater (RD, 0.00; 95% CI, -0.02 to 0.02; P=.77), or nasal symptoms (RD, -0.01; 95% CI, -0.04 to 0.02; P=.42) occurred with COX-2 inhibitors (eg, celecoxib). Selective NSAID exposure caused respiratory symptoms in approximately 1 in 13 patients with AERD (RD, 0.08; 95% CI, 0.02 to 0.14; P=.01). No significant differences were found according to leukotriene antagonist exposure or whether NSAIDs were randomly allocated. Conclusion: According to clinical trial evidence in patients with stable mild-to-moderate asthma with AERD, acute exposure to COX-2 inhibitors is safe, and selective NSAIDs exhibit a small risk. Thus COX-2 inhibitors could be used in patients with AERD or in patients with general asthma unwilling to risk nonselective NSAID exposure when oral challenge tests are unavailable.	[Morales, Daniel R.; Guthrie, Bruce; Santiago, Virginia H.] Univ Dundee, Med Res Inst, Qual Safety & Informat Grp, Dundee DD2 4BF, Scotland; [Lipworth, Brian J.] Univ Dundee, Med Res Inst, Asthma & Allergy Res Grp, Dundee DD2 4BF, Scotland; [Jackson, Cathy] Univ St Andrews, Sch Med, St Andrews KY16 9AJ, Fife, Scotland; [Donnan, Peter T.] Univ Dundee, Med Res Inst, Dundee Epidemiol & Biostat Unit, Dundee DD2 4BF, Scotland	University of Dundee; University of Dundee; University of St Andrews; University of Dundee	Morales, DR (corresponding author), Univ Dundee, Med Res Inst, Qual Safety & Informat Grp, Mackenzie Bldg, Dundee DD2 4BF, Scotland.	d.r.z.morales@dundee.ac.uk	Guthrie, Bruce/HHM-9696-2022	Donnan, Peter/0000-0001-7828-0610; Hernandez Santiago, Virginia/0000-0001-9033-8352; Hernandez Santiago, Virginia/0000-0002-8544-1483; Guthrie, Bruce/0000-0003-4191-4880	Scottish Government Chief Scientist Office Clinical Academic Fellowship; Chief Scientist Office [CAF/12/07, CAF/11/07] Funding Source: researchfish	Scottish Government Chief Scientist Office Clinical Academic Fellowship; Chief Scientist Office	Supported by a Scottish Government Chief Scientist Office Clinical Academic Fellowship that provided support to D.R.M.	Alobid I, 2005, QUAL LIFE RES, V14, P789, DOI 10.1007/s11136-004-1597-x; AYRES JG, 1987, LANCET, V1, P1082; Bavbek S, 2004, J ASTHMA, V41, P67, DOI 10.1081/JAS-120026063; Bavbek S, 2007, INT ARCH ALLERGY IMM, V142, P64, DOI 10.1159/000096000; British Thoracic Society Scottish Intercollegiate Guidelines Network (SIGN), 2012, SIGN GUID; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Deeks JJ, COCHRANE HDB SYSTEMA; El Miedany Y, 2006, ANN ALLERG ASTHMA IM, V97, P105, DOI 10.1016/S1081-1206(10)61378-6; Gaber F, 2008, THORAX, V63, P1076, DOI 10.1136/thx.2008.101196; Grimm V, 2002, J ALLERGY CLIN IMMUN, V109, P370, DOI 10.1067/mai.2002.121315; Grob M, 2002, ALLERGY, V57, P264, DOI 10.1034/j.1398-9995.2002.1n3581.x; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Martin-Garcia C, 2003, J INVEST ALLERG CLIN, V13, P20; Martin-Garcia C, 2002, CHEST, V121, P1812, DOI 10.1378/chest.121.6.1812; Micheletto C, 2006, Eur Ann Allergy Clin Immunol, V38, P10; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; Olsen AMS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054309; PICADO C, 1989, EUR RESPIR J, V2, P127; Prieto A, 2007, J ALLERGY CLIN IMMUN, V119, P960, DOI 10.1016/j.jaci.2006.12.616; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Santiago AV, 2003, ALLERGY, V58, P367; Schellenberg RR, 2001, NEW ENGL J MED, V345, P1856, DOI 10.1056/NEJM200112203452518; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 2009, CURR ALLERGY ASTHM R, V9, P155, DOI 10.1007/s11882-009-0023-4; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; UK Medicines and Healthcare products Regulatory Agency, SUMM PROD CHAR CELEC; Umemoto J, 2011, ALLERGY ASTHMA PROC, V32, P259, DOI 10.2500/aap.2011.32.3413; US Food and Drug Administration, SUMM PROD CHAR CELEB; Valero A, 2002, ALLERGY, V57, P1214, DOI 10.1034/j.1398-9995.2002.23893_6.x; Vally H, 2002, THORAX, V57, P569, DOI 10.1136/thorax.57.7.569; Vane J, 2000, THORAX, V55, pS3, DOI 10.1136/thorax.55.suppl_2.S3; Woessner KM, 2004, ANN ALLERG ASTHMA IM, V93, P339, DOI 10.1016/S1081-1206(10)61392-0; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201, DOI 10.1067/mai.2000.110926	40	47	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					40	+		10.1016/j.jaci.2013.10.057	http://dx.doi.org/10.1016/j.jaci.2013.10.057			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24388008				2022-12-18	WOS:000338930300006
J	van Zelm, MC; Bartol, SJW; Driessen, GJ; Mascart, F; Reisli, I; Franco, JL; Wolska-Kusnierz, B; Kanegane, H; Boon, L; van Dongen, JJM; van der Burg, M				van Zelm, Menno C.; Bartol, Sophinus J. W.; Driessen, Gertjan J.; Mascart, Francoise; Reisli, Ismail; Franco, Jose L.; Wolska-Kusnierz, Beata; Kanegane, Hirokazu; Boon, Louis; van Dongen, Jacques J. M.; van der Burg, Mirjam			Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD19; CD40L; somatic hypermutation; selection; immunoglobulin; autoreactivity	CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; DNA-POLYMERASE-ETA; HUMAN B-CELLS; GENE HYPERMUTATION; IMMUNOGLOBULIN; MICE; REPERTOIRE; MUTATIONS; IG	Background: Individuals with genetic defects in CD40 ligand (CD40L) or B-cell antigen receptor coreceptor molecules CD19 and CD81 suffer from an antibody deficiency. Still, these patients carry low levels of memory B cells and serum antibodies. Objective: We sought to assess why the remaining memory B cells and antibodies in the blood of these patients do not provide functional immunity. Methods: We included CD19-deficient patients (n = 8), CD40L-deficient patients (n = 8), and healthy controls (n = 50) to perform detailed flow cytometry on blood B cells, molecular analysis of IgA and IgG transcripts, as well as functional analysis of B-cell activation. Results: CD19-deficient and CD40L-deficient patients carried reduced numbers of all memory B-cell subsets except CD27(-) IgA(+) B cells. Their immunoglobulin heavy chain class-switched transcripts contained less somatic mutations and reduced usage of IgM-distal IgG2 and IgA2 subclasses. The selection strength of mutations for antigen binding was significantly lower than in controls, whereas selection to maintain superantigen binding was normal. Furthermore, the patients showed impaired selection against inherently autoreactive properties of their immunoglobulins. Somatic hypermutation analysis revealed decreased activation-induced cytidine deaminase and uracil-DNA glycosylase 2 activity in CD40L deficiency and increased uracil-DNA glycosylase 2 but decreased mismatch repair in CD19 deficiency. B-cell activation studies revealed that this was at least in part due to transcriptional regulation of DNA repair genes. Conclusions: This study on CD19 and CD40L deficiencies illustrates that both the B-cell antigen receptor and CD40 signaling pathways are required for the selection of immunoglobulin reactivity. Still, they differentially mediate DNA repair pathways during somatic hypermutation, thereby together shaping the human in vivo antigen-experienced B-cell repertoire.	[van Zelm, Menno C.; Bartol, Sophinus J. W.; Driessen, Gertjan J.; van Dongen, Jacques J. M.; van der Burg, Mirjam] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Driessen, Gertjan J.] Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Mascart, Francoise] Univ Libre Brussels, Hop Erasme, Immunobiol Clin, B-1070 Brussels, Belgium; [Mascart, Francoise] Univ Libre Brussels, Lab Vaccinol & Mucosal Immun, Brussels, Belgium; [Reisli, Ismail] Necmettin Erbakan Univ, Dept Pediat Immunol & Allergy, Meram Med Fac, Konya, Turkey; [Franco, Jose L.] Univ Antioquia, Grp Primary Immunodeficiencies, Medellin, Colombia; [Wolska-Kusnierz, Beata] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pediat, Toyama 930, Japan; [Boon, Louis] Bioceros BV, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Necmettin Erbakan University; Selcuk University; Universidad de Antioquia; Children's Memorial Health Institute; University of Toyama; Bioceros B.V.	van Zelm, MC (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Unit Mol Immunol, Dept Immunol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.vanzelm@erasmusmc.nl	van Zelm, Menno C/O-4404-2015; FRANCO, JOSE/AAK-1590-2020; Driessen, Gertjan/AAI-9711-2020; Boon, Laurence/HCI-3629-2022; van Dongen, Jacques J.M./F-8537-2015	van Zelm, Menno C/0000-0003-4161-1919; FRANCO, JOSE/0000-0001-5664-6415; van Dongen, Jacques J.M./0000-0001-7686-0021; van Dongen, Jacques J.M./0000-0002-3650-7087; Boon, Louis/0000-0002-0937-9171; Wolska-Kusnierz, Beata/0000-0003-4863-4443	Erasmus University Rotterdam (EUR-Fellowship); ZonMW Vidi grant [015.008.046]	Erasmus University Rotterdam (EUR-Fellowship); ZonMW Vidi grant	This work was supported by a grant from Erasmus University Rotterdam (EUR-Fellowship) to M.C.v.Z., and ZonMW Vidi grant 015.008.046 to M.v.d.B.	Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; Artac H, 2010, GENES IMMUN, V11, P523, DOI 10.1038/gene.2010.22; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; Delbos F, 2007, J EXP MED, V204, P17, DOI 10.1084/jem.20062131; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Foote LC, 1996, J IMMUNOL, V157, P2749; Gardes P, 2012, J IMMUNOL, V188, P2023, DOI 10.4049/jimmunol.1102984; Goodyear CS, 2003, J EXP MED, V197, P1125, DOI 10.1084/jem.20020552; Gourzi P, 2007, J EXP MED, V204, P259, DOI 10.1084/jem.20061801; Graille M, 2000, P NATL ACAD SCI USA, V97, P5399, DOI 10.1073/pnas.97.10.5399; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Kanegane H, 2007, GENES IMMUN, V8, P663, DOI 10.1038/sj.gene.6364431; KRISTIANSEN SV, 1994, J IMMUNOL, V153, P2974; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Liu M, 2009, TRENDS IMMUNOL, V30, P173, DOI 10.1016/j.it.2009.01.007; Longo NS, 2009, BLOOD, V113, P3706, DOI 10.1182/blood-2008-10-183632; Meyers G, 2011, P NATL ACAD SCI USA, V108, P11554, DOI 10.1073/pnas.1102600108; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Potter KN, 2002, J IMMUNOL, V169, P3777, DOI 10.4049/jimmunol.169.7.3777; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Rao SP, 1999, J IMMUNOL, V163, P2732; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Roa S, 2008, P NATL ACAD SCI USA, V105, P16248, DOI 10.1073/pnas.0808182105; Saribasak H, 2012, SEMIN IMMUNOL, V24, P287, DOI 10.1016/j.smim.2012.05.002; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Srinivasan L, 2009, CELL, V139, P573, DOI 10.1016/j.cell.2009.08.041; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; SUZUKI I, 1995, J IMMUNOL, V154, P3902; Uduman M, 2011, NUCLEIC ACIDS RES, V39, pW499, DOI 10.1093/nar/gkr413; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2011, HUM MOL GENET, V20, P1854, DOI 10.1093/hmg/ddr068; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Wilson TM, 2005, J EXP MED, V201, P637, DOI 10.1084/jem.20042066; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; Yavuz S, 2002, J IMMUNOL, V169, P3825, DOI 10.4049/jimmunol.169.7.3825; Yu KF, 2002, J BIOL CHEM, V277, P5040, DOI 10.1074/jbc.M109772200	50	47	47	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					135	+		10.1016/j.jaci.2013.11.015	http://dx.doi.org/10.1016/j.jaci.2013.11.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24418477				2022-12-18	WOS:000338930300018
J	Uysal, P; Eller, E; Mortz, CG; Bindslev-Jensen, C				Uysal, Pinar; Eller, Esben; Mortz, Charlotte G.; Bindslev-Jensen, Carsten			An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Uysal, Pinar] Univ Southern Denmark, Dept Dermatol, DK-5000 Odense C, Denmark; Univ Southern Denmark, Allergy Ctr, Odense Res Ctr Anaphylaxis, Odense Univ Hosp, DK-5000 Odense C, Denmark	University of Southern Denmark; University of Southern Denmark; Odense University Hospital	Uysal, P (corresponding author), Univ Southern Denmark, Dept Dermatol, DK-5000 Odense C, Denmark.	carsten.bindslev-Jensen@rsyd.dk	Bindslev-Jensen, Carsten/H-1877-2011	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Mortz, Charlotte G/0000-0001-8710-0829; Uysal, Pinar/0000-0003-0288-608X				Altman MC, 2013, NEW ENGL J MED, V368, P2528, DOI 10.1056/NEJMc1305687; Bindslev-Jensen C, 2010, ALLERGY, V65, P138, DOI 10.1111/j.1398-9995.2009.02188.x; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Tan RA, 2011, EXPERT OPIN DRUG SAF, V10, P463, DOI 10.1517/14740338.2011.563840; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	9	47	50	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					914	915		10.1016/j.jaci.2013.10.015	http://dx.doi.org/10.1016/j.jaci.2013.10.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24360324				2022-12-18	WOS:000332397600046
J	Mueller, GA; Pedersen, LC; Lih, FB; Glesner, J; Moon, AF; Chapman, MD; Tomer, KB; London, RE; Pomes, A				Mueller, Geoffrey A.; Pedersen, Lars C.; Lih, Fred B.; Glesner, Jill; Moon, Andrea F.; Chapman, Martin D.; Tomer, Kenneth B.; London, Robert E.; Pomes, Anna			The novel structure of the cockroach allergen Bla g 1 has implications for allergenicity and exposure assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; asthma; Bla g 1; cockroach; structure; ligand-binding proteins; exposure assessment	INNER-CITY CHILDREN; GREEN FLUORESCENT PROTEIN; MAJOR HUMAN ALLERGEN; AMERICAN COCKROACH; BLATTELLA-GERMANICA; INDOOR ALLERGENS; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; GENE-EXPRESSION; ASTHMA	Background: Sensitization to cockroach allergens is a major risk factor for asthma. The cockroach allergen Bla g 1 has multiple repeats of approximately 100 amino acids, but the fold of the protein and its biological function are unknown. Objective: We sought to determine the structure of Bla g 1, investigate the implications for allergic disease, and standardize cockroach exposure assays. Methods: nBla g 1 and recombinant constructs were compared by using ELISA with specific murine IgG and human IgE. The structure of Bla g 1 was determined by x-ray crystallography. Mass spectrometry and nuclear magnetic resonance spectroscopy were used to examine the ligand-binding properties of the allergen. Results: The structure of an rBla g 1 construct with comparable IgE and IgG reactivity to the natural allergen was solved by x-ray crystallography. The Bla g 1 repeat forms a novel fold with 6 helices. Two repeats encapsulate a large and nearly spherical hydrophobic cavity, defining the basic structural unit. Lipids in the cavity varied depending on the allergen origin. Palmitic, oleic, and stearic acids were associated with nBla g 1 from cockroach frass. One unit of Bla g 1 was equivalent to 104 ng of allergen. Conclusions: Bla g 1 has a novel fold with a capacity to bind various lipids, which suggests a digestive function associated with nonspecific transport of lipid molecules in cockroaches. Defining the basic structural unit of Bla g 1 facilitates the standardization of assays in absolute units for the assessment of environmental allergen exposure.	[Mueller, Geoffrey A.; Pedersen, Lars C.; Lih, Fred B.; Moon, Andrea F.; Tomer, Kenneth B.; London, Robert E.] NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; [Glesner, Jill; Chapman, Martin D.; Pomes, Anna] Indoor Biotechnol, Charlottesville, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); INDOOR Biotechnologies	Mueller, GA (corresponding author), NIEHS, 111 TW Alexander Dr,MD MR 01, Res Triangle Pk, NC 27709 USA.	Mueller3@niehs.nih.gov	Mueller, Geoffrey A/I-2909-2017; London, Robert E/F-7990-2019; Pedersen, Lars/C-6173-2019; Pomés, Anna/H-7010-2019	Mueller, Geoffrey A/0000-0001-8361-5323; London, Robert E/0000-0001-9108-8463; Pedersen, Lars/0000-0002-4488-4077; Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632	Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health [Z01-ES102885-01, Z01-ES50161, ZIA-ES102645]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI077653]; US department of Energy, Basic Energy Sciences, Office of Science [W-31-109-Eng-38]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050161, ZIAES102645, ZIAES102906] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US department of Energy, Basic Energy Sciences, Office of Science(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by Research Project no. Z01-ES102885-01 to R.E.L., Z01-ES50161 to K.B.T., and ZIA-ES102645 to L.C.P. in the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health. Research reported in this publication was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award no. R01AI077653 (to A.P. and M.D.C.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Use of the Advanced Photon Source, Argonne National Laboratory, was supported by the US department of Energy, Basic Energy Sciences, Office of Science, under contract no. W-31-109-Eng-38.	Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; Diraphat P, 2003, ASIAN PAC J ALLERGY, V21, P11; Dostalova A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-223; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fischer HM, 2008, MOL BIOL EVOL, V25, P809, DOI 10.1093/molbev/msn014; FOLCH J, 1957, J BIOL CHEM, V226, P497; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gore JC, 2007, ANNU REV ENTOMOL, V52, P439, DOI 10.1146/annurev.ento.52.110405.091313; Gore JC, 2005, MED VET ENTOMOL, V19, P127, DOI 10.1111/j.0269-283X.2005.00550.x; Gore JC, 2004, J MED ENTOMOL, V41, P953, DOI 10.1603/0022-2585-41.5.953; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Huang SR, 2012, J LIPID RES, V53, P2002, DOI 10.1194/jlr.D029546; Jimenez-Morales D, 2012, EUR BIOPHYS J BIOPHY, V41, P449, DOI 10.1007/s00249-012-0798-4; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Moon AF, 2010, PROTEIN SCI, V19, P901, DOI 10.1002/pro.368; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mueller GA, 2011, ALLERGY, V66, P878, DOI 10.1111/j.1398-9995.2010.02532.x; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Nolan T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016471; Oseroff C, 2012, J IMMUNOL, V189, P679, DOI 10.4049/jimmunol.1200694; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patterson ML, 2002, CLIN EXP ALLERGY, V32, P721, DOI 10.1046/j.1365-2222.2002.01397.x; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pomes A, 2007, PROTEIN PEPTIDE LETT, V14, P960, DOI 10.2174/092986607782541178; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Shao L, 2005, INSECT BIOCHEM MOLEC, V35, P947, DOI 10.1016/j.ibmb.2005.03.012; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Suazo A, 2009, INSECT MOL BIOL, V18, P727, DOI 10.1111/j.1365-2583.2009.00912.x; Suzuki N, 2010, ACTA CRYSTALLOGR D, V66, P1059, DOI 10.1107/S0907444910032944; Tsai WJ, 2003, J IMMUNOL METHODS, V276, P163, DOI 10.1016/S0022-1759(03)00105-4; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Wittstock U, 2004, P NATL ACAD SCI USA, V101, P4859, DOI 10.1073/pnas.0308007101; Wu CH, 2002, MOL IMMUNOL, V39, P459, DOI 10.1016/S0161-5890(02)00145-1; Yang CY, 2000, BBA-GENE STRUCT EXPR, V1517, P153, DOI 10.1016/S0167-4781(00)00235-9; Zwart Peter H., 2008, V426, P419, DOI 10.1007/978-1-60327-058-8_28	60	47	48	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1420	+		10.1016/j.jaci.2013.06.014	http://dx.doi.org/10.1016/j.jaci.2013.06.014			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23915714	Green Accepted			2022-12-18	WOS:000327538200021
J	Colice, G; Martin, RJ; Israel, E; Roche, N; Barnes, N; Burden, A; Polos, P; Dorinsky, P; Hillyer, EV; Lee, AJ; Chisholm, A; von Ziegenweidt, J; Barion, F; Price, D				Colice, Gene; Martin, Richard J.; Israel, Elliot; Roche, Nicolas; Barnes, Neil; Burden, Anne; Polos, Peter; Dorinsky, Paul; Hillyer, Elizabeth V.; Lee, Amanda J.; Chisholm, Alison; von Ziegenweidt, Julie; Barion, Francesca; Price, David			Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma control; beclomethasone dipropionate; extrafine particle; fluticasone propionate; observational study; United States	SMALL AIRWAYS; HYDROFLUOROALKANE-134A BECLOMETHASONE; INHALED CORTICOSTEROIDS; HFA-BECLOMETHASONE; PERSISTENT ASTHMA; LUNG DEPOSITION; DOSE-RESPONSE; PARTICLE-SIZE; DIPROPIONATE; PROPIONATE	Background: Characteristics of inhaled corticosteroids (ICSs) differ, but data comparing the real-life effectiveness of various ICSs for asthma are lacking. Objective: We sought to compare real-life asthma outcomes and costs of extrafine hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pressurized metered-dose inhaler. Methods: This retrospective matched cohort study examined database markers of asthma control from a large US longitudinal health care claims database over 1 baseline and 1 outcome year for 10,312 patients with asthma aged 12 to 80 years receiving their first ICS as HFA-beclomethasone or fluticasone and matched on baseline demographic characteristics and asthma severity. Results: Patients started on HFA-beclomethasone had significantly higher odds (adjusted odds ratio, 1.19; 95% CI; 1.08-1.31) of achieving overall control (risk and impairment), which was defined as no hospital attendance for asthma, oralcorticosteroids, or antibiotics for lower respiratory tract infection and less than 2 puffs per day of short-acting beta-agonist; they also experienced a lower rate of respiratory-related hospitalizations or referrals (adjusted rate ratio, 0.82; 95% CI, 0.73-0.93) than patients started on fluticasone. Other database outcome measures were similar in the 2 cohorts. Prescribed HFA-beclomethasone doses were lower (P <.001) than fluticasone doses (median, 320 mu g/d [interquartile range, 160320 mg/d] vs 440 mg/d [interquartile range, 176-440 mg/d]). Adjusted respiratory-related health care costs were significantly lower for HFA-beclomethasone than fluticasone (mean, $ 1869 [95% CI, $ 1727-$ 2032] vs $ 2259 [95% CI, $ 2111-$ 2404]), representing a mean annual savings of $ 390 (95% CI, $ 165$ 620) per patient prescribed HFA-beclomethasone rather than fluticasone. Conclusions: Asthma treatment outcomes were similar or better with HFA-beclomethasone prescribed at significantly lower doses and with lower costs than fluticasone.	[Colice, Gene] Washington Hosp Ctr, Washington, DC 20010 USA; [Colice, Gene] George Washington Univ, Sch Med, Washington, DC USA; [Martin, Richard J.] Natl Jewish Hlth, Denver, CO USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Israel, Elliot] Harvard Univ, Sch Med, Boston, MA USA; [Roche, Nicolas] Univ Paris 05, Hotel Dieu, AP HP, Paris, France; [Barnes, Neil] Barts Hlth NHS Trust, London Chest Hosp, London, England; [Burden, Anne; Hillyer, Elizabeth V.; Chisholm, Alison; von Ziegenweidt, Julie; Barion, Francesca; Price, David] Res Real Life, Cambridge, England; [Polos, Peter] I3 Global, Basking Ridge, NJ USA; [Dorinsky, Paul] Teva Global Resp Res & Dev, Horsham, PA USA; [Lee, Amanda J.] Univ Aberdeen, Med Stat Team, Aberdeen AB25 2ZD, Scotland; [Price, David] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen AB25 2ZD, Scotland	MedStar Washington Hospital Center; George Washington University; National Jewish Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Barts Health NHS Trust; University of London; Queen Mary University London; University of Aberdeen; University of Aberdeen	Price, D (corresponding author), Univ Aberdeen, Ctr Acad Primary Care, Polwarth Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland.	david@rirl.org	Roche, Nicolas/AAP-4445-2021; Price, David/H-2837-2019; Roche, Nicolas/AAE-9206-2021	Price, David/0000-0002-9728-9992; roche, nicolas/0000-0002-3162-5033; Hillyer, Elizabeth/0000-0003-3022-5692	Teva Pharmaceuticals Limited of Petach Tikva, Israel; Research in Real Life (RIRL); GlaxoSmithKline	Teva Pharmaceuticals Limited of Petach Tikva, Israel; Research in Real Life (RIRL); GlaxoSmithKline(GlaxoSmithKline)	Supported by Teva Pharmaceuticals Limited of Petach Tikva, Israel.; Disclosure of potential conflict of interest: G. Colice has been supported by one or more grants from Research in Real Life (RIRL); is a Board member for Merck, Ikana, Teva, MedImmune, and Dey; has consultancy arrangements with Teva, Prairie, and Dey; has provided expert testimony for Teva and Dey; has received one or more payments for lecturing from or is on the speakers' bureaus for Teva and Merck; and has received one or more payments for the development of educational presentations forCME Integrity. R. J. Martin has received support for travel from Teva; has consultancy arrangements with Merck, MedImmune, Graceway, Amgen, Sunovian, and Pearl; has received one or more grants from or has one or more grants pending with MedImmune and the National Heart, Lung, and Blood Institute; has received one or more payments for lecturing from or is on the speakers' bureaus for Merck, Graceway, and Genentech; and has received royalties from UpToDate. E. Israel has received one or more consulting fees or honoraria from, has received support for travel from, and has been provided with writing assistance, medicines, equipment, or administrative support by Teva; has consultancy arrangements with Abbott, Amgen, Cowen & Co, Infinity Pharmaceuticals, MedImmune (now AstraZeneca), Merck, newMentor, NKT Therapeutics, Ono Pharmaceuticals, Pulmatrix, Regeneron Pharmaceuticals, Schering Plough, Teva Specialty Pharmaceuticals, Agenzia Italiana del Farmico (AIFA), Gilead Sciences, and Johnson& Johnson; has provided expert testimony for Campbell, Campbell, Edwards & Conroy, Diedrich & Donohue, Ficksman & Conley, Gold & Gold, PA, Ryan Ryan Deluca LLP, and Sullway & Hollis; has received one or more grants from or has one or more grants pending with Aerovance, Amgen, i3 Research (Biota), Genentech, Icagen, MedImmune, and Novartis; has received one or more payments for lecturing fromor is on the speakers' bureau for Genentech, Novartis, and Merck; and has received royalties from UpToDate. N. Roche has received support for travel from Teva; is a Board member for Chiesi, GlaxoSmithKline, Novartis, Nycomed, Mundipharma, Almirall, and Boehringer; has consultancy arrangements with GlaxoSmithKline, Chiesi, Novartis, Boehringer, Mundipharma, and Nycomed; has received one or more grants from or has one or more grants pending with Boehringer Ingelheim, Novartis, and Pfizer; has received one or more payments for lecturing from or is on the speakers' bureaus for GlaxoSmithKline, Chiesi, Novartis, Boehringer Ingelheim, Pfizer, Nycomed, Mundipharma, MEDA, MSD, and Teva; and has received one or more payments for the development of educational presentations for Novartis and for Nycomed. N. Barnes has been supported by one or more grants from and has received one or more consulting fees or honoraria from Teva; is a Board member for GlaxoSmithKline, Chiesi, Teva, Nycomed, NAPP, Mundipharma, and Novartis; has consultancy arrangements with GlaxoSmithKline, Chiesi, Teva, Nycomed, NAPP, Pfizer, Mundipharma, Novartis, Merck Sharp & Dohme, and Sandoz; and has received one or more grants from or has one or more grants pending with AstraZeneca and Novartis. A. Burden has received support for travel from, has received one or more fees for participation from, and has received one or more payments for writing or reviewing fromTeva and has received one ormore payments for manuscript preparation from Mundipharma, Teva, GlaxoSmithKline, Chiesi, Orion, Novartis, and Aerocrine. P. Dorinsky was a full-time employee of Teva at the time this work was conducted. E. V.; Hillyer has received one or more consulting fees or honoraria from, has received one or more payments for writing or reviewing from, and has consultancy arrangements with RIRL; has received support for travel from Teva; and has received one or more payments for manuscript preparation from Merck, Teva France, and Aerocrine. A. J. Lee has received one or more consulting fees or honoraria from RIRL. A. Chisholm has received support for travel from, has received one ormore fees for participation from, and has received one or more payments for writing or reviewing from Teva. J. von Ziegenweidt has received support for travel from, has received one or more fees for participation from, and has received one or more payments for writing or reviewing from Teva and has received one or more payments for manuscript preparation fromMundipharma, Teva, GlaxoSmithKline, Orion, Chiesi, Novartis, and Aerocrine. F. Barion has received support for travel from, has received one or more fees for participation from, and has received one or more payments for writing or reviewing from Teva and has received one or more payments for manuscript preparation from Teva and from Almirall. D. Price has been supported by one or more grants from, has received support for travel from, has received one or more fees for participation from, and has been provided with writing assistance, medicines, equipment, or administrative support by Teva; is a Board member for Almirral, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz, and Teva; has consultancy arrangements with Almirral, Astra Zeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Medapharma, Novartis, Napp, Nycomed, Pfizer, Sandoz, and Teva; has received one or more grants from or has one or more grants pending with the UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Orion, Pfizer, and Teva; has received one or more payments for lecturing from or is on the speakers' bureaus for Almirral, AstraZeneca, Activaero, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Novartis, Merck, Mundipharma, Pfizer, and Teva; has received one or more payments for manuscript preparation from Mundipharma, Teva, Merck Sharp and Dohme; has one or more patents (planned, pending, or issued) with AKL Ltd; has received one ormore payments for the development of educational presentations for GlaxoSmithKline; owns stock/stock options in AKL Ltd and is an owner of RIRL (80%); and has received one or more payments for travel/accommodations/ meeting expenses from Mundipharma, Napp, Novartis and Boehringer Ingelheim. P. Polos declares that he has no relevant conflicts of interest.	Akinbami Lara J, 2012, NCHS Data Brief, P1; Akinbami LJ, 2012, J ALLERGY CLIN IMMUN, V129, pS49, DOI 10.1016/j.jaci.2011.12.984; Anderson WJ, 2012, ANN ALLERG ASTHMA IM, V109, P185, DOI 10.1016/j.anai.2012.06.022; Aubier M, 2001, RESP MED, V95, P212, DOI 10.1053/rmed.2000.1025; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benjamini Y, 1999, RPSOR993 TEL AV U DE; Black PN, 2000, EUR J CLIN PHARMACOL, V56, P431, DOI 10.1007/s002280000140; Broder MS, 2010, AM J MANAG CARE, V16, P170; BROOKS CM, 1994, MED CARE, V32, P298, DOI 10.1097/00005650-199403000-00008; Burgel PR, 2011, EUR RESPIR REV, V20, P23, DOI 10.1183/09059180.00010410; Cohen J, 2011, EUR RESPIR J, V37, P532, DOI 10.1183/09031936.00204109; Derendorf H, 2006, EUR RESPIR J, V28, P1042, DOI 10.1183/09031936.00074905; Erickson SR, 2001, ANN PHARMACOTHER, V35, P997, DOI 10.1345/aph.10379; Fairfax A, 2001, ANN ALLERG ASTHMA IM, V86, P575, DOI 10.1016/S1081-1206(10)62907-9; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Gentile DA, 2010, CURR OPIN PHARMACOL, V10, P260, DOI 10.1016/j.coph.2010.06.001; Hall Jason, 2003, N Z Med J, V116, pU563; Harrison LI, 1999, J PHARM PHARMACOL, V51, P263, DOI 10.1211/0022357991772439; Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039; Ivanova JI, 2008, AM J MANAG CARE, V14, P801; Kozyrskyj AL, 2006, PEDIATRICS, V117, pE1104, DOI 10.1542/peds.2005-2443; Krishnan JA, 2011, J ALLERGY CLIN IMMUN, V127, P123, DOI 10.1016/j.jaci.2010.08.032; Lasserson TJ, 2010, COCHRANE DB SYST REV; Lawrence M, 1997, AM J RESP CRIT CARE, V156, P744, DOI 10.1164/ajrccm.156.3.9608058; Leach CL, 2012, ANN ALLERG ASTHMA IM, V108, P195, DOI 10.1016/j.anai.2012.01.010; Leach CL, 2005, J AEROSOL MED, V18, P379, DOI 10.1089/jam.2005.18.379; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma, 2007, 3 NAT ASTHM ED PREV; Price D, 2011, CURR ALLERGY ASTHM R, V11, P526, DOI 10.1007/s11882-011-0222-7; Price D, 2010, J ALLERGY CLIN IMMUN, V126, P511, DOI 10.1016/j.jaci.2010.06.040; Rawlins MD, 2008, HARVEIAN ORATION; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Schatz M, 2011, J ALLERGY CLIN IMMUN, V128, P273, DOI 10.1016/j.jaci.2011.03.027; Schirm E, 2006, BRIT J CLIN PHARMACO, V62, P383, DOI 10.1111/j.1365-2125.2006.02699.x; Turner S, 2009, ARCH DIS CHILD, V94, P16, DOI 10.1136/adc.2008.140681; van Aalderen WMC, 2007, RESP MED, V101, P1585, DOI 10.1016/j.rmed.2006.11.020; Vanderweil SG, 2008, ACAD EMERG MED, V15, P736, DOI 10.1111/j.1553-2712.2008.00167.x; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Wilson AM, 1999, BRIT J CLIN PHARMACO, V48, P579	41	47	50	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					45	U102		10.1016/j.jaci.2013.02.008	http://dx.doi.org/10.1016/j.jaci.2013.02.008			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23591272	Bronze			2022-12-18	WOS:000321052300005
J	Johansson, SGO; Adedoyin, J; van Hage, M; Gronneberg, R; Nopp, A				Johansson, S. G. O.; Adedoyin, Justus; van Hage, Marianne; Gronneberg, Reidar; Nopp, Anna			False-positive penicillin immunoassay: An unnoticed common problem	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGEN THRESHOLD-SENSITIVITY		[Johansson, S. G. O.; Adedoyin, Justus; van Hage, Marianne; Nopp, Anna] Karolinska Univ Hosp & Inst, Clin Immunol & Allergy Unit, Dept Med, Stockholm, Sweden; [Gronneberg, Reidar] Karolinska Univ Hosp & Inst, Resp Med Unit, Dept Med, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Johansson, SGO (corresponding author), Karolinska Univ Hosp & Inst, Clin Immunol & Allergy Unit, Dept Med, Stockholm, Sweden.	s.g.o.johansson@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Nopp, Anna/0000-0003-1389-8676				BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; Dahlen B, 2011, CLIN EXP ALLERGY, V41, P1091, DOI 10.1111/j.1365-2222.2011.03763.x; Johansson SGO, 2010, ALLERGY, V65, P124, DOI 10.1111/j.1398-9995.2009.02191.x; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; SABELLI HC, 1995, J NEUROPSYCH CLIN N, V7, P6; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; SHAPIRO S, 1969, LANCET, V2, P969; Vervloet D, 2009, DRUG ALLERGY	9	47	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					235	237		10.1016/j.jaci.2012.11.017	http://dx.doi.org/10.1016/j.jaci.2012.11.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23270810				2022-12-18	WOS:000321052300036
J	Kohler, M; Sandberg, A; Kjellqvist, S; Thomas, A; Karimi, R; Nyren, S; Eklund, A; Thevis, M; Skold, CM; Wheelock, AM				Kohler, Maxie; Sandberg, AnnSofi; Kjellqvist, Sanela; Thomas, Andreas; Karimi, Reza; Nyren, Sven; Eklund, Anders; Thevis, Mario; Skold, C. Magnus; Wheelock, Asa M.			Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; alveolar macrophage; proteomics; multivariate modeling; gender; difference gel electrophoresis; bronchoalveolar lavage	SEX-DIFFERENCES; SMOKERS; COPD; IDENTIFICATION; PATHOGENESIS; BIOMARKERS; DISCOVERY; EMPHYSEMA; AUTOPHAGY; DEPLETION	Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and is increasing, primarily among women. Underdiagnosis is common, and because of the heterogeneous disease characteristics, molecular markers of specific disease phenotypes and more efficacious treatment regimens are urgently needed. Objective: In this study the soluble proteome of bronchoalveolar lavage cells, primarily consisting of macrophages, was investigated with the aim of identifying phenotypic differences in early disease development. Methods: Two-dimensional difference gel electrophoresis was used for relative quantification of protein levels, and multivariate modeling was applied to identify proteins of interest that were subsequently identified by means of liquid chromatography-mass spectrometry. Results: Significant gender differences were unveiled, with numerous alterations in the bronchoalveolar lavage cell proteome occurring in female but not male patients with COPD. Specifically, a subset of 19 proteins provided classification of female healthy smokers from female patients with COPD with 78% predictive power. Subsequent pathway analyses linked the observed alterations to downregulation of the lysosomal pathway and upregulation of the oxidative phosphorylation pathway, possibly linking dysregulation of macroautophagy to a female-dominated COPD disease phenotype. Conclusion: This investigation makes an important contribution to the elucidation of putative molecular mechanisms underlying gender-based differences in the pathophysiology of COPD, linking alterations of specific molecular pathways to previously observed gender differences in clinical COPD phenotypes. Furthermore, these results stress the importance of the gender-specific search for biomarkers, diagnosis, and treatment in COPD. (J Allergy Clin Immunol 2013;131:743-51.)	[Kohler, Maxie; Sandberg, AnnSofi; Karimi, Reza; Nyren, Sven; Eklund, Anders; Skold, C. Magnus; Wheelock, Asa M.] Karolinska Inst, Resp Med Unit, Dept Med Solna, Ctr Mol Med,Univ Hosp, S-17176 Stockholm, Sweden; [Kjellqvist, Sanela] Karolinska Univ Hosp, Ctr Mol Med, Atherosclerosis Res Unit, Stockholm, Sweden; [Thevis, Mario] German Sport Univ Cologne, Ctr Prevent Doping Res, Inst Biochem, Cologne, Germany	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; German Sport University Cologne; University of Cologne	Wheelock, AM (corresponding author), Karolinska Inst, Resp Med Unit, Dept Med, Lung Res Lab L4 01, S-17176 Stockholm, Sweden.	maxie.kohler@uni-koeln.de; asa.wheelock@ki.se	Thomas, Andreas/AAA-3222-2019; Wheelock, Åsa/B-7904-2017; Thomas, Andreas/AAL-7574-2020	Thomas, Andreas/0000-0003-1199-0743; Wheelock, Åsa/0000-0002-8013-2745; Nyren, Sven/0000-0003-3586-8785	Swedish Heart-Lung Foundation; Swedish Foundation for Strategic Research (SSF); VINNOVA (VINN-MER); EU Fp6 Marie Curie; King Oscar II Jubilee Foundation; Mats Kleeberg Foundation, King Gustaf V's; Queen Victoria's Freemasons Foundation; Hesselman's Foundation; Stockholm County Council; Karolinska Institutet; AFA Insurances; Swedish Research Council; Swedish Heart Lung Foundation	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Foundation for Strategic Research (SSF)(Swedish Foundation for Strategic Research); VINNOVA (VINN-MER)(Vinnova); EU Fp6 Marie Curie(European Commission); King Oscar II Jubilee Foundation; Mats Kleeberg Foundation, King Gustaf V's; Queen Victoria's Freemasons Foundation; Hesselman's Foundation; Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); AFA Insurances; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation)	Supported by the Swedish Heart-Lung Foundation, the Swedish Foundation for Strategic Research (SSF), VINNOVA (VINN-MER), EU Fp6 Marie Curie, the Karolinska Institutet, AFA Insurances for financial support, the King Oscar II Jubilee Foundation, the Mats Kleeberg Foundation, King Gustaf V's, and Queen Victoria's Freemasons, and Hesselman's Foundations, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council, and the Karolinska Institutet.; Disclosure of potential conflict of interest: M. Kohler has received grants from the Karolinska Institutet and AFA Insurances. S. Kjellqvist has received grants from the Swedish Research Council. A. Eklund has received grants from the Swedish Heart Lung Foundation. A. M. Wheelock has received grants from the Swedish Heart Lung Foundation, the Swedish Foundation for Strategic Research, VINNOVA, EU Fp6 Marie Curie, and the King Oscar II Jubilee Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2005, USERS GUIDE PRINCIPA; Apweiler R, 2011, NUCLEIC ACIDS RES, V39, pD214, DOI 10.1093/nar/gkq1020; Barnes Peter J, 2004, COPD, V1, P59, DOI 10.1081/COPD-120028701; Camp PG, 2009, CHEST, V136, P1480, DOI 10.1378/chest.09-0676; Casado B, 2011, EXPERT REV CLIN IMMU, V7, P111, DOI [10.1586/eci.10.75, 10.1586/ECI.10.75]; Chen H, 2010, J PROTEOME RES, V9, P2798, DOI 10.1021/pr100063r; de Torres JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016021; Decramer M, 2005, RESP MED, V99, pS3, DOI 10.1016/j.rmed.2005.09.010; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dransfield MT, 2006, RESP MED, V100, P1110, DOI 10.1016/j.rmed.2005.09.019; EKLUND A, 1986, THORAX, V41, P629, DOI 10.1136/thx.41.8.629; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gan WQ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-52; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.3.CO;2-Y; Green HJ, 2008, AM J PHYSIOL-REG I, V295, pR935, DOI 10.1152/ajpregu.00167.2008; Grydeland TB, 2009, EUR RESPIR J, V34, P858, DOI 10.1183/09031936.00167908; Haspel JA, 2011, AM J RESP CRIT CARE, V184, P1237, DOI 10.1164/rccm.201106-0966CI; Hu RC, 2011, RESPIROLOGY, V16, P983, DOI 10.1111/j.1440-1843.2011.01993.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jain E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-136; Jain NK, 2011, LUNG INDIA, V28, P258, DOI 10.4103/0970-2113.85686; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Larsson S, 2011, INT J CHRONIC OBSTR, V6, P83, DOI 10.2147/COPD.S15351; Lee EJ, 2009, CHEST, V135, P344, DOI 10.1378/chest.08-1583; Lofdahl JM, 2006, CLIN EXP IMMUNOL, V145, P428, DOI 10.1111/j.1365-2249.2006.03154.x; Lofdahl JM, 2005, EUR RESPIR J, V25, P275, DOI 10.1183/09031936.05.00033504; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; Magi B, 2006, PROTEOMICS, V6, P6354, DOI 10.1002/pmic.200600303; Martinez FJ, 2007, AM J RESP CRIT CARE, V176, P243, DOI 10.1164/rccm.200606-828OC; Mathers CD, 2009, BRIT MED BULL, V92, P7, DOI 10.1093/bmb/ldp028; Monick MM, 2010, J IMMUNOL, V185, P5425, DOI 10.4049/jimmunol.1001603; Morjaria JB, 2010, DRUG DISCOV TODAY, V15, P396, DOI 10.1016/j.drudis.2010.03.001; Nicholas BL, 2009, COPD, V6, P298, DOI 10.1080/15412550903049140; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ohar J, 2011, PRIM CARE RESP J, V20, P370, DOI 10.4104/pcrj.2011.00070; Ohlmeier S, 2012, J PROTEOME RES, V11, P599, DOI 10.1021/pr2006395; Plymoth A, 2007, CLIN CHEM, V53, P636, DOI 10.1373/clinchem.2006.076075; RENNARD SI, 1990, AM REV RESPIR DIS, V141, P208, DOI 10.1164/ajrccm/141.1.208; Schildge J, 2007, RESPIRATION, V74, P553, DOI 10.1159/000102890; Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473; Silva E, 2010, J PROTEOME RES, V9, P1522, DOI 10.1021/pr9010298; Sorheim IC, 2010, THORAX, V65, P480, DOI 10.1136/thx.2009.122002; Stockley Robert A, 2009, Proc Am Thorac Soc, V6, P524, DOI 10.1513/pats.200904-016DS; STOCKS J, 1995, EUR RESPIR J, V8, P492, DOI 10.1183/09031936.95.08030492; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tewari AK, 2011, PROTEOMICS, V11, P2051, DOI 10.1002/pmic.201000159; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Verhage TL, 2011, CLIN NUTR, V30, P332, DOI 10.1016/j.clnu.2010.09.013; Vermeeren MAP, 2006, RESP MED, V100, P1349, DOI 10.1016/j.rmed.2005.11.023; Verrills NM, 2011, AM J RESP CRIT CARE, V183, P1633, DOI 10.1164/rccm.201010-1623OC; Waldburg N, 2004, PATHOL RES PRACT, V200, P147, DOI 10.1016/j.prp.2004.02.006; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6; York TP, 2010, BIOMARKERS, V15, P367, DOI 10.3109/13547501003789901	57	47	48	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					743	+		10.1016/j.jaci.2012.09.024	http://dx.doi.org/10.1016/j.jaci.2012.09.024			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23146379	Bronze			2022-12-18	WOS:000315587800016
J	Jacobs, RL; Harper, N; He, WJ; Andrews, CP; Rather, CG; Ramirez, DA; Ahuja, SK				Jacobs, Robert L.; Harper, Nathan; He, Weijing; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.; Ahuja, Sunil K.			Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic diseases; environmental chamber; ragweed; endotypes	VALIDATION; NASAL; RHINITIS; ASTHMA; ONSET; UNIT	Background: The level of concordance between allergic symptoms induced on exposure to pollen in a pollen challenge chamber (PCC) versus the natural season is unknown. Objective: We sought to test the hypothesis that the symptom levels of allergic rhinoconjunctivitis elicited after out-of-season exposure to short ragweed in a PCC and during the natural season for giant ragweed pollen are highly correlated. Methods: Thirty-one ragweed-sensitive participants recorded symptoms for 15 days during the natural giant ragweed season in San Antonio, Texas. Twenty-six of these participants were challenged to short ragweed pollen in a PCC for 3 hours per day for up to 4 days. Results: In the PCC participants were dichotomized into those in whom low versus high levels of symptoms developed slowly or rapidly (ie, slow/low vs rapid/high). Each successive exposure visit associated with a progressive increase in symptom levels that approximated those experienced during the natural season. Hierarchic clustering identified 3 endotypes: endotypes I and II reflected concordantly low (n = 7) versus high (n = 14) total symptom scores (TSSs) in both the natural season and the PCC, respectively. Accordingly, the correlation between the TSSs recorded in the natural season and in the PCC for these 21 participants was very high. Although participants with endotype III (n = 5) had greater TSSs in the natural season than in the PCC, the degree of correlation between the TSSs remained high. Conclusions: Our findings affirm our hypothesis, underscore the high cross-reactivity between distinct pollens, and highlight the utility of the PCC to identify novel allergy endotypes that might have contrasting mechanistic underpinnings and potentially therapeutic responses. (J Allergy Clin Immunol 2012;130:122-7.)	[Jacobs, Robert L.; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.] Biogen Res Chamber LLC, San Antonio, TX 78229 USA; [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA; [Harper, Nathan; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Jacobs, RL (corresponding author), Biogen Res Chamber LLC, 8299 Fredericksburg Rd, San Antonio, TX 78229 USA.	robert.jacobs7025@sbcglobal.net		Andrews, Charles/0000-0002-8944-8404; Jacobs, Robert/0000-0002-2831-9086	Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome Clinical Scientist in Translational Research Award; Max and Minnie Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the South Texas Veterans Health Care System; National Institutes of Health	Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); Burroughs Wellcome Clinical Scientist in Translational Research Award; Max and Minnie Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the South Texas Veterans Health Care System; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	S.K.A. received support from the following grants: the Doris Duke Distinguished Clinical Scientist Award, the Burroughs Wellcome Clinical Scientist in Translational Research Award, the Max and Minnie Tomerlin Voelcker Scholar Award, and the Center for Personalized Medicine at the South Texas Veterans Health Care System.; Disclosure of potential conflict of interest: R. L. Jacobs is the owner of the Biogenics Research Chamber and Biogenics Research Institute. C. P. Andrews is a partner in the Biogenics Research Chamber and Director of Clinical Research at the Diagnostics Research Group. C. G. Rather is Executive Director of the Biogenics Research Chamber. D. A. Ramirez is a partner in the Biogenics Research Chamber. S. K. Ahuja has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Akerlund Anders, 2005, J Allergy Clin Immunol, V115, pS460, DOI 10.1016/j.jaci.2004.12.016; ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; BACON JR, 1981, J ALLERGY CLIN IMMUN, V67, P111, DOI 10.1016/0091-6749(81)90005-1; Badorrek P, 2011, ANN ALLERG ASTHMA IM, V106, P336, DOI 10.1016/j.anai.2010.12.018; Berkowitz RB, 2002, ANN ALLERG ASTHMA IM, V89, P38, DOI 10.1016/S1081-1206(10)61909-6; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Day JH, 2009, ALLERGY ASTHMA PROC, V30, P270, DOI 10.2500/aap.2009.30.3234; Day JH, 1999, ANN ALLERG ASTHMA IM, V83, P83, DOI 10.1016/S1081-1206(10)62616-6; Ellis AK, 2010, ANN ALLERG ASTHMA IM, V104, P293, DOI 10.1016/j.anai.2010.01.012; Everitt J.H., 2007, WEEDS S TEXAS NO MEX; Graif Y, 2006, CLIN EXP ALLERGY, V36, P1532, DOI 10.1111/j.1365-2222.2006.02589.x; Hashiguchi K, 2009, INT ARCH ALLERGY IMM, V149, P141, DOI 10.1159/000189197; Hohlfeld JM, 2010, CLIN EXP ALLERGY, V40, P998, DOI 10.1111/j.1365-2222.2010.03498.x; Jacobs RL, 2011, ANN ALLERG ASTHMA IM, V107, P133, DOI 10.1016/j.anai.2011.04.009; Kraft M, 2011, NEW ENGL J MED, V365, P1141, DOI 10.1056/NEJMe1108666; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; Patel D, 2007, ALLERGY ASTHMA PROC, V28, P592, DOI 10.2500/aap2007.28.3033; Ronborg SM, 1996, ALLERGY, V51, P82, DOI 10.1111/j.1398-9995.1996.tb00039.x	20	47	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					122	+		10.1016/j.jaci.2012.03.031	http://dx.doi.org/10.1016/j.jaci.2012.03.031			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22554707				2022-12-18	WOS:000306644800017
J	Jouvin, MH; Kinet, JP				Jouvin, Marie-Helene; Kinet, Jean-Pierre			Trichuris suis ova: Testing a helminth-based therapy as an extension of the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Hygiene hypothesis; helminth; Trichuris suis; peanut and tree nut allergy; mucosal immunity; immunomodulation; ES-62; clinical trial	NEMATODE SECRETED PRODUCT; PLACEBO-CONTROLLED TRIAL; HOOKWORM INFECTION; ALLERGIC DISEASE; RESPONSES; INFLAMMATION; IMMUNE; ES-62; ASTHMA; CELLS	The hygiene hypothesis, which was put forward more than 20 years ago by Strachan, proposes that the recent increase in allergic and autoimmune diseases is due to increasing hygiene standards. Since then, numerous epidemiologic and animal studies have provided support for this hypothesis and showed that certain microorganisms, helminths in particular, have immunomodulatory effects. More recently, studies have led to the identification of some of the mechanisms underlying these immunomodulatory effects. Substances, or crude extracts, produced by worms and responsible for these effects have been analyzed. Clinical trials have been performed mainly with pig whipworm, which was chosen because it is likely to be nonpathogenic in human subjects. Eggs of the pig whipworm (Trichuris suis ova) have been shown to be safe in multiple studies. Efficacy has been demonstrated in patients with inflammatory bowel diseases and in 1 case of pecan allergy. Altogether, this information supports further investigation of T suis ova in patients with immune-mediated diseases, particularly in areas in which there is currently no therapy, such as food allergy. (J Allergy Clin Immunol 2012;130:3-10.)	[Jouvin, Marie-Helene] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Jouvin, MH (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Allergy & Immunol, 330 Brookline Ave, Boston, MA 02215 USA.	mjouvin@bidmc.harvard.edu			Food Allergy Initiative (FAI)	Food Allergy Initiative (FAI)	M.-H. Jouvin has received research support from the Food Allergy Initiative (FAI) and support from Ovamed in the form of free supply of TSO for the food allergy study she conducted with J.-P. Kinet. J.-P. Kinet was on the Medical Advisory Board and has received research support from the FAI and received support from Ovamed in the form of free supply of TSO for the food allergy study he conducted with M.-H. Jouvin.	Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Al-Riyami L, 2009, J PARASITOL, V95, P1201, DOI 10.1645/GE-2017.1; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Bager P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022346; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BEER RJS, 1973, PARASITOLOGY, V67, P253, DOI 10.1017/S0031182000046497; BEER RJS, 1976, RES VET SCI, V20, P47, DOI 10.1016/S0034-5288(18)33478-7; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Broadhurst MJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001500; Cantacessi C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023590; Croft AM, 2012, COCHRANE LIB; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Daveson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017366; Elliott DE, 2007, INT J PARASITOL, V37, P457, DOI 10.1016/j.ijpara.2006.12.009; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Feary J, 2011, ALLERGY, V66, P569, DOI 10.1111/j.1398-9995.2010.02512.x; Feary J, 2009, CLIN EXP ALLERGY, V39, P1060, DOI 10.1111/j.1365-2222.2009.03187.x; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flohr C, 2010, CLIN EXP ALLERGY, V40, P131, DOI 10.1111/j.1365-2222.2009.03346.x; Flohr C, 2011, CURR PROBL DERMATOL, V41, P1, DOI 10.1159/000323290; Garcia LS, 1999, CLIN INFECT DIS, V29, P734, DOI 10.1086/520425; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Harnett W, 2006, PARASITE IMMUNOL, V28, P535, DOI 10.1111/j.1365-3024.2006.00893.x; Harnett W, 2006, CLIN EXP PHARMACOL P, V33, P511, DOI 10.1111/j.1440-1681.2006.04400.x; Harnett W, 2011, EXP PARASITOL; Harnett W, 2010, NAT REV IMMUNOL, V10, P278, DOI 10.1038/nri2730; Harnett W, 2009, ADV EXP MED BIOL, V666, P88; Hartmann S, 2009, CLIN EXP ALLERGY, V39, P1585, DOI 10.1111/j.1365-2222.2009.03290.x; Hepworth MR, 2010, J ALLERGY CLIN IMMUN, V125, P767, DOI 10.1016/j.jaci.2009.11.041; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Jackson JA, 2009, IMMUNOLOGY, V126, P18, DOI 10.1111/j.1365-2567.2008.03010.x; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Kradin RL, 2006, ARCH PATHOL LAB MED, V130, P718; Kuijk LM, 2012, MOL IMMUNOL, V51, P210, DOI 10.1016/j.molimm.2012.03.020; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007; Maizels RM, 2011, EXP PARASITOL; Melendez AJ, 2007, NAT MED, V13, P1375, DOI 10.1038/nm1654; Molehin AJ, 2012, PARASITOLOGY, V139, P681, DOI 10.1017/S0031182011002435; Newell EW, 2012, IMMUNITY, V36, P142, DOI 10.1016/j.immuni.2012.01.002; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Summers RW, 2010, J ALLERGY CLIN IMMUN, V125, P766, DOI 10.1016/j.jaci.2009.12.937; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI [10.1016/S0002-9270(03)00623-3, 10.1111/j.1572-0241.2003.07660.x]; Voldsgaard A, 2012, NEUROLOGY, V78; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wilson MS, 2010, EUR J IMMUNOL, V40, P1682, DOI 10.1002/eji.200939721; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Wright VJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000433	58	47	49	2	74	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					3	12		10.1016/j.jaci.2012.05.028	http://dx.doi.org/10.1016/j.jaci.2012.05.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22742834				2022-12-18	WOS:000306644800001
J	Martinez, CA; Shah, S; Shearer, WT; Rosenblatt, HM; Paul, ME; Chinen, J; Leung, KS; Kennedy-Nasser, A; Brenner, MK; Heslop, HE; Liu, H; Wu, MF; Hanson, IC; Krance, RA				Martinez, Caridad A.; Shah, Sweta; Shearer, William T.; Rosenblatt, Howard M.; Paul, Mary E.; Chinen, Javier; Leung, Kathryn S.; Kennedy-Nasser, Alana; Brenner, Malcolm K.; Heslop, Helen E.; Liu, Hao; Wu, Meng-Fen; Hanson, Imelda C.; Krance, Robert A.			Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; primary immunodeficiencies; bone marrow transplantation; graft-versus-host disease	BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; TERM-FOLLOW-UP; EUROPEAN EXPERIENCE; GENE-THERAPY; INFECTION; CHILDREN; PREVENT	Background: Matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a successful treatment for chronic granulomatous disease (CGD), but the safety and efficacy of HSCT from unrelated donors is less certain. Objective: We evaluated the outcomes and overall survival in patients with CGD after HSCT. Methods: We report the outcomes for 11 children undergoing HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children were boys, and the median age was 3.8 years (range, 1-13 years). We treated both X-linked (n = 9) and autosomal recessive (n = 2) disease. Nine children had serious clinical infections before transplantation. The conditioning regimens contained busulfan, cyclophosphamide, cytarabine, or fludarabine according to the donor used. All patients received alemtuzumab (anti-CD52 antibody). Additional graft-versus-host disease (GvHD) prophylaxis included cyclosporine and methotrexate for MUD recipients and cyclosporine and prednisone for MRD recipients. Results: Neutrophil recovery took a median of 16 days (range, 12-40 days) and 18 days (range, 13-24 days) for MRD and MUD recipients, respectively. Full donor neutrophil engraftment occurred in 9 patients, and 2 had stable mixed chimerism; all patients had sustained correction of neutrophil oxidative burst defect. Four patients had grade I skin acute GVHD responding to topical treatment. No patient had grade II to IV acute GvHD or chronic GvHD. All patients are alive between 1 and 8 years after HSCT. Conclusion: For CGD, equivalent outcomes can be obtained with MRD or MUD stem cells, and HSCT should be considered an early treatment option. (J Allergy Clin Immunol 2012; 129: 176-83.)	[Martinez, Caridad A.; Leung, Kathryn S.; Kennedy-Nasser, Alana; Brenner, Malcolm K.; Heslop, Helen E.; Krance, Robert A.] Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Martinez, Caridad A.; Leung, Kathryn S.; Kennedy-Nasser, Alana; Brenner, Malcolm K.; Heslop, Helen E.; Krance, Robert A.] Texas Childrens Hosp, Houston, TX 77030 USA; [Martinez, Caridad A.; Leung, Kathryn S.; Kennedy-Nasser, Alana; Brenner, Malcolm K.; Heslop, Helen E.; Krance, Robert A.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Shah, Sweta; Shearer, William T.; Paul, Mary E.; Chinen, Javier; Hanson, Imelda C.] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; [Rosenblatt, Howard M.] Dell ChildrensMed Ctr Cent Texas, Austin, TX USA; [Liu, Hao; Wu, Meng-Fen] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Martinez, CA (corresponding author), Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.		Heslop, Helen/AAC-9500-2020; Paul, Mary/AAA-2722-2021; Brenner, Malcolm/Y-2509-2019	Shearer, William/0000-0002-2483-2130	National Institutes of Health Primary Immune Deficiency Treatment Consortium [AI082979]; National Institutes of Health/National Heart Lung and Blood Institute; National Institutes of Health/National Cancer Institute; National Institutes of Health; Leukemia and Lymphoma Society; Allergy and Immunology Section; Hematology and Oncology Section, Department of Pediatrics, Baylor College of Medicine; Stem Cell Transplant Unit at Texas Children's Hospital; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069441] Funding Source: NIH RePORTER	National Institutes of Health Primary Immune Deficiency Treatment Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Allergy and Immunology Section; Hematology and Oncology Section, Department of Pediatrics, Baylor College of Medicine; Stem Cell Transplant Unit at Texas Children's Hospital; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health Primary Immune Deficiency Treatment Consortium (AI082979).; M. K. Brenner receives research support from the National Institutes of Health/National Heart Lung and Blood Institute and the National Institutes of Health/National Cancer Institute. H. E. Heslop receives research support from the National Institutes of Health and the Leukemia and Lymphoma Society. The rest of the authors declare that they have no relevant conflicts of interest.; We thank the supporting faculty of the Allergy and Immunology Section and the Hematology and Oncology Section, Department of Pediatrics, Baylor College of Medicine. Also, we thank the supporting personnel of the Stem Cell Transplant Unit at Texas Children's Hospital. Finally, we thank the courageous families who entrusted the care of their children to us in a search for a better life for their children. We also thank Bobby Gaspar, Luigi Notarangelo, Paul Landais, Nizar Mahlaoui, Alain Fischer, and Reinhard Seger for their verbal communications regarding the most current European data of outcomes of patients with CGD after stem cell transplantation.	Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; Fleisher TA, 2004, J ALLERGY CLIN IMMUN, V114, P227, DOI 10.1016/j.jaci.2004.06.001; Gallin JI, 2003, NEW ENGL J MED, V348, P2416, DOI 10.1056/NEJMoa021931; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Hale G, 2000, BONE MARROW TRANSPL, V26, P69, DOI 10.1038/sj.bmt.1702477; Heslop HE, 2010, BLOOD, V115, P925, DOI 10.1182/blood-2009-08-239186; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Kang EM, 2011, J ALLERGY CLIN IMMUN, V127, P1319, DOI 10.1016/j.jaci.2011.03.028; Kennedy-Nasser AA, 2011, BIOL BLOOD MARROW TR, V17, pS310, DOI 10.1016/j.bbmt.2010.12.468; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Liese J, 2000, J PEDIATR-US, V137, P687, DOI 10.1067/mpd.2000.109112; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; MARGOLIS DM, 1990, J INFECT DIS, V162, P723, DOI 10.1093/infdis/162.3.723; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Pinheiro JC, 2009, MIXED EFFECTS MODELS; Qasim W, 2009, PEDIATRICS, V123, P836, DOI 10.1542/peds.2008-1191; Schuetz C, 2009, IMMUNOL RES, V44, P35, DOI 10.1007/s12026-008-8068-3; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Seger RA, 2008, BRIT J HAEMATOL, V140, P255, DOI 10.1111/j.1365-2141.2007.06880.x; Shah AJ, 2007, BIOL BLOOD MARROW TR, V13, P584, DOI 10.1016/j.bbmt.2007.01.076; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Soncini E, 2009, BRIT J HAEMATOL, V145, P73, DOI 10.1111/j.1365-2141.2009.07614.x; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; WEENING RS, 1983, J PEDIATR-US, V103, P127, DOI 10.1016/S0022-3476(83)80798-7; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	29	47	50	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					176	183		10.1016/j.jaci.2011.10.005	http://dx.doi.org/10.1016/j.jaci.2011.10.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22078471	Green Accepted			2022-12-18	WOS:000298634000023
J	Warm, K; Backman, H; Lindberg, A; Lundback, B; Ronmark, E				Warm, Katja; Backman, Helena; Lindberg, Anne; Lundback, Bo; Ronmark, Eva			Low incidence and high remission of allergic sensitization among adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic sensitization; skin prick test; specific IgE; epidemiology; adults; incidence; remission; risk factors	ATOPIC SENSITIZATION; AEROALLERGEN SENSITIZATION; CLINICAL-RELEVANCE; ASTHMA; PREVALENCE; SMOKING; POPULATION; COMMUNITY; CHILDREN; IGE	Background: Prospective studies on the incidence and remission of allergic sensitization among adults are rare. Objective: We sought to assess the incidence, remission, risk factors, and prevalence of allergic sensitization in relation to aging over a 10-year period. Methods: In 1994, a sample of 664 adults (68% of invited) participated in clinical examinations, including a structured interview and skin prick tests (SPTs). The sample was randomly selected from a large questionnaire survey in Northern Sweden. In 2004, 555 subjects (93% of invited) were re-examined by using the same methods as in 1994. IgE levels were also measured in 2004. Results: In 1994, the prevalence of any positive SPT response was significantly related to age, with the highest prevalence (55%) in subjects aged 20 to 29 years and the lowest prevalence (26%) in subjects aged 50 to 60 years. A similar age-related prevalence was found in 2004, and sensitization to pollen and pets was most common in both years. The results of the SPTs were verified by means of specific IgE measurement. The incidence of any positive SPT response was low. Only 9 subjects had any positive SPT response (ie, a cumulative incidence of 5% over 10 years). Remission was greater (ie, 32% over 10 years). The main risk factors for allergic sensitization were young age and a family history of allergy. Having had furred animals at home during childhood was negatively related to specific IgE levels. Conclusion: The low incidence and high remission in adulthood explain the decreasing prevalence of allergic sensitization by age. Thus the low prevalence of allergic sensitization among the elderly found in cross-sectional studies is an effect of normal aging and not primarily a birth cohort effect. (J Allergy Clin Immunol 2012; 129: 136-42.)	[Warm, Katja; Lindberg, Anne; Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden; [Warm, Katja] Sunderby Cent Hosp Norrbotten, Dept Resp Med & Allergol, Lulea, Sweden; [Lundback, Bo] Univ Gothenburg, Sahlgrenska Acad, Krefting Res Ctr, Dept Internal Med, Gothenburg, Sweden	Umea University; University of Gothenburg	Ronmark, E (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden.	eva.ronmark@nll.se	Backman, Helena/I-3921-2016	Backman, Helena/0000-0002-0553-8067; Lindberg, Anne/0000-0002-3292-7471	Swedish Heart-Lung Foundation; Swedish Asthma Allergy Foundation; Visare Norr and Umea University; Swedish Research Council; ALK-Abello; Phadia	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma Allergy Foundation; Visare Norr and Umea University; Swedish Research Council(Swedish Research CouncilEuropean Commission); ALK-Abello; Phadia(Phadia)	The studies were funded by the Swedish Heart-Lung Foundation, the Swedish Asthma Allergy Foundation, Visare Norr and Umea University, and the Swedish Research Council. Additional funding was provided by ALK-Abello and Phadia.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; [Anonymous], 1989, ALLERGY, V44, P1; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Canfield SM, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Canfield SM, 2008, J ALLERGY CLIN IMMUN, V121, P1422, DOI 10.1016/j.jaci.2008.03.011; Dottorini ML, 2007, CLIN EXP ALLERGY, V37, P188, DOI 10.1111/j.1365-2222.2007.02652.x; Eriksson J, 2010, ALLERGY, V65, P1397, DOI 10.1111/j.1398-9995.2010.02397.x; Hancox RJ, 2008, J ALLERGY CLIN IMMUN, V121, P38, DOI 10.1016/j.jaci.2007.09.052; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Keil T, 2009, ALLERGY, V64, P445, DOI 10.1111/j.1398-9995.2008.01867.x; Lannero E, 2008, THORAX, V63, P172, DOI 10.1136/thx.2007.079053; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Lindberg A, 2005, RESPIRATION, V72, P471, DOI 10.1159/000087670; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; Linneberg A, 2010, INT ARCH ALLERGY IMM, V151, P142, DOI 10.1159/000236004; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; Mortaz E, 2009, CLIN EXP ALLERGY, V39, P679, DOI 10.1111/j.1365-2222.2009.03209.x; Ownby DR, 2003, CURR OPIN ALLERGY CL, V3, P517, DOI 10.1097/01.all.0000104444.09202.ae; Pallasaho P, 2006, CLIN EXP ALLERGY, V36, P503, DOI 10.1111/j.1365-2222.2006.02460.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb00163.x; Raukas-Kivioja A, 2007, INT ARCH ALLERGY IMM, V142, P247, DOI 10.1159/000097027; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Zollner IK, 2005, THORAX, V60, P545, DOI 10.1136/thx.2004.029561	36	47	48	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					136	142		10.1016/j.jaci.2011.08.033	http://dx.doi.org/10.1016/j.jaci.2011.08.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21975174	Bronze			2022-12-18	WOS:000298634000017
J	Bucca, CB; Bugiani, M; Culla, B; Guida, G; Heffler, E; Mietta, S; Moretto, A; Rolla, G; Brussino, L				Bucca, Caterina B.; Bugiani, Massimiliano; Culla, Beatrice; Guida, Giuseppe; Heffler, Enrico; Mietta, Sabrina; Moretto, Antonella; Rolla, Giovanni; Brussino, Luisa			Chronic cough and irritable larynx	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic cough; asthma; rhinosinusitis; laryngeal hyperresponsiveness; irritable larynx	EXHALED NITRIC-OXIDE; EXTRATHORACIC AIRWAY; ALLERGIC RHINITIS; VARIANT ASTHMA; HYPERRESPONSIVENESS; REFLUX; METHACHOLINE; PREVALENCE; INHALATION; GUIDELINES	Background: Perennial rhinitis (PR), chronic rhinosinusitis (CRS), or both, asthma, and gastroesophageal reflux disease (GERD) are the most frequent triggers of chronic cough (CC). Extrathoracic airway receptors might be involved in all 3 conditions because asthma is often associated with PR/CRS and gastroesophageal refluxate might reach the upper airway. We previously found that most patients with rhinosinusitis, postnasal drip, and pharyngolaryngitis show laryngeal hyperresponsiveness (LHR; ie, vocal cord adduction on histamine challenge) that is consistent with an irritable larynx. Objective: We sought to evaluate the role of LHR in patients with CC. Methods: LHR and bronchial hyperresponsiveness (BHR) to histamine were assessed in 372 patients with CC and in 52 asthmatic control subjects without cough (asthma/CC-). In 172 patients the challenge was repeated after treatment for the underlying cause of cough. Results: The primary trigger of CC was PR/CRS in 208 (56%) patients, asthma in 41 (11%) patients (asthma/CC+), GERD in 62 (17%) patients, and unexplained chronic cough (UNEX) in 61 (16%) patients. LHR prevalence was 76% in patients with PR/CRS, 77% in patients with GERD, 66% in patients with UNEX, 93% in asthma/CC+ patients, and 11% in asthma/CC- patients. Upper airway disease was found in most (95%) asthma/CC+ patients and in 6% of asthma/CC- patients. BHR discriminated asthmatic patients and atopy discriminated patients with PR/CRS from patients with GERD and UNEX. Absence of LHR discriminated asthmatic patients without cough. After treatment, LHR resolved in 63% of the patients and improved in 11%, and BHR resolved in 57% and improved in 18%. Conclusions: An irritable larynx is common in patients with CC and indicates upper airway involvement, whether from rhinitis/sinusitis, gastric reflux, or idiopathic sensory neuropathy. (J Allergy Clin Immunol 2011;127:412-9.)	[Bucca, Caterina B.; Culla, Beatrice; Moretto, Antonella] Univ Turin, Dept Clin Pathophysiol, I-10128 Turin, Italy; [Guida, Giuseppe; Heffler, Enrico; Mietta, Sabrina; Rolla, Giovanni; Brussino, Luisa] Univ Turin, Dept Biomed Sci & Human Oncol, I-10128 Turin, Italy; [Bugiani, Massimiliano] Univ Turin, Unit Pneumol Consorzio Prov AntiTB, Local Hlth Agcy, I-10128 Turin, Italy	University of Turin; University of Turin; University of Turin	Bucca, CB (corresponding author), Univ Turin, Dept Clin Pathophysiol, Via Lamarmora 41, I-10128 Turin, Italy.	caterina.bucca@unito.it	Guida, Giuseppe/B-9713-2008; Bucca, Caterina/C-9886-2009; Heffler, Enrico/F-9455-2010; brussino, luisa/J-2486-2012; Rolla, Giovanni/C-9901-2009; Guida, Giuseppe/AAD-2118-2021	Guida, Giuseppe/0000-0003-3876-8587; Bucca, Caterina/0000-0002-9941-9236; Heffler, Enrico/0000-0002-0492-5663; brussino, luisa/0000-0001-7249-7616; Rolla, Giovanni/0000-0001-5997-7172; 	Regione Piemonte; funds for Applied Scientific Research; Italian Ministry of Instruction, University and Research (MIUR)	Regione Piemonte(Regione Piemonte); funds for Applied Scientific Research; Italian Ministry of Instruction, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	Supported by grants from Regione Piemonte, funds for Applied Scientific Research (2004), and the Italian Ministry of Instruction, University and Research (MIUR, 2002).	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; Barry DW, 2010, CLEV CLIN J MED, V77, P327, DOI 10.3949/ccjm.77a.09121; Belafsky Peter C, 2002, Ear Nose Throat J, V81, P10; Belvisi MG, 2003, PULM PHARMACOL THER, V16, P1, DOI 10.1016/S1094-5539(02)00180-3; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1991, ALLERGY, V46, P147, DOI 10.1111/j.1398-9995.1991.tb00559.x; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysiol.2003.057885; Canning BJ, 2006, RESP PHYSIOL NEUROBI, V152, P223, DOI 10.1016/j.resp.2006.03.001; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAUSOW AM, 1983, J APPL PHYSIOL, V55, P541, DOI 10.1152/jappl.1983.55.2.541; Chung KF, 2008, LANCET, V371, P1364, DOI 10.1016/S0140-6736(08)60595-4; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DeVault KR, 2005, AM J GASTROENTEROL, V100, P190, DOI 10.1111/j.1572-0241.2005.41217.x; Fujimura M, 2003, THORAX, V58, P14, DOI 10.1136/thorax.58.1.14; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Irwin RS, 2006, CHEST, V129, P1, DOI 10.1378/chest.129.1.1; Jang AS, 2002, J KOREAN MED SCI, V17, P761, DOI 10.3346/jkms.2002.17.6.761; Kowal K, 2009, J ASTHMA, V46, P692, DOI 10.1080/02770900903056187; Lee B, 2005, ANN OTO RHINOL LARYN, V114, P253, DOI 10.1177/000348940511400401; LONG JS, 2006, MODELS NOMINAL OUTCO; Mochizuki H, 2005, CHEST, V128, P2427, DOI 10.1378/chest.128.4.2427; Morice AH, 2007, EUR RESPIR J, V29, P1256, DOI 10.1183/09031936.00101006; Ohkura N, 2010, J ASTHMA, V47, P51, DOI 10.3109/02770900903362650; Osman LM, 2001, THORAX, V56, P138, DOI 10.1136/thorax.56.2.138; Pratter MR, 2006, CHEST, V129, p59S, DOI 10.1378/chest.129.1_suppl.59S; Pratter MR, 2006, CHEST, V129, p63S, DOI 10.1378/chest.129.1_suppl.63S; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rabe-Hesketh S.S.A., 2005, MULTILEVEL LONGITUDI; Ribeiro M, 2008, ALLERGY, V63, P527, DOI 10.1111/j.1398-9995.2007.01589.x; Rolla G, 1998, J ALLERGY CLIN IMMUN, V102, P204, DOI 10.1016/S0091-6749(98)70087-9; Rolla G, 1997, J ALLERGY CLIN IMMUN, V100, P52, DOI 10.1016/S0091-6749(97)70194-5; Rolla G, 2007, CHEST, V131, P1345, DOI 10.1378/chest.06-2618; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS32, DOI 10.1016/j.otohns.2007.06.724; Tai CF, 2002, CURR OPIN ALLERGY CL, V2, P11, DOI 10.1097/00130832-200202000-00003; Ternesten-Hasseus E, 2006, PULM PHARMACOL THER, V19, P172, DOI 10.1016/j.pupt.2005.04.010; Thach BT, 2007, PULM PHARMACOL THER, V20, P365, DOI 10.1016/j.pupt.2006.11.011; Theodoropoulos DS, 2001, AM J RESP CRIT CARE, V164, P72, DOI 10.1164/ajrccm.164.1.2006002; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; Yoo Y, 2004, ALLERGY, V59, P1055, DOI 10.1111/j.1398-9995.2004.00655.x; 2000, J RESP CRIT CARE MED, V161, P309	43	47	50	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					412	419		10.1016/j.jaci.2010.10.038	http://dx.doi.org/10.1016/j.jaci.2010.10.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167571				2022-12-18	WOS:000286808000015
J	McDonald, DR; Massaad, MJ; Johnston, A; Keles, S; Chatila, T; Geha, RS; Pai, SY				McDonald, Douglas R.; Massaad, Michel J.; Johnston, Alicia; Keles, Sevgi; Chatila, Talal; Geha, Raif S.; Pai, Sung-Yun			Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS; DOCK8		[McDonald, Douglas R.; Massaad, Michel J.; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Pai, Sung-Yun] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; [McDonald, Douglas R.; Massaad, Michel J.; Geha, Raif S.; Pai, Sung-Yun] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Johnston, Alicia] Baystate Med Ctr, Div Infect Dis, Springfield, MA USA; [Keles, Sevgi] Selcuk Univ, Div Pediat Allergy & Immunol, Konya, Turkey; [Chatila, Talal] Univ Calif Los Angeles, David Geffen Sch Med, Div Immunol, Dept Pediat, Los Angeles, CA 90095 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Baystate Medical Center; Selcuk University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	McDonald, DR (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Pai, Sung-Yun/AAH-7762-2019	Pai, Sung-Yun/0000-0002-0158-8147; Chatila, Talal/0000-0001-7439-2762	NIAID NIH HHS [P01 AI035714, R21 AI083907, 1R21AI083907, K08 AI076625, AI76625, N01 AI400030, P01AI035714, AI065617, R01 AI065617, AI087627, R21 AI087627] Funding Source: Medline; NIAMS NIH HHS [R01 AR047417, R01 AR047417-08] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI083907, K08AI076625, R01AI065617, R21AI087627, P01AI035714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Freeman AF, 2008, IMMUNOL ALLERGY CLIN, V28, P277, DOI 10.1016/j.iac.2008.01.005; GATZ SA, 2010, BONE MARROW IN PRESS; WALDMAN JD, 1977, J PEDIATR-US, V90, P555, DOI 10.1016/S0022-3476(77)80365-X; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	6	47	51	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1304	U360		10.1016/j.jaci.2010.07.034	http://dx.doi.org/10.1016/j.jaci.2010.07.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20810158	Green Accepted, Bronze			2022-12-18	WOS:000284947800032
J	Loock, J; Lamprecht, P; Timmann, C; Mrowietz, U; Csernok, E; Gross, WL				Loock, Jan; Lamprecht, Peter; Timmann, Christian; Mrowietz, Ulrich; Csernok, Elena; Gross, Wolfgang L.			Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INNATE IMMUNE-RESPONSE		[Loock, Jan; Lamprecht, Peter; Csernok, Elena; Gross, Wolfgang L.] Univ Lubeck, Dept Rheumatol, Vasculitis Ctr, Lubeck, Germany; [Loock, Jan; Lamprecht, Peter; Csernok, Elena; Gross, Wolfgang L.] Univ Lubeck, Rheumaklin Bad Bramstedt, Lubeck, Germany; [Timmann, Christian] Bernhard Nocht Inst Trop Med, Hamburg, Germany; [Mrowietz, Ulrich] Univ Med Ctr Schleswig Holstein, Dept Dermatol, Kiel, Germany	University of Lubeck; University of Lubeck; Bernhard Nocht Institut fur Tropenmedizin; University of Kiel; Schleswig Holstein University Hospital	Loock, J (corresponding author), Univ Lubeck, Dept Rheumatol, Vasculitis Ctr, Lubeck, Germany.	loock.rostock@freenet.de	Gross, Wolfgang Ludwig WG/C-8733-2011; Lamprecht, Peter/F-1063-2013; Mrowietz, U/B-1645-2010	Lamprecht, Peter/0000-0001-5929-868X; Mrowietz, U/0000-0002-9539-0712				Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Lipsker D, 2001, MEDICINE, V80, P37, DOI 10.1097/00005792-200101000-00004; Martinez-Taboada VM, 2005, ARTHRITIS RHEUM, V52, P2226, DOI 10.1002/art.21101; Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021	9	47	51	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					500	502		10.1016/j.jaci.2009.10.066	http://dx.doi.org/10.1016/j.jaci.2009.10.066			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159265				2022-12-18	WOS:000274764000035
J	Ono, E; Taniguchi, M; Higashi, N; Mita, H; Kajiwara, K; Yamaguchi, H; Tatsuno, S; Fukutomi, Y; Tanimoto, H; Sekiya, K; Oshikata, C; Tsuburai, T; Tsurikisawa, N; Otomo, M; Maeda, Y; Hasegawa, M; Miyazaki, E; Kumamoto, T; Akiyama, K				Ono, Emiko; Taniguchi, Masami; Higashi, Noritaka; Mita, Haruhisa; Kajiwara, Keiichi; Yamaguchi, Hiromichi; Tatsuno, Sayaka; Fukutomi, Yuma; Tanimoto, Hidenori; Sekiya, Kiyoshi; Oshikata, Chiyako; Tsuburai, Takahiro; Tsurikisawa, Naomi; Otomo, Mamoru; Maeda, Yuji; Hasegawa, Maki; Miyazaki, Eishi; Kumamoto, Toshihide; Akiyama, Kazuo			CD203c expression on human basophils is associated with asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; asthma exacerbation; basophil activation; basophil surface marker; biomarker; CD203c	RECEPTOR; DIAGNOSIS; RELEASE; CELLS; CRTH2; IL-3	Background: CD203c is a basophil cell surface marker used to diagnose and monitor various allergic diseases, but its relationship to asthma is not clear. Objective: We determined whether CD203c expression levels are associated with stable and exacerbated asthma. Methods: We used flow cytometry to compare spontaneous expression levels of surface markers on basophils from patients with stable or exacerbated asthma and from healthy subjects. Longitudinal changes in these expression levels were measured after basophil stimulation by IgE-dependent or IgE-independent mechanisms and compared with patients' asthma status. Results: Spontaneous expression levels of CD203c were significantly higher on basophils from patients with asthma exacerbation than patients with stable asthma or healthy subjects. In contrast, no differences in spontaneous expression levels of CD63 or CD69 were observed among the 3 groups. Anti-IgE-induced expression of CD203c significantly increased in basophils during asthma exacerbation (P=.005). Low concentrations of Dermatophagoides pteronyssinus or IL-3 induced higher expression levels of CD203c during asthma exacerbation than during clinical improvement; induction of CD203c expression by these antigens therefore correlates with asthma control. In the patients with clinical improvement, there was a correlation between spontaneous CD203c expression levels and the percent predicted values of FEV(1) (r = -0.761; P = .022). Conclusion: Asthma exacerbation was accompanied by increased expression of CD203c on basophils that decreased significantly during remission. Basophil expression levels of CD203c might therefore be used to monitor asthma in patients. (J Allergy Clin Immunol 2010;125:483-9.)	[Ono, Emiko; Taniguchi, Masami; Higashi, Noritaka; Mita, Haruhisa; Kajiwara, Keiichi; Yamaguchi, Hiromichi; Tatsuno, Sayaka; Fukutomi, Yuma; Tanimoto, Hidenori; Sekiya, Kiyoshi; Oshikata, Chiyako; Tsuburai, Takahiro; Tsurikisawa, Naomi; Otomo, Mamoru; Maeda, Yuji; Hasegawa, Maki; Akiyama, Kazuo] Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Ono, Emiko; Miyazaki, Eishi; Kumamoto, Toshihide] Oita Univ, Fac Med, Div Dept Internal Med 3, Yufu, Japan	Oita University	Ono, E (corresponding author), Oita Univ, Fac Med, Dept Internal Med 3, Div Pulm Dis, 1-1 Idaigaoka, Oita 8795593, Japan.	onoemii@e-ml.jp	Fukutomi, Yuma/AFQ-4306-2022	Fukutomi, Yuma/0000-0001-9913-4524	Grants-in-Aid for Scientific Research [22590866] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Bohm E, 2004, J BIOL CHEM, V279, P7663, DOI 10.1074/jbc.M310270200; Boumiza Radhia, 2005, Clin Mol Allergy, V3, P9, DOI 10.1186/1476-7961-3-9; Ebo DG, 2006, ALLERGY, V61, P1028, DOI 10.1111/j.1398-9995.2006.01039.x; Gamboa P, 2004, CLIN EXP ALLERGY, V34, P1448, DOI 10.1111/j.1365-2222.2004.02050.x; Global Initiative for Asthma, 2004, GLOB STRAT ASTHM MAN; Gober LM, 2007, J ALLERGY CLIN IMMUN, V119, P1181, DOI 10.1016/j.jaci.2007.01.008; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086, DOI 10.1164/ajrccm.150.4.7921441; Mita H, 1999, PROSTAG LEUKOTR ESS, V60, P175, DOI 10.1054/plef.1999.0022; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Nakano Y, 2003, J ALLERGY CLIN IMMUN, V112, P525, DOI 10.1067/mai.2003.1710; Oosaki R, 1998, CLIN EXP ALLERGY, V28, P1138; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Schroeder JT, 2009, J IMMUNOL, V182, P2432, DOI 10.4049/jimmunol.0801782; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; TSUKIOKA K, 1996, ARERUGI, V45, P4442; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724; Yoshimura-Uchiyama C, 2003, BIOCHEM BIOPH RES CO, V302, P201, DOI 10.1016/S0006-291X(03)00153-0; 1999, AM J RESP CRIT CARE, V160, P2104	24	47	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					483	489		10.1016/j.jaci.2009.10.074	http://dx.doi.org/10.1016/j.jaci.2009.10.074			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159259	Bronze			2022-12-18	WOS:000274764000029
J	Steinke, JW; Payne, SC; Tessier, ME; Borish, LO; Han, JK; Borish, LC				Steinke, John W.; Payne, Spencer C.; Tessier, M. Elizabeth; Borish, Lori O.; Han, Joseph K.; Borish, Larry C.			Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NASAL POLYPOSIS		[Steinke, John W.; Tessier, M. Elizabeth; Borish, Lori O.; Borish, Larry C.] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22903 USA; [Payne, Spencer C.] Univ Virginia Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA; [Han, Joseph K.] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA	University of Virginia; University of Virginia; Eastern Virginia Medical School	Steinke, JW (corresponding author), Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22903 USA.	js3ch@virginia.edu		Payne, Spencer/0000-0001-9736-4561	NIAID NIH HHS [R01 AI01793, P01 AI50989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050989] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhattacharyya N, 2006, LARYNGOSCOPE, V116, P1, DOI 10.1097/01.mlg.0000224508.59725.19; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Harvey R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006394; Jankowski R, 2003, RHINOLOGY, V41, P211; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; *NAT HEART L BLOOD, 2007, 3 NIH NAT HEART L BL; Poole M D, 1992, Ear Nose Throat J, V71, P622; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Stjarne P, 2006, ACTA OTO-LARYNGOL, V126, P606, DOI 10.1080/00016480500452566	9	47	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1352	1354		10.1016/j.jaci.2009.09.018	http://dx.doi.org/10.1016/j.jaci.2009.09.018			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910027				2022-12-18	WOS:000273071500031
J	Dowden, AM; Rullo, OJ; Aziz, N; Fasano, MB; Chatila, T; Ballas, ZK				Dowden, Amy M.; Rullo, Ornella J.; Aziz, Najib; Fasano, Mary Beth; Chatila, Talal; Ballas, Zuhair K.			Idiopathic systemic capillary leak syndrome: Novel therapy for acute attacks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Dowden, Amy M.; Fasano, Mary Beth; Ballas, Zuhair K.] Univ Iowa, Dept Internal Med, Div Allergy Immunol, Iowa City, IA 52242 USA; [Rullo, Ornella J.; Aziz, Najib; Chatila, Talal] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol Allergy & Immunol, Dept Pediat, Los Angeles, CA 90095 USA; [Ballas, Zuhair K.] Iowa City VA Med Ctr, Iowa City, IA USA	University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Dowden, AM (corresponding author), Univ Iowa, Dept Internal Med, Div Allergy Immunol, Iowa City, IA 52242 USA.	amy-dowden@uiowa.edu		Knaack, Aaron/0000-0001-7712-1415; Yoder Dowden, Amy/0000-0003-2274-0782; Chatila, Talal/0000-0001-7439-2762; Fasano, Mary/0000-0001-8468-1605; Ballas, Zuhair/0000-0001-5569-1230				Airaghi L, 2000, J INTERN MED, V247, P731, DOI 10.1046/j.1365-2796.2000.00693.x; Amoura Z, 1997, AM J MED, V103, P514, DOI 10.1016/S0002-9343(97)00272-6; ATKINSON JP, 1977, MEDICINE, V56, P225, DOI 10.1097/00005792-197705000-00004; Banerji A, 2006, IMMUNOL ALLERGY CLIN, V26, P769, DOI 10.1016/j.iac.2006.09.001; Dhir V, 2007, INTERNAL MED, V46, P899, DOI 10.2169/internalmedicine.46.6129; Fischmeister R, 2006, CIRC RES, V98, P582, DOI 10.1161/01.RES.0000215564.22445.7e; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; Spina D, 2003, DRUGS, V63, P2575, DOI 10.2165/00003495-200363230-00002; Tahirkheli NK, 1999, ANN INTERN MED, V130, P905, DOI 10.7326/0003-4819-130-11-199906010-00015; Vadlamani Lou, 2004, Congest Heart Fail, V10, P289, DOI 10.1111/j.1527-5299.2004.02020.x	10	47	50	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1111	1113		10.1016/j.jaci.2009.06.043	http://dx.doi.org/10.1016/j.jaci.2009.06.043			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19703708	Bronze			2022-12-18	WOS:000272108000037
J	Jensen, JM; Pfeiffer, S; Witt, M; Brautigam, M; Neumann, C; Weichenthal, M; Schwarz, T; Foelster-Holst, R; Proksch, E				Jensen, Jens-Michael; Pfeiffer, Stephan; Witt, Magdalena; Braeutigam, Matthias; Neumann, Claudia; Weichenthal, Michael; Schwarz, Thomas; Foelster-Holst, Regina; Proksch, Ehrhardt			Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis (Reprinted from J Allergy Clin Immunol vol 123, pg 1124-33, 2009)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Reprint						Atopic dermatitis; skin barrier; pimecrolimus; corticosteroid; skin penetration	TRANSEPIDERMAL WATER-LOSS; STRATUM-CORNEUM; PERMEABILITY BARRIER; EPIDERMAL DIFFERENTIATION; LANGERHANS CELLS; UNINVOLVED SKIN; IN-VIVO; FILAGGRIN; ECZEMA; PENETRATION	Background: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. Objectives: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier. Methods: In a randomized study 15 patients with AD were treated on one upper limb with pimecrolimus and on the other with betamethasone twice daily for 3 weeks. Results: Stratum corneum hydration and transepidermal water loss, a marker of the inside-outside barrier, improved in both groups. Dye penetration, a marker of the outside-inside barrier, was also reduced in both drugs. Electron microscopic evaluation of barrier structure displayed prevalently ordered stratum corneum lipid layers and regular lamellar body extrusion in pimecrolimus-treated skin but inconsistent extracellular lipid bilayers and only partially filled lamellar bodies after betamethasone treatment. Both drugs normalized epidermal differentiation and reduced epidermal hyperproliferation. Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to epidermal thinning. Conclusion: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD. (Reprinted from J Allergy Clin Immunol 2009; 123: 1124-33.)	[Jensen, Jens-Michael; Witt, Magdalena; Neumann, Claudia; Weichenthal, Michael; Schwarz, Thomas; Foelster-Holst, Regina; Proksch, Ehrhardt] Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany; [Pfeiffer, Stephan] Microscopy Serv, Flintbek, Germany; [Braeutigam, Matthias] Novartis Pharma GmbH, Clin Res, Nurnberg, Germany	University of Kiel; Novartis	Proksch, E (corresponding author), Univ Kiel, Dept Dermatol, Schittenhelmstr 7, D-24105 Kiel, Germany.	eproksch@dermatology.uni-kiel.de	Weichenthal, Michael/A-5692-2009; Proksch, Ehrhardt/C-6195-2009; Fölster-Holst, Regina/A-9560-2010	Braeutigam, Matthias/0000-0002-1961-6396				AALTOKORTE K, 1995, J AM ACAD DERMATOL, V33, P969, DOI 10.1016/0190-9622(95)90288-0; AGNER T, 1992, ACTA DERM-VENEREOL, P1; Allam JP, 2006, CLIN EXP DERMATOL, V31, P89, DOI 10.1111/j.1365-2230.2005.01980.x; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; ELIAS PM, 1991, ADV LIPID RES, V24, P1; ELIAS PM, 1975, J CELL BIOL, V65, P180, DOI 10.1083/jcb.65.1.180; Elias PM, 2001, ARCH DERMATOL, V137, P1079; Endo K, 2007, SKIN RES TECHNOL, V13, P425, DOI 10.1111/j.1600-0846.2007.00247.x; FARTASCH M, 1992, BRIT J DERMATOL, V127, P221, DOI 10.1111/j.1365-2133.1992.tb00118.x; Folster-Holst R, 2006, ALLERGY, V61, P629, DOI 10.1111/j.1398-9995.2006.01076.x; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HASHIMOTOKUMASAKA K, 1993, ACTA DERM-VENEREOL, V73, P335; Hazelbag HM, 2003, AM J SURG PATHOL, V27, P1530, DOI 10.1097/00000478-200312000-00005; Hengge UR, 2006, J AM ACAD DERMATOL, V54, P1, DOI 10.1016/j.jaad.2005.01.010; Hoetzenecker W, 2004, J INVEST DERMATOL, V122, P673, DOI 10.1111/j.0022-202X.2004.22324.x; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Kato JS, 2003, J INVEST DERMATOL, V120, P456, DOI 10.1046/j.1523-1747.2003.12053.x; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kolbe L, 2001, SKIN RES TECHNOL, V7, P73, DOI 10.1034/j.1600-0846.2001.70203.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Luger T, 2001, EUR J DERMATOL, V11, P343; Meingassner JG, 2005, EXP DERMATOL, V14, P752, DOI 10.1111/j.1600-0625.2005.00354.x; Meingassner JG, 2003, BRIT J DERMATOL, V149, P853, DOI 10.1046/j.1365-2133.2003.05559.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Novak N, 2005, CLIN EXP DERMATOL, V30, P160, DOI 10.1111/j.1365-2230.2005.01709.x; Ogawa Hideoki, 1993, Journal of Dermatological Science, V5, P197, DOI 10.1016/0923-1811(93)90767-J; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Sheu HM, 1997, BRIT J DERMATOL, V136, P884, DOI 10.1111/j.1365-2133.1997.tb03929.x; Stuetz A, 2001, SEMIN CUTAN MED SURG, V20, P233, DOI 10.1053/sder.2001.29066; Stuetz A, 2006, INT ARCH ALLERGY IMM, V141, P199, DOI 10.1159/000095289; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Tate M, 2007, SKIN RES TECHNOL, V13, P293, DOI 10.1111/j.1600-0846.2007.00227.x; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Yoshiiki Takashi, 1993, Journal of Dermatological Science, V5, P92, DOI 10.1016/0923-1811(93)90076-2; ZESCH A, 1975, ARCH DERMATOL FORSCH, V252, P245, DOI 10.1007/BF00560364	52	47	51	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3		2			R19	R28		10.1016/j.jaci.2009.07.015	http://dx.doi.org/10.1016/j.jaci.2009.07.015			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553NC	19720208	Bronze			2022-12-18	WOS:000274372800005
J	Triggiani, M; Giannattasio, G; Calabrese, C; Loffredo, S; Granata, F; Fiorello, A; Santini, M; Gelb, MH; Marone, G				Triggiani, Massimo; Giannattasio, Giorgio; Calabrese, Cecilia; Loffredo, Stefania; Granata, Francescopaolo; Fiorello, Alfonso; Santini, Mario; Gelb, Michael H.; Marone, Gianni			Lung mast cells are a source of secreted phospholipases A(2)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung mast cells; secreted phospholipase A(2); leukotriene C-4; arachidonic acid	ARACHIDONIC-ACID RELEASE; BRONCHOALVEOLAR LAVAGE FLUID; GROUP-II SUBFAMILY; M-TYPE RECEPTOR; GROUP-X; GROUP-V; EICOSANOID GENERATION; HUMAN NEUTROPHILS; HUMAN EOSINOPHILS; HUMAN BASOPHILS	Background: Secreted phospholipases A(2) (sPLA(2)s) are released in plasma and other biologic fluids of patients with inflammatory, autoimmune, and allergic diseases. Objective: We sought to evaluate sPLA(2) activity in the bronchoalveolar lavage fluid (BALF) of asthmatic patients and to examine the expression and release of sPLA(2)s from primary human lung mast cells (HLMCs). Methods: sPLA(2) activity was measured in BALF and supernatants of either unstimulated or anti-IgE-activated HLMCs as hydrolysis of oleic acid from radiolabeled Escherichia coli membranes. Expression of sPLA(2)s was examined by using RT-PCR. The release of cysteinyl leukotriene (LT) C-4 was measured by means of enzyme immunoassay. Results: Phospholipase A(2) (PLA(2)) activity was higher in the BALF of asthmatic patients than in the control group. BALF PLA(2) activity was blocked by the sPLA(2) inhibitors dithiothreitol and Me-Indoxam but not by the cytosolic PLA(2) inhibitor AZ-1. HLMCs spontaneously released a PLA(2) activity that was increased on stimulation with anti-IgE. This PLA(2) activity was blocked by dithiothreitol and Me-Indoxam but not by AZ-1. HLMCs constitutively express mRNA for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA(2)s. Anti-IgE did not modify the expression of sPLA(2)s. The cell-impermeable inhibitor Me-Indoxam significantly reduced (up to 40%) the production of LTC4 from anti-IgE-stimulated HLMCs. Conclusions: sPLA(2) activity is increased in the airways of asthmatic patients. HLMCs express multiple sPLA(2)s and release 1 or more of them when activated by anti-IgE. The sPLA(2)s released by mast cells contribute to LTC4 production by acting in an autocrine fashion. Mast cells can be a source of sPLA(2)s in the airways of asthmatic patients. (J Allergy Clin Immunol 2009;124:558-65.)	[Triggiani, Massimo; Giannattasio, Giorgio; Loffredo, Stefania; Granata, Francescopaolo; Marone, Gianni] Univ Naples Federico II, Dept Clin Immunol & Allergy, I-80131 Naples, Italy; [Triggiani, Massimo; Giannattasio, Giorgio; Loffredo, Stefania; Granata, Francescopaolo; Marone, Gianni] Univ Naples Federico II, Ctr Basic & Clin Immunol Res CISI, I-80131 Naples, Italy; [Gelb, Michael H.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Gelb, Michael H.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Calabrese, Cecilia] Univ Naples 2, Div Resp Dis, Naples, Italy; [Fiorello, Alfonso; Santini, Mario] Univ Naples 2, Div Thorac Surg, Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Triggiani, M (corresponding author), Univ Naples Federico II, Dept Clin Immunol & Allergy, Via S Pansini 5, I-80131 Naples, Italy.	triggian@unina.it	SANTINI, Mario/AFE-1150-2022; SANTINI, Mario/AAE-9589-2022; Triggiani, Massimo/K-8271-2016; Fiorelli, Alfonso/AAO-2709-2020; SANTINI, Mario/AFE-6002-2022; SANTINI, Mario/AAE-9516-2022	SANTINI, Mario/0000-0003-1162-7805; SANTINI, Mario/0000-0003-1162-7805; Triggiani, Massimo/0000-0001-7318-2093; SANTINI, Mario/0000-0003-1162-7805; SANTINI, Mario/0000-0003-1162-7805; Calabrese, Cecilia/0000-0003-4293-4461; Fiorelli, Alfonso/0000-0002-0628-613X; gelb, michael/0000-0001-7000-5219	Ministero dell'Istruzione, dell'Universita e della Ricerca; Regione Campania; Istituto Superiore di Sanita; National Institutes of Health [HL50040, HL36235]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R01HL050040, R01HL036235, R37HL036235] Funding Source: NIH RePORTER	Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Regione Campania(Regione Campania); Istituto Superiore di Sanita; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported in part by grants from the Ministero dell'Istruzione, dell'Universita e della Ricerca (M.T., G.M.), the Regione Campania (M.T.), the Istituto Superiore di Sanita (AIDS Project 40D.57; G.M.), and the National Institutes of Health (HL50040 and HL36235 to M.H.G.).	Beck GC, 2003, BIOCHEM BIOPH RES CO, V300, P731, DOI 10.1016/S0006-291X(02)02920-0; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Blom M, 1998, BLOOD, V91, P3037; Boilard E, 2006, BIOCHEMISTRY-US, V45, P13203, DOI 10.1021/bi061376d; Bowton DL, 1997, AM J RESP CRIT CARE, V155, P421, DOI 10.1164/ajrccm.155.2.9032172; Busse WW, 2005, AM J RESP CRIT CARE, V172, P807, DOI 10.1164/rccm.200407-966WS; Chilton FH, 1996, J EXP MED, V183, P2235, DOI 10.1084/jem.183.5.2235; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; Connolly S, 2002, J MED CHEM, V45, P1348, DOI 10.1021/jm011050x; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; FONTEH AN, 1994, J IMMUNOL, V152, P5438; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Giannattasio G, 2009, BBA-MOL CELL BIOL L, V1791, P92, DOI 10.1016/j.bbalip.2008.12.002; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Granata F, 2005, J IMMUNOL, V174, P464, DOI 10.4049/jimmunol.174.1.464; Granata F, 2003, INT ARCH ALLERGY IMM, V131, P153, DOI 10.1159/000071481; Hallstrand TS, 2007, AM J RESP CRIT CARE, V176, P1072, DOI 10.1164/rccm.200707-1088OC; Hamaguchi K, 2003, BBA-MOL CELL BIOL L, V1635, P37, DOI 10.1016/j.bbalip.2003.10.004; Henderson WR, 2007, J EXP MED, V204, P865, DOI 10.1084/jem.20070029; Hohlfeld JM, 2001, RESPIR RES, V3, DOI 10.1186/rr176; Hundley TR, 1998, J PHARMACOL EXP THER, V284, P847; Jamal OS, 1998, ANN RHEUM DIS, V57, P550, DOI 10.1136/ard.57.9.550; Jo EJ, 2004, J IMMUNOL, V173, P6433, DOI 10.4049/jimmunol.173.10.6433; Kikawada E, 2007, BLOOD, V110, P561, DOI 10.1182/blood-2006-10-052258; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007; Lilja I, 2000, CLIN CHEM LAB MED, V38, P1231, DOI 10.1515/CCLM.2000.194; Liu Z, 2007, ALLERGY, V62, P999, DOI 10.1111/j.1398-9995.2007.01381.x; Marone G., 2000, MAST CELLS BASOPHILS; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Piris-Gimenez A, 2005, J IMMUNOL, V175, P6786, DOI 10.4049/jimmunol.175.10.6786; Saiga A, 2001, BBA-MOL CELL BIOL L, V1530, P67, DOI 10.1016/S1388-1981(00)00167-0; Samet JM, 1996, EXP LUNG RES, V22, P299, DOI 10.3109/01902149609031777; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; STADEL JM, 1994, AM J RESP CELL MOL, V11, P108, DOI 10.1165/ajrcmb.11.1.8018333; Triggiani M, 1997, AM J RESP CRIT CARE, V156, P94, DOI 10.1164/ajrccm.156.1.9608084; Triggiani M, 2004, CLIN EXP ALLERGY, V34, P241, DOI 10.1111/j.1365-2222.2004.01851.x; Triggiani M, 2003, J IMMUNOL, V170, P3279, DOI 10.4049/jimmunol.170.6.3279; Triggiani M, 2005, J ALLERGY CLIN IMMUN, V116, P1000, DOI 10.1016/j.jaci.2005.08.011; Triggiani M, 2006, BBA-MOL CELL BIOL L, V1761, P1289, DOI 10.1016/j.bbalip.2006.07.003; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485	50	47	48	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					558	U240		10.1016/j.jaci.2009.04.035	http://dx.doi.org/10.1016/j.jaci.2009.04.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19541351	Green Accepted, Bronze			2022-12-18	WOS:000274315900023
J	Salam, MT; Islam, T; Gauderman, J; Gilliland, FD				Salam, Muhammad T.; Islam, Talat; Gauderman, James; Gilliland, Frank D.			Roles of arginase variants, atopy, and ozone in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; asthma genetics; atopy; gene-environment interaction; nitrosative stress	NITRIC-OXIDE SYNTHASE; SOUTHERN CALIFORNIA COMMUNITIES; SMOOTH-MUSCLE RELAXATION; GENE-EXPRESSION; NITROSATIVE STRESS; MULTIETHNIC COHORT; MATERNAL SMOKING; DIFFERING LEVELS; AIR-POLLUTION; CELLS	Background: Arginases; (encoded by ARG1 and ARG2 genes) might play an important role in asthma pathogenesis through effects on nitrosative stress. Arginase expression is upregulated in asthma and varies with T(H)2 cytokine levels and oxidative stress. Objective: We aimed to examine whether variants in these genes are associated with asthma and whether atopy and exposures to smoking and air pollution influence the associations. Methods: Among non-Hispanic and Hispanic white participants of the Children's Health Study (n = 2946), we characterized variation in each locus (including promoter region) with 6 tag single nucleotide polymorphisms for ARG1 and 10 for ARG2. Asthma was defined by parental report of physician-diagnosed asthma at study entry. Results: Both ARG1 and ARG2 genetic loci were significantly associated with asthma (global locus level P = .02 and .04, respectively). Compared with the most common haplotype within each locus, I ARG1 haplotype was associated with reduced risk (odds ratio [OR] per haplotype copy, 0.55; 95% CI, 0.36-0.84), and I ARG2 haplotype was associated with increased risk (OR per haplotype copy, 1.35; 95% CI, 1.04-1.76) of asthma. The effect of the ARG1 haplotype that was significantly associated with asthma varied by the child's history of atopy and ambient ozone (P-interaction = .04 and .02, respectively). Among atopic children living in high-ozone communities, those carrying the ARG1 haplotype had reduced asthma risk (OR per haplotype copy, 0.12; 95% CI, 0.04-0.43; P-heterogeneity across atopy/ozone categories = .008). Conclusions: ARG1 and ARG2 loci are associated with childhood asthma. The association between ARG1 variation and asthma might depend on atopy and ambient ozone levels. (J Allergy Clin Immunol 2009;123:596-602.)	[Salam, Muhammad T.; Islam, Talat; Gauderman, James; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	University of Southern California	Gilliland, FD (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	, Talat/AAV-6834-2020	, Talat/0000-0002-2837-865X; Salam, Muhammad/0000-0002-3565-8916	National Heart, Lung, and Blood Institute [5R01HL61768, 5R01HL76647]; Southern California Environmental Health Sciences Center [5P30ES007048]; National Institute of Environmental Health Sciences [5P01ES011627]; Children's Environmental Health Center [5P01ES009581, R826708-01, RD831861-01]; Environmental Protection Agency; Hastings Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061768, R01HL076647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P30ES007048, P01ES011627] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Southern California Environmental Health Sciences Center; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Children's Environmental Health Center; Environmental Protection Agency(United States Environmental Protection Agency); Hastings Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Heart, Lung, and Blood Institute (grants 5R01HL61768 and 5R01HL76647), the Southern California Environmental Health Sciences Center (grant 5P30ES007048) funded by the National Institute of Environmental Health Sciences, the Children's Environmental Health Center (grants 5P01ES009581, R826708-01 and RD831861-01) funded by the National Institute of Environmental Health Sciences and the Environmental Protection Agency, the National Institute of Environmental Health Sciences (grant 5P01ES011627), and the Hastings Foundation.	Baraldi E, 2006, ALLERGY, V61, P90, DOI 10.1111/j.1398-9995.2006.00996.x; Belik J, 2008, AM J PHYSIOL-LUNG C, V294, pL498, DOI 10.1152/ajplung.00242.2007; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Bronte V, 2003, TRENDS IMMUNOL, V24, P302, DOI 10.1016/S1471-4906(03)00132-7; Choi IW, 2004, INT IMMUNOPHARMACOL, V4, P1817, DOI 10.1016/j.intimp.2004.07.030; Ckless K, 2007, AM J RESP CELL MOL, V36, P645, DOI 10.1165/rcmb.2006-0329SM; Conneely KN, 2007, AM J HUM GENET, V81, P1158, DOI 10.1086/522036; Fakhrzadeh L, 2002, AM J RESP CELL MOL, V26, P413, DOI 10.1165/ajrcmb.26.4.4516; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Gauderman WJ, 2007, GENET EPIDEMIOL, V31, P383, DOI 10.1002/gepi.20219; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Hu CB, 2002, AM J PHYSIOL-LUNG C, V282, pL757, DOI 10.1152/ajplung.00271.2001; Islam T, 2008, AM J RESP CRIT CARE, V177, P388, DOI 10.1164/rccm.200706-863OC; Jacobsen LC, 2007, BLOOD, V109, P3084, DOI 10.1182/blood-2006-06-032599; Jang AS, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-5; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346, DOI 10.1093/oxfordjournals.aje.a010213; Li HL, 2006, J ALLERGY CLIN IMMUN, V117, P119, DOI 10.1016/j.jaci.2005.09.026; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; Maarsingh H, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-6; Maarsingh H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-23; Maarsingh H, 2008, AM J RESP CRIT CARE, V178, P565, DOI 10.1164/rccm.200710-1588OC; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Munder M, 1999, J IMMUNOL, V163, P3771; Munder M, 2005, BLOOD, V105, P2549, DOI 10.1182/blood-2004-07-2521; Noris M, 2004, HYPERTENSION, V43, P614, DOI 10.1161/01.HYP.0000116220.39793.c9; Ohtsu H, 2008, J PHARMACOL SCI, V106, P347, DOI 10.1254/jphs.FM0070294; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760, DOI 10.1164/ajrccm.159.3.9804143; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; Pijnenburg MWH, 2008, CLIN EXP ALLERGY, V38, P246, DOI 10.1111/j.1365-2222.2007.02897.x; Que LG, 1998, AM J PHYSIOL-LUNG C, V275, pL96, DOI 10.1152/ajplung.1998.275.1.L96; Ricciardolo FLM, 2006, EUR J PHARMACOL, V533, P240, DOI 10.1016/j.ejphar.2005.12.057; Rodriguez PC, 2003, J IMMUNOL, V171, P1232, DOI 10.4049/jimmunol.171.3.1232; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Takemoto K, 2007, AM J PHYSIOL-LUNG C, V293, pL1419, DOI 10.1152/ajplung.00418.2006; Wei LH, 2000, AM J PHYSIOL-CELL PH, V279, pC248, DOI 10.1152/ajpcell.2000.279.1.C248; Yang M, 2006, J IMMUNOL, V177, P5595, DOI 10.4049/jimmunol.177.8.5595; Zhang YZ, 2007, DEVELOPMENT, V134, P189, DOI 10.1242/dev.02720; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	42	47	49	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					596	602		10.1016/j.jaci.2008.12.020	http://dx.doi.org/10.1016/j.jaci.2008.12.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281908	Green Accepted			2022-12-18	WOS:000264731200017
J	Ueta, M; Matsuoka, T; Narumiya, S; Kinoshita, S				Ueta, Mayumi; Matsuoka, Toshiyuki; Narumiya, Shuh; Kinoshita, Shigeru			Prostaglandin E receptor subtype EP3 in conjunctival epithelium regulates late-phase reaction of experimental allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Conjunctival epithelium; prostaglandin E receptor subtype EP3; allergic conjunctivitis; eosinophilic conjunctival inflammation; EP3 agonist	PATHOPHYSIOLOGY; INFLAMMATION; EOTAXIN	Background: We previously demonstrated that the prostaglandin E-2 (PGE(2))-EP3 pathway negatively regulates allergic reactions in a murine allergic asthma model. Objectives: We investigated whether the PGE(2)-EP3 pathway also regulates the development of murine experimental allergic conjunctivitis (EAC). Methods: The expression of EP3 was examined by means of RTPCR and immunohistochemistry in wild-type mice, as well as by means of 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside staining in mice deficient in EP3 (Ptger3(-/-) mice) carrying the R-galactosidase gene at the EP3 gene locus. EAC was induced by immunization of mice with short ragweed pollen (RW), followed by challenge with eye drops of RW, and eosinophil infiltration and eotaxin-1 mRNA expression in the conjunctiva were examined. Mice were also treated with a topical application of an EP3-selective agonist during the elicitation phase. Quantitative RT-PCR was used to detect expression of COXs and prostaglandin E synthases, and ELISA was used to measure PGE(2) production in the eyelid. Results: EP3 was constitutively expressed in conjunctival epithelium on the ocular surface. Ptger3(-/-) mice demonstrated significantly increased eosinophil infiltration in conjunctiva after RW challenge compared with wild-type mice. Consistently, significantly higher expression of eotaxin-1 mRNA was observed in Ptger3(-/-) mice. Conversely, treatment of wild-type mice with an EP3-selective agonist resulted in a significant decrease in eosinophil infiltration, which was blunted in Ptger3(-/-) mice. Expression of COX-2 and prostaglandin E synthases was upregulated and PGE(2) content was increased in the eyelids after RW challenge. Conclusion: These data suggest that PGE(2) acts on EP3 in conjunctival epithelium and downregulates the progression of EAC. (J Allergy Clin Immunol 2009;123:466-71.)	[Ueta, Mayumi] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan; [Ueta, Mayumi] Doshisha Univ, Fac Life & Med Sci, Res Ctr Regenerat Med, Kyoto 602, Japan; [Matsuoka, Toshiyuki; Narumiya, Shuh] Kyoto Univ, Dept Pharmacol, Kyoto 6068501, Japan; [Matsuoka, Toshiyuki; Narumiya, Shuh] Kyoto Univ, Fac Med, Kyoto 6068501, Japan	Kyoto Prefectural University of Medicine; Doshisha University; Kyoto University; Kyoto University	Ueta, M (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.	mueta@koto.kpu-m.ac.jp			Japanese Ministry of Health, Labour, and Welfare; Japanese Ministry of Education, Culture, Sports, Science, and Technology; JST; Kyoto Foundation for the Promotion of Medical Science; National Institute of Biomedical Innovation of Japan; Intramural Research Fund of Kyoto Prefectural University of Medicine; Takeda Scientific Foundation; ONO Research Foundation	Japanese Ministry of Health, Labour, and Welfare(Ministry of Health, Labour and Welfare, Japan); Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JST(Japan Science & Technology Agency (JST)); Kyoto Foundation for the Promotion of Medical Science(Kyoto Foundation for the Promotion of Medical Science); National Institute of Biomedical Innovation of Japan(National Institute of Biomedical Innovation); Intramural Research Fund of Kyoto Prefectural University of Medicine; Takeda Scientific Foundation(Takeda Science Foundation (TSF)); ONO Research Foundation	Supported in part by grants-in-aid for scientific research from the Japanese Ministry of Health, Labour, and Welfare; the Japanese Ministry of Education, Culture, Sports, Science, and Technology; CREST from JST; the Kyoto Foundation for the Promotion of Medical Science; the National Institute of Biomedical Innovation of Japan; the Intramural Research Fund of Kyoto Prefectural University of Medicine; the Takeda Scientific Foundation; and the ONO Research Foundation. Financial relationship with manufacturer: We declare that the work described in the present paper was carried out in collaboration with Ono Pharmaceutical Co., Ltd., which supplied ONO-AE-248 used in this study and partially supported colonies of Ptger3<SUP>-/-</SUP> mice.	Abu El-Asrar AM, 2000, BRIT J OPHTHALMOL, V84, P1360; Broide DH, 2007, ALLERGY ASTHMA PROC, V28, P398, DOI 10.2500/aap.2007.28.3011; Chandler HL, 2007, MOL VIS, V13, P677; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Fukagawa K, 1999, J ALLERGY CLIN IMMUN, V103, P1220, DOI 10.1016/S0091-6749(99)70206-X; Fukuda Ken, 2006, Allergol Int, V55, P121, DOI 10.2332/allergolint.55.121; Fukushima A, 2007, CORNEA, V26, pS36, DOI 10.1097/ICO.0b013e31812f6970; Hashimoto T, 2003, J OCUL PHARMACOL TH, V19, P569, DOI 10.1089/108076803322660486; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Leonardi A, 2003, OPHTHALMOLOGY, V110, P487, DOI 10.1016/S0161-6420(02)01767-0; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Miyazaki Dai, 2004, Cornea, V23, pS48, DOI 10.1097/01.ico.0000136671.50777.fe; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P476, DOI 10.1016/j.jaci.2007.04.024; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97	22	47	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					466	471		10.1016/j.jaci.2008.09.044	http://dx.doi.org/10.1016/j.jaci.2008.09.044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	18996575				2022-12-18	WOS:000263495000027
J	Martin, MA; Catrambone, CD; Kee, RA; Evans, AT; Sharp, LK; Lyttle, C; Rucker-Whitaker, C; Weiss, KB; Shannon, JJ				Martin, Molly A.; Catrambone, Catherine D.; Kee, Romina A.; Evans, Arthur T.; Sharp, Lisa K.; Lyttle, Christopher; Rucker-Whitaker, Cheryl; Weiss, Kevin B.; Shannon, John Jay		Chicago Initiative Raise Asthma Hl	Improving asthma self-efficacy: Developing and testing a pilot community-based asthma intervention for African American adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adult asthma; asthma self-efficacy; behavioral randomized controlled trial; African American; low income; community health worker	INNER-CITY CHILDREN; DIABETES EMPOWERMENT SCALE; HEALTHY HOMES PROJECT; MANAGEMENT BEHAVIOR; OUTCOMES; QUALITY; TRIAL; VALIDATION; MORTALITY; KNOWLEDGE	Background: Low-income African American adults in Chicago have disproportionately high asthma morbidity and mortality rates. Interventions that improve asthma self-efficacy for appropriate self-management behaviors might ultimately improve asthma control in this population. Objective: We sought to pilot test an intervention to improve asthma self-efficacy for appropriate self-management behaviors. Methods: Participants for this trial were recruited through 2 primary care clinics located in the largest African American community in Chicago. Participants were then randomized into one of 2 groups. The control group received mailed asthma education materials. The intervention group was offered 4 group sessions led by a community social worker and 6 home visits by community health workers. Telephone interviews were conducted at baseline (before intervention), 3 months (after intervention), and 6 months (maintenance). Results: The 42 participants were predominantly African American and low income and had poorly controlled persistent asthma. The intervention group had significantly higher asthma self-efficacy at 3 months (P < .001) after the completion of the intervention. Asthma action plans were more common in the intervention group at 3 months (P = .06). At 6 months, the intervention group had improved asthma quality of life (P = .002) and improved coping (P = .01) compared with control subjects. Trends in behavioral and clinical outcomes favored the intervention group but were not statistically significant. Conclusions This community-based asthma intervention improved asthma self-efficacy, self-perceived coping skills, and asthma quality of life for low-income African American adults. Larger trials are needed to test the efficacy of this intervention to reduce asthma morbidity in similar high-risk populations. (J Allergy Clin Immunol 2009;123:153-9.)	[Martin, Molly A.; Rucker-Whitaker, Cheryl] Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; [Lyttle, Christopher; Weiss, Kevin B.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA; [Catrambone, Catherine D.] Rush Univ, Coll Nursing, Chicago, IL 60612 USA; [Sharp, Lisa K.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA; [Kee, Romina A.; Evans, Arthur T.] Cook Cty Hosp, Dept Internal Med, Chicago, IL 60612 USA	Rush University; Northwestern University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County	Martin, MA (corresponding author), Rush Univ, Med Ctr, Dept Prevent Med, 1700 W Van Buren St,Suite 470, Chicago, IL 60612 USA.	molly_a_martin@rush.edu		Sharp, Lisa/0000-0002-7809-9042	National Heart, Lung, and Blood Institute [1 U01 HL072496-05]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072496, U01HL072478] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grant 1 U01 HL072496-05, PI to K.B.W. and.I.J.S.	AKINBAMI L, 2003, ASTHMA PREVALENCE HL; *AM AC FAM PHYS AM, JOINT PRINC PAT CENT; Anderson RM, 2003, DIABETES CARE, V26, P1641, DOI 10.2337/diacare.26.5.1641-a; Anderson RM, 2000, DIABETES CARE, V23, P739, DOI 10.2337/diacare.23.6.739; Baier C, 1999, CHEST, V116, p204S, DOI 10.1378/chest.116.suppl_2.204S; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Braitman LE, 2002, ANN INTERN MED, V137, P693, DOI 10.7326/0003-4819-137-8-200210150-00015; BRAVATA DM, 2007, AHRQ PUBLICATION; Bursch B, 1999, J ASTHMA, V36, P115, DOI 10.3109/02770909909065155; BUTZ AM, 1994, CLIN PEDIATR, V33, P135, DOI 10.1177/000992289403300302; Campbell TS, 2006, INT J PSYCHOPHYSIOL, V62, P109, DOI 10.1016/j.ijpsycho.2006.02.005; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DELEON CFM, 2006, J CARDIOPULM REHABIL, V26, P9; DUNCAN GJ, 1987, INT STAT REV, V55, P97, DOI 10.2307/1403273; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Fisher EB, 2004, PEDIATRICS, V114, P116, DOI 10.1542/peds.114.1.116; Freimuth VS, 2001, SOC SCI MED, V52, P797, DOI 10.1016/S0277-9536(00)00178-7; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001005, DOI 10.1002/14651858.CD001005]; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114, DOI 10.1001/archpedi.156.2.114; Guevara JP, 2003, BMJ-BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kolbe J, 1996, CHEST, V110, P1463, DOI 10.1378/chest.110.6.1463; Krieger J, 2002, ENVIRON HEALTH PERSP, V110, P311, DOI 10.1289/ehp.02110s2311; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; LENKER SL, 1984, PATIENT EDUC COUNS, V6, P69, DOI 10.1016/0738-3991(84)90036-3; Lewis, 2002, HLTH BEHAV HLTH ED T, P45; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Mancuso CA, 2001, MED CARE, V39, P1326, DOI 10.1097/00005650-200112000-00008; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; National Asthma Education and Prevention Program Third Expert Panel on the Diagnosis and Management of Asthma, 2007, 3 NAT ASTHM ED PREV; Naureckas ET, 2007, CHEST, V132, p858S, DOI 10.1378/chest.07-1913; Radloff L, 1986, COMMUNITY SURVEYS PS, P177; RADLOFF LS, 1977, APPL PSYCH MEAS, V1, P395; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; Smith JR, 2005, HEALTH TECHNOL ASSES, V9, P1; Stout JW, 1998, J ASTHMA, V35, P119, DOI 10.3109/02770909809055413; Thomas SD, 1999, CHEST, V116, p135S, DOI 10.1378/chest.116.suppl_2.135S; van der Palen J, 1997, PATIENT EDUC COUNS, V32, pS35, DOI 10.1016/S0738-3991(97)00094-3; WEISS KB, 1990, AM J EPIDEMIOL, V132, pS107; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144; Wolf F, 2003, COCHRANE DB SYST REV, V1	46	47	47	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					153	159		10.1016/j.jaci.2008.10.057	http://dx.doi.org/10.1016/j.jaci.2008.10.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	399IP	19130936	Green Accepted			2022-12-18	WOS:000262793900025
J	Hunninghake, GM; Soto-Quiros, ME; Lasky-Su, J; Avila, L; Ly, NP; Liang, C; Klanderman, BJ; Raby, BA; Gold, DR; Weiss, ST; Celedon, JC				Hunninghake, Gary M.; Soto-Quiros, Manuel E.; Lasky-Su, Jessica; Avila, Lycliana; Ly, Ngoc P.; Liang, Catherine; Klanderman, Barbara J.; Raby, Benjamin A.; Gold, Diane R.; Weiss, Scott T.; Celedon, Juan C.			Dust mite exposure modifies the effect of functional IL10 polymorphisms on allergy and asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL10; asthma; IgE; dust mite; interaction; exacerbations; Costa Rica; CAMP	SINGLE-NUCLEOTIDE POLYMORPHISMS; CHILDHOOD ASTHMA; DIFFERENTIAL EXPRESSION; EARLY-LIFE; RISK; GENE; INTERLEUKIN-10; SENSITIZATION; CELLS; ATOPY	Background: The allergenicity of dust mite exposure might be dependent on variants in the gene for IL-10 (IL10). Objectives: To evaluate whether dust mite exposure modifies the effect of single nucleotide polymorphisms (SNPs) in IL10 on allergy and asthma exacerbations. Methods: We genotyped 6 SNPs in IL10 in 417 Costa Rican children and 503 white children in the Childhood Asthma Management Program (CAMP) with asthma and their parents. We used family-based and population-based approaches to test for interactions between IL10 SNPs and dust mite allergen on serum IgE to dust mite in Costa Rica and on asthma exacerbations in Costa Rica and CAMP. Results: Dust mite exposure significantly modified the relation between 3 SNPs in IL10 (rs1800896, rs3024492, and rs3024496) and IgE to dust mite in Costa Rica (P for interaction, .0004 for SNP rs1800896). For each of these SNPs, homozygosity for the minor allele was associated with increased levels of IgE to dust mite with increased dust mite exposure. Homozygosity for the minor allele of each of the 3 SNPs was associated with increased risk of occurrence (similar to 3-fold to 39-fold increase) and frequency of asthma exacerbations among children exposed to >= 10 mu g/g dust mite allergen in Costa Rica. Similar results were obtained for 2 of these SNPs (rs1800896 and rs3024496) among white children in CAMP. Conclusion: Our findings suggest that dust mite allergen levels modify the effect of IL10 SNPs on allergy and asthma exacerbations and may partly explain conflicting findings in this field.	[Hunninghake, Gary M.; Lasky-Su, Jessica; Ly, Ngoc P.; Liang, Catherine; Klanderman, Barbara J.; Raby, Benjamin A.; Gold, Diane R.; Weiss, Scott T.; Celedon, Juan C.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Hunninghake, Gary M.; Raby, Benjamin A.; Celedon, Juan C.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Hunninghake, Gary M.; Lasky-Su, Jessica; Ly, Ngoc P.; Klanderman, Barbara J.; Raby, Benjamin A.; Gold, Diane R.; Weiss, Scott T.; Celedon, Juan C.] Harvard Univ, Sch Med, Boston, MA USA; [Soto-Quiros, Manuel E.; Avila, Lycliana] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica; [Lasky-Su, Jessica] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Ly, Ngoc P.] Massachusetts Gen Hosp, Pediat Pulm Div, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Celedon, JC (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Raby, Benjamin/AAK-3866-2021	Avila, Lydiana/0000-0002-9579-1591	DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075419, R37HL066289, F32HL083634, K08HL074193, T32HL007427, U01HL065899, P01HL083069, R01HL066289, R01HL086601, K01HL004370] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66289, 1F32HL083634, HL074193, P01 HL083069, P01HL083069, U01 HL065899, U01HL65899, R37 HL066289, T32HL07427, R01HL086601, R01 HL066289, K08 HL074193, R01 HL086601, F32 HL083634, T32 HL007427, K01 HL004370, N01-HR-16049, U01 HL075419, U01HL075419, F32 HL083634-02, N01HR16049, HL04370] Funding Source: Medline; Wellcome Trust Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Carvajal-Carmona LG, 2003, HUM GENET, V112, P534, DOI 10.1007/s00439-002-0899-8; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Chung EY, 2007, GENES IMMUN, V8, P577, DOI 10.1038/sj.gene.6364420; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Demeo DL, 2008, AM J RESP CELL MOL, V38, P114, DOI 10.1165/rcmb.2007-0107OC; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65, DOI 10.1164/ajrccm.164.1.9911066; Escamilla MA, 1996, AM J MED GENET, V67, P244, DOI 10.1002/(SICI)1096-8628(19960531)67:3<244::AID-AJMG2>3.3.CO;2-8; Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465; Gibson AW, 2001, J IMMUNOL, V166, P3915, DOI 10.4049/jimmunol.166.6.3915; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Hakonarson H, 2001, AM J RESP CRIT CARE, V164, P2036, DOI 10.1164/ajrccm.164.11.2101086; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jeannin P, 1998, J IMMUNOL, V160, P3555; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Jungerius BJ, 2003, MOL BIOTECHNOL, V25, P283, DOI 10.1385/MB:25:3:283; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kurreeman FAS, 2004, HUM MOL GENET, V13, P1755, DOI 10.1093/hmg/ddh187; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Lake SL, 2004, ANN HUM GENET, V68, P55, DOI 10.1046/j.1529-8817.2003.00073.x; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lazarus R, 2002, GENOMICS, V80, P223, DOI 10.1006/geno.2002.6820; Lim S, 2004, ALLERGY, V59, P505, DOI 10.1111/j.1398-9995.2004.00455.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Matsumura Y, 2006, J IMMUNOL, V177, P4810, DOI 10.4049/jimmunol.177.7.4810; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Van Steen K, 2005, NAT GENET, V37, P683, DOI 10.1038/ng1582; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wong CK, 2006, INT IMMUNOL, V18, P1327, DOI 10.1093/intimm/dxl065	46	47	48	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					93	98		10.1016/j.jaci.2008.03.015	http://dx.doi.org/10.1016/j.jaci.2008.03.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18440625	Green Accepted			2022-12-18	WOS:000257605100015
J	Scordamaglia, F; Balsamo, M; Scordamaglia, A; Moretta, A; Mingari, MC; Canonica, GW; Moretta, L; Vitale, M				Scordamaglia, Francesca; Balsamo, Mirna; Scordamaglia, Antonio; Moretta, Alessandro; Mingari, Maria Cristina; Canonica, Giorgio Walter; Moretta, Lorenzo; Vitale, Massimo			Perturbations of natural killer cell regulatory functions in respiratory allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NK cells; allergy; DC; NK1/NK2; T(H)1/T(H)2 cytokines; rhinitis; asthma	HUMAN NK CELLS; HUMAN DENDRITIC CELLS; T-CELLS; RECEPTOR; INDUCTION; RESPONSES; IL-5; PATHOGENESIS; ACTIVATION; MATURATION	Background: Allergic diseases are characterized by abnormal responses to allergens favored by an inappropriate regulation of the T(H)1-T(H)2 polarization. Natural killer (NK) cells give rise to a complex NK/dendritic cell (DC) cross-talk that would help T(H)1 responses. Objective: By analyzing peripheral blood NK cells from 12 patients with either allergic rhinitis or rhinitis and intermittent asthma, we evaluated whether these cells were impaired in their ability to interact with DCs. Methods: Different circulating NK cell subsets were analyzed by flow cytofluorimetry. Mixed NK/DC cultures were performed to assess the reciprocal functional interactions. NK cells were analyzed for their ability to induce DC maturation and cytokine production, and to kill immature DCs. In addition, DCs were assessed for their ability to induce cytokine production by NK cells. Results: We first analyzed the CD56(++)CD16(+/-) cells, a subset of circulating NK cells that is able to respond to DCs by proliferating and producing IFN-gamma. Our analysis revealed that this NK cell subpopulation was significantly reduced in most patients. This was reflected by reduced NK cell-mediated IFN-gamma production in response to DCs. Also, the capability of promoting DC maturation and/or killing immature DCs, a function sustained by CD56(+)CD16(+) NK cells, was reduced in most patients. Conclusions: We suggest that allergic diseases are accompanied by a partial impairment of the NK cell capability of promoting and maintaining appropriate TO responses.	[Scordamaglia, Francesca; Scordamaglia, Antonio; Canonica, Giorgio Walter] Univ Genoa, Clin Malattie Apparato Resp Allergol, Dipartimento Med Interna, Genoa, Italy; [Moretta, Alessandro; Mingari, Maria Cristina; Moretta, Lorenzo] Univ Genoa, Dipartimento Med Sperimentale, Genoa, Italy; [Moretta, Alessandro; Moretta, Lorenzo] Univ Genoa, Ctr Eccellenza Ricerca Biomed, Genoa, Italy; [Mingari, Maria Cristina; Vitale, Massimo] Ist Nazl Ric Canc, SC Immunol Sperimentale, Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IRCCS AOU San Martino IST	Canonica, GW (corresponding author), Univ Genoa, Allergy & Resp Dis Clin, Dept Internal Med, Pad Maragliano Largo R Benzi, I-16132 Genoa, Italy.	canonica@unige.it	Moretta, Lorenzo/AAA-7239-2020; Vitale, Massimo/G-5135-2016; Mingari, Maria Cristina/AAB-1315-2019; canonica, giorgio walter/ABF-2037-2020	Moretta, Lorenzo/0000-0003-4658-1747; Vitale, Massimo/0000-0001-5372-7885; canonica, giorgio walter/0000-0001-8467-2557	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Aktas E, 2005, CLIN EXP IMMUNOL, V140, P301, DOI 10.1111/j.1365-2249.2005.02777.x; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Borg C, 2004, BLOOD, V104, P3267, DOI 10.1182/blood-2004-01-0380; Broide D, 1998, J IMMUNOL, V161, P7054; Canonica GW, 2002, ALLERGY, V57, P8, DOI 10.1034/j.1398-9995.57.s75.2.x; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2004, TRENDS IMMUNOL, V25, P47, DOI 10.1016/j.it.2003.10.012; Della Chiesa M, 2003, EUR J IMMUNOL, V33, P2947, DOI 10.1002/eji.200390042; Deniz G, 2002, EUR J IMMUNOL, V32, P879, DOI 10.1002/1521-4141(200203)32:3<879::AID-IMMU879>3.0.CO;2-2; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Jenmalm MC, 2001, CLIN EXP ALLERGY, V31, P1528, DOI 10.1046/j.1365-2222.2001.01190.x; Kalinski P, 2005, MOL IMMUNOL, V42, P535, DOI 10.1016/j.molimm.2004.07.038; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Loza MJ, 2004, J IMMUNOL, V172, P88, DOI 10.4049/jimmunol.172.1.88; Loza MJ, 2002, EUR J IMMUNOL, V32, P413, DOI 10.1002/1521-4141(200202)32:2<413::AID-IMMU413>3.0.CO;2-X; Marcenaro E, 2005, J IMMUNOL, V174, P3992, DOI 10.4049/jimmunol.174.7.3992; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; Moretta A, 2005, TRENDS IMMUNOL, V26, P668, DOI 10.1016/j.it.2005.09.008; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moretta L, 2004, TRENDS IMMUNOL, V25, P670, DOI 10.1016/j.it.2004.09.008; Moretta L, 2006, IMMUNOL REV, V214, P219, DOI 10.1111/j.1600-065X.2006.00450.x; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Peritt D, 1998, J IMMUNOL, V161, P5821; Perussia B, 2005, MOL IMMUNOL, V42, P385, DOI 10.1016/j.molimm.2004.07.017; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Vitale M, 2005, BLOOD, V106, P566, DOI 10.1182/blood-2004-10-4035; Vitale M, 2004, EUR J IMMUNOL, V34, P1715, DOI 10.1002/eji.200425100; Walker C, 1998, J IMMUNOL, V161, P1962; WARREN HS, 1995, J IMMUNOL, V154, P5144; Wei HM, 2005, J ALLERGY CLIN IMMUN, V115, P841, DOI 10.1016/j.jaci.2004.11.026; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040	45	47	56	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					479	485		10.1016/j.jaci.2007.09.047	http://dx.doi.org/10.1016/j.jaci.2007.09.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18061653				2022-12-18	WOS:000253337800030
J	van Schayck, OCP; Maas, T; Kaper, J; Knottnerus, AJA; Sheikh, A				van Schayck, Onno C. P.; Maas, Tanja; Kaper, Janneke; Knottnerus, Andre J. A.; Sheikh, Aziz			Is there any role for allergen avoidance in the primary prevention of childhood asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; prevention; multifaceted	BRONCHIAL HYPERREACTIVITY; MITE ALLERGEN; CHILDREN; SENSITIZATION; SYMPTOMS; EXPOSURE; OUTCOMES; RISK; REDUCTION; INFANCY	In this article we discuss 3 hypotheses to attempt to understand why preventive measures thus far studied with the aim of preventing (or delaying) the development of asthma have shown such disappointing results. The most likely explanation is that the development of a multifactorial disease, such as asthma, is extremely difficult, if not impossible, to prevent by eliminating only one risk factor. In a meta-analysis we investigated the effect of a multifaceted and monofaceted intervention in 10 prospective birth cohorts of a total of 3473 children on a diagnosis of asthma. Multifaceted intervention studies had an odds ratio (OR) of 0.73 (95% CI, 0.55-0.97), whereas the monointervention studies had an OR of 1.22 (95% CI, 0.83-1.78) in patients younger than 5 years and an OR of 0.52 (95% CI, 0.32-0.84) versus 0.93 (95% CI, 0.66-1.31) in patients older than 5 years. We therefore hypothesize that studies with a multifaceted approach will have a much greater chance of being successful than studies using a monofaceted approach, with the latter being unlikely to yield a clinically relevant reduction of asthma.	Maastricht Univ, Dept Gen Practice, Res Inst Caphri, NL-6200 MD Maastricht, Netherlands; Univ Edinburgh, Allergy & Resp Res Grp, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9YL, Midlothian, Scotland	Maastricht University; University of Edinburgh	van Schayck, OCP (corresponding author), Maastricht Univ, Dept Gen Practice, Res Inst Caphri, POB 616, NL-6200 MD Maastricht, Netherlands.	onno.vanschayck@hag.unimaas.nl	Knottnerus, Andre/F-4866-2013; Sheikh, Aziz/D-2818-2009; Knottnerus, Johannes A/A-3829-2009	Sheikh, Aziz/0000-0001-7022-3056; 				Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; BONER AL, 1985, ANN ALLERGY, V54, P42; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chen Y, 2002, EUR RESPIR J, V20, P1162, DOI 10.1183/09031936.02.00273102; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; GOTZSCHE PC, 2004, COCHRANE DB SYST REV, V18; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SCHONBERGER HJ, 2005, EUR RESPIR J, V25, P1, DOI DOI 10.1183/09031936.05.00067704; Sheffer AL, 2004, NEW ENGL J MED, V351, P1134, DOI 10.1056/NEJMe048177; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; van den Bemt L, 2004, J ALLERGY CLIN IMMUN, V114, P858, DOI 10.1016/j.jaci.2004.05.069; van Schayck CP, 2004, J CLIN EPIDEMIOL, V57, P435, DOI 10.1016/j.jclinepi.2003.12.011; vanStrien RT, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/j.1365-2222.1995.tb03042.x; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	33	47	49	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1323	1328		10.1016/j.jaci.2007.02.024	http://dx.doi.org/10.1016/j.jaci.2007.02.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17399772				2022-12-18	WOS:000247232800005
J	Hallstrand, TS; Debley, JS; Farin, FM; Henderson, WR				Hallstrand, Teal S.; Debley, Jason S.; Farin, Federico M.; Henderson, William R., Jr.			Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise-induced bronchoconstriction; epithelial cell; goblet cell; mucin	CANINE PERIPHERAL AIRWAYS; HYPERPNEA-INDUCED BRONCHOCONSTRICTION; LEUKOTRIENE-RECEPTOR ANTAGONIST; SUBSTANCE-P; INDUCED BRONCHOSPASM; CAUSES INFLAMMATION; EPITHELIAL-CELLS; MUCIN PRODUCTION; ASTHMA; MUCUS	Background: The pathogenesis of exercise-induced bronchoconstriction (EIB) involves the release of mediators from several airway cells in response to exercise challenge, but the mechanism leading to airflow obstruction during EIB is incompletely understood. Objective: To evaluate the role of secreted mucin in the pathogenesis of EIB. Methods: Induced sputum was collected at baseline and 30 minutes after exercise challenge in patients with asthma with EIB. The expression of gel-forming mucins and epidermal growth factor receptor ligands were assessed by quantitative polymerase chain reaction. Secreted mucin 5AC (MUC5AC), the eicosanoids cysteinyl leukotrienes (cysLTs) and 15Shydroxyeicosatetraenoic acid (15S-HETE), and tachykinins neurokinin A (NKA) and substance P (SP) were measured in induced sputum supernatant. Results: Among the gel-forming mucins, MUC5AC was expressed at the highest level. The gene expression of MUC5AC increased after exercise challenge compared with baseline and was associated with EIB severity by regression analysis. The relative levels of MUC5AC in induced sputum increased from a geometric mean of 9.5 at baseline to 18.4 postexercise challenge. Associations between the levels of MUC5AC and cysLTs and between the levels of cysLTs and NKA postexercise challenge were identified by regression analysis. Conclusions: These data indicate that (1) the predominant gel-forming mucin expressed in induced sputum of patients with asthma with EIB is MUC5AC; (2) an increase in MUC5AC gene expression and release of MUC5AC protein occurs after exercise challenge; and (3) MUC5AC release may occur through the cysLT-associated activation of sensory airway nerves.	Univ Washington, Dept Med, Div Pulm & Crit Care, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hallstrand, TS (corresponding author), Univ Washington, Dept Med, Div Pulm & Crit Care, Box 356522, Seattle, WA 98195 USA.	tealh@u.washington.edu		Hallstrand, Teal/0000-0002-5059-6872	NHLBI NIH HHS [K23 HL004231, K23 HL004231-05, K23HL04231] Funding Source: Medline; NIEHS NIH HHS [P30 ES007033, P30ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson SD, 2005, CURR ALLERGY ASTHM R, V5, P116, DOI 10.1007/s11882-005-0084-y; Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; Becker JM, 2004, J ALLERGY CLIN IMMUN, V113, P264, DOI 10.1016/j.jaci.2003.10.052; BLOOMQUIST EI, 1987, J PHARMACOL EXP THER, V240, P523; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; Cabral ALB, 1999, AM J RESP CRIT CARE, V159, P1819, DOI 10.1164/ajrccm.159.6.9805093; Crimi N, 2005, J ALLERGY CLIN IMMUN, V115, P870, DOI 10.1016/j.jaci.2005.01.041; Crimi N, 2003, J ALLERGY CLIN IMMUN, V111, P833, DOI 10.1067/mai.2003.161; Davis MS, 2003, MED SCI SPORT EXER, V35, P608, DOI 10.1249/01.MSS.0000058660.88987.A0; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121, DOI 10.1152/ajplung.1997.272.6.L1121; ELLIS JL, 1991, J PHYSIOL-LONDON, V436, P469, DOI 10.1113/jphysiol.1991.sp018561; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P879, DOI 10.1164/ajrccm.152.3.7663799; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Fehder WP, 1998, CLIN DIAGN LAB IMMUN, V5, P303, DOI 10.1128/CDLI.5.3.303-307.1998; Forsythe P, 2000, CLIN EXP ALLERGY, V30, P225; FREED AN, 1994, AM J RESP CELL MOL, V11, P724, DOI 10.1165/ajrcmb.11.6.7946400; Freed AN, 2003, AM J RESP CRIT CARE, V167, P1102, DOI 10.1164/rccm.200201-055OC; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hallstrand TS, 2002, J PEDIATR-US, V141, P343, DOI 10.1067/mpd.2002.125729; Hays SR, 2001, J ALLERGY CLIN IMMUN, V108, P784; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Ichinose M, 1996, AM J RESP CRIT CARE, V153, P936, DOI 10.1164/ajrccm.153.3.8630576; Ishikawa J, 1996, EUR RESPIR J, V9, P486, DOI 10.1183/09031936.96.09030486; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; KIM KC, 1989, AM J RESP CELL MOL, V1, P137, DOI 10.1165/ajrcmb/1.2.137; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; KUO HP, 1990, J PHYSIOL-LONDON, V431, P629, DOI 10.1113/jphysiol.1990.sp018351; Lai YL, 1999, N-S ARCH PHARMACOL, V360, P597, DOI 10.1007/s002109900090; Lamb JP, 2002, AM J RESP CRIT CARE, V166, P1269, DOI 10.1164/rccm.2112018; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; Mickleborough TD, 2005, MED SCI SPORT EXER, V37, P904, DOI 10.1249/01.mss.0000166949.11296.2b; NALINE E, 1989, AM REV RESPIR DIS, V140, P679, DOI 10.1164/ajrccm/140.3.679; Omori C, 1996, J APPL PHYSIOL, V81, P1255, DOI 10.1152/jappl.1996.81.3.1255; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; PEATFIELD AC, 1986, J PHYSIOL-LONDON, V380, P429, DOI 10.1113/jphysiol.1986.sp016295; SHEEHAN JK, 1991, AM REV RESPIR DIS, V144, pS4, DOI 10.1164/ajrccm/144.3_pt_2.S4; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Thornton David J, 2004, Proc Am Thorac Soc, V1, P54, DOI 10.1513/pats.2306016	44	47	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1092	1098		10.1016/j.jaci.2007.01.005	http://dx.doi.org/10.1016/j.jaci.2007.01.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17321575	Green Accepted			2022-12-18	WOS:000246427200007
J	Dharajiya, N; Choudhury, BK; Bacsi, A; Boldogh, I; Alam, R; Sur, S				Dharajiya, Nilesh; Choudhury, Barun K.; Bacsi, Attila; Boldogh, Istvan; Alam, Rafeul; Sur, Sanjiv			Inhibiting pollen reduced nicotinamide adenine dinucleotide phosphate oxidase-induced signal by intrapulmonary administration of antioxidants blocks allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; inflammation; antioxidants; eosinophils; T(H)2	MUCIN GENE-EXPRESSION; LUNG INFLAMMATION; OXIDATIVE STRESS; ASTHMATIC-PATIENTS; REACTIVE OXYGEN; IN-VIVO; HYPERRESPONSIVENESS; MODEL; EOSINOPHILS; RECRUITMENT	Background: Ragweed extract (RWE) contains NADPH oxidases that induce oxidative stress in the airways independent of adaptive immunity (signal 1) and augment antigen (signal 2)-induced allergic airway inflammation. Objective: To test whether inhibiting signal I by administering antioxidants inhibits allergic airway inflammation in mice. Methods: The ability of ascorbic acid (AA), N-acetyl cystenine (NAC), and tocopherol to scavenge pollen NADPH oxidase-generated reactive oxygen species (ROS) was measured. These antioxidants were administered locally to inhibit signal 1 in the airways of RWE-sensitized mice. Recruitment of inflammatory cells, mucin production, calcium-activated chloride channel 3, IL-4, and IL-13 mRNA expression was quantified in the lungs. Results: Antioxidants inhibited ROS generation by pollen NADPH oxidases and intracellular ROS generation in cultured epithelial cells. AA in combination with NAC or Tocopherol decreased RWE-induced ROS levels in cultured bronchial epithelial cells. Coadministration of antioxidants with RWE challenge inhibited 4-hydroxymmenal adduct formation, upregulation of Clca3 and IL-4 in lungs, mucin production, recruitment of eosinophils, and total inflammatory cells into the airways. Administration of antioxidants with a second RWE challenge also inhibited airway inflammation. However, administration of AA+NAC 4 or 24 hours after RWE challenge failed to inhibit allergic inflammation. Conclusion: Signal I plays a proinflammatory role during repeated exposure to pollen extract. We propose that inhibiting signal I by increasing antioxidant potential in the airways may be a novel therapeutic strategy to attenuate pollen-induced allergic airway inflammation. Clinical implications: Administration of antioxidants in the airways may constitute a novel therapeutic strategy to prevent pollen induced allergic airway inflammation.	Univ Texas, NHLBI, Proteom Ctr,Med Branch, Div Allergy & Immunol,Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Debrecen, Inst Immunol, H-4012 Debrecen, Hungary; Natl Jewish Med & Res Ctr, Denver, CO USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Debrecen; National Jewish Health	Sur, S (corresponding author), Univ Texas, Med Branch, Dept Internal Med & Microbiol, 8-104 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	sasur@utmb.edu		Bacsi, Attila/0000-0002-2311-2975	NCI NIH HHS [CA84461, R01 CA084461] Funding Source: Medline; NHLBI NIH HHS [R01 HL071163-02, N01HV28184, R01 HL071163, R01 HL071163-01A2, N01-HV28184, N01 HV028184-13] Funding Source: Medline; NIAID NIH HHS [P01 AI062885-03, P01 AI062885, P01 AI062885-02, P01 AI062885-01] Funding Source: Medline; NIEHS NIH HHS [P30 ES006676-11, P30 ES006676, P30 ES006676-09, P30 ES006676-10, ES06676] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA084461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI062885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacsi A, 2005, J ALLERGY CLIN IMMUN, V116, P836, DOI 10.1016/j.jaci.2005.06.002; Baulig A, 2003, AM J PHYSIOL-LUNG C, V285, pL671, DOI 10.1152/ajplung.00419.2002; Becker S, 2002, TOXICOL IN VITRO, V16, P209, DOI 10.1016/S0887-2333(02)00015-2; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Girotti AW, 1998, J LIPID RES, V39, P1529; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hiltermann TJN, 1998, FREE RADICAL BIO MED, V24, P952, DOI 10.1016/S0891-5849(97)00381-X; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kloek J, 2003, INFLAMM RES, V52, P126, DOI 10.1007/s000110300025; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Michalec L, 2002, J IMMUNOL, V168, P846, DOI 10.4049/jimmunol.168.2.846; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Pourazar J, 2005, AM J PHYSIOL-LUNG C, V289, pL724, DOI 10.1152/ajplung.00055.2005; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Schneider T, 1997, AM J RESP CELL MOL, V17, P702, DOI 10.1165/ajrcmb.17.6.2849; Stafford S, 1997, J IMMUNOL, V158, P4953; SUR S, 1995, ALLERGY, V50, P891, DOI 10.1111/j.1398-9995.1995.tb02495.x; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Sur S, 1996, J IMMUNOL, V157, P4173; Sur S, 1999, J IMMUNOL, V162, P6284; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; Vural H, 2000, Can Respir J, V7, P476	34	47	50	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					646	653		10.1016/j.jaci.2006.11.634	http://dx.doi.org/10.1016/j.jaci.2006.11.634			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336614	Green Accepted, Green Published			2022-12-18	WOS:000244925000018
J	Zeidler, MR; Goldin, JG; Kleerup, EC; Kim, HJ; Truong, DA; Gjertson, DW; Kennedy, NJ; Newman, KB; Tashkin, DP; Silverman, JM; Corren, J				Zeidler, Michelle R.; Goldin, Jonathan G.; Kleerup, Eric C.; Kim, Hyun J.; Truong, Dao A.; Gjertson, David W.; Kennedy, Nola J.; Newman, Kenneth B.; Tashkin, Donald P.; Silverman, Jeffrey M.; Corren, Jonathan			Small airways response to naturalistic cat allergen exposure in subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial hyperreactinity; Fel d 1 protein; image analysis; computer-assisted; tomography; x-ray computed	ALVEOLAR TISSUE; INFLAMMATION; AIR; CHALLENGE; VALUES	Background: It is currently unclear whether the small airways (diameter < 2 mu m) contribute significantly to late asthmatic reactions to inhaled allergen. Objectives: We sought to determine whether naturalistic exposure to cat allergen induced late responses in the small airways as measured by pulmonary function testing and high-resolution computed tomography (HRCT) of the chest performed at end-expiration. Methods: In a group of 10 subjects with cat-induced asthma, physiologic studies (spirometry and lung volumes, including closing volume) and HRCT were performed before and 6 and 23 hours after a cat room challenge that caused a 20% or greater acute fall in FEV1. Results: There was no significant decline in FEV1 at 6 or 23 hours after cat exposure. Forced expiratory flow at 25% to 75% of forced vital capacity was significantly decreased at, 6 hours after the challenge and returned to normal by 23 hours. HRCT image analysis as well as closing volume demonstrated increased air trapping from baseline at both 6 and 23 hours. after the challenge. In addition, image analysis demonstrated a significant increase in small airways hyperresponsiveness to methacholine at 23 hours after the challenge. No significant mean changes were noted in lung volumes at either 6 or 23 hours or in PC20 FEV1 at 23 hours postchallenge. Conclusion: These findings demonstrate that naturalistic exposure to cat allergen results in significant small airways obstruction and hyperresponsiveness persisting for at least 23 hours, at which time these changes cannot be detected by conventional physiologic measures. Clinical implications: Physiologically silent distal lung inflammation persists after an antigenic challenge.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm Crit Care Med & Hosp, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Thorac Radiol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med & Allergy Res Fdn, Div Clin Immunol & Allergy, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA; Forest Labs Inc, New York, NY USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Southern California	Corren, J (corresponding author), Allergy Res Fdn, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.	jcorren@ucla.edu		Goldin, Jonathan/0000-0003-3007-9947				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1994, Respir Care, V39, P1184; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Buist AS, 1973, CHEST J, V63, p29S; CARROLL N, 1993, AM REV RESPIR DIS, V147, pS29; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS105; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P211, DOI 10.1016/S1081-1206(10)62228-4; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Evans DJ, 1996, THORAX, V51, P1185, DOI 10.1136/thx.51.12.1185; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Jarry G, 2003, PHYS MED BIOL, V48, P2645, DOI 10.1088/0031-9155/48/16/306; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MACHADO L, 1990, ALLERGY, V45, P268, DOI 10.1111/j.1398-9995.1990.tb00495.x; MARTIN R, 1973, SUGGESTED STANDARDIZ; MCFADDEN ER, 1975, AM REV RESPIR DIS, V111, P135; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Peebles RS, 2001, CLIN EXP ALLERGY, V31, P239; Pifferi M, 2002, J PEDIATR-US, V141, P104, DOI 10.1067/mpd.2002.125006; Popa V, 2001, AM J RESP CRIT CARE, V163, P292, DOI 10.1164/ajrccm.163.1.16310b; RASMUSSEN JB, 1991, ALLERGY, V46, P419, DOI 10.1111/j.1398-9995.1991.tb04220.x; SHERTER CB, 1978, CHEST, V73, P568, DOI 10.1378/chest.73.5.568; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Tashkin DP, 2002, ALLERGY ASTHMA PROC, V23, P233; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605; 2003, IMPACT CT DOSIMETRY	35	47	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1075	1081		10.1016/j.jaci.2006.06.042	http://dx.doi.org/10.1016/j.jaci.2006.06.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088132				2022-12-18	WOS:000244282300012
J	Feng, Y; Hong, XM; Wang, L; Jiang, SQ; Chen, CZ; Wang, BY; Yang, JH; Fang, Z; Zang, TH; Xu, XP; Xu, X				Feng, Y; Hong, XM; Wang, L; Jiang, SQ; Chen, CZ; Wang, BY; Yang, JH; Fang, Z; Zang, TH; Xu, XP; Xu, X			G protein-coupled receptor 154 gene polymorphism is associated with airway hyperresponsiveness to methacholine in a Chinese population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway responsiveness to methacholine; asthma; GPR154; polymorphism	ASTHMA-RELATED TRAITS; SUSCEPTIBILITY LOCUS; HAPLOTYPES; CHILDHOOD; DIAGNOSIS; ALGORITHM; DISEASE; GENOME; TESTS	Background: A new asthma susceptibility gene, the G protein-coupled receptor for asthma susceptibility (GPRA, GPR154), has recently been identified and the association was replicated in 2 white populations, but not in a Korean population. Objective: To test the association between GPR154 gene polymorphisms and airway responsiveness to methacholine in a Chinese population. Methods: Eight single nucleotide polymorphisms (SNPs) in the GPR154 gene were genotyped in 451 cases and 232 controls in stage I. The association of I SNP, rs324981, was tested in an additional 264 case and 241 control subjects in stage If. Both single marker and haplotype associations were tested. Results: In stage I, we found that airway hyperresponsiveness to methacholine was associated with 2 single SNPs, rs324981 and rs324987, but not with the haplotypes of GPR154. The minor allele homozygotes of rs324981 (AA) and rs324987 (TT) were at a significantly lower risk of hyperresponsiveness to methacholine with odds ratios of 0.59 (P = .02) and 0.56 (P = .01), respectively. In stage II, we found a similar trend of association between rs324981 and airway hyperresponsiveness (P = .09). In the pooled analysis, the odds ratio of the AA homozygote of rs324981 was 0.61 (P = .004). The permutation test resulted in a study-wide empirical P value of .023, which meant that the association remained significant after adjustment for multiple tests. Conclusions: Our study supports a role of the GPR154 gene in asthma susceptibility and suggests that the AA homozygote of rs324981 is a protective factor for airway hyperresponsiveness to methacholine in a Chinese population. Clinical implications: Our findings confirmed a role of GPR154 in the genetic susceptibility of asthma and suggest that GPR154 polymorphism should be taken into consideration to improve the assessment of an individual's risk of asthma.	Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA; Anhui Med Univ, Anhui Inst Biomed, Hefei, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China; Univ Illinois, Sch Publ Hlth, Ctr Populat Genet, Chicago, IL 60680 USA	Harvard University; Harvard T.H. Chan School of Public Health; Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Xu, X (corresponding author), Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave,FXB-101, Boston, MA 02115 USA.	xin_xu@harvard.edu	Xu, Xin/A-1687-2016	Xu, Xin/0000-0002-6324-5211	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Celedon JC, 2000, AM J RESP CRIT CARE, V162, P1679, DOI 10.1164/ajrccm.162.5.2003007; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Irvin C G, 1995, Respir Care Clin N Am, V1, P265; James A, 1997, Respirology, V2, P97, DOI 10.1111/j.1440-1843.1997.tb00061.x; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Kjellman B, 2000, RESP MED, V94, P454, DOI 10.1053/rmed.1999.0764; Koppelman GH, 1999, CLIN EXP ALLERGY, V29, P1; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Melen E, 2005, AM J RESP CRIT CARE, V171, P1089, DOI 10.1164/rccm.200410-1317OC; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shin HD, 2004, J ALLERGY CLIN IMMUN, V114, P1226, DOI 10.1016/j.jaci.2004.08.003; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Xu XP, 1999, AM J RESP CRIT CARE, V160, P1928, DOI 10.1164/ajrccm.160.6.9902013	18	47	51	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					612	617		10.1016/j.jaci.2005.11.045	http://dx.doi.org/10.1016/j.jaci.2005.11.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522461				2022-12-18	WOS:000236263100017
J	Lemanske, RF; Busse, WW				Lemanske, RF; Busse, WW			Asthma: Factors underlying inception, exacerbation, and disease progression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; respiratory syncytial virus; rhinovirus; allergen; prevention; exacerbation; inception; treatment	PRIMARY PREVENTION; LUNG-FUNCTION; RISK-FACTORS; AIRWAY HYPERRESPONSIVENESS; 1ST YEAR; CHILDREN; CHILDHOOD; ENVIRONMENT; EXPOSURE; ALLERGEN	Asthma is a heterogeneous disorder that is characterized by variable airflow obstruction, airway inflammation and hyperresponsiveness, and reversibility either spontaneously or as a result of treatment. Multiple causes no doubt exist for both its inception and symptom exacerbation once the disease is established. Factors underlying inception can range from viral respiratory tract infections in infancy to occupational exposures in adults. Factors underlying asthma exacerbations include allergen exposure in sensitized individuals, viral infections, exercise, irritants, and ingestion of nonsteroidal anti-inflammatory agents among others. Exacerbating factors might include one or all of these exposures and vary both among and within patients. Asthma treatment is determined to a large extent after an assessment of severity, which can be variable over time and assessed in 2 domains: impairment (current) and risk (long-term consequences). Unfortunately, despite the availability of effective therapies, suboptimal asthma control exists in many patients on a worldwide basis. The future development of novel therapies and treatment paradigms should address these disparities.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, Dept Pediat, 600 Highland Ave,K4-916, Madison, WI 53792 USA.	rfl@medicine.wisc.edu			NHLBI NIH HHS [P01 HL070831, P50 HL056396] Funding Source: Medline; NIAID NIH HHS [P01 AI050500] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Bisgaard H, 2005, J ALLERGY CLIN IMMUN, V115, P708, DOI 10.1016/j.jaci.2004.11.018; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Casale TB, 2004, J ALLERGY CLIN IMMUN, V113, P1036, DOI 10.1016/j.jaci.2004.04.017; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; DUFF AL, 1992, PEDIATR CLIN N AM, V39, P1277; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS824, DOI 10.1067/mai.2003.151; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; GEM JE, 2004, J ALLERGY CLIN IMMUN, V113, P307; Gore C, 2002, Paediatr Respir Rev, V3, P205, DOI 10.1016/S1526-0542(02)00194-X; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Harding SM, 1999, J ALLERGY CLIN IMMUN, V104, P251, DOI 10.1016/S0091-6749(99)70360-X; Hasler G, 2005, AM J RESP CRIT CARE, V171, P1224, DOI 10.1164/rccm.200412-1669OC; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUNDELL KW, 2005, EXERCISE INDUCED AST, P181; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schonberger HJAM, 2005, EUR RESPIR J, V25, P660, DOI 10.1183/09031936.05.00067704; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Storms WW, 2005, IMMUNOL ALLERGY CLIN, V25, P31, DOI 10.1016/j.iac.2004.09.007; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Webley WC, 2005, AM J RESP CRIT CARE, V171, P1083, DOI 10.1164/rccm.200407-917OC; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118	75	47	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S456	S461		10.1016/j.jaci.2005.07.006	http://dx.doi.org/10.1016/j.jaci.2005.07.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455346	Bronze, Green Published			2022-12-18	WOS:000235865400007
J	Mak, JCW; Leung, HCM; Ho, SP; Law, BKW; Ho, ASS; Lam, WK; Ip, MSM; Chan-Yeung, MMW				Mak, JCW; Leung, HCM; Ho, SP; Law, BKW; Ho, ASS; Lam, WK; Ip, MSM; Chan-Yeung, MMW			Analysis of TGF-beta(1) gene polymorphisms in Hong Kong Chinese patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transforming growth factor-beta(1); polymorphism; asthma; disease severity; Hong Kong Chinese population	TRANSFORMING GROWTH-FACTOR-BETA-1 GENE; GROWTH FACTOR-BETA(1) GENE; NECROSIS-FACTOR-ALPHA; BRONCHIAL-ASTHMA; JAPANESE WOMEN; FATAL ASTHMA; ASSOCIATION; FIBROSIS; EXPRESSION; PROMOTER	Background: The C-509T polymorphism of TGF-beta 1 gene has been associated with asthma and atopy in white populations. Objective: We investigated the association between asthma and previously identified polymorphisms at C-509T and T869C of the TGF-beta(1) gene among 250 Chinese patients with asthma and 308 healthy controls in Hong Kong. Methods: Genotyping was performed on peripheral blood genomic DNA by using PCR-RFLP. Results: There were no differences in the frequencies of genotypes and alleles between patients and controls. The C-509T and T869C polymorphisms were in tight linkage disequilibriurn (P < .01). Among atopic subjects, significant differences were found in genotype and allele frequencies for T869C polymorphism between patients and controls (P = .014 and P = .019, respectively), and individuals bearing the CC genotype were associated with increased risk for the development of asthma (odds ratio, 2.58; 95% CI, 1.17-5.66; P = .018) after adjusting for age, sex, and smoking status. Individuals with asthma bearing the CT genotype of the C-509T polymorphism had significantly increased risk for severe airflow obstruction compared with individuals who had mild obstruction (odds ratio, 4.00; 95% CI, 1.06-15.08; P = .035). Conclusion: Our results indicate that the polymorphisms at C-509T and T869C of the TGF-beta(1) gene are associated with asthma susceptibility in atopic subjects of the Hong Kong Chinese population, and the C-509T polymorphism may play a role in the pathogenesis of airflow obstruction.	Univ Hong Kong, Dept Med, Div Resp Med, Hong Kong, Hong Kong, Peoples R China; Alice Ho Miu Ling Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Alice Ho Miu Ling Nethersole Hospital	Mak, JCW (corresponding author), Queen Mary Hosp, Dept Med, Room 804,Adm Block, Hong Kong, Hong Kong, Peoples R China.	judithmak@hkucc.hku.hk	Mak, Judith/C-4363-2009; Ip, Mary Sau Man/C-4284-2009	Ip, Mary Sau Man/0000-0002-8692-6933; Mak, Judith/0000-0002-8234-1313				Arkwright PD, 2000, THORAX, V55, P459, DOI 10.1136/thorax.55.6.459; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Buckova D, 2001, ALLERGY, V56, P1236, DOI 10.1034/j.1398-9995.2001.00373.x; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278, DOI 10.1164/ajrccm.160.1.9808032; Chou HT, 2004, AM HEART J, V148, P181, DOI 10.1016/j.ahj.2004.03.032; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281, DOI 10.1007/BF01570787; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Heinzmann A, 2005, PEDIAT ALLERG IMM-UK, V16, P310, DOI 10.1111/j.1399-3038.2005.00287.x; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Joseph J, 2003, ANN ALLERG ASTHMA IM, V91, P472, DOI 10.1016/S1081-1206(10)61516-5; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kokturk N, 2003, J ASTHMA, V40, P887, DOI 10.1081/JAS-120023580; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nagpal K, 2005, J ALLERGY CLIN IMMUN, V115, P527, DOI 10.1016/j.jaci.2004.11.048; Nakao A, 2001, TRENDS IMMUNOL, V22, P115, DOI 10.1016/S1471-4906(00)01827-5; *OFF AM THOR SOC, 2000, AM J RESP CRIT CARE, V162, P2341; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Perrey C, 1998, TRANSPL IMMUNOL, V6, P193, DOI 10.1016/S0966-3274(98)80045-2; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROCHE WR, 1989, LANCET, V1, P520; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Sato F, 2004, TISSUE ANTIGENS, V64, P35, DOI 10.1111/j.1399-0039.2004.00256.x; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Stoenescu M, 1999, ALLERGY, V54, P640, DOI 10.1034/j.1398-9995.1999.00214.x; Watanabe Y, 2002, J HUM GENET, V47, P478, DOI 10.1007/s100380200069; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035; Xaubet A, 2003, AM J RESP CRIT CARE, V168, P431, DOI 10.1164/rccm.200210-1165OC; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; Yamada Y, 2001, J MOL MED-JMM, V79, P149, DOI 10.1007/s001090100190; Yokota M, 2000, CIRCULATION, V101, P2783, DOI 10.1161/01.CIR.101.24.2783	39	47	54	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					92	96		10.1016/j.jaci.2005.08.049	http://dx.doi.org/10.1016/j.jaci.2005.08.049			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387590				2022-12-18	WOS:000235687100015
J	Lee, SJ; Kavanaugh, A				Lee, SJ; Kavanaugh, A			Adverse reactions to biologic agents: Focus on autoimmune disease therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rheumatoid arthritis; biologic agents; adverse reactions; monoclonal antibodies	NECROSIS-FACTOR-ALPHA; INDUCED GRANULOMA-FORMATION; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; MONOCLONAL-ANTIBODY; TNF-ALPHA; RITUXIMAB TREATMENT; FUSION PROTEIN; HEART-FAILURE; INFLIXIMAB	In recent years, a growing number of biologic agents have become available for the treatment of various autoimmune, neoplastic, cardiovascular, infectious, allergic, and other conditions. Their introduction has resulted in marked clinical improvements for many patients. Nevertheless, a variety of adverse reactions have been observed with these agents. Because many biologic agents affect key components of sundry physiologic processes, a number of important adverse reactions might be considered mechanism based. Other adverse reactions relate to the agent rather than the target, including hypersensitivity reactions. As a means of exploring the spectrum of potential adverse effects related to biologic agents and their mechanisms, this review will focus on the experience to date with biologic agents used for the treatment of autoimmune disorders. An understanding of the spectrum and types of reactions possible with biologic agents, as well as the mechanisms underlying such reactions, will help clinicians use them optimally.	Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kavanaugh, A (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	akavanaugh@ucsd.edu						Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Benini J, 1999, J PATHOL, V189, P127, DOI 10.1002/(SICI)1096-9896(199909)189:1<127::AID-PATH398>3.0.CO;2-S; Bieber J, 2004, RHEUM DIS CLIN N AM, V30, P257, DOI 10.1016/j.rdc.2004.01.003; Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2; Colombel JF, 2004, GASTROENTEROLOGY, V126, P19, DOI 10.1053/j.gastro.2003.10.047; Debandt M, 2003, CLIN RHEUMATOL, V22, P56, DOI 10.1007/s10067-002-0654-5; Dereure O, 2001, DERMATOLOGY, V203, P83, DOI 10.1159/000051713; Fleishmann RM, 2002, CLIN EXP RHEUMATOL, V20, pS35; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; Gonzalez-Stawinski GV, 2001, CLIN IMMUNOL, V98, P175, DOI 10.1006/clim.2000.4980; Hellerstedt B, 2003, ANN ONCOL, V14, P1792, DOI 10.1093/annonc/mdg488; Kaneko H, 1999, LAB INVEST, V79, P379; Kavanaugh A, 2004, J RHEUMATOL, V31, P1881; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kugathasan S, 2002, AM J GASTROENTEROL, V97, P1408, DOI 10.1016/S0002-9270(02)04140-0; Lee SJ, 2003, CURR ALLERGY ASTHM R, V3, P389, DOI 10.1007/s11882-003-0072-z; Magnano MD, 2004, CLIN EXP RHEUMATOL, V22, pS134; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; Mohan N, 2004, J RHEUMATOL, V31, P1955; Mohan N, 2001, ARTHRITIS RHEUM-US, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Nagle PC, 2003, AM J MANAG CARE, V9, pS124; Rojas M, 1999, J IMMUNOL, V162, P6122; Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815; Senaldi G, 1996, J IMMUNOL, V157, P5022; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; Soykan I, 2000, AM J GASTROENTEROL, V95, P2395; Symmons DPM, 2004, ARTHRITIS RHEUM-US, V50, P1703, DOI 10.1002/art.20312; van der Kolk LE, 2002, BLOOD, V100, P2257, DOI 10.1182/blood.V100.6.2257.h81802002257_2257_2259; van Vollenhoven RF, 2004, CLIN EXP RHEUMATOL, V22, pS122; van Vollenhoven RF, 2004, CLIN EXP RHEUMATOL, V22, pS115; Wasserman MJ, 2004, J RHEUMATOL, V31, P1912; Webb LMC, 1996, EUR J IMMUNOL, V26, P2320, DOI 10.1002/eji.1830261008; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Wolfe F, 2004, ARTHRITIS RHEUM-US, V50, P1740, DOI 10.1002/art.20311; Zeltser R, 2001, ARCH DERMATOL, V137, P893	38	47	47	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					900	905		10.1016/j.jaci.2005.03.028	http://dx.doi.org/10.1016/j.jaci.2005.03.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210067	Bronze			2022-12-18	WOS:000235686600027
J	Thien, R; Baier, K; Pietschmann, P; Peterlik, M; Willheim, M				Thien, R; Baier, K; Pietschmann, P; Peterlik, M; Willheim, M			Interactions of 1 alpha,25-dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vitamin D; immune system; CD4; CD8; IL-2; IL-6; IL-13; IFN-gamma; allergy; autoimmune disease	PERIPHERAL-BLOOD LYMPHOCYTES; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D-3; CELL CLONES; IFN-GAMMA; LYMPHOKINE PRODUCTION; FUNCTIONAL SUBSETS; HUMAN TH1; DIFFERENTIATION; INHIBITION	Background: 1 alpha,25-Dihydroxy vitamin D3 (1 alpha,25[OH](2)D-3) exerts its effects on the immune system, particularly through suppression of T helper/cytotoxic cell 1 (T-H/T(C)1)-mediated reactions, although direct actions of 1 alpha,25(OH)(2)D-3 on human T lymphocytes have not yet been studied in detail. Objective: We evaluated the effect of 1 alpha,25(OH)(2)D-3 on basal and cytokine-driven T-cell functions at the single-cell level. Methods: We used 4-color flow cytometry for simultaneous detection of intracellular cytokines in CD4+ and CD8+ human PBMCs that had been cultured in the presence of 1 alpha,5(OH)(2)D-3 singly or in combination with either IL-12 or IL-4. According to the exploratory nature of these investigations, the Bonferroni correction was not applied for data analysis and presentation. Results: 1 alpha,25(OH)(2)D-3 had little effect on T-H/T(C)1 cytokines but significantly inhibited IL-12-induced IFN-gamma production. Constitutive synthesis of T-H/T(C)2-related cytokines was also only modestly affected by 1 alpha,25(OH)(2)D-3 alone. When T-H/T(C)2 differentiation was induced by IL-4, 1 alpha,25(OH)(2)D-3 significantly expanded the percentages of IL-4(+) and IL-13(+) cells. However, the predominant effect of 1 alpha,25(OH)(2)D-3 on T lymphocytes, particularly in the presence of IL-4, was the induction of separate CD4(+) and CD8(+) subpopulations with almost exclusive expression of IL-6. This might be an important facet of the immunomodulatory action of 1 alpha,25(OH)(2)D-3 because IL-6 might act in parallel with 1 alpha,25(OH)(2)D-3 in modulation of T-H/T-C effector cell functions. Conclusions: Our data imply that the specific actions of 1 alpha,25(OH)(2)D-3 on cytokine-stimulated T-cell functions could play a role in the prevention of T-H/T(C)1-related autoimmune diseases but also predispose toward T-H/T(C)2-mediated allergic reactions.	Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria	Medical University of Vienna	Willheim, M (corresponding author), Med Univ Vienna, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	willheim@meduniwien.ac.at	Peterlik, Meinrad/A-6597-2009					BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; BHALLA AK, 1984, J IMMUNOL, V133, P1748; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; BOUILLON R, 1995, EUR J ENDOCRINOL, V133, P7, DOI 10.1530/eje.0.1330007; BRANISTEANU DD, 1995, J NEUROIMMUNOL, V61, P151, DOI 10.1016/0165-5728(95)00076-E; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Casteels K, 1995, Curr Opin Nephrol Hypertens, V4, P313, DOI 10.1097/00041552-199507000-00005; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; DEMEURE CE, 1994, J IMMUNOL, V152, P4775; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; HUSTMYER FG, 1992, IMMUNOLOGY, V77, P520; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; LEMIRE JM, 1995, J STEROID BIOCHEM, V53, P599, DOI 10.1016/0960-0760(95)00106-A; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANOLAGAS SC, 1990, KIDNEY INT S, V29, P9; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI [10.1016/S0091-6749(03)01855-4, 10.1037/mai.2003.1703]; Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471-4914(02)02294-3; Merlino LA, 2004, ARTHRITIS RHEUM-US, V50, P72, DOI 10.1002/art.11434; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER K, 1996, J INVEST DERMATOL S, V1, P68; Mullins LL, 2003, J PEDIATR PSYCHOL, V28, P115, DOI 10.1093/jpepsy/28.2.115; NOBLE A, 1995, J IMMUNOL, V155, P2928; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1203/01.PDR.0000017267.23950.48; Rausch-Fan X, 2002, INT ARCH ALLERGY IMM, V128, P33, DOI 10.1159/000058001; REICHEL H, 1987, P NATL ACAD SCI USA, V84, P3385, DOI 10.1073/pnas.84.10.3385; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; RIGBY WFC, 1987, J CLIN INVEST, V79, P1659, DOI 10.1172/JCI113004; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Staeva-Vieira TP, 2002, J IMMUNOL, V168, P1181, DOI 10.4049/jimmunol.168.3.1181; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Willheim M, 1999, J CLIN ENDOCR METAB, V84, P3739, DOI 10.1210/jc.84.10.3739; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x	41	47	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					683	689		10.1016/j.jaci.2005.05.013	http://dx.doi.org/10.1016/j.jaci.2005.05.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159643				2022-12-18	WOS:000235686500033
J	Grunstein, MM; Veler, H; Shan, XY; Larson, J; Grunstein, JS; Chuang, S				Grunstein, MM; Veler, H; Shan, XY; Larson, J; Grunstein, JS; Chuang, S			Proasthmatic effects and mechanisms of action of the dust mite allergen, Der p 1, in airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; dust mite allergen; airway smooth muscle; MAP kinases; airway hyperresponsiveness; cysteine protease	P38 MAP KINASE; RESPIRATORY EPITHELIAL-CELLS; PROTEASE-ACTIVATED RECEPTORS; SIGNAL-REGULATED KINASE; CYTOKINE PRODUCTION; GENE-EXPRESSION; ASTHMA; INHIBITION; RELEASE; PAR-2	Background: House dust mite allergen exposure is a key risk factor for the development of allergic asthma. Beyond provoking immune cell-mediated allergic responses, house dust mite allergens were recently shown to exert direct effects on airway structural cells secondary to their intrinsic protease activities. Objective: This study tested the hypothesis that house dust mite allergen exposure can produce changes in airway responsiveness through a direct effect on airway smooth muscle (ASM). Methods: Isolated rabbit ASM tissues were exposed to the house dust mite allergen, Der p 1, and induced changes in ASM responsiveness and activation of mitogen-activated protein kinase (MAPK) signaling pathways were examined under different experimental conditions. Results: The observations demonstrated the following: (1) Der p I exposure elicited enhanced constrictor responses and impaired relaxation responses in the ASM tissues, (2) these proasthmatic-like effects of Der p I were attributed to its intrinsic cysteine protease activity, and (3) the induced changes in ASM responsiveness were associated with activation of both the extracellular signal-regulated kinase (ERK) 1/2 and the p38 MAPK signaling pathways. Additionally, specific blockade of ERK1/2 signaling was found to prevent the Der p 1-induced changes in ASM responsiveness, whereas inhibition of p38 MAPK signaling enhanced the proasthmatic-like action of Der p 1, with the latter effect a result of augmented activation of ERK1/2. Conclusion: These findings are the first to demonstrate that the dust mite allergen, Der p 1, can directly elicit changes in ASM responsiveness that are associated with activation of MAPK signaling, wherein proasthmatic effects induced by Der p I are attributed to activation of ERK1/2, whereas coactivation of p38 MAPK exerts a homeostatic action by negatively regulating ERK1/2 signaling.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Pulm Med,Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grunstein, MM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Pulm Med,Joseph Stokes Jr Res Inst, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	grunstein@email.chop.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061038, R01HL031467] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61038, HL-31467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrani Y, 2001, MOL PHARMACOL, V60, P646; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Chambers LS, 2003, AM J PHYSIOL-LUNG C, V285, pL619, DOI 10.1152/ajplung.00416.2002; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Gerthoffer WT, 2003, RESP PHYSIOL NEUROBI, V137, P237, DOI 10.1016/S1569-9048(03)00150-2; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V280, pL229, DOI 10.1152/ajplung.2001.280.2.L229; Hallsworth MP, 2001, AM J RESP CRIT CARE, V164, P688, DOI 10.1164/ajrccm.164.4.2011004; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86, DOI 10.1165/ajrcmb.23.1.4014; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Page K, 2003, J ALLERGY CLIN IMMUN, V112, P1112, DOI 10.1016/j.jaci.2003.08.050; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Rice AB, 2002, AM J RESP CELL MOL, V27, P759, DOI 10.1165/rcmb.2002-0070OC; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; TANAKA DT, 1990, J CLIN INVEST, V85, P345, DOI 10.1172/JCI114444; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Tsang F, 1998, BRIT J PHARMACOL, V125, P61, DOI 10.1038/sj.bjp.0702049; Wan H, 2000, EUR RESPIR J, V15, P1058, DOI 10.1034/j.1399-3003.2000.01514.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200	39	47	52	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					94	101		10.1016/j.jaci.2005.03.046	http://dx.doi.org/10.1016/j.jaci.2005.03.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990780				2022-12-18	WOS:000235686300015
J	Saadane, A; Soltys, J; Berger, M				Saadane, A; Soltys, J; Berger, M			Role of IL-10 deficiency in excessive nuclear factor-kappa B activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cystic fibrosis; neutrophils; cytokines; chemokines; IL-10; NF-kappa B; I-kappa B	BRONCHIAL EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; CYTOKINE PRODUCTION; INTERLEUKIN-10; INFECTION; CFTR(-/-); ALPHA; MODEL	Background: Patients with cystic fibrosis (CF) and CF transmembrane conductance regulator knockout (CF-KO) mice are deficient in pulmonary IL-10 and have excessive inflammatory response to Pseudomonas aeruginosa infection. Objective: We hypothesized that local IL-10 deficiency in the lung was responsible for prolonged and excessive inflammatory responses and observations of inflammation in the absence of infection. Methods: To determine whether IL-10 deficiency could account for persistent inflammation in CF mice independent of interactions of bacteria with epithelial cells, we challenged IL-10-knockout (IL-10-KO), CF-KO, and wild-type (WT) mice intratracheally with LPS and determined the effects of IL-10 replacement in CF-KO mice. Results: In response to LPS, IL-10-KO and CF-KO mice had more neutrophils and proinflammatory cytokines in bronchoalveolar lavage than WT mice. Both types of knockout mice had more profound and prolonged consumption Of I-kappaB and increased activation of nuclear factor kappaB (NF-kappaB). Activated NF-kappaB persisted for 6 to 8 hours in CF-KO and IL-10-KO mice but was not detected beyond 2 hours in WT mice. IL-10 treatment of CF-KO mice attenuated the reduction in I-kappaBalpha and activation of NF-kappaB and reduced the excessive inflammation. Conclusion: Similarities in the responses of CF-KO and IL-10-KO mice and correction of excessive responses in CF mice by exogenous IL-10 suggest that deficiency of IL-10 may be responsible for prolonged and excessive inflammatory responses in CF. Because LPS was used as the stimulus, these excessive responses are independent of any possible differences in the interactions of bacteria with CF epithelial cells.	Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Berger, M (corresponding author), Case Western Reserve Univ, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	mxb12@cwru.edu	Soltys, Jindrich/P-3576-2019; Soltys, Jindrich/C-2399-2011	Soltys, Jindrich/0000-0002-4490-3151; Saadane, Aicha/0000-0001-9985-2147				BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BERGER M, 1999, IMMUNOPATHOGENESIS C; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chmiel JF, 2002, AM J RESP CRIT CARE, V165, P1176, DOI 10.1164/ajrccm.165.8.2107051; CHRISTIAN J, 2000, AM J PHYSIOL-CELL PH, V278, pC451; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; ECKMAN EA, 1995, AM J PHYSIOL-LUNG C, V269, pL625, DOI 10.1152/ajplung.1995.269.5.L625; Fernandez S, 2004, J IMMUNOL, V172, P2613, DOI 10.4049/jimmunol.172.4.2613; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Freedman SD, 2002, J APPL PHYSIOL, V92, P2169, DOI 10.1152/japplphysiol.00927.2001; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Muhlebach MS, 2002, AM J RESP CRIT CARE, V165, P911, DOI 10.1164/ajrccm.165.7.2107114; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; RUTH B, 1998, AM J RESP CELL MOL B, V19, P269; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; SKERRETT SJ, 2004, AM J PHYSL LUNG CELL; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Soltys J, 2002, J IMMUNOL, V168, P1903, DOI 10.4049/jimmunol.168.4.1903; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; Thomas GR, 2000, J IMMUNOL, V164, P3870, DOI 10.4049/jimmunol.164.7.3870; van Heeckeren AM, 2000, AM J RESP CRIT CARE, V161, P271, DOI 10.1164/ajrccm.161.1.9903019; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; Yu H, 1998, INFECT IMMUN, V66, P280, DOI 10.1128/IAI.66.1.280-288.1998	31	47	49	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					405	411		10.1016/j.jaci.2004.10.044	http://dx.doi.org/10.1016/j.jaci.2004.10.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696103				2022-12-18	WOS:000227043600031
J	Schubert, MS; Hutcheson, PS; Graff, RJ; Santiago, L; Slavin, RG				Schubert, MS; Hutcheson, PS; Graff, RJ; Santiago, L; Slavin, RG			HLA-DQB1*03 in allergic fungal sinusitis and other chronic hypertrophic rhinosinusitis disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 18-23, 2004	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol		chronic sinusitis; nasal polyps; allergic fungal sinusitis; fungal diseases; class II histocompatibility antigens; major histocompatibility complex; HLA-DQB1*03; immediate hypersensitivity; aspirin hypersensitivity; allergic bronchopulmonary aspergillosis; superantigen; T lymphocytes; antigen-presenting cells	LONG-TERMINAL REPEAT; LOCUS CONFERS SUSCEPTIBILITY; HLA-DQ LOCUS; RHEUMATOID-ARTHRITIS; NASAL POLYPOSIS; HLA-DQB1 GENE; MULTIPLE-SCLEROSIS; MOLECULAR-BASIS; SUPERANTIGEN; DISEASE	Background: Many common chronic inflammatory disorders have strong HLA gene associations, particularly with MHC class II. Allergic fungal rhinosinusitis (AFS) and hypertrophic sinus disease (HSD) are chronic sinonasal mucosal inflammatory disorders. Allergic bronchopulmonary aspergillosis, a disorder analogous to AFS, was recently reported to have HLA-MHC class II associations. Objective: We sought to determine whether MHC class II is also associated with AFS and HSD. Methods: HLA DNA genotyping was obtained on 44 patients with AFS and 30 patients with HSD (of which 21 were atopic). Results: Sixty-six percent of patients with AFS carried at least one HLA-DQB1*03 allele; DQB1*0301 and DQB1*0302 were the most frequent allelic variants (odds ratio [OR] vs healthy subjects = 8.22; 95% CI, 4.30-15.73; P <.001; OR vs all patients with HSD = 1.93; 95% CI, 1.09-3.41; P <.01; OR vs atopic patients with HSD = 2.57; 95% CI, 1.46-4.53; P <.001). Of the 31 patients with AFS and positive Bipolaris spicifera cultures, 68% had DQB1*03, with DQB1*0301 and DQB1*0302 being most frequent (OR vs healthy subjects = 8.93; 95% CI, 4.65-17.15; P <.001; OR vs patients with HSD = 2.10; 95% CI, 1.18-3.73; P <.001). Of the 30 patients with HSD, 50% carried DQB1*03 (OR vs healthy subjects = 4.25; 95% CI, 2.25-8.02; P <.001) but differed in frequencies of DQB1*03 allelic variants compared with patients with AFS (P = .0004). For HSD, nonatopic subjects bad the highest DQB1*03 association (OR vs healthy subjects = 8.63; 95% CI, 4.50-16.54; P <.001). DQBI*03 allelic variants did not correlate with allergy skin test results, atopic status, total serum IgE levels, culture results, asthma, or aspirin-nonsteroidal anti-inflammatory drug hypersensitivity. Conclusion: Patients with AFS and HSD have HLA-DQB1*03 alleles as a risk factor for disease, with AFS having the highest association. However, they differ in DQB1*03 allelic variant frequencies, suggesting several potential roles for MHC class 11 in their immunopathogenesis.	Allergy Asthma Clin Ltd, Phoenix, AZ 85013 USA; Univ Arizona, Coll Med, Dept Med, Phoenix, AZ USA; St Louis Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO USA	University of Arizona; Saint Louis University; Saint Louis University	Schubert, MS (corresponding author), Allergy Asthma Clin Ltd, 300 W Clarendon,Suite 120, Phoenix, AZ 85013 USA.							ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Berger G, 2002, LARYNGOSCOPE, V112, P738, DOI 10.1097/00005537-200204000-00026; Bieda K, 2002, DIABETOLOGIA, V45, P443, DOI 10.1007/s00125-001-0753-x; Chauhan B, 2000, J ALLERGY CLIN IMMUN, V106, P723, DOI 10.1067/mai.2000.109913; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; Domansky AN, 2000, FEBS LETT, V472, P191, DOI 10.1016/S0014-5793(00)01460-5; Emanuel IA, 2000, OTOLARYNG HEAD NECK, V123, P687, DOI 10.1067/mhn.2000.110961; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Firouzi R, 2003, J NEUROVIROL, V9, P79, DOI 10.1080/13550280390173328; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; HAMILOS DL, 2001, ACI INT, V13, P27; HIRAIWA A, 1990, P NATL ACAD SCI USA, V87, P8051, DOI 10.1073/pnas.87.20.8051; Horton R, 1998, J MOL BIOL, V282, P71, DOI 10.1006/jmbi.1998.2018; KAMBHU S, 1990, P NATL ACAD SCI USA, V87, P4927, DOI 10.1073/pnas.87.13.4927; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106; Kotb M, 2002, NAT MED, V8, P1398, DOI 10.1038/nm800; Krakauer T, 1999, IMMUNOL RES, V20, P163, DOI 10.1007/BF02786471; Lamblin C, 1999, J ALLERGY CLIN IMMUN, V104, P85, DOI 10.1016/S0091-6749(99)70118-1; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Lara JF, 2001, ARCH PATHOL LAB MED, V125, P1442; LEE TD, 1990, HLA SYSTEM NEW APPRO, P142; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Luxenberger W, 2000, EUR ARCH OTO-RHINO-L, V257, P137, DOI 10.1007/s004050050210; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Molnar-Gabor E, 2000, LARYNGOSCOPE, V110, P422, DOI 10.1097/00005537-200003000-00017; Mowat AM, 2003, LANCET, V361, P1290; Pani MA, 2002, CLIN ENDOCRINOL, V56, P773, DOI 10.1046/j.1365-2265.2002.t01-1-01548.x; Pascual M, 2001, IMMUNOGENETICS, V53, P114, DOI 10.1007/s002510100307; Raju R, 1997, HUM IMMUNOL, V58, P21, DOI 10.1016/S0198-8859(97)00212-7; Ramadan HH, 1997, AM J RHINOL, V11, P145, DOI 10.2500/105065897782537269; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; Sanchez-Segura A, 1998, J ALLERGY CLIN IMMUN, V102, P953, DOI 10.1016/S0091-6749(98)70333-1; Schubert M S, 2001, Curr Allergy Asthma Rep, V1, P268, DOI 10.1007/s11882-001-0018-2; SCHUBERT MS, 1992, ANN ALLERGY, V69, P231; Schubert MS, 2000, ANN ALLERG ASTHMA IM, V85, P90, DOI 10.1016/S1081-1206(10)62445-3; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Schubert MS, 2001, ANN ALLERG ASTHMA IM, V87, P181, DOI 10.1016/S1081-1206(10)62222-3; Seidl C, 2001, HUM IMMUNOL, V62, P523, DOI 10.1016/S0198-8859(01)00226-9; Seidl C, 1999, HUM IMMUNOL, V60, P63, DOI 10.1016/S0198-8859(98)00095-0; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P269, DOI 10.2500/108854196778662237; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; Stauffer Y, 2001, IMMUNITY, V15, P591, DOI 10.1016/S1074-7613(01)00212-6; Sutkowski N, 2001, IMMUNITY, V15, P579, DOI 10.1016/S1074-7613(01)00210-2; SVEJGAAR.A, 1974, TISSUE ANTIGENS, V4, P95; SZEZEKLIK A, 2003, J ALLERGY CLIN IMMUN, V111, P913; Wen L, 2000, J EXP MED, V191, P97, DOI 10.1084/jem.191.1.97; WINCHESTER R, 1994, ADV IMMUNOL, V56, P389, DOI 10.1016/S0065-2776(08)60456-3; Yasunaga S, 1996, TISSUE ANTIGENS, V47, P37, DOI 10.1111/j.1399-0039.1996.tb02512.x; Zanelli E, 1997, J IMMUNOL, V158, P3545	55	47	55	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1376	1383		10.1016/j.jaci.2004.08.029	http://dx.doi.org/10.1016/j.jaci.2004.08.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	877NN	15577839				2022-12-18	WOS:000225577400019
J	Sayers, I; Severn, W; Scanga, CB; Hudson, J; Le Gros, G; Harper, JL				Sayers, I; Severn, W; Scanga, CB; Hudson, J; Le Gros, G; Harper, JL			Suppression of allergic airway disease using mycobacterial lipoglycans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic airway disease; mycobacteria; lipoglycan; suppression; mouse model; T cell; immunoglobulin E; regulatory T cell; interleukin 10	BACILLUS-CALMETTE-GUERIN; BCG INFECTION; BOVIS-BCG; DC-SIGN; LIPOARABINOMANNAN; TUBERCULOSIS; VACCAE; CELLS; HYPERRESPONSIVENESS; EOSINOPHILIA	Background: Administration of heat-killed mycobacteria can suppress allergic disease in mice and humans. The active components of mycobacteria mediating these effects remain unresolved. Objective: We sought to identify the active components of mycobacteria mediating suppression of allergic disease and to determine structural features important for function. Methods: Using a murine model of allergic airway disease, we tested the ability of the lipoglycan fractions of the mycobacterial cell wall to suppress airway eosinophilia. Lipoglycans isolated from different strains of mycobacteria and chemical modifications were used to explore structure-function relationships. Markers of allergic disease including bronchoalvealor lavage cytokines, spleen and lymph node T-cell cytokine production, and serum specific immunoglobulin (Ig) E/IgG1 were examined. Results: We identified the mycobacterial cell wall lipoglycans lipoarabinomannan and phosphatidylinositol mannan as components of mycobacteria capable of suppressing airway disease (>70% reduction in airway eosinophilia; P < .03). Structure-function analysis identified the acyl chains and mannose groups of the molecules as having a role in mediating this effect. Mechanistic studies provided no evidence for a T-helper cell (Th) 1-mediated suppression of an ongoing Th2 response. An increased capacity of T cells to secrete interleukin 10 in the spleen and lymph node of treated animals was identified, suggesting a potential T-cell-mediated suppression mechanism. Conclusion: We have identified immunomodulatory component(s) of mycobacteria responsible for the protective effects observed in allergic disease; these findings will lead to the generation of synthetic compounds or agonists devoid of the unwanted characteristics of whole mycobacteria for evaluation in a human clinical setting.	Malaghan Inst Med Res, Wellington Sch Med, Wellington 6039, New Zealand; AgResearch, Wallaceville Anim Res Ctr, Upper Hutt, New Zealand	Malaghan Institute; University of Otago; Victoria University Wellington; AgResearch - New Zealand	Harper, JL (corresponding author), Malaghan Inst Med Res, Wellington Sch Med, POB 7060, Wellington 6039, New Zealand.	jharper@malaghan.org.nz	Harper, Jacquie/A-8920-2014; Le Gros, Graham/C-6725-2011	Sayers, Ian/0000-0001-5601-5410; Le Gros, Graham/0000-0002-5721-0442				Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; BARNES PF, 1992, J IMMUNOL, V149, P541; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516, DOI 10.4049/jimmunol.168.5.2516; Hopfenspirger MT, 2001, INT IMMUNOPHARMACOL, V1, P1743, DOI 10.1016/S1567-5769(01)00084-4; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Koh YI, 2000, J KOREAN MED SCI, V15, P265, DOI 10.3346/jkms.2000.15.3.265; LORDAN JL, 2002, IGE ANTI IGE THERAPY, P125; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Major T, 2002, VACCINE, V20, P1532, DOI 10.1016/S0264-410X(01)00496-0; Means TK, 1999, J IMMUNOL, V163, P6748; Nahori MA, 2001, VACCINE, V19, P1484, DOI 10.1016/S0264-410X(00)00345-5; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; Sano K, 1999, AM J RESP CELL MOL, V20, P1260, DOI 10.1165/ajrcmb.20.6.3546; Sayers I., 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P143, DOI 10.2174/1568014033483842; Severn WB, 1997, J MICROBIOL METH, V28, P123, DOI 10.1016/S0167-7012(97)00985-8; Severn WB, 1998, CARBOHYD RES, V308, P397, DOI 10.1016/S0008-6215(98)00108-6; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Wang CC, 1998, IMMUNOLOGY, V93, P307; YAMAMOTO S, 1988, JPN J CANCER RES, V79, P866, DOI 10.1111/j.1349-7006.1988.tb00049.x; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492, DOI 10.4049/jimmunol.169.3.1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	36	47	49	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					302	309		10.1016/j.jaci.2004.03.057	http://dx.doi.org/10.1016/j.jaci.2004.03.057			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316507				2022-12-18	WOS:000223405600014
J	Hackett, CJ				Hackett, CJ			Innate immune activation as a broad-spectrum biodefense strategy: Prospects and research challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						innate immune defense; adaptive immune system; vaccination; immunotherapeutic approaches	TOLL-LIKE RECEPTOR-2; MANNOSE-BINDING LECTIN; ANTHRAX LETHAL FACTOR; NF-KAPPA-B; PATTERN-RECOGNITION; CUTTING EDGE; DEPENDENT PROTECTION; NEGATIVE REGULATION; CPG MOTIFS; IN-VITRO	Biodefense strategies require protection against a broad and largely unforeseen spectrum of pathogens-the forte of innate immune system defenses-that have evolved over millennia to function within moments of encountering either ancient or newly emerging pathogens. Although constitutive, the innate immune system is activated by the presence of microbes or their products, providing a rationale for a potential biodefense strategy. Both prophylactic and postexposure strategies involving innate immune stimulation have been shown to be plausible to prevent or ameliorate infections in animal models. Innate immune-activating compounds based on conserved microbial components recognized by toll-like molecules and other receptors could be synthesized and delivered like drugs by using an entirely different strategy from conventional vaccination. However, important theoretic and practical questions, emerge about developing and deploying innate immune protective strategies for biodefense. This rostrum discusses prospects and. problems in the overall approach itself. Important topics include microbe-specific issues about innate immune system effectiveness against highly virulent pathogens and general questions, such as whether innate immune responses will be safe and effective if used in a diverse human population of different age groups and with different genetic makeups.	NIAID, Mol & Struct Immunol Sect, Basic Immunol Branch, Div Allergy Immunol & Transplantat,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Hackett, CJ (corresponding author), NIAID, Mol & Struct Immunol Sect, Basic Immunol Branch, Div Allergy Immunol & Transplantat,NIH, 6610 Rockledge Dr,Room 3009, Bethesda, MD 20892 USA.			Hackett, Charles/0000-0003-4586-9669				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1008; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cornelie S, 2002, INTENS CARE MED, V28, P1340, DOI 10.1007/s00134-002-1418-z; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Dornand J, 2002, VET MICROBIOL, V90, P383, DOI 10.1016/S0378-1135(02)00223-7; Elkins KL, 1999, J IMMUNOL, V162, P2291; Engele M, 2002, J IMMUNOL, V168, P1328, DOI 10.4049/jimmunol.168.3.1328; Equils O, 2003, J IMMUNOL, V170, P5159, DOI 10.4049/jimmunol.170.10.5159; Ezekowitz RAB, 2001, LANCET, V358, P598, DOI 10.1016/S0140-6736(01)05814-7; Fehlbaum P, 2000, P NATL ACAD SCI USA, V97, P12723, DOI 10.1073/pnas.220424597; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Giles FJ, 2002, EXPERT OPIN INV DRUG, V11, P1161; Ginaldi L, 2001, MICROBES INFECT, V3, P851, DOI 10.1016/S1286-4579(01)01443-5; Gramzinski RA, 2001, INFECT IMMUN, V69, P1643, DOI 10.1128/IAI.69.3.1643-1649.2001; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hickman-Davis JM, 2001, AM J PHYSIOL-LUNG C, V281, pL517, DOI 10.1152/ajplung.2001.281.3.L517; Hillman MR, 2002, VACCINE, V20, P3055, DOI 10.1016/S0264-410X(02)00300-6; HOOVER DL, 1994, INFECT IMMUN, V62, P4432, DOI 10.1128/IAI.62.10.4432-4439.1994; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jones CA, 2002, J ALLERGY CLIN IMMUN, V109, P858, DOI 10.1067/mai.2002.123535; Jude BA, 2003, NAT IMMUNOL, V4, P573, DOI 10.1038/ni926; Juffermans NP, 2002, INFECT IMMUN, V70, P147, DOI 10.1128/IAI.70.1.147-152.2002; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kopp E, 2002, J EXP MED, V196, P1009, DOI 10.1084/jem.20021311; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krieg AM, 1998, J IMMUNOL, V161, P2428; Labeta MO, 2000, J EXP MED, V191, P1807, DOI 10.1084/jem.191.10.1807; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; Madsen HO, 1998, J IMMUNOL, V161, P3169; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mills KHG, 2001, MICROBES INFECT, V3, P655, DOI 10.1016/S1286-4579(01)01421-6; Moser JM, 2002, CURR OPIN IMMUNOL, V14, P509, DOI 10.1016/S0952-7915(02)00357-6; Mushegian A, 2001, J CELL BIOL, V155, P705, DOI 10.1083/jcb.200107040; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Nau GJ, 2003, J IMMUNOL, V170, P5203, DOI 10.4049/jimmunol.170.10.5203; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Park MS, 2003, J VIROL, V77, P1501, DOI 10.1128/JVI.77.2.1501-1511.2003; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Price NO, 2001, CLIN INFECT DIS, V33, P260, DOI 10.1086/321831; Reading PC, 1995, BIOCHEM BIOPH RES CO, V217, P1128, DOI 10.1006/bbrc.1995.2886; ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; SINGH Y, 1989, J BIOL CHEM, V264, P11099; Smirnova I, 2003, P NATL ACAD SCI USA, V100, P6075, DOI 10.1073/pnas.1031605100; Smith HRC, 2002, P NATL ACAD SCI USA, V99, P8826, DOI 10.1073/pnas.092258599; Stunz LL, 2002, EUR J IMMUNOL, V32, P1212, DOI 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D; Symons JA, 2002, J GEN VIROL, V83, P1953, DOI 10.1099/0022-1317-83-8-1953; Verthelyi D, 2003, J IMMUNOL, V170, P4717, DOI 10.4049/jimmunol.170.9.4717; Walker PS, 1999, P NATL ACAD SCI USA, V96, P6970, DOI 10.1073/pnas.96.12.6970; Wang LL, 2002, J CLIN INVEST, V110, P1175, DOI 10.1172/JCI200215536; Yamada H, 2002, J IMMUNOL, V169, P5590, DOI 10.4049/jimmunol.169.10.5590; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Zimmermann S, 1998, J IMMUNOL, V160, P3627	89	47	52	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					686	694		10.1016/S0091-6749(03)02025-6	http://dx.doi.org/10.1016/S0091-6749(03)02025-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564345	Bronze, Green Published			2022-12-18	WOS:000185831200006
J	Alexis, NE; Eldridge, MW; Peden, DB				Alexis, NE; Eldridge, MW; Peden, DB			Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; phagocytosis; CD11b; neutrophil response	LIPOPOLYSACCHARIDE-BINDING PROTEIN; ACUTE LUNG INJURY; SOLUBLE CD14; ALLERGEN PROVOCATION; ALVEOLAR MACROPHAGES; NEUTROPHIL RESPONSE; LPS INHALATION; TNF-ALPHA; MONOCYTES; IL-10	Background: In a cohort of 8 normal and 10 allergic asthmatic volunteers, we previously reported that inhalation of 5 mug of endotoxin (LPS) induced airway inflammation that correlated with CD14 expression that was, in turn, correlated with eosinophil numbers in the airway. Macrophage and neutrophil functions have been reported to be modified by endotoxin in vitro and in vivo, and response to endotoxin is mediated largely by airway phagocytes and related to allergic inflammation. Objective: We sought to examine functional and cell-surface phenotype changes in phagocytes recovered from atopic asthmatic subjects after endotoxin challenge. Methods: Sputum and peripheral blood from 10 allergic asthmatic subjects was recovered after saline and LPS challenge. Assessment of phagocytosis and cell-surface phenotype (CD11b. CD14, and CD64) was performed on phagocytes obtained from sputum (n = 7) and blood samples (n = 10). Results: Phagocytosis of blood and sputum phagocytes was blunted after LPS challenge in a fashion that correlated with the increase in airway neutrophils after LPS challenge. Cell-surface expression of CD14 (membrane-bound CD14) was increased in sputum cells, whereas CD11b was decreased in sputum and circulating phagocytes. Baseline expression of CD11b in blood correlated with the magnitude of the neutrophil response after LPS inhalation, as well as (inversely) with baseline airway eosinophil levels. Conclusions: Inhalation of endotoxin at levels adequate to induce a neutrophil influx to the airways (but not systemic symptoms) and circulating cells and modifies CD11b expression in a way that implicates its involvement in pbagocyte responsiveness to inhaled LPS.	Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Gen Clin Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; NIEHS, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Peden, DB (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [N01ES035356] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL62624-01] Funding Source: Medline; NIEHS NIH HHS [N01-ES-35356] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; BROWN DM, 1995, AM J RESP CELL MOL, V13, P531, DOI 10.1165/ajrcmb.13.5.7576688; Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Gardinali M, 2000, AM J RESP CRIT CARE, V161, P1022, DOI 10.1164/ajrccm.161.3.9901066; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; GRISWOLD J, 1988, J SURG RES, V44, P417, DOI 10.1016/0022-4804(88)90184-9; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; Ingalls RR, 1998, J IMMUNOL, V161, P5413; Jean D, 1998, AM J RESP CRIT CARE, V158, P1702, DOI 10.1164/ajrccm.158.6.9709122; Judd Deborah M, 2003, J Am Acad Nurse Pract, V15, P151; Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129; LAURENT T, 1994, AM J RESP CRIT CARE, V149, P1534, DOI 10.1164/ajrccm.149.6.7911707; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307; LEUNG DYM, 1988, J IMMUNOL, V140, P84; LIAO GJ, 1994, J LEUKOCYTE BIOL, V55, P702, DOI 10.1002/jlb.55.6.702; Martin TR, 1997, AM J RESP CRIT CARE, V155, P937, DOI 10.1164/ajrccm.155.3.9117029; Martin TR, 2000, AM J RESP CELL MOL, V23, P128, DOI 10.1165/ajrcmb.23.2.f189; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; Quinn TJ, 2000, J APPL PHYSIOL, V88, P173, DOI 10.1152/jappl.2000.88.1.173; Reddy RC, 2001, INFECT IMMUN, V69, P1394, DOI 10.1128/IAI.69.3.1394-1401.2001; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; SANDSTROM T, 1994, AM J IND MED, V25, P103, DOI 10.1002/ajim.4700250127; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; SIMMS HH, 1990, J SURG RES, V49, P49, DOI 10.1016/0022-4804(90)90110-N; Spark JI, 2001, BRIT J SURG, V88, P1583, DOI 10.1046/j.0007-1323.2001.01925.x; Troelstra A, 1999, J IMMUNOL, V162, P4220; Viksman MY, 2002, CLIN IMMUNOL, V104, P77, DOI 10.1006/clim.2002.5233; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017; Virchow JC, 1998, EUR RESPIR J, V11, P317, DOI 10.1183/09031936.98.11020317	38	47	47	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					353	361		10.1067/mai.2003.1651	http://dx.doi.org/10.1067/mai.2003.1651			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897742				2022-12-18	WOS:000184650600020
J	Bryce, PJ; Geha, R; Oettgen, HC				Bryce, PJ; Geha, R; Oettgen, HC			Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T cell responses in murine models of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; antihistamine; mouse model	PLACEBO-CONTROLLED TRIAL; DENDRITIC CELLS; EOSINOPHILIC INFLAMMATION; H-1-RECEPTOR ANTAGONIST; CYTOKINE PRODUCTION; HISTAMINE-RECEPTOR; ATOPIC-DERMATITIS; EPITHELIAL-CELLS; H2 RECEPTORS; MOUSE MODEL	Background: Histamine elicits many features of immediate hypersensitivity reactions. Recent evidence indicates that HI receptors modulate immune responses to antigens. Desloratadine (DL), a new, long-acting, H1 receptor antagonist, has both a potent antihistaminic function and anti-inflammatory properties. Objective: We sought to evaluate the effect of DL on allergic-airway responses in mice after inhalation of the naturally occurring aeroallergen Aspergillus fumigatus (Af) and to examine the effects of DL on specific immune responses to a defined protein antigen with the use of an ovalbumin (OVA) model of asthma. Methods: Mice were subjected either to repeated, intranasal application of Af extract or to intraperitoneal immunization with OVA, followed by inhalation challenge. DL or a control fluid was given daily throughout the sensitization process. Immunoglobulin E (IgE) levels, bronchoalveolar lavage-fluid cytokines and cytology, lung histology, and physiologic responses to methacholine were assessed in the allergen-treated mice. Anti-OVA IgE responses and OVA-driven T-cell cytokine production were examined. Results: Treatment with DL did not impair IgE production but did inhibit bronchial inflammation and bronchial hyperresponsiveness in both Af- and OVA-treated mice. This inhibition required that DL be administered concurrently with allergen sensitization, indicating that the attenuation of bronchial hyperresponsiveness and inflammation was not caused by anticholinergic receptor effects. OVA-responsive T cells from DL-treated mice exhibited depressed production of IL-4, IL-5, and IL-13 and normal amounts of interferon-gamma. The amounts of IL-5 and IL-13 were also diminished in the bronchoalveolar lavage fluid. Conclusion: DL, given at the time of exposure to the allergen, inhibits T(H)2 responses, the induction of allergic pulmonary inflammation, and bronchial hyperresponsiveness. These results suggest that DL or similar agents given during times of antigen exposure might alter disease progression in patients with respiratory allergy.	Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Oettgen, HC (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Enders 8,320 Longwood Ave, Boston, MA 02115 USA.				NIAID NIH HHS [AI054471-01] Funding Source: Medline; NIAMS NIH HHS [AR47417] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Bentley AM, 1996, CLIN EXP ALLERGY, V26, P909, DOI 10.1111/j.1365-2222.1996.tb00626.x; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Busse WW, 1996, AM J RESP CRIT CARE, V153, P122, DOI 10.1164/ajrccm.153.1.8542104; CAMERON W, 1986, J IMMUNOL, V136, P2116; Canny GJ, 1997, EUR RESPIR J, V10, P65, DOI 10.1183/09031936.97.10010065; Cardelus I, 1999, EUR J PHARMACOL, V374, P249, DOI 10.1016/S0014-2999(99)00310-6; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; CASALE TB, 1985, BIOCHEM PHARMACOL, V34, P3285, DOI 10.1016/0006-2952(85)90347-8; COLLEY DG, 1972, EXP PARASITOL, V32, P520, DOI 10.1016/0014-4894(72)90070-7; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; CRIMI N, 1993, EUR RESPIR J, V6, P1462; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; DRIVER AG, 1987, EUR J PHARMACOL, V139, P287, DOI 10.1016/0014-2999(87)90586-3; EKSTROM T, 1995, ANN ALLERG ASTHMA IM, V75, P287; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FINNERTY JP, 1992, EUR RESPIR J, V5, P323; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770a; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1111/j.1365-2222.1997.tb00745.x; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gutzmer R, 2002, J ALLERGY CLIN IMMUN, V109, P524, DOI 10.1067/mai.2002.121944; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HILL SJ, 1990, PHARMACOL REV, V42, P45; HOLGATE ST, 1994, CLIN REV ALLERG, V12, P65; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Jutel M, 2001, INT ARCH ALLERGY IMM, V124, P190, DOI 10.1159/000053707; Kemp JP, 1996, J ALLERGY CLIN IMMUN, V97, P1218; Kjellman N I, 1993, Pediatr Allergy Immunol, V4, P38; Kreutner W, 2000, ARZNEIMITTEL-FORSCH, V50, pE345; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1994, J ALLERGY CLIN IMMUN, V93, P1013, DOI 10.1016/S0091-6749(94)70050-8; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; Lippert U, 2000, EXP DERMATOL, V9, P118, DOI 10.1034/j.1600-0625.2000.009002118.x; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Molet S, 1997, CLIN EXP ALLERGY, V27, P1167; Naclerio R, 1999, J ALLERGY CLIN IMMUN, V103, pS382, DOI 10.1016/S0091-6749(99)70216-2; Papi A, 2001, J ALLERGY CLIN IMMUN, V108, P221, DOI 10.1067/mai.2001.116861; REDINGTON AE, 1995, CHEM IMMUNOL, V62, P22; Reicin A, 2000, ARCH INTERN MED, V160, P2481, DOI 10.1001/archinte.160.16.2481; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Sawada K, 1997, CLIN EXP ALLERGY, V27, P225; Shimada K, 2001, METHOD FIND EXP CLIN, V23, P383, DOI 10.1358/mf.2001.23.7.662126; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Tasaka K, 1995, Inflamm Res, V44 Suppl 1, pS76, DOI 10.1007/BF01674404; To Y, 2001, LAB INVEST, V81, P1385, DOI 10.1038/labinvest.3780352; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; TWENTYMAN OP, 1993, J ALLERGY CLIN IMMUN, V91, P1169, DOI 10.1016/0091-6749(93)90320-F; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VanGanse E, 1997, EUR RESPIR J, V10, P2216, DOI 10.1183/09031936.97.10102216; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; VIGNOLA AM, 1995, ALLERGY, V50, P200, DOI 10.1111/j.1398-9995.1995.tb01133.x; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WOODBAKER R, 1995, BRIT J CLIN PHARMACO, V39, P671, DOI 10.1111/j.1365-2125.1995.tb05727.x; WOODBAKER R, 1993, J ALLERGY CLIN IMMUN, V91, P1005, DOI 10.1016/0091-6749(93)90213-Y	69	47	50	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					149	158		10.1067/mai.2003.1616	http://dx.doi.org/10.1067/mai.2003.1616			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847492				2022-12-18	WOS:000184010600023
J	Brown, SGA; Franks, RW; Baldo, BA; Heddle, RJ				Brown, SGA; Franks, RW; Baldo, BA; Heddle, RJ			Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DIAGNOSTIC METHODS; INSECT STINGS; HYMENOPTERA; HYPERSENSITIVITY; SENSITIVITY; BEE; ANAPHYLAXIS; FORMICIDAE; AUSTRALIA; DEATHS	Background: The jack jumper ant (Myrmecia pilosula) is responsible for greater than 90% of Australian ant venom allergy. However, deaths have only been recorded in the island of Tasmania. Objectives: We sought to determine the prevalence, clinical features, natural history, and predictors of severity of M pilosula sting allergy in Tasmania. Methods: We performed a random telephone survey supported by serum venom-specific IgE analysis, review of emergency department presentations, and follow-up of allergic volunteers. Results: M pilosula, honeybee (Apis mellifera), and yellow jacket wasp (Vespula germanica) sting allergy prevalences were 2.7%, 1.4%, and 0.6% compared with annual sting exposure rates of 12%, 7%, and 2%, respectively. Similarly, emergency department presentations with anaphylaxis to M pilosula were double those for honeybee. M pilosula allergy prevalence increased with age of 35 years or greater (odds ratio [OR], 2.4) and bee sting allergy (OR, 16.9). Patients 35 years of age or older had a greater risk of hypotensive reactions (OR, 2.9). Mueller reaction grades correlated well with adrenaline use. During follow-up, 79 (70%) of 113 jack jumper stings caused anaphylaxis. Prior worst reaction severity predicted the likelihood and severity of follow-up reactions; only 3 subjects had more severe reactions. Venom-specific IgE levels and other clinical features, including comorbidities, were not predictive of severity. Conclusions: Sting allergy prevalence is determined by age and exposure rate. M pilosula sting exposure in Tasmania is excessive compared with that found in mainland Australia, and there is a high systemic reaction risk in allergic people on re-sting. Prior worst reaction severity (Mueller grade) and age predict reaction severity and might be used to guide management.	Royal Hobart Hosp, Dept Emergency Med, Hobart, Tas 7000, Australia; Flinders Med Ctr, Dept Immunol Allergy & Arthrit, Bedford Pk, SA, Australia; NSL Hlth Ltd, Res Lab, Melbourne, Vic, Australia	Royal Hobart Hospital; Flinders Medical Centre	Brown, SGA (corresponding author), Royal Hobart Hosp, Dept Emergency Med, GPO 106L, Hobart, Tas 7000, Australia.			Brown, Simon/0000-0002-9961-0890				*AUSTR BUR STAT, 1996, CENS POP HOUS STAT T; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BAUER JH, 1993, DRUG AGING, V3, P238, DOI 10.2165/00002512-199303030-00005; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; Brown SGA, 2001, MED J AUSTRALIA, V175, P644, DOI 10.5694/j.1326-5377.2001.tb143761.x; CLARKE PS, 1986, MED J AUSTRALIA, V145, P564, DOI 10.5694/j.1326-5377.1986.tb139498.x; Douglas RG, 1998, J ALLERGY CLIN IMMUN, V101, P129, DOI 10.1016/S0091-6749(98)70206-4; Fernandez J, 1999, CLIN EXP ALLERGY, V29, P1069, DOI 10.1046/j.1365-2222.1999.00614.x; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HARVEY P, 1984, MED J AUSTRALIA, V140, P209, DOI 10.5694/j.1326-5377.1984.tb103996.x; HERMANN K, 1993, CLIN EXP ALLERGY, V23, P762, DOI 10.1111/j.1365-2222.1993.tb00364.x; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; McGain F, 2002, TOXICON, V40, P1095, DOI 10.1016/S0041-0101(02)00097-1; Mueller H.L., 1990, INSECT STING ALLERGY; OGATA K, 1991, J NAT HIST, V25, P1623, DOI 10.1080/00222939100771021; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SASVARY T, 1994, SCHWEIZ MED WSCHR, V124, P1887; SCHUMACHER MJ, 1994, J ALLERGY CLIN IMMUN, V93, P831, DOI 10.1016/0091-6749(94)90373-5; SETTIPANE GA, 1989, ALLERGY PROC, V10, P109, DOI 10.2500/108854189778961053; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; STREET MD, 1994, CLIN EXP ALLERGY, V24, P590, DOI 10.1111/j.1365-2222.1994.tb00957.x; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; Weiner JM, 1995, ANN ALLERG ASTHMA IM, V74, P60	25	47	49	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					187	192		10.1067/mai.2003.48	http://dx.doi.org/10.1067/mai.2003.48			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532117				2022-12-18	WOS:000180465500029
J	Gelfand, EW; Cui, ZH; Takeda, K; Kanehiro, A; Joetham, A				Gelfand, EW; Cui, ZH; Takeda, K; Kanehiro, A; Joetham, A			Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fexofenadine; allergen; inflammation; airway hyperresponsiveness	HISTAMINE H1-RECEPTOR ANTAGONIST; CHEMOKINE PRODUCTION; DENDRITIC CELLS; IL-6 PRODUCTION; EXPRESSION; TERFENADINE; RESPONSES; EOSINOPHILIA; CETIRIZINE; ICAM-1	Background: Antihistamines have been evaluated for usefulness in the treatment of asthma for more than 50 years. Interest was limited until the introduction of newer compounds that were free of much of the dose-limiting sedation associated with the earlier drugs. Objective: In a murine model of allergen-induced airway inflammation and hyperresponsiveness, the efficacy of an HI receptor antagonist to prevent allergic inflammation and altered airway function was evaluated. Methods: Mice were sensitized and challenged to an allergen, ovalbumin, which elicited marked airway and tissue eosinophilia and airway hyperresponsiveness. Fexofenadine was administered before challenge, and airway responsiveness to inhaled methacholine, airway and tissue eosinophilia, bronchoalveolar lavage fluid cytokine levels, and serum IgE levels were assayed. In a second group of experiments, sensitized and challenged mice were treated or not treated with fexofenadine before challenge. T cells were isolated from the lungs and adoptively transferred into naive recipients before exposure to limited airway allergen challenge, and lung function and inflammation were evaluated. Results: Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. These changes were accompanied by decreases in bronchoalveolar lavage and tissue eosinophilia, lymphocyte numbers, and T(H)2 cytokine production. Conclusion. The results demonstrate the efficacy of an H1 receptor antagonist in preventing allergen-induced alterations in pulmonary inflammation and airway function. The data support the evaluation of drugs such as fexofenadine in the treatment of allergic asthma.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.		KANEHIRO, Arihiko/B-1926-2011		NHLBI NIH HHS [HL-36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Bachert C, 1998, CLIN EXP ALLERGY, V28, P15; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; BEER DJ, 1984, ADV IMMUNOL, V35, P209, DOI 10.1016/S0065-2776(08)60577-5; Bentley AM, 1996, CLIN EXP ALLERGY, V26, P909, DOI 10.1111/j.1365-2222.1996.tb00626.x; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; CHAN TB, 1986, BRIT J DIS CHEST, V80, P375, DOI 10.1016/0007-0971(86)90091-4; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; DELNESTE Y, 1994, CLIN EXP IMMUNOL, V98, P344; EISER N, 1991, RESP MED, V85, P393, DOI 10.1016/S0954-6111(06)80184-8; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; GHOSH SK, 1991, THORAX, V46, P242, DOI 10.1136/thx.46.4.242; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HAMID M, 1990, CLIN EXP ALLERGY, V20, P261, DOI 10.1111/j.1365-2222.1990.tb02681.x; HILL SJ, 1990, PHARMACOL REV, V42, P45; JEANNIN P, 1994, BLOOD, V84, P2229; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; LICHTENSTEIN LM, 1976, PROGR IMMUNOL, V2, P73; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MELMON KL, 1976, MOL PHARMACOL, V12, P701; Miki I, 1996, CELL IMMUNOL, V171, P285; MOR S, 1995, J LEUKOCYTE BIOL, V58, P445, DOI 10.1002/jlb.58.4.445; Naclerio R, 1999, J ALLERGY CLIN IMMUN, V103, pS382, DOI 10.1016/S0091-6749(99)70216-2; Novak I, 1997, ACTA BIOL HUNG, V48, P385; Paolieri F, 1998, ANN ALLERG ASTHMA IM, V81, P601, DOI 10.1016/S1081-1206(10)62712-3; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SIMONS REF, 1993, ALLERGY PRINCIPLES P, P856; Slater JW, 1999, DRUGS, V57, P31, DOI 10.2165/00003495-199957010-00004; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; Triggiani M, 2001, J IMMUNOL, V166, P4083, DOI 10.4049/jimmunol.166.6.4083; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; White M, 1999, J ALLERGY CLIN IMMUN, V103, pS378, DOI 10.1016/S0091-6749(99)70215-0; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; WOODBAKER R, 1995, BRIT J CLIN PHARMACO, V39, P671, DOI 10.1111/j.1365-2125.1995.tb05727.x	49	47	49	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					85	95		10.1067/mai.2002.124770a	http://dx.doi.org/10.1067/mai.2002.124770a			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110826				2022-12-18	WOS:000176870300018
J	Yoshimura, C; Yamaguchi, M; Iikura, M; Izumi, S; Kudo, K; Nagase, H; Ishii, A; Walls, AF; Ra, C; Iwata, T; Igarashi, T; Yamamoto, K; Hirai, K				Yoshimura, C; Yamaguchi, M; Iikura, M; Izumi, S; Kudo, K; Nagase, H; Ishii, A; Walls, AF; Ra, C; Iwata, T; Igarashi, T; Yamamoto, K; Hirai, K			Activation markers of human basophils: CD69 expression is strongly and preferentially induced by 163	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; eosinophils; allergy; bronchial asthma; cytokines; bronchoalveolar lavage fluid; CD69; IL-3; human	AFFINITY IGE RECEPTOR; FC-EPSILON-RI; HUMAN EOSINOPHILS; MONOCLONAL-ANTIBODIES; LUNG EOSINOPHILS; MESSENGER-RNA; CELL-SURFACE; MAST-CELLS; ALLERGEN; CXCR4	Background: The biological functions of basophils are precisely regulated by various cytokines in vitro, but little is known about surface markers that are upregulated during the cytokine-mediated activation process. Objective: It has been well established that CD69, CD44, and CD54 represent "activation markers" for cytokine-mediated eosinophil activation. The objective of this study was to elucidate the expression and regulation of these molecules in human basophils in vitro as well as in vivo. Methods: Basophils were purified from venous blood by means of density gradient centrifugation followed by negative selection. Surface expression was analyzed by means of flow cytometry. We also studied the expression of CD69, CD44, and CD54 on basophils in bronchoalveolar lavage fluid and blood specimens from patients with asthma. Results: CD44 and CD54 were constitutively expressed on basophils and moderately upregulated by IL-3. On the other hand, CD69 expression was only weakly observed in freshly isolated basophils, but IL-3 induced extremely high levels of expression. Surface CD69 appeared rather slowly in comparison with CD63 and CD11b, and the induction of expression was completed within 24 hours. Basophil CD69 had no functional relevance, but it did have biological relevance. Whole blood basophils from asthmatic individuals expressed significantly higher levels of CD69 than did those from normal individuals. Furthermore, bronchoalveolar lavage fluid basophils showed higher levels of CD69 expression than did blood basophils from the same donors. Conclusion: CD69 expression on basophils was preferentially and strongly upregulated by IL-3. CD69 on basophils might be useful as an in vitro as well as in vivo marker of activation of these cells by IL-3.	Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Allery & Rheumatol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1138655, Japan; Int Med Ctr Japan, Dept Pulmonol, Tokyo, Japan; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England; Nihon Univ, Sch Med, Adv Med Res Ctr, Dept Mol Cell Immunol & Allergol, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan; University of Southampton; Nihon University	Hirai, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Yamamoto, Kazuhiko/N-5096-2015; Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901; Walls, Andrew/0000-0003-4803-4595				BOCHNER BS, 1990, J IMMUNOL, V145, P1832; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; GAVIOLI R, 1992, CELL IMMUNOL, V142, P186, DOI 10.1016/0008-8749(92)90279-X; Hirai K, 1997, CRIT REV IMMUNOL, V17, P325, DOI 10.1615/CritRevImmunol.v17.i3-4.40; Iikura M, 1998, J IMMUNOL, V161, P1510; Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Kayaba H, 2001, J IMMUNOL, V167, P995, DOI 10.4049/jimmunol.167.2.995; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Luttmann W, 1996, J IMMUNOL, V157, P1678; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; Mawhorter SD, 1996, J IMMUNOL, V156, P4851; McEuen AR, 1999, LAB INVEST, V79, P27; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nagase H, 2001, J ALLERGY CLIN IMMUN, V108, P563, DOI 10.1067/mai.2001.118292; *NAT ASTHM ED PREV, 1997, NIH PUBL, V97, P4051; NISHIKAWA K, 1992, J ALLERGY CLIN IMMUN, V90, P169, DOI 10.1016/0091-6749(92)90068-D; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; Smith SJ, 2000, J ALLERGY CLIN IMMUN, V105, P309, DOI 10.1016/S0091-6749(00)90081-2; Takai T, 2000, BIOSCI BIOTECH BIOCH, V64, P1856, DOI 10.1271/bbb.64.1856; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; Walsh GM, 1996, BLOOD, V87, P2815, DOI 10.1182/blood.V87.7.2815.bloodjournal8772815; Ying S, 1999, J IMMUNOL, V163, P3976; Yoshimura C, 2001, J ALLERGY CLIN IMMUN, V108, P215, DOI 10.1067/mai.2001.116575	30	47	51	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					817	823		10.1067/mai.2002.123532	http://dx.doi.org/10.1067/mai.2002.123532			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994706				2022-12-18	WOS:000175687800012
J	Foster, B; Schwartz, LB; Devouassoux, G; Metcalfe, DD; Prussin, C				Foster, B; Schwartz, LB; Devouassoux, G; Metcalfe, DD; Prussin, C			Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; mast cell; tryptase; human; asthma; mastocytosis; IgE; flow cytometry; FACS; Kit; 2D7; IgE; BB-1	ALLERGEN CHALLENGE; ASTHMATIC SUBJECTS; IL-4 PRODUCTION; FLOW-CYTOMETRY; IDENTIFICATION; MASTOCYTOSIS; ACTIVATION; FIBROBLASTS; ANTIBODIES; HISTAMINE	Background: Mast-cell tryptase is a protease with proinflammatory activity, the expression of which by peripheral blood leukocytes (PBLs) has not been fully characterized. Objective: We examined tryptase expression in human PBLs to further characterize this tryptase-expressing cell population for lineage and disease association. Methods: PBLs were fixed, permeabilized, stained with antibodies to tryptase and a panel of mast cell- and basophil-specific markers, and analyzed by means of flow cytometry. Results: Tryptase expression was restricted to a population of cells that stained positive for IgE and negative for the panel of lineage markers (IgE(+), lin(-)). This IgE(+), lin(-) population did not stain for the mast-cell markers Kit or chymase but did stain for the basophil-specific granule proteins recognized by the 2D7 and BB1 mAbs. Per-cell tryptase expression demonstrated a greater than 100-fold range of expression among donors but did not correlate with disease status (asthma or mastocytosis), FEV1, or serum tryptase concentration. Tryptase was released by purified basophils after anti-IgE activation. Conclusions: The phenotype of tryptase-expressing PBLs and their lack of increase in patients with mastocytosis demonstrates that these cells are basophils. Per-cell basophil tryptase expression is highly variable between donors, with some donors expressing levels approaching those of mast cells. As such, anti-tryptase antibodies cannot be used to distinguish these 2 cell types from one another by means of flow cytometry. These results demonstrate that tryptase represents an additional mediator through which basophils may contribute to allergic inflammation.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Virginia Commonwealth University	Prussin, C (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C205,10 Ctr Dr MSC 1881, Bethesda, MD 20892 USA.			Prussin, Calman/0000-0002-3917-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020487, Z01AI000709, R37AI020487, R21AI020487, Z01AI000513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045441] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20487] Funding Source: Medline; NIAMS NIH HHS [AR45441] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; Devouassoux G, 1999, J IMMUNOL, V163, P2877; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Falcone FH, 2000, BLOOD, V96, P4028; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gruber BL, 1997, J IMMUNOL, V158, P2310; Heaney LG, 1998, CLIN EXP ALLERGY, V28, P196; HOFFMAN RA, 1997, CURRENT PROTOCOLS CY; Huang CF, 1998, J IMMUNOL, V160, P1910; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Li LX, 1998, J IMMUNOL, V161, P5079; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; McEuen AR, 1999, LAB INVEST, V79, P27; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; PRUSSIN C, 1998, CURRENT PROTOCOLS IM; ROTTEM M, 1994, BLOOD, V84, P2489; Schroeder JT, 1997, J ALLERGY CLIN IMMUN, V99, P429, DOI 10.1016/S0091-6749(97)70065-4; SCHWARTZ A, 1993, ANN NY ACAD SCI, V677, P28, DOI 10.1111/j.1749-6632.1993.tb38760.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; 1987, AM REV RESP DIS, V136, P225	28	47	48	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					287	293		10.1067/mai.2002.121454	http://dx.doi.org/10.1067/mai.2002.121454			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842299				2022-12-18	WOS:000174232600014
J	Smith, WA; Hales, BJ; Jarnicki, AG; Thomas, WR				Smith, WA; Hales, BJ; Jarnicki, AG; Thomas, WR			Allergens of wild house dust mites: Environmental Der p 1 and Der p 2 sequence polymorphisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mites; allergens; environment; polymorphism; epitopes; T cells	T-CELL RESPONSES; GROUP-I ALLERGEN; EUROGLYPHUS-MAYNEI; MAJOR ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; MOLECULAR CHARACTERIZATION; GRASS-POLLEN; EXPRESSION; DER-P-2; ISOFORMS	Background: Sequence diversity is a common feature of mite allergens, Previous studies, using predominantly commercial mite clones, have described several polymorphic residues for Der p 1 and Her p 2. Objective: This study aimed at determining the occurrence of sequence diversity in environmental mite isolates. Methods: Mites were isolated from houses in Perth and Sydney, Australia. Total RNA was extracted from 1 to 30 Perth mites, and cDNA was synthesized by reverse transcriptase PCR, Der p 1 and Der p 2 cDNAs were PCR amplified and sequenced, Genomic Her p 1 DNA was amplified from whole Sydney mites directly by PCR and then sequenced, Results: Twelve Der p 1 and 9 Der p 2 cDNA clones and 3 Der p 1 genomic DNA were analyzed and showed a high frequency of amino acid polymorphisms. Der p 2 displayed a clear pattern of divergence toward 2 alleles that differed by 4 amino acids and had characteristic silent nucleotide changes. The pattern for Der p 1 was different and unusual, with almost no silent nucleotide substitutions but frequent sporadic missense changes. Proliferative responses of peripheral blood mononuclear cells to peptides containing polymorphic residues of Der p 1 were detected in 8 of 19 subjects, with stimulation being found only for either one of the variant forms of the peptides, However, the responses to variants of whole recombinant allergens were similar, as shown for 4 variants of Der p 2, Conclusion: Two clones for each of the allergens were identified as containing sequences that were largely representative of environmental isolates, A small-scale reverse transcriptase PCR used to produce cDNA from individual mites isolated From house dust will have wide application for studies on mite genetics and the production of recombinant mite allergens. Differences in T-cell responses to peptides representing variant epitopes were found, but responses to variants of whole recombinant allergens were similar. The GenBank and Swiss Prot database entries for Her p 1 (U11695) and Her p 2 (P49278) have been updated with the inclusion of the sequence polymorphisms described in this study.	Univ Western Australia, TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, W Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Thomas, WR (corresponding author), Univ Western Australia, TVW Telethon Inst Child Hlth Res, POB 855, W Perth, WA 6872, Australia.		Hales, Belinda J/C-3858-2013	Hales, Belinda J/0000-0003-2193-3996				CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364, DOI 10.1159/000236478; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Hales BJ, 1997, CLIN EXP ALLERGY, V27, P868, DOI 10.1111/j.1365-2222.1997.tb01226.x; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; KENT NA, 1992, INT ARCH ALLERGY IMM, V99, P150, DOI 10.1159/000236349; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; Olsson S, 1998, CLIN EXP ALLERGY, V28, P984, DOI 10.1046/j.1365-2222.1998.00375.x; ONG EK, 1993, GENE, V134, P235, DOI 10.1016/0378-1119(93)90099-O; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x	25	47	59	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					985	992		10.1067/mai.2001.114652	http://dx.doi.org/10.1067/mai.2001.114652			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398075				2022-12-18	WOS:000169454800008
J	Woodward, AL; Spergel, JM; Alenius, H; Mizoguchi, E; Bhan, AK; Castigli, E; Brodeur, SR; Oettgen, HC; Geha, RS				Woodward, AL; Spergel, JM; Alenius, H; Mizoguchi, E; Bhan, AK; Castigli, E; Brodeur, SR; Oettgen, HC; Geha, RS			An obligate role for T-cell receptor alpha beta T+ cells but not T-cell receptor gamma delta T+ cells, B cells, or CD40/CD40L interactions in a mouse model of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; alpha beta T cells; gamma delta T cells; B cells; CD40L; CD40	INFLAMMATORY RESPONSES; ALLERGIC DERMATITIS; IMMUNE-RESPONSE; IN-SITU; MICE; CD40; LYMPHOCYTES; HYPERRESPONSIVENESS; AEROALLERGEN; EXPRESSION	Background: We recently described a murine model of atopic dermatitis (AD) elicited by epicutaneous sensitization with ovalbumin (OVA). The skin lesions in these mice were characterized by a dermal infiltrate consisting of eosinophils and T cells and by increased expression of the T(H)2 cytokines IL-4 and IL-5. Epicutaneous sensitization induces a rise in the levels of serum total IgE and OVA-specific antibodies, further indicating that it elicits a predominantly T(H)2 response. Objective: This study was undertaken to assess the roles of T cells, B cells, and CD40L-CD40 interactions in AD. Methods: Mice with targeted gene deletions were sensitized with OVA. Histologic and immunohistochemical examinations, as well as measurements of IL-4 mRNA, were performed on OVA-sensitized skin. Total and antigen-specific serum IgE levels were determined. Results: RAG2(-/-) mice, which lack both T and B cells, did not exhibit cellular infiltration, induction of dermal IL-4 mRNA, or elevation of serum IgE after OVA sensitization: all of these features were present in B-cell-deficient IgH(-/-) mice. T-cell receptor alpha (-/-) mice did not display cellular infiltration, IL-4 mRNA expression, or increased IgE levels after OVA sensitization, but these responses were elicited in T-cell receptor delta (-/-) mice after sensitization. Absence of CD40 had no effect on these responses. Conclusion: These results suggest that alpha beta T cells, but not gamma delta T cells, B cells, or CD40L-CD40 interactions, are critical for skin inflammation and the T(H)2 response in AD.	Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Immunopathol Unit, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Geha, RS (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.			Alenius, Harri/0000-0003-0106-8923; Spergel, Jonathan/0000-0002-4658-5353	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031136, R21AI042202, U01AI031541, U19AI031541] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-42202, AI-31541, AI-31136] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhan AK, 1999, IMMUNOL REV, V169, P195, DOI 10.1111/j.1600-065X.1999.tb01316.x; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; FERREIRA AM, 1981, J IMMUNOL, V127, P2366; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hedrick SM, 1998, IMMUNOL REV, V165, P95, DOI 10.1111/j.1600-065X.1998.tb01233.x; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hollander GA, 1996, P NATL ACAD SCI USA, V93, P4994, DOI 10.1073/pnas.93.10.4994; Killeen N, 1998, CURR OPIN IMMUNOL, V10, P360, DOI 10.1016/S0952-7915(98)80176-3; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Lei XF, 1998, J CLIN INVEST, V101, P1342, DOI 10.1172/JCI1662; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Leung DYM, 1995, J ALLERGY CLIN IMMUN, V96, P312; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; MOMBAERTS P, 1994, INT IMMUNOL, V6, P106; Salerno A, 1998, CRIT REV IMMUNOL, V18, P327, DOI 10.1615/CritRevImmunol.v18.i4.30; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; STEINER G, 1988, EUR J IMMUNOL, V18, P1323, DOI 10.1002/eji.1830180904; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; TIGELAAR RE, 1995, J INVEST DERMATOL, V105, pS43, DOI 10.1111/1523-1747.ep12315280; Wiley JA, 1997, J IMMUNOL, V158, P2932; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	28	47	51	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					359	366		10.1067/mai.2001.112695	http://dx.doi.org/10.1067/mai.2001.112695			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174205				2022-12-18	WOS:000167071400025
J	Midoro-Horiuti, T; Goldblum, RM; Kurosky, A; Goetz, DW; Brooks, EG				Midoro-Horiuti, T; Goldblum, RM; Kurosky, A; Goetz, DW; Brooks, EG			Isolation and characterization of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Cha o 1; Cry j 1; Chamaecyparis obtusa; Cryptomeria japonica; Jun a 1; Juniperus ashei; Juniperus sabinoides; mountain cedar; pollinosis	CRYPTOMERIA-JAPONICA POLLEN; AMB-A-I; SHORT RAGWEED; ANTIBODIES; CLONING; IGE; IMMUNOTHERAPY; NOMENCLATURE; SEQUENCE; PROTEINS	Background: Cedar pollens are important causes of seasonal allergic disease in diverse geographic areas. Objective: A major allergen from mountain cedar (Juniperus ashei) pollen, termed Jun a 1, was isolated and characterized. Methods: Water-soluble pollen glycoproteins were extracted, salt precipitated, and purified with use of concanavalin A affinity chromatography or HPLC. The purified fractions were characterized by SDS-PAGE, immunoblotting, and N-terminal amino acid sequence analysis. Binding of allergen-specific IgE from the sera of cedar-hypersensitive patients was detected by ELISA and antigen-specific responses of peripheral blood T cells by tritiated thymidine incorporation. Results: The major extractable cedar pollen glycoprotein had a molecular weight and N-terminal amino acid sequence that was similar to that of the major allergen Cha o 1, from Japanese cypress (Chamaecyparis obtusa), and Cry j 1, from Japanese cedar (Cryptomeria japonica). IgE from cedar-hypersensitive patients' sera bound to the isolated glycoprotein, Conclusion: The predominance of Jun a 1 in the soluble proteins of mountain cedar pollen and its high degree of homology with Cha o 1 and Cry j 1 make it likely to be the major allergen of this pollen. Amino acid sequence conservation also makes Jun a 1 a potential target for cross-reactivity between these pollen allergens. The observed reactivity of IgE from the sera of Japanese cedar-sensitive patients with Jun a 1 is consistent with this proposition.	Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77550 USA; Wilford Hall USAF Med Ctr, Dept Allergy Immunol, Lackland AFB, TX 78236 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; United States Department of Defense; United States Air Force	Brooks, EG (corresponding author), Univ Texas, Med Branch, Dept Pediat, 301 Univ Blvd, Galveston, TX 77555 USA.		Midoro-Horiuti, Terumi M/AIE-7522-2022	Midoro-Horiuti, Terumi/0000-0002-0527-3644	NIEHS NIH HHS [P30 ES006676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKOS MA, 1991, J IMMUNOL, V146, P162; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; GOETZ DW, 1995, ANN ALLERG ASTHMA IM, V75, P256; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296, DOI 10.1159/000235512; GROSS GN, 1978, SCAND J IMMUNOL, V8, P437, DOI 10.1111/j.1365-3083.1978.tb00539.x; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANTLE M, 1978, Biochemical Society Transactions, V6, P607; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; Midoro-Horiuti T, 1992, Acta Paediatr Jpn, V34, P501; PANZANI R, 1986, ANN ALLERGY, V56, P460; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; Platts-Mills TAE, 1998, J ALLERGY CLIN IMMUN, V102, P335, DOI 10.1016/S0091-6749(98)70117-4; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; ROGERS BL, 1991, J IMMUNOL, V147, P2547; Sato K, 1997, ANN ALLERG ASTHMA IM, V79, P57, DOI 10.1016/S1081-1206(10)63085-2; SCHWIETZ LA, 1989, J ALLERGY CLIN IMMUN, V83, P253; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6; TAKAHASHI Y, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb00692.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X	25	47	50	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				608	612		10.1016/S0091-6749(99)70331-3	http://dx.doi.org/10.1016/S0091-6749(99)70331-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482835				2022-12-18	WOS:000082870000023
J	Brockow, K; Vieluf, D; Puschel, K; Grosch, J; Ring, J				Brockow, K; Vieluf, D; Puschel, K; Grosch, J; Ring, J			Increased postmortem serum mast cell tryptase in a fatal anaphylactoid reaction to nonionic radiocontrast medium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTRAST-MEDIA		Tech Univ Munich, Dept Dermatol Biederstein, D-80802 Munich, Germany; Univ Hamburg, Dept Dermatol & Allergy, Hamburg, Germany; Univ Hamburg, Dept Forens Med, Hamburg, Germany	Technical University of Munich; University of Hamburg; University of Hamburg	Brockow, K (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Brockow K, 1997, ALLERGOLOGIE, V20, P400; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; RANDALL B, 1995, J FORENSIC SCI, V40, P208; RING J, 1996, ALLERGY CLIN IMMUNOL, V8, P123; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	6	47	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					237	238		10.1016/S0091-6749(99)70141-7	http://dx.doi.org/10.1016/S0091-6749(99)70141-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400867				2022-12-18	WOS:000081738900037
J	Kanthawatana, S; Carias, K; Arnaout, R; Hu, J; Irani, AMA; Schwartz, LB				Kanthawatana, S; Carias, K; Arnaout, R; Hu, J; Irani, AMA; Schwartz, LB			The potential clinical utility of serum alpha-protryptase levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mastocytosis; anaphylaxis; tryptase; mast cell	HUMAN MAST-CELL; INFANT-DEATH-SYNDROME; PROTOONCOGENE C-KIT; SYSTEMIC MASTOCYTOSIS; HUMAN TRYPTASE; ANAPHYLAXIS; BLOOD; ACTIVATION; MUTATION; IDENTIFICATION	Background: Because biopsy criteria for diagnosing systemic mastocytosis are not precise, the value of serum alpha-protryptase levels in the work-up of suspected systemic mastocytosis should be considered. Objective: A retrospective analysis was performed on subjects with total tryptase serum levels that were high (greater than or equal to 20 ng/mL), while beta-tryptase serum levels were normal (<1 ng/mL) or modestly elevated (1 to 5 ng/mL). Methods: Over a 3.5-year period, 52 qualifying specimens mere identified from 1369 consecutive samples. The corresponding subjects were divided into those with suspected mastocytosis and those with suspected anaphylaxis. Subjects with suspected mastocytosis were subdivided into 3 subgroups on the basis of biopsy results (positive, negative, or not available). Subjects with suspected anaphylaxis were subdivided into living and deceased subgroups. Results: Among the 15 subjects who underwent biopsy, alpha-protryptase serum levels (the difference between directly-measured levels of serum total tryptase and beta-tryptase), when greater than 75 ng/mL (n = 9), were always associated with a positive biopsy result for systemic mastocytosis; levels from 20 to 75 ng/mL (n = 6) were associated with a positive biopsy resort in 50% of subjects. alpha-Protryptase serum levels may be a more sensitive screening test than a bone marrow biopsy for this disorder. Also, elevated alpha-protryptase serum levels in some adult patients return to normal over time, suggesting that mast cell hyperplasia resolved in these patients. Finally, a high alpha-protryptase level may reveal anaphylaxis to be a presenting manifestation of systemic mastocytosis or mast cell hyperplasia. Conclusion: Levels of serum alpha-protryptase, relative to those of beta-tryptase, appear to be useful in the diagnostic work-up and follow-up of subjects with suspected systemic mastocytosis.	Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, POB 980263, Richmond, VA 23298 USA.				NIAID NIH HHS [AI20487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R01AI020487, R21AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANSARI MQ, 1993, AM J CLIN PATHOL, V99, P101, DOI 10.1093/ajcp/99.1.101; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CASTLEMAN WL, 1990, AM J PATHOL, V137, P821; CASTLEMAN WL, 1989, VET PATHOL, V26, P18, DOI 10.1177/030098588902600104; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ESTON E, 1998, FORENSIC SCI INT, V93, P135; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hagan LL, 1998, ANN ALLERG ASTHMA IM, V80, P227, DOI 10.1016/S1081-1206(10)62962-6; HOLGATE ST, 1994, CLIN EXP ALLERGY, V24, P1115, DOI 10.1111/j.1365-2222.1994.tb03316.x; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; KETTELHUT BV, 1989, AM J CLIN PATHOL, V91, P558, DOI 10.1093/ajcp/91.5.558; Kitayama H, 1996, BLOOD, V88, P995; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; Nagata H, 1998, LEUKEMIA, V12, P175, DOI 10.1038/sj.leu.2400906; PLATT MS, 1994, J ALLERGY CLIN IMMUN, V94, P250, DOI 10.1016/0091-6749(94)90047-7; RANDALL B, 1995, J FORENSIC SCI, V40, P208; SCHWARTZ HJ, 1995, CLIN EXP ALLERGY, V25, P866, DOI 10.1111/j.1365-2222.1995.tb00029.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Shah PY, 1998, J AM ACAD DERMATOL, V39, P119, DOI 10.1016/S0190-9622(98)70413-X; SORDEN SD, 1995, LAB INVEST, V73, P197; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; XIA HZ, 1995, J IMMUNOL, V154, P5472; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	33	47	48	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1092	1099		10.1016/S0091-6749(99)70184-3	http://dx.doi.org/10.1016/S0091-6749(99)70184-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359891				2022-12-18	WOS:000080929500018
J	Novembre, E; Moriondo, M; Bernardini, R; Azzari, C; Rossi, ME; Vierucci, A				Novembre, E; Moriondo, M; Bernardini, R; Azzari, C; Rossi, ME; Vierucci, A			Lupin allergy in a child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LEGUME		Univ Florence, A Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, I-50132 Florence, Italy	University of Florence	Novembre, E (corresponding author), Univ Florence, A Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Via L Giordano 13, I-50132 Florence, Italy.		Moriondo, Maria/AAB-7883-2019; Azzari, Chiara/AAB-8584-2019	Moriondo, Maria/0000-0001-9653-8371; Azzari, Chiara/0000-0001-7236-1655				ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; Gutierrez D, 1997, CONTACT DERMATITIS, V36, P311, DOI 10.1111/j.1600-0536.1997.tb00012.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1	5	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1214	1216		10.1016/S0091-6749(99)70203-4	http://dx.doi.org/10.1016/S0091-6749(99)70203-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359910				2022-12-18	WOS:000080929500037
J	Holla, L; Vasku, A; Znojil, V; Siskova, L; Vacha, J				Holla, L; Vasku, A; Znojil, V; Siskova, L; Vacha, J			Association of 3 gene polymorphisms with atopic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						angiotensin-converting enzyme; angiotensinogen; endothelin-1; genes; polymorphism; enzymes; asthma bronchiale; atopy	SMOOTH-MUSCLE CELLS; I-CONVERTING ENZYME; ANGIOTENSINOGEN GENE; DELETION POLYMORPHISM; ENDOTHELIAL-CELLS; MESSENGER-RNA; ASTHMA; HYPERTENSION; TISSUE; RAT	Background: Various peptidases, including angiotensin-converting enzyme (ACE), inactivate some inflammatory peptides that are considered to influence the pathogenesis of atopic diseases. This enzyme is also involved in the conversion or activation of 2 bronchoconstriction mediators: angiotensin II from angiotensinogen and endothelin (ET), respectively. Objective: We tested a hypothesis that asthma or other atopic diseases are associated with insertion/deletion ACE, M235T angiotensinogen, and TaqI ET-1 gene polymorphisms, Methods: A case-control approach was used in the study, Healthy subjects (141 persons) were used as control subjects, and 231 patients with histories of atopic asthma, allergic rhinitis, atopic dermatitis, or a combination thereof were studied. ACE genotype was determined by PCR, angiotensinogen M235T and ET-1 by PCR, and restriction analysis by AspI and TaqI, respectively, Results: We Found the significant association of the insertion/deletion polymorphism of the ACE, as well as that of M235T polymorphism of the angiotensinogen genes, with the group of patients with atopic diseases (P =.0025 and P =.0204, respectively). No difference was proved for the intron 4 (position 8000) polymorphism in the ET-1 gene when comparing the atopic patients with the control group (P =.1774), A significant difference was found between groups of patients with both asthma and rhinitis and patients without both respiratory atopic diseases (P =.0033). Conclusion: It follows that the examined polymorphisms in the genes for ACE, angiotensinogen, and ET-1 could participate in the etiopathogenesis of atopic diseases.	Masaryk Univ, Fac Med, Inst Pathol Physiol, CZ-62500 Brno, Czech Republic	Masaryk University Brno	Holla, L (corresponding author), Masaryk Univ, Fac Med, Inst Pathol Physiol, Kamenice 3, CZ-62500 Brno, Czech Republic.		Holla, Lydie Izakovicova/H-7627-2014	Holla, Lydie Izakovicova/0000-0002-7610-8929				ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Benessiano J, 1997, J ALLERGY CLIN IMMUN, V99, P53, DOI 10.1016/S0091-6749(97)70300-2; Bonini S, 1996, ALLERGY, V51, P203; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DETEJADA IS, 1992, J UROLOGY, V148, P1290, DOI 10.1016/S0022-5347(17)36895-7; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GIAID A, 1990, J PATHOL, V162, P15, DOI 10.1002/path.1711620105; HAHN AWA, 1990, CELL REGUL, V1, P649, DOI 10.1091/mbc.1.9.649; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; HOLGATE ST, 1993, EUR RESPIR J, V6, P1507; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; JANDANSER AH, 1995, CIRCULATION, V92, P1387; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P564; KATO H, 1991, J HYPERTENS, V9, P17; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; LAZZARINIROBERT.A, 1972, CIRC RES, V31, P923; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAI K, 1994, CIRCULATION, V90, P2199, DOI 10.1161/01.CIR.90.5.2199; PADGETT RC, 1992, HYPERTENSION, V20, P408; RIGGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433; RIGGAT B, 1990, J CLIN INVEST, V86, P1343; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; RUSS AP, 1993, HUM MOL GENET, V2, P609, DOI 10.1093/hmg/2.5.609; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SCHIFFRIN EL, 1995, HYPERTENSION, V25, P1135, DOI 10.1161/01.HYP.25.6.1135; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SHINDLER R, 1995, CYTOKINE, V7, P526; SIMONSON MS, 1992, J LAB CLIN MED, V119, P622; SPORN MB, 1986, J CLIN INVEST, V78, P329, DOI 10.1172/JCI112580; SUZUKI N, 1989, J BIOCHEM-TOKYO, V106, P736, DOI 10.1093/oxfordjournals.jbchem.a122925; TIRET L, 1992, AM J HUM GENET, V51, P197; UEMASU J, 1994, CLIN NEPHROL, V41, P150; VUK PZ, 1989, J LEUKOCYTE BIOL, V45, P503; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WINTROUB BU, 1984, BIOCHEMISTRY-US, V23, P227, DOI 10.1021/bi00297a009; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YU JCM, 1995, BRIT J PHARMACOL, V114, P551, DOI 10.1111/j.1476-5381.1995.tb13262.x	51	47	50	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					702	708		10.1016/S0091-6749(99)70246-0	http://dx.doi.org/10.1016/S0091-6749(99)70246-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200023				2022-12-18	WOS:000079723900027
J	Mashikian, MV; Tarpy, RE; Saukkonen, JJ; Lim, KG; Fine, GD; Cruikshank, WW; Center, DM				Mashikian, MV; Tarpy, RE; Saukkonen, JJ; Lim, KG; Fine, GD; Cruikshank, WW; Center, DM			Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchoalveolar lavage; IL-16; lymphocyte chemotaxis; histamine	BEARING MONONUCLEAR-CELLS; CHEMOATTRACTANT FACTOR; FUNCTIONAL-CHARACTERISTICS; MUCOSAL INFLAMMATION; HUMAN EOSINOPHILS; ATOPIC ASTHMA; LYMPHOKINES; ACTIVATION; MIGRATION	Objective: We have previously demonstrated that the earliest lymphocyte chemotactic factors present in bronchoalveolar lavage fluid (BALF) of subjects with atopic asthma after subsegmental antigen challenge are IL-16 and MIP-1 alpha, of which IL-16 appears to contribute a majority of the chemotactic activity. Because IL-16 is released in vitro after histamine stimulation of CD8+ T cells and epithelial cells, we evaluated the potential role of histamine in the release of IL-16 into the airways of allergic asthmatics in vivo. Methods: Eight allergic asthmatic subjects, six normal subjects, and six atopic nonasthmatic subjects were challenged with saline in the lingula and with serial concentrations of histamine (1 x 10(-7) to 5 x 10(-5) mol/L) in the right middle lobe followed by bronchoalveolar lavage (BAL) 15 minutes and 6 hours later. Results: The BALF from saline- and histamine-challenged lobes of normal subjects and atopic nonasthmatic subjects contained no significant lymphocyte chemoattractant activity. In six of the eight atopic asthmatic subjects, the histamine-challenged but not saline-challenged segment contained IL-16 chemotactic activity but no other identifiable lymphocyte chemoattractant activities at 6 hours. Conclusions: IL16 appears in the airways after histamine challenge and therefore could contribute to the earliest infiltration of CD4+ T cells and eosinophils observed after antigen challenge due to histamine release from mast cells.	Boston Univ, Sch Med, Pulm Ctr R3, Boston, MA 02118 USA	Boston University	Center, DM (corresponding author), Boston Univ, Sch Med, Pulm Ctr R3, 80 E Concord St, Boston, MA 02118 USA.			Lim, Kaiser/0000-0002-4551-6559; Center, David/0000-0002-5879-7978	NHLBI NIH HHS [R01-HL32802, P50 SCOR HL46563] Funding Source: Medline; NIAID NIH HHS [R01-AI35680] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL046563, R01HL032802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035680] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELLINI A, 1993, J ALLERGY CLIN IMMUN, V92, P412, DOI 10.1016/0091-6749(93)90120-5; BERMAN JS, 1984, J IMMUNOL, V133, P1495; BERMAN JS, 1992, AM REV RESPIR DIS, V145, P1246, DOI 10.1164/ajrccm/145.6.1246; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; CENTER DM, 1983, J IMMUNOL, V131, P1854; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUNILL MS, 1960, J CLIN PATHOL, V13, P27; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; LABERGE S, 1995, J IMMUNOL, V155, P2902; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lim KG, 1996, J IMMUNOL, V156, P2566; MELTZER SS, 1995, AM J RESP CRIT CARE, V151, pA777; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MOLLER A, 1993, J IMMUNOL, V151, P3261; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958	23	47	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				786	792		10.1016/S0091-6749(98)70403-8	http://dx.doi.org/10.1016/S0091-6749(98)70403-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648706	hybrid			2022-12-18	WOS:000074414200012
J	Busse, WW; Gern, JE				Busse, WW; Gern, JE			Viruses in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COMMON COLD; RHINOVIRUS; INFECTION; INFLAMMATION; CHILDREN		UNIV WISCONSIN,SCH MED,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034891, U19AI034891, R29AI040685, R01AI026609] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26609, AI 40685, AI 34891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; DUFF AL, 1993, PEDIATRICS, V92, P535; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; OPENSHAW PJM, 1994, THORAX, V49, P101, DOI 10.1136/thx.49.2.101; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067	12	47	55	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					147	150		10.1016/S0091-6749(97)70216-1	http://dx.doi.org/10.1016/S0091-6749(97)70216-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275132				2022-12-18	WOS:A1997XR35100001
J	Hoffman, DR; Jacobson, RS				Hoffman, DR; Jacobson, RS			Allergens in hymenoptera venom .27. Bumblebee venom allergy and allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cross-reactivity; bee; phospholipase; venom; bumblebee; protease; Hymenoptera	AMINO-ACID SEQUENCE; 4 TANDEM REPEATS; BEE-VENOM; PLASMA PREKALLIKREIN; PHOSPHOLIPASE-A2; PROTEIN; IDENTIFICATION; CDNA	Background: Allergic reactions to bumblebee stings are much less common than allergic reactions to honeybee stings. Preliminary studies suggest that there may be a high degree of cross-reactivity between honeybee and bumblebee venoms. Objective: This study was done to determine the immunochemical and structural relationships between bumblebee and honeybee venom allergens. Methods: Allergens well purified from bumblebee venom and compared immunochemically with sera from patients with allergy and hyperimmunized rabbits. The purified proteins were characterized, enzyme activities were measured, and the complete amino acid sequences of two proteins were determined. Results: The venoms were highly a cross-reactive, consistent with the degree of structural similarity in the phospholipases. Hyaluronidases and acid phosphatases were also similar. Bumblebee venom contained several proteins not found in honeybee venom, including an interesting tryptic amidase related to clotting enzymes and acrosin. Conclusion: Skin testing with honeybee venom will detect almost all cases of bumbleebee venom allergy, however; RAST with bumblebee venom can detect some additional cases.			Hoffman, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858, USA.							Alford D.V., 1975, BUMBLEBEES; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; BARNARD JH, 1966, NEW YORK STATE J MED, V66, P1206; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; COOK JM, 1993, HEREDITY, V71, P421, DOI 10.1038/hdy.1993.157; DONNOVAN BJ, 1978, NZ ENTOMOL, V6, P385; FREE J.B, 1958, BEHAVIOUR, V12, P233, DOI 10.1163/156853957X00128; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; HAZELTINE WILLIAM E., 1964, J KANS ENTOMOL SOC, V37, P77; Heinrich B., 1979, BUMBLEBEE EC; HOFFMAN D, 1982, Journal of Allergy and Clinical Immunology, V69, P139; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; JACOBSON RS, 1995, J ALLERGY CLIN IMMUN, V95, P372; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KING T P, 1990, Protein Sequences and Data Analysis, V3, P263; KOCHUYT AM, 1993, CLIN EXP ALLERGY, V23, P190, DOI 10.1111/j.1365-2222.1993.tb00881.x; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAVERTY TM, 1988, CAN ENTOMOL, V120, P965, DOI 10.4039/Ent120965-11; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; MARQUADT M, 1982, ACTA CRYSTALLOGR B, V39, P480; MUTA T, 1990, J BIOL CHEM, V265, P22426; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RICHARDS OW, 1968, ENTOMOLOGY, V22, P209; RONKKO S, 1995, COMP BIOCHEM PHYS B, V110, P503, DOI 10.1016/0305-0491(94)00190-6; SCOTT DL, 1991, SCIENCE, V252, P764, DOI 10.1126/science.2028251; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SLADEN FWL, 1912, BUMBLE BEE ITS LIFE; TAKAYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P1505, DOI 10.1016/0006-291X(91)91064-J; VANDERMEERS A, 1991, EUR J BIOCHEM, V196, P537, DOI 10.1111/j.1432-1033.1991.tb15847.x; WATANABE K, 1991, J BIOCHEM-TOKYO, V109, P828, DOI 10.1093/oxfordjournals.jbchem.a123466; Whiting PW, 1943, GENETICS, V28, P365	44	47	53	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					812	821		10.1016/S0091-6749(96)80159-X	http://dx.doi.org/10.1016/S0091-6749(96)80159-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613638				2022-12-18	WOS:A1996UA97500012
J	YOSHIZAWA, Y; MIYAKE, S; SUMI, Y; HISAUCHI, K; SATO, T; KURUP, VP; MIYAMOTO, K				YOSHIZAWA, Y; MIYAKE, S; SUMI, Y; HISAUCHI, K; SATO, T; KURUP, VP; MIYAMOTO, K			A FOLLOW-UP-STUDY OF PULMONARY-FUNCTION TESTS, BRONCHOALVEOLAR LAVAGE CELLS, AND HUMORAL AND CELLULAR-IMMUNITY IN BIRD FANCIERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PULMONARY FUNCTION TESTS; BRONCHOALVEOLAR LAVAGE; HUMORAL IMMUNITY; CELLULAR IMMUNITY; BIRD FANCIERS LUNG	ASYMPTOMATIC PIGEON-BREEDERS; HYPERSENSITIVITY PNEUMONITIS; DISEASE; ANTIGEN; ALVEOLITIS; PATHOGENESIS; PRECIPITINS; ANTIBODIES; ABSENCE; FLUIDS	Background and Objective: The long-term outcome of bird fancier's lung appears to be variable. The objective of this study is to clarify the sequelae of disease process in bird fancier's lung, with special reference to the humoral and cellular immune responses after avoidance of direct antigen exposure. Methods: Five patients with bird fancier's lung were studied for various parameters including pulmonary function tests, cellular profiles of bronchoalveolar lavage (BAL) fluids, determinations of antibodies in BAL fluids and sera, and antigen-induced proliferation of peripheral and bronchoalveolar lymphocytes during the 5 years of follow-up. Results: Four of five patients showed improvement in pulmonary function and one showed marked deterioration. This patient's room was close to the pigeon coop where her son was breeding pigeons, resulting in low-grade antigenic stimulation. Three patients demonstrated an increase in CD8(+) cells in BAL fluid, but the remaining two showed an increase in CD4(+) cells. The levels of IgA antibodies remained unchanged, whereas IgG levels started declining after the first 3 years of follow-up. Antigen-induced proliferation of BAL lymphocytes from ail five patients and blood lymphocytes from four of five patients became weaker and gradually approached normal levels. One patient had pulmonary fibrosis and showed significant reduction in pulmonary functions but elevated reactivity of BAL lymphocytes to pigeon antigens. Conclusion: This follow-up study demonstrates persistence of sensitized lymphocytes and antibody production in the respiratory tract and warrants careful evaluation of patients with bird fancier's lung, even after antigen avoidance.	UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,DIV PULM MED,TSUKUBA,IBARAKI 305,JAPAN; CLEMENT J ZABLOCKI VET ADM MED CTR,RES SERV 151,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,MILWAUKEE,WI 53226	University of Tsukuba; Medical College of Wisconsin	YOSHIZAWA, Y (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,BUNKYO KU,5-45 YUSHIMA 1-CHOME,TOKYO 113,JAPAN.							BERRENS L, 1986, CLIN ALLERGY, V16, P355, DOI 10.1111/j.1365-2222.1986.tb01968.x; BICE DE, 1991, IMMUNOLOGY, V74, P215; BOUIC PJ, 1989, INT ARCH ALLER A IMM, V89, P222, DOI 10.1159/000234950; BOURKE SJ, 1989, THORAX, V44, P415, DOI 10.1136/thx.44.5.415; BOYD G, 1990, RESP MED, V84, P5, DOI 10.1016/S0954-6111(08)80085-6; CALVANICO NJ, 1986, J ALLERGY CLIN IMMUN, V77, P80, DOI 10.1016/0091-6749(86)90327-1; CRAIG TJ, 1992, ANN ALLERGY, V69, P510; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V85, P655, DOI 10.1016/0091-6749(90)90107-F; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; MOORE VL, 1975, J LAB CLIN MED, V85, P540; MURAYAMA J, 1993, CHEST, V104, P38, DOI 10.1378/chest.104.1.38; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; REYNAUD C, 1990, EUR RESPIR J, V3, P1155; REYNOLDS SP, 1991, CLIN EXP IMMUNOL, V86, P278; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; ROSKA AKB, 1977, CLIN IMMUNOL IMMUNOP, V8, P213, DOI 10.1016/0090-1229(77)90111-8; TEBO TH, 1975, J RETICULOENDOTH SOC, V18, P196; TODD A, 1991, CLIN EXP IMMUNOL, V85, P453; TRENTIN L, 1988, J ALLERGY CLIN IMMUN, V82, P577, DOI 10.1016/0091-6749(88)90967-0; YOSHIZAWA Y, 1989, ANN INTERN MED, V110, P31, DOI 10.7326/0003-4819-110-1-31; YOSHIZAWA Y, 1986, INT ARCH ALLER A IMM, V80, P376, DOI 10.1159/000234084; YOSHIZAWA Y, 1988, INT ARCH ALLER A IMM, V87, P417, DOI 10.1159/000234712	23	47	50	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					122	129		10.1016/S0091-6749(95)70041-2	http://dx.doi.org/10.1016/S0091-6749(95)70041-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622754	Bronze			2022-12-18	WOS:A1995RK38300016
J	WEILER, JM; MELTZER, EO; BENSON, PM; WEILER, K; WIDLITZ, MD; FREITAG, J				WEILER, JM; MELTZER, EO; BENSON, PM; WEILER, K; WIDLITZ, MD; FREITAG, J			A DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF AZELASTINE NASAL SPRAY IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS WITH AN ACUTE MODEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AZELASTINE; ALLERGIC RHINITIS; CHLORPHENIRAMINE	HISTAMINE-RELEASE; PARALLEL-GROUPS; DOUBLE-BLIND; GUINEA-PIGS; ASTHMA; INHIBITION; PLACEBO; TIME	Background: Oral azelastine, a nonsteroidal antiinflammatory respiratory investigational drug has demonstrated activity in the treatment of allergic rhinitis and asthma with a good safety profile. Methods: Azelastine nasal spray was compared with sustained-release oral chlorpheniramine maleate and placebo for efficacy and safety in the treatment of seasonal allergic rhinitis in a double-dummy, two-center a-day, double-blind, randomized, dose-ranging, parallell-groups, onset and duration of action study. Two hundred sixty-forty subjects reported to an outdoor park on Saturday morning during the height of the fall pollen season and remained there for 8 hours that day and the next to ensure maximal exposure to seasonal aeroallergens. Symptom diary cards were collected hourly Saturday from 8:00 AM to 10:00 AM (baseline period). Subjects who had sufficient symptoms were randomized into five groups and received medication at 10.00 AM and 10:00 PM on Saturday and at 10:00 AM on Sunday: azelastine 0.1% (1 spray [0.12 mg] per nostril every 12 hours, 2 sprays per nostril every 12 hours, or 2 sprays per nostril once daily), Chlor-Trimeton Repetabs (12 mg twice daily), or placebo (twice daily). Diary cards were completed hourly (11:00 AM to 4:00 PM) and at 6:00, 8:00, and 1O:00 PM on Saturday and again hourly on Sunday (from 8:00 AM to 4:00 PM) to evaluate rhinitis symptoms and adverse events. Results: Two hundred fifty-nine subjects completed the study The groups that received 2 sprays of azelastine per nostril once and twice daily and the chlorpheniramine group had statistically significantly more improvement in total rhinitis symptoms than the placebo group without serious adverse events. Conclusions: This study supports a once to twice daily dosing regimen for 2 sprays of 0.1% azelastine in the acute treatment of allergic rhinitis with onset of action within 2 to 3 hours.	UNIV IOWA,COLL MED,IOWA CITY,IA; UNIV IOWA,COLL NURSING,IOWA CITY,IA; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; WALLACE LABS,PRINCETON,NJ	University of Iowa; University of Iowa								BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; CHAND N, 1986, AGENTS ACTIONS, V19, P164, DOI 10.1007/BF01966201; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CONNELL JT, 1979, ANN ALLERGY, V42, P278; FUJIMORI T, 1986, MED CONSULT NEW REME, V23, P2251; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; NAKAMURA T, 1988, EUR J PHARMACOL, V148, P35, DOI 10.1016/0014-2999(88)90451-7; PERHACH JL, 1987, NEW ENGL REG ALLERGY, V8, P121; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; SHINDOH J, 1991, CHEST, V99, P1274, DOI 10.1378/chest.99.5.1274; TINKELMAN DG, 1990, AM REV RESPIR DIS, V141, P569, DOI 10.1164/ajrccm/141.3.569; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6; WEILER JM, 1990, ANN ALLERGY, V64, P63; YIN KS, 1991, ARZNEIMITTEL-FORSCH, V41-1, P525; 1979, US DHEW NIH79387 PUB	18	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				972	980		10.1016/0091-6749(94)90115-5	http://dx.doi.org/10.1016/0091-6749(94)90115-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798545				2022-12-18	WOS:A1994PY23000005
J	SKONER, DP; WHITESIDE, TL; WILSON, JW; DOYLE, WJ; HERBERMAN, RB; FIREMAN, P				SKONER, DP; WHITESIDE, TL; WILSON, JW; DOYLE, WJ; HERBERMAN, RB; FIREMAN, P			EFFECT OF RHINOVIRUS 39 INFECTION ON CELLULAR IMMUNE PARAMETERS IN ALLERGIC AND NONALLERGIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EUSTACHIAN-TUBE OBSTRUCTION; BRONCHIAL-ASTHMA; LYMPHOCYTES; IMMUNODEFICIENCY; CYTOTOXICITY; CHALLENGE; SUBSETS; CELLS; IGE	Patients with allergic rhinitis (AR), compared with nonallergic persons, have been reported to respond differently to a variety of stimuli, some of which are immunologic in nature. This study compared the systemic cellular immune responses to experimental rhinovirus (RV) 39 challenge in RV-39-seronegative AR (n = 20) and nonallergic (n = 18) subjects. Peripheral blood was obtained before, 4 or 7 days after, and 23 days after RV-39 intranasal challenge and assayed for the number and function of various white blood cells. All subjects were infected, as manifested by viral shedding in nasal secretions or seroconversion. RV-39 induced marked changes from baseline values in both immune cell number and functions. Compared with nonallergic subjects, AR subjects manifested different responses for the following parameters: (1) numbers of total white blood cells and lymphocytes (smaller increases on day 4), (2) helper/suppressor T cell ratio (absence of an increase on day 7 and presence of an increase on day 23), (3) number of IL-2 receptor-positive suppressor T cells (presence of a decrease on day 7), (4) natural killer (NK) cell numbers (absence of an increase on day 4 and presence of increases on days 7 and 23), (5) NK/T cell ratio (absence of an increase on day 4 and a decrease on day 7), (6) NK cell activity (a blunted decrease on day 7 and absence of a decrease on day 23), and (7) RV-39-induced lymphocyte proliferation (exaggerated increase on day 4). The results show that intranasal challenge with RV-39 induced RV-39-specific and nonspecific systemic cellular immune responses and a unique immunologic response pattern in AR subjects.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT BIOSTAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15261; CHILDRENS HOSP,PITTSBURGH,PA 15213; PITTSBURGH CANC INST,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR00084] Funding Source: Medline; NIAID NIH HHS [AI19262] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAVENA P, 1985, CANCER IMMUNOL IMMUN, V19, P121; BUKOWSKI JF, 1983, J IMMUNOL, V131, P1531; BUSH RK, 1978, J ALLERGY CLIN IMMUN, V61, P80, DOI 10.1016/0091-6749(78)90229-4; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; CATE TR, 1964, J CLIN INVEST, V43, P56, DOI 10.1172/JCI104894; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P432; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; HENDERSON FW, 1988, AM REV RESPIR DIS, V137, P1124, DOI 10.1164/ajrccm/137.5.1124; HEO DS, 1987, CANCER RES, V47, P6353; HOPP RJ, 1987, J ALLERGY CLIN IMMUN, V80, P821, DOI 10.1016/S0091-6749(87)80272-5; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; HSIA J, 1989, LYMPHOKINE RES, V8, P383; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; KRAUT R P, 1986, Natural Immunity and Cell Growth Regulation, V5, P28; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEVANDOWSKI RA, 1983, J INFECT DIS, V148, P1125; LEVANDOWSKI RA, 1986, J INFECT DIS, V153, P743, DOI 10.1093/infdis/153.4.743; LEVANDOWSKI RA, 1988, J MED VIROL, V25, P423, DOI 10.1002/jmv.1890250406; LEVY SM, 1991, LIFE SCI, V48, P107, DOI 10.1016/0024-3205(91)90403-X; LOTZOVA E, 1986, IMMUNOBIOLOGY NATURA, V1; MACCIA CA, 1977, J ALLERGY CLIN IMMUN, V59, P101, DOI 10.1016/0091-6749(77)90210-X; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1989, AM J RHINOL, V3, P53; SLEASMAN JW, 1990, CLIN IMMUNOL IMMUNOP, V55, P401, DOI 10.1016/0090-1229(90)90127-C; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; TIMONEN T, 1985, CLIN EXP IMMUNOL, V59, P85; VESTERINEN E, 1988, ANN ALLERGY, V60, P247; WELLER FR, 1985, J ALLERGY CLIN IMMUN, V76, P29, DOI 10.1016/0091-6749(85)90800-0; WELSH RM, 1981, ANTIVIR RES, V1, P5, DOI 10.1016/0166-3542(81)90027-9; WHITESIDE TL, 1990, J CLIN LAB ANAL, V4, P102, DOI 10.1002/jcla.1860040207	35	47	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					732	743		10.1016/0091-6749(93)90017-A	http://dx.doi.org/10.1016/0091-6749(93)90017-A			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227865				2022-12-18	WOS:A1993MG98200015
J	VOLLENWEIDER, S; SAURAT, JH; ROCKEN, M; HAUSER, C				VOLLENWEIDER, S; SAURAT, JH; ROCKEN, M; HAUSER, C			EVIDENCE SUGGESTING INVOLVEMENT OF INTERLEUKIN-4 (IL-4) PRODUCTION IN SPONTANEOUS INVITRO IGE SYNTHESIS IN PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN B-CELLS; INTERFERON-GAMMA; IFN-GAMMA; CLONES; ALPHA	To investigate the regulatory role of interleukin-4 (IL-4) and interferon-gamma (INF-gamma) and their involvement in the abnormality of IgE synthesis in patients with atopic dermatitis (AD), we studied the effect of recombinant human IL-4 and INF-gamma, as well as blocking antibodies (Abs) to these lymphokines on spontaneous IgE synthesis by peripheral blood lymphocytes (PBLs) from patients with AD and from healthy control subjects. PBLs from patients with AD demonstrated elevated spontaneous IgE production that was not stimulated further by the addition of recombinant IL-4, whereas for the healthy control subjects, recombinant IL-4 increased spontaneous IgE production by PBLs. INF-gamma that has been previously demonstrated to antagonize the effect of IL-4 on IgE synthesis, decreased IgE production of patients with AD. Addition of Abs to INF-gamma did not change spontaneous IgE production for patients with AD or for healthy control subjects. Together with our observation that IL-4 Abs lowered the high spontaneous IgE production by PBLs from patients with AD, these results suggest that in AD, IL-4 production by lymphocytes, together with a lack of INF-gamma production, is at least partially responsible for the increased spontaneous IgE production.	HOP CANTONAL GENEVA,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva				Rocken, Martin/0000-0003-3795-7001				ALEVY YG, 1986, J IMMUNOL METHODS, V87, P273, DOI 10.1016/0022-1759(86)90542-9; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; FISER PM, 1979, J IMMUNOL, V123, P1788; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; JONES HE, 1975, BRIT J DERMATOL, V92, P17; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; LEUNG DYM, 1986, J CLIN IMMUNOL, V6, P273, DOI 10.1007/BF00917327; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MAGGI E, 1988, CLIN EXP IMMUNOL, V73, P57; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; TJIO AH, 1979, J IMMUNOL, V122, P2131; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	21	47	47	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1088	1095		10.1016/0091-6749(91)92154-S	http://dx.doi.org/10.1016/0091-6749(91)92154-S			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	1904459				2022-12-18	WOS:A1991FR06600008
J	SHEERIN, KA; BUCKLEY, RH				SHEERIN, KA; BUCKLEY, RH			ANTIBODY-RESPONSES TO PROTEIN, POLYSACCHARIDE, AND PHI-X174 ANTIGENS IN THE HYPERIMMUNOGLOBULINEMIA-E (HYPER-IGE) SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RECURRENT INFECTION SYNDROME; JOBS SYNDROME; MONONUCLEAR-CELLS; CHEMOTAXIS; DEFICIENCY	To investigate whether an underlying defect in antibody (Ab)-forming capacity could contribute to the infection susceptibility of patients with hyper-IgE syndrome, we evaluated 11 such patients for their responses to bacteriophage PHI-X174 (PHI-X174), diphtheria and tetanus toxoids, and pneumococcal (Pneumovax) and Hemophilus influenzae vaccines. Three of nine patients immunized with PHI-X174 had normal primary and secondary Ab responses, five had accelerated declines in their titers after initially normal primary Ab responses and lower than normal secondary Ab responses, and two of the latter patients failed to switch normally from IgM to IgG Ab production. Only one of 10 patients tested had normal Ab responses to diphtheria toxoid, and postimmunization antitetanus titers were abnormally low in five of the 10 patients tested. Serum Abs to H. influenzae polyribose phosphate were protective in seven of the eight immunized patients. Five of the nine patients administered Pneumovax had poor Ab responses to at least one of the pneumococcal serotypes 7, 9, or 14. Abnormal antipolysaccharide responses did not correlate with IgG2 deficiency. All patients responded with protective Ab levels to type 3. Thus, patients with hyper-IgE syndrome are heterogeneous with respect to their Ab-forming capacities. Ab deficiency may contribute to infection susceptibility in some of these patients.	DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 2898,DURHAM,NC 27710	Duke University			Buckley, Rebecca/AAB-1578-2019		NCRR NIH HHS [MO1-RR30] Funding Source: Medline; NIAID NIH HHS [AI28414, 2T32 AI07062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028414, T32AI007062] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BUCKLEY RH, 1967, J ALLERGY, V40, P294, DOI 10.1016/0021-8707(67)90077-9; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; DONABEDIAN H, 1982, J CLIN INVEST, V69, P1155, DOI 10.1172/JCI110551; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; FISER PM, 1979, J IMMUNOL, V123, P1788; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GORIN LJ, 1989, J ALLERGY CLIN IMMUN, V83, P5, DOI 10.1016/0091-6749(89)90471-5; HILL HR, 1974, LANCET, V2, P617; LALLEMAND L, 1979, ANN RADIOL, V22, P108; LAVOIE A, 1989, AM J DIS CHILD, V143, P1038, DOI 10.1001/archpedi.1989.02150210064021; LEUNG DY, 1988, J ALLERGY CLIN IMMUN, V81, P1081; MERTEN DF, 1979, PEDIATR RADIOL, V132, P71; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506	19	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					803	811		10.1016/0091-6749(91)90126-9	http://dx.doi.org/10.1016/0091-6749(91)90126-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	1826506				2022-12-18	WOS:A1991FG05900009
J	BERLOW, BA; LIEBHABER, MI; DYER, Z; SPIEGEL, TM				BERLOW, BA; LIEBHABER, MI; DYER, Z; SPIEGEL, TM			THE EFFECT OF DAPSONE IN STEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NEUTROPHIL CHEMOTACTIC ACTIVITY; LATE PHASE REACTIONS; MAST-CELL GRANULES; AIRWAY HYPERRESPONSIVENESS; GUINEA-PIGS; BRONCHOALVEOLAR LAVAGE; BIOLOGIC ACTIVITY; OZONE EXPOSURE; ANIMAL-MODEL; GOLD SALT	We studied the steroid-sparing effect of dapsone in 10 subjects with chronic asthma in a preliminary open trial. Dapsone was chosen because it inhibits neutrophil function and possesses anti-inflammatory effects in a variety of disorders. The study group consisted of 10 subjects with stable, steroid-dependent asthma, aged 23 to 80 years, with normal glucose-6-phosphate dehydrogenase levels. Average daily baseline prednisone dose ranged from 5 to 60 mg. Dapsone, 100 mg, twice daily, by mouth, was started after a 1-month baseline period. Baseline steroid dose, symptom scores, and daily peak flow rates were compared to the latest available 4-week period of dapsone treatment. Average cumulative monthly prednisone dose was reduced from 428 mg to 82 mg (p < 0.02). Five of 10 patients stopped steroids by month 6 and two additional patients by month 13. Two additional patients demonstrated a coincidental 74% reduction in steroid dose, and one patient demonstrated no response. Clinical parameters remained stable despite steroid reduction. These preliminary data suggest dapsone may have steroid-sparing effects in chronic asthma.	SANTA BARBARA MED FDN CLIN,DIV ALLERGY & IMMUNOL,SANTA BARBARA,CA; SANSUM MED CLIN,DEPT MED,DIV RHEUMATOL,SANTA BARBARA,CA		BERLOW, BA (corresponding author), SANSUM MED CLIN,DIV ALLERGY & IMMUNOL,317 W PUEBLO ST,SANTA BARBARA,CA 93105, USA.							ANDERSON R, 1981, ANTIMICROB AGENTS CH, V19, P495, DOI 10.1128/AAC.19.4.495; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BARNES P, 1989, NEW ENGL J MED, V21, P1517; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BUCHANAN DR, 1987, AM REV RESPIR DIS, V136, P1397, DOI 10.1164/ajrccm/136.6.1397; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CHAROUS BL, 1990, ANN ALLERGY, V65, P53; CZARNETZKI M, 1981, CHEM PHYS LIPIDS, V29, P317; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FABBRI L, 1987, AM RESPIR DIS, V136, P32; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; GORDON T, 1985, AM REV RESPIR DIS, V132, P1106; Graham W R Jr, 1975, Int J Dermatol, V14, P494, DOI 10.1111/j.1365-4362.1975.tb04283.x; HARVATH L, 1986, J IMMUNOL, V137, P1305; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; HOLLINGSWORTH HM, 1984, AM REV RESPIR DIS, V130, P373; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; ILJIMA H, 1987, AM REV RESPIR DIS, V136, P922; IRVIN CG, 1986, AM REV RESPIR DIS, V134, P777; KAZMIEROWSKI JA, 1984, J CLIN IMMUNOL, V4, P55, DOI 10.1007/BF00915288; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; LEMANSKE RF, 1983, J IMMUNOL, V131, P929; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MARTIN WJ, 1985, AM REV RESPIR DIS, V131, P544, DOI 10.1164/arrd.1985.131.4.544; MCDOUGALL AC, 1979, CLIN EXP DERMATOL, V4, P139, DOI 10.1111/j.1365-2230.1979.tb01608.x; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; METZGER WJ, 1985, CHEST S, V87, P155; MIYACHI Y, 1982, BRIT J DERMATOL, V107, P209, DOI 10.1111/j.1365-2133.1982.tb00340.x; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NICKLAS RA, 1986, J ALLERGY CLIN IMMUN, V78, P507, DOI 10.1016/0091-6749(86)90097-7; NIWA Y, 1984, BIOCHEM PHARMACOL, V33, P2355, DOI 10.1016/0006-2952(84)90705-6; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; PAPAGEORGIOU N, 1983, J ALLERGY CLIN IMMUN, V72, P75, DOI 10.1016/0091-6749(83)90055-6; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; RUZICKA T, 1983, J ALLERGY CLIN IMMUN, V72, P365, DOI 10.1016/0091-6749(83)90501-8; SANERKIN NG, 1965, J PATHOL BACTERIOL, V89, P535, DOI 10.1002/path.1700890211; SASTRE J, 1990, J ALLERGY CLIN IMMUN, V85, P567, DOI 10.1016/0091-6749(90)90094-K; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SILBAUGH SA, 1987, AM REV RESPIR DIS, V136, P930, DOI 10.1164/ajrccm/136.4.930; STENDAHL O, 1978, J CLIN INVEST, V62, P214, DOI 10.1172/JCI109109; STYRT B, 1988, J ALLERGY CLIN IMMUN, V81, P20, DOI 10.1016/0091-6749(88)90215-1; THERON A, 1985, AM REV RESPIR DIS, V132, P1049; WEBSTER GF, 1984, BRIT J DERMATOL, V110, P657, DOI 10.1111/j.1365-2133.1984.tb04701.x; YAMAUCHI N, 1984, J ALLERGY CLIN IMMUN, V74, P802, DOI 10.1016/0091-6749(84)90182-9; 1987, AM REV RESPIR DIS, V136, P225	54	47	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					710	715		10.1016/0091-6749(91)90393-3	http://dx.doi.org/10.1016/0091-6749(91)90393-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005324				2022-12-18	WOS:A1991FB80100017
J	CHANYEUNG, M; LAM, S; CHAN, H; TSE, KS; SALARI, H				CHANYEUNG, M; LAM, S; CHAN, H; TSE, KS; SALARI, H			THE RELEASE OF PLATELET-ACTIVATING-FACTOR INTO PLASMA DURING ALLERGEN-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PAF-ACETHER; ASTHMA; RESPONSIVENESS; ACCUMULATION; CHALLENGE	Plasma histamine and platelet-activating factor (PAF) were measured in six subjects with mild seasonal asthma before and after allergen-induced bronchoconstriction, and in six other patients with asthma before and after methacholine-induced bronchoconstriction. A significant increase in plasma histamine and PAF levels was found in patients with mild seasonal asthma after allergen-induced bronchoconstriction but not in patients with asthma after bronchoconstriction induced by methacholine. There was a significant correlation between the baseline plasma PAF levels and the degree of bronchial hyperresponsiveness to methacholine. These findings suggest that PAF may be an important mediator in the pathogenesis of asthma and bronchial hyperresponsiveness.			CHANYEUNG, M (corresponding author), UNIV BRITISH COLUMBIA, VANCOUVER GEN HOSP, DEPT MED, DIV RESP, 2775 HEATHER ST, VANCOUVER V5Z 3J5, BC, CANADA.							ALAM I, 1982, J CHROMATOGR, V234, P218, DOI 10.1016/S0021-9673(00)81796-3; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; ATKINS PC, 1984, J ALLERGY CLIN IMMUN, V73, P341, DOI 10.1016/0091-6749(84)90406-8; BARNES PJ, 1987, BRIT J PHARMACOL, V90, P709, DOI 10.1111/j.1476-5381.1987.tb11224.x; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHRISTMAN BW, 1987, AM REV RESPIR DIS, V135, P1267; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; COYLE A, 1987, American Review of Respiratory Disease, V135, pA161; CUSS FM, 1986, LANCET, V2, P189; DURHAM SR, 1985, LANCET, V2, P36; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; Farr R S, 1987, Agents Actions Suppl, V21, P129; GREEN K, 1974, LANCET, V2, P1419; HENOCQ E, 1986, LANCET, V1, P1378; HENSON PM, 1977, J IMMUNOL, V119, P2179; HOLGATE ST, 1986, EUR J RESPIR DIS, V68, P34; KALINER M, 1985, CHEST, V87, pS2, DOI 10.1378/chest.87.1_Supplement.2S; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1989, American Review of Respiratory Disease, V139, pA326; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; MAZZONI L, 1985, J PHYSIOL-LONDON, V365, pP107; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NAKAMURA T, 1987, INT ARCH ALLER A IMM, V82, P57, DOI 10.1159/000234290; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; ODONNELL SR, 1987, EUR J PHARMACOL, V138, P385, DOI 10.1016/0014-2999(87)90477-8; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; ROBERTS NM, 1988, J ALLERGY CLIN IMMUN, V82, P236, DOI 10.1016/0091-6749(88)91005-6; SCHMITZSCHUMANN M, 1987, AGENTS ACTIONS, V21, P217; STEVENSON JS, 1987, FED PROC, V46, P1461; THOMPSON P J, 1984, American Review of Respiratory Disease, V129, pA3; TOUVAY C, 1986, AGENTS ACTIONS, V17, P371, DOI 10.1007/BF01982650; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450	35	47	48	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					667	673		10.1016/0091-6749(91)90386-3	http://dx.doi.org/10.1016/0091-6749(91)90386-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005318				2022-12-18	WOS:A1991FB80100010
J	PLATTSMILLS, TAE; CHAPMAN, MD				PLATTSMILLS, TAE; CHAPMAN, MD			ALLERGEN STANDARDIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							1ST INTERNATIONAL STANDARD; EXTRACTS; DERMATOPHAGOIDES				PLATTSMILLS, TAE (corresponding author), UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Chapman, Martin/0000-0002-0845-3632				BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; CHAPMAN MD, 1988, ALLERGY, V43, P7, DOI 10.1111/j.1398-9995.1988.tb05042.x; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; REED CE, 1989, J ALLERGY CLIN IMMUN, V84, P4, DOI 10.1016/0091-6749(89)90171-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Turkeltaub PC, 1988, ALLERGY PRINCIPLES P, V3rd, P388; WIDE L, 1967, LANCET, V2, P1105	14	47	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					621	625		10.1016/0091-6749(91)90379-3	http://dx.doi.org/10.1016/0091-6749(91)90379-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005313	Bronze			2022-12-18	WOS:A1991FB80100003
J	WASSERMAN, SI				WASSERMAN, SI			MAST-CELL BIOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM							WASSERMAN, SI (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,402 W DICKINSON ST,SUITE 380,SAN DIEGO,CA 92103, USA.							BAEZA ML, 1988, J IMMUNOL, V141, P2688; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BROIDE DH, 1989, J IMMUNOL, V143, P1591; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DENBURG JA, 1988, MAST CELLS MEDIATORS, P1; GALLI SJ, 1990, LAB INVEST, V62, P5; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0	9	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			590	593		10.1016/S0091-6749(05)80221-0	http://dx.doi.org/10.1016/S0091-6749(05)80221-0			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229821				2022-12-18	WOS:A1990EH09300002
J	SAXON, A; KE, Z; BAHATI, L; STEVENS, RH				SAXON, A; KE, Z; BAHATI, L; STEVENS, RH			SOLUBLE CD23 CONTAINING-B CELL SUPERNATANTS INDUCE IGE FROM PERIPHERAL-BLOOD LYMPHOCYTES-B AND COSTIMULATE WITH INTERLEUKIN-4 IN INDUCTION OF IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SAXON, A (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL ALLERGY,LOS ANGELES,CA 90024, USA.							CARINI C, 1988, P NATL ACAD SCI USA, V85, P9212; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DELPRETE G, 1986, EUR J IMMUNOL, V16, P1509, DOI 10.1002/eji.1830161207; DELPRETE G, 1988, J IMMUNOL, V140, P4193; GORDON J, 1989, IMMUNOL TODAY, V10, P153, DOI 10.1016/0167-5699(89)90171-0; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; KIMATA H, 1988, J CLIN INVEST, V82, P160, DOI 10.1172/JCI113565; KIMATA H, 1988, J CLIN IMMUNOL, V8, P213; LANZAVECCHIA A, 1984, CLIN EXP IMMUNOL, V55, P197; LEVKOVITS L, 1979, LIMITING DILUTION AN, P38; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; NUTMAN TB, 1987, J IMMUNOL, V139, P4049; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; ROMAGNANI S, 1987, J IMMUNOL, V138, P1744; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; SARFATI M, 1988, J IMMUNOL, V141, P2195; SARFATI M, 1984, IMMUNOLOGY, V53, P207; SARFATI M, 1984, IMMUNOLOGY, V53, P197; SAXON A, 1977, J IMMUNOL, V118, P1872; SAXON A, 1989, J ALLERGY CLIN IMMUN, V84, P44, DOI 10.1016/0091-6749(89)90177-2; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SHERR E, 1989, J IMMUNOL, V142, P481; SHERR EH, 1988, INT ARCH ALLER A IMM, V85, P154, DOI 10.1159/000234495; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; UCHIBAYASHI N, 1989, J IMMUNOL, V142, P3901; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; WALDSCHMIDT TJ, 1989, J IMMUNOL, V143, P2820	37	47	50	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				333	344		10.1016/S0091-6749(05)80096-X	http://dx.doi.org/10.1016/S0091-6749(05)80096-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	1698844				2022-12-18	WOS:A1990EA85900007
J	DRUCE, HM; SCHUMACHER, MJ				DRUCE, HM; SCHUMACHER, MJ			NASAL PROVOCATION CHALLENGE - REPORT OF THE COMMITTEE ON UPPER AIRWAY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DRUCE, HM (corresponding author), ST LOUIS UNIV,SCH MED,DIV ENDOCRINOL,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.							BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; Dirksen A, 1982, Dan Med Bull, V29, P5; DRUCE H, 1985, J ALLERGY CLIN IMMUN, V75, P111, DOI 10.1016/0091-6749(85)90162-9; Druce H M, 1988, J Allergy Clin Immunol, V81, P505, DOI 10.1016/0091-6749(88)90186-8; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; DRUCE HM, 1988, ANN ALLERGY, V60, P191; FIREMAN P, 1988, J ALLERGY CLIN IMMUN, V81, P953, DOI 10.1016/0091-6749(88)90159-5; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; GEORGITIS JW, 1987, J RESPIR DIS, V8, P57; KALINER M, 1987, JAMA-J AM MED ASSOC, V258, P2851, DOI 10.1001/jama.258.20.2851; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; MCLEAN JA, 1985, IMMUNOL ALLERGY PRAC, V7, P131; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OKUDA M, 1983, ANN ALLERGY, V51, P51; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SCHUMACHER MJ, 1988, IMMUNOL ALLERGY CLIN, V7, P15; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563	22	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					261	264						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2200822				2022-12-18	WOS:A1990DV31600018
J	GRUBBE, RE; HOPP, R; DAVE, NK; BRENNAN, B; BEWTRA, A; TOWNLEY, R				GRUBBE, RE; HOPP, R; DAVE, NK; BRENNAN, B; BEWTRA, A; TOWNLEY, R			EFFECT OF INHALED FUROSEMIDE ON THE BRONCHIAL RESPONSE TO METHACHOLINE AND COLD-AIR HYPERVENTILATION CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,CTR ALLERG DIS,2500 CALIF ST,OMAHA,NE 68178	Creighton University			Hopp, Russell/K-4578-2019					ANDERSON SA, 1986, J ALLERGY CLIN IMMUN, V76, P763; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; HOPP RJ, 1987, J ALLERGY CLIN IMMUN, V80, P821, DOI 10.1016/S0091-6749(87)80272-5; KNOWLES M, 1984, J APPL PHYSIOL, V56, P868, DOI 10.1152/jappl.1984.56.4.868; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NAIR N, 1986, ANN ALLERGY, V56, P226; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; ROBUSCHI M, 1988, American Review of Respiratory Disease, V137, P412; SOUHRADA M, 1988, BRIT J PHARMACOL, V93, P884, DOI 10.1111/j.1476-5381.1988.tb11476.x; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; WELSH MJ, 1983, J CLIN INVEST, V71, P1392, DOI 10.1172/JCI110892; WELSH MJ, 1983, J MEMBRANE BIOL, V71, P219, DOI 10.1007/BF01875463; ZEBALLOS RJ, 1978, AM REV RESPIR DIS, V118, P877	17	47	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					881	884		10.1016/0091-6749(90)90072-C	http://dx.doi.org/10.1016/0091-6749(90)90072-C			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332565				2022-12-18	WOS:A1990DD95900010
J	ALBER, G; SCHEUBER, PH; RECK, B; SAILERKRAMER, B; HARTMANN, A; HAMMER, DK				ALBER, G; SCHEUBER, PH; RECK, B; SAILERKRAMER, B; HARTMANN, A; HAMMER, DK			ROLE OF SUBSTANCE-P IN IMMEDIATE-TYPE SKIN REACTIONS INDUCED BY STAPHYLOCOCCAL ENTERO-TOXIN-B IN UNSENSITIZED MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; UNIV MUNICH,DEPT CLIN CHEM & CLIN BIOCHEM,W-8000 MUNICH 2,GERMANY	Max Planck Society; University of Munich								BERGDOLL MS, 1970, MICROBIAL TOXINS, P265; DALSGAARD CJ, 1985, HISTOCHEMISTRY, V83, P37, DOI 10.1007/BF00495297; DEACON CF, 1987, NEUROCHEM INT, V10, P559, DOI 10.1016/0197-0186(87)90085-4; DEACON CF, 1987, J NEUROCHEM, V48, P141, DOI 10.1111/j.1471-4159.1987.tb13138.x; ELWELL MR, 1975, P SOC EXP BIOL MED, V148, P424; ENDE IA, 1983, APPL ENVIRON MICROB, V46, P1323, DOI 10.1128/AEM.46.6.1323-1330.1983; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FOREMAN JC, 1987, BRIT MED BULL, V43, P386, DOI 10.1093/oxfordjournals.bmb.a072189; HAYES AG, 1980, J PHYSIOL-LONDON, V300, pP25; LEE CM, 1980, LIFE SCI, V27, P535, DOI 10.1016/0024-3205(80)90302-1; MARTLING CR, 1988, REGUL PEPTIDES, V20, P125, DOI 10.1016/0167-0115(88)90046-8; MAZUREK N, 1981, NEUROPHARMACOLOGY, V20, P1025, DOI 10.1016/0028-3908(81)90091-5; MERKENSCHLAGER M, 1979, SCHRIFTENREIHE VERSU, V6; MROZ EA, 1979, METHOD HORM RADIOIMM, P121; MUDGE AW, 1979, P NATL ACAD SCI USA, V76, P526, DOI 10.1073/pnas.76.1.526; PERNOW B, 1983, PHARMACOL REV, V35, P85; SCHEUBER PH, 1985, INFECT IMMUN, V50, P869, DOI 10.1128/IAI.50.3.869-876.1985; SCHEUBER PH, 1987, EUR J CLIN INVEST, V17, P455, DOI 10.1111/j.1365-2362.1987.tb01142.x; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185	20	47	51	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				880	885		10.1016/0091-6749(89)90383-7	http://dx.doi.org/10.1016/0091-6749(89)90383-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2480969				2022-12-18	WOS:A1989CG29300004
J	PARKER, WA; WHISMAN, BA; APALISKI, SJ; REID, MJ				PARKER, WA; WHISMAN, BA; APALISKI, SJ; REID, MJ			THE RELATIONSHIPS BETWEEN LATE CUTANEOUS RESPONSES AND SPECIFIC ANTIBODY-RESPONSES WITH OUTCOME OF IMMUNOTHERAPY FOR SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILFORD HALL USAF MED CTR,DIV MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force								ADKINSON NFV, 1989, J ALLERGY CLIN IMMUN, V83, P202; ATKINS PC, 1988, ANN ALLERGY, V60, P27; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; FEIN BT, 1962, J ALLERGY, V33, P141; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; FRENCH SW, 1930, J ALLERGY, V1, P286; Kahn IS, 1924, J AMER MED ASSOC, V82, P871, DOI 10.1001/jama.1924.02650370039013; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LARSEN GL, 1985, J ALLERGY CLIN IMMUN, V76, P665, DOI 10.1016/0091-6749(85)90668-2; LEMANSKE RF, 1988, J CLIN IMMUNOL, V8, P1, DOI 10.1007/BF00915151; LICHTENSTEIN LM, 1988, HOSP PRACT, V23, P119; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; PINESS G, 1929, J ALLERGY, V1, P117; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; SMITH JM, 1988, ALLERGY PRINCIPLE PR, V1, P891; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; SURUNGSI R, 1982, J ALLERGY CLIN IMMUN, V69, P126; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	29	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				667	677		10.1016/0091-6749(89)90294-7	http://dx.doi.org/10.1016/0091-6749(89)90294-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2809024				2022-12-18	WOS:A1989CA31400003
J	APPEL, D; KARPEL, JP; SHERMAN, M				APPEL, D; KARPEL, JP; SHERMAN, M			EPINEPHRINE IMPROVES EXPIRATORY FLOW-RATES IN PATIENTS WITH ASTHMA WHO DO NOT RESPOND TO INHALED METAPROTERENOL SULFATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	APPEL, D (corresponding author), N CENTR BRONX HOSP,MONTEFIORE MED CTR,DEPT MED,DIV PULM,3424 KOSSUTH AVE,ROOM 10C-07,BRONX,NY 10467, USA.							APPEL D, 1981, LUNG, V159, P243, DOI 10.1007/BF02713922; AUBIER M, 1984, J APPL PHYSIOL, V56, P922, DOI 10.1152/jappl.1984.56.4.922; BAUGHMAN RP, 1984, ANN ALLERGY, V53, P131; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BENZVI Z, 1982, PEDIATRICS, V70, P348; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; GLASS P, 1973, CURR THER RES CLIN E, V15, P141; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; JOSEPHSON GW, 1979, JAMA-J AM MED ASSOC, V242, P643; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; PATERSON JW, 1974, TUBERCLE S4, V25, P61; PIAFSKY KM, 1975, NEW ENGL J MED, V292, P1218, DOI 10.1056/NEJM197506052922305; PIERCE RJ, 1981, CHEST, V79, P506, DOI 10.1378/chest.79.5.506; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SACLEMAR MA, 1974, CLIN PHARMACOL THER, V16, P499; SHIM C, 1980, ANN INTERN MED, V93, P428; SHIM CS, 1984, J ALLERGY CLIN IMMUN, V73, P387, DOI 10.1016/0091-6749(84)90413-5; THRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; TINKELMAN DG, 1983, ANN ALLERGY, V50, P398; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; 1962, AM REV RESPIR DIS, V85, P762	24	47	48	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					90	98		10.1016/0091-6749(89)90182-6	http://dx.doi.org/10.1016/0091-6749(89)90182-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754149				2022-12-18	WOS:A1989AG12000013
J	RING, J; KUNZ, B; BIEBER, T; VIELUF, D; PRZYILLA, B				RING, J; KUNZ, B; BIEBER, T; VIELUF, D; PRZYILLA, B			THE ATOPY PATCH TEST WITH AEROALLERGENS IN ATOPIC ECZEMA (AE)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152					0	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					195	195						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900117
J	ANDERSSON, M; ANDERSSON, P; PIPKORN, U				ANDERSSON, M; ANDERSSON, P; PIPKORN, U			TOPICAL GLUCOCORTICOSTEROIDS AND ALLERGEN-INDUCED INCREASE IN NASAL REACTIVITY - RELATIONSHIP BETWEEN TREATMENT TIME AND INHIBITORY EFFECT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AB DRACO, DEPT PHARMACOL, S-22101 LUND, SWEDEN		ANDERSSON, M (corresponding author), UNIV LUND HOSP, DEPT EAR NOSE & THROAT, S-22185 LUND, SWEDEN.							ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BASCOM R, 1986, J ALLERGY CLIN IMMUN, V77, P246; BASCOM R, IN PRESS AM REV RESP; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DAHL R, 1987, ALLERGIC VASOMOTOR R, P136; EIWOOD RK, 1983, AM REV RESPIR DIS, V128, P523; ELLULMICALLEF R, 1982, EUR J RESPIR DIS, V63, P118; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOGG JC, 1981, J ALLERGY CLIN IMMUN, V67, P421, DOI 10.1016/0091-6749(81)90094-4; IMANARI T, 1976, DHEW NIH76791 PUBL, P295; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; MYGIND N, 1986, ESSENTIAL ALLERGY; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; PIPKORN U, 1985, CLIN ASPECTS ALLERGI, P165; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; WILSVIIK JS, 1975, CLIN ALLERGY, V5, P291	27	47	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1019	1026		10.1016/0091-6749(88)90139-X	http://dx.doi.org/10.1016/0091-6749(88)90139-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3060511	Bronze			2022-12-18	WOS:A1988R631100010
J	SIMONS, FER; SIMONS, KJ				SIMONS, FER; SIMONS, KJ			H-1 RECEPTOR ANTAGONIST TREATMENT OF CHRONIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BATENHORST RL, 1986, EUR J CLIN PHARMACOL, V31, P247, DOI 10.1007/BF00606669; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BONIVER R, 1986, CURR THER RES CLIN E, V39, P244; BRANDON ML, 1980, ANN ALLERGY, V44, P71; BROOKS CD, 1982, J ALLERGY CLIN IMMUN, V70, P373, DOI 10.1016/0091-6749(82)90027-6; BRUTTMANN G, 1987, J INT MED RES, V15, P63, DOI 10.1177/030006058701500201; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; CALLIER J, 1981, CURR THER RES CLIN E, V29, P24; CARPENTER GB, 1983, J ALLERGY CLIN IMMUN, V71, P412, DOI 10.1016/0091-6749(83)90071-4; CONNELL JT, 1987, AM J RHINOL, V1, P3; COOK CE, 1980, J PHARM SCI, V69, P1419, DOI 10.1002/jps.2600691218; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; DIAMOND L, 1981, ANN ALLERGY, V47, P87; EMPEY DW, 1975, ANN ALLERGY, V34, P41; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; HUANG SM, 1982, EUR J CLIN PHARMACOL, V22, P359, DOI 10.1007/BF00548406; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; KEMP JP, 1985, ANN ALLERGY, V54, P502; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MALMBERG H, 1983, ALLERGY, V38, P227, DOI 10.1111/j.1398-9995.1983.tb01615.x; OKERHOLM RA, 1981, BIOPHARM DRUG DISPOS, V2, P185, DOI 10.1002/bdd.2510020211; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; SALO OP, 1986, ACTA DERM-VENEREOL, V66, P349; SCHAAF L, 1979, J ALLERGY CLIN IMMUN, V63, P129, DOI 10.1016/0091-6749(79)90203-3; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P884; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS FER, 1986, CHILD ASTHMA, P140; SIMONS KJ, 1986, J ALLERGY CLIN IMMUN, V77, P326, DOI 10.1016/S0091-6749(86)80112-9; SIMONS KJ, 1987, J ALLERGY CLIN IMMUN, V79, P928, DOI 10.1016/0091-6749(87)90242-9; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5; THOMPSON JA, 1981, J PHARM SCI-US, V70, P1284, DOI 10.1002/jps.2600701127; VALLNER JJ, 1979, CURR THER RES CLIN E, V26, P449; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9; WILSON JD, 1982, CLIN ALLERGY, V12, P131; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924; 1986, CETIRIZINE INVESTIGA	50	47	47	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			975	980		10.1016/0091-6749(88)90164-9	http://dx.doi.org/10.1016/0091-6749(88)90164-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	2897389				2022-12-18	WOS:A1988N703700009
J	MARSH, DG; GOODFRIEND, L; KING, TP; LOWENSTEIN, H; PLATTSMILLS, TAE				MARSH, DG; GOODFRIEND, L; KING, TP; LOWENSTEIN, H; PLATTSMILLS, TAE			ALLERGEN NOMENCLATURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV,FAC MED,MONTREAL H3A 2T5,QUEBEC,CANADA; ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; UNIV VIRGINIA,MED CTR,SCH MED,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22901	McGill University; Rockefeller University; University of Copenhagen; University of Virginia	MARSH, DG (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.							ANSARI AA, IN PRESS J IMMUNOL; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; BAUR X, 1986, SCIENCE, V233, P351, DOI 10.1126/science.2425431; BELIN L, 1972, INT ARCH ALLER A IMM, V42, P329, DOI 10.1159/000230616; BORCH SM, 1980, ALLERGY, V35, P194, DOI 10.1111/j.1398-9995.1980.tb01741.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; EKRAMODDOULLAH AKM, 1981, INT ARCH ALLER A IMM, V65, P367, DOI 10.1159/000232778; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; ELSAYED S, 1971, INT ARCH ALLER A IMM, V40, P439, DOI 10.1159/000230426; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; ELSAYED S, 1983, THEORETICAL CLIN ASP, P237; FLORVAAG E, 1982, INT ARCH ALLER A IMM, V67, P49, DOI 10.1159/000232987; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GOODFRIEND L, 1981, J ALLERGY CLIN IMMUN, V67, P299, DOI 10.1016/0091-6749(81)90025-7; GOODMAN M, 1983, H-S Z PHYSIOL CHEM, V364, P205, DOI 10.1515/bchm2.1983.364.1.205; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HUSSAIN R, 1973, J IMMUNOL, V111, P260; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1987, J ALLERGY CLIN IMMUN, V79, P113, DOI 10.1016/S0091-6749(87)80025-8; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KLAPPER DG, 1980, BIOCHEMISTRY-US, V19, P5729, DOI 10.1021/bi00566a010; LANGELAND T, 1983, ALLERGY, V38, P131, DOI 10.1111/j.1398-9995.1983.tb01597.x; LANGELAND T, 1983, ALLERGY, V38, P493, DOI 10.1111/j.1398-9995.1983.tb02358.x; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; LONGBOTTOM JL, 1984, J IMMUNOL METHODS, V68, P297, DOI 10.1016/0022-1759(84)90160-1; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P48, DOI 10.1159/000231578; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DG, 1973, ALLERGOLOGY, P381; MECHERI S, IN PRESS INT ARCH AL; MOLE LE, 1975, BIOCHEMISTRY-US, V14, P1216, DOI 10.1021/bi00677a019; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; PRAHL P, 1982, INT ARCH ALLER A IMM, V67, P293, DOI 10.1159/000233036; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROEBBER M, 1983, J IMMUNOL, V131, P706; ROEBBER MG, 1975, THESIS MCGILL U MONT; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHIPOLINI RA, 1971, FEBS LETT, V17, P39, DOI 10.1016/0014-5793(71)80558-6; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; VIDUSEK DA, 1985, BIOCHEMISTRY-US, V24, P2747, DOI 10.1021/bi00332a023; VIK H, 1982, INT ARCH ALLER A IMM, V68, P70, DOI 10.1159/000233069; VIK H, IN PRESS INT ARCH AL; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	79	47	47	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					639	645		10.1016/0091-6749(87)90282-X	http://dx.doi.org/10.1016/0091-6749(87)90282-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930		Bronze			2022-12-18	WOS:A1987K993000002
J	SLADE, HB; SCHWARTZ, SA				SLADE, HB; SCHWARTZ, SA			MUCOSAL IMMUNITY - THE IMMUNOLOGY OF BREAST-MILK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV MICHIGAN,CS MOTT CHILDRENS HOSP,DEPT PEDIAT,IMMUNOL SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Schwartz, Stanley A./AAP-8852-2021	Schwartz, Stanley A./0000-0002-8664-1380				ABRAHAM SN, 1985, ADV HOST DEFENSE MEC, V4, P63; AHLSTEDT S, 1975, SCAND J IMMUNOL, V4, P535, DOI 10.1111/j.1365-3083.1975.tb02659.x; AMENT ME, 1985, SCAND J GASTROENTERO, V20, P127, DOI 10.3109/00365528509093773; ANDERSON JA, 1984, NIH PHS842442 PUBL; ANDERSSON B, 1985, LANCET, V1, P643; ATHERTON DJ, 1983, BRIT MED J, V287, P775, DOI 10.1136/bmj.287.6395.775; AVITAL A, 1985, IMMUNOL LETT, V9, P23, DOI 10.1016/0165-2478(85)90089-6; AXELROD DA, 1984, FED P, V43, P1676; BARLOW B, 1974, J PEDIATR SURG, V9, P587, DOI 10.1016/0022-3468(74)90093-1; BENNO Y, 1984, MICROBIOL IMMUNOL, V28, P975, DOI 10.1111/j.1348-0421.1984.tb00754.x; BERMAN MA, 1981, TRANSPLANTATION, V32, P426, DOI 10.1097/00007890-198111000-00018; Bienenstock J, 1978, Adv Exp Med Biol, V107, P53; BIENENSTOCK J, 1983, ANN NY ACAD SCI, V409, P164, DOI 10.1111/j.1749-6632.1983.tb26866.x; BIONDI A, 1984, J IMMUNOL, V132, P1237; BJORKSTEN B, 1983, IMMUNOL TODAY, V4, P215, DOI 10.1016/0167-5699(83)90029-4; BLAU H, 1983, PEDIATR RES, V17, P241, DOI 10.1203/00006450-198304000-00001; BRANDTZAEG P, 1985, SCAND J GASTROENTERO, V20, P17, DOI 10.3109/00365528509093765; BURGIO GR, 1980, PEDIATR RES, V14, P1111, DOI 10.1203/00006450-198010000-00004; BUSH JF, 1979, AM J OBSTET GYNECOL, V133, P708, DOI 10.1016/0002-9378(79)90023-1; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; CAMPBELL DA, 1984, TRANSPLANTATION, V37, P340, DOI 10.1097/00007890-198404000-00004; CANT AJ, 1984, HUM NUTR-APPL NUTR, V38A, P455; CARMAN PS, 1986, J IMMUNOL, V136, P1548; CARPENTER G, 1980, SCIENCE, V210, P198, DOI 10.1126/science.6968093; CEBRA JJ, 1982, RECENT ADV MUCOSAL I, P155; CHIN YH, 1986, J IMMUNOL, V136, P2556; CLANCY RL, 1983, INFECT IMMUN, V39, P491, DOI 10.1128/IAI.39.2.491-496.1983; CLEMENT LT, 1986, J IMMUNOL, V136, P2375; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CRAGO SS, 1984, CELL IMMUNOL, V86, P222, DOI 10.1016/0008-8749(84)90374-5; CRAGO SS, 1979, CLIN EXP IMMUNOL, V38, P585; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; CUNNINGHAM AS, 1984, J PEDIATR-US, V105, P854, DOI 10.1016/S0022-3476(84)80338-8; CUNNINGHAM AS, 1981, ADV INT MATERNAL CHI, V1, P128; CZINN SJ, 1986, J IMMUNOL, V136, P3607; DAHLGREN U, 1981, SCAND J IMMUNOL, V14, P95, DOI 10.1111/j.1365-3083.1981.tb00188.x; DAILEY MO, 1985, J MOL CELL IMMUNOL, V2, P27; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DIAZJOUA.E, 1974, CLIN IMMUNOL IMMUNOP, V3, P248, DOI 10.1016/0090-1229(74)90011-7; ELSON CO, 1984, J IMMUNOL, V133, P2892; ELSON CO, 1979, J EXP MED, V149, P632, DOI 10.1084/jem.149.3.632; ELSON CO, 1985, SCAND J GASTROENTERO, V114, P1; ERNST PB, 1986, J IMMUNOL, V136, P2121; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GALLIN JJ, 1985, ADV HOST DEFENSE MEC; GEARHART PJ, 1975, P NATL ACAD SCI USA, V72, P1707, DOI 10.1073/pnas.72.5.1707; GILBERT JV, 1983, ANN NY ACAD SCI, V409, P625, DOI 10.1111/j.1749-6632.1983.tb26904.x; GILLIN FD, 1983, SCIENCE, V221, P1290, DOI 10.1126/science.6310751; GOLDBLUM RM, 1975, NATURE, V257, P797, DOI 10.1038/257797a0; GOLDBLUM RM, 1985, PEDIATR RES, V19, pA342, DOI 10.1203/00006450-198504000-01415; GOLDBLUM RM, 1977, SECRETORY IMMUNITY I, P87; GREENWOOD JH, 1983, GASTROENTEROLOGY, V85, P1023; HALSEY JF, 1976, J IMMUNOL, V116, P1204; HALSTEAD TE, 1972, TRANSPLANTATION, V14, P339, DOI 10.1097/00007890-197209000-00009; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HANSON LA, 1961, INT ARCH ALLER A IMM, V18, P241, DOI 10.1159/000229177; HEAD JR, 1977, TRANSPLANT P, V9, P1465; HO PC, 1978, J PEDIATR-US, V93, P910, DOI 10.1016/S0022-3476(78)81210-4; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; JATSYK GV, 1985, ACTA PAEDIATR SCAND, V74, P246, DOI 10.1111/j.1651-2227.1985.tb10958.x; JUTO P, 1985, ARCH DIS CHILD, V60, P610, DOI 10.1136/adc.60.7.610; KAWANISHI H, 1983, J EXP MED, V158, P649, DOI 10.1084/jem.158.3.649; KELLER M, 1984, ACTA PAEDIATR SCAND, V73, P465, DOI 10.1111/j.1651-2227.1984.tb09956.x; KETT K, 1986, J IMMUNOL, V136, P3631; KILIAN M, 1983, ANN NY ACAD SCI, V409, P612, DOI 10.1111/j.1749-6632.1983.tb26903.x; KIYONO H, 1984, J EXP MED, V159, P798, DOI 10.1084/jem.159.3.798; KLEIN JR, 1986, 6TH P INT C IMM OTT, P42; KLIEGMAN RM, 1979, J PEDIATR-US, V95, P450, DOI 10.1016/S0022-3476(79)80534-X; KMETZ M, 1970, AM J VET RES, V31, P637; KOOPMAN JS, 1985, AM J PUBLIC HEALTH, V75, P477, DOI 10.2105/AJPH.75.5.477; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KRAAL G, 1983, J IMMUNOL, V130, P1097; KRAKAUER R, 1975, AM J GASTROENTEROL, V64, P319; KUHN LC, 1981, J BIOL CHEM, V256, P2490; KUMAR SN, 1985, J REPROD IMMUNOL, V8, P235, DOI 10.1016/0165-0378(85)90043-9; LUNDEQUIST B, 1985, ACTA PAEDIATR SCAND, V74, P45, DOI 10.1111/j.1651-2227.1985.tb10919.x; MACKENZIE N, 1984, IMMUNOL TODAY, V5, P364, DOI 10.1016/0167-5699(84)90080-X; MAVER L, 1982, J EXP MED, V156, P1860; MAY JT, 1984, AUST PAEDIATR J, V20, P265; MAYER L, 1985, J EXP MED, V161, P134, DOI 10.1084/jem.161.1.134; MCCAUGHAN GW, 1984, J IMMUNOL, V132, P1190; MCDERMOTT MR, 1986, IMMUNOLOGY, V57, P213; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MCDERMOTT MR, 1982, INT REV EXP PATHOL, V23, P47; MCNAAB PC, 1981, ANNU REV MICROBIOL, V138, P976; MCWILLIAMS M, 1977, J EXP MED, V145, P866, DOI 10.1084/jem.145.4.866; MELLANDER L, 1986, J CLIN IMMUNOL, V6, P284, DOI 10.1007/BF00917328; MITO K, 1984, J MED VIROL, V14, P323, DOI 10.1002/jmv.1890140405; MORGAN EL, 1979, J EXP MED, V150, P256, DOI 10.1084/jem.150.2.256; MORIARTEY RR, 1979, J PEDIATR-US, V94, P295, DOI 10.1016/S0022-3476(79)80848-3; MORO I, 1983, J CLIN IMMUNOL, V3, P382, DOI 10.1007/BF00915800; MOSMANN TR, 1978, EUR J IMMUNOL, V8, P94, DOI 10.1002/eji.1830080205; MOWET AM, 1986, 6TH P INT C IMM OTT, P45; MURILLO GJ, 1970, PEDIATR RES, V4, P71, DOI 10.1203/00006450-197001000-00008; MYERS MG, 1984, AM J DIS CHILD, V138, P629, DOI 10.1001/archpedi.1984.02140450011003; NAGAOKI T, 1981, J IMMUNOL, V126, P2015; NAIR MPN, 1985, J REPROD IMMUNOL, V7, P199, DOI 10.1016/0165-0378(85)90051-8; NORO N, 1986, J IMMUNOL, V136, P2910; Ogra S. S., 1979, Immunology of breast milk, P185; OGRA SS, 1978, J PEDIATR-US, V92, P550, DOI 10.1016/S0022-3476(78)80286-8; PABST R, 1986, J IMMUNOL, V136, P2011; PAINE R, 1982, AM J DIS CHILD, V136, P36, DOI 10.1001/archpedi.1982.03970370038009; PANIAGUA R, 1985, ANAT ANZEIGER, V160, P333; PARMELY MJ, 1976, J EXP MED, V144, P358, DOI 10.1084/jem.144.2.358; PARROTT DMV, 1974, IMMUNOLOGY, V26, P571; PERI BA, 1981, J IMMUNOL, V127, P2520; PERI BA, 1982, CLIN EXP IMMUNOL, V48, P91; PICKERING LK, 1983, INFECT IMMUN, V40, P8, DOI 10.1128/IAI.40.1.8-15.1983; PIERCE NF, 1982, J IMMUNOL, V128, P1311; PITT J, 1977, PEDIATR RES, V11, P906, DOI 10.1203/00006450-197708000-00011; PITT J, 1977, PEDIATR RES, V11, P909; PITTARD WB, 1979, CELL IMMUNOL, V42, P437, DOI 10.1016/0008-8749(79)90210-7; PITTARD WB, 1979, CLIN IMMUNOL IMMUNOP, V13, P430, DOI 10.1016/0090-1229(79)90085-0; PUENTE I, 1984, ANN M SOC GYNECOLOGI; PUSKAS M, 1983, B I SIEROTER MILAN, V62, P262; REICHERT RA, 1986, J IMMUNOL, V136, P3535; REISNER SH, 1977, LANCET, V2, P507; RICHIE ER, 1982, J IMMUNOL, V129, P1116; RICHMAN LK, 1981, CELL IMMUNOL, V62, P110, DOI 10.1016/0008-8749(81)90304-X; ROUX ME, 1977, J EXP MED, V146, P1311, DOI 10.1084/jem.146.5.1311; SCHNORR KL, 1984, J REPROD IMMUNOL, V6, P329, DOI 10.1016/0165-0378(84)90031-7; SCHWARTZ SA, 1980, J IMMUNOL, V124, P2034; SCHWARTZ SA, 1986, J ALLERGY CLIN IMMUN, V77, P174; SEELIG LL, IN PRESS J REPROD IM; SEELIG LL, 1981, TRANSPLANT P, V8, P1245; SELBY WS, 1984, GUT, V25, P32, DOI 10.1136/gut.25.1.32; SHEN L, 1981, CELL IMMUNOL, V59, P75, DOI 10.1016/0008-8749(81)90435-4; SLADE HB, 1986, J ALLERGY CLIN IMMUN, V77, P174; SMITH CW, 1968, PEDIATR RES, V2, P103, DOI 10.1203/00006450-196803000-00005; Smith M E, 1980, Monogr Allergy, V16, P203; SOOTHILL JF, 1984, ANN ALLERGY, V53, P689; SPENCER J, 1986, GUT, V27, P153, DOI 10.1136/gut.27.2.153; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STEPHENS S, 1986, PEDIATR RES, V20, P227, DOI 10.1203/00006450-198603000-00006; STEPHENS S, 1984, ACTA PAEDIATR SCAND, V73, P426, DOI 10.1111/j.1651-2227.1984.tb09950.x; STEVENS SK, 1982, J IMMUNOL, V128, P844; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; STOLL BJ, 1980, J PEDIATR-US, V96, P447; STOOLMAN L M, 1985, Journal of Cell Biology, V101, p233A; STROBER S, 1973, J EXP MED, V138, P1331, DOI 10.1084/jem.138.6.1331; STROBER W, 1985, ADV HOST DEFENSE MEC, V4, P1; SULLIVAN DA, 1984, IMMUNOLOGY, V53, P791; SVENNERHOLM AM, 1981, J INFECT DIS, V143, P707, DOI 10.1093/infdis/143.5.707; TAGLIABUE A, 1983, NATURE, V306, P184, DOI 10.1038/306184a0; TAPPER D, 1979, J PEDIATR SURG, V14, P803, DOI 10.1016/S0022-3468(79)80270-5; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; TOMASI TB, 1985, ADV HOST DEFENSE MEC, V4, P31; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VUKAVIC T, 1984, J PEDIATR GASTR NUTR, V3, P700, DOI 10.1097/00005176-198411000-00011; WEAVER EA, 1984, J IMMUNOL, V132, P684; WEAVER EA, 1982, INFECT IMMUN, V38, P1073, DOI 10.1128/IAI.38.3.1073-1077.1982; WEICKER J, 1975, J IMMUNOL, V114, P1337; WEISZCARRINGTON P, 1979, J IMMUNOL, V123, P1705; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; YOSHIOKA H, 1983, PEDIATRICS, V72, P317	159	47	47	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				348	356		10.1016/0091-6749(87)90041-8	http://dx.doi.org/10.1016/0091-6749(87)90041-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3305665	Green Published, Bronze			2022-12-18	WOS:A1987K103600017
J	FINEGOLD, I				FINEGOLD, I			ORAL DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN A PATIENT WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MIAMI,SCH MED,MIAMI,FL 33152	University of Miami								DESWARTE RD, 1985, ALLERGIC DISEASES DI, P595; GIBBONS RB, 1985, JAMA-J AM MED ASSOC, V253, P1259, DOI 10.1001/jama.1985.03350330053008; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; JAFFE HS, 1983, LANCET, V2, P1109; LANDESMAN SH, 1985, NEW ENGL J MED, V312, P521, DOI 10.1056/NEJM198502213120829; PURDY BH, 1984, ANN INTERN MED, V100, P512, DOI 10.7326/0003-4819-100-4-512; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; TAFFET SL, 1982, AM J MED, V73, P520, DOI 10.1016/0002-9343(82)90330-8	8	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				905	908		10.1016/0091-6749(86)90238-1	http://dx.doi.org/10.1016/0091-6749(86)90238-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3782658				2022-12-18	WOS:A1986E971300013
J	STEJSKAL, VDM; OLIN, RG; FORSBECK, M				STEJSKAL, VDM; OLIN, RG; FORSBECK, M			THE LYMPHOCYTE-TRANSFORMATION TEST FOR DIAGNOSIS OF DRUG-INDUCED OCCUPATIONAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AB ASTRA,DEPT OCCUPAT HLTH SERV,S-15185 SODERTALJE,SWEDEN; SODERSJUKHUSET,DEPT DERMATOL,S-10064 STOCKHOLM,SWEDEN	AstraZeneca; Sodersjukhuset Hospital	STEJSKAL, VDM (corresponding author), AB ASTRA,TOXICOL LABS,S-15185 SODERTALJE,SWEDEN.							AMOS HE, 1981, IMMUNOLOGICAL CLIN A, P389; ASSEM ESK, 1974, POSTGRAD MED J S, V65; BAIN B, 1970, CLIN EXP IMMUNOL, V6, P255; BASGER B, 1979, MED J AUSTRALIA, V1, P246; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CALDERON J, 1974, P NATL ACAD SCI USA, V71, P4273, DOI 10.1073/pnas.71.11.4273; DAVIES RJ, 1974, CLIN ALLERGY, V4, P227; DEWDNEY JM, 1977, ANTIGENS, V4, P74; EDWARDS RG, 1982, INT ARCH ALLER A IMM, V68, P352, DOI 10.1159/000233125; EKENVALL L, 1978, CONTACT DERMATITIS, V4, P190, DOI 10.1111/j.1600-0536.1978.tb03787.x; FERNSTROM AI, 1965, ACTA DERM-VENEREOL, V45, P129; FISCHER AB, 1977, J LAB CLIN MED, V90, P101; FUJINO T, 1982, P NATL ACAD SCI-BIOL, V79, P3682, DOI 10.1073/pnas.79.12.3682; HALPERN B, 1967, J ALLERGY, V40, P168, DOI 10.1016/0021-8707(67)90006-8; HARDIE RA, 1978, CONTACT DERMATITIS, V4, P121, DOI 10.1111/j.1600-0536.1978.tb03755.x; HAVEN J, 1974, ACTA ALLERGOL, V29, P225; JENSEN B, 1977, CLIN EXP IMMUNOL, V27, P303; KASAHARA T, 1976, J IMMUNOL, V116, P1251; MARSHALL WH, 1969, J EXP MED, V130, P327, DOI 10.1084/jem.130.2.327; MILLS JA, 1966, J IMMUNOL, V97, P239; MULLER HK, 1983, INT ARCH ALLER A IMM, V70, P65; OLIVE A, 1980, ALLERGOL IMMUNOPATH, V8, P105; PEARMAIN G, 1963, LANCET, V1, P637; Pirila V, 1975, Contact Dermatitis, V1, P48, DOI 10.1111/j.1600-0536.1975.tb05311.x; RAY A, 1980, MOL IMMUNOL, V17, P1011, DOI 10.1016/0161-5890(80)90094-2; RUDZKI E, 1965, ACTA ALLERGOL, V20, P206, DOI 10.1111/j.1398-9995.1965.tb03371.x; SARKANY I, 1978, AUSTRALAS J DERMATOL, V19, P45, DOI 10.1111/j.1440-0960.1978.tb00189.x; SCHLOSSMAN SF, 1969, J EXP MED, V130, P1031, DOI 10.1084/jem.130.5.1031; SCHULZ KH, 1970, BERUFSDERMATOSEN, V3, P132; SHMUNES E, 1976, ANN ALLERGY, V36, P313; SIEGEL B B, 1959, Bull World Health Organ, V21, P703; SONG BJ, 1985, SCIENCE, V228, P490, DOI 10.1126/science.2580351; TURK JL, 1979, DRUGS IMMUNE RESPONS; VICKERS MR, 1974, IMMUNOLOGY, V26, P425; WAHLBERG JE, 1981, CONTACT DERMATITIS, V7, P27, DOI 10.1111/j.1600-0536.1981.tb03955.x; WARRINGTON RJ, 1979, CAN MED ASSOC J, V120, P1089	36	47	48	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					411	426		10.1016/0091-6749(86)90175-2	http://dx.doi.org/10.1016/0091-6749(86)90175-2			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	2936791				2022-12-18	WOS:A1986A536700004
J	RICHMAN, PG; KHAN, HA; TURKELTAUB, PC; MALVEAUX, FJ; BAER, H				RICHMAN, PG; KHAN, HA; TURKELTAUB, PC; MALVEAUX, FJ; BAER, H			THE IMPORTANT SOURCES OF GERMAN-COCKROACH ALLERGENS AS DETERMINED BY RAST ANALYSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOWARD UNIV HOSP,DEPT MED,WASHINGTON,DC 20060	Howard University	RICHMAN, PG (corresponding author), US FDA,OFF BIOLOG,ALLERGEN PROD BRANCH,8800 ROCKVILLE PIKE,BETHESDA,MD 20205, USA.		turkeltaub, paul/AAG-6160-2019; turkeltaub, paul/U-7729-2019	turkeltaub, paul/0000-0002-7350-1469				ANDERSON MC, 1981, RAST INHIBITION PROC; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHOOVIVATHANAVANICH P, 1971, Journal of the Medical Association of Thailand, V54, P476; FRASER BN, 1979, S AFR MED J, V55, P637; KANG B, 1978, ANN ALLERGY, V41, P333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; SCHULANER FA, 1970, PEDIATRICS, V45, P465; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WIDE L, 1967, LANCET, V2, P1105	14	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					590	595		10.1016/0091-6749(84)90516-5	http://dx.doi.org/10.1016/0091-6749(84)90516-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6715725				2022-12-18	WOS:A1984SS04500009
J	MATLOFF, SM; KISELIS, IK; ROCKLIN, RE				MATLOFF, SM; KISELIS, IK; ROCKLIN, RE			REDUCED PRODUCTION OF HISTAMINE-INDUCED SUPPRESSOR FACTOR (HSF) BY ATOPIC MONONUCLEAR-CELLS AND DECREASED PROSTAGLANDIN-E2 OUTPUT BY HSF-STIMULATED ATOPIC MONOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV ALLERGY,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NIAID NIH HHS [AI-16362] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016362] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEER DJ, 1982, CELL IMMUNOL, V69, P101, DOI 10.1016/0008-8749(82)90054-5; BEER DJ, 1982, J CLIN INVEST, V70, P393, DOI 10.1172/JCI110629; BEER DJ, 1982, NEW ENGL J MED, V306, P454, DOI 10.1056/NEJM198202253060804; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GRAMSTROM E, 1976, PROSTAGLANDIN THROMB, P81; HALL TJ, 1982, INT J IMMUNOPHARMACO; HEBERT J, 1980, CELL IMMUNOL, V54, P49, DOI 10.1016/0008-8749(80)90188-4; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; LIMA M, 1981, CELL IMMUNOL, V64, P324, DOI 10.1016/0008-8749(81)90484-6; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; ROCKLIN RE, 1980, CELL IMMUNOL, V51, P226, DOI 10.1016/0008-8749(80)90255-5; ROCKLIN RE, 1981, J CLIN IMMUNOL, V1, P73, DOI 10.1007/BF00915479; ROCKLIN RE, 1983, CELL IMMUNOL; STASZAK C, 1980, CELL IMMUNOL, V54, P351, DOI 10.1016/0008-8749(80)90215-4; STENSON WF, 1980, J IMMUNOL, V125, P1	16	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					359	364		10.1016/0091-6749(83)90500-6	http://dx.doi.org/10.1016/0091-6749(83)90500-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6604743				2022-12-18	WOS:A1983RN33000005
J	JENNE, JW				JENNE, JW			WHITHER BETA-ADRENERGIC TACHYPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA	Loyola University Chicago	JENNE, JW (corresponding author), VET ADM MED CTR, PULM DIS SECT, HINES, IL 60141 USA.							CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; CONOLLY ME, 1982, J ALLERGY CLIN IMMUN, V70, P423, DOI 10.1016/0091-6749(82)90004-5; CROMPTON GK, 1981, NEW CONCEPTS TOPICAL, P10; DAVIS C, 1980, BRIT J CLIN PHARMACO, V10, P417, DOI 10.1111/j.1365-2125.1980.tb01782.x; DAVIS C, 1977, CLIN SCI MOL MED, V52, pP28; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FALLIERS CJ, 1981, ANN ALLERGY, V47, P387; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1980, CLIN SCI, V59, P155, DOI 10.1042/cs0590155; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LARSSON S, 1979, SCAND J RESPIR DIS, P84; LEWIS RA, 1982, AM REV RESPIR DIS, V125, P94; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; REPSHER LH, 1981, ANN ALLERGY, V47, P405; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WILSON JD, 1981, LANCET, V1, P1235	26	47	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					413	416		10.1016/0091-6749(82)90002-1	http://dx.doi.org/10.1016/0091-6749(82)90002-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6128356				2022-12-18	WOS:A1982PT74400002
J	TOOGOOD, JH; JENNINGS, B; LEFCOE, NM				TOOGOOD, JH; JENNINGS, B; LEFCOE, NM			A CLINICAL-TRIAL OF COMBINED CROMOLYN-BECLOMETHASONE TREATMENT FOR CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,SCH MED,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP,ALLERGY CLIN,LONDON N6A 4G5,ONTARIO,CANADA.							[Anonymous], 1959, Thorax, V14, P286, DOI 10.1136/thx.14.4.286; ARNER B, 1971, ACTA ALLERGOL, V26, P383, DOI 10.1111/j.1398-9995.1971.tb01311.x; BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P72, DOI 10.1016/0091-6749(78)90081-7; BASKERVILLE J, 1979, CLIN PHARMACOL THER, V25, P213; BENSON MK, 1973, CLIN ALLERGY, V3, P389, DOI 10.1111/j.1365-2222.1973.tb01346.x; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CHOOVORAVECH P, 1978, PRACTITIONER, V220, P639; CURRY SH, 1975, BRIT J CLIN PHARMACO, V2, P267, DOI 10.1111/j.1365-2125.1975.tb01586.x; DAWOOD AG, 1977, CLIN ALLERGY, V7, P161, DOI 10.1111/j.1365-2222.1977.tb01437.x; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; DOLOVICH MB, 1976, J APPL PHYSIOL, V40, P468, DOI 10.1152/jappl.1976.40.3.468; EDMUNDS AT, 1979, BRIT J DIS CHEST, V73, P149, DOI 10.1016/S0007-0971(79)80124-2; Eriksson N E, 1975, Allergol Immunopathol (Madr), V3, P77; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GADDIE J, 1973, LANCET, V2, P280; GODFREY S, 1974, CLIN SCI MOL MED, V46, P265, DOI 10.1042/cs0460265; GODFREY S, 1980, J ALLERGY CLIN IMMUN, V65, P97, DOI 10.1016/0091-6749(80)90192-X; GWIN E, 1977, CHEST, V72, P148, DOI 10.1378/chest.72.2.148; HAMBLETON G, 1977, LANCET, V1, P381; HARRIS DM, 1975, J STEROID BIOCHEM, V6, P711, DOI 10.1016/0022-4731(75)90057-6; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; KERSHNAR H, 1978, PEDIATRICS, V62, P189; LANGAKER KE, 1975, ACTA ALLERGOL, V30, P306, DOI 10.1111/j.1398-9995.1975.tb00207.x; MATHISON DA, 1971, J AMER MED ASSOC, V216, P1454, DOI 10.1001/jama.216.9.1454; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MESSERLI C, 1975, PNEUMONOLOGIE, V153, P29, DOI 10.1007/BF02096333; MITCHELL I, 1976, BRIT MED J, V4, P457; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; MYGIND N, 1973, ACTA ALLERGOL, V28, P211, DOI 10.1111/j.1398-9995.1973.tb01327.x; NEWHOUSE MT, 1978, CHEST, V73, P936, DOI 10.1378/chest.73.6.936; NEWTH C J L, 1980, American Review of Respiratory Disease, V121, P297; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PEPYS J, 1973, ASTHMA PHYSL IMMUNOP; READ J, 1969, MED J AUSTRALIA, V1, P566, DOI 10.5694/j.1326-5377.1969.tb92293.x; Spitzer S A, 1971, Harefuah, V81, P130; TOOGOOD JH, 1979, LANCET, V2, P1185; TOOGOOD JH, 1973, J ALLERGY CLIN IMMUN, V52, P334, DOI 10.1016/0091-6749(73)90092-4; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; TOOGOOD JH, 1980, TOPICAL STEROID TREA, P107; WEINBERGER M, 1979, LANCET, V1, P871; WOOLCOCK AJ, 1977, AM REV RESPIR DIS, V115, P191; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; YEARNAULT JC, 1977, CHEST, V71, P698; 1962, AM REV RESPIR DIS, V85, P762; 1976, BRIT J DIS CHEST, V70, P95; 1969, STANDARDS EPIDEMIOLO	49	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					317	324		10.1016/0091-6749(81)90028-2	http://dx.doi.org/10.1016/0091-6749(81)90028-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	6782146				2022-12-18	WOS:A1981LL69700011
J	PINCKARD, RN; KNIKER, WT; LEE, L; HANAHAN, DJ; MCMANUS, LM				PINCKARD, RN; KNIKER, WT; LEE, L; HANAHAN, DJ; MCMANUS, LM			VASOACTIVE EFFECTS OF 1-0-ALKYL-2-ACETYL-SN-GLYCERYL-3-PHOSPHORYCHOLINE (ACGEPC) IN HUMAN-SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																		1979, J BIOL CHEM, V254, P9355	1	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	3					196	196						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ620					2022-12-18	WOS:A1980JJ62000107
J	ZIMMERMANN, EM; YUNGINGER, JW; GLEICH, GJ				ZIMMERMANN, EM; YUNGINGER, JW; GLEICH, GJ			INTERFERENCE IN RAGWEED POLLEN AND HONEYBEE VENOM RADIOALLERGOSORBENT TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO MED SCH,DEPT MED,ROCHESTER,MN 55901; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1973, INT ARCH ALLER A IMM, V45, P46, DOI 10.1159/000230999; Coca AF, 1925, J IMMUNOL, V10, P445; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V58, P31; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Loveless MH, 1940, J IMMUNOL, V38, P25; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; PAULL BR, 1978, J IMMUNOL, V120, P1917; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	30	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					386	393		10.1016/0091-6749(80)90118-9	http://dx.doi.org/10.1016/0091-6749(80)90118-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7440856				2022-12-18	WOS:A1980KQ96500007
J	ARROYAVE, CM; SCHATZ, M; SIMON, RA				ARROYAVE, CM; SCHATZ, M; SIMON, RA			ACTIVATION OF THE COMPLEMENT-SYSTEM BY RADIOGRAPHIC CONTRAST-MEDIA - STUDIES INVIVO AND INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DEPT PEDIAT,DENVER,CO 80262; USN,REG MED CTR,SAN DIEGO,CA 92134; SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; United States Department of Defense; United States Navy; Scripps Research Institute	ARROYAVE, CM (corresponding author), UNIV COLORADO,MED CTR,DEPT MED,DENVER,CO 80262, USA.							ARROYAVE CM, 1977, CLIN EXP IMMUNOL, V29, P89; ARROYAVE CM, 1976, J IMMUNOL METHODS, V13, P101, DOI 10.1016/0022-1759(76)90148-4; ARROYAVE CM, 1973, J IMMUNOL, V111, P536; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109; BRASCH RC, 1976, INVEST RADIOL, V11, P1, DOI 10.1097/00004424-197601000-00001; CORBIN NC, 1976, ANAL BIOCHEM, V73, P41, DOI 10.1016/0003-2697(76)90139-1; GOTZE O, 1971, J EXP MED, V134, pS90; GOUDIE RBC, 1966, LANCET, V11, P1224; KLEINKNECHT D, 1974, CLIN NEPHROL, V2, P116; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LEPOW IH, 1970, AM J PATHOL, V61, P13; MANCINI G, 1964, PROTIDES BIOLOGICAL, P370; MARTIN A, 1976, IMMUNOCHEMISTRY, V13, P317, DOI 10.1016/0019-2791(76)90341-4; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MEDICUS RG, 1976, P NATL ACAD SCI USA, V73, P612, DOI 10.1073/pnas.73.2.612; MINDEN P, 1973, HDB EXPTL IMMUNOLOGY, P151; MULLEREBERHARD HJ, 1965, J EXP MED, V121, P819, DOI 10.1084/jem.121.5.819; MULLEREBERHARD HJ, 1966, ARCH PATHOL, V82, P205; MULLEREBERHARD HJ, 1969, ANNU REV BIOCH, V38, P359; NICOL PAE, 1973, IMMUNOLOGY, V24, P259; OSLER AG, 1973, PROG ALLERGY, V17, P51, DOI 10.1159/000313290; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V62, P281; THEOFILOPOULOS AN, 1974, J EXP MED, V139, P696, DOI 10.1084/jem.139.3.696; TILL G, 1977, FED PROC, V36, P1264; WAKKERSGARRITSEN BG, 1976, ANN ALLERGY, V36, P122; WARD PA, 1967, J EXP MED, V126, P189, DOI 10.1084/jem.126.2.189; WUEPPER KD, 1972, CLIN EXP IMMUNOL, V11, P13	29	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					276	280		10.1016/0091-6749(79)90113-1	http://dx.doi.org/10.1016/0091-6749(79)90113-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	429705				2022-12-18	WOS:A1979GR84200009
J	JUTO, P; STRANNEGARD, O				JUTO, P; STRANNEGARD, O			LYMPHOCYTES-T AND BLOOD EOSINOPHILS IN EARLY INFANCY IN RELATION TO HEREDITY FOR ALLERGY AND TYPE OF FEEDING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UMEA UNIV,DEPT PEDIAT,S-90185 UMEA,SWEDEN	Umea University	JUTO, P (corresponding author), UMEA UNIV,DEPT CLIN VIROL,S-90185 UMEA,SWEDEN.							ANDERSEN E, 1975, ACTA DERM-VENEREOL, V55, P345; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; BYROM NA, 1978, CLIN EXP IMMUNOL, V31, P490; FLEISHER TA, 1975, PEDIATRICS, V55, P162; GUPTA S, 1975, CLIN EXP IMMUNOL, V22, P438; HOVMARK A, 1977, ACTA DERM-VENEREOL, V57, P237; HSIEH KH, 1976, ANN ALLERGY, V37, P383; JARRETT, 1977, LANCET, V2, P223; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; JUTO P, 1979, LANCET, V1, P102; LUCKASEN JR, 1974, ARCH DERMATOL, V110, P374; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; NIKLASSON PM, 1974, INFECT IMMUN, V9, P1; SANDAHLCHRISTIA.J, 1976, ACTA PAEDIATR SCAND, V65, P425; SANDILANDS GP, 1978, LANCET, V1, P1260; SARACLAR Y, 1977, J ALLERGY CLIN IMMUN, V60, P301, DOI 10.1016/0091-6749(77)90109-9; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; STRANNEGARD IL, 1977, INT ARCH ALLER A IMM, V55, P217, DOI 10.1159/000231930; STRANNEGARD IL, 1977, SCAND J IMMUNOL, V6, P1225; STRANNEGARD IL, 1978, INT ARCH ALLERGY APP, V58, P167; STRANNEGARD O, 1978, IMMUNOL REV, V41, P149, DOI 10.1111/j.1600-065X.1978.tb01463.x; STRANNEGARD O, 1978, LANCET, V2, P385; THOMSON NC, 1977, CLIN EXP IMMUNOL, V30, P429; VERHAEGEN H, 1977, J ALLERGY CLIN IMMUN, V59, P266, DOI 10.1016/0091-6749(77)90161-0; WYBRAN J, 1973, J CLIN INVEST, V52, P1026, DOI 10.1172/JCI107267	25	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					38	42		10.1016/0091-6749(79)90081-2	http://dx.doi.org/10.1016/0091-6749(79)90081-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	312813				2022-12-18	WOS:A1979HC42400009
J	SIRAGANIAN, RP; BAER, H; HOCHSTEIN, HD; MAY, JC				SIRAGANIAN, RP; BAER, H; HOCHSTEIN, HD; MAY, JC			ALLERGENIC AND BIOLOGIC ACTIVITY OF COMMERCIAL PREPARATIONS OF HOUSE DUST EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									US FDA, BUR BIOL, BETHESDA, MD 20014 USA	US Food & Drug Administration (FDA)	SIRAGANIAN, RP (corresponding author), NIDR, MICROBIOL & IMMUNOL LAB, CLIN IMMUNOL SECT, BLDG 10, RM 2B12, BETHESDA, MD 20205 USA.							Berrens L, 1970, Prog Allergy, V14, P259, DOI 10.1159/000289384; BERRENS L, 1965, INT ARCH ALLER A IMM, V27, P129, DOI 10.1159/000229607; BOATNER C. H., 1942, JOUR INVEST DERMAT, V5, P7; BULLOCK JD, 1972, AM J DIS CHILD, V123, P222, DOI 10.1001/archpedi.1972.02110090092010; FURNESS G, 1952, BRIT J IND MED, V9, P138; HOCHSTEIN HD, 1972, B PARENTERAL DRUG AS, V26, P153; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P117, DOI 10.1016/0091-6749(72)90007-3; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MAY JC, 1979, J ALLERGY CLIN IMMUN, V63, P87, DOI 10.1016/0091-6749(79)90197-0; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; RAFFARD M, 1973, CONCOURS MED, V47, P95; RUDBACH JA, 1976, J CLIN MICROBIOL, V3, P21; SIRAGANIAN RP, 1977, J ALLERGY CLIN IMMUN, V59, P214, DOI 10.1016/0091-6749(77)90152-X; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WHARTON GW, 1970, SCIENCE, V167, P1382, DOI 10.1126/science.167.3923.1382; WOLFENBERGER V, 1974, ANN ALLERGY, V32, P252; 1976, 21CFR61013 PUBL HLTH	21	47	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					526	533		10.1016/0091-6749(79)90063-0	http://dx.doi.org/10.1016/0091-6749(79)90063-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	92488				2022-12-18	WOS:A1979HX84000009
J	NORMAN, PS; MARSH, DG				NORMAN, PS; MARSH, DG			HUMAN-SERUM ALBUMIN AND TWEEN 80 AS STABILIZERS OF ALLERGEN SOLUTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21218; HOWARD HUGHES MED INST,MIAMI,FL	Johns Hopkins University; Howard Hughes Medical Institute	NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							BAER H, 1973, J ALLERGY CLIN IMMUN, V51, P116, DOI 10.1016/S0091-6749(73)80081-8; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; GULD J, 1955, AM REV TUBERC PULM, V72, P126; HJORTH NIELS, 1957, ACTA ALLERGOL, V11, P249, DOI 10.1111/j.1398-9995.1957.tb03036.x; HJORTH NIELS, 1958, ACTA ALLERGOL, V12, P316, DOI 10.1111/j.1398-9995.1958.tb03088.x; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LOWENSTEIN H, 1978, J ALLERGY CLIN IMMUN, V61, P180, DOI 10.1016/0091-6749(78)90411-6; MAGNUS K, 1956, AM REV TUBERC PULM, V74, P297; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1976, MANUAL CLIN IMMUNOLO, P585; STULL ARTHUR, 1933, JOUR ALLERGY, V4, P455, DOI 10.1016/S0021-8707(33)90098-2	12	47	50	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					314	319		10.1016/0091-6749(78)90164-1	http://dx.doi.org/10.1016/0091-6749(78)90164-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	701667	Bronze			2022-12-18	WOS:A1978FW43200010
J	BORUT, TC; TASHKIN, DP; FISCHER, TJ; KATZ, R; RACHELEFSKY, G; SIEGEL, SC; LEE, E; HARPER, C				BORUT, TC; TASHKIN, DP; FISCHER, TJ; KATZ, R; RACHELEFSKY, G; SIEGEL, SC; LEE, E; HARPER, C			COMPARISON OF AEROSOLIZED ATROPINE SULFATE AND SCH-1000 ON EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES, MED CTR, DEPT PEDIAT & MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BIERMAN CW, 1975, PEDIATRICS, V56, P843; CAVANAUGH MJ, 1976, AM REV RESPIR DIS, V114, P517; CHAMBERLAIN DA, 1962, LANCET, V2, P1019; CROMPTON GK, 1968, THORAX, V23, P165, DOI 10.1136/thx.23.2.165; DECKERS W, 1975, POSTGRAD MED J, V51, P76; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DIXON W.J., 1975, BMDP BIOMEDICAL COMP; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EMIRGIL C, 1975, CURR THER RES CLIN E, V17, P215; ENGELHARDT A, 1975, POSTGRAD MED J, V51, P82; FISHER HK, 1970, AM REV RESPIR DIS, V101, P885; GAYARD P, 1970, B PHYSIOPATHOL RESPI, V10, P451; GODFREY S, 1975, PEDIATRICS, V56, P930; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; GOLDBERG R, 1975, POSTGRAD MED J, V51, P53, DOI 10.1136/pgmj.51.592.53; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; HAMM J, 1975, POSTGRAD MED J    S7, V51, P149; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KIVILOOG J, 1975, PEDIATRICS, V56, P940; MCNEILL RS, 1966, Q J MED, V35, P55; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724, DOI 10.1111/j.1476-5381.1970.tb09898.x; MINETTE A, 1975, POSTGRAD MED J    S7, V51, P153; NADEL JA, 1975, POSTGRAD MED J, V51, P86; NOLTE D, 1975, POSTGRAD MED J, V51, P103; PARKER CD, 1963, ARCH INTERN MED, V115, P45; PETRIE GR, 1975, BRIT MED J, V1, P430, DOI 10.1136/bmj.1.5955.430; POPPIUS H, 1972, B PHYSIO-PATHOL RESP, V8, P643; POPPIUS H, 1971, SCAND J RESPIR DIS, P30; POPPIUS H, 1973, SCAND J RESPIR DIS, V54, P142; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SIMONSSON BG, 1975, SCAND J RESPIR DIS, V56, P138; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; STANUS WN, 1975, AM REV RESPIR DIS, V111, P419; STEMMANN EA, 1975, POSTGRAD MED J, V51, P105; STERLING GM, 1968, CLIN SCI, V34, P277; TASHKIN DP, TO BE PUBLISHED; TINKELMAN DG, 1976, AM REV RESPIR DIS, V114, P87; VLAGOPOULOS T, 1976, ANN ALLERGY, V36, P223; WAHL D, 1974, PARASYMPATHETIC DRUG; WARD FG, 1969, BRIT MED J, V3, P176, DOI 10.1136/bmj.3.5663.176-d; YEAGER H, 1976, J CLIN PHARMACOL, V16, P198, DOI 10.1002/j.1552-4604.1976.tb01518.x; ZARD G, 1966, NEW ENGL J MED, V275, P580; ZARD G, 1968, J ALLERGY, V42, P177	45	47	47	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					127	133		10.1016/0091-6749(77)90038-0	http://dx.doi.org/10.1016/0091-6749(77)90038-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	141471				2022-12-18	WOS:A1977DR44800007
J	CHUA, YY; BREMNER, K; LLOBET, JL; KOKUBU, HL; COLLINSWILLIAMS, C				CHUA, YY; BREMNER, K; LLOBET, JL; KOKUBU, HL; COLLINSWILLIAMS, C			DIAGNOSIS OF FOOD ALLERGY BY RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DIV ALLERGY,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; COLLINSWILLIAM.C, 1963, SOMATIC PSYCHIATRIC; COLLINSWILLIAMS C, 1954, J PEDIATR-US, V45, P337, DOI 10.1016/S0022-3476(54)80199-5; FEINGOLD BF, 1968, ANN ALLERGY, V26, P309; FOUCARD T, 1973, J ALLERGY CLIN IMMUN, V51, P39, DOI 10.1016/0091-6749(73)90007-9; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOGARTHSCOTT RS, 1973, MED J AUSTRALIA, V1, P1293, DOI 10.5694/j.1326-5377.1973.tb111120.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Rowe A., 1944, ELIMINATION DIETS PA; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; SHINER M, 1975, LANCET, V1, P136; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WIDE L, 1967, LANCET, V2, P1105	17	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					477	482		10.1016/0091-6749(76)90191-3	http://dx.doi.org/10.1016/0091-6749(76)90191-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	972215				2022-12-18	WOS:A1976CH21000004
J	SANTIVES, T; ROSKA, AK; HENSLEY, GT; MOORE, VL; FINK, JN; ABRAMOFF, P				SANTIVES, T; ROSKA, AK; HENSLEY, GT; MOORE, VL; FINK, JN; ABRAMOFF, P			IMMUNOLOGICALLY INDUCED LUNG-DISEASE IN GUINEA-PIGS - COMPARISON OF OVALBUMIN AND PIGEON SERUM AS ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM CTR,SERV RES,WOOD,WI 53193; MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233; MARQUETTE UNIV,DEPT BIOL,MILWAUKEE,WI 53233; UNIV MIAMI,SCH MED,DEPT PATHOL,MIAMI,FL	Medical College of Wisconsin; Marquette University; University of Miami								BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; BENVENISTE J, 1972, INFLAMMATION MECHANI, P179; BLOCH KJ, 1963, J EXP MED, V117, P965, DOI 10.1084/jem.117.6.965; BRENTJENS JR, 1974, J EXP MED, V140, P105, DOI 10.1084/jem.140.1.105; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CAMPBELL DH, 1970, METHOD IMMUNOL, P279; DWYER RSC, 1974, INT ARCH ALLER A IMM, V46, P910, DOI 10.1159/000231192; ELLMAN L, 1971, J EXP MED, V134, P162, DOI 10.1084/jem.134.1.162; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HENSLEY GT, 1969, ARCH PATHOL, V87, P572; HENSLEY GT, 1974, ARCH PATHOL, V97, P33; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; KNIKER WT, 1972, INFLAMMATION MECHANI, P335; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ W, 1973, HDB EXPT IMMUNOLOGY, pA1; MAILLARD JL, 1970, P SOC EXP BIOL MED, V133, P1184; MOORE VL, 1975, J LAB CLIN MED, V85, P540; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; PEPYS J, 1967, 6 INT C ALL MONTR; PERINI A, 1973, IMMUNOLOGY, V25, P297; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745	27	47	47	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					582	594		10.1016/0091-6749(76)90010-5	http://dx.doi.org/10.1016/0091-6749(76)90010-5			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	932343				2022-12-18	WOS:A1976BV05400010
J	REIMER, LG; MORRIS, HG; ELLIS, EF				REIMER, LG; MORRIS, HG; ELLIS, EF			GROWTH OF ASTHMATIC CHILDREN DURING TREATMENT WITH ALTERNATE-DAY STEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,PEDIAT ALLERGY DIV,DENVER,CO	National Jewish Health								BLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402; COHEN MB, 1948, J ALLERGY, V19, P165, DOI 10.1016/0021-8707(48)90049-5; FALLIERS CJ, 1961, J ALLERGY, V32, P420, DOI 10.1016/0021-8707(61)90020-X; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; MIGEON CJ, 1956, J CLIN ENDOCR METAB, V16, P1137, DOI 10.1210/jcem-16-9-1137b; MIGEON CJ, 1968, J PEDIATR-US, V73, P805, DOI 10.1016/S0022-3476(68)80199-4; MORRIS H, 1973, ANN REV ALLERGY 1972, P105; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; MORRIS HG, TO BE PUBLISHED; RAITI S, 1971, ARCH DIS CHILD, V46, P376, DOI 10.1136/adc.46.247.376; SMITH JM, 1965, ANN ALLERGY, V23, P492; SPOCK A, 1965, ANN ALLERGY, V23, P608; VANMETRE TE, 1959, J ALLERGY, V30, P103, DOI 10.1016/0021-8707(59)90079-6; VANMETRE TE, 1960, J ALLERGY, V31, P531, DOI 10.1016/0021-8707(60)90088-5; VAUGHAN VC, 1969, TXB PEDIATRICS, P44; VERMEULEN A, 1959, J ENDOCRINOL, V18, P278, DOI 10.1677/joe.0.0180278; ZACHMANN M, 1970, RESPIRATION, V27, P244, DOI 10.1159/000192752	17	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					224	231		10.1016/0091-6749(75)90141-4	http://dx.doi.org/10.1016/0091-6749(75)90141-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	W1385	1123495	Bronze			2022-12-18	WOS:A1975W138500003
J	MURANAKA, M; SUZUKI, S; MIYAMOTO, T; TAKEDA, K; OKUMURA, H; MAKINO, S				MURANAKA, M; SUZUKI, S; MIYAMOTO, T; TAKEDA, K; OKUMURA, H; MAKINO, S			BRONCHIAL REACTIVITIES TO ACETYLCHOLINE AND IGE LEVELS IN ASTHMATIC SUBJECTS AFTER LONG-TERM REMISSIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,7-3-1 HONGO,BUNKYO,TOKYO,JAPAN	University of Tokyo								CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; CURRY JJ, 1948, J ALLERGY, V19, P9, DOI 10.1016/0021-8707(48)90072-0; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOHANSSON SGO, 1968, IMMUNOLOGY, V14, P256; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MAKINO S, 1964, JAP J ALLERGY, V13, P32; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MIYAMOTO T, 1968, JAP J ALLERGY, V17, P91; MURANAKA M, 1970, J ALLERGY, V46, P138, DOI 10.1016/0021-8707(70)90092-4; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SALVAGGIO J, 1966, J ALLERGY, V38, P31, DOI 10.1016/0021-8707(66)90070-0; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SPARKS DB, 1962, J ALLERGY, V33, P245, DOI 10.1016/0021-8707(62)90091-6; TIFFENEAU R, 1959, PRESSE MED, V67, P2017; TIFFENEAU R, 1955, PRESSE MED, V63, P227; TOWNLEY RG, 1971, J ALLERGY, V47, P91; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1964, Allergie Asthma, V10, P329; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8	24	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	1					32	40		10.1016/S0091-6749(74)80006-0	http://dx.doi.org/10.1016/S0091-6749(74)80006-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T5232	4834050				2022-12-18	WOS:A1974T523200005
J	ISAACS, NJ; ERTEL, NH				ISAACS, NJ; ERTEL, NH			URTICARIA AND PRURITUS - UNCOMMON MANIFESTATIONS OF HYPERTHYROIDISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ARTHUR RP, 1958, ANN INTERN MED, V49, P900, DOI 10.7326/0003-4819-49-4-900; BARROW MV, 1966, ARCH DERMATOL, V93, P237, DOI 10.1001/archderm.93.2.237; BEALL GN, 1964, MEDICINE, V43, P131; BUCCINO RA, 1967, J CLIN INVEST, V46, P1669, DOI 10.1172/JCI105658; CARAVATI CM, 1969, SOUTH MED J, V62, P1127, DOI 10.1097/00007611-196909000-00020; CHAPMAN EM, 1956, NEW ENGL J MED, V254, P1, DOI 10.1056/NEJM195601052540101; CORMIA FE, 1957, J INVEST DERMATOL, V28, P425, DOI 10.1038/jid.1957.56; ELIAKIM M., 1959, ISRAEL MED JOUR, V18, P262; GOLDBERG M, 1962, J CLIN ENDOCR METAB, V22, P892, DOI 10.1210/jcem-22-9-892; GRAHAM DT, 1957, AM J MED SCI, V230, P420; HALL R, 1962, NEW ENGL J MED, V266, P1204, DOI 10.1056/NEJM196206072662306; HARRISON TS, 1964, PHYSIOL REV, V44, P161, DOI 10.1152/physrev.1964.44.2.161; HAVARD CWH, 1963, Q J MED, V32, P145; HERXHEIMER A, 1959, NATURE, V183, P1510, DOI 10.1038/1831510a0; HUSAIN MK, 1971, PROGRAM ENDOCRINE SO; HUSAIN MK, 1971, CLIN RES, V19, P374; INGBAR SH, 1968, TEXTBOOK ENDOCRINOLO, P182; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P37; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KRISS JP, 1964, J CLIN ENDOCR METAB, V24, P1005, DOI 10.1210/jcem-24-10-1005; LEVEY GS, 1971, AM J MED, V50, P413, DOI 10.1016/0002-9343(71)90331-7; LOCKE W, 1967, MED CLIN N AM, V51, P915, DOI 10.1016/S0025-7125(16)33005-X; LUNDHOLM L, 1966, PHARMACOL REV, V18, P255; MICHAELS.G, 1969, ACTA DERM-VENEREOL, V49, P404; MICHEL B, 1968, J CLIN INVEST, V47, pA68; RIDDLE MC, 1970, ANN INTERN MED, V72, P749, DOI 10.7326/0003-4819-72-5-749; ROCHAESILVA M, 1963, ANN NY ACAD SCI, V104, P190; Rose N R, 1968, Adv Metab Disord, V3, P231; Rothfeld B, 1968, JAMA, V205, P122; STEINBECK AW, 1963, MED J AUSTRALIA, V2, P50, DOI 10.5694/j.1326-5377.1963.tb24609.x; THOMPSON JS, 1968, ANN INTERN MED, V69, P361, DOI 10.7326/0003-4819-69-2-361; VOLPE R, 1969, AM J MED, V46, P217, DOI 10.1016/0002-9343(69)90006-0; WALDSTEIN SS, 1966, ANNU REV MED, V17, P123, DOI 10.1146/annurev.me.17.020166.001011; WINKLEMANN RK, 1957, MAYO CLIN P, V32, P329; WISWELL JG, 1963, J CLIN ENDOCR METAB, V23, P1102, DOI 10.1210/jcem-23-11-1102; ZACHARIAE H, 1967, J PHYSIOL-LONDON, V190, P81, DOI 10.1113/jphysiol.1967.sp008194	36	47	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	2					73	&		10.1016/0091-6749(71)90089-3	http://dx.doi.org/10.1016/0091-6749(71)90089-3			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K0446	4104292				2022-12-18	WOS:A1971K044600002
J	Santos, AF; Du Toit, G; O'Rourke, C; Becares, N; Couto-Francisco, N; Radulovic, S; Khaleva, E; Basting, M; Harris, KM; Larson, D; Sayre, P; Plaut, M; Roberts, G; Bahnson, HT; Lack, G				Santos, Alexandra F.; Du Toit, George; O'Rourke, Colin; Becares, Natalia; Couto-Francisco, Natalia; Radulovic, Suzana; Khaleva, Ekaterina; Basting, Monica; Harris, Kristina M.; Larson, David; Sayre, Peter; Plaut, Marshall; Roberts, Graham; Bahnson, Henry T.; Lack, Gideon			Biomarkers of severity and threshold of allergic reactions during oral peanut challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil; basophil activation test; diagnosis; food allergy; LEAP study; peanut allergy; severity; threshold; adverse events	BASOPHIL ACTIVATION TEST; SKIN PRICK TESTS; DOUBLE-BLIND; NUT ALLERGY; IGE; ANAPHYLAXIS; SENSITIZATION; CONSUMPTION; FATALITIES; COMPONENTS	Background: Oral food challenge (OFC) is the criterion standard to assess peanut allergy (PA), but it involves a risk of allergic reactions of unpredictable severity. Objective: Our aim was to identify biomarkers for risk of severe reactions or low dose threshold during OFC to peanut. Methods: We assessed Learning Early about Peanut Allergy study, Persistance of Oral Tolerance to Peanut study, and Peanut Allergy Sensitization study participants by administering the basophil activation test (BAT) and the skin prick test (SPT) and measuring the levels of peanut-specific IgE, Arachis hypogaea 2 specific IgE, and peanut-specific IgG4, and we analyzed the utility of the different biomarkers in relation to PA status, severity, and threshold dose of allergic reactions to peanut during OFC. Results: When a previously defined optimal cutoff was used, the BAT diagnosed PA with 98% specificity and 75% sensitivity. The BAT identified severe reactions with 97% specificity and 100% sensitivity. The SPT, level of Arachis hypogaea 2 specific IgE, level of peanut-specific IgE, and IgG4/IgE ratio also had 100% sensitivity but slightly lower specificity (92%, 93%, 90%, and 88%, respectively) to predict severity. Participants with lower thresholds of reactivity had higher basophil activation to peanut in vitro. The SPT and the BAT were the best individual predictors of threshold. Multivariate models were superior to individual biomarkers and were used to generate nomograms to calculate the probability of serious adverse events during OFC for individual patients. Conclusions: The BAT diagnosed PA with high specificity and identified severe reactors and low threshold with high specificity and high sensitivity. The BAT was the best biomarker for severity, surpassed only by the SPT in predicting threshold. Nomograms can help estimate the likelihood of severe reactions and reactions to a low dose of allergen in individual patients with PA.	[Santos, Alexandra F.; Du Toit, George; Becares, Natalia; Couto-Francisco, Natalia; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Kings Coll London, Dept Women & Childrens Hlth Pediat Allergy, Sch Life Course Sci, Fac Life Sci & Med, London, England; [Santos, Alexandra F.; Du Toit, George; Becares, Natalia; Couto-Francisco, Natalia; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Kings Coll London, Peter Gorer Dept Immunobiol, Sch Immunol & Microbial Sci, London, England; [Santos, Alexandra F.; Du Toit, George; Radulovic, Suzana; Khaleva, Ekaterina; Lack, Gideon] Guys & St Thomas Hosp, Evelina London Childrens Hosp, Childrens Allergy Serv, London, England; [Santos, Alexandra F.; Becares, Natalia; Couto-Francisco, Natalia; Lack, Gideon] Asthma UK Ctr Allerg Mechanisms Asthma, London, England; [O'Rourke, Colin; Bahnson, Henry T.] Benaroya Res Inst, Immune Tolerance Network, Seattle, WA USA; [Harris, Kristina M.; Larson, David] Immune Tolerance Network, Bethesda, MD USA; [Sayre, Peter] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; [Plaut, Marshall] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Roberts, Graham] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Roberts, Graham] Univ Southampton, Natl Inst Hlth Res, Biomed Res Ctr, Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Roberts, Graham] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton, Hants, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Benaroya Research Institute; Immune Tolerance Network; Immune Tolerance Network; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton	Santos, AF; Lack, G (corresponding author), St Thomas Hosp, Dept Pediat Allergy, 2nd Floor,South Wing,Westminster Bridge Rd, London SE1 7EH, England.	alexandra.santos@kcl.ac.uk; gideon.lack@kcl.ac.uk	Khaleva, Ekaterina/GWV-5979-2022; Khaleva, Ekaterina/AGF-7857-2022	Khaleva, Ekaterina/0000-0002-2220-7745; Santos, Alexandra/0000-0002-7805-1436; O'Rourke, Colin/0000-0002-7913-1323; Roberts, Graham/0000-0003-2252-1248	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [UM1AI109565]; Medical Research Council (MRC) [G090218, MR/M008517/1]; Asthma UK Centre; UK Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre; King's College London; King's College HospitalNHS Foundation Trust; National Peanut Board, Atlanta, Ga; Davis Foundation; MRC [MR/M008517/1, G0902018] Funding Source: UKRI	Immune Tolerance Network; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK Centre; UK Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre; King's College London; King's College HospitalNHS Foundation Trust; National Peanut Board, Atlanta, Ga; Davis Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The research reported in this publication was sponsored by the Immune Tolerance Network and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award UM1AI109565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support came from the Medical Research Council (MRC Clinical Research Training Fellowship G090218, MRC Clinician Scientist Fellowship MR/M008517/1, and MRC Centenary Early Career Award awarded to A.F. Santos), the Asthma UK Centre, and the UK Department of Health through the National Institute for Health Research Comprehensive Biomedical Research Centre Award to Guy's & St. Thomas' NHS Foundation Trust, in partnership with King's College London and King's College HospitalNHS Foundation Trust. The PaediatricAllergy clinical trials unit is supported by the National Peanut Board, Atlanta, Ga, and The Davis Foundation. The UK Food Standards Agency provided additional support for the costs of phlebotomy.	[Anonymous], NCI COMM TERM CRIT A, V39; Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Ballmer-Weber BK, 2015, ALLERGY, V70, P391, DOI 10.1111/all.12574; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Chan JCK, 2017, J ALLERGY CLIN IMMUN, V5, P398; Chinthrajah RS, 2018, ANN ALLERG ASTHMA IM, V121, P69, DOI 10.1016/j.anai.2018.04.020; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dubois AEJ, 2018, ALLERGY, V73, P1383, DOI 10.1111/all.13405; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Klemans RJB, 2013, CLIN EXP ALLERGY, V43, P967, DOI 10.1111/cea.12136; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Pouessel G, 2019, ALLERGY, V74, P1193, DOI 10.1111/all.13717; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0100-4; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Song Y, 2015, ANN ALLERG ASTHMA IM, V114, P319, DOI 10.1016/j.anai.2015.01.006; Sturm GJ, 2009, ALLERGY, V64, P1319, DOI 10.1111/j.1398-9995.2009.02004.x; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Ta Von, 2011, Br J Med Med Res, V1, P410; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Upton J, 2019, ALLERGY, V74, P1035, DOI 10.1111/all.13791; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x	39	46	47	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					344	355		10.1016/j.jaci.2020.03.035	http://dx.doi.org/10.1016/j.jaci.2020.03.035			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32311390	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000558835000025
J	Tsai, M; Mukai, K; Chinthrajah, RS; Nadeau, KC; Galli, SJ				Tsai, Mindy; Mukai, Kaori; Chinthrajah, R. Sharon; Nadeau, Kari C.; Galli, Stephen J.			Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil; basophil activation test; biomarkers; CD63; CD203c; oral immunotherapy; peanut allergy; peanut-specific IgE; peanut-specific IgG(4)	DOUBLE-BLIND; ALLERGY; CHILDREN; MILK; EXPRESSION; TOLERANCE; DIAGNOSIS; EFFICACY; SAFETY	Background: Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. Objective: We evaluated whether basophil activation in whole blood, and plasma levels of peanut-specific immunoglobulins, are useful biomarkers for peanut OIT. Methods: We longitudinally measured, before, during, and after OIT, basophil activation in whole blood ex vivo in response to peanut stimulation, and peanut-specific IgE (sIgE) and peanut-specific IgG(4) (sIgG(4)), in a large, single-site, double-blind, randomized, placebo-controlled, phase 2 peanut OIT study. We compared basophil responsiveness and peanut-specific immunoglobulins between those who were clinically reactive and those who were tolerant to peanut oral challenges. Results: Peanut OIT significantly decreased basophil activation, peanut sIgE, Ara h 1, Ara h 2, and Ara h 3 IgE levels, and sIgE/total IgE, but increased sIgG(4)/sIgE. Participants who became reactive to 4 g of peanut 13 weeks off active OIT exhibited higher peanut-induced basophil activation ex vivo and higher peanut sIgE levels and sIgE/total IgE, but lower sIgG(4)/sIgE. Notably, participants entering the study with low basophil responsiveness were more likely to achieve treatment success. Substantial suppression of basophil activation was required to maintain long-term clinical tolerance after peanut OIT. Conclusions: Assessments of peanut-induced basophil activation and peanut-specific immunoglobulins can help to predict treatment outcomes, and to differentiate transient desensitization versus sustained unresponsiveness after OIT.	[Tsai, Mindy; Mukai, Kaori; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Tsai, Mindy; Mukai, Kaori; Chinthrajah, R. Sharon; Nadeau, Kari C.; Galli, Stephen J.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Chinthrajah, R. Sharon; Nadeau, Kari C.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Galli, SJ (corresponding author), Stanford Univ, 269 Campus Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu		Tsai, Mindy/0000-0002-8421-4721	National Institutes of Health [U19 AI104209]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (grant no. U19 AI104209).	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Berin MC, 2018, J ALLERGY CLIN IMMUN, V142, P149, DOI 10.1016/j.jaci.2018.01.044; Bird JA, 2018, J ALLER CL IMM-PRACT, V6, P476, DOI 10.1016/j.jaip.2017.09.016; Blumchen K, 2019, J ALLER CL IMM-PRACT, V7, P479, DOI 10.1016/j.jaip.2018.10.048; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Cherkaoui S, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0055-x; Chinthrajah RS, 2019, LANCET, V394, P1437, DOI 10.1016/S0140-6736(19)31793-3; Chu DK, 2019, LANCET, V393, P2222, DOI 10.1016/S0140-6736(19)30420-9; Cook QS, 2019, ALLERGY ASTHMA PROC, V40, P14, DOI 10.2500/aap.2019.40.4190; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Hoffmann HJ, 2015, ALLERGY, V70, P1393, DOI 10.1111/all.12698; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Koplin JJ, 2019, J ALLER CL IMM-PRACT, V7, P375, DOI 10.1016/j.jaip.2018.11.010; Kulis M, 2019, CLIN EXP ALLERGY, V49, P180, DOI 10.1111/cea.13256; Kulis MD, 2018, J ALLERGY CLIN IMMUN, V141, P491, DOI 10.1016/j.jaci.2017.12.979; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Mehlich J, 2019, J ALLERGY CLIN IMMUN, V143, P182, DOI 10.1016/j.jaci.2018.06.049; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Orgel K, 2019, CLIN EXP ALLERGY, V49, P461, DOI 10.1111/cea.13305; Patil SU, 2019, J ALLERGY CLIN IMMUN, V144, P1310, DOI 10.1016/j.jaci.2019.07.028; Renz H, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.98; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Santos AF, 2017, CLIN EXP ALLERGY, V47, P1115, DOI 10.1111/cea.12964; Santos AF, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0098-7; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Shan MM, 2018, IMMUNITY, V49, P709, DOI 10.1016/j.immuni.2018.08.013; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stallings V. A., 2016, FINDING PATH SAFETY; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2019, J ALLER CL IMM-PRACT, V7, P357, DOI 10.1016/j.jaip.2018.11.049; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895	47	46	48	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					885	+		10.1016/j.jaci.2019.10.038	http://dx.doi.org/10.1016/j.jaci.2019.10.038			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31805311	Bronze, Green Accepted			2022-12-18	WOS:000518756700026
J	Bissonnette, R; Pavel, AB; Diaz, A; Werth, JL; Zang, CB; Vranic, I; Purohit, VS; Zielinski, MA; Vlahos, B; Estrada, YD; Proulx, ESC; Ports, WC; Guttman-Yassky, E				Bissonnette, Robert; Pavel, Ana B.; Diaz, Aisleen; Werth, John L.; Zang, Chuanbo; Vranic, Ivana; Purohit, Vivek S.; Zielinski, Michael A.; Vlahos, Bonnie; Estrada, Yeriel D.; Proulx, Etienne Saint-Cyr; Ports, William C.; Guttman-Yassky, Emma			Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; crisaborole; phosphodiesterase 4; pruritus; transcriptome; gene expression; inflammation; biomarker; transepidermal water loss	PHOSPHODIESTERASE-4 PDE4 INHIBITOR; EPIDERMAL DIFFERENTIATION COMPLEX; TOPICAL OINTMENT; OPEN-LABEL; PSORIASIS; APREMILAST; 2-PERCENT; IMMUNE; MODERATE; SAFETY	Background: Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action of crisaborole and its effects on lesional measures of disease severity are not yet well defined. Objective: This phase 2a, single-center, vehicle-controlled, intrapatient study was designed to further characterize the mechanism of action of crisaborole through evaluation of clinical efficacy and changes in skin biomarkers in adults (n = 40) with mild-to-moderate AD. Methods: Two target lesions were randomized in an intrapatient (14) manner to double-blind crisaborole/vehicle applied twice daily for 14 days. Patients then applied crisaborole (open-label) to all affected areas for 28 days. Punch biopsy specimens were collected for biomarker analysis at baseline, day 8 (optional), and day 15. Results: Crisaborole treatment resulted in early improvement in lesional signs/symptoms versus vehicle, with improvement in pruritus (pruritus numeric rating scale) observed as early as 24 hours after the first application. Crisaborole-treated lesions showed significant percentage improvement from baseline in lesional transcriptomic profile compared with vehicle at day 8 (91.15% vs 36.02%, P < 10(-15)) that was sustained until day 15 (92.90% vs 49.59%, P < 10(-15)). Crisaborole significantly modulated key AD biomarkers versus vehicle, including T(H)2 and T(H)17/T(H)22 pathways and epidermal hyperplasia/proliferation. Molecular profiles and epidermal pathology normalized toward nonlesional skin and correlated with clinical changes in lesion severity and barrier function. Conclusion: Crisaborole reversed biomarker profiles of skin inflammation and barrier function, with associated improvements in clinical efficacy measures, highlighting the therapeutic utility of targeting phosphodiesterase 4 in patients with AD.	[Bissonnette, Robert; Proulx, Etienne Saint-Cyr] Innovaderm Res, Montreal, PQ, Canada; [Pavel, Ana B.; Diaz, Aisleen; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 East 98th St, New York, NY 10029 USA; [Pavel, Ana B.; Diaz, Aisleen; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 East 98th St, New York, NY 10029 USA; [Diaz, Aisleen] Ponce Hlth Sci Univ, Sch Med, Ponce, PR USA; [Werth, John L.; Zang, Chuanbo; Zielinski, Michael A.; Vlahos, Bonnie] Pfizer, Collegeville, PA USA; [Vranic, Ivana] Pfizer, Surrey, England; [Purohit, Vivek S.; Ports, William C.] Pfizer, Groton, CT USA	Innovaderm Research Inc.; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Ponce Health Sciences University; Pfizer; Pfizer; Pfizer	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 East 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, 5 East 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Purohit, Vivek/GXH-0278-2022	, Ana Brandusa/0000-0002-8155-8553	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.	Ahluwalia J, 2017, DRUGS, V77, P1389, DOI 10.1007/s40265-017-0784-3; Baurecht H, 2015, AM J HUM GENET, V96, P104, DOI 10.1016/j.ajhg.2014.12.004; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2018, ANN ALLERG ASTHMA IM, V120, P10, DOI 10.1016/j.anai.2017.10.039; Boguniewicz M, 2017, J ALLER CL IMM-PRACT, V5, P1477, DOI 10.1016/j.jaip.2017.08.031; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V140, P134, DOI 10.1016/j.jaci.2016.09.060; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dong C, 2016, J PHARMACOL EXP THER, V358, P413, DOI 10.1124/jpet.116.232819; Draelos ZD, 2016, J DRUGS DERMATOL, V15, P172; Eichenfield LF, 2017, J AM ACAD DERMATOL, V77, P641, DOI 10.1016/j.jaad.2017.06.010; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Garcet S, 2018, J ALLERGY CLIN IMMUN, V142, P1010, DOI 10.1016/j.jaci.2018.05.039; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gold LFS, 2015, J DRUGS DERMATOL, V14, P1394; Gooderham M, 2014, BRIT J DERMATOL, V171, P1470, DOI 10.1111/bjd.13235; Gooderham M, 2015, BIODRUGS, V29, P327, DOI 10.1007/s40259-015-0144-3; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V144, P482, DOI 10.1016/j.jaci.2018.11.053; Guttman-Yassky E, 2019, EXP DERMATOL, V28, P3, DOI 10.1111/exd.13808; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Guttman-Yassky E, 2017, J ALLERGY CLIN IMMUN, V140, P1032, DOI 10.1016/j.jaci.2017.01.027; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2018, EXP DERMATOL, V27, P409, DOI 10.1111/exd.13336; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Imhof B., 2014, NONINVASIVE DIAGNOST, P345, DOI 10.1007/978-3-642-32109-2_31; Jacob SE, 2006, J AM ACAD DERMATOL, V54, P723, DOI 10.1016/j.jaad.2005.12.028; Jarnagin K, 2016, J DRUGS DERMATOL, V15, P390; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Krueger JG, 2017, J AM ACAD DERMATOL, V76, pAB47; Levy J, 2016, J CLIN EXP DERMATOL; Li H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01048; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Luo YC, 2014, P NATL ACAD SCI USA, V111, P15178, DOI 10.1073/pnas.1416714111; Mansouri Y, 2015, J CLIN MED, V4, P858, DOI 10.3390/jcm4050858; Mrowietz U, 2003, ACTA DERM-VENEREOL, V83, P351, DOI 10.1080/00015550310003791; Murrell DF, 2015, J DRUGS DERMATOL, V14, P1108; Phan NQ, 2012, ACTA DERM-VENEREOL, V92, P502, DOI 10.2340/00015555-1246; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Perez-Aso M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0771-6; Peter D, 2007, J IMMUNOL, V178, P4820, DOI 10.4049/jimmunol.178.8.4820; Pincelli C, 2018, J DRUGS DERMATOL, V17, P835; Raker VK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00123; Rerknimitr P, 2017, INFLAMM REGEN, V37, DOI 10.1186/s41232-017-0044-7; Sakkas LI, 2017, CURR MED CHEM, V24, P3054, DOI 10.2174/0929867324666170530093902; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Schafer PH, 2014, CELL SIGNAL, V26, P2016, DOI 10.1016/j.cellsig.2014.05.014; Schafer PH, 2010, BRIT J PHARMACOL, V159, P842, DOI 10.1111/j.1476-5381.2009.00559.x; Schafer P, 2012, BIOCHEM PHARMACOL, V83, P1583, DOI 10.1016/j.bcp.2012.01.001; Schafer PH, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/906349; Schafer PH, 2013, J AM ACAD DERMATOL, V68, P1041, DOI 10.1016/j.jaad.2012.10.064; Schett G, 2010, THER ADV MUSCULOSKEL, V2, P271, DOI 10.1177/1759720X10381432; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Simpson EL, 2019, J INVEST DERMATOL, V139, P1063, DOI 10.1016/j.jid.2018.10.043; Simpson EL, 2016, J AM ACAD DERMATOL, V75, P506, DOI 10.1016/j.jaad.2016.04.054; Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tamari M, 2014, J DERMATOL, V41, P213, DOI 10.1111/1346-8138.12321; Tan H, 2018, ITCH, V3, pE12; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tom WL, 2016, PEDIATR DERMATOL, V33, P150, DOI 10.1111/pde.12780; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Wen HC, 2018, J ALLERGY CLIN IMMUN, V142, P324, DOI 10.1016/j.jaci.2018.02.047; Yang MY, 2018, J DERMATOL TREAT, V29, P129, DOI 10.1080/09546634.2017.1350256; Zane LT, 2016, AM J CLIN DERMATOL, V17, P519, DOI 10.1007/s40257-016-0204-6; Zane LT, 2016, PEDIATR DERMATOL, V33, P380, DOI 10.1111/pde.12872; Zebda R, 2018, J AM ACAD DERMATOL, V78, pS43, DOI 10.1016/j.jaad.2017.11.056	95	46	46	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1274	1289		10.1016/j.jaci.2019.06.047	http://dx.doi.org/10.1016/j.jaci.2019.06.047			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31419544	hybrid			2022-12-18	WOS:000495004700019
J	Sharma, A; Laxman, B; Naureckas, ET; Hogarth, DK; Sperling, AI; Solway, J; Ober, C; Gilbert, JA; White, SR				Sharma, Anukriti; Laxman, Bharathi; Naureckas, Edward T.; Hogarth, D. Kyle; Sperling, Anne I.; Solway, Julian; Ober, Carole; Gilbert, Jack A.; White, Steven R.			Associations between fungal and bacterial microbiota of airways and asthma endotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microbiota; corticosteroids; FEV1; bacteria; fungi; airway inflammation; 16S ribosomal RNA	SMOOTH-MUSCLE; IDENTIFICATION; INFLAMMATION; ALTERNARIA; PROTEIN; SENSITIZATION; COLONIZATION; CALMODULIN; DIVERSITY; INFECTION	Background: The relationship between asthma, atopy, and underlying type 2 (T2) airway inflammation is complex. Although the bacterial airway microbiota is known to differ in asthmatic patients, the fungal and bacterial markers that discriminate T2-high (eosinophilic) and T2-low (neutrophilid mixed-inflammation) asthma and atopy are still incompletely identified. Objectives: The aim of this study was to demonstrate the fungal microbiota structure of airways in asthmatic patients associated with T2 inflammation, atopy, and key clinical parameters. Methods: We collected endobronchial brush (EB) and bronchoalveolar lavage (BAL) samples from 39 asthmatic patients and 19 healthy subjects followed by 16S gene and internal transcribed spacer-based microbiota sequencing. The microbial sequences were classified into exact sequence variants. The T2 phenotype was defined by using a blood eosinophil count with a threshold of 300 cells/mu L. Results: Fungal diversity was significantly lower in EB samples from patients with T2-high compared with T2-low inflammation; key fungal genera enriched in patients with T2- high inflammation included Trichoderma species, whereas Penicillium species was enriched in patients with atopy. In BAL fluid samples the dominant genera were Cladosporium, Fusarium, Aspergillus, and Alternaria. Using generalized linear models, we identified significant associations between specific fungal exact sequence variants and FEV1, fraction of exhaled nitric oxide values, BAL fluid cell counts, and corticosteroid use. Investigation of interkingdom (bacterial-fungal) co-occurrence patterns revealed different topologies between asthmatic patients and healthy control subjects. Random forest models with fungal classifiers predicted asthma status with 75% accuracy for BAL fluid samples and 80% accuracy for EB samples. Conclusions: We demonstrate clear differences in bacterial and fungal microbiota in asthma-associated phenotypes. Our study provides additional support for considering microbial signatures in delineating asthma phenotypes.	[Sharma, Anukriti; Gilbert, Jack A.] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Laxman, Bharathi; Naureckas, Edward T.; Hogarth, D. Kyle; Sperling, Anne I.; Solway, Julian; White, Steven R.] Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Sharma, Anukriti; Gilbert, Jack A.] Argonne Natl Lab, Biosci Div BIO, 9700 S Cass Ave, Argonne, IL 60439 USA; [Sharma, Anukriti; Gilbert, Jack A.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Sharma, Anukriti; Gilbert, Jack A.] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of Chicago; University of Chicago; University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography	White, SR (corresponding author), Univ Chicago, Sect Pulm & Crit Care Med, 5841 S Maryland Ave,MC6076, Chicago, IL 60637 USA.	swhite@bsd.uchicago.edu	Gilbert, Jack/AAF-3270-2019; Sperling, Anne/ACZ-2351-2022	Sharma, Anukriti/0000-0002-5388-3981; Sperling, Anne I./0000-0002-4265-9212	National Institute of Allergy and Infectious Diseases [AI-095230]; National Center for Advancing Translational Sciences [UL1-TR000430]; Office of Research on Women's Health [AI-095230]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by AI-095230 cofunded by the National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health and by UL1-TR000430 from the National Center for Advancing Translational Sciences.	Aich J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1880; Alam R, 2011, CLIN EXP ALLERGY, V41, P149, DOI 10.1111/j.1365-2222.2010.03658.x; Amir A, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00199-16; Anderson M.J., 2014, STAT REFERENCE ONLIN, P1, DOI [10.1002/9781118445112.stat07841, DOI 10.1002/9781118445112.STAT07841]; Baselga A, 2013, METHODS ECOL EVOL, V4, P552, DOI 10.1111/2041-210X.12029; Bastian M., 2009, 3 INT AAAI C WEBLOGS; Benson Renee C, 2011, J Allergy (Cairo), V2011, P736319, DOI 10.1155/2011/736319; Berry D, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00219; Borish L, 2008, ANN ALLERG ASTHMA IM, V101, P1, DOI 10.1016/S1081-1206(10)60826-5; Brandt J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02140; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chai AB, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0526-9; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Comhair SAA, 2015, J IMMUNOL, V195, P643, DOI 10.4049/jimmunol.1500736; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dekkers BGJ, 2013, J PHARMACOL EXP THER, V346, P86, DOI 10.1124/jpet.113.203042; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Douglas GM, 2018, METHODS MOL BIOL, V1849, P169, DOI 10.1007/978-1-4939-8728-3_11; Durack J, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0487-3; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Farrant J, 2016, J ASTHMA, V53, P732, DOI 10.3109/02770903.2016.1154073; Fekri MS, 2013, IRAN J BASIC MED SCI, V16, P790; Fujita SI, 2001, J CLIN MICROBIOL, V39, P3617, DOI 10.1128/JCM.39.10.3617-3622.2001; Gelman A, 2008, STAT MED, V27, P2865, DOI 10.1002/sim.3107; Goldman DL, 2009, MED MYCOL, V47, P445, DOI 10.1080/13693780802641904; Guntur VP, 2012, CURR OPIN ALLERGY CL, V12, P68, DOI 10.1097/ACI.0b013e32834ecb4f; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Khosravi AR, 2012, ARH HIG RADA TOKSIKO, V63, P1, DOI 10.2478/10004-1254-63-2012-2155; Kim Hae-Young, 2014, Restor Dent Endod, V39, P74, DOI 10.5395/rde.2014.39.1.74; Kim HK, 2013, EXP LUNG RES, V39, P399, DOI 10.3109/01902148.2013.835009; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Koljalg U, 2013, MOL ECOL, V22, P5271, DOI 10.1111/mec.12481; Kolwijck E, 2014, EUR J IMMUNOL, V44, P3156, DOI 10.1002/eji.201344404; Langfelder P, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-54; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Langfelder P, 2012, J STAT SOFTW, V46, P1; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Li JQ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18705-z; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Lule SA, 2017, PEDIAT ALLERG IMM-UK, V28, P377, DOI 10.1111/pai.12719; Mandal Siddhartha, 2015, Microbial Ecology in Health and Disease, V26, P27663, DOI 10.3402/mehd.v26.27663; McDonald D, 2012, GIGASCIENCE, V1, DOI 10.1186/2047-217X-1-7; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; MIDDLETON E, 1984, J ALLERGY CLIN IMMUN, V73, P643, DOI 10.1016/0091-6749(84)90298-7; Morris EK, 2014, ECOL EVOL, V4, P3514, DOI 10.1002/ece3.1155; National Asthma Education and Prevention Program, 2007, 3 EXP PAN DIAGN MAN; OFULUE AF, 1993, PEDIATR PULM, V15, P145, DOI 10.1002/ppul.1950150304; Ogawa H, 2012, CLIN EXP ALLERGY, V42, P1540, DOI 10.1111/j.1365-2222.2012.04072.x; Reinke SN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01740-2016; Robinson D, 2017, CLIN EXP ALLERGY, V47, P161, DOI 10.1111/cea.12880; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Saint RJ, 2016, EUR J CLIN MICROBIOL, V35, P2015, DOI 10.1007/s10096-016-2754-1; Saraya T, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00226; Shah A, 2016, ALLERGY ASTHMA IMMUN, V8, P282, DOI 10.4168/aair.2016.8.4.282; Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Suratt BT, 2017, ANN AM THORAC SOC, V14, P1050, DOI 10.1513/AnnalsATS.201703-263WS; Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g; Tabatabaian F, 2017, IMMUNOL ALLERGY CLIN, V37, P329, DOI 10.1016/j.iac.2017.01.007; Tanaka T, 2013, NUTRIENTS, V5, P2128, DOI 10.3390/nu5062128; Tang P, 2003, J CLIN MICROBIOL, V41, P5333, DOI 10.1128/JCM.41.11.5333-5336.2003; Thompson LR, 2017, NATURE, V551, P457, DOI 10.1038/nature24621; Toews GB, 2001, EUR RESPIR J, V18, p3S, DOI 10.1183/09031936.01.00266001; Weathington NM, 2013, AM J RESP CRIT CARE, V188, P530, DOI 10.1164/rccm.201304-0754PP; Weiss S, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0237-y; Wen L, 2017, J NUTR, V147, p1468S, DOI 10.3945/jn.116.240754; Yip AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-22; Yonekawa T, 2005, FEMS MICROBIOL LETT, V244, P315, DOI 10.1016/j.femsle.2005.02.003	75	46	49	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1214	+		10.1016/j.jaci.2019.06.025	http://dx.doi.org/10.1016/j.jaci.2019.06.025			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31279011	Green Accepted, Bronze			2022-12-18	WOS:000495004700014
J	Steelant, B; Wawrzyniak, P; Martens, K; Jonckheere, AC; Pugin, B; Schrijvers, R; Bullens, DM; Vanoirbeek, JA; Krawczyk, K; Dreher, A; Akdis, CA; Hellings, PW				Steelant, Brecht; Wawrzyniak, Paulina; Martens, Katleen; Jonckheere, Anne-Charlotte; Pugin, Benoit; Schrijvers, Rik; Bullens, Dominique M.; Vanoirbeek, Jeroen A.; Krawczyk, Krzysztof; Dreher, Anita; Akdis, Cezmi A.; Hellings, Peter W.			Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; tight junctions; primary nasal epithelial cells; epigenetic changes; histone deacetylase	DNA METHYLATION; TIGHT JUNCTION; EXPRESSION; ASTHMA; DYSFUNCTION; EPIGENETICS; INHIBITORS; ANGIOGENESIS; INFLAMMATION; MECHANISMS	Background: A defective epithelial barrier is found in patients with allergic rhinitis (AR) and asthma; however, the underlying mechanisms remain poorly understood. Histone deacetylase (HDAC) activity has been identified as a crucial driver of allergic inflammation and tight junction dysfunction. Objective: We investigated whether HDAC activity has been altered in patients with AR and in a mouse model of house dust mite (HDM)-induced allergic asthma and whether it contributed to epithelial barrier dysfunction. Methods: Primary nasal epithelial cells of control subjects and patients with AR were cultured at the air-liquid interface to study transepithelial electrical resistance and paracellular flux of fluorescein isothiocyanate-clextran (4 kDa) together with mRNA expression and immunofluorescence staining of tight junctions. Air-liquid interface cultures were stimulated with different concentrations of JNJ-26481585, a broad-spectrum HDAC inhibitor. In vivo the effect of JNJ-26481585 on mucosal permeability and tight junction function was evaluated in a mouse model of HDM-induced allergic airway inflammation. Results: General HDAC activity was greater in nasal epithelial cells of patients with AR and correlated inversely with epithelial integrity. Treatment of nasal epithelial cells with JNJ-26481585 restored epithelial integrity by promoting tight junction expression and protein reorganization. HDM-sensitized mice were treated with JNJ-26481585 to demonstrate the in vivo role of HDACs. Treated mice did not have allergic airway inflammation and had no bronchial hyperreactivity. Moreover, JNJ-26481585 treatment restored nasal mucosal function by promoting tight junction expression. Conclusion: Our findings identify increased HDAC activity as a potential tissue-injury mechanism responsible for dysregulated epithelial cell repair, leading to defective epithelial barriers in AR. Blocking HDAC activity is a promising novel target for therapeutic intervention in patients with airway diseases.	[Steelant, Brecht; Martens, Katleen; Jonckheere, Anne-Charlotte; Pugin, Benoit; Schrijvers, Rik; Bullens, Dominique M.; Hellings, Peter W.] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Allergy & Clin Immunol Res Grp, Leuven, Belgium; [Vanoirbeek, Jeroen A.] Katholieke Univ Leuven, Lab Environm & Hlth, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Steelant, Brecht; Wawrzyniak, Paulina; Krawczyk, Krzysztof; Dreher, Anita; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Bullens, Dominique M.] Univ Hosp Leuven, Clin Dept Pediat, Leuven, Belgium; [Hellings, Peter W.] Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Krawczyk, Krzysztof] Univ Lodz, Dept Immunol & Infect Biol, Fac Biol & Environm Protect, Lodz, Poland; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	KU Leuven; KU Leuven; Swiss Institute of Allergy & Asthma Research; University of Zurich; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; University of Lodz; University of Amsterdam; Academic Medical Center Amsterdam	Hellings, PW (corresponding author), Katholieke Univ Leuven, Univ Hosp Leuven, Clin Div Otorhinolaryngol Head & Neck Surg, Kapucijnenvoer 33, B-3000 Leuven, Belgium.	Peter.hellings@kuleuven.be	Wawrzyniak, Paulina/AAG-3548-2019; Pugin, Benoit/X-2984-2018; Jonckheere, Anne-Charlotte/P-4556-2019; Akdis, Cezmi/AAV-4844-2020; Vanoirbeek, Jeroen/D-5183-2016; Wawrzyniak, Paulina/AAD-7265-2020; Wawrzyniak, Paulina/HCG-8924-2022; Bullens, Dominique M A/T-6211-2017	Pugin, Benoit/0000-0001-7132-9477; Jonckheere, Anne-Charlotte/0000-0003-4943-892X; Akdis, Cezmi/0000-0001-8020-019X; Vanoirbeek, Jeroen/0000-0001-5508-3518; Wawrzyniak, Paulina/0000-0001-9641-2103; Krawczyk, Krzysztof/0000-0003-0415-6363; Bullens, Dominique M A/0000-0002-4595-9579	Belgian Federal Government [IUAP P7/30]; Innovatie door Wetenschap en Technologie (IWT) (TBM project) [130260]; research council of the KU Leuven [GOA 14/011]; Fund of Scientific Research (FWO), Flanders, Belgium; Swiss National Science Foundation [320030_176190]	Belgian Federal Government; Innovatie door Wetenschap en Technologie (IWT) (TBM project); research council of the KU Leuven(KU Leuven); Fund of Scientific Research (FWO), Flanders, Belgium(FWO); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The author's laboratories are supported by grants from the Belgian Federal Government (IUAP P7/30), Innovatie door Wetenschap en Technologie (IWT) (TBM project 130260), and the research council of the KU Leuven (GOA 14/011). P.W.H. and D.M.B. received a senior researcher fellowship from the Fund of Scientific Research (FWO), Flanders, Belgium. B.S. is currently a Postdoctoral Fellow of the FWO, Flanders, Belgium. Support was also received from the Swiss National Science Foundation (grant no. 320030_176190).	Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Banerjee Audreesh, 2012, Am J Respir Cell Mol Biol, V46, P132, DOI 10.1165/rcmb.2010-0276OC; Bergeron C, 2006, J ALLERGY CLIN IMMUN, V117, P703, DOI 10.1016/j.jaci.2005.12.1344; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bobic S, 2012, AM J RESP CELL MOL, V46, P781, DOI 10.1165/rcmb.2011-0152OC; Bordin M, 2004, MOL CANCER RES, V2, P692; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Chang ZG, 2016, J TRAUMA ACUTE CARE, V81, P512, DOI 10.1097/TA.0000000000001137; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Corner BS, 2015, PHARMACOL THERAPEUT, V147, P91, DOI 10.1016/j.pharmthera.2014.11.006; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Devos FC, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0610-1; Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414; Fukuoka A, 2018, ALLERGOL INT, V67, P18, DOI 10.1016/j.alit.2017.10.006; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Harb H, 2015, J ALLERGY CLIN IMMUN, V135, P15, DOI 10.1016/j.jaci.2014.11.009; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Joshi P, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.26; Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1; Loffredo LF, 2017, ALLERGY, V72, P1988, DOI 10.1111/all.13222; Miller CP, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/514261; Murphy J, 2018, ALLERGY, V73, P2095, DOI 10.1111/all.13532; Nicodemus-Johnson J, 2016, AM J RESP CRIT CARE, V193, P376, DOI 10.1164/rccm.201506-1243OC; Ren Y, 2016, INFLAMM RES, V65, P995, DOI 10.1007/s00011-016-0984-4; Rezaee F, 2014, AM J RESP CELL MOL, V50, P857, DOI 10.1165/rcmb.2013-0541RT; Shang Y, 2013, AM J RESP CELL MOL, V49, P279, DOI 10.1165/rcmb.2012-0403OC; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Steelant B, 2018, J ALLERGY CLIN IMMUN, V141, P951, DOI 10.1016/j.jaci.2017.08.039; Steelant B, 2016, RHINOLOGY, V54, P195, DOI 10.4193/Rhino15.376; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tsou PS, 2016, ARTHRITIS RHEUMATOL, V68, P2975, DOI 10.1002/art.39828; Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485; Vanoirbeek JAJ, 2010, AM J RESP CELL MOL, V42, P96, DOI 10.1165/rcmb.2008-0487OC; Venugopal B, 2013, CLIN CANCER RES, V19, P4262, DOI 10.1158/1078-0432.CCR-13-0312; Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673; Wang J, 2016, DNA CELL BIOL, V35, P203, DOI 10.1089/dna.2015.3037; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052	50	46	49	4	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1242	+		10.1016/j.jaci.2019.04.027	http://dx.doi.org/10.1016/j.jaci.2019.04.027			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31082457	Bronze, Green Accepted			2022-12-18	WOS:000495004700016
J	Impellizzieri, D; Ridder, F; Raeber, ME; Egholm, C; Woytschak, J; Kolios, AGA; Legler, DF; Boyman, O				Impellizzieri, Daniela; Ridder, Frederike; Raeber, Miro E.; Egholm, Cecilie; Woytschak, Janine; Kolios, Antonios G. A.; Legler, Daniel F.; Boyman, Onur			IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; neutrophil; innate immunity; IL-4; IL-13; IL-4 receptor; inflammation	INTERLEUKIN-4; INFLAMMATION; ASTHMA; CELLS; RESPONSES; MECHANISMS; POPULATION; PHENOTYPE; CYTOKINES; RELEASE	Background: Type 2 immunity serves to resist parasitic helminths, venoms, and toxins, but the role and regulation of neutrophils during type 2 immune responses are controversial. Helminth models suggested a contribution of neutrophils to type 2 immunity, whereas neutrophils are associated with increased disease severity during type 2 inflammatory disorders, such as asthma. Objective: We sought to evaluate the effect of the prototypic type 2 cytokines IL-4 and IL-13 on human neutrophils. Methods: Human neutrophils from peripheral blood were assessed without or with IL-4 or IL-13 for (1) expression of IL-4 receptor subunits, (2) neutrophil extracellular trap (NET) formation, (3) migration toward CXCL8 in vitro and in humanized mice, and (4) CXCR1, CXCR2, and CXCR4 expression, as well as (5) in nonallergic versus allergic subjects. Results: Human neutrophils expressed both types of IL-4 receptors, and their stimulation through IL-4 or IL-13 diminished their ability to form NETs and migrate toward CXCL8 in vitro. Likewise, in vivo chemotaxis in NOD-scid-Il2rg(-/-) mice was reduced in IL-4-stimulated human neutrophils compared with control values. These effects were accompanied by downregulation of the CXCL8-binding chemokine receptors CXCR1 and CXCR2 on human neutrophils on IL-4 or IL-13 stimulation in vitro. Ex vivo analysis of neutrophils from allergic patients or exposure of neutrophils from nonallergic subjects to allergic donor serum in vitro impaired their NET formation and migration toward CXCL8, thereby mirroring IL-4/IL-13-stimulated neutrophils. Conclusion: IL-4 receptor signaling in human neutrophils affects several neutrophil effector functions, which bears important implications for immunity in type 2 inflammatory disorders.	[Impellizzieri, Daniela; Ridder, Frederike; Raeber, Miro E.; Egholm, Cecilie; Woytschak, Janine; Kolios, Antonios G. A.; Boyman, Onur] Univ Hosp Zurich, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland; [Legler, Daniel F.] Univ Konstanz, Biotechnol Inst Thurgau BITg, Kreuzlingen, Switzerland; [Boyman, Onur] Univ Zurich, Fac Med, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Geneva; University of Zurich	Boyman, O (corresponding author), Univ Hosp Zurich, Dept Immunol, Gloriastr 23, CH-8091 Zurich, Switzerland.	onur.boyman@uzh.ch	Raeber, Miro E/J-7626-2012	Raeber, Miro E/0000-0003-2609-0246; Kolios, Antonios/0000-0002-3897-4578; Legler, Daniel F./0000-0001-8610-4764; Boyman, Onur/0000-0001-8279-5545	Swiss National Science Foundation [310030-172978]; Rare Disease Initiative Zurich (radiz); Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); Clinical Research Priority Program of the University of Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Rare Disease Initiative Zurich (radiz); Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); Clinical Research Priority Program of the University of Zurich	Supported by the Swiss National Science Foundation (#310030-172978), the Rare Disease Initiative Zurich (radiz), the Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie), and the Clinical Research Priority Program of the University of Zurich for the CRPP CYTIMM-Z (all to O.B.).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Allen JE, 2015, CURR OPIN IMMUNOL, V34, P99, DOI 10.1016/j.coi.2015.03.001; Arenas-Ramirez N, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag3187; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Bober LA, 2000, ARTHRITIS RHEUM, V43, P2660, DOI 10.1002/1529-0131(200012)43:12<2660::AID-ANR5>3.0.CO;2-4; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; Eash KJ, 2010, J CLIN INVEST, V120, P2423, DOI 10.1172/JCI41649; Eyles JL, 2008, BLOOD, V112, P5193, DOI 10.1182/blood-2008-02-139535; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Girard D, 1997, BIOCHEM J, V325, P147, DOI 10.1042/bj3250147; Hauser MA, 2016, IMMUNITY, V44, P59, DOI 10.1016/j.immuni.2015.12.010; Heeb LEM, 2018, CURR OPIN IMMUNOL, V54, P115, DOI 10.1016/j.coi.2018.06.009; Hemmerle T, 2014, P NATL ACAD SCI USA, V111, P12008, DOI 10.1073/pnas.1402783111; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Liu Y, 2012, BLOOD, V119, P445, DOI 10.1182/blood-2011-07-368860; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Massoud AH, 2016, NAT MED, V22, P1013, DOI 10.1038/nm.4147; Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Rabe KF, 2018, NEW ENGL J MED, V378, P2475, DOI 10.1056/NEJMoa1804093; Radermecker C, 2018, CURR OPIN IMMUNOL, V54, P28, DOI 10.1016/j.coi.2018.05.006; Raeber ME, 2018, IMMUNOL REV, V283, P176, DOI 10.1111/imr.12644; Ratthe C, 2007, J LEUKOCYTE BIOL, V81, P1287, DOI 10.1189/jlb.0306209; Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144; Rebernick R, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575-018-0072-y; Schmid AS, 2018, J BIOTECHNOL, V271, P29, DOI 10.1016/j.jbiotec.2018.02.004; Shikotra A, 2017, J IMMUNOL, V198, P3307, DOI 10.4049/jimmunol.1600606; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Sollberger G, 2018, DEV CELL, V44, P542, DOI 10.1016/j.devcel.2018.01.019; Spohn G, 2017, J ALLERGY CLIN IMMUN, V139, P1957, DOI 10.1016/j.jaci.2016.09.033; Sutherland TE, 2014, NAT IMMUNOL, V15, P1116, DOI 10.1038/ni.3023; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Trinidad EM, 2009, BLOOD, V114, P5081, DOI 10.1182/blood-2009-03-210617; Valladao AC, 2016, J IMMUNOL, V197, P4541, DOI 10.4049/jimmunol.1600007; Wermeling F, 2013, P NATL ACAD SCI USA, V110, P13487, DOI 10.1073/pnas.1312525110; Woytschak J, 2016, IMMUNITY, V45, P172, DOI 10.1016/j.immuni.2016.06.025; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96	52	46	47	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					267	+		10.1016/j.jaci.2019.01.042	http://dx.doi.org/10.1016/j.jaci.2019.01.042			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30768990	Green Accepted, Bronze			2022-12-18	WOS:000473432800028
J	Gamradt, P; Laoubi, L; Nosbaum, A; MUtez, V; Lenief, V; Grande, S; Redoules, D; Schmitt, AM; Nicolas, JF; Vocanson, M				Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Grande, Sophie; Redoules, Daniel; Schmitt, Anne-Marie; Nicolas, Jean-Francois; Vocanson, Marc			Inhibitory checkpoint receptors control CD8(+) resident memory T cells to prevent skin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Resident memory T cells; eczema; allergic contact dermatitis; inhibitory check point receptors; immunopathology	NONLYMPHOID TISSUE; LOCAL ANTIGEN; RM CELLS; IMMUNITY; INFECTION; LYMPHOCYTES; DERMATITIS; EXPRESSION; RESPONSES; EFFECTOR	Background: Tissue-resident memory T (Trm) cells are detrimental in patients with numerous chronic inflammatory diseases, including allergic contact dermatitis (ACD). Objectives: We sought to analyze the contribution of Trm cells to the chronicity and severity of ACD and to define the local parameters regulating their development and functions. Methods: We used an experimental model of ACD (ie, contact hypersensitivity to 2,4-dinitrofluorobenzene) that is mediated by CD8(+) T cells. Results: Our data show that early effector T cells accumulated in the skin during the acute contact hypersensitivity reaction and gave rise to epidermal CD8(+) Trm cells expressing a specific set of inhibitory checkpoint receptors (ICRs), such as programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain 3 (TIM-3). Those Trm cells remained in the epidermis for several weeks and mediated the eczema exacerbations, which developed on allergen re-exposure without the contribution of circulating specific T cells. Furthermore, allergen-induced Trm cell reactivation was constrained because treatment with ICR antagonists dramatically enhanced the magnitude and severity of eczema exacerbations. Finally, we show that the persistence of the allergen in the epidermis for long periods of time was responsible for both the development and maintenance of epidermal Trm cells, as well as the sustained expression of ICRs. Conclusion: Although CD8(+) Trm cells are key for the pathophysiology of ACD, intrinsic mechanisms control their reactivation to prevent damaging immunopathology. Developing strategies targeting the reactivation of skin Trm cells in situ through their ICRs should open new perspectives for the treatment of ACD.	[Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Nicolas, Jean-Francois; Vocanson, Marc] Univ Lyon, Int Ctr Infectiol Res, CIRI, Lyon, France; [Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Nicolas, Jean-Francois; Vocanson, Marc] INSERM, U1111, Lyon, France; [Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Nicolas, Jean-Francois; Vocanson, Marc] Ecole Normale Super Lyon, Lyon, France; [Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Nicolas, Jean-Francois; Vocanson, Marc] Univ Lyon 1, Ctr Int Rech Infectiol, Lyon, France; [Gamradt, Pia; Laoubi, Leo; Nosbaum, Audrey; MUtez, Virginie; Lenief, Vanina; Nicolas, Jean-Francois; Vocanson, Marc] CNRS, UMR 5308, Lyon, France; [Grande, Sophie; Nicolas, Jean-Francois] CH Lyon Sud, Allergol & Clin Immunol, Pierre Benite, France; [Redoules, Daniel] Pierre Fabre R&D Dermocosmet, Toulouse, France; [Schmitt, Anne-Marie] Pierre Fabre R&D Pharmaceut, Toulouse, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon	Vocanson, M (corresponding author), CIRI INSERM U1111, 21 Ave Tony Garnier, F-69007 Lyon, France.	marc.vocanson@inserm.fr	Nosbaum, Audrey/AAC-9329-2020; Nicolas, Jean-François/AAW-9289-2020; Vocanson, Marc/G-5431-2017	Nosbaum, Audrey/0000-0003-2281-9052; Vocanson, Marc/0000-0002-0181-8862; Laoubi, Leo/0000-0001-9388-4826; Gamradt, Pia/0000-0002-5567-9722; lenief, vanina/0000-0002-7561-6235; NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X	Pierre Fabre R&D Dermocosmetique	Pierre Fabre R&D Dermocosmetique	Supported by Pierre Fabre R&D Dermocosmetique.	Adachi T, 2015, NAT MED, V21, P1272, DOI 10.1038/nm.3962; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Bergsbaken T, 2015, NAT IMMUNOL, V16, P406, DOI 10.1038/ni.3108; Boldison J, 2014, J IMMUNOL, V192, P4541, DOI 10.4049/jimmunol.1301390; Brunner PM, 2017, ALLERGY, V72, P2017, DOI 10.1111/all.13223; Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cho JH, 2018, IMMUNOL REV, V283, P129, DOI 10.1111/imr.12646; Clark RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010641; Clark RA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003008; Cunningham AL, 2006, J INFECT DIS, V194, pS11, DOI 10.1086/505359; Davies B, 2017, J IMMUNOL, V198, P2233, DOI 10.4049/jimmunol.1601367; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Enamorado M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16073; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Gaide O, 2015, NAT MED, V21, P647, DOI 10.1038/nm.3860; GARRIGUE JL, 1994, CONTACT DERMATITIS, V30, P231, DOI 10.1111/j.1600-0536.1994.tb00650.x; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; Hombrink P, 2016, NAT IMMUNOL, V17, P1467, DOI 10.1038/ni.3589; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Khan TN, 2016, J EXP MED, V213, P951, DOI 10.1084/jem.20151855; Kohlmeier JE, 2010, IMMUNITY, V33, P96, DOI 10.1016/j.immuni.2010.06.016; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; Mackay LK, 2012, J IMMUNOL, V188, P2173, DOI 10.4049/jimmunol.1102719; MARTIN S, 1992, J IMMUNOL, V149, P2569; Mascre G, 2012, NATURE, V489, P257, DOI 10.1038/nature11393; Moed H, 2004, J PATHOL, V204, P39, DOI 10.1002/path.1619; Mohammed J, 2016, NAT IMMUNOL, V17, P414, DOI 10.1038/ni.3396; Morris AB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01810; Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954; Muschaweckh A, 2016, J EXP MED, V213, P3075, DOI 10.1084/jem.20160888; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Nowak EC, 2017, IMMUNOL REV, V276, P66, DOI 10.1111/imr.12525; Pallett LJ, 2017, J EXP MED, V214, P1567, DOI 10.1084/jem.20162115; Park CO, 2015, NAT MED, V21, P688, DOI 10.1038/nm.3883; Peng H, 2013, J CLIN INVEST, V123, P1444, DOI 10.1172/JCI66381; Petrelli A, 2018, J CLIN INVEST, V128, P4669, DOI 10.1172/JCI96107; Raue HP, 2013, IMMUNITY, V38, P131, DOI 10.1016/j.immuni.2012.09.019; Rouzaire P, 2012, EUR J IMMUNOL, V42, P80, DOI 10.1002/eji.201141820; Roy E, 2016, EMBO J, V35, P2658, DOI 10.15252/embj.201693806; Sada A, 2016, NAT CELL BIOL, V18, P619, DOI 10.1038/ncb3359; Schenkel JM, 2013, NAT IMMUNOL, V14, P509, DOI 10.1038/ni.2568; SCHEPER RJ, 1983, CLIN EXP IMMUNOL, V51, P141; Schmidt JD, 2017, CONTACT DERMATITIS, V76, P218, DOI 10.1111/cod.12715; Shiohara T, 2007, EUR J DERMATOL, V17, P201; Shwetank, 2017, IMMUNOL CELL BIOL, V95, P953, DOI 10.1038/icb.2017.62; Soudja SM, 2012, IMMUNITY, V37, P549, DOI 10.1016/j.immuni.2012.05.029; Steinert EM, 2015, CELL, V161, P737, DOI 10.1016/j.cell.2015.03.031; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Yoshizawa A, 2018, EUR J IMMUNOL, V48, P128, DOI 10.1002/eji.201747174	58	46	48	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2147	+		10.1016/j.jaci.2018.11.048	http://dx.doi.org/10.1016/j.jaci.2018.11.048			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30654051	Green Published, Bronze			2022-12-18	WOS:000470113200019
J	Poole, JA; Barnes, CS; Demain, JG; Bernstein, JA; Padukudru, MA; Sheehan, WJ; Fogelbach, GG; Wedner, J; Codina, R; Levetin, E; Cohn, JR; Kagen, S; Portnoy, JM; Nel, AE				Poole, Jill A.; Barnes, Charles S.; Demain, Jeffrey G.; Bernstein, Jonathan A.; Padukudru, Mahesh A.; Sheehan, William J.; Guidos Fogelbach, Guillermo; Wedner, James; Codina, Rosa; Levetin, Estelle; Cohn, John R.; Kagen, Steve; Portnoy, Jay M.; Nel, Andre E.			Impact of weather and climate change with indoor and outdoor air quality in asthma: A Work Group Report of the AAAAI Environmental Exposure and Respiratory Health Committee	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Weather; climate; allergy; asthma; pollution; pollen	OBSTRUCTIVE PULMONARY-DISEASE; AMBROSIA-ARTEMISIIFOLIA L.; DIESEL EXHAUST PARTICLES; MOSQUITO COIL EMISSIONS; POLLEN SEASONS; ELEVATED CO2; HURRICANE-KATRINA; ALLERGENIC POLLEN; ATMOSPHERIC CO2; COMMON RAGWEED	Weather and climate change are constant and ever-changing processes that affect allergy and asthma. The purpose of this report is to provide information since the last climate change review with a focus on asthmatic disease. PubMed and Internet searches for topics included climate and weather change, air pollution, particulates, greenhouse gasses, traffic, insect habitat, and mitigation in addition to references contributed by the individual authors. Changes in patterns of outdoor aeroallergens caused by increasing temperatures and amounts of carbon dioxide in the atmosphere are major factors linked to increased duration of pollen seasons, increased pollen production, and possibly increased allergenicity of pollen. Indoor air pollution threats anticipated from climate changes include microbial and mold growth secondary to flooding, resulting in displacement of persons and need for respiratory protection of exposed workers. Air pollution from indoor burning of mosquito repellants is a potential anticipatory result of an increase in habitat regions. Air pollution from fossil fuel burning and traffic-related emissions can alter respiratory defense mechanisms and work synergistically with specific allergens to enhance immunogenicity to worsen asthma in susceptible subjects. Community efforts can significantly reduce air pollution, thereby reducing greenhouse gas emission and improving air quality. The allergist's approach to weather pattern changes should be integrated and anticipatory to protect at-risk patients.	[Poole, Jill A.] Univ Nebraska Med Ctr, Dept Internal Med, Pulm Crit Care Sleep & Allergy Div, Omaha, NE USA; [Barnes, Charles S.] Univ Missouri, Sch Med, Childrens Mercy Hosp, Div Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Demain, Jeffrey G.] Allergy Asthma & Immunol Ctr Alaska, Anchorage, AK USA; [Demain, Jeffrey G.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Demain, Jeffrey G.] Univ Alaska Anchorage, WWAMI Sch Med Educ, Anchorage, AK USA; [Bernstein, Jonathan A.] Univ Cincinnati, Div Immunol, Allergy Sect, Dept Internal Med, Cincinnati, OH 45221 USA; [Padukudru, Mahesh A.] JSSAHER, JSS Med Coll, Dept Resp Med, Mysore, Karnataka, India; [Sheehan, William J.] George Washington Sch Med & Hlth Sci, Dept Pediat, Childrens Natl Med Ctr, Div Allergy, Washington, DC USA; [Guidos Fogelbach, Guillermo] Natl Sch Med & Homeopathy, Natl Polytech Inst, Mexico City, DF, Mexico; [Wedner, James] Washington Univ, John T Milliken Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63130 USA; [Codina, Rosa] Allergen Sci & Consulting, Lenoir, NC USA; [Codina, Rosa] Univ S Florida, Morsani Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL USA; [Levetin, Estelle] Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA; [Cohn, John R.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Korman Resp Inst, Philadelphia, PA 19107 USA; [Kagen, Steve] Med Coll Wisconsin, Dept Med, Div Allergy & Clin Immunol, Milwaukee, WI 53226 USA; [Portnoy, Jay M.] Univ Missouri Kansas City, Childrens Mercy Hosp, Div Allergy Asthma & Immunol, Kansas City, MO USA; [Nel, Andre E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Nel, Andre E.] Calif NanoSyst Inst, Los Angeles, CA USA	University of Nebraska System; University of Nebraska Medical Center; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of Washington; University of Washington Seattle; University of Alaska System; University of Alaska Anchorage; University System of Ohio; University of Cincinnati; JSS Academy of Higher Education & Research; JSS Medical College, Mysuru; Children's National Health System; George Washington University; Instituto Politecnico Nacional - Mexico; Washington University (WUSTL); State University System of Florida; University of South Florida; University of Tulsa; Jefferson University; Medical College of Wisconsin; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Poole, JA (corresponding author), 985900 Nebraska Med Ctr, Omaha, NE 68198 USA.	japoole@unmc.edu	Guidos, Guillermo/AAR-4909-2020; Nel, Andre E/J-2808-2012; Guidos, Guillermo/HFZ-9470-2022	Guidos, Guillermo/0000-0003-1675-3894; Bernstein, Jonathan/0000-0002-3476-1196	NIAID NIH HHS [K23 AI104780, L40 AI107923] Funding Source: Medline; NIOSH CDC HHS [U54 OH010162] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIOSH CDC HHS		Adhikari A, 2009, ENVIRON RES, V109, P215, DOI 10.1016/j.envres.2008.12.010; Agrawal S, 2012, J ASTHMA, V49, P355, DOI 10.3109/02770903.2012.663030; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Albertine JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111712; American Lung Association, AM LUNG ASS STAT AIR; Anenberg SC, 2017, GEOHEALTH, V1, P80, DOI 10.1002/2017GH000055; [Anonymous], AIR PLAN APPR AK FAI; [Anonymous], ANCHORAGE DAILY NEWS; [Anonymous], 3 IGU CAND TOP PRIOR; [Anonymous], US ENV PROT AG AL FA; Ariano R, 2010, ANN ALLERG ASTHMA IM, V104, P215, DOI 10.1016/j.anai.2009.12.005; Balmes JR, 2009, J ALLERGY CLIN IMMUN, V123, P626, DOI 10.1016/j.jaci.2008.10.062; Beggs PJ., 2016, IMPACTS CLIMATE CHAN; Behera D, 2001, Indian J Chest Dis Allied Sci, V43, P27; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bertin RI, 2008, J TORREY BOT SOC, V135, P126, DOI 10.3159/07-RP-035R.1; Bogawski P, 2014, INT J BIOMETEOROL, V58, P1759, DOI 10.1007/s00484-013-0781-5; Boulet L, 2018, ASTHMA COPD OVERLAP; Bowatte G, 2015, ALLERGY, V70, P245, DOI 10.1111/all.12561; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Briggs JM, 2002, ECOSYSTEMS, V5, P578, DOI 10.1007/s10021-002-0187-4; Cai C, 2016, GLOBAL CHANGE BIOL, V22, P856, DOI 10.1111/gcb.13065; Carracedo-Martinez E, 2010, ENVIRON HEALTH PERSP, V118, P1173, DOI 10.1289/ehp.0901485; Cecchi L, 2018, J ALLERGY CLIN IMMUN, V141, P846, DOI 10.1016/j.jaci.2018.01.016; Chew GL, 2006, ENVIRON HEALTH PERSP, V114, P1883, DOI 10.1289/ehp.9258; Clifford RL, 2017, J ALLERGY CLIN IMMUN, V139, P112, DOI 10.1016/j.jaci.2016.03.046; Cohn JR, 2018, J ALLER CL IMM-PRACT, V6, P872, DOI 10.1016/j.jaip.2017.12.027; Costello A, 2009, LANCET, V373, P1693, DOI [10.1016/S0140-6736(09)60935-1, 10.1016/S0140-6736(09)60929-6]; Diette GB, 2012, GLOB HEART, V7, P265, DOI 10.1016/j.gheart.2012.06.016; Dubey SK, 2015, CRIT REV ENV SCI TEC, V45, P2283, DOI 10.1080/10643389.2014.1000749; Fann N, 2015, J AIR WASTE MANAGE, V65, P570, DOI 10.1080/10962247.2014.996270; Finkelman FD, 2014, J ALLERGY CLIN IMMUN, V134, P73, DOI 10.1016/j.jaci.2014.04.002; Fiore AM, 2015, J AIR WASTE MANAGE, V65, P645, DOI 10.1080/10962247.2015.1040526; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Flonard M, 2018, INT J BIOMETEOROL, V62, P229, DOI 10.1007/s00484-017-1444-8; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; Gargano LM, 2018, DISASTER MED PUBLIC, V12, P697, DOI 10.1017/dmp.2017.140; Gasana J, 2012, ENVIRON RES, V117, P36, DOI 10.1016/j.envres.2012.05.001; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gordon SB, 2014, LANCET RESP MED, V2, P823, DOI 10.1016/S2213-2600(14)70168-7; Grecequet M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050720; Grimsley LF, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/427358; Grimsley LF, 2012, ENVIRON HEALTH PERSP, V120, P1600, DOI 10.1289/ehp.1104840; Hamaoui-Laguel L, 2015, NAT CLIM CHANGE, V5, P766, DOI [10.1038/nclimate2652, 10.1038/NCLIMATE2652]; Hew KM, 2015, CLIN EXP ALLERGY, V45, P238, DOI 10.1111/cea.12377; Holopainen JK, 2017, TRENDS PLANT SCI, V22, P744, DOI 10.1016/j.tplants.2017.07.004; Howard LE, 2014, ANN ALLERG ASTHMA IM, V113, P641, DOI 10.1016/j.anai.2014.08.019; Katelaris CH, 2018, INTERN MED J, V48, P129, DOI 10.1111/imj.13699; Kinney PL, 2018, CURR ENV HLTH REP, V5, P179, DOI 10.1007/s40572-018-0188-x; Lake IR, 2017, ENVIRON HEALTH PERSP, V125, P385, DOI 10.1289/EHP173; Lake JA, 2009, J EXP BOT, V60, P3123, DOI 10.1093/jxb/erp147; Lane K, 2013, J ENVIRON PUBLIC HEA, V2013, DOI 10.1155/2013/913064; Li N, 2016, J ALLERGY CLIN IMMUN, V138, P386, DOI 10.1016/j.jaci.2016.02.023; Lin YH, 2017, ENVIRON SCI TECHNOL, V51, P8166, DOI 10.1021/acs.est.7b01967; Liu WL, 2003, ENVIRON HEALTH PERSP, V111, P1454, DOI 10.1289/ehp.6286; Long SP, 2006, SCIENCE, V312, P1918, DOI 10.1126/science.1114722; Makra L, 2012, GRANA, V51, P215, DOI 10.1080/00173134.2012.661764; Mazdiyasni O, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700066; McCracken JP, 2012, GLOB HEART, V7, P223, DOI 10.1016/j.gheart.2012.06.010; Mertz O, 2009, ENVIRON MANAGE, V43, P743, DOI 10.1007/s00267-008-9259-3; Morgan JA, 2007, P NATL ACAD SCI USA, V104, P14724, DOI 10.1073/pnas.0703427104; Myers SS, 2014, NATURE, V510, P139, DOI 10.1038/nature13179; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Niu XY, 2017, SCI TOTAL ENVIRON, V579, P212, DOI 10.1016/j.scitotenv.2016.11.018; Orellano P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174050; Padhi BK, 2008, ANN NY ACAD SCI, V1140, P209, DOI 10.1196/annals.1454.015; Prospero JM, 2003, SCIENCE, V302, P1024, DOI 10.1126/science.1089915; Provencal S, 2017, URBAN CLIM, V20, P168, DOI 10.1016/j.uclim.2017.04.001; Rao CY, 2007, APPL ENVIRON MICROB, V73, P1630, DOI 10.1128/AEM.01973-06; Richter R, 2013, J APPL ECOL, V50, P1422, DOI 10.1111/1365-2664.12156; Rochlin I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060874; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Romeo Elisa, 2006, Epidemiol Prev, V30, P245; . S. Department of the Interior/ U. S. Geological Survey, 2016, IMP PRED COAST CHANG; Salvi D, 2016, CHEST, V149, P459, DOI 10.1378/chest.14-2554; Samy AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163863; Sapkota A, 2005, ENVIRON SCI TECHNOL, V39, P24, DOI 10.1021/es035311z; Shaposhnikov D, 2014, EPIDEMIOLOGY, V25, P359, DOI 10.1097/EDE.0000000000000090; Shrestha A, 1999, WEED SCI, V47, P557, DOI 10.1017/S0043174500092262; Singer BD, 2005, FUNCT PLANT BIOL, V32, P667, DOI 10.1071/FP05039; Spann K, 2016, ANN GLOB HEALTH, V82, P28, DOI 10.1016/j.aogh.2016.01.007; To T, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00644-2017; To T, 2016, AM J RESP CRIT CARE, V194, P429, DOI 10.1164/rccm.201510-1932OC; Tousa S, 2017, P NATL ACAD SCI USA, V114, pE2891, DOI 10.1073/pnas.1616942114; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1; Whyand T, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0785-0; Wong GWK, 2013, LANCET RESP MED, V1, P386, DOI 10.1016/S2213-2600(13)70073-0; Yang B, 2018, ENVIRON POLLUT, V234, P960, DOI 10.1016/j.envpol.2017.12.048; Zhang L, 2010, INDOOR AIR, V20, P176, DOI 10.1111/j.1600-0668.2009.00639.x; Zhang Y, 2015, GLOBAL CHANGE BIOL, V21, P1581, DOI 10.1111/gcb.12755; Zhang Y, 2014, INT J BIOMETEOROL, V58, P909, DOI 10.1007/s00484-013-0674-7; Zhao C, 2017, P NATL ACAD SCI USA, V114, P9326, DOI 10.1073/pnas.1701762114; Ziello C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034076; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108; Ziska LH, 2012, J ALLERGY CLIN IMMUN, V129, P27, DOI 10.1016/j.jaci.2011.10.032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53; 2003, ENV HLTH PERSPECT, V111, P1454	100	46	47	3	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1702	1710		10.1016/j.jaci.2019.02.018	http://dx.doi.org/10.1016/j.jaci.2019.02.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30826366	Bronze			2022-12-18	WOS:000466784600004
J	Fadlallah, J; Sterlin, D; Fieschi, C; Parizot, C; Dorgham, K; El Kafsi, H; Autaa, G; Ghillani-Dalbin, P; Juste, C; Lepage, P; Malphettes, M; Galicier, L; Boutboul, D; Clement, K; Andre, S; Marquet, F; Tresallet, C; Mathian, A; Miyara, M; Oksenhendler, E; Amoura, Z; Yssel, H; Larsen, M; Gorochov, G				Fadlallah, Jehane; Sterlin, Delphine; Fieschi, Claire; Parizot, Christophe; Dorgham, Karim; El Kafsi, Hela; Autaa, Gaelle; Ghillani-Dalbin, Pascale; Juste, Catherine; Lepage, Patricia; Malphettes, Marion; Galicier, Lionel; Boutboul, David; Clement, Karine; Andre, Sebastien; Marquet, Florian; Tresallet, Christophe; Mathian, Alexis; Miyara, Makoto; Oksenhendler, Eric; Amoura, Zahir; Yssel, Hans; Larsen, Martin; Gorochov, Guy			Synergistic convergence of microbiota-specific systemic IgG and secretory IgA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gut microbiota; anticommensal IgG; secretory IgA; IgA deficiency; common variable immunodeficiency; intravenous immunoglobulin	INFLAMMATORY-BOWEL-DISEASE; GUT MICROBIOTA; ANTIBODIES; RESPONSES; BACTERIA; TRANSLOCATION; AFFINITY; INNATE; TRACT; SERUM	Background: Commensals induce local IgA responses essential to the induction of tolerance to gut microbiota, but it remains unclear whether antimicrobiota responses remain confined to the gut. Objective: The aim of this study was to investigate systemic and intestinal responses against the whole microbiota under homeostatic conditions and in the absence of IgA. Methods: We analyzed blood and feces from healthy donors, patients with selective IgA deficiency (SIgAd), and patients with common variable immunodeficiency (CVID). Immunoglobulin-coated bacterial repertoires were analyzed by using combined bacterial fluorescence-activated cell sorting and 16S rRNA sequencing. Bacterial lysates were probed by using Western blot analysis with healthy donor sera. Results: Although absent from the healthy gut, serum antimicrobiota IgG are present in healthy subjects and increased in patients with SIgAd. IgG converges with nonoverlapping secretory IgA specificities to target the same bacteria. Each individual subject targets a diverse microbiota repertoire with a proportion that correlates inversely with systemic inflammation. Finally, intravenous immunoglobulin preparations target CVID gut microbiota much less efficiently than healthy microbiota. Conclusion: Secretory IgA and systemic IgG converge to target gut microbiota at the cellular level. SIgAd-associated inflammation is inversely correlated with systemic anticommensal IgG responses, which might serve as a second line of defense. We speculate that patients with SIgAd could benefit from oral IgA supplementation. Our data also suggest that intravenous immunoglobulin preparations can be supplemented with IgG from IgA-deficient patient pools to offer better protection against gut bacterial translocations in patients with CVID.	[Fadlallah, Jehane; Sterlin, Delphine; Parizot, Christophe; Dorgham, Karim; El Kafsi, Hela; Autaa, Gaelle; Ghillani-Dalbin, Pascale; Mathian, Alexis; Miyara, Makoto; Amoura, Zahir; Yssel, Hans; Larsen, Martin; Gorochov, Guy] Sorbonne Univ, INSERM, Ctr Immunol & Malad Infect CIMI Paris, Grp Hosp Pitie Salpetriere,AP HP,Dept Immunol, Paris, France; [Juste, Catherine; Lepage, Patricia] Univ Paris Saclay, AgroParisTech, INRA, Micalis Inst, F-78350 Paris, France; [Fadlallah, Jehane; Fieschi, Claire; Malphettes, Marion; Galicier, Lionel; Boutboul, David; Oksenhendler, Eric] Univ Paris Diderot Paris 7, Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Clement, Karine; Andre, Sebastien; Marquet, Florian] Sorbonne Univ, INSERM, UMRS1166, NutriOm Team,ICAN, Paris, France; [Clement, Karine] Hop La Pitie Salpetriere, AP HP, Nutr Dept, Paris, France; [Tresallet, Christophe] Hop La Pitie Salpetriere, AP HP, Dept Surg, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Larsen, M; Gorochov, G (corresponding author), INSERM, UMR S1135, Ctr Immunol & Malad Infect CIMI Paris, 83 Blvd Hop, F-75013 Paris, France.	Martin.Larsen@sorbonne-universite.fr; Guy.Gorochov@sorbonne-universite.fr	Lepage, Patricia/D-4362-2014; FADLALLAH, Jehane/AAJ-3272-2021; Sterlin, Delphine/M-4319-2019; Dorgham, karim/A-2241-2016; Larsen, Martin/A-7316-2014; Yssel, Hans/AFV-2907-2022	Lepage, Patricia/0000-0002-9501-6771; Dorgham, karim/0000-0001-9539-3203; Larsen, Martin/0000-0003-1375-4816; Yssel, Hans/0000-0001-7454-1836; Gorochov, Guy/0000-0003-2097-9677; PARIZOT, Christophe/0000-0001-5723-4471; ANDRE, Sebastien/0000-0002-7543-153X; Sterlin, Delphine/0000-0002-5993-687X; AUTAA, Gaelle/0000-0002-6652-7003	Institut National de la Sante et de la Recherche Medicale (INSERM); Agence Nationale de la Recherche [ANR-14-CE14-0013]; Fondation pour l'Aide a la Recherche sur la Sclerose en Plaques (ARSEP)	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation pour l'Aide a la Recherche sur la Sclerose en Plaques (ARSEP)	The study was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Agence Nationale de la Recherche (MetAntibody, ANR-14-CE14-0013), and Fondation pour l'Aide a la Recherche sur la Sclerose en Plaques (ARSEP).	BAZIL V, 1991, J IMMUNOL, V147, P1567; Beaugerie L, 2012, WORLD J GASTROENTERO, V18, P3806, DOI 10.3748/wjg.v18.i29.3806; Benckert J, 2011, J CLIN INVEST, V121, P1946, DOI 10.1172/JCI44447; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Christmann BS, 2015, J ALLERGY CLIN IMMUN, V136, P1378, DOI 10.1016/j.jaci.2015.03.036; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; D'Auria G, 2013, SCI REP-UK, V3, DOI 10.1038/srep03515; de Aguero MG, 2016, SCIENCE, V351, P1296, DOI 10.1126/science.aad2571; Donskey CJ, 2004, CLIN INFECT DIS, V39, P219, DOI 10.1086/422002; Fadlallah J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan1217; Favre O, 2005, ALLERGY, V60, P385, DOI 10.1111/j.1398-9995.2005.00756.x; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Iversen R, 2017, CELL REP, V20, P2357, DOI 10.1016/j.celrep.2017.08.036; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Jorgensen SF, 2016, MUCOSAL IMMUNOL, V9, P1455, DOI 10.1038/mi.2016.18; Juste C, 2014, GUT, V63, P1566, DOI 10.1136/gutjnl-2012-303786; Kau AL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4877; Koch MA, 2016, CELL, V165, P827, DOI 10.1016/j.cell.2016.04.055; Landers CJ, 2002, GASTROENTEROLOGY, V123, P689, DOI 10.1053/gast.2002.35379; MacFie J, 2004, BRIT MED BULL, V71, P1, DOI 10.1093/bmb/ldh029; Macpherson A, 1996, GUT, V38, P365, DOI 10.1136/gut.38.3.365; Moor K, 2016, NAT PROTOC, V11, P1531, DOI 10.1038/nprot.2016.091; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Okai S, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.103, 10.1038/nmicrobiol.2016.103]; Palm NW, 2014, CELL, V158, P1000, DOI 10.1016/j.cell.2014.08.006; Perreau M, 2014, J EXP MED, V211, P2033, DOI 10.1084/jem.20140039; Rollenske T, 2018, NAT IMMUNOL, V19, P617, DOI 10.1038/s41590-018-0106-2; RUSSELL MW, 1989, SCAND J IMMUNOL, V30, P175, DOI 10.1111/j.1365-3083.1989.tb01199.x; Sandolo C, 2011, EUR J PHARM BIOPHARM, V79, P566, DOI 10.1016/j.ejpb.2011.05.011; Schneider C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010524; Slack E, 2009, SCIENCE, V325, P617, DOI 10.1126/science.1172747; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; White AL, 2015, CANCER CELL, V27, P138, DOI 10.1016/j.ccell.2014.11.001; Wilmore JR, 2018, CELL HOST MICROBE, V23, P302, DOI 10.1016/j.chom.2018.01.005; Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006	39	46	46	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1575	+		10.1016/j.jaci.2018.09.036	http://dx.doi.org/10.1016/j.jaci.2018.09.036			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30554723	Bronze, Green Submitted			2022-12-18	WOS:000463348900031
J	Shen, LM; Tenzer, S; Storck, W; Hobernik, D; Raker, VK; Fischer, K; Decker, S; Dzionek, A; Krauthauser, S; Diken, M; Nikolaev, A; Maxeiner, J; Schuster, P; Kappel, C; Verschoor, A; Schild, H; Grabbe, S; Bros, M				Shen, Limei; Tenzer, Stefan; Storck, Wiebke; Hobernik, Dominika; Raker, Verena Katherina; Fischer, Karl; Decker, Sandra; Dzionek, Andrzej; Krauthaeuser, Susanne; Diken, Mustafa; Nikolaev, Alexej; Maxeiner, Joachim; Schuster, Petra; Kappel, Cinja; Verschoor, Admar; Schild, Hansjoerg; Grabbe, Stephan; Bros, Matthias			Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; B cells; complement; antibody; complement factor 3; lectin pathway; IgG(2a)	REGULATORY T-CELLS; DENDRITIC CELLS; MICE DEFICIENT; CPG-DNA; IMMUNOTHERAPY; COMPLEMENT; VACCINE; NANOPARTICLES; ANTIGENS; INNATE	Background: Nanoparticle (NP)-based vaccines are attractive immunotherapy tools because of their capability to codeliver antigen and adjuvant to antigen-presenting cells. Their cellular distribution and serum protein interaction ("protein corona'') after systemic administration and their effect on the functional properties of NPs is poorly understood. Objectives: We analyzed the relevance of the protein corona on cell type-selective uptake of dextran-coated NPs and determined the outcome of vaccination with NPs that codeliver antigen and adjuvant in disease models of allergy. Methods: The role of protein corona constituents for cellular binding/uptake of dextran-coated ferrous nanoparticles (DEX-NPs) was analyzed both in vitro and in vivo. DEX-NPs conjugated with the model antigen ovalbumin (OVA) and immunostimulatory CpG-rich oligodeoxynucleotides were administered to monitor the induction of cellular and humoral immune responses. Therapeutic effects of this DEX-NP vaccine in mouse models of OVA-induced anaphylaxis and allergic asthma were assessed. Results: DEX-NPs triggered lectin-induced complement activation, yielding deposition of activated complement factor 3 on the DEX-NP surface. In the spleen DEX-NPs targeted predominantly B cells through complement receptors 1 and 2. The DEX-NP vaccine elicited much stronger OVA-specific IgG(2a) production than coadministered soluble OVA plus CpG oligodeoxynucleotides. B-cell binding of the DEX-NP vaccine was critical for IgG(2a) production. Treatment of OVA-sensitized mice with the DEX-NP vaccine prevented induction of anaphylactic shock and allergic asthma accompanied by IgE inhibition. Conclusions: Opsonization of lectin-coated NPs by activated complement components results in selective B-cell targeting. The intrinsic B-cell targeting property of lectin-coated NPs can be exploited for treatment of allergic immune responses.	[Shen, Limei; Hobernik, Dominika; Raker, Verena Katherina; Kappel, Cinja; Grabbe, Stephan; Bros, Matthias] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Dermatol, Mainz, Germany; [Tenzer, Stefan; Storck, Wiebke; Schild, Hansjoerg] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Immunol, Mainz, Germany; [Nikolaev, Alexej] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Mol Med, Mainz, Germany; [Maxeiner, Joachim; Schuster, Petra] Johannes Gutenberg Univ Mainz, Med Ctr, Asthma Core Facil, Res Ctr Immunotherapy, Mainz, Germany; [Fischer, Karl; Decker, Sandra] Johannes Gutenberg Univ Mainz, Dept Phys Chem, Mainz, Germany; [Dzionek, Andrzej; Krauthaeuser, Susanne] Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; [Diken, Mustafa] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Mainz, Germany; [Verschoor, Admar] Univ Lubeck, Inst Syst Inflammat Res, Lubeck, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Miltenyi Biotec; Johannes Gutenberg University of Mainz; University of Lubeck	Grabbe, S (corresponding author), Univ Med Ctr Mainz, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	stephan.grabbe@unimedizin-mainz.de	Grabe, Stephan/AAJ-4578-2021; Tenzer, Stefan/AAE-2180-2020	Grabe, Stephan/0000-0002-6863-8719; Tenzer, Stefan/0000-0003-3034-0017; Raker, Verena/0000-0001-7264-0371	Hoffmann Klose Stiftung; Stiftung Rheinland-Pfalz (NANOSCH); DFG [SFB 1066]	Hoffmann Klose Stiftung; Stiftung Rheinland-Pfalz (NANOSCH); DFG(German Research Foundation (DFG))	L.S. and S.G. were supported by a grant of the Hoffmann Klose Stiftung. W.S., S.T., and H.S. were supported by Stiftung Rheinland-Pfalz (NANOSCH). L.S., W.S., S.T., H.S., S.G., and M.B. were supported by grants from the DFG (SFB 1066).	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Beltrame MH, 2015, MOL IMMUNOL, V67, P85, DOI 10.1016/j.molimm.2015.03.245; Bochner BS, 2013, J ALLERGY CLIN IMM S, V111, P819; Bohm L, 2015, J IMMUNOL, V194, P887, DOI 10.4049/jimmunol.1401612; Buchweitz JP, 2007, J PHARMACOL EXP THER, V323, P675, DOI 10.1124/jpet.107.124719; Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338; Cohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255; CONSTANT S, 1995, J IMMUNOL, V155, P3734; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Daver N, 2013, CURR HEMATOL MALIG R, V8, P123, DOI 10.1007/s11899-013-0160-7; Distler U, 2014, EXPERT REV PROTEOMIC, V11, P675, DOI 10.1586/14789450.2014.971114; Docter D, 2014, NAT PROTOC, V9, P2030, DOI 10.1038/nprot.2014.139; Fischer MB, 1996, J IMMUNOL, V157, P549; Gamazo C, 2014, IMMUNOTHERAPY-UK, V6, P885, DOI [10.2217/IMT.14.63, 10.2217/imt.14.63]; Goldman B, 2009, NAT BIOTECHNOL, V27, P129, DOI 10.1038/nbt0209-129; GUSTAVSSON S, 1995, J IMMUNOL, V154, P6524; Hartwell BL, 2015, J PHARM SCI-US, V104, P346, DOI 10.1002/jps.24273; Heesters BA, 2014, NAT REV IMMUNOL, V14, P495, DOI 10.1038/nri3689; Heit A, 2004, J IMMUNOL, V172, P1501, DOI 10.4049/jimmunol.172.3.1501; Hoffmann HJ, 2017, ALLERGY, V72, P1022, DOI 10.1111/all.13135; Joshi VB, 2014, AAPS J, V16, P975, DOI 10.1208/s12248-014-9624-5; Jutel M, 2016, ALLERGY ASTHMA IMMUN, V8, P191, DOI 10.4168/aair.2016.8.3.191; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Keever-Taylor CA, 2012, BIOL BLOOD MARROW TR, V18, P690, DOI 10.1016/j.bbmt.2011.08.017; Kusaykin Mikhail, 2008, Biotechnology Journal, V3, P904, DOI 10.1002/biot.200700054; Li DP, 2012, J EXP MED, V209, P109, DOI 10.1084/jem.20110399; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Pike RN, 2013, CURR OPIN STRUC BIOL, V23, P820, DOI 10.1016/j.sbi.2013.07.016; Prantner AM, 2014, J NANOSCI NANOTECHNO, V14, P115, DOI 10.1166/jnn.2014.8899; Ricklin D, 2016, IMMUNOL REV, V274, P33, DOI 10.1111/imr.12500; Ritz S, 2015, BIOMACROMOLECULES, V16, P1311, DOI 10.1021/acs.biomac.5b00108; Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]; Shen LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080904; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Sirvent S, 2016, J ALLERGY CLIN IMMUN, V138, P558, DOI 10.1016/j.jaci.2016.02.029; SOLTIS RD, 1979, CLIN EXP IMMUNOL, V37, P310; Srivastava KD, 2016, J ALLERGY CLIN IMMUN, V138, P536, DOI 10.1016/j.jaci.2016.01.047; Sullivan-Chang L, 2013, BIODRUGS, V27, P293, DOI 10.1007/s40259-013-0016-7; Takahashi K, 2002, MICROBES INFECT, V4, P773, DOI 10.1016/S1286-4579(02)01597-6; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	43	46	46	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1558	1570		10.1016/j.jaci.2017.08.049	http://dx.doi.org/10.1016/j.jaci.2017.08.049			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29382591	hybrid			2022-12-18	WOS:000449429800019
J	Werder, RB; Zhang, V; Lynch, JP; Snape, N; Upham, JW; Spann, K; Phipps, S				Werder, Rhiannon B.; Zhang, Vivian; Lynch, Jason P.; Snape, Natale; Upham, John W.; Spann, Kirsten; Phipps, Simon			Chronic IL-33 expression predisposes to virus-induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; rhinovirus; asthma; exacerbation; antiviral	RESPIRATORY SYNCYTIAL VIRUS; ALLERGIC AIRWAY INFLAMMATION; INNATE LYMPHOID-CELLS; EPITHELIAL-CELLS; RHINOVIRUS INFECTION; EARLY-LIFE; PNEUMOVIRUS INFECTION; VIRAL-INFECTIONS; LUNG-FUNCTION; MOUSE MODELS	Background: Rhinovirus infection triggers acute asthma exacerbations. IL-33 is an instructive cytokine of type 2 inflammation whose expression is associated with viral load during experimental rhinovirus infection of asthmatic patients. Objective: We sought to determine whether anti-IL-33 therapy is effective during disease progression, established disease, or viral exacerbation using a preclinical model of chronic asthma and in vitro human primary airway epithelial cells (AECs). Methods: Mice were exposed to pneumonia virus of mice and cockroach extract in early and later life and then challenged with rhinovirus to model disease onset, progression, and chronicity. Interventions included anti-IL-33 or dexamethasone at various stages of disease. AECs were obtained from asthmatic patients and healthy subjects and treated with anti-IL-33 after rhinovirus infection. Results: Anti-IL-33 decreased type 2 inflammation in all phases of disease; however, the ability to prevent airway smooth muscle growth was lost after the progression phase. After the chronic phase, IL-33 levels were persistently high, and rhinovirus challenge exacerbated the type 2 inflammatory response. Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti-IL-33, but not dexamethasone, promoted antiviral interferon expression and decreased viral load. Rhinovirus replication was higher and IFN-l levels were lower in AECs from asthmatic patients compared with those from healthy subjects. Anti-IL-33 decreased rhinovirus replication and increased IFN-l levels at the gene and protein levels. Conclusion: Anti-IL-33 or dexamethasone suppressed the magnitude of type 2 inflammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted antiviral immunity and decreased viral replication. The latter phenotype was replicated in rhinovirus-infected human AECs, suggesting that anti-IL-33 therapy has the additional benefit of enhancing host defense.	[Werder, Rhiannon B.; Zhang, Vivian; Lynch, Jason P.; Phipps, Simon] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Upham, John W.; Spann, Kirsten; Phipps, Simon] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia; [Snape, Natale; Spann, Kirsten] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia; [Upham, John W.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld, Australia; [Werder, Rhiannon B.; Zhang, Vivian; Phipps, Simon] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia	University of Queensland; University of Queensland; Queensland University of Technology (QUT); University of Queensland; QIMR Berghofer Medical Research Institute	Phipps, S (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia.	simon.phipps@qimrberghofer.edu.au	Upham, John/F-4420-2010; Werder, Rhiannon/AAL-5192-2021; Phipps, Simon/F-9170-2010; Lynch, Jason/G-2991-2016; Spann, Kirsten/B-4524-2013	Upham, John/0000-0002-0017-3433; Werder, Rhiannon/0000-0002-6432-4587; Phipps, Simon/0000-0002-7388-3612; Lynch, Jason/0000-0003-0889-2616; Spann, Kirsten/0000-0003-0567-8382	Pfizer; Rebecca L. Cooper Medical Research Foundation; Australian Infectious Disease Research Excellence Award; Australian Research Council Future Fellowship	Pfizer(Pfizer); Rebecca L. Cooper Medical Research Foundation; Australian Infectious Disease Research Excellence Award; Australian Research Council Future Fellowship(Australian Research Council)	Supported by a research grant from Pfizer, an equipment grant from the Rebecca L. Cooper Medical Research Foundation, an Australian Infectious Disease Research Excellence Award awarded (to S.P., J.P.L., and J.W.U.), and an Australian Research Council Future Fellowship (to S.P.).	Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Clarke DL, 2014, CLIN SCI, V126, P567, DOI 10.1042/CS20130149; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Davidson S, 2011, J IMMUNOL, V186, P5938, DOI 10.4049/jimmunol.1002635; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kumar RK, 2016, RESPIROLOGY, V21, P842, DOI 10.1111/resp.12760; Lee HY, 2014, EXP LUNG RES, V40, P66, DOI 10.3109/01902148.2013.870261; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Newcomb DC, 2013, THORAX, V68, P717, DOI 10.1136/thoraxjnl-2012-202404; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Oczypok EA, 2015, J ALLERGY CLIN IMMUN, V136, P747, DOI 10.1016/j.jaci.2015.03.011; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Parsons KS, 2014, CLIN EXP ALLERGY, V44, P91, DOI 10.1111/cea.12218; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Phan JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092163; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Rochlitzer S, 2014, CLIN SCI, V126, P55, DOI 10.1042/CS20130174; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stewart A, 2012, AM J RESP CRIT CARE, V185, P1035, DOI 10.1164/rccm.201203-0457ED; Tuthill TJ, 2003, J GEN VIROL, V84, P2829, DOI 10.1099/vir.0.19109-0; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	56	46	47	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1607	+		10.1016/j.jaci.2017.07.051	http://dx.doi.org/10.1016/j.jaci.2017.07.051			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28947081	Bronze, Green Submitted			2022-12-18	WOS:000432148200009
J	Moens, L; Van Eyck, L; Jochmans, D; Mitera, T; Frans, G; Bossuyt, X; Matthys, P; Neyts, J; Ciancanelli, M; Zhang, SY; Gijsbers, R; Casanova, JL; Boisson-Dupuis, S; Meyts, I; Liston, A				Moens, Leen; Van Eyck, Lien; Jochmans, Dirk; Mitera, Tania; Frans, Glynis; Bossuyt, Xavier; Matthys, Patrick; Neyts, Johan; Ciancanelli, Michael; Zhang, Shen-Ying; Gijsbers, Rik; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie; Meyts, Isabelle; Liston, Adrian			A novel kindred with inherited STAT2 deficiency and severe viral illness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HUMANS; CELLS		[Moens, Leen; Frans, Glynis; Bossuyt, Xavier] Katholieke Univ KU Leuven, Dept Immunol & Microbiol, Expt Immunol Lab, Childhood Immunol, Leuven, Belgium; [Van Eyck, Lien; Liston, Adrian] Vlaams Inst Biotechnol, Autoimmune Genet Lab, Dept Immunol & Microbiol, Ghent, Belgium; [Van Eyck, Lien; Liston, Adrian] Katholieke Univ Leuven, Ghent, Belgium; [Jochmans, Dirk; Neyts, Johan] Katholieke Univ Leuven, Lab Virol & Chemotherapy, Rega Inst, Dept Immunol & Microbiol, Leuven, Belgium; [Mitera, Tania; Matthys, Patrick] Katholieke Univ Leuven, Dept Immunol & Microbiol, Rega Inst, Lab Immunobiol, Leuven, Belgium; [Meyts, Isabelle] Univ Hosp Leuven, Dept Immunol & Microbiol, Childhood Immunol, Leuven, Belgium; [Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Meyts, Isabelle] Katholieke Univ Leuven, Leuven, Belgium; [Gijsbers, Rik] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Leuven, Flanders, Belgium; [Ciancanelli, Michael; Zhang, Shen-Ying; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Zhang, Shen-Ying; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie] INSERM, U1163, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol & Immunol Unit, Paris, France; [Zhang, Shen-Ying; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie] Paris Descartes Univ, Imagine Inst, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute	Meyts, I (corresponding author), Univ Hosp Leuven, Dept Immunol & Microbiol, Childhood Immunol, Leuven, Belgium.; Meyts, I (corresponding author), Univ Hosp Leuven, Dept Pediat, Leuven, Belgium.; Meyts, I (corresponding author), Katholieke Univ Leuven, Leuven, Belgium.	Isabelle.Meyts@uzleuven.be; adrian.liston@vib.be	Neyts, Johan/U-8267-2017; Matthys, Patrick/B-4813-2018; Bossuyt, Xavier/B-2085-2019; Boisson-Dupuis, Stephanie/AAF-5066-2021; Meyts, Isabelle/Z-3295-2019; Zhang, Shen-Ying/I-2685-2017; Boisson-Dupuis, Stéphanie/I-2040-2017; Casanova, Jean-Laurent/I-3418-2017; JOCHMANS, DIRK/T-6223-2017	Neyts, Johan/0000-0002-0033-7514; Matthys, Patrick/0000-0002-9685-6836; Bossuyt, Xavier/0000-0001-6856-8485; Zhang, Shen-Ying/0000-0002-9449-3672; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; JOCHMANS, DIRK/0000-0002-9265-6028; Casanova, Jean-Laurent/0000-0002-7782-4169	Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek Vlaanderen); KU Leuven (Globale Onderzoeks Actie grant); European Research Council grant IMMUNO; Klinisch Onderzoeks Fonds; International Mobility Grant of the Fonds Wetenschappelijk Onderzoek Vlaanderen; Klinische Onderzoeks Raad UZ Leuven; Jeffrey Modell Foundation; BELSPO (Interuniversity Attraction Poles, Belvir); St. Giles Foundation; Institut National de la Sante et de la Recherche Medicale, University Paris Descartes; Rockefeller University	Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek Vlaanderen)(FWO); KU Leuven (Globale Onderzoeks Actie grant); European Research Council grant IMMUNO; Klinisch Onderzoeks Fonds; International Mobility Grant of the Fonds Wetenschappelijk Onderzoek Vlaanderen; Klinische Onderzoeks Raad UZ Leuven; Jeffrey Modell Foundation; BELSPO (Interuniversity Attraction Poles, Belvir); St. Giles Foundation; Institut National de la Sante et de la Recherche Medicale, University Paris Descartes(Institut National de la Sante et de la Recherche Medicale (Inserm)); Rockefeller University	Supported by the Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek Vlaanderen), the KU Leuven (Globale Onderzoeks Actie grant), and the European Research Council grant IMMUNO. I.M. is supported by a Klinisch Onderzoeks Fonds mandate of the KU Leuven, Belgium, by an International Mobility Grant of the Fonds Wetenschappelijk Onderzoek Vlaanderen, by a grant of the Klinische Onderzoeks Raad UZ Leuven, and by the Jeffrey Modell Foundation. J.N. is supported by BELSPO (Interuniversity Attraction Poles, Belvir). J.-L.C. is supported by the St. Giles Foundation, Institut National de la Sante et de la Recherche Medicale, University Paris Descartes, and The Rockefeller University.	Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Buchanan R, 2012, SEMIN PEDIATR NEUROL, V19, P107, DOI 10.1016/j.spen.2012.02.003; Casanova JL, 2015, P NATL ACAD SCI USA, V112, pE7128, DOI 10.1073/pnas.1521651112; Casanova JL, 2011, ANNU REV IMMUNOL, V29, P447, DOI 10.1146/annurev-immunol-030409-101335; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Hambleton S, 2013, P NATL ACAD SCI USA, V110, P3053, DOI 10.1073/pnas.1220098110; Munz C, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00308; Shahni R, 2015, BRAIN, V138, P2834, DOI 10.1093/brain/awv182; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Vairo D, 2011, BLOOD, V118, P1806, DOI 10.1182/blood-2011-01-330571; Zhang SY, 2013, CURR OPIN IMMUNOL, V25, P19, DOI 10.1016/j.coi.2012.11.001; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06	14	46	46	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1995	+		10.1016/j.jaci.2016.10.033	http://dx.doi.org/10.1016/j.jaci.2016.10.033			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28087227	Green Accepted, Bronze			2022-12-18	WOS:000402724600034
J	Iribarren, C; Rahmaoui, A; Long, AA; Szefler, SJ; Bradley, MS; Carrigan, G; Eisner, MD; Chen, H; Omachi, TA; Farkouh, ME; Rothman, KJ				Iribarren, Carlos; Rahmaoui, Abdelkader; Long, Aidan A.; Szefler, Stanley J.; Bradley, Mary S.; Carrigan, Gillis; Eisner, Mark D.; Chen, Hubert; Omachi, Theodore A.; Farkouh, Michael E.; Rothman, Kenneth J.			Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adverse event; arterial thromboembolic event; clinical trials; moderate to severe asthma; omalizumab; safety; serious adverse event	ANTIIMMUNOGLOBULIN-E THERAPY; EXHALED BREATH CONDENSATE; CORONARY-HEART-DISEASE; ADULT-ONSET ASTHMA; ANTI-IGE ANTIBODY; ALLERGIC-ASTHMA; RISK; GLUCOCORTICOIDS; EFFICACY; EXACERBATIONS	Background: EXCELS, a postmarketing observational cohort study, was a commitment to the US Food and Drug Administration to assess the long-term safety of omalizumab in an observational setting, focusing predominantly on malignancies. Objective: The aim of this study was to examine a potential association between omalizumab and cardiovascular (CV)/cerebrovascular (CBV) events in EXCELS. Methods: Patients (>= 12 years of age) with moderate to severe allergic asthma and who were being treated with omalizumab (n = 5007) or not (n = 2829) at baseline were followed up for <= 5 years. Analyses included overall CV/CBV events, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myocardial infarction, ischemic stroke, transient ischemic attack, and unstable angina. A prespecified analysis of the end point of ATE was conducted to control for available potential confounders. A blinded independent expert panel adjudicated all events. Results: At baseline, the 2 cohorts had similar demographic characteristics, but severe asthma was more common in the omalizumab versus the non-omalizumab group (50% vs 23%). Omalizumab-treated patients had a higher rate of CV/CBV serious adverse events (13.4 per 1,000 person years [PYs]) than did non-omalizumab-treated patients (8.1 per 1,000 PYs). The ATE rates per 1,000 PYs were 6.66 (101 patients/15,160 PYs) in the omalizumab cohort and 4.64 (46 patients/9,904 PYs) in the non-omalizumab cohort. After control for available confounding factors, the hazard ratio was 1.32 (95% CI, 0.91-1.91). Conclusion: This observational study demonstrated a higher incidence rate of CV/CBV events in the omalizumab versus the non-omalizumab cohort. Differences in asthma severity between cohorts likely contributed to this imbalance, but some increase in risk cannot be excluded.	[Iribarren, Carlos] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; [Rahmaoui, Abdelkader; Bradley, Mary S.; Carrigan, Gillis; Eisner, Mark D.; Chen, Hubert; Omachi, Theodore A.] Genentech Inc, San Francisco, CA 94080 USA; [Long, Aidan A.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Long, Aidan A.] Harvard Med Sch, Cambridge, MA USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Pediat Asthma Res Program, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO USA; [Farkouh, Michael E.] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Farkouh, Michael E.] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON, Canada; [Rothman, Kenneth J.] RTI Hlth Solut, Res Triangle Pk, NC USA	Kaiser Permanente; Roche Holding; Genentech; Harvard University; Massachusetts General Hospital; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Toronto; Peter Munk Cardiac Centre; University of Toronto; Research Triangle Institute	Rahmaoui, A (corresponding author), 1 DNA Way, San Francisco, CA 94080 USA.	abdelkar@gene.com		Omachi, Theodore/0000-0001-9167-768X; Chen, Hubert/0000-0002-6630-239X; Szefler, Stanley/0000-0002-6911-3199	Genentech, Inc, South San Francisco, Calif; Novartis Pharma AG, Basel, Switzerland; Genentech, Inc; Novartis Pharmaceuticals Corporation	Genentech, Inc, South San Francisco, Calif(Roche HoldingGenentech); Novartis Pharma AG, Basel, Switzerland; Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis)	Supported by Genentech, Inc, South San Francisco, Calif, and Novartis Pharma AG, Basel, Switzerland. Medical writing support for this manuscript was funded by Genentech, Inc, and Novartis Pharmaceuticals Corporation. ClinicalTrials.gov identifier: NCT00252135.	Appleton SL, 2009, J ALLERGY CLIN IMMUN, V123, P124, DOI 10.1016/j.jaci.2008.10.032; Avina-Zubieta JA, 2013, RHEUMATOLOGY, V52, P68, DOI 10.1093/rheumatology/kes353; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Cazzola M, 2012, RESP MED, V106, P249, DOI 10.1016/j.rmed.2011.07.021; CRIQUI MH, 1987, AM J MED, V82, P964, DOI 10.1016/0002-9343(87)90159-8; Eisner MD, 2012, J ASTHMA, V49, P642, DOI 10.3109/02770903.2012.690477; Fardet L, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4928; Food and Drug Administration, 2009, EARL COMM ONG SAF RE; Glynn RJ, 2006, BASIC CLIN PHARMACOL, V98, P253, DOI 10.1111/j.1742-7843.2006.pto_293.x; Grobbee DE, 1997, BRIT MED J, V315, P1151; Halasz A, 2002, RESP MED, V96, P262, DOI 10.1053/rmed.2001.1256; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Humbert M, 2008, ALLERGY, V63, P592, DOI 10.1111/j.1398-9995.2008.01654.x; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Iribarren C, 2017, J ALLERGY CLIN IMMUN, V139, P1678, DOI 10.1016/j.jaci.2016.12.953; Iribarren C, 2012, AM J EPIDEMIOL, V176, P1014, DOI 10.1093/aje/kws181; KORKMAZ ME, 1991, INT J CARDIOL, V31, P199, DOI 10.1016/0167-5273(91)90216-C; Kremers HM, 2007, ARTHRIT RHEUM-ARTHR, V57, P279, DOI 10.1002/art.22548; Lee HM, 2012, RESP MED, V106, P948, DOI 10.1016/j.rmed.2012.02.017; Lefebvre P, 2015, J ALLERGY CLIN IMMUN, V136, P1488, DOI 10.1016/j.jaci.2015.07.046; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Long AA, 2009, ANN ALLERG ASTHMA IM, V103, P212, DOI 10.1016/S1081-1206(10)60184-6; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Niven R, 2008, RESP MED, V102, P1371, DOI 10.1016/j.rmed.2008.06.002; Nussinovitch U, 2010, CURR PHARM DESIGN, V16, P3574, DOI 10.2174/138161210793797870; Omachi TA, 2014, ANN ALLERG ASTHMA IM, V113, pA37; Onufrak SJ, 2008, AM J CARDIOL, V101, P1247, DOI 10.1016/j.amjcard.2007.12.024; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x; Salpeter SR, 2004, DRUG AGING, V21, P405, DOI 10.2165/00002512-200421060-00005; Schanen JG, 2005, THORAX, V60, P633, DOI 10.1136/thx.2004.026484; Sinkiewicz Wladyslaw, 2008, Cardiol J, V15, P122; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Song YQ, 2010, DIABETES RES CLIN PR, V90, P365, DOI 10.1016/j.diabres.2010.09.010; Tattersall M, 2014, CIRCULATION S2, V130; US Food and Drug Administration, 2014, FDA DRUG SAF COMM FD; Varas-Lorenzo C, 2007, ATHEROSCLEROSIS, V192, P376, DOI 10.1016/j.atherosclerosis.2006.05.019; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007; Zietkowski Z, 2010, RESPIRATION, V80, P534, DOI 10.1159/000317137; Zietkowski Z, 2009, RESP MED, V103, P379, DOI 10.1016/j.rmed.2008.10.003	44	46	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1489	+		10.1016/j.jaci.2016.07.038	http://dx.doi.org/10.1016/j.jaci.2016.07.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27639934	hybrid			2022-12-18	WOS:000400465300009
J	Stone, CA; Hemler, JA; Commins, SP; Schuyler, AJ; Phillips, EJ; Peebles, RS; Fahrenholz, JM				Stone, Cosby A., Jr.; Hemler, Jonathan A.; Commins, Scott P.; Schuyler, Alexander J.; Phillips, Elizabeth J.; Peebles, R. Stokes, Jr.; Fahrenholz, John M.			Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GELATIN; SAFETY		[Stone, Cosby A., Jr.; Hemler, Jonathan A.; Peebles, R. Stokes, Jr.; Fahrenholz, John M.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37235 USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA; [Commins, Scott P.] Univ N Carolina, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol, Chapel Hill, NC USA; [Schuyler, Alexander J.] Univ Virginia Hlth Syst, Dept Med, Carter Immunol Ctr, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Peebles, R. Stokes, Jr.; Fahrenholz, John M.] Tennessee Valley Healthcare Syst, Vet Adm Med Ctr, Med Serv, Allergy & Immunol Sect, Nashville, TN USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia	Vanderbilt University; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Virginia; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Murdoch University	Stone, CA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37235 USA.	cosby.a.stone@vanderbilt.edu			Elizabeth and John Murray Endowment, Vanderbilt University; National Institutes of Health (NIH) [1P50GM115305-01, 1R01AI103348-01, 1P30AI110527-01A1]; National Health and Medical Research Foundation of Australia; Australian Centre for HIV and Hepatitis Virology Research; NIH [R56AI113095]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI103348, R01AI135049, R21AI087985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER	Elizabeth and John Murray Endowment, Vanderbilt University; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health and Medical Research Foundation of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Centre for HIV and Hepatitis Virology Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the Elizabeth and John Murray Endowment, Vanderbilt University. E.J.P. receives funding related to this project from the National Institutes of Health (NIH; 1P50GM115305-01, 1R01AI103348-01, and 1P30AI110527-01A1), National Health and Medical Research Foundation of Australia, and the Australian Centre for HIV and Hepatitis Virology Research. S.P.C. receives funding related to this project from NIH R56AI113095.	[Anonymous], 2015, VACC EXC MED SUMM; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; Manivannan V, 2009, INT J EMERG MED, V2, P3, DOI 10.1007/s12245-009-0093-z; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Nakayama T, 2000, J ALLERGY CLIN IMMUN, V106, P591, DOI 10.1067/mai.2000.108433; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pinson ML, 2015, VACCINE, V33, P1231, DOI 10.1016/j.vaccine.2015.01.020; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Tseng HF, 2012, J INTERN MED, V271, P510, DOI 10.1111/j.1365-2796.2011.02474.x	10	46	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1710	+		10.1016/j.jaci.2016.10.037	http://dx.doi.org/10.1016/j.jaci.2016.10.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27986511	Green Accepted, Bronze			2022-12-18	WOS:000400465300041
J	Ferreira, MAR; Jansen, R; Willemsen, G; Penninx, B; Bain, LM; Vicente, CT; Revez, JA; Matheson, MC; Hui, J; Tung, JY; Baltic, S; Le Souef, P; Montgomery, GW; Martin, NG; Robertson, CF; James, A; Thompson, PJ; Boomsma, DI; Hopper, JL; Hinds, DA; Werder, RB; Phipps, S				Ferreira, Manuel A. R.; Jansen, Rick; Willemsen, Gonneke; Penninx, Brenda; Bain, Lisa M.; Vicente, Cristina T.; Revez, Joana A.; Matheson, Melanie C.; Hui, Jennie; Tung, Joyce Y.; Baltic, Svetlana; Le Souef, Peter; Montgomery, Grant W.; Martin, Nicholas G.; Robertson, Colin F.; James, Alan; Thompson, Philip J.; Boomsma, Dorret I.; Hopper, John L.; Hinds, David A.; Werder, Rhiannon B.; Phipps, Simon		Australian Asthma Genetics Consort	Gene-based analysis of regulatory variants identifies 4 putative novel asthma risk genes related to nucleotide synthesis and signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammation; expression quantitative trait locus; transcriptome; predisposition; obesity; EUGENE; VEGAS; PrediXcan; TWAS; ZNF707; AOAH; CLK3; UDP-glucose; P2Y14; P2Y13	GENOME-WIDE ASSOCIATION; PLASMACYTOID DENDRITIC CELLS; UDP-GLUCOSE; P2Y(14) RECEPTOR; EXTRACELLULAR ATP; HUMAN NEUTROPHILS; EPITHELIAL-CELLS; ADP RECEPTOR; LARGE-SCALE; HAY-FEVER	Background: Hundreds of genetic variants are thought to contribute to variation in asthma risk by modulating gene expression. Methods that increase the power of genome-wide association studies (GWASs) to identify risk-associated variants are needed. Objective: We sought to develop a method that aggregates the evidence for association with disease risk across expression quantitative trait loci (eQTLs) of a gene and use this approach to identify asthma risk genes. Methods: We developed a gene-based test and software package called EUGENE that (1) is applicable to GWAS summary statistics; (2) considers both cis- and trans-eQTLs; (3) incorporates eQTLs identified in different tissues; and (4) uses simulations to account for multiple testing. We applied this approach to 2 published asthma GWASs (combined n = 46,044) and used mouse studies to provide initial functional insights into 2 genes with novel genetic associations. Results: We tested the association between asthma and 17,190 genes that were found to have cis- and/or trans-eQTLs across 16 published eQTL studies. At an empirical FDR of 5%, 48 genes were associated with asthma risk. Of these, for 37, the association was driven by eQTLs located in established risk loci for allergic disease, including 6 genes not previously implicated in disease cause (eg, LIMS1, TINF2, and SAFB). The remaining 11 significant genes represent potential novel genetic associations with asthma. The association with 4 of these replicated in an independent GWAS: B4GALT3, USMG5, P2RY13, and P2RY14, which are genes involved in nucleotide synthesis or nucleotide-dependent cell activation. In mouse studies, P2ry13 and P2ry14-purinergic receptors activated by adenosine 5-diphosphate and UDP-sugars, respectively-were upregulated after allergen challenge, notably in airway epithelial cells, eosinophils, and neutrophils. Intranasal exposure with receptor agonists induced the release of IL-33 and subsequent eosinophil infiltration into the lungs. Conclusion: We identified novel associations between asthma and eQTLs for 4 genes related to nucleotide synthesis/signaling and demonstrated the power of gene-based analyses of GWASs.	[Ferreira, Manuel A. R.; Bain, Lisa M.; Vicente, Cristina T.; Revez, Joana A.; Montgomery, Grant W.; Martin, Nicholas G.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Jansen, Rick; Penninx, Brenda] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Willemsen, Gonneke; Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands; [Hui, Jennie; Hopper, John L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Hui, Jennie] PathWest Lab Med Western Australia, Nedlands, WA, Australia; [Hui, Jennie] Univ Western Australia, Sch Populat Hlth, Nedlands, WA, Australia; [Hui, Jennie] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA, Australia; [James, Alan; Thompson, Philip J.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia; [Hui, Jennie; James, Alan] Sir Charles Gairdner Hosp, Busselton Populat Med Res Fdn, Nedlands, WA, Australia; [Tung, Joyce Y.; Hinds, David A.] 23andMe Inc, Mountain View, CA USA; [Baltic, Svetlana; Thompson, Philip J.] Harry Perkins Inst Med Res, Inst Resp Hlth, Nedlands, WA, Australia; [Le Souef, Peter] Princess Margaret Hosp Children, Sch Paediat & Child Hlth, Subiaco, WA, Australia; [Robertson, Colin F.] Murdoch Childrens Res Inst, Resp Med, Melbourne, Vic, Australia; [James, Alan] West Australian Sleep Disorders Res Inst, Dept Pulm Physiol & Sleep Med, Nedlands, WA, Australia; [Werder, Rhiannon B.; Phipps, Simon] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; University of Melbourne; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; Harry Perkins Institute of Medical Research; Murdoch Children's Research Institute; University of Queensland	Ferreira, MAR (corresponding author), Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Locked Bag 2000, Herston, Qld 4029, Australia.	manuel.ferreira@qimrberghofer.edu.au	Werder, Rhiannon/AAL-5192-2021; Hui, Jennie/A-9543-2013; Bain, Lisa/R-9884-2017; Phipps, Simon/F-9170-2010; Matheson, Melanie C/O-4721-2015; Revez, Joana/ABA-2920-2020; Penninx, Brenda WJH/S-7627-2017; Boomsma, Dorret I/AAX-4470-2020; Montgomery, Grant W/B-7148-2008; Vicente, Cristina/ABD-3690-2020; Le Souef, Peter N/H-5256-2014	Werder, Rhiannon/0000-0002-6432-4587; Hui, Jennie/0000-0002-1653-2496; Phipps, Simon/0000-0002-7388-3612; Matheson, Melanie C/0000-0002-5822-3499; Revez, Joana/0000-0003-3204-5396; Penninx, Brenda WJH/0000-0001-7779-9672; Montgomery, Grant W/0000-0002-4140-8139; Jansen, Rick/0000-0002-3333-6737; Willemsen, Gonneke/0000-0003-3755-0236; Hinds, David/0000-0002-4911-803X; Le Souef, Peter/0000-0003-0930-1654; Teixeira Vicente, Cristina/0000-0002-7882-9543	National Human Genome Research Institute of the National Institutes of Health [R44HG006981]; National Health and Medical Research Council of Australia [613627, APP1036550]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL115873] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R44HG006981] Funding Source: NIH RePORTER	National Human Genome Research Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported in part by the National Human Genome Research Institute of the National Institutes of Health (R44HG006981) and the National Health and Medical Research Council of Australia (613627 and APP1036550).	Arase T, 2009, J IMMUNOL, V182, P7074, DOI 10.4049/jimmunol.0900001; Barrett MO, 2013, MOL PHARMACOL, V84, P41, DOI 10.1124/mol.113.085654; Berndt SI, 2013, NAT GENET, V45, P501, DOI 10.1038/ng.2606; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Davidson S, 2011, J IMMUNOL, V186, P5938, DOI 10.4049/jimmunol.1002635; Ferreira MAR, 2014, TWIN RES HUM GENET, V17, P505, DOI 10.1017/thg.2014.59; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Galesloot TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095923; Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367; Gao ZG, 2010, PHARMACOL RES, V62, P500, DOI 10.1016/j.phrs.2010.08.003; Gao ZG, 2010, BIOCHEM PHARMACOL, V79, P873, DOI 10.1016/j.bcp.2009.10.024; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506; Harden TK, 2010, ACTA PHYSIOL, V199, P149, DOI 10.1111/j.1748-1716.2010.02116.x; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Inoue K, 2007, J INVEST DERMATOL, V127, P362, DOI 10.1038/sj.jid.5700526; Jacquet S, 2005, CELL MOL LIFE SCI, V62, P2508, DOI 10.1007/s00018-005-5194-0; Jokela TA, 2014, J BIOL CHEM, V289, P18569, DOI 10.1074/jbc.M114.551804; Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6236; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kreda SM, 2007, J PHYSIOL-LONDON, V584, P245, DOI 10.1113/jphysiol.2007.139840; Kreda SM, 2010, J PHYSIOL-LONDON, V588, P2255, DOI 10.1113/jphysiol.2009.186643; Kuga W, 2008, BIOCHEM BIOPH RES CO, V377, P1062, DOI 10.1016/j.bbrc.2008.10.143; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lazarowski ER, 2010, ANAL BIOCHEM, V396, P23, DOI 10.1016/j.ab.2009.08.022; Lazarowski ER, 2003, MOL PHARMACOL, V63, P1190, DOI 10.1124/mol.63.5.1190; Ledderose C, 2014, J BIOL CHEM, V289, P25936, DOI 10.1074/jbc.M114.575308; Li MX, 2011, AM J HUM GENET, V88, P283, DOI 10.1016/j.ajhg.2011.01.019; Liao WC, 2015, PLACENTA, V36, P357, DOI 10.1016/j.placenta.2015.01.008; Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Meyer B, 2007, MOL CELL PROTEOMICS, V6, P1690, DOI 10.1074/mcp.M700097-MCP200; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Muller T, 2005, AM J RESP CELL MOL, V33, P601, DOI 10.1165/rcmb.2005-0181OC; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Ohsakaya S, 2011, J BIOL CHEM, V286, P20292, DOI 10.1074/jbc.M110.198523; Okada SF, 2011, AM J RESP CELL MOL, V45, P253, DOI 10.1165/rcmb.2010-0253OC; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Pierce BL, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004818; Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012; Sesma JI, 2012, AM J PHYSIOL-CELL PH, V303, pC490, DOI 10.1152/ajpcell.00138.2012; Shin A, 2008, BLOOD, V111, P3062, DOI 10.1182/blood-2007-02-071910; Soranzo N, 2009, NAT GENET, V41, P1182, DOI 10.1038/ng.467; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Ullah MA, 2015, J ALLERGY CLIN IMMUN, V136, P1065, DOI 10.1016/j.jaci.2015.02.032; Vantourout P, 2010, WORLD J GASTROENTERO, V16, P5925, DOI 10.3748/wjg.v16.i47.5925; Vicente CT, 2015, AM J HUM GENET, V97, P329, DOI 10.1016/j.ajhg.2015.06.010; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Xu JF, 2012, J IMMUNOL, V189, P1992, DOI 10.4049/jimmunol.1103207; Yip L, 2009, FASEB J, V23, P1685, DOI 10.1096/fj.08-126458; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693; Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705	59	46	47	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1148	1157		10.1016/j.jaci.2016.07.017	http://dx.doi.org/10.1016/j.jaci.2016.07.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27554816	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000398771800010
J	Speckmann, C; Doerken, S; Aiuti, A; Albert, MH; Al-Herz, W; Allende, LM; Scarselli, A; Avcin, T; Perez-Becker, R; Cancrini, C; Cant, A; Di Cesare, S; Finocchi, A; Fischer, A; Gaspar, HB; Ghosh, S; Gennery, A; Gilmour, K; Gonzalez-Granado, LI; Martinez-Gallo, M; Hambleton, S; Hauck, F; Hoenig, M; Moshous, D; Neven, B; Niehues, T; Notarangelo, L; Picard, C; Rieber, N; Schulz, A; Schwarz, K; Seidel, MG; Soler-Palacin, P; Stepensky, P; Strahm, B; Vraetz, T; Warnatz, K; Winterhalter, C; Worth, A; Fuchs, S; Uhlmann, A; Ehl, S				Speckmann, Carsten; Doerken, Sam; Aiuti, Alessandro; Albert, Michael H.; Al-Herz, Waleed; Allende, Luis M.; Scarselli, Alessia; Avcin, Tadej; Perez-Becker, Ruy; Cancrini, Caterina; Cant, Andrew; Di Cesare, Silvia; Finocchi, Andrea; Fischer, Alain; Gaspar, H. Bobby; Ghosh, Sujal; Gennery, Andrew; Gilmour, Kimberly; Gonzalez-Granado, Luis I.; Martinez-Gallo, Monica; Hambleton, Sophie; Hauck, Fabian; Hoenig, Manfred; Moshous, Despina; Neven, Benedicte; Niehues, Tim; Notarangelo, Luigi; Picard, Capucine; Rieber, Nikolaus; Schulz, Ansgar; Schwarz, Klaus; Seidel, Markus G.; Soler-Palacin, Pere; Stepensky, Polina; Strahm, Brigitte; Vraetz, Thomas; Warnatz, Klaus; Winterhalter, Christine; Worth, Austen; Fuchs, Sebastian; Uhlmann, Annette; Ehl, Stephan		P-CID Study Inborn Errors Working	A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell deficiency; combined immunodeficiency; hematopoietic stem cell transplantation; natural history	DIAGNOSTIC-CRITERIA; DEFICIENCY; SELECTION; FEATURES	Background: Absent T-cell immunity resulting in life-threatening infections provides a clear rationale for hematopoetic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency ( SCID). Combined immunodeficiencies (CIDs) and "atypical" SCID show reduced, not absent T-cell immunity. If associated with infections or autoimmunity, they represent profound combined immunodeficiency (P-CID), for which outcome data are insufficient for unambiguous early transplant decisions. Objectives: We sought to compare natural histories of severity-matched patients with/without subsequent transplantation and to determine whether immunologic and/or clinical parameters may be predictive for outcome. Methods: In this prospective and retrospective observational study, we recruited nontransplanted patients with P-CID aged 1 to 16 years to compare natural histories of severity-matched patients with/without subsequent transplantation and to determine whether immunologic and/or clinical parameters may be predictive for outcome. Results: A total of 51 patients were recruited (median age, 9.6 years). Thirteen of 51 had a genetic diagnosis of "atypical" SCID and 14 of 51 of CID. About half of the patients had less than 10% naive T cells, reduced/absent T-cell proliferation, and at least 1 significant clinical event/year, demonstrating their profound immunodeficiency. Nineteen patients (37%) underwent transplantation within 1 year of enrolment, and 5 of 51 patients died. Analysis of the HSCT decisions revealed the anticipated heterogeneity, favoring an ongoing prospective matched-pair analysis of patients with similar disease severity with or without transplantation. Importantly, so far neither the genetic diagnosis nor basic measurements of T-cell immunity were good predictors of disease evolution. Conclusions: The P-CID study for the first time characterizes a group of patients with nontypical SCID T-cell deficiencies from a therapeutic perspective. Because genetic and basic T-cell parameters provide limited guidance, prospective data from this study will be a helpful resource for guiding the difficult HSCT decisions in patients with P-CID.	[Speckmann, Carsten; Strahm, Brigitte; Vraetz, Thomas; Fuchs, Sebastian] Univ Freiburg, Fac Med, Dept Pediat Hematol & Oncol, Ctr Pediat,Med Ctr, Freiburg, Germany; [Speckmann, Carsten; Fuchs, Sebastian; Uhlmann, Annette; Ehl, Stephan] Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency, Med Ctr, Freiburg, Germany; [Doerken, Sam] Univ Freiburg, Inst Med Biometry & Stat, Ctr Med Biometry & Med Informat, Med Ctr, Freiburg, Germany; [Aiuti, Alessandro; Scarselli, Alessia] Ist Sci San Raffaele, Pediat Immunohematol & Bone Marrow Transplant Uni, Milan, Italy; [Aiuti, Alessandro] Osped Pediat Bambino Gesu, Dept Pediat, Rome, Italy; [Aiuti, Alessandro; Cancrini, Caterina; Di Cesare, Silvia] Univ Roma Tor Vergata, Rome, Italy; [Albert, Michael H.] Ludwig Maximilians Univ Munchen, Dr Von Hauner Childrens Hosp, Munich, Germany; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Allende, Luis M.] Hosp Univ 12 Octubre, Serv Inmunol, Madrid, Spain; [Allende, Luis M.] Inst Invest 12, Madrid, Spain; [Avcin, Tadej] Univ Med Ctr, Univ Childrens Hosp, Dept Allergol Rheumatol & Clin Immunol, Ljubljana, Slovenia; [Perez-Becker, Ruy] Helios Hosp Krefeld, Ctr Pediat & Adolescent Med, Krefeld, Germany; [Cant, Andrew; Gennery, Andrew; Hambleton, Sophie] Newcastle Univ, Immunodeficiency Grp, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Fischer, Alain; Neven, Benedicte; Picard, Capucine] Hop Necker Enfants Malad, AP HP, Immunol & Hematol Pediat, Paris, France; [Gaspar, H. Bobby; Gilmour, Kimberly] Great Ormond St Hosp NHS Fdn Trust, Dept Immunol, London, England; [Ghosh, Sujal] Heinrich Heine Univ, Ctr Child & Adolescent Hlth, Dept Pediat Oncol Hematol & Clin Immunol, Fac Med, Dusseldorf, Germany; [Gonzalez-Granado, Luis I.] Hosp 12 Octubre, Immunodeficiencies Unit, Hematol & Oncol Unit, Madrid, Spain; [Martinez-Gallo, Monica; Soler-Palacin, Pere] Univ Autonoma Barcelona, Vall Hebron Inst Recerca, Div Immunol, Hosp Univ Vall Hebron, Barcelona, Spain; [Hauck, Fabian] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Immunodeficiency Unit & Immunol Diagnost Lab, Munich, Germany; [Notarangelo, Luigi] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Picard, Capucine] Harvard Med Sch, Div Immunol, Boston Childrens Hosp, Boston, MA USA; [Picard, Capucine] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Rieber, Nikolaus] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Genome Dynam Immune Syst,INSERM UMR1163, Paris, France; [Rieber, Nikolaus; Stepensky, Polina] Univ Tubingen, Dept Pediat 1, Tubingen, Germany; [Seidel, Markus G.] StKM GmbH, Dept Pediat, Munich, Germany; [Seidel, Markus G.] Tech Univ Muenchen, Munich, Germany; [Stepensky, Polina] Univ Ulm, Ulm, Germany; [Stepensky, Polina] Baden Wurttemberg Hessen, German Red Cross Blood Serv, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany; [Seidel, Markus G.] Med Univ Graz, Div Pediat Hematol Oncol, Dept Pediat & Adolescent Med, Graz, Austria; [Stepensky, Polina] Hadassah Hebrew Univ Hosp, Pediat Hematol Oncol & Bone Marrow Transplantat, Jerusalem, Israel; [Winterhalter, Christine; Uhlmann, Annette] Univ Freiburg, Med Ctr, Clin Trials Unit, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Bambino Gesu; University of Rome Tor Vergata; University of Munich; Kuwait University; Hospital Universitario 12 de Octubre; University Medical Centre Ljubljana; Newcastle University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Heinrich Heine University Dusseldorf; Hospital Universitario 12 de Octubre; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Munich; Ulm University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Eberhard Karls University of Tubingen; Technical University of Munich; Ulm University; Medical University of Graz; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Freiburg	Ehl, S (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany.	stephan.ehl@uniklinik-freiburg.de	Soler-Palacin, Pere/N-2373-2014; Warnatz, Klaus/AAD-3464-2022; Gonzalez-Granado, Luis Ignacio/ABG-4515-2020; Ehl, Stephan/AAM-6006-2020; Moshous, Despina/B-7507-2017; Finocchi, Andrea/K-5926-2016; DI CESARE, SILVIA/AAB-5754-2020; AIUTI, ALESSANDRO/K-3918-2016; scarselli, alessia/AAB-5815-2020; Martinez-Gallo, Monica/S-1368-2019; Gonzalez-Granado, Luis Ignacio/B-9257-2009; Hauck, Fabian/H-5556-2016; Seidel, Markus G/N-9951-2017	Soler-Palacin, Pere/0000-0002-0346-5570; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Moshous, Despina/0000-0001-6719-3693; Finocchi, Andrea/0000-0003-0958-8536; DI CESARE, SILVIA/0000-0002-9912-7997; AIUTI, ALESSANDRO/0000-0002-5398-1717; Martinez-Gallo, Monica/0000-0002-7340-2161; Gonzalez-Granado, Luis Ignacio/0000-0001-6917-8980; Seidel, Markus G/0000-0003-0981-8661; /0000-0001-9586-8539; Speckmann, Carsten/0000-0002-6217-1556; Fuchs, Sebastian/0000-0001-9191-7970; Hauck, Fabian/0000-0001-9644-2003; Hambleton, Sophie/0000-0001-7954-3267; Ehl, Stephan/0000-0002-9265-2721	German Federal Ministry of Education and Research (BMBF) [01 EO 0803]; Chaim Roifman Scholar Award from the Canadian Immunodeficiency Society; European Union [N8643578]; The Sir Jules Thorn Charitable Trust [12JTA] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Chaim Roifman Scholar Award from the Canadian Immunodeficiency Society; European Union(European Commission); The Sir Jules Thorn Charitable Trust; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The P-CID study is funded by the German Federal Ministry of Education and Research (BMBF grant no. 01 EO 0803) and a Chaim Roifman Scholar Award from the Canadian Immunodeficiency Society. This project has further received funding from the European Union's Horizon 2020 Research and Innovation Programme under the ERA-NET Cofund action N8643578.	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Ameratunga R, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00415; [Anonymous], 2015, ESID REG WORK DEF CL; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Dvorak CC, 2013, J CLIN IMMUNOL, V33, P1156, DOI 10.1007/s10875-013-9917-y; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Fuchs S, 2014, EUR J IMMUNOL, V44, P3129, DOI 10.1002/eji.201444689; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Hauck F, 2015, CLIN IMMUNOL, V161, P103, DOI 10.1016/j.clim.2015.07.002; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; Speckmann C., 2015, LYMPHOSIGN J, V2, P91; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Wolkewitz M, 2010, AM STAT, V64, P205, DOI 10.1198/tast.2010.08259; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	27	46	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1302	+		10.1016/j.jaci.2016.07.040	http://dx.doi.org/10.1016/j.jaci.2016.07.040			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27658761	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000398771800025
J	Hofman, ZLM; Relan, A; Zeerleder, S; Drouet, C; Zuraw, B; Hack, CE				Hofman, Zonne L. M.; Relan, Anurag; Zeerleder, Sacha; Drouet, Christian; Zuraw, Bruce; Hack, C. Erik			Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hereditary angioedema; angioedema attack; human C1-inhibitor; efficacy; complement system; contact system	MOLECULAR-WEIGHT KININOGEN; XII HAGEMAN-FACTOR; BRADYKININ-RECEPTOR ANTAGONIST; PLASMA PROTEINASE-INHIBITORS; HUMAN LUNG FIBROBLASTS; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; C1 INHIBITOR; IN-VIVO; CARBOXYPEPTIDASE-M	Hereditary angioedema (HAE) caused by a deficiency of functional C1-inhibitor (C1INH) becomes clinically manifest as attacks of angioedema. C1INH is the main inhibitor of the contact system. Poor control of a local activation process of this system at the site of the attack is believed to lead to the formation of bradykinin (BK), which increases local vasopermeability and mediates angioedema on interaction with BK receptor 2 on the endothelium. However, several observations in patients with HAE are difficult to explain from a pathogenic model claiming a local activation process at the site of the angioedema attack. Therefore we postulate an alternative model for angioedema attacks in patients with HAE, which assumes a systemic, fluid-phase activation of the contact system to generate BK and its breakdown products. Interaction of these peptides with endothelial receptors that are locally expressed in the affected tissues rather than with receptors constitutively expressed by the endothelium throughout the whole body explains that such a systemic activation process results in local manifestations of an attack. In particular, BK receptor 1, which is induced on the endothelium by inflammatory stimuli, such as kinins and cytokines, meets the specifications of the involved receptor. The pathogenic model discussed here also provides an explanation for why angioedema can occur at multiple sites during an attack and why HAE attacks respond well to modest increases of circulating C1INH activity levels because inhibition of fluid-phase Factor XIIa and kallikrein requires lower C1INH levels than inhibition of activator-bound factors.	[Hofman, Zonne L. M.; Hack, C. Erik] Univ Med Ctr Utrecht, Lab Translat Immunol, Lundlaan 6, Utrecht, Netherlands; [Relan, Anurag] Pharming Technol BV, Leiden, Netherlands; [Zeerleder, Sacha] Acad Med Ctr, Dept Immunopathol, Sanquin Res, Amsterdam, Netherlands; [Zeerleder, Sacha] Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands; [Drouet, Christian] Univ Grenoble 1, Grenoble, France; [Zuraw, Bruce] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Zuraw, Bruce] San Diego VA Healthcare, La Jolla, CA USA	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of California System; University of California San Diego	Hack, CE (corresponding author), Univ Med Ctr Utrecht, Lab Translat Immunol, Lundlaan 6, Utrecht, Netherlands.	C.E.Hack@UMCUtrecht.nl	DROUET, Christian/AAE-5682-2020; Relan, Anurag/AAA-7372-2022; DROUET, Christian/J-8775-2019; Levi, Marcel/AAZ-8559-2020	DROUET, Christian/0000-0003-1318-4278; DROUET, Christian/0000-0003-1318-4278; Zuraw, Bruce/0000-0003-0640-6768; Relan, Anurag/0000-0002-5521-4538	University Medical Center Utrecht; Viropharma; GREPI; Ionis	University Medical Center Utrecht; Viropharma; GREPI; Ionis	Z. L. M. Hofman receives research support from University Medical Center Utrecht. A. Relan is an employee of and stockholder in Pharming Technologies. S. Zeerleder receives research support from Viropharma. C. Drouet receives research support from GREPI and travel support from UCSD and the National Institutes of health. B. Zuraw serves as a consultant for Allan, Arrowhead, BioCryst, CSL Behring, Dyax, Ionis, Nektar, Shire and Salix; receives clinical research support from Ionis and received travel assistances from US HAEA. C. E. Hack is the founder of and a stockholder in Prothix BV.	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Arcoleo F, 2014, CLIN CHEM LAB MED, V52, pE91, DOI 10.1515/cclm-2013-1008; Barratt-Due A, 2011, SHOCK, V36, P517, DOI 10.1097/SHK.0b013e3182336a34; BERRETTINI M, 1986, BLOOD, V68, P455; Blais C, 1999, PEPTIDES, V20, P421, DOI 10.1016/S0196-9781(99)00020-0; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bossi F, 2009, J ALLERGY CLIN IMMUN, V124, P1303, DOI 10.1016/j.jaci.2009.08.007; Brovkovych V, 2011, J CELL MOL MED, V15, P258, DOI 10.1111/j.1582-4934.2009.00992.x; Cayla C, 2007, FASEB J, V21, P1689, DOI 10.1096/fj.06-7175com; CHAN JYC, 1977, BIOCHEM BIOPH RES CO, V74, P150, DOI 10.1016/0006-291X(77)91387-0; Charignon D, 2014, ALLERGY, V69, P1659, DOI 10.1111/all.12515; Charignon D, 2012, EXPERT OPIN PHARMACO, V13, P2233, DOI 10.1517/14656566.2012.723692; Christiansen SC, 2002, J IMMUNOL, V169, P2054, DOI 10.4049/jimmunol.169.4.2054; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Cicardi M, 2010, NEW ENGL J MED, V363, P523, DOI 10.1056/NEJMoa0905079; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; Csuka D, 2012, MOL IMMUNOL, V49, P649, DOI 10.1016/j.molimm.2011.11.005; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Cugno M, 1996, IMMUNOPHARMACOLOGY, V33, P361, DOI 10.1016/0162-3109(96)00086-0; CUGNO M, 1993, J LAB CLIN MED, V121, P38; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; Defendi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070140; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Dobo J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020036; DORS DM, 1992, THROMB HAEMOSTASIS, V67, P644; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; DUNN JT, 1982, J CLIN INVEST, V70, P627, DOI 10.1172/JCI110656; Enquist J, 2007, MOL PHARMACOL, V71, P494, DOI 10.1124/mol.106.030858; Erdos EG, 2002, CARDIOVASC RES, V54, P485, DOI 10.1016/S0008-6363(02)00284-5; Etscheid M, 2002, BIOL CHEM, V383, P1633, DOI 10.1515/BC.2002.184; Faxalv L, 2013, BLOOD, V122, P3818, DOI 10.1182/blood-2013-05-499384; Gailani D, 2007, ARTERIOSCL THROM VAS, V27, P2507, DOI 10.1161/ATVBAHA.107.155952; GHEBREHIWET B, 1981, J EXP MED, V153, P665, DOI 10.1084/jem.153.3.665; Gompels MM, 2002, J CLIN PATHOL, V55, P145, DOI 10.1136/jcp.55.2.145; Hack CE, 2012, ALLERGY, V67, P123, DOI 10.1111/j.1398-9995.2011.02716.x; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hofman ZLM, 2014, CLIN EXP IMMUNOL, V177, P280, DOI 10.1111/cei.12314; Hofman ZLM, 2016, CLIN REV ALLERG IMMU, V50, P34, DOI 10.1007/s12016-014-8463-6; Joseph K, 2004, THROMB HAEMOSTASIS, V91, P61, DOI 10.1160/TH03-07-0471; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2013, J ALLERGY CLIN IMMUN, V132, P470, DOI 10.1016/j.jaci.2013.03.026; Joseph K, 2010, ANN ALLERG ASTHMA IM, V104, P50, DOI 10.1016/j.anai.2009.11.014; Kaplan AP, 1998, CLIN REV ALLERG IMMU, V16, P403, DOI 10.1007/BF02737659; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; Konings J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074043; Kusuma A, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.12.016; LAMMLE B, 1988, THROMB HAEMOSTASIS, V59, P151; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Longhurst H, 2012, LANCET, V379, P474, DOI 10.1016/S0140-6736(11)60935-5; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Maas C, 2008, J CLIN INVEST, V118, P3208, DOI [10.1172/JC135424, 10.1172/JCI35424]; Magerl M, 2014, CLIN EXP DERMATOL, V39, P298, DOI 10.1111/ced.12285; Marceau F, 2002, INT IMMUNOPHARMACOL, V2, P1729, DOI 10.1016/S1567-5769(02)00189-3; Marceau F, 1998, PHARMACOL REV, V50, P357; McLean PG, 2000, J EXP MED, V192, P367, DOI 10.1084/jem.192.3.367; Merino VF, 2008, J MOL MED, V86, P791, DOI 10.1007/s00109-008-0345-z; Muller F, 2009, CELL, V139, P1143, DOI 10.1016/j.cell.2009.11.001; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; NUIJENS JH, 1988, BLOOD, V72, P1841; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; OGSTON D, 1969, J CLIN INVEST, V48, P1786, DOI 10.1172/JCI106145; Oschatz C, 2011, IMMUNITY, V34, P258, DOI 10.1016/j.immuni.2011.02.008; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pathak M, 2015, J THROMB HAEMOST, V13, P580, DOI 10.1111/jth.12849; Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325; PIXLEY RA, 1987, ARCH BIOCHEM BIOPHYS, V256, P490, DOI 10.1016/0003-9861(87)90606-0; PIXLEY RA, 1985, J BIOL CHEM, V260, P1723; Prechel MM, 1995, J PHARMACOL EXP THER, V275, P1136; Prematta MJ, 2009, ALLERGY ASTHMA PROC, V30, P506, DOI 10.2500/aap.2009.30.3279; RATNOFF OD, 1958, AM J MED, V25, P160, DOI 10.1016/0002-9343(58)90023-8; Ravindran S, 2004, THROMB HAEMOSTASIS, V92, P1277, DOI 10.1160/TH04-01-0008; REGOLI DC, 1981, EUR J PHARMACOL, V71, P105, DOI 10.1016/0014-2999(81)90391-5; Sanchez J, 2008, THROMB RES, V122, P257, DOI 10.1016/j.thromres.2007.11.008; Sangsree S, 2003, AM J PHYSIOL-HEART C, V284, pH1959, DOI 10.1152/ajpheart.00036.2003; Schanstra JP, 1998, J CLIN INVEST, V101, P2080, DOI 10.1172/JCI1359; SCHAPIRA M, 1982, J CLIN INVEST, V69, P462, DOI 10.1172/JCI110470; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; Schmaier AH, 2008, INT IMMUNOPHARMACOL, V8, P161, DOI 10.1016/j.intimp.2007.08.022; Schousboe I, 2003, EUR J BIOCHEM, V270, P111, DOI 10.1046/j.1432-1033.2003.03367.x; Schremmer-Danninger E, 1998, BIOCHEM BIOPH RES CO, V243, P246, DOI 10.1006/bbrc.1997.7999; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; SIEBECK M, 1994, J APPL PHYSIOL, V77, P2675, DOI 10.1152/jappl.1994.77.6.2675; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; Stanisavljevic S, 2006, J PHARMACOL EXP THER, V316, P1153, DOI 10.1124/jpet.105.093849; Suffritti C, 2014, CLIN EXP ALLERGY, V44, P1503, DOI 10.1111/cea.12293; van der Meijden PEJ, 2009, BLOOD, V114, P881, DOI 10.1182/blood-2008-07-171066; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; VANDERGRAAF F, 1983, J CLIN INVEST, V71, P149, DOI 10.1172/JCI110743; VANHOOF G, 1992, BIOCHEM PHARMACOL, V44, P479, DOI 10.1016/0006-2952(92)90439-P; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621; Wuillemin WA, 1996, BRIT J HAEMATOL, V93, P950, DOI 10.1046/j.1365-2141.1996.d01-1740.x; Zhang XM, 2008, J BIOL CHEM, V283, P7994, DOI 10.1074/jbc.M709837200; Zhang XM, 2013, J BIOL CHEM, V288, P33226, DOI 10.1074/jbc.M113.520791; Zhang XM, 2011, J BIOL CHEM, V286, P18547, DOI 10.1074/jbc.M110.214940; Zhang YK, 2007, J BIOL CHEM, V282, P32453, DOI 10.1074/jbc.M706242200; Zubakova R, 2008, INT IMMUNOPHARMACOL, V8, P276, DOI 10.1016/j.intimp.2007.10.001; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; Zuraw B, 2010, J ALLERGY CLIN IMMUN, V126, P821, DOI 10.1016/j.jaci.2010.07.021; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	109	46	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					359	366		10.1016/j.jaci.2016.02.041	http://dx.doi.org/10.1016/j.jaci.2016.02.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27246526	Bronze			2022-12-18	WOS:000380835800004
J	LeBovidge, JS; Elverson, W; Timmons, KG; Hawryluk, EB; Rea, C; Lee, M; Schneider, LC				LeBovidge, Jennifer S.; Elverson, Wendy; Timmons, Karol G.; Hawryluk, Elena B.; Rea, Corinna; Lee, Margaret; Schneider, Lynda C.			Multidisciplinary interventions in the management of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; eczema; multidisciplinary; education; treatment; quality of life; psychology; nutrition; nursing	THERAPEUTIC PATIENT EDUCATION; SHARED MEDICAL APPOINTMENTS; VITAMIN-D DEFICIENCY; COWS MILK ALLERGY; QUALITY-OF-LIFE; FOOD ALLERGY; CLINICAL MANAGEMENT; INITIAL VALIDATION; TRAINING-PROGRAM; BEDTIME PROBLEMS	Atopic dermatitis (AD) is the most common pediatric skin disease. AD has a significant effect on patient and family quality of life caused by intense pruritus, sleep disruption, dietary and nutritional concerns, and psychological stress associated with the disease and its management. Multidisciplinary approaches to AD care have been developed in appreciation of the complex interplay among biological, psychological, behavioral, and dietary factors that affect disease control and the wide range of knowledge, skills, and support that patients and families require to effectively manage and cope with this condition. Common components of multidisciplinary treatment approaches include medical evaluation and management by an AD specialist, education and nursing care, psychological and behavioral support, and nutritional assessment and guidance. Models of care include both clinical programs and structured educational groups provided as adjuncts to standard clinical care. Available evidence suggests beneficial effects of multidisciplinary interventions in improving disease severity and quality of life, particularly for patients with moderate-to-severe disease. Additional research is needed to identify the best candidates for the various multidisciplinary approaches and evaluate the cost-effectiveness of these programs.	[LeBovidge, Jennifer S.; Timmons, Karol G.; Schneider, Lynda C.] Boston Childrens Hosp, Div Immunol, Allergy Program, Boston, MA USA; [Elverson, Wendy] Boston Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Ctr Nutr, Boston, MA USA; [Hawryluk, Elena B.; Lee, Margaret] Boston Childrens Hosp, Div Immunol, Dermatol Program, Boston, MA USA; [Rea, Corinna] Boston Childrens Hosp, Dept Med, Div Gen Pediat, Boston, MA USA; [LeBovidge, Jennifer S.; Hawryluk, Elena B.; Rea, Corinna; Schneider, Lynda C.] Harvard Med Sch, Boston, MA USA; [Hawryluk, Elena B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; [Lee, Margaret] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Boston University	LeBovidge, JS (corresponding author), Boston Childrens Hosp, Div Immunol, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.	jennifer.lebovidge@childrens.harvard.edu		Hawryluk, Elena/0000-0002-0862-3339; Lee, Margaret/0000-0003-0421-6290	APGNN	APGNN	J. S. LeBovidge is a member of National Eczema Association Workgroup. W. Elverson has received lecture fees from APGNN. L. C. Schneider is on the National Eczema Association Scientific Advisory Board. The rest of the authors declare that they have no relevant conflicts of interest.	Ahrens B, 2015, PEDIAT ALLERG IMM-UK, V26, P190, DOI 10.1111/pai.12358; Alanne S, 2011, ACTA PAEDIATR, V100, pE65, DOI 10.1111/j.1651-2227.2011.02229.x; Aubert-Wastiaux H, 2011, BRIT J DERMATOL, V165, P808, DOI 10.1111/j.1365-2133.2011.10449.x; Bae BG, 2012, ACTA DERM-VENEREOL, V92, P57, DOI 10.2340/00015555-1189; Barbarot S, 2014, BRIT J DERMATOL, V170, P44, DOI 10.1111/bjd.12932; Barbarot S, 2013, PEDIATR DERMATOL, V30, P199, DOI 10.1111/pde.12045; Bath-Hextall F, 2009, ALLERGY, V64, P258, DOI 10.1111/j.1398-9995.2008.01917.x; Beebe DW, 2011, PEDIATR CLIN N AM, V58, P649, DOI 10.1016/j.pcl.2011.03.002; Boguniewicz M, 2008, SEMIN CUTAN MED SURG, V27, P115, DOI 10.1016/j.sder.2008.05.001; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Bostoen J, 2012, BRIT J DERMATOL, V167, P1025, DOI 10.1111/j.1365-2133.2012.11113.x; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Buske-Kirschbaum A, 2002, J NEUROIMMUNOL, V129, P161, DOI 10.1016/S0165-5728(02)00168-6; Camargo CA, 2014, J ALLERGY CLIN IMMUN, V134, P831, DOI 10.1016/j.jaci.2014.08.002; Camfferman D, 2013, INT J PSYCHOPHYSIOL, V89, P265, DOI 10.1016/j.ijpsycho.2013.01.006; Camfferman D, 2010, SLEEP MED REV, V14, P359, DOI 10.1016/j.smrv.2010.01.004; Canani RB, 2014, J ACAD NUTR DIET, V114, P1432, DOI 10.1016/j.jand.2014.03.018; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Chamlin SL, 2005, ARCH PEDIAT ADOL MED, V159, P745, DOI 10.1001/archpedi.159.8.745; Chamlin SL, 2004, PEDIATRICS, V114, P607, DOI 10.1542/peds.2004-0374; Chang A, 2016, J ALLER CL IMM-PRACT, V4, P229, DOI 10.1016/j.jaip.2015.08.006; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Chaudhry SB, 2013, J AM ACAD DERMATOL, V68, P738, DOI 10.1016/j.jaad.2012.10.034; Chiang C, 2009, PEDIATR DERMATOL, V26, P273, DOI 10.1111/j.1525-1470.2009.00911.x; Chida Y, 2007, INT ARCH ALLERGY IMM, V144, P1, DOI 10.1159/000101940; Chou JS, 2011, ALLERGY ASTHMA PROC, V32, P377, DOI 10.2500/aap.2011.32.3462; Christie L, 2002, J AM DIET ASSOC, V102, P1648, DOI 10.1016/S0002-8223(02)90351-2; Cork MJ, 2003, BRIT J DERMATOL, V149, P582, DOI 10.1046/j.1365-2133.2003.05595.x; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; De Marchi F, 2015, ALLERGY ASTHMA PROC, V36, pE127, DOI 10.2500/aap.2015.36.3872; Devillers ACA, 2006, BRIT J DERMATOL, V154, P579, DOI 10.1111/j.1365-2133.2006.07157.x; Duncan Christina L, 2014, Clin Pract Pediatr Psychol, V2, P322; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; Evers AWM, 2009, ACTA DERM-VENEREOL, V89, P57, DOI 10.2340/00015555-0556; Fiocchi A, 2010, J ALLERGY CLIN IMMUN, V126, P1119, DOI 10.1016/j.jaci.2010.10.011; Fishbein AB, 2015, J ALLERGY CLIN IMMUN, V136, P1170, DOI 10.1016/j.jaci.2015.08.028; Flammarion S, 2011, PEDIAT ALLERG IMM-UK, V22, P161, DOI 10.1111/j.1399-3038.2010.01028.x; Fogel AL, 2015, PEDIATR DERMATOL, V32, P825, DOI 10.1111/pde.12680; Grillo M, 2006, PEDIATR DERMATOL, V23, P428, DOI 10.1111/j.1525-1470.2006.00277.x; Gutman AB, 2005, ARCH DERMATOL, V141, P1556, DOI 10.1001/archderm.141.12.1556; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Henriksen C, 2000, ACTA PAEDIATR, V89, P272, DOI 10.1080/080352500750028393; Holick Michael F, 2011, J Clin Endocrinol Metab, V96, P1; Isolauri E, 1998, J PEDIATR-US, V132, P1004, DOI 10.1016/S0022-3476(98)70399-3; Jou PC, 2012, ARCH DERMATOL, V148, P847, DOI 10.1001/archdermatol.2012.774; Keller MD, 2012, ISR MED ASSOC J, V14, P40; Kupfer J, 2010, J PSYCHOSOM RES, V68, P353, DOI 10.1016/j.jpsychores.2009.04.014; Lambert J, 2011, ARCH DERMATOL RES, V303, P57, DOI 10.1007/s00403-010-1082-z; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Lawson V, 1998, BRIT J DERMATOL, V138, P107; LeBovidge JS, 2007, J PEDIATR PSYCHOL, V32, P617, DOI 10.1093/jpepsy/jsl045; Lewis-Jones MS, 2001, BRIT J DERMATOL, V144, P104, DOI 10.1046/j.1365-2133.2001.03960.x; LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942; Lio PA, 2014, J ALLER CL IMM-PRACT, V2, P361, DOI 10.1016/j.jaip.2014.02.015; Meadows S, 2016, J ALLERGY CLIN IMMUN, V4; Mehta H, 2013, CURR OPIN ALLERGY CL, V13, P275, DOI 10.1097/ACI.0b013e328360949d; Mejino A, 2012, ADOLESC HEALTH MED T, V3, P75, DOI 10.2147/AHMT.S32417; Meltzer LJ, 2014, J PEDIATR PSYCHOL, V39, P932, DOI 10.1093/jpepsy/jsu041; Meltzer LJ, 2010, BEHAV SLEEP MED, V8, P172, DOI 10.1080/15402002.2010.487464; Moore EJ, 2009, AUSTRALAS J DERMATOL, V50, P100, DOI 10.1111/j.1440-0960.2009.00515.x; Morgenthaler TI, 2006, SLEEP, V29, P1277; Nachshon L, 2014, J ALLERGY CLIN IMMUN, V134, P1108, DOI 10.1016/j.jaci.2014.06.026; Nicol NH, 2014, J ALLER CL IMM-PRACT, V2, P400, DOI 10.1016/j.jaip.2014.04.009; Nicol NH, 2010, IMMUNOL ALLERGY CLIN, V30, P369, DOI 10.1016/j.iac.2010.06.007; Nowak-Wegrzyn A, 2015, CHEM IMMUNOL ALLERGY, V101, P209, DOI 10.1159/000373904; Oh SH, 2010, ACTA DERM-VENEREOL, V90, P582, DOI 10.2340/00015555-0933; de Frutos FJO, 2014, ACTAS DERMO-SIFILOGR, V105, P487, DOI 10.1016/j.ad.2014.01.004; Owens JA, 2005, J CLIN SLEEP MED, V1, P49; Paller AS, 2002, CLIN PEDIATR, V41, P323, DOI 10.1177/000992280204100505; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Ricci G, 2009, PEDIATR DERMATOL, V26, P1, DOI 10.1111/j.1525-1470.2008.00813.x; Rolinck-Werninghaus C, 2015, PEDIAT ALLERG IMM-UK, V26, P805, DOI 10.1111/pai.12338; Rork JF, 2012, ARCH DERMATOL, V148, P391, DOI 10.1001/archdermatol.2011.2267; Ross AC, 2011, DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN D, P35; Santer M, 2013, J ADV NURS, V69, P2493, DOI 10.1111/jan.12133; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V108, P455, DOI 10.1067/mai.2001.117800; Schmitt J, 2011, ALLERGY, V66, P404, DOI 10.1111/j.1398-9995.2010.02487.x; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Schut C, 2012, J DTSCH DERMATOL GES, V10, P657, DOI 10.1111/j.1610-0387.2012.07920.x; Shi VY, 2013, JAMA DERMATOL, V149, P481, DOI 10.1001/jamadermatol.2013.2143; Silverberg JI, 2015, JAMA DERMATOL, V151, P401, DOI 10.1001/jamadermatol.2014.3432; Simpson EL, 2012, SEMIN CUTAN MED SURG, V31, pS6, DOI 10.1016/j.sder.2012.08.001; Springston EE, 2010, ANN ALLERG ASTHMA IM, V105, P287, DOI 10.1016/j.anai.2010.08.003; Staab D, 2006, BMJ-BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Staab D, 2002, PEDIAT ALLERG IMM-UK, V13, P84, DOI 10.1034/j.1399-3038.2002.01005.x; Stalder JF, 2013, PEDIATR DERMATOL, V30, P329, DOI 10.1111/pde.12024; Suarez AL, 2012, ACTA DERM-VENEREOL, V92, P7, DOI 10.2340/00015555-1188; Thompson MM, 2005, J AM ACAD DERMATOL, V53, pS214, DOI 10.1016/j.jaad.2005.04.065; Vestita M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/257879; Wall-Haas CL, 2012, J PEDIATR HEALTH CAR, V26, P37, DOI 10.1016/j.pedhc.2010.06.007; Wang SS, 2014, PEDIAT ALLERG IMM-UK, V25, P30, DOI 10.1111/pai.12167; Wenninger K, 2000, PATIENT EDUC COUNS, V40, P253, DOI 10.1016/S0738-3991(99)00074-9; Woo Baidal J, NUTR PEDIAT BASIC SC; Yaghmaie P, 2013, J ALLERGY CLIN IMMUN, V131, P428, DOI 10.1016/j.jaci.2012.10.041; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	97	46	48	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					325	334		10.1016/j.jaci.2016.04.003	http://dx.doi.org/10.1016/j.jaci.2016.04.003			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	DS5PY	27497275				2022-12-18	WOS:000380835800001
J	Han, YY; Forno, E; Gogna, M; Celedon, JC				Han, Yueh-Ying; Forno, Erick; Gogna, Mudita; Celedon, Juan C.			Obesity and rhinitis in a nationwide study of children and adults in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; central obesity; allergic rhinitis; nonallergic rhinitis; National Health and Nutrition Examination Survey	BODY-MASS INDEX; OBSTRUCTIVE SLEEP-APNEA; ALLERGIC RHINITIS; NUTRITION EXAMINATION; INCIDENT ASTHMA; ASSOCIATION; CHILDHOOD; ATOPY; PREVALENCE; DISEASES	Background: Obesity has been associated with higher risk of asthma and asthma severity both in children and adults. However, studies evaluating the relation between obesity and rhinitis have yielded conflicting results. Methods: We performed a cross-sectional study of obesity indicators and rhinitis using data from 8165 participants in the 2005-2006 National Health and Nutrition Examination Survey. Allergic rhinitis was defined as physician-diagnosed hay fever or allergy, the presence of symptoms in the past 12 months, and at least 1 positive allergen-specific IgE level. Nonallergic rhinitis was defined as a physician's diagnosis and symptoms but no positive allergen-specific IgE levels. Multivariate regression was used to assess the relationship between obesity and rhinitis in children and adults. Results: In adults, overweight or obesity was associated with increased odds of nonallergic rhinitis (adjusted odds ratio, 1.43; 95% CI, 1.06-1.93; P = .02). Similarly, central obesity was associated with increased odds of nonallergic rhinitis in adults (adjusted odds ratio, 1.61; 95% CI, 1.20-2.16; P < .01). In an analysis stratified by sex, the observed associations were attenuated and became nonstatistically significant in female adults but remained significant in male adults. Overweight, obesity, or central obesity were not associated with allergic rhinitis in adults. In children, central obesity was associated with reduced odds of allergic rhinitis (adjusted odds ratio, 0.35; 95% CI, 0.19-0.64; P < .01). After stratification by sex, this association was similar in female and male children. Conclusions: In adults, obesity is associated with increased odds of nonallergic rhinitis, particularly in male subjects. In children, central obesity is associated with reduced odds of allergic rhinitis, regardless of sex.	[Han, Yueh-Ying; Forno, Erick; Gogna, Mudita; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Celedon, JC (corresponding author), UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885	US National Institutes of Health (NIH) [HL125666, HD052892]; NIH [HL079966, HL117191]; Heinz Endowments; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191, K08HL125666] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Heinz Endowments; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	E.F.'s contribution was supported by grants HL125666 HD052892 from the US National Institutes of Health (NIH). J.C.C.'s contribution was supported by grants HL079966 and HL117191 from the NIH and the Heinz Endowments.	[Anonymous], 2011, SAS PROGR CDC GROWTH; Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; Baumann S, 2013, INT ARCH ALLERGY IMM, V162, P205, DOI 10.1159/000353972; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Chen Y, 2006, CHEST, V130, P890, DOI 10.1378/chest.130.3.890; Chirakalwasan N, 2014, ASIAN PAC J ALLERGY, V32, P276; Coutinho T, 2013, J AM COLL CARDIOL, V61, P553, DOI 10.1016/j.jacc.2012.10.035; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, P1308, DOI 10.1016/j.jaci.2013.09.041; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Han YY, 2014, AM J RESP CRIT CARE, V190, P32, DOI 10.1164/rccm.201403-0565OC; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Kalpaklioglu AF, 2009, ANN ALLERG ASTHMA IM, V103, P20, DOI 10.1016/S1081-1206(10)60138-X; Kilpelainen M, 2006, RESP MED, V100, P1518, DOI 10.1016/j.rmed.2006.01.011; Kusunoki T, 2008, PEDIAT ALLERG IMM-UK, V19, P527, DOI 10.1111/j.1399-3038.2007.00686.x; Leiria LOS, 2015, METABOLISM, V64, P172, DOI 10.1016/j.metabol.2014.10.002; Leung TF, 2009, INT ARCH ALLERGY IMM, V149, P133, DOI 10.1159/000189196; Mai XM, 2003, ACTA PAEDIATR, V92, P1144, DOI 10.1080/08035250310005666; Mathis D, 2013, CELL METAB, V17, P851, DOI 10.1016/j.cmet.2013.05.008; Musaad SMA, 2009, J ALLERGY CLIN IMMUN, V123, P1321, DOI 10.1016/j.jaci.2009.03.023; Parikh NG, 2014, AM J RHINOL ALLERGY, V28, pE52, DOI 10.2500/ajra.2014.28.3977; Permaul P, 2014, ANN ALLERG ASTHMA IM, V113, P244, DOI 10.1016/j.anai.2014.07.001; Povitz M, 2015, ANN AM THORAC SOC, V12, P921, DOI 10.1513/AnnalsATS.201412-551OC; Radon K, 2006, J ALLERGY CLIN IMMUN, V118, P1279, DOI 10.1016/j.jaci.2006.08.033; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Rotiroti G, 2015, PEDIAT ALLERG IMM-UK, V26, P103, DOI 10.1111/pai.12339; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Sybilski AJ, 2015, PUBLIC HEALTH NUTR, V18, P530, DOI 10.1017/S1368980014000676; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weinmayr G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113996; Yanagisawa R, 2014, J APPL TOXICOL, V34, P688, DOI 10.1002/jat.2925; Yoo S, 2011, INT ARCH ALLERGY IMM, V154, P42, DOI 10.1159/000319207	38	46	46	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1460	1465		10.1016/j.jaci.2015.12.1307	http://dx.doi.org/10.1016/j.jaci.2015.12.1307			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26883461	Bronze, Green Accepted			2022-12-18	WOS:000376180200022
J	Jandl, K; Stacher, E; Balint, Z; Sturm, EM; Maric, J; Peinhaupt, M; Luschnig, P; Aringer, I; Fauland, A; Konya, V; Dahlen, SE; Wheelock, CE; Kratky, D; Olschewski, A; Marsche, G; Schuligoi, R; Heinemann, A				Jandl, Katharina; Stacher, Elvira; Balint, Zoltan; Sturm, Eva Maria; Maric, Jovana; Peinhaupt, Miriam; Luschnig, Petra; Aringer, Ida; Fauland, Alexander; Konya, Viktoria; Dahlen, Sven-Erik; Wheelock, Craig E.; Kratky, Dagmar; Olschewski, Andrea; Marsche, Gunther; Schuligoi, Rufina; Heinemann, Akos			Activated prostaglandin D-2 receptors on macrophages enhance neutrophil recruitment into the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						D-type prostanoid receptor 1; D-type prostanoid receptor 2/chemoattractant receptor-homologous molecule expressed on T(H)2 cells; prostaglandin D-2; hematopoietic prostaglandin D synthase; macrophages; pulmonary inflammation; neutrophils	CRTH2 ANTAGONIST OC000459; EOSINOPHILIC AIRWAY INFLAMMATION; HOMOLOGOUS MOLECULE; PULMONARY INFLAMMATION; ALLERGIC INFLAMMATION; ALVEOLAR MACROPHAGES; UP-REGULATION; DOUBLE-BLIND; T(H)2 CELLS; INJURY	Background: Prostaglandin (PG) D-2 is an early-phase mediator in inflammation, but its action and the roles of the 2 D-type prostanoid receptors (DPs) DP1 and DP2 (also called chemoattractant receptor-homologous molecule expressed on T(H)2 cells) in regulating macrophages have not been elucidated to date. Objective: We investigated the role of PGD(2) receptors on primary human macrophages, as well as primary murine lung macrophages, and their ability to influence neutrophil action in vitro and in vivo. Methods: In vitro studies, including migration, Ca2+ flux, and cytokine secretion, were conducted with primary human monocyte-derived macrophages and neutrophils and freshly isolated murine alveolar and pulmonary interstitial macrophages. In vivo pulmonary inflammation was assessed in male BALB/c mice. Results: Activation of DP1, DP2, or both receptors on human macrophages induced strong intracellular Ca2+ flux, cytokine release, and migration of macrophages. In a murine model of LPS-induced pulmonary inflammation, activation of each PGD(2) receptor resulted in aggravated airway neutrophilia, tissue myeloperoxidase activity, cytokine contents, and decreased lung compliance. Selective depletion of alveolar macrophages abolished the PGD(2)-enhanced inflammatory response. Activation of PGD(2) receptors on human macrophages enhanced the migratory capacity and prolonged the survival of neutrophils in vitro. In human lung tissue specimens both DP1 and DP2 receptors were located on alveolar macrophages along with hematopoietic PGD synthase, the rate-limiting enzyme of PGD(2) synthesis. Conclusion: For the first time, our results show that PGD(2) markedly augments disease activity through its ability to enhance the proinflammatory actions of macrophages and subsequent neutrophil activation.	[Jandl, Katharina; Sturm, Eva Maria; Maric, Jovana; Peinhaupt, Miriam; Luschnig, Petra; Aringer, Ida; Konya, Viktoria; Marsche, Gunther; Schuligoi, Rufina; Heinemann, Akos] Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria; [Stacher, Elvira] Med Univ Graz, Inst Pathol, A-8010 Graz, Austria; [Aringer, Ida] Med Univ Graz, Dept Internal Med, Div Nephrol, A-8010 Graz, Austria; [Kratky, Dagmar] Med Univ Graz, Inst Mol Biol & Biochem, A-8010 Graz, Austria; [Balint, Zoltan; Olschewski, Andrea] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria; [Fauland, Alexander; Wheelock, Craig E.] Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden; [Konya, Viktoria] Dept Med, Ctr Infect Med, Huddinge, Sweden; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res Unit, Stockholm, Sweden	Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz; Ludwig Boltzmann Institute; Karolinska Institutet	Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@medunigraz.at	Bálint, Zoltán/AAJ-3080-2020; Kratky, Dagmar/ABF-5699-2021	Schuligoi, Rufina/0000-0002-9338-6904; Heinemann, Akos/0000-0002-8554-2372; Balint, Zoltan/0000-0001-8598-2784; Marsche, Gunther/0000-0002-2422-5381; Sturm, Eva/0000-0003-4898-884X; Kratky, Dagmar/0000-0003-1357-7573; Konya, Viktoria/0000-0002-7999-9093; Fauland, Alexander/0000-0002-2239-1597; Olschewski, Andrea/0000-0002-8189-3634	Austrian Science Fund FWF [P22521-B18, P25531-B23, P26185-B19, P27070]; Austrian National Bank [14263, 14446]; Swedish Heart-Lung Foundation; PhD Program DK-MOLIN [FWF-W1241]; Austrian Science Fund (FWF) [P 22976, P 22521] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian National Bank; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); PhD Program DK-MOLIN; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Austrian Science Fund FWF (grant P22521-B18 to A.H., P25531-B23 to V.K., P26185-B19 to R.S., and P27070 to D.K.), the Austrian National Bank (grant 14263 to A.H. and 14446 to E.M.S.), and the Swedish Heart-Lung Foundation. K.J., J.M., and M.P. were funded by the PhD Program DK-MOLIN (FWF-W1241).	Balint Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063776; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Beck-Schimmer B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-61; Bohm E, 2004, J BIOL CHEM, V279, P7663, DOI 10.1074/jbc.M310270200; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; Dayer JM, 2004, BEST PRACT RES CL RH, V18, P31, DOI 10.1016/j.berh.2003.09.009; Dhaliwal K, 2012, AM J RESP CRIT CARE, V186, P514, DOI 10.1164/rccm.201112-2132OC; DOHERTY DE, 1988, LAB INVEST, V59, P200; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Gil MA, 2014, EUR J PHARMACOL, V743, P106, DOI 10.1016/j.ejphar.2014.09.021; Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943; Heinemann A, 2005, J ALLERGY CLIN IMMUN, V116, P820, DOI 10.1016/j.jaci.2005.06.008; Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065; Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042; Huang FF, 2011, AM J RESP CRIT CARE, V184, P259, DOI 10.1164/rccm.201012-2036OC; Ito Y, 2014, AM J PHYSIOL-LUNG C, V307, pL94, DOI 10.1152/ajplung.00233.2013; Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775; Konya V, 2014, J IMMUNOL, V192, P4774, DOI 10.4049/jimmunol.1302013; Krug N, 2014, J ALLERGY CLIN IMMUN, V133, P414, DOI 10.1016/j.jaci.2013.10.013; Kubota Y, 2001, CLIN DIAGN LAB IMMUN, V8, P1258, DOI 10.1128/CDLI.8.6.1258-1262.2001; LISTON TE, 1985, P NATL ACAD SCI USA, V82, P6030, DOI 10.1073/pnas.82.18.6030; Liu JW, 2012, BIOORG MED CHEM LETT, V22, P1686, DOI 10.1016/j.bmcl.2011.12.107; Lundstrom SL, 2013, J LIPID RES, V54, P116, DOI 10.1194/jlr.M030171; Luschnig-Schratl P, 2011, CELL MOL LIFE SCI, V68, P3573, DOI 10.1007/s00018-011-0642-5; Maniatis NA, 2008, CURR OPIN CRIT CARE, V14, P22, DOI 10.1097/MCC.0b013e3282f269b9; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Murata T, 2013, P NATL ACAD SCI USA, V110, P5205, DOI 10.1073/pnas.1218091110; Nemmar A, 2011, BRIT J PHARMACOL, V164, P1871, DOI 10.1111/j.1476-5381.2011.01442.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarashina H, 2014, J IMMUNOL, V192, P459, DOI 10.4049/jimmunol.1302080; Satoh T, 2006, J IMMUNOL, V177, P2621, DOI 10.4049/jimmunol.177.4.2621; Schicho R, 2012, PHARMACOLOGY, V89, P149, DOI 10.1159/000336871; Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836; Sedej M, 2012, J ALLERGY CLIN IMMUN, V129, P492, DOI 10.1016/j.jaci.2011.08.015; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Singh D, 2013, EUR RESPIR J, V41, P46, DOI 10.1183/09031936.00092111; Soehnlein O, 2008, BLOOD, V112, P1461, DOI 10.1182/blood-2008-02-139634; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Stebbins KJ, 2010, EUR J PHARMACOL, V638, P142, DOI 10.1016/j.ejphar.2010.04.031; Stinson SE, 2015, J ALLERGY CLIN IMMUN, V135, P395, DOI 10.1016/j.jaci.2014.08.027; Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096; Sturm EM, 2014, J IMMUNOL, V193, P827, DOI 10.4049/jimmunol.1303484; Tajima T, 2008, J PHARMACOL EXP THER, V326, P493, DOI 10.1124/jpet.108.137992; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006	46	46	49	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					833	843		10.1016/j.jaci.2015.11.012	http://dx.doi.org/10.1016/j.jaci.2015.11.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26792210	hybrid, Green Accepted			2022-12-18	WOS:000371897500027
J	Mikuls, TR; Payne, JB; Deane, KD; Thiele, GM				Mikuls, Ted R.; Payne, Jeffrey B.; Deane, Kevin D.; Thiele, Geoffrey M.			Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: The spark that lights the fire in rheumatoid arthritis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rheumatoid arthritis; autoantibody; mucosal inflammation; anti-citrullinated protein antibody; rheumatoid factor	CYCLIC CITRULLINATED PEPTIDE; PORPHYROMONAS-GINGIVALIS; PERIODONTAL-DISEASE; PROTEIN ANTIBODIES; CIGARETTE-SMOKING; LYMPHOID-TISSUE; INCREASED RISK; ASSOCIATION; MALONDIALDEHYDE; AUTOANTIBODIES	There is a growing body of evidence to suggest that autoimmunity in patients with rheumatoid arthritis (RA) is initiated outside the joint. This is supported by the observation that circulating autoantibodies, including both rheumatoid factor and anti-citrullinated protein antibody, can be detected in many subjects years before the development of initial joint symptoms leading to an RA diagnosis. Of the potential extra-articular sites implicated in disease initiation, mucosal tissues have garnered increasing attention. Several lines of investigation have separately implicated mucosal tissues from varying anatomic locations as possible initiating sites for RA, including those from the lung and oral cavity. In this review we summarize recent reports incriminating these mucosal tissues as the initial site of autoantibody generation and inflammation in patients with RA.	[Mikuls, Ted R.; Payne, Jeffrey B.; Thiele, Geoffrey M.] Univ Nebraska Med Ctr, Dept Med, Div Rheumatol, Coll Med, Omaha, NE 68198 USA; [Mikuls, Ted R.; Thiele, Geoffrey M.] Vet Affairs VA Nebraska Western Iowa Hlth Care Sy, Omaha, NE USA; [Payne, Jeffrey B.] Univ Nebraska Med Ctr, Coll Dent, Dept Surg Specialties, Div Periodont, Lincoln, NE 68198 USA; [Deane, Kevin D.] Univ Colorado, Div Rheumatol, Dept Med, Aurora, CO USA	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus	Mikuls, TR (corresponding author), Univ Nebraska Med Ctr, Dept Med, Div Rheumatol, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA.	tmikuls@unmc.edu		Payne, Jeffrey/0000-0001-9920-7746				Birnbaum H, 2010, CURR MED RES OPIN, V26, P77, DOI 10.1185/03007990903422307; BONAGURA VR, 1993, J IMMUNOL, V151, P3840; Bright R, 2015, MED HYPOTHESES, V84, P570, DOI 10.1016/j.mehy.2015.03.006; Cantley MD, 2011, J CLIN PERIODONTOL, V38, P532, DOI 10.1111/j.1600-051X.2011.01714.x; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; Cesta MF, 2006, TOXICOL PATHOL, V34, P599, DOI 10.1080/01926230600865531; Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007; Criswell LA, 2002, AM J MED, V112, P465, DOI 10.1016/S0002-9343(02)01051-3; Darrah E, 2015, ARTHRITIS RHEUMATOL, V67, P604, DOI 10.1002/art.38970; de Hair MJH, 2014, ARTHRITIS RHEUMATOL, V66, P513, DOI 10.1002/art.38273; de Pablo P, 2008, J RHEUMATOL, V35, P70; de Smit M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4061; Demoruelle MK, 2013, ARTHRITIS RHEUM-US, V65, P2243, DOI 10.1002/art.38017; Demoruelle MK, 2012, ARTHRITIS RHEUM-US, V64, P1756, DOI 10.1002/art.34344; Dissick A, 2010, J PERIODONTOL, V81, P223, DOI 10.1902/jop.2009.090309; Ebringer Alan, 2009, Front Biosci (Elite Ed), V1, P577; Falkenburg WJJ, 2015, ARTHRITIS RHEUMATOL, V67, P3124, DOI 10.1002/art.39299; Fischer A, 2012, RESP MED, V106, P1040, DOI 10.1016/j.rmed.2012.03.006; FRANKLIN EC, 1957, J EXP MED, V105, P425, DOI 10.1084/jem.105.5.425; Gan RW, 2015, J RHEUMATOL, V42, P572, DOI 10.3899/jrheum.140767; GARGIULO AV, 1982, J PERIODONTOL, V53, P568, DOI 10.1902/jop.1982.53.9.568; Giles JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098794; Harris ML, 2008, ARTHRITIS RHEUM-US, V58, P1958, DOI 10.1002/art.23596; Harvey GP, 2013, J PERIODONTAL RES, V48, P252, DOI 10.1111/jre.12002; Hitchon CA, 2010, J RHEUMATOL, V37, P1105, DOI 10.3899/jrheum.091323; Janssen KMJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0690-6; Kallberg H, 2007, AM J HUM GENET, V80, P867, DOI 10.1086/516736; Kallberg H, 2011, ANN RHEUM DIS, V70, P508, DOI 10.1136/ard.2009.120899; Kasser U, 1997, ARTHRITIS RHEUM, V40, P2248; Kaur S, 2014, SEMIN ARTHRITIS RHEU, V44, P113, DOI 10.1016/j.semarthrit.2014.04.009; Khatter S, 2014, ARTHRITIS RHEUMATO S, V66, ps2929; Klareskog L, 2006, ARTHRITIS RHEUM-US, V54, P38, DOI 10.1002/art.21575; Krishnan E, 2003, ARTHRITIS RES THER, V5, pR158, DOI 10.1186/ar750; Longman RS, 2015, CURR OPIN RHEUMATOL, V27, P381, DOI 10.1097/BOR.0000000000000190; Lundberg K, 2008, ARTHRITIS RHEUM-US, V58, P3009, DOI 10.1002/art.23936; Makrygiannakis D, 2008, ANN RHEUM DIS, V67, P1488, DOI 10.1136/ard.2007.075192; MALMSTROM M, 1975, SCAND J RHEUMATOL, V4, P49, DOI 10.3109/03009747509095615; Marchesan JT, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4376; Masson-Bessiere C, 2000, CLIN EXP IMMUNOL, V119, P544, DOI 10.1046/j.1365-2249.2000.01171.x; McCaskill ML, 2011, ALCOHOL CLIN EXP RES, V35, P1106, DOI 10.1111/j.1530-0277.2011.01443.x; McGhee JR, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001397; Mercado FB, 2001, J PERIODONTOL, V72, P779, DOI 10.1902/jop.2001.72.6.779; Mikuls TR, 2014, ARTHRITIS RHEUMATOL, V66, P1090, DOI 10.1002/art.38348; Mikuls TR, 2012, ARTHRITIS RHEUM-US, V64, P3522, DOI 10.1002/art.34595; Mikuls TR, 2009, INT IMMUNOPHARMACOL, V9, P38, DOI 10.1016/j.intimp.2008.09.008; Nesse W, 2012, J CLIN PERIODONTOL, V39, P599, DOI 10.1111/j.1600-051X.2012.01885.x; Nielen MMJ, 2004, ARTHRITIS RHEUM-US, V50, P380, DOI 10.1002/art.20018; Ogrendik Mesut, 2005, MedGenMed, V7, P2; Okada M, 2013, J PERIODONTOL, V84, pE74, DOI 10.1902/jop.2013.130079; Payne Jeffrey B, 2015, Curr Oral Health Rep, V2, P20; Pischon N, 2008, J PERIODONTOL, V79, P979, DOI [10.1902/jop.2008.070501, 10.1902/jop.2008.070501 ]; Quirke AM, 2015, ARTHRITIS RHEUMATOL, V67, P2335, DOI 10.1002/art.39226; Rangel-Moreno J, 2006, J CLIN INVEST, V116, P3183, DOI 10.1172/JCI28756; Reynisdottir G, 2014, ARTHRITIS RHEUMATO S, V66, ps434; Reynisdottir G, 2014, ARTHRITIS RHEUMATOL, V66, P31, DOI 10.1002/art.38201; Ribeiro J, 2005, J CLIN PERIODONTOL, V32, P412, DOI 10.1111/j.1600-051X.2005.00689.x; Rosenstein ED, 2004, INFLAMMATION, V28, P311, DOI 10.1007/s10753-004-6641-z; Schellekens GA, 2000, ARTHRITIS RHEUM-US, V43, P155, DOI 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3; Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202; Scher JU, 2012, ARTHRITIS RHEUM-US, V64, P3083, DOI 10.1002/art.34539; Seror R, 2015, ARTHRITIS RHEUMATOL, V67, P1729, DOI 10.1002/art.39118; Shi J, 2011, P NATL ACAD SCI USA, V108, P17372, DOI 10.1073/pnas.1114465108; Silman AJ, 1996, ARTHRITIS RHEUM, V39, P732, DOI 10.1002/art.1780390504; Snir O, 2009, ANN RHEUM DIS, V68, P736, DOI 10.1136/ard.2008.091355; Snir O, 2010, ARTHRITIS RHEUM-US, V62, P44, DOI 10.1002/art.25036; Sokolove J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035296; The J, 1996, Oral Dis, V2, P253; Thiele GM, 2015, ARTHRITIS RHEUMATOL, V67, P645, DOI 10.1002/art.38969; Thiele GM, 1998, ALCOHOL CLIN EXP RES, V22, P1731, DOI 10.1111/j.1530-0277.1998.tb03973.x; TOLO K, 1990, J CLIN PERIODONTOL, V17, P288, DOI 10.1111/j.1600-051X.1990.tb01091.x; Tuma DJ, 2001, CHEM RES TOXICOL, V14, P822, DOI 10.1021/tx000222a; van de Stadt LA, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3028; Wang Z, 2007, NAT MED, V13, P1176, DOI 10.1038/nm1637; Wegner N, 2010, ARTHRITIS RHEUM-US, V62, P2662, DOI 10.1002/art.27552; Willis VC, 2013, ARTHRITIS RHEUM-US, V65, P2545, DOI 10.1002/art.38066; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Ytterberg AJ, 2015, ANN RHEUM DIS, V74, P1772, DOI 10.1136/annrheumdis-2013-204912	77	46	46	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					28	34		10.1016/j.jaci.2015.10.024	http://dx.doi.org/10.1016/j.jaci.2015.10.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26768760	Bronze			2022-12-18	WOS:000367724300020
J	Bateman, ED; Esser, D; Chirila, C; Fernandez, M; Fowler, A; Moroni-Zentgraf, P; FitzGerald, JM				Bateman, Eric D.; Esser, Dirk; Chirila, Costel; Fernandez, Maria; Fowler, Andy; Moroni-Zentgraf, Petra; FitzGerald, J. Mark			Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; quality of life; network meta-analysis; questionnaire	RANDOMIZED CONTROLLED-TRIALS; MIXED TREATMENT COMPARISONS; PATIENT PREFERENCES; CLINICAL-TRIALS; VALIDATION; INCONSISTENCY; OMALIZUMAB; THERAPY; POINT	Background: The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire (ACQ) are widely used in asthma research; however, in studies of newer asthma treatments, mean improvements in these measures compared with placebo arms do not exceed the minimal important difference (MID), particularly when a new treatment is added to current treatment. Objective: We performed a systematic review and network meta-analysis to examine the magnitude of AQLQ and ACQ responses achieved with commonly used asthma drugs and factors influencing these end points in clinical trials. Methods: A systematic literature search was conducted to identify blinded randomized controlled trials reporting AQLQ or ACQ results. Mixed treatment comparisons, combined with meta-regression, were then performed. Results: Of the 64 randomized controlled trials (42,527 patients) identified, 54 included the AQLQ and 11 included the ACQ as end points. The presence of a run-in period, the nature of treatment during the run-in period, concurrent treatment during the treatment period, and instrument version significantly influenced the change in AQLQ score from baseline and whether it exceeded the MID. When compared with placebo, only inhaled corticosteroids (ICSs), with or without a long-acting beta-agonist, achieved the MID. The ACQ results were comparable with those of the AQLQ: no differences from placebo exceeded the MID, and ICS-based treatments provided the greatest improvements. Conclusion: The established within-patient MID for the ACQ and AQLQ is not achievable as a group-wise efficacy threshold between treatment arms in clinical studies in which controllers are added to ICS treatment. Thus in addition to reporting mean changes of the instruments, other measurement criteria should be considered, including responder analyses.	[Bateman, Eric D.] Univ Cape Town, Dept Med, ZA-7700 Cape Town, South Africa; [Esser, Dirk] Boehringer Ingelheim GmbH & Co KG, Global Hlth Econ & Outcomes Res, Ingelheim, Germany; [Chirila, Costel; Fernandez, Maria] RTI Hlth Solut, Res Triangle Pk, NC USA; [Fowler, Andy] Boehringer Ingelheim Ltd, Clin Res, Bracknell, Berks, England; [Moroni-Zentgraf, Petra] Boehringer Ingelheim GmbH & Co KG, TA Resp Dis, Ingelheim, Germany; [FitzGerald, J. Mark] Gordon & Leslie Diamond Hlth Care Ctr, Lung Ctr, Vancouver, BC, Canada	University of Cape Town; Boehringer Ingelheim; Research Triangle Institute; Boehringer Ingelheim; Boehringer Ingelheim	Bateman, ED (corresponding author), Univ Cape Town, Dept Med, ZA-7700 Cape Town, South Africa.	Eric.Bateman@uct.ac.za		Chirila, Costel/0000-0002-7495-382X				Barnes PJ, 2014, ALLERGY, V69, P1119, DOI 10.1111/all.12415; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Centre for Reviews and Dissemination, 2008, SYSTEMATIC REV CRDS; Coons SJ, 2011, CLIN PHARMACOL THER, V90, P743, DOI 10.1038/clpt.2011.203; Dias S, 2013, MED DECIS MAKING, V33, P641, DOI 10.1177/0272989X12455847; Garcia G, 2013, CHEST, V144, P411, DOI 10.1378/chest.12-1961; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Jones PW, 2014, AM J RESP CRIT CARE, V189, P250, DOI 10.1164/rccm.201310-1863PP; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; King MT, 2007, HEALTH ECON, V16, P703, DOI 10.1002/hec.1193; King MT, 2011, EXPERT REV PHARM OUT, V11, P171, DOI [10.1586/ERP.11.9, 10.1586/erp.11.9]; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; McKenzie L, 2001, HEALTH POLICY, V57, P193, DOI 10.1016/S0168-8510(01)00128-2; National Institute for Health and Care Excellence, 2012, SINGL TECHN APPR SPE; Nixon RM, 2007, STAT MED, V26, P1237, DOI 10.1002/sim.2624; Patel M, 2013, J ALLER CL IMM-PRACT, V1, P83, DOI 10.1016/j.jaip.2012.08.004; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Salanti G, 2009, J CLIN EPIDEMIOL, V62, P857, DOI 10.1016/j.jclinepi.2008.10.001	28	46	46	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					914	922		10.1016/j.jaci.2015.03.023	http://dx.doi.org/10.1016/j.jaci.2015.03.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25936565	hybrid			2022-12-18	WOS:000362976300010
J	Kim, JH; Bae, HC; Ko, NY; Lee, SH; Jeong, SH; Lee, H; Ryu, WI; Kye, YC; Son, SW				Kim, Jin Hee; Bae, Hyun Cheol; Ko, Na Young; Lee, See Hyun; Jeong, Sang Hoon; Lee, Hana; Ryu, Woo-In; Kye, Young Chul; Son, Sang Wook			Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS		[Kim, Jin Hee] Korea Univ, Coll Med, Dept Dermatol, Seoul 136705, South Korea; Korea Univ, Coll Med, Div Brain Korea Project Biomed Sci 21, Seoul 136705, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Kim, JH (corresponding author), Korea Univ, Coll Med, Dept Dermatol, Seoul 136705, South Korea.	skin4u@korea.ac.kr		Jeong, Sang Hoon/0000-0001-9027-7625; , Woo-In/0000-0001-9400-4798; Son, Sang Wook/0000-0002-3332-7056				Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Kubo T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105498; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Shan LY, 2010, J IMMUNOL, V184, P7134, DOI 10.4049/jimmunol.0902515; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	9	46	51	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					205	208		10.1016/j.jaci.2015.04.026	http://dx.doi.org/10.1016/j.jaci.2015.04.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	26026341	Bronze			2022-12-18	WOS:000357542200028
J	Oskeritzian, CA; Hait, NC; Wedman, P; Chumanevich, A; Kolawole, EM; Price, MM; Falanga, YT; Harikumar, KB; Ryan, JJ; Milstien, S; Sabbadini, R; Spiegel, S				Oskeritzian, Carole A.; Hait, Nitai C.; Wedman, Piper; Chumanevich, Alena; Kolawole, Elizabeth M.; Price, Megan M.; Falanga, Yves T.; Harikumar, Kuzhuvelil B.; Ryan, John J.; Milstien, Sheldon; Sabbadini, Roger; Spiegel, Sarah			The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; allergy; mast cells; recruitment; T cells; sphingosine-1-phosphate; sphingosine-1-phosphate receptor 2; signal transducer and activator of transcription 3	PERSISTENT STAT3 ACTIVATION; SPHINGOSINE KINASE; IN-VIVO; SPHINGOSINE-1-PHOSPHATE; INFLAMMATION; IGE; HYPERRESPONSIVENESS; MODEL; MICE; ANAPHYLAXIS	Background: Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid produced by mast cells (MCs) on cross-linking of their high-affinity receptors for IgE by antigen that can amplify MC responses by binding to its S1P receptors. An acute MC-dependent allergic reaction can lead to systemic shock, but the early events of its development in lung tissues have not been investigated, and S1P functions in the onset of allergic processes remain to be examined. Objective: We used a highly specific neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JTE-013 to study the signaling contributions of S1P and S1PR2 to MC-and IgE-dependent airway allergic responses in mice within minutes after antigen challenge. Methods: Allergic reaction was triggered by a single intraperitoneal dose of antigen in sensitized mice pretreated intraperitoneally with anti-S1P, isotype control mAb, JTE-013, or vehicle before antigen challenge. Results: Kinetics experiments revealed early pulmonary infiltration of mostly T cells around blood vessels of sensitized mice 20 minutes after antigen exposure. Pretreatment with anti-S1P mAb inhibited in vitro MC activation, as well as in vivo development of airway infiltration and MC activation, reducing serum levels of histamine, cytokines, and the chemokines monocyte chemoattractant protein 1/CCL2, macrophage inflammatory protein 1 alpha/CCL3, and RANTES/CCL5. S1PR2 antagonism or deficiency or MC deficiency recapitulated these results. Both in vitro and in vivo experiments demonstrated MC S1PR2 dependency for chemokine release and the necessity for signal transducer and activator of transcription 3 activation. Conclusion: Activation of S1PR2 by S1P and downstream signal transducer and activator of transcription 3 signaling in MCs regulate early T-cell recruitment to antigen-challenged lungs through chemokine production.	[Oskeritzian, Carole A.; Wedman, Piper; Chumanevich, Alena] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Oskeritzian, Carole A.; Hait, Nitai C.; Price, Megan M.; Harikumar, Kuzhuvelil B.; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA USA; [Kolawole, Elizabeth M.; Falanga, Yves T.; Ryan, John J.] Virginia Commonwealth Univ, Dept Biol, Richmond, VA 23284 USA; [Sabbadini, Roger] Lpath, San Diego, CA USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Virginia Commonwealth University; Virginia Commonwealth University	Oskeritzian, CA (corresponding author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Bldg 2,Rm C10,6439 Garners Ferry Rd, Columbia, SC 29208 USA.	Carole.Oskeritzian@uscmed.sc.edu	Harikumar, Kuzhuvelil/AAC-2407-2020	Harikumar, Kuzhuvelil/0000-0002-1763-4179	National Institutes of Health (NIH) [K01AR053186, R01 AI095494, R01 AI50094, U19 AI077435]; NATIONAL CANCER INSTITUTE [R01CA061774, R44CA110298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077435, R01AI101153, R01AI050094, R01AI059638, R01AI095494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR053186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R44NS087641] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health (NIH) grants K01AR053186 and R01 AI095494 (to C.A.O.), R01 AI50094 (to S.S.), and U19 AI077435 (to S.S. and J.J.R.).	Barnes PJ, 2011, IMMUNOL REV, V242, P31, DOI 10.1111/j.1600-065X.2011.01020.x; Chiba Yoshihiko, 2010, Open Respir Med J, V4, P82, DOI 10.2174/1874306401004010082; Cui H, 2013, J ALLERGY CLIN IMMUN, V132, P1205, DOI 10.1016/j.jaci.2013.07.026; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Frias MA, 2009, CARDIOVASC RES, V82, P313, DOI 10.1093/cvr/cvp024; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gonzalo JA, 2007, J IMMUNOL, V179, P1740, DOI 10.4049/jimmunol.179.3.1740; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Karmouty-Quintana H, 2012, AM J PHYSIOL-LUNG C, V302, pL736, DOI 10.1152/ajplung.00050.2011; Kashyap M, 2008, J IMMUNOL, V180, P2039, DOI 10.4049/jimmunol.180.4.2039; Kovacic JC, 2010, J CLIN INVEST, V120, P303, DOI 10.1172/JCI40364; Koya T, 2006, AM J RESP CELL MOL, V35, P147, DOI 10.1165/rcmb.2005-0394OC; Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Loh KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037218; Marsolais D, 2011, MOL PHARMACOL, V79, P61, DOI 10.1124/mol.110.066811; McAlpine SM, 2012, FASEB J, V26, P1280, DOI 10.1096/fj.11-188979; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Miyahara N, 2009, AM J RESP CELL MOL, V40, P672, DOI 10.1165/rcmb.2008-0095OC; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; O'Brien N, 2009, J LIPID RES, V50, P2245, DOI 10.1194/jlr.M900048-JLR200; Ohsawa Y, 2012, ALLERGY, V67, P1014, DOI 10.1111/j.1398-9995.2012.02854.x; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Olivera A, 2013, IMMUNOL LETT, V150, P89, DOI 10.1016/j.imlet.2013.01.005; Olivera A, 2013, BBA-MOL CELL BIOL L, V1831, P193, DOI 10.1016/j.bbalip.2012.06.007; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Oskeritzian CA, 2008, BLOOD, V111, P4193, DOI 10.1182/blood-2007-09-115451; Oskeritzian CA, 2010, J EXP MED, V207, P465, DOI 10.1084/jem.20091513; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Roviezzo F, 2010, AM J RESP CELL MOL, V42, P572, DOI 10.1165/rcmb.2009-0108OC; Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x; Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Sensken SC, 2011, J IMMUNOL, V186, P3432, DOI 10.4049/jimmunol.1002169; Shulman Z, 2012, NAT IMMUNOL, V13, P67, DOI 10.1038/ni.2173; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Speiran K, 2009, J LEUKOCYTE BIOL, V85, P826, DOI 10.1189/jlb.0708448; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Trifilieff A, 2012, J PHARMACOL EXP THER, V342, P399, DOI 10.1124/jpet.112.191585; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wu ZL, 2013, J IMMUNOL, V190, P4500, DOI 10.4049/jimmunol.1203158; Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588; Zhang CC, 2013, J BIOL CHEM, V288, P1489, DOI 10.1074/jbc.M112.419788; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	51	46	46	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1008	+		10.1016/j.jaci.2014.10.044	http://dx.doi.org/10.1016/j.jaci.2014.10.044			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25512083	Green Accepted			2022-12-18	WOS:000352238600024
J	Cicutto, L; Gleason, M; Szefler, SJ				Cicutto, Lisa; Gleason, Melanie; Szefler, Stanley J.			Establishing school-centered asthma programs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; childhood asthma; asthma prevalence; asthma statistics; schools; school-centered asthma programs	RANDOMIZED CONTROLLED-TRIAL; INNER-CITY CHILDREN; EDUCATION-PROGRAM; MANAGEMENT PROGRAM; CONSULTING PHYSICIAN; HEALTH CENTERS; URBAN CHILDREN; UNITED-STATES; ACTION PLANS; STUDENTS	Asthma is a common chronic childhood disease associated with significant morbidity and high rates of school absenteeism, along with excessive costs for the patient and society. Asthma is a leading cause of school absenteeism, but this absenteeism is not equally distributed among those with asthma. Second to their home, school-aged children spend the largest portion of their wakeful hours at school. Opportunities exist to partner with schools to reach most children with asthma and those at the highest risk for asthma burden and in need of assistance. Asthma management at schools is important for pediatric pulmonologists and allergists, primary care providers, and the whole interdisciplinary team working alongside them to provide quality asthma care. The variability of asthma care services and programs provided in schools should prompt clinicians to understand their own school system and to advocate for appropriate services. Models of asthma care that place schools at the center or core of the model and coordinate evidence-based asthma care are applicable nationwide and might serve as a model for managing other chronic illnesses.	[Cicutto, Lisa] Univ Colorado, Denver AMC, Natl Jewish Hlth, Denver, CO 80202 USA; [Cicutto, Lisa] Univ Colorado, Denver AMC, Clin Sci Program, Denver, CO 80202 USA; [Gleason, Melanie] Univ Colorado, Sch Med, Childrens Hosp Colorado, Bldg Bridges Asthma Program, Aurora, CO USA; [Gleason, Melanie] Univ Colorado, Sch Med, Dept Pediat, Sect Pediat Pulm Med, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Childrens Hosp Colorado, Breathing Inst,Sect Pediat Pulm Med,Pediat Asthma, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO USA	National Jewish Health; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Breathing Inst, Pediat Asthma Res Program, 13123 East 16th Ave,Box 395, Aurora, CO 80045 USA.	stanley.szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	Colorado Department of Public Health and Environment [14 FLA 62707, 15 FLA 65726]; Caring for Colorado Foundation; McCormick Foundation; GlaxoSmithKline [FLV 116794]; National Heart, Lung, and Blood Institute AsthmaNet grant [U10 HL098075]; Colorado CTSA from National Center for Research Resources/National Institutes of Health (NIH) [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences (NCATS) [UL1 TR000154]; NIH/NCRR [UL1 TR001082]; Jessie Ball duPont Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098075] Funding Source: NIH RePORTER	Colorado Department of Public Health and Environment; Caring for Colorado Foundation; McCormick Foundation; GlaxoSmithKline(GlaxoSmithKline); National Heart, Lung, and Blood Institute AsthmaNet grant; Colorado CTSA from National Center for Research Resources/National Institutes of Health (NIH); NIH/National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Jessie Ball duPont Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	S.J.S. was supported by the Colorado Department of Public Health and Environment (14 FLA 62707), the Caring for Colorado Foundation, the McCormick Foundation, and GlaxoSmithKline (FLV 116794). Supported by the National Heart, Lung, and Blood Institute AsthmaNet grant U10 HL098075 and supported in part by Colorado CTSA grant UL1 RR025780 from National Center for Research Resources/National Institutes of Health (NIH) and UL1 TR000154 from NIH/National Center for Advancing Translational Sciences (NCATS). L.C. is supported by Colorado Department of Public Health and Environment (14 FLA 62707), Colorado CTSA grant UL1 TR001082 from NIH/NCRR and the Jessie Ball duPont Fund. M.G. is supported by the Colorado Department of Public Health and Environment (15 FLA 65726), the Caring for Colorado Foundation, the McCormick Foundation, and GlaxoSmithKline (FLV 116794).	Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Al Aloola NA, 2014, J ASTHMA, V19, P1; [Anonymous], CREAT HLTH IND ENV S; Asthma and Allergy Foundation of America, ASTHM FACTS FIG; Asthma Plan of Action, CREAT ASTHM FRIENDL; Basch CE, 2011, J SCHOOL HEALTH, V81, P593, DOI 10.1111/j.1746-1561.2011.00632.x; Bruzzese JM, 2011, AM J RESP CRIT CARE, V183, P998, DOI 10.1164/rccm.201003-0429OC; Bruzzese JM, 2001, J ASTHMA, V38, P337, DOI 10.1081/JAS-100000261; Butz A, 2005, J ASTHMA, V42, P813, DOI 10.1080/02770900500369850; Center for Disease Control. Healthy youth, STRAT ADDR ASTHM COO; Centers for Disease Control, IN CHANG ASTHM FRIEN; Christiansen SC, 1997, J ALLERGY CLIN IMMUN, V100, P613, DOI 10.1016/S0091-6749(97)70164-7; Cicutto L, 2005, CHEST, V128, P1928, DOI 10.1378/chest.128.4.1928; Cicutto L, 2014, AM J RESP CRIT CARE, V189; Cicutto L, 2006, J SCHOOL HEALTH, V76, P255, DOI 10.1111/j.1746-1561.2006.00107.x; Cicutto L, 2013, J SCHOOL HEALTH, V83, P876, DOI 10.1111/josh.12106; Cicutto L, 2009, J ALLERGY CLIN IMMUN, V124, P390, DOI 10.1016/j.jaci.2009.04.042; Clark NM, 2004, CHEST, V125, P1674, DOI 10.1378/chest.125.5.1674; Cloutier MM, 2008, ANN ALLERG ASTHMA IM, V100, P545, DOI 10.1016/S1081-1206(10)60058-0; Cloutier MM, 2009, AM J MANAG CARE, V15, P345; Coffman JM, 2009, PEDIATRICS, V124, P729, DOI 10.1542/peds.2008-2085; Davis A, 2008, J URBAN HEALTH, V85, P361, DOI 10.1007/s11524-008-9266-y; Egginton JS, 2013, J SCHOOL HEALTH, V83, P885, DOI 10.1111/josh.12107; EISENBERG JD, 1993, J ASTHMA, V30, P351; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; FOWLER MG, 1992, PEDIATRICS, V90, P939; Frankowski BL, 2009, PEDIATRICS, V124, P793, DOI 10.1542/peds.2009-0100; Gerald JK, 2012, PEDIAT ALLER IMM PUL, V25, P11, DOI 10.1089/ped.2011.0118; Gerald LB, 2009, PEDIATRICS, V123, P466, DOI 10.1542/peds.2008-0499; Goei R, 2006, J SCHOOL HEALTH, V76, P259, DOI 10.1111/j.1746-1561.2006.00108.x; Greiling AK, 2005, J SCHOOL HEALTH, V75, P286, DOI 10.1111/j.1746-1561.2005.00039.x; Guo JJ, 2005, J ADOLESCENT HEALTH, V37, P266, DOI 10.1016/j.jadohealth.2004.09.006; Halterman JS, 2011, ARCH PEDIAT ADOL MED, V165, P262, DOI 10.1001/archpediatrics.2011.1; Halterman JS, 2004, ARCH PEDIAT ADOL MED, V158, P460, DOI 10.1001/archpedi.158.5.460; Hanson TK, 2013, J SCHOOL HEALTH, V83, P915, DOI 10.1111/josh.12110; Jones Craig A, 2005, Dis Manag, V8, P205, DOI 10.1089/dis.2005.8.205; Jones SE, 2004, AM J PUBLIC HEALTH, V94, P1102, DOI 10.2105/AJPH.94.7.1102; Joseph CLM, 2013, J ADOLESCENT HEALTH, V52, P419, DOI 10.1016/j.jadohealth.2012.07.009; Kann L, 2007, J SCHOOL HEALTH, V77, P385, DOI 10.1111/j.1746-1561.2007.00226.x; Keysser J, 2006, J SCHOOL HEALTH, V76, P264, DOI 10.1111/j.1746-1561.2006.00109.x; Kouba J, 2013, J SCH NURS, V29, P235, DOI 10.1177/1059840512466110; Levy M, 2006, J SCHOOL HEALTH, V76, P320, DOI 10.1111/j.1746-1561.2006.00120.x; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; Liberatos P, 2013, J SCHOOL HEALTH, V83, P867, DOI 10.1111/josh.12105; Magzamen S, 2008, J SCHOOL HEALTH, V78, P655, DOI 10.1111/j.1746-1561.2008.00362.x; McGhan SL, 2010, CAN RESPIR J, V17, P67, DOI 10.1155/2010/327650; McGhan SL, 2003, J ASTHMA, V40, P523, DOI 10.1081/JAS-120018785; Meng YY, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110312; National Institutes of Health, 2007, NIH PUBL, V97-4051; Neuharth-Pritchett S, 2001, J Sch Nurs, V17, P323; Patel B, 2007, J ASTHMA, V44, P113, DOI 10.1080/02770900601182343; Portwood SG, 2013, J SCHOOL HEALTH, V83, P851, DOI 10.1111/josh.12103; Richmond CM, 2006, J SCHOOL HEALTH, V76, P333, DOI 10.1111/j.1746-1561.2006.00123.x; Rodriguez E, 2013, J SCHOOL HEALTH, V83, P842, DOI 10.1111/josh.12102; Shah S, 2001, BRIT MED J, V322, P583, DOI 10.1136/bmj.322.7286.583; Splett PL, 2006, J SCHOOL HEALTH, V76, P276, DOI 10.1111/j.1746-1561.2006.00112.x; Szefler SJ, 2009, J ALLERGY CLIN IMMUN, V124, P201, DOI 10.1016/j.jaci.2009.05.045; Taras H, 2004, J SCHOOL HEALTH, V74, P213, DOI 10.1111/j.1746-1561.2004.tb07935.x; Walker TJ, 2014, J ASTHMA, V51, P808, DOI 10.3109/02770903.2014.920875; Webber MP, 2003, ARCH PEDIAT ADOL MED, V157, P125, DOI 10.1001/archpedi.157.2.125; Wheeler Lani, 2009, Pediatric Asthma Allergy & Immunology, V22, P197, DOI 10.1089/pai.2009.0023; Wheeler LS, 2006, J SCHOOL HEALTH, V76, P340, DOI 10.1111/j.1746-1561.2006.00125.x; Wilson KD, 2009, J SCHOOL HEALTH, V79, P1, DOI 10.1111/j.1746-1561.2008.00367.x	63	46	47	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1223	1230		10.1016/j.jaci.2014.10.004	http://dx.doi.org/10.1016/j.jaci.2014.10.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AW1UG	25482867				2022-12-18	WOS:000346075400001
J	Lemoine, R; Pachlopnik-Schmid, J; Farin, HF; Bigorgne, A; Debre, M; Sepulveda, F; Heritier, S; Lemale, J; Talbotec, C; Rieux-Laucat, F; Ruemmele, F; Morali, A; Cathebras, P; Nitschke, P; Bole-Feysot, C; Blanche, S; Brousse, N; Picard, C; Clevers, H; Fischer, A; de Saint Basile, G				Lemoine, Roxane; Pachlopnik-Schmid, Jana; Farin, Henner F.; Bigorgne, Amelie; Debre, Marianne; Sepulveda, Fernando; Heritier, Sebastien; Lemale, Julie; Talbotec, Cecile; Rieux-Laucat, Frederic; Ruemmele, Frank; Morali, Alain; Cathebras, Pascal; Nitschke, Patrick; Bole-Feysot, Christine; Blanche, Stephane; Brousse, Nicole; Picard, Capucine; Clevers, Hans; Fischer, Alain; de Saint Basile, Genevieve			Immune deficiency-related enteropathy-lymphocytopenia-alopecia syndrome results from tetratricopeptide repeat domain 7A deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inflammatory bowel disease; immune deficiency; tetratricopeptide repeat domain 7A deficiency; lymphocytes; cytoskeleton gut organoid; RhoA kinase; cell homeostasis	FLAKY SKIN; DENDRITIC CELLS; TTC7A MUTATIONS; PLASMA-MEMBRANE; CROHNS-DISEASE; RHO GTPASES; GENE; IMMUNODEFICIENCY; PATHOGENESIS; MECHANISMS	Background: Inflammatory bowel disease (IBD) is one of the most common chronic gastrointestinal diseases, but the underlying molecular mechanisms remain largely unknown. Studies of monogenic diseases can provide insight into the pathogenesis of IBD. Objective: We thought to determine the underlying molecular causes of IBD occurring in 2 unrelated families in association with an immune deficiency. Methods: We performed genetic linkage analysis and candidate gene sequencing on 13 patients from a large consanguineous family affected by early-onset IBD, progressive immune deficiency, and, in some cases, autoimmunity and alopecia, a condition we named enteropathy-lymphocytopenia-alopecia. The candidate gene was also sequenced in an unrelated patient with a similar phenotype. We performed histologic analysis of patients' intestinal biopsy specimens and carried out functional assays on PBMCs. Gut organoids derived from a patient's biopsy specimen were analyzed. Results: We identified biallelic missense mutations in tetratricopeptide repeat domain 7A (TTC7A) in all patients from both families. The resulting TTC7A depletion modified the proliferation, adhesion, and migratory capacities of lymphocytes through inappropriate activation of the RhoA signaling pathway. Normal function was restored by wild-type TTC7A expression or addition of a RhoA kinase inhibitor. The growth and polarity of gut epithelial organoids were also found to be dependent on the RhoA signaling pathway. Conclusions: We show that TTC7A regulates the actin cytoskeleton dynamics in lymphocytes through the RhoA signaling pathway and is required in both lymphocytes and epithelial cells for maintaining equilibrium between cell proliferation, migration, polarization, and cell death. Our study highlights variability in the phenotypic expression resulting from TTC7A deficiency and outlines that impairment of both epithelial cells and lymphocytes cooperatively causes IBD.	[Lemoine, Roxane; Pachlopnik-Schmid, Jana; Bigorgne, Amelie; Sepulveda, Fernando; Rieux-Laucat, Frederic; Blanche, Stephane; Fischer, Alain; de Saint Basile, Genevieve] Hop Necker Enfants Malad, INSERM, Lab Homeostasie Normale & Pathol Syst Imm, Unite U1163, Paris, France; [Lemoine, Roxane; Pachlopnik-Schmid, Jana; Bigorgne, Amelie; Sepulveda, Fernando; Rieux-Laucat, Frederic; Nitschke, Patrick; Bole-Feysot, Christine; Blanche, Stephane; Brousse, Nicole; Picard, Capucine; Fischer, Alain; de Saint Basile, Genevieve] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Lemoine, Roxane; Pachlopnik-Schmid, Jana; Bigorgne, Amelie; Debre, Marianne; Sepulveda, Fernando; Heritier, Sebastien; Rieux-Laucat, Frederic; Picard, Capucine; Fischer, Alain; de Saint Basile, Genevieve] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, Paris, France; [Farin, Henner F.] Hubrecht Inst Dev Biol & Stem Cell Res, Cincinnati, OH USA; [Farin, Henner F.; Clevers, Hans] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Lemale, Julie] Hop Trousseau, Unite Nutr & Gastroenterol Pediatr, F-75571 Paris, France; [Talbotec, Cecile; Ruemmele, Frank] Hop Necker Enfants Malad, Serv Gastroenterol Hepatol & Nutr Pediat, Paris, France; [Morali, Alain] CHU Nancy Brabois, Hop Enfants, Unite Hepatogastro Enterol & Nutr Pediat, F-54500 Vandoeuvre Les Nancy, France; [Cathebras, Pascal] CHU St Etienne, Serv Med Interne, St Etienne, France; [Brousse, Nicole] Hop Necker Enfants Malad, AP HP, Lab Anat Pathol, Paris, France; [Picard, Capucine; de Saint Basile, Genevieve] AP HP, Ctr Etud Dficits Immunitaires, Paris, France; [Fischer, Alain] Coll France, F-75231 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Nancy; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; PSL Research University Paris; College de France	de Saint Basile, G (corresponding author), Hop Necker Enfants Malad, INSERM, Lab Homeostasie Normale & Pathol Syst Imm, Unite U1163, Paris, France.	genevieve.de-saint-basile@inserm.fr	Rieux-Laucat, Frédéric/A-7916-2017; Picard, Capucine/H-3914-2017; Farin, Henner/AAC-2574-2021; Sepulveda, Fernando/O-7803-2016; Héritier, Sébastien/D-8139-2017; de Saint Basile, Genevieve/G-9731-2017; Pachlopnik Schmid, Jana/N-8018-2018	Rieux-Laucat, Frédéric/0000-0001-7858-7866; Picard, Capucine/0000-0001-8788-5056; Farin, Henner/0000-0003-1558-5366; Sepulveda, Fernando/0000-0001-5865-4929; Héritier, Sébastien/0000-0003-0384-6370; de Saint Basile, Genevieve/0000-0002-1913-5269; Pachlopnik Schmid, Jana/0000-0002-6653-9047	INSERM, Agence Nationale de la Recherche [12-BSV1-0020-01]; European Research Council (ERC) [249816]; ARC Foundation; Imagine Foundation; Swiss National Science Foundation (SNSF); ARC Foundation and Becas Chile	INSERM, Agence Nationale de la Recherche(Institut National de la Sante et de la Recherche Medicale (Inserm)French National Research Agency (ANR)); European Research Council (ERC)(European Research Council (ERC)); ARC Foundation(Australian Research Council); Imagine Foundation; Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); ARC Foundation and Becas Chile	Supported by INSERM, Agence Nationale de la Recherche-12-BSV1-0020-01, and an advanced grant from the European Research Council (ERC; PIDImmun [ref 249816]), the ARC Foundation (R2011 confocal equipment), and the Imagine Foundation. J.P.-S. was supported by the Swiss National Science Foundation (SNSF), and F.S. was supported by the ARC Foundation and Becas Chile.	Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Avitzur Y, 2014, GASTROENTEROLOGY, V146, P1028, DOI 10.1053/j.gastro.2014.01.015; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Bigorgne AE, 2014, J CLIN INVEST, V124, P328, DOI 10.1172/JCI71471; Bouma G, 2011, BLOOD, V118, P2492, DOI 10.1182/blood-2011-03-340265; Brandl K, 2012, CURR OPIN IMMUNOL, V24, P678, DOI 10.1016/j.coi.2012.10.005; Budarf ML, 2009, TRENDS GENET, V25, P137, DOI 10.1016/j.tig.2009.01.001; Chen R, 2013, J ALLERGY CLIN IMMUN, V132, P656, DOI 10.1016/j.jaci.2013.06.013; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Cote M, 2009, J CLIN INVEST, V119, P3765, DOI 10.1172/JCI40732; de Curtis I, 2012, J CELL SCI, V125, P4435, DOI 10.1242/jcs.108266; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Gismera CS, 2008, WORLD J GASTROENTERO, V14, P5491, DOI 10.3748/wjg.14.5491; Glocker EO, 2010, LANCET, V376, P1272, DOI 10.1016/S0140-6736(10)61008-2; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Hartley JL, 2010, GASTROENTEROLOGY, V138, P2388, DOI 10.1053/j.gastro.2010.02.010; Helms C, 2005, EXP BIOL MED, V230, P659; Iqbal N, 2002, J EXP MED, V195, P71, DOI 10.1084/jem.2001889; Jacobelli J, 2009, J IMMUNOL, V182, P2041, DOI 10.4049/jimmunol.0803267; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106; Lapaquette P, 2012, J MOL MED, V90, P987, DOI 10.1007/s00109-012-0934-8; Nakatsu F, 2012, J CELL BIOL, V199, P1003, DOI 10.1083/jcb.201206095; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Samuels ME, 2013, J MED GENET, V50, P324, DOI 10.1136/jmedgenet-2012-101483; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schappi MG, 2008, SEMIN IMMUNOPATHOL, V30, P255, DOI 10.1007/s00281-008-0119-2; Schmid JP, 2012, J EXP MED, V209, P2323, DOI 10.1084/jem.20121303; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sims TN, 2007, CELL, V129, P773, DOI 10.1016/j.cell.2007.03.037; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Sundberg JP, 1997, PATHOBIOLOGY, V65, P271, DOI 10.1159/000164138; SUNDBERG JP, 1992, J VET DIAGN INVEST, V4, P312, DOI 10.1177/104063879200400314; SUNDBERG JP, 1995, J INVEST DERMATOL, V104, P577; Takabayashi S, 2007, EXP BIOL MED, V232, P695; White RA, 2005, GENOMICS, V85, P330, DOI 10.1016/j.ygeno.2004.11.008; White RA, 2004, BLOOD, V104, P1511, DOI 10.1182/blood-2004-01-0076; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005	44	46	47	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1354	+		10.1016/j.jaci.2014.07.019	http://dx.doi.org/10.1016/j.jaci.2014.07.019			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25174867				2022-12-18	WOS:000346075400018
J	Legrand, F; Tomasevic, N; Simakova, O; Lee, CCR; Wang, ZF; Raffeld, M; Makiya, MA; Palath, V; Leung, J; Baer, M; Yarranton, G; Maric, I; Bebbington, C; Klion, AD				Legrand, Fanny; Tomasevic, Nenad; Simakova, Olga; Lee, Chyi-Chia Richard; Wang, Zengfang; Raffeld, Mark; Makiya, Michelle A.; Palath, Varghese; Leung, John; Baer, Mark; Yarranton, Geoffrey; Maric, Irina; Bebbington, Christopher; Klion, Amy D.			The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): A novel therapeutic target for eosinophilic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epidermal growth factor-like module containing mucin-like hormone receptor 1; eosinophil; hypereosinophilic syndrome; mAb therapy; afucosylated antibody; eosinophilia	EGF-TM7 FAMILY; CELLS; ANTIBODY; CD34(+); F4/80; CD97; CYTOTOXICITY; INFLAMMATION; ACTIVATION; EXPRESSION	Background: Although several novel agents are currently in clinical trials for eosinophilic disorders, none has demonstrated efficacy in reducing blood and tissue eosinophilia in all subjects. Additional approaches are clearly needed. Objective: We sought to explore the potential of the human eosinophil surface receptor epidermal growth factor- like module containing mucin- like hormone receptor 1 ( EMR1) as a therapeutic target for eosinophilic disorders. Methods: EMR1 expression was assessed in blood and bone marrow specimens from eosinophilic and healthy subjects, cell lines, CD34(+) cells differentiated in vitro, and tissue biopsy specimens by using flow cytometry, quantitative PCR, and immunostaining. Eosinophil targeting by a novel, humanized, afucosylated anti- EMR1 IgG(1) was evaluated in vitro by using a natural killer cell- mediated killing assay and in vivo in cynomolgus monkeys. Results: Analysis of blood and bone marrow cells from healthy and eosinophilic donors and in vitro- differentiated CD34(+) cells confirmed restriction of human EMR1 surface and mRNA expression to mature eosinophils. Tissue eosinophils also expressed EMR1. Although EMR1 was highly expressed on eosinophils from all subjects, surface expression was negatively correlated with absolute eosinophil counts ( r=520.46, P <.001), and soluble plasma levels correlated positively with absolute eosinophil counts ( r= 0.69, P <.001), suggesting modulation of EMR1 in vivo. Nevertheless, afucosylated anti- EMR1 mAb dramatically enhanced natural killer cell- mediated killing of eosinophils from healthy and eosinophilic donors and induced a rapid and sustained depletion of eosinophils in monkeys. Conclusion: EMR1 expression is restricted to mature blood and tissue eosinophils. Targeting of eosinophils with afucosylated anti- EMR1 antibody shows promise as a treatment for eosinophilic disorders.	[Legrand, Fanny; Makiya, Michelle A.; Klion, Amy D.] NIAID, Eosinophil Pathol Unit, Parasit Dis Lab, Bethesda, MD 20892 USA; [Tomasevic, Nenad; Palath, Varghese; Leung, John; Baer, Mark; Yarranton, Geoffrey; Bebbington, Christopher] KaloBios Pharmaceut, San Francisco, CA USA; [Simakova, Olga; Maric, Irina] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Lee, Chyi-Chia Richard; Wang, Zengfang; Raffeld, Mark] NCI, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Legrand, F (corresponding author), NIH, Bldg 4,Rm B1-28, Bethesda, MD 20892 USA.	legrandfa@niaid.nih.gov	Lee, Chyi-Chia Richard/AAO-1149-2020; Legrand, Fanny/I-4880-2017; Lee, Chyi-Chia/I-1938-2013	Legrand, Fanny/0000-0001-9373-7789; Lee, Chyi-Chia/0000-0002-5306-7781; Klion, Amy/0000-0002-4986-5326	Division of Intramural Research of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health; KaloBios Pharmaceuticals; NATIONAL CANCER INSTITUTE [ZICBC011087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080004] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health; KaloBios Pharmaceuticals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Division of Intramural Research of the National Institutes of Allergy and Infectious Diseases/National Institutes of Health and by KaloBios Pharmaceuticals. G.Y. and M.B. are employed by KaloBios Pharmaceuticals. N.T, J.L, V. and C.B were previously employed by and own stock/stock options in KaloBios Pharmaceuticals.	Al-Rabia MW, 2003, CLIN EXP ALLERGY, V33, P640, DOI 10.1046/j.1365-2222.2003.01639.x; Bochner BS, 2012, J ALLERGY CLIN IMMUN, V130, P587, DOI 10.1016/j.jaci.2012.07.024; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Cerutti A, 2012, EUR J IMMUNOL, V42, P1956, DOI 10.1002/eji.201242594; Furuta GT, 2013, GUT, V62, P1395, DOI 10.1136/gutjnl-2012-303171; Gopinath R, 2000, INFECT IMMUN, V68, P93, DOI 10.1128/IAI.68.1.93-99.2000; Gordon S, 2011, EUR J IMMUNOL, V41, P2472, DOI 10.1002/eji.201141715; Gray JX, 1996, J IMMUNOL, V157, P5438; Hamann J, 1999, ARTHRITIS RHEUM-US, V42, P650, DOI 10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S; Hamann J, 2007, EUR J IMMUNOL, V37, P2797, DOI 10.1002/eji.200737553; Hart TK, 2001, J ALLERGY CLIN IMMUN, V108, P250, DOI 10.1067/mai.2001.116576; Huang YS, 2012, MOL CELL BIOL, V32, P1408, DOI 10.1128/MCB.06557-11; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Klion AD, 2013, BLOOD, V121, P2364, DOI 10.1182/blood-2012-12-472720; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kwakkenbos MJ, 2006, FASEB J, V20, P2582, DOI 10.1096/fj.06-6500fje; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Schaller E, 2002, MOL CELL BIOL, V22, P8035, DOI 10.1128/MCB.22.22.8035-8043.2002; Shalit M, 1996, J ALLERGY CLIN IMMUN, V98, P344, DOI 10.1016/S0091-6749(96)70159-8; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Wandel E, 2012, J IMMUNOL, V188, P1442, DOI 10.4049/jimmunol.1003944; Wechsler ME, 2012, J ALLERGY CLIN IMMUN, V130, P563, DOI 10.1016/j.jaci.2012.07.027; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151; Yona S, 2008, FASEB J, V22, P741, DOI 10.1096/fj.07-9435com	30	46	48	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1439	U350		10.1016/j.jaci.2013.11.041	http://dx.doi.org/10.1016/j.jaci.2013.11.041			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24530099	Green Accepted, Bronze			2022-12-18	WOS:000335450700027
J	IJspeert, H; Driessen, GJ; Moorhouse, MJ; Hartwig, NG; Wolska-Kusnierz, B; Kalwak, K; Pituch-Noworolska, A; Kondratenko, I; van Montfrans, JM; Mejstrikova, E; Lankester, AC; Langerak, AW; van Gent, DC; Stubbs, AP; van Dongen, JJM; van der Burg, M				IJspeert, Hanna; Driessen, Gertjan J.; Moorhouse, Michael J.; Hartwig, Nico G.; Wolska-Kusnierz, Beata; Kalwak, Krzysztof; Pituch-Noworolska, Anna; Kondratenko, Irina; van Montfrans, Joris M.; Mejstrikova, Ester; Lankester, Arjan C.; Langerak, Anton W.; van Gent, Dik C.; Stubbs, Andrew P.; van Dongen, Jacques J. M.; van der Burg, Mirjam			Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAG deficiency; V(D)J recombination; B- and T-cell receptor repertoire; receptor editing; autoimmunity; next generation sequencing; immune repertoire analysis	T-CELL-RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-SECRETING CELLS; OMENN-SYNDROME; SEQUENCE-ANALYSIS; SCID PATIENTS; DEFECTS; REARRANGEMENTS; DEFICIENCY; RETICULOENDOTHELIOSIS	Background: V(D)J recombination takes place during lymphocyte development to generate a large repertoire of T-and B-cell receptors. Mutations in recombination-activating gene 1 (RAG1) and RAG2 result in loss or reduction of V(D) J recombination. It is known that different mutations in RAG genes vary in residual recombinase activity and give rise to a broad spectrum of clinical phenotypes. Objective: We sought to study the immunologic mechanisms causing the clinical spectrum of RAG deficiency. Methods: We included 22 patients with similar RAG1 mutations (c.519delT or c.368_369delAA) resulting in N-terminal truncated RAG1 protein with residual recombination activity but presenting with different clinical phenotypes. We studied precursor B-cell development, immunoglobulin and T-cell receptor repertoire formation, receptor editing, and B-and T-cell numbers. Results: Clinically, patients were divided into 3 main categories: T-B- severe combined immunodeficiency, Omenn syndrome, and combined immunodeficiency. All patients showed a block in the precursor B-cell development, low B-and T-cell numbers, normal immunoglobulin gene use, limited B-and T-cell repertoires, and slightly impaired receptor editing. Conclusion: This study demonstrates that similar RAG mutations can result in similar immunobiological effects but different clinical phenotypes, indicating that the level of residual recombinase activity is not the only determinant for clinical outcome. We postulate a model in which the type and moment of antigenic pressure affect the clinical phenotypes of these patients.	[IJspeert, Hanna; Driessen, Gertjan J.; Langerak, Anton W.; van Dongen, Jacques J. M.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [IJspeert, Hanna; Driessen, Gertjan J.; Hartwig, Nico G.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Moorhouse, Michael J.] Stichting Sanquin Bloedvoorziening, Dept Blood Cell Res, Amsterdam, Netherlands; [Wolska-Kusnierz, Beata] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Kalwak, Krzysztof] Wroclaw Med Univ, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Wroclaw, Poland; [Pituch-Noworolska, Anna] Jagiellonian Univ, Coll Med, Dept Clin Immunol, Polish Amer Inst Pediat, Krakow, Poland; [Kondratenko, Irina] Russian State Childrens Hosp, Dept Clin Immunol, Moscow, Russia; [van Montfrans, Joris M.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands; [van Montfrans, Joris M.] Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Mejstrikova, Ester] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Lankester, Arjan C.] Leiden Univ, Dept Pediat, Med Ctr, NL-2300 RA Leiden, Netherlands; [van Gent, Dik C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, Rotterdam, Netherlands; [Stubbs, Andrew P.] Erasmus Univ, Dept Bioinformat, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Children's Memorial Health Institute; Wroclaw Medical University; Jagiellonian University; Collegium Medicum Jagiellonian University; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Charles University Prague; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van der Burg, M (corresponding author), Erasmus MC, Dept Immunol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	m.vanderburg@erasmusmc.nl	van Dongen, Jacques J.M./F-8537-2015; IJspeert, Hanna/U-9479-2019; Hartwig, Nico/ABI-5467-2020; Driessen, Gertjan/AAI-9711-2020; Kalwak, Krzysztof/U-1724-2019	van Dongen, Jacques J.M./0000-0001-7686-0021; Kalwak, Krzysztof/0000-0003-1174-5799; van Gent, Dik C./0000-0003-1473-8148; van Dongen, Jacques J.M./0000-0002-3650-7087; Wolska-Kusnierz, Beata/0000-0003-4863-4443	foundation "Sophia Kinderziekenhuis Fonds" [589]; Dutch Organization for Scientific Research (NWO/ZonMw VIDI) [91712323]; IGA [NT/13271]; MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]; Sophia Kinderziekenhuis Fonds [589]; Baxter; Russian Children's Clinical Hospital; Russian National Scientific Medical University; ZonMW [91712323]	foundation "Sophia Kinderziekenhuis Fonds"; Dutch Organization for Scientific Research (NWO/ZonMw VIDI); IGA(Chinese Academy of Sciences); MH CZ-DRO, University Hospital Motol, Prague, Czech Republic; Sophia Kinderziekenhuis Fonds; Baxter; Russian Children's Clinical Hospital; Russian National Scientific Medical University; ZonMW(Netherlands Organization for Health Research and Development)	Supported by grants from the foundation "Sophia Kinderziekenhuis Fonds" (grant 589 to H. I. and M.v.d.B.), the Dutch Organization for Scientific Research (NWO/ZonMw VIDI grant 91712323 to M.v.d.B.), and the IGA NT/13271, MH CZ-DRO, University Hospital Motol, Prague, Czech Republic (grant 00064203 to E. M.).; H. IJspeert has received research support from Sophia Kinderziekenhuis Fonds (grant 589). G. J. Driessen has received research support from Baxter. I. Kondratenko has received consultancy fees from and is employed by Russian Children's Clinical Hospital and has received lecture fees from and has received payment for manuscript preparation from Russian National Scientific Medical University. M. van der Burg has received research support from ZonMW (Vidi grant 91712323). The rest of the authors declare that they have no relevant conflicts of interest.	Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; [Anonymous], 2013, R LANG ENV STAT COMP; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Boeckx N, 2002, LEUKEMIA, V16, P368, DOI 10.1038/sj.leu.2402387; Breit TM, 1997, J IMMUNOL, V159, P4341; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Haq IJ, 2007, CLIN IMMUNOL, V124, P165, DOI 10.1016/j.clim.2007.04.013; Klonowski KD, 1999, J IMMUNOL, V162, P1566; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Lefranc MP, 2003, LEUKEMIA, V17, P260, DOI 10.1038/sj.leu.2402637; Lefranc MP, 2003, NUCLEIC ACIDS RES, V31, P307, DOI 10.1093/nar/gkg085; Martinez-Martinez L, 2012, PEDIAT ALLERG IMM-UK, V23, P660, DOI 10.1111/j.1399-3038.2012.01339.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Niehues T, 2010, CLIN IMMUNOL, V135, P183, DOI 10.1016/j.clim.2010.01.013; Noordzij JG, 2000, BLOOD, V96, P203, DOI 10.1182/blood.V96.1.203.013k33_203_209; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Noordzij JG, 2002, BLOOD, V100, P2145; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; OCHS HD, 1974, J PEDIATR-US, V85, P463, DOI 10.1016/S0022-3476(74)80445-2; Ohm-Laursen L, 2008, J CLIN IMMUNOL, V28, P588, DOI 10.1007/s10875-008-9210-7; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; PASCUAL V, 1991, J IMMUNOL, V146, P4385; Pasic S, 2009, ACTA PAEDIATR, V98, P1062, DOI 10.1111/j.1651-2227.2009.01250.x; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Santagata S, 2000, P NATL ACAD SCI USA, V97, P14572, DOI 10.1073/pnas.97.26.14572; Schatz DG, 2004, IMMUNOL REV, V200, P5, DOI 10.1111/j.0105-2896.2004.00173.x; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SILBERSTEIN LE, 1991, BLOOD, V78, P2372; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Zelm MC, 2005, J IMMUNOL, V175, P5912, DOI 10.4049/jimmunol.175.9.5912; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907	47	46	46	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1124	+		10.1016/j.jaci.2013.11.028	http://dx.doi.org/10.1016/j.jaci.2013.11.028			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24418478	Green Published, Bronze, Green Submitted			2022-12-18	WOS:000333531700024
J	Beasley, R; Weatherall, M; Shirtcliffe, P; Hancox, R; Reddel, HK				Beasley, Richard; Weatherall, Mark; Shirtcliffe, Philippa; Hancox, Robert; Reddel, Helen K.			Combination corticosteroid/beta-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; combination therapy; inhaled steroid; beta-agonist	DOUBLE-BLIND; PERSISTENT ASTHMA; EARLY INTERVENTION; RESCUE TREATMENT; SINGLE INHALER; EXACERBATIONS; BUDESONIDE; MAINTENANCE; FORMOTEROL; CHILDREN	The recommended treatment of mild asthma is regular maintenance inhaled corticosteroids (ICSs) with a short-acting beta-agonist as a separate inhaler used when needed for symptom relief. However, the benefits of regular ICS use in actual clinical practice are limited by poor adherence and low prescription rates. An alternative strategy would be the symptom-driven (as-required or "prn") use of a combination ICS/short-acting beta-agonist or ICS/long-acting beta-agonist inhaler as a reliever rather than regular maintenance use. The rationale for this approach is to titrate both the ICS and beta-agonist dose according to need and enhance ICS use in otherwise poorly adherent patients who overrely on their reliever beta-agonist inhaler. This strategy will only work if the beta-agonist component has a rapid onset of action for symptom relief. There is evidence to suggest that this regimen has advantages over regular ICS therapy and might represent an effective, safe, and novel therapy for the treatment of intermittent and mild asthma. In this commentary we review this evidence and propose that randomized controlled trials investigating different combination ICS/beta-agonist inhaler products prescribed according to this regimen in intermittent and mild asthma are an important priority.	[Beasley, Richard; Shirtcliffe, Philippa] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Weatherall, Mark] Univ Otago Wellington, Dept Med, Wellington, New Zealand; [Hancox, Robert] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; [Reddel, Helen K.] Woolcock Inst Med Res, Clin Med Grp, Sydney, NSW, Australia	Medical Research Institute Of New Zealand; University of Otago; University of Otago; University of Sydney; Woolcock Institute of Medical Research	Beasley, R (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	Richard.Beasley@mrinz.ac.nz	Weatherall, Mark/Y-6824-2019; Beasley, Richard/AAH-3908-2019; Reddel, Helen/ABD-6338-2021; Reddel, Helen/AAC-3394-2020	Weatherall, Mark/0000-0002-0051-9107; Beasley, Richard/0000-0003-0337-406X; Reddel, Helen/0000-0002-6695-6350	Cytos Biotechnology; Pharmaxis; AstraZeneca; Chiesi; Cephalon; GlaxoSmithKline; Genentech; Novartis; Health Research Council of New Zealand; Otsuka; Mundipharma	Cytos Biotechnology; Pharmaxis; AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); Cephalon; GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Novartis(Novartis); Health Research Council of New Zealand(Health Research Council of New Zealand); Otsuka(Otsuka Pharmaceutical); Mundipharma	R. Beasley is a board member for the Health Research Council of New Zealand and GlaxoSmithKline; has received consultancy fees from Cytos Biotechnology and Pharmaxis; has received research support from AstraZeneca, Chiesi, Cephalon, GlaxoSmithKline, Genentech, Novartis, and the Health Research Council of New Zealand; has received lecture fees from GlaxoSmithKline, Novartis, and Otsuka; and has received travel support from Boehringer Ingelheim, Nycomed, and Novartis. R. Hancox has received lecture fees from GlaxoSmithKline and has received travel support from Boehringer Ingelheim. H. K. Reddel is a board member for AstraZeneca, GlaxoSmithKline, Merck, and Novartis; has received consultancy fees from AstraZeneca, Mundipharma, and Novartis; has received research support from GlaxoSmithKline and AstraZeneca; and has received payment for manuscript preparation from AstraZeneca, GlaxoSmithKline, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 3 NAT HEART LUNG BLO; Barnes PJ, 2007, EUR RESPIR J, V29, P587, DOI 10.1183/09031936.00080306; Beasley R, 2006, J ALLERGY CLIN IMMUN, V117, P225, DOI 10.1016/j.jaci.2005.10.029; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Beasley R, 1997, CIBA F SYMP, V206, P140; Beasley R, 2010, LANCET, V376, P750, DOI 10.1016/S0140-6736(10)61158-0; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Chowdhury BA, 2011, NEW ENGL J MED, V364, P2473, DOI 10.1056/NEJMp1104375; Dusser D, 2007, ALLERGY, V62, P591, DOI 10.1111/j.1398-9995.2007.01394.x; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Papi A, 2009, ALLERGY, V64, P1463, DOI 10.1111/j.1398-9995.2009.02134.x; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Papi A, 2013, LANCET RESP MED, V1, P23, DOI 10.1016/S2213-2600(13)70012-2; Papi A, 2009, CHEST, V135, P1628, DOI 10.1378/chest.08-2536; Patel M, 2013, LANCET RESP MED, V1, P32, DOI 10.1016/S2213-2600(13)70007-9; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rodrigo GJ, 2006, CHEST, V130, P1301, DOI 10.1378/chest.130.5.1301; Rodrigo GJ, 2012, THORAX, V67, P342, DOI 10.1136/thx.2010.155648; Stempel DA, 2005, RESP MED, V99, P1263, DOI 10.1016/j.rmed.2005.03.002; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Turpeinen M, 2008, ARCH DIS CHILD, V93, P654, DOI 10.1136/adc.2007.116632; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	32	46	48	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					39	41		10.1016/j.jaci.2013.10.053	http://dx.doi.org/10.1016/j.jaci.2013.10.053			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369798				2022-12-18	WOS:000329105700005
J	Kerkhof, M; Boezen, HM; Granell, R; Wijga, AH; Brunekreef, B; Smit, HA; de Jongste, JC; Thijs, C; Mommers, M; Penders, J; Henderson, J; Koppelman, GH; Postma, DS				Kerkhof, Marjan; Boezen, H. Marike; Granell, Raquel; Wijga, Alet H.; Brunekreef, Bert; Smit, Henriette A.; de Jongste, Johan C.; Thijs, Carel; Mommers, Monique; Penders, John; Henderson, John; Koppelman, Gerard H.; Postma, Dirkje S.			Transient early wheeze and lung function in early childhood associated with chronic obstructive pulmonary disease genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; transient early wheeze; lung function growth; in utero exposure	1ST 6 YEARS; KOALA BIRTH COHORT; SMOKE EXPOSURE; SERPINE2 GENE; ASTHMA; CHILDREN; RISK; LIFE; POLYMORPHISMS; INFANCY	Background: It has been hypothesized that a disturbed early lung development underlies the susceptibility to chronic obstructive pulmonary disease (COPD). Little is known about whether subjects genetically predisposed to COPD show their first symptoms or reduced lung function in childhood. Objective: We investigated whether replicated genes for COPD associate with transient early wheeze (TEW) and lung function levels in 6-to 8-year-old children and whether cigarette smoke exposure in utero and after birth (environmental tobacco smoke [ETS]) modifies these effects. Methods: The association of COPD-related genotypes of 20 single nucleotide polymorphisms in 15 genes with TEW, FEV1, forced vital capacity (FVC), and FEV1/FVC ratio was studied in the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort (n = 1996) and replicated in the Child, parents and health: lifestyle and genetic constitution (KOALA) and Avon Longitudinal Study of Parents and Children (ALSPAC) cohorts. Results: AGER showed replicated association with FEV1/FVC ratio. TNS1 associated withmoreTEWinPIAMAand lower FEV1 in ALSPAC. TNS1 interacted with ETS in PIAMA, showing lower FEV1 in exposed children. HHIP rs1828591 interacted with cigarette smoke exposure in utero in PIAMA and with ETS in ALSPAC, with lower lung function in nonexposed children. SERPINE2, FAM13A, and MMP12 associated with higher FEV1 and FVC, and SERPINE2, HHIP, and TGFB1 interacted with cigarette smoke exposure in utero in PIAMAonly, showing adverse effects of exposure on FEV1 being limited to children with genotypes conferring the lowest risk of COPD. Conclusion: Our findings indicate relevant involvement of at least 3 COPD genes in lung development and lung growth by demonstrating associations pointing toward reduced airway caliber in early childhood. Furthermore, our results suggest that COPD genes are involved in the infant's lung response to smoke exposure in utero and in early life.	[Kerkhof, Marjan; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 GZ Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Paediat Pulm, NL-9713 GZ Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9713 GZ Groningen, Netherlands; [Kerkhof, Marjan; Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, GRIAC Inst, NL-9713 GZ Groningen, Netherlands; [Granell, Raquel; Henderson, John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Wijga, Alet H.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [de Jongste, Johan C.] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat,Div Resp Mes, Rotterdam, Netherlands; [Thijs, Carel; Mommers, Monique; Penders, John] Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, Dept Epidemiol, Maastricht, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Bristol; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Maastricht University	Kerkhof, M (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.kerkhof@umcg.nl	Thijs, Carel/H-8340-2019; Penders, John/A-1280-2011; Granell, Raquel/AAB-5256-2022; Granell, Raquel/AAY-4846-2020; Koppelman, Gerard/AAG-9187-2020	Thijs, Carel/0000-0001-6646-5458; Penders, John/0000-0001-9146-5919; Granell, Raquel/0000-0002-4890-4012; brunekreef, bert/0000-0001-9908-0060; Koppelman, Gerard/0000-0001-8567-3252	Dutch Asthma Foundation [3.2.09.043]; ZonMw (the Netherlands Organization for Health Research and Development); Netherlands Ministry of Spatial Planning, Housing and the Environment; Netherlands Ministry of Health, Welfare and Sport; Wellcome Trust [092731]; Medical Research Council [G9815508, MC_PC_15018, G0401540] Funding Source: researchfish; MRC [G0401540] Funding Source: UKRI	Dutch Asthma Foundation; ZonMw (the Netherlands Organization for Health Research and Development)(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Netherlands Ministry of Spatial Planning, Housing and the Environment; Netherlands Ministry of Health, Welfare and Sport; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Dutch Asthma Foundation (grant 3.2.09.043); ZonMw (the Netherlands Organization for Health Research and Development); the Netherlands Ministry of Spatial Planning, Housing and the Environment; and the Netherlands Ministry of Health, Welfare and Sport. The UK Medical Research Council, Wellcome Trust (grant 092731), and the University of Bristol provided core support for the Avon Longitudinal Study of Parents and Children (ALSPAC).	Alejandre-Alcazar MA, 2008, DEV DYNAM, V237, P259, DOI 10.1002/dvdy.21403; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Artigas MS, 2011, AM J RESP CRIT CARE, V184, P786, DOI 10.1164/rccm.201102-0192OC; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Bush A, 2008, COPD, V5, P53, DOI 10.1080/15412550701815965; Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535; Ciencewicki J, 2008, J ALLERGY CLIN IMMUN, V122, P456, DOI 10.1016/j.jaci.2008.08.004; Conneely KN, 2007, AM J HUM GENET, V81, P1158, DOI 10.1086/522036; Cook DG, 1998, THORAX, V53, P884, DOI 10.1136/thx.53.10.884; Cremers E, 2011, THORAX, V66, P474, DOI 10.1136/thx.2010.151985; Demeo DL, 2009, AM J HUM GENET, V85, P493, DOI 10.1016/j.ajhg.2009.09.004; DeMeo DL, 2006, AM J HUM GENET, V78, P253, DOI 10.1086/499828; Gaens KHJ, 2009, J CLIN ENDOCR METAB, V94, P5174, DOI 10.1210/jc.2009-1067; Greenlee KJ, 2007, PHYSIOL REV, V87, P69, DOI 10.1152/physrev.00022.2006; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hersh CP, 2005, AM J RESP CELL MOL, V33, P71, DOI 10.1165/rcmb.2005-0073OC; Himes BE, 2011, CHEST, V140, P667, DOI 10.1378/chest.10-2973; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Jones LL, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-5; Kotecha SJ, 2010, AM J RESP CRIT CARE, V181, P969, DOI 10.1164/rccm.200906-0897OC; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Landau LI, 2008, PAEDIATR RESPIR REV, V9, P39, DOI 10.1016/j.prrv.2007.11.002; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2002, PEDIATRICS, V109, P362; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Postma DS, 2012, THORAX, V67, P88, DOI 10.1136/thoraxjnl-2011-200758; Postma DS, 2011, AM J RESP CRIT CARE, V183, P1588, DOI 10.1164/rccm.201011-1796PP; Reijmerink NE, 2009, ALLERGY, V64, P898, DOI 10.1111/j.1398-9995.2009.01939.x; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Reynolds PR, 2008, AM J PHYSIOL-LUNG C, V294, pL1094, DOI 10.1152/ajplung.00318.2007; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Shi Wei, 2009, Proc Am Thorac Soc, V6, P558, DOI 10.1513/pats.200905-031RM; Silverman M, 2007, LANCET, V370, P717, DOI 10.1016/S0140-6736(07)61354-3; Smolonska J, 2009, AM J RESP CRIT CARE, V180, P618, DOI 10.1164/rccm.200905-0722OC; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Warburton David, 2006, Proc Am Thorac Soc, V3, P668, DOI 10.1513/pats.200605-122SF; Wilk JB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000429; Zhang YG, 2010, RESPIROLOGY, V15, P643, DOI 10.1111/j.1440-1843.2010.01748.x; Zhu G, 2007, AM J RESP CRIT CARE, V176, P167, DOI 10.1164/rccm.200611-1723OC	48	46	50	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					68	+		10.1016/j.jaci.2013.06.004	http://dx.doi.org/10.1016/j.jaci.2013.06.004			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23886569	Green Published			2022-12-18	WOS:000329105700009
J	Hartmann, K; Wagner, N; Rabenhorst, A; Pflanz, L; Leja, S; Forster, A; Gehring, M; Kapp, A; Raap, U				Hartmann, Karin; Wagner, Nicola; Rabenhorst, Anja; Pflanz, Liselotte; Leja, Silke; Foerster, Anja; Gehring, Manuela; Kapp, Alexander; Raap, Ulrike			Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DERMATITIS		[Hartmann, Karin; Rabenhorst, Anja; Pflanz, Liselotte; Leja, Silke; Foerster, Anja] Univ Cologne, Dept Dermatol, Cologne, Germany; [Wagner, Nicola] Klinikum Darmstadt, Dept Dermatol, Darmstadt, Germany; [Gehring, Manuela; Kapp, Alexander; Raap, Ulrike] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany	University of Cologne; Klinikum Darmstadt; Hannover Medical School	Hartmann, K (corresponding author), Univ Cologne, Dept Dermatol, Cologne, Germany.	karin.hartmann@uni-koeln.de	Rabenhorst, Anja/J-3217-2016; Hartmann, Karin/N-4865-2015	Hartmann, Karin/0000-0002-4595-8226; Kapp, Alexander/0000-0002-1748-6276				Akin C, 2002, INT ARCH ALLERGY IMM, V127, P133, DOI 10.1159/000048184; Cornelissen C, 2012, EUR J CELL BIOL, V91, P552, DOI 10.1016/j.ejcb.2011.07.006; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Kushnir-Sukhov NM, 2006, INT ARCH ALLERGY IMM, V139, P265, DOI 10.1159/000091172; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84	9	46	48	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					232	235		10.1016/j.jaci.2012.11.008	http://dx.doi.org/10.1016/j.jaci.2012.11.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23260756				2022-12-18	WOS:000321052300035
J	Kulis, M; MacQueen, I; Li, YF; Guo, RS; Zhong, XP; Burks, AW				Kulis, Mike; MacQueen, Ian; Li, Yifan; Guo, Rishu; Zhong, Xiao-Ping; Burks, A. Wesley			Pepsinized cashew proteins are hypoallergenic and immunogenic and provide effective immunotherapy in mice with cashew allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; tree nut allergy; cashew; immunotherapy; pepsin; murine model	CELL EPITOPE PEPTIDES; MURINE MODEL; MAST-CELLS; PEANUT; DIGESTION; FOOD; ANAPHYLAXIS; REACTIVITY; RESPONSES	Background: IgE-mediated allergic reactions to cashews and other nuts can trigger life-threatening anaphylaxis. Proactive therapies to decrease reaction severity do not exist. Objectives: We aimed to determine the efficacy of pepsin-digested cashew proteins used as immunotherapy in a murine model of cashew allergy. Methods: Mice were sensitized to cashew and then underwent challenges with digested or native cashew allergens to assess the allergenicity of the protein preparations. Using native or pepsinized cashew proteins, mice underwent oral or intraperitoneal sensitization protocols to determine the immunogenic properties of the protein preparations. Finally, cashew-sensitized mice underwent an immunotherapy protocol with native or pepsinized cashew proteins and subsequent provocation challenges. Results: Pepsinized cashew proteins elicited weaker allergic reactions than native cashew proteins but importantly retained the ability to stimulate cellular proliferation and cytokine production. Mice sensitized with pepsinized proteins reacted on challenge with native allergens, demonstrating that pepsinized allergens retain immunogenicity in vivo. Immunotherapy with pepsinized cashew allergens significantly decreased allergic symptoms and body temperature decrease relative to placebo after challenge with native and pepsinized proteins. Immunologic changes were comparable after immunotherapy with native or pepsinized allergens: T(H)2-type cytokine secretion from splenocytes was decreased, whereas specific IgG(1) and IgG(2a) levels were increased. Conclusions: Pepsinized cashew proteins are effective in treating cashew allergy in mice and appear to work through the same mechanisms as native protein immunotherapy. (J Allergy Clin Immunol 2012;130:716-23.)	[Kulis, Mike; MacQueen, Ian; Li, Yifan; Guo, Rishu; Zhong, Xiao-Ping; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat Allergy & Immunol, Durham, NC 27710 USA	Duke University	Kulis, M (corresponding author), Duke Univ, Med Ctr, Dept Pediat Allergy & Immunol, Med Sci Res Bldg 1,Rm 141, Durham, NC 27710 USA.	Michael.kulis@duke.edu			NRSA [1F32AI084332-01]; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); NIH; American Cancer Society; Food Allergy & Anaphylaxis Network (FAAN); Food Allergy Initiative; National Peanut Board; Scientific Hospital Supplies; Wallace Research Foundation; Dannon Co Probiotics; ExploraMed Development; Intelliject; McNeil Nutritionals; Merck Co; Novartis; Nutricia; Pfizer; Portola Pharmaceuticals; Schering- Plough; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI084332, R01AI079088, R01AI101206, R21AI079873] Funding Source: NIH RePORTER	NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Food Allergy & Anaphylaxis Network (FAAN); Food Allergy Initiative; National Peanut Board; Scientific Hospital Supplies; Wallace Research Foundation; Dannon Co Probiotics; ExploraMed Development; Intelliject; McNeil Nutritionals; Merck Co(Merck & Company); Novartis(Novartis); Nutricia(Danone Nutricia); Pfizer(Pfizer); Portola Pharmaceuticals; Schering- Plough(Merck & CompanySchering Plough Corporation); UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by an NRSA F32 Fellowship to M.K. (1F32AI084332-01).; M. Kulis has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and is employed by Duke University. R. Guo is employed by Duke University. X.-P. Zhong has received research support from the NIH, the American Cancer Society, and the Food Allergy & Anaphylaxis Network (FAAN). A. W. Burks has received research support from the NIAID/NIH, the FAAN, the Food Allergy Initiative, the NIH, the National Peanut Board, Scientific Hospital Supplies, and the Wallace Research Foundation; has received travel support from the NIAID/NIH, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology, and the European Academy of Allergy and Clinical Immunology; is on the board for the AAAAI, the FAAN, the US Food and Drug Administration, the Journal of Allergy and Clinical Immunology, and the NIH HAI; has received consultancy fees from Dannon Co Probiotics, ExploraMed Development, Intelliject, McNeil Nutritionals, Merck & Co, Novartis, Nutricia, Pfizer, Portola Pharmaceuticals, and Schering- Plough; is employed by the Duke University Medical Center and UNC North Carolina Children's Hospital; receives royalties from UpToDate; has received payment for educational presentations development from Current Views; and has stock/stock options in Allertein and MastCell. The rest of the authors declare that they have no relevant conflicts of interest.	Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bogh KL, 2009, CLIN EXP ALLERGY, V39, P1611, DOI 10.1111/j.1365-2222.2009.03333.x; Campana R, 2010, J ALLERGY CLIN IMMUN, V126, P1024, DOI 10.1016/j.jaci.2010.05.023; Clark AT, 2007, ALLERGY, V62, P913, DOI 10.1111/j.1398-9995.2007.01447.x; Clark S, 2011, J ALLERGY CLIN IMMUN, V127, P682, DOI 10.1016/j.jaci.2010.10.040; Ditto AM, 2010, ALLERGY, V65, P1485, DOI 10.1111/j.1398-9995.2010.02371.x; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; Hong SJ, 1999, J ALLERGY CLIN IMMUN, V104, P473, DOI 10.1016/S0091-6749(99)70396-9; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Kulis M, 2009, INT ARCH ALLERGY IMM, V148, P109, DOI 10.1159/000155741; Kulis M, 2011, J ALLERGY CLIN IMMUN, V127, P81, DOI 10.1016/j.jaci.2010.09.014; Larche Mark, 2007, Allergy Asthma Clin Immunol, V3, P53, DOI 10.1186/1710-1492-3-2-53; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Song Y, 2010, J ALLERGY CLIN IMMUN, V126, P1208, DOI 10.1016/j.jaci.2010.09.013; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Untersmayr E, 2007, J ALLERGY CLIN IMMUN, V119, P711, DOI 10.1016/j.jaci.2006.10.039; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, pe81; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Yang M, 2010, CLIN EXP ALLERGY, V40, P668, DOI 10.1111/j.1365-2222.2009.03442.x	34	46	51	2	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					716	723		10.1016/j.jaci.2012.05.044	http://dx.doi.org/10.1016/j.jaci.2012.05.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22795369	Green Accepted			2022-12-18	WOS:000308463500021
J	Haneda, Y; Kando, N; Yasui, M; Kobayashi, T; Maeda, T; Hino, A; Hasegawa, S; Ichiyama, T; Ito, K				Haneda, Yasuhiro; Kando, Naoyuki; Yasui, Masahiro; Kobayashi, Takae; Maeda, Toru; Hino, Asuka; Hasegawa, Shunji; Ichiyama, Takashi; Ito, Komei			Ovomucoids IgE is a better marker than egg white-specific IgE to diagnose boiled egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Haneda, Yasuhiro; Kando, Naoyuki; Yasui, Masahiro; Kobayashi, Takae; Maeda, Toru; Hino, Asuka; Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Japan; [Haneda, Yasuhiro; Hasegawa, Shunji; Ichiyama, Takashi] Yamaguchi Univ, Grad Sch Med, Dept Pediat, Ube, Yamaguchi 755, Japan	Yamaguchi University	Haneda, Y (corresponding author), Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Japan.	haneda0413@yahoo.co.jp						Ando H, 1997, J ALLERGY CLIN IMMUN, V122, P583; Ito Komei, 2004, Arerugi, V53, P24; Ito Komei, 2009, Allergology International, V58, P467, DOI 10.2332/allergolint.09-RAI-0140; Japanese Society of Pediatric Allergy and Clinical Immunology, 2009, JAP PED GUID OR FOOD; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3	8	46	47	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1681	1682		10.1016/j.jaci.2012.03.041	http://dx.doi.org/10.1016/j.jaci.2012.03.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22552111				2022-12-18	WOS:000304764600035
J	Gingo, MR; Wenzel, SE; Steele, C; Kessinger, CJ; Lucht, L; Lawther, T; Busch, M; Hillenbrand, ME; Weinman, R; Slivka, WA; McMahon, DK; Zhang, YZ; Sciurba, FC; Morris, A				Gingo, Matthew R.; Wenzel, Sally E.; Steele, Chad; Kessinger, Cathy J.; Lucht, Lorrie; Lawther, Tammi; Busch, Michelle; Hillenbrand, Maria E.; Weinman, Renee; Slivka, William A.; McMahon, Deborah K.; Zhang, Yingze; Sciurba, Frank C.; Morris, Alison			Asthma diagnosis and airway bronchodilator response in HIV-infected patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; asthma; airway obstruction; allergy	HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; GEORGES RESPIRATORY QUESTIONNAIRE; CD8(+) T-CELLS; INDUCED SPUTUM; CUSHINGS-SYNDROME; REFERENCE VALUES; INCIDENT ASTHMA; ALLERGIC-ASTHMA; UNITED-STATES	Background: Despite the high prevalence of respiratory symptoms and obstructive lung disease in HIV-infected subjects, the prevalence of bronchodilator reversibility (BDR) and asthma has not been systematically studied during the era of combination antiretroviral therapy (ART). Objective: We sought to determine the prevalence of asthma diagnosis and related pulmonary function abnormalities in an HIV-infected cohort and to identify potential mechanisms. Methods: We performed a cross-sectional analysis of 223 HIV-infected subjects with data on respiratory symptoms and diagnoses, pulmonary function, sputum cell counts, and asthma-related cytokines and chemokines in serum/sputum. Results: Doctor-diagnosed asthma was present in 46 (20.6%), and BDR (>= 200 mL and >= 12% increase in FEV1 or forced vital capacity) was present in 20 (9.0%) participants. Pulmonary symptoms and function were worse in those with doctor-diagnosed asthma. Doctor-diagnosed asthma was independently associated with female sex (P = .04), body mass index of greater than 29.6 kg/m(2) (vs < 29.6 kg/m(2), P = .03), history of bacterial or Pneumocystis pneumonia (P = .01), and not currently taking ART (P = .04) and in univariate analysis with parental history of asthma (n = 180, P = .004). High sputum eosinophil percentages (> 2.3% based on the highest decile) were more likely in those with doctor-diagnosed asthma (P = .02) or BDR (P = .02). Doctor-diagnosed asthma tended to be more common with high sputum IL-4 (P = .02) and RANTES (P = .02) levels, whereas BDR was associated with high plasma macrophage inflammatory protein 1 alpha (P = .002) and sputum macrophage inflammatory protein 1 beta (P = .001) levels. Conclusion: Asthma diagnosis and BDR are prevalent in an HIV-infected outpatient cohort, and associations with family history, obesity, allergic inflammation, prior infection, absence of ART, and increased HIV-stimulated cytokines suggest possible mechanisms of HIV-associated asthma. (J Allergy Clin Immunol 2012; 129: 708-14.)	[Gingo, Matthew R.; Wenzel, Sally E.; Kessinger, Cathy J.; Lucht, Lorrie; Lawther, Tammi; Busch, Michelle; Hillenbrand, Maria E.; Weinman, Renee; Slivka, William A.; McMahon, Deborah K.; Zhang, Yingze; Sciurba, Frank C.; Morris, Alison] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15260 USA; [Morris, Alison] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15260 USA; [Steele, Chad] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham	Morris, A (corresponding author), 3459 5th Ave,628NW, Pittsburgh, PA 15213 USA.	morrisa@upmc.edu	Sciurba, Frank/AAZ-9339-2021; Gingo, Matthew/K-7203-2013	Wenzel, Sally/0000-0002-4242-0164; sciurba, frank/0000-0001-7468-2225	National Institutes of Health [T32 HL007563, K23 HL108697, P50 HL084948, N01 HR46163R01, R01 HL083461, HL083461S]; University of Pittsburgh CTSI [UL1 RR024153]; National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL046163, R01HL083461, P50HL084948, K23HL108697, F32HL008346, T32HL007563] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pittsburgh CTSI; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants T32 HL007563, K23 HL108697 (both to M. R. G.), P50 HL084948, N01 HR46163R01 (both to F. C. S.), R01 HL083461, and HL083461S (both to A. M.) and the University of Pittsburgh CTSI (UL1 RR024153).; M. R. Gingo and A. Morris have received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Barr JT, 2000, CLIN THER, V22, P1121, DOI 10.1016/S0149-2918(00)80089-2; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bisset LR, 2005, CURR OPIN PULM MED, V11, P35, DOI 10.1097/01.mcp.0000144502.50149.e0; Bogaert P, 2011, AM J PHYSIOL-LUNG C, V300, pL679, DOI 10.1152/ajplung.00202.2010; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celli BR, 2005, AM J MED, V118, P1364, DOI 10.1016/j.amjmed.2005.06.041; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P262; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Crothers K, 2011, AM J RESP CRIT CARE, V183, P388, DOI 10.1164/rccm.201006-0836OC; Diaz PT, 2000, ANN INTERN MED, V132, P369, DOI 10.7326/0003-4819-132-5-200003070-00006; Diaz PT, 1999, AM J RESP CRIT CARE, V160, P272, DOI 10.1164/ajrccm.160.1.9812089; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Foisy MM, 2008, HIV MED, V9, P389, DOI 10.1111/j.1468-1293.2008.00579.x; Foster SB, 2008, J ALLERGY CLIN IMMUN, V122, P159, DOI 10.1016/j.jaci.2008.04.043; George MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006328; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Gingo MR, 2010, AM J RESP CRIT CARE, V182, P790, DOI 10.1164/rccm.200912-1858OC; Gougeon ML, 2004, ANTIVIR THER, V9, P161; Grob M, 2003, ALLERGY, V58, P239, DOI 10.1034/j.1398-9995.2003.00035.x; Gutin F, 2009, ANN ALLERG ASTHMA IM, V102, P438, DOI 10.1016/S1081-1206(10)60518-2; Han SH, 2009, TOHOKU J EXP MED, V219, P145, DOI 10.1620/tjem.219.145; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Hosmer DW, 1997, STAT MED, V16, P965; Jesser RD, 2006, VIROLOGY, V352, P408, DOI 10.1016/j.virol.2006.04.035; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Kaviani N, 2011, ENDOCR PRACT, V17, P74, DOI 10.4158/EP09288.CR; Kedem E, 2010, J ASTHMA, V47, P830, DOI 10.3109/02770903.2010.485666; KESTEN S, 1994, CHEST, V105, P1042, DOI 10.1378/chest.105.4.1042; Kronander UN, 2004, RESP MED, V98, P1108, DOI 10.1016/j.rmed.2004.03.022; Louie JK, 2002, J INFECT DIS, V186, P1023, DOI 10.1086/343862; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; MILLER A, 1983, AM REV RESPIR DIS, V127, P270; Miller J, 2003, HIV Med, V4, P293; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moreno S, 2009, AIDS REV, V11, P126; Moreno-Fernandez ME, 2009, J VIROL, V83, P12925, DOI 10.1128/JVI.01352-09; MOSCATO G, 1993, CHEST, V103, P796, DOI 10.1378/chest.103.3.796; ODONNELL CR, 1988, CHEST, V94, P945, DOI 10.1378/chest.94.5.945; Onat A, 2004, INT J OBESITY, V28, P1018, DOI 10.1038/sj.ijo.0802695; Pakhale S, 2010, CHEST, V137, P1316, DOI 10.1378/chest.09-2491; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Poirier CD, 2001, AM J RESP CRIT CARE, V164, P542, DOI 10.1164/ajrccm.164.4.2010019; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Shore SA, 2010, J APPL PHYSIOL, V108, P735, DOI 10.1152/japplphysiol.00749.2009; Sitbon O, 2008, AM J RESP CRIT CARE, V177, P108, DOI 10.1164/rccm.200704-541OC; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Tsiodras S, 2010, J INFECTION, V61, P101, DOI 10.1016/j.jinf.2010.06.002; Wallace JM, 1997, CHEST, V111, P121, DOI 10.1378/chest.111.1.121; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	55	46	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					708	U168		10.1016/j.jaci.2011.11.015	http://dx.doi.org/10.1016/j.jaci.2011.11.015			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22177327	Green Accepted			2022-12-18	WOS:000301189300015
J	Krause, K; Feist, E; Fiene, M; Kallinich, T; Maurer, M				Krause, Karoline; Feist, Eugen; Fiene, Michael; Kallinich, Tilmann; Maurer, Marcus			Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAKINRA		[Krause, Karoline; Feist, Eugen; Kallinich, Tilmann; Maurer, Marcus] Charite, Autoinflammat Reference Ctr Charite, D-13353 Berlin, Germany; [Krause, Karoline; Maurer, Marcus] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Feist, Eugen] Charite, Dept Rheumatol, D-13353 Berlin, Germany; [Kallinich, Tilmann] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Fiene, Michael] Univ Med Greifswald, Dept Internal Med A, Greifswald, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Greifswald Medical School	Krause, K (corresponding author), Charite, Autoinflammat Reference Ctr Charite, D-13353 Berlin, Germany.	marcus.maurer@charite.de	Krause, Karoline/G-5218-2018; Maurer, Marcus/ABG-2174-2020	Krause, Karoline/0000-0001-9711-9654; Maurer, Marcus/0000-0002-4121-481X				de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; deKleijn EMHA, 1997, NETH J MED, V51, P140, DOI 10.1016/S0300-2977(97)00041-7; Dybowski F, 2008, CLIN EXP RHEUMATOL, V26, P354; Goldbach-Mansky R, 2008, ARTHRITIS RHEUM-US, V58, P2432, DOI 10.1002/art.23620; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Lattanzio G, 1997, AM J PATHOL, V151, P689; Lipsker D, 2001, MEDICINE, V80, P37, DOI 10.1097/00005792-200101000-00004; Martinez-Taboada VM, 2005, ARTHRITIS RHEUM, V52, P2226, DOI 10.1002/art.21101; Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021; Schneider SW, 2007, J AM ACAD DERMATOL, V56, pS120, DOI 10.1016/j.jaad.2006.05.057; Vaitla PM, 2011, ARTHRITIS RHEUM-US, V63, P1151, DOI 10.1002/art.30215; Worm M, 2003, BRIT J DERMATOL, V148, P601, DOI 10.1046/j.1365-2133.2003.05209_9.x	13	46	49	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					848	850		10.1016/j.jaci.2011.10.031	http://dx.doi.org/10.1016/j.jaci.2011.10.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22154381				2022-12-18	WOS:000301189300035
J	Keet, CA; McCormack, MC; Peng, RD; Matsui, EC				Keet, Corinne A.; McCormack, Meredith C.; Peng, Roger D.; Matsui, Elizabeth C.			Age- and atopy-dependent effects of vitamin D on wheeze and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Keet, Corinne A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA; [McCormack, Meredith C.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Keet, CA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21218 USA.	ckeet1@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593; Koehl, Rachelle/0000-0002-7797-7456; McCormack, Meredith/0000-0003-1702-3201; Pham, Hewlett/0000-0003-0330-6104; Keet, Corinne/0000-0002-6585-239X; Ayers, Andrew/0000-0001-5305-7156	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015903, K23ES016819, P01ES018176] Funding Source: NIH RePORTER; NCRR NIH HHS [KL2 RR025006, KL2 RR025006-02] Funding Source: Medline; NIAID NIH HHS [R01AI070630, R01 AI070630, R01 AI070630-01] Funding Source: Medline; NIEHS NIH HHS [P50ES015903, P50 ES015903, K23 ES016819-03, K23ES016819, P01 ES018176-01, K23 ES016819, P01 ES018176, P50 ES015903-01] Funding Source: Medline; PHS HHS [1KL2R R025006-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Herr C, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-31; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sandhu MS, 2010, ANN ALLERG ASTHMA IM, V105, P191, DOI 10.1016/j.anai.2010.01.013; Searing DA, 2010, IMMUNOL ALLERGY CLIN, V30, P397, DOI 10.1016/j.iac.2010.05.005; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Taylor CE, 2011, NUTR REV, V69, P259, DOI 10.1111/j.1753-4887.2011.00386.x; Zosky GR, 2011, AM J RESP CRIT CARE, V183, P1336, DOI 10.1164/rccm.201010-1596OC	8	46	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					414	416		10.1016/j.jaci.2011.06.011	http://dx.doi.org/10.1016/j.jaci.2011.06.011			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807254	Green Accepted			2022-12-18	WOS:000293280800025
J	Ozturk, F; Bakirtas, A; Ileri, F; Turktas, I				Ozturk, Fadil; Bakirtas, Arzu; Ileri, Fikret; Turktas, Ipek			Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; methylprednisolone; computed tomographic scan	CHRONIC SINUSITIS; SURGERY; SPRAY	Background: The place of systemic corticosteroids in the treatment of children with chronic rhinosinusitis (CRS) remains unclear. Objective: We sought to assess the effectiveness and tolerability of oral methylprednisolone as an anti-inflammatory adjunct in the treatment of CRS in children. Methods: Forty-eight children (age, 6-17 years) with clinically and radiologically proved CRS were included. Patients were randomly assigned to either oral amoxicillin/clavulanate (AMX/C) and methylprednisolone or AMX/C and placebo twice daily for 30 days. Oral methylprednisolone was administered for the first 15 days with a tapering schedule. Primary parameters were mean change in symptom and sinus computed tomographic (CT) scan scores after treatment. Secondary study parameters were mean changes in individual symptom scores after treatment, relapse rate, and tolerability. Results: Forty-five patients completed the study: 22 received AMX/C and methylprednisolone, and 23 received AMX/C and placebo. Both groups demonstrated significant improvements in symptom and sinus CT scores when comparing baseline values with end-of-treatment values (P < .001). Methylprednisolone as an adjunct was significantly more effective than placebo in reducing CT scores (P = .004), total rhinosinusitis symptoms (P = .001), and individual symptoms of nasal obstruction (P = .001), postnasal discharge (P = .007), and cough (P = .009). At the end of treatment, 48% of the children in the placebo group still had abnormal findings on CT scans versus 14% in the methylprednisolone group (P = .013). Therapy-related adverse events were not different between groups. Although insignificant, the incidence of clinical relapses was also less in the methylprednisolone group (25%) compared with that in the placebo group (43%, P = .137). Conclusion: Oral methylprednisolone is well tolerated and provides added benefit to treatment with antibiotics for children with CRS. (J Allergy Clin Immunol 2011;128:348-52.)	[Ozturk, Fadil] Ondokuz Mayis Univ, Fac Med, Div Pediat Allergy & Clin Immunol, Dept Pediat, TR-55200 Samsun, Turkey; [Bakirtas, Arzu; Turktas, Ipek] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Allergy & Asthma, Ankara, Turkey; [Ileri, Fikret] Gazi Univ, Fac Med, Dept Otorhinolaryngol, Ankara, Turkey	Ondokuz Mayis University; Gazi University; Gazi University	Ozturk, F (corresponding author), Ondokuz Mayis Univ, Fac Med, Div Pediat Allergy & Clin Immunol, Dept Pediat, TR-55200 Samsun, Turkey.	fadil@doctor.com	İleri, Fikret/GXN-0779-2022					Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Chan KH, 2004, J PEDIATR-US, V144, P206, DOI 10.1016/j.jpeds.2003.11.009; Danielsen A, 1996, ACTA OTO-LARYNGOL, V116, P611, DOI 10.3109/00016489609137898; Desrosiers MY, 2008, RHINOLOGY, V46, P3; Dijkstra MD, 2004, CLIN EXP ALLERGY, V34, P1395, DOI 10.1111/j.1365-2222.2004.02044.x; Driscoll PV, 1996, ARCH OTOLARYNGOL, V122, P1071; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; Hill M, 2004, OTOLARYNG HEAD NECK, V130, P171, DOI 10.1016/j.otohns.2003.11.006; Isaacson G, 1996, PEDIATR CLIN N AM, V43, P1297, DOI 10.1016/S0031-3955(05)70520-4; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Metson R, 1997, OTOLARYNG HEAD NECK, V117, P372, DOI 10.1016/S0194-5998(97)70129-3; Mullol J, 2009, IMMUNOL ALLERGY CLIN, V29, P657, DOI 10.1016/j.iac.2009.07.001; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Parsons DS, 1996, OTOLARYNG CLIN N AM, V29, P1; Pujols L, 2010, FRONT BIOSCI-LANDMRK, V15, P789, DOI 10.2741/3646; SCHLEISS MR, 2007, PRINCIPLES ANTIBACTE, P1110; Subramanian HN, 2002, AM J RHINOL, V16, P303, DOI 10.1177/194589240201600605; Triulzi F, 2007, PEDIAT ALLERG IMM-UK, V18, P46, DOI 10.1111/j.1399-3038.2007.00633.x; van Drunen CM, 2009, IMMUNOL ALLERGY CLIN, V29, P621, DOI 10.1016/j.iac.2009.07.003; Wallwork B, 2002, LARYNGOSCOPE, V112, P1827, DOI 10.1097/00005537-200210000-00022; Weinberger M, 2007, J ALLERGY CLIN IMMUN, V119, P567, DOI 10.1016/j.jaci.2006.12.641; Wu AW, 2009, IMMUNOL ALLERGY CLIN, V29, P705, DOI 10.1016/j.iac.2009.07.007; Zacharek Mark A, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P196, DOI 10.1097/00020840-200306000-00012	26	46	47	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					348	352		10.1016/j.jaci.2011.04.045	http://dx.doi.org/10.1016/j.jaci.2011.04.045			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21624649				2022-12-18	WOS:000293280800015
J	Wood, RA; Bloomberg, GR; Kattan, M; Conroy, K; Sandel, MT; Dresen, A; Gergen, PJ; Gold, DR; Schwarz, JC; Visness, CM; Gern, JE				Wood, Robert A.; Bloomberg, Gordon R.; Kattan, Meyer; Conroy, Kathleen; Sandel, Megan T.; Dresen, Amy; Gergen, Peter J.; Gold, Diane R.; Schwarz, John C.; Visness, Cynthia M.; Gern, James E.			Relationships among environmental exposures, cord blood cytokine responses, allergy, and wheeze at 1 year of age in an inner-city birth cohort (Urban Environment and Childhood Asthma study)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immune development; birth cohort; atopy; asthma; cytokines; allergen exposure; inner city	INTERFERON-GAMMA PRODUCTION; PRENATAL MATERNAL STRESS; ATOPIC DISEASE; MOUSE ALLERGEN; SUBSEQUENT DEVELOPMENT; MONONUCLEAR-CELLS; IL-13 PRODUCTION; CONTROLLED-TRIAL; NATURAL COURSE; EUROPE SPACE	Background: The Urban Environment and Childhood Asthma study was established to investigate the immunologic and environmental causes of asthma in inner-city children. Objective: We sought to evaluate potential atopic outcomes in the first 12 months and their relationships to environmental exposures and immune development. Methods: A birth cohort of 560 children with at least 1 parent with allergy or asthma was established in Baltimore, Boston, New York, and St Louis. Wheezing is assessed every 3 months, allergen-specific IgE yearly, and mononuclear cell cytokine responses at birth and yearly; environmental assessments include dust allergen and endotoxin, maternal stress, and indoor nicotine and nitrogen dioxide levels. Results: Key outcomes in the first year include wheeze in 49%, 2 or more episodes of wheeze in 23%, eczema in 30%, and detectable IgE to milk, egg, and/or peanut in 32% and to cockroach in 4%. Household dust revealed levels of greater than 2 mu g/g to cockroach in 40%, mite in 19%, cat in 25%, and mouse in 29%, and 66% of homes housed at least 1 smoker. Positive associations were detected between multiple wheeze and cotinine levels, maternal stress, and maternal depression, whereas cytokine responses to a variety of innate, adaptive, and mitogenic stimuli were inversely related to eczema. Conclusions: This high-risk cohort of inner-city infants is exhibiting high rates of wheeze, eczema, and allergic sensitization. Low cytokine responses at birth might be a risk factor for eczema, whereas a variety of adverse environmental exposures contribute to the risk of wheezing in infancy. These findings provide evidence of specificity in the interactions between immune development, environmental exposures, and the development of early features that might predict future asthma. (J Allergy Clin Immunol 2011;127:913-9.)	[Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, St Louis, MO USA; [Kattan, Meyer] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Conroy, Kathleen; Sandel, Megan T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Dresen, Amy; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Gergen, Peter J.] NIH, Div Allergy Immunol & Transplantat, Bethesda, MD 20892 USA; [Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Schwarz, John C.; Visness, Cynthia M.] Rho Fed Syst Div Inc, Chapel Hill, NC USA	Johns Hopkins University; Washington University (WUSTL); Columbia University; Boston University; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; Harvard University; Brigham & Women's Hospital	Wood, RA (corresponding author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu		Sandel, Megan/0000-0001-7324-6325	National Institute of Allergy and Infectious Diseases/National Institutes of Health [NO1-AI-25496, NO1-AI-25482]; National Center for Research Resources/National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02]; National Institutes of Health (NIH); Medical Advisory Board for the Food Allergy and Anaphylaxis Network; NIH/National Institute of Allergy and Infectious Diseases (NIAID); NIH; Environmental Protection Agency; AstraZeneca and Merck; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071, M01RR000533, UL1RR024992, M01RR000052, UL1RR024156, UL1RR025771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Advisory Board for the Food Allergy and Anaphylaxis Network; NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency(United States Environmental Protection Agency); AstraZeneca and Merck(AstraZeneca); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases/National Institutes of Health under contracts NO1-AI-25496 and NO1-AI-25482. Additional funds were provided by the National Center for Research Resources/National Institutes of Health under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02.; Disclosure of potential conflict of interest: R. A. Wood has received research support from the National Institutes of Health (NIH) and is on the Medical Advisory Board for the Food Allergy and Anaphylaxis Network. G. R. Bloomberg has received research support from the NIH/National Institute of Allergy and Infectious Diseases (NIAID). M. Kattan and C. M. Visness have received research support from the NIH. D. R. Gold has received research support from the NIH and the Environmental Protection Agency. J. E. Gern is on the Scientific Advisory Board and has stock options with 3V Biosciences; is a consultant and has stock options with EraGen Biosciences; is a consultant for Synairgen, Centocor, Boehringer Ingelheim, Pulmatrix, GlaxoSmithKline, and Biota; and has received research support from AstraZeneca and Merck. The rest of the authors have declared that they have no conflict of interest.	AKINBAMI LJ, 2007, ASTHMA PREVALENCE HL; Alwis KU, 2006, AM J IND MED, V49, P296, DOI 10.1002/ajim.20264; BOOTH CL, 1989, DEV PSYCHOL, V25, P403, DOI 10.1037/0012-1649.25.3.403; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Chew GL, 2006, ANN ALLERG ASTHMA IM, V97, P502, DOI 10.1016/S1081-1206(10)60942-8; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Halmerbauer G, 2002, PEDIAT ALLERG IMM-UK, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; Halmerbauer G, 2003, PEDIAT ALLERG IMM-UK, V14, P10, DOI 10.1034/j.1399-3038.2003.02069.x; Halonen M, 2009, J IMMUNOL, V182, P3285, DOI 10.4049/jimmunol.0711996; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Koopman LP, 2001, PEDIATRICS, V108, P943, DOI 10.1542/peds.108.4.943; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Lilly CM, 2005, J ALLERGY CLIN IMMUN, V115, pS526, DOI 10.1016/j.jaci.2005.01.028; LOBEL M, 1992, HEALTH PSYCHOL, V11, P32, DOI 10.1037/0278-6133.11.1.32; *NAT CTR HLTH STAT, 2009, 2008 CHARTB; Ohshima Y, 2002, PEDIATR RES, V51, P195, DOI 10.1203/00006450-200202000-00012; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593, DOI 10.1016/S1081-1206(10)61139-8; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sharma Sanjiv, 2007, Paediatr Drugs, V9, P107, DOI 10.2165/00148581-200709020-00004; Sharp MJ, 2003, CLIN EXP ALLERGY, V33, P435, DOI 10.1046/j.1365-2222.2003.01627.x; Shreffler WG, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-29; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; Venables W.N., 2002, MODERN APPL STAT S, V4th ed., DOI DOI 10.1198/TECH.2003.S33; Wahn U, 1997, PEDIAT ALLERG IMM-UK, V8, P16; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC	48	46	46	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					913	U136		10.1016/j.jaci.2010.12.1122	http://dx.doi.org/10.1016/j.jaci.2010.12.1122			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	743YL	21333343	Green Accepted			2022-12-18	WOS:000289055800012
J	Li, CW; Shi, L; Zhang, KK; Li, TY; Bin Lin, Z; Lim, MK; McKeon, F; Xian, W; Wang, DY				Li, Chun Wei; Shi, Li; Zhang, Ke Ke; Li, Tian Ying; Bin Lin, Zhi; Lim, Mei Kee; McKeon, Frank; Xian, Wa; Wang, De Yun			Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyposis; epithelial remodeling; p63; p73; glucocorticosteroids	INDUCED AIRWAY INFLAMMATION; STRESS-INDUCED APOPTOSIS; UP-REGULATION; P53 FAMILY; DOWN-REGULATION; DIRECT TARGET; STEM-CELLS; KAPPA-B; P63; DELTA-NP63-ALPHA	Background: Nasal polyposis (NP) is recognized as aberrant epithelial remodeling, but the molecular mechanism underlying this process is poorly understood. Two important p53 homologues (p63 and p73) play a key role in orchestrating the epithelial development. Objective: We intended to study whether p63 and p73 are involved in the epithelial remodeling seen in patients with NP and their response to oral glucocorticosteroid (GC) treatment. Methods: Nasal polyp tissues were obtained from 65 patients, and inferior turbinates were obtained from 19 control subjects without NP. Among patients with NP, 20 were treated with oral prednisone, so that 2 sets of polyp biopsy specimens were taken before (GC naive) and after (GC treated) treatment. Immunohistochemistry and quantitative PCR were performed to determine the expression levels of p63 and p73. Results: The increase in p63-positive cell numbers was significant in GC-naive NP epithelium (46%) compared with that seen in control epithelium (5%), and it was positively related to the epithelial hyperplasia in patients with NP. The increase in N-terminal transactivation domain p73-positive cell numbers was found in 27% of GC-naive patients with NP and 16% of control subjects, with no statistical difference. The mRNA expression of both p63 and p73 was significantly upregulated in GC-naive patients with NP versus control subjects, and a positive correlation between the p63 and p73 mRNAs was found in all nasal tissues. Furthermore, the improvement of epithelial structure and reduction of p63 mRNA/protein levels were found in patients with NP after GC treatment. Conclusions: Our results suggest that the ectopic expression of p63 in multiple cell layers is an important pathologic phenomenon in the epithelial remodeling seen in chronically inflamed airway epithelium (eg, in patients with NP), and its aberrant expression can be suppressed with GC treatment. (J Allergy Clin Immunol 2011;127:765-72.)	[Li, Chun Wei; Wang, De Yun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 119260, Singapore; [Shi, Li; Zhang, Ke Ke] Shandong Univ, Qilu Hosp, Dept Otolaryngol, Jinan 250100, Peoples R China; [Li, Tian Ying; Bin Lin, Zhi] Sun Yat Sen Univ, Affiliated Med Hosp 1, Dept Otolaryngol, Guangzhou 510275, Guangdong, Peoples R China; [Lim, Mei Kee; McKeon, Frank] Genom Inst Singapore, Singapore, Singapore; [McKeon, Frank] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; [Xian, Wa] Inst Med Biol, Singapore, Singapore	National University of Singapore; Shandong University; Sun Yat Sen University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Harvard University; Harvard Medical School; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Wang, DY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, 10 Lower Kent Ridge Rd, Singapore 119260, Singapore.	entwdy@nus.edu.sg			National Medical Research Council (NMRC) of Singapore [NMRC/0396/1999, NMRC/03nov036]	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore)	Supported by grants (NMRC/0396/1999 and NMRC/03nov036) from the National Medical Research Council (NMRC) of Singapore.	Aoki T, 2009, CLIN EXP ALLERGY, V39, P213, DOI 10.1111/j.1365-2222.2008.03186.x; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Cascallana JL, 2005, ENDOCRINOLOGY, V146, P2629, DOI 10.1210/en.2004-1246; Chatterjee A, 2010, CANCER RES, V70, P1419, DOI 10.1158/0008-5472.CAN-09-2613; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Dittrich AM, 2010, EUR RESPIR J, V35, P1148, DOI 10.1183/09031936.00026108; Fardioni-Laurens L, 2001, ONCOGENE, V20, P5302, DOI 10.1038/sj.onc.1204687; Fokkens W, 2007, RHINOLOGY, P1; Gallucci RM, 2000, FASEB J, V14, P2525, DOI 10.1096/fj.00-0073com; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P37; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leung SY, 2005, J ALLERGY CLIN IMMUN, V115, P989, DOI 10.1016/j.jaci.2005.01.036; Li CW, 2009, THORAX, V64, P306, DOI 10.1136/thx.2008.106096; Liefer KM, 2000, CANCER RES, V60, P4016; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu LX, 2003, AM J RESP CELL MOL, V28, P713, DOI 10.1165/rcmb.4771; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Ortt K, 2008, J CELL BIOCHEM, V104, P1204, DOI 10.1002/jcb.21700; Osada M, 2006, BIOCHEM BIOPH RES CO, V339, P1120, DOI 10.1016/j.bbrc.2005.11.118; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Romano RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005623; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Taille C, 2010, AM J RESP CRIT CARE; Tilley AE, 2009, AM J RESP CRIT CARE, V179, P457, DOI 10.1164/rccm.200705-795OC; Tomkova K, 2008, NEOPLASMA, V55, P177; Veraldi KL, 2009, AM J RESP CRIT CARE, V180, P611, DOI 10.1164/rccm.200810-1555OC; Wang BY, 2002, HUM PATHOL, V33, P921, DOI 10.1053/hupa.2002.126878; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047, DOI 10.1164/ajrccm.164.6.2010045; Woo CH, 2005, AM J PHYSIOL-LUNG C, V288, pL307, DOI 10.1152/ajplung.00105.2004; Wu GJ, 2003, CANCER RES, V63, P2351; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	47	46	47	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					765	U418		10.1016/j.jaci.2010.12.011	http://dx.doi.org/10.1016/j.jaci.2010.12.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21269671				2022-12-18	WOS:000288018400032
J	Sachs-Olsen, C; Sanak, M; Lang, AM; Gielicz, A; Mowinckel, P; Carlsen, KCL; Carlsen, KH; Szczeklik, A				Sachs-Olsen, Christine; Sanak, Marek; Lang, Astri Maria; Gielicz, Anna; Mowinckel, Petter; Carlsen, Karin Cecilie Lodrup; Carlsen, Kai-Hakon; Szczeklik, Andrzej			Eoxins: A new inflammatory pathway in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled breath condensate; leukotrienes; 15-hydroxyeicosatetraenoic acid; eoxins; asthma; child	EXHALED BREATH CONDENSATE; CYSTEINYL LEUKOTRIENES; CHILDREN; EICOSANOIDS; 15-LIPOXYGENASE-1; METHACHOLINE; MONTELUKAST; PROSTANOIDS; EXPRESSION; CHALLENGE	Background: Increased levels of leukotrienes (LTs) in exhaled breath condensate (EBC) are associated with asthma and bronchial hyperresponsiveness (BHR), whereas eicosanoids generated through the 15-lipoxygenase (LO) pathway (15-hydroxyeicosatetraenoic acid [ HETE] and eoxins) have been less studied. Objective: We investigated whether metabolites of the 5- and 15-LO pathways in EBC are associated with childhood asthma, asthma severity, and clinical parameters. Methods: The present study included 131 school-aged children (27 children with problematic severe asthma, 80 children with mild-to-moderate asthma, and 24 healthy children) from the Severe Asthma Recognized in Childhood study and 19 children with other nonasthmatic chronic lung diseases. Clinical work-up included spirometry, fractional exhaled nitric oxide measurements, skin prick testing, and methacholine challenge. Eicosanoids were analyzed in EBC by using mass spectrometry and are reported as concentrations (in picograms per milliliter) and eicosanoid/palmitic acid (PA) ratios. Results: Eoxin C-4/PA, eoxin D-4/PA, eoxin E-4/PA, 15-HETE/PA, and LTC4/PA ratios were significantly increased in asthmatic versus healthy children. Eoxin D-4/PA and LTE4/PA ratios were also significantly higher in children with BHR. A nonsignificant trend was observed toward higher eoxin/PA ratios with increasing asthma severity. In contrast to asthma, children with chronic lung disease had the highest 15-HETE/PA, LTC4/PA, LTE4/PA, and LTB4/PA ratios. Conclusion: The results point to increased activity of the 15-LO inflammatory pathway in childhood asthma. Mass spectrometric analyses of EBC demonstrate that increased eoxin levels not only accompany the increased 5- LO product LTC4 but are also associated with BHR. These markers might represent a new therapeutic target for asthma treatment. (J Allergy Clin Immunol 2010;126:859-67.)	[Sachs-Olsen, Christine; Lang, Astri Maria; Mowinckel, Petter; Carlsen, Karin Cecilie Lodrup; Carlsen, Kai-Hakon] Oslo Univ Hosp, Dept Paediat, NO-0027 Oslo, Norway; [Sanak, Marek; Gielicz, Anna; Szczeklik, Andrzej] Jagiellonian Univ, Coll Med, Dept Med, Krakow, Poland; [Carlsen, Karin Cecilie Lodrup; Carlsen, Kai-Hakon] Univ Oslo, Fac Med, N-0316 Oslo, Norway	University of Oslo; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Oslo	Sachs-Olsen, C (corresponding author), Oslo Univ Hosp, Dept Paediat, Sognsvannsveien 20, NO-0027 Oslo, Norway.	c.sachs@online.no	Sanak, Marek/AAV-1628-2021	Sanak, Marek/0000-0001-7635-8103	European Economic Area (EEA); European Community; Polish Ministry of Science and Higher Education; Kloster foundation; South Norway Health Region; GlaxoSmithKline; GA2LEN	European Economic Area (EEA); European Community(European Commission); Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Kloster foundation; South Norway Health Region; GlaxoSmithKline(GlaxoSmithKline); GA2LEN	The study was performed within the ORAACLE (Oslo Research Group of Asthma and Allergy in Childhood, the Lung and Environment) and Nordic SEARCH (Severe Asthma Recognized in Childhood) affiliations, both of which are part of the GA<SUP>2</SUP>LEN network. The study was supported through the European Economic Area (EEA) financial mechanism. EBC analysis by HPLC-tandem MS has come about as a cooperation project between Norway and Poland sponsored by a Norwegian grant within the framework of the European Community and funds of the Polish Ministry of Science and Higher Education. C. S.-O. has received a research grant from the Kloster foundation, and A. L. has received a research grant from the South Norway Health Region.; C. Sachs Olsen and A. M. Lang received a fee for scientific lectures from GlaxoSmithKline. M. Sanak, A. Gielicz, and A. Szczeklik have received research support from the European Community and Polish Ministry of Science and Higher Education. K. C. Lodrup Carlsen and K.-H. Carlsen received research support from GA<SUP>2</SUP>LEN. P. Mowinckel has declared that he has no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Andersson CK, 2008, AM J RESP CELL MOL, V39, P648, DOI 10.1165/rcmb.2007-0443OC; Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x; Biernacki WA, 2005, CHEST, V128, P1958, DOI 10.1378/chest.128.4.1958; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Carraro S, 2005, J ALLERGY CLIN IMMUN, V115, P764, DOI 10.1016/j.jaci.2004.10.043; *CDCP, 2007, BMI CALC CHILD TEEN; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Claesson HE, 2009, PROSTAG OTH LIPID M, V89, P120, DOI 10.1016/j.prostaglandins.2008.12.003; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Esther CR, 2009, AM J PHYSIOL-LUNG C, V296, pL987, DOI 10.1152/ajplung.90512.2008; Feltenmark S, 2008, P NATL ACAD SCI USA, V105, P680, DOI 10.1073/pnas.0710127105; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kielbasa B, 2008, PEDIAT ALLERG IMM-UK, V19, P660, DOI 10.1111/j.1399-3038.2008.00770.x; Kostikas K, 2008, CLIN EXP ALLERGY, V38, P557, DOI 10.1111/j.1365-2222.2008.02940.x; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Lex C, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-63; Liu C, 2009, AM J PHYSIOL-LUNG C, V297, pL196, DOI 10.1152/ajplung.00036.2008; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Montuschi P, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-119; Montuschi P, 2006, J ALLERGY CLIN IMMUN, V118, P347, DOI 10.1016/j.jaci.2006.04.010; Montuschi P, 2009, J CHROMATOGR B, V877, P1272, DOI 10.1016/j.jchromb.2009.01.036; NIEMINEN MM, 1988, THORAX, V43, P896, DOI 10.1136/thx.43.11.896; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Ono E, 2008, CLIN EXP ALLERGY, V38, P1866, DOI 10.1111/j.1365-2222.2008.03108.x; Ono E, 2009, CLIN EXP ALLERGY, V39, P1348, DOI 10.1111/j.1365-2222.2009.03261.x; Profita M, 2000, J ALLERGY CLIN IMMUN, V105, P711, DOI 10.1067/mai.2000.105122; Ramires R, 2004, BIOCHEM BIOPH RES CO, V324, P815, DOI 10.1016/j.bbrc.2004.09.125; Sanak M, 2004, CLIN EXP ALLERGY, V34, P1899, DOI 10.1111/j.1365-2222.2004.02123.x; Sanak M, 2010, J CHROMATOGR B, V878, P1796, DOI 10.1016/j.jchromb.2010.05.012; Shibata A, 2006, CHEST, V130, P1718, DOI 10.1378/chest.130.6.1718; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Steiss JO, 2008, ALLERGY ASTHMA PROC, V29, P371, DOI 10.2500/aap.2008.29.3135; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2009, J ALLERGY CLIN IMMUN, V124, P422, DOI 10.1016/j.jaci.2009.06.035; Zanconato S, 2004, J ALLERGY CLIN IMMUN, V113, P257, DOI 10.1016/j.jaci.2003.10.046; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	41	46	46	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					859	U304		10.1016/j.jaci.2010.07.015	http://dx.doi.org/10.1016/j.jaci.2010.07.015			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920774	Green Submitted			2022-12-18	WOS:000282510000026
J	Toelle, BG; Ng, KKW; Crisafulli, D; Belousova, EG; Almqvist, C; Webb, K; Tovey, ER; Kemp, AS; Mellis, CM; Leeder, SR; Marks, GB				Toelle, Brett G.; Ng, Kitty K. W.; Crisafulli, Daniele; Belousova, Elena G.; Almqvist, Catarina; Webb, Karen; Tovey, Euan R.; Kemp, Andrew S.; Mellis, Craig M.; Leeder, Stephen R.; Marks, Guy B.		Childhood Asthma Prevention Team	Eight-year outcomes of the Childhood Asthma Prevention Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FATTY-ACID MODIFICATION; TRIAL; CAPS		[Toelle, Brett G.; Ng, Kitty K. W.; Crisafulli, Daniele; Belousova, Elena G.; Almqvist, Catarina; Tovey, Euan R.; Marks, Guy B.] Woolcock Inst Med Res, Glebe, NSW, Australia; [Toelle, Brett G.; Webb, Karen; Tovey, Euan R.; Mellis, Craig M.; Leeder, Stephen R.; Marks, Guy B.] Univ Sydney, Sydney, NSW 2006, Australia; [Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Kemp, Andrew S.] Childrens Hosp, Westmead, NSW, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Karolinska Institutet; University of Sydney	Toelle, BG (corresponding author), Woolcock Inst Med Res, Glebe, NSW, Australia.	bgt@woolcock.org.au	Tovey, Euan R/G-8604-2017; Toelle, Brett G/B-1531-2008; Marks, Guy B./F-5058-2013	Tovey, Euan R/0000-0002-1802-7266; Toelle, Brett G/0000-0002-7375-0019; Marks, Guy B./0000-0002-8976-8053				Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307	6	46	46	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					388	389		10.1016/j.jaci.2010.04.031	http://dx.doi.org/10.1016/j.jaci.2010.04.031			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20646752				2022-12-18	WOS:000281203800027
J	Sanchez-Morillas, L; Perez-Ezquerra, PR; Reano-Martos, M; Laguna-Martinez, JJ; Sanz, ML; Martinez, LM				Sanchez-Morillas, Leticia; Rojas Perez-Ezquerra, Patricia; Reano-Martos, Mar; Julio Laguna-Martinez, Jose; Sanz, Maria L.; Morales Martinez, Lorena			Selective allergic reactions to clavulanic acid: A report of 9 cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BETA-LACTAM ANTIBIOTICS; BASOPHIL ACTIVATION; HYPERSENSITIVITY; SENSITIZATION; DIAGNOSIS		[Sanchez-Morillas, Leticia; Rojas Perez-Ezquerra, Patricia; Julio Laguna-Martinez, Jose] Hosp Cent Cruz Roja, Dept Allergol, Madrid, Spain; [Morales Martinez, Lorena] Hosp Cent Cruz Roja, Chemist Dept, Madrid, Spain; [Reano-Martos, Mar] Hosp Puerta Hierro, Dept Allergol, Madrid, Spain; [Sanz, Maria L.] Univ Navarra Clin, Dept Allergol, Pamplona, Spain	Hospital Puerta de Hierro-Majadahonda; University of Navarra	Sanchez-Morillas, L (corresponding author), Hosp Cent Cruz Roja, Dept Allergol, Madrid, Spain.	lsanchezmorillas@hotmail.com	Martinez, Jose Julio Laguna/L-6891-2017	Martinez, Jose Julio Laguna/0000-0001-5909-8979				Bonadonna P, 2005, J INVEST ALLERG CLIN, V15, P302; Cahen YD, 1997, ALLERGY, V52, P117, DOI 10.1111/j.1398-9995.1997.tb02560.x; FERNANDEZRIVAS M, 1995, J ALLERGY CLIN IMMUN, V95, P748, DOI 10.1016/S0091-6749(95)70181-8; de Olano DG, 2007, J INVEST ALLERG CLIN, V17, P119; Kamphof WG, 2002, CONTACT DERMATITIS, V47, P47, DOI 10.1034/j.1600-0536.2002.470109.x; Kim YH, 2008, CONTACT DERMATITIS, V59, DOI 10.1111/j.1600-0536.2008.01393.x; Longo N, 2008, J INVEST ALLERG CLIN, V18, P473; Raison-Peyron N, 2003, ANN PHARMACOTHER, V37, P1146, DOI 10.1345/aph.1C285; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Girbes MT, 2008, ALLERGOL IMMUNOPATH, V36, P308, DOI 10.1016/S0301-0546(08)75228-5	12	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					177	179		10.1016/j.jaci.2010.03.012	http://dx.doi.org/10.1016/j.jaci.2010.03.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20434202				2022-12-18	WOS:000280061800036
J	Kanda, A; Driss, V; Hornez, N; Abdallah, M; Roumier, T; Abboud, G; Legrand, F; Staumont-Salle, D; Queant, S; Bertout, J; Fleury, S; Remy, P; Papin, JP; Julia, V; Capron, M; Dombrowicz, D				Kanda, Akira; Driss, Virginie; Hornez, Nicolas; Abdallah, Marwan; Roumier, Thomas; Abboud, Georges; Legrand, Fanny; Staumont-Salle, Delphine; Queant, Severine; Bertout, Julie; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Julia, Valerie; Capron, Monique; Dombrowicz, David			Eosinophil-derived IFN-gamma induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adoptive transfer; airway hyperresponsiveness; asthma; eosinophil; IFN-gamma; lung inflammation; severe combined immunodeficiency	HUMAN PERIPHERAL EOSINOPHILS; INTERFERON-GAMMA; T-CELLS; ALLERGIC-ASTHMA; HYPEREOSINOPHILIC SYNDROME; TRANSGENIC MICE; INTERLEUKIN-5; RECRUITMENT; EXPRESSION; MOUSE	Background: Eosinophils are key players in T(H)2-driven pathologies, such as allergic lung inflammation. After IL-5- and eotaxin-mediated tissue recruitment, they release several cytotoxic and inflammatory mediators. However, their exact contribution to asthma remains controversial. Indeed, in human subjects anti-IL-5 treatment inhibits eosinophilia but not antigen-induced airway hyperresponsiveness (AHR). Likewise, lung fibrosis is abrogated in 2 strains of eosinophil-deficient mice, whereas AHR is inhibited in only one of them. Finally, eosinophils have been shown to attract T(H)2 lymphocytes at the inflammatory site. Objective: The ability of eosinophils to promote AHR and lung inflammation independently of lymphocytes was investigated. Methods: Adoptive transfers of resting or activated eosinophils from IL-5 transgenic mice were performed into naive BALB/c mice, mice with severe combined immunodeficiency, and IFN-gamma-deficient BALB/c recipients. Results: Adoptively transferred eosinophils induced lung inflammation, fibrosis, collagen deposition, and AHR not only in BALB/c mice but also in recipient mice with severe combined immunodeficiency. Surprisingly, IFN-gamma expression was increased in lungs from eosinophil-transferred animals. Furthermore, IFN-gamma neutralization in recipients partially inhibited eosinophil- induced AHR. Moreover, IFN-gamma-deficient eosinophils or eosinophils treated with a blocking anti-IFN-gamma receptor antibody failed to induce AHR in IFN-gamma-deficient recipients. Finally, in vitro and at low concentrations, IFN-gamma increased eosinophil peroxidase release, potentiated chemotaxis, and prolonged survival, suggesting the existence of an autocrine mechanism. Conclusions: These results support the important and previously unsuspected contribution of eosinophils to lung inflammation independently of lymphocytes through production of IFN-gamma, the prototypical T(H)1 cytokine. (J Allergy Clin Immunol 2009;124:573-82.)	[Kanda, Akira; Driss, Virginie; Hornez, Nicolas; Abdallah, Marwan; Roumier, Thomas; Abboud, Georges; Legrand, Fanny; Staumont-Salle, Delphine; Queant, Severine; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Capron, Monique; Dombrowicz, David] Inst Pasteur Lille 1, INSERM, U547, F-59019 Lille, France; [Kanda, Akira; Driss, Virginie; Hornez, Nicolas; Abdallah, Marwan; Roumier, Thomas; Abboud, Georges; Legrand, Fanny; Staumont-Salle, Delphine; Queant, Severine; Bertout, Julie; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Capron, Monique; Dombrowicz, David] Inst Pasteur, Lille, France; [Kanda, Akira; Driss, Virginie; Hornez, Nicolas; Abdallah, Marwan; Roumier, Thomas; Abboud, Georges; Legrand, Fanny; Staumont-Salle, Delphine; Queant, Severine; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Capron, Monique; Dombrowicz, David] Univ Lille 2, Lille, France; [Kanda, Akira] Akita Univ, Sch Med, Dept Clin & Lab Med, Akita 010, Japan; [Staumont-Salle, Delphine] CRHU Lille, Hop Huriez, Serv Dermatol, Lille, France; [Julia, Valerie] INSERM, U924, F-59045 Lille, France; [Capron, Monique] Univ Nice, Valbonne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Akita University; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Dombrowicz, D (corresponding author), Inst Pasteur Lille 1, INSERM, U547, Rue Prof Calmette BP245, F-59019 Lille, France.	david.dombrowicz@pasteur-lille.fr	Dombrowicz, David/F-7044-2013; Capron, monique/Z-2207-2019; Staumont-Salle, Delphine/R-6903-2018; Legrand, Fanny/I-4880-2017	Dombrowicz, David/0000-0002-0485-8923; Capron, monique/0000-0001-5625-5158; Staumont-Salle, Delphine/0000-0002-4780-4212; Legrand, Fanny/0000-0001-9373-7789; Fleury, Sebastien/0000-0002-0679-3086	European Union (Feder and Interreg); Nord-Pas-de-Calais Region (ARCIR); Fondation pour la Recherche Medicale (FRM)	European Union (Feder and Interreg)(European Commission); Nord-Pas-de-Calais Region (ARCIR)(Region Hauts-de-France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	Supported in part by grants from the European Union (Feder and Interreg), Nord-Pas-de-Calais Region (ARCIR), and Fondation pour la Recherche Medicale (FRM; to T.R.).	Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950; Bogdan C, 2006, TRENDS IMMUNOL, V27, P282, DOI 10.1016/j.it.2006.04.004; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coyle AJ, 1996, J IMMUNOL, V156, P2680; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Fischer R, 2007, BIOCHEM BIOPH RES CO, V357, P44, DOI 10.1016/j.bbrc.2007.03.058; Hayashi N, 2007, P NATL ACAD SCI USA, V104, P14765, DOI 10.1073/pnas.0706378104; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hofstra CL, 1998, AM J RESP CELL MOL, V19, P826, DOI 10.1165/ajrcmb.19.5.3027; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Ishihara C, 1997, CLIN EXP IMMUNOL, V110, P524, DOI 10.1046/j.1365-2249.1997.4511469.x; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kelchtermans H, 2008, TRENDS IMMUNOL, V29, P479, DOI 10.1016/j.it.2008.07.002; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Klion A, 2009, ANNU REV MED, V60, P293, DOI 10.1146/annurev.med.60.062107.090340; Kobayashi T, 2003, J IMMUNOL, V170, P5756, DOI 10.4049/jimmunol.170.11.5756; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Legrand Fanny, 2008, V415, P215, DOI 10.1007/978-1-59745-570-1_13; O'Byrne PM, 2007, AM J RESP CRIT CARE, V176, P1059, DOI 10.1164/rccm.200708-1264ED; Ochiai K, 1999, CLIN EXP IMMUNOL, V118, P340; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Salvi S, 1999, AM J RESP CELL MOL, V20, P984, DOI 10.1165/ajrcmb.20.5.3463; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shen HHH, 2003, J IMMUNOL, V170, P3296, DOI 10.4049/jimmunol.170.6.3296; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; VALERIUS T, 1990, J IMMUNOL, V145, P2950; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Walsh ER, 2008, J EXP MED, V205, P1285, DOI 10.1084/jem.20071836; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Yoshida M, 2002, AM J RESP CRIT CARE, V166, P451, DOI 10.1164/rccm.200202-095OC	38	46	49	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					573	U269		10.1016/j.jaci.2009.04.031	http://dx.doi.org/10.1016/j.jaci.2009.04.031			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19539982	Bronze			2022-12-18	WOS:000274315900025
J	Duan, QL; Binkley, K; Rouleau, GA				Duan, Qing Ling; Binkley, Karen; Rouleau, Guy A.			Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Estrogen-dependent inherited angioedema; bradykinin; coagulation Factor XII; angiotensin I-converting enzyme; aminopeptidase P	HORMONE REPLACEMENT THERAPY; HEREDITARY ANGIOEDEMA; POSTMENOPAUSAL WOMEN; HYPERSENSITIVITY REACTIONS; ESSENTIAL-HYPERTENSION; NORMAL C1-INHIBITOR; AMINOPEPTIDASE-P; ACE; METABOLISM; INHIBITOR	Background: Recent studies reported a gain-of-function mutation in the gene encoding coagulation Factor XII (F12) among 5 German and French families with estrogen-associated angioedema who share a common ancestor. The role of this factor, additional pathways that might contribute to increased bradykinin levels, or both remain to be determined in other families with estrogen-dependent or estrogen-associated inherited angioedema. Objective: The purpose of this study was to determine whether mutations in F12 and polymorphisms in the genes encoding aminopeptidase P (APP) and angiotensin I-converting enzyme (ACE), which have been associated with increased bradykinin levels, contribute to estrogen-dependent inherited angioedema in a large family of Italian origin. Methods: We screened the coding regions of F12 and the gene encoding membrane-bound APP (XPNPEP2), for genetic variants in the 3 affected female subjects. In addition, we genotyped this family for the insertion/deletion polymorphism in the ACE gene, which accounts for variable ACE levels. Results: The 3 affected female subjects all have the threonine-to-lysine (Thre328Lys) mutation, which is associated with higher Factor XII activity. In addition, they have at least one A allele of rs3788853 at the XPNPEP2 locus, which is associated with lower APP activity, and at least one I allele in ACE, which is associated with reduced ACE activity. Conclusion: A missense mutation in F12 is present in the 3 affected female subjects of this family with estrogen-dependent inherited angioedema. In addition, these affected females have polymorphisms associated with lower levels of both APP and ACE, the major enzymes responsible for bradykinin degradation. Thus, our study suggests that multiple genes might contribute to estrogen-dependent or estrogen-associated inherited angioedema and explain some of the observed heterogeneity. (J Allergy Clin Immunol 2009;123:906-10.)	[Duan, Qing Ling; Rouleau, Guy A.] Univ Montreal, Ctr Excellence Neurom, Montreal, PQ, Canada; [Duan, Qing Ling; Rouleau, Guy A.] CHU Montreal, Montreal, PQ, Canada; [Duan, Qing Ling; Rouleau, Guy A.] Hop St Justine, Montreal, PQ H3T 1C5, Canada; [Duan, Qing Ling] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Binkley, Karen] Univ Toronto, Dept Med, Div Clin Immunol & Allergy, Toronto, ON, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; University of Toronto	Rouleau, GA (corresponding author), JA de Seve Pavil,Room Y-3633,1560 Sherbrooke S, Montreal, PQ H2L 4M1, Canada.	guy.rouleau@umontreal.ca			Canadian Institute of Health Research; Allergy, Asthma and Immunology Society of Ontario; Heart and Stroke Foundation of Canada	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Allergy, Asthma and Immunology Society of Ontario; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	Supported by the Canadian Institute of Health Research (G.A.R.) and the Allergy, Asthma and Immunology Society of Ontario (K.B.). Q.L.D. was supported by the Heart and Stroke Foundation of Canada.	Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Binkley KE, 2003, TRANSFUS APHER SCI, V29, P215, DOI 10.1016/j.transci.2003.08.002; Blais C, 1999, IMMUNOPHARMACOLOGY, V43, P293, DOI 10.1016/S0162-3109(99)00133-2; Blais C, 1999, PEPTIDES, V20, P421, DOI 10.1016/S0196-9781(99)00020-0; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; Cicardi M, 1999, AM J MED, V106, P650, DOI 10.1016/S0002-9343(99)00123-0; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Cyr M, 2001, TRANSFUSION, V41, P136, DOI 10.1046/j.1537-2995.2001.41010136.x; Davis AE, 2003, TRANSFUS APHER SCI, V29, P195, DOI 10.1016/j.transci.2003.08.012; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; Duan QL, 2005, AM J HUM GENET, V77, P617, DOI 10.1086/496899; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; Molinaro G, 2006, KIDNEY INT, V70, P1823, DOI 10.1038/sj.ki.5001873; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; Nogawa N, 2001, MENOPAUSE, V8, P210, DOI 10.1097/00042192-200105000-00011; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; Rafii MS, 2005, NEUROLOGY, V65, P1906, DOI 10.1212/01.wnl.0000190262.59672.4c; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Scheer WD, 2005, ATHEROSCLEROSIS, V178, P241, DOI 10.1016/j.atherosclerosis.2004.09.019; Stevenson JC, 2004, BRIT J HAEMATOL, V124, P802, DOI 10.1111/j.1365-2141.2004.04846.x; Suehiro T, 2004, HUM GENET, V115, P91, DOI 10.1007/s00439-004-1136-4; Sumino H, 2003, HYPERTENS RES, V26, P53; Sumino H, 1999, AM J HYPERTENS, V12, P1044, DOI 10.1016/S0895-7061(99)00094-1; Vleeming W, 1998, DRUG SAFETY, V18, P171, DOI 10.2165/00002018-199818030-00003	31	46	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					906	910		10.1016/j.jaci.2008.12.010	http://dx.doi.org/10.1016/j.jaci.2008.12.010			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19178938				2022-12-18	WOS:000265058600019
J	Kim, JS; Ouyang, FX; Pongracic, JA; Fang, YP; Wang, BY; Liu, X; Xing, HX; Caruso, D; Liu, X; Zhang, SC; Xu, X; Wang, X				Kim, Jennifer S.; Ouyang, Fengxiu; Pongracic, Jacqueline A.; Fang, Yaping; Wang, Binyan; Liu, Xue; Xing, Houxun; Caruso, Deanna; Liu, Xin; Zhang, Shanchun; Xu, Xiping; Wang, Xiaobin			Dissociation between the prevalence of atopy and allergic disease in rural China among children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aeroallergens; rural; farming community; Chinese; food allergens; prevalence; sensitization; skin prick tests	HONG-KONG; FOOD ALLERGY; RISK-FACTORS; BIRTH-ORDER; ASTHMA; SENSITIZATION; LIFE; RHINOCONJUNCTIVITIS; SCHOOLCHILDREN; ADOLESCENTS	Background: The prevalence of allergic diseases is increasing worldwide, but the reasons are not well understood. Previous studies suggest that this trend might be associated with lifestyle and urbanization. Objective: We sought to describe patterns of sensitization and allergic disease in an unselected agricultural Chinese population. Methods: The data were derived from a community-based twin study in Anqing, China. Skin prick tests were performed to foods and aeroallergens. Atopy was defined as sensitization to 1 or more allergens. Allergic disease was ascertained by means of self-report. The analysis was stratified by sex and age (children [11-17 years] and adults [>= 18 years]) and included 1059 same-sex twin pairs. Results: Of 2118 subjects, 57.6% were male (n = 1220). Ages ranged from 11 to 71 years, and 43.3% were children (n = 918). Atopy was observed in 47.2% (n = 999) of participants. The most common sensitizing foods were shellfish (16.7%) and peanut (12.3%). The most common sensitizing aeroallergens were dust mite (30.6%) and cockroach (25.2%). Birth order and zygosity had no effect on sensitization rates. Multivariate logistic regression models revealed that risk factors for sensitization include age for foods and sex for aeroallergens. The rates of food allergy and asthma were estimated to be less than 1%. Conclusions: Atopic sensitization was common in this rural farming Chinese population, particularly to shellfish, peanut, dust mite, and cockroach. The prevalence of allergic disease, in contrast, was quite low. Q Allergy Clin Immunol 2008;122: 929-35.)	[Kim, Jennifer S.; Pongracic, Jacqueline A.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Ouyang, Fengxiu; Wang, Binyan; Caruso, Deanna; Liu, Xin; Zhang, Shanchun; Wang, Xiaobin] Childrens Mem Hosp, Childrens Mem Res Ctr, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Fang, Yaping; Liu, Xue; Xing, Houxun] Anhui Med Univ, Inst Biomed, Hefei, Peoples R China; [Xu, Xiping] Univ Illinois, Sch Publ Hlth, Ctr Populat Genet, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Anhui Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kim, JS (corresponding author), 2300 Childrens Plaza,Box 60, Chicago, IL 60614 USA.	jskim@childrensmemorial.org			National Institutes of Health [R01 HD049059, R01 HL0864619, 3R01 AG032227]; Food Allergy Project; National Institute of Allergy and Infectious Diseases (NIAID); Novartis/Genentech; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049059] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032227] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Project; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis/Genentech(Roche HoldingGenentech); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Chinese Twin Cohort was supported in part by National Institutes of Health grants R01 HD049059, R01 HL0864619, and R01 AG032227. This work was supported in part by the Food Allergy Project.; Disclosure of potential conflict of interest: J. S. Kim hits received research support front the National Institute of Allergy and Infectious Diseases (NIAID) and the Food Allergy Project and is employed by the Pediatric Faculty Foundation. J. A. Pongracic has received research support from the NIAID, Novartis/Genentech, and the Food Allergy Project and is employed by the Pediatric Faculty Foundation. The rest of the authors have declared that they have no conflict of interest.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BOCK SA, 1987, PEDIATRICS, V79, P683; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Hamilton Robert G., 2008, P63, DOI 10.1201/9781420003710.ch3; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Jeffreys AJ, 1985, BIOTECHNOLOGY, V24, P467; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Leung R, 1998, CLIN EXP ALLERGY, V28, P585, DOI 10.1046/j.1365-2222.1998.00281.x; Leung TF, 2002, J ASTHMA, V39, P523, DOI 10.1081/JAS-120004922; Leung TF, 2002, J ASTHMA, V39, P323, DOI 10.1081/JAS-120002289; LI CS, 1994, J ALLERGY CLIN IMMUN, V94, P131, DOI 10.1016/0091-6749(94)90080-9; Liu ZG, 2007, INT ARCH ALLERGY IMM, V144, P85, DOI 10.1159/000102619; Naleway Allison L, 2004, Clin Med Res, V2, P5; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x; Viinanen A, 2005, ALLERGY, V60, P1370, DOI 10.1111/j.1398-9995.2005.00877.x; von Mutius E, 1998, CLIN EXP ALLERGY, V28, P1454; von Mutius Erika, 2007, Proc Am Thorac Soc, V4, P212, DOI 10.1513/pats.200701-028AW; Wang BY, 2007, PREV MED, V45, P358, DOI 10.1016/j.ypmed.2007.07.014; Wang HJ, 2007, PEDIATRICS, V120, pE94, DOI 10.1542/peds.2006-2114; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Wong GWK, 2002, EUR RESPIR J, V19, P288, DOI 10.1183/09031936.02.002319.02; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161; Yu YX, 2007, SLEEP, V30, P1688, DOI 10.1093/sleep/30.12.1688; Zekveld C, 2006, EUR RESPIR J, V28, P82, DOI 10.1183/09031936.06.00021305	37	46	53	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					929	935		10.1016/j.jaci.2008.08.009	http://dx.doi.org/10.1016/j.jaci.2008.08.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18805578	Green Accepted			2022-12-18	WOS:000260940100011
J	Slats, AM; Janssen, K; Van Schadewijk, A; Van der Plas, DT; Schot, R; Van den Aardweg, JG; De Jongste, JC; Hiernstra, PS; Mauad, T; Rabe, KF; Sterk, PJ				Slats, Annelies M.; Janssen, Kirsten; Van Schadewijk, Annemarie; Van der Plas, Dirk T.; Schot, Robert; Van den Aardweg, Joost G.; De Jongste, Johan C.; Hiernstra, Pieter S.; Mauad, Thais; Rabe, Klaus F.; Sterk, Peter J.			Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						actin; desmin; elastin; airway smooth muscle; extracellular matrix; lung function; hyperresponsiveness; deep inspiration-induced bronchodilation; bronchial biopsies	BRONCHIAL THERMOPLASTY; CONTRACTILE APPARATUS; CELL PROLIFERATION; STRUCTURAL-CHANGES; MECHANICAL STRAIN; DYNAMICS; HYPERRESPONSIVENESS; INFLAMMATION; PATHWAY; DESMIN	Background: Smooth muscle content is increased within the airway wall in patients with asthma and is likely to play a role in airway hyperresponsiveness. However, smooth muscle cells express several contractile and structural proteins, and each of these proteins may influence airway function distinctly. Objective: We examined the expression of contractile and structural proteins of smooth muscle cells, as well as extracellular matrix proteins, in bronchial biopsies of patients with asthma, and related these to lung function, airway hyperresponsiveness, and responses to deep inspiration. Methods: Thirteen patients with asthma (mild persistent, atopic, nonsmoking) participated in this cross-sectional study. FEV1 % predicted, PC20 methacholine, and resistance of the respiratory system by the forced oscillation technique during tidal breathing and deep breath were measured. Within 1 week, a bronchoscopy was performed to obtain 6 bronchial biopsies that were immunuhistochemically stained for alpha-SM-actin, desmin, myosin light chain kinase (MLCK), myosin, calponin, vimentin, elastin, type III collagen, and fibronectin. The level of expression was determined by automated densitometry. Results: PC20 methacholine was inversely related to the expression of alpha-smooth muscle actin (r = -0.62), desmin (r = -0.56), and elastin (r = -0.78). In addition, FEV1% predicted was positively related and deep inspiration-induced bronchodilation inversely related to desmin (r = -0.60), MLCK (r = -0.60), and calponin (r = -0.54) expression. Conclusion: Airway hyperresponsiveness, FEV1% predicted, and airway responses to deep inspiration are associated with selective expression of airway smooth muscle proteins and components of the extracellular matrix.	[Slats, Annelies M.; Janssen, Kirsten; Van Schadewijk, Annemarie; Van der Plas, Dirk T.; Schot, Robert; Hiernstra, Pieter S.; Rabe, Klaus F.; Sterk, Peter J.] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands; [De Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; [Mauad, Thais] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05508 Sao Paulo, Brazil; [Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1012 WX Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Universidade de Sao Paulo; University of Amsterdam; Academic Medical Center Amsterdam	Slats, AM (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C2-P-62,POB 9600, NL-2300 RC Leiden, Netherlands.	A.M.Slats@LUMC.nl	Mauad, Thais/G-1254-2012; Sterk, P.J./AAK-8175-2020; Hiemstra, Pieter S/K-8587-2018; Rabe, Klaus F./AAW-6296-2021; /V-8478-2019	Mauad, Thais/0000-0002-3354-1466; Hiemstra, Pieter S/0000-0002-0238-5982; Rabe, Klaus F./0000-0002-7020-1401; 				An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Bai TR, 2005, CLIN SCI, V108, P463, DOI 10.1042/CS20040342; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Black JL, 2003, RESP PHYSIOL NEUROBI, V137, P339, DOI 10.1016/S1569-9048(03)00157-5; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Cox G, 2006, AM J RESP CRIT CARE, V173, P965, DOI 10.1164/rccm.200507-1162OC; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; de Kluijver J, 2005, CLIN EXP ALLERGY, V35, P1361, DOI 10.1111/j.1365-2222.2005.02334.x; Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; Goldsmith AM, 2007, AM J PHYSIOL-LUNG C, V292, pL99, DOI 10.1152/ajplung.00269.2006; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Gunst SJ, 2000, EUR RESPIR J, V15, P600, DOI 10.1034/j.1399-3003.2000.15.29.x; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201, DOI 10.1164/ajrccm.158.supplement_2.13tac190; Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1; Jarjour NN, 1998, AM J RESP CRIT CARE, V157, P692, DOI 10.1164/ajrccm.157.3.9705020; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Kuo KH, 2003, RESP PHYSIOL NEUROBI, V137, P197, DOI 10.1016/S1569-9048(03)00147-2; Lakser OJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1117, DOI 10.1152/ajplung.00230.2000; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Maksym GN, 2005, CAN J PHYSIOL PHARM, V83, P913, DOI 10.1139/Y05-091; McVicker CG, 2007, AM J RESP CELL MOL, V36, P721, DOI 10.1165/rcmb.2006-0409OC; Meiss RA, 2004, J APPL PHYSIOL, V96, P655, DOI 10.1152/japplphysiol.00388.2003; Meiss RA, 1999, J APPL PHYSIOL, V86, P5, DOI 10.1152/jappl.1999.86.1.5; Moir LM, 2003, AM J PHYSIOL-LUNG C, V284, pL148, DOI 10.1152/ajplung.00105.2002; *NHLBI WHO, 1991, PUB NHLBI WHO; Pare PD, 2003, AM J RESP CRIT CARE, V168, P913, DOI 10.1164/rccm.2307005; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Shardonofsky FR, 2006, AM J PHYSIOL-LUNG C, V290, pL890, DOI 10.1152/ajplung.00397.2005; Sjuve R, 1998, J MUSCLE RES CELL M, V19, P415, DOI 10.1023/A:1005353805699; Slats AM, 2007, AM J RESP CRIT CARE, V176, P121, DOI 10.1164/rccm.200612-1814OC; Smith PG, 2003, AM J PHYSIOL-LUNG C, V285, pL456, DOI 10.1152/ajplung.00329.2002; Solway J, 2003, CHEST, V123, p392S, DOI 10.1378/chest.123.3_suppl.392S; Sont JK, 2003, AM J RESP CRIT CARE, V167, P1496, DOI 10.1164/rccm.2205003; Stephens NL, 2003, RESP PHYSIOL NEUROBI, V137, P125, DOI 10.1016/S1569-9048(03)00142-3; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749, DOI 10.1164/ajrccm.154.3.8810615; Thorpe CW, 2004, J APPL PHYSIOL, V97, P1643, DOI 10.1152/japplphysiol.01300.2003; Wang L, 2005, AM J PHYSIOL-LUNG C, V289, pL909, DOI 10.1152/ajplung.00128.2005; Wang L, 2003, CHEST, V123, p356S, DOI 10.1378/chest.123.3_suppl.356S-a; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; [No title captured]	52	46	46	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1196	1202		10.1016/j.jaci.2008.02.017	http://dx.doi.org/10.1016/j.jaci.2008.02.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18405955				2022-12-18	WOS:000255961700019
J	Moir, LM; Burgess, JK; Black, JL				Moir, Lyn M.; Burgess, Janette K.; Black, Judith L.			Transforming growth factor beta(1) increases fibronectin deposition through integrin receptor alpha(5)beta(1) on human airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human airway smooth muscle; integrins; transforming growth factor beta; proliferation; fibronectin; fibrosis; extracellular matrix	EXTRACELLULAR-MATRIX PROTEINS; HUMAN-LUNG FIBROBLASTS; GROWTH-FACTOR; CELL-PROLIFERATION; ALPHA-5-BETA-1 INTEGRIN; CULTURED HUMAN; MEDIATE ENHANCEMENT; EXPRESSION; PHENOTYPE; STIMULATION	Background: Integrin receptors signal to and from the extracellular matrix. Altered expression of the integrin receptors, such as the fibronectin receptor alpha(5)beta(1), might be implicated in extracellular matrix accumulation in airway remodeling in asthma. Objective: We examined the effect of TGF-beta stimulation on integrin alpha(5)beta(1), expression and the role of alpha(5)beta(1), in fibronectin deposition and proliferation. Methods: Integrin subunit alpha(5) and PI expression in airway smooth muscle (ASM) from subjects with and without asthma was examined by means of PCR and flow cytometry. The effect of blocking alpha(5)beta(1) receptor on ASM proliferation to FBS was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium assay. Cells were stimulated with TGF-beta in the presence or absence of extracellular signal-regulated kinase, phosphoinositide-3 kinase, or p38 inhibitors and antibodies to the alpha(5) and beta(1) subunits. The effect of blocking alpha(5)beta(1) receptor on fibronectin deposition was assessed by means of immunocytochemistry. Results: Proliferation of ASM cells from asthmatic and nonasthmatic subjects was inhibited by blocking the fibronectin receptor subunit alpha(5)beta(1). TGF-beta-induced alpha(5)beta(1) was extracellular signal-regulated kinase dependent but not phosphoinositide-3 kinase or p38 dependent. Blockade of the 041 receptor inhibited TGF-beta-induced fibronectin matrix deposition. Conclusion: Through its increased expression by the profibrotic stimulus TGF-beta, integrin alpha(5)beta(1) might be important in regulating fibronectin deposition.	[Burgess, Janette K.; Black, Judith L.] Univ Sydney, Discipline Pharmacol, Sydney, NSW 2006, Australia; [Moir, Lyn M.; Burgess, Janette K.; Black, Judith L.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Moir, LM (corresponding author), Univ Sydney, Discipline Pharmacol, Bosch Bldg D05, Sydney, NSW 2006, Australia.	lynmoir@med.usyd.edu.au	Moir, Lyn/A-8967-2011; Burgess, Janette K/A-3597-2010; Burgess, Janette/M-7117-2019; Black, Judith L/C-6559-2008	Burgess, Janette/0000-0001-9868-9966				Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; Chan V, 2006, AM J RESP CRIT CARE, V174, P379, DOI 10.1164/rccm.200509-1420OC; Dekkers BGJ, 2007, AM J PHYSIOL-LUNG C, V292, pL1405, DOI 10.1152/ajplung.00331.2006; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Han S, 2005, INT J CANCER, V116, P536, DOI 10.1002/ijc.21125; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574, DOI 10.1165/ajrcmb/7.6.574; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking DC, 2000, J BIOL CHEM, V275, P10673, DOI 10.1074/jbc.275.14.10673; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Johnson PRA, 2006, AM J RESP CRIT CARE, V173, P32, DOI 10.1164/rccm.200406-703OC; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kucich U, 2000, ARCH BIOCHEM BIOPHYS, V374, P313, DOI 10.1006/abbi.1999.1625; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; Nguyen TTB, 2005, AM J RESP CRIT CARE, V171, P217, DOI 10.1164/rccm.200408-1046OC; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Pare P D, 1997, Monaldi Arch Chest Dis, V52, P589; Peng Q, 2005, J IMMUNOL, V174, P2258, DOI 10.4049/jimmunol.174.4.2258; Pickering JG, 2000, AM J PATHOL, V156, P453, DOI 10.1016/S0002-9440(10)64750-5; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; Schwartz MA, 2001, J CELL SCI, V114, P2553; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; Zhou XH, 2000, CHINESE MED J-PEKING, V113, P272	31	46	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1034	1039		10.1016/j.jaci.2007.12.1159	http://dx.doi.org/10.1016/j.jaci.2007.12.1159			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18243286				2022-12-18	WOS:000254884000033
J	Maggi, L; Santarlasci, V; Liotta, F; Frosali, F; Angeli, R; Cosmi, L; Maggi, E; Romagnani, S; Annunziato, F				Maggi, Laura; Santarlasci, Veronica; Liotta, Francesco; Frosali, Francesca; Angeli, Roberta; Cosmi, Lorenzo; Maggi, Enrico; Romagnani, Sergio; Annunziato, Francesco			Demonstration of circulating allergen-specific CD4(+)CD25(high)Foxp3(+) T-regulatory cells in both nonatopic and atopic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; immune suppression; T-regulatory cells	IMMUNE-RESPONSES; IN-VITRO; SUPPRESSION; EXPRESSION; MECHANISM; DISEASE	Background: CD4(+)CD25(+)Foxp3(+) T-regulatory (Treg) cells play a fundamental role in the control of autoimmunity. Whether human CD4(+)CD25(+)Foxp3(+) Treg cells that recognize foreign antigens also exist is less clear. Objective: To investigate the existence in humans of circulating Treg cells able to recognize exogenous antigens, including allergens. Methods: CD4(+)CD25(high)Foxp3(+) and CD4(+)CD25(-)Foxp3(-) cells were purified from human peripheral blood and cultured for 15 days with autologous dendritic cells (DCs), unloaded, or loaded with Der p I allergen or the bacterial antigen streptokinase (SK). Results: CD4(+)CD25(high)Foxp3(+) circulating T cells obtained from healthy nonatopic subjects and cultured with Der p 1-loaded DCs, but not those cultured with either unloaded or SK-loaded DCs, suppressed the proliferative response to Der p I of autologous Der p 1-specific T cells generated from the CD4(+)CD25(-)Foxp3(-) subset. The antigen specificity of either Der p 1-CD4(+)CD25(high) Foxp3(+) or SK-CD4(+)CD25(high)Foxp3(+) T cells was confirmed even at clonal level. Finally, under the same experimental conditions, functionally active Der p 1-specific Treg cells were obtained from the pool of circulating CD4(+)CD25(high)Foxp3(+) T cells of Der p 1-sensitive, atopic individuals. Conclusion: These data provide undoubted demonstration of the existence of human CD4(+)CD25 (high)Foxp3(+) circulating Treg cells specific for exogenous antigens, including the Der p 1 allergen, and indicate that CD4(+)CD25 high Foxp3(+) Treg cells specific for Der p 1 are present and functionally active in both nonatopic and Der p 1sensitive, atopic individuals. Clinical implications: Caution should be advised in interpreting allergic disorders as simply resulting from defective Treg cell activity.	Univ Florence, Excellence Ctr Res Transfer & High Educ DENOthe, I-50121 Florence, Italy	University of Florence	Romagnani, S (corresponding author), Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it	Annunziato, Francesco/C-1155-2013; Maggi, Laura/B-6693-2013; Maggi, Enrico/AAA-8045-2019	Maggi, Laura/0000-0003-2862-9591; Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; Romagnani P, 2005, J ALLERGY CLIN IMMUN, V116, P1372, DOI 10.1016/j.jaci.2005.09.035; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x	15	46	48	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					429	436		10.1016/j.jaci.2007.05.002	http://dx.doi.org/10.1016/j.jaci.2007.05.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17604089				2022-12-18	WOS:000248654900032
J	Beyer, K; Grishina, G; Bardina, L; Sampson, HA				Beyer, Kirsten; Grishina, Galina; Bardina, Ludmilla; Sampson, Hugh A.			Identification of 2 new sesame seed allergens: Ses i 6 and Ses i 7	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY		Univ Berlin, Childrens Hosp, Charite, Dept Pneumol & Immunol, Berlin, Germany; Mt Sinai Sch Med, Div Pediat Allergy, New York, NY USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Univ Berlin, Childrens Hosp, Charite, Dept Pneumol & Immunol, Berlin, Germany.	kirsten.beyer@charite.de						Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Beyer K, 2003, CURR OPIN ALLERGY CL, V3, P189, DOI 10.1097/01.all.0000072716.82112.85; Gangur V, 2005, ANN ALLERG ASTHMA IM, V95, P4, DOI 10.1016/S1081-1206(10)61181-7; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; Pastorello EA, 2001, J CHROMATOGR B, V756, P85, DOI 10.1016/S0378-4347(01)00073-1; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Teuber SS, 2004, CURR OPIN ALLERGY CL, V4, P201, DOI 10.1097/01.all.0000129451.19469.e2	7	46	49	3	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1554	1556		10.1016/j.jaci.2007.03.041	http://dx.doi.org/10.1016/j.jaci.2007.03.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17556061				2022-12-18	WOS:000247232800041
J	de Marco, R; Marcon, A; Jarvis, D; Accordini, SD; Bugiani, M; Cazzoletti, L; Cerveri, I; Corsico, A; Gislason, D; Gulsvik, A; Jogi, R; Martinez-Moratalla, J; Pin, I; Janson, C				de Marco, Roberto; Marcon, Alessandro; Jarvis, Deborah; Accordini, Simone D.; Bugiani, Massimiliano; Cazzoletti, Lucia; Cerveri, Isa; Corsico, Angelo; Gislason, David; Gulsvik, Amund; Jogi, Rain; Martinez-Moratalla, Jesus; Pin, Isabelle; Janson, Christer		ECRHS Therapy Grp	Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; lung function decline; inhaled corticosteroids; total IgE; eosinophils; prospective cohort study; FEV1 decline; European Community Respiratory Health Survey; ECRHS	LONGITUDINAL CHANGES; CORTICOSTEROIDS; EOSINOPHIL; SMOKING; BUDESONIDE; AIRWAYS; GLUCOCORTICOIDS; INFLAMMATION; PREVENTION; OMALIZUMAB	Background: Few studies have investigated the long-term association between inhaled corticosteroids (ICSs) and lung function decline in asthma. Objective: To evaluate whether prolonged treatment with ICSs is associated with FEV1 decline in adults with asthma. Methods: An international cohort of 667 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1999 to 2002. Spirometry was performed on both occasions. FEV1 decline was analyzed according to age, sex, height, body mass index, total IgE, time of ICS use, and smoking, while adjusting for potential confounders. Results: As ICS use increased, the decline in FEV1 was lower (P trend = .025): on average, decline passed from 34 mL/y in nonusers (half of the sample) to 20 mL/y in subjects treated for 48 months or more (18%). When adjusting for all covariates, there was an interaction (P = .02) between ICS use and total IgE: in subjects with high (> 100 kU/L) IgE, ICS use for 4 years or more was associated with a lower FEV1 decline (23 mL/y; 95% CI, 8-38 compared with nonusers). This association was not seen in those with lower IgE. Conclusion: Although confirming a beneficial long-term association between ICSs and lung function in asthma, our study suggests that subjects with high IgE could maximally benefit from a prolonged ICS treatment. Clinical implications: This study adds further evidence to the beneficial effect of inhaled steroids on lung function in asthma; future studies will clarify whether calibrating the corticosteroid dose according to the level of total IgE is a feasible approach in asthma management.	Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Ist Biol 2, I-37134 Verona, Italy; Imperial Coll Sch Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London, England; Consorzio Provinciale Antitubercolare, Unit Pneumol, Turin, Italy; Univ Padua, San Matteo Hosp, Ist Ric & Cura Carattere Sci, Div Resp Dis, I-35100 Padua, Italy; Landspitali Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; Univ Bergen, Haukeland Univ Hosp, Dept Thorac Med, N-5020 Bergen, Norway; Tartu Univ Hosp Clin, Lung Clin, Tartu, Estonia; CHU Grenoble, Dept Pediat, F-38043 Grenoble, France; CHU Grenoble, INSERM U578, F-38043 Grenoble, France; Uppsala Univ, Dept Med Sci Resp Med & Allergol, S-75105 Uppsala, Sweden	University of Verona; Imperial College London; University of Padua; Landspitali National University Hospital; University of Bergen; Haukeland University Hospital; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Uppsala University	de Marco, R (corresponding author), Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Ist Biol 2, Strada Le Grazie 8, I-37134 Verona, Italy.	roberto.demarco@univr.it	Corsico, Angelo Guido/AAC-8138-2019; de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011; PIN, Isabelle/N-3020-2013; Marcon, Alessandro/C-3349-2012	Corsico, Angelo Guido/0000-0002-8716-4694; Marcon, Alessandro/0000-0002-2778-658X; Jarvis, Deborah/0000-0002-1753-3896; Cerveri, Isa/0000-0003-0337-043X				Adams N P, 2005, COCHRANE DB SYST REV, V1; ADAMS NP, 2005, COCHRANE DB SYST REV, V2, P3135; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baatjes AJ, 2002, PHARMACOL THERAPEUT, V95, P63, DOI 10.1016/S0163-7258(02)00233-4; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Belvisi Maria G, 2004, Proc Am Thorac Soc, V1, P207, DOI 10.1513/pats.200402-002MS; BJORNSSON E, 1994, ALLERGY, V49, P730, DOI 10.1111/j.1398-9995.1994.tb02095.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1986, AM REV RESPIR DIS, V133, P974; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chinn S, 2005, AM J RESP CRIT CARE, V172, P956, DOI 10.1164/rccm.200503-323OC; Chinn S, 2005, LANCET, V365, P1629, DOI 10.1016/S0140-6736(05)66511-7; de Marco R, 1998, EUR RESPIR J, V11, P599; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Fletcher CM, 1976, NATURAL HIST CHRONIC; Guenegou A, 2006, THORAX, V61, P320, DOI 10.1136/thx.2005.047373; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Homer RJ, 2005, PHYSIOLOGY, V20, P28, DOI 10.1152/physiol.00035.2004; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Kupczyk M, 2004, RESPIRATION, V71, P233, DOI 10.1159/000077420; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Meagher LC, 1996, J IMMUNOL, V156, P4422; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218, DOI 10.1152/ajplung.1994.267.2.L218; *NAT HEART LUNG BL, 1995, NIH PUBL; Ohrui T, 1999, CLIN EXP ALLERGY, V29, P357; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519, DOI 10.1164/ajrccm.153.5.8630596; PETO R, 1981, LANCET, V2, P467; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; VILLANOVE X, 1993, AM REV RESPIR DIS, V148, P107, DOI 10.1164/ajrccm/148.1.107; White SR, 2002, CHEST, V122, p278S, DOI 10.1378/chest.122.6_suppl.278S	52	46	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					611	617		10.1016/j.jaci.2006.11.696	http://dx.doi.org/10.1016/j.jaci.2006.11.696			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17258304				2022-12-18	WOS:000244925000013
J	Triggiani, M; Petraroli, A; Loffredo, S; Frattini, A; Granata, F; Morabito, P; Staiano, RI; Secondo, A; Annunziato, L; Marone, G				Triggiani, Massimo; Petraroli, Angelica; Loffredo, Stefania; Frattini, Annunziata; Granata, Francescopaolo; Morabito, Paolo; Staiano, Rosaria Ilaria; Secondo, Agnese; Annunziato, Lucio; Marone, Gianni			Differentiation of monocytes into macrophages induces the upregulation of histamine H-1 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; H-1 receptor; macrophage; dendritic cells; monocyte; IL-8	DENDRITIC CELLS; IMMUNE REGULATION; MESSENGER-RNA; T-CELL; EXPRESSION; H1; RESPONSES; H2; BLOOD; LUNG	Background: Histamine modulates several functions in human monocytes, macrophages, and dendritic cells. However, responses elicited by histamine differ depending on cell type, suggesting variable expression of histamine receptors in the monocyte/macrophage lineage. Objective: We sought to examine whether the expression of H-1 receptors was regulated by cell differentiation of human monocytes into macrophages or dendritic cells. Methods: Expression of H-1 receptor was evaluated by RT-PCR and western blot in monocytes, monocyte-derived macrophages (MDMs), monocyte-derived dendritic cells (DCs) and human lung macrophages (HLMs). Results: Expression of H, receptor mRNA and protein was higher in HLMs and DCs than in monocytes. H-I expression was approximately 15-fold and 4-fold higher in MDMs and HLMs, respectively, as compared with that seen in monocytes. Hi receptor protein was undetectable in monocytes, whereas it was conspicuous in MDMs. Simultaneous analysis of H-2 and H-1 mRNA expression indicated that the H-2/H-1 ratio decreased from 202.7 +/- 14.8 in monocytes to 2.2 +/- 0.4 in MDM and 39.5 +/- 5.0 in DCs. Incubation of monocytes with histamine neither affected intracellular Ca2+ concentrations nor influenced IL-8 production. In contrast, histamine rapidly induced a Ca2+ signal and stimulated IL-8 production in MDMs. Both effects were inhibited by H-1 blockade with levocetirizine, but not by H-2 blockade with ranitidine. Conclusions: Differentiation of monocytes into macrophages or dendritic cells is associated with profound changes of histamine receptor expression. Upregulation of H, receptors confers on macrophages the capacity of being activated by histamine. Clinical implications: Regulation of H-1 and H-2 receptor expression in the monocyte/macrophage lineage can be relevant to the pathogenesis of allergic inflammation.	Univ Naples Federico II, Div Clin Immunol & Allergy, I-80131 Naples, Italy; Ctr Basic & Clin Immunol Res, CISI, Naples, Italy; A Cardarelli Hosp, Div Immunohematol & Transfus Med, Naples, Italy; Univ Naples Federico II, Dept Neurosci, Div Pharmacol, I-80131 Naples, Italy	University of Naples Federico II; Antonio Cardarelli Hospital; University of Naples Federico II	Triggiani, M (corresponding author), Univ Naples Federico II, Div Clin Immunol & Allergy, Via S Pansini 5, I-80131 Naples, Italy.	triggian@unina.it	Triggiani, Massimo/K-8271-2016; Secondo, Agnese/AAA-3407-2022	Triggiani, Massimo/0000-0001-7318-2093; ANNUNZIATO, LUCIO/0000-0002-8534-8270; Secondo, Agnese/0000-0001-5054-4098				Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Giustizieri ML, 2004, J ALLERGY CLIN IMMUN, V114, P1176, DOI 10.1016/j.jaci.2004.07.054; Hill SJ, 1997, PHARMACOL REV, V49, P253; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; Iriyoshi N, 1996, CLIN EXP ALLERGY, V26, P379, DOI 10.1111/j.1365-2222.1996.tb00553.x; JEANNIN P, 1994, BLOOD, V84, P2229; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kawakami N, 2004, J PHARMACOL SCI, V94, P449, DOI 10.1254/jphs.94.449; Kohda F, 2002, J DERMATOL SCI, V28, P34, DOI 10.1016/S0923-1811(01)00147-5; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Marone G., 2000, MAST CELLS BASOPHILS; Marone Gianni, 2003, Journal of Allergy and Clinical Immunology, V112, pS83, DOI 10.1016/S0091-6749(03)01881-5; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; MIROSSAY L, 1994, AM J PHYSIOL, V267, pR602, DOI 10.1152/ajpregu.1994.267.2.R602; Murata Y, 2005, ARTERIOSCL THROM VAS, V25, P430, DOI 10.1161/01.ATV.0000148705.13411.65; Naclerio R, 1999, J ALLERGY CLIN IMMUN, V103, pS382, DOI 10.1016/S0091-6749(99)70216-2; Ratnala VRP, 2004, EUR J BIOCHEM, V271, P2636, DOI 10.1111/j.1432-1033.2004.04192.x; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Sirois J, 2000, J IMMUNOL, V164, P2964, DOI 10.4049/jimmunol.164.6.2964; Smit MJ, 1996, BRIT J PHARMACOL, V117, P1071, DOI 10.1111/j.1476-5381.1996.tb16699.x; Snedecor GW, 1980, STAT METHODS, V7th; Triggiani M., 2004, Clinical and Experimental Allergy Reviews, V4, P129, DOI 10.1111/j.1472-9725.2004.00045.x; Triggiani M, 2002, EUR J IMMUNOL, V32, P67, DOI 10.1002/1521-4141(200201)32:1<67::AID-IMMU67>3.0.CO;2-3; Triggiani M, 2001, J IMMUNOL, V166, P4083, DOI 10.4049/jimmunol.166.6.4083; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017; Wang KY, 2000, FEBS LETT, V473, P345, DOI 10.1016/S0014-5793(00)01560-X; Wierzbicki T, 2003, J LEUKOCYTE BIOL, V74, P420, DOI 10.1189/jlb.1102571	37	46	47	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					472	481		10.1016/j.jaci.2006.09.027	http://dx.doi.org/10.1016/j.jaci.2006.09.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17125827				2022-12-18	WOS:000244327900028
J	Miyahara, S; Miyahara, N; Matsubara, S; Takeda, K; Koya, T; Gelfand, EW				Miyahara, Satoko; Miyahara, Nobuaki; Matsubara, Shigeki; Takeda, Katsuyuki; Koya, Toshiyuki; Gelfand, Erwin W.			IL-13 is essential to the late-phase response in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; early phase; late phase; nasal resistance; IL-13	MESSENGER-RNA; NASAL-MUCOSA; STIMULATING FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; INTERLEUKIN-13; RECEPTOR; ASTHMA; MICE; EOSINOPHILIA	Background: The pathophysiology of the early- and late-phase nasal response to allergen challenge is not completely defined. Recent technical advances enable direct monitoring of these responses in mice. Objective: IL-13 is detected in the nasal membranes of both human beings and mice with allergic rhinitis, but its role in disease pathogenesis is unclear. We measured early and late nasal allergic responses after treatment with soluble IL-13R alpha 2-IgG fusion protein (sIL-13R alpha 2-Fc), and in IL-13-deficient mice (IL-13(-/-)). Methods: IL-13(-/-) mice (BALB/c background) and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged intranasally with ovalbumin without sedation. The sIL-13R alpha 2-Fc or control human IgG was administered by intraperitoneal (i.p.) injection 24 hours and 1 hour before each ovalbumin challenge. Early nasal responses after the 4th ovalbumin challenge and late nasal responses 24 hours after the 6th ovalbumin challenge were assessed. Results: Sensitized/challenged wild-type mice treated with sIL-13R alpha 2-Fc or IL-13(-/-) mice demonstrated significantly reduced late nasal responses in face of persistent nasal tissue eosinophilia; the early nasal response was little affected by targeting IL-13. Goblet cell hyperplasia was not detected in nasal membranes. Conclusion: The data indicate that IL-13 is a major contributor to the development of a late nasal response with little influence on the early response, and without affecting nasal eosinophilic inflammation. Inhibition of IL-13 may have an important therapeutic application in preventing the persistent nasal blockage in allergic rhinitis. Clinical implications: Current therapies for allergic rhinitis may not take into account the important differences in the pathophysiology of the early and late responses and the important role of IL-13 in sustaining chronic nasal congestion and obstruction.	Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL-36577, HL-61005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bastien Y, 1999, J IMMUNOL, V162, P5498; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Burgel PR, 2001, J IMMUNOL, V167, P5948, DOI 10.4049/jimmunol.167.10.5948; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Donaldson DD, 1998, J IMMUNOL, V161, P2317; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hoshino T, 1999, J IMMUNOL, V162, P5070; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Li HM, 1996, J IMMUNOL, V156, P4833; Lou YP, 1998, AM J RESP CRIT CARE, V157, P1927, DOI 10.1164/ajrccm.157.6.9709113; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Miyahara S, 2005, J ALLERGY CLIN IMMUN, V116, P1020, DOI 10.1016/j.jaci.2005.08.020; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Padilla J, 2005, J IMMUNOL, V174, P8097, DOI 10.4049/jimmunol.174.12.8097; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; TERADA N, 1994, ACTA OTO-LARYNGOL, V114, P203, DOI 10.3109/00016489409126043; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wang DY, 2004, CURR OPIN ALLERGY CL, V4, P165, DOI 10.1097/01.all.0000129445.81350.6a; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	29	46	50	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1110	1116		10.1016/j.jaci.2006.06.014	http://dx.doi.org/10.1016/j.jaci.2006.06.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088137				2022-12-18	WOS:000244282300017
J	Weidinger, S; Novak, N; Klopp, N; Baurecht, H; Wagenpfeil, S; Rummler, L; Ring, J; Behrendt, H; Illig, T				Weidinger, Stephan; Novak, Natalija; Klopp, Norman; Baurecht, Hansjoerg; Wagenpfeil, Stefan; Rummler, Lars; Ring, Johannes; Behrendt, Heidrun; Illig, Thomas			Lack of association between Toll-like receptor 2 and Toll-like receptor 4 polymorphisms and atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TLR4; ASTHMA; GENE		Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-8000 Munich, Germany; Tech Univ Munich, GSF Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-8000 Munich, Germany; Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; GSF Natl Res Ctr Environm & Hlth, Dept Epidemiol, Neuherberg, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; University of Bonn; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany.		Baurecht, Hansjoerg/C-4035-2013; Weidinger, Stephan/C-8461-2011; Ring, Johannes/GLN-4341-2022	Baurecht, Hansjoerg/0000-0002-9265-5594; Weidinger, Stephan/0000-0003-3944-252X; Ring, Johannes/0000-0001-8236-3152				Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; Vandenbulcke L, 2006, INT ARCH ALLERGY IMM, V139, P159, DOI 10.1159/000090393; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648	10	46	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					277	279		10.1016/j.jaci.2006.04.034	http://dx.doi.org/10.1016/j.jaci.2006.04.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815166				2022-12-18	WOS:000239184800034
J	Ferrara, TJ; Mueller, C; Sahu, N; Ben-Jebria, A; August, A				Ferrara, TJ; Mueller, C; Sahu, N; Ben-Jebria, A; August, A			Reduced airway hyperresponsiveness and tracheal responses during allergic asthma in mice lacking tyrosine kinase inducible T-cell kinase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airways hyperresponsiveness; tracheal responses; Tec kinase; T(H)2 cells; cytokines; asthma; smooth muscle contractility	SMOOTH-MUSCLE; TRANSCRIPTION FACTOR; CYTOKINE PRODUCTION; MAST-CELLS; EXPRESSION; GATA-3; BET; IL-13; ITK; HYPERREACTIVITY	Background: Patients with allergic asthma have symptoms of a predominant T(H)2 response, including airway eosinophilic inflammation and increased mucous production in the lungs. This accompanies increased airways responsiveness, which can be life threatening. Because T(H)2 cells and cytokines have been implicated in contributing to these symptoms, pathways that control the development of these cells or that regulate their cytokine production represent good targets for controlling this disease. Objective: We have previously shown that mice lacking the tyrosine kinase inducible T-cell kinase (ITK) have drastically reduced airway inflammation in a model of allergic asthma. However, it was not clear whether this translated into reduced airways hyperresponsiveness. We have analyzed tracheal responsiveness and airways hyperresponsiveness of wild-type (WT) and ITK null mice during induction of experimental allergic asthma. Methods: Experimental allergic asthma was induced in WT and ITK knockout mice. Tracheal responses to carbachol, acetylcholine, and potassium chloride were analyzed. Airways hyperresponsiveness to methacholine challenge was also analyzed in allergen-challenged mice, along with lung and bronchoalveolar lavage fluid T(H)2 cytokine message and protein. Results: ITK null mice have reduced tracheal responses to cholinergic challenge in vitro before as well as after allergen challenge. These mice also have reduced airways hyperresponsiveness in response to allergen challenge, which could be rescued by transferring WT splenocytes or purified WT CD4(+) T cells. This reduced airways response was preferentially accompanied by reduced expression of T(H)2 cytokines in the lungs. Conclusion: Our results indicate that the tyrosine kinase ITK and its function in T cells represent an attractive target for antiasthmatic drugs. Clinical implications: Modulating the expression or activity of ITK may be a novel strategy to block allergic airway inflammation.	Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Immunol & Infect Dis, University Pk, PA 16802 USA; Penn State Univ, Physiol Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Chem Engn, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	August, A (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Immunol & Infect Dis, 115 Henning Bldg, University Pk, PA 16802 USA.	axa45@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI51626, R01 AI051626, R01 AI051626-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Ferrara TJ, 2004, PULM PHARMACOL THER, V17, P301, DOI 10.1016/j.pupt.2004.07.002; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Forssell J, 2005, AM J RESP CELL MOL, V32, P511, DOI 10.1165/rcmb.2004-0348OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Lametschwandtner G, 2004, J ALLERGY CLIN IMMUN, V113, P987, DOI 10.1016/j.jaci.2004.02.004; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Lin TA, 2004, BIOCHEMISTRY-US, V43, P11056, DOI 10.1021/bi049428r; Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Schaeffer EM, 2001, NAT IMMUNOL, V2, P1183, DOI 10.1038/ni734; Shore SA, 2002, CLIN EXP PHARMACOL P, V29, P859, DOI 10.1046/j.1440-1681.2002.03756.x; SUGITA M, 2004, ANNU REV IMMUNOL, V22, P789; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	36	46	52	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					780	786		10.1016/j.jaci.2005.12.1330	http://dx.doi.org/10.1016/j.jaci.2005.12.1330			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630934				2022-12-18	WOS:000236862800010
J	Pham-Thi, N; de Blic, J; Le Bourgeois, M; Dy, M; Scheinmann, P; Leite-De-Moraes, MC				Pham-Thi, N; de Blic, J; Le Bourgeois, M; Dy, M; Scheinmann, P; Leite-De-Moraes, MC			Enhanced frequency of immunoregulatory invariant natural killer T cells in the airways of children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION		Hop Necker Enfants Malad, CNRS, UMR 8147, Serv Pneumol & Allergol Pediat, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Pham-Thi, N (corresponding author), Hop Necker Enfants Malad, CNRS, UMR 8147, Serv Pneumol & Allergol Pediat, 161,Rue Sevres, F-75743 Paris, France.		Pham-Thi, Nhan/HCH-6032-2022; de Moraes, Maria Leite/AAV-9159-2020	de Moraes, Maria Leite/0000-0002-2891-2269				AKBARI O, 2003, NAT MED, V189, P553; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P868, DOI 10.1016/j.jaci.2004.02.016; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; Ho LP, 2005, LANCET, V365, P1062, DOI 10.1016/S0140-6736(05)71143-0; Hodges E, 1998, CLIN EXP IMMUNOL, V112, P363; Ikegami Y, 2004, J ASTHMA, V41, P877, DOI 10.1081/JAS-200038364; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Lisbonne M, 2003, EUR CYTOKINE NETW, V14, P4; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123	10	46	47	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					217	218		10.1016/j.jaci.2005.09.052	http://dx.doi.org/10.1016/j.jaci.2005.09.052			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387611				2022-12-18	WOS:000235687100037
J	Casanova, JL; Fieschi, C; Bustamante, J; Reichenbach, J; Remus, N; von Bernuth, H; Picard, C				Casanova, JL; Fieschi, C; Bustamante, J; Reichenbach, J; Remus, N; von Bernuth, H; Picard, C			From idiopathic infectious diseases to novel primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiency; infectious diseases; idiopathic injections; inborn errors; Mendelian disorders; predisposition to infection	LINKED LYMPHOPROLIFERATIVE DISEASE; CHRONIC MUCOCUTANEOUS CANDIDIASIS; RECEPTOR BETA-1 DEFICIENCY; CALMETTE-GUERIN INFECTION; GENETIC DISSECTION; INTERFERON-GAMMA; IMMUNOLOGICAL IMPLICATIONS; HUMAN-MODEL; INTERLEUKIN-12; SUSCEPTIBILITY	Primary immunodeficiencies are typically seen as rare monogenic conditions associated with detectable immunologic abnormalities, resulting in a broad susceptibility to multiple and recurrent infections caused by weakly pathogenic and more virulent microorganisms. By opposition to these conventional primary immunodeficiencies, we describe nonconventional primary immunodeficiencies; as Mendelian conditions manifesting in otherwise healthy patients as a narrow susceptibility to infections, recurrent or otherwise, caused by weakly pathogenic or more virulent microbes. Conventional primary immunodeficiencies are suspected on the basis of a rare, striking, clinical phenotype and are defined on the basis of an overt immunologic phenotype, often leading to identification of the disease-causing gene. Nonconventional primary immunodeficiencies are defined on the basis of a more common and less marked clinical phenotype, which remains isolated until molecular cloning of the causal gene reveals a hitherto undetected immunologic phenotype. Similar concepts can be applied to primary immunodeficiencies presenting other clinical features, such as allergy and autoimmunity. Nonconventional primary immunodeficiencies thus expand the clinical boundaries of this group of inherited disorders considerably, suggesting that Mendelian primary immunodeficiencies are more common in the general population than previously thought and might affect children with a single infectious, allergic, or autoimmune disease.	Univ Paris 05, Lab Genet Humaine Malad Infect, INSERM, U550,Fac Med Necker, F-75015 Paris, France; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; Hop St Louis, Serv Immunol Clin, Paris, France; Univ Frankfurt Klinikum, Klin Kinderheilkunde, D-6000 Frankfurt, Germany; Ctr Hosp Intercommunal, Serv Pediat, Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil	Casanova, JL (corresponding author), Univ Paris 05, Lab Genet Humaine Malad Infect, INSERM, U550,Fac Med Necker, F-75015 Paris, France.	casanova@necker.fr	Picard, Capucine/H-3914-2017; Casanova, Jean-Laurent/I-3418-2017; von Bernuth, Horst/AAQ-9797-2021; Remus, Natascha/R-1783-2018; Reichenbach, Janine/U-2171-2018; Bustamante, Jacinta/H-7877-2017	Picard, Capucine/0000-0001-8788-5056; von Bernuth, Horst/0000-0002-5812-7675; Reichenbach, Janine/0000-0002-9008-1312; Bustamante, Jacinta/0000-0002-3439-2482; Casanova, Jean-Laurent/0000-0002-7782-4169				Alcais A, 2005, CURR OPIN IMMUNOL, V17, P44, DOI 10.1016/j.coi.2004.11.006; Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999; Arkwright PD, 2002, BLOOD, V99, P2694, DOI 10.1182/blood.V99.8.2694; Bertrand Y, 2002, BONE MARROW TRANSPL, V29, P759, DOI 10.1038/sj.bmt.1703531; BRUTON OC, 1962, J PEDIATR-US, V60, P672, DOI 10.1016/S0022-3476(62)80092-4; BRUTON OC, 1952, PEDIATRICS, V9, P722; Cairns J, 1997, MATTERS LIFE DEATH; Caragol I, 2003, CLIN INFECT DIS, V37, P302, DOI 10.1086/375587; Casanova Jean-Laurent, 2002, Trends in Immunology, V23, P469, DOI 10.1016/S1471-4906(02)02289-5; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 2004, NAT REV IMMUNOL, V4, P55, DOI 10.1038/nri1264; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Casanova JL, 1996, PEDIATRICS, V98, P774; Conley ME, 2005, IMMUNOL REV, V203, P5, DOI 10.1111/j.0105-2896.2005.00237.x; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; de Saint Basile G, 2003, CURR OPIN RHEUMATOL, V15, P436, DOI 10.1097/00002281-200307000-00011; Dorman SE, 2000, CYTOKINE GROWTH F R, V11, P321, DOI 10.1016/S1359-6101(00)00010-1; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; Fieschi C, 2003, EUR J IMMUNOL, V33, P1461, DOI 10.1002/eji.200324038; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Fischer A, 2001, LANCET, V357, P1863, DOI 10.1016/S0140-6736(00)04959-X; Good RA, 1971, IMMUNOLOGIC INCOMPET, P149; Hitzig WH, 2003, EUR J PEDIATR, V162, P289, DOI 10.1007/s00431-003-1153-7; Hull KM, 2003, CURR OPIN RHEUMATOL, V15, P61, DOI 10.1097/00002281-200301000-00011; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kirkpatrick CH, 2001, PEDIATR INFECT DIS J, V20, P197, DOI 10.1097/00006454-200102000-00017; Ku CL, 2005, IMMUNOL REV, V203, P10, DOI 10.1111/j.0105-2896.2005.00235.x; Lawrence T, 2005, CURR OPIN HEMATOL, V12, P22, DOI 10.1097/01.moh.0000149609.37309.0a; LEJEUNE J, 1959, CR HEBD ACAD SCI, V248, P1721; Lilic D, 2002, CURR OPIN INFECT DIS, V15, P143, DOI 10.1097/00001432-200204000-00007; McKusick V.A., 1998, MENDELIAN INHERITANC; Mira MT, 2003, NAT GENET, V33, P412, DOI 10.1038/ng1096; Mira MT, 2004, NATURE, V427, P636, DOI 10.1038/nature02326; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Notarangelo L, 2004, J ALLERGY CLIN IMMUN, V114, P677, DOI 10.1016/j.jaci.2004.06.044; OCHS H, 2005, PRIMARY IMMUNODEFICI; Orth G, 2004, J INVEST DERMATOL, V123, pXI, DOI 10.1111/j.0022-202X.2004.23243.x; Ozbek N, 2005, CLIN INFECT DIS, V40, pE55, DOI 10.1086/427879; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Picard C, 2003, CURR OPIN ALLERGY CL, V3, P451, DOI 10.1097/01.all.0000104457.09202.c0; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Reichenbach J, 2001, CURR OPIN ALLERGY CL, V1, P503, DOI 10.1097/00130832-200112000-00003; STICHM ER, 2005, IN PRESS PEDIAT RES; STIEHM E, 2004, IMMUNOLOGIC DISORDER; STIEHM ER, 1993, PEDIATR RES, V33, pS2, DOI 10.1203/00006450-199304001-00002; Wurzner R, 1992, Immunodefic Rev, V3, P123; Wurzner R, 1998, EXP CLIN IMMUNOGENET, V15, P268, DOI 10.1159/000019082	51	46	49	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					426	430		10.1016/j.jaci.2005.03.053	http://dx.doi.org/10.1016/j.jaci.2005.03.053			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083801				2022-12-18	WOS:000235686400029
J	Laouini, D; ElKhal, A; Yalcindag, A; Kawamoto, S; Oettgen, H; Geha, RS				Laouini, D; ElKhal, A; Yalcindag, A; Kawamoto, S; Oettgen, H; Geha, RS			COX-2 inhibition enhances the T(H)2 immune response to epicutaneous sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; allergic skin inflammation; NS-398; COX-2; T(H)1; T(H)2	NECROSIS-FACTOR-ALPHA; NORMAL HUMAN SKIN; DENDRITIC CELLS; PROSTAGLANDIN E-2; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; ALLERGIC INFLAMMATION; ATOPIC-DERMATITIS; DEFICIENT MICE; MOUSE SKIN	Background: Mechanical injury to the skin by scratching is an important feature of atopic dermatitis (AD). Objective: To investigate the role of COX-2 in allergic skin inflammation elicited by epicutaneous (EC) sensitization via introduction of ovalbumin through shaved tape-stripped skin. Methods: COX-2 mRNA was measured by quantitative PCR, and COX-2 protein was measured by Western blotting. We investigated the effect of administration of the COX-2 selective inhibitor NS-398 during EC sensitization with ovalbumin in a mouse model of AD characterized by eosinophil skin infiltration, elevated total and antigen specific IgE, and a systemic T(H)2 response to antigen. We further examined the response of COX-2-deficient mice to EC immunization with ovalbumin. Results: Tape stripping caused a transient increase in skin COX-2 mRNA. In contrast, COX-2 mRNA was not increased after ovalbumin sensitization. Infiltration by eosinophils and expression of IL-4 mRNA in ovalbumin-sensitized skin sites, ovalbumin specific IgE and IgG(1) antibody responses, and IL-4 secretion by splenocytes after ovalbumin stimulation were all significantly increased in EC mice that received NS-398. In contrast, ovalbumin specific IgG(2a). antibody response and IFN-gamma secretion by splenocytes after ovalbumin stimulation were significantly decreased in these mice. COX-2-deficient mice also exhibited an enhanced systemic TH2 response to EC sensitization. Conclusion: These results demonstrate that COX-2 limits the TH2 response to EC sensitization and suggest that COX inhibitors may worse. allergic skin inflammation in patients with AD.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Kawamoto, Seiji/F-3423-2015; Laouini, Dhafer/Q-6535-2019; Yalcindag, Ali/GLU-9728-2022	Kawamoto, Seiji/0000-0002-2056-4802; Laouini, Dhafer/0000-0003-1222-4880; Yalcindag, Ali/0000-0002-5752-0360	NIAID NIH HHS [AI-31541] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541, U01AI031541] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abd-El-Aleem SA, 2001, J PATHOL, V195, P616, DOI 10.1002/path.992; Athar M, 2001, BIOCHEM BIOPH RES CO, V280, P1042, DOI 10.1006/bbrc.2000.4201; Azuma Y, 2001, BIOCHEM BIOPH RES CO, V283, P344, DOI 10.1006/bbrc.2001.4783; Carey MA, 2003, AM J RESP CRIT CARE, V167, P1509, DOI 10.1164/rccm.200211-1383OC; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; FOGH K, 1989, J ALLERGY CLIN IMMUN, V83, P450, DOI 10.1016/0091-6749(89)90132-2; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Goppelt-Struebe M, 2000, N-S ARCH PHARMACOL, V361, P636, DOI 10.1007/s002100000231; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; Jaffar Z, 2002, J IMMUNOL, V169, P5997, DOI 10.4049/jimmunol.169.10.5997; Kalinski P, 1997, J IMMUNOL, V159, P28; KATAMURA K, 1995, J IMMUNOL, V155, P4604; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Machida I, 2004, J IMMUNOL, V172, P1833, DOI 10.4049/jimmunol.172.3.1833; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Muller-Decker K, 1999, INT J CANCER, V82, P648, DOI 10.1002/(SICI)1097-0215(19990827)82:5<648::AID-IJC6>3.0.CO;2-D; Muller-Decker K, 1998, EXP CELL RES, V242, P84, DOI 10.1006/excr.1998.4068; PARKER CW, 1995, CELL IMMUNOL, V160, P278, DOI 10.1016/0008-8749(95)80039-L; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RAZ A, 1988, J BIOL CHEM, V263, P3022; Reilly DM, 1999, ACTA DERM-VENEREOL, V79, P187; RHEINS LA, 1987, CELL IMMUNOL, V106, P33, DOI 10.1016/0008-8749(87)90147-X; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; ROPER RL, 1995, J IMMUNOL, V154, P162; RUZICKA T, 1987, J IMMUNOL, V138, P539; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; SCHOLZ K, 1995, BIOCHEM J, V309, P263, DOI 10.1042/bj3090263; SHIRE D, 1995, GENE EXPRESSION ANAL; Simon Lee S., 1996, Current Opinion in Rheumatology, V8, P169, DOI 10.1097/00002281-199605000-00001; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Takahashi Y, 2002, BRIT J PHARMACOL, V137, P315, DOI 10.1038/sj.bjp.0704872; Takemura N, 2002, PHOTOCHEM PHOTOBIOL, V76, P657, DOI 10.1562/0031-8655(2002)076&lt;0657:DBNTAL&gt;2.0.CO;2; WARNOCK LJ, 1995, J CELL PHYSIOL, V163, P172, DOI 10.1002/jcp.1041630120; Wu CY, 1998, J IMMUNOL, V161, P2723; Yu CL, 1998, INFLAMM RES, V47, P167, DOI 10.1007/s000110050312	49	46	50	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					390	396		10.1016/j.jaci.2005.03.042	http://dx.doi.org/10.1016/j.jaci.2005.03.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083795				2022-12-18	WOS:000235686400023
J	Hantusch, B; Krieger, S; Untersmayr, E; Scholl, I; Knittelfelder, R; Flicker, S; Spitzauer, S; Valenta, R; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Hantusch, B; Krieger, S; Untersmayr, E; Scholl, I; Knittelfelder, R; Flicker, S; Spitzauer, S; Valenta, R; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phl p 5; major grass pollen allergen; IgE; B-cell epitope; conformational epitope; phage display; mimotopes; molecular modeling	GRASS-POLLEN ALLERGEN; TIMOTHY-GRASS; MAJOR ALLERGEN; STRUCTURAL-CHARACTERIZATION; BINDING CAPACITY; PRATENSE POLLEN; PEPTIDE LIBRARY; P 5; ANTIBODY; PROTEIN	Background: Phi p 5 represents a major allergen of timothy grass pollen (Phleum pratense). Detailed knowledge about the structures responsible for IgE binding would allow the design of a novel generation of allergy vaccines. Objective: We aimed to characterize the IgE epitopes of Phi p 5a using phage display combined with a molecular modeling approach. Methods: Phi p 5a-specific IgE from sera of patients with grass pollen allergy was used for screening of a random peptide phage library displaying constrained decamers. Results: Fifteen phage clones that shared sequence motifs and could be grouped into families were selected by using Phi p 5a-specific IgE. Peptide alignment with the solvent-accessible amino acids of Phi p 5a revealed 3 sequence sections with frequent hits of identical or similar amino acids. On the surface of Phi p 5a, these sections assembled in compact patches, most likely representing conformational IgE epitopes, whereas no matching clusters were found on the back sides of the 2 Phi p 5a halves. In surface plasmon resonance experiments, the high-affinity interaction between IgE and Phi p 5 could be competed by phage-displayed peptides up to 24%, indicating that they represent true epitope mimics tie, mimotopes). Allergen-specific immunogenicity of the mimotopes was proved in Biozzi mice. Conclusion: The selected mimotopes facilitated the localization of conformational IgE epitopes of Phi p 5. We suggest them to be suitable candidates for the development of an epitope-specific immunotherapy.	Med Univ Vienna AKH3Q, Dept Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna AKH3Q, Dept Pathol, A-1090 Vienna, Austria; Med Univ Vienna AKH3Q, Clin Chem & Lab Med, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Jensen-Jarolim, E (corresponding author), Med Univ Vienna AKH3Q, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	erika.jensen-jarolim@meduniwien.ac.at	Hantusch, Brigitte/AAM-9822-2021; Untersmayr, Eva/GRY-4470-2022; Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Hantusch, Brigitte/0000-0002-9126-003X; Untersmayr, Eva/0000-0002-1963-499X; Valenta, Rudolf/0000-0001-5944-3365; Flicker, Sabine/0000-0003-4768-8693				Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; ASTWOOD JD, 1995, CLIN EXP ALLERGY, V25, P66, DOI 10.1111/j.1365-2222.1995.tb01004.x; BECKER WM, 1995, INT ARCH ALLERGY IMM, V107, P242, DOI 10.1159/000236991; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BIOZZI G, 1979, IMMUNOLOGY, V36, P427; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; Bufe A, 1996, J BIOL CHEM, V271, P27193, DOI 10.1074/jbc.271.44.27193; Davies JM, 2000, J ALLERGY CLIN IMMUN, V105, P1085, DOI 10.1067/mai.2000.107040; Demangel C, 1996, MOL IMMUNOL, V33, P909, DOI 10.1016/S0161-5890(96)00058-2; Demangel C, 2000, EUR J BIOCHEM, V267, P2345, DOI 10.1046/j.1432-1327.2000.01244.x; FEDOROV AA, 2003, CRYSTAL STRUCTURE PH; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; FOLGORI A, 1994, EMBO J, V13, P2236, DOI 10.1002/j.1460-2075.1994.tb06501.x; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P31, DOI 10.1016/S0091-6749(05)80038-7; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; LIN TC, 1980, J BIOL CHEM, V255, P331; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Mazzucchelli L, 1999, BLOOD, V93, P1738, DOI 10.1182/blood.V93.5.1738.405a18_1738_1748; MEOLA A, 1995, J IMMUNOL, V154, P3162; Myers MA, 2000, J IMMUNOL, V165, P3830, DOI 10.4049/jimmunol.165.7.3830; PETERSEN A, 1995, INT ARCH ALLERGY IMM, V108, P49, DOI 10.1159/000237117; Rajashankar K, 2002, ACTA CRYSTALLOGR D, V58, P1175, DOI 10.1107/S0907444902007254; Schoell I., 2002, Clinical and Experimental Allergy, V32, P1583, DOI 10.1046/j.1365-2222.2002.01527.x; Schramm G, 1999, J IMMUNOL, V162, P2406; Schramm G, 2001, CLIN EXP ALLERGY, V31, P331, DOI 10.1046/j.1365-2222.2001.01049.x; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; Suphioglu C, 2001, FEBS LETT, V502, P46, DOI 10.1016/S0014-5793(01)02661-8; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1999, J IMMUNOL, V163, P5489; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	40	46	53	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1294	1300		10.1016/j.jaci.2004.06.048	http://dx.doi.org/10.1016/j.jaci.2004.06.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577826				2022-12-18	WOS:000225577400007
